<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="0" size="14" family="Times" color="#000000"/>
	<fontspec id="1" size="19" family="Times" color="#000000"/>
	<fontspec id="2" size="14" family="Times" color="#000000"/>
	<fontspec id="3" size="12" family="Times" color="#000000"/>
<text top="803" left="593" width="12" height="21" font="0">1 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="417" width="365" height="27" font="1"><b>2017 VA/SCD Guideline Data Supplement </b></text>
<text top="133" left="597" width="4" height="21" font="0"> </text>
<text top="153" left="537" width="125" height="21" font="2"><b>Table of Contents </b></text>
<text top="174" left="115" width="968" height="19" font="3"><a href="data_supplement.html#6">Data Supplement 1.  Nonrandomized Trials, Observational Studies, and/or Registries for History and Physical Examination – (Section 4.1) ................................. 6 </a></text>
<text top="192" left="115" width="887" height="19" font="3"><a href="data_supplement.html#8">Data Supplement 2. Nonrandomized Trials, Observational Studies, and/or Registries of Noninvasive Evaluation (12-lead ECG, Exercise Testing and </a></text>
<text top="210" left="115" width="968" height="19" font="3"><a href="data_supplement.html#8">Electrocardiographic Monitoring) – (Section 4.2.1) ............................................................................................................................................................................ 8 </a></text>
<text top="229" left="115" width="968" height="19" font="3"><a href="data_supplement.html#14">Data Supplement 3. RCTs Comparing Ambulatory Electrocardiography – (Section 4.2.2) ............................................................................................................... 14 </a></text>
<text top="247" left="115" width="968" height="19" font="3"><a href="data_supplement.html#15">Data Supplement 4. Nonrandomized Trials, Observational Studies, and/or Registries of Ambulatory Monitors – (Section 4.2.2) ................................................ 15 </a></text>
<text top="266" left="115" width="968" height="19" font="3"><a href="data_supplement.html#16">Data Supplement 5. Nonrandomized Trials, Observational Studies, and/or Registries of Implanted Cardiac Monitors – (Section 4.2.3) ...................................... 16 </a></text>
<text top="284" left="115" width="968" height="19" font="3"><a href="data_supplement.html#18">Data Supplement 6. Nonrandomized Trials, Observational Studies, and/or Registries Comparing Noninvasive Cardiac Assessment– (Section 4.2.4) ................. 18 </a></text>
<text top="302" left="115" width="968" height="19" font="3"><a href="data_supplement.html#19">Data Supplement 7. Nonrandomized Trials, Observational Studies, and/or Registries Comparing Biomarkers – (Section 4.2.5) ................................................... 19 </a></text>
<text top="320" left="115" width="968" height="19" font="3"><a href="data_supplement.html#22">Data Supplement 8. RCTs Evaluating EP Study for VA – (Section 4.3.2) ........................................................................................................................................... 22 </a></text>
<text top="339" left="115" width="968" height="19" font="3"><a href="data_supplement.html#26">Data Supplement 9. Nonrandomized Trials, Observational Studies, and/or Registries of EP Study for VA - (Section 4.3.2) ........................................................... 26 </a></text>
<text top="357" left="115" width="968" height="19" font="3"><a href="data_supplement.html#32">Data Supplement 10. RCTs for Preventing SCD with HF Medications - (Section 5.2) ....................................................................................................................... 32 </a></text>
<text top="375" left="115" width="968" height="19" font="3"><a href="data_supplement.html#37">Data Supplement 11. RCTs and Nonrandomized Trials, Observational Studies, and/or Registries Related to Surgery and Revascularization Procedures – (Section </a></text>
<text top="394" left="115" width="968" height="19" font="3"><a href="data_supplement.html#37">5.5) .................................................................................................................................................................................................................................................... 37 </a></text>
<text top="412" left="115" width="888" height="19" font="3"><a href="data_supplement.html#44">Data Supplement 12. Nonrandomized Trials, Observational Studies, and/or Registries of Arrhythmic Surgery and Revascularization for Arrhythmia </a></text>
<text top="430" left="115" width="968" height="19" font="3"><a href="data_supplement.html#44">Management – (Section 5.5.1) ......................................................................................................................................................................................................... 44 </a></text>
<text top="449" left="115" width="968" height="19" font="3"><a href="data_supplement.html#48">Data Supplement 13. RCTs for Autonomic Modulation – (Section 5.6) ............................................................................................................................................ 48 </a></text>
<text top="467" left="115" width="968" height="19" font="3"><a href="data_supplement.html#50">Data Supplement 14. Nonrandomized Trials, Observational Studies, Guidelines, and/or Registries for Autonomic Modulation – (Section 5.6) .......................... 50 </a></text>
<text top="485" left="115" width="968" height="19" font="3"><a href="data_supplement.html#51">Data Supplement 15. RCTs Comparing Acute Management of Specific Arrythmias - (Section 6) .................................................................................................... 51 </a></text>
<text top="503" left="115" width="968" height="19" font="3"><a href="data_supplement.html#58">Data Supplement 16. Nonrandomized Trials, Observational Studies, and/or Registries Comparing Acute Management of Specific Arrythmias – (Section 6) ..... 58 </a></text>
<text top="522" left="115" width="968" height="19" font="3"><a href="data_supplement.html#64">Data Supplement 17. RCTs Secondary Prevention Sudden Death in Ischemic Heart Disease – (Section 7.1.1) ............................................................................... 64 </a></text>
<text top="540" left="115" width="938" height="19" font="3"><a href="data_supplement.html#69">Data Supplement 18. Nonrandomized Trials, Observational Studies, and/or Registries for Secondary Prevention Sudden Death in Ischemic Heart Disease – </a></text>
<text top="558" left="115" width="968" height="19" font="3"><a href="data_supplement.html#69">(Section 7.1.1) ................................................................................................................................................................................................................................... 69 </a></text>
<text top="577" left="115" width="968" height="19" font="3"><a href="data_supplement.html#71">Data Supplement 19. Nonrandomized Trials, Observational Studies, and/or Registries for Coronary Artery Spasm – (Section 7.1.1.1) ....................................... 71 </a></text>
<text top="595" left="115" width="968" height="19" font="3"><a href="data_supplement.html#75">Data Supplement 20. Nonrandomized Trials, Observational Studies, and/or Registries for Post CABG VT/VF – (Section 7.1.1.2) ................................................. 75 </a></text>
<text top="613" left="115" width="951" height="19" font="3"><a href="data_supplement.html#77">Data Supplement 21. RCTs and Nonrandomized Trials, Observational Studies, and/or Registries of ICDs Primary Prevention VA and Sudden Death in Patients </a></text>
<text top="632" left="115" width="968" height="19" font="3"><a href="data_supplement.html#77">with Ischemic Cardiomyopathy – (Section 7.1.2) ............................................................................................................................................................................. 77 </a></text>
<text top="650" left="115" width="968" height="19" font="3"><a href="data_supplement.html#84">Data Supplement 22. RCTs Evaluating Treatment and Prevention of Recurrent VA in Patients with Ischemic Heart Disease – (Section 7.1.3) ............................. 84 </a></text>
<text top="668" left="115" width="968" height="19" font="3"><a href="data_supplement.html#90">Data Supplement 23. Nonrandomized Trials, Observational Studies, and/or Registries of Treatment of Recurrent Arrhythmias in IHD – (Section 7.1.3) ........... 90 </a></text>
<text top="687" left="115" width="968" height="19" font="3"><a href="data_supplement.html#98">Data Supplement 24. Nonrandomized Trials, Observational Studies, and/or Registries of NICM – (Section 7.2) ........................................................................... 98 </a></text>
<text top="705" left="115" width="968" height="19" font="3"><a href="data_supplement.html#107">Data Supplement 25. RCTs Secondary Prevention SCD in NICM – (Section 7.2.1) ......................................................................................................................... 107 </a></text>
<text top="723" left="115" width="968" height="19" font="3"><a href="data_supplement.html#112">Data Supplement 26. Nonrandomized Trials, Observational Studies, and/or Registries of Secondary Prevention SCD in NICM – (Section 7.2.1) ....................... 112 </a></text>
<text top="741" left="115" width="968" height="19" font="3"><a href="data_supplement.html#116">Data Supplement 27. RCTs Primary Prevention SCD in NICM – (Section 7.2.2) ............................................................................................................................. 116 </a></text>
<text top="760" left="115" width="968" height="19" font="3"><a href="data_supplement.html#119">Data Supplement 28. Nonrandomized Trials, Observational Studies, and/or Registries of Primary Prevention of SCD in NICM – (Section 7.2.2) ....................... 119 </a></text>
</page>
<page number="2" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="593" width="12" height="21" font="0">2 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="966" height="19" font="3"><a href="data_supplement.html#125">Data Supplement 29. RCTs and Nonrandomized Trials, Observational Studies, and/or Registries of Treatment of Recurrent VA in Patients With NICM – (Section </a></text>
<text top="126" left="115" width="968" height="19" font="3"><a href="data_supplement.html#125">7.2.3) ............................................................................................................................................................................................................................................... 125 </a></text>
<text top="145" left="115" width="968" height="19" font="3"><a href="data_supplement.html#127">Data Supplement 30. Nonrandomized Trials, Observational Studies, and/or Registries of Arrhythmogenic Right Ventricular Cardiomyopathy – (Section 7.3) 127 </a></text>
<text top="163" left="115" width="968" height="19" font="3"><a href="data_supplement.html#145">Data Supplement 31. Nonrandomized Trials, Observational Studies, and/or Registries of Hypertrophic Cardiomyopathy – (Section 7.4) ................................. 145 </a></text>
<text top="181" left="115" width="968" height="19" font="3"><a href="data_supplement.html#159">Data Supplement 32. Nonrandomized Trials, Observational Studies, and/or Registries of Myocarditis – (Section 7.5) ............................................................... 159 </a></text>
<text top="199" left="115" width="968" height="19" font="3"><a href="data_supplement.html#160">Data Supplement 33. Nonrandomized Trials, Observational Studies, and/or Registries of Cardiac Sarcoidosis – (Section 7.6) ................................................... 160 </a></text>
<text top="218" left="115" width="968" height="19" font="3"><a href="data_supplement.html#168">Data Supplement 34. Nonrandomized Trials, Observational Studies, and/or Registries of Other Infiltrative Cardiomyopathies – (Section 7.6.1) ...................... 168 </a></text>
<text top="236" left="115" width="968" height="19" font="3"><a href="data_supplement.html#170">Data Supplement 35. Nonrandomized Trials, Observational Studies, and/or Registries of Use of ICD and WCD in Patients with HFrEF - (Section 7.8.1) ........... 170 </a></text>
<text top="255" left="115" width="968" height="19" font="3"><a href="data_supplement.html#173">Data Supplement 36. Nonrandomized Trials, Observational Studies, and/or Registries Related to LVAD – (Section 7.8.3) ......................................................... 173 </a></text>
<text top="273" left="115" width="968" height="19" font="3"><a href="data_supplement.html#173">Data Supplement 37. Nonrandomized Trials, Observational Studies, and/or Registries Related to ICD Use After Heart Transplantation – (Section 7.8.4) ........ 173 </a></text>
<text top="291" left="115" width="879" height="19" font="3"><a href="data_supplement.html#175">Data Supplement 38. Nonrandomized Trials, Observational Studies, and/or Registries Evaluating the Risk of Sudden Death or VA in Patients with </a></text>
<text top="309" left="115" width="968" height="19" font="3"><a href="data_supplement.html#175">Neuromuscular Disorders – (Section 7.8) ....................................................................................................................................................................................... 175 </a></text>
<text top="328" left="115" width="968" height="19" font="3"><a href="data_supplement.html#184">Data Supplement 39. Nonrandomized Trials Related to Cardiac Channelopathies – (Section 7.9) ............................................................................................... 184 </a></text>
<text top="346" left="115" width="968" height="19" font="3"><a href="data_supplement.html#196">Data Supplement 40. Nonrandomized Trials Related to Congenital LQTS – (Section 7.9.1.1.) ...................................................................................................... 196 </a></text>
<text top="364" left="115" width="968" height="19" font="3"><a href="data_supplement.html#207">Data Supplement 41. Nonrandomized Trials Related to Catecholaminergic Polymorphic Ventricular Tachycardia – (Section 7.9.1.2.) ...................................... 207 </a></text>
<text top="383" left="115" width="968" height="19" font="3"><a href="data_supplement.html#211">Data Supplement 42. Nonrandomized Trials Related to Brugada Syndrome – (Secction7.9.1.3) .................................................................................................. 211 </a></text>
<text top="401" left="115" width="968" height="19" font="3"><a href="data_supplement.html#221">Data Supplement 43. Nonrandomized Trials Related to Early Repolarization “J-wave” Syndrome – (Secction 7.9.1.4) ............................................................... 221 </a></text>
<text top="419" left="115" width="968" height="19" font="3"><a href="data_supplement.html#225">Data Supplement 44. Nonrandomized Trials Related to Short-QT Syndrome – (Secction 7.9.1.5) ................................................................................................ 225 </a></text>
<text top="438" left="115" width="968" height="19" font="3"><a href="data_supplement.html#228">Data Supplement 45.  RCTs Related to VA in the Structurally Normal Heart – (Section 8) ............................................................................................................ 228 </a></text>
<text top="456" left="115" width="968" height="19" font="3"><a href="data_supplement.html#230">Data Supplement 46.  Nonrandomized Trials, Observational Studies, and/or Registries Related to Outflow Tract and AV Annular VA – (Section 8.1) .............. 230 </a></text>
<text top="474" left="115" width="968" height="19" font="3"><a href="data_supplement.html#238">Data Supplement 47.  Nonrandomized Trials, Observational Studies, and/or Registries of Catheter Ablation in Papillary Muscle VA - (Section 8.2) ................. 238 </a></text>
<text top="493" left="115" width="919" height="19" font="3"><a href="data_supplement.html#241">Data Supplement 48.  Nonrandomized Trials, Observational Studies, and/or Registries Related to Interfascicular Reentrant VT (Belhassen Tachycardia)- </a></text>
<text top="511" left="115" width="968" height="19" font="3"><a href="data_supplement.html#241">(Section 8.3) .................................................................................................................................................................................................................................... 241 </a></text>
<text top="529" left="115" width="968" height="19" font="3"><a href="data_supplement.html#242">Data Supplement 49. Nonrandomized Trials, Observational Studies, and/or Registries Related to Idiopathic Polymorphic VT/VF - (Section 8.5) ...................... 242 </a></text>
<text top="547" left="115" width="968" height="19" font="3"><a href="data_supplement.html#247">Data Supplement 50. Nonrandomized Trials, Observational Studies, and/or Registries of PVC-induced Cardiomyopathy - (Section 9) ...................................... 247 </a></text>
<text top="566" left="115" width="968" height="19" font="3"><a href="data_supplement.html#258">Data Supplement 51. Nonrandomized Trials, Observational Studies, and/or Registries Related to Pregnancy - (Section 10.2) ................................................... 258 </a></text>
<text top="584" left="115" width="968" height="19" font="3"><a href="data_supplement.html#267">Data Supplement 52. RCTs Comparing Medication-Induced Arrhythmias - (Section 10.7) ............................................................................................................ 267 </a></text>
<text top="602" left="115" width="968" height="19" font="3"><a href="data_supplement.html#268">Data Supplement 53. Nonrandomized Trials, Observational Studies, and/or Registries of Medication-Induced Arrhythmias (Section 10.7) .............................. 268 </a></text>
<text top="621" left="115" width="968" height="19" font="3"><a href="data_supplement.html#274">Data Supplement 54. Nonrandomized Trials, Observational Studies, and/or Registries Related to ACHD - (Section 10.8) .......................................................... 274 </a></text>
<text top="639" left="115" width="968" height="19" font="3"><a href="data_supplement.html#293">Data Supplement 55. Nonrandomized Trials, Observational Studies, and/or Registries of S-ICD - (Section 11.1) ........................................................................ 293 </a></text>
<text top="657" left="115" width="968" height="19" font="3"><a href="data_supplement.html#299">Data Supplement 56. Nonrandomized Trials, Observational Studies, Guidelines, and/or Registries for WCD – (Section 11.2) .................................................... 299 </a></text>
<text top="676" left="115" width="950" height="19" font="3"><a href="data_supplement.html#300">Data Supplement 57. Nonrandomized Trials, Observational Studies, Guidelines, and/or Registries for Special Considerations for Catheter Ablation – (Section </a></text>
<text top="694" left="115" width="968" height="19" font="3"><a href="data_supplement.html#300">12) ................................................................................................................................................................................................................................................... 300 </a></text>
<text top="712" left="115" width="968" height="19" font="3"><a href="data_supplement.html#304">Data Supplement 58.  Nonrandomized Trials, Observational Studies, and/or Registries Related to Post-Mortem Evaluation of SCD - (Section 13) ................... 304 </a></text>
<text top="730" left="115" width="968" height="19" font="3"><a href="data_supplement.html#308">Data Supplement 59. Nonrandomized Trials, Observational Studies, Guidelines, and/or Registries of Terminal Care - (Section 14)........................................... 308 </a></text>
<text top="749" left="115" width="968" height="19" font="3"><a href="data_supplement.html#314">Data Supplement 60. Nonrandomized Trials, Observational Studies, Guidelines, and/or Registries for Shared Decision Making – (Section 15) ........................ 314 </a></text>
<text top="767" left="115" width="968" height="19" font="3"><a href="data_supplement.html#317">Data Supplement 61. Randomized Trials, Observational Studies, and/or Registries Related to Cost and Value Considerations - (Section 16) ............................ 317 </a></text>
</page>
<page number="3" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="4" size="12" family="Times" color="#000000"/>
<text top="803" left="593" width="12" height="21" font="0">3 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="968" height="19" font="3"><a href="data_supplement.html#321">References: ..................................................................................................................................................................................................................................... 321 </a></text>
<text top="126" left="115" width="3" height="19" font="4"><b> </b></text>
</page>
<page number="4" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="5" size="12" family="Times" color="#000000"/>
<text top="803" left="593" width="12" height="21" font="0">4 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="226" height="19" font="4"><b>Methodology and Evidence Review  </b></text>
<text top="126" left="115" width="923" height="19" font="3">The recommendations listed in this guideline are, whenever possible, evidence based. An extensive evidence review was conducted from April through </text>
<text top="145" left="115" width="965" height="19" font="3">September 2016, that included literature published through September 2016. Other selected references published through March 2017 were incorporated by </text>
<text top="163" left="115" width="927" height="19" font="3">the writing committee. Literature included was derived from research involving human subjects, published in English, and indexed in MEDLINE (through </text>
<text top="181" left="115" width="965" height="19" font="3">PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Key search </text>
<text top="199" left="115" width="939" height="19" font="3">words included but were not limited to the following: <i>accelerated idioventricular rhythm, advanced cardiac life support,  ambulatory electrocardiography, </i></text>
<text top="217" left="115" width="939" height="19" font="5"><i>amiodarone, amyloidosis, Antiarrhythmic drugs ARNI – Angiotensin Receptor-Neprilysin Inhibitor, arrhythmias, arrhythmogenic right ventricular dysplasia, </i></text>
<text top="235" left="115" width="952" height="19" font="5"><i>atenolol, autonomic modulation, biomarkers, CABG, cardiac, catheter ablation, cardiac arrest, cardiac arrhythmia, cardiac catheterization, cardiac magnetic </i></text>
<text top="254" left="115" width="948" height="19" font="5"><i>resonance imaging, cardiac sympathetic denervation, cardiac troponin, cardiomyopathy, catecholaminergic polymorphic ventricular tachycardia, carvedilol, </i></text>
<text top="272" left="115" width="958" height="19" font="5"><i>choice behavior, coronary artery bypass surgery, coronary stent, cryoablation deactivation, decision-making, digoxin toxicity, dilated cardiomyopathy, dilated </i></text>
<text top="290" left="115" width="949" height="19" font="5"><i>non ischemic cardiomyopathy, disease management, Dor Procedure, drug induced arrhythmia, drug induced long QT, emergency medical services, electrical </i></text>
<text top="309" left="115" width="911" height="19" font="5"><i>storm, electrocardiography, electrophysiologic study, electrophysiologic techniques, electrophysiological testing, emergency management, end of life, </i></text>
<text top="327" left="115" width="925" height="20" font="5"><i>endocardiectomy exercise test, Fabry’s disease, fibrillation, flecainide,heart arrest, heart disease, hemochromatosis, h</i>e<i>modynamically stable ventricular </i></text>
<text top="345" left="115" width="926" height="20" font="5"><i>tachycardia</i>, <i>holter monitor, hypertrophic, implantable cardiac monitor, incessant,</i> <i>infiltrative heart disease, intervention,</i> lamin a/c<i> left ventricular assist </i></text>
<text top="364" left="115" width="898" height="19" font="5"><i>device, left ventricular reconstruction, lidocaine, long QT syndrome, loop recorder, LV dysfunction, metoprolol, monomorphic, muscular dystrophies, </i></text>
<text top="382" left="115" width="925" height="20" font="5"><i>myocardial infarction/therapy, myotonic dystrophy</i>,<i> nadolol, natriuetic peptides, papillary muscle, patient perspective, patient preference, percutaneous </i></text>
<text top="400" left="115" width="945" height="19" font="5"><i>coronary, polymorphic, Polymorphous Ventricular Tachycardia, premature ventricular contractions, procainamide, propranolol,  pulseless electrical activity, </i></text>
<text top="418" left="115" width="943" height="19" font="5"><i>PVC induced cardiomyopathy, resting ecg, renal denervation, resuscitation, risk stratification, secondary prevention, shared decision making, sotalol, spinal </i></text>
<text top="437" left="115" width="956" height="19" font="5"><i>cord stimulation, subcutaneous implantable cardioverter defibrillators, sudden cardiac death, sudden death, syncope, tachycardia, torsades de pointes, vagal </i></text>
<text top="455" left="115" width="958" height="19" font="5"><i>nerve stimulation ventricular, ventricular arrhythmias, ventricle extrasystole, ventricular fibrillation, ventricular premature complexes, ventricular tachycardia </i></text>
<text top="474" left="115" width="3" height="19" font="3"> </text>
<text top="492" left="115" width="964" height="19" font="4"><b>Abbreviations:</b> 1° indicates primary; 2°, secondary; AAD, antiarrhythmic drugs;<i> </i>ACA, aborted cardiac arrest; ACC, American College of Cardiology; ACHD, adult </text>
<text top="511" left="115" width="944" height="19" font="3">congenital heart disease; ACLS, advanced cardiac life support; ACS, acute coronary syndrome; AF, atrial fibrillation; AHA, American Heart Association; AMI, </text>
<text top="529" left="115" width="934" height="19" font="3">acute myocardial infarction; ARVC, arrhythmogenic right ventricular cardiomyopathy; AS, atrial stenosis; AT, atrial tachyarrhythmias; AV, atrioventricular;</text>
<text top="527" left="1048" width="4" height="21" font="0"> </text>
<text top="547" left="115" width="959" height="19" font="3">AVID, antiarrhythmics versus implantable defibrillators; BB, beta blocker; BBB, bundle branch block; BBRVT, bundle branch reentrant ventricular tachycardia; </text>
<text top="566" left="115" width="746" height="19" font="3">BID, two times a day; BNP, brain natriuretic peptide; BP, blood pressure; BrS, Brugada syndrome; CA, cardiac arrest; CABG,</text>
<text top="564" left="861" width="4" height="21" font="0"> </text>
<text top="566" left="864" width="180" height="19" font="3">coronary artery bypass graft; </text>
<text top="584" left="115" width="83" height="19" font="3">CABG-PATCH,</text>
<text top="583" left="198" width="4" height="21" font="0"> </text>
<text top="584" left="202" width="690" height="19" font="3">coronary artery bypass graft patch trial; CAD, coronary artery disease; CASH, cardiac arrest study Hamburg; CASS,</text>
<text top="583" left="892" width="4" height="21" font="0"> </text>
<text top="584" left="896" width="147" height="19" font="3">coronary artery surgery </text>
<text top="602" left="115" width="944" height="19" font="3">study; CE, cardiac event; CHF, congestive heart failure; CHFSTAT, survival trial of antiarrhythmic therapy in congestive heart failure; CI, confidence interval; </text>
<text top="621" left="115" width="935" height="19" font="3">CIBIS II, cardiac insufficiency bisoprolol study II; CIDS, Canadian implantable defibrillator; ICD, cardiovascular implantable electronic device; CMRI, cardiac </text>
<text top="639" left="115" width="925" height="19" font="3">magnetic resonance imaging; COPD, chronic obstructive pulmonary disease; CPR, cardiopulmonary resuscitation; CPVT, catecholaminergic polymorphic </text>
<text top="657" left="115" width="956" height="19" font="3">ventricular tachycardia; CRT, cardiac reshynchronization therapy; CS, carotid sarcoidosis; CT, computed tomography; CV, cardiovascular; CVD, cardiovascular </text>
<text top="676" left="115" width="932" height="19" font="3">disease; CXR, chest x-ray; DCM, dilated cardiomyopathy; DEFINITE, defibrillator in nonischemic cardiomyopathy treatment evaluation; DFT, defibrillation </text>
<text top="694" left="115" width="896" height="19" font="3">threshold; DINAMIT, defibrillator in acute myocardial infarction trial; DM1, myotonic dystrophy 1; DM2, myotonic dystrophy; DYS, dystrophin;ECG, </text>
<text top="712" left="115" width="922" height="19" font="3">electrocardiogram; EDMD2, Emery-Dreifuss muscular dystrophy type 2; EF, ejection fraction; EFFORTLESS S-ICD, evaluation of factors impacting clinical </text>
<text top="730" left="115" width="968" height="19" font="3">outcome and cost effectiveness of the S-ICD; EGM, electorgram EMD, electromechanical dissociation; EP, electrophysiological; EPS, electrophysiological study; </text>
<text top="750" left="115" width="195" height="19" font="3">ERP, effective refractory period;</text>
<text top="748" left="310" width="564" height="21" font="0"> ESRD, end stage renal disease; EURO-VT Study, Euro–ventricular tachycardia study; </text>
<text top="750" left="874" width="161" height="19" font="3">GDMT, guideline-directed </text>
<text top="769" left="115" width="947" height="19" font="3">management and therapy; GFR, glomerular filtration rate; HCM, hypertrophic cardiomyopathy; HELP-VT, heart center of Leipzig VT study; HF, heart failure; </text>
</page>
<page number="5" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="593" width="12" height="21" font="0">5 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="28" height="19" font="3">HPS,</text>
<text top="106" left="143" width="4" height="21" font="0"> </text>
<text top="108" left="146" width="924" height="19" font="3">His-Purkinje system; HR, hazard ratio; HTN, hypertension; Hx, history; HV, His Purkinje conduction rate; ICD, implantable cardioverter-defibrillator; ICU, </text>
<text top="126" left="115" width="943" height="19" font="3">intensive care unit; IDCM, idiopathic dilated cardiomyopathy; IDE, investigational device exemption; ILR, implantable loop recorder; IRIS, insulin resistance </text>
<text top="145" left="115" width="964" height="19" font="3">intervention after stroke; IV, intravenous; KM, Kaplan-Meier; LBBB, left bundle branch block; LCSD, left cardiac sympathetic denervation; LGE, late gadolinium </text>
<text top="163" left="115" width="933" height="19" font="3">enhancement; LQTS, long QT syndrome; LV, left ventricle; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; LVH, left ventricular </text>
<text top="181" left="115" width="954" height="19" font="3">hypertrophy; LVOT, left ventricular outflow tract; MACE, major adverse cardiac event; MADIT, multicenter automatic defibrillator implantation trial; MAGIC, </text>
<text top="199" left="115" width="893" height="19" font="3">magnesium in coronaries; MD, muscular dystrophy; MI, myocardial infarction; MR, mitral regurgitation; MRI, magnetic resonance imaging; MTWA,</text>
<text top="198" left="1008" width="4" height="21" font="0"> </text>
<text top="199" left="1012" width="61" height="19" font="3">microvolt </text>
<text top="218" left="115" width="965" height="19" font="3">T-wave alternans; MUSTT, multicenter unsustained tachycardia trial; N/A, not available; NICM, nonischemic dilated cardiomyopathy; NPV, negative predictive </text>
<text top="236" left="115" width="919" height="19" font="3">value; NS, not significant; NSVT, nonsustained ventricular tachycardia; NYHA, New York Heart Association classification for heart failure; NT-proBNP, N-</text>
<text top="255" left="115" width="469" height="19" font="3">terminal pro b-type natriuretic peptide; OHCA, out-of-hospital cardiac arrest;</text>
<text top="253" left="584" width="4" height="21" font="0"> </text>
<text top="255" left="588" width="475" height="19" font="3">OPTIC, optimal pharmacological therapy in cardioverter defibrillator patients; </text>
<text top="273" left="115" width="91" height="19" font="3">OR, odds ratio;</text>
<text top="271" left="206" width="4" height="21" font="0"> </text>
<text top="273" left="210" width="833" height="19" font="3">PainFREE Rx II, pacing fast ventricular tachycardia reduces shock therapies; PARADIGM-HF, prospective comparison of ARNI with ACEI to </text>
<text top="291" left="115" width="887" height="19" font="3">determine impact on global mortality and morbidity in heart failure trial; PCI, percutaneous coronary intervention; PE, physical examination; PES, </text>
<text top="309" left="115" width="938" height="19" font="3">programmed electrical stimulation; PM, papillary muscle; PMCD, Perimortem Cesarian Delivery; PMCS, Perimortem Cesarian Section; PMVT, polymorphic </text>
<text top="328" left="115" width="800" height="19" font="3">ventricular tachycardia; PO, per os; PROCAT, Parisian region out of hospital cardiac arrest; PVC, premature ventricular contractions;</text>
<text top="326" left="915" width="4" height="21" font="0"> </text>
<text top="328" left="918" width="136" height="19" font="3">PVR, pulmonary valve </text>
<text top="346" left="115" width="947" height="19" font="3">replacement; QoL, quality of life; RBB, right bundle branch; RBBB, right bundle branch block; RCSD right cardiac sympathetic denervation; RCT, randomized </text>
<text top="364" left="115" width="951" height="19" font="3">controlled trials; RNA, radionuclide angiography; RR, relative risk; RRR relative risk ratio; RyR2, Ryanodine receptor type 2; S-ICD, subcutaneous implantable </text>
<text top="383" left="115" width="849" height="19" font="3">cardioverter-defibrillator; SAECG, signal averaged ECG; SBP, systolic blood pressure; SCA, sudden cardiac arrest; SCD, sudden cardiac death;</text>
<text top="381" left="964" width="4" height="21" font="0"> </text>
<text top="383" left="968" width="115" height="19" font="3">SCD-HeFT, sudden </text>
<text top="401" left="115" width="952" height="19" font="3">cardiac death in heart failure trial; SCS, spinal cord stimulation; SHD, structural heart disease; SMASH VT, substrate mapping and ablation in sinus rhythm to </text>
<text top="419" left="115" width="942" height="19" font="3">halt ventricular tachycardia; SND, sinus node dysfunction; SQTS, short QT syndrome; STICH, surgical treatment for ischemic heart failure; STICHES, surgical </text>
<text top="438" left="115" width="947" height="19" font="3">treatment for ischemic heart failure extension study; SVT, supraventricular tachycardia; SYNTAX, synergy between PCI with Taxus and cardiac surgery; TdP, </text>
<text top="456" left="115" width="944" height="19" font="3">torsades de pointes; TIA, transient ischemic attack; TOF, tetralogy of Fallot; VA, ventricular arrhythmias; VALIANT, valsartan in acute myocardial infarction; </text>
<text top="474" left="115" width="966" height="19" font="3">VANISH, ventricular tachycardia ablation versus escalated antiarrhythmic drug therapy in ischemic heart disease; VERP, ventricular effective refractory period; </text>
<text top="492" left="115" width="966" height="19" font="3">VF, ventricular fibrillation; VFL, ventricular flutter; VHD, valvular heart disease; VT, ventricular tachycardia; VTE, ventricular tachyarrhythmic events; and WCD, </text>
<text top="511" left="115" width="186" height="19" font="3">wearable cardiac defibrillator. </text>
<text top="529" left="115" width="3" height="19" font="3"> </text>
<text top="547" left="115" width="4" height="21" font="0"> </text>
<text top="547" left="331" width="4" height="21" font="2"><b> </b></text>
</page>
<page number="6" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="6" size="12" family="Times" color="#0000ff"/>
	<fontspec id="7" size="11" family="Times" color="#000000"/>
	<fontspec id="8" size="12" family="Times" color="#660066"/>
<text top="803" left="593" width="12" height="21" font="0">6 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="938" height="21" font="2"><b>Data Supplement 1.  Nonrandomized Trials, Observational Studies, and/or Registries for History and Physical Examination – (Section 4.1) </b></text>
<text top="129" left="146" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="147" left="171" width="51" height="19" font="4"><b>Author; </b></text>
<text top="165" left="149" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="129" left="293" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="147" left="322" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="129" left="460" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="129" left="651" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="147" left="664" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="165" left="695" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="129" left="896" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="147" left="924" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="184" left="123" width="132" height="19" font="3">● Ruwald, et al. 2012 </text>
<text top="203" left="123" width="20" height="19" font="3">(1) </text>
<text top="221" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22588456">● </a></text>
<text top="221" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22588456">22588456</a></text>
<text top="221" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22588456"> </a></text>
<text top="239" left="123" width="3" height="19" font="3"> </text>
<text top="184" left="283" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="203" left="283" width="87" height="19" font="3">Retrospective </text>
<text top="221" left="283" width="124" height="19" font="3">observational study </text>
<text top="239" left="283" width="137" height="19" font="3">from a registry cohort </text>
<text top="258" left="283" width="88" height="19" font="3">with matched </text>
<text top="276" left="283" width="57" height="19" font="3">controls. </text>
<text top="294" left="283" width="3" height="19" font="3"> </text>
<text top="313" left="283" width="138" height="19" font="4"><b>Size:</b> 127,508 patients </text>
<text top="331" left="283" width="125" height="19" font="3">with first episode of </text>
<text top="349" left="283" width="140" height="19" font="3">syncope.  Each subject </text>
<text top="368" left="283" width="135" height="19" font="3">paired with 5 age and </text>
<text top="386" left="283" width="137" height="19" font="3">sex matched controls.<b> </b></text>
<text top="184" left="440" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="203" left="440" width="146" height="19" font="3">Patients hospitalized or </text>
<text top="221" left="440" width="118" height="19" font="3">seen in emergency </text>
<text top="239" left="440" width="134" height="19" font="3">department with first </text>
<text top="258" left="440" width="121" height="19" font="3">episode of syncope </text>
<text top="276" left="440" width="155" height="19" font="3">between 1997 and 2009. </text>
<text top="294" left="440" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="313" left="440" width="84" height="19" font="3">Not specified </text>
<text top="185" left="613" width="85" height="19" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="204" left="613" width="158" height="19" font="3">Incidence of syncope and </text>
<text top="222" left="613" width="221" height="19" font="3">associations with comorbidities and </text>
<text top="240" left="613" width="112" height="19" font="3">pharmacotherapy </text>
<text top="258" left="613" width="52" height="19" font="4"><b>Results:</b> </text>
<text top="260" left="665" width="3" height="17" font="7"> </text>
<text top="277" left="613" width="209" height="19" font="3">Age distribution peaked at 20, 60, </text>
<text top="295" left="613" width="205" height="19" font="3">and 80 y. Incidence was higher in </text>
<text top="314" left="613" width="213" height="19" font="3">women in all age groups, although </text>
<text top="332" left="613" width="201" height="19" font="3">the peak in the oldest age group </text>
<text top="350" left="613" width="215" height="19" font="3">occurred 5–7 y earlier in men. CVD </text>
<text top="368" left="613" width="218" height="19" font="3">was present in 28% of the subjects, </text>
<text top="387" left="613" width="223" height="19" font="3">and drug therapy was being used by </text>
<text top="405" left="613" width="189" height="19" font="3">48%. There was an association </text>
<text top="423" left="613" width="199" height="19" font="3">between CVD and admission for </text>
<text top="442" left="613" width="211" height="19" font="3">syncope, inversely related to age - </text>
<text top="460" left="613" width="217" height="19" font="3">0–29 y (OR: 5.8); 30–49 y (OR: 4.4); </text>
<text top="478" left="613" width="205" height="19" font="3">50–79 y (OR: 2.9), and &gt;80 y (OR: </text>
<text top="497" left="613" width="124" height="19" font="3">2.0). Cardiovascular </text>
<text top="515" left="613" width="210" height="19" font="3">pharmacotherapy associated with </text>
<text top="533" left="613" width="221" height="19" font="3">age and risk of syncope was similar. </text>
<text top="184" left="854" width="217" height="19" font="3">● The incidence rates observed are </text>
<text top="203" left="854" width="197" height="19" font="3">higher than previously reported </text>
<text top="221" left="854" width="219" height="19" font="3">and the age distribution of syncope </text>
<text top="239" left="854" width="192" height="19" font="3">is widely different according to </text>
<text top="258" left="854" width="211" height="19" font="3">gender. Syncope is more common </text>
<text top="276" left="854" width="170" height="19" font="3">in females, in the elderly, is </text>
<text top="294" left="854" width="197" height="19" font="3">generally a diagnosis associated </text>
<text top="313" left="854" width="193" height="19" font="3">with considerable comorbidity. </text>
<text top="331" left="854" width="203" height="19" font="3">● The data may be influenced by </text>
<text top="349" left="854" width="152" height="19" font="3">the fact that the study is </text>
<text top="368" left="854" width="206" height="19" font="3">dominated by syncope leading to </text>
<text top="386" left="854" width="190" height="19" font="3">hospitalization and emergency </text>
<text top="404" left="854" width="114" height="19" font="3">department visits. </text>
<text top="423" left="854" width="3" height="19" font="3"> </text>
<text top="552" left="123" width="114" height="19" font="3">● Soteriades et al. </text>
<text top="571" left="123" width="57" height="19" font="3">2002 (2)  </text>
<text top="589" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12239256">● </a></text>
<text top="589" left="136" width="61" height="19" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12239256">12239256</a></text>
<text top="589" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12239256"> </a></text>
<text top="552" left="283" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="571" left="283" width="138" height="19" font="3">Retrospective analysis </text>
<text top="589" left="283" width="111" height="19" font="3">of a prospectively </text>
<text top="607" left="283" width="117" height="19" font="3">enrolled long term </text>
<text top="626" left="283" width="114" height="19" font="3">population cohort </text>
<text top="644" left="283" width="89" height="19" font="3">(Framingham) </text>
<text top="662" left="283" width="3" height="19" font="3"> </text>
<text top="680" left="283" width="141" height="19" font="4"><b>Size:</b> 727 patients with </text>
<text top="699" left="283" width="137" height="19" font="3">reported syncope and </text>
<text top="717" left="283" width="123" height="19" font="3">long term follow up </text>
<text top="735" left="283" width="129" height="19" font="3">from a population of </text>
<text top="754" left="283" width="109" height="19" font="3">7814 participants </text>
<text top="772" left="283" width="129" height="19" font="3">(3563 men and 4251 </text>
<text top="552" left="440" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="571" left="440" width="133" height="19" font="3">Reported episodes of </text>
<text top="589" left="440" width="139" height="19" font="3">syncope by subjects in </text>
<text top="607" left="440" width="117" height="19" font="3">Framingham study </text>
<text top="626" left="440" width="133" height="19" font="3">population examined </text>
<text top="644" left="440" width="155" height="19" font="3">between 1971 and 1998. </text>
<text top="662" left="440" width="148" height="19" font="3">Reports coded as “yes,” </text>
<text top="680" left="440" width="110" height="19" font="3">“no,” or “maybe.”</text>
<text top="682" left="549" width="3" height="17" font="7"> </text>
<text top="699" left="440" width="3" height="19" font="4"><b> </b></text>
<text top="717" left="440" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="735" left="440" width="125" height="19" font="3">Equivocal reports of </text>
<text top="754" left="440" width="110" height="19" font="3">syncope (N=120), </text>
<text top="772" left="440" width="156" height="19" font="3">participants who had not </text>
<text top="553" left="613" width="85" height="19" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="571" left="613" width="216" height="19" font="3">Death from any cause, MI or death </text>
<text top="590" left="613" width="206" height="19" font="3">from coronary heart disease, and </text>
<text top="608" left="613" width="147" height="19" font="3">fatal or nonfatal stroke. </text>
<text top="626" left="613" width="215" height="19" font="4"><b>Results: </b>Overall incidence of a first </text>
<text top="645" left="613" width="219" height="19" font="3">report of syncope was 6.2 per 1000 </text>
<text top="663" left="613" width="194" height="19" font="3">person-y, with an increase with </text>
<text top="681" left="613" width="212" height="19" font="3">increasing age, most prominent at </text>
<text top="699" left="613" width="227" height="19" font="3">70 y. Age-adjusted incidence was 7.2 </text>
<text top="718" left="613" width="223" height="19" font="3">per 1000 person-y among both men </text>
<text top="736" left="613" width="228" height="19" font="3">and women. Causes among men and </text>
<text top="755" left="613" width="224" height="19" font="3">women were: cardiac causes (13.2% </text>
<text top="773" left="613" width="222" height="19" font="3">and 6.7%), unknown (31.0% 40.7%), </text>
<text top="552" left="854" width="196" height="19" font="3">● Cardiac syncope constitutes a </text>
<text top="571" left="854" width="205" height="19" font="3">high-risk group for morbidity and </text>
<text top="589" left="854" width="194" height="19" font="3">premature mortality from CVD. </text>
<text top="607" left="854" width="218" height="19" font="3">● Patients with unknown cause are </text>
<text top="625" left="854" width="165" height="19" font="3">a mixed group at apparent </text>
<text top="644" left="854" width="173" height="19" font="3">increased risk for death and </text>
<text top="662" left="854" width="213" height="19" font="3">warrant further diagnostic testing. </text>
<text top="680" left="854" width="210" height="19" font="3">● Vasovagal syncope has a benign </text>
<text top="699" left="854" width="66" height="19" font="3">prognosis. </text>
<text top="717" left="854" width="3" height="19" font="3"> </text>
<text top="735" left="854" width="3" height="19" font="3"> </text>
</page>
<page number="7" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="593" width="12" height="21" font="0">7 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="283" width="132" height="19" font="3">women) followed for </text>
<text top="127" left="283" width="130" height="19" font="3">an average of 17 y in </text>
<text top="145" left="283" width="137" height="19" font="3">the outcome analysis.<b> </b></text>
<text top="109" left="440" width="124" height="19" font="3">had an examination </text>
<text top="127" left="440" width="145" height="19" font="3">within 4 y of the report </text>
<text top="145" left="440" width="153" height="19" font="3">(N=101), syncope due to </text>
<text top="164" left="440" width="130" height="19" font="3">head trauma (N=47), </text>
<text top="182" left="440" width="121" height="19" font="3">incomplete records </text>
<text top="200" left="440" width="41" height="19" font="3">(N=7). </text>
<text top="109" left="613" width="183" height="19" font="3">stroke or TIA (4.3%and 4.0%), </text>
<text top="127" left="613" width="206" height="19" font="3">seizure disorder (7.2% and 3.2%), </text>
<text top="145" left="613" width="227" height="19" font="3">vasovagal (19.8% 22.2%), orthostatic </text>
<text top="164" left="613" width="215" height="19" font="3">(8.6% and 9.9%), medication (6.3% </text>
<text top="182" left="613" width="208" height="19" font="3">and 7.2%), and “other” (9.5% and </text>
<text top="200" left="613" width="227" height="19" font="3">6.1%). Recurrences were reported in </text>
<text top="219" left="613" width="52" height="19" font="3">21.6%).  </text>
<text top="237" left="613" width="194" height="19" font="3">There were 847 deaths from all </text>
<text top="255" left="613" width="188" height="19" font="3">causes, 263 MI or deaths from </text>
<text top="273" left="613" width="199" height="19" font="3">coronary heart disease, and 178 </text>
<text top="292" left="613" width="203" height="19" font="3">fatal or nonfatal strokes during a </text>
<text top="310" left="613" width="206" height="19" font="3">mean follow-up of 8.6 y (median, </text>
<text top="329" left="613" width="184" height="19" font="3">7.7). Participants with cardiac </text>
<text top="347" left="613" width="199" height="19" font="3">syncope had lower survival than </text>
<text top="365" left="613" width="146" height="19" font="3">those without syncope. </text>
<text top="384" left="123" width="123" height="19" font="3">● Middlekauff et al. </text>
<text top="402" left="123" width="54" height="19" font="3">1993 (3) </text>
<text top="421" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8417050">● </a></text>
<text top="421" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8417050">8417050</a></text>
<text top="421" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8417050"> </a></text>
<text top="384" left="283" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="402" left="283" width="138" height="19" font="3">Retrospective analysis </text>
<text top="421" left="283" width="102" height="19" font="3">of a consecutive </text>
<text top="439" left="283" width="94" height="19" font="3">patient cohort  </text>
<text top="457" left="283" width="3" height="19" font="3"> </text>
<text top="476" left="283" width="111" height="19" font="4"><b>Size:</b> 491 patients<b> </b></text>
<text top="384" left="440" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="402" left="440" width="132" height="19" font="3">Consecutive series of </text>
<text top="421" left="440" width="145" height="19" font="3">patients with advanced </text>
<text top="439" left="440" width="137" height="19" font="3">HF without a Hx of CA </text>
<text top="457" left="440" width="155" height="19" font="3">referred for optimization </text>
<text top="476" left="440" width="158" height="19" font="3">of medical therapy, often </text>
<text top="494" left="440" width="146" height="19" font="3">in conjunction with pre-</text>
<text top="512" left="440" width="137" height="19" font="3">transplant evaluation, </text>
<text top="531" left="440" width="151" height="19" font="3">between 1983 and 1991 </text>
<text top="549" left="440" width="3" height="19" font="3"> </text>
<text top="567" left="440" width="113" height="19" font="4"><b>Exclusion criteria: </b></text>
<text top="586" left="440" width="99" height="19" font="3">Prior Hx of CA.   </text>
<text top="385" left="613" width="85" height="19" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="403" left="613" width="27" height="19" font="3">SCD </text>
<text top="422" left="613" width="3" height="19" font="3"> </text>
<text top="440" left="613" width="197" height="19" font="4"><b>Results:</b> After a mean follow-up </text>
<text top="458" left="613" width="205" height="19" font="3">of 365+419 d, 165 patients (35%) </text>
<text top="476" left="613" width="161" height="19" font="3">were alive, 148 (30%) had </text>
<text top="495" left="613" width="226" height="19" font="3">undergone heart transplantation, 69 </text>
<text top="513" left="613" width="214" height="19" font="3">(14%) had died suddenly, 66 (13%) </text>
<text top="531" left="613" width="218" height="19" font="3">had died of progressive HF, 19 (4%) </text>
<text top="550" left="613" width="220" height="19" font="3">had died of noncardiac or unknown </text>
<text top="568" left="613" width="196" height="19" font="3">causes and 24 (4%) were lost to </text>
<text top="586" left="613" width="163" height="19" font="3">follow-up. All-causes at I y </text>
<text top="605" left="613" width="197" height="19" font="3">was 29% and sudden death was </text>
<text top="623" left="613" width="225" height="19" font="3">15%. All cause mortality was greater </text>
<text top="641" left="613" width="152" height="19" font="3">in patients with syncope </text>
<text top="660" left="613" width="216" height="19" font="3">(65% vs. 25%, p&lt;0.00001). SCD risk </text>
<text top="678" left="613" width="219" height="19" font="3">was significantly greater in patients </text>
<text top="696" left="613" width="182" height="19" font="3">with syncope (45% vs. 12%, p </text>
<text top="714" left="613" width="72" height="19" font="3">&lt;0.00001).  </text>
<text top="384" left="854" width="204" height="19" font="3">● Patients with advanced HF and </text>
<text top="402" left="854" width="213" height="19" font="3">syncope are at increased risk of all </text>
<text top="421" left="854" width="213" height="19" font="3">cause mortality, largely associated </text>
<text top="439" left="854" width="183" height="19" font="3">with an increased risk of SCD. </text>
<text top="457" left="881" width="3" height="19" font="3"> </text>
<text top="733" left="115" width="3" height="19" font="3"> </text>
<text top="752" left="115" width="3" height="19" font="3"> </text>
</page>
<page number="8" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="9" size="7" family="Times" color="#000000"/>
<text top="803" left="593" width="12" height="21" font="0">8 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="969" height="21" font="2"><b>Data Supplement 2. Nonrandomized Trials, Observational Studies, and/or Registries of Noninvasive Evaluation (12-lead ECG, Exercise Testing </b></text>
<text top="128" left="115" width="371" height="21" font="2"><b>and Electrocardiographic Monitoring) – (Section 4.2.1)</b></text>
<text top="129" left="486" width="3" height="19" font="4"><b> </b></text>
<text top="151" left="137" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="170" left="163" width="51" height="19" font="4"><b>Author; </b></text>
<text top="188" left="141" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="151" left="283" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="170" left="312" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="151" left="465" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="151" left="653" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="170" left="665" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="188" left="696" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="151" left="898" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="170" left="926" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="207" left="131" width="107" height="19" font="3">● Steinman et al. </text>
<text top="225" left="131" width="54" height="19" font="3">1989 (4) </text>
<text top="244" left="131" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2915409">● </a></text>
<text top="244" left="144" width="53" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2915409">2915409</a></text>
<text top="244" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2915409"> </a></text>
<text top="207" left="259" width="159" height="19" font="4"><b>Study type:</b> retrospective </text>
<text top="225" left="259" width="44" height="19" font="3">cohort </text>
<text top="244" left="259" width="3" height="19" font="3"> </text>
<text top="262" left="259" width="103" height="19" font="4"><b>Size</b>: 20 patients </text>
<text top="207" left="444" width="158" height="19" font="4"><b>Inclusion criteria:</b> regular </text>
<text top="225" left="444" width="150" height="19" font="3">wide QRS tachycardia in </text>
<text top="244" left="444" width="103" height="19" font="3">conscious adults </text>
<text top="262" left="444" width="3" height="19" font="3"> </text>
<text top="280" left="444" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="299" left="444" width="153" height="19" font="3">hemodynamic instability </text>
<text top="208" left="619" width="176" height="19" font="4"><b>1</b>°<b> endpoint:</b> diagnosis of VT </text>
<text top="226" left="619" width="3" height="19" font="4"><b> </b></text>
<text top="244" left="619" width="177" height="19" font="4"><b>Results: </b>75% of patients had </text>
<text top="263" left="619" width="214" height="19" font="3">atherosclerotic heart disease, with </text>
<text top="281" left="619" width="112" height="19" font="3">remote MI in 73% </text>
<text top="299" left="619" width="184" height="19" font="3">Diagnosis of VT established in </text>
<text top="318" left="619" width="211" height="19" font="3">17/20 patients, by AV dissociation </text>
<text top="336" left="619" width="203" height="19" font="3">or the use of Wellens’criteria. EP </text>
<text top="354" left="619" width="198" height="19" font="3">testing in 17 patients confirmed </text>
<text top="373" left="619" width="167" height="19" font="3">the diagnosis of VT in 94%. </text>
<text top="391" left="619" width="3" height="19" font="4"><b> </b></text>
<text top="207" left="850" width="219" height="19" font="3">● VT is the most common diagnosis </text>
<text top="225" left="850" width="217" height="19" font="3">in adults with stable, wide complex </text>
<text top="244" left="850" width="74" height="19" font="3">tachycardia </text>
<text top="410" left="131" width="100" height="19" font="3">● Brugada et al. </text>
<text top="428" left="131" width="57" height="19" font="3">1991 (5)  </text>
<text top="447" left="131" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2022022">● </a></text>
<text top="447" left="144" width="53" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2022022">2022022</a></text>
<text top="447" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2022022"> </a></text>
<text top="410" left="259" width="149" height="19" font="4"><b>Study type:</b> prospective </text>
<text top="428" left="259" width="44" height="19" font="3">cohort </text>
<text top="447" left="259" width="3" height="19" font="3"> </text>
<text top="465" left="259" width="138" height="19" font="4"><b>Size</b>: 554 tachycardias </text>
<text top="410" left="444" width="145" height="19" font="4"><b>Inclusion criteria:</b> ECGs </text>
<text top="428" left="444" width="148" height="19" font="3">with wide QRS (&gt;0.12 s) </text>
<text top="447" left="444" width="3" height="19" font="3"> </text>
<text top="465" left="444" width="143" height="19" font="4"><b>Exclusion criteria: </b>AAD </text>
<text top="483" left="444" width="66" height="19" font="3">treatment<b> </b></text>
<text top="410" left="619" width="8" height="19" font="4"><b>1</b></text>
<text top="410" left="627" width="5" height="12" font="9"><b>o</b></text>
<text top="410" left="632" width="141" height="19" font="4"><b> endpoint:</b> mechanism </text>
<text top="428" left="619" width="110" height="19" font="3">confirmed by EPS </text>
<text top="446" left="619" width="3" height="19" font="4"><b> </b></text>
<text top="465" left="619" width="157" height="19" font="4"><b>Results:</b> New criteria had </text>
<text top="483" left="619" width="208" height="19" font="3">sensitivity of 0.987 and specificity </text>
<text top="502" left="619" width="57" height="19" font="3">of 0.965. </text>
<text top="410" left="850" width="199" height="19" font="3">● Absence of RS in all precordial </text>
<text top="428" left="850" width="191" height="19" font="3">leads was highly specific for VT </text>
<text top="447" left="850" width="212" height="19" font="3">● When RS is present in 1 or more </text>
<text top="465" left="850" width="222" height="19" font="3">precordial leads, RS interval of &gt;100 </text>
<text top="483" left="850" width="163" height="19" font="3">ms is highly specific for VT </text>
<text top="502" left="850" width="174" height="19" font="3">● Other criteria included AV </text>
<text top="520" left="850" width="229" height="19" font="3">dissociation and morphology in leads </text>
<text top="538" left="850" width="78" height="19" font="3">V1-2 and V6 </text>
<text top="557" left="131" width="98" height="19" font="3">● Wellens HJ et </text>
<text top="576" left="131" width="72" height="19" font="3">al. 1978 (6) </text>
<text top="594" left="131" width="9" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=623134">●</a></text>
<text top="594" left="140" width="49" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=623134"> 623134</a></text>
<text top="594" left="189" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=623134"> </a></text>
<text top="557" left="259" width="149" height="19" font="4"><b>Study type: </b>Prospective </text>
<text top="576" left="259" width="44" height="19" font="3">cohort </text>
<text top="594" left="259" width="3" height="19" font="3"> </text>
<text top="612" left="259" width="130" height="19" font="4"><b>Size: </b>140 ECGs, 70 of </text>
<text top="631" left="259" width="152" height="19" font="3">sustained VT and 70 SVT </text>
<text top="649" left="259" width="140" height="19" font="3">with aberrancy, in 122 </text>
<text top="667" left="259" width="53" height="19" font="3">patients </text>
<text top="557" left="444" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="576" left="444" width="145" height="19" font="3">Diagnosis confirmed by </text>
<text top="594" left="444" width="158" height="19" font="3">His bundle ECG recording </text>
<text top="612" left="444" width="3" height="19" font="3"> </text>
<text top="630" left="444" width="150" height="19" font="4"><b>Exclusion criteria</b>: Atrial </text>
<text top="649" left="444" width="140" height="19" font="3">fibrillation or flutter in </text>
<text top="667" left="444" width="110" height="19" font="3">patients with SVT </text>
<text top="557" left="619" width="8" height="19" font="4"><b>1</b></text>
<text top="557" left="627" width="5" height="12" font="9"><b>o</b></text>
<text top="557" left="632" width="168" height="19" font="4"><b> endpoint:</b> development of </text>
<text top="576" left="619" width="210" height="19" font="3">algorithm for differentiation of VT </text>
<text top="594" left="619" width="59" height="19" font="3">from SVT </text>
<text top="612" left="619" width="3" height="19" font="3"> </text>
<text top="630" left="619" width="212" height="19" font="4"><b>Results:</b> Findings suggestive of VT: </text>
<text top="649" left="619" width="194" height="19" font="3">QRS &gt;0.14 s; left axis deviation; </text>
<text top="667" left="619" width="206" height="19" font="3">QRS morphology; AV dissociation </text>
<text top="557" left="850" width="220" height="19" font="3">● Capture or fusion beats seen only </text>
<text top="576" left="850" width="78" height="19" font="3">infrequently </text>
<text top="686" left="131" width="98" height="19" font="3">● Elhendy et al. </text>
<text top="705" left="131" width="54" height="19" font="3">2002 (7) </text>
<text top="723" left="131" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12106835">● </a></text>
<text top="723" left="144" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12106835">12106835</a></text>
<text top="723" left="204" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12106835"> </a></text>
<text top="741" left="131" width="3" height="19" font="3"> </text>
<text top="686" left="259" width="162" height="19" font="4"><b>Study type:</b>  retrospective </text>
<text top="705" left="259" width="98" height="19" font="3">cohort analysis  </text>
<text top="723" left="259" width="3" height="19" font="3"> </text>
<text top="741" left="259" width="66" height="19" font="4"><b>Size:</b> 1460<b> </b></text>
<text top="686" left="444" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="705" left="444" width="135" height="19" font="3">intermediate pre-test </text>
<text top="723" left="444" width="115" height="19" font="3">probability of CAD </text>
<text top="741" left="444" width="3" height="19" font="3"> </text>
<text top="759" left="444" width="152" height="19" font="4"><b>Exclusion criteria:</b>  Hx of </text>
<text top="778" left="444" width="147" height="19" font="3">MI or revascularization, </text>
<text top="687" left="619" width="187" height="19" font="4"><b>1</b>°<b> endpoint:</b>  cardiac death or </text>
<text top="705" left="619" width="74" height="19" font="3">nonfatal MI </text>
<text top="724" left="619" width="3" height="19" font="3"> </text>
<text top="742" left="619" width="183" height="19" font="4"><b>Results:</b>  Exercise-induced VA </text>
<text top="760" left="619" width="194" height="19" font="3">occurred in 146 patients (10%). </text>
<text top="686" left="850" width="150" height="19" font="3">● 41 patients had NSVT. </text>
<text top="705" left="850" width="226" height="19" font="3">● Study was aimed more at ischemic </text>
<text top="723" left="850" width="176" height="19" font="3">outcomes than arrhythmias. </text>
<text top="741" left="850" width="3" height="19" font="3"> </text>
</page>
<page number="9" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="593" width="12" height="21" font="0">9 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="444" width="130" height="19" font="3">CAD documented on </text>
<text top="127" left="444" width="133" height="19" font="3">angiography, or LBBB<b> </b></text>
<text top="109" left="619" width="216" height="19" font="3">During follow-up (median 2.7 y), 1° </text>
<text top="127" left="619" width="207" height="19" font="3">endpoint occurred in 36 patients. </text>
<text top="145" left="619" width="147" height="19" font="3">In multivariate analysis, </text>
<text top="164" left="619" width="210" height="19" font="3">independent predictors of cardiac </text>
<text top="182" left="619" width="205" height="19" font="3">events were exercise-induced VA </text>
<text top="200" left="619" width="174" height="19" font="3">(chi-square 4.7, p=0.03) and </text>
<text top="219" left="619" width="212" height="19" font="3">exercise heart rate (chi-square 18, </text>
<text top="237" left="619" width="69" height="19" font="3">p=0.0001).<b> </b></text>
<text top="256" left="131" width="86" height="19" font="3">● Grady et al. </text>
<text top="274" left="131" width="54" height="19" font="3">1998 (8) </text>
<text top="292" left="131" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9440667">● </a></text>
<text top="292" left="144" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9440667">9440667</a></text>
<text top="292" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9440667"> </a></text>
<text top="311" left="131" width="3" height="19" font="4"><b> </b></text>
<text top="329" left="131" width="3" height="19" font="3"> </text>
<text top="256" left="259" width="162" height="19" font="4"><b>Study type:</b>  retrospective </text>
<text top="274" left="259" width="148" height="19" font="3">matched control cohort </text>
<text top="292" left="259" width="37" height="19" font="3">study </text>
<text top="311" left="259" width="3" height="19" font="3"> </text>
<text top="329" left="259" width="135" height="19" font="4"><b>Size:</b>  70 cases and 70 </text>
<text top="347" left="259" width="110" height="19" font="3">matched controls<b> </b></text>
<text top="256" left="444" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="274" left="444" width="141" height="19" font="3">Exercise-induced LBBB </text>
<text top="292" left="444" width="3" height="19" font="3"> </text>
<text top="311" left="444" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="329" left="444" width="101" height="19" font="3">preexcitation or </text>
<text top="347" left="444" width="148" height="19" font="3">permanent pacemakers<b> </b></text>
<text top="257" left="619" width="206" height="19" font="4"><b>1</b>°<b> endpoint:</b>  All-cause mortality, </text>
<text top="275" left="619" width="204" height="19" font="3">PCI, open heart surgery, nonfatal </text>
<text top="293" left="619" width="204" height="19" font="3">MI, documented symptomatic or </text>
<text top="312" left="619" width="209" height="19" font="3">sustained VT, or implantation of a </text>
<text top="330" left="619" width="206" height="19" font="3">permanent pacemaker or an ICD. </text>
<text top="348" left="619" width="205" height="19" font="4"><b>Results:</b>  37 events (28 in LBBB, 9 </text>
<text top="367" left="619" width="211" height="19" font="3">in controls) occurred during mean </text>
<text top="385" left="619" width="94" height="19" font="3">3.7 y follow-up </text>
<text top="403" left="619" width="208" height="19" font="3">Adjusted relative risk in LBBB was </text>
<text top="422" left="619" width="201" height="19" font="3">2.78 (95% CI: 1.16–6.65, p=0.02)<b> </b></text>
<text top="256" left="850" width="216" height="19" font="3">● Exercise-induced LBBB predicts a </text>
<text top="274" left="850" width="188" height="19" font="3">higher risk of death and major </text>
<text top="292" left="850" width="95" height="19" font="3">cardiac events. </text>
<text top="441" left="131" width="51" height="19" font="3">● <b>ABCD</b> </text>
<text top="459" left="131" width="111" height="19" font="3">● Costantini et al. </text>
<text top="477" left="131" width="54" height="19" font="3">2009 (9) </text>
<text top="496" left="131" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19195603">● </a></text>
<text top="496" left="144" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19195603">19195603</a></text>
<text top="496" left="204" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19195603"> </a></text>
<text top="514" left="131" width="3" height="19" font="3"> </text>
<text top="532" left="131" width="3" height="19" font="3"> </text>
<text top="441" left="259" width="153" height="19" font="4"><b>Study type:</b> prospective, </text>
<text top="459" left="259" width="148" height="19" font="3">non-randomized cohort </text>
<text top="477" left="259" width="3" height="19" font="3"> </text>
<text top="495" left="259" width="111" height="19" font="4"><b>Size:</b> 566 patients<b> </b></text>
<text top="441" left="444" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="459" left="444" width="56" height="19" font="3">ischemic </text>
<text top="477" left="444" width="161" height="19" font="3">cardiomyopathy, EF&lt;40%, </text>
<text top="496" left="444" width="62" height="19" font="3">and NSVT </text>
<text top="514" left="444" width="3" height="19" font="3"> </text>
<text top="532" left="444" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="550" left="444" width="159" height="19" font="3">unstable CAD, NYHA class </text>
<text top="569" left="444" width="158" height="19" font="3">IV HF, prior CA, sustained </text>
<text top="587" left="444" width="160" height="19" font="3">VA, unexplained syncope; </text>
<text top="605" left="444" width="154" height="19" font="3">recent (&lt;28 d) MI, CABG, </text>
<text top="624" left="444" width="138" height="19" font="3">or PCI; permanent AF; </text>
<text top="642" left="444" width="140" height="19" font="3">taking AAD at baseline<b> </b></text>
<text top="441" left="619" width="181" height="19" font="4"><b>1</b>°<b> endpoint:</b> appropriate ICD </text>
<text top="460" left="619" width="106" height="19" font="3">discharge or SCD </text>
<text top="478" left="619" width="3" height="19" font="3"> </text>
<text top="496" left="619" width="194" height="19" font="4"><b>Results:</b> 39 patients (7.5%) met </text>
<text top="515" left="619" width="191" height="19" font="3">the 1° endpoint after a median </text>
<text top="533" left="619" width="197" height="19" font="3">follow-up of 1.9 y; MTWA had a </text>
<text top="551" left="619" width="216" height="19" font="3">positive predictive value of 9% and </text>
<text top="570" left="619" width="196" height="19" font="3">NPV of 95%, comparable to EPS </text>
<text top="588" left="619" width="171" height="19" font="3">(11% and 95% respectively) </text>
<text top="606" left="619" width="180" height="19" font="3">Event rate with both positive </text>
<text top="624" left="619" width="199" height="19" font="3">MTWA and EPS was 12%, vs. 2% </text>
<text top="643" left="619" width="180" height="19" font="3">with both negative (p=0.017)<b> </b></text>
<text top="441" left="850" width="207" height="19" font="3">● Combination of MTWA and EPS </text>
<text top="459" left="850" width="217" height="19" font="3">identifies a subset of patients most </text>
<text top="477" left="850" width="159" height="19" font="3">likely to benefit from ICD. </text>
<text top="496" left="850" width="207" height="19" font="3">● Negative predictive value is not </text>
<text top="514" left="850" width="221" height="19" font="3">100%, indicating that a small subset </text>
<text top="532" left="850" width="233" height="19" font="3">of patients may still have events even </text>
<text top="550" left="850" width="159" height="19" font="3">if both tests are negative. </text>
<text top="569" left="850" width="3" height="19" font="3"> </text>
<text top="662" left="131" width="83" height="19" font="3">● Desai et al. </text>
<text top="680" left="131" width="62" height="19" font="3">2006 (10) </text>
<text top="698" left="131" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16828632">● </a></text>
<text top="698" left="144" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16828632">16828632</a></text>
<text top="698" left="204" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16828632"> </a></text>
<text top="717" left="131" width="3" height="19" font="3"> </text>
<text top="662" left="259" width="166" height="19" font="4"><b>Study type:</b>   retrospective </text>
<text top="680" left="259" width="3" height="19" font="3"> </text>
<text top="698" left="259" width="156" height="19" font="4"><b>Size:</b>  46,933 consecutive </text>
<text top="717" left="259" width="118" height="19" font="3">patients with ECGs<b> </b></text>
<text top="662" left="444" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="680" left="444" width="144" height="19" font="3">Patients with ECGs at a </text>
<text top="698" left="444" width="81" height="19" font="3">single center </text>
<text top="717" left="444" width="3" height="19" font="3"> </text>
<text top="735" left="444" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="753" left="444" width="132" height="19" font="3">preexcitation; BBB or </text>
<text top="662" left="619" width="215" height="19" font="4"><b>1</b>°<b> endpoint:</b>  cardiovascular death </text>
<text top="681" left="619" width="3" height="19" font="3"> </text>
<text top="699" left="619" width="202" height="19" font="4"><b>Results:</b>  After adjustment in the </text>
<text top="718" left="619" width="194" height="19" font="3">Cox model for age, gender, and </text>
<text top="736" left="619" width="212" height="19" font="3">heart rate, the QRS duration score </text>
<text top="754" left="619" width="162" height="19" font="3">was a strong independent </text>
<text top="773" left="619" width="167" height="19" font="3">predictor of cardiovascular </text>
<text top="662" left="850" width="230" height="19" font="3">● 801 patients (1.8%) had a QRS&gt;120 </text>
<text top="680" left="850" width="165" height="19" font="3">ms; another 2300 had BBB </text>
<text top="698" left="850" width="165" height="19" font="3">No specific information on </text>
<text top="717" left="850" width="109" height="19" font="3">arrhythmic death </text>
<text top="735" left="850" width="3" height="19" font="3"> </text>
</page>
<page number="10" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">10 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="444" width="93" height="19" font="3">paced patients </text>
<text top="127" left="444" width="138" height="19" font="3">considered separately<b> </b></text>
<text top="109" left="619" width="214" height="19" font="3">mortality. For every 10ms increase </text>
<text top="127" left="619" width="214" height="19" font="3">in QRS duration, there was an 18% </text>
<text top="145" left="619" width="189" height="19" font="3">increase in cardiovascular risk.<b> </b></text>
<text top="164" left="131" width="111" height="19" font="3">● Freedman et al. </text>
<text top="183" left="131" width="62" height="19" font="3">1987 (11) </text>
<text top="201" left="131" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3597997">● </a></text>
<text top="201" left="144" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3597997">3597997</a></text>
<text top="201" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3597997"> </a></text>
<text top="219" left="131" width="3" height="19" font="3"> </text>
<text top="164" left="259" width="159" height="19" font="4"><b>Study type:</b> retrospective </text>
<text top="183" left="259" width="3" height="19" font="4"><b> </b></text>
<text top="201" left="259" width="167" height="19" font="4"><b>Size:  </b>15,609 patients from </text>
<text top="219" left="259" width="159" height="19" font="3">the CASS study (Coronary </text>
<text top="238" left="259" width="164" height="19" font="3">Artery Surgery Study); 522 </text>
<text top="256" left="259" width="58" height="19" font="3">with BBB<b> </b></text>
<text top="164" left="444" width="130" height="19" font="4"><b>Inclusion criteria:</b> All </text>
<text top="183" left="444" width="152" height="19" font="3">patients from CASS; BBB </text>
<text top="201" left="444" width="135" height="19" font="3">patients compared to </text>
<text top="219" left="444" width="89" height="19" font="3">those without<b> </b></text>
<text top="237" left="444" width="3" height="19" font="4"><b> </b></text>
<text top="256" left="444" width="117" height="19" font="4"><b>Exclusion criteria:  </b></text>
<text top="274" left="444" width="157" height="19" font="3">preexcitation, ventricular </text>
<text top="292" left="444" width="156" height="19" font="3">pacing, nonspecific IVCD, </text>
<text top="311" left="444" width="127" height="19" font="3">previous myocardial </text>
<text top="329" left="444" width="49" height="19" font="3">surgery<b> </b></text>
<text top="165" left="619" width="141" height="19" font="4"><b>1</b>°<b> endpoint:</b> mortality </text>
<text top="183" left="619" width="3" height="19" font="4"><b> </b></text>
<text top="202" left="619" width="197" height="19" font="4"><b>Results:</b> LBBB associated with 5-</text>
<text top="220" left="619" width="214" height="19" font="3">fold greater mortality; RBBB 2-fold </text>
<text top="238" left="619" width="194" height="19" font="3">greater mortality (p&lt;0.0001 for </text>
<text top="257" left="619" width="37" height="19" font="3">both) </text>
<text top="275" left="619" width="3" height="19" font="4"><b> </b></text>
<text top="164" left="850" width="220" height="19" font="3">● Mean EF in LBBB patients 40% vs. </text>
<text top="183" left="850" width="204" height="19" font="3">49% in RBBB and 57% in patients </text>
<text top="201" left="850" width="79" height="19" font="3">without BBB </text>
<text top="219" left="850" width="3" height="19" font="3"> </text>
<text top="238" left="850" width="3" height="19" font="3"> </text>
<text top="348" left="131" width="9" height="19" font="3">●</text>
<text top="347" left="140" width="4" height="21" font="0"> </text>
<text top="348" left="144" width="97" height="19" font="3">Baldasseroni et </text>
<text top="366" left="131" width="83" height="19" font="3">al. 2002 (12)  </text>
<text top="385" left="131" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11868043">● </a></text>
<text top="385" left="144" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11868043">11868043</a></text>
<text top="385" left="204" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11868043"> </a></text>
<text top="403" left="131" width="3" height="19" font="3"> </text>
<text top="348" left="259" width="159" height="19" font="4"><b>Study type:</b> retrospective </text>
<text top="366" left="259" width="135" height="19" font="3">analysis of outpatient </text>
<text top="385" left="259" width="49" height="19" font="3">registry </text>
<text top="403" left="259" width="3" height="19" font="4"><b> </b></text>
<text top="421" left="259" width="119" height="19" font="4"><b>Size:</b> 5517 patients<b> </b></text>
<text top="348" left="444" width="115" height="19" font="4"><b>Inclusion criteria:  </b></text>
<text top="366" left="444" width="144" height="19" font="3">unselected outpatients </text>
<text top="385" left="444" width="50" height="19" font="3">with HF </text>
<text top="403" left="444" width="3" height="19" font="4"><b> </b></text>
<text top="421" left="444" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="349" left="619" width="141" height="19" font="4"><b>1</b>°<b> endpoint:</b> mortality </text>
<text top="367" left="619" width="3" height="19" font="4"><b> </b></text>
<text top="386" left="619" width="212" height="19" font="4"><b>Results:</b> LBBB was present in 1391 </text>
<text top="404" left="619" width="156" height="19" font="3">patients (25.2%) and was </text>
<text top="422" left="619" width="196" height="19" font="3">associated with an increased 1y </text>
<text top="441" left="619" width="209" height="19" font="3">mortality rate from any cause (HR </text>
<text top="459" left="619" width="177" height="19" font="3">1.70; 95% CI: 1.41–2.05) and </text>
<text top="477" left="619" width="199" height="19" font="3">sudden death (HR: 1.58; 95% CI: </text>
<text top="496" left="619" width="72" height="19" font="3">1.21–2.06). </text>
<text top="514" left="619" width="3" height="19" font="4"><b> </b></text>
<text top="348" left="850" width="200" height="19" font="3">● LBBB Is associated with higher </text>
<text top="366" left="850" width="102" height="19" font="3">mortality in CHF </text>
<text top="385" left="850" width="3" height="19" font="3"> </text>
<text top="533" left="131" width="64" height="19" font="3">● <b>MUSTT  </b></text>
<text top="551" left="131" width="102" height="19" font="3">● Zimetbaum et </text>
<text top="570" left="131" width="79" height="19" font="3">al. 2004 (13) </text>
<text top="588" left="131" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15289365">● </a></text>
<text top="588" left="144" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15289365">15289365</a></text>
<text top="588" left="204" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15289365"> </a></text>
<text top="606" left="131" width="3" height="19" font="3"> </text>
<text top="624" left="131" width="3" height="19" font="3"> </text>
<text top="533" left="259" width="162" height="19" font="4"><b>Study type: </b> retrospective </text>
<text top="551" left="259" width="58" height="19" font="3">substudy </text>
<text top="569" left="259" width="3" height="19" font="4"><b> </b></text>
<text top="588" left="259" width="61" height="19" font="4"><b>Size:</b> 431 <b> </b></text>
<text top="533" left="444" width="144" height="19" font="4"><b>Inclusion criteria:</b> CAD, </text>
<text top="551" left="444" width="90" height="19" font="3">EF&lt;40%, NSVT </text>
<text top="569" left="444" width="3" height="19" font="4"><b> </b></text>
<text top="588" left="444" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="606" left="444" width="161" height="19" font="3">treatment with AAD or an </text>
<text top="624" left="444" width="24" height="19" font="3">ICD<b> </b></text>
<text top="534" left="619" width="188" height="19" font="4"><b>1</b>°<b> endpoint:</b> CA or arrhythmic </text>
<text top="552" left="619" width="39" height="19" font="3">death </text>
<text top="570" left="619" width="3" height="19" font="4"><b> </b></text>
<text top="588" left="619" width="211" height="19" font="4"><b>Results:</b> LBBB and intraventricular </text>
<text top="607" left="619" width="210" height="19" font="3">conduction delay were associated </text>
<text top="625" left="619" width="204" height="19" font="3">with a 50% increase in the risk of </text>
<text top="644" left="619" width="161" height="19" font="3">both arrhythmic and total </text>
<text top="662" left="619" width="150" height="19" font="3">mortality. RBBB was not </text>
<text top="680" left="619" width="217" height="19" font="3">associated with arrhythmic or total </text>
<text top="698" left="619" width="199" height="19" font="3">mortality. LVH was the only ECG </text>
<text top="717" left="619" width="205" height="19" font="3">predictor of arrhythmic (HR 1.35; </text>
<text top="735" left="619" width="197" height="19" font="3">95% CI: 1.08–1.69) but not total </text>
<text top="753" left="619" width="63" height="19" font="3">mortality. </text>
<text top="772" left="619" width="3" height="19" font="4"><b> </b></text>
<text top="533" left="850" width="177" height="19" font="3">● Likely reflects the effect of </text>
<text top="551" left="850" width="156" height="19" font="3">ventricular dyssynchrony </text>
<text top="570" left="850" width="3" height="19" font="3"> </text>
</page>
<page number="11" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">11 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="131" width="93" height="19" font="3">● Buxton et al. </text>
<text top="127" left="131" width="65" height="19" font="3">2005 (14)  </text>
<text top="145" left="131" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16022960">● </a></text>
<text top="145" left="144" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16022960">16022960</a></text>
<text top="145" left="204" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16022960"> </a></text>
<text top="164" left="131" width="3" height="19" font="3"> </text>
<text top="109" left="259" width="165" height="19" font="4"><b>Study type:   </b>retrospective </text>
<text top="127" left="259" width="169" height="19" font="3">substudy from PainFREE Rx </text>
<text top="145" left="259" width="11" height="19" font="3">II </text>
<text top="164" left="259" width="3" height="19" font="4"><b> </b></text>
<text top="182" left="259" width="111" height="19" font="4"><b>Size:</b> 431 patients<b> </b></text>
<text top="109" left="444" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="127" left="444" width="159" height="19" font="3">patients in the study with </text>
<text top="145" left="444" width="152" height="19" font="3">CAD and a baseline ECG. </text>
<text top="164" left="444" width="3" height="19" font="3"> </text>
<text top="182" left="444" width="154" height="19" font="4"><b>Exclusion criteria:  </b>HCM, </text>
<text top="200" left="444" width="61" height="19" font="3">BrS, LQTS<b> </b></text>
<text top="109" left="619" width="207" height="19" font="4"><b>1</b>°<b> endpoint:</b> recurrence of VT/VF<b> </b></text>
<text top="128" left="619" width="3" height="19" font="4"><b> </b></text>
<text top="146" left="619" width="212" height="19" font="4"><b>Results: </b>QRSd was &lt;120 ms in 291 </text>
<text top="165" left="619" width="195" height="19" font="3">of 431 (68%) patients (LBBB 65, </text>
<text top="183" left="619" width="197" height="19" font="3">RBBB 48, IVCD 124). Over 12mo </text>
<text top="201" left="619" width="197" height="19" font="3">follow-up, VT/VF occurred in 95 </text>
<text top="219" left="619" width="194" height="19" font="3">(22%) patients (22% of patients </text>
<text top="238" left="619" width="138" height="19" font="3">with QRSd &lt;120ms vs. </text>
<text top="256" left="619" width="165" height="19" font="3">23% of patients with QRSd </text>
<text top="274" left="619" width="99" height="19" font="3">&gt;120ms, p=NS). </text>
<text top="293" left="619" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="850" width="189" height="19" font="3">● QRS duration is not useful in </text>
<text top="127" left="850" width="170" height="19" font="3">predicting recurrent VT/VF. </text>
<text top="145" left="850" width="3" height="19" font="3"> </text>
<text top="312" left="131" width="71" height="19" font="3">● <b>MADIT-II</b> </text>
<text top="330" left="131" width="102" height="19" font="3">● Monasterio et </text>
<text top="348" left="131" width="79" height="19" font="3">al. 2013 (15) </text>
<text top="367" left="131" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24028998">● </a></text>
<text top="367" left="144" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24028998">24028998</a></text>
<text top="367" left="204" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24028998"> </a></text>
<text top="385" left="131" width="3" height="19" font="3"> </text>
<text top="311" left="259" width="149" height="19" font="4"><b>Study type:</b> substudy of </text>
<text top="330" left="259" width="147" height="19" font="3">prospective clinical trial </text>
<text top="348" left="259" width="3" height="19" font="4"><b> </b></text>
<text top="367" left="259" width="111" height="19" font="4"><b>Size:</b> 175 patients<b> </b></text>
<text top="311" left="444" width="162" height="19" font="4"><b>Inclusion criteria:</b> CAD, EF </text>
<text top="330" left="444" width="37" height="19" font="3">&lt;30% </text>
<text top="348" left="444" width="3" height="19" font="4"><b> </b></text>
<text top="367" left="444" width="136" height="19" font="4"><b>Exclusion criteria:</b> AF; </text>
<text top="385" left="444" width="156" height="19" font="3">heart rate &lt;80 beats/min<b> </b></text>
<text top="312" left="619" width="181" height="19" font="4"><b>1</b>°<b> endpoint:</b> appropriate ICD </text>
<text top="331" left="619" width="105" height="19" font="3">therapy and SCD </text>
<text top="349" left="619" width="3" height="19" font="4"><b> </b></text>
<text top="367" left="619" width="188" height="19" font="4"><b>Results:</b> Neither QTV nor TWA </text>
<text top="386" left="619" width="195" height="19" font="3">predicted SCD. Appropriate ICD </text>
<text top="404" left="619" width="158" height="19" font="3">therapy was predicted by </text>
<text top="422" left="619" width="186" height="19" font="3">combining IAA90 from T wave </text>
<text top="441" left="619" width="204" height="19" font="3">alternans testing and QTVN after </text>
<text top="459" left="619" width="202" height="19" font="3">adjusting for relevant correlates. </text>
<text top="477" left="619" width="3" height="19" font="4"><b> </b></text>
<text top="312" left="850" width="187" height="19" font="3">● Increased TWA and QTV are </text>
<text top="330" left="850" width="163" height="19" font="3">independent predictors of </text>
<text top="348" left="850" width="223" height="19" font="3">appropriate ICD therapy in MADIT-II </text>
<text top="367" left="850" width="220" height="19" font="3">patients with elevated heart rate at </text>
<text top="385" left="850" width="58" height="19" font="3">baseline. </text>
<text top="403" left="850" width="3" height="19" font="3"> </text>
<text top="496" left="131" width="68" height="19" font="3">● <b>MASTER </b></text>
<text top="515" left="131" width="84" height="19" font="3">● Chow et al. </text>
<text top="533" left="131" width="62" height="19" font="3">2008 (16) </text>
<text top="551" left="131" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18992649">● </a></text>
<text top="551" left="144" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18992649">18992649</a></text>
<text top="551" left="204" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18992649"> </a></text>
<text top="570" left="131" width="3" height="19" font="3"> </text>
<text top="496" left="259" width="153" height="19" font="4"><b>Study type:</b> prospective, </text>
<text top="515" left="259" width="148" height="19" font="3">non-randomized cohort<b> </b></text>
<text top="533" left="259" width="143" height="19" font="3">study of MTWA testing<b> </b></text>
<text top="551" left="259" width="3" height="19" font="4"><b> </b></text>
<text top="569" left="259" width="133" height="19" font="4"><b>Size:</b> 575 patients; all </text>
<text top="588" left="259" width="86" height="19" font="3">received ICDs<b> </b></text>
<text top="496" left="444" width="142" height="19" font="4"><b>Inclusion criteria:</b> post-</text>
<text top="515" left="444" width="75" height="19" font="3">MI, EF&lt;30% </text>
<text top="533" left="444" width="3" height="19" font="4"><b> </b></text>
<text top="551" left="444" width="149" height="19" font="4"><b>Exclusion criteria:</b> AF or </text>
<text top="570" left="444" width="116" height="19" font="3">atrial flutter, Hx of </text>
<text top="588" left="444" width="142" height="19" font="3">sustained VT/VF or CA, </text>
<text top="606" left="444" width="91" height="19" font="3">MI in past mo, </text>
<text top="624" left="444" width="160" height="19" font="3">revascularization within 3 </text>
<text top="643" left="444" width="106" height="19" font="3">mo, class IV CHF, </text>
<text top="661" left="444" width="62" height="19" font="3">advanced </text>
<text top="680" left="444" width="149" height="19" font="3">cerebrovascular disease<b> </b></text>
<text top="497" left="619" width="201" height="19" font="4"><b>1</b>°<b> endpoint:</b> SCD or appropriate </text>
<text top="515" left="619" width="75" height="19" font="3">ICD therapy </text>
<text top="534" left="619" width="3" height="19" font="4"><b> </b></text>
<text top="552" left="619" width="197" height="19" font="4"><b>Results:</b> SCD or appropriate ICD </text>
<text top="570" left="619" width="158" height="19" font="3">therapy occurred in 48 of </text>
<text top="589" left="619" width="188" height="19" font="3">361 (13%, 6.3%/y) MTWA non-</text>
<text top="607" left="619" width="180" height="19" font="3">negative and 22 of 214 (10%, </text>
<text top="625" left="619" width="208" height="19" font="3">5.0%/y) MTWA negative patients. </text>
<text top="644" left="619" width="96" height="19" font="3">A non-negative </text>
<text top="662" left="619" width="162" height="19" font="3">MTWA test result was not </text>
<text top="680" left="619" width="202" height="19" font="3">associated with 1° endpoint (HR: </text>
<text top="699" left="619" width="197" height="19" font="3">1.26; 95% CI 0.76–2.09; p=0.37) </text>
<text top="717" left="619" width="3" height="19" font="4"><b> </b></text>
<text top="496" left="850" width="209" height="19" font="3">● Total mortality was significantly </text>
<text top="515" left="850" width="206" height="19" font="3">increased in MTWA non-negative </text>
<text top="533" left="850" width="199" height="19" font="3">patients (HR: 2.04; 95% CI: 1.10–</text>
<text top="551" left="850" width="88" height="19" font="3">3.78; p=0.02). </text>
<text top="570" left="850" width="221" height="19" font="3">MTWA did not identify patients at a </text>
<text top="588" left="850" width="117" height="19" font="3">higher risk of a VT. </text>
<text top="606" left="850" width="3" height="19" font="3"> </text>
<text top="736" left="131" width="87" height="19" font="3">● Gupta et al. </text>
<text top="754" left="131" width="65" height="19" font="3">2012 (17)  </text>
<text top="773" left="131" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22424005">● </a></text>
<text top="773" left="144" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22424005">22424005</a></text>
<text top="773" left="204" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22424005"> </a></text>
<text top="736" left="259" width="162" height="19" font="4"><b>Study type:</b> meta-analysis </text>
<text top="754" left="259" width="3" height="19" font="4"><b> </b></text>
<text top="736" left="444" width="115" height="19" font="4"><b>Inclusion criteria:  </b></text>
<text top="754" left="444" width="146" height="19" font="3">predominantly prior MI </text>
<text top="737" left="619" width="178" height="19" font="4"><b>1</b>°<b> endpoint:</b> VT events were </text>
<text top="755" left="619" width="148" height="19" font="3">defined as the total and </text>
<text top="736" left="850" width="195" height="19" font="3">● Negative MTWA result would </text>
<text top="754" left="850" width="219" height="19" font="3">decrease the annualized risk of VTE </text>
<text top="773" left="850" width="207" height="19" font="3">from 8.85% to 6.37% in MADIT-II–</text>
</page>
<page number="12" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">12 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="131" width="3" height="19" font="3"> </text>
<text top="109" left="259" width="169" height="19" font="4"><b>Size:</b> 20 prospective cohort </text>
<text top="127" left="259" width="164" height="19" font="3">studies consisting of 5,945 </text>
<text top="145" left="259" width="53" height="19" font="3">subjects </text>
<text top="164" left="259" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="444" width="110" height="19" font="3">or left ventricular </text>
<text top="127" left="444" width="75" height="19" font="3">dysfunction </text>
<text top="145" left="444" width="3" height="19" font="4"><b> </b></text>
<text top="164" left="444" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="182" left="444" width="134" height="19" font="3">healthy patients; BrS; </text>
<text top="200" left="444" width="34" height="19" font="3">LQTS<b> </b></text>
<text top="109" left="619" width="211" height="19" font="3">arrhythmic mortality and nonfatal </text>
<text top="127" left="619" width="172" height="19" font="3">sustained or ICD-treated VT </text>
<text top="145" left="619" width="3" height="19" font="4"><b> </b></text>
<text top="164" left="619" width="186" height="19" font="4"><b>Results:</b> Although there was a </text>
<text top="182" left="619" width="178" height="19" font="3">modest association between </text>
<text top="200" left="619" width="212" height="19" font="3">positive MTWA and VTE (RR: 2.45; </text>
<text top="219" left="619" width="216" height="19" font="3">95% CI:1.58-3.79) and nonnegative </text>
<text top="237" left="619" width="209" height="19" font="3">MTWA and VTE (RR: 3.68; 95% CI: </text>
<text top="255" left="619" width="209" height="19" font="3">2.23–6.07), test performance was </text>
<text top="273" left="619" width="197" height="19" font="3">poor (positive MTWA: LR+ 1.78, </text>
<text top="292" left="619" width="213" height="19" font="3">LR− 0.43; nonnegative MTWA: LR+ </text>
<text top="310" left="619" width="94" height="19" font="3">1.38, LR− 0.56)<b> </b></text>
<text top="109" left="850" width="200" height="19" font="3">type patients and from 5.91% to </text>
<text top="127" left="850" width="210" height="19" font="3">2.60% in SCD-HeFT–type patients. </text>
<text top="145" left="850" width="198" height="19" font="3">● Despite a modest association, </text>
<text top="164" left="850" width="217" height="19" font="3">results of spectrally derived MTWA </text>
<text top="182" left="850" width="228" height="19" font="3">testing do not sufficiently modify the </text>
<text top="200" left="850" width="176" height="19" font="3">risk of VTE to change clinical </text>
<text top="219" left="850" width="60" height="19" font="3">decisions </text>
<text top="237" left="850" width="3" height="19" font="3"> </text>
<text top="329" left="131" width="71" height="19" font="3">● <b>MADIT-II</b> </text>
<text top="347" left="131" width="113" height="19" font="3">● Dhar et al. 2008 </text>
<text top="366" left="131" width="28" height="19" font="3">(18) </text>
<text top="384" left="131" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18534364">● </a></text>
<text top="384" left="144" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18534364">18534364</a></text>
<text top="384" left="204" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18534364"> </a></text>
<text top="402" left="131" width="3" height="19" font="3"> </text>
<text top="329" left="259" width="149" height="19" font="4"><b>Study type:</b> substudy of </text>
<text top="347" left="259" width="149" height="19" font="3">randomized clinical trial </text>
<text top="366" left="259" width="117" height="19" font="3">that estimated the </text>
<text top="384" left="259" width="153" height="19" font="3">association of prolonged </text>
<text top="402" left="259" width="118" height="19" font="3">QRSd &gt;140ms with </text>
<text top="421" left="259" width="134" height="19" font="3">arrhythmic outcomes </text>
<text top="439" left="259" width="3" height="19" font="4"><b> </b></text>
<text top="457" left="259" width="122" height="19" font="4"><b>Size:</b> 1232 patients<b>  </b></text>
<text top="329" left="444" width="144" height="19" font="4"><b>Inclusion criteria:</b> prior </text>
<text top="347" left="444" width="78" height="19" font="3">MI, EF &lt;30% </text>
<text top="366" left="444" width="3" height="19" font="4"><b> </b></text>
<text top="384" left="444" width="113" height="19" font="4"><b>Exclusion criteria</b>: </text>
<text top="402" left="444" width="128" height="19" font="3">indicated for an ICD; </text>
<text top="421" left="444" width="148" height="19" font="3">NYHA class IV; coronary </text>
<text top="439" left="444" width="107" height="19" font="3">revascularization </text>
<text top="457" left="444" width="140" height="19" font="3">within the preceding 3 </text>
<text top="476" left="444" width="142" height="19" font="3">mo; MI within the past </text>
<text top="494" left="444" width="89" height="19" font="3">mo; advanced </text>
<text top="512" left="444" width="153" height="19" font="3">cerebrovascular disease; </text>
<text top="531" left="444" width="129" height="19" font="3">other potentially life-</text>
<text top="549" left="444" width="142" height="19" font="3">threatening conditions </text>
<text top="567" left="444" width="3" height="19" font="4"><b> </b></text>
<text top="330" left="619" width="209" height="19" font="4"><b>1</b>°<b> endpoint:</b> SCD in the medically </text>
<text top="348" left="619" width="174" height="19" font="3">treated arm and SCD or first </text>
<text top="367" left="619" width="207" height="19" font="3">appropriate ICD therapy for rapid </text>
<text top="385" left="619" width="181" height="19" font="3">VT/VF in the ICD-treated arm </text>
<text top="403" left="619" width="3" height="19" font="4"><b> </b></text>
<text top="421" left="619" width="201" height="19" font="4"><b>Results</b>: In the medically treated </text>
<text top="440" left="619" width="164" height="19" font="3">arm, prolonged QRS was a </text>
<text top="458" left="619" width="207" height="19" font="3">significant independent predictor </text>
<text top="476" left="619" width="216" height="19" font="3">of SCD (HR: 2.12; 95% CI1.20–3.76, </text>
<text top="495" left="619" width="167" height="19" font="3">p=0.01). In the ICD-treated </text>
<text top="513" left="619" width="173" height="19" font="3">arm, prolonged QRS did not </text>
<text top="531" left="619" width="195" height="19" font="3">predict SCD or rapid VT/VF (HR: </text>
<text top="550" left="619" width="200" height="19" font="3">0.77; 95% CI 0.47–1.24, p=0.28). </text>
<text top="568" left="619" width="3" height="19" font="4"><b> </b></text>
<text top="329" left="850" width="210" height="19" font="3">● Prolonged QRS does not predict </text>
<text top="347" left="850" width="211" height="19" font="3">SCD/VT/VF in ICD treated patients </text>
<text top="366" left="850" width="207" height="19" font="3">but does predict SCD in medically </text>
<text top="384" left="850" width="106" height="19" font="3">treated patients. </text>
<text top="402" left="850" width="3" height="19" font="3"> </text>
<text top="587" left="131" width="98" height="19" font="3">● Bloomfield et </text>
<text top="605" left="131" width="79" height="19" font="3">al. 2004 (19) </text>
<text top="624" left="131" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15451804">● </a></text>
<text top="624" left="144" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15451804">15451804</a></text>
<text top="624" left="204" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15451804"> </a></text>
<text top="642" left="131" width="3" height="19" font="3"> </text>
<text top="587" left="259" width="149" height="19" font="4"><b>Study type:</b> prospective </text>
<text top="605" left="259" width="44" height="19" font="3">cohort </text>
<text top="624" left="259" width="3" height="19" font="4"><b> </b></text>
<text top="642" left="259" width="115" height="19" font="4"><b>Size: </b> 177 patients<b> </b></text>
<text top="587" left="444" width="144" height="19" font="4"><b>Inclusion criteria:</b> prior </text>
<text top="605" left="444" width="75" height="19" font="3">MI, EF&lt;30% </text>
<text top="624" left="444" width="3" height="19" font="4"><b> </b></text>
<text top="642" left="444" width="152" height="19" font="4"><b>Exclusion criteria:</b>  AF or </text>
<text top="660" left="444" width="161" height="19" font="3">atrial flutter; requirement </text>
<text top="679" left="444" width="21" height="19" font="3">for </text>
<text top="697" left="444" width="116" height="19" font="3">ventricular pacing; </text>
<text top="715" left="444" width="160" height="19" font="3">unstable CAD; NYHA class </text>
<text top="734" left="444" width="154" height="19" font="3">IV HF; unable to exercise </text>
<text top="752" left="444" width="150" height="19" font="3">on a bicycle or treadmill<b> </b></text>
<text top="770" left="444" width="3" height="19" font="4"><b> </b></text>
<text top="588" left="619" width="215" height="19" font="4"><b>1</b>°<b> endpoint:</b> 2y all-cause mortality </text>
<text top="606" left="619" width="3" height="19" font="4"><b> </b></text>
<text top="624" left="619" width="183" height="19" font="4"><b>Results: </b>For abnormal MTWA </text>
<text top="643" left="619" width="193" height="19" font="3">compared to normal (negative) </text>
<text top="661" left="619" width="205" height="19" font="3">test, the HR: 4.8; p=0.02; for QRS </text>
<text top="680" left="619" width="212" height="19" font="3">&gt;120ms compared to &lt;120ms, the </text>
<text top="698" left="619" width="169" height="19" font="3">HR for 2y mortality was 1.5 </text>
<text top="716" left="619" width="208" height="19" font="3">(p=0.367). The actuarial mortality </text>
<text top="734" left="619" width="174" height="19" font="3">rate was substantially lower </text>
<text top="753" left="619" width="176" height="19" font="3">among patients with normal </text>
<text top="771" left="619" width="209" height="19" font="3">MTWA (3.8%; 95% CI: 0–9.0) than </text>
<text top="587" left="850" width="201" height="19" font="3">● Among MADIT II–like patients, </text>
<text top="605" left="850" width="231" height="19" font="3">MTWA is better than QRS duration at </text>
<text top="624" left="850" width="230" height="19" font="3">identifying a high-risk group; it is also </text>
<text top="642" left="850" width="227" height="19" font="3">better at identifying a low-risk group </text>
<text top="660" left="850" width="226" height="19" font="3">unlikely to benefit from ICD therapy. </text>
<text top="679" left="850" width="3" height="19" font="3"> </text>
</page>
<page number="13" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="10" size="16" family="Times" color="#000000"/>
<text top="803" left="589" width="20" height="21" font="0">13 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="680" left="115" width="4" height="23" font="10"><b> </b></text>
<text top="109" left="619" width="210" height="19" font="3">the mortality rate in patients with </text>
<text top="127" left="619" width="211" height="19" font="3">a narrow QRS (12.0%; 95% CI: 5.6–</text>
<text top="145" left="619" width="38" height="19" font="3">18.5).<b> </b></text>
<text top="164" left="131" width="91" height="19" font="3">● Iuliano et al. </text>
<text top="183" left="131" width="62" height="19" font="3">2002 (20) </text>
<text top="201" left="131" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12075267">● </a></text>
<text top="201" left="144" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12075267">12075267</a></text>
<text top="201" left="204" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12075267"> </a></text>
<text top="219" left="131" width="3" height="19" font="3"> </text>
<text top="164" left="259" width="159" height="19" font="4"><b>Study type:</b> retrospective </text>
<text top="183" left="259" width="129" height="19" font="3">analysis of CHF-STAT </text>
<text top="201" left="259" width="3" height="19" font="4"><b> </b></text>
<text top="219" left="259" width="118" height="19" font="4"><b>Size: </b>669 patients<b>   </b></text>
<text top="164" left="444" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="183" left="444" width="152" height="19" font="3">ischemic or nonischemic </text>
<text top="201" left="444" width="145" height="19" font="3">cardiomyopathy, NYHA </text>
<text top="219" left="444" width="158" height="19" font="3">class II-IV, &gt;10 PVCs/h, EF </text>
<text top="238" left="444" width="37" height="19" font="3">&lt;40% </text>
<text top="256" left="444" width="3" height="19" font="4"><b> </b></text>
<text top="274" left="444" width="110" height="19" font="4"><b>Exclusion criteria:</b></text>
<text top="273" left="554" width="4" height="21" font="0"> </text>
<text top="274" left="558" width="43" height="19" font="3">recent </text>
<text top="292" left="444" width="120" height="19" font="3">MI, Hx of ACA, QRS </text>
<text top="311" left="444" width="55" height="19" font="3">&gt;180ms, </text>
<text top="329" left="444" width="106" height="19" font="3">or a QTc &gt;500ms<b> </b></text>
<text top="165" left="619" width="199" height="19" font="4"><b>1</b>°<b> endpoint:</b> total mortality and </text>
<text top="183" left="619" width="87" height="19" font="3">sudden death </text>
<text top="202" left="619" width="3" height="19" font="4"><b> </b></text>
<text top="220" left="619" width="211" height="19" font="4"><b>Results:</b> Prolonged QRS (&gt;120 ms) </text>
<text top="238" left="619" width="201" height="19" font="3">was associated with a significant </text>
<text top="257" left="619" width="190" height="19" font="3">increase in mortality (49.3% vs </text>
<text top="275" left="619" width="184" height="19" font="3">34.0%, p=0.0001) and sudden </text>
<text top="293" left="619" width="213" height="19" font="3">death (24.8% vs 17.4%, p=0.0004). </text>
<text top="312" left="619" width="200" height="19" font="3">LBBB was associated with worse </text>
<text top="330" left="619" width="209" height="19" font="3">survival (p=0.006) but not sudden </text>
<text top="348" left="619" width="39" height="19" font="3">death </text>
<text top="164" left="850" width="154" height="19" font="3">● QRS prolongation is an </text>
<text top="183" left="850" width="189" height="19" font="3">independent predictor of both </text>
<text top="201" left="850" width="228" height="19" font="3">increased total mortality and sudden </text>
<text top="219" left="850" width="161" height="19" font="3">death in patients with HF. </text>
<text top="238" left="850" width="3" height="19" font="3"> </text>
<text top="367" left="131" width="114" height="19" font="3">● Perez-Rodon, et </text>
<text top="386" left="131" width="79" height="19" font="3">al. 2014 (21) </text>
<text top="404" left="131" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24993462">● </a></text>
<text top="404" left="144" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24993462">24993462</a></text>
<text top="404" left="204" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24993462"> </a></text>
<text top="422" left="131" width="3" height="19" font="3"> </text>
<text top="367" left="259" width="162" height="19" font="4"><b>Study type:</b> Retrospective </text>
<text top="386" left="259" width="169" height="19" font="3">observational study, aimed </text>
<text top="404" left="259" width="166" height="19" font="3">at studying the association </text>
<text top="422" left="259" width="134" height="19" font="3">between specific ECG </text>
<text top="441" left="259" width="114" height="19" font="3">abnormalities and </text>
<text top="459" left="259" width="158" height="19" font="3">mortality in patients with </text>
<text top="477" left="259" width="169" height="19" font="3">syncope from the GESINUR </text>
<text top="496" left="259" width="41" height="19" font="3">study. </text>
<text top="514" left="259" width="3" height="19" font="4"><b> </b></text>
<text top="532" left="259" width="111" height="19" font="4"><b>Size:</b> 524 patients<b> </b></text>
<text top="550" left="259" width="3" height="19" font="3"> </text>
<text top="367" left="444" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="386" left="444" width="150" height="19" font="3">Patients in the GESINUR </text>
<text top="404" left="444" width="147" height="19" font="3">study who had syncope </text>
<text top="422" left="444" width="114" height="19" font="3">and had available, </text>
<text top="441" left="444" width="153" height="19" font="3">readable ECG and 12 mo </text>
<text top="459" left="444" width="92" height="19" font="3">follow-up data </text>
<text top="368" left="619" width="197" height="19" font="4"><b>1</b>°<b> endpoint:</b> all-cause mortality </text>
<text top="386" left="619" width="3" height="19" font="3"> </text>
<text top="405" left="619" width="191" height="19" font="4"><b>Results</b>: Abnormal ECGs in 344 </text>
<text top="423" left="619" width="110" height="19" font="3">patients (65.6%).  </text>
<text top="441" left="619" width="206" height="19" font="3">33 Patients died during follow-up </text>
<text top="460" left="619" width="46" height="19" font="3">(6.3%): </text>
<text top="477" left="619" width="108" height="20" font="3">-  1 due to SCD </text>
<text top="495" left="619" width="215" height="20" font="3">-  Atrial fibrillation (OR: 6.8; 95% </text>
<text top="515" left="646" width="137" height="19" font="3">CI: 2.8–16.3, p&lt;0.001) </text>
<text top="532" left="619" width="197" height="20" font="3">-  intraventricular conduction </text>
<text top="551" left="646" width="186" height="19" font="3">disturbances (OR: 3.8; 95% CI: </text>
<text top="570" left="646" width="117" height="19" font="3">1.7–8.3; p=0.001),  </text>
<text top="587" left="619" width="199" height="20" font="3">-  LV hypertrophy ECG criteria </text>
<text top="606" left="646" width="165" height="19" font="3">(OR: 6.3, 95% CI: 1.5–26.3; </text>
<text top="624" left="646" width="61" height="19" font="3">p=0.011)  </text>
<text top="641" left="619" width="199" height="20" font="3">-  ventricular pacing (OR 21.8, </text>
<text top="661" left="646" width="169" height="19" font="3">95% CI 4.1–115.3, P &lt;.001) <b> </b></text>
<text top="367" left="850" width="195" height="19" font="3">● Although an abnormal ECG in </text>
<text top="386" left="850" width="218" height="19" font="3">patients with syncope is a common </text>
<text top="404" left="850" width="212" height="19" font="3">finding, only the presence of atrial </text>
<text top="422" left="850" width="168" height="19" font="3">fibrillation, intraventricular </text>
<text top="441" left="850" width="181" height="19" font="3">conduction disturbances, left </text>
<text top="459" left="850" width="227" height="19" font="3">ventricular hypertrophy ECG criteria, </text>
<text top="477" left="850" width="219" height="19" font="3">and ventricular pacing is associated </text>
<text top="496" left="850" width="193" height="19" font="3">with 1-year all-cause mortality. </text>
</page>
<page number="14" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">14 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="595" height="21" font="2"><b>Data Supplement 3. RCTs Comparing Ambulatory Electrocardiography – (Section 4.2.2) </b></text>
<text top="129" left="131" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="147" left="157" width="55" height="19" font="4"><b>Author;  </b></text>
<text top="165" left="134" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="129" left="267" width="88" height="19" font="4"><b>Aim of Study; </b></text>
<text top="147" left="273" width="76" height="19" font="4"><b>Study Type; </b></text>
<text top="165" left="266" width="89" height="19" font="4"><b>Study Size (N) </b></text>
<text top="129" left="404" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="129" left="573" width="123" height="19" font="4"><b>Study Intervention  </b></text>
<text top="147" left="591" width="88" height="19" font="4"><b>(# patients) /  </b></text>
<text top="165" left="574" width="121" height="19" font="4"><b>Study Comparator  </b></text>
<text top="184" left="595" width="75" height="19" font="4"><b>(# patients) </b></text>
<text top="129" left="734" width="108" height="19" font="4"><b>Endpoint Results </b></text>
<text top="147" left="737" width="102" height="19" font="4"><b>(Absolute Event </b></text>
<text top="165" left="767" width="45" height="19" font="4"><b>Rates,  </b></text>
<text top="184" left="720" width="136" height="19" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="202" left="763" width="49" height="19" font="4"><b>95% CI) </b></text>
<text top="129" left="880" width="186" height="19" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="148" left="915" width="116" height="19" font="4"><b>Study Limitations; </b></text>
<text top="166" left="924" width="99" height="19" font="4"><b>Adverse Events </b></text>
<text top="221" left="123" width="93" height="19" font="3">● Barrett et al. </text>
<text top="239" left="123" width="62" height="19" font="3">2014 (22) </text>
<text top="258" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24384108">● </a></text>
<text top="258" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24384108">24384108</a></text>
<text top="258" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24384108"> </a></text>
<text top="276" left="123" width="3" height="19" font="3"> </text>
<text top="221" left="254" width="95" height="19" font="4"><b>Aim:</b>  Compare </text>
<text top="239" left="254" width="99" height="19" font="3">Holter to a 14 d </text>
<text top="258" left="254" width="99" height="19" font="3">patch electrode </text>
<text top="276" left="254" width="3" height="19" font="3"> </text>
<text top="294" left="254" width="110" height="19" font="4"><b>Study type:</b> Head </text>
<text top="313" left="254" width="50" height="19" font="3">to head </text>
<text top="331" left="254" width="79" height="19" font="3">comparison, </text>
<text top="349" left="254" width="85" height="19" font="3">simultaneous </text>
<text top="368" left="254" width="3" height="19" font="3"> </text>
<text top="386" left="254" width="45" height="19" font="4"><b>Size:</b>     </text>
<text top="404" left="254" width="42" height="19" font="3">146 pt </text>
<text top="221" left="380" width="168" height="19" font="4"><b>Inclusion criteria:</b>  patients </text>
<text top="239" left="380" width="151" height="19" font="3">for evaluation of cardiac </text>
<text top="258" left="380" width="71" height="19" font="3">arrhythmia </text>
<text top="276" left="380" width="3" height="19" font="3"> </text>
<text top="294" left="380" width="148" height="19" font="4"><b>Exclusion criteria:</b>   skin </text>
<text top="313" left="380" width="145" height="19" font="3">allergies, conditions, or </text>
<text top="331" left="380" width="156" height="19" font="3">sensitivities to any of the </text>
<text top="349" left="380" width="95" height="19" font="3">components of </text>
<text top="368" left="380" width="119" height="19" font="3">the adhesive patch </text>
<text top="386" left="380" width="131" height="19" font="3">monitor, receiving or </text>
<text top="404" left="380" width="136" height="19" font="3">anticipated to receive </text>
<text top="423" left="380" width="152" height="19" font="3">pacing or external direct </text>
<text top="441" left="380" width="155" height="19" font="3">current cardioversion, or </text>
<text top="459" left="380" width="153" height="19" font="3">the anticipation of being </text>
<text top="478" left="380" width="166" height="19" font="3">exposed to high-frequency </text>
<text top="496" left="380" width="163" height="19" font="3">surgical equipment during </text>
<text top="514" left="380" width="138" height="19" font="3">the monitoring period </text>
<text top="221" left="562" width="115" height="19" font="4"><b>Intervention:</b> 24 h </text>
<text top="239" left="562" width="98" height="19" font="3">Holter and 14 d </text>
<text top="258" left="562" width="95" height="19" font="3">adhesive patch </text>
<text top="276" left="562" width="7" height="19" font="3">  </text>
<text top="294" left="562" width="83" height="19" font="4"><b>Comparator:</b> </text>
<text top="313" left="562" width="79" height="19" font="3">Detection of </text>
<text top="331" left="562" width="134" height="19" font="3">arrhythmia over total </text>
<text top="349" left="562" width="69" height="19" font="3">wear time. </text>
<text top="368" left="562" width="65" height="19" font="3">Any 1 of 6 </text>
<text top="386" left="562" width="139" height="19" font="3">arrhythmias, including </text>
<text top="404" left="562" width="103" height="19" font="3">supraventricular </text>
<text top="423" left="562" width="78" height="19" font="3">tachycardia, </text>
<text top="441" left="562" width="107" height="19" font="3">AF/flutter, pause </text>
<text top="459" left="562" width="120" height="19" font="3">greater than 3s, AV </text>
<text top="478" left="562" width="79" height="19" font="3">block, VT, or </text>
<text top="496" left="562" width="124" height="19" font="3">polymorphic VT/VF. </text>
<text top="514" left="562" width="3" height="19" font="4"><b> </b></text>
<text top="222" left="717" width="85" height="19" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="240" left="717" width="141" height="19" font="3">Adhesive 96, Holter 61 </text>
<text top="258" left="717" width="106" height="19" font="3">events (p&lt;0.001) </text>
<text top="277" left="717" width="3" height="19" font="3"> </text>
<text top="295" left="717" width="3" height="19" font="4"><b> </b></text>
<text top="221" left="872" width="134" height="19" font="3">● Prolonged duration </text>
<text top="239" left="872" width="170" height="19" font="3">monitoring for detection of </text>
<text top="258" left="872" width="189" height="19" font="3">arrhythmia events using single </text>
<text top="276" left="872" width="128" height="19" font="3">lead, less-obtrusive,  </text>
<text top="294" left="872" width="169" height="19" font="3">Adhesive-patch monitoring </text>
<text top="313" left="872" width="148" height="19" font="3">platforms could replace </text>
<text top="331" left="872" width="196" height="19" font="3">conventional Holter monitoring </text>
<text top="349" left="872" width="143" height="19" font="3">in patients referred for </text>
<text top="368" left="872" width="177" height="19" font="3">ambulatory ECG monitoring. </text>
<text top="386" left="872" width="3" height="19" font="3"> </text>
<text top="404" left="872" width="3" height="19" font="3"> </text>
<text top="423" left="872" width="3" height="19" font="3"> </text>
<text top="533" left="123" width="110" height="19" font="3">● de Asmundis et </text>
<text top="552" left="123" width="79" height="19" font="3">al. 2014 (23) </text>
<text top="570" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24574492">● </a></text>
<text top="570" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24574492">24574492</a></text>
<text top="570" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24574492"> </a></text>
<text top="588" left="127" width="3" height="19" font="4"><b> </b></text>
<text top="533" left="254" width="86" height="19" font="4"><b>Aim:</b>  head to </text>
<text top="552" left="254" width="109" height="19" font="3">head comparison </text>
<text top="570" left="254" width="87" height="19" font="3">of 24 h Holter </text>
<text top="588" left="254" width="91" height="19" font="3">and hand held </text>
<text top="606" left="254" width="108" height="19" font="3">patient-activated </text>
<text top="625" left="254" width="86" height="19" font="3">even monitor </text>
<text top="643" left="254" width="64" height="19" font="3">(not loop) </text>
<text top="661" left="254" width="3" height="19" font="3"> </text>
<text top="680" left="254" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="698" left="254" width="68" height="19" font="3">Sequential </text>
<text top="716" left="254" width="75" height="19" font="3">comparison </text>
<text top="735" left="254" width="82" height="19" font="3">(Holter, then </text>
<text top="753" left="254" width="67" height="19" font="3">monitor)    </text>
<text top="771" left="254" width="3" height="19" font="3"> </text>
<text top="533" left="380" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="552" left="380" width="138" height="19" font="3">Indication for monitor </text>
<text top="570" left="380" width="124" height="19" font="3">(palpitations 92.3%, </text>
<text top="588" left="380" width="95" height="19" font="3">dizziness 7.7%) </text>
<text top="606" left="380" width="3" height="19" font="3"> </text>
<text top="625" left="380" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="643" left="380" width="156" height="19" font="3">presence of a pacemaker </text>
<text top="661" left="380" width="120" height="19" font="3">or an ICD, syncope, </text>
<text top="680" left="380" width="99" height="19" font="3">structural heart </text>
<text top="698" left="380" width="86" height="19" font="3">diseases, ECG </text>
<text top="716" left="380" width="163" height="19" font="3">abnormalities, and a Hx of </text>
<text top="735" left="380" width="159" height="19" font="3">documented arrhythmia.  </text>
<text top="533" left="562" width="115" height="19" font="4"><b>Intervention:</b> 24 h </text>
<text top="552" left="562" width="109" height="19" font="3">monitor and 15 d </text>
<text top="570" left="562" width="66" height="19" font="3">HeartScan </text>
<text top="588" left="562" width="7" height="19" font="3">  </text>
<text top="606" left="562" width="133" height="19" font="4"><b>Comparator:</b> Percent </text>
<text top="625" left="562" width="138" height="19" font="3">diagnosis of symptom-</text>
<text top="643" left="562" width="134" height="19" font="3">related arrhythmias <b>   </b></text>
<text top="534" left="717" width="131" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Clinical </text>
<text top="552" left="717" width="81" height="19" font="3">diagnosis for </text>
<text top="571" left="717" width="71" height="19" font="3">symptoms: </text>
<text top="589" left="717" width="75" height="19" font="3">Holter 1.8% </text>
<text top="607" left="717" width="95" height="19" font="3">HeartScan 89% </text>
<text top="626" left="717" width="55" height="19" font="3">(p&lt;0.01) </text>
<text top="644" left="717" width="3" height="19" font="3"> </text>
<text top="662" left="717" width="3" height="19" font="4"><b> </b></text>
<text top="533" left="872" width="164" height="19" font="3">● Longer time and patient-</text>
<text top="552" left="872" width="174" height="19" font="3">activated monitor improved </text>
<text top="570" left="872" width="163" height="19" font="3">yield. This was NOT a loop </text>
<text top="588" left="872" width="56" height="19" font="3">recorder </text>
<text top="606" left="872" width="3" height="19" font="3"> </text>
<text top="625" left="872" width="3" height="19" font="3"> </text>
<text top="643" left="872" width="3" height="19" font="3"> </text>
</page>
<page number="15" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">15 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="254" width="45" height="19" font="4"><b>Size:</b>     </text>
<text top="127" left="254" width="26" height="19" font="3">625 </text>
<text top="231" left="115" width="863" height="21" font="2"><b>Data Supplement 4. Nonrandomized Trials, Observational Studies, and/or Registries of Ambulatory Monitors – (Section 4.2.2) </b></text>
<text top="252" left="143" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="270" left="169" width="51" height="19" font="4"><b>Author; </b></text>
<text top="288" left="147" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="252" left="282" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="270" left="311" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="252" left="433" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="252" left="623" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="270" left="635" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="288" left="667" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="252" left="886" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="270" left="914" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="307" left="123" width="136" height="19" font="3">● Turakhia et al. 2013 </text>
<text top="326" left="123" width="31" height="19" font="3">(24)  </text>
<text top="344" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23672988">● </a></text>
<text top="344" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23672988">23672988</a></text>
<text top="344" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23672988"> </a></text>
<text top="363" left="127" width="3" height="19" font="3"> </text>
<text top="307" left="279" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="326" left="279" width="87" height="19" font="3">observational </text>
<text top="344" left="279" width="3" height="19" font="3"> </text>
<text top="362" left="279" width="77" height="19" font="4"><b>Size:</b> 26,751 </text>
<text top="307" left="422" width="136" height="19" font="4"><b>Inclusion criteria:</b>  Zio </text>
<text top="326" left="422" width="44" height="19" font="3">placed </text>
<text top="344" left="422" width="3" height="19" font="3"> </text>
<text top="362" left="422" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="381" left="422" width="27" height="19" font="3">N/A </text>
<text top="308" left="576" width="225" height="19" font="4"><b>1</b>°<b> endpoint:</b>  evaluated compliance, </text>
<text top="327" left="576" width="207" height="19" font="3">analyzable signal time, interval to </text>
<text top="345" left="576" width="228" height="19" font="3">arrhythmia detection, and diagnostic </text>
<text top="363" left="576" width="135" height="19" font="3">yield of the Zio Patch, </text>
<text top="382" left="576" width="238" height="19" font="3">COMPARED: first 48h with later (mean </text>
<text top="400" left="576" width="38" height="19" font="3">7.6 d) </text>
<text top="418" left="576" width="3" height="19" font="3"> </text>
<text top="436" left="576" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="455" left="576" width="199" height="19" font="3">Any arrhythmia: 62.2% vs 43.9% </text>
<text top="473" left="576" width="241" height="19" font="3">Symptomatic arrhythmia: 9.7% vs 4.4% </text>
<text top="491" left="576" width="104" height="19" font="3">VT 187 pt (0.7%) </text>
<text top="510" left="576" width="162" height="19" font="3">PMVT, TdP, VF 6 pt (0.0%) </text>
<text top="307" left="834" width="234" height="19" font="3">● Demonstrates yield and compliance </text>
<text top="326" left="834" width="219" height="19" font="3">with patch monitor although VT/VF </text>
<text top="344" left="834" width="139" height="19" font="3">not a major issue here </text>
<text top="363" left="834" width="3" height="19" font="3"> </text>
<text top="381" left="834" width="3" height="19" font="3"> </text>
<text top="529" left="123" width="119" height="19" font="3">● Linzer et al. 1990 </text>
<text top="547" left="123" width="28" height="19" font="3">(25) </text>
<text top="565" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2371954">● </a></text>
<text top="565" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2371954">2371954</a></text>
<text top="565" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2371954"> </a></text>
<text top="584" left="123" width="3" height="19" font="3"> </text>
<text top="602" left="123" width="3" height="19" font="3"> </text>
<text top="620" left="150" width="3" height="19" font="3"> </text>
<text top="529" left="279" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="547" left="279" width="87" height="19" font="3">observational </text>
<text top="565" left="279" width="3" height="19" font="3"> </text>
<text top="584" left="279" width="50" height="19" font="4"><b>Size:</b> 57 </text>
<text top="529" left="422" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="547" left="422" width="141" height="19" font="3">Syncope with negative </text>
<text top="565" left="422" width="42" height="19" font="3">Holter </text>
<text top="584" left="422" width="3" height="19" font="3"> </text>
<text top="602" left="422" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="620" left="422" width="109" height="19" font="3">Patients who had </text>
<text top="639" left="422" width="95" height="19" font="3">undergone EPS </text>
<text top="529" left="576" width="238" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Monitor up to 1 mo with </text>
<text top="548" left="576" width="33" height="19" font="3">Loop </text>
<text top="566" left="576" width="3" height="19" font="3"> </text>
<text top="584" left="576" width="232" height="19" font="4"><b>Results:</b>  arrhythmia was the cause of </text>
<text top="603" left="576" width="137" height="19" font="3">symptoms (diagnostic </text>
<text top="621" left="576" width="175" height="19" font="3">yield 25%; 95% CI: 14–38%). </text>
<text top="640" left="576" width="215" height="19" font="3">VT (1 patient), high grade AV block </text>
<text top="658" left="576" width="174" height="19" font="3">(2 patients), SVT (1 patient), </text>
<text top="676" left="576" width="242" height="19" font="3">asystole or junctional bradycardia from </text>
<text top="694" left="576" width="188" height="19" font="3">neutrally mediated syncope (3 </text>
<text top="713" left="576" width="178" height="19" font="3">patients) and normal cardiac </text>
<text top="731" left="576" width="220" height="19" font="3">rhythms (the remaining 7 patients). </text>
<text top="529" left="834" width="201" height="19" font="3">● 25% yield for syncope Dx after </text>
<text top="547" left="834" width="98" height="19" font="3">negative Holter </text>
<text top="565" left="834" width="162" height="19" font="3">● VT/VF uncommon (1 pt) </text>
</page>
<page number="16" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">16 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="906" height="21" font="2"><b>Data Supplement 5. Nonrandomized Trials, Observational Studies, and/or Registries of Implanted Cardiac Monitors – (Section 4.2.3) </b></text>
<text top="129" left="145" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="147" left="170" width="51" height="19" font="4"><b>Author; </b></text>
<text top="165" left="148" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="129" left="293" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="147" left="322" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="129" left="476" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="129" left="656" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="147" left="669" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="165" left="700" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="129" left="886" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="147" left="914" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="184" left="123" width="134" height="19" font="3">● Turakhia et al. Am J </text>
<text top="203" left="123" width="85" height="19" font="3">Car 2013 (24) </text>
<text top="221" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23672988">● </a></text>
<text top="221" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23672988">23672988</a></text>
<text top="221" left="197" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23672988"><b> </b></a></text>
<text top="184" left="282" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="203" left="282" width="87" height="19" font="3">observational </text>
<text top="221" left="282" width="3" height="19" font="3"> </text>
<text top="239" left="282" width="77" height="19" font="4"><b>Size:</b> 26,751<b> </b></text>
<text top="184" left="442" width="180" height="19" font="4"><b>Inclusion criteria:</b>  Zio placed </text>
<text top="203" left="442" width="3" height="19" font="3"> </text>
<text top="221" left="442" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="185" left="643" width="148" height="19" font="4"><b>1</b>°<b> endpoint:</b>  evaluated </text>
<text top="204" left="643" width="145" height="19" font="3">compliance, analyzable </text>
<text top="222" left="643" width="139" height="19" font="3">signal time, interval to </text>
<text top="240" left="643" width="163" height="19" font="3">arrhythmia detection, and </text>
<text top="258" left="643" width="159" height="19" font="3">diagnostic yield of the Zio </text>
<text top="277" left="643" width="38" height="19" font="3">Patch </text>
<text top="295" left="643" width="167" height="19" font="3">COMPARED: first 48 h with </text>
<text top="314" left="643" width="112" height="19" font="3">later (mean 7.6 d) </text>
<text top="332" left="643" width="3" height="19" font="3"> </text>
<text top="350" left="643" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="368" left="643" width="159" height="19" font="3">Any arrhythmia: 62.2% vs </text>
<text top="387" left="643" width="41" height="19" font="3">43.9% </text>
<text top="405" left="643" width="159" height="19" font="3">Symptomatic arrhythmia: </text>
<text top="423" left="643" width="82" height="19" font="3">9.7% vs 4.4% </text>
<text top="442" left="643" width="104" height="19" font="3">VT 187 pt (0.7%) </text>
<text top="460" left="643" width="156" height="19" font="3">PMVT, TdP, VF 6 patients </text>
<text top="478" left="643" width="42" height="19" font="3">(0.0%) </text>
<text top="184" left="834" width="234" height="19" font="3">● Demonstrates yield and compliance </text>
<text top="203" left="834" width="219" height="19" font="3">with patch monitor although VT/VF </text>
<text top="221" left="834" width="139" height="19" font="3">not a major issue here </text>
<text top="239" left="834" width="3" height="19" font="3"> </text>
<text top="258" left="834" width="3" height="19" font="4"><b> </b></text>
<text top="497" left="123" width="75" height="19" font="3">● <b>CARISMA</b> </text>
<text top="516" left="123" width="143" height="19" font="3">● Bloch Thomsen et al. </text>
<text top="534" left="123" width="62" height="19" font="3">2010 (26) </text>
<text top="552" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20837897">● </a></text>
<text top="552" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20837897">20837897</a></text>
<text top="552" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20837897"> </a></text>
<text top="570" left="123" width="3" height="19" font="4"><b> </b></text>
<text top="589" left="123" width="3" height="19" font="3"> </text>
<text top="497" left="282" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="516" left="282" width="87" height="19" font="3">observational </text>
<text top="534" left="282" width="3" height="19" font="3"> </text>
<text top="552" left="282" width="32" height="19" font="4"><b>Size: </b></text>
<text top="571" left="282" width="102" height="19" font="3">297 participants </text>
<text top="497" left="442" width="170" height="19" font="4"><b>Inclusion criteria:</b>  AMI and </text>
<text top="516" left="442" width="86" height="19" font="3">reduced LVEF </text>
<text top="534" left="442" width="3" height="19" font="3"> </text>
<text top="552" left="442" width="169" height="19" font="4"><b>Exclusion criteria:</b>  Refusal; </text>
<text top="571" left="442" width="155" height="19" font="3">inability of the patient to </text>
<text top="589" left="442" width="145" height="19" font="3">participate in the study </text>
<text top="607" left="442" width="153" height="19" font="3">because of other serious </text>
<text top="626" left="442" width="97" height="19" font="3">illness (N=312), </text>
<text top="644" left="442" width="188" height="19" font="3">planned coronary bypass graft </text>
<text top="662" left="442" width="160" height="19" font="3">surgery (N=184), or death </text>
<text top="680" left="442" width="49" height="19" font="3">(N=89). </text>
<text top="498" left="643" width="173" height="19" font="4"><b>1</b>°<b> endpoint:</b>  incidence and </text>
<text top="516" left="643" width="158" height="19" font="3">prognostic significance of </text>
<text top="535" left="643" width="157" height="19" font="3">arrhythmias post MI with </text>
<text top="553" left="643" width="86" height="19" font="3">reduced LVEF </text>
<text top="571" left="643" width="3" height="19" font="3"> </text>
<text top="590" left="643" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="608" left="643" width="65" height="19" font="3">Brady and </text>
<text top="626" left="643" width="161" height="19" font="3">tachyarrhythmia’s seen in </text>
<text top="645" left="643" width="152" height="19" font="3">137 patients (46%), with </text>
<text top="663" left="643" width="152" height="19" font="3">86% asymptomatic. 13% </text>
<text top="681" left="643" width="174" height="19" font="3">incidence of NSVT (≥16 bts), </text>
<text top="699" left="643" width="165" height="19" font="3">3% sustained VT (≥30 sec), </text>
<text top="718" left="643" width="160" height="19" font="3">3% VF (≥16 bts). Also 28% </text>
<text top="736" left="643" width="169" height="19" font="3">AF with fast vent response; </text>
<text top="755" left="643" width="165" height="19" font="3">10% high degree AV block; </text>
<text top="497" left="834" width="174" height="19" font="3">● Intermittent AV block was </text>
<text top="516" left="834" width="204" height="19" font="3">associated with “very high risk of </text>
<text top="534" left="834" width="92" height="19" font="3">cardiac death” </text>
<text top="552" left="834" width="3" height="19" font="3"> </text>
</page>
<page number="17" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">17 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="643" width="154" height="19" font="3">7% sinus brady, 5% sinus </text>
<text top="127" left="643" width="43" height="19" font="3">arrest  </text>
<text top="146" left="123" width="119" height="19" font="3">● Linzer et al. 1990 </text>
<text top="164" left="123" width="28" height="19" font="3">(25) </text>
<text top="183" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2371954">● </a></text>
<text top="183" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2371954">2371954</a></text>
<text top="183" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2371954"> </a></text>
<text top="201" left="127" width="3" height="19" font="3"> </text>
<text top="146" left="282" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="164" left="282" width="87" height="19" font="3">observational </text>
<text top="183" left="282" width="3" height="19" font="3"> </text>
<text top="201" left="282" width="45" height="19" font="4"><b>Size:</b>     </text>
<text top="219" left="282" width="94" height="19" font="3">57 participants </text>
<text top="146" left="442" width="169" height="19" font="4"><b>Inclusion criteria:</b>  Syncope </text>
<text top="164" left="442" width="128" height="19" font="3">with negative Holter </text>
<text top="183" left="442" width="3" height="19" font="3"> </text>
<text top="201" left="442" width="179" height="19" font="4"><b>Exclusion criteria:</b>  Prior EPS. </text>
<text top="147" left="643" width="174" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Monitor up to </text>
<text top="165" left="643" width="98" height="19" font="3">1 mo with Loop </text>
<text top="183" left="643" width="3" height="19" font="3"> </text>
<text top="202" left="643" width="154" height="19" font="4"><b>Results:</b>  arrhythmia was </text>
<text top="220" left="643" width="144" height="19" font="3">the cause of symptoms </text>
<text top="238" left="643" width="165" height="19" font="3">(diagnostic yield 25%; 95% </text>
<text top="257" left="643" width="166" height="19" font="3">CI 14–38%). VT (1 patient), </text>
<text top="275" left="643" width="140" height="19" font="3">high grade AV block (2 </text>
<text top="293" left="643" width="159" height="19" font="3">patients), SVT (1 patient), </text>
<text top="312" left="643" width="133" height="19" font="3">asystole or junctional </text>
<text top="330" left="643" width="166" height="19" font="3">bradycardia from neutrally </text>
<text top="348" left="643" width="131" height="19" font="3">mediated syncope (3 </text>
<text top="367" left="643" width="131" height="19" font="3">patients) and normal </text>
<text top="385" left="643" width="129" height="19" font="3">cardiac rhythms (the </text>
<text top="403" left="643" width="137" height="19" font="3">remaining 7 patients). </text>
<text top="146" left="834" width="209" height="19" font="3">● 25% yield for syncope diagnosis </text>
<text top="164" left="834" width="130" height="19" font="3">after negative Holter </text>
<text top="183" left="834" width="3" height="19" font="3"> </text>
<text top="201" left="834" width="3" height="19" font="3"> </text>
<text top="422" left="123" width="128" height="19" font="3">● Volosin et al. 2013 </text>
<text top="441" left="123" width="28" height="19" font="3">(27) </text>
<text top="459" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23439867">● </a></text>
<text top="459" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23439867">23439867</a></text>
<text top="459" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23439867"> </a></text>
<text top="477" left="127" width="3" height="19" font="3"> </text>
<text top="422" left="282" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="441" left="282" width="113" height="19" font="3">Observational, for </text>
<text top="459" left="282" width="127" height="19" font="3">CareLink monitoring </text>
<text top="477" left="282" width="46" height="19" font="3">service </text>
<text top="495" left="282" width="45" height="19" font="4"><b>Size:</b>     </text>
<text top="514" left="282" width="132" height="19" font="3">2190 patients overall </text>
<text top="532" left="282" width="140" height="19" font="3">who transmitted data. </text>
<text top="550" left="282" width="130" height="19" font="3">Also studied induced </text>
<text top="569" left="282" width="77" height="19" font="3">arrhythmias </text>
<text top="422" left="442" width="171" height="19" font="4"><b>Inclusion criteria:</b>   Patients </text>
<text top="441" left="442" width="185" height="19" font="3">who transmitted data studied </text>
<text top="459" left="442" width="166" height="19" font="3">with induced VA at time of </text>
<text top="477" left="442" width="124" height="19" font="3">ICD implant testing. </text>
<text top="496" left="442" width="3" height="19" font="3"> </text>
<text top="514" left="442" width="173" height="19" font="4"><b>Exclusion criteria:</b>   Patients </text>
<text top="532" left="442" width="173" height="19" font="3">who did not transmit over 4 </text>
<text top="550" left="442" width="67" height="19" font="3">mo period </text>
<text top="423" left="643" width="140" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Evaluate </text>
<text top="441" left="643" width="152" height="19" font="3">tachycardia detection of </text>
<text top="460" left="643" width="126" height="19" font="3">device and software </text>
<text top="478" left="643" width="3" height="19" font="3"> </text>
<text top="496" left="643" width="159" height="19" font="4"><b>Results:</b>  15.1% had VT or </text>
<text top="515" left="643" width="174" height="19" font="3">FVT detected, although true </text>
<text top="533" left="643" width="167" height="19" font="3">VT was seen in only 10.4%. </text>
<text top="551" left="643" width="109" height="19" font="3">For induced 1909 </text>
<text top="570" left="643" width="131" height="19" font="3">tachycardia episodes </text>
<text top="588" left="643" width="145" height="19" font="3">reviewed. Sensitivity of </text>
<text top="606" left="643" width="108" height="19" font="3">VT/VF was 99.3% </text>
<text top="422" left="834" width="234" height="19" font="3">● Sensitivity is high (96.5% or 99.3% if </text>
<text top="441" left="834" width="171" height="19" font="3">programmed for slower VT. </text>
<text top="459" left="834" width="190" height="19" font="3">● Shows excellent detection in </text>
<text top="477" left="834" width="139" height="19" font="3">artificial environment. </text>
<text top="496" left="834" width="3" height="19" font="3"> </text>
<text top="625" left="123" width="119" height="19" font="3">● Krahn et al. 1999 </text>
<text top="643" left="123" width="28" height="19" font="3">(28) </text>
<text top="662" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9918528">● </a></text>
<text top="662" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9918528">9918528</a></text>
<text top="662" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9918528"> </a></text>
<text top="680" left="123" width="3" height="19" font="3"> </text>
<text top="625" left="282" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="643" left="282" width="89" height="19" font="3">Observational </text>
<text top="662" left="282" width="3" height="19" font="3"> </text>
<text top="680" left="282" width="45" height="19" font="4"><b>Size:</b>     </text>
<text top="698" left="282" width="18" height="19" font="3">85 </text>
<text top="625" left="442" width="176" height="19" font="4"><b>Inclusion criteria:</b>  recurrent </text>
<text top="643" left="442" width="135" height="19" font="3">undiagnosed syncope </text>
<text top="662" left="442" width="3" height="19" font="3"> </text>
<text top="680" left="442" width="184" height="19" font="4"><b>Exclusion criteria:</b>  unlikely to </text>
<text top="698" left="442" width="164" height="19" font="3">survive 1y, were unable to </text>
<text top="717" left="442" width="180" height="19" font="3">give informed consent, had a </text>
<text top="735" left="442" width="132" height="19" font="3">previously implanted </text>
<text top="753" left="442" width="145" height="19" font="3">programmable medical </text>
<text top="772" left="442" width="160" height="19" font="3">device, were pregnant, or </text>
<text top="626" left="643" width="164" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Detection of </text>
<text top="644" left="643" width="140" height="19" font="3">arrhythmias related to </text>
<text top="663" left="643" width="149" height="19" font="3">recurrent syncope, with </text>
<text top="681" left="643" width="75" height="19" font="3">prior Holter </text>
<text top="699" left="643" width="3" height="19" font="3"> </text>
<text top="718" left="643" width="169" height="19" font="4"><b>Results:</b>  68% had syncope. </text>
<text top="736" left="643" width="149" height="19" font="3">Arrhythmia seen in 42% </text>
<text top="754" left="643" width="153" height="19" font="3">who transmitted rhythm </text>
<text top="773" left="643" width="113" height="19" font="3">during symptoms. </text>
<text top="625" left="834" width="187" height="19" font="3">● Demonstrates utility of loop </text>
<text top="643" left="834" width="189" height="19" font="3">although no VT/VF seen in this </text>
<text top="662" left="834" width="135" height="19" font="3">relatively small study. </text>
<text top="680" left="834" width="3" height="19" font="3"> </text>
<text top="698" left="834" width="3" height="19" font="3"> </text>
</page>
<page number="18" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">18 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="442" width="178" height="19" font="3">were women of childbearing </text>
<text top="127" left="442" width="162" height="19" font="3">potential not on a reliable </text>
<text top="145" left="442" width="142" height="19" font="3">form of contraception. </text>
<text top="109" left="643" width="144" height="19" font="3">Bradyarrhythmia in 18, </text>
<text top="127" left="643" width="176" height="19" font="3">tachyarrhythmia in 3 (SVT 2, </text>
<text top="145" left="643" width="104" height="19" font="3">AFL 1; no VT/VF) </text>
<text top="164" left="643" width="3" height="19" font="3"> </text>
<text top="183" left="123" width="128" height="19" font="3">● Solbiati et al. 2016 </text>
<text top="201" left="123" width="28" height="19" font="3">(29) </text>
<text top="219" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27092427">● </a></text>
<text top="219" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27092427">27092427</a></text>
<text top="219" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27092427"> </a></text>
<text top="238" left="127" width="7" height="19" font="3">  </text>
<text top="183" left="282" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="201" left="282" width="118" height="19" font="3">Systematic review, </text>
<text top="219" left="282" width="88" height="19" font="3">Meta-analysis </text>
<text top="238" left="282" width="3" height="19" font="3"> </text>
<text top="256" left="282" width="45" height="19" font="4"><b>Size:</b>     </text>
<text top="274" left="282" width="128" height="19" font="3">579 participants in 4 </text>
<text top="292" left="282" width="34" height="19" font="3">trials </text>
<text top="183" left="442" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="201" left="442" width="144" height="19" font="3">Unexplained Recurrent </text>
<text top="219" left="442" width="172" height="19" font="3">Syncope, evaluation of loop </text>
<text top="238" left="442" width="178" height="19" font="3">recorder vs no loop recorder </text>
<text top="256" left="442" width="3" height="19" font="3"> </text>
<text top="274" left="442" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="183" left="643" width="165" height="19" font="4"><b>1</b>°<b> endpoint:</b> To assess the </text>
<text top="202" left="643" width="172" height="19" font="3">incidence of mortality, QoL, </text>
<text top="220" left="643" width="172" height="19" font="3">adverse events and costs of </text>
<text top="239" left="643" width="130" height="19" font="3">ILRs vs. conventional </text>
<text top="257" left="643" width="175" height="19" font="3">diagnostic workup in people </text>
<text top="275" left="643" width="162" height="19" font="3">with unexplained syncope </text>
<text top="293" left="643" width="7" height="19" font="3">  </text>
<text top="311" left="643" width="157" height="19" font="4"><b>Results:</b>  No difference in </text>
<text top="330" left="643" width="123" height="19" font="3">long-term mortality </text>
<text top="348" left="643" width="3" height="19" font="3"> </text>
<text top="367" left="643" width="162" height="19" font="3">2 studies showed trend of </text>
<text top="385" left="643" width="131" height="19" font="3">reduction in syncope </text>
<text top="403" left="643" width="171" height="19" font="3">relapse after diagnosis with </text>
<text top="422" left="643" width="45" height="19" font="3">the ILR </text>
<text top="440" left="643" width="3" height="19" font="3"> </text>
<text top="458" left="643" width="176" height="19" font="3">Higher rate of diagnosis (RR: </text>
<text top="476" left="643" width="151" height="19" font="3">0.61; 95% CI: 0.54–0.68) </text>
<text top="183" left="834" width="237" height="19" font="3">● This confirmed the advantage of the </text>
<text top="201" left="834" width="169" height="19" font="3">ILR in making a diagnosis in </text>
<text top="219" left="834" width="235" height="19" font="3">unexplained syncope, with trend seen </text>
<text top="238" left="834" width="145" height="19" font="3">in reduction of relapse. </text>
<text top="256" left="834" width="3" height="19" font="3"> </text>
<text top="274" left="834" width="3" height="19" font="3"> </text>
<text top="531" left="115" width="952" height="21" font="2"><b>Data Supplement 6. Nonrandomized Trials, Observational Studies, and/or Registries Comparing Noninvasive Cardiac Assessment– (Section </b></text>
<text top="551" left="115" width="43" height="21" font="2"><b>4.2.4)</b> </text>
<text top="572" left="123" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="591" left="149" width="55" height="19" font="4"><b>Author;  </b></text>
<text top="609" left="127" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="572" left="262" width="88" height="19" font="4"><b>Aim of Study; </b></text>
<text top="591" left="268" width="76" height="19" font="4"><b>Study Type; </b></text>
<text top="609" left="261" width="89" height="19" font="4"><b>Study Size (N) </b></text>
<text top="572" left="401" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="572" left="550" width="123" height="19" font="4"><b>Study Intervention  </b></text>
<text top="591" left="568" width="88" height="19" font="4"><b>(# patients) /  </b></text>
<text top="609" left="551" width="121" height="19" font="4"><b>Study Comparator  </b></text>
<text top="627" left="573" width="75" height="19" font="4"><b>(# patients) </b></text>
<text top="572" left="726" width="108" height="19" font="4"><b>Endpoint Results </b></text>
<text top="591" left="708" width="148" height="19" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="609" left="713" width="136" height="19" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="627" left="756" width="49" height="19" font="4"><b>95% CI) </b></text>
<text top="573" left="906" width="152" height="19" font="4"><b>Relevant 2</b>°<b> Endpoint (if </b></text>
<text top="592" left="965" width="35" height="19" font="4"><b>any); </b></text>
<text top="610" left="924" width="116" height="19" font="4"><b>Study Limitations; </b></text>
<text top="628" left="933" width="99" height="19" font="4"><b>Adverse Events </b></text>
<text top="647" left="123" width="74" height="19" font="3">● <b>VALIANT  </b></text>
<text top="666" left="123" width="85" height="19" font="3">● Solomon et </text>
<text top="684" left="123" width="79" height="19" font="3">al. 2005 (30) </text>
<text top="702" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15972864">● </a></text>
<text top="702" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15972864">15972864</a></text>
<text top="702" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15972864"> </a></text>
<text top="721" left="123" width="7" height="19" font="3">  </text>
<text top="647" left="239" width="110" height="19" font="4"><b>Aim:</b>  To evaluate </text>
<text top="666" left="239" width="132" height="19" font="3">risk and predictors of </text>
<text top="684" left="239" width="125" height="19" font="3">SCD in patients post </text>
<text top="702" left="239" width="74" height="19" font="3">MI with left </text>
<text top="721" left="239" width="69" height="19" font="3">ventricular </text>
<text top="739" left="239" width="120" height="19" font="3">dysfunction and/or </text>
<text top="757" left="239" width="20" height="19" font="3">HF </text>
<text top="775" left="239" width="3" height="19" font="3"> </text>
<text top="647" left="386" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="666" left="386" width="128" height="19" font="3">patients with first or </text>
<text top="684" left="386" width="148" height="19" font="3">subsequent MI with HF, </text>
<text top="702" left="386" width="145" height="19" font="3">LV dysfunction, or both </text>
<text top="721" left="386" width="3" height="19" font="3"> </text>
<text top="739" left="386" width="141" height="19" font="4"><b>Exclusion criteria:</b>  ICD </text>
<text top="757" left="386" width="100" height="19" font="3">in place prior to </text>
<text top="775" left="386" width="92" height="19" font="3">randomization </text>
<text top="647" left="548" width="85" height="19" font="4"><b>Intervention:</b> </text>
<text top="666" left="548" width="118" height="19" font="3">Analysis of rates of </text>
<text top="684" left="548" width="114" height="19" font="3">SCD. Evaluation of </text>
<text top="702" left="548" width="111" height="19" font="3">EF determined by </text>
<text top="721" left="548" width="113" height="19" font="3">echocardiography </text>
<text top="739" left="548" width="98" height="19" font="3">as well as other </text>
<text top="757" left="548" width="78" height="19" font="3">parameters. </text>
<text top="775" left="548" width="7" height="19" font="3">  </text>
<text top="648" left="685" width="151" height="19" font="4"><b>1</b>°<b> endpoint:</b>  The risk of </text>
<text top="667" left="685" width="183" height="19" font="3">sudden death was greatest in </text>
<text top="685" left="685" width="171" height="19" font="3">the first 30 d after MI: 1.4% </text>
<text top="703" left="685" width="170" height="19" font="3">per mo, 95% CI: 1.2%–1.6% </text>
<text top="721" left="685" width="173" height="19" font="3">and decreased to 0.14% per </text>
<text top="740" left="685" width="161" height="19" font="3">mo 95% CI:  0.11%–0.18% </text>
<text top="758" left="685" width="167" height="19" font="3">after 2 y after MI.  Patients </text>
<text top="647" left="889" width="164" height="19" font="3">● Each 5% lower LVEF was </text>
<text top="666" left="889" width="138" height="19" font="3">associated with a 21% </text>
<text top="684" left="889" width="166" height="19" font="3">increase in adjusted risk of </text>
<text top="702" left="889" width="180" height="19" font="3">SCD or CA with resuscitation. </text>
<text top="721" left="889" width="3" height="19" font="3"> </text>
<text top="739" left="889" width="3" height="19" font="3"> </text>
</page>
<page number="19" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">19 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="239" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="127" left="239" width="125" height="19" font="3">Observational study </text>
<text top="145" left="239" width="123" height="19" font="3">of patients enrolled </text>
<text top="164" left="239" width="52" height="19" font="3">in a RCT </text>
<text top="182" left="239" width="3" height="19" font="3"> </text>
<text top="200" left="239" width="130" height="19" font="4"><b>Size:</b> 14,609 patients </text>
<text top="109" left="548" width="96" height="19" font="4"><b>Comparator:</b>  <b>   </b></text>
<text top="127" left="548" width="27" height="19" font="3">N/A<b> </b></text>
<text top="109" left="685" width="173" height="19" font="3">with LVEF &lt;30% were at the </text>
<text top="127" left="685" width="127" height="19" font="3">greatest risk for SCD </text>
<text top="145" left="685" width="3" height="19" font="3"> </text>
<text top="164" left="685" width="3" height="19" font="3"> </text>
<text top="219" left="123" width="79" height="19" font="3">● <b>SCD-HEFT  </b></text>
<text top="238" left="123" width="77" height="19" font="3">● Gula et al. </text>
<text top="256" left="123" width="62" height="19" font="3">2008 (31) </text>
<text top="274" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19033019">● </a></text>
<text top="274" left="136" width="61" height="19" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19033019">19033019</a></text>
<text top="274" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19033019"> </a></text>
<text top="219" left="239" width="122" height="19" font="4"><b>Aim:</b>  To determine </text>
<text top="238" left="239" width="84" height="19" font="3">with baseline </text>
<text top="256" left="239" width="107" height="19" font="3">assessment of EF </text>
<text top="274" left="239" width="106" height="19" font="3">being performed </text>
<text top="293" left="239" width="35" height="19" font="3">using </text>
<text top="311" left="239" width="117" height="19" font="3">echocardiography, </text>
<text top="329" left="239" width="104" height="19" font="3">RNA, or contrast </text>
<text top="347" left="239" width="79" height="19" font="3">angiography </text>
<text top="366" left="239" width="84" height="19" font="3">impacted the </text>
<text top="384" left="239" width="133" height="19" font="3">likelihood of survival. </text>
<text top="402" left="239" width="3" height="19" font="3"> </text>
<text top="421" left="239" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="439" left="239" width="88" height="19" font="3">Observational </text>
<text top="457" left="239" width="120" height="19" font="3">analysis of patients </text>
<text top="476" left="239" width="119" height="19" font="3">enrolled into a RCT </text>
<text top="494" left="239" width="3" height="19" font="3"> </text>
<text top="512" left="239" width="123" height="19" font="4"><b>Size:</b> 2,521 patients </text>
<text top="219" left="386" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="238" left="386" width="145" height="19" font="3">Patients with HF, NYHA </text>
<text top="256" left="386" width="118" height="19" font="3">class II-III and LVEF </text>
<text top="274" left="386" width="37" height="19" font="3">≤35% </text>
<text top="292" left="386" width="3" height="19" font="3"> </text>
<text top="311" left="386" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="329" left="386" width="121" height="19" font="3">Contraindication to </text>
<text top="347" left="386" width="110" height="19" font="3">amiodarone or 1° </text>
<text top="366" left="386" width="95" height="19" font="3">prevention ICD </text>
<text top="219" left="548" width="118" height="19" font="4"><b>Intervention:</b> Type </text>
<text top="238" left="548" width="89" height="19" font="3">of modality to </text>
<text top="256" left="548" width="114" height="19" font="3">evaluate LVEF and </text>
<text top="274" left="548" width="112" height="19" font="3">clinical outcomes. </text>
<text top="292" left="548" width="7" height="19" font="3">  </text>
<text top="311" left="548" width="114" height="19" font="4"><b>Comparator:</b>  N/A<b> </b></text>
<text top="220" left="685" width="169" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Multivariable </text>
<text top="238" left="685" width="167" height="19" font="3">analysis showed that there </text>
<text top="257" left="685" width="178" height="19" font="3">was no significant difference </text>
<text top="275" left="685" width="175" height="19" font="3">in survival between patients </text>
<text top="293" left="685" width="145" height="19" font="3">enrolled based on LVEF </text>
<text top="312" left="685" width="125" height="19" font="3">determined RNA vs. </text>
<text top="330" left="685" width="176" height="19" font="3">echocardiography (HR: 1.06; </text>
<text top="348" left="685" width="151" height="19" font="3">95% CI: 0.88–1.28), RNA </text>
<text top="367" left="685" width="164" height="19" font="3">Vs. angiography (HR: 1.25; </text>
<text top="385" left="685" width="137" height="19" font="3">95% CI: 0.97–1.62), or </text>
<text top="403" left="685" width="133" height="19" font="3">echocardiography vs. </text>
<text top="422" left="685" width="191" height="19" font="3">angiography (HR: 1.18; 95% CI: </text>
<text top="440" left="685" width="72" height="19" font="3">0.94–1.48). </text>
<text top="458" left="685" width="3" height="19" font="3"> </text>
<text top="476" left="685" width="3" height="19" font="4"><b> </b></text>
<text top="219" left="889" width="181" height="19" font="3">● Among HF patients with an </text>
<text top="238" left="889" width="178" height="19" font="3">LVEF between 20% and 35%, </text>
<text top="256" left="889" width="182" height="19" font="3">each 5% increase in LVEF was </text>
<text top="274" left="889" width="147" height="19" font="3">associated with a lower </text>
<text top="293" left="889" width="177" height="19" font="3">mortality risk (HR: 0.81; 95% </text>
<text top="311" left="889" width="169" height="19" font="3">CI: 0.75–0.88). The findings </text>
<text top="329" left="889" width="169" height="19" font="3">were similar for each initial </text>
<text top="347" left="889" width="184" height="19" font="3">EF imaging modality, with the </text>
<text top="366" left="889" width="170" height="19" font="3">interaction term combining </text>
<text top="384" left="889" width="177" height="19" font="3">imaging method and LVEF in </text>
<text top="402" left="889" width="139" height="19" font="3">the Cox model was NS </text>
<text top="421" left="889" width="58" height="19" font="3">(p=0.71). </text>
<text top="439" left="889" width="3" height="19" font="3"> </text>
<text top="457" left="889" width="3" height="19" font="3"> </text>
<text top="567" left="115" width="853" height="21" font="2"><b>Data Supplement 7. Nonrandomized Trials, Observational Studies, and/or Registries Comparing Biomarkers – (Section 4.2.5) </b></text>
<text top="588" left="126" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="606" left="151" width="55" height="19" font="4"><b>Author;  </b></text>
<text top="625" left="129" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="588" left="266" width="88" height="19" font="4"><b>Aim of Study; </b></text>
<text top="606" left="272" width="76" height="19" font="4"><b>Study Type; </b></text>
<text top="625" left="266" width="89" height="19" font="4"><b>Study Size (N) </b></text>
<text top="588" left="404" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="588" left="560" width="123" height="19" font="4"><b>Study Intervention  </b></text>
<text top="606" left="578" width="88" height="19" font="4"><b>(# patients) /  </b></text>
<text top="625" left="561" width="121" height="19" font="4"><b>Study Comparator  </b></text>
<text top="643" left="583" width="75" height="19" font="4"><b>(# patients) </b></text>
<text top="588" left="731" width="108" height="19" font="4"><b>Endpoint Results </b></text>
<text top="606" left="713" width="148" height="19" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="625" left="717" width="136" height="19" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="643" left="760" width="49" height="19" font="4"><b>95% CI) </b></text>
<text top="589" left="884" width="186" height="19" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="607" left="919" width="116" height="19" font="4"><b>Study Limitations; </b></text>
<text top="626" left="928" width="99" height="19" font="4"><b>Adverse Events </b></text>
<text top="662" left="123" width="105" height="19" font="3">● Korngold et al. </text>
<text top="681" left="123" width="62" height="19" font="3">2009 (32) </text>
<text top="699" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19470888">● </a></text>
<text top="699" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19470888">19470888</a></text>
<text top="699" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19470888"> </a></text>
<text top="662" left="244" width="91" height="19" font="4"><b>Aim:</b>  Evaluate </text>
<text top="681" left="244" width="125" height="19" font="3">baseline NT-proBNP </text>
<text top="699" left="244" width="125" height="19" font="3">levels to predict risk </text>
<text top="717" left="244" width="118" height="19" font="3">of SCD in a general </text>
<text top="735" left="244" width="86" height="19" font="3">population of </text>
<text top="754" left="244" width="53" height="19" font="3">women. </text>
<text top="772" left="244" width="3" height="19" font="3"> </text>
<text top="662" left="390" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="681" left="390" width="147" height="19" font="3">Women nurses 30–55 y </text>
<text top="699" left="390" width="41" height="19" font="3">of age </text>
<text top="717" left="390" width="3" height="19" font="3"> </text>
<text top="735" left="390" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="754" left="390" width="110" height="19" font="3">Blood sample not </text>
<text top="772" left="390" width="59" height="19" font="3">collected </text>
<text top="662" left="551" width="110" height="19" font="4"><b>Intervention:</b>  NT-</text>
<text top="681" left="551" width="96" height="19" font="3">proBNP data at </text>
<text top="699" left="551" width="104" height="19" font="3">baseline. 99 SCD </text>
<text top="717" left="551" width="89" height="19" font="3">cases and 294 </text>
<text top="735" left="551" width="121" height="19" font="3">matched controls.   </text>
<text top="754" left="551" width="7" height="19" font="3">  </text>
<text top="772" left="551" width="120" height="19" font="4"><b>Comparator:</b>  N/A<b>   </b></text>
<text top="663" left="702" width="164" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Relationship </text>
<text top="681" left="702" width="141" height="19" font="3">of NT-proBNP and SCD </text>
<text top="700" left="702" width="115" height="19" font="3">(RR for 1-standard </text>
<text top="718" left="702" width="160" height="19" font="3">deviation increment 1.49; </text>
<text top="736" left="702" width="116" height="19" font="3">95% Cl: 1.09–2.05; </text>
<text top="755" left="702" width="50" height="19" font="3">p<i>=</i>0.01) </text>
<text top="773" left="702" width="3" height="19" font="3"> </text>
<text top="662" left="880" width="166" height="19" font="3">● Women with NT-proBNP </text>
<text top="681" left="880" width="176" height="19" font="3">levels above the cut point of </text>
<text top="699" left="880" width="181" height="19" font="3">389 pg/mL were at increased </text>
<text top="717" left="880" width="175" height="19" font="3">risk of SCD (RR 5.68; 95% CI: </text>
<text top="735" left="880" width="129" height="19" font="3">1.78–18.2; p<i>=</i>0.003). </text>
<text top="754" left="880" width="3" height="19" font="3"> </text>
<text top="772" left="880" width="3" height="19" font="3"> </text>
</page>
<page number="20" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="11" size="12" family="Times" color="#231f20"/>
<text top="803" left="589" width="20" height="21" font="0">20 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="244" width="106" height="19" font="4"><b>Study type:</b> Case </text>
<text top="127" left="244" width="49" height="19" font="3">Control </text>
<text top="145" left="244" width="3" height="19" font="3"> </text>
<text top="164" left="244" width="130" height="19" font="4"><b>Size:</b>  32,826 women </text>
<text top="182" left="244" width="128" height="19" font="3">with biomarker data </text>
<text top="200" left="244" width="93" height="19" font="3">out of 121,700 </text>
<text top="219" left="244" width="58" height="19" font="3">enrolled  </text>
<text top="109" left="702" width="3" height="19" font="3"> </text>
<text top="238" left="123" width="90" height="19" font="3">● Patton et al. </text>
<text top="256" left="123" width="65" height="19" font="3">2011 (33)  </text>
<text top="274" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21044699">● </a></text>
<text top="274" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21044699">21044699</a></text>
<text top="274" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21044699"> </a></text>
<text top="292" left="150" width="3" height="19" font="3"> </text>
<text top="237" left="244" width="132" height="19" font="4"><b>Aim:</b>  Evaluate risk of </text>
<text top="256" left="244" width="114" height="19" font="3">SCD as function of </text>
<text top="274" left="244" width="125" height="19" font="3">baseline NT-proBNP </text>
<text top="293" left="244" width="98" height="19" font="3">in a community </text>
<text top="311" left="244" width="126" height="19" font="3">cohort of older men </text>
<text top="329" left="244" width="76" height="19" font="3">and women </text>
<text top="347" left="244" width="3" height="19" font="3"> </text>
<text top="366" left="244" width="126" height="19" font="4"><b>Study type:</b>   Cohort </text>
<text top="384" left="244" width="37" height="19" font="3">study </text>
<text top="402" left="244" width="3" height="19" font="3"> </text>
<text top="421" left="244" width="133" height="19" font="4"><b>Size:</b>   5,447 men and </text>
<text top="439" left="244" width="49" height="19" font="3">women </text>
<text top="237" left="390" width="146" height="19" font="4"><b>Inclusion criteria:</b>  Men </text>
<text top="256" left="390" width="145" height="19" font="3">and women 65 y of age </text>
<text top="274" left="390" width="123" height="19" font="3">and older randomly </text>
<text top="293" left="390" width="98" height="19" font="3">selected from 4 </text>
<text top="311" left="390" width="83" height="19" font="3">communities </text>
<text top="329" left="390" width="3" height="19" font="3"> </text>
<text top="347" left="390" width="138" height="19" font="4"><b>Exclusion criteria:</b>  NT-</text>
<text top="366" left="390" width="112" height="19" font="3">proBNP levels not </text>
<text top="384" left="390" width="57" height="19" font="3">available </text>
<text top="237" left="551" width="107" height="19" font="4"><b>Intervention:</b> NT-</text>
<text top="256" left="551" width="122" height="19" font="3">proBNP levels were </text>
<text top="274" left="551" width="116" height="19" font="3">analyzed both as a </text>
<text top="293" left="551" width="71" height="19" font="3">continuous </text>
<text top="311" left="551" width="122" height="19" font="3">variable, where the </text>
<text top="329" left="551" width="106" height="19" font="3">natural log of NT-</text>
<text top="347" left="551" width="113" height="19" font="3">proBNP was used, </text>
<text top="366" left="551" width="117" height="19" font="3">and as categorized </text>
<text top="384" left="551" width="83" height="19" font="3">into quintiles </text>
<text top="402" left="551" width="7" height="19" font="3">  </text>
<text top="421" left="551" width="117" height="19" font="4"><b>Comparator:</b>  <b> </b>N/A<b> </b></text>
<text top="238" left="702" width="150" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Higher NT-</text>
<text top="257" left="702" width="122" height="19" font="3">proBNP levels were </text>
<text top="275" left="702" width="160" height="19" font="3">associated with SCD, with </text>
<text top="293" left="702" width="142" height="19" font="3">an unadjusted HR: 4.2; </text>
<text top="312" left="702" width="154" height="19" font="3">95% CI: 2.9, 6.1; p=0.001 </text>
<text top="330" left="702" width="156" height="19" font="3">for the highest vs. lowest </text>
<text top="348" left="702" width="50" height="19" font="3">quintile </text>
<text top="367" left="702" width="3" height="19" font="3"> </text>
<text top="385" left="702" width="3" height="19" font="4"><b> </b></text>
<text top="238" left="880" width="179" height="19" font="3">● NT-proBNP was associated </text>
<text top="256" left="880" width="185" height="19" font="3">with SCD after adjustment for </text>
<text top="274" left="880" width="187" height="19" font="3">clinical characteristics and risk </text>
<text top="293" left="880" width="166" height="19" font="3">factors (age, sex, race, and </text>
<text top="311" left="880" width="180" height="19" font="3">other associated conditions), </text>
<text top="329" left="880" width="171" height="19" font="3">with an adjusted HR for the </text>
<text top="347" left="880" width="188" height="19" font="3">fifth vs. the first quintile of 2.5 </text>
<text top="366" left="880" width="167" height="19" font="3">(95% CI: 1.6, 3.8; p=0.001). </text>
<text top="384" left="880" width="3" height="19" font="3"> </text>
<text top="402" left="880" width="3" height="19" font="3"> </text>
<text top="458" left="123" width="81" height="19" font="3">● Scott et al. </text>
<text top="476" left="123" width="30" height="19" font="3">2009</text>
<text top="475" left="154" width="4" height="21" font="0"> </text>
<text top="476" left="157" width="28" height="19" font="3">(34) </text>
<text top="495" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19789399">● </a></text>
<text top="495" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19789399">19789399</a></text>
<text top="495" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19789399"> </a></text>
<text top="513" left="123" width="3" height="19" font="3"> </text>
<text top="458" left="244" width="91" height="19" font="4"><b>Aim:</b>  Evaluate </text>
<text top="476" left="244" width="122" height="19" font="3">whether BNP levels </text>
<text top="495" left="244" width="125" height="19" font="3">can predict SCD and </text>
<text top="513" left="244" width="88" height="19" font="3">VA in patients </text>
<text top="531" left="244" width="81" height="19" font="3">without ICDs </text>
<text top="550" left="244" width="3" height="19" font="3"> </text>
<text top="568" left="244" width="118" height="19" font="4"><b>Study type:</b>   Meta-</text>
<text top="586" left="244" width="68" height="19" font="3">Analysis of </text>
<text top="605" left="244" width="88" height="19" font="3">Observational </text>
<text top="623" left="244" width="48" height="19" font="3">Studies </text>
<text top="641" left="244" width="3" height="19" font="3"> </text>
<text top="659" left="244" width="113" height="19" font="4"><b>Size:</b> 14 studies (6 </text>
<text top="678" left="244" width="115" height="19" font="3">studies with 3,543 </text>
<text top="696" left="244" width="129" height="19" font="3">patients without ICD </text>
<text top="714" left="244" width="100" height="19" font="3">and 8 studies of </text>
<text top="733" left="244" width="121" height="19" font="3">1,047 patients with </text>
<text top="751" left="244" width="29" height="19" font="3">ICD) </text>
<text top="458" left="390" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="476" left="390" width="143" height="19" font="3">Studies evaluating BNP </text>
<text top="495" left="390" width="147" height="19" font="3">or NT-proBNP levels for </text>
<text top="513" left="390" width="65" height="19" font="3">SCD or VA </text>
<text top="531" left="390" width="3" height="19" font="3"> </text>
<text top="550" left="390" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="568" left="390" width="124" height="19" font="3">Overlapping studies </text>
<text top="458" left="551" width="114" height="19" font="4"><b>Intervention:</b> BNP </text>
<text top="476" left="551" width="136" height="19" font="3">and NT-proBNP levels </text>
<text top="495" left="551" width="137" height="19" font="3">evaluated for SCD risk </text>
<text top="513" left="551" width="119" height="19" font="3">in patients without </text>
<text top="531" left="551" width="101" height="19" font="3">ICD or VA risk in </text>
<text top="550" left="551" width="108" height="19" font="3">patients with ICD </text>
<text top="568" left="551" width="7" height="19" font="3">  </text>
<text top="586" left="551" width="120" height="19" font="4"><b>Comparator:</b>  <b>  </b>N/A<b> </b></text>
<text top="459" left="702" width="147" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Increased </text>
<text top="477" left="702" width="117" height="19" font="11">BNP or NT-proBNP </text>
<text top="496" left="702" width="154" height="19" font="11">predicted SCD with a RR: </text>
<text top="514" left="702" width="161" height="19" font="11">3.68; 95% CI: 1.90–7.14 in </text>
<text top="532" left="702" width="142" height="19" font="11">patients without ICDs.  </text>
<text top="550" left="702" width="129" height="19" font="11">Increased BNP or NT-</text>
<text top="569" left="702" width="163" height="19" font="11">proBNP predicted VA with </text>
<text top="587" left="702" width="151" height="19" font="11">a RR: 2.54; 95% CI: 1.87–</text>
<text top="605" left="702" width="30" height="19" font="11">3.44.</text>
<text top="605" left="733" width="3" height="19" font="3"> </text>
<text top="624" left="702" width="3" height="19" font="4"><b> </b></text>
<text top="458" left="880" width="20" height="19" font="3">● T</text>
<text top="458" left="900" width="154" height="19" font="11">he risk of SCD associated </text>
<text top="476" left="880" width="160" height="19" font="11">with increased BNP or NT-</text>
<text top="495" left="880" width="189" height="19" font="11">proBNP tended to be higher in </text>
<text top="513" left="880" width="168" height="19" font="11">patients with a lower LVEF. </text>
<text top="531" left="880" width="160" height="19" font="11">However, there was not a </text>
<text top="550" left="880" width="193" height="19" font="11">significant interaction between </text>
<text top="568" left="880" width="164" height="19" font="11">BNP level and LVEF on risk </text>
<text top="586" left="880" width="73" height="19" font="11">prediction.  </text>
<text top="605" left="880" width="3" height="19" font="3"> </text>
<text top="623" left="880" width="3" height="19" font="3"> </text>
</page>
<page number="21" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="12" size="12" family="Times" color="#292526"/>
	<fontspec id="13" size="12" family="Times" color="#221e1f"/>
<text top="803" left="589" width="20" height="21" font="0">21 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="90" height="19" font="3">● Blangy et al. </text>
<text top="127" left="123" width="65" height="19" font="3">2007 (35)  </text>
<text top="145" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17526509">● </a></text>
<text top="145" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17526509">17526509</a></text>
<text top="145" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17526509"> </a></text>
<text top="164" left="123" width="7" height="19" font="3">  </text>
<text top="182" left="123" width="3" height="19" font="3"> </text>
<text top="109" left="244" width="91" height="19" font="4"><b>Aim:</b>  Evaluate </text>
<text top="127" left="244" width="111" height="19" font="3">biomarkers on VT </text>
<text top="145" left="244" width="123" height="19" font="3">risk in patients with </text>
<text top="164" left="244" width="74" height="19" font="3">ICD post MI </text>
<text top="182" left="244" width="3" height="19" font="3"> </text>
<text top="200" left="244" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="219" left="244" width="89" height="19" font="3">Observational </text>
<text top="237" left="244" width="3" height="19" font="3"> </text>
<text top="255" left="244" width="118" height="19" font="4"><b>Size:</b>  121 men and </text>
<text top="273" left="244" width="49" height="19" font="3">women </text>
<text top="109" left="390" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="127" left="390" width="83" height="19" font="3">Patients with </text>
<text top="145" left="390" width="144" height="19" font="3">spontaneous sustained </text>
<text top="164" left="390" width="128" height="19" font="3">VT post MI receiving </text>
<text top="182" left="390" width="24" height="19" font="3">ICD </text>
<text top="200" left="390" width="3" height="19" font="3"> </text>
<text top="218" left="390" width="148" height="19" font="4"><b>Exclusion criteria:</b>   N/A </text>
<text top="109" left="551" width="128" height="19" font="4"><b>Intervention:</b> Serum </text>
<text top="127" left="551" width="108" height="19" font="3">BNP, hs-CRP, and </text>
<text top="145" left="551" width="113" height="19" font="3">procollagen levels </text>
<text top="164" left="551" width="132" height="19" font="3">measures at baseline </text>
<text top="182" left="551" width="7" height="19" font="3">  </text>
<text top="200" left="551" width="117" height="19" font="4"><b>Comparator:</b>  <b> </b>N/A<b> </b></text>
<text top="109" left="702" width="85" height="19" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="109" left="787" width="26" height="19" font="12">In a </text>
<text top="128" left="702" width="151" height="19" font="12">multivariate analysis, an </text>
<text top="146" left="702" width="163" height="19" font="12">increased serum BNP (OR: </text>
<text top="165" left="702" width="155" height="19" font="12">3.75; 95% CI: 1.46–9.67), </text>
<text top="183" left="702" width="156" height="19" font="12">an increased hs-CRP (OR: </text>
<text top="201" left="702" width="143" height="19" font="12">3.2; 95% CI: 1.26–8.10, </text>
<text top="219" left="702" width="139" height="19" font="12">and an increased PINP </text>
<text top="238" left="702" width="146" height="19" font="12">(OR: 3.71; 95% CI: 1.40–</text>
<text top="256" left="702" width="162" height="19" font="12">9.88 were associated with </text>
<text top="274" left="702" width="134" height="19" font="12">a higher VT incidence.</text>
<text top="274" left="836" width="3" height="19" font="3"> </text>
<text top="293" left="702" width="3" height="19" font="3"> </text>
<text top="311" left="702" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="880" width="12" height="19" font="3">● </text>
<text top="109" left="892" width="169" height="19" font="12">In addition, LVEF &lt;0.35 (OR </text>
<text top="127" left="880" width="178" height="19" font="12">2.19; 95% CI: 1.00–4.79) was </text>
<text top="145" left="880" width="170" height="19" font="12">associated with a higher VT </text>
<text top="164" left="880" width="62" height="19" font="12">incidence.</text>
<text top="164" left="942" width="3" height="19" font="3"> </text>
<text top="182" left="880" width="3" height="19" font="3"> </text>
<text top="200" left="880" width="3" height="19" font="3"> </text>
<text top="330" left="123" width="84" height="19" font="3">● <b>HF ACTION </b></text>
<text top="348" left="123" width="93" height="19" font="3">● Ahmad et al. </text>
<text top="367" left="123" width="62" height="19" font="3">2014 (36) </text>
<text top="385" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24952693">● </a></text>
<text top="385" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24952693">24952693</a></text>
<text top="385" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24952693"> </a></text>
<text top="403" left="123" width="7" height="19" font="3">  </text>
<text top="330" left="244" width="91" height="19" font="4"><b>Aim:</b>  Evaluate </text>
<text top="348" left="244" width="87" height="19" font="3">biomarkers in </text>
<text top="367" left="244" width="130" height="19" font="3">prediction of sudden </text>
<text top="385" left="244" width="62" height="19" font="3">deathand </text>
<text top="403" left="244" width="132" height="19" font="3">progressive HF death </text>
<text top="422" left="244" width="118" height="19" font="3">in patients with HF </text>
<text top="440" left="244" width="102" height="19" font="3">with reduced EF </text>
<text top="458" left="244" width="3" height="19" font="3"> </text>
<text top="476" left="244" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="495" left="244" width="88" height="19" font="3">Observational </text>
<text top="513" left="244" width="120" height="19" font="3">analysis of subjects </text>
<text top="531" left="244" width="110" height="19" font="3">enrolled in a RCT  </text>
<text top="550" left="244" width="3" height="19" font="3"> </text>
<text top="568" left="244" width="115" height="19" font="4"><b>Size:</b>  813 subjects </text>
<text top="330" left="390" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="348" left="390" width="113" height="19" font="3">NYHA class II to IV </text>
<text top="367" left="390" width="98" height="19" font="3">chronic HF with </text>
<text top="385" left="390" width="54" height="19" font="3">EF≤35%  </text>
<text top="403" left="390" width="3" height="19" font="3"> </text>
<text top="421" left="390" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="440" left="390" width="132" height="20" font="3">• Biomarker data not </text>
<text top="459" left="390" width="58" height="19" font="3">obtained </text>
<text top="477" left="390" width="132" height="20" font="3">• Inability to exercise </text>
<text top="330" left="551" width="107" height="19" font="4"><b>Intervention:</b> NT-</text>
<text top="348" left="551" width="121" height="19" font="3">proBNP, galectin-3, </text>
<text top="367" left="551" width="124" height="19" font="3">and ST2 levels were </text>
<text top="385" left="551" width="126" height="19" font="3">assessed at baseline </text>
<text top="403" left="551" width="137" height="19" font="3">in patients enrolled in </text>
<text top="422" left="551" width="120" height="19" font="3">the trial of exercise </text>
<text top="440" left="551" width="139" height="19" font="3">training vs. usual care  </text>
<text top="458" left="551" width="7" height="19" font="3">  </text>
<text top="476" left="551" width="114" height="19" font="4"><b>Comparator:</b>  N/A<b> </b></text>
<text top="331" left="702" width="150" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Elevations </text>
<text top="349" left="702" width="141" height="19" font="3">in each biomarker was </text>
<text top="367" left="702" width="160" height="19" font="3">associated with increased </text>
<text top="386" left="702" width="159" height="19" font="3">risk for SCD death in both </text>
<text top="404" left="702" width="154" height="19" font="3">adjusted and unadjusted </text>
<text top="422" left="702" width="62" height="19" font="3">analyses.  </text>
<text top="441" left="702" width="161" height="19" font="3">However, increases in the </text>
<text top="459" left="702" width="154" height="19" font="3">biomarkers had stronger </text>
<text top="477" left="702" width="147" height="19" font="3">associations with pump </text>
<text top="496" left="702" width="152" height="19" font="3">failure than SCD. Clinical </text>
<text top="514" left="702" width="147" height="19" font="3">variables along with NT-</text>
<text top="532" left="702" width="122" height="19" font="3">proBNP levels were </text>
<text top="550" left="702" width="161" height="19" font="3">predictors sudden cardiac </text>
<text top="569" left="702" width="151" height="19" font="3">death (C statistic: 0.73).  </text>
<text top="330" left="880" width="147" height="19" font="3">● NT-proBNP was more </text>
<text top="348" left="880" width="172" height="19" font="3">strongly predictive of pump </text>
<text top="367" left="880" width="151" height="19" font="3">failure (C statistic: 0.87)  </text>
<text top="385" left="880" width="135" height="19" font="3">● Addition of ST2 and </text>
<text top="403" left="880" width="188" height="19" font="3">galectin-3 led to improved net </text>
<text top="422" left="880" width="172" height="19" font="3">risk classification of 11% for </text>
<text top="440" left="880" width="35" height="19" font="3">SCD.  </text>
<text top="458" left="880" width="184" height="19" font="3">● There was no improvement </text>
<text top="476" left="880" width="178" height="19" font="3">in net risk reclassification for </text>
<text top="495" left="880" width="193" height="19" font="3">pump failure death with ST2 or </text>
<text top="513" left="880" width="63" height="19" font="3">galectin-3 </text>
<text top="531" left="880" width="3" height="19" font="3"> </text>
<text top="550" left="880" width="3" height="19" font="3"> </text>
<text top="588" left="123" width="89" height="19" font="3">● Levine et al. </text>
<text top="606" left="123" width="62" height="19" font="3">2014 (37) </text>
<text top="624" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24837348">● </a></text>
<text top="624" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24837348">24837348</a></text>
<text top="624" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24837348"> </a></text>
<text top="588" left="244" width="110" height="19" font="4"><b>Aim:</b>  To evaluate </text>
<text top="606" left="244" width="126" height="19" font="3">the ability of BNP or </text>
<text top="624" left="244" width="88" height="19" font="3">NT-proBNP to </text>
<text top="643" left="244" width="82" height="19" font="3">predict VA in </text>
<text top="661" left="244" width="99" height="19" font="3">patients with 1° </text>
<text top="680" left="244" width="101" height="19" font="3">prevention ICDs </text>
<text top="698" left="244" width="3" height="19" font="3"> </text>
<text top="716" left="244" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="734" left="244" width="89" height="19" font="3">Observational </text>
<text top="753" left="244" width="3" height="19" font="3"> </text>
<text top="771" left="244" width="115" height="19" font="4"><b>Size:</b> 564 patients  </text>
<text top="588" left="390" width="144" height="19" font="4"><b>Inclusion criteria:</b>  BNP </text>
<text top="606" left="390" width="126" height="19" font="3">or NT-proBNP levels </text>
<text top="624" left="390" width="137" height="19" font="3">and 1° prevention ICD </text>
<text top="643" left="390" width="3" height="19" font="3"> </text>
<text top="661" left="390" width="146" height="19" font="4"><b>Exclusion criteria:</b>  BNP </text>
<text top="679" left="390" width="112" height="19" font="3">or NT-proBNP not </text>
<text top="698" left="390" width="137" height="19" font="3">available within 12mo </text>
<text top="716" left="390" width="126" height="19" font="3">of ICD implantation. </text>
<text top="588" left="551" width="131" height="19" font="4"><b>Intervention:</b> BNP or </text>
<text top="606" left="551" width="126" height="19" font="3">NT-proBNP levels to </text>
<text top="624" left="551" width="111" height="19" font="3">predict risk of VA  </text>
<text top="643" left="551" width="7" height="19" font="3">  </text>
<text top="661" left="551" width="124" height="19" font="4"><b>Comparator:</b>  <b>   </b>N/A<b> </b></text>
<text top="588" left="702" width="100" height="19" font="4"><b>1</b>°<b> endpoint:</b>  In </text>
<text top="607" left="702" width="150" height="19" font="3">multivariate analysis NT-</text>
<text top="625" left="702" width="144" height="19" font="3">proBNP was associated </text>
<text top="644" left="702" width="154" height="19" font="3">with increased risk of VA </text>
<text top="662" left="702" width="142" height="19" font="3">with HR: 5.75; p&lt;0.001 </text>
<text top="680" left="702" width="150" height="19" font="3">and BNP was associated </text>
<text top="699" left="702" width="148" height="19" font="3">with increased risk with </text>
<text top="717" left="702" width="101" height="19" font="3">HR: 3.40; p&lt;0.01</text>
<text top="717" left="803" width="4" height="19" font="13">.</text>
<text top="717" left="807" width="3" height="19" font="3"> </text>
<text top="735" left="702" width="3" height="19" font="3"> </text>
<text top="753" left="702" width="3" height="19" font="3"> </text>
<text top="588" left="880" width="172" height="19" font="3">● Quartile analyses showed </text>
<text top="606" left="880" width="153" height="19" font="3">higher relative risk of VA </text>
<text top="624" left="880" width="180" height="19" font="3">compared to the relative risk </text>
<text top="643" left="880" width="185" height="19" font="3">of all-cause mortality for both </text>
<text top="661" left="880" width="131" height="19" font="3">BNP and NT-proBNP. </text>
<text top="679" left="880" width="3" height="19" font="3"> </text>
<text top="698" left="880" width="3" height="19" font="3"> </text>
</page>
<page number="22" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">22 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="90" height="19" font="3">● Berger et al. </text>
<text top="127" left="123" width="62" height="19" font="3">2002 (38) </text>
<text top="145" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12021226">● </a></text>
<text top="145" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12021226">12021226</a></text>
<text top="145" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12021226"> </a></text>
<text top="164" left="123" width="3" height="19" font="3"> </text>
<text top="109" left="244" width="110" height="19" font="4"><b>Aim:</b>  To evaluate </text>
<text top="127" left="244" width="87" height="19" font="3">role of BNP in </text>
<text top="145" left="244" width="107" height="19" font="3">predicting SCD in </text>
<text top="164" left="244" width="103" height="19" font="3">patients with HF </text>
<text top="182" left="244" width="100" height="19" font="3">with LVEF ≤35% </text>
<text top="200" left="244" width="3" height="19" font="3"> </text>
<text top="218" left="244" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="237" left="244" width="89" height="19" font="3">Observational </text>
<text top="255" left="244" width="3" height="19" font="3"> </text>
<text top="273" left="244" width="111" height="19" font="4"><b>Size:</b> 452 patients </text>
<text top="109" left="390" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="127" left="390" width="129" height="19" font="3">Patients with HF and </text>
<text top="145" left="390" width="130" height="19" font="3">reduced EF with BNP </text>
<text top="164" left="390" width="112" height="19" font="3">level measured at </text>
<text top="182" left="390" width="54" height="19" font="3">baseline </text>
<text top="200" left="390" width="3" height="19" font="3"> </text>
<text top="218" left="390" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="237" left="390" width="120" height="19" font="3">Patients with heart </text>
<text top="255" left="390" width="144" height="19" font="3">transplantation or VAD </text>
<text top="109" left="551" width="114" height="19" font="4"><b>Intervention:</b> BNP </text>
<text top="127" left="551" width="134" height="19" font="3">levels at baseline and </text>
<text top="145" left="551" width="102" height="19" font="3">association with </text>
<text top="164" left="551" width="102" height="19" font="3">subsequent SCD </text>
<text top="182" left="551" width="7" height="19" font="3">  </text>
<text top="200" left="551" width="120" height="19" font="4"><b>Comparator:</b>  <b> </b> N/A<b> </b></text>
<text top="109" left="702" width="100" height="19" font="4"><b>1</b>°<b> endpoint:</b>  In </text>
<text top="128" left="702" width="154" height="19" font="3">multivariate analysis, log </text>
<text top="146" left="702" width="141" height="19" font="3">BNP level was the only </text>
<text top="165" left="702" width="157" height="19" font="3">independent predictor of </text>
<text top="183" left="702" width="87" height="19" font="3">sudden death </text>
<text top="201" left="702" width="3" height="19" font="3"> </text>
<text top="219" left="702" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="880" width="173" height="19" font="3">● Using a cutoff point of log </text>
<text top="127" left="880" width="188" height="19" font="3">BNP 2.11 (130 pg/mL), the KM </text>
<text top="145" left="880" width="169" height="19" font="3">sudden death–free survival </text>
<text top="164" left="880" width="187" height="19" font="3">rates were significantly higher </text>
<text top="182" left="880" width="147" height="19" font="3">in patients below (99%) </text>
<text top="200" left="880" width="189" height="19" font="3">compared with patients above </text>
<text top="219" left="880" width="139" height="19" font="3">(81%) this cutoff point </text>
<text top="237" left="880" width="70" height="19" font="3">(p=0.0001) </text>
<text top="255" left="880" width="3" height="19" font="3"> </text>
<text top="273" left="880" width="3" height="19" font="3"> </text>
<text top="292" left="115" width="3" height="19" font="3"> </text>
<text top="346" left="115" width="476" height="21" font="2"><b>Data Supplement 8. RCTs Evaluating EP Study for VA – (Section 4.3.2) </b></text>
<text top="368" left="155" width="39" height="19" font="4"><b>Study </b></text>
<text top="386" left="142" width="64" height="19" font="4"><b>Acronym; </b></text>
<text top="404" left="149" width="55" height="19" font="4"><b>Author;  </b></text>
<text top="423" left="126" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="368" left="260" width="88" height="19" font="4"><b>Aim of Study; </b></text>
<text top="386" left="265" width="76" height="19" font="4"><b>Study Type; </b></text>
<text top="404" left="259" width="89" height="19" font="4"><b>Study Size (N) </b></text>
<text top="368" left="406" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="368" left="563" width="123" height="19" font="4"><b>Study Intervention  </b></text>
<text top="386" left="581" width="88" height="19" font="4"><b>(# patients) /  </b></text>
<text top="404" left="565" width="121" height="19" font="4"><b>Study Comparator  </b></text>
<text top="423" left="586" width="75" height="19" font="4"><b>(# patients) </b></text>
<text top="368" left="725" width="108" height="19" font="4"><b>Endpoint Results </b></text>
<text top="386" left="707" width="148" height="19" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="404" left="711" width="136" height="19" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="423" left="754" width="49" height="19" font="4"><b>95% CI) </b></text>
<text top="368" left="881" width="186" height="19" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="387" left="917" width="116" height="19" font="4"><b>Study Limitations; </b></text>
<text top="405" left="925" width="99" height="19" font="4"><b>Adverse Events </b></text>
<text top="442" left="123" width="98" height="19" font="3">● Buxton AE, et </text>
<text top="460" left="123" width="78" height="19" font="3">al. Circ 2002 </text>
<text top="478" left="123" width="28" height="19" font="3">(39) </text>
<text top="497" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12417544">● </a></text>
<text top="497" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12417544">12417544</a></text>
<text top="497" left="197" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12417544"><b> </b></a></text>
<text top="442" left="238" width="125" height="19" font="4"><b>Aim:</b>  to analyze the </text>
<text top="460" left="238" width="109" height="19" font="3">relationship of EF </text>
<text top="478" left="238" width="122" height="19" font="3">and inducible VA to </text>
<text top="497" left="238" width="93" height="19" font="3">mode of death </text>
<text top="515" left="238" width="3" height="19" font="3"> </text>
<text top="533" left="238" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="552" left="238" width="78" height="19" font="3">Prospective, </text>
<text top="570" left="238" width="110" height="19" font="3">randomized, RCT  </text>
<text top="588" left="238" width="3" height="19" font="3"> </text>
<text top="606" left="238" width="122" height="19" font="4"><b>Size:</b>  1791 patients<b> </b></text>
<text top="442" left="382" width="148" height="19" font="4"><b>Inclusion criteria:</b>  CAD, </text>
<text top="460" left="382" width="81" height="19" font="3">EF&lt;40%, and </text>
<text top="478" left="382" width="94" height="19" font="3">asymptomatic, </text>
<text top="497" left="382" width="97" height="19" font="3">unsustained VT </text>
<text top="515" left="382" width="3" height="19" font="3"> </text>
<text top="533" left="382" width="164" height="19" font="4"><b>Exclusion criteria:</b>  History </text>
<text top="552" left="382" width="135" height="19" font="3">of syncope, sustained </text>
<text top="570" left="382" width="76" height="19" font="3">VT/VF more </text>
<text top="588" left="382" width="126" height="19" font="3">than 48 h after AMI, </text>
<text top="607" left="382" width="97" height="19" font="3">unsustained VT </text>
<text top="625" left="382" width="162" height="19" font="3">only in the setting of drug-</text>
<text top="643" left="382" width="148" height="19" font="3">induced LQTS or AMI or </text>
<text top="662" left="382" width="132" height="19" font="3">that was attributable </text>
<text top="680" left="382" width="118" height="19" font="3">to acute metabolic </text>
<text top="698" left="382" width="160" height="19" font="3">disorders or drug toxicity, </text>
<text top="716" left="382" width="103" height="19" font="3">or symptomatic, </text>
<text top="735" left="382" width="97" height="19" font="3">unsustained VT<b> </b></text>
<text top="442" left="563" width="115" height="19" font="4"><b>Intervention:</b> AAD </text>
<text top="460" left="563" width="62" height="19" font="3">or ICD for </text>
<text top="478" left="563" width="112" height="19" font="3">inducible patients </text>
<text top="497" left="563" width="3" height="19" font="3"> </text>
<text top="515" left="563" width="104" height="19" font="4"><b>Comparator:</b>  EF </text>
<text top="533" left="563" width="115" height="19" font="3">30–40% vs. &lt;30%<b>   </b></text>
<text top="442" left="696" width="81" height="19" font="4"><b>1</b>°<b> endpoint:</b> </text>
<text top="461" left="696" width="132" height="19" font="3">● Total mortality and </text>
<text top="479" left="696" width="164" height="19" font="3">arrhythmic deaths/cardiac </text>
<text top="498" left="696" width="153" height="19" font="3">arrests more common in </text>
<text top="516" left="696" width="138" height="19" font="3">patients with EF &lt;30% </text>
<text top="534" left="696" width="129" height="19" font="3">● Arrhythmic deaths </text>
<text top="552" left="696" width="160" height="19" font="3">similar in patients with EF </text>
<text top="571" left="696" width="115" height="19" font="3">&lt;30% and 30–40% </text>
<text top="589" left="696" width="160" height="19" font="3">● Relative contribution of </text>
<text top="607" left="696" width="163" height="19" font="3">arrhythmic deaths to total </text>
<text top="626" left="696" width="144" height="19" font="3">mortality was higher in </text>
<text top="644" left="696" width="162" height="19" font="3">inducible patients (58% of </text>
<text top="662" left="696" width="154" height="19" font="3">deaths vs. 46% of deaths </text>
<text top="681" left="696" width="154" height="19" font="3">in noninducible patients, </text>
<text top="699" left="696" width="53" height="19" font="3">p=0.004 </text>
<text top="717" left="696" width="3" height="19" font="4"><b> </b></text>
<text top="442" left="874" width="136" height="19" font="3">● 61% of events were </text>
<text top="460" left="874" width="175" height="19" font="3">arrhythmic among inducible </text>
<text top="478" left="874" width="194" height="19" font="3">patients with EF ≥30% and only </text>
<text top="497" left="874" width="157" height="19" font="3">42% among noninducible </text>
<text top="515" left="874" width="110" height="19" font="3">patients, p=0.002 </text>
<text top="533" left="874" width="3" height="19" font="4"><b> </b></text>
</page>
<page number="23" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">23 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="61" height="19" font="3">● <b>MUSTT </b></text>
<text top="127" left="123" width="98" height="19" font="3">● Buxton AE, et </text>
<text top="145" left="123" width="86" height="19" font="3">al NEJM 1999 </text>
<text top="164" left="123" width="28" height="19" font="3">(40) </text>
<text top="182" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10601507">● </a></text>
<text top="182" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10601507">10601507</a></text>
<text top="182" left="197" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10601507"><b> </b></a></text>
<text top="109" left="238" width="103" height="19" font="4"><b>Aim:</b>  to test the </text>
<text top="127" left="238" width="130" height="19" font="3">usefulness of EPS for </text>
<text top="145" left="238" width="127" height="19" font="3">risk stratification for </text>
<text top="164" left="238" width="27" height="19" font="3">SCD </text>
<text top="182" left="238" width="3" height="19" font="3"> </text>
<text top="200" left="238" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="219" left="238" width="78" height="19" font="3">Prospective, </text>
<text top="237" left="238" width="110" height="19" font="3">randomized, RCT  </text>
<text top="255" left="238" width="3" height="19" font="3"> </text>
<text top="273" left="238" width="114" height="19" font="4"><b>Size:</b>  704 patients </text>
<text top="292" left="238" width="93" height="19" font="3">with inducible, </text>
<text top="310" left="238" width="82" height="19" font="3">sustained VA<b> </b></text>
<text top="109" left="382" width="148" height="19" font="4"><b>Inclusion criteria:</b>  CAD, </text>
<text top="127" left="382" width="81" height="19" font="3">EF&lt;40%, and </text>
<text top="145" left="382" width="94" height="19" font="3">asymptomatic, </text>
<text top="164" left="382" width="97" height="19" font="3">unsustained VT </text>
<text top="182" left="382" width="3" height="19" font="3"> </text>
<text top="200" left="382" width="164" height="19" font="4"><b>Exclusion criteria:</b>  History </text>
<text top="219" left="382" width="135" height="19" font="3">of syncope, sustained </text>
<text top="237" left="382" width="76" height="19" font="3">VT/VF more </text>
<text top="255" left="382" width="126" height="19" font="3">than 48 h after AMI, </text>
<text top="273" left="382" width="97" height="19" font="3">unsustained VT </text>
<text top="292" left="382" width="162" height="19" font="3">only in the setting of drug-</text>
<text top="310" left="382" width="148" height="19" font="3">induced LQTS or AMI or </text>
<text top="329" left="382" width="132" height="19" font="3">that was attributable </text>
<text top="347" left="382" width="118" height="19" font="3">to acute metabolic </text>
<text top="365" left="382" width="160" height="19" font="3">disorders or drug toxicity, </text>
<text top="383" left="382" width="103" height="19" font="3">or symptomatic, </text>
<text top="402" left="382" width="97" height="19" font="3">unsustained VT<b> </b></text>
<text top="109" left="563" width="111" height="19" font="4"><b>ntervention:</b> AAD </text>
<text top="127" left="563" width="41" height="19" font="3">or ICD </text>
<text top="145" left="563" width="3" height="19" font="3"> </text>
<text top="164" left="563" width="86" height="19" font="4"><b>Comparator:</b>  </text>
<text top="182" left="563" width="83" height="19" font="3">Patients with </text>
<text top="200" left="563" width="115" height="19" font="3">inducible VT/VF at </text>
<text top="219" left="563" width="118" height="19" font="3">EPS randomized to </text>
<text top="237" left="563" width="96" height="19" font="3">treatment with </text>
<text top="255" left="563" width="110" height="19" font="3">AAD or ICD vs. no </text>
<text top="273" left="563" width="49" height="19" font="3">specific </text>
<text top="292" left="563" width="94" height="19" font="3">antiarrhythmic </text>
<text top="310" left="563" width="66" height="19" font="3">treatment<b> </b></text>
<text top="109" left="696" width="121" height="19" font="4"><b>1</b>°<b> endpoint:</b>  CA or </text>
<text top="128" left="696" width="109" height="19" font="3">arrhythmic death </text>
<text top="146" left="696" width="114" height="19" font="3">● At 5 y, inducible </text>
<text top="165" left="696" width="132" height="19" font="3">patients treated with </text>
<text top="183" left="696" width="94" height="19" font="3">AAD/ICD had a </text>
<text top="201" left="696" width="154" height="19" font="3">significantly lower risk of </text>
<text top="219" left="696" width="146" height="19" font="3">arrhythmic death or CA </text>
<text top="238" left="696" width="147" height="19" font="3">(25%) than patients not </text>
<text top="256" left="696" width="152" height="19" font="3">receiving antiarrhythmic </text>
<text top="274" left="696" width="151" height="19" font="3">therapy (32%) (RR: 0.73; </text>
<text top="293" left="696" width="117" height="19" font="3">95% CI: 0.53–0.99) </text>
<text top="311" left="696" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="874" width="182" height="19" font="3">● The risk of cardiac arrest or </text>
<text top="127" left="874" width="188" height="19" font="3">death from arrhythmia among </text>
<text top="145" left="874" width="138" height="19" font="3">patients who received </text>
<text top="164" left="874" width="153" height="19" font="3">treatment with ICDs was </text>
<text top="182" left="874" width="174" height="19" font="3">significantly lower than that </text>
<text top="200" left="874" width="192" height="19" font="3">among the patients discharged </text>
<text top="219" left="874" width="185" height="19" font="3">without receiving defibrillator </text>
<text top="237" left="874" width="176" height="19" font="3">treatment (RR: 0.24; 95% CI: </text>
<text top="255" left="874" width="129" height="19" font="3">0.13–0.45; p&lt;0.001). </text>
<text top="273" left="874" width="9" height="19" font="3">●</text>
<text top="272" left="883" width="4" height="21" font="0"> </text>
<text top="273" left="887" width="170" height="19" font="3">Reduction in 1° endpoint in </text>
<text top="292" left="874" width="155" height="19" font="3">AAD/ICD arm was due to </text>
<text top="310" left="874" width="189" height="19" font="3">reduction in events in patients </text>
<text top="329" left="874" width="167" height="19" font="3">treated with ICDs, not AAD<b> </b></text>
<text top="421" left="123" width="61" height="19" font="3">● <b>MUSTT </b></text>
<text top="439" left="123" width="93" height="19" font="3">● Buxton et al. </text>
<text top="457" left="123" width="62" height="19" font="3">2000 (41) </text>
<text top="476" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10874061">● </a></text>
<text top="476" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10874061">10874061</a></text>
<text top="476" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10874061"> </a></text>
<text top="494" left="123" width="3" height="19" font="3"> </text>
<text top="421" left="238" width="103" height="19" font="4"><b>Aim:</b>  to test the </text>
<text top="439" left="238" width="130" height="19" font="3">usefulness of EPS for </text>
<text top="457" left="238" width="127" height="19" font="3">risk stratification for </text>
<text top="476" left="238" width="27" height="19" font="3">SCD </text>
<text top="494" left="238" width="3" height="19" font="3"> </text>
<text top="512" left="238" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="531" left="238" width="78" height="19" font="3">Prospective, </text>
<text top="549" left="238" width="110" height="19" font="3">randomized, RCT  </text>
<text top="567" left="238" width="3" height="19" font="3"> </text>
<text top="585" left="238" width="122" height="19" font="4"><b>Size:</b>  1750 patients </text>
<text top="604" left="238" width="127" height="19" font="3">(353 inducible; 1397 </text>
<text top="622" left="238" width="87" height="19" font="3">noninducible) </text>
<text top="421" left="382" width="165" height="19" font="4"><b>Inclusion criteria:</b>  CAD, EF </text>
<text top="439" left="382" width="161" height="19" font="3">&lt;40%, and asymptomatic, </text>
<text top="457" left="382" width="97" height="19" font="3">unsustained VT </text>
<text top="476" left="382" width="3" height="19" font="3"> </text>
<text top="494" left="382" width="164" height="19" font="4"><b>Exclusion criteria:</b>  History </text>
<text top="512" left="382" width="135" height="19" font="3">of syncope, sustained </text>
<text top="531" left="382" width="76" height="19" font="3">VT/VF more </text>
<text top="549" left="382" width="126" height="19" font="3">than 48 h after AMI, </text>
<text top="567" left="382" width="97" height="19" font="3">unsustained VT </text>
<text top="586" left="382" width="162" height="19" font="3">only in the setting of drug-</text>
<text top="604" left="382" width="148" height="19" font="3">induced LQTS or AMI or </text>
<text top="622" left="382" width="132" height="19" font="3">that was attributable </text>
<text top="640" left="382" width="118" height="19" font="3">to acute metabolic </text>
<text top="659" left="382" width="160" height="19" font="3">disorders or drug toxicity, </text>
<text top="677" left="382" width="103" height="19" font="3">or symptomatic, </text>
<text top="695" left="382" width="97" height="19" font="3">unsustained VT </text>
<text top="421" left="563" width="111" height="19" font="4"><b>Intervention:</b> EPS </text>
<text top="439" left="563" width="3" height="19" font="3"> </text>
<text top="457" left="563" width="86" height="19" font="4"><b>Comparator:</b>  </text>
<text top="476" left="563" width="115" height="19" font="3">Inducible VT/VF at </text>
<text top="494" left="563" width="76" height="19" font="3">EPS and not </text>
<text top="512" left="563" width="109" height="19" font="3">treated with AAD </text>
<text top="531" left="563" width="106" height="19" font="3">or ICD compared </text>
<text top="549" left="563" width="99" height="19" font="3">to noninducible </text>
<text top="567" left="563" width="60" height="19" font="3">patients<b>   </b></text>
<text top="421" left="696" width="121" height="19" font="4"><b>1</b>°<b> endpoint:</b>  CA or </text>
<text top="440" left="696" width="109" height="19" font="3">arrhythmic death </text>
<text top="458" left="696" width="162" height="19" font="3">At 2 and 5 y, noninducible </text>
<text top="476" left="696" width="90" height="19" font="3">patients had a </text>
<text top="495" left="696" width="154" height="19" font="3">significantly lower risk of </text>
<text top="513" left="696" width="146" height="19" font="3">arrhythmic death or CA </text>
<text top="531" left="696" width="162" height="19" font="3">(12%, 24%) than inducible </text>
<text top="550" left="696" width="125" height="19" font="3">patients (18%. 32%) </text>
<text top="568" left="696" width="125" height="19" font="3">(adjusted p&lt;0.001).  </text>
<text top="586" left="696" width="143" height="19" font="3">Overall mortality at 5 y </text>
<text top="605" left="696" width="163" height="19" font="3">was lower in noninducible </text>
<text top="623" left="696" width="140" height="19" font="3">patients (44% vs. 48%, </text>
<text top="641" left="696" width="118" height="19" font="3">adjusted p=0.005). </text>
<text top="660" left="696" width="3" height="19" font="3"> </text>
<text top="678" left="696" width="119" height="19" font="4"><b>Safety endpoint (if </b></text>
<text top="696" left="696" width="95" height="19" font="4"><b>relevant):</b> N/A  </text>
<text top="714" left="696" width="3" height="19" font="4"><b> </b></text>
<text top="421" left="874" width="152" height="19" font="3">● Patients with ischemic </text>
<text top="439" left="874" width="129" height="19" font="3">cardiomyopathy and </text>
<text top="457" left="874" width="191" height="19" font="3">asymptomatic, unsustained VT </text>
<text top="476" left="874" width="152" height="19" font="3">with inducible VT have a </text>
<text top="494" left="874" width="192" height="19" font="3">significantly greater risk of SCD </text>
<text top="512" left="874" width="150" height="19" font="3">or CA and higher overall </text>
<text top="531" left="874" width="188" height="19" font="3">mortality than similar patients </text>
<text top="549" left="874" width="136" height="19" font="3">who are noninducible </text>
<text top="567" left="874" width="3" height="19" font="3"> </text>
<text top="586" left="874" width="3" height="19" font="3"> </text>
<text top="604" left="874" width="3" height="19" font="3"> </text>
</page>
<page number="24" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">24 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="67" height="19" font="3">● <b>MADIT-I </b></text>
<text top="127" left="123" width="82" height="19" font="3">● Moss et al. </text>
<text top="145" left="123" width="62" height="19" font="3">1996 (42) </text>
<text top="164" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8960472">● </a></text>
<text top="164" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8960472">8960472</a></text>
<text top="164" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8960472"> </a></text>
<text top="182" left="123" width="3" height="19" font="3"> </text>
<text top="109" left="238" width="110" height="19" font="4"><b>Aim:</b>  To evaluate </text>
<text top="127" left="238" width="55" height="19" font="3">whether </text>
<text top="145" left="238" width="123" height="19" font="3">prophylactic ICD, as </text>
<text top="164" left="238" width="96" height="19" font="3">compared with </text>
<text top="182" left="238" width="82" height="19" font="3">conventional </text>
<text top="200" left="238" width="106" height="19" font="3">medical therapy, </text>
<text top="219" left="238" width="95" height="19" font="3">would improve </text>
<text top="237" left="238" width="131" height="19" font="3">survival in a high-risk </text>
<text top="255" left="238" width="108" height="19" font="3">group of patients </text>
<text top="273" left="238" width="123" height="19" font="3">with NSVT, reduced </text>
<text top="292" left="238" width="114" height="19" font="3">LVEF and previous </text>
<text top="310" left="238" width="24" height="19" font="3">MI. </text>
<text top="328" left="238" width="3" height="19" font="3"> </text>
<text top="347" left="238" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="365" left="238" width="75" height="19" font="3">prospective </text>
<text top="383" left="238" width="101" height="19" font="3">multicenter RCT </text>
<text top="402" left="238" width="3" height="19" font="3"> </text>
<text top="420" left="238" width="118" height="19" font="4"><b>Size:</b> 196 patients   </text>
<text top="109" left="382" width="143" height="19" font="4"><b>Inclusion:</b> Previous MI, </text>
<text top="127" left="382" width="112" height="19" font="3">LVEF ≤35%, NSVT, </text>
<text top="145" left="382" width="148" height="19" font="3">inducible VT at EPS that </text>
<text top="164" left="382" width="158" height="19" font="3">was non-suppressed with </text>
<text top="182" left="382" width="119" height="19" font="3">IV procainamide or </text>
<text top="200" left="382" width="98" height="19" font="3">equivalent AAD </text>
<text top="219" left="382" width="3" height="19" font="3"> </text>
<text top="237" left="382" width="158" height="19" font="4"><b>Exclusion: </b>previous CA or </text>
<text top="255" left="382" width="150" height="19" font="3">VT causing syncope that </text>
<text top="273" left="382" width="168" height="19" font="3">was not associated with an </text>
<text top="292" left="382" width="115" height="19" font="3">AMI; symptomatic </text>
<text top="310" left="382" width="141" height="19" font="3">hypotension while in a </text>
<text top="329" left="382" width="157" height="19" font="3">stable rhythm; and MI &lt;3 </text>
<text top="347" left="382" width="154" height="19" font="3">wk, prior CABG &lt;2 mo or </text>
<text top="365" left="382" width="119" height="19" font="3">PCI &lt;3 mo, as were </text>
<text top="383" left="382" width="144" height="19" font="3">women of childbearing </text>
<text top="402" left="382" width="149" height="19" font="3">age who were not using </text>
<text top="420" left="382" width="129" height="19" font="3">medically prescribed </text>
<text top="438" left="382" width="150" height="19" font="3">contraceptives, patients </text>
<text top="457" left="382" width="92" height="19" font="3">with advanced </text>
<text top="475" left="382" width="153" height="19" font="3">cerebrovascular disease, </text>
<text top="493" left="382" width="109" height="19" font="3">patients with any </text>
<text top="512" left="382" width="130" height="19" font="3">condition other than </text>
<text top="530" left="382" width="151" height="19" font="3">cardiac disease that was </text>
<text top="548" left="382" width="162" height="19" font="3">associated with a reduced </text>
<text top="566" left="382" width="150" height="19" font="3">likelihood of survival for </text>
<text top="585" left="382" width="151" height="19" font="3">the duration of the trial, </text>
<text top="603" left="382" width="144" height="19" font="3">and patients who were </text>
<text top="621" left="382" width="132" height="19" font="3">participating in other </text>
<text top="640" left="382" width="78" height="19" font="3">clinical trials </text>
<text top="109" left="563" width="86" height="19" font="4"><b>Comparator</b>:  </text>
<text top="127" left="563" width="79" height="19" font="3">Control (101 </text>
<text top="145" left="563" width="58" height="19" font="3">patients) </text>
<text top="164" left="563" width="3" height="19" font="3"> </text>
<text top="182" left="563" width="89" height="19" font="4"><b>Intervention:</b>  </text>
<text top="200" left="563" width="105" height="19" font="3">ICD (95 patients) </text>
<text top="109" left="696" width="125" height="19" font="4"><b>All-cause mortality</b>: </text>
<text top="127" left="696" width="152" height="19" font="3">Control 32% vs. ICD 13% </text>
<text top="145" left="696" width="133" height="19" font="3">(RRR -59% ARR -19%) </text>
<text top="109" left="874" width="178" height="19" font="3">● In patients with a prior MI, </text>
<text top="127" left="874" width="187" height="19" font="3">low EF who are at high risk for </text>
<text top="145" left="874" width="183" height="19" font="3">VT, prophylactic therapy with </text>
<text top="164" left="874" width="156" height="19" font="3">an ICD leads to improved </text>
<text top="182" left="874" width="162" height="19" font="3">survival as compared with </text>
<text top="200" left="874" width="188" height="19" font="3">conventional medical therapy. </text>
<text top="659" left="123" width="76" height="19" font="3">● <b>SCD-HeFT </b></text>
<text top="677" left="123" width="85" height="19" font="3">● Bardy et al. </text>
<text top="695" left="123" width="62" height="19" font="3">2005 (43) </text>
<text top="714" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15659722">● </a></text>
<text top="714" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15659722">15659722</a></text>
<text top="714" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15659722"> </a></text>
<text top="659" left="238" width="91" height="19" font="4"><b>Aim:</b>  Evaluate </text>
<text top="677" left="238" width="55" height="19" font="3">whether </text>
<text top="695" left="238" width="105" height="19" font="3">amiodarone or a </text>
<text top="714" left="238" width="91" height="19" font="3">conservatively </text>
<text top="732" left="238" width="122" height="19" font="3">programmed shock-</text>
<text top="750" left="238" width="127" height="19" font="3">only, single-lead ICD </text>
<text top="769" left="238" width="123" height="19" font="3">would decrease the </text>
<text top="659" left="382" width="157" height="19" font="4"><b>Inclusion:</b> NYHA class I-III </text>
<text top="677" left="382" width="89" height="19" font="3">HF, LVEF≤35% </text>
<text top="695" left="382" width="3" height="19" font="3"> </text>
<text top="714" left="382" width="167" height="19" font="4"><b>Exclusion:</b> &lt;18 y, unable to </text>
<text top="732" left="382" width="80" height="19" font="3">give consent </text>
<text top="659" left="563" width="100" height="19" font="4"><b>Intervention 1:</b>  </text>
<text top="677" left="563" width="105" height="19" font="3">GDMT plus a ICD </text>
<text top="695" left="563" width="92" height="19" font="3">(829 patients)  </text>
<text top="714" left="563" width="3" height="19" font="4"><b> </b></text>
<text top="732" left="563" width="96" height="19" font="4"><b>Intervention 2:</b> </text>
<text top="659" left="696" width="125" height="19" font="4"><b>All-cause mortality: </b></text>
<text top="677" left="696" width="150" height="19" font="3">control 36% vs. ICD 29% </text>
<text top="695" left="696" width="152" height="19" font="3">(RRR -23% and ARR -7%) </text>
<text top="659" left="874" width="193" height="19" font="3">● In patients with NYHA class II </text>
<text top="677" left="874" width="147" height="19" font="3">or III HF and LVEF≤35%, </text>
<text top="695" left="874" width="182" height="19" font="3">amiodarone has no favorable </text>
<text top="714" left="874" width="167" height="19" font="3">effect on survival, whereas </text>
<text top="732" left="874" width="166" height="19" font="3">single-lead, shock-only ICD </text>
<text top="750" left="874" width="147" height="19" font="3">therapy reduces overall </text>
</page>
<page number="25" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">25 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="238" width="112" height="19" font="3">risk of death from </text>
<text top="127" left="238" width="128" height="19" font="3">any cause in a broad </text>
<text top="145" left="238" width="86" height="19" font="3">population of </text>
<text top="164" left="238" width="115" height="19" font="3">patients with mild-</text>
<text top="182" left="238" width="101" height="19" font="3">to-moderate HF </text>
<text top="200" left="238" width="3" height="19" font="3"> </text>
<text top="218" left="238" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="237" left="238" width="75" height="19" font="3">prospective </text>
<text top="255" left="238" width="101" height="19" font="3">multicenter RCT </text>
<text top="273" left="238" width="3" height="19" font="3"> </text>
<text top="292" left="238" width="126" height="19" font="4"><b>Size:</b> 2521 patients   </text>
<text top="109" left="563" width="71" height="19" font="3">GDMT plus </text>
<text top="127" left="563" width="108" height="19" font="3">amiodarone (845 </text>
<text top="145" left="563" width="58" height="19" font="3">patients) </text>
<text top="164" left="563" width="3" height="19" font="3"> </text>
<text top="182" left="563" width="97" height="19" font="4"><b>Comparator 1:</b>  </text>
<text top="200" left="563" width="71" height="19" font="3">GDMT plus </text>
<text top="219" left="563" width="82" height="19" font="3">Placebo (847 </text>
<text top="237" left="563" width="58" height="19" font="3">patients) </text>
<text top="255" left="563" width="3" height="19" font="4"><b> </b></text>
<text top="273" left="563" width="3" height="19" font="3"> </text>
<text top="109" left="874" width="190" height="19" font="3">mortality. This was the longest </text>
<text top="127" left="874" width="127" height="19" font="3">and largest ICD trial. </text>
<text top="311" left="123" width="71" height="19" font="3">● <b>MADIT-II </b></text>
<text top="329" left="123" width="82" height="19" font="3">● Moss et al. </text>
<text top="347" left="123" width="65" height="19" font="3">2002 (44)  </text>
<text top="366" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11907286">● </a></text>
<text top="366" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11907286">11907286</a></text>
<text top="366" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11907286"> </a></text>
<text top="384" left="123" width="3" height="19" font="3"> </text>
<text top="311" left="238" width="110" height="19" font="4"><b>Aim:</b>  To evaluate </text>
<text top="329" left="238" width="126" height="19" font="3">the benefit of ICD in </text>
<text top="347" left="238" width="117" height="19" font="3">patients with prior </text>
<text top="366" left="238" width="100" height="19" font="3">MI and reduced </text>
<text top="384" left="238" width="32" height="19" font="3">LVEF </text>
<text top="402" left="238" width="3" height="19" font="3"> </text>
<text top="421" left="238" width="108" height="19" font="4"><b>Study type:</b>   RCT </text>
<text top="439" left="238" width="3" height="19" font="3"> </text>
<text top="457" left="238" width="126" height="19" font="4"><b>Size: </b>1232 patients  <b> </b></text>
<text top="311" left="382" width="143" height="19" font="4"><b>Inclusion:</b>  Prior MI (&gt;1 </text>
<text top="329" left="382" width="86" height="19" font="3">mo), EF ≤30% </text>
<text top="347" left="382" width="3" height="19" font="3"> </text>
<text top="366" left="382" width="115" height="19" font="4"><b>Exclusion:</b> existing </text>
<text top="384" left="382" width="152" height="19" font="3">indication for ICD; NYHA </text>
<text top="402" left="382" width="165" height="19" font="3">class IV at enrollment; had </text>
<text top="421" left="382" width="128" height="19" font="3">undergone coronary </text>
<text top="439" left="382" width="152" height="19" font="3">revascularization &lt;3 mo; </text>
<text top="457" left="382" width="123" height="19" font="3">MI &lt;30 d, advanced </text>
<text top="476" left="382" width="153" height="19" font="3">cerebrovascular disease, </text>
<text top="494" left="382" width="154" height="19" font="3">childbearing age and not </text>
<text top="512" left="382" width="127" height="19" font="3">using contraceptive, </text>
<text top="531" left="382" width="161" height="19" font="3">presence of any condition </text>
<text top="549" left="382" width="164" height="19" font="3">other than cardiac disease </text>
<text top="567" left="382" width="164" height="19" font="3">that was associated with a </text>
<text top="586" left="382" width="147" height="19" font="3">high likelihood of death </text>
<text top="604" left="382" width="115" height="19" font="3">during the trial, or </text>
<text top="622" left="382" width="125" height="19" font="3">unwilling to provide </text>
<text top="640" left="382" width="52" height="19" font="3">consent<b> </b></text>
<text top="311" left="563" width="82" height="19" font="4"><b>Comparator</b>: </text>
<text top="329" left="563" width="79" height="19" font="3">Control (490 </text>
<text top="347" left="563" width="58" height="19" font="3">patients) </text>
<text top="366" left="563" width="3" height="19" font="3"> </text>
<text top="384" left="563" width="89" height="19" font="4"><b>Intervention:</b>  </text>
<text top="402" left="563" width="113" height="19" font="3">ICD (742 patients) </text>
<text top="421" left="563" width="3" height="19" font="4"><b> </b></text>
<text top="311" left="696" width="125" height="19" font="4"><b>All-cause mortality: </b></text>
<text top="329" left="696" width="150" height="19" font="3">control 22% vs. ICD 16% </text>
<text top="347" left="696" width="152" height="19" font="3">(RRR -28% and ARR -6%)<b> </b></text>
<text top="311" left="874" width="175" height="19" font="3">● In patients with a prior MI </text>
<text top="329" left="874" width="181" height="19" font="3">and advanced left ventricular </text>
<text top="347" left="874" width="182" height="19" font="3">dysfunction, prophylactic ICD </text>
<text top="366" left="874" width="199" height="19" font="3">improves survival and should be </text>
<text top="384" left="874" width="191" height="19" font="3">considered as a recommended </text>
<text top="402" left="874" width="55" height="19" font="3">therapy. </text>
<text top="659" left="115" width="4" height="21" font="0"> </text>
<text top="659" left="331" width="4" height="21" font="2"><b> </b></text>
</page>
<page number="26" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">26 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="818" height="21" font="2"><b>Data Supplement 9. Nonrandomized Trials, Observational Studies, and/or Registries of EP Study for VA - (Section 4.3.2) </b></text>
<text top="129" left="141" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="147" left="167" width="51" height="19" font="4"><b>Author; </b></text>
<text top="165" left="145" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="129" left="275" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="147" left="304" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="129" left="443" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="129" left="634" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="147" left="647" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="165" left="678" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="129" left="882" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="147" left="911" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="184" left="123" width="127" height="19" font="3">● Hilfiker et al. 2015 </text>
<text top="203" left="123" width="28" height="19" font="3">(45) </text>
<text top="221" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26131339">● </a></text>
<text top="221" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26131339">26131339</a></text>
<text top="221" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26131339"> </a></text>
<text top="239" left="123" width="3" height="19" font="3"> </text>
<text top="184" left="275" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="203" left="275" width="118" height="19" font="3">prospective cohort </text>
<text top="221" left="275" width="3" height="19" font="4"><b> </b></text>
<text top="239" left="275" width="111" height="19" font="4"><b>Size:</b> 265 patients </text>
<text top="184" left="414" width="164" height="19" font="4"><b>Inclusion criteria:</b> Patients </text>
<text top="203" left="414" width="175" height="19" font="3">who underwent EPS for SCD </text>
<text top="221" left="414" width="161" height="19" font="3">risk evaluation because of </text>
<text top="239" left="414" width="144" height="19" font="3">structural or functional </text>
<text top="258" left="414" width="130" height="19" font="3">heart disease and/or </text>
<text top="276" left="414" width="131" height="19" font="3">electrical conduction </text>
<text top="294" left="414" width="155" height="19" font="3">abnormality and/or after </text>
<text top="313" left="414" width="80" height="19" font="3">syncope/CA. </text>
<text top="331" left="414" width="3" height="19" font="4"><b> </b></text>
<text top="349" left="414" width="139" height="19" font="4"><b>Exclusion criteria:</b> Not </text>
<text top="368" left="414" width="58" height="19" font="3">specified </text>
<text top="185" left="606" width="201" height="19" font="4"><b>1</b>°<b> endpoint:</b> SCD or appropriate </text>
<text top="204" left="606" width="75" height="19" font="3">ICD therapy </text>
<text top="222" left="606" width="3" height="19" font="4"><b> </b></text>
<text top="240" left="606" width="162" height="19" font="4"><b>Results:</b> Sustained VT was </text>
<text top="258" left="606" width="196" height="19" font="3">induced in 125 patients (47.2%) </text>
<text top="277" left="606" width="169" height="19" font="3">and non-sustained VT in 60 </text>
<text top="295" left="606" width="103" height="19" font="3">patients (22.6%) </text>
<text top="314" left="606" width="200" height="19" font="3">153 patients (57.7%) underwent </text>
<text top="332" left="606" width="106" height="19" font="3">ICD implantation </text>
<text top="350" left="606" width="204" height="19" font="3">1° endpoint event occurred in 49 </text>
<text top="368" left="606" width="107" height="19" font="3">patients (18.5%). </text>
<text top="387" left="606" width="195" height="19" font="3">Cox regression analysis showed </text>
<text top="405" left="606" width="184" height="19" font="3">that both sustained VT during </text>
<text top="423" left="606" width="205" height="19" font="3">EPS (HR: 2.26; 95% CI: 1.22–4.19, </text>
<text top="442" left="606" width="191" height="19" font="3">p=0.009) and EF&lt;5% (HR: 2.00; </text>
<text top="460" left="606" width="208" height="19" font="3">95% CI: 1.13–3.54, p=0.018) were </text>
<text top="478" left="606" width="179" height="19" font="3">independent predictors of 1° </text>
<text top="497" left="606" width="106" height="19" font="3">endpoint events. </text>
<text top="184" left="827" width="193" height="19" font="3">● Mixed population of patients </text>
<text top="203" left="827" width="239" height="19" font="3">● EPS identifies patients who are likely </text>
<text top="221" left="827" width="179" height="19" font="3">to have recurrent VA or SCD. </text>
<text top="516" left="123" width="127" height="19" font="3">● Bourke et al. 1991 </text>
<text top="534" left="123" width="28" height="19" font="3">(46) </text>
<text top="552" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1907984">● </a></text>
<text top="552" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1907984">1907984</a></text>
<text top="552" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1907984"> </a></text>
<text top="571" left="123" width="3" height="19" font="3"> </text>
<text top="516" left="275" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="534" left="275" width="118" height="19" font="3">prospective cohort </text>
<text top="552" left="275" width="3" height="19" font="4"><b> </b></text>
<text top="570" left="275" width="126" height="19" font="4"><b>Size: </b> 1209 patients<b>  </b></text>
<text top="516" left="414" width="154" height="19" font="4"><b>Inclusion criteria:</b> recent </text>
<text top="534" left="414" width="29" height="19" font="3">AMI </text>
<text top="552" left="414" width="3" height="19" font="4"><b> </b></text>
<text top="570" left="414" width="147" height="19" font="4"><b>Exclusion criteria:</b> early </text>
<text top="589" left="414" width="130" height="19" font="3">recurrence of angina </text>
<text top="607" left="414" width="128" height="19" font="3">requiring treatment; </text>
<text top="626" left="414" width="172" height="19" font="3">spontaneous VT or VF more </text>
<text top="644" left="414" width="170" height="19" font="3">than 48 h after MI; CHF not </text>
<text top="662" left="414" width="173" height="19" font="3">controlled with furosemide; </text>
<text top="680" left="414" width="136" height="19" font="3">significant noncardiac </text>
<text top="699" left="414" width="49" height="19" font="3">disease </text>
<text top="516" left="606" width="162" height="19" font="4"><b>1</b>°<b> endpoint:</b> documented </text>
<text top="535" left="606" width="184" height="19" font="3">sustained VT/VF or witnessed </text>
<text top="553" left="606" width="87" height="19" font="3">sudden death </text>
<text top="571" left="606" width="3" height="19" font="4"><b> </b></text>
<text top="590" left="606" width="205" height="19" font="4"><b>Results:</b> Sustained monomorphic </text>
<text top="608" left="606" width="207" height="19" font="3">VT was inducible by programmed </text>
<text top="626" left="606" width="165" height="19" font="3">electrical stimulation in 75 </text>
<text top="645" left="606" width="46" height="19" font="3">(6.2%). </text>
<text top="663" left="606" width="189" height="19" font="3">14 infarct survivors (19%) with </text>
<text top="681" left="606" width="157" height="19" font="3">inducible VT experienced </text>
<text top="699" left="606" width="202" height="19" font="3">spontaneous VT or VF compared </text>
<text top="718" left="606" width="196" height="19" font="3">with 34 (2.9%) of those without </text>
<text top="736" left="606" width="152" height="19" font="3">inducible VT (p&lt;0.0005). </text>
<text top="754" left="606" width="3" height="19" font="4"><b> </b></text>
<text top="516" left="827" width="223" height="19" font="3">● EPS predicts VT/VF in follow-up of </text>
<text top="534" left="827" width="103" height="19" font="3">survivors of AMI </text>
<text top="552" left="827" width="3" height="19" font="3"> </text>
</page>
<page number="27" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">27 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="120" height="19" font="3">● Bailey et al. 2001 </text>
<text top="127" left="123" width="28" height="19" font="3">(47) </text>
<text top="145" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11738292">● </a></text>
<text top="145" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11738292">11738292</a></text>
<text top="145" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11738292"> </a></text>
<text top="164" left="123" width="3" height="19" font="3"> </text>
<text top="109" left="275" width="110" height="19" font="4"><b>Study type:</b> meta-</text>
<text top="127" left="275" width="51" height="19" font="3">analysis </text>
<text top="145" left="275" width="3" height="19" font="4"><b> </b></text>
<text top="164" left="275" width="117" height="19" font="4"><b>Size:</b> 4022 post-MI </text>
<text top="182" left="275" width="53" height="19" font="3">patients </text>
<text top="109" left="414" width="178" height="19" font="4"><b>Inclusion criteria:</b> 44 reports </text>
<text top="127" left="414" width="177" height="19" font="3">for which incidence of major </text>
<text top="145" left="414" width="141" height="19" font="3">arrhythmic events and </text>
<text top="164" left="414" width="177" height="19" font="3">predictive accuracy could be </text>
<text top="182" left="414" width="53" height="19" font="3">inferred </text>
<text top="200" left="414" width="3" height="19" font="4"><b> </b></text>
<text top="218" left="414" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="109" left="606" width="187" height="19" font="4"><b>1</b>°<b> endpoint:</b> sustained VT/VF, </text>
<text top="128" left="606" width="111" height="19" font="3">CA, sudden death </text>
<text top="146" left="606" width="3" height="19" font="4"><b> </b></text>
<text top="164" left="606" width="196" height="19" font="4"><b>Results:</b> positive EPS had 61.6% </text>
<text top="183" left="606" width="196" height="19" font="3">sensitivity and 84.1% specificity </text>
<text top="201" left="606" width="172" height="19" font="3">2 y probability of event was </text>
<text top="219" left="606" width="41" height="19" font="3">25.5% </text>
<text top="238" left="606" width="90" height="19" font="3">RR 6.6; OR 8.5 </text>
<text top="256" left="606" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="827" width="215" height="19" font="3">● Multiple tests evaluated: SAECG; </text>
<text top="127" left="827" width="215" height="19" font="3">heart rate variability; severe VA on </text>
<text top="145" left="827" width="226" height="19" font="3">ambulatory electrocardiography; EF; </text>
<text top="164" left="827" width="59" height="19" font="3">and EPS.  </text>
<text top="182" left="827" width="229" height="19" font="3">● Results for all tests evaluated were </text>
<text top="200" left="827" width="44" height="19" font="3">similar </text>
<text top="219" left="827" width="247" height="19" font="3">● EPS has moderate predictive value for </text>
<text top="237" left="827" width="123" height="19" font="3">life-threatening VA. </text>
<text top="275" left="123" width="130" height="19" font="3">● Schmitt et al. 2001 </text>
<text top="293" left="123" width="28" height="19" font="3">(48) </text>
<text top="312" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11401129">● </a></text>
<text top="312" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11401129">11401129</a></text>
<text top="312" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11401129"> </a></text>
<text top="330" left="123" width="3" height="19" font="3"> </text>
<text top="275" left="275" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="293" left="275" width="118" height="19" font="3">prospective cohort </text>
<text top="311" left="275" width="3" height="19" font="4"><b> </b></text>
<text top="330" left="275" width="101" height="19" font="4"><b>Size:</b> 98 post-MI </text>
<text top="348" left="275" width="115" height="19" font="3">patients identified </text>
<text top="367" left="275" width="89" height="19" font="3">as high risk by </text>
<text top="385" left="275" width="76" height="19" font="3">noninvasive </text>
<text top="403" left="275" width="60" height="19" font="3">markers<b>   </b></text>
<text top="275" left="414" width="162" height="19" font="4"><b>Inclusion criteria:</b> post-MI </text>
<text top="293" left="414" width="158" height="19" font="3">patents identified as high </text>
<text top="312" left="414" width="136" height="19" font="3">risk by scoring system </text>
<text top="330" left="414" width="144" height="19" font="3">including EF, PVCs, and </text>
<text top="348" left="414" width="106" height="19" font="3">abnormal SAECG </text>
<text top="367" left="414" width="3" height="19" font="4"><b> </b></text>
<text top="385" left="414" width="149" height="19" font="4"><b>Exclusion criteria:</b> Hx of </text>
<text top="403" left="414" width="163" height="19" font="3">spontaneous sustained VT </text>
<text top="276" left="606" width="172" height="19" font="4"><b>1</b>°<b> endpoint:</b> sudden death, </text>
<text top="294" left="606" width="126" height="19" font="3">symptomatic VT, CA </text>
<text top="312" left="606" width="3" height="19" font="4"><b> </b></text>
<text top="331" left="606" width="205" height="19" font="4"><b>Results:</b> Patients underwent EPS. </text>
<text top="349" left="606" width="164" height="19" font="3">Event rate was 33% with a </text>
<text top="367" left="606" width="199" height="19" font="3">positive EPS vs. 2.6% (p&lt;0.0001) </text>
<text top="386" left="606" width="126" height="19" font="3">with a negative EPS. </text>
<text top="404" left="606" width="3" height="19" font="4"><b> </b></text>
<text top="275" left="827" width="229" height="19" font="3">● A subgroup of 96 high-risk patients </text>
<text top="293" left="827" width="59" height="19" font="3">declined  </text>
<text top="312" left="827" width="205" height="19" font="3">● EPS. In this non-consent group, </text>
<text top="330" left="827" width="223" height="19" font="3">cardiac mortality (combined sudden </text>
<text top="348" left="827" width="206" height="19" font="3">and nonsudden) was significantly </text>
<text top="367" left="827" width="243" height="19" font="3">higher (log-rank chi-square 9.38 RR 4.7; </text>
<text top="385" left="827" width="239" height="19" font="3">95% CI: 1.6–13.9, p=0.0022) compared </text>
<text top="403" left="827" width="243" height="19" font="3">to group treated according to results of </text>
<text top="422" left="827" width="29" height="19" font="3">EPS. </text>
<text top="440" left="827" width="237" height="19" font="3">20/21 patients with a positive EPS had </text>
<text top="458" left="827" width="94" height="19" font="3">ICD implanted. </text>
<text top="476" left="827" width="3" height="19" font="3"> </text>
<text top="496" left="123" width="133" height="19" font="3">● Brembilla-Perrot et </text>
<text top="514" left="123" width="79" height="19" font="3">al. 2004 (49) </text>
<text top="532" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15358027">● </a></text>
<text top="532" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15358027">15358027</a></text>
<text top="532" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15358027"> </a></text>
<text top="550" left="123" width="3" height="19" font="3"> </text>
<text top="495" left="275" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="514" left="275" width="74" height="19" font="3">Prospective </text>
<text top="532" left="275" width="87" height="19" font="3">observational </text>
<text top="550" left="275" width="3" height="19" font="3"> </text>
<text top="569" left="275" width="111" height="19" font="4"><b>Size:</b> 180 patients </text>
<text top="587" left="275" width="118" height="19" font="3">(119 CAD, group 1; </text>
<text top="605" left="275" width="111" height="19" font="3">61 DCM, group 2) </text>
<text top="495" left="414" width="165" height="19" font="4"><b>Inclusion criteria:</b>  EF&lt;40% </text>
<text top="514" left="414" width="80" height="19" font="3">and syncope </text>
<text top="532" left="414" width="3" height="19" font="3"> </text>
<text top="550" left="414" width="173" height="19" font="4"><b>Exclusion criteria:</b>  unstable </text>
<text top="569" left="414" width="166" height="19" font="3">angina; recent AMI; recent </text>
<text top="587" left="414" width="148" height="19" font="3">coronary angioplasty or </text>
<text top="605" left="414" width="144" height="19" font="3">CABG; second- or third-</text>
<text top="624" left="414" width="168" height="19" font="3">degree AV block; sustained </text>
<text top="642" left="414" width="120" height="19" font="3">supraventricular or </text>
<text top="660" left="414" width="144" height="19" font="3">ventricular arrhythmia; </text>
<text top="679" left="414" width="173" height="19" font="3">clinical HF not controlled by </text>
<text top="697" left="414" width="159" height="19" font="3">furosemide; uncontrolled </text>
<text top="715" left="414" width="160" height="19" font="3">electrolyte abnormalities; </text>
<text top="734" left="414" width="136" height="19" font="3">significant noncardiac </text>
<text top="752" left="414" width="146" height="19" font="3">disease; or amiodarone </text>
<text top="770" left="414" width="69" height="19" font="3">treatment. </text>
<text top="496" left="606" width="191" height="19" font="4"><b>1</b>°<b> endpoint:</b>  cardiac mortality </text>
<text top="515" left="606" width="3" height="19" font="3"> </text>
<text top="533" left="606" width="165" height="19" font="4"><b>Results:</b>  Sustained VT was </text>
<text top="551" left="606" width="185" height="19" font="3">induced in 44 group I patients </text>
<text top="570" left="606" width="187" height="19" font="3">(37%) and 13 group II patients </text>
<text top="588" left="606" width="193" height="19" font="3">(21%); VFL (&gt;270 beats/min) or </text>
<text top="606" left="606" width="178" height="19" font="3">VF was induced in 24 group I </text>
<text top="624" left="606" width="179" height="19" font="3">patients (19%) and 9 group II </text>
<text top="643" left="606" width="92" height="19" font="3">patients (15%) </text>
<text top="661" left="606" width="207" height="19" font="3">VT or VF induction was predictive </text>
<text top="679" left="606" width="207" height="19" font="3">of mortality in CAD and identified </text>
<text top="698" left="606" width="157" height="19" font="3">a group with high cardiac </text>
<text top="716" left="606" width="197" height="19" font="3">mortality (46%), compared with </text>
<text top="734" left="606" width="191" height="19" font="3">patients with a negative study, </text>
<text top="753" left="606" width="195" height="19" font="3">who had a lower mortality (6%; </text>
<text top="496" left="827" width="210" height="19" font="3">● EPS may be useful to determine </text>
<text top="514" left="827" width="241" height="19" font="3">mechanism of syncope in patients with </text>
<text top="532" left="827" width="163" height="19" font="3">ischemic cardiomyopathy. </text>
<text top="550" left="827" width="3" height="19" font="3"> </text>
</page>
<page number="28" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">28 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="606" width="196" height="19" font="3">p&lt;0.001). Cardiac mortality was </text>
<text top="127" left="606" width="196" height="19" font="3">only correlated with EF in DCM. </text>
<text top="146" left="123" width="117" height="19" font="3">● Bhandari AK Circ </text>
<text top="164" left="123" width="30" height="19" font="3">1985</text>
<text top="163" left="154" width="4" height="21" font="0"> </text>
<text top="164" left="157" width="28" height="19" font="3">(50) </text>
<text top="183" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2856866">● </a></text>
<text top="183" left="136" width="53" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2856866">2856866</a></text>
<text top="183" left="189" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2856866"> </a></text>
<text top="146" left="275" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="164" left="275" width="123" height="19" font="3">retrospective single </text>
<text top="183" left="275" width="43" height="19" font="3">center </text>
<text top="201" left="275" width="3" height="19" font="3"> </text>
<text top="219" left="275" width="50" height="19" font="4"><b>Size:</b> 15<b> </b></text>
<text top="146" left="414" width="149" height="19" font="4"><b>Inclusion criteria:</b>  LQTS </text>
<text top="164" left="414" width="129" height="19" font="3">with syncope or ACA </text>
<text top="183" left="414" width="127" height="19" font="3">Mean QTc 550 msec </text>
<text top="201" left="414" width="3" height="19" font="3"> </text>
<text top="219" left="414" width="170" height="19" font="3">11 control subjects, normal </text>
<text top="238" left="414" width="27" height="19" font="3">QTc </text>
<text top="256" left="414" width="113" height="19" font="4"><b>Exclusion criteria: </b></text>
<text top="274" left="414" width="34" height="19" font="3">N/A   </text>
<text top="147" left="606" width="197" height="19" font="4"><b>1</b>°<b> endpoint:</b>  EP testing in LQTS </text>
<text top="165" left="606" width="3" height="19" font="3"> </text>
<text top="183" left="606" width="161" height="19" font="4"><b>Results:</b>  RV and LV EPS, 3 </text>
<text top="202" left="606" width="188" height="19" font="3">extrastimuli, with and without </text>
<text top="220" left="606" width="45" height="19" font="3">isuprel </text>
<text top="238" left="606" width="171" height="19" font="3">Rapid polymorphic VT: 40% </text>
<text top="257" left="606" width="208" height="19" font="3">No pt with inducible sustained VT </text>
<text top="275" left="606" width="35" height="19" font="3">or VF </text>
<text top="146" left="827" width="217" height="19" font="3">● Inducibility of nonsust VT did not </text>
<text top="164" left="827" width="198" height="19" font="3">provide prognostic information. </text>
<text top="183" left="827" width="191" height="19" font="3">● EP studies of limited value in </text>
<text top="201" left="827" width="236" height="19" font="3">diagnosis, treatment of LQTS patients. </text>
<text top="219" left="827" width="3" height="19" font="3"> </text>
<text top="294" left="123" width="109" height="19" font="3">● Giustetto<b> </b>C EHJ </text>
<text top="312" left="123" width="62" height="19" font="3">2006 (51) </text>
<text top="331" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16926178">● </a></text>
<text top="331" left="136" width="64" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16926178">16926178 </a></text>
<text top="331" left="200" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16926178"> </a></text>
<text top="294" left="275" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="312" left="275" width="126" height="19" font="3">Retrospective single </text>
<text top="331" left="275" width="43" height="19" font="3">center </text>
<text top="349" left="275" width="3" height="19" font="3"> </text>
<text top="367" left="275" width="61" height="19" font="4"><b>Size:</b>    29<b> </b></text>
<text top="294" left="414" width="178" height="19" font="4"><b>Inclusion criteria:</b>  Short QTc </text>
<text top="312" left="414" width="168" height="19" font="3">≤340 msec and personal or </text>
<text top="331" left="414" width="172" height="19" font="3">family Hx of CA. 73% males. </text>
<text top="349" left="414" width="3" height="19" font="3"> </text>
<text top="367" left="414" width="148" height="19" font="4"><b>Exclusion criteria:</b> N/A  <b> </b></text>
<text top="386" left="501" width="3" height="19" font="3"> </text>
<text top="295" left="606" width="179" height="19" font="4"><b>1</b>°<b> endpoint:</b>  outcomes with </text>
<text top="313" left="606" width="146" height="19" font="3">AICD or hydroquinidine </text>
<text top="332" left="606" width="3" height="19" font="3"> </text>
<text top="350" left="606" width="187" height="19" font="4"><b>Results:</b> Median age dx 30y (4-</text>
<text top="368" left="606" width="197" height="19" font="3">80); 62% symptomatic: syncope </text>
<text top="386" left="606" width="166" height="19" font="3">24%, AF 31%. 34% ACA (10 </text>
<text top="405" left="606" width="206" height="19" font="3">patients); 2/10 had CA in infancy. </text>
<text top="423" left="606" width="206" height="19" font="3">In 28% ACA was initial symptom.  </text>
<text top="441" left="606" width="146" height="19" font="3">ICD implanted in 14; 10 </text>
<text top="460" left="606" width="207" height="19" font="3">hydroquinidine. Median followup </text>
<text top="478" left="606" width="159" height="19" font="3">23 mo (9-49), one pt with </text>
<text top="496" left="605" width="199" height="19" font="3">appropriate ICD shock. No pt on </text>
<text top="515" left="605" width="167" height="19" font="3">hydroquinidine had SCD or </text>
<text top="533" left="605" width="64" height="19" font="3">syncope.   </text>
<text top="551" left="605" width="3" height="19" font="3"> </text>
<text top="570" left="606" width="186" height="19" font="3">ES 18/29: Ventricular ERP 140-</text>
<text top="588" left="606" width="180" height="19" font="3">180 msec. VF induced in 61% </text>
<text top="606" left="606" width="208" height="19" font="3">(11/18); 3/6 with documented VF </text>
<text top="624" left="606" width="206" height="19" font="3">had inducible VF: sensitivity 50%. </text>
<text top="643" left="606" width="200" height="19" font="3">AERP CL 600: 120-180 ms, mean </text>
<text top="661" left="606" width="30" height="19" font="3">157. </text>
<text top="294" left="827" width="228" height="19" font="3">●Short QTS may be a cause of SCD in </text>
<text top="312" left="827" width="47" height="19" font="3">infancy </text>
<text top="331" left="827" width="234" height="19" font="3">● Hydroquinidine may be proposed in </text>
<text top="349" left="827" width="219" height="19" font="3">children or patients not suitable for </text>
<text top="367" left="827" width="33" height="19" font="3">AICD </text>
<text top="386" left="827" width="132" height="19" font="3">● PES sensitivity 50% </text>
<text top="404" left="827" width="3" height="19" font="3"> </text>
<text top="422" left="827" width="3" height="19" font="3"> </text>
<text top="680" left="123" width="105" height="19" font="3">● Mahida S JACC </text>
<text top="698" left="123" width="62" height="19" font="3">2015 (52)<b> </b></text>
<text top="717" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25593056">● </a></text>
<text top="717" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25593056">25593056</a></text>
<text top="717" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25593056"> </a></text>
<text top="680" left="275" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="698" left="275" width="74" height="19" font="3">multicenter </text>
<text top="717" left="275" width="87" height="19" font="3">observational </text>
<text top="735" left="275" width="3" height="19" font="3"> </text>
<text top="753" left="275" width="50" height="19" font="4"><b>Size:</b> 81<b> </b></text>
<text top="680" left="414" width="171" height="19" font="4"><b>Inclusion criteria:</b>   Patients </text>
<text top="698" left="414" width="166" height="19" font="3">with ER and ACA due to VF </text>
<text top="717" left="414" width="164" height="19" font="3">underwent EPS. Mean age </text>
<text top="735" left="414" width="173" height="19" font="3">36 ± 13y. Followup with ICD </text>
<text top="753" left="414" width="97" height="19" font="3">interrogations.  </text>
<text top="772" left="414" width="3" height="19" font="3"> </text>
<text top="681" left="606" width="201" height="19" font="4"><b>1</b>°<b> endpoint:</b> Inducibility of VF in </text>
<text top="699" left="606" width="205" height="19" font="3">patients with ACA and ER on ECG </text>
<text top="718" left="606" width="204" height="19" font="3">and outcomes. Followup 7±4.9 y  </text>
<text top="736" left="606" width="3" height="19" font="3"> </text>
<text top="754" left="606" width="185" height="19" font="4"><b>Results:</b>  VF inducible in 22%.  </text>
<text top="680" left="827" width="243" height="19" font="3">● EPS not useful to risk stratify patients </text>
<text top="698" left="827" width="167" height="19" font="3">with prior VF arrest and ER </text>
<text top="717" left="827" width="3" height="19" font="3"> </text>
</page>
<page number="29" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">29 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="414" width="151" height="19" font="4"><b>Exclusion criteria:</b>  N/A  <b> </b></text>
<text top="109" left="606" width="202" height="19" font="3">Recurrent VF in 33% of inducible </text>
<text top="127" left="606" width="184" height="19" font="3">VF, vs. 33% of those with non-</text>
<text top="145" left="606" width="158" height="19" font="3">inducible VF. p=NS, 0.93.  </text>
<text top="164" left="606" width="195" height="19" font="3">VF inducibility did not correlate </text>
<text top="182" left="606" width="185" height="19" font="3">with max J wave amplitude or </text>
<text top="200" left="606" width="74" height="19" font="3">distribution </text>
<text top="218" left="606" width="3" height="19" font="4"><b> </b></text>
<text top="238" left="123" width="117" height="19" font="3">● Giustetto<b> </b>C JACC </text>
<text top="256" left="123" width="62" height="19" font="3">2011 (53) </text>
<text top="274" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21798421">● </a></text>
<text top="274" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21798421">21798421</a></text>
<text top="274" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21798421"> </a></text>
<text top="237" left="275" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="256" left="275" width="121" height="19" font="3">retrospective multi-</text>
<text top="274" left="275" width="46" height="19" font="3">center  </text>
<text top="292" left="275" width="3" height="19" font="3"> </text>
<text top="311" left="275" width="64" height="19" font="4"><b>Size: </b>53    <b> </b></text>
<text top="237" left="414" width="177" height="19" font="4"><b>Inclusion criteria</b>:  European </text>
<text top="256" left="414" width="162" height="19" font="3">Short QT Registry<b> </b>patients<b> </b></text>
<text top="274" left="414" width="176" height="19" font="3">with QTc ≤360 msec with Hx </text>
<text top="293" left="414" width="123" height="19" font="3">sudden death, ACA, </text>
<text top="311" left="414" width="61" height="19" font="3">syncope;  </text>
<text top="329" left="414" width="144" height="19" font="3">patients with QTc ≤340 </text>
<text top="347" left="414" width="142" height="19" font="3">msec included without </text>
<text top="366" left="414" width="74" height="19" font="3">symptoms.  </text>
<text top="384" left="414" width="7" height="19" font="3">  </text>
<text top="402" left="414" width="76" height="19" font="3">75% males.  </text>
<text top="421" left="414" width="3" height="19" font="3"> </text>
<text top="439" left="414" width="151" height="19" font="3">Family Hx SCD/CA (11).   </text>
<text top="457" left="414" width="160" height="19" font="3">Genotype positive 23% of </text>
<text top="476" left="414" width="132" height="19" font="3">probands:  HERG in 4 </text>
<text top="494" left="414" width="169" height="19" font="3">families (N588K in 2, T6181 </text>
<text top="512" left="414" width="178" height="19" font="3">in 2; CACNB2b in one family) </text>
<text top="531" left="414" width="3" height="19" font="3"> </text>
<text top="549" left="414" width="151" height="19" font="4"><b>Exclusion criteria:</b>  N/A  <b> </b></text>
<text top="238" left="606" width="175" height="19" font="4"><b>1</b>°<b> endpoint:</b> syncope, CA or </text>
<text top="257" left="606" width="154" height="19" font="3">approp ICD shocks SQTS  </text>
<text top="275" left="606" width="3" height="19" font="3"> </text>
<text top="293" left="606" width="195" height="19" font="4"><b>Results:</b>  Mean Followup 64±27 </text>
<text top="312" left="606" width="183" height="19" font="3">mo. Median age 26 y (IQR 17–</text>
<text top="330" left="606" width="203" height="19" font="3">39). 62% symptomatic: 32% with </text>
<text top="348" left="606" width="174" height="19" font="3">ACA (13 patients) or sudden </text>
<text top="367" left="606" width="183" height="19" font="3">death (4), syncope (8), AF (6), </text>
<text top="385" left="606" width="114" height="19" font="3">palpatations (13).  </text>
<text top="403" left="606" width="133" height="19" font="3">Age at CA 3 mo–62 y. </text>
<text top="422" left="606" width="181" height="19" font="3"> Males:  &gt;90% of CA occurred </text>
<text top="440" left="606" width="116" height="19" font="3">between 14–40 y.  </text>
<text top="458" left="606" width="163" height="19" font="3">Prevalence CA males 35%, </text>
<text top="476" left="606" width="88" height="19" font="3">females 30%.  </text>
<text top="495" left="606" width="207" height="19" font="3">AICD in 24, hydroquinidine in 12.  </text>
<text top="513" left="606" width="207" height="19" font="3">11/12 with prior CA received ICD: </text>
<text top="531" left="606" width="160" height="19" font="3">2 approp ICD shocks. 58% </text>
<text top="550" left="606" width="191" height="19" font="3">complications of ICD, inapprop </text>
<text top="568" left="606" width="133" height="19" font="3">shocks due to T wave </text>
<text top="586" left="606" width="115" height="19" font="3">oversensing 4/14.  </text>
<text top="605" left="606" width="185" height="19" font="3">PES: 28 patients. VERP CL 600-</text>
<text top="623" left="606" width="195" height="19" font="3">500: mean 166 msec. AERP 166 </text>
<text top="641" left="606" width="200" height="19" font="3">msec. VF induced in 16/28: 3/28 </text>
<text top="660" left="606" width="192" height="19" font="3">with prior CA = sensitivity 37%, </text>
<text top="678" left="606" width="72" height="19" font="3">NPVs 58%.  </text>
<text top="696" left="606" width="196" height="19" font="3">Overall event rate 3.3%/y: 4.9% </text>
<text top="714" left="606" width="184" height="19" font="3">in patients without AA drugs.  </text>
<text top="733" left="606" width="195" height="19" font="3">Asymptomatic patients: 27. ICD </text>
<text top="751" left="606" width="205" height="19" font="3">implanted in 9 due to + family Hx </text>
<text top="769" left="606" width="183" height="19" font="3">or induced VF. Two long term </text>
<text top="238" left="827" width="205" height="19" font="3">● SQTS assoc with SCD in all ages </text>
<text top="256" left="827" width="237" height="19" font="3">● Symptomatic patients have high risk </text>
<text top="274" left="827" width="191" height="19" font="3">of recurrent arrhythmic events </text>
<text top="293" left="827" width="242" height="19" font="3">● Patients treated with Hydroquinidine </text>
<text top="311" left="827" width="194" height="19" font="3">did not have arrhythmic events </text>
<text top="329" left="827" width="227" height="19" font="3">● Asymptomatic patients: no CA/ICD </text>
<text top="347" left="827" width="51" height="19" font="3">shocks.  </text>
<text top="366" left="827" width="122" height="19" font="3">● PES not sensitive  </text>
</page>
<page number="30" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">30 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="606" width="161" height="19" font="3">quinidine. One syncope; 2 </text>
<text top="127" left="606" width="122" height="19" font="3">nonsust VT on ICD.  </text>
<text top="146" left="123" width="125" height="19" font="3">● Raczak et al. 2004 </text>
<text top="164" left="123" width="28" height="19" font="3">(54) </text>
<text top="183" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15226627">● </a></text>
<text top="183" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15226627">15226627</a></text>
<text top="183" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15226627"> </a></text>
<text top="201" left="123" width="3" height="19" font="3"> </text>
<text top="146" left="275" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="164" left="275" width="122" height="19" font="3">prospective cohort  </text>
<text top="183" left="275" width="3" height="19" font="3"> </text>
<text top="201" left="275" width="115" height="19" font="4"><b>Size:</b>  112 patients </text>
<text top="146" left="414" width="166" height="19" font="4"><b>Inclusion criteria:</b>  post-MI </text>
<text top="164" left="414" width="165" height="19" font="3">patients with documented </text>
<text top="183" left="414" width="177" height="19" font="3">VF, sustained VT, or syncope </text>
<text top="201" left="414" width="62" height="19" font="3">and NSVT </text>
<text top="219" left="414" width="3" height="19" font="3"> </text>
<text top="237" left="414" width="165" height="19" font="4"><b>Exclusion criteria:</b> AF, SND </text>
<text top="256" left="414" width="121" height="19" font="3">or AV block, insulin-</text>
<text top="274" left="414" width="156" height="19" font="3">dependent DM, frequent </text>
<text top="293" left="414" width="123" height="19" font="3">(&gt;5%) ectopic beats </text>
<text top="147" left="606" width="181" height="19" font="4"><b>1</b>°<b> endpoint:</b> appropriate ICD </text>
<text top="165" left="606" width="200" height="19" font="3">shock or sudden or unwitnessed </text>
<text top="183" left="606" width="39" height="19" font="3">death </text>
<text top="202" left="606" width="3" height="19" font="3"> </text>
<text top="220" left="606" width="202" height="19" font="4"><b>Results:</b> Sustained VT induced in </text>
<text top="238" left="606" width="207" height="19" font="3">84% and 77% of patients who did </text>
<text top="257" left="606" width="202" height="19" font="3">or did not develop arrhythmia in </text>
<text top="275" left="606" width="116" height="19" font="3">follow-up (p=0.34) </text>
<text top="293" left="606" width="161" height="19" font="3">Baroreflex sensitivity &lt;3.3 </text>
<text top="312" left="606" width="200" height="19" font="3">ms/mmHg was only predictor of </text>
<text top="330" left="606" width="156" height="19" font="3">arrhythmia recurrence in </text>
<text top="348" left="606" width="207" height="19" font="3">patients with EF &lt;35% (sensitivity </text>
<text top="367" left="606" width="208" height="19" font="3">79%, specificity 74%, positive and </text>
<text top="385" left="606" width="125" height="19" font="3">NPVs 83% and 68%) </text>
<text top="403" left="606" width="3" height="19" font="3"> </text>
<text top="146" left="827" width="206" height="19" font="3">● 97 patients had ICDs implanted </text>
<text top="164" left="827" width="182" height="19" font="3">● EPS not useful in predicting </text>
<text top="183" left="827" width="153" height="19" font="3">arrhythmias in follow-up </text>
<text top="201" left="827" width="3" height="19" font="3"> </text>
<text top="422" left="123" width="47" height="19" font="3">● <b>AVID</b> </text>
<text top="441" left="123" width="132" height="19" font="3">● Brodsky et al. 2002 </text>
<text top="459" left="123" width="28" height="19" font="3">(55) </text>
<text top="477" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12228785">● </a></text>
<text top="477" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12228785">12228785</a></text>
<text top="477" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12228785"> </a></text>
<text top="496" left="123" width="3" height="19" font="3"> </text>
<text top="422" left="275" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="441" left="275" width="91" height="19" font="3">substudy from </text>
<text top="459" left="275" width="120" height="19" font="3">prospective clinical </text>
<text top="477" left="275" width="28" height="19" font="3">trial </text>
<text top="496" left="275" width="3" height="19" font="3"> </text>
<text top="514" left="275" width="115" height="19" font="4"><b>Size:</b>  572 patients </text>
<text top="422" left="414" width="168" height="19" font="4"><b>Inclusion criteria:</b>  patients </text>
<text top="441" left="414" width="176" height="19" font="3">with VF, VT with syncope, or </text>
<text top="459" left="414" width="164" height="19" font="3">sustained VT in the setting </text>
<text top="477" left="414" width="139" height="19" font="3">of LV dysfunction who </text>
<text top="496" left="414" width="96" height="19" font="3">underwent EPS </text>
<text top="514" left="414" width="3" height="19" font="3"> </text>
<text top="532" left="414" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="423" left="606" width="201" height="19" font="4"><b>1</b>°<b> endpoint:</b>  death or recurrent </text>
<text top="441" left="606" width="40" height="19" font="3">VT/VF </text>
<text top="460" left="606" width="3" height="19" font="3"> </text>
<text top="478" left="606" width="206" height="19" font="4"><b>Results:</b>  384 (67%) had inducible </text>
<text top="496" left="606" width="179" height="19" font="3">sustained VT or VF. Inducible </text>
<text top="515" left="606" width="207" height="19" font="3">patients were more likely to have </text>
<text top="533" left="606" width="200" height="19" font="3">CAD, previous infarction, and VT </text>
<text top="551" left="606" width="198" height="19" font="3">as their index arrhythmic event. </text>
<text top="570" left="606" width="188" height="19" font="3">Inducibility of VT or VF did not </text>
<text top="588" left="606" width="199" height="19" font="3">predict death or recurrent VT or </text>
<text top="606" left="606" width="23" height="19" font="3">VF. </text>
<text top="624" left="606" width="3" height="19" font="3"> </text>
<text top="422" left="827" width="247" height="19" font="3">● EPS is of limited value in patients with </text>
<text top="441" left="827" width="132" height="19" font="3">a Hx of sustained VA. </text>
<text top="459" left="827" width="3" height="19" font="3"> </text>
<text top="477" left="827" width="3" height="19" font="3"> </text>
<text top="643" left="123" width="70" height="19" font="3">● <b>MADIT II </b></text>
<text top="662" left="123" width="133" height="19" font="3">● Daubert et al. 2006 </text>
<text top="680" left="123" width="28" height="19" font="3">(56) </text>
<text top="698" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16386671">● </a></text>
<text top="698" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16386671">16386671</a></text>
<text top="698" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16386671"> </a></text>
<text top="717" left="123" width="3" height="19" font="3"> </text>
<text top="643" left="275" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="662" left="275" width="91" height="19" font="3">substudy from </text>
<text top="680" left="275" width="120" height="19" font="3">prospective clinical </text>
<text top="698" left="275" width="28" height="19" font="3">trial </text>
<text top="717" left="275" width="3" height="19" font="3"> </text>
<text top="735" left="275" width="121" height="19" font="4"><b>Size:</b>    593 patients </text>
<text top="643" left="414" width="168" height="19" font="4"><b>Inclusion criteria:</b>  Patients </text>
<text top="662" left="414" width="173" height="19" font="3">from MADIT II (previous MI, </text>
<text top="680" left="414" width="171" height="19" font="3">EF&lt;30%) who received ICDs </text>
<text top="698" left="414" width="123" height="19" font="3">and underwent EPS </text>
<text top="717" left="414" width="3" height="19" font="3"> </text>
<text top="735" left="414" width="164" height="19" font="4"><b>Exclusion criteria:</b>  control </text>
<text top="753" left="414" width="165" height="19" font="3">patients; ICD patients with </text>
<text top="772" left="414" width="45" height="19" font="3">no EPS </text>
<text top="644" left="606" width="187" height="19" font="4"><b>1</b>°<b> endpoint:</b>  sustained VT/VF </text>
<text top="663" left="606" width="3" height="19" font="3"> </text>
<text top="681" left="606" width="193" height="19" font="4"><b>Results:</b>  The 2 y KM event rate </text>
<text top="699" left="606" width="165" height="19" font="3">for VT or VF was 29.4% for </text>
<text top="718" left="606" width="200" height="19" font="3">inducible patients and 25.5% for </text>
<text top="736" left="606" width="197" height="19" font="3">noninducible patients (p=0.280, </text>
<text top="754" left="606" width="131" height="19" font="3">by log-rank analysis). </text>
<text top="643" left="827" width="237" height="19" font="3">● ICD therapy for spontaneous VF was </text>
<text top="662" left="827" width="219" height="19" font="3">less common (p=0.021) in inducible </text>
<text top="680" left="827" width="239" height="19" font="3">patients than in noninducible patients. </text>
<text top="698" left="827" width="3" height="19" font="3"> </text>
</page>
<page number="31" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">31 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="606" width="198" height="19" font="3">Inducible patients had a greater </text>
<text top="127" left="606" width="185" height="19" font="3">likelihood of experiencing ICD </text>
<text top="145" left="606" width="205" height="19" font="3">therapy for VT than noninducible </text>
<text top="164" left="606" width="119" height="19" font="3">patients (p=0.023). </text>
<text top="182" left="606" width="3" height="19" font="3"> </text>
<text top="201" left="123" width="54" height="19" font="3">● <b>ABCD</b> <b> </b></text>
<text top="219" left="123" width="111" height="19" font="3">● Costantini et al. </text>
<text top="238" left="123" width="57" height="19" font="3">2009 (9)  </text>
<text top="256" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19195603">● </a></text>
<text top="256" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19195603">19195603</a></text>
<text top="256" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19195603"> </a></text>
<text top="274" left="123" width="3" height="19" font="3"> </text>
<text top="201" left="275" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="219" left="275" width="122" height="19" font="3">Prospective cohort; </text>
<text top="238" left="275" width="124" height="19" font="3">patients underwent </text>
<text top="256" left="275" width="98" height="19" font="3">EPS and T wave </text>
<text top="274" left="275" width="110" height="19" font="3">alternans testing; </text>
<text top="293" left="275" width="65" height="19" font="3">ICDs were </text>
<text top="311" left="275" width="117" height="19" font="3">implanted if either </text>
<text top="329" left="275" width="105" height="19" font="3">test was positive </text>
<text top="347" left="275" width="3" height="19" font="3"> </text>
<text top="366" left="275" width="111" height="19" font="4"><b>Size:</b> 566 patients </text>
<text top="201" left="414" width="171" height="19" font="4"><b>Inclusion criteria:</b>  ischemic </text>
<text top="219" left="414" width="166" height="19" font="3">cardiomyopathy (EF &lt;40%) </text>
<text top="238" left="414" width="62" height="19" font="3">and NSVT </text>
<text top="256" left="414" width="3" height="19" font="3"> </text>
<text top="274" left="414" width="169" height="19" font="4"><b>Exclusion criteria:</b> unstable </text>
<text top="292" left="414" width="156" height="19" font="3">CAD; NYHA class IV; prior </text>
<text top="311" left="414" width="125" height="19" font="3">CA, sustained VT, or </text>
<text top="329" left="414" width="173" height="19" font="3">unexplained syncope; &lt;28 d </text>
<text top="347" left="414" width="142" height="19" font="3">from MI, CABG, or PCI; </text>
<text top="366" left="414" width="166" height="19" font="3">permanent AF; on an AAD. </text>
<text top="202" left="606" width="185" height="19" font="4"><b>1</b>°<b> endpoint:</b>  appropriate ICD </text>
<text top="220" left="606" width="165" height="19" font="3">discharge or sudden death </text>
<text top="238" left="606" width="3" height="19" font="3"> </text>
<text top="257" left="606" width="184" height="19" font="4"><b>Results:</b>  39 (7.5%) met the 1° </text>
<text top="275" left="606" width="96" height="19" font="3">end point at 1y </text>
<text top="293" left="606" width="186" height="19" font="3">T wave alternans achieved 1 y </text>
<text top="312" left="606" width="202" height="19" font="3">positive (9%) and negative (95%) </text>
<text top="330" left="606" width="199" height="19" font="3">predictive values comparable to </text>
<text top="348" left="606" width="123" height="19" font="3">EPS (11% and 95%). </text>
<text top="367" left="606" width="161" height="19" font="3">Event rate with both tests </text>
<text top="385" left="606" width="184" height="19" font="3">negative was 2% vs. 12% with </text>
<text top="403" left="606" width="182" height="19" font="3">both tests positive (p=0.017). </text>
<text top="201" left="827" width="230" height="19" font="3">● Both tests somewhat helpful in risk </text>
<text top="219" left="827" width="212" height="19" font="3">stratification, but NPV is not 100% </text>
<text top="238" left="854" width="3" height="19" font="3"> </text>
<text top="422" left="123" width="72" height="19" font="3">● <b>DEFINITE </b></text>
<text top="441" left="123" width="133" height="19" font="3">● Daubert et al. 2009 </text>
<text top="459" left="123" width="28" height="19" font="3">(57) </text>
<text top="477" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19545338">● </a></text>
<text top="477" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19545338">19545338</a></text>
<text top="477" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19545338"> </a></text>
<text top="496" left="123" width="3" height="19" font="3"> </text>
<text top="422" left="275" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="441" left="275" width="74" height="19" font="3">substudy of </text>
<text top="459" left="275" width="59" height="19" font="3">DEFINITE </text>
<text top="477" left="275" width="3" height="19" font="3"> </text>
<text top="495" left="275" width="111" height="19" font="4"><b>Size:</b> 204 patients </text>
<text top="422" left="414" width="160" height="19" font="4"><b>Inclusion criteria:</b>  dilated </text>
<text top="441" left="414" width="166" height="19" font="3">cardiomyopathy (EF&lt;35%), </text>
<text top="459" left="414" width="173" height="19" font="3">NSVT or frequent PVCs, and </text>
<text top="477" left="414" width="173" height="19" font="3">NYHA class I-III, randomized </text>
<text top="496" left="414" width="174" height="19" font="3">to ICD arm; noninvasive EPS </text>
<text top="514" left="414" width="146" height="19" font="3">performed through ICD </text>
<text top="532" left="414" width="3" height="19" font="3"> </text>
<text top="550" left="414" width="155" height="19" font="4"><b>Exclusion criteria:</b>  NYHA </text>
<text top="569" left="414" width="136" height="19" font="3">class IV or permanent </text>
<text top="587" left="414" width="71" height="19" font="3">pacemaker </text>
<text top="423" left="606" width="185" height="19" font="4"><b>1</b>°<b> endpoint:</b>  appropriate ICD </text>
<text top="441" left="606" width="199" height="19" font="3">therapy for VT/VF or arrhythmic </text>
<text top="460" left="606" width="39" height="19" font="3">death </text>
<text top="478" left="606" width="3" height="19" font="3"> </text>
<text top="496" left="606" width="205" height="19" font="4"><b>Results:</b> Inducibility was found in </text>
<text top="515" left="606" width="208" height="19" font="3">29 of 204 patients (VT in 13, VF in </text>
<text top="533" left="606" width="206" height="19" font="3">16). 34.5% of the inducible group </text>
<text top="551" left="606" width="165" height="19" font="3">(10 of 29) experienced ICD </text>
<text top="570" left="606" width="143" height="19" font="3">therapy for VT or VF or </text>
<text top="588" left="606" width="193" height="19" font="3">arrhythmic death vs. 12.0% (21 </text>
<text top="606" left="606" width="169" height="19" font="3">of 175) of the noninducible </text>
<text top="624" left="606" width="181" height="19" font="3">patients (HR: 2.60; p=0.014).  </text>
<text top="643" left="606" width="3" height="19" font="3"> </text>
<text top="422" left="827" width="220" height="19" font="3">● Inducibility of either VT or VF was </text>
<text top="441" left="827" width="242" height="19" font="3">associated with an increased likelihood </text>
<text top="459" left="827" width="245" height="19" font="3">of subsequent ICD therapy for VT or VF. </text>
<text top="477" left="827" width="3" height="19" font="3"> </text>
<text top="662" left="123" width="112" height="19" font="3">● Gold et al. 2000 </text>
<text top="680" left="123" width="28" height="19" font="3">(58) </text>
<text top="698" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11127468">● </a></text>
<text top="698" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11127468">11127468</a></text>
<text top="698" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11127468"> </a></text>
<text top="717" left="123" width="3" height="19" font="3"> </text>
<text top="662" left="275" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="680" left="275" width="78" height="19" font="3">prospective, </text>
<text top="698" left="275" width="74" height="19" font="3">multicenter </text>
<text top="717" left="275" width="3" height="19" font="4"><b> </b></text>
<text top="735" left="275" width="111" height="19" font="4"><b>Size:</b> 215 patients </text>
<text top="662" left="414" width="164" height="19" font="4"><b>Inclusion criteria:</b> patients </text>
<text top="680" left="414" width="164" height="19" font="3">undergoing diagnostic EPS </text>
<text top="698" left="414" width="161" height="19" font="3">who were in sinus rhythm </text>
<text top="717" left="414" width="136" height="19" font="3">and able to do bicycle </text>
<text top="735" left="414" width="154" height="19" font="3">exercise; reasons for EPS </text>
<text top="753" left="414" width="137" height="19" font="3">included syncope, CA, </text>
<text top="772" left="414" width="111" height="19" font="3">sustained VT, SVT </text>
<text top="662" left="606" width="174" height="19" font="4"><b>1</b>°<b> endpoint:</b> SCD, sustained </text>
<text top="681" left="606" width="208" height="19" font="3">VT/VF or appropriate ICD therapy </text>
<text top="699" left="606" width="3" height="19" font="4"><b> </b></text>
<text top="718" left="606" width="193" height="19" font="4"><b>Results:</b> KM survival analysis of </text>
<text top="736" left="606" width="193" height="19" font="3">the 1° end point showed that T-</text>
<text top="754" left="606" width="202" height="19" font="3">wave alternans predicted events </text>
<text top="662" left="827" width="224" height="19" font="3">● Both T-wave alternans testing and </text>
<text top="680" left="827" width="110" height="19" font="3">EPS predicted VT. </text>
<text top="698" left="827" width="3" height="19" font="3"> </text>
</page>
<page number="32" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">32 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="414" width="3" height="19" font="4"><b> </b></text>
<text top="127" left="414" width="138" height="19" font="4"><b>Exclusion criteria:</b> not </text>
<text top="145" left="414" width="58" height="19" font="3">specified </text>
<text top="109" left="606" width="207" height="19" font="3">with a RR:10.9; EPS had a RR: 7.1; </text>
<text top="127" left="606" width="160" height="19" font="3">and SAECG had a RR:  4.5. </text>
<text top="145" left="606" width="164" height="19" font="3">Multivariate analysis of 11 </text>
<text top="164" left="606" width="181" height="19" font="3">clinical parameters identified </text>
<text top="182" left="606" width="205" height="19" font="3">only T-wave alternans and EPS as </text>
<text top="200" left="606" width="163" height="19" font="3">independent predictors of </text>
<text top="219" left="606" width="48" height="19" font="3">events. </text>
<text top="237" left="606" width="3" height="19" font="4"><b> </b></text>
<text top="256" left="123" width="105" height="19" font="3">● Gatzoulis et al. </text>
<text top="274" left="123" width="62" height="19" font="3">2013 (59) </text>
<text top="292" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23588627">● </a></text>
<text top="292" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23588627">23588627</a></text>
<text top="292" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23588627"> </a></text>
<text top="311" left="123" width="3" height="19" font="3"> </text>
<text top="256" left="275" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="274" left="275" width="118" height="19" font="3">prospective cohort </text>
<text top="292" left="275" width="3" height="19" font="4"><b> </b></text>
<text top="311" left="275" width="111" height="19" font="4"><b>Size:</b> 158 patients </text>
<text top="256" left="414" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="274" left="414" width="147" height="19" font="3">symptomatic idiopathic </text>
<text top="292" left="414" width="75" height="19" font="3">DCM &gt;6 mo </text>
<text top="311" left="414" width="3" height="19" font="4"><b> </b></text>
<text top="329" left="414" width="149" height="19" font="4"><b>Exclusion criteria:</b> Hx of </text>
<text top="347" left="414" width="158" height="19" font="3">aborted SCD or sustained </text>
<text top="366" left="414" width="169" height="19" font="3">VT; NYHA class IV; Hx of MI </text>
<text top="384" left="414" width="161" height="19" font="3">or myocarditis; significant </text>
<text top="402" left="414" width="133" height="19" font="3">VHD; hypertrophic or </text>
<text top="421" left="414" width="171" height="19" font="3">restrictive cardiomyopathy; </text>
<text top="439" left="414" width="169" height="19" font="3">alcohol-associated disease; </text>
<text top="457" left="414" width="95" height="19" font="3">cardiac toxicity </text>
<text top="257" left="606" width="199" height="19" font="4"><b>1</b>°<b> endpoint:</b> total mortality and </text>
<text top="275" left="606" width="164" height="19" font="3">appropriate ICD activation </text>
<text top="293" left="606" width="3" height="19" font="4"><b> </b></text>
<text top="311" left="606" width="179" height="19" font="4"><b>Results:</b> EPS performed in all </text>
<text top="330" left="606" width="152" height="19" font="3">patients; 44 (27.8%) had </text>
<text top="348" left="606" width="103" height="19" font="3">inducible VT/VF. </text>
<text top="367" left="606" width="150" height="19" font="3">ICDs implanted in 41/44 </text>
<text top="385" left="606" width="186" height="19" font="3">inducible patients and 28/114 </text>
<text top="403" left="606" width="140" height="19" font="3">noninducible patients. </text>
<text top="422" left="606" width="161" height="19" font="3">No difference in mortality </text>
<text top="440" left="606" width="196" height="19" font="3">Inducibility was associated with </text>
<text top="458" left="606" width="176" height="19" font="3">ICD activation events (30/41 </text>
<text top="476" left="606" width="182" height="19" font="3">inducible patients (73.2%) vs. </text>
<text top="495" left="606" width="168" height="19" font="3">5/28 noninducible patients </text>
<text top="513" left="606" width="110" height="19" font="3">(17.9%), p=0.001. </text>
<text top="256" left="827" width="239" height="19" font="3">● EPS inducibility of sustained VT/VF is </text>
<text top="274" left="827" width="234" height="19" font="3">predictive of future ICD activation but </text>
<text top="292" left="827" width="247" height="19" font="3">not total mortality in patients with CDM </text>
<text top="311" left="827" width="3" height="19" font="3"> </text>
<text top="532" left="115" width="3" height="19" font="3"> </text>
<text top="586" left="115" width="560" height="21" font="2"><b>Data Supplement 10. RCTs for Preventing SCD with HF Medications - (Section 5.2) </b></text>
<text top="607" left="142" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="626" left="168" width="55" height="19" font="4"><b>Author;  </b></text>
<text top="644" left="146" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="607" left="296" width="88" height="19" font="4"><b>Aim of Study; </b></text>
<text top="626" left="301" width="76" height="19" font="4"><b>Study Type; </b></text>
<text top="644" left="295" width="89" height="19" font="4"><b>Study Size (N) </b></text>
<text top="607" left="426" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="607" left="586" width="123" height="19" font="4"><b>Study Intervention  </b></text>
<text top="626" left="604" width="88" height="19" font="4"><b>(# patients) /  </b></text>
<text top="644" left="588" width="121" height="19" font="4"><b>Study Comparator  </b></text>
<text top="662" left="609" width="75" height="19" font="4"><b>(# patients) </b></text>
<text top="607" left="771" width="108" height="19" font="4"><b>Endpoint Results </b></text>
<text top="626" left="753" width="148" height="19" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="644" left="757" width="136" height="19" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="662" left="800" width="49" height="19" font="4"><b>95% CI) </b></text>
<text top="608" left="933" width="135" height="19" font="4"><b>Relevant 2</b>°<b> Endpoint </b></text>
<text top="626" left="975" width="51" height="19" font="4"><b>(if any); </b></text>
<text top="645" left="943" width="116" height="19" font="4"><b>Study Limitations; </b></text>
<text top="663" left="952" width="99" height="19" font="4"><b>Adverse Events </b></text>
<text top="682" left="123" width="90" height="19" font="3">● <b>CAPRICORN </b></text>
<text top="700" left="123" width="123" height="19" font="3">● Dargie et al. 2001 </text>
<text top="719" left="123" width="28" height="19" font="3">(60) </text>
<text top="737" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11356434?dopt=Citation">● </a></text>
<text top="737" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11356434?dopt=Citation">11356434</a></text>
<text top="737" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11356434?dopt=Citation"> </a></text>
<text top="755" left="123" width="3" height="19" font="3"> </text>
<text top="682" left="277" width="101" height="19" font="4"><b>Study type:</b> RCT </text>
<text top="700" left="277" width="3" height="19" font="3"> </text>
<text top="719" left="277" width="75" height="19" font="4"><b>Aim:</b> to test </text>
<text top="737" left="277" width="117" height="19" font="3">whether carvedilol </text>
<text top="755" left="277" width="116" height="19" font="3">added to standard </text>
<text top="774" left="277" width="73" height="19" font="3">AMI care in </text>
<text top="682" left="415" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="700" left="415" width="138" height="19" font="3">Recent MI (3-12 d); EF </text>
<text top="719" left="415" width="37" height="19" font="3">&lt;40% </text>
<text top="737" left="415" width="3" height="19" font="3"> </text>
<text top="755" left="415" width="113" height="19" font="4"><b>Exclusion criteria</b>  </text>
<text top="682" left="569" width="149" height="19" font="4"><b>Intervention:</b> Carvedilol </text>
<text top="700" left="569" width="98" height="19" font="3">up to 25mg BID </text>
<text top="719" left="569" width="3" height="19" font="3"> </text>
<text top="737" left="569" width="144" height="19" font="4"><b>Comparator:</b>  <b> </b> Placebo </text>
<text top="755" left="569" width="3" height="19" font="4"><b> </b></text>
<text top="683" left="736" width="143" height="19" font="4"><b>1</b>°<b> endpoint:</b>  All-cause </text>
<text top="701" left="736" width="163" height="19" font="3">mortality 12% vs 15%, HR: </text>
<text top="720" left="736" width="146" height="19" font="3">0.77; 95% CI 0.60–0.98, </text>
<text top="738" left="736" width="54" height="19" font="3">p=0·03). </text>
<text top="756" left="736" width="3" height="19" font="3"> </text>
<text top="682" left="927" width="146" height="19" font="3">● BB improve mortality </text>
<text top="700" left="927" width="119" height="19" font="3">post-MI in patients </text>
<text top="719" left="927" width="124" height="19" font="3">with LV dysfunction </text>
<text top="737" left="927" width="3" height="19" font="3"> </text>
<text top="755" left="927" width="129" height="19" font="3">● VT/VF significantly </text>
<text top="774" left="927" width="57" height="19" font="3">reduced. </text>
</page>
<page number="33" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">33 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="277" width="107" height="19" font="3">patients with left </text>
<text top="127" left="277" width="69" height="19" font="3">ventricular </text>
<text top="145" left="277" width="116" height="19" font="3">dysfunction would </text>
<text top="164" left="277" width="122" height="19" font="3">improve outcomes. </text>
<text top="182" left="277" width="3" height="19" font="3"> </text>
<text top="200" left="277" width="66" height="19" font="4"><b>Size:</b> 1959 </text>
<text top="219" left="277" width="3" height="19" font="3"> </text>
<text top="237" left="277" width="3" height="19" font="3"> </text>
<text top="109" left="415" width="107" height="19" font="3">Uncontrolled HF, </text>
<text top="127" left="415" width="104" height="19" font="3">unstable angina, </text>
<text top="145" left="415" width="83" height="19" font="3">hypotension, </text>
<text top="164" left="415" width="76" height="19" font="3">bradycardia </text>
<text top="182" left="415" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="736" width="159" height="19" font="3">VT/VF: 3.9% vs. 0.9%. HR: </text>
<text top="127" left="736" width="146" height="19" font="3">0.24; 95% CI 0.11–0.49; </text>
<text top="145" left="736" width="64" height="19" font="3">p&lt;0.0001. </text>
<text top="164" left="736" width="3" height="19" font="3"> </text>
<text top="182" left="736" width="3" height="19" font="3"> </text>
<text top="200" left="736" width="3" height="19" font="3"> </text>
<text top="218" left="736" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="927" width="3" height="19" font="3"> </text>
<text top="127" left="927" width="3" height="19" font="3"> </text>
<text top="256" left="123" width="114" height="19" font="3">● <b>US CARVEDILOL </b></text>
<text top="274" left="123" width="127" height="19" font="3">● Packer et al.  1996 </text>
<text top="292" left="123" width="28" height="19" font="3">(61) </text>
<text top="311" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8614419?dopt=Citation">● </a></text>
<text top="311" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8614419?dopt=Citation">8614419</a></text>
<text top="311" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8614419?dopt=Citation"> </a></text>
<text top="256" left="277" width="101" height="19" font="4"><b>Study type: </b>RCT </text>
<text top="274" left="277" width="3" height="19" font="3"> </text>
<text top="292" left="277" width="122" height="19" font="4"><b>Aim:</b>  To determine </text>
<text top="311" left="277" width="84" height="19" font="3">the effects of </text>
<text top="329" left="277" width="82" height="19" font="3">carvedilol on </text>
<text top="347" left="277" width="76" height="19" font="3">survival and </text>
<text top="366" left="277" width="93" height="19" font="3">hospitalization </text>
<text top="384" left="277" width="3" height="19" font="3"> </text>
<text top="402" left="277" width="66" height="19" font="4"><b>Size:</b> 1094 </text>
<text top="421" left="277" width="3" height="19" font="3"> </text>
<text top="439" left="277" width="3" height="19" font="3"> </text>
<text top="256" left="415" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="274" left="415" width="97" height="19" font="3">CHF, LVEF&lt;35% </text>
<text top="292" left="415" width="3" height="19" font="3"> </text>
<text top="311" left="415" width="113" height="19" font="4"><b>Exclusion criteria</b> <b> </b></text>
<text top="329" left="415" width="123" height="19" font="3">Major procedure or </text>
<text top="347" left="415" width="132" height="19" font="3">surgery within 3 mo.  </text>
<text top="256" left="569" width="150" height="19" font="4"><b>Intervention:</b> Carvedilol </text>
<text top="274" left="569" width="137" height="19" font="4"><b>Comparator:</b>  Placebo </text>
<text top="292" left="569" width="3" height="19" font="4"><b> </b></text>
<text top="257" left="736" width="161" height="19" font="4"><b>1</b>°<b> endpoint:</b>  survival and </text>
<text top="275" left="736" width="93" height="19" font="3">hospitalization </text>
<text top="293" left="736" width="162" height="19" font="3">- Mortality: 7.8% vs. 3.2 % </text>
<text top="312" left="736" width="121" height="19" font="3">- SCD 3.8% vs. 1.7% </text>
<text top="330" left="736" width="3" height="19" font="3"> </text>
<text top="348" left="736" width="10" height="19" font="3">   </text>
<text top="367" left="736" width="3" height="19" font="3"> </text>
<text top="385" left="736" width="3" height="19" font="3"> </text>
<text top="403" left="736" width="3" height="19" font="4"><b> </b></text>
<text top="256" left="927" width="109" height="19" font="3">● BB have a large </text>
<text top="274" left="927" width="140" height="19" font="3">effect on all cause and </text>
<text top="292" left="927" width="91" height="19" font="3">SCD mortality. </text>
<text top="311" left="927" width="3" height="19" font="3"> </text>
<text top="329" left="927" width="3" height="19" font="3"> </text>
<text top="458" left="123" width="59" height="19" font="3">● <b>CIBIS II </b></text>
<text top="476" left="123" width="122" height="19" font="3">● No Authors listed </text>
<text top="495" left="123" width="28" height="19" font="3">(62) </text>
<text top="513" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10023943?dopt=Citation">● </a></text>
<text top="513" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10023943?dopt=Citation">10023943</a></text>
<text top="513" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10023943?dopt=Citation"> </a></text>
<text top="458" left="277" width="101" height="19" font="4"><b>Study type: </b>RCT </text>
<text top="476" left="277" width="3" height="19" font="3"> </text>
<text top="495" left="277" width="121" height="19" font="4"><b>Aim:</b> To investigate </text>
<text top="513" left="277" width="90" height="19" font="3">the efficacy of </text>
<text top="531" left="277" width="79" height="19" font="3">bisoprolol in </text>
<text top="550" left="277" width="88" height="19" font="3">decreasing all-</text>
<text top="568" left="277" width="112" height="19" font="3">cause mortality in </text>
<text top="586" left="277" width="68" height="19" font="3">chronic HF </text>
<text top="605" left="277" width="3" height="19" font="3"> </text>
<text top="623" left="277" width="66" height="19" font="4"><b>Size:</b> 2647 </text>
<text top="641" left="277" width="3" height="19" font="3"> </text>
<text top="660" left="277" width="3" height="19" font="3"> </text>
<text top="458" left="415" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="476" left="415" width="128" height="19" font="3">EF &lt;35%, class III, IV, </text>
<text top="495" left="415" width="116" height="19" font="3">standard therapy,  </text>
<text top="513" left="415" width="3" height="19" font="3"> </text>
<text top="531" left="415" width="113" height="19" font="4"><b>Exclusion criteria</b> <b> </b></text>
<text top="550" left="415" width="27" height="19" font="3">N/A<b> </b></text>
<text top="458" left="569" width="150" height="19" font="4"><b>Intervention:</b> Bisoprolol </text>
<text top="476" left="569" width="3" height="19" font="3"> </text>
<text top="495" left="569" width="134" height="19" font="4"><b>Comparator:</b> Placebo </text>
<text top="513" left="569" width="3" height="19" font="4"><b> </b></text>
<text top="459" left="736" width="141" height="19" font="4"><b>1</b>°<b> endpoint:</b>  all-cause </text>
<text top="477" left="736" width="59" height="19" font="3">mortality </text>
<text top="496" left="736" width="3" height="19" font="3"> </text>
<text top="514" left="736" width="164" height="19" font="3">CIBIS-II was stopped early, </text>
<text top="532" left="736" width="174" height="19" font="3">All-cause mortality 11.8% vs </text>
<text top="550" left="736" width="112" height="19" font="3">17.3%. p&lt;0.0001.  </text>
<text top="569" left="736" width="3" height="19" font="3"> </text>
<text top="587" left="736" width="174" height="19" font="3">SCD 3.6% vs 6.3% p=0.0011. </text>
<text top="605" left="736" width="3" height="19" font="3"> </text>
<text top="624" left="736" width="10" height="19" font="3">   </text>
<text top="642" left="736" width="3" height="19" font="3"> </text>
<text top="660" left="736" width="3" height="19" font="4"><b> </b></text>
<text top="458" left="927" width="128" height="19" font="3">● Bisoprolol reduces </text>
<text top="476" left="927" width="143" height="19" font="3">all-cause mortality and </text>
<text top="495" left="927" width="124" height="19" font="3">mortality from SCD. </text>
<text top="513" left="927" width="3" height="19" font="3"> </text>
<text top="531" left="927" width="3" height="19" font="3"> </text>
<text top="679" left="123" width="76" height="19" font="3">● <b>MERIT HF </b></text>
<text top="698" left="123" width="119" height="19" font="3">● Hjalmarson et al. </text>
<text top="716" left="123" width="62" height="19" font="3">(63)2000  </text>
<text top="734" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10714728?dopt=Citation">● </a></text>
<text top="734" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10714728?dopt=Citation">10714728</a></text>
<text top="734" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10714728?dopt=Citation"> </a></text>
<text top="679" left="277" width="101" height="19" font="4"><b>Study type:</b> RCT </text>
<text top="698" left="277" width="3" height="19" font="3"> </text>
<text top="716" left="277" width="106" height="19" font="4"><b>Aim:</b> To examine </text>
<text top="734" left="277" width="84" height="19" font="3">the effects of </text>
<text top="753" left="277" width="111" height="19" font="3">metoprolol CR/XL </text>
<text top="771" left="277" width="82" height="19" font="3">on mortality, </text>
<text top="679" left="415" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="698" left="415" width="117" height="19" font="3">NYHA class II to IV, </text>
<text top="716" left="415" width="114" height="19" font="3">EF&lt;40%; optimum </text>
<text top="734" left="415" width="112" height="19" font="3">standard therapy. </text>
<text top="753" left="415" width="3" height="19" font="3"> </text>
<text top="771" left="415" width="113" height="19" font="4"><b>Exclusion criteria</b> <b> </b></text>
<text top="679" left="569" width="85" height="19" font="4"><b>Intervention:</b> </text>
<text top="698" left="569" width="133" height="19" font="3">Metoprolol succinate </text>
<text top="716" left="569" width="134" height="19" font="4"><b>Comparator:</b> Placebo </text>
<text top="734" left="569" width="3" height="19" font="4"><b> </b></text>
<text top="680" left="736" width="171" height="19" font="4"><b>1</b>°<b> endpoint:</b>  mortality and </text>
<text top="698" left="736" width="145" height="19" font="3">hospitalization (time to </text>
<text top="717" left="736" width="46" height="19" font="3">event). </text>
<text top="735" left="736" width="3" height="19" font="3"> </text>
<text top="752" left="736" width="181" height="20" font="3">-  All-cause mortality: 34%  </text>
<text top="770" left="736" width="108" height="20" font="3">-  SCD: 41% RR </text>
<text top="679" left="927" width="137" height="19" font="3">● BB reduce mortality </text>
<text top="698" left="927" width="125" height="19" font="3">in patients with HF.  </text>
<text top="716" left="927" width="3" height="19" font="3"> </text>
<text top="734" left="927" width="3" height="19" font="3"> </text>
<text top="753" left="927" width="3" height="19" font="3"> </text>
<text top="771" left="927" width="3" height="19" font="3"> </text>
</page>
<page number="34" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">34 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="277" width="97" height="19" font="3">hospitalization, </text>
<text top="127" left="277" width="125" height="19" font="3">symptoms, and QoL </text>
<text top="145" left="277" width="122" height="19" font="3">in patients with HF. </text>
<text top="164" left="277" width="3" height="19" font="3"> </text>
<text top="182" left="277" width="66" height="19" font="4"><b>Size:</b> 3991 </text>
<text top="109" left="415" width="27" height="19" font="3">N/A<b> </b></text>
<text top="109" left="736" width="10" height="19" font="3">   </text>
<text top="127" left="736" width="3" height="19" font="3"> </text>
<text top="145" left="736" width="3" height="19" font="4"><b> </b></text>
<text top="201" left="123" width="73" height="19" font="3">● <b>V-HEFT-II </b></text>
<text top="219" left="123" width="115" height="19" font="3">● Cohn et al. 1991 </text>
<text top="238" left="123" width="28" height="19" font="3">(64) </text>
<text top="256" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2057035?dopt=Citation">● </a></text>
<text top="256" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2057035?dopt=Citation">2057035</a></text>
<text top="256" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2057035?dopt=Citation"> </a></text>
<text top="201" left="277" width="101" height="19" font="4"><b>Study type:</b> RCT </text>
<text top="219" left="277" width="3" height="19" font="3"> </text>
<text top="237" left="277" width="93" height="19" font="4"><b>Aim:</b> To better </text>
<text top="256" left="277" width="113" height="19" font="3">define vasodilator </text>
<text top="274" left="277" width="85" height="19" font="3">therapy in HF </text>
<text top="292" left="277" width="3" height="19" font="3"> </text>
<text top="311" left="277" width="58" height="19" font="4"><b>Size:</b> 804 </text>
<text top="329" left="277" width="3" height="19" font="3"> </text>
<text top="347" left="277" width="3" height="19" font="3"> </text>
<text top="201" left="415" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="219" left="415" width="99" height="19" font="3">NYHA Class II-III </text>
<text top="238" left="415" width="3" height="19" font="3"> </text>
<text top="256" left="415" width="3" height="19" font="3"> </text>
<text top="274" left="415" width="3" height="19" font="3"> </text>
<text top="292" left="415" width="113" height="19" font="4"><b>Exclusion criteria</b> <b> </b></text>
<text top="311" left="415" width="27" height="19" font="3">N/A<b> </b></text>
<text top="201" left="569" width="142" height="19" font="4"><b>Intervention:</b> Enalapril </text>
<text top="219" left="569" width="149" height="19" font="4"><b>Comparator:</b> Isosorbide </text>
<text top="238" left="569" width="54" height="19" font="3">Dinitrite<b> </b></text>
<text top="202" left="736" width="144" height="19" font="4"><b>1</b>°<b> endpoint:</b>  mortality </text>
<text top="220" left="736" width="3" height="19" font="3"> </text>
<text top="238" left="736" width="139" height="19" font="3">Mortality 18% vs. 25% </text>
<text top="257" left="736" width="57" height="19" font="3">p=0.016. </text>
<text top="275" left="736" width="3" height="19" font="3"> </text>
<text top="293" left="736" width="159" height="19" font="3">SCD: 14% vs. 23%, p&lt;0.05 </text>
<text top="312" left="736" width="113" height="19" font="3">favoring enalapril  </text>
<text top="330" left="736" width="3" height="19" font="3"> </text>
<text top="348" left="736" width="3" height="19" font="3"> </text>
<text top="367" left="736" width="3" height="19" font="4"><b> </b></text>
<text top="201" left="927" width="137" height="19" font="3">● Enalapril in patients </text>
<text top="219" left="927" width="101" height="19" font="3">with HF reduces </text>
<text top="238" left="927" width="113" height="19" font="3">mortality and SCD </text>
<text top="256" left="927" width="81" height="19" font="3">compared to </text>
<text top="274" left="927" width="120" height="19" font="3">Isosorbide Dinitrite </text>
<text top="292" left="927" width="3" height="19" font="3"> </text>
<text top="311" left="927" width="3" height="19" font="3"> </text>
<text top="386" left="123" width="72" height="19" font="3">● <b>Val-HeFT </b></text>
<text top="404" left="123" width="115" height="19" font="3">● Cohn et al. 2001 </text>
<text top="422" left="123" width="31" height="19" font="3">(65)  </text>
<text top="441" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11759645?dopt=Citation">● </a></text>
<text top="441" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11759645?dopt=Citation">11759645</a></text>
<text top="441" left="197" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11759645?dopt=Citation"><b> </b></a></text>
<text top="386" left="277" width="105" height="19" font="4"><b>Study type: </b>RCT. </text>
<text top="404" left="277" width="3" height="19" font="3"> </text>
<text top="422" left="277" width="124" height="19" font="4"><b>Aim:</b> To explore the </text>
<text top="441" left="277" width="90" height="19" font="3">efficacy of the </text>
<text top="459" left="277" width="115" height="19" font="3">addition of ARB to </text>
<text top="477" left="277" width="94" height="19" font="3">ACE-I therapy.  </text>
<text top="496" left="277" width="3" height="19" font="3"> </text>
<text top="514" left="277" width="66" height="19" font="4"><b>Size:</b> 5010 </text>
<text top="532" left="277" width="3" height="19" font="3"> </text>
<text top="550" left="277" width="3" height="19" font="3"> </text>
<text top="386" left="415" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="404" left="415" width="68" height="19" font="3">NYHA II, III </text>
<text top="422" left="415" width="3" height="19" font="3"> </text>
<text top="441" left="415" width="113" height="19" font="4"><b>Exclusion criteria</b> <b> </b></text>
<text top="459" left="415" width="27" height="19" font="3">N/A<b> </b></text>
<text top="386" left="569" width="146" height="19" font="4"><b>Intervention:</b> Valsartan </text>
<text top="404" left="569" width="103" height="19" font="3">(added to ACE-I) </text>
<text top="422" left="569" width="134" height="19" font="4"><b>Comparator</b>: Placebo </text>
<text top="441" left="569" width="3" height="19" font="4"><b> </b></text>
<text top="386" left="736" width="141" height="19" font="4"><b>1</b>°<b> endpoint:</b>  all-cause </text>
<text top="405" left="736" width="59" height="19" font="3">mortality </text>
<text top="423" left="736" width="3" height="19" font="3"> </text>
<text top="441" left="736" width="163" height="19" font="3">Result: no difference in all-</text>
<text top="460" left="736" width="105" height="19" font="3">cause mortality.  </text>
<text top="478" left="736" width="3" height="19" font="3"> </text>
<text top="496" left="736" width="3" height="19" font="3"> </text>
<text top="515" left="736" width="10" height="19" font="3">   </text>
<text top="533" left="736" width="3" height="19" font="3"> </text>
<text top="551" left="736" width="3" height="19" font="4"><b> </b></text>
<text top="386" left="927" width="134" height="19" font="3">● ARB added to ACE-I </text>
<text top="404" left="927" width="123" height="19" font="3">are not additionally </text>
<text top="422" left="927" width="46" height="19" font="3">helpful </text>
<text top="441" left="927" width="3" height="19" font="3"> </text>
<text top="459" left="927" width="3" height="19" font="3"> </text>
<text top="570" left="123" width="71" height="19" font="3">● <b>VALIANT </b></text>
<text top="589" left="123" width="125" height="19" font="3">● Pfeffer et al. 2003 </text>
<text top="607" left="123" width="28" height="19" font="3">(66) </text>
<text top="625" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14610160?dopt=Citation">● </a></text>
<text top="625" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14610160?dopt=Citation">14610160</a></text>
<text top="625" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14610160?dopt=Citation"> </a></text>
<text top="570" left="277" width="101" height="19" font="4"><b>Study type:</b> RCT </text>
<text top="589" left="277" width="3" height="19" font="3"> </text>
<text top="607" left="277" width="124" height="19" font="4"><b>Aim:</b> To explore the </text>
<text top="625" left="277" width="89" height="19" font="3">effects of ARB </text>
<text top="643" left="277" width="94" height="19" font="3">added to ACE-I </text>
<text top="662" left="277" width="58" height="19" font="3">therapy.  </text>
<text top="680" left="277" width="3" height="19" font="3"> </text>
<text top="698" left="277" width="77" height="19" font="4"><b>Size:</b> 14,703 </text>
<text top="717" left="277" width="3" height="19" font="3"> </text>
<text top="735" left="277" width="3" height="19" font="3"> </text>
<text top="570" left="415" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="589" left="415" width="128" height="19" font="3">Post-MI, LVEF&lt;35%.  </text>
<text top="607" left="415" width="95" height="19" font="3">Class I or II HF.  </text>
<text top="625" left="415" width="3" height="19" font="3"> </text>
<text top="643" left="415" width="113" height="19" font="4"><b>Exclusion criteria</b> <b> </b></text>
<text top="662" left="415" width="27" height="19" font="3">N/A<b> </b></text>
<text top="570" left="569" width="146" height="19" font="4"><b>Intervention:</b> Valsartan </text>
<text top="589" left="569" width="51" height="19" font="3">160 BID </text>
<text top="607" left="569" width="143" height="19" font="4"><b>Comparator:</b> Valsartan </text>
<text top="625" left="569" width="39" height="19" font="3">80 BD </text>
<text top="643" left="569" width="3" height="19" font="3"> </text>
<text top="662" left="569" width="147" height="19" font="3">Both added to enalapril </text>
<text top="680" left="569" width="3" height="19" font="4"><b> </b></text>
<text top="571" left="736" width="178" height="19" font="4"><b>1</b>°<b> endpoint:</b>  all-cause or CV </text>
<text top="589" left="736" width="59" height="19" font="3">mortality </text>
<text top="608" left="736" width="3" height="19" font="3"> </text>
<text top="626" left="736" width="160" height="19" font="3">No difference in either all-</text>
<text top="644" left="736" width="122" height="19" font="3">cause or CV related </text>
<text top="663" left="736" width="59" height="19" font="3">mortality </text>
<text top="681" left="736" width="3" height="19" font="3"> </text>
<text top="699" left="736" width="3" height="19" font="3"> </text>
<text top="718" left="736" width="10" height="19" font="3">   </text>
<text top="570" left="927" width="134" height="19" font="3">● ARB added to ACE-I </text>
<text top="589" left="927" width="123" height="19" font="3">are not additionally </text>
<text top="607" left="927" width="46" height="19" font="3">helpful </text>
<text top="625" left="927" width="3" height="19" font="3"> </text>
<text top="643" left="927" width="3" height="19" font="3"> </text>
<text top="754" left="123" width="52" height="19" font="3">● <b>ELITE  </b></text>
<text top="754" left="277" width="101" height="19" font="4"><b>Study type:</b> RCT </text>
<text top="773" left="277" width="3" height="19" font="3"> </text>
<text top="754" left="415" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="754" left="569" width="141" height="19" font="4"><b>Intervention:</b> Losartan </text>
<text top="772" left="569" width="142" height="19" font="4"><b>Comparator:</b> Captopril </text>
<text top="755" left="736" width="154" height="19" font="4"><b>1</b>°<b> endpoint:</b>  tolerability </text>
<text top="773" left="736" width="56" height="19" font="3">measure </text>
<text top="754" left="927" width="148" height="19" font="3">● ARB better than ACE,  </text>
</page>
<page number="35" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">35 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="114" height="19" font="3">● Pitt et al. Lancet </text>
<text top="127" left="123" width="65" height="19" font="3">1997 (67)  </text>
<text top="145" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9074572">● </a></text>
<text top="145" left="136" width="53" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9074572">9074572</a></text>
<text top="145" left="189" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9074572"> </a></text>
<text top="164" left="150" width="3" height="19" font="3"> </text>
<text top="109" left="277" width="118" height="19" font="4"><b>Aim:</b> To determine </text>
<text top="127" left="277" width="123" height="19" font="3">the relative efficacy </text>
<text top="145" left="277" width="106" height="19" font="3">of ACE vs. ARB in </text>
<text top="164" left="277" width="20" height="19" font="3">HF </text>
<text top="182" left="277" width="3" height="19" font="3"> </text>
<text top="200" left="277" width="58" height="19" font="4"><b>Size:</b> 722 </text>
<text top="219" left="277" width="3" height="19" font="3"> </text>
<text top="237" left="277" width="3" height="19" font="3"> </text>
<text top="109" left="415" width="138" height="19" font="3">NYHA II – IV, EF &lt;40%, </text>
<text top="127" left="415" width="61" height="19" font="3">age &gt;65 y </text>
<text top="145" left="415" width="113" height="19" font="4"><b>Exclusion criteria</b> <b> </b></text>
<text top="164" left="415" width="27" height="19" font="3">N/A<b> </b></text>
<text top="109" left="569" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="736" width="3" height="19" font="3"> </text>
<text top="127" left="736" width="136" height="19" font="3">2° measure: mortality </text>
<text top="145" left="736" width="3" height="19" font="3"> </text>
<text top="164" left="736" width="170" height="19" font="3">All-cause mortality 4.8% vs. </text>
<text top="182" left="736" width="95" height="19" font="3">8.7% (p=0.035) </text>
<text top="200" left="736" width="3" height="19" font="3"> </text>
<text top="219" left="736" width="166" height="19" font="3">36% relative risk reduction </text>
<text top="237" left="736" width="46" height="19" font="3">in SCD  </text>
<text top="109" left="927" width="116" height="19" font="3">● Only ARB trial to </text>
<text top="127" left="927" width="127" height="19" font="3">show a difference in </text>
<text top="145" left="927" width="31" height="19" font="3">SCD. </text>
<text top="164" left="927" width="80" height="19" font="3">● Small trial, </text>
<text top="182" left="927" width="126" height="19" font="3">● Mortality was a 2° </text>
<text top="200" left="927" width="74" height="19" font="3">end-point.   </text>
<text top="219" left="927" width="3" height="19" font="3"> </text>
<text top="237" left="927" width="3" height="19" font="3"> </text>
<text top="256" left="123" width="60" height="19" font="3">● <b>ELITE II </b></text>
<text top="274" left="123" width="136" height="19" font="3">● Pitt et al. 2000 (68)  </text>
<text top="292" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10821361?dopt=Citation">● </a></text>
<text top="292" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10821361?dopt=Citation">10821361</a></text>
<text top="292" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10821361?dopt=Citation"> </a></text>
<text top="256" left="277" width="101" height="19" font="4"><b>Study type:</b> RCT </text>
<text top="274" left="277" width="3" height="19" font="3"> </text>
<text top="292" left="277" width="102" height="19" font="4"><b>Aim:</b> To confirm </text>
<text top="311" left="277" width="121" height="19" font="3">whether losartan is </text>
<text top="329" left="277" width="71" height="19" font="3">superior to </text>
<text top="347" left="277" width="58" height="19" font="3">captopril </text>
<text top="366" left="277" width="3" height="19" font="3"> </text>
<text top="384" left="277" width="66" height="19" font="4"><b>Size:</b> 3152 </text>
<text top="256" left="415" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="274" left="415" width="126" height="19" font="3">Age &gt;60 y, class II-IV </text>
<text top="292" left="415" width="81" height="19" font="3">HF, EF &lt;40%. </text>
<text top="311" left="415" width="3" height="19" font="3"> </text>
<text top="329" left="415" width="113" height="19" font="4"><b>Exclusion criteria</b> <b> </b></text>
<text top="347" left="415" width="27" height="19" font="3">N/A<b> </b></text>
<text top="256" left="569" width="141" height="19" font="4"><b>Intervention:</b> Losartan </text>
<text top="274" left="569" width="142" height="19" font="4"><b>Comparator:</b> Captopril<b> </b></text>
<text top="292" left="569" width="3" height="19" font="4"><b> </b></text>
<text top="257" left="736" width="141" height="19" font="4"><b>1</b>°<b> endpoint:</b>  all-cause </text>
<text top="275" left="736" width="113" height="19" font="3">mortality and SCD </text>
<text top="293" left="736" width="3" height="19" font="3"> </text>
<text top="312" left="736" width="167" height="19" font="3">all-cause mortality (11.7 vs </text>
<text top="330" left="736" width="90" height="19" font="3">10.4%) p=0.16 </text>
<text top="348" left="736" width="120" height="19" font="3">or sudden death or </text>
<text top="367" left="736" width="166" height="19" font="3">resuscitated arrests (9.0 vs </text>
<text top="385" left="736" width="83" height="19" font="3">7.3%) p=0.08 </text>
<text top="256" left="927" width="105" height="19" font="3">● There were no </text>
<text top="274" left="927" width="137" height="19" font="3">significant differences </text>
<text top="292" left="927" width="147" height="19" font="3">in all-cause mortality or </text>
<text top="311" left="927" width="104" height="19" font="3">sudden death or </text>
<text top="329" left="927" width="123" height="19" font="3">resuscitated arrests </text>
<text top="347" left="927" width="3" height="19" font="3"> </text>
<text top="366" left="927" width="3" height="19" font="3"> </text>
<text top="404" left="123" width="51" height="19" font="3">●<b>RALES </b></text>
<text top="422" left="123" width="129" height="19" font="3">●Pitt et al. 1999 (69) </text>
<text top="441" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10471456?dopt=Citation">● </a></text>
<text top="441" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10471456?dopt=Citation">10471456</a></text>
<text top="441" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10471456?dopt=Citation"> </a></text>
<text top="404" left="277" width="105" height="19" font="4"><b>Study type:</b>  RCT </text>
<text top="422" left="277" width="3" height="19" font="3"> </text>
<text top="441" left="277" width="104" height="19" font="4"><b>Aim:</b>  To explore </text>
<text top="459" left="277" width="66" height="19" font="3">whether a </text>
<text top="477" left="277" width="111" height="19" font="3">mineralocorticoid </text>
<text top="496" left="277" width="105" height="19" font="3">antagonist could </text>
<text top="514" left="277" width="120" height="19" font="3">reduce mortality in </text>
<text top="532" left="277" width="110" height="19" font="3">patients with HF.  </text>
<text top="550" left="277" width="3" height="19" font="3"> </text>
<text top="569" left="277" width="66" height="19" font="4"><b>Size:</b> 1663 </text>
<text top="404" left="415" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="422" left="415" width="109" height="19" font="3">Class III, IV HF, EF </text>
<text top="441" left="415" width="44" height="19" font="3">&lt;35%,  </text>
<text top="459" left="415" width="3" height="19" font="3"> </text>
<text top="477" left="415" width="113" height="19" font="4"><b>Exclusion criteria</b> <b> </b></text>
<text top="496" left="415" width="27" height="19" font="3">N/A </text>
<text top="404" left="569" width="85" height="19" font="4"><b>Intervention:</b> </text>
<text top="422" left="569" width="95" height="19" font="3">spironolactone </text>
<text top="441" left="569" width="3" height="19" font="4"><b> </b></text>
<text top="459" left="569" width="134" height="19" font="4"><b>Comparator:</b> placebo<b> </b></text>
<text top="477" left="569" width="3" height="19" font="4"><b> </b></text>
<text top="405" left="736" width="138" height="19" font="4"><b>1</b>°<b> endpoint:</b> all-cause </text>
<text top="423" left="736" width="59" height="19" font="3">mortality </text>
<text top="441" left="736" width="3" height="19" font="3"> </text>
<text top="460" left="736" width="126" height="19" font="3">Death: 46% vs. 35%. </text>
<text top="478" left="736" width="53" height="19" font="3">p&lt;0.001 </text>
<text top="496" left="736" width="159" height="19" font="3">SCD: 13% vs. 10%, p=0.02 </text>
<text top="515" left="736" width="3" height="19" font="3"> </text>
<text top="533" left="736" width="3" height="19" font="3"> </text>
<text top="551" left="736" width="3" height="19" font="3"> </text>
<text top="569" left="736" width="3" height="19" font="4"><b> </b></text>
<text top="404" left="927" width="108" height="19" font="3">● Spironolactone </text>
<text top="422" left="927" width="110" height="19" font="3">reduced all-cause </text>
<text top="441" left="927" width="128" height="19" font="3">mortality and SCD in </text>
<text top="459" left="927" width="110" height="19" font="3">patients with HF.  </text>
<text top="589" left="123" width="75" height="19" font="3">● <b>EPHESUS  </b></text>
<text top="607" left="123" width="132" height="19" font="3">● Pitt et al. 2003 (70) </text>
<text top="625" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12668699?dopt=Citation">● </a></text>
<text top="625" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12668699?dopt=Citation">12668699</a></text>
<text top="625" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12668699?dopt=Citation"> </a></text>
<text top="588" left="277" width="101" height="19" font="4"><b>Study type:</b> RCT </text>
<text top="607" left="277" width="3" height="19" font="3"> </text>
<text top="625" left="277" width="118" height="19" font="4"><b>Aim:</b> To determine </text>
<text top="643" left="277" width="78" height="19" font="3">the effect of </text>
<text top="662" left="277" width="93" height="19" font="3">eplerenone on </text>
<text top="680" left="277" width="105" height="19" font="3">mortality among </text>
<text top="698" left="277" width="112" height="19" font="3">patients with AMI </text>
<text top="717" left="277" width="119" height="19" font="3">and LV dysfunction </text>
<text top="735" left="277" width="3" height="19" font="3"> </text>
<text top="753" left="277" width="66" height="19" font="4"><b>Size:</b> 6632 </text>
<text top="772" left="277" width="3" height="19" font="3"> </text>
<text top="588" left="415" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="607" left="415" width="93" height="19" font="3">3-14 d post-MI </text>
<text top="625" left="415" width="69" height="19" font="3">LVEF &lt;40% </text>
<text top="644" left="415" width="3" height="19" font="3"> </text>
<text top="662" left="415" width="113" height="19" font="4"><b>Exclusion criteria</b> <b> </b></text>
<text top="680" left="415" width="96" height="19" font="3">Creatinine &gt;2.5<b> </b></text>
<text top="588" left="569" width="85" height="19" font="4"><b>Intervention:</b> </text>
<text top="607" left="569" width="77" height="19" font="3">Eplerenone  </text>
<text top="625" left="569" width="134" height="19" font="4"><b>Comparator:</b> Placebo </text>
<text top="643" left="569" width="3" height="19" font="4"><b> </b></text>
<text top="589" left="736" width="143" height="19" font="4"><b>1</b>°<b> endpoint:</b>  All-cause </text>
<text top="608" left="736" width="63" height="19" font="3">mortality. </text>
<text top="626" left="736" width="3" height="19" font="3"> </text>
<text top="644" left="736" width="146" height="19" font="3">Death: 14% vs. 17%. RR </text>
<text top="663" left="736" width="90" height="19" font="3">0.85, p=0.008. </text>
<text top="681" left="736" width="3" height="19" font="3"> </text>
<text top="699" left="736" width="149" height="19" font="3">SCD: 5% vs. 6% (p=0.03) </text>
<text top="718" left="736" width="3" height="19" font="3"> </text>
<text top="736" left="736" width="3" height="19" font="3"> </text>
<text top="754" left="736" width="119" height="19" font="4"><b>Safety endpoint (if </b></text>
<text top="772" left="736" width="71" height="19" font="4"><b>relevant):</b>   </text>
<text top="589" left="927" width="139" height="19" font="3">● Eplerenone reduced </text>
<text top="607" left="927" width="125" height="19" font="3">all-cause and SCD in </text>
<text top="625" left="927" width="103" height="19" font="3">patients with HF </text>
<text top="643" left="927" width="3" height="19" font="3"> </text>
<text top="662" left="927" width="3" height="19" font="3"> </text>
</page>
<page number="36" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">36 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="277" width="3" height="19" font="3"> </text>
<text top="109" left="736" width="125" height="19" font="3">Hyperkalemia: 5.5% </text>
<text top="127" left="736" width="126" height="19" font="3">eplerenone vs. 3.9% </text>
<text top="145" left="736" width="120" height="19" font="3">Hypokalemia: 8.4% </text>
<text top="164" left="736" width="137" height="19" font="3">eplerenone vs. 13.1%  </text>
<text top="182" left="736" width="3" height="19" font="4"><b> </b></text>
<text top="201" left="123" width="81" height="19" font="3">● <b>EMPHASIS </b></text>
<text top="219" left="123" width="128" height="19" font="3">● Zannad et al. 2011 </text>
<text top="238" left="123" width="28" height="19" font="3">(71) </text>
<text top="256" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21073363?dopt=Citation">● </a></text>
<text top="256" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21073363?dopt=Citation">21073363</a></text>
<text top="256" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21073363?dopt=Citation"> </a></text>
<text top="201" left="277" width="101" height="19" font="4"><b>Study type:</b> RCT </text>
<text top="219" left="277" width="3" height="19" font="3"> </text>
<text top="237" left="277" width="107" height="19" font="4"><b>Aim:</b> To evaluate </text>
<text top="256" left="277" width="78" height="19" font="3">the effect of </text>
<text top="274" left="277" width="93" height="19" font="3">eplerenone on </text>
<text top="293" left="277" width="83" height="19" font="3">patients with </text>
<text top="311" left="277" width="123" height="19" font="3">chronic systolic HF.  </text>
<text top="329" left="277" width="3" height="19" font="3"> </text>
<text top="347" left="277" width="66" height="19" font="4"><b>Size:</b> 2737 </text>
<text top="366" left="277" width="3" height="19" font="3"> </text>
<text top="384" left="277" width="3" height="19" font="3"> </text>
<text top="201" left="415" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="219" left="415" width="64" height="19" font="3">Class II HF </text>
<text top="238" left="415" width="58" height="19" font="3">EF &lt;35%  </text>
<text top="256" left="415" width="3" height="19" font="3"> </text>
<text top="274" left="415" width="113" height="19" font="4"><b>Exclusion criteria</b> <b> </b></text>
<text top="292" left="415" width="136" height="19" font="3">AMI, NYHA III, IV, GFR </text>
<text top="311" left="415" width="26" height="19" font="3">&lt;30 </text>
<text top="201" left="569" width="85" height="19" font="4"><b>Intervention:</b> </text>
<text top="219" left="569" width="73" height="19" font="3">Eplerenone </text>
<text top="238" left="569" width="3" height="19" font="3"> </text>
<text top="256" left="569" width="134" height="19" font="4"><b>Comparator</b>: Placebo </text>
<text top="274" left="569" width="3" height="19" font="4"><b> </b></text>
<text top="202" left="736" width="162" height="19" font="4"><b>1</b>°<b> endpoint:</b>  composite – </text>
<text top="220" left="736" width="178" height="19" font="3">death and HF hospitalization </text>
<text top="238" left="736" width="3" height="19" font="3"> </text>
<text top="257" left="736" width="146" height="19" font="3">1° composite endpoint: </text>
<text top="275" left="736" width="163" height="19" font="3">18.3% vs. 25.9% (p&lt;0.001) </text>
<text top="293" left="736" width="3" height="19" font="3"> </text>
<text top="312" left="736" width="167" height="19" font="3">SCD: 4.4% vs. 5.5%, p=0.12 </text>
<text top="330" left="736" width="3" height="19" font="3"> </text>
<text top="348" left="736" width="119" height="19" font="4"><b>Safety endpoint (if </b></text>
<text top="367" left="736" width="71" height="19" font="4"><b>relevant):</b>   </text>
<text top="385" left="736" width="152" height="19" font="3">Hyperkalemia: 11.8% vs. </text>
<text top="403" left="736" width="33" height="19" font="3">7.2% </text>
<text top="201" left="927" width="142" height="19" font="3">● Significant reduction </text>
<text top="219" left="927" width="86" height="19" font="3">on composite </text>
<text top="238" left="927" width="96" height="19" font="3">endpoint.  Non-</text>
<text top="256" left="927" width="143" height="19" font="3">significant reduction in </text>
<text top="274" left="927" width="31" height="19" font="3">SCD. </text>
<text top="292" left="927" width="3" height="19" font="3"> </text>
<text top="311" left="927" width="3" height="19" font="3"> </text>
<text top="422" left="123" width="87" height="19" font="3">● <b>PARADIGM </b></text>
<text top="441" left="123" width="116" height="19" font="3">● Desai et al. 2015 </text>
<text top="459" left="123" width="28" height="19" font="3">(72) </text>
<text top="477" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26022006?dopt=Citation">● </a></text>
<text top="477" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26022006?dopt=Citation">26022006</a></text>
<text top="477" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26022006?dopt=Citation"> </a></text>
<text top="422" left="277" width="101" height="19" font="4"><b>Study type:</b> RCT </text>
<text top="441" left="277" width="3" height="19" font="3"> </text>
<text top="459" left="277" width="115" height="19" font="4"><b>Aim:</b> 2° analysis of </text>
<text top="477" left="277" width="73" height="19" font="3">the original </text>
<text top="496" left="277" width="120" height="19" font="3">PARADIGM-HF trial </text>
<text top="514" left="277" width="120" height="19" font="3">to explore mode of </text>
<text top="532" left="277" width="46" height="19" font="3">death.  </text>
<text top="550" left="277" width="3" height="19" font="3"> </text>
<text top="569" left="277" width="66" height="19" font="4"><b>Size:</b> 8399 </text>
<text top="422" left="415" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="441" left="415" width="81" height="19" font="3">Class II-IV HF </text>
<text top="459" left="415" width="58" height="19" font="3">EF &lt;40%  </text>
<text top="477" left="415" width="119" height="19" font="3">Guideline rec. med </text>
<text top="496" left="415" width="51" height="19" font="3">therapy </text>
<text top="514" left="415" width="3" height="19" font="3"> </text>
<text top="532" left="415" width="113" height="19" font="4"><b>Exclusion criteria</b> <b> </b></text>
<text top="550" left="415" width="136" height="19" font="3">AMI, NYHA III, IV, GFR </text>
<text top="569" left="415" width="26" height="19" font="3">&lt;30 </text>
<text top="422" left="569" width="85" height="19" font="4"><b>Intervention:</b> </text>
<text top="441" left="569" width="73" height="19" font="3">Eplerenone </text>
<text top="459" left="569" width="3" height="19" font="3"> </text>
<text top="477" left="569" width="134" height="19" font="4"><b>Comparator</b>: Placebo </text>
<text top="495" left="569" width="3" height="19" font="4"><b> </b></text>
<text top="423" left="736" width="164" height="19" font="4"><b>1</b>°<b> endpoint:</b>  CV death (2° </text>
<text top="441" left="736" width="166" height="19" font="3">analysis exploring mode of </text>
<text top="460" left="736" width="43" height="19" font="3">death) </text>
<text top="478" left="736" width="3" height="19" font="3"> </text>
<text top="496" left="736" width="166" height="19" font="3">CV death: HR: 0.80; 95% CI </text>
<text top="515" left="736" width="128" height="19" font="3">0.72–0.89, p&lt;0.001.  </text>
<text top="533" left="736" width="3" height="19" font="3"> </text>
<text top="551" left="736" width="119" height="19" font="3">Among CV deaths,  </text>
<text top="570" left="736" width="143" height="19" font="3">SCD: HR: 0.80; p=0.008 </text>
<text top="588" left="736" width="3" height="19" font="3"> </text>
<text top="606" left="736" width="172" height="19" font="3">death due to worsening HF: </text>
<text top="624" left="736" width="112" height="19" font="3">HR: 0.79; p=0.034 </text>
<text top="422" left="927" width="3" height="19" font="3"> </text>
<text top="643" left="115" width="3" height="19" font="3"> </text>
<text top="662" left="115" width="4" height="21" font="0"> </text>
<text top="661" left="331" width="4" height="21" font="2"><b> </b></text>
</page>
<page number="37" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">37 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="937" height="21" font="2"><b>Data Supplement 11. RCTs and Nonrandomized Trials, Observational Studies, and/or Registries Related to Surgery and Revascularization </b></text>
<text top="128" left="115" width="182" height="21" font="2"><b>Procedures – (Section 5.5) </b></text>
<text top="149" left="127" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="167" left="152" width="55" height="19" font="4"><b>Author;  </b></text>
<text top="185" left="130" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="149" left="267" width="88" height="19" font="4"><b>Aim of Study; </b></text>
<text top="167" left="273" width="76" height="19" font="4"><b>Study Type; </b></text>
<text top="185" left="266" width="89" height="19" font="4"><b>Study Size (N) </b></text>
<text top="149" left="404" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="149" left="560" width="123" height="19" font="4"><b>Study Intervention  </b></text>
<text top="167" left="578" width="88" height="19" font="4"><b>(# patients) /  </b></text>
<text top="185" left="561" width="121" height="19" font="4"><b>Study Comparator  </b></text>
<text top="204" left="583" width="75" height="19" font="4"><b>(# patients) </b></text>
<text top="149" left="729" width="108" height="19" font="4"><b>Endpoint Results </b></text>
<text top="167" left="712" width="148" height="19" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="185" left="716" width="136" height="19" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="204" left="759" width="49" height="19" font="4"><b>95% CI) </b></text>
<text top="150" left="883" width="186" height="19" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="168" left="918" width="116" height="19" font="4"><b>Study Limitations; </b></text>
<text top="186" left="927" width="99" height="19" font="4"><b>Adverse Events </b></text>
<text top="223" left="123" width="52" height="19" font="3">● <b>STICH </b></text>
<text top="241" left="123" width="91" height="19" font="3">● Carson et al. </text>
<text top="260" left="123" width="62" height="19" font="3">2013 (73) </text>
<text top="278" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24621972">● </a></text>
<text top="278" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24621972">24621972</a></text>
<text top="278" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24621972"> </a></text>
<text top="223" left="246" width="127" height="19" font="4"><b>Aim:</b> Cause of death </text>
<text top="241" left="246" width="122" height="19" font="3">analysis for the 462 </text>
<text top="260" left="246" width="111" height="19" font="3">deaths during the </text>
<text top="278" left="246" width="111" height="19" font="3">original follow-up </text>
<text top="296" left="246" width="119" height="19" font="3">period of a median </text>
<text top="314" left="246" width="97" height="19" font="3">of 56 mo of the </text>
<text top="333" left="246" width="100" height="19" font="3">parent trial that </text>
<text top="351" left="246" width="103" height="19" font="3">compared CABG </text>
<text top="370" left="246" width="79" height="19" font="3">plus medical </text>
<text top="388" left="246" width="118" height="19" font="3">therapy to medical </text>
<text top="406" left="246" width="105" height="19" font="3">therapy alone to </text>
<text top="424" left="246" width="117" height="19" font="3">reduce death from </text>
<text top="443" left="246" width="63" height="19" font="3">any cause </text>
<text top="461" left="246" width="3" height="19" font="3"> </text>
<text top="479" left="246" width="108" height="19" font="4"><b>Study type:</b>   RCT </text>
<text top="498" left="246" width="122" height="19" font="4"><b>Size:</b>  1212 patients </text>
<text top="223" left="389" width="140" height="19" font="4"><b>Inclusion criteria:</b>  age </text>
<text top="241" left="389" width="149" height="19" font="3">≥18 y, CAD amenable to </text>
<text top="260" left="389" width="137" height="19" font="3">CABG, and LVEF ≤35% </text>
<text top="278" left="389" width="3" height="19" font="3"> </text>
<text top="296" left="389" width="117" height="19" font="4"><b>Exclusion criteria:  </b></text>
<text top="314" left="389" width="116" height="19" font="3">left main coronary </text>
<text top="333" left="389" width="106" height="19" font="3">stenosis ≥50% or </text>
<text top="351" left="389" width="60" height="19" font="3">Canadian </text>
<text top="370" left="389" width="140" height="19" font="3">Cardiovascular Society </text>
<text top="388" left="389" width="112" height="19" font="3">III-IV angina while </text>
<text top="406" left="389" width="110" height="19" font="3">receiving medical </text>
<text top="424" left="389" width="51" height="19" font="3">therapy<b> </b></text>
<text top="223" left="552" width="123" height="19" font="4"><b>Intervention: </b>CABG </text>
<text top="241" left="552" width="84" height="19" font="3">(plus medical </text>
<text top="260" left="552" width="55" height="19" font="3">therapy) </text>
<text top="278" left="552" width="7" height="19" font="3">  </text>
<text top="296" left="552" width="134" height="19" font="4"><b>Comparator:</b> medical </text>
<text top="314" left="552" width="88" height="19" font="3">therapy alone<b> </b></text>
<text top="223" left="702" width="152" height="19" font="3">CABG therapy tended to </text>
<text top="241" left="702" width="137" height="19" font="3">reduce cardiovascular </text>
<text top="260" left="702" width="156" height="19" font="3">deaths (HR: 0.83; 95% CI: </text>
<text top="278" left="702" width="144" height="19" font="3">0.68–1.03; p=0.09) and </text>
<text top="296" left="702" width="153" height="19" font="3">significantly reduced the </text>
<text top="314" left="702" width="152" height="19" font="3">most common modes of </text>
<text top="333" left="702" width="159" height="19" font="3">death: sudden death (HR: </text>
<text top="351" left="702" width="150" height="19" font="3">0.73; 95% CI: 0.54–0.99; </text>
<text top="370" left="702" width="154" height="19" font="3">p=0.041) and fatal pump </text>
<text top="388" left="702" width="150" height="19" font="3">failure events (HR: 0.64; </text>
<text top="406" left="702" width="116" height="19" font="3">95% CI: 0.41–1.00; </text>
<text top="424" left="702" width="158" height="19" font="3">p=0.05). Time-dependent </text>
<text top="443" left="702" width="151" height="19" font="3">estimates indicated that </text>
<text top="461" left="702" width="144" height="19" font="3">the protective effect of </text>
<text top="479" left="702" width="162" height="19" font="3">CABG principally occurred </text>
<text top="498" left="702" width="122" height="19" font="3">after 24 mo in both </text>
<text top="516" left="702" width="70" height="19" font="3">categories.<b> </b></text>
<text top="223" left="878" width="3" height="19" font="4"><b> </b></text>
<text top="535" left="123" width="66" height="19" font="3">● <b>STICHES </b></text>
<text top="553" left="123" width="93" height="19" font="3">● Velazquez et </text>
<text top="572" left="123" width="79" height="19" font="3">al. 2016 (74) </text>
<text top="590" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27040723">● </a></text>
<text top="590" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27040723">27040723</a></text>
<text top="590" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27040723"> </a></text>
<text top="608" left="123" width="3" height="19" font="3"> </text>
<text top="535" left="246" width="129" height="19" font="4"><b>Aim:</b> Compare CABG </text>
<text top="553" left="246" width="79" height="19" font="3">plus medical </text>
<text top="572" left="246" width="118" height="19" font="3">therapy to medical </text>
<text top="590" left="246" width="105" height="19" font="3">therapy alone to </text>
<text top="608" left="246" width="117" height="19" font="3">reduce death from </text>
<text top="627" left="246" width="63" height="19" font="3">any cause </text>
<text top="645" left="246" width="3" height="19" font="3"> </text>
<text top="663" left="246" width="101" height="19" font="4"><b>Study type: </b>RCT </text>
<text top="681" left="246" width="3" height="19" font="3"> </text>
<text top="700" left="246" width="126" height="19" font="4"><b>Size:</b>  1212 patients, </text>
<text top="718" left="246" width="112" height="19" font="3">with 9.8 y median </text>
<text top="736" left="246" width="57" height="19" font="3">followup </text>
<text top="535" left="389" width="140" height="19" font="4"><b>Inclusion criteria:</b>  age </text>
<text top="553" left="389" width="149" height="19" font="3">≥18 y, CAD amenable to </text>
<text top="572" left="389" width="137" height="19" font="3">CABG, and LVEF ≤35% </text>
<text top="590" left="389" width="3" height="19" font="3"> </text>
<text top="608" left="389" width="117" height="19" font="4"><b>Exclusion criteria:  </b></text>
<text top="627" left="389" width="116" height="19" font="3">left main coronary </text>
<text top="645" left="389" width="106" height="19" font="3">stenosis ≥50% or </text>
<text top="663" left="389" width="60" height="19" font="3">Canadian </text>
<text top="681" left="389" width="140" height="19" font="3">Cardiovascular Society </text>
<text top="700" left="389" width="112" height="19" font="3">III-IV angina while </text>
<text top="718" left="389" width="110" height="19" font="3">receiving medical </text>
<text top="736" left="389" width="54" height="19" font="3">therapy  </text>
<text top="535" left="552" width="123" height="19" font="4"><b>Intervention: </b>CABG </text>
<text top="553" left="552" width="84" height="19" font="3">(plus medical </text>
<text top="572" left="552" width="55" height="19" font="3">therapy) </text>
<text top="590" left="552" width="7" height="19" font="3">  </text>
<text top="608" left="552" width="134" height="19" font="4"><b>Comparator:</b> medical </text>
<text top="627" left="552" width="88" height="19" font="3">therapy alone<b> </b></text>
<text top="536" left="702" width="119" height="19" font="4"><b>1</b>°<b> endpoint:</b> lower </text>
<text top="554" left="702" width="128" height="19" font="3">mortality with CABG </text>
<text top="572" left="702" width="156" height="19" font="3">(58.9%) than the medical </text>
<text top="591" left="702" width="144" height="19" font="3">therapy (66.1%) group. </text>
<text top="609" left="702" width="109" height="19" font="3">CABG vs. medical </text>
<text top="627" left="702" width="162" height="19" font="3">therapy, HR: 0.84; 95% CI: </text>
<text top="646" left="702" width="154" height="19" font="3">0.73–0.97; p=0.02 by log-</text>
<text top="664" left="702" width="64" height="19" font="3">rank test.  </text>
<text top="682" left="702" width="3" height="19" font="3"> </text>
<text top="701" left="702" width="3" height="19" font="3"> </text>
<text top="535" left="878" width="178" height="19" font="3">● <b>Cardiac arrest outcomes:</b>   </text>
<text top="553" left="878" width="173" height="19" font="3">● Sudden/arrhythmic death </text>
<text top="572" left="878" width="170" height="19" font="3">116 (19%) CABG, 154 (26%) </text>
<text top="590" left="878" width="102" height="19" font="3">medical therapy </text>
<text top="608" left="878" width="119" height="19" font="3">● Within 30 d after </text>
<text top="627" left="878" width="92" height="19" font="3">randomization </text>
<text top="645" left="878" width="172" height="19" font="3">● CA requiring CPR, 25 (4%) </text>
<text top="663" left="878" width="168" height="19" font="3">CABG and 2 (0.3%) medical </text>
<text top="681" left="878" width="61" height="19" font="3">therapy.   </text>
<text top="700" left="878" width="3" height="19" font="3"> </text>
<text top="718" left="878" width="3" height="19" font="3"> </text>
<text top="736" left="878" width="3" height="19" font="3"> </text>
</page>
<page number="38" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">38 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="101" height="19" font="3">● <b>AVID Registry </b></text>
<text top="127" left="123" width="80" height="19" font="3">● Cook et al. </text>
<text top="145" left="123" width="62" height="19" font="3">2002 (75) </text>
<text top="164" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12040343">● </a></text>
<text top="164" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12040343">12040343</a></text>
<text top="164" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12040343"> </a></text>
<text top="182" left="123" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="246" width="100" height="19" font="4"><b>Aim:</b> determine </text>
<text top="127" left="246" width="108" height="19" font="3">whether patients </text>
<text top="145" left="246" width="90" height="19" font="3">with CAD who </text>
<text top="164" left="246" width="71" height="19" font="3">underwent </text>
<text top="182" left="246" width="107" height="19" font="3">revascularization </text>
<text top="200" left="246" width="67" height="19" font="3">after a life-</text>
<text top="219" left="246" width="128" height="19" font="3">threatening VA have </text>
<text top="237" left="246" width="112" height="19" font="3">improved survival </text>
<text top="255" left="246" width="66" height="19" font="3">rate when </text>
<text top="273" left="246" width="96" height="19" font="3">compared with </text>
<text top="292" left="246" width="114" height="19" font="3">those who did not </text>
<text top="310" left="246" width="127" height="19" font="3">undergo revasc; and </text>
<text top="329" left="246" width="79" height="19" font="3">evaluate the </text>
<text top="347" left="246" width="86" height="19" font="3">interaction of </text>
<text top="365" left="246" width="107" height="19" font="3">revascularization </text>
<text top="383" left="246" width="106" height="19" font="3">with ICD therapy </text>
<text top="402" left="246" width="3" height="19" font="3"> </text>
<text top="420" left="246" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="438" left="246" width="87" height="19" font="3">observational </text>
<text top="457" left="246" width="3" height="19" font="4"><b> </b></text>
<text top="475" left="246" width="119" height="19" font="4"><b>Size:</b> 3117 patients </text>
<text top="493" left="246" width="129" height="19" font="3">with life-threatening </text>
<text top="512" left="246" width="116" height="19" font="3">VA, of whom 2321 </text>
<text top="530" left="246" width="120" height="19" font="3">(77%) had CAD and </text>
<text top="548" left="246" width="64" height="19" font="3">281 (17%) </text>
<text top="566" left="246" width="108" height="19" font="3">underwent CABG </text>
<text top="585" left="246" width="93" height="19" font="3">after the index </text>
<text top="603" left="246" width="38" height="19" font="3">event<b> </b></text>
<text top="109" left="389" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="127" left="389" width="137" height="19" font="3">Ventricular fibrillation </text>
<text top="145" left="389" width="118" height="19" font="3">or symptomatic VT </text>
<text top="164" left="389" width="55" height="19" font="3">(defined </text>
<text top="182" left="389" width="136" height="19" font="3">as VT with syncope or </text>
<text top="200" left="389" width="143" height="19" font="3">VT with symptoms and </text>
<text top="219" left="389" width="128" height="19" font="3">LVEF ≤0.40 [VT/VF]). </text>
<text top="237" left="389" width="117" height="19" font="3">Also, patients with </text>
<text top="255" left="389" width="132" height="19" font="3">unexplained syncope </text>
<text top="273" left="389" width="142" height="19" font="3">who had inducible and </text>
<text top="292" left="389" width="145" height="19" font="3">symptomatic VT during </text>
<text top="310" left="389" width="29" height="19" font="3">EPS.<b> </b></text>
<text top="109" left="552" width="85" height="19" font="4"><b>Intervention:</b> </text>
<text top="127" left="552" width="135" height="19" font="3">revascularization; ICD </text>
<text top="109" left="702" width="154" height="19" font="3">Patients who underwent </text>
<text top="127" left="702" width="107" height="19" font="3">revascularization </text>
<text top="145" left="702" width="149" height="19" font="3">had better survival than </text>
<text top="164" left="702" width="147" height="19" font="3">those who did not after </text>
<text top="182" left="702" width="162" height="19" font="3">the index event (HR: 0.67; </text>
<text top="200" left="702" width="143" height="19" font="3">p=0.002). With a mean </text>
<text top="219" left="702" width="121" height="19" font="3">follow-up period of </text>
<text top="237" left="702" width="129" height="19" font="3">24.2±13.5 mo, crude </text>
<text top="255" left="702" width="137" height="19" font="3">death rates (with 95% </text>
<text top="273" left="702" width="146" height="19" font="3">confidence limits) were </text>
<text top="292" left="702" width="116" height="19" font="3">21.4%±4.8% in the </text>
<text top="310" left="702" width="146" height="19" font="3">revascularization group </text>
<text top="329" left="702" width="143" height="19" font="3">and 29.4%±2.0% in the </text>
<text top="347" left="702" width="153" height="19" font="3">medically treated group. </text>
<text top="365" left="702" width="3" height="19" font="3"> </text>
<text top="383" left="702" width="132" height="19" font="3">After adjustment, HR </text>
<text top="402" left="702" width="120" height="19" font="3">unchanged at 0.67, </text>
<text top="420" left="702" width="157" height="19" font="3">significance decreased to </text>
<text top="438" left="702" width="49" height="19" font="3">p=0.01. </text>
<text top="457" left="702" width="3" height="19" font="3"> </text>
<text top="475" left="702" width="155" height="19" font="3">The association of better </text>
<text top="493" left="702" width="132" height="19" font="3">survival with ICD was </text>
<text top="512" left="702" width="148" height="19" font="3">consistent regardless of </text>
<text top="530" left="702" width="147" height="19" font="3">revascularization status<b> </b></text>
<text top="109" left="878" width="3" height="19" font="4"><b> </b></text>
<text top="622" left="123" width="99" height="19" font="3">● Mondésert et </text>
<text top="640" left="123" width="79" height="19" font="3">al. 2016 (76) </text>
<text top="659" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26806581">● </a></text>
<text top="659" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26806581">26806581</a></text>
<text top="659" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26806581"> </a></text>
<text top="677" left="123" width="3" height="19" font="4"><b> </b></text>
<text top="622" left="246" width="123" height="19" font="4"><b>Aim: </b>determine the </text>
<text top="640" left="246" width="61" height="19" font="3">impact of </text>
<text top="659" left="246" width="126" height="19" font="3">revascularization on </text>
<text top="677" left="246" width="98" height="19" font="3">recurrent VA or </text>
<text top="695" left="246" width="39" height="19" font="3">death </text>
<text top="714" left="246" width="3" height="19" font="3"> </text>
<text top="732" left="246" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="750" left="246" width="87" height="19" font="3">observational </text>
<text top="769" left="246" width="3" height="19" font="3"> </text>
<text top="622" left="389" width="144" height="19" font="4"><b>Inclusion criteria:</b> LVEF </text>
<text top="640" left="389" width="113" height="19" font="3">≥40%, first clinical </text>
<text top="659" left="389" width="137" height="19" font="3">sustained VA, without </text>
<text top="677" left="389" width="27" height="19" font="3">ACS<b> </b></text>
<text top="622" left="552" width="82" height="19" font="4"><b>Intervention:</b></text>
<text top="621" left="634" width="4" height="21" font="0"> </text>
<text top="640" left="552" width="58" height="19" font="3">coronary </text>
<text top="659" left="552" width="107" height="19" font="3">revascularization<b> </b></text>
<text top="622" left="702" width="161" height="19" font="3">Revascularization was not </text>
<text top="640" left="702" width="98" height="19" font="3">associated with </text>
<text top="659" left="702" width="158" height="19" font="3">significantly lower rate of </text>
<text top="677" left="702" width="137" height="19" font="3">recurrent VA or death </text>
<text top="695" left="702" width="147" height="19" font="3">(multivariable HR: 0.86; </text>
<text top="714" left="702" width="162" height="19" font="3">95% CI 0.60–1.24, p=0.43) </text>
<text top="732" left="702" width="137" height="19" font="3">regardless of whether </text>
<text top="750" left="702" width="150" height="19" font="3">complete or incomplete </text>
<text top="769" left="702" width="142" height="19" font="3">(HR: 0.65; 95% CI 0.25–</text>
<text top="622" left="878" width="3" height="19" font="4"><b> </b></text>
</page>
<page number="39" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">39 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="246" width="118" height="19" font="4"><b>Size:</b>  274 patients, </text>
<text top="127" left="246" width="122" height="19" font="3">mean follow-up 6.2 </text>
<text top="145" left="246" width="10" height="19" font="3">y<b> </b></text>
<text top="109" left="702" width="140" height="19" font="3">1.69, p=0.37) or PCI or </text>
<text top="127" left="702" width="145" height="19" font="3">CABG (HR: 1.02; 95% CI </text>
<text top="145" left="702" width="149" height="19" font="3">0.53–1.94, p=0.96).  ICD </text>
<text top="164" left="702" width="98" height="19" font="3">associated with </text>
<text top="182" left="702" width="114" height="19" font="3">significantly lower </text>
<text top="200" left="702" width="152" height="19" font="3">mortality (HR: 0.23; 95% </text>
<text top="219" left="702" width="148" height="19" font="3">CI 0.09– 0.55, p=0.001). </text>
<text top="238" left="123" width="95" height="19" font="3">● Ngaage et al. </text>
<text top="256" left="123" width="62" height="19" font="3">2008 (77) </text>
<text top="274" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18355509">● </a></text>
<text top="274" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18355509">18355509</a></text>
<text top="274" left="196" width="7" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18355509"> <b> </b></a></text>
<text top="237" left="246" width="101" height="19" font="4"><b>Aim:  </b>assess the </text>
<text top="256" left="246" width="78" height="19" font="3">outcomes in </text>
<text top="274" left="246" width="126" height="19" font="3">patients undergoing </text>
<text top="293" left="246" width="127" height="19" font="3">CABG after ischemic </text>
<text top="311" left="246" width="102" height="19" font="3">VT/VF (after MI, </text>
<text top="329" left="246" width="118" height="19" font="3">with exercise, with </text>
<text top="347" left="246" width="25" height="19" font="3">CA) </text>
<text top="366" left="246" width="3" height="19" font="3"> </text>
<text top="384" left="246" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="402" left="246" width="87" height="19" font="3">observational </text>
<text top="421" left="246" width="3" height="19" font="3"> </text>
<text top="439" left="246" width="107" height="19" font="4"><b>Size:</b>  93 patients </text>
<text top="457" left="246" width="111" height="19" font="3">undergoing CABG<b> </b></text>
<text top="237" left="389" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="256" left="389" width="83" height="19" font="3">patients who </text>
<text top="274" left="389" width="139" height="19" font="3">underwent CABG with </text>
<text top="293" left="389" width="119" height="19" font="3">preceding VT or VF<b> </b></text>
<text top="237" left="552" width="123" height="19" font="4"><b>Intervention: </b>CABG </text>
<text top="256" left="552" width="3" height="19" font="4"><b> </b></text>
<text top="238" left="702" width="145" height="19" font="3">Perioperative mortality </text>
<text top="256" left="702" width="162" height="19" font="3">was 6.5%, and 5 y survival </text>
<text top="274" left="702" width="88" height="19" font="3">rate was 88%, </text>
<text top="293" left="702" width="145" height="19" font="3">comparable to patients </text>
<text top="311" left="702" width="132" height="19" font="3">without prior VT/VF.  </text>
<text top="237" left="878" width="3" height="19" font="4"><b> </b></text>
<text top="476" left="123" width="83" height="19" font="3">● Every et al. </text>
<text top="495" left="123" width="62" height="19" font="3">1992 (78) </text>
<text top="513" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1593036">● </a></text>
<text top="513" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1593036">1593036</a></text>
<text top="513" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1593036"> </a></text>
<text top="476" left="246" width="113" height="19" font="4"><b>Aim: </b>estimate the </text>
<text top="495" left="246" width="108" height="19" font="3">possible effect of </text>
<text top="513" left="246" width="81" height="19" font="3">CABG on the </text>
<text top="531" left="246" width="74" height="19" font="3">subsequent </text>
<text top="550" left="246" width="127" height="19" font="3">outcome of patients </text>
<text top="568" left="246" width="97" height="19" font="3">who have been </text>
<text top="586" left="246" width="115" height="19" font="3">resuscitated from  </text>
<text top="605" left="246" width="23" height="19" font="3">CA  </text>
<text top="623" left="246" width="3" height="19" font="3"> </text>
<text top="641" left="246" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="660" left="246" width="87" height="19" font="3">observational </text>
<text top="678" left="246" width="3" height="19" font="3"> </text>
<text top="696" left="246" width="118" height="19" font="4"><b>Size:</b>  265 patients, </text>
<text top="714" left="246" width="98" height="19" font="3">85 treated with </text>
<text top="733" left="246" width="119" height="19" font="3">CABG, 180 medical </text>
<text top="751" left="246" width="92" height="19" font="3">management, <b> </b></text>
<text top="476" left="389" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="495" left="389" width="101" height="19" font="3">OHCA survivors, </text>
<text top="513" left="389" width="89" height="19" font="3">neurologically </text>
<text top="531" left="389" width="127" height="19" font="3">recovered, coronary </text>
<text top="550" left="389" width="142" height="19" font="3">disease, no prior CABG </text>
<text top="568" left="389" width="53" height="19" font="3">or other </text>
<text top="586" left="389" width="107" height="19" font="3">revascularization<b> </b></text>
<text top="476" left="552" width="3" height="19" font="4"><b> </b></text>
<text top="476" left="702" width="154" height="19" font="3">Significant association of </text>
<text top="495" left="702" width="147" height="19" font="3">CABG with lower risk of </text>
<text top="513" left="702" width="137" height="19" font="3">subsequent CA during </text>
<text top="531" left="702" width="149" height="19" font="3">follow-up RR: 0.48; 95% </text>
<text top="550" left="702" width="136" height="19" font="3">CI 0.24–0.97, p=0.04). </text>
<text top="568" left="702" width="118" height="19" font="3">Also, lower cardiac </text>
<text top="586" left="702" width="154" height="19" font="3">mortality (RR: 0 .65; 95% </text>
<text top="605" left="702" width="137" height="19" font="3">CI 0.39–1.10, p=0.10). </text>
<text top="623" left="702" width="7" height="19" font="3">  </text>
<text top="476" left="878" width="3" height="19" font="4"><b> </b></text>
</page>
<page number="40" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">40 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="109" height="19" font="3">● van der Burg et </text>
<text top="127" left="123" width="79" height="19" font="3">al. 2003 (79) </text>
<text top="145" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14530201">● </a></text>
<text top="145" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14530201">14530201</a></text>
<text top="145" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14530201"> </a></text>
<text top="109" left="246" width="100" height="19" font="4"><b>Aim: </b>determine </text>
<text top="127" left="246" width="108" height="19" font="3">relation between </text>
<text top="145" left="246" width="115" height="19" font="3">ischemia, viability, </text>
<text top="164" left="246" width="98" height="19" font="3">scar tissue (and </text>
<text top="182" left="246" width="115" height="19" font="3">revascularization), </text>
<text top="200" left="246" width="127" height="19" font="3">and the incidence of </text>
<text top="219" left="246" width="121" height="19" font="3">VA (and survival) in </text>
<text top="237" left="246" width="130" height="19" font="3">patients with CA and </text>
<text top="255" left="246" width="106" height="19" font="3">coronary disease </text>
<text top="273" left="246" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="292" left="246" width="87" height="19" font="3">observational </text>
<text top="310" left="246" width="3" height="19" font="3"> </text>
<text top="328" left="246" width="118" height="19" font="4"><b>Size:</b>  153 patients, </text>
<text top="347" left="246" width="118" height="19" font="3">follow-up up to 3 y<b> </b></text>
<text top="109" left="389" width="132" height="19" font="4"><b>Inclusion criteria:</b> VA </text>
<text top="127" left="389" width="138" height="19" font="3">CA survivors with CAD<b> </b></text>
<text top="109" left="552" width="113" height="19" font="4"><b>Intervention:</b> N/A<b> </b></text>
<text top="109" left="702" width="83" height="19" font="3">Patients with </text>
<text top="127" left="702" width="98" height="19" font="3">ischemic/viable </text>
<text top="145" left="702" width="159" height="19" font="3">myocardium (N=73) were </text>
<text top="164" left="702" width="162" height="19" font="3">revascularized if possible.  </text>
<text top="182" left="702" width="161" height="19" font="3">ICD in 112 (72%) patients. </text>
<text top="200" left="702" width="110" height="19" font="3">15 cardiac deaths </text>
<text top="219" left="702" width="141" height="19" font="3">occurred and 42 (29%) </text>
<text top="237" left="702" width="140" height="19" font="3">patients had recurrent </text>
<text top="255" left="702" width="152" height="19" font="3">VA. Patients with events </text>
<text top="273" left="702" width="134" height="19" font="3">(death or recurrence) </text>
<text top="292" left="702" width="143" height="19" font="3">exhibited more often a </text>
<text top="310" left="702" width="153" height="19" font="3">severely depressed LVEF </text>
<text top="329" left="702" width="147" height="19" font="3">(≤30%), more extensive </text>
<text top="347" left="702" width="123" height="19" font="3">scar tissue, and less </text>
<text top="365" left="702" width="98" height="19" font="3">ischemic/viable </text>
<text top="383" left="702" width="160" height="19" font="3">myocardium on perfusion </text>
<text top="402" left="702" width="78" height="19" font="3">imaging and </text>
<text top="420" left="702" width="93" height="19" font="3">less frequently </text>
<text top="438" left="702" width="71" height="19" font="3">underwent </text>
<text top="457" left="702" width="114" height="19" font="3">revascularization.  </text>
<text top="475" left="702" width="3" height="19" font="3"> </text>
<text top="493" left="702" width="129" height="19" font="3">Multivariate analysis </text>
<text top="512" left="702" width="151" height="19" font="3">identified extensive scar </text>
<text top="530" left="702" width="151" height="19" font="3">tissue and LVEF ≤30% as </text>
<text top="548" left="702" width="135" height="19" font="3">the only predictors of </text>
<text top="566" left="702" width="126" height="19" font="3">death/recurrent VA  </text>
<text top="109" left="878" width="3" height="19" font="4"><b> </b></text>
<text top="586" left="123" width="70" height="19" font="3">● <b>PROCAT  </b></text>
<text top="604" left="123" width="92" height="19" font="3">● Dumas et al. </text>
<text top="622" left="123" width="62" height="19" font="3">2010 (80) </text>
<text top="640" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20484098">● </a></text>
<text top="640" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20484098">20484098</a></text>
<text top="640" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20484098"> </a></text>
<text top="585" left="246" width="77" height="19" font="4"><b>Aim:  </b>assess </text>
<text top="604" left="246" width="97" height="19" font="3">the effect of an </text>
<text top="622" left="246" width="126" height="19" font="3">invasive strategy for </text>
<text top="640" left="246" width="123" height="19" font="3">patients with OHCA </text>
<text top="659" left="246" width="125" height="19" font="3">on hospital survival. </text>
<text top="677" left="246" width="3" height="19" font="3"> </text>
<text top="695" left="246" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="714" left="246" width="87" height="19" font="3">observational </text>
<text top="732" left="246" width="3" height="19" font="3"> </text>
<text top="750" left="246" width="114" height="19" font="4"><b>Size:</b>  435 patients </text>
<text top="769" left="246" width="98" height="19" font="3">treated with an </text>
<text top="585" left="389" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="604" left="389" width="123" height="19" font="3">patients with OHCA </text>
<text top="622" left="389" width="142" height="19" font="3">with presumed cardiac </text>
<text top="640" left="389" width="109" height="19" font="3">etiology and with </text>
<text top="659" left="389" width="126" height="19" font="3">coronary angiogram </text>
<text top="677" left="389" width="150" height="19" font="3">performed at admission<b> </b></text>
<text top="585" left="552" width="85" height="19" font="4"><b>Intervention: </b></text>
<text top="604" left="552" width="92" height="19" font="3">immediate PCI </text>
<text top="622" left="552" width="3" height="19" font="3"> </text>
<text top="586" left="702" width="126" height="19" font="3">At least 1 significant </text>
<text top="604" left="702" width="124" height="19" font="3">coronary lesion was </text>
<text top="622" left="702" width="119" height="19" font="3">found in 304 (70%) </text>
<text top="640" left="702" width="152" height="19" font="3">patients, in 128 (96%) of </text>
<text top="659" left="702" width="129" height="19" font="3">134 patients with ST-</text>
<text top="677" left="702" width="161" height="19" font="3">segment elevation, and in </text>
<text top="695" left="702" width="160" height="19" font="3">176 (58%) of 301 patients </text>
<text top="714" left="702" width="126" height="19" font="3">without ST-segment </text>
<text top="732" left="702" width="148" height="19" font="3">elevation. Multivariable </text>
<text top="750" left="702" width="102" height="19" font="3">analysis showed </text>
<text top="769" left="702" width="123" height="19" font="3">successful coronary </text>
<text top="585" left="878" width="3" height="19" font="4"><b> </b></text>
</page>
<page number="41" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">41 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="246" width="127" height="19" font="3">immediate coronary </text>
<text top="127" left="246" width="84" height="19" font="3">angiogram at </text>
<text top="145" left="246" width="95" height="19" font="3">admission with </text>
<text top="164" left="246" width="58" height="19" font="3">coronary </text>
<text top="182" left="246" width="84" height="19" font="3">angioplasty if </text>
<text top="200" left="246" width="53" height="19" font="3">possible<b> </b></text>
<text top="109" left="702" width="127" height="19" font="3">angioplasty to be an </text>
<text top="127" left="702" width="157" height="19" font="3">independent predictor of </text>
<text top="145" left="702" width="159" height="19" font="3">survival, regardless of the </text>
<text top="164" left="702" width="140" height="19" font="3">post resuscitation ECG </text>
<text top="182" left="702" width="161" height="19" font="3">pattern (OR: 2.06; 95% CI: </text>
<text top="200" left="702" width="72" height="19" font="3">1.16–3.66). </text>
<text top="219" left="123" width="78" height="19" font="3">● <b>PROCAT II </b></text>
<text top="237" left="123" width="54" height="19" font="4"><b>registry  </b></text>
<text top="256" left="123" width="92" height="19" font="3">● Dumas et al. </text>
<text top="274" left="123" width="65" height="19" font="3">2016 (81)  </text>
<text top="293" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27131438">● </a></text>
<text top="293" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27131438">27131438</a></text>
<text top="292" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27131438"> </a></text>
<text top="311" left="123" width="3" height="19" font="4"><b> </b></text>
<text top="219" left="246" width="101" height="19" font="4"><b>Aim:  </b>assess the </text>
<text top="238" left="246" width="129" height="19" font="3">association between </text>
<text top="256" left="246" width="83" height="19" font="3">early PCI and </text>
<text top="274" left="246" width="119" height="19" font="3">favorable outcome </text>
<text top="293" left="246" width="58" height="19" font="3">(cerebral </text>
<text top="311" left="246" width="82" height="19" font="3">performance </text>
<text top="329" left="246" width="110" height="19" font="3">category 1 to 2 at </text>
<text top="347" left="246" width="66" height="19" font="3">discharge) </text>
<text top="366" left="246" width="3" height="19" font="3"> </text>
<text top="384" left="246" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="402" left="246" width="87" height="19" font="3">observational </text>
<text top="421" left="246" width="3" height="19" font="3"> </text>
<text top="439" left="246" width="114" height="19" font="4"><b>Size:</b>  695 patients </text>
<text top="457" left="246" width="98" height="19" font="3">treated with an </text>
<text top="476" left="246" width="127" height="19" font="3">immediate coronary </text>
<text top="494" left="246" width="84" height="19" font="3">angiogram at </text>
<text top="512" left="246" width="116" height="19" font="3">admission without </text>
<text top="531" left="246" width="97" height="19" font="3">ST elevation on </text>
<text top="549" left="246" width="113" height="19" font="3">post-resuscitation </text>
<text top="567" left="246" width="28" height="19" font="3">ECG<b> </b></text>
<text top="219" left="389" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="238" left="389" width="123" height="19" font="3">patients with OHCA </text>
<text top="256" left="389" width="142" height="19" font="3">with presumed cardiac </text>
<text top="274" left="389" width="109" height="19" font="3">etiology and with </text>
<text top="293" left="389" width="126" height="19" font="3">coronary angiogram </text>
<text top="311" left="389" width="150" height="19" font="3">performed at admission<b> </b></text>
<text top="219" left="552" width="85" height="19" font="4"><b>Intervention: </b></text>
<text top="238" left="552" width="92" height="19" font="3">immediate PCI </text>
<text top="256" left="552" width="3" height="19" font="4"><b> </b></text>
<text top="219" left="702" width="126" height="19" font="3">At least 1 significant </text>
<text top="238" left="702" width="124" height="19" font="3">coronary lesion was </text>
<text top="256" left="702" width="122" height="19" font="3">found in 403 of 695 </text>
<text top="274" left="702" width="157" height="19" font="3">patients (58%). A PCI was </text>
<text top="293" left="702" width="152" height="19" font="3">performed in 199 of 695 </text>
<text top="311" left="702" width="115" height="19" font="3">(29%). A favorable </text>
<text top="329" left="702" width="160" height="19" font="3">outcome was observed in </text>
<text top="347" left="702" width="114" height="19" font="3">87 of 200 (43%) in </text>
<text top="366" left="702" width="106" height="19" font="3">patients with PCI </text>
<text top="384" left="702" width="138" height="19" font="3">compared with 164 of </text>
<text top="402" left="702" width="132" height="19" font="3">495 (33%) in patients </text>
<text top="421" left="702" width="132" height="19" font="3">without PCI (p=0.02). </text>
<text top="439" left="702" width="161" height="19" font="3">After adjustment, PCI was </text>
<text top="457" left="702" width="150" height="19" font="3">associated with a better </text>
<text top="476" left="702" width="144" height="19" font="3">outcome (adjusted OR: </text>
<text top="494" left="702" width="154" height="19" font="3">1.80; 95% CI: 1.09–2.97,  </text>
<text top="512" left="702" width="54" height="19" font="3">p=0.02). </text>
<text top="219" left="878" width="3" height="19" font="4"><b> </b></text>
<text top="586" left="123" width="65" height="19" font="3">● <b>SYNTAX </b></text>
<text top="605" left="123" width="95" height="19" font="3">● Serruys et al. </text>
<text top="623" left="123" width="62" height="19" font="3">2009 (82) </text>
<text top="641" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19228612">● </a></text>
<text top="641" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19228612">19228612</a></text>
<text top="641" left="197" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19228612"><b> </b></a></text>
<text top="586" left="246" width="106" height="19" font="4"><b>Aim:</b> To show PCI</text>
<text top="585" left="352" width="4" height="21" font="0"> </text>
<text top="586" left="356" width="13" height="19" font="3">is </text>
<text top="605" left="246" width="126" height="19" font="3">noninferior to CABG </text>
<text top="623" left="246" width="112" height="19" font="3">for major adverse </text>
<text top="641" left="246" width="64" height="19" font="3">cardiac or </text>
<text top="660" left="246" width="101" height="19" font="3">cerebrovascular </text>
<text top="678" left="246" width="107" height="19" font="3">event (i.e., death </text>
<text top="696" left="246" width="100" height="19" font="3">from any cause, </text>
<text top="714" left="246" width="69" height="19" font="3">stroke, MI, </text>
<text top="733" left="246" width="60" height="19" font="3">or repeat </text>
<text top="751" left="246" width="111" height="19" font="3">revascularization) </text>
<text top="769" left="246" width="85" height="19" font="3">during 12 mo </text>
<text top="586" left="389" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="605" left="389" width="130" height="19" font="3">previously untreated </text>
<text top="623" left="389" width="118" height="19" font="3">three-vessel or left </text>
<text top="641" left="389" width="117" height="19" font="3">main CAD (or both)</text>
<text top="640" left="506" width="4" height="21" font="0"> </text>
<text top="659" left="389" width="34" height="21" font="0">with </text>
<text top="661" left="423" width="98" height="19" font="3">stable/unstable </text>
<text top="680" left="389" width="147" height="19" font="3">angina or atypical chest </text>
<text top="698" left="389" width="30" height="19" font="3">pain </text>
<text top="716" left="389" width="3" height="19" font="4"><b> </b></text>
<text top="734" left="389" width="113" height="19" font="4"><b>Exclusion criteria: </b></text>
<text top="586" left="552" width="108" height="19" font="4"><b>Intervention: </b>PCI </text>
<text top="605" left="552" width="118" height="19" font="3">with Taxus Express </text>
<text top="623" left="552" width="108" height="19" font="3">paclitaxel-eluting </text>
<text top="641" left="552" width="40" height="19" font="3">stents </text>
<text top="660" left="552" width="7" height="19" font="3">  </text>
<text top="678" left="552" width="120" height="19" font="4"><b>Comparator:</b> CABG<b> </b></text>
<text top="587" left="702" width="131" height="19" font="4"><b>1</b>°<b> endpoint:</b> rates of </text>
<text top="605" left="702" width="154" height="19" font="3">major adverse cardiac or </text>
<text top="624" left="702" width="160" height="19" font="3">cerebrovascular events at </text>
<text top="642" left="702" width="152" height="19" font="3">12 mo were significantly </text>
<text top="660" left="702" width="143" height="19" font="3">higher in the PCI group </text>
<text top="679" left="702" width="131" height="19" font="3">(17.8%, vs. 12.4% for </text>
<text top="697" left="702" width="99" height="19" font="3">CABG; p=0.002) </text>
<text top="715" left="702" width="3" height="19" font="3"> </text>
<text top="586" left="878" width="188" height="19" font="3">● At 12 mo, the rates of death </text>
<text top="605" left="878" width="182" height="19" font="3">and MI were similar between </text>
<text top="623" left="878" width="153" height="19" font="3">the 2 groups; stroke was </text>
<text top="641" left="878" width="163" height="19" font="3">significantly more likely to </text>
<text top="660" left="878" width="166" height="19" font="3">occur with CABG (2.2%, vs. </text>
<text top="678" left="878" width="152" height="19" font="3">0.6% with PCI; p=0.003).<b> </b></text>
</page>
<page number="42" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">42 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="246" width="3" height="19" font="3"> </text>
<text top="127" left="246" width="108" height="19" font="4"><b>Study type:</b>   RCT </text>
<text top="145" left="246" width="3" height="19" font="3"> </text>
<text top="164" left="246" width="122" height="19" font="4"><b>Size:</b>  1800 patients </text>
<text top="182" left="246" width="115" height="19" font="3">with 12 mo follow-</text>
<text top="200" left="246" width="19" height="19" font="3">up </text>
<text top="219" left="246" width="3" height="19" font="3"> </text>
<text top="237" left="246" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="389" width="136" height="19" font="3">Previous PCI or CABG, </text>
<text top="127" left="389" width="128" height="19" font="3">AMI, or the need for </text>
<text top="145" left="389" width="127" height="19" font="3">concomitant cardiac </text>
<text top="164" left="389" width="49" height="19" font="3">surgery<b> </b></text>
<text top="256" left="123" width="65" height="19" font="3">● <b>SYNTAX </b></text>
<text top="274" left="123" width="105" height="19" font="3">● Milojevic et al. </text>
<text top="292" left="123" width="62" height="19" font="3">2016 (83) </text>
<text top="311" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26764065">● </a></text>
<text top="311" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26764065">26764065</a></text>
<text top="311" left="197" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26764065"><b> </b></a></text>
<text top="256" left="246" width="119" height="19" font="4"><b>Aim:</b> to investigate </text>
<text top="274" left="246" width="109" height="19" font="3">specific causes of </text>
<text top="292" left="246" width="87" height="19" font="3">death, and its </text>
<text top="311" left="246" width="102" height="19" font="3">predictors, after </text>
<text top="329" left="246" width="107" height="19" font="3">revascularization </text>
<text top="347" left="246" width="120" height="19" font="3">for complex CAD in </text>
<text top="366" left="246" width="53" height="19" font="3">patients </text>
<text top="384" left="246" width="3" height="19" font="3"> </text>
<text top="402" left="246" width="108" height="19" font="4"><b>Study type:</b>   RCT </text>
<text top="421" left="246" width="3" height="19" font="3"> </text>
<text top="439" left="246" width="122" height="19" font="4"><b>Size:</b>  1800 patients </text>
<text top="457" left="246" width="115" height="19" font="3">with 12 mo follow-</text>
<text top="476" left="246" width="19" height="19" font="3">up<b> </b></text>
<text top="256" left="389" width="115" height="19" font="3"> <b>Inclusion criteria:</b> </text>
<text top="274" left="389" width="143" height="19" font="3">previously untreated 3-</text>
<text top="292" left="389" width="81" height="19" font="3">vessel or left </text>
<text top="311" left="389" width="117" height="19" font="3">main CAD (or both)</text>
<text top="309" left="506" width="4" height="21" font="0"> </text>
<text top="329" left="389" width="34" height="21" font="0">with </text>
<text top="330" left="423" width="98" height="19" font="3">stable/unstable </text>
<text top="349" left="389" width="147" height="19" font="3">angina or atypical chest </text>
<text top="368" left="389" width="30" height="19" font="3">pain </text>
<text top="386" left="389" width="3" height="19" font="4"><b> </b></text>
<text top="404" left="389" width="113" height="19" font="4"><b>Exclusion criteria: </b></text>
<text top="423" left="389" width="136" height="19" font="3">Previous PCI or CABG, </text>
<text top="441" left="389" width="128" height="19" font="3">AMI, or the need for </text>
<text top="459" left="389" width="127" height="19" font="3">concomitant cardiac </text>
<text top="478" left="389" width="49" height="19" font="3">surgery </text>
<text top="256" left="552" width="108" height="19" font="4"><b>Intervention: </b>PCI </text>
<text top="274" left="552" width="118" height="19" font="3">with Taxus Express </text>
<text top="292" left="552" width="108" height="19" font="3">paclitaxel-eluting </text>
<text top="311" left="552" width="40" height="19" font="3">stents </text>
<text top="329" left="552" width="7" height="19" font="3">  </text>
<text top="347" left="552" width="120" height="19" font="4"><b>Comparator:</b> CABG<b> </b></text>
<text top="257" left="702" width="78" height="19" font="4"><b>1</b>°<b> endpoint:</b></text>
<text top="255" left="780" width="7" height="21" font="0">  </text>
<text top="275" left="702" width="160" height="19" font="3">97 deaths after CABG and </text>
<text top="293" left="702" width="127" height="19" font="3">123 deaths after PCI </text>
<text top="312" left="702" width="139" height="19" font="3">during a 5 y followup.  </text>
<text top="330" left="702" width="132" height="19" font="3">After CABG, 49.4% of </text>
<text top="348" left="702" width="79" height="19" font="3">deaths were </text>
<text top="367" left="702" width="149" height="19" font="3">cardiovascular, with the </text>
<text top="385" left="702" width="129" height="19" font="3">greatest cause being </text>
<text top="403" left="702" width="157" height="19" font="3">heart failure, arrhythmia, </text>
<text top="422" left="702" width="151" height="19" font="3">or other causes (24.6%). </text>
<text top="440" left="702" width="155" height="19" font="3">After PCI, the majority of </text>
<text top="458" left="702" width="79" height="19" font="3">deaths were </text>
<text top="476" left="702" width="141" height="19" font="3">cardiovascular (67.5%) </text>
<text top="495" left="702" width="127" height="19" font="3">and as a result of MI </text>
<text top="513" left="702" width="57" height="19" font="3">(29.3%).  </text>
<text top="531" left="702" width="141" height="19" font="3">Treatment with PCI vs. </text>
<text top="550" left="702" width="83" height="19" font="3">CABG was an </text>
<text top="568" left="702" width="157" height="19" font="3">independent predictor of </text>
<text top="586" left="702" width="149" height="19" font="3">cardiac death (HR: 1.55; </text>
<text top="605" left="702" width="139" height="19" font="3">95% CI: 1.09–2.33; p = </text>
<text top="623" left="702" width="49" height="19" font="3">0.045).  </text>
<text top="256" left="878" width="180" height="19" font="3">● SCD: 24 (2.8%) with PCI, 15 </text>
<text top="274" left="878" width="173" height="19" font="3">(1.9%) with CABG, HR: 1.61; </text>
<text top="292" left="878" width="165" height="19" font="3">95% CI: 0.83–3.11, p=0.16. </text>
<text top="311" left="905" width="3" height="19" font="3"> </text>
<text top="642" left="123" width="76" height="19" font="3">● <b>SCD-HeFT </b></text>
<text top="660" left="123" width="105" height="19" font="3">● Al-Khatib et al. </text>
<text top="679" left="123" width="62" height="19" font="3">2008 (84) </text>
<text top="697" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18479330">● </a></text>
<text top="697" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18479330">18479330</a></text>
<text top="697" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18479330"> </a></text>
<text top="642" left="246" width="111" height="19" font="4"><b>Aim: </b>examine the </text>
<text top="660" left="246" width="122" height="19" font="3">effect of the ICD on </text>
<text top="679" left="246" width="103" height="19" font="3">the outcomes of </text>
<text top="697" left="246" width="117" height="19" font="3">patients with prior </text>
<text top="715" left="246" width="58" height="19" font="3">coronary </text>
<text top="734" left="246" width="107" height="19" font="3">revascularization </text>
<text top="752" left="246" width="97" height="19" font="3">enrolled in SCD-</text>
<text top="770" left="246" width="34" height="19" font="3">HeFT </text>
<text top="642" left="389" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="660" left="389" width="113" height="19" font="3">Overall SCD-HeFT, </text>
<text top="679" left="389" width="140" height="19" font="3">NYHA class II or III CHF </text>
<text top="697" left="389" width="136" height="19" font="3">symptoms and a LVEF </text>
<text top="715" left="389" width="136" height="19" font="3">≤35% due to ischemic </text>
<text top="734" left="389" width="132" height="19" font="3">or nonischemic heart </text>
<text top="752" left="389" width="52" height="19" font="3">disease. </text>
<text top="642" left="552" width="110" height="19" font="4"><b>Intervention: </b>ICD </text>
<text top="660" left="552" width="7" height="19" font="3">  </text>
<text top="678" left="552" width="126" height="19" font="4"><b>Comparator:</b> no ICD<b> </b></text>
<text top="642" left="702" width="151" height="19" font="3">There was no significant </text>
<text top="660" left="702" width="152" height="19" font="3">difference in ICD benefit </text>
<text top="679" left="702" width="65" height="19" font="3">across the </text>
<text top="697" left="702" width="107" height="19" font="3">revascularization </text>
<text top="715" left="702" width="135" height="19" font="3">subgroups (all p<i>&gt;</i>0.1). </text>
<text top="733" left="702" width="161" height="19" font="3">There was a trend toward </text>
<text top="752" left="702" width="161" height="19" font="3">improved survival with an </text>
<text top="770" left="702" width="148" height="19" font="3">ICD in patients who had </text>
<text top="642" left="878" width="3" height="19" font="3"> </text>
</page>
<page number="43" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">43 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="246" width="3" height="19" font="3"> </text>
<text top="127" left="246" width="108" height="19" font="4"><b>Study type:</b>   RCT </text>
<text top="145" left="246" width="3" height="19" font="3"> </text>
<text top="164" left="246" width="101" height="19" font="4"><b>Size:</b>  of the 882 </text>
<text top="182" left="246" width="111" height="19" font="3">patients who met </text>
<text top="200" left="246" width="95" height="19" font="3">these inclusion </text>
<text top="219" left="246" width="115" height="19" font="3">criteria, 255 (29%) </text>
<text top="237" left="246" width="79" height="19" font="3">had no prior </text>
<text top="255" left="246" width="110" height="19" font="3">revascularization, </text>
<text top="273" left="246" width="124" height="19" font="3">178 (20%) had prior </text>
<text top="292" left="246" width="121" height="19" font="3">PCI only, 284 (32%) </text>
<text top="310" left="246" width="130" height="19" font="3">had prior CABG only, </text>
<text top="329" left="246" width="117" height="19" font="3">and 165 (19%) had </text>
<text top="347" left="246" width="124" height="19" font="3">prior PCI and CABG. </text>
<text top="109" left="389" width="143" height="19" font="3">This substudy, patients </text>
<text top="127" left="389" width="123" height="19" font="3">with ischemic heart </text>
<text top="145" left="389" width="137" height="19" font="3">disease who were not </text>
<text top="164" left="389" width="92" height="19" font="3">randomized to </text>
<text top="182" left="389" width="133" height="19" font="3">amiodarone (N= 884) </text>
<text top="200" left="389" width="143" height="19" font="3">and who had complete </text>
<text top="219" left="389" width="137" height="19" font="3">revascularization data </text>
<text top="237" left="389" width="111" height="19" font="3">(revascularization </text>
<text top="255" left="389" width="144" height="19" font="3">data were missing on 2 </text>
<text top="273" left="389" width="62" height="19" font="3">patients).<b> </b></text>
<text top="109" left="702" width="143" height="19" font="3">their CABG &gt;2 y before </text>
<text top="127" left="702" width="156" height="19" font="3">randomization (HR: 0.71; </text>
<text top="145" left="702" width="146" height="19" font="3">95% CI: 0.49–1.04) that </text>
<text top="164" left="702" width="126" height="19" font="3">was not observed in </text>
<text top="182" left="702" width="142" height="19" font="3">patients who had their </text>
<text top="200" left="702" width="110" height="19" font="3">CABG <i>≤</i>2 y before </text>
<text top="219" left="702" width="152" height="19" font="3">randomization (HR:1.40; </text>
<text top="237" left="702" width="117" height="19" font="3">95% CI: 0.61–3.24)<b> </b></text>
<text top="366" left="123" width="89" height="19" font="3">● Nageh et al. </text>
<text top="384" left="123" width="62" height="19" font="3">2014 (85) </text>
<text top="402" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25146702">● </a></text>
<text top="402" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25146702">25146702</a></text>
<text top="402" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25146702"> </a></text>
<text top="366" left="246" width="125" height="19" font="4"><b>Aim: </b>assess the role </text>
<text top="384" left="246" width="102" height="19" font="3">of ICD in cardiac </text>
<text top="402" left="246" width="102" height="19" font="3">surgery patients </text>
<text top="421" left="246" width="116" height="19" font="3">with perioperative </text>
<text top="439" left="246" width="98" height="19" font="3">resuscitated VA </text>
<text top="457" left="246" width="43" height="19" font="3">arrest  </text>
<text top="476" left="246" width="72" height="19" font="3">&lt;3 mo post </text>
<text top="494" left="246" width="110" height="19" font="3">revascularization, </text>
<text top="512" left="246" width="124" height="19" font="3">and the role of ICDs </text>
<text top="531" left="246" width="15" height="19" font="3">in </text>
<text top="549" left="246" width="109" height="19" font="3">patients who had </text>
<text top="567" left="246" width="107" height="19" font="3">revascularization </text>
<text top="586" left="246" width="60" height="19" font="3">after SCD </text>
<text top="604" left="246" width="3" height="19" font="3"> </text>
<text top="622" left="246" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="640" left="246" width="90" height="19" font="3">observational, </text>
<text top="659" left="246" width="99" height="19" font="3">evaluating total </text>
<text top="677" left="246" width="105" height="19" font="3">mortality and/or </text>
<text top="695" left="246" width="100" height="19" font="3">appropriate ICD </text>
<text top="714" left="246" width="51" height="19" font="3">therapy </text>
<text top="732" left="246" width="3" height="19" font="3"> </text>
<text top="750" left="246" width="114" height="19" font="4"><b>Size:</b>  164 patients </text>
<text top="769" left="246" width="122" height="19" font="3">had cardiac surgery </text>
<text top="366" left="389" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="384" left="389" width="147" height="19" font="3">cardiac surgery and ICD </text>
<text top="402" left="389" width="76" height="19" font="3">within 3 mo </text>
<text top="366" left="552" width="120" height="19" font="3">Overall group rates </text>
<text top="366" left="702" width="149" height="19" font="3">The 1° endpoint of total </text>
<text top="384" left="702" width="162" height="19" font="3">mortality and appropriate </text>
<text top="402" left="702" width="153" height="19" font="3">shocks were observed in </text>
<text top="421" left="702" width="18" height="19" font="3">52 </text>
<text top="439" left="702" width="156" height="19" font="3">35 (38%) and 28 (30%) of </text>
<text top="457" left="702" width="134" height="19" font="3">patients, respectively </text>
<text top="476" left="702" width="3" height="19" font="3"> </text>
<text top="494" left="702" width="126" height="19" font="3">Conclusion was that </text>
<text top="512" left="702" width="129" height="19" font="3">recurrent VA are not </text>
<text top="531" left="702" width="122" height="19" font="3">prevented by CABG </text>
<text top="366" left="878" width="3" height="19" font="3"> </text>
</page>
<page number="44" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="14" size="12" family="Times" color="#121212"/>
<text top="803" left="589" width="20" height="21" font="0">44 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="246" width="104" height="19" font="3">and ICD within 3 </text>
<text top="127" left="246" width="119" height="19" font="3">mo; 93/164 had an </text>
<text top="145" left="246" width="107" height="19" font="3">ICD for sustained </text>
<text top="164" left="246" width="45" height="19" font="3">pre- or </text>
<text top="182" left="246" width="124" height="19" font="3">postoperative VT or </text>
<text top="200" left="246" width="125" height="19" font="3">fibrillation requiring </text>
<text top="219" left="246" width="124" height="19" font="3">resuscitation, mean </text>
<text top="237" left="246" width="104" height="19" font="3">follow-up 49 mo<b> </b></text>
<text top="292" left="115" width="919" height="21" font="2"><b>Data Supplement 12. Nonrandomized Trials, Observational Studies, and/or Registries of Arrhythmic Surgery and Revascularization for </b></text>
<text top="312" left="115" width="292" height="21" font="2"><b>Arrhythmia Management – (Section 5.5.1) </b></text>
<text top="333" left="147" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="351" left="173" width="51" height="19" font="4"><b>Author; </b></text>
<text top="369" left="151" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="333" left="295" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="351" left="324" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="333" left="464" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="333" left="637" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="351" left="650" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="369" left="681" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="334" left="854" width="186" height="19" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="352" left="889" width="116" height="19" font="4"><b>Study Limitations; </b></text>
<text top="370" left="898" width="99" height="19" font="4"><b>Adverse Events </b></text>
<text top="390" left="125" width="123" height="19" font="3">● Kumar et al. 2015 </text>
<text top="408" left="125" width="28" height="19" font="3">(86) </text>
<text top="426" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25925229">● </a></text>
<text top="426" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25925229">25925229</a></text>
<text top="426" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25925229"> </a></text>
<text top="444" left="125" width="3" height="19" font="3"> </text>
<text top="389" left="286" width="137" height="19" font="4"><b>Aim: </b>To characterized </text>
<text top="408" left="286" width="115" height="19" font="3">the reasons for VT </text>
<text top="426" left="286" width="122" height="19" font="3">ablation failure and </text>
<text top="444" left="286" width="124" height="19" font="3">describe alternative </text>
<text top="463" left="286" width="89" height="19" font="3">interventional </text>
<text top="481" left="286" width="76" height="19" font="3">procedures.<b> </b></text>
<text top="499" left="286" width="3" height="19" font="4"><b> </b></text>
<text top="518" left="286" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="536" left="286" width="113" height="19" font="3">center experience </text>
<text top="554" left="286" width="3" height="19" font="3"> </text>
<text top="572" left="286" width="61" height="19" font="4"><b>Size:</b>    62<b> </b></text>
<text top="389" left="442" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="390" left="557" width="33" height="19" font="14">Sixty-</text>
<text top="408" left="442" width="142" height="19" font="14">seven patients with VT </text>
<text top="426" left="442" width="163" height="19" font="14">refractory to 4±2 AAD and </text>
<text top="444" left="442" width="82" height="19" font="14">2±1 previous </text>
<text top="463" left="442" width="140" height="19" font="14">endocardial/epicardial </text>
<text top="481" left="442" width="108" height="19" font="14">catheter ablation </text>
<text top="499" left="442" width="130" height="19" font="14">attempts underwent </text>
<text top="518" left="442" width="139" height="19" font="14">transcoronary ethanol </text>
<text top="536" left="442" width="107" height="19" font="14">ablation, surgical </text>
<text top="554" left="442" width="142" height="19" font="14">epicardial window (Epi-</text>
<text top="573" left="442" width="127" height="19" font="14">window), or surgical </text>
<text top="591" left="442" width="76" height="19" font="14">cryoablation</text>
<text top="591" left="519" width="3" height="19" font="3"> </text>
<text top="630" left="442" width="3" height="19" font="3"> </text>
<text top="649" left="442" width="3" height="19" font="3"> </text>
<text top="688" left="442" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="390" left="619" width="85" height="19" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="390" left="704" width="95" height="19" font="14">abolishment of </text>
<text top="409" left="619" width="141" height="19" font="14">at least 1 inducible VT, </text>
<text top="427" left="619" width="156" height="19" font="14">complete success, partial </text>
<text top="445" left="619" width="164" height="19" font="14">success (abolishment of at </text>
<text top="464" left="619" width="179" height="19" font="14">least 1 spontaneous VT), and </text>
<text top="482" left="619" width="185" height="19" font="14">failure (residual inducibility of </text>
<text top="500" left="619" width="106" height="19" font="14">spontaneous VT).</text>
<text top="500" left="725" width="3" height="19" font="3"> </text>
<text top="518" left="619" width="3" height="19" font="3"> </text>
<text top="537" left="619" width="147" height="19" font="4"><b>Results:</b>  Transcoronary </text>
<text top="555" left="619" width="168" height="19" font="3">ethanol ablation alone was </text>
<text top="573" left="619" width="181" height="19" font="3">attempted in 37 patients, OR-</text>
<text top="592" left="619" width="185" height="19" font="3">Cryo alone in 21 patients, and </text>
<text top="610" left="619" width="107" height="19" font="3">a combination of </text>
<text top="628" left="619" width="139" height="19" font="3">transcoronary ethanol </text>
<text top="647" left="619" width="149" height="19" font="3">ablation and OR-Cryo (5 </text>
<text top="665" left="619" width="167" height="19" font="3">patients), or transcoronary </text>
<text top="683" left="619" width="153" height="19" font="3">ethanol ablation and Epi-</text>
<text top="701" left="619" width="167" height="19" font="3">window (4 patients), in the </text>
<text top="720" left="619" width="122" height="19" font="3">remainder. Overall, </text>
<text top="738" left="619" width="159" height="19" font="3">alternative interventional </text>
<text top="757" left="619" width="153" height="19" font="3">procedures abolished ≥1 </text>
<text top="775" left="619" width="176" height="19" font="3">inducible VT and terminated </text>
<text top="390" left="820" width="173" height="19" font="3">● The conclusion was that a </text>
<text top="408" left="820" width="221" height="19" font="3">collaborative strategy of alternative </text>
<text top="426" left="820" width="225" height="19" font="3">interventional procedures offers the </text>
<text top="444" left="820" width="212" height="19" font="3">possibility of achieving arrhythmia </text>
<text top="463" left="820" width="249" height="19" font="3">control in high-risk patients with VT that </text>
<text top="481" left="820" width="230" height="19" font="3">is otherwise uncontrollable with AAD </text>
<text top="499" left="820" width="226" height="19" font="3">and standard percutaneous catheter </text>
<text top="518" left="820" width="128" height="19" font="3">ablation techniques. </text>
</page>
<page number="45" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">45 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="619" width="155" height="19" font="3">storm in 69% and 74% of </text>
<text top="127" left="619" width="137" height="19" font="3">patients, respectively, </text>
<text top="145" left="619" width="182" height="19" font="3">although 25% of patients had </text>
<text top="164" left="619" width="174" height="19" font="3">at least 1 complication. By 6 </text>
<text top="182" left="619" width="166" height="19" font="3">mo post procedures, there </text>
<text top="200" left="619" width="180" height="19" font="3">was a significant reduction in </text>
<text top="219" left="619" width="182" height="19" font="3">ICD shocks (from a median of </text>
<text top="237" left="619" width="182" height="19" font="3">8/mo to 1; p&lt;0.001) and AAD </text>
<text top="255" left="619" width="183" height="19" font="3">requirement although 55% of </text>
<text top="273" left="619" width="158" height="19" font="3">patients had at least 1 VT </text>
<text top="292" left="619" width="187" height="19" font="3">recurrence, and mortality was </text>
<text top="310" left="619" width="33" height="19" font="3">17%.<b> </b></text>
<text top="329" left="125" width="145" height="19" font="3">● Anter et al. 2011 (87) </text>
<text top="347" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21673018">● </a></text>
<text top="347" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21673018">21673018</a></text>
<text top="347" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21673018"> </a></text>
<text top="366" left="125" width="3" height="19" font="3"> </text>
<text top="329" left="286" width="112" height="19" font="4"><b>Aim: </b>Evaluate the </text>
<text top="347" left="286" width="66" height="19" font="3">efficacy of </text>
<text top="366" left="286" width="82" height="19" font="3">preoperative </text>
<text top="384" left="286" width="130" height="19" font="3">electroanatomic and </text>
<text top="402" left="286" width="136" height="19" font="3">EP characterization of </text>
<text top="421" left="286" width="130" height="19" font="3">the VT substrate and </text>
<text top="439" left="286" width="95" height="19" font="3">circuit to guide </text>
<text top="457" left="286" width="118" height="19" font="3">surgical ablation in </text>
<text top="476" left="286" width="121" height="19" font="3">patients with NICM<b> </b></text>
<text top="494" left="286" width="3" height="19" font="4"><b> </b></text>
<text top="512" left="286" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="531" left="286" width="113" height="19" font="3">center experience </text>
<text top="549" left="286" width="3" height="19" font="3"> </text>
<text top="567" left="286" width="61" height="19" font="4"><b>Size:</b>    62<b> </b></text>
<text top="329" left="442" width="149" height="19" font="4"><b>Inclusion criteria:</b>  Eight </text>
<text top="347" left="442" width="145" height="19" font="3">patients with recurrent </text>
<text top="366" left="442" width="162" height="19" font="3">sustained VT refractory to </text>
<text top="384" left="442" width="100" height="19" font="3">AAD underwent </text>
<text top="402" left="442" width="121" height="19" font="3">endocardial and/or </text>
<text top="421" left="442" width="116" height="19" font="3">epicardial ablation </text>
<text top="439" left="442" width="134" height="19" font="3">procedures. After the </text>
<text top="457" left="442" width="81" height="19" font="3">unsuccessful </text>
<text top="476" left="442" width="152" height="19" font="3">percutaneous approach, </text>
<text top="494" left="442" width="156" height="19" font="3">surgical cryoablation was </text>
<text top="512" left="442" width="119" height="19" font="3">applied to the sites </text>
<text top="531" left="442" width="154" height="19" font="3">previously identified and </text>
<text top="549" left="442" width="122" height="19" font="3">targeted during the </text>
<text top="567" left="442" width="158" height="19" font="3">percutaneous procedure. </text>
<text top="606" left="442" width="141" height="19" font="4"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="606" left="603" width="7" height="19" font="4"><b> </b> </text>
<text top="330" left="619" width="177" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Clinical VT and </text>
<text top="348" left="619" width="72" height="19" font="3">ICD shocks  </text>
<text top="367" left="619" width="3" height="19" font="3"> </text>
<text top="385" left="619" width="148" height="19" font="4"><b>Results:</b>  During a mean </text>
<text top="403" left="619" width="180" height="19" font="3">followup period of 23 ± 6 mo </text>
<text top="422" left="619" width="187" height="19" font="3">(range, 15– 34 mo), 6 patients </text>
<text top="440" left="619" width="169" height="19" font="3">had significant reduction in </text>
<text top="458" left="619" width="161" height="19" font="3">VT burden as evident by a </text>
<text top="476" left="619" width="145" height="19" font="3">reduced number of ICD </text>
<text top="495" left="619" width="184" height="19" font="3">shocks after ablation (6.6–0.6 </text>
<text top="513" left="619" width="179" height="19" font="3">shocks per pt; p=0.026). Two </text>
<text top="531" left="619" width="187" height="19" font="3">patients died, 1 of progressive </text>
<text top="550" left="619" width="116" height="19" font="3">HF and 1 of sepsis.<b> </b></text>
<text top="329" left="820" width="217" height="20" font="3">•  The authors concluded that VT </text>
<text top="348" left="847" width="227" height="19" font="3">circuits inaccessible to percutaneous </text>
<text top="367" left="847" width="225" height="19" font="3">ablation techniques are rare but can </text>
<text top="385" left="847" width="199" height="19" font="3">be encountered in patients with </text>
<text top="403" left="847" width="226" height="19" font="3">nonischemic cardiomyopathy. These </text>
<text top="422" left="847" width="218" height="19" font="3">VTs can be successfully targeted by </text>
<text top="440" left="847" width="193" height="19" font="3">surgical cryoablation guided by </text>
<text top="458" left="847" width="212" height="19" font="3">preoperative electroanatomic and </text>
<text top="476" left="847" width="79" height="19" font="3">EP mapping. </text>
<text top="625" left="125" width="132" height="19" font="3">● Bhavani et al. 2007 </text>
<text top="644" left="125" width="28" height="19" font="3">(88) </text>
<text top="662" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18039225">● </a></text>
<text top="662" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18039225">18039225</a></text>
<text top="662" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18039225"> </a></text>
<text top="681" left="125" width="3" height="19" font="3"> </text>
<text top="699" left="125" width="3" height="19" font="3"> </text>
<text top="625" left="286" width="101" height="19" font="4"><b>Aim: </b>To present </text>
<text top="644" left="286" width="114" height="19" font="3">variety of ablation </text>
<text top="662" left="286" width="89" height="19" font="3">strategies and </text>
<text top="681" left="286" width="102" height="19" font="3">technologies for </text>
<text top="699" left="286" width="129" height="19" font="3">surgical cryoablation </text>
<text top="717" left="286" width="35" height="19" font="3">of VT<b> </b></text>
<text top="735" left="286" width="3" height="19" font="4"><b> </b></text>
<text top="625" left="442" width="126" height="19" font="4"><b>Inclusion criteria:</b>  3 </text>
<text top="644" left="442" width="154" height="19" font="3">patients who underwent </text>
<text top="662" left="442" width="116" height="19" font="3">succeesful surgical </text>
<text top="681" left="442" width="112" height="19" font="3">cryoablation after </text>
<text top="699" left="442" width="96" height="19" font="3">catheter failed. </text>
<text top="738" left="442" width="141" height="19" font="4"><b>Exclusion criteria: </b>N/A </text>
<text top="777" left="442" width="3" height="19" font="4"><b> </b></text>
<text top="626" left="619" width="150" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Successful </text>
<text top="645" left="619" width="108" height="19" font="3">elimination of VT </text>
<text top="663" left="619" width="3" height="19" font="3"> </text>
<text top="681" left="619" width="160" height="19" font="4"><b>Results:</b>  Case report. The </text>
<text top="700" left="619" width="110" height="19" font="3">specific approach </text>
<text top="718" left="619" width="166" height="19" font="3">(endocardial vs. epicardial, </text>
<text top="736" left="619" width="165" height="19" font="3">beating heart vs. arrested) </text>
<text top="755" left="619" width="175" height="19" font="3">and ablation device must be </text>
<text top="625" left="820" width="236" height="19" font="3">● Patient with intraoperatively CARTO </text>
</page>
<page number="46" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="15" size="7" family="Times" color="#000000"/>
<text top="803" left="589" width="20" height="21" font="0">46 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="286" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="127" left="286" width="114" height="19" font="3">center experience-</text>
<text top="145" left="286" width="72" height="19" font="3">case report </text>
<text top="164" left="286" width="3" height="19" font="3"> </text>
<text top="182" left="286" width="53" height="19" font="4"><b>Size:</b>    3<b> </b></text>
<text top="109" left="619" width="147" height="19" font="3">tailored to the patient's </text>
<text top="127" left="619" width="165" height="19" font="3">anatomy and presentation<b> </b></text>
<text top="201" left="125" width="126" height="19" font="3">● Sartipy et al. 2006 </text>
<text top="219" left="125" width="28" height="19" font="3">(89) </text>
<text top="238" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16368337">● </a></text>
<text top="238" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16368337">16368337</a></text>
<text top="238" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16368337"> </a></text>
<text top="256" left="101" width="3" height="19" font="3"> </text>
<text top="274" left="125" width="3" height="19" font="3"> </text>
<text top="292" left="125" width="3" height="19" font="3"> </text>
<text top="201" left="286" width="126" height="19" font="4"><b>Aim: </b>The aim of this </text>
<text top="219" left="286" width="136" height="19" font="3">study was to evaluate </text>
<text top="238" left="286" width="116" height="19" font="3">the Dor procedure </text>
<text top="256" left="286" width="130" height="19" font="3">including VT surgery <b> </b></text>
<text top="274" left="286" width="3" height="19" font="4"><b> </b></text>
<text top="292" left="286" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="311" left="286" width="113" height="19" font="3">center experience </text>
<text top="329" left="286" width="3" height="19" font="3"> </text>
<text top="347" left="286" width="61" height="19" font="4"><b>Size:</b>    53 </text>
<text top="201" left="442" width="150" height="19" font="4"><b>Inclusion criteria:</b>  From </text>
<text top="219" left="442" width="143" height="19" font="3">July 1997 to December </text>
<text top="238" left="442" width="132" height="19" font="3">2003, 53 consecutive </text>
<text top="256" left="442" width="107" height="19" font="3">patients with left </text>
<text top="274" left="442" width="159" height="19" font="3">ventricular aneurysm and </text>
<text top="292" left="442" width="140" height="19" font="3">VT underwent surgical </text>
<text top="311" left="442" width="141" height="19" font="3">ventricular restoration </text>
<text top="329" left="442" width="127" height="19" font="3">including nonguided </text>
<text top="347" left="442" width="136" height="19" font="3">endocardiectomy and </text>
<text top="366" left="442" width="162" height="19" font="3">cryoablation. Twenty-four </text>
<text top="384" left="442" width="138" height="19" font="3">patients had at least 1 </text>
<text top="402" left="442" width="149" height="19" font="3">preoperative episode of </text>
<text top="421" left="442" width="150" height="19" font="3">spontaneous VT, and 29 </text>
<text top="439" left="442" width="140" height="19" font="3">patients had inducible-</text>
<text top="457" left="442" width="56" height="19" font="3">only VT.  </text>
<text top="497" left="442" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="202" left="619" width="188" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Mortality and Vt </text>
<text top="220" left="619" width="158" height="19" font="3">inducible or spontaneous </text>
<text top="238" left="619" width="3" height="19" font="3"> </text>
<text top="257" left="619" width="187" height="19" font="4"><b>Results:</b>  Early mortality was 2 </text>
<text top="275" left="619" width="176" height="19" font="3">of 53 (3.8%). Mean followup </text>
<text top="293" left="619" width="158" height="19" font="3">was 3.7 y. At 1, 3, and 5 y </text>
<text top="312" left="619" width="178" height="19" font="3">overall actuarial survival was </text>
<text top="330" left="619" width="125" height="19" font="3">94%, 80%, and 59%, </text>
<text top="348" left="619" width="180" height="19" font="3">respectively. Surgical success </text>
<text top="367" left="619" width="126" height="19" font="3">rate in patients with </text>
<text top="385" left="619" width="184" height="19" font="3">preoperative spontaneous VT </text>
<text top="403" left="619" width="166" height="19" font="3">was 91%. Inducible VT was </text>
<text top="422" left="619" width="183" height="19" font="3">found in 5 of 35 patients who </text>
<text top="440" left="619" width="159" height="19" font="3">underwent postoperative </text>
<text top="458" left="619" width="159" height="19" font="3">programmed stimulation. </text>
<text top="476" left="619" width="157" height="19" font="3">There was no arrhythmia-</text>
<text top="495" left="619" width="175" height="19" font="3">related late death and there </text>
<text top="513" left="619" width="155" height="19" font="3">was no loss to follow-up. </text>
<text top="201" left="820" width="209" height="19" font="3">● Authors concluded that the Dor </text>
<text top="219" left="820" width="235" height="19" font="3">procedure including endocardiectomy </text>
<text top="238" left="820" width="252" height="19" font="3">and cryoablation yields a very high (90%) </text>
<text top="256" left="820" width="217" height="19" font="3">freedom from spontaneous VT and </text>
<text top="274" left="820" width="237" height="19" font="3">eliminates the need for an ICD in most </text>
<text top="293" left="820" width="53" height="19" font="3">patients </text>
<text top="311" left="820" width="226" height="19" font="3">● Karolinska Institute is a specialized </text>
<text top="329" left="820" width="47" height="19" font="3">center. </text>
<text top="347" left="820" width="3" height="19" font="3"> </text>
<text top="532" left="125" width="138" height="19" font="3">● Choi et al. 2015 (90) </text>
<text top="550" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25697752">● </a></text>
<text top="550" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25697752">25697752</a></text>
<text top="550" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25697752"> </a></text>
<text top="569" left="125" width="3" height="19" font="3"> </text>
<text top="532" left="286" width="113" height="19" font="4"><b>Aim:</b> The aim is to </text>
<text top="550" left="286" width="105" height="19" font="3">describe surgical </text>
<text top="569" left="286" width="116" height="19" font="3">cryoablation of VA </text>
<text top="587" left="286" width="135" height="19" font="3">from the LVOT region </text>
<text top="605" left="286" width="97" height="19" font="3">inaccessible for </text>
<text top="624" left="286" width="123" height="19" font="3">ablation because of </text>
<text top="642" left="286" width="100" height="19" font="3">epicardial fat or </text>
<text top="660" left="286" width="117" height="19" font="3">overlying coronary </text>
<text top="679" left="286" width="54" height="19" font="3">arteries<b>  </b></text>
<text top="697" left="286" width="3" height="19" font="4"><b> </b></text>
<text top="715" left="286" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="733" left="286" width="113" height="19" font="3">center experience </text>
<text top="752" left="286" width="3" height="19" font="3"> </text>
<text top="770" left="286" width="53" height="19" font="4"><b>Size:</b>    4<b> </b></text>
<text top="532" left="442" width="159" height="19" font="4"><b>Inclusion criteria:</b>  During </text>
<text top="550" left="442" width="143" height="19" font="3">the period from March </text>
<text top="569" left="442" width="157" height="19" font="3">2009 to March 2014, 190 </text>
<text top="587" left="442" width="159" height="19" font="3">consecutive patients with </text>
<text top="605" left="442" width="155" height="19" font="3">focal VA originating from </text>
<text top="624" left="442" width="130" height="19" font="3">the LVOT underwent </text>
<text top="642" left="442" width="150" height="19" font="3">ablation at Brigham and </text>
<text top="660" left="442" width="118" height="19" font="3">Women's Hospital, </text>
<text top="679" left="442" width="113" height="19" font="3">Boston. The study </text>
<text top="697" left="442" width="156" height="19" font="3">describes 4 patients (2%) </text>
<text top="715" left="442" width="150" height="19" font="3">who underwent surgical </text>
<text top="734" left="442" width="83" height="19" font="3">cryoablation. </text>
<text top="752" left="442" width="3" height="19" font="3"> </text>
<text top="533" left="619" width="138" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Patients </text>
<text top="551" left="619" width="68" height="19" font="3">outcomes. </text>
<text top="570" left="619" width="3" height="19" font="3"> </text>
<text top="588" left="619" width="186" height="19" font="4"><b>Results:</b>  Surgical cryoablation </text>
<text top="606" left="619" width="168" height="19" font="3">was successful in 3 of the 4 </text>
<text top="624" left="619" width="90" height="19" font="3">patients. The 4</text>
<text top="624" left="709" width="9" height="12" font="15">th</text>
<text top="624" left="718" width="51" height="19" font="3"> patient </text>
<text top="643" left="619" width="176" height="19" font="3">subsequently had successful </text>
<text top="661" left="619" width="187" height="19" font="3">endocardial catheter ablation. </text>
<text top="680" left="619" width="184" height="19" font="3">During a mean followup of 22 </text>
<text top="698" left="619" width="178" height="19" font="3">± 16 mo (range 4–42 mo), all </text>
<text top="716" left="619" width="178" height="19" font="3">patients showed abolition of </text>
<text top="734" left="619" width="144" height="19" font="3">or marked reduction in </text>
<text top="753" left="619" width="180" height="19" font="3">symptomatic VA. However, 1 </text>
<text top="771" left="619" width="188" height="19" font="3">patient subsequently required </text>
<text top="532" left="820" width="233" height="19" font="3">● The authors concluded that surgical </text>
<text top="550" left="820" width="215" height="19" font="3">cryoablation is an option for highly </text>
<text top="569" left="820" width="198" height="19" font="3">symptomatic drug-resistant VAs </text>
<text top="587" left="820" width="234" height="19" font="3">emanating from the LVOT region. Yet, </text>
<text top="605" left="820" width="223" height="19" font="3">the procedure is not effective for all </text>
<text top="624" left="820" width="231" height="19" font="3">patients, and coronary injury is a risk. </text>
</page>
<page number="47" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">47 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="129" left="442" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="109" left="619" width="182" height="19" font="3">percutaneous intervention to </text>
<text top="127" left="619" width="175" height="19" font="3">the LAD; another developed </text>
<text top="145" left="619" width="167" height="19" font="3">progressive left ventricular </text>
<text top="164" left="619" width="187" height="19" font="3">systolic dysfunction caused by </text>
<text top="182" left="619" width="159" height="19" font="3">NICM; and a third patient </text>
<text top="200" left="619" width="142" height="19" font="3">underwent permanent </text>
<text top="219" left="619" width="153" height="19" font="3">pacemaker implantation </text>
<text top="237" left="619" width="187" height="19" font="3">because of complete AV block </text>
<text top="255" left="619" width="187" height="19" font="3">after concomitant aortic valve </text>
<text top="273" left="619" width="85" height="19" font="3">replacement.<b> </b></text>
<text top="292" left="125" width="142" height="19" font="3">● Patel et al. 2016 (91) </text>
<text top="311" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26377813">● </a></text>
<text top="311" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26377813">26377813</a></text>
<text top="311" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26377813"> </a></text>
<text top="329" left="125" width="3" height="19" font="3"> </text>
<text top="347" left="125" width="3" height="19" font="3"> </text>
<text top="292" left="286" width="116" height="19" font="4"><b>Aim: </b>to determine </text>
<text top="311" left="286" width="142" height="19" font="3">effectiveness of hybrid </text>
<text top="329" left="286" width="113" height="19" font="3">surgical epicardial </text>
<text top="347" left="286" width="137" height="19" font="3">mapping and ablation </text>
<text top="366" left="286" width="123" height="19" font="3">at the time to LVAD </text>
<text top="384" left="286" width="68" height="19" font="3">placement </text>
<text top="402" left="286" width="3" height="19" font="3"> </text>
<text top="421" left="286" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="439" left="286" width="117" height="19" font="3">center experience. </text>
<text top="457" left="286" width="136" height="19" font="3">Retrospective review. </text>
<text top="476" left="286" width="3" height="19" font="3"> </text>
<text top="494" left="286" width="43" height="19" font="4"><b>Size: </b>5<b> </b></text>
<text top="292" left="442" width="153" height="19" font="4"><b>Inclusion criteria:</b>   From </text>
<text top="311" left="442" width="146" height="19" font="3">March 2009 to October </text>
<text top="329" left="442" width="148" height="19" font="3">2012, 5 patients (4 men </text>
<text top="347" left="442" width="153" height="19" font="3">and 1 woman, age range </text>
<text top="366" left="442" width="161" height="19" font="3">52–73 y) underwent open </text>
<text top="384" left="442" width="150" height="19" font="3">chest EPS and epicardial </text>
<text top="404" left="442" width="139" height="19" font="3">mapping for recurrent </text>
<text top="402" left="581" width="17" height="21" font="0">VT</text>
<text top="404" left="599" width="3" height="19" font="3"> </text>
<text top="423" left="442" width="123" height="19" font="3">while the heart was </text>
<text top="441" left="442" width="121" height="19" font="3">exposed during the </text>
<text top="459" left="442" width="95" height="19" font="3">period of LVAD </text>
<text top="478" left="442" width="82" height="19" font="3">implantation </text>
<text top="496" left="442" width="3" height="19" font="3"> </text>
<text top="514" left="442" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="292" left="619" width="155" height="19" font="4"><b>Endpoint:</b> post LVAD VA. </text>
<text top="311" left="619" width="3" height="19" font="3"> </text>
<text top="329" left="619" width="175" height="19" font="4"><b>Results:</b>  Epicardial mapping </text>
<text top="347" left="619" width="162" height="19" font="3">was considered if patients </text>
<text top="366" left="619" width="155" height="19" font="3">had recurrent VT despite </text>
<text top="384" left="619" width="146" height="19" font="3">failed prior endocardial </text>
<text top="402" left="619" width="99" height="19" font="3">ablation and/or </text>
<text top="421" left="619" width="153" height="19" font="3">electrocardiogram (EKG) </text>
<text top="439" left="619" width="181" height="19" font="3">features of an epicardial exit. </text>
<text top="457" left="619" width="182" height="19" font="3">Activation and/or a substrate </text>
<text top="476" left="619" width="152" height="19" font="3">mapping approach were </text>
<text top="494" left="619" width="124" height="19" font="3">employed during all </text>
<text top="512" left="619" width="167" height="19" font="3">procedures. 3 of 5 patients </text>
<text top="531" left="619" width="172" height="19" font="3">(60%) had acute procedural </text>
<text top="549" left="619" width="161" height="19" font="3">success. In all patients, VT </text>
<text top="567" left="619" width="152" height="19" font="3">was either eliminated or </text>
<text top="586" left="619" width="160" height="19" font="3">significantly reduced with </text>
<text top="604" left="619" width="178" height="19" font="3">epicardial ablation. 1 patient </text>
<text top="622" left="619" width="156" height="19" font="3">had mediastinal bleeding </text>
<text top="640" left="619" width="151" height="19" font="3">delaying sternal closure. </text>
<text top="659" left="619" width="176" height="19" font="3">During a follow-up period of </text>
<text top="677" left="619" width="165" height="19" font="3">363±368 d, 4 patients died </text>
<text top="695" left="619" width="185" height="19" font="3">due to nonarrhythmic causes.<b> </b></text>
<text top="292" left="820" width="248" height="19" font="3">● Open-chest hybrid epicardial mapping </text>
<text top="311" left="820" width="244" height="19" font="3">and ablation for recurrent VT is feasible </text>
<text top="329" left="820" width="247" height="19" font="3">and can be considered in select patients </text>
<text top="347" left="820" width="247" height="19" font="3">during the period of LVAD implantation. </text>
<text top="714" left="125" width="125" height="19" font="3">● Mulloy et al. 2013 </text>
<text top="733" left="125" width="28" height="19" font="3">(92) </text>
<text top="751" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22520722">● </a></text>
<text top="751" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22520722">22520722</a></text>
<text top="751" left="198" width="7" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22520722"> </a> </text>
<text top="714" left="286" width="116" height="19" font="4"><b>Aim: </b>to determine </text>
<text top="733" left="286" width="55" height="19" font="3">whether </text>
<text top="751" left="286" width="90" height="19" font="3">intraoperative </text>
<text top="769" left="286" width="133" height="19" font="3">cryoablation in select </text>
<text top="714" left="442" width="133" height="19" font="4"><b>Inclusion criteria:</b>  50 </text>
<text top="733" left="442" width="129" height="19" font="3">consecutive patients </text>
<text top="751" left="442" width="155" height="19" font="3">undergoing implantation </text>
<text top="769" left="442" width="157" height="19" font="3">of the HeartMate II LVAD </text>
<text top="715" left="619" width="147" height="19" font="4"><b>1</b>°<b> endpoint:</b> post LVAD </text>
<text top="733" left="619" width="150" height="19" font="3">ventricualr arrhythmias. </text>
<text top="752" left="619" width="3" height="19" font="3"> </text>
<text top="714" left="820" width="250" height="19" font="3">● Postoperative VA can be minimized by </text>
<text top="733" left="820" width="207" height="19" font="3">preoperative risk assessment and </text>
<text top="751" left="820" width="219" height="19" font="3">intraoperative treatment. Localized </text>
<text top="769" left="820" width="225" height="19" font="3">cryoablation in select patients offers </text>
</page>
<page number="48" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">48 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="286" width="128" height="19" font="3">patients reduces the </text>
<text top="127" left="286" width="77" height="19" font="3">incidence of </text>
<text top="145" left="286" width="142" height="19" font="3">postoperative VA after </text>
<text top="164" left="286" width="40" height="19" font="3">LVAD. </text>
<text top="182" left="286" width="3" height="19" font="3"> </text>
<text top="200" left="286" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="219" left="286" width="117" height="19" font="3">center experience. </text>
<text top="237" left="286" width="136" height="19" font="3">Retrospective review. </text>
<text top="255" left="286" width="3" height="19" font="3"> </text>
<text top="273" left="286" width="50" height="19" font="4"><b>Size: </b>14<b> </b></text>
<text top="109" left="442" width="136" height="19" font="3">were examined. 14 of </text>
<text top="127" left="442" width="117" height="19" font="3">these patients had </text>
<text top="145" left="442" width="143" height="19" font="3">recurrent preoperative </text>
<text top="164" left="442" width="163" height="19" font="3">VA. Of those patients with </text>
<text top="182" left="442" width="112" height="19" font="3">recurrent VA, half </text>
<text top="200" left="442" width="161" height="19" font="3">underwent intraoperative </text>
<text top="219" left="442" width="152" height="19" font="3">cryoablation (Cryo: N=7) </text>
<text top="237" left="442" width="157" height="19" font="3">and half did not (NoCryo: </text>
<text top="255" left="442" width="36" height="19" font="3">N=7). </text>
<text top="273" left="442" width="3" height="19" font="3"> </text>
<text top="292" left="442" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="109" left="619" width="153" height="19" font="4"><b>Results:</b>  Compared with </text>
<text top="127" left="619" width="174" height="19" font="3">NoCryo, the Cryo group had </text>
<text top="145" left="619" width="142" height="19" font="3">significantly decreased </text>
<text top="164" left="619" width="170" height="19" font="3">postoperative resource use </text>
<text top="182" left="619" width="172" height="19" font="3">and complications (p&lt;0.05). </text>
<text top="200" left="619" width="173" height="19" font="3">Recurrent postoperative VA </text>
<text top="219" left="619" width="179" height="19" font="3">did not develop in any of the </text>
<text top="237" left="619" width="143" height="19" font="3">Cryo patients (p=0.02).<b> </b></text>
<text top="109" left="820" width="197" height="19" font="3">promising early feasibility when </text>
<text top="127" left="820" width="229" height="19" font="3">performed during HeartMate II LVAD </text>
<text top="145" left="820" width="85" height="19" font="3">implantation. </text>
<text top="164" left="820" width="199" height="19" font="3">● None of the Cryo patients had </text>
<text top="182" left="820" width="236" height="19" font="3">recurrent postoperative VA compared </text>
<text top="200" left="820" width="208" height="19" font="3">with 4 (57%) of the NoCryo group </text>
<text top="219" left="820" width="58" height="19" font="3">(p=0.02). </text>
<text top="311" left="115" width="3" height="19" font="3"> </text>
<text top="365" left="115" width="473" height="21" font="2"><b>Data Supplement 13. RCTs for Autonomic Modulation – (Section 5.6) </b></text>
<text top="386" left="142" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="404" left="168" width="55" height="19" font="4"><b>Author;  </b></text>
<text top="423" left="146" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="386" left="296" width="88" height="19" font="4"><b>Aim of Study; </b></text>
<text top="404" left="301" width="76" height="19" font="4"><b>Study Type; </b></text>
<text top="423" left="295" width="89" height="19" font="4"><b>Study Size (N) </b></text>
<text top="386" left="426" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="386" left="586" width="123" height="19" font="4"><b>Study Intervention  </b></text>
<text top="404" left="604" width="88" height="19" font="4"><b>(# patients) /  </b></text>
<text top="423" left="587" width="121" height="19" font="4"><b>Study Comparator  </b></text>
<text top="441" left="609" width="75" height="19" font="4"><b>(# patients) </b></text>
<text top="386" left="756" width="108" height="19" font="4"><b>Endpoint Results </b></text>
<text top="404" left="738" width="148" height="19" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="423" left="742" width="136" height="19" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="441" left="785" width="49" height="19" font="4"><b>95% CI) </b></text>
<text top="387" left="910" width="152" height="19" font="4"><b>Relevant 2</b>°<b> Endpoint (if </b></text>
<text top="405" left="969" width="35" height="19" font="4"><b>any); </b></text>
<text top="423" left="928" width="116" height="19" font="4"><b>Study Limitations; </b></text>
<text top="442" left="937" width="99" height="19" font="4"><b>Adverse Events </b></text>
<text top="461" left="123" width="121" height="19" font="3">● Schwartz PJ et al. </text>
<text top="479" left="123" width="30" height="19" font="3">1992</text>
<text top="478" left="154" width="4" height="21" font="0"> </text>
<text top="479" left="157" width="28" height="19" font="3">(93) </text>
<text top="498" left="123" width="3" height="19" font="3"> </text>
<text top="461" left="276" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="479" left="276" width="27" height="19" font="3">RCT </text>
<text top="498" left="276" width="3" height="19" font="3"> </text>
<text top="516" left="276" width="124" height="19" font="4"><b>Aim:</b> To explore the </text>
<text top="534" left="276" width="115" height="19" font="3">influence of BB vs. </text>
<text top="552" left="276" width="117" height="19" font="3">LCSD in patients at </text>
<text top="571" left="276" width="107" height="19" font="3">high risk for SCD. </text>
<text top="589" left="276" width="3" height="19" font="3"> </text>
<text top="607" left="276" width="116" height="19" font="4"><b>Size:</b> 144 high risk; </text>
<text top="626" left="276" width="76" height="19" font="3">869 low risk </text>
<text top="461" left="415" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="479" left="415" width="127" height="19" font="3">Patients post-MI (30 </text>
<text top="498" left="415" width="138" height="19" font="3">d); High risk (evidence </text>
<text top="516" left="415" width="132" height="19" font="3">of Vfib or Vtach); low </text>
<text top="534" left="415" width="141" height="19" font="3">risk (no evidence of VF </text>
<text top="552" left="415" width="40" height="19" font="3">or VT. </text>
<text top="571" left="415" width="3" height="19" font="3"> </text>
<text top="589" left="415" width="113" height="19" font="4"><b>Exclusion criteria</b> <b> </b></text>
<text top="607" left="415" width="27" height="19" font="3">N/A </text>
<text top="461" left="569" width="145" height="19" font="4"><b>Intervention:</b> High risk: </text>
<text top="479" left="569" width="152" height="19" font="3">1:1:1 BB (oxprenolol) vs. </text>
<text top="498" left="569" width="38" height="19" font="3">LCSD; </text>
<text top="516" left="569" width="155" height="19" font="3">Low risk: BB vs. placebo.  </text>
<text top="534" left="569" width="7" height="19" font="3">  </text>
<text top="552" left="569" width="144" height="19" font="4"><b>Comparator:</b>  <b>  </b>Placebo </text>
<text top="571" left="569" width="3" height="19" font="4"><b> </b></text>
<text top="462" left="736" width="116" height="19" font="4"><b>1</b>°<b> endpoint:</b>  SCD. </text>
<text top="480" left="736" width="42" height="19" font="3">22 mo </text>
<text top="498" left="736" width="63" height="19" font="3">High Risk: </text>
<text top="517" left="736" width="96" height="19" font="3">Placebo 21.3%  </text>
<text top="535" left="736" width="107" height="19" font="3">Oxprenolol 2.7%  </text>
<text top="553" left="736" width="67" height="19" font="3">LCSD 3.6% </text>
<text top="572" left="736" width="3" height="19" font="3"> </text>
<text top="590" left="736" width="60" height="19" font="3">Low Risk: </text>
<text top="608" left="736" width="89" height="19" font="3">Placebo: 5.2% </text>
<text top="627" left="736" width="112" height="19" font="3">Oxprenolol: 1.6%  </text>
<text top="461" left="897" width="165" height="19" font="3">● LCSD may be considered </text>
<text top="479" left="897" width="171" height="19" font="3">as a possible alternative for </text>
<text top="498" left="897" width="139" height="19" font="3">high-risk patients with </text>
<text top="516" left="897" width="152" height="19" font="3">contraindications to BB.  </text>
<text top="534" left="897" width="3" height="19" font="3"> </text>
<text top="552" left="897" width="3" height="19" font="3"> </text>
<text top="646" left="123" width="136" height="19" font="3">● Krittayaphong et al. </text>
<text top="664" left="123" width="62" height="19" font="3">2002 (94) </text>
<text top="682" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12486439?dopt=Citation">● </a></text>
<text top="682" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12486439?dopt=Citation">12486439</a></text>
<text top="682" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12486439?dopt=Citation"> </a></text>
<text top="646" left="276" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="664" left="276" width="27" height="19" font="3">RCT </text>
<text top="682" left="276" width="3" height="19" font="3"> </text>
<text top="700" left="276" width="118" height="19" font="4"><b>Aim:</b> To determine </text>
<text top="719" left="276" width="90" height="19" font="3">the efficacy of </text>
<text top="737" left="276" width="92" height="19" font="3">atenolol in the </text>
<text top="755" left="276" width="81" height="19" font="3">treatment of </text>
<text top="774" left="276" width="103" height="19" font="3">symptomatic VA </text>
<text top="646" left="415" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="664" left="415" width="137" height="19" font="3">VA with LBBB, inferior </text>
<text top="682" left="415" width="111" height="19" font="3">axis morphology.  </text>
<text top="701" left="415" width="109" height="19" font="3">Symptomatic (VA </text>
<text top="719" left="415" width="126" height="19" font="3">disturbed their daily </text>
<text top="737" left="415" width="62" height="19" font="3">activities) </text>
<text top="755" left="415" width="3" height="19" font="3"> </text>
<text top="774" left="415" width="113" height="19" font="4"><b>Exclusion criteria</b> <b> </b></text>
<text top="646" left="569" width="85" height="19" font="4"><b>Intervention: </b></text>
<text top="664" left="569" width="148" height="19" font="3">Atenolol 50-100mg/day </text>
<text top="682" left="569" width="3" height="19" font="3"> </text>
<text top="700" left="569" width="144" height="19" font="4"><b>Comparator:</b>  <b>  </b>Placebo </text>
<text top="719" left="569" width="3" height="19" font="4"><b> </b></text>
<text top="646" left="736" width="88" height="19" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="665" left="736" width="131" height="19" font="3">Atenolol significantly </text>
<text top="683" left="736" width="132" height="19" font="3">decreased PVC count </text>
<text top="701" left="736" width="140" height="19" font="3">(p=0.001) and average </text>
<text top="720" left="736" width="126" height="19" font="3">heart rate (p&lt;0.001) </text>
<text top="738" left="736" width="140" height="19" font="3">compared to placebo.  </text>
<text top="756" left="736" width="110" height="19" font="3">Both placebo and </text>
<text top="646" left="897" width="142" height="19" font="3">● BB may be useful for </text>
<text top="664" left="897" width="147" height="19" font="3">patients with RVOT and </text>
<text top="682" left="897" width="107" height="19" font="3">symptomatic VA. </text>
<text top="701" left="897" width="3" height="19" font="3"> </text>
<text top="719" left="897" width="3" height="19" font="3"> </text>
</page>
<page number="49" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">49 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="201" left="115" width="3" height="19" font="3"> </text>
<text top="219" left="115" width="3" height="19" font="3"> </text>
<text top="237" left="115" width="4" height="21" font="0"> </text>
<text top="237" left="331" width="4" height="21" font="2"><b> </b></text>
<text top="109" left="276" width="70" height="19" font="3">from RVOT </text>
<text top="127" left="276" width="96" height="19" font="3">compared with </text>
<text top="145" left="276" width="51" height="19" font="3">placebo </text>
<text top="164" left="276" width="3" height="19" font="3"> </text>
<text top="182" left="276" width="50" height="19" font="4"><b>Size:</b> 52 </text>
<text top="109" left="415" width="33" height="19" font="3">SHD. </text>
<text top="109" left="736" width="120" height="19" font="3">atenolol decreased </text>
<text top="127" left="736" width="133" height="19" font="3">symptom frequency.  </text>
<text top="145" left="736" width="3" height="19" font="3"> </text>
</page>
<page number="50" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">50 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="956" height="21" font="2"><b>Data Supplement 14. Nonrandomized Trials, Observational Studies, Guidelines, and/or Registries for Autonomic Modulation – (Section 5.6) </b></text>
<text top="129" left="148" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="147" left="174" width="51" height="19" font="4"><b>Author; </b></text>
<text top="165" left="152" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="129" left="298" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="147" left="327" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="129" left="465" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="129" left="662" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="147" left="674" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="165" left="705" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="129" left="903" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="147" left="932" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="184" left="123" width="131" height="19" font="3">● Vaseghi et al. 2014 </text>
<text top="203" left="123" width="31" height="19" font="3">(95)  </text>
<text top="221" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24291775?dopt=Citation">● </a></text>
<text top="221" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24291775?dopt=Citation">24291775</a></text>
<text top="221" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24291775?dopt=Citation"> </a></text>
<text top="184" left="289" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="203" left="289" width="120" height="19" font="3">retrospective chart </text>
<text top="221" left="289" width="44" height="19" font="3">review<b> </b></text>
<text top="239" left="289" width="3" height="19" font="3"> </text>
<text top="258" left="289" width="130" height="19" font="4"><b>Aim:</b> To describe the </text>
<text top="276" left="289" width="92" height="19" font="3">experiences of </text>
<text top="294" left="289" width="142" height="19" font="3">patients with VT storm </text>
<text top="313" left="289" width="101" height="19" font="3">who underwent </text>
<text top="331" left="289" width="125" height="19" font="3">cardiac sympathetic </text>
<text top="349" left="289" width="81" height="19" font="3">denervation. </text>
<text top="368" left="289" width="3" height="19" font="3"> </text>
<text top="386" left="289" width="132" height="19" font="4"><b>Size: </b>N= 41 (14 LCSD; </text>
<text top="404" left="289" width="59" height="19" font="3">27 BCSD) </text>
<text top="184" left="445" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="203" left="445" width="125" height="19" font="3">VT storm (&gt;3 events </text>
<text top="221" left="445" width="158" height="19" font="3">requiring treatment in 24 </text>
<text top="239" left="445" width="144" height="19" font="3">h) or refractory VA and </text>
<text top="258" left="445" width="98" height="19" font="3">ICD shocks who </text>
<text top="276" left="445" width="118" height="19" font="3">underwent cardiac </text>
<text top="294" left="445" width="156" height="19" font="3">sympathetic denervation </text>
<text top="313" left="445" width="149" height="19" font="3">between April 2009 and </text>
<text top="331" left="445" width="104" height="19" font="3">December 2012. </text>
<text top="349" left="445" width="3" height="19" font="4"><b> </b></text>
<text top="367" left="445" width="113" height="19" font="4"><b>Exclusion criteria: </b></text>
<text top="386" left="445" width="27" height="19" font="3">N/A </text>
<text top="185" left="618" width="204" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Survival free of ICD </text>
<text top="204" left="618" width="48" height="19" font="3">shocks. </text>
<text top="222" left="618" width="3" height="19" font="3"> </text>
<text top="240" left="618" width="56" height="19" font="4"><b>Results:</b>  </text>
<text top="259" left="618" width="224" height="20" font="3">•  Survival free of ICD shocks: 30% </text>
<text top="278" left="645" width="160" height="19" font="3">in LCSD; 48% in the BCSD. </text>
<text top="296" left="645" width="55" height="19" font="3">(p=0.04) </text>
<text top="314" left="618" width="3" height="19" font="3"> </text>
<text top="333" left="618" width="230" height="20" font="3">•  number of shocks decrease from </text>
<text top="352" left="645" width="163" height="19" font="3">Mean of 19 pre CSD to 2.3 </text>
<text top="370" left="645" width="62" height="19" font="3">(p&lt;0.001) </text>
<text top="184" left="869" width="192" height="19" font="3">● Bilateral cardiac sympathetic </text>
<text top="203" left="869" width="202" height="19" font="3">denervation appears better than </text>
<text top="221" left="869" width="37" height="19" font="3">LCSD  </text>
<text top="239" left="869" width="3" height="19" font="3"> </text>
<text top="423" left="123" width="149" height="19" font="3">● Ajijola et al. 2012 (96) </text>
<text top="442" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22192676?dopt=Citation">● </a></text>
<text top="442" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22192676?dopt=Citation">22192676</a></text>
<text top="442" left="196" width="7" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22192676?dopt=Citation">  </a></text>
<text top="423" left="289" width="106" height="19" font="4"><b>Study type:</b> Case </text>
<text top="442" left="289" width="40" height="19" font="3">Series<b> </b></text>
<text top="460" left="289" width="3" height="19" font="3"> </text>
<text top="478" left="289" width="130" height="19" font="4"><b>Aim:</b> To describe the </text>
<text top="497" left="289" width="92" height="19" font="3">experiences of </text>
<text top="515" left="289" width="137" height="19" font="3">patients with bilateral </text>
<text top="533" left="289" width="125" height="19" font="3">cardiac sympathetic </text>
<text top="552" left="289" width="134" height="19" font="3">denervation (or RCSD </text>
<text top="570" left="289" width="113" height="19" font="3">after unsuccessful </text>
<text top="588" left="289" width="38" height="19" font="3">LCSD) </text>
<text top="606" left="289" width="3" height="19" font="3"> </text>
<text top="625" left="289" width="60" height="19" font="4"><b>Size: </b>N=6 </text>
<text top="423" left="445" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="442" left="445" width="136" height="19" font="3">Patients with ongoing </text>
<text top="460" left="445" width="117" height="19" font="3">VAs with LCSD and </text>
<text top="478" left="445" width="137" height="19" font="3">maximal med therapy </text>
<text top="497" left="445" width="3" height="19" font="4"><b> </b></text>
<text top="515" left="445" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="424" left="618" width="236" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Reduction in Ventricular </text>
<text top="442" left="618" width="44" height="19" font="3">events </text>
<text top="461" left="618" width="3" height="19" font="3"> </text>
<text top="479" left="618" width="56" height="19" font="4"><b>Results:</b>  </text>
<text top="497" left="645" width="191" height="20" font="3">•  Complete response in 4/6  </text>
<text top="517" left="645" width="168" height="20" font="3">•  Partial response in 1/6 </text>
<text top="536" left="645" width="195" height="20" font="3">•  No response in 1/6 (PMVT) </text>
<text top="423" left="869" width="160" height="19" font="3">● Our study suggests that </text>
<text top="442" left="869" width="186" height="19" font="3">patients with incessant VA for </text>
<text top="460" left="869" width="172" height="19" font="3">whom no other therapeutic </text>
<text top="478" left="869" width="185" height="19" font="3">options exist, bilateral cardiac </text>
<text top="497" left="869" width="204" height="19" font="3">sympathetic denervation may be </text>
<text top="515" left="869" width="66" height="19" font="3">beneficial. </text>
<text top="533" left="869" width="3" height="19" font="3"> </text>
<text top="644" left="123" width="116" height="19" font="3">● Ukena et al. (97) </text>
<text top="662" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27364940?dopt=Citation">● </a></text>
<text top="662" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27364940?dopt=Citation">27364940</a></text>
<text top="662" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27364940?dopt=Citation"> </a></text>
<text top="644" left="289" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="662" left="289" width="127" height="19" font="3">Multicenter (5) Case </text>
<text top="680" left="289" width="40" height="19" font="3">Series<b> </b></text>
<text top="699" left="289" width="3" height="19" font="3"> </text>
<text top="717" left="289" width="130" height="19" font="4"><b>Aim:</b> To describe the </text>
<text top="735" left="289" width="89" height="19" font="3">effect of renal </text>
<text top="754" left="289" width="97" height="19" font="3">denervation on </text>
<text top="772" left="289" width="84" height="19" font="3">refractory VT </text>
<text top="644" left="445" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="662" left="445" width="116" height="19" font="3">CHF; Recurrent VA </text>
<text top="680" left="445" width="158" height="19" font="3">refractory to medications </text>
<text top="699" left="445" width="80" height="19" font="3">and ablation </text>
<text top="717" left="445" width="3" height="19" font="4"><b> </b></text>
<text top="735" left="445" width="141" height="19" font="4"><b>Exclusion criteria: </b>N/A </text>
<text top="644" left="618" width="236" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Reduction in Ventricular </text>
<text top="663" left="618" width="44" height="19" font="3">events </text>
<text top="681" left="618" width="3" height="19" font="3"> </text>
<text top="699" left="618" width="56" height="19" font="4"><b>Results:</b>  </text>
<text top="718" left="618" width="94" height="19" font="3">Median VT/VF: </text>
<text top="736" left="645" width="118" height="20" font="3">•  4 wk prior =21 </text>
<text top="755" left="645" width="172" height="20" font="3">•  1 mo post =2 (p=0.004) </text>
<text top="774" left="645" width="172" height="20" font="3">•  3 mo post =0 (p=0.006) </text>
<text top="644" left="869" width="206" height="19" font="3">● Renal sympathetic denervation </text>
<text top="662" left="869" width="144" height="19" font="3">appeared safe and was </text>
<text top="680" left="869" width="186" height="19" font="3">associated with a reduction in </text>
<text top="699" left="869" width="91" height="19" font="3">VT/VF events.  </text>
</page>
<page number="51" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">51 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="289" width="3" height="19" font="3"> </text>
<text top="127" left="289" width="68" height="19" font="4"><b>Size: </b>N=13 </text>
<text top="109" left="618" width="3" height="19" font="3"> </text>
<text top="127" left="618" width="215" height="19" font="3">No peri-procedural adverse events </text>
<text top="145" left="618" width="231" height="19" font="3">Baseline BP was low but no change in </text>
<text top="164" left="618" width="23" height="19" font="3">BP. </text>
<text top="183" left="123" width="135" height="19" font="3">● Grimaldi et al. 2012 </text>
<text top="201" left="123" width="28" height="19" font="3">(98) </text>
<text top="219" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22877745?dopt=Citation">● </a></text>
<text top="219" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22877745?dopt=Citation">22877745</a></text>
<text top="219" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22877745?dopt=Citation"> </a></text>
<text top="183" left="289" width="106" height="19" font="4"><b>Study type:</b> Case </text>
<text top="201" left="289" width="130" height="19" font="3">Series (from patients </text>
<text top="219" left="289" width="128" height="19" font="3">enrolled in an under-</text>
<text top="238" left="289" width="119" height="19" font="3">enrolled RCT – trial </text>
<text top="256" left="289" width="142" height="19" font="3">was a 2 mo alternating </text>
<text top="274" left="289" width="93" height="19" font="3">on/off design.)<b> </b></text>
<text top="292" left="289" width="3" height="19" font="3"> </text>
<text top="311" left="289" width="130" height="19" font="4"><b>Aim:</b> To describe the </text>
<text top="329" left="289" width="92" height="19" font="3">experiences of </text>
<text top="347" left="289" width="128" height="19" font="3">patients with SCS on </text>
<text top="366" left="289" width="3" height="19" font="3"> </text>
<text top="384" left="289" width="60" height="19" font="4"><b>Size: </b>N=2<b> </b></text>
<text top="183" left="445" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="201" left="445" width="141" height="19" font="3">Patients with CM, ICDs </text>
<text top="219" left="445" width="151" height="19" font="3">and previous VF or 2xVT </text>
<text top="237" left="445" width="3" height="19" font="4"><b> </b></text>
<text top="256" left="445" width="141" height="19" font="4"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="183" left="618" width="227" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Ventricular arrhythmia </text>
<text top="202" left="618" width="3" height="19" font="3"> </text>
<text top="220" left="618" width="56" height="19" font="4"><b>Results:</b>  </text>
<text top="238" left="618" width="222" height="19" font="3">Patient 1 had a 75% reduction in VA </text>
<text top="257" left="618" width="75" height="19" font="3">with SCS on </text>
<text top="275" left="618" width="230" height="19" font="3">Patient 2 had a 100% reduction in VA </text>
<text top="293" left="618" width="82" height="19" font="3">with SCS on.  </text>
<text top="312" left="618" width="193" height="19" font="3">(These are the authors reports, </text>
<text top="330" left="618" width="228" height="19" font="3">numbers in the table don’t quite add </text>
<text top="348" left="618" width="221" height="19" font="3">to this.  Not sure how the math was </text>
<text top="367" left="618" width="39" height="19" font="3">done) </text>
<text top="183" left="869" width="193" height="19" font="3">● SCS may decrease the rate of </text>
<text top="201" left="869" width="31" height="19" font="3">VA.   </text>
<text top="403" left="115" width="3" height="19" font="3"> </text>
<text top="422" left="115" width="3" height="19" font="3"> </text>
<text top="475" left="115" width="641" height="21" font="2"><b>Data Supplement 15. RCTs Comparing Acute Management of Specific Arrythmias - (Section 6) </b></text>
<text top="497" left="127" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="515" left="153" width="55" height="19" font="4"><b>Author;  </b></text>
<text top="533" left="130" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="497" left="268" width="88" height="19" font="4"><b>Aim of Study; </b></text>
<text top="515" left="273" width="76" height="19" font="4"><b>Study Type; </b></text>
<text top="533" left="267" width="89" height="19" font="4"><b>Study Size (N) </b></text>
<text top="497" left="405" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="497" left="561" width="123" height="19" font="4"><b>Study Intervention  </b></text>
<text top="515" left="579" width="88" height="19" font="4"><b>(# patients) /  </b></text>
<text top="533" left="563" width="121" height="19" font="4"><b>Study Comparator  </b></text>
<text top="552" left="584" width="75" height="19" font="4"><b>(# patients) </b></text>
<text top="497" left="730" width="108" height="19" font="4"><b>Endpoint Results </b></text>
<text top="515" left="712" width="148" height="19" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="533" left="717" width="136" height="19" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="552" left="760" width="49" height="19" font="4"><b>95% CI) </b></text>
<text top="499" left="883" width="66" height="19" font="4"><b>Relevant 2</b></text>
<text top="497" left="949" width="7" height="20" font="0">°</text>
<text top="499" left="956" width="115" height="19" font="4"><b> Endpoint (if any); </b></text>
<text top="517" left="919" width="116" height="19" font="4"><b>Study Limitations; </b></text>
<text top="536" left="928" width="99" height="19" font="4"><b>Adverse Events </b></text>
<text top="571" left="123" width="99" height="19" font="3">● Kudenchuk et </text>
<text top="589" left="123" width="83" height="19" font="3">al. 2016 (99)  </text>
<text top="607" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=27043165">● </a></text>
<text top="607" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=27043165">27043165</a></text>
<text top="607" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=27043165"> </a></text>
<text top="626" left="123" width="3" height="19" font="3"> </text>
<text top="644" left="123" width="3" height="19" font="3"> </text>
<text top="570" left="246" width="95" height="19" font="4"><b>Aim:</b>  Compare </text>
<text top="589" left="246" width="81" height="19" font="3">amiodarone, </text>
<text top="607" left="246" width="128" height="19" font="3">lidocaine, placebo in </text>
<text top="626" left="246" width="109" height="19" font="3">OHCA with shock-</text>
<text top="644" left="246" width="100" height="19" font="3">refractory VF or </text>
<text top="662" left="246" width="78" height="19" font="3">pulseless VT </text>
<text top="681" left="246" width="3" height="19" font="3"> </text>
<text top="699" left="246" width="108" height="19" font="4"><b>Study type:</b>   RCT </text>
<text top="717" left="246" width="85" height="19" font="3">double-blind, </text>
<text top="735" left="246" width="118" height="19" font="3">placebo controlled </text>
<text top="754" left="246" width="3" height="19" font="3"> </text>
<text top="772" left="246" width="126" height="19" font="4"><b>Size:</b>  3,026 patients </text>
<text top="570" left="390" width="143" height="19" font="4"><b>Inclusion criteria:</b>  18 y </text>
<text top="589" left="390" width="148" height="19" font="3">or older with OHCA and </text>
<text top="607" left="390" width="138" height="19" font="3">shock refractory VF or </text>
<text top="626" left="390" width="140" height="19" font="3">pulseless VT. IV access </text>
<text top="644" left="390" width="3" height="19" font="3"> </text>
<text top="662" left="390" width="113" height="19" font="4"><b>Exclusion criteria: </b></text>
<text top="681" left="390" width="106" height="19" font="3">Already received </text>
<text top="699" left="390" width="75" height="19" font="3">lidocaine or </text>
<text top="717" left="390" width="81" height="19" font="3">amiodarone, </text>
<text top="735" left="390" width="116" height="19" font="3">hypersensitivity to </text>
<text top="754" left="390" width="78" height="19" font="3">these drugs  </text>
<text top="570" left="553" width="101" height="19" font="4"><b>Intervention:</b> IV </text>
<text top="589" left="553" width="94" height="19" font="3">amiodarone or </text>
<text top="607" left="553" width="121" height="19" font="3">lidocaine; repeated </text>
<text top="626" left="553" width="85" height="19" font="3">once if VF/VT </text>
<text top="644" left="553" width="129" height="19" font="3">persisted after initial </text>
<text top="662" left="553" width="102" height="19" font="3">dose and repeat </text>
<text top="681" left="553" width="44" height="19" font="3">shocks </text>
<text top="699" left="553" width="7" height="19" font="3">  </text>
<text top="717" left="553" width="98" height="19" font="4"><b>Comparator:</b> IV </text>
<text top="735" left="553" width="85" height="19" font="3">normal saline<b> </b></text>
<text top="754" left="553" width="103" height="19" font="3">repeated once if </text>
<text top="772" left="553" width="133" height="19" font="3">VF/VT persisted after </text>
<text top="571" left="703" width="102" height="19" font="4"><b>1</b>°<b> endpoint:</b> No </text>
<text top="590" left="703" width="147" height="19" font="3">difference in survival to </text>
<text top="608" left="703" width="118" height="19" font="3">hospital discharge: </text>
<text top="626" left="703" width="131" height="19" font="3">amiodarone (24.4%), </text>
<text top="645" left="703" width="112" height="19" font="3">lidocaine (23.7%), </text>
<text top="663" left="703" width="105" height="19" font="3">placebo (21.0%). </text>
<text top="681" left="703" width="150" height="19" font="3">Amiodarone vs. placebo </text>
<text top="700" left="703" width="158" height="19" font="3">3.2% points (95% CI: -0.4–</text>
<text top="718" left="703" width="158" height="19" font="3">7.0; p=0.08); lidocaine vs. </text>
<text top="736" left="703" width="160" height="19" font="3">placebo 2.6% points (95% </text>
<text top="755" left="703" width="130" height="19" font="3">CI: -1.0–6.3; p=0.16); </text>
<text top="773" left="703" width="157" height="19" font="3">Amiodarone vs. lidocaine </text>
<text top="571" left="879" width="190" height="19" font="3">● Neurologic outcomes similar </text>
<text top="589" left="879" width="167" height="19" font="3">More amiodarone patients </text>
<text top="607" left="879" width="171" height="19" font="3">required temporary pacing; </text>
<text top="626" left="879" width="168" height="19" font="3">otherwise, no difference in </text>
<text top="644" left="879" width="174" height="19" font="3">drug related adverse events </text>
<text top="662" left="879" width="138" height="19" font="3">● Trial may have been </text>
<text top="681" left="879" width="146" height="19" font="3">underpowered to show </text>
<text top="699" left="879" width="155" height="19" font="3">amiodarone benefit over </text>
<text top="717" left="879" width="51" height="19" font="3">placebo </text>
<text top="735" left="879" width="3" height="19" font="3"> </text>
<text top="754" left="879" width="147" height="19" font="3">Note: An editorial (100) </text>
<text top="772" left="879" width="186" height="19" font="3">suggesting use of amiodarone </text>
</page>
<page number="52" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">52 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="553" width="96" height="19" font="3">initial dose and </text>
<text top="127" left="553" width="88" height="19" font="3">repeat shocks<b> </b></text>
<text top="109" left="703" width="158" height="19" font="3">0.7% points (95% CI: -3.2–</text>
<text top="127" left="703" width="76" height="19" font="3">4.7; p=0.70) </text>
<text top="145" left="703" width="3" height="19" font="3"> </text>
<text top="164" left="703" width="123" height="19" font="3">In witnessed arrest, </text>
<text top="182" left="703" width="118" height="19" font="3">survival to hospital </text>
<text top="200" left="703" width="92" height="19" font="3">discharge with </text>
<text top="219" left="703" width="162" height="19" font="3">amiodarone and lidocaine </text>
<text top="237" left="703" width="131" height="19" font="3">was higher than with </text>
<text top="255" left="703" width="162" height="19" font="3">placebo. The absolute risk </text>
<text top="273" left="703" width="87" height="19" font="3">difference for </text>
<text top="292" left="703" width="149" height="19" font="3">amiodarone vs. placebo </text>
<text top="310" left="703" width="163" height="19" font="3">was (5.0 % points, p=0.04) </text>
<text top="329" left="703" width="125" height="19" font="3">and for lidocaine vs. </text>
<text top="347" left="703" width="120" height="19" font="3">placebo was (5.2 % </text>
<text top="365" left="703" width="95" height="19" font="3">points, p=0.05) </text>
<text top="109" left="879" width="161" height="19" font="3">or lidocaine for witnessed </text>
<text top="127" left="879" width="196" height="19" font="3">arrest as there was a significant </text>
<text top="145" left="879" width="186" height="19" font="3">reduction in shocks and fewer </text>
<text top="164" left="879" width="142" height="19" font="3">CPR events in hospital. </text>
<text top="182" left="879" width="3" height="19" font="3"> </text>
<text top="200" left="879" width="3" height="19" font="3"> </text>
<text top="219" left="879" width="3" height="19" font="3"> </text>
<text top="384" left="123" width="89" height="19" font="3">● Jacobs et al. </text>
<text top="402" left="123" width="69" height="19" font="3">2011 (101) </text>
<text top="421" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21745533">● </a></text>
<text top="421" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21745533">21745533</a></text>
<text top="421" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21745533"> </a></text>
<text top="439" left="123" width="3" height="19" font="3"> </text>
<text top="457" left="123" width="3" height="19" font="3"> </text>
<text top="384" left="246" width="95" height="19" font="4"><b>Aim:</b>  Compare </text>
<text top="402" left="246" width="108" height="19" font="3">epinephrine with </text>
<text top="421" left="246" width="128" height="19" font="3">normal saline during </text>
<text top="439" left="246" width="88" height="19" font="3">OHCA treated </text>
<text top="457" left="246" width="93" height="19" font="3">following ACLS </text>
<text top="476" left="246" width="65" height="19" font="3">guidelines </text>
<text top="494" left="246" width="3" height="19" font="3"> </text>
<text top="512" left="246" width="101" height="19" font="4"><b>Study type:</b> RCT </text>
<text top="531" left="246" width="84" height="19" font="3">double blind, </text>
<text top="549" left="246" width="124" height="19" font="3">placebo controlled   </text>
<text top="567" left="246" width="3" height="19" font="3"> </text>
<text top="585" left="246" width="115" height="19" font="4"><b>Size:</b>  601 patients </text>
<text top="384" left="390" width="141" height="19" font="4"><b>Inclusion criteria:</b>  Age </text>
<text top="402" left="390" width="137" height="19" font="3">≤18 y with OHCA, CPR </text>
<text top="421" left="390" width="139" height="19" font="3">started by paramedics </text>
<text top="439" left="390" width="3" height="19" font="3"> </text>
<text top="457" left="390" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="476" left="390" width="104" height="19" font="3">Traumatic OHCA </text>
<text top="384" left="553" width="115" height="19" font="4"><b>Intervention:</b> 1 ml </text>
<text top="402" left="553" width="68" height="19" font="3">aliquots of </text>
<text top="421" left="553" width="123" height="19" font="3">epinephrine 1:1000 </text>
<text top="439" left="553" width="108" height="19" font="3">following current </text>
<text top="457" left="553" width="98" height="19" font="3">ACLS guidelines </text>
<text top="476" left="553" width="7" height="19" font="3">  </text>
<text top="494" left="553" width="116" height="19" font="4"><b>Comparator:</b>  1 ml </text>
<text top="512" left="553" width="101" height="19" font="3">aliquots of 0.9% </text>
<text top="531" left="553" width="101" height="19" font="3">sodium chloride </text>
<text top="549" left="553" width="108" height="19" font="3">following current </text>
<text top="567" left="553" width="102" height="19" font="3">ACLS guidelines<b>  </b></text>
<text top="385" left="703" width="152" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Survival to </text>
<text top="403" left="703" width="138" height="19" font="3">hospital discharge not </text>
<text top="422" left="703" width="115" height="19" font="3">different: 1.9% for </text>
<text top="440" left="703" width="121" height="19" font="3">placebo and 4% for </text>
<text top="458" left="703" width="163" height="19" font="3">epinephrine (OR: 2.2; 95% </text>
<text top="476" left="703" width="137" height="19" font="3">CI: 0.7–6.3). Return of </text>
<text top="495" left="703" width="149" height="19" font="3">spontaneous circulation </text>
<text top="513" left="703" width="132" height="19" font="3">8.4% for placebo and </text>
<text top="531" left="703" width="139" height="19" font="3">23.5% for epinephrine </text>
<text top="550" left="703" width="158" height="19" font="3">(OR: 3.4; 95% CI: 2.0–5.6) </text>
<text top="568" left="703" width="3" height="19" font="3"> </text>
<text top="586" left="703" width="3" height="19" font="4"><b> </b></text>
<text top="384" left="879" width="194" height="19" font="3">● Epinephrine improved return </text>
<text top="402" left="879" width="190" height="19" font="3">to spontaneous circulation but </text>
<text top="421" left="879" width="142" height="19" font="3">not survival to hospital </text>
<text top="439" left="879" width="62" height="19" font="3">discharge </text>
<text top="457" left="879" width="160" height="19" font="3">● Limitations: Inadequate </text>
<text top="476" left="879" width="184" height="19" font="3">sample size to access hospital </text>
<text top="494" left="879" width="61" height="19" font="3">survival.   </text>
<text top="512" left="879" width="133" height="19" font="3">● Quality of ACLS not </text>
<text top="531" left="879" width="64" height="19" font="3">evaluated </text>
<text top="549" left="879" width="170" height="19" font="3">● Adverse events not listed </text>
<text top="567" left="879" width="3" height="19" font="3"> </text>
<text top="586" left="879" width="3" height="19" font="3"> </text>
</page>
<page number="53" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">53 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="88" height="19" font="3">● Piccini et al. </text>
<text top="127" left="123" width="69" height="19" font="3">2008 (102) </text>
<text top="145" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19026290">● </a></text>
<text top="145" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19026290">19026290</a></text>
<text top="145" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19026290"> </a></text>
<text top="109" left="246" width="95" height="19" font="4"><b>Aim:</b>  Compare </text>
<text top="127" left="246" width="78" height="19" font="3">outcomes in </text>
<text top="145" left="246" width="130" height="19" font="3">patients with MI and </text>
<text top="164" left="246" width="102" height="19" font="3">sustained VT/VF </text>
<text top="182" left="246" width="89" height="19" font="3">treated or not </text>
<text top="200" left="246" width="99" height="19" font="3">treated with BB </text>
<text top="218" left="246" width="3" height="19" font="4"><b> </b></text>
<text top="237" left="246" width="81" height="19" font="4"><b>Study type:   </b></text>
<text top="255" left="246" width="78" height="19" font="3">Prospective, </text>
<text top="273" left="246" width="124" height="19" font="3">multicenter registry </text>
<text top="292" left="246" width="99" height="19" font="3">of patients with </text>
<text top="310" left="246" width="57" height="19" font="3">acute MI<b> </b></text>
<text top="328" left="246" width="3" height="19" font="4"><b> </b></text>
<text top="347" left="246" width="114" height="19" font="4"><b>Size:</b>  306 patients </text>
<text top="365" left="246" width="92" height="19" font="3">with sustained </text>
<text top="383" left="246" width="40" height="19" font="3">VT/VF<b> </b></text>
<text top="109" left="390" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="127" left="390" width="150" height="19" font="3">acute MI with sustained </text>
<text top="145" left="390" width="148" height="19" font="3">VT/VF and/or high Killip </text>
<text top="164" left="390" width="81" height="19" font="3">classification </text>
<text top="182" left="390" width="3" height="19" font="3"> </text>
<text top="200" left="390" width="141" height="19" font="4"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="109" left="553" width="105" height="19" font="4"><b>Intervention:</b> BB </text>
<text top="127" left="553" width="108" height="19" font="3">within 24 h of MI </text>
<text top="145" left="553" width="7" height="19" font="3">  </text>
<text top="164" left="553" width="123" height="19" font="4"><b>Comparator:</b> No BB<b> </b></text>
<text top="109" left="703" width="152" height="19" font="4"><b>1</b>°<b> endpoint:</b> BB therapy </text>
<text top="128" left="703" width="99" height="19" font="3">within 24 h was </text>
<text top="146" left="703" width="98" height="19" font="3">associated with </text>
<text top="165" left="703" width="134" height="19" font="3">decreased in-hospital </text>
<text top="183" left="703" width="158" height="19" font="3">mortality in patients with </text>
<text top="201" left="703" width="130" height="19" font="3">sustained VT/VF (RR: </text>
<text top="219" left="703" width="150" height="19" font="3">0.28; 95% CI: 0.10–0.75, </text>
<text top="238" left="703" width="109" height="19" font="3">p=0.013) without </text>
<text top="256" left="703" width="161" height="19" font="3">evidence of worsening HF </text>
<text top="274" left="703" width="153" height="19" font="3">● 55.2% of patients with </text>
<text top="293" left="703" width="137" height="19" font="3">sustained VT/VF were </text>
<text top="311" left="703" width="159" height="19" font="3">treated with BB within 24 </text>
<text top="329" left="703" width="47" height="19" font="3">h of MI </text>
<text top="348" left="703" width="3" height="19" font="3"> </text>
<text top="366" left="703" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="879" width="193" height="19" font="3">● Sustained VT/VF was a major </text>
<text top="127" left="879" width="182" height="19" font="3">predictor of in-hospital death </text>
<text top="145" left="879" width="179" height="19" font="3">(RR: 4.18; 95% CI: 2.91–5.93) </text>
<text top="164" left="879" width="3" height="19" font="3"> </text>
<text top="410" left="123" width="90" height="19" font="3">● Dorian et al. </text>
<text top="428" left="123" width="69" height="19" font="3">2002 (103) </text>
<text top="446" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=11907287">● </a></text>
<text top="446" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=11907287">11907287</a></text>
<text top="446" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=11907287"> </a></text>
<text top="465" left="123" width="3" height="19" font="3"> </text>
<text top="483" left="123" width="3" height="19" font="3"> </text>
<text top="410" left="246" width="111" height="19" font="4"><b>Aim:</b>  Compare IV </text>
<text top="428" left="246" width="104" height="19" font="3">lidocaine with IV </text>
<text top="446" left="246" width="94" height="19" font="3">amiodarone as </text>
<text top="465" left="246" width="66" height="19" font="3">adjunct to </text>
<text top="483" left="246" width="96" height="19" font="3">defibrillation in </text>
<text top="501" left="246" width="39" height="19" font="3">OHCA </text>
<text top="520" left="246" width="3" height="19" font="3"> </text>
<text top="538" left="246" width="101" height="19" font="4"><b>Study type:</b> RCT </text>
<text top="556" left="246" width="118" height="19" font="3">placebo controlled </text>
<text top="575" left="246" width="3" height="19" font="3"> </text>
<text top="593" left="246" width="115" height="19" font="4"><b>Size:</b>  347 patients<b> </b></text>
<text top="410" left="390" width="141" height="19" font="4"><b>Inclusion criteria:</b>  Age </text>
<text top="428" left="390" width="149" height="19" font="3">≤18 y with OHCA due to </text>
<text top="446" left="390" width="29" height="19" font="3">VF.   </text>
<text top="465" left="390" width="3" height="19" font="3"> </text>
<text top="483" left="390" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="501" left="390" width="122" height="19" font="3">traumatic, or OHCA<b> </b></text>
<text top="410" left="553" width="85" height="19" font="4"><b>Intervention:</b> </text>
<text top="428" left="553" width="129" height="19" font="3">Patients randomized </text>
<text top="446" left="553" width="109" height="19" font="3">to IV amiodarone </text>
<text top="465" left="553" width="102" height="19" font="3">plus IV lidocaine </text>
<text top="483" left="553" width="84" height="19" font="3">placebo or IV </text>
<text top="501" left="553" width="102" height="19" font="3">lidocaine plus IV </text>
<text top="520" left="553" width="129" height="19" font="3">amiodarone placebo </text>
<text top="538" left="553" width="125" height="19" font="3">to treat VF resistant </text>
<text top="556" left="553" width="134" height="19" font="3">to 3 shocks, at least 1 </text>
<text top="575" left="553" width="64" height="19" font="3">dose of IV </text>
<text top="593" left="553" width="107" height="19" font="3">epinephrine, and </text>
<text top="611" left="553" width="39" height="19" font="3">then 4</text>
<text top="611" left="592" width="8" height="12" font="15">th</text>
<text top="611" left="600" width="71" height="19" font="3"> shock.  Or, </text>
<text top="629" left="553" width="113" height="19" font="3">recurrent VF after </text>
<text top="648" left="553" width="102" height="19" font="3">successful initial </text>
<text top="666" left="553" width="42" height="19" font="3">shock. </text>
<text top="684" left="553" width="7" height="19" font="3">  </text>
<text top="703" left="553" width="116" height="19" font="4"><b>Comparator:</b>  1 ml </text>
<text top="721" left="553" width="101" height="19" font="3">aliquots of 0.9% </text>
<text top="739" left="553" width="101" height="19" font="3">sodium chloride </text>
<text top="758" left="553" width="108" height="19" font="3">following current </text>
<text top="776" left="553" width="98" height="19" font="3">ACLS guidelines </text>
<text top="410" left="703" width="160" height="19" font="4"><b>1</b>°<b> endpoint:</b> Amiodarone </text>
<text top="429" left="703" width="135" height="19" font="3">had higher survival to </text>
<text top="447" left="703" width="148" height="19" font="3">hospital admission than </text>
<text top="465" left="703" width="122" height="19" font="3">lidocaine: 28% with </text>
<text top="484" left="703" width="157" height="19" font="3">amiodarone vs. 12% with </text>
<text top="502" left="703" width="152" height="19" font="3">lidocaine (OR: 2.17; 95% </text>
<text top="520" left="703" width="148" height="19" font="3">CI: 1.21–3.83; p=0.009). </text>
<text top="539" left="703" width="147" height="19" font="3">Of 42 patients surviving </text>
<text top="557" left="703" width="148" height="19" font="3">to hospital admission, 9 </text>
<text top="575" left="703" width="154" height="19" font="3">(5%) survived to hospital </text>
<text top="594" left="703" width="100" height="19" font="3">discharge in the </text>
<text top="612" left="703" width="159" height="19" font="3">amiodarone group and of </text>
<text top="630" left="703" width="153" height="19" font="3">20 initial survivors in the </text>
<text top="649" left="703" width="143" height="19" font="3">lidocaine group, 5 (3%) </text>
<text top="667" left="703" width="162" height="19" font="3">were discharged (p=0.34). </text>
<text top="685" left="703" width="3" height="19" font="3"> </text>
<text top="703" left="703" width="3" height="19" font="4"><b> </b></text>
<text top="410" left="879" width="155" height="19" font="3">● Increased survival with </text>
<text top="428" left="879" width="186" height="19" font="3">shorter interval from dispatch </text>
<text top="446" left="879" width="153" height="19" font="3">to receiving study drugs. </text>
<text top="465" left="879" width="182" height="19" font="3">● Patients with VF had better </text>
<text top="483" left="879" width="149" height="19" font="3">survival than those with </text>
<text top="501" left="879" width="100" height="19" font="3">asystole or PEA. </text>
<text top="520" left="879" width="192" height="19" font="3">● Amiodarone did not improve </text>
<text top="538" left="879" width="180" height="19" font="3">survival to hospital discharge </text>
<text top="556" left="879" width="180" height="19" font="3">● Limitation: not powered to </text>
<text top="575" left="879" width="175" height="19" font="3">show amiodarone improved </text>
<text top="593" left="879" width="135" height="19" font="3">survival to discharge.  </text>
<text top="611" left="879" width="172" height="19" font="3">● No adverse events noted. </text>
<text top="629" left="879" width="3" height="19" font="3"> </text>
<text top="648" left="879" width="3" height="19" font="3"> </text>
<text top="666" left="879" width="3" height="19" font="3"> </text>
</page>
<page number="54" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">54 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="553" width="3" height="19" font="4"><b> </b></text>
<text top="128" left="123" width="93" height="19" font="3">● Hassan et al. </text>
<text top="146" left="123" width="72" height="19" font="3">2002 (104)  </text>
<text top="164" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=11777881">● </a></text>
<text top="164" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=11777881">11777881</a></text>
<text top="164" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=11777881"> </a></text>
<text top="183" left="123" width="3" height="19" font="3"> </text>
<text top="201" left="123" width="3" height="19" font="3"> </text>
<text top="128" left="246" width="126" height="19" font="4"><b>Aim:</b>  IV magnesium </text>
<text top="146" left="246" width="112" height="19" font="3">given early during </text>
<text top="164" left="246" width="91" height="19" font="3">CPR for VF will </text>
<text top="183" left="246" width="108" height="19" font="3">improve survival. </text>
<text top="201" left="246" width="3" height="19" font="3"> </text>
<text top="219" left="246" width="108" height="19" font="4"><b>Study type:</b>  RCT, </text>
<text top="238" left="246" width="84" height="19" font="3">double blind, </text>
<text top="256" left="246" width="121" height="19" font="3">placebo controlled  </text>
<text top="274" left="246" width="3" height="19" font="3"> </text>
<text top="292" left="246" width="115" height="19" font="4"><b>Size:</b>  105 patients </text>
<text top="128" left="390" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="146" left="390" width="120" height="19" font="3">Patients ≥18 y with </text>
<text top="164" left="390" width="147" height="19" font="3">OHCA and refractory or </text>
<text top="183" left="390" width="83" height="19" font="3">recurrent VF  </text>
<text top="201" left="390" width="3" height="19" font="3"> </text>
<text top="219" left="390" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="238" left="390" width="104" height="19" font="3">Traumatic OHCA </text>
<text top="128" left="553" width="85" height="19" font="4"><b>Intervention:</b> </text>
<text top="146" left="553" width="134" height="19" font="3">Patients received 2–4 </text>
<text top="164" left="553" width="100" height="19" font="3">g of magnesium </text>
<text top="183" left="553" width="7" height="19" font="3">  </text>
<text top="201" left="553" width="86" height="19" font="4"><b>Comparator:</b>  </text>
<text top="219" left="553" width="55" height="19" font="3">Placebo<b>  </b></text>
<text top="128" left="703" width="100" height="19" font="4"><b>1</b>°<b> endpoint:</b>  IV </text>
<text top="147" left="703" width="121" height="19" font="3">magnesium did not </text>
<text top="165" left="703" width="120" height="19" font="3">improve survival to </text>
<text top="183" left="703" width="150" height="19" font="3">hospital admission: 17% </text>
<text top="202" left="703" width="151" height="19" font="3">for magnesium and 13% </text>
<text top="220" left="703" width="136" height="19" font="3">for placebo (OR: 1.69; </text>
<text top="239" left="703" width="120" height="19" font="3">95% CI: -10%–18%) </text>
<text top="257" left="703" width="3" height="19" font="3"> </text>
<text top="275" left="703" width="3" height="19" font="4"><b> </b></text>
<text top="128" left="879" width="188" height="19" font="3">● No benefit from magnesium </text>
<text top="146" left="879" width="140" height="19" font="3">● Limitations: Possible </text>
<text top="164" left="879" width="179" height="19" font="3">inadequate magnesium dose </text>
<text top="183" left="879" width="166" height="19" font="3">● No adverse effects listed </text>
<text top="201" left="879" width="3" height="19" font="3"> </text>
<text top="219" left="879" width="3" height="19" font="3"> </text>
<text top="312" left="123" width="60" height="19" font="3">● <b>MAGIC </b></text>
<text top="330" left="123" width="109" height="19" font="3">● Thel et al. 1997 </text>
<text top="348" left="123" width="39" height="19" font="3">(105)  </text>
<text top="366" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=9357406">● </a></text>
<text top="366" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=9357406">9357406</a></text>
<text top="366" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=9357406"> </a></text>
<text top="385" left="123" width="3" height="19" font="3"> </text>
<text top="403" left="123" width="3" height="19" font="3"> </text>
<text top="311" left="246" width="116" height="19" font="4"><b>Aim:</b>  Determine if </text>
<text top="330" left="246" width="90" height="19" font="3">IV magnesium </text>
<text top="348" left="246" width="119" height="19" font="3">improves return to </text>
<text top="366" left="246" width="82" height="19" font="3">spontaneous </text>
<text top="385" left="246" width="67" height="19" font="3">circulation </text>
<text top="403" left="246" width="125" height="19" font="3">(measurable BP and </text>
<text top="422" left="246" width="117" height="19" font="3">pulse) for 1 h after </text>
<text top="440" left="246" width="91" height="19" font="3">in-hospital CA  </text>
<text top="458" left="246" width="3" height="19" font="3"> </text>
<text top="476" left="246" width="105" height="19" font="4"><b>Study type:</b> RCT, </text>
<text top="495" left="246" width="124" height="19" font="3">placebo controlled   </text>
<text top="513" left="246" width="3" height="19" font="3"> </text>
<text top="531" left="246" width="115" height="19" font="4"><b>Size:</b>  156 patients<b> </b></text>
<text top="311" left="390" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="330" left="390" width="140" height="19" font="3">Adult patients with CA </text>
<text top="348" left="390" width="132" height="19" font="3">in the ICU or hospital </text>
<text top="366" left="390" width="44" height="19" font="3">wards  </text>
<text top="385" left="390" width="3" height="19" font="3"> </text>
<text top="403" left="390" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="422" left="390" width="139" height="19" font="3">Patients in emergency </text>
<text top="440" left="390" width="144" height="19" font="3">department. Advanced </text>
<text top="458" left="390" width="124" height="19" font="3">heart block, chronic </text>
<text top="476" left="390" width="149" height="19" font="3">renal failure, already on </text>
<text top="495" left="390" width="74" height="19" font="3">magnesium<b> </b></text>
<text top="311" left="553" width="101" height="19" font="4"><b>Intervention:</b> IV </text>
<text top="330" left="553" width="110" height="19" font="3">magnesium bolus </text>
<text top="348" left="553" width="115" height="19" font="3">followed by a 24 h </text>
<text top="366" left="553" width="52" height="19" font="3">infusion </text>
<text top="385" left="553" width="7" height="19" font="3">  </text>
<text top="403" left="553" width="135" height="19" font="4"><b>Comparator:</b>  Normal </text>
<text top="422" left="553" width="42" height="19" font="3">saline<b>  </b></text>
<text top="312" left="703" width="159" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Magnesium </text>
<text top="331" left="703" width="159" height="19" font="3">did not improve return to </text>
<text top="349" left="703" width="154" height="19" font="3">spontaneous circulation: </text>
<text top="367" left="703" width="160" height="19" font="3">54% with magnesium and </text>
<text top="386" left="703" width="145" height="19" font="3">60% with placebo (95% </text>
<text top="404" left="703" width="137" height="19" font="3">CI: 0.41–0.47; p=0.44) </text>
<text top="422" left="703" width="3" height="19" font="3"> </text>
<text top="441" left="703" width="3" height="19" font="4"><b> </b></text>
<text top="312" left="879" width="192" height="19" font="3">● No benefit of magnesium for </text>
<text top="330" left="879" width="165" height="19" font="3">survival to 24 h or hospital </text>
<text top="348" left="879" width="62" height="19" font="3">discharge </text>
<text top="366" left="879" width="129" height="19" font="3">● No adverse effects </text>
<text top="385" left="879" width="3" height="19" font="3"> </text>
<text top="403" left="879" width="3" height="19" font="3"> </text>
<text top="550" left="123" width="104" height="19" font="3">● Somberg et al. </text>
<text top="569" left="123" width="73" height="19" font="3">2002 (106)  </text>
<text top="587" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=12372573">● </a></text>
<text top="587" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=12372573">12372573</a></text>
<text top="587" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=12372573"> </a></text>
<text top="605" left="123" width="3" height="19" font="3"> </text>
<text top="624" left="123" width="3" height="19" font="3"> </text>
<text top="550" left="246" width="113" height="19" font="4"><b>Aim:</b> Establish the </text>
<text top="569" left="246" width="115" height="19" font="3">effectiveness of IV </text>
<text top="587" left="246" width="98" height="19" font="3">amiodarone for </text>
<text top="605" left="246" width="128" height="19" font="3">shock resistant VT.    </text>
<text top="624" left="246" width="3" height="19" font="3"> </text>
<text top="642" left="246" width="105" height="19" font="4"><b>Study type:</b> RCT, </text>
<text top="660" left="246" width="100" height="19" font="3">double-blinded, </text>
<text top="679" left="246" width="98" height="19" font="3">parallel design   </text>
<text top="697" left="246" width="3" height="19" font="3"> </text>
<text top="715" left="246" width="107" height="19" font="4"><b>Size:</b>  29 patients<b> </b></text>
<text top="550" left="390" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="569" left="390" width="144" height="19" font="3">Patients with incessant </text>
<text top="587" left="390" width="147" height="19" font="3">(shock resistant) VT not </text>
<text top="605" left="390" width="112" height="19" font="3">treated with prior </text>
<text top="624" left="390" width="100" height="19" font="3">antiarrhythmics </text>
<text top="642" left="390" width="3" height="19" font="3"> </text>
<text top="660" left="390" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="679" left="390" width="99" height="19" font="3">Already on AAD<b> </b></text>
<text top="550" left="553" width="101" height="19" font="4"><b>Intervention:</b> IV </text>
<text top="569" left="553" width="114" height="19" font="3">amiodarone (or IV </text>
<text top="587" left="553" width="120" height="19" font="3">lidocaine) followed </text>
<text top="605" left="553" width="130" height="19" font="3">by a 24 h infusion.  If </text>
<text top="624" left="553" width="123" height="19" font="3">the first medication </text>
<text top="642" left="553" width="118" height="19" font="3">failed to terminate </text>
<text top="660" left="553" width="110" height="19" font="3">VT, patients were </text>
<text top="679" left="553" width="121" height="19" font="3">crossed over to the </text>
<text top="697" left="553" width="69" height="19" font="3">alternative </text>
<text top="715" left="553" width="76" height="19" font="3">medication. </text>
<text top="733" left="553" width="7" height="19" font="3">  </text>
<text top="752" left="553" width="83" height="19" font="4"><b>Comparator:</b> </text>
<text top="770" left="553" width="65" height="19" font="3">Lidocaine <b> </b></text>
<text top="551" left="703" width="85" height="19" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="570" left="703" width="142" height="19" font="3">Amiodarone was more </text>
<text top="588" left="703" width="150" height="19" font="3">effective than lidocaine: </text>
<text top="606" left="703" width="149" height="19" font="3">amiodarone terminated </text>
<text top="624" left="703" width="148" height="19" font="3">VT in 78% and lidocaine </text>
<text top="643" left="703" width="154" height="19" font="3">27% (p&lt;0.01).  OR and CI </text>
<text top="661" left="703" width="144" height="19" font="3">not listed. 24 h survival </text>
<text top="679" left="703" width="152" height="19" font="3">39% on amiodarone and </text>
<text top="698" left="703" width="157" height="19" font="3">9% on lidocaine (p&lt;0.01). </text>
<text top="716" left="703" width="146" height="19" font="3">More hypotension with </text>
<text top="734" left="703" width="90" height="19" font="3">lidocaine than </text>
<text top="753" left="703" width="156" height="19" font="3">amiodarone (28% vs. 7%, </text>
<text top="550" left="879" width="154" height="19" font="3">● Amiodarone was more </text>
<text top="569" left="879" width="167" height="19" font="3">effective than lidocaine for </text>
<text top="587" left="879" width="187" height="19" font="3">terminating VT with improved </text>
<text top="605" left="879" width="84" height="19" font="3">24 h survival. </text>
<text top="624" left="879" width="167" height="19" font="3">● Limitations: Drug related </text>
<text top="642" left="879" width="187" height="19" font="3">hypotension with amiodarone </text>
<text top="660" left="879" width="145" height="19" font="3">less frequent than with </text>
<text top="679" left="879" width="62" height="19" font="3">lidocaine. </text>
<text top="697" left="879" width="3" height="19" font="3"> </text>
<text top="715" left="879" width="3" height="19" font="3"> </text>
</page>
<page number="55" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">55 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="703" width="133" height="19" font="3">p=0.06).  Bradycardia </text>
<text top="127" left="703" width="37" height="19" font="3">equal </text>
<text top="195" left="123" width="99" height="19" font="3">● Kudenchuk et </text>
<text top="213" left="123" width="87" height="19" font="3">al. 1999 (107) </text>
<text top="232" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=10486418">● </a></text>
<text top="232" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=10486418">10486418</a></text>
<text top="232" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=10486418"> </a></text>
<text top="250" left="123" width="3" height="19" font="3"> </text>
<text top="268" left="123" width="3" height="19" font="3"> </text>
<text top="195" left="246" width="112" height="19" font="4"><b>Aim:</b> Determine if </text>
<text top="213" left="246" width="77" height="19" font="3">amiodarone </text>
<text top="232" left="246" width="128" height="19" font="3">improves the rate of </text>
<text top="250" left="246" width="65" height="19" font="3">successful </text>
<text top="268" left="246" width="115" height="19" font="3">resuscitation after </text>
<text top="287" left="246" width="43" height="19" font="3">OHCA  </text>
<text top="305" left="246" width="3" height="19" font="3"> </text>
<text top="323" left="246" width="105" height="19" font="4"><b>Study type:</b> RCT, </text>
<text top="341" left="246" width="99" height="19" font="3">double blinded, </text>
<text top="360" left="246" width="124" height="19" font="3">placebo controlled   </text>
<text top="378" left="246" width="3" height="19" font="3"> </text>
<text top="396" left="246" width="125" height="19" font="4"><b>Size:  </b>504 patients   <b> </b></text>
<text top="195" left="390" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="213" left="390" width="149" height="19" font="3">Patients &lt;18 with OHCA </text>
<text top="232" left="390" width="137" height="19" font="3">due to VF or pulseless </text>
<text top="250" left="390" width="110" height="19" font="3">VT that remained </text>
<text top="268" left="390" width="149" height="19" font="3">present after ≥3 shocks, </text>
<text top="287" left="390" width="92" height="19" font="3">with IV access  </text>
<text top="305" left="390" width="3" height="19" font="3"> </text>
<text top="323" left="390" width="113" height="19" font="4"><b>Exclusion criteria: </b></text>
<text top="341" left="390" width="133" height="19" font="3">Absence of IV access, </text>
<text top="360" left="390" width="120" height="19" font="3">VF, or pulseless VT <b> </b></text>
<text top="195" left="553" width="101" height="19" font="4"><b>Intervention:</b> IV </text>
<text top="213" left="553" width="120" height="19" font="3">amiodarone (single </text>
<text top="232" left="553" width="128" height="19" font="3">dose) after receiving </text>
<text top="250" left="553" width="111" height="19" font="3">1 mg epinephrine </text>
<text top="268" left="553" width="7" height="19" font="3">  </text>
<text top="286" left="553" width="86" height="19" font="4"><b>Comparator:</b>  </text>
<text top="305" left="553" width="132" height="19" font="3">Placebo (polysorbate </text>
<text top="323" left="553" width="116" height="19" font="3">80, dilutant, single </text>
<text top="341" left="553" width="128" height="19" font="3">dose) after receiving </text>
<text top="360" left="553" width="111" height="19" font="3">1 mg epinephrine<b> </b></text>
<text top="196" left="703" width="160" height="19" font="4"><b>1</b>°<b> endpoint:</b> Amiodarone </text>
<text top="214" left="703" width="128" height="19" font="3">improved survival to </text>
<text top="232" left="703" width="150" height="19" font="3">hospital admission: 44% </text>
<text top="251" left="703" width="152" height="19" font="3">on amiodarone and 34% </text>
<text top="269" left="703" width="156" height="19" font="3">on placebo (OR: 1.6; 95% </text>
<text top="287" left="703" width="122" height="19" font="3">CI: 1.1–2.4; p=0.02) </text>
<text top="306" left="703" width="3" height="19" font="4"><b> </b></text>
<text top="195" left="879" width="153" height="19" font="3">● Amiodarone improved </text>
<text top="213" left="879" width="168" height="19" font="3">survival to hospital with no </text>
<text top="232" left="879" width="152" height="19" font="3">difference in duration of </text>
<text top="250" left="879" width="153" height="19" font="3">resuscitation, number of </text>
<text top="268" left="879" width="140" height="19" font="3">shocks, need for other </text>
<text top="287" left="879" width="100" height="19" font="3">antiarrhythmics </text>
<text top="305" left="879" width="195" height="19" font="3">● Limitations: lack for power to </text>
<text top="323" left="879" width="166" height="19" font="3">detect treatment effect on </text>
<text top="341" left="879" width="180" height="19" font="3">survival to hospital discharge </text>
<text top="360" left="879" width="159" height="19" font="3">● More hypotension with </text>
<text top="378" left="879" width="164" height="19" font="3">amiodarone (59% vs. 48%, </text>
<text top="396" left="879" width="50" height="19" font="3">p=0.04) </text>
<text top="415" left="879" width="3" height="19" font="3"> </text>
<text top="433" left="879" width="3" height="19" font="3"> </text>
<text top="452" left="123" width="106" height="19" font="3">● Callaham et al. </text>
<text top="470" left="123" width="73" height="19" font="3">1992 (108)  </text>
<text top="489" left="123" width="16" height="19" font="3">● <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=1433686"> </a></text>
<text top="489" left="139" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=1433686">1433686</a></text>
<text top="489" left="192" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=1433686"> </a></text>
<text top="507" left="123" width="3" height="19" font="3"> </text>
<text top="525" left="123" width="3" height="19" font="3"> </text>
<text top="452" left="246" width="118" height="19" font="4"><b>Aim:</b> To determine </text>
<text top="470" left="246" width="123" height="19" font="3">the relative efficacy </text>
<text top="489" left="246" width="123" height="19" font="3">of high vs. standard </text>
<text top="507" left="246" width="32" height="19" font="3">dose </text>
<text top="525" left="246" width="113" height="19" font="3">catecholamines in </text>
<text top="544" left="246" width="119" height="19" font="3">initial treatment of </text>
<text top="562" left="246" width="43" height="19" font="3">OHCA  </text>
<text top="580" left="246" width="3" height="19" font="3"> </text>
<text top="598" left="246" width="105" height="19" font="4"><b>Study type:</b> RCT, </text>
<text top="617" left="246" width="87" height="19" font="3">double blind   </text>
<text top="635" left="246" width="3" height="19" font="3"> </text>
<text top="653" left="246" width="115" height="19" font="4"><b>Size:</b>  816 patients<b> </b></text>
<text top="452" left="390" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="470" left="390" width="142" height="19" font="3">Adults with OHCA who </text>
<text top="489" left="390" width="89" height="19" font="3">would receive </text>
<text top="507" left="390" width="125" height="19" font="3">epinephrine by AHA </text>
<text top="525" left="390" width="98" height="19" font="3">ACLS guidelines </text>
<text top="544" left="390" width="3" height="19" font="3"> </text>
<text top="562" left="390" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="580" left="390" width="73" height="19" font="3">None listed<b> </b></text>
<text top="452" left="553" width="117" height="19" font="4"><b>Intervention:</b> High </text>
<text top="470" left="553" width="133" height="19" font="3">dose epinephrine (15 </text>
<text top="489" left="553" width="93" height="19" font="3">mg), high dose </text>
<text top="507" left="553" width="121" height="19" font="3">norepinephrine (11 </text>
<text top="525" left="553" width="105" height="19" font="3">mg), or standard </text>
<text top="544" left="553" width="110" height="19" font="3">dose epinephrine </text>
<text top="562" left="553" width="117" height="19" font="3">blindly substituted </text>
<text top="580" left="553" width="109" height="19" font="3">for ACLS doses of </text>
<text top="599" left="553" width="81" height="19" font="3">epinephrine  </text>
<text top="617" left="553" width="7" height="19" font="3">  </text>
<text top="635" left="553" width="83" height="19" font="4"><b>Comparator</b>: </text>
<text top="653" left="553" width="90" height="19" font="3">standard dose </text>
<text top="672" left="553" width="101" height="19" font="3">epinephrine (no </text>
<text top="690" left="553" width="59" height="19" font="3">placebo) <b> </b></text>
<text top="453" left="703" width="148" height="19" font="4"><b>1</b>°<b> endpoint:</b>  High dose </text>
<text top="471" left="703" width="153" height="19" font="3">epinephrine significantly </text>
<text top="489" left="703" width="130" height="19" font="3">improved the rate of </text>
<text top="508" left="703" width="140" height="19" font="3">return of spontaneous </text>
<text top="526" left="703" width="152" height="19" font="3">circulation: 13% for high </text>
<text top="544" left="703" width="135" height="19" font="3">dose epinephrine, 8% </text>
<text top="563" left="703" width="148" height="19" font="3">receiving standard dose </text>
<text top="581" left="703" width="135" height="19" font="3">epinephrine (p=0.01). </text>
<text top="599" left="703" width="107" height="19" font="3">18% of high dose </text>
<text top="618" left="703" width="149" height="19" font="3">epinephrine and 10% of </text>
<text top="636" left="703" width="90" height="19" font="3">standard dose </text>
<text top="654" left="703" width="130" height="19" font="3">epinephrine patients </text>
<text top="673" left="703" width="128" height="19" font="3">admitted to hospital </text>
<text top="691" left="703" width="55" height="19" font="3">(p=0.02) </text>
<text top="709" left="703" width="3" height="19" font="4"><b> </b></text>
<text top="452" left="879" width="153" height="19" font="3">● High dose epinephrine </text>
<text top="470" left="879" width="195" height="19" font="3">improved admission to hospital </text>
<text top="489" left="879" width="182" height="19" font="3">but no difference in dismissal </text>
<text top="507" left="879" width="89" height="19" font="3">from hospital  </text>
<text top="525" left="879" width="177" height="19" font="3">● Trends for norepinephrine </text>
<text top="544" left="879" width="115" height="19" font="3">were not different </text>
<text top="562" left="879" width="165" height="19" font="3">● Limitations: low hospital </text>
<text top="580" left="879" width="87" height="19" font="3">dismissal rate </text>
<text top="599" left="879" width="129" height="19" font="3">● No adverse effects </text>
<text top="617" left="879" width="3" height="19" font="3"> </text>
<text top="635" left="879" width="3" height="19" font="3"> </text>
</page>
<page number="56" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">56 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="106" height="19" font="3">● Gueugniaud et </text>
<text top="127" left="123" width="90" height="19" font="3">al. 1998 (109)  </text>
<text top="145" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=9828247">● </a></text>
<text top="145" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=9828247">9828247</a></text>
<text top="145" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=9828247"> </a></text>
<text top="164" left="123" width="3" height="19" font="3"> </text>
<text top="109" left="246" width="93" height="19" font="4"><b>Aim: </b> compare </text>
<text top="127" left="246" width="117" height="19" font="3">repeated low dose </text>
<text top="145" left="246" width="78" height="19" font="3">vs high dose </text>
<text top="164" left="246" width="92" height="19" font="3">epinephrine in </text>
<text top="182" left="246" width="39" height="19" font="3">OHCA </text>
<text top="200" left="246" width="3" height="19" font="4"><b> </b></text>
<text top="218" left="246" width="78" height="19" font="4"><b>Study type:  </b></text>
<text top="237" left="246" width="78" height="19" font="3">Prospective, </text>
<text top="255" left="246" width="78" height="19" font="3">multicenter, </text>
<text top="273" left="246" width="76" height="19" font="3">randomized </text>
<text top="292" left="246" width="3" height="19" font="4"><b> </b></text>
<text top="310" left="246" width="122" height="19" font="4"><b>Size</b>: 3327 patients <b> </b></text>
<text top="109" left="390" width="115" height="19" font="4"><b>Inclusion criteria</b>:  </text>
<text top="127" left="390" width="123" height="19" font="3">OHCA patients with </text>
<text top="145" left="390" width="89" height="19" font="3">VF/VT despite </text>
<text top="164" left="390" width="146" height="19" font="3">defibrillation shocks, or </text>
<text top="182" left="390" width="136" height="19" font="3">asystole /hypotensive </text>
<text top="200" left="390" width="19" height="19" font="3">VT </text>
<text top="219" left="390" width="3" height="19" font="3"> </text>
<text top="237" left="390" width="117" height="19" font="4"><b>Exclusion criteria:  </b></text>
<text top="255" left="390" width="104" height="19" font="3">Inadequate data<b> </b></text>
<text top="109" left="553" width="117" height="19" font="4"><b>Intervention: </b>High </text>
<text top="127" left="553" width="124" height="19" font="3">dose epinephrine, 5 </text>
<text top="145" left="553" width="119" height="19" font="3">mg, up to 15 doses </text>
<text top="164" left="553" width="7" height="19" font="3">  </text>
<text top="182" left="553" width="89" height="19" font="4"><b>Comparator</b>:   </text>
<text top="200" left="553" width="90" height="19" font="3">standard dose </text>
<text top="219" left="553" width="118" height="19" font="3">epinephrine, 1 mg, </text>
<text top="237" left="553" width="93" height="19" font="3">following ACLS </text>
<text top="255" left="553" width="58" height="19" font="3">protocol <b> </b></text>
<text top="109" left="703" width="138" height="19" font="4"><b>1</b>°<b> endpoint:</b> 40.4% of </text>
<text top="128" left="703" width="155" height="19" font="3">1677 patients in the high </text>
<text top="146" left="703" width="151" height="19" font="3">dose group had a return </text>
<text top="165" left="703" width="98" height="19" font="3">of spontaneous </text>
<text top="183" left="703" width="149" height="19" font="3">circulation compared to </text>
<text top="201" left="703" width="158" height="19" font="3">36.4% of 1650 patients in </text>
<text top="219" left="703" width="153" height="19" font="3">the standard dose group </text>
<text top="238" left="703" width="143" height="19" font="3">(p=0.02). There was no </text>
<text top="256" left="703" width="147" height="19" font="3">difference in survival to </text>
<text top="274" left="703" width="151" height="19" font="3">hospital discharge (2.3% </text>
<text top="293" left="703" width="107" height="19" font="3">vs 2.8%. p=0.34). </text>
<text top="311" left="703" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="879" width="162" height="19" font="3">● Long-term survival after </text>
<text top="127" left="879" width="158" height="19" font="3">OHCA was no better with </text>
<text top="145" left="879" width="143" height="19" font="3">repeated high doses of </text>
<text top="164" left="879" width="139" height="19" font="3">epinephrine than with </text>
<text top="182" left="879" width="159" height="19" font="3">repeated standard doses. </text>
<text top="200" left="879" width="3" height="19" font="3"> </text>
<text top="219" left="879" width="3" height="19" font="3"> </text>
<text top="330" left="123" width="96" height="19" font="3">● Gorgels et al. </text>
<text top="348" left="123" width="73" height="19" font="3">1996 (110)  </text>
<text top="367" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=8712116">● </a></text>
<text top="367" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=8712116">8712116</a></text>
<text top="367" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=8712116"> </a></text>
<text top="385" left="123" width="3" height="19" font="3"> </text>
<text top="403" left="123" width="3" height="19" font="3"> </text>
<text top="330" left="246" width="128" height="19" font="4"><b>Aim:</b>  Determine the </text>
<text top="348" left="246" width="115" height="19" font="3">relative efficacy of </text>
<text top="367" left="246" width="113" height="19" font="3">procainamide and </text>
<text top="385" left="246" width="79" height="19" font="3">lidocaine for </text>
<text top="403" left="246" width="52" height="19" font="3">treating </text>
<text top="422" left="246" width="82" height="19" font="3">spontaneous </text>
<text top="440" left="246" width="109" height="19" font="3">monomorphic VT </text>
<text top="458" left="246" width="3" height="19" font="3"> </text>
<text top="476" left="246" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="495" left="246" width="117" height="19" font="3">Randomized, open </text>
<text top="513" left="246" width="129" height="19" font="3">label, parallel study   </text>
<text top="531" left="246" width="3" height="19" font="3"> </text>
<text top="550" left="246" width="107" height="19" font="4"><b>Size:</b>  29 patients<b> </b></text>
<text top="330" left="390" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="348" left="390" width="120" height="19" font="3">Adult patients with </text>
<text top="367" left="390" width="82" height="19" font="3">spontaneous </text>
<text top="385" left="390" width="109" height="19" font="3">monomorphic VT </text>
<text top="403" left="390" width="3" height="19" font="3"> </text>
<text top="421" left="390" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="440" left="390" width="138" height="19" font="3">Patients with AMI and </text>
<text top="458" left="390" width="100" height="19" font="3">those with poor </text>
<text top="476" left="390" width="90" height="19" font="3">hemodynamic </text>
<text top="495" left="390" width="61" height="19" font="3">tolerance<b> </b></text>
<text top="330" left="553" width="101" height="19" font="4"><b>Intervention:</b> IV </text>
<text top="348" left="553" width="110" height="19" font="3">procainamide (10 </text>
<text top="367" left="553" width="84" height="19" font="3">mg/kg at 100 </text>
<text top="385" left="553" width="131" height="19" font="3">mg/min) or lidocaine </text>
<text top="403" left="553" width="111" height="19" font="3">(1.5 mg/kg over 2 </text>
<text top="422" left="553" width="31" height="19" font="3">min) </text>
<text top="440" left="553" width="7" height="19" font="3">  </text>
<text top="458" left="553" width="89" height="19" font="4"><b>Comparator:</b>   </text>
<text top="476" left="553" width="103" height="19" font="3">Procainamide or </text>
<text top="495" left="553" width="82" height="19" font="3">lidocaine (no </text>
<text top="513" left="553" width="56" height="19" font="3">placebo)<b> </b></text>
<text top="331" left="703" width="85" height="19" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="349" left="703" width="150" height="19" font="3">Procainamide was more </text>
<text top="367" left="703" width="150" height="19" font="3">effective than lidocaine: </text>
<text top="386" left="703" width="122" height="19" font="3">27% of VT episodes </text>
<text top="404" left="703" width="143" height="19" font="3">responded to lidocaine </text>
<text top="422" left="703" width="159" height="19" font="3">and 77% to procainamide </text>
<text top="441" left="703" width="55" height="19" font="3">(p&lt;0.01) </text>
<text top="459" left="703" width="3" height="19" font="3"> </text>
<text top="477" left="703" width="3" height="19" font="4"><b> </b></text>
<text top="330" left="879" width="181" height="19" font="3">● Procainamide was superior </text>
<text top="348" left="879" width="190" height="19" font="3">to lidocaine for terminating VT </text>
<text top="367" left="879" width="192" height="19" font="3">● Limitations: No patients with </text>
<text top="385" left="879" width="102" height="19" font="3">AMI or ischemia </text>
<text top="403" left="879" width="171" height="19" font="3">● Significant lengthening of </text>
<text top="422" left="879" width="182" height="19" font="3">QRS and QT on procainamide </text>
<text top="440" left="879" width="3" height="19" font="3"> </text>
<text top="458" left="879" width="3" height="19" font="3"> </text>
<text top="569" left="123" width="97" height="19" font="3">● Ho et al. 1994</text>
<text top="567" left="220" width="4" height="21" font="0"> </text>
<text top="587" left="123" width="39" height="19" font="3">(111)  </text>
<text top="605" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=7912296">● </a></text>
<text top="605" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=7912296">7912296</a></text>
<text top="605" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=7912296"> </a></text>
<text top="624" left="123" width="3" height="19" font="3"> </text>
<text top="642" left="123" width="3" height="19" font="3"> </text>
<text top="569" left="246" width="128" height="19" font="4"><b>Aim:</b>  Determine the </text>
<text top="587" left="246" width="115" height="19" font="3">relative efficacy of </text>
<text top="605" left="246" width="129" height="19" font="3">lidocaine and sotalol </text>
<text top="624" left="246" width="96" height="19" font="3">for terminating </text>
<text top="642" left="246" width="125" height="19" font="3">spontaneous VT not </text>
<text top="660" left="246" width="69" height="19" font="3">causing CA </text>
<text top="679" left="246" width="3" height="19" font="3"> </text>
<text top="697" left="246" width="105" height="19" font="4"><b>Study type:</b> RCT, </text>
<text top="715" left="246" width="87" height="19" font="3">double blind   </text>
<text top="733" left="246" width="3" height="19" font="3"> </text>
<text top="752" left="246" width="107" height="19" font="4"><b>Size:</b>  33 patients<b> </b></text>
<text top="569" left="390" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="587" left="390" width="120" height="19" font="3">Adult patients with </text>
<text top="605" left="390" width="81" height="19" font="3">sustained VT </text>
<text top="624" left="390" width="3" height="19" font="3"> </text>
<text top="642" left="390" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="660" left="390" width="88" height="19" font="3">Already on an </text>
<text top="679" left="390" width="98" height="19" font="3">antiarrhythmic, </text>
<text top="697" left="390" width="138" height="19" font="3">hypotension requiring </text>
<text top="715" left="390" width="69" height="19" font="3">immediate </text>
<text top="734" left="390" width="134" height="19" font="3">cardioversion, known </text>
<text top="752" left="390" width="121" height="19" font="3">adverse reaction to </text>
<text top="770" left="390" width="120" height="19" font="3">either medicantion<b> </b></text>
<text top="569" left="553" width="101" height="19" font="4"><b>Intervention: </b>IV </text>
<text top="587" left="553" width="102" height="19" font="3">sotalol (100 mg) </text>
<text top="605" left="553" width="7" height="19" font="3">  </text>
<text top="624" left="553" width="105" height="19" font="4"><b>Comparator:</b>  <b> </b>IV </text>
<text top="642" left="553" width="119" height="19" font="3">lidocaine (100 mg)  </text>
<text top="660" left="553" width="3" height="19" font="3"> </text>
<text top="679" left="553" width="131" height="19" font="3">Cross-over to second </text>
<text top="697" left="553" width="122" height="19" font="3">drug if VT persisted </text>
<text top="715" left="553" width="78" height="19" font="3">after 15 min<b> </b></text>
<text top="569" left="703" width="157" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Sotalol was </text>
<text top="588" left="703" width="124" height="19" font="3">more effective than </text>
<text top="606" left="703" width="154" height="19" font="3">lidocaine for terminating </text>
<text top="624" left="703" width="154" height="19" font="3">VT: 69% with sotalol and </text>
<text top="643" left="703" width="152" height="19" font="3">18% with lidocaine (95% </text>
<text top="661" left="703" width="143" height="19" font="3">CI: 22%–80%; p=0.003) </text>
<text top="679" left="703" width="3" height="19" font="3"> </text>
<text top="698" left="703" width="3" height="19" font="4"><b> </b></text>
<text top="569" left="879" width="114" height="19" font="3">● No 2° endpoints </text>
<text top="587" left="879" width="158" height="19" font="3">● Limitations: no placebo </text>
<text top="605" left="879" width="154" height="19" font="3">control; small number of </text>
<text top="624" left="879" width="53" height="19" font="3">patients </text>
<text top="642" left="879" width="180" height="19" font="3">● 1 death in each drug group </text>
<text top="660" left="879" width="192" height="19" font="3">after the first drug and 1 death </text>
<text top="679" left="879" width="189" height="19" font="3">in each group after both drugs </text>
<text top="697" left="879" width="3" height="19" font="3"> </text>
<text top="715" left="879" width="3" height="19" font="3"> </text>
</page>
<page number="57" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">57 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="92" height="19" font="3">● Levine et al., </text>
<text top="127" left="123" width="73" height="19" font="3">1996 (112)  </text>
<text top="145" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=8522712">● </a></text>
<text top="145" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=8522712">8522712</a></text>
<text top="145" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=8522712"> </a></text>
<text top="164" left="123" width="3" height="19" font="3"> </text>
<text top="182" left="123" width="3" height="19" font="3"> </text>
<text top="109" left="246" width="123" height="19" font="4"><b>Aim:</b> Response rate </text>
<text top="127" left="246" width="67" height="19" font="3">and safety </text>
<text top="145" left="246" width="92" height="19" font="3">of intravenous </text>
<text top="164" left="246" width="92" height="19" font="3">amiodarone in </text>
<text top="182" left="246" width="103" height="19" font="3">patients with VT </text>
<text top="200" left="246" width="81" height="19" font="3">refractory to </text>
<text top="219" left="246" width="122" height="19" font="3">standard therapies. </text>
<text top="237" left="246" width="3" height="19" font="4"><b> </b></text>
<text top="255" left="246" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="273" left="246" width="78" height="19" font="3">prospective, </text>
<text top="292" left="246" width="66" height="19" font="3">controlled </text>
<text top="310" left="246" width="3" height="19" font="4"><b> </b></text>
<text top="328" left="246" width="111" height="19" font="4"><b>Size:</b> 273 patients<b> </b></text>
<text top="109" left="390" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="127" left="390" width="145" height="19" font="3">Patients with recurrent </text>
<text top="145" left="390" width="97" height="19" font="3">hypotensive VT </text>
<text top="164" left="390" width="143" height="19" font="3">refractory to lidocaine, </text>
<text top="182" left="390" width="113" height="19" font="3">procainamide and </text>
<text top="200" left="390" width="66" height="19" font="3">bretylium. </text>
<text top="218" left="390" width="3" height="19" font="4"><b> </b></text>
<text top="237" left="390" width="117" height="19" font="4"><b>Exclusion criteria:  </b></text>
<text top="255" left="390" width="118" height="19" font="3">Cardiogenic shock; </text>
<text top="273" left="390" width="114" height="19" font="3">significant hepatic </text>
<text top="292" left="390" width="91" height="19" font="3">dysfunction or </text>
<text top="310" left="390" width="141" height="19" font="3">pulmonary disease; Hx </text>
<text top="329" left="390" width="134" height="19" font="3">of TdP; congenital QT </text>
<text top="347" left="390" width="86" height="19" font="3">prolongation; </text>
<text top="365" left="390" width="149" height="19" font="3">bradyarrhythmias or AV </text>
<text top="383" left="390" width="82" height="19" font="3">block (unless </text>
<text top="402" left="390" width="130" height="19" font="3">pacemaker present).<b> </b></text>
<text top="109" left="553" width="85" height="19" font="4"><b>Intervention:</b> </text>
<text top="127" left="553" width="53" height="19" font="3">Patients </text>
<text top="145" left="553" width="127" height="19" font="3">were randomized to </text>
<text top="164" left="553" width="124" height="19" font="3">receive 1 of 3 doses </text>
<text top="182" left="553" width="92" height="19" font="3">of intravenous </text>
<text top="200" left="553" width="111" height="19" font="3">amiodarone: 525, </text>
<text top="219" left="553" width="135" height="19" font="3">1,050 or 2,100 mg/24 </text>
<text top="237" left="553" width="101" height="19" font="3">h by continuous </text>
<text top="255" left="553" width="117" height="19" font="3">infusion over 24 h. </text>
<text top="273" left="553" width="3" height="19" font="4"><b> </b></text>
<text top="292" left="553" width="100" height="19" font="4"><b>Comparator:</b> As </text>
<text top="310" left="553" width="44" height="19" font="3">above<b>  </b></text>
<text top="109" left="703" width="161" height="19" font="4"><b>1</b>°<b> endpoint: </b>110 patients </text>
<text top="128" left="703" width="134" height="19" font="3">(40.3%) survived 24 h </text>
<text top="146" left="703" width="103" height="19" font="3">without another </text>
<text top="165" left="703" width="148" height="19" font="3">hypotensive VT episode </text>
<text top="183" left="703" width="3" height="19" font="4"><b> </b></text>
<text top="201" left="703" width="159" height="19" font="4"><b>Safety endpoint:</b> Adverse </text>
<text top="219" left="703" width="134" height="19" font="3">events requiring drug </text>
<text top="238" left="703" width="98" height="19" font="3">discontinuation </text>
<text top="256" left="703" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="879" width="179" height="19" font="3">● Significantly longer time to </text>
<text top="127" left="879" width="189" height="19" font="3">first recurrence in the 2 higher </text>
<text top="145" left="879" width="78" height="19" font="3">dose groups </text>
<text top="164" left="879" width="149" height="19" font="3">● Hypotension required </text>
<text top="182" left="879" width="161" height="19" font="3">vasopressor therapy in 38 </text>
<text top="200" left="879" width="195" height="19" font="3">patients (14%) and led to death </text>
<text top="219" left="879" width="60" height="19" font="3">in 6 (2%). </text>
<text top="237" left="879" width="3" height="19" font="3"> </text>
<text top="255" left="879" width="3" height="19" font="3"> </text>
<text top="421" left="123" width="109" height="19" font="3">●  Teo et al. 1993 </text>
<text top="439" left="123" width="39" height="19" font="3">(113)  </text>
<text top="457" left="123" width="16" height="19" font="3">● <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=8371471"> </a></text>
<text top="457" left="139" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=8371471">8371471</a></text>
<text top="457" left="192" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=8371471"> </a></text>
<text top="476" left="123" width="3" height="19" font="3"> </text>
<text top="421" left="246" width="103" height="19" font="4"><b>Aim: </b> Assess the </text>
<text top="439" left="246" width="129" height="19" font="3">effectiveness of AAD </text>
<text top="457" left="246" width="93" height="19" font="3">on mortality in </text>
<text top="476" left="246" width="112" height="19" font="3">patients with AMI </text>
<text top="494" left="246" width="3" height="19" font="4"><b> </b></text>
<text top="512" left="246" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="531" left="246" width="76" height="19" font="3">Metanalysis </text>
<text top="549" left="246" width="3" height="19" font="4"><b> </b></text>
<text top="567" left="246" width="58" height="19" font="4"><b>Size:</b> 138 </text>
<text top="586" left="246" width="113" height="19" font="3">randomized trials, </text>
<text top="604" left="246" width="98" height="19" font="3">98,000 patients<b> </b></text>
<text top="421" left="390" width="114" height="19" font="4"><b>Inclusion criteria</b>:  </text>
<text top="439" left="390" width="112" height="19" font="3">Patients with AMI </text>
<text top="457" left="390" width="122" height="19" font="3">randomized to AAD </text>
<text top="476" left="390" width="51" height="19" font="3">therapy </text>
<text top="494" left="390" width="3" height="19" font="3"> </text>
<text top="512" left="390" width="117" height="19" font="4"><b>Exclusion criteria:  </b></text>
<text top="531" left="390" width="110" height="19" font="3">Inadequate study </text>
<text top="549" left="390" width="43" height="19" font="3">design<b> </b></text>
<text top="421" left="553" width="115" height="19" font="4"><b>Intervention: </b>AAD </text>
<text top="439" left="553" width="7" height="19" font="3">  </text>
<text top="457" left="553" width="93" height="19" font="4"><b>Comparator</b>:    </text>
<text top="476" left="553" width="113" height="19" font="3">Placebo, standard </text>
<text top="494" left="553" width="44" height="19" font="3">agents<b> </b></text>
<text top="421" left="703" width="152" height="19" font="4"><b>1</b>°<b> endpoint:</b> 660 deaths </text>
<text top="440" left="703" width="113" height="19" font="3">in 11,712 patients </text>
<text top="458" left="703" width="143" height="19" font="3">receiving Class I agents </text>
<text top="476" left="703" width="157" height="19" font="3">and 571 deaths in 11,517 </text>
<text top="495" left="703" width="146" height="19" font="3">controls (OR: 1.14; 95% </text>
<text top="513" left="703" width="141" height="19" font="3">CI: 1.01–1.28; p=0.03). </text>
<text top="531" left="703" width="135" height="19" font="3">778 patients received </text>
<text top="550" left="703" width="156" height="19" font="3">amiodarone and 77 died, </text>
<text top="568" left="703" width="122" height="19" font="3">compared with 101 </text>
<text top="586" left="703" width="133" height="19" font="3">deaths in 779 control </text>
<text top="605" left="703" width="146" height="19" font="3">patients (OR, 0.71; 95% </text>
<text top="623" left="703" width="144" height="19" font="3">CI, 0.51–0.97, p=0.03).  </text>
<text top="641" left="703" width="154" height="19" font="3">26,973 patients received </text>
<text top="660" left="703" width="114" height="19" font="3">BB and 1,464 died </text>
<text top="678" left="703" width="133" height="19" font="3">compared with 1,727 </text>
<text top="696" left="703" width="158" height="19" font="3">deaths in 26,295 controls </text>
<text top="714" left="703" width="146" height="19" font="3">(OR: 0.81; 95% CI, 0.75–</text>
<text top="733" left="703" width="106" height="19" font="3">0.87, p=0.00001) </text>
<text top="421" left="879" width="168" height="19" font="3">● The routine use of Class I </text>
<text top="439" left="879" width="111" height="19" font="3">agents (lidocaine, </text>
<text top="457" left="879" width="186" height="19" font="3">procainamide) was associated </text>
<text top="476" left="879" width="185" height="19" font="3">with increased mortality after </text>
<text top="494" left="879" width="24" height="19" font="3">MI. </text>
<text top="512" left="879" width="140" height="19" font="3">● BB reduced morality </text>
<text top="531" left="879" width="174" height="19" font="3">● The amiodarone data was </text>
<text top="549" left="879" width="147" height="19" font="3">limited “but promising” </text>
<text top="567" left="879" width="3" height="19" font="3"> </text>
<text top="586" left="879" width="3" height="19" font="3"> </text>
</page>
<page number="58" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">58 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="82" height="19" font="3">● Elzari et al. </text>
<text top="127" left="123" width="73" height="19" font="3">2000 (114)  </text>
<text top="145" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=10639301">● </a></text>
<text top="145" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=10639301">10639301</a></text>
<text top="145" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=10639301"> </a></text>
<text top="164" left="123" width="3" height="19" font="3"> </text>
<text top="182" left="123" width="3" height="19" font="3"> </text>
<text top="109" left="246" width="103" height="19" font="4"><b>Aim: </b> Assess the </text>
<text top="127" left="246" width="127" height="19" font="3">mortality associated </text>
<text top="145" left="246" width="123" height="19" font="3">with amiodarone in </text>
<text top="164" left="246" width="112" height="19" font="3">patients with AMI </text>
<text top="182" left="246" width="3" height="19" font="4"><b> </b></text>
<text top="200" left="246" width="117" height="19" font="4"><b>Study type:  </b>Single </text>
<text top="219" left="246" width="123" height="19" font="3">center, randomized </text>
<text top="237" left="246" width="3" height="19" font="4"><b> </b></text>
<text top="255" left="246" width="123" height="19" font="4"><b>Size:</b> 1,073 patients<b> </b></text>
<text top="109" left="390" width="115" height="19" font="4"><b>Inclusion criteria</b>:  </text>
<text top="127" left="390" width="82" height="19" font="3">Acute MI, no </text>
<text top="145" left="390" width="126" height="19" font="3">contraindications to </text>
<text top="164" left="390" width="68" height="19" font="3">study drug </text>
<text top="218" left="390" width="3" height="19" font="3"> </text>
<text top="236" left="390" width="113" height="19" font="4"><b>Exclusion criteria: </b></text>
<text top="255" left="390" width="121" height="19" font="3">Contraindication to </text>
<text top="273" left="390" width="78" height="19" font="3">amiodarone<b> </b></text>
<text top="109" left="553" width="118" height="19" font="4"><b>Intervention</b>: IV or </text>
<text top="127" left="553" width="99" height="19" font="3">PO amiodarone </text>
<text top="145" left="553" width="7" height="19" font="3">  </text>
<text top="164" left="553" width="147" height="19" font="4"><b>Comparator</b>: Placebo    <b> </b></text>
<text top="109" left="703" width="144" height="19" font="4"><b>1</b>°<b> endpoint:</b> The study </text>
<text top="128" left="703" width="142" height="19" font="3">was modified after the </text>
<text top="146" left="703" width="158" height="19" font="3">first 516 patients showed </text>
<text top="165" left="703" width="121" height="19" font="3">higher mortality on </text>
<text top="183" left="703" width="160" height="19" font="3">amiodarone than placebo </text>
<text top="201" left="703" width="125" height="19" font="3">(16.30% vs. 10.16%; </text>
<text top="219" left="703" width="54" height="19" font="3">p=0.04). </text>
<text top="238" left="703" width="3" height="19" font="3"> </text>
<text top="256" left="703" width="107" height="19" font="4"><b>Safety endpoint</b>: </text>
<text top="274" left="703" width="141" height="19" font="3">Increased mortality on </text>
<text top="293" left="703" width="140" height="19" font="3">high dose amiodarone </text>
<text top="109" left="879" width="188" height="19" font="3">● Amiodarone given by IV and </text>
<text top="127" left="879" width="194" height="19" font="3">PO to a total of 2,700 mg in the </text>
<text top="145" left="879" width="137" height="19" font="3">first 48 h after MI was </text>
<text top="164" left="879" width="160" height="19" font="3">associated with increased </text>
<text top="182" left="879" width="63" height="19" font="3">mortality. </text>
<text top="200" left="879" width="173" height="19" font="3">● Reducing the dose by half </text>
<text top="219" left="879" width="155" height="19" font="3">showed amiodarone and </text>
<text top="237" left="879" width="189" height="19" font="3">placebo mortality were similar </text>
<text top="311" left="115" width="4" height="23" font="10"><b> </b></text>
<text top="333" left="115" width="4" height="21" font="2"><b> </b></text>
<text top="389" left="115" width="958" height="21" font="2"><b>Data Supplement 16. Nonrandomized Trials, Observational Studies, and/or Registries Comparing Acute Management of Specific Arrythmias </b></text>
<text top="410" left="115" width="89" height="21" font="2"><b>– (Section 6) </b></text>
<text top="431" left="147" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="449" left="173" width="51" height="19" font="4"><b>Author; </b></text>
<text top="467" left="151" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="431" left="295" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="449" left="325" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="431" left="463" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="431" left="635" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="449" left="647" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="467" left="679" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="431" left="877" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="449" left="906" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="487" left="125" width="120" height="20" font="3">• Piccini et al. 2008 </text>
<text top="506" left="125" width="35" height="19" font="3">(102)<b> </b></text>
<text top="524" left="125" width="10" height="20" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19026290">• </a></text>
<text top="525" left="135" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19026290">19026290</a></text>
<text top="525" left="196" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19026290"> </a></text>
<text top="543" left="125" width="3" height="19" font="3"> </text>
<text top="561" left="125" width="3" height="19" font="3"> </text>
<text top="486" left="286" width="143" height="19" font="4"><b>Study type: </b>Registry of </text>
<text top="505" left="286" width="92" height="19" font="3">patients in the </text>
<text top="523" left="286" width="119" height="19" font="3">VALsartan In Acute </text>
<text top="541" left="286" width="137" height="19" font="3">myocardial iNfarcTion </text>
<text top="560" left="286" width="93" height="19" font="3">trial (VALIANT)<b> </b></text>
<text top="578" left="286" width="3" height="19" font="3"> </text>
<text top="596" left="286" width="111" height="19" font="4"><b>Size:</b> 306 patients </text>
<text top="615" left="286" width="3" height="19" font="4"><b> </b></text>
<text top="486" left="442" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="505" left="442" width="142" height="19" font="3">Patients with AMI who </text>
<text top="523" left="442" width="140" height="19" font="3">experienced sustained </text>
<text top="541" left="442" width="40" height="19" font="3">VT/VF </text>
<text top="560" left="442" width="113" height="19" font="4"><b>Exclusion criteria</b>: </text>
<text top="578" left="442" width="103" height="19" font="3">inadequate data </text>
<text top="486" left="617" width="119" height="19" font="4"><b>1° endpoint: </b>death </text>
<text top="505" left="617" width="181" height="19" font="4"><b>Results </b>306 of 5,391 patients </text>
<text top="523" left="617" width="186" height="19" font="3">(5.7%) in the VALIANT registry </text>
<text top="541" left="617" width="169" height="19" font="3">had sustained VT/VF with a </text>
<text top="560" left="617" width="164" height="19" font="3">mortality of 20.3%.  55.2% </text>
<text top="578" left="617" width="173" height="19" font="3">were treated with IV or oral </text>
<text top="596" left="617" width="161" height="19" font="3">BB which were associated </text>
<text top="615" left="617" width="164" height="19" font="3">with decreased in-hospital </text>
<text top="633" left="617" width="170" height="19" font="3">mortality (RR: 0.28; 95% CI: </text>
<text top="651" left="617" width="125" height="19" font="3">0.10–0.75, p=0.013)<b> </b></text>
<text top="487" left="817" width="257" height="20" font="3">• Sustained VT/VF was common with AMI </text>
<text top="506" left="817" width="235" height="20" font="3">• In patients with sustained VT/VF, BB </text>
<text top="525" left="817" width="235" height="19" font="3">therapy in the first 24 h after AMI was </text>
<text top="543" left="817" width="257" height="19" font="3">associated with decreased early mortality </text>
<text top="561" left="817" width="142" height="19" font="3">without worsening HF. </text>
<text top="580" left="817" width="3" height="19" font="3"> </text>
<text top="670" left="125" width="143" height="19" font="3">● Link et al 2015 (115)  </text>
<text top="689" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=26472995">● </a></text>
<text top="689" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=26472995">26472995</a></text>
<text top="689" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=26472995"> </a></text>
<text top="707" left="125" width="3" height="19" font="3"> </text>
<text top="670" left="286" width="142" height="19" font="4"><b>Study type: </b>Guidelines </text>
<text top="689" left="286" width="3" height="19" font="4"><b> </b></text>
<text top="670" left="443" width="150" height="19" font="4"><b>Inclusion criteria:</b> Acute </text>
<text top="689" left="443" width="135" height="19" font="3">treatment of patients </text>
<text top="707" left="443" width="51" height="19" font="3">with VA </text>
<text top="670" left="617" width="176" height="19" font="3">Expert developed guidelines </text>
<text top="689" left="617" width="3" height="19" font="3"> </text>
<text top="707" left="617" width="184" height="19" font="3">Reviews role of direct current </text>
<text top="725" left="617" width="171" height="19" font="3">cardioversion, epinephrine, </text>
<text top="744" left="617" width="185" height="19" font="3">magnesium, and AAD therapy </text>
<text top="762" left="617" width="184" height="19" font="3">for the treatment of acute VA </text>
<text top="670" left="817" width="170" height="19" font="3">● Electrical cardioversion is </text>
<text top="689" left="817" width="256" height="19" font="3">recommended for the initial treatment of </text>
<text top="707" left="817" width="254" height="19" font="3">VF, poorly tolerated VT, and polymorphic </text>
<text top="725" left="817" width="23" height="19" font="3">VT. </text>
<text top="744" left="817" width="188" height="19" font="3">● The appropriate use of AAD, </text>
<text top="762" left="817" width="226" height="19" font="3">epinephrine, and magnesium for the </text>
<text top="780" left="817" width="214" height="19" font="3">treatment of acute VA is discussed </text>
</page>
<page number="59" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">59 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="120" height="19" font="3">● Herlitz et al.1997 </text>
<text top="127" left="125" width="35" height="19" font="3">(116) </text>
<text top="145" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=9044490">● </a></text>
<text top="145" left="137" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=9044490">9044490</a></text>
<text top="145" left="190" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=9044490"> </a></text>
<text top="164" left="125" width="3" height="19" font="3"> </text>
<text top="182" left="125" width="3" height="19" font="3"> </text>
<text top="109" left="286" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="127" left="286" width="91" height="19" font="3">Retrospective, </text>
<text top="145" left="286" width="139" height="19" font="3">observational study of </text>
<text top="164" left="286" width="123" height="19" font="3">patients with OHCA </text>
<text top="182" left="286" width="62" height="19" font="3">due to VF </text>
<text top="200" left="286" width="3" height="19" font="3"> </text>
<text top="218" left="286" width="139" height="19" font="4"><b>Size:</b>  1,212 cases; 405 </text>
<text top="237" left="286" width="117" height="19" font="3">receiving lidocaine </text>
<text top="109" left="443" width="134" height="19" font="4"><b>Inclusion criteria:</b>  All </text>
<text top="127" left="443" width="149" height="19" font="3">patients with OHCA due </text>
<text top="145" left="443" width="123" height="19" font="3">to VF. CPR by single </text>
<text top="164" left="443" width="114" height="19" font="3">center emergency </text>
<text top="182" left="443" width="76" height="19" font="3">department </text>
<text top="200" left="443" width="3" height="19" font="3"> </text>
<text top="218" left="443" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="237" left="443" width="158" height="19" font="3">Traumatic cause of OHCA </text>
<text top="109" left="617" width="152" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Survival to </text>
<text top="128" left="617" width="114" height="19" font="3">hospital discharge </text>
<text top="146" left="617" width="3" height="19" font="3"> </text>
<text top="164" left="617" width="171" height="19" font="4"><b>Results:</b>   Patients receiving </text>
<text top="183" left="617" width="180" height="19" font="3">lidocaine had a higher return </text>
<text top="201" left="617" width="165" height="19" font="3">of spontaneous circulation </text>
<text top="219" left="617" width="165" height="19" font="3">(p&lt;0.001) and hospitalized </text>
<text top="238" left="617" width="172" height="19" font="3">alive (38% vs. 18%; p&lt;0.01). </text>
<text top="256" left="617" width="176" height="19" font="3">Survival to discharge did not </text>
<text top="274" left="617" width="36" height="19" font="3">differ </text>
<text top="109" left="817" width="218" height="19" font="3">● Lidocaine improved the return to </text>
<text top="127" left="817" width="176" height="19" font="3">spontaneous circulation and </text>
<text top="145" left="817" width="93" height="19" font="3">hospitalization </text>
<text top="164" left="817" width="219" height="19" font="3">● Lidocaine did not improve rate of </text>
<text top="182" left="817" width="147" height="19" font="3">discharge from hospital </text>
<text top="200" left="817" width="3" height="19" font="3"> </text>
<text top="293" left="125" width="126" height="19" font="3">● Markel et al.<b> </b>2010 </text>
<text top="312" left="125" width="35" height="19" font="3">(117) </text>
<text top="330" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20624142">● </a></text>
<text top="330" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20624142">20624142</a></text>
<text top="330" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20624142"> </a></text>
<text top="348" left="125" width="3" height="19" font="3"> </text>
<text top="367" left="125" width="3" height="19" font="3"> </text>
<text top="293" left="286" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="312" left="286" width="91" height="19" font="3">Retrospective, </text>
<text top="330" left="286" width="134" height="19" font="3">observational, cohort </text>
<text top="348" left="286" width="3" height="19" font="3"> </text>
<text top="367" left="286" width="122" height="19" font="4"><b>Size:</b>   665 patients, </text>
<text top="385" left="286" width="82" height="19" font="3">176 received </text>
<text top="403" left="286" width="91" height="19" font="3">procainamide  </text>
<text top="293" left="443" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="312" left="443" width="152" height="19" font="3">Witnesses, OHCA due to </text>
<text top="330" left="443" width="113" height="19" font="3">VF or pulseless VT </text>
<text top="348" left="443" width="147" height="19" font="3">treated by King County, </text>
<text top="367" left="443" width="163" height="19" font="3">WA, emergency services.   </text>
<text top="385" left="443" width="3" height="19" font="3"> </text>
<text top="403" left="443" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="422" left="443" width="119" height="19" font="3">Traumatic cause of </text>
<text top="440" left="443" width="138" height="19" font="3">OHCA, asystolic OHCA </text>
<text top="294" left="617" width="182" height="19" font="4"><b>1</b>°<b> endpoint:</b>  The association </text>
<text top="312" left="617" width="171" height="19" font="3">between procainamide and </text>
<text top="331" left="617" width="53" height="19" font="3">survival  </text>
<text top="349" left="617" width="3" height="19" font="3"> </text>
<text top="367" left="617" width="143" height="19" font="4"><b>Results:</b>  Procainamide </text>
<text top="386" left="617" width="147" height="19" font="3">associated with a lower </text>
<text top="404" left="617" width="180" height="19" font="3">survival to hospital discharge </text>
<text top="422" left="617" width="181" height="19" font="3">(OR: 0.52; 95% CI: 0.36–0.75) </text>
<text top="441" left="617" width="3" height="19" font="3"> </text>
<text top="293" left="817" width="233" height="19" font="3">● Procainamide associated with more </text>
<text top="312" left="817" width="256" height="19" font="3">shocks, pharmacologic interventions, and </text>
<text top="330" left="817" width="134" height="19" font="3">longer resuscitations. </text>
<text top="348" left="817" width="251" height="19" font="3">● Procainamide did not improve survival </text>
<text top="367" left="817" width="3" height="19" font="3"> </text>
<text top="460" left="125" width="113" height="19" font="3">● Stiell et al. 2004 </text>
<text top="478" left="125" width="35" height="19" font="3">(118) </text>
<text top="496" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=15306666">● </a></text>
<text top="496" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=15306666">15306666</a></text>
<text top="496" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=15306666"> </a></text>
<text top="515" left="125" width="3" height="19" font="3"> </text>
<text top="533" left="125" width="3" height="19" font="3"> </text>
<text top="460" left="286" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="478" left="286" width="79" height="19" font="3">Multicenter, </text>
<text top="496" left="286" width="140" height="19" font="3">controlled prospective </text>
<text top="515" left="286" width="28" height="19" font="3">trial </text>
<text top="533" left="286" width="3" height="19" font="3"> </text>
<text top="551" left="286" width="126" height="19" font="4"><b>Size:</b>  5638 patients; </text>
<text top="570" left="286" width="126" height="19" font="3">1391 enrolled in the </text>
<text top="588" left="286" width="117" height="19" font="3">rapid defibrillation </text>
<text top="606" left="286" width="138" height="19" font="3">phase and 4247 in the </text>
<text top="624" left="286" width="73" height="19" font="3">ACLS phase </text>
<text top="460" left="443" width="151" height="19" font="4"><b>Inclusion criteria: </b>OHCA </text>
<text top="478" left="443" width="3" height="19" font="3"> </text>
<text top="496" left="443" width="113" height="19" font="4"><b>Exclusion criteri</b>a: </text>
<text top="515" left="443" width="144" height="19" font="3">traumatic cause of SCD </text>
<text top="460" left="617" width="148" height="19" font="4"><b>1</b>°<b> endpoint:</b> survival to </text>
<text top="479" left="617" width="143" height="19" font="3">hospital admission and </text>
<text top="497" left="617" width="62" height="19" font="3">discharge </text>
<text top="515" left="617" width="3" height="19" font="3"> </text>
<text top="534" left="617" width="175" height="19" font="4"><b>Results:</b> The rate of hospital </text>
<text top="552" left="617" width="184" height="19" font="3">admission increased from the </text>
<text top="570" left="617" width="161" height="19" font="3">defibrillation phase to the </text>
<text top="589" left="617" width="179" height="19" font="3">ACLS phase (10.9% vs 14.6%, </text>
<text top="607" left="617" width="180" height="19" font="3">p&lt;0.001). Survival after rapid </text>
<text top="625" left="617" width="187" height="19" font="3">defibrillation (OR: 3.4; 95% CI: </text>
<text top="644" left="617" width="187" height="19" font="3">1.4–8.4) was better than ACLS </text>
<text top="662" left="617" width="185" height="19" font="3">(OR: 1.1; 95% CI: 0.8–1.5) and </text>
<text top="680" left="617" width="177" height="19" font="3">bystander CPR (OR: 3.7; 95% </text>
<text top="699" left="617" width="72" height="19" font="3">CI: 2.5–5.4) </text>
<text top="460" left="817" width="242" height="19" font="3">● The addition of ACLS did not improve </text>
<text top="478" left="817" width="248" height="19" font="3">the rate of survival over the use of rapid </text>
<text top="496" left="817" width="139" height="19" font="3">defibrillation in OHCA. </text>
<text top="718" left="125" width="139" height="19" font="3">● Haqihara et al.<b> </b>2012 </text>
<text top="736" left="125" width="35" height="19" font="3">(119) </text>
<text top="754" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22436956">● </a></text>
<text top="754" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22436956">22436956</a></text>
<text top="754" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22436956"> </a></text>
<text top="773" left="125" width="3" height="19" font="3"> </text>
<text top="718" left="286" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="736" left="286" width="78" height="19" font="3">Prospective, </text>
<text top="754" left="286" width="87" height="19" font="3">observational </text>
<text top="773" left="286" width="3" height="19" font="3"> </text>
<text top="718" left="443" width="141" height="19" font="4"><b>Inclusion criteria:</b>  Age </text>
<text top="736" left="443" width="155" height="19" font="3">≥18 y with OHCA treated </text>
<text top="754" left="443" width="141" height="19" font="3">by emergence medical </text>
<text top="773" left="443" width="110" height="19" font="3">service personnel </text>
<text top="718" left="617" width="146" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Return of </text>
<text top="737" left="617" width="153" height="19" font="3">spontaneous circulation, </text>
<text top="755" left="617" width="171" height="19" font="3">survival at 1 mo, neurologic </text>
<text top="773" left="617" width="58" height="19" font="3">outcome </text>
<text top="718" left="817" width="254" height="19" font="3">● Pre-hospital epinephrine for OHCA was </text>
<text top="736" left="817" width="218" height="19" font="3">associated with improved return to </text>
<text top="754" left="817" width="153" height="19" font="3">spontaneous circulation. </text>
</page>
<page number="60" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">60 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="3" height="19" font="3"> </text>
<text top="109" left="286" width="161" height="19" font="4"><b>Size:</b> 417,188 patients    </text>
<text top="127" left="443" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="145" left="443" width="162" height="19" font="3">Traumatic cause of OHCA  </text>
<text top="109" left="617" width="3" height="19" font="3"> </text>
<text top="127" left="617" width="133" height="19" font="4"><b>Results:</b>  Epinephrine </text>
<text top="145" left="617" width="120" height="19" font="3">improved return of </text>
<text top="164" left="617" width="179" height="19" font="3">spontaneous circulation (OR: </text>
<text top="182" left="617" width="150" height="19" font="3">2.36; 95% CI: 2.22–2.50; </text>
<text top="200" left="617" width="182" height="19" font="3">p&lt;0.001); but had an adverse </text>
<text top="219" left="617" width="180" height="19" font="3">effect on long-term outcome </text>
<text top="237" left="617" width="180" height="19" font="3">measures (1 mo survival, OR: </text>
<text top="255" left="617" width="177" height="19" font="3">0.46; 95% CI: 0.42–0.51; and </text>
<text top="273" left="617" width="179" height="19" font="3">neurologic, OR: 0.31; 95% CI: </text>
<text top="292" left="617" width="69" height="19" font="3">0.26–0.36) </text>
<text top="109" left="817" width="254" height="19" font="3">● Pre-hospital epinephrine for OHCA was </text>
<text top="127" left="817" width="249" height="19" font="3">associated with worse 1 mo survival and </text>
<text top="145" left="817" width="135" height="19" font="3">neurologic outcomes. </text>
<text top="164" left="817" width="3" height="19" font="3"> </text>
<text top="311" left="125" width="132" height="19" font="3">● Donnino et al.<b> </b>2014</text>
<text top="309" left="257" width="4" height="21" font="0"> </text>
<text top="329" left="125" width="35" height="19" font="3">(120) </text>
<text top="347" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=24846323">● </a></text>
<text top="347" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=24846323">24846323</a></text>
<text top="347" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=24846323"> </a></text>
<text top="366" left="125" width="3" height="19" font="3"> </text>
<text top="384" left="125" width="3" height="19" font="3"> </text>
<text top="311" left="286" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="329" left="286" width="105" height="19" font="3">Prospective data </text>
<text top="347" left="286" width="66" height="19" font="3">collection, </text>
<text top="366" left="286" width="90" height="19" font="3">observational  </text>
<text top="384" left="286" width="3" height="19" font="3"> </text>
<text top="402" left="286" width="137" height="19" font="4"><b>Size:</b>  25,095 patients  </text>
<text top="311" left="443" width="157" height="19" font="4"><b>Inclusion criteria:</b>  Adults </text>
<text top="329" left="443" width="148" height="19" font="3">with CA in hospital with </text>
<text top="347" left="443" width="147" height="19" font="3">asystole or pulseless VT </text>
<text top="366" left="443" width="126" height="19" font="3">as the initial rhythm </text>
<text top="384" left="443" width="3" height="19" font="3"> </text>
<text top="402" left="443" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="421" left="443" width="103" height="19" font="3">Cardiac arrest in </text>
<text top="439" left="443" width="151" height="19" font="3">emergency department, </text>
<text top="457" left="443" width="112" height="19" font="3">ICU, missing data, </text>
<text top="476" left="443" width="130" height="19" font="3">received vasopressin </text>
<text top="311" left="617" width="149" height="19" font="4"><b>1</b>°<b> endpoint:</b> Survival to </text>
<text top="330" left="617" width="117" height="19" font="3">hospital discharge  </text>
<text top="348" left="617" width="3" height="19" font="3"> </text>
<text top="367" left="617" width="131" height="19" font="4"><b>Results:</b> Survival was </text>
<text top="385" left="617" width="114" height="19" font="3">increased by early </text>
<text top="403" left="617" width="108" height="19" font="3">administration of </text>
<text top="422" left="617" width="134" height="19" font="3">epinephrine: 1–3 min </text>
<text top="440" left="617" width="172" height="19" font="3">(reference group) (OR: 1.0); </text>
<text top="458" left="617" width="165" height="19" font="3">4–6 min (OR: 0.91; 95% CI: </text>
<text top="476" left="617" width="175" height="19" font="3">0.82–1.0; p=0.055); 7–9 min </text>
<text top="495" left="617" width="181" height="19" font="3">(OR: 0.63; 95% CI: 0.52–0.76; </text>
<text top="513" left="617" width="65" height="19" font="3">p&lt;0.001).  </text>
<text top="311" left="817" width="223" height="19" font="3">● Patients with non-shockable CA in </text>
<text top="329" left="817" width="198" height="19" font="3">hospital had improved return of </text>
<text top="347" left="817" width="218" height="19" font="3">spontaneous circulation, survival in </text>
<text top="366" left="817" width="209" height="19" font="3">hospital, and neurologically intact </text>
<text top="384" left="817" width="232" height="19" font="3">survival with earlier administration of </text>
<text top="402" left="817" width="77" height="19" font="3">epinephrine </text>
<text top="421" left="817" width="3" height="19" font="3"> </text>
<text top="532" left="125" width="121" height="19" font="3">● Koscik et al.<b> </b>2013 </text>
<text top="550" left="125" width="35" height="19" font="3">(121) </text>
<text top="569" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23523823">● </a></text>
<text top="569" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23523823">23523823</a></text>
<text top="569" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23523823"> </a></text>
<text top="587" left="125" width="3" height="19" font="3"> </text>
<text top="605" left="125" width="3" height="19" font="3"> </text>
<text top="532" left="286" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="550" left="286" width="87" height="19" font="3">Retrospective </text>
<text top="569" left="286" width="114" height="19" font="3">database analysis  </text>
<text top="587" left="286" width="3" height="19" font="3"> </text>
<text top="605" left="286" width="121" height="19" font="4"><b>Size:</b>   686 patients  </text>
<text top="532" left="443" width="153" height="19" font="4"><b>Inclusion criteria:</b> Adults </text>
<text top="550" left="443" width="73" height="19" font="3">with OHCA  </text>
<text top="569" left="443" width="3" height="19" font="3"> </text>
<text top="587" left="443" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="605" left="443" width="158" height="19" font="3">Traumatic cause of OHCA </text>
<text top="533" left="617" width="176" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Does timing of </text>
<text top="551" left="617" width="170" height="19" font="3">epinephrine administration </text>
<text top="570" left="617" width="112" height="19" font="3">improve outcome </text>
<text top="588" left="617" width="3" height="19" font="3"> </text>
<text top="606" left="617" width="166" height="19" font="4"><b>Results:</b>  Early epinephrine </text>
<text top="624" left="617" width="147" height="19" font="3">was more likely to have </text>
<text top="643" left="617" width="140" height="19" font="3">return of spontaneous </text>
<text top="661" left="617" width="166" height="19" font="3">circulation (32% vs. 23.4%; </text>
<text top="679" left="617" width="177" height="19" font="3">OR: 1.59; 95% CI: 1.07–2.38) </text>
<text top="532" left="817" width="232" height="19" font="3">● Early administration of epinephrine </text>
<text top="550" left="817" width="202" height="19" font="3">improved return of spontaneous </text>
<text top="569" left="817" width="67" height="19" font="3">circulation </text>
<text top="587" left="817" width="254" height="19" font="3">● Early administration of epinephrine did </text>
<text top="605" left="817" width="226" height="19" font="3">not increase survival to admission or </text>
<text top="624" left="817" width="62" height="19" font="3">discharge </text>
<text top="642" left="817" width="251" height="19" font="3">● Similar results were reported with PEA </text>
<text top="698" left="125" width="143" height="19" font="3">● Spaulding et al. 1997 </text>
<text top="717" left="125" width="39" height="19" font="3">(122)  </text>
<text top="735" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=9171064">● </a></text>
<text top="735" left="137" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=9171064">9171064</a></text>
<text top="735" left="190" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=9171064"> </a></text>
<text top="753" left="125" width="3" height="19" font="3"> </text>
<text top="772" left="125" width="3" height="19" font="3"> </text>
<text top="698" left="286" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="717" left="286" width="91" height="19" font="3">Retrospective, </text>
<text top="735" left="286" width="90" height="19" font="3">observational, </text>
<text top="753" left="286" width="129" height="19" font="3">consecutive patients </text>
<text top="772" left="286" width="3" height="19" font="3"> </text>
<text top="698" left="443" width="150" height="19" font="4"><b>Inclusion criteria:</b> OHCA </text>
<text top="717" left="443" width="53" height="19" font="3">survival  </text>
<text top="735" left="443" width="3" height="19" font="3"> </text>
<text top="753" left="443" width="147" height="19" font="4"><b>Exclusion criteria:</b>  Non-</text>
<text top="772" left="443" width="140" height="19" font="3">cardiac cause of arrest<b> </b></text>
<text top="699" left="617" width="159" height="19" font="4"><b>1</b>°<b> endpoint:</b> Incidence of </text>
<text top="718" left="617" width="182" height="19" font="3">acute coronary occlusion and </text>
<text top="736" left="617" width="172" height="19" font="3">role of reperfusion therapy  </text>
<text top="754" left="617" width="3" height="19" font="3"> </text>
<text top="698" left="817" width="254" height="19" font="3">● Acute coronary occlusion is frequent in </text>
<text top="717" left="817" width="257" height="19" font="3">survivors of OHCA and is predicted poorly </text>
<text top="735" left="817" width="169" height="19" font="3">by clinical and ECG findings </text>
<text top="753" left="817" width="228" height="19" font="3">● Coronary angioplasty may improve </text>
<text top="772" left="817" width="50" height="19" font="3">survival </text>
</page>
<page number="61" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">61 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="286" width="110" height="19" font="4"><b>Size:</b>  84 patients <b> </b></text>
<text top="109" left="617" width="177" height="19" font="4"><b>Results:</b>  71% had significant </text>
<text top="127" left="617" width="169" height="19" font="3">CAD and 48% had coronary </text>
<text top="145" left="617" width="173" height="19" font="3">artery occlusion. In-hospital </text>
<text top="164" left="617" width="149" height="19" font="3">survival 38%. Successful </text>
<text top="182" left="617" width="185" height="19" font="3">angioplasty predicted survival </text>
<text top="200" left="617" width="165" height="19" font="3">(OR: 5.2; 95% CI: 1.1–24.5; </text>
<text top="219" left="617" width="50" height="19" font="3">p=0.04) </text>
<text top="109" left="817" width="3" height="19" font="3"> </text>
<text top="238" left="125" width="128" height="19" font="3">● Cronier et al.<b> </b>2011 </text>
<text top="256" left="125" width="35" height="19" font="3">(123) </text>
<text top="274" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21569361">● </a></text>
<text top="274" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21569361">21569361</a></text>
<text top="274" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21569361"> </a></text>
<text top="292" left="125" width="3" height="19" font="3"> </text>
<text top="237" left="286" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="256" left="286" width="91" height="19" font="3">Retrospective, </text>
<text top="274" left="286" width="90" height="19" font="3">observational, </text>
<text top="293" left="286" width="136" height="19" font="3">consecutive patients   </text>
<text top="311" left="286" width="3" height="19" font="3"> </text>
<text top="329" left="286" width="115" height="19" font="4"><b>Size:</b>  111 patients<b> </b></text>
<text top="237" left="443" width="150" height="19" font="4"><b>Inclusion criteria:</b> OHCA </text>
<text top="256" left="443" width="121" height="19" font="3">survivor, age &lt;80 y, </text>
<text top="274" left="443" width="109" height="19" font="3">treated with mild </text>
<text top="293" left="443" width="86" height="19" font="3">hypothermia, </text>
<text top="311" left="443" width="155" height="19" font="3">hemodynamically stable  </text>
<text top="329" left="443" width="3" height="19" font="3"> </text>
<text top="347" left="443" width="147" height="19" font="4"><b>Exclusion criteria:</b>  Non-</text>
<text top="366" left="443" width="140" height="19" font="3">cardiac cause of arrest<b> </b></text>
<text top="238" left="617" width="149" height="19" font="4"><b>1</b>°<b> endpoint:</b> Prognostic </text>
<text top="257" left="617" width="136" height="19" font="3">impact of routine PCI  </text>
<text top="275" left="617" width="3" height="19" font="3"> </text>
<text top="293" left="617" width="175" height="19" font="4"><b>Results:</b> 73% had CAD. Time </text>
<text top="312" left="617" width="160" height="19" font="3">from collapse to return of </text>
<text top="330" left="617" width="149" height="19" font="3">spontaneous circulation </text>
<text top="348" left="617" width="188" height="19" font="3">associated with mortality (OR: </text>
<text top="367" left="617" width="49" height="19" font="3">1.05; 25</text>
<text top="366" left="666" width="8" height="12" font="15">th</text>
<text top="367" left="674" width="23" height="19" font="3">–75</text>
<text top="366" left="697" width="14" height="12" font="15">tth </text>
<text top="367" left="711" width="65" height="19" font="3">percentile </text>
<text top="385" left="617" width="171" height="19" font="3">range, 1.03–1.08; p&lt;0.001); </text>
<text top="403" left="617" width="166" height="19" font="3">Percutaneous intervention </text>
<text top="422" left="617" width="178" height="19" font="3">associated with survival (OR: </text>
<text top="440" left="617" width="49" height="19" font="3">0.30; 25</text>
<text top="440" left="666" width="8" height="12" font="15">th</text>
<text top="440" left="674" width="23" height="19" font="3">–75</text>
<text top="440" left="697" width="9" height="12" font="15">th</text>
<text top="440" left="705" width="68" height="19" font="3"> percentile </text>
<text top="458" left="617" width="160" height="19" font="3">range, 0.11–0.79; p=0.01) </text>
<text top="238" left="817" width="231" height="19" font="3">● Routine coronary angiography with </text>
<text top="256" left="817" width="249" height="19" font="3">percutaneous intervention may improve </text>
<text top="274" left="817" width="217" height="19" font="3">survival following OHCA in patients </text>
<text top="293" left="817" width="244" height="19" font="3">treated with mild hypothermia who are </text>
<text top="311" left="817" width="151" height="19" font="3">hemodynamically stable </text>
<text top="329" left="817" width="3" height="19" font="3"> </text>
<text top="477" left="125" width="138" height="19" font="3">● Zanuttini et al. 2012 </text>
<text top="496" left="125" width="35" height="19" font="3">(124) </text>
<text top="514" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22975468">● </a></text>
<text top="514" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22975468">22975468</a></text>
<text top="514" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22975468"> </a></text>
<text top="532" left="125" width="3" height="19" font="3"> </text>
<text top="550" left="125" width="3" height="19" font="3"> </text>
<text top="477" left="286" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="496" left="286" width="91" height="19" font="3">Retrospective, </text>
<text top="514" left="286" width="90" height="19" font="3">observational, </text>
<text top="532" left="286" width="136" height="19" font="3">consecutive patients   </text>
<text top="550" left="286" width="3" height="19" font="3"> </text>
<text top="569" left="286" width="107" height="19" font="4"><b>Size:</b>  93 patients </text>
<text top="477" left="443" width="150" height="19" font="4"><b>Inclusion criteria:</b> OHCA </text>
<text top="496" left="443" width="116" height="19" font="3">survival, remained </text>
<text top="514" left="443" width="144" height="19" font="3">unconscious soon after </text>
<text top="532" left="443" width="154" height="19" font="3">recovery of spontaneous </text>
<text top="550" left="443" width="71" height="19" font="3">circulation  </text>
<text top="569" left="443" width="3" height="19" font="3"> </text>
<text top="587" left="443" width="144" height="19" font="4"><b>Exclusion criteria:</b> Non-</text>
<text top="605" left="443" width="144" height="19" font="3">cardiac cause of OHCA  </text>
<text top="478" left="617" width="167" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Independent </text>
<text top="496" left="617" width="169" height="19" font="3">determinants of in-hospital </text>
<text top="515" left="617" width="50" height="19" font="3">survival </text>
<text top="533" left="617" width="3" height="19" font="3"> </text>
<text top="551" left="617" width="112" height="19" font="4"><b>Results:</b> Coronary </text>
<text top="570" left="617" width="181" height="19" font="3">angiography performed in 66 </text>
<text top="588" left="617" width="177" height="19" font="3">patients (71%); 48 emergent </text>
<text top="606" left="617" width="154" height="19" font="3">and 18 at 13±10 d. PCI in </text>
<text top="624" left="617" width="183" height="19" font="3">52%; in hospital survival 54%. </text>
<text top="643" left="617" width="179" height="19" font="3">Emergency angiography (HR: </text>
<text top="661" left="617" width="150" height="19" font="3">2.32; 95% CI: 1.23–4.38; </text>
<text top="680" left="617" width="170" height="19" font="3">p=0.009) and PCI (HR: 2.54; </text>
<text top="698" left="617" width="166" height="19" font="3">95% CI: 1.35–4.8; p=0.004) </text>
<text top="716" left="617" width="180" height="19" font="3">related to in hospital survival </text>
<text top="477" left="817" width="247" height="19" font="3">● Emergency coronary angiography and </text>
<text top="496" left="817" width="233" height="19" font="3">PCI, if indicated, appeared to improve </text>
<text top="514" left="817" width="54" height="19" font="3">survival. </text>
<text top="532" left="817" width="256" height="19" font="3">● The study has significant limitations: no </text>
<text top="550" left="817" width="248" height="19" font="3">control group; and unconscious patients </text>
<text top="569" left="817" width="243" height="19" font="3">who had delayed procedures 18 d after </text>
<text top="587" left="817" width="221" height="19" font="3">OHCA is a poor comparative group.  </text>
<text top="605" left="817" width="3" height="19" font="3"> </text>
<text top="735" left="125" width="125" height="19" font="3">● Dumas et al.<b> </b>2016 </text>
<text top="753" left="125" width="28" height="19" font="3">(81) </text>
<text top="772" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27131438">● </a></text>
<text top="772" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27131438">27131438</a></text>
<text top="772" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27131438"> </a></text>
<text top="735" left="286" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="753" left="286" width="92" height="19" font="3">Observational, </text>
<text top="772" left="286" width="127" height="19" font="3">multicenter registry  </text>
<text top="735" left="443" width="150" height="19" font="4"><b>Inclusion criteria:</b> OHCA </text>
<text top="753" left="443" width="141" height="19" font="3">survivor without an ST-</text>
<text top="772" left="443" width="80" height="19" font="3">elevation MI </text>
<text top="736" left="617" width="145" height="19" font="4"><b>1</b>°<b> endpoint:</b> Favorable </text>
<text top="754" left="617" width="126" height="19" font="3">neurologic outcome </text>
<text top="773" left="617" width="3" height="19" font="3"> </text>
<text top="735" left="817" width="214" height="19" font="3">● 1/3 of OHCA patients without ST </text>
<text top="753" left="817" width="242" height="19" font="3">elevation had a culprit lesion and had a </text>
</page>
<page number="62" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">62 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="3" height="19" font="3"> </text>
<text top="127" left="125" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="286" width="3" height="19" font="3"> </text>
<text top="127" left="286" width="115" height="19" font="4"><b>Size:</b>  695 patients<b> </b></text>
<text top="109" left="443" width="3" height="19" font="3"> </text>
<text top="127" left="443" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="145" left="443" width="104" height="19" font="3">Inadequate data<b> </b></text>
<text top="109" left="617" width="173" height="19" font="4"><b>Results:</b>  199 patients (29%) </text>
<text top="127" left="617" width="187" height="19" font="3">had a PCI.  43% with PCI had a </text>
<text top="145" left="617" width="174" height="19" font="3">favorable outcome and 33% </text>
<text top="164" left="617" width="171" height="19" font="3">without PCI. (OR: 1.80; 95% </text>
<text top="182" left="617" width="141" height="19" font="3">CI: 1.09–2.97; p=0.02). </text>
<text top="109" left="817" width="211" height="19" font="3">nearly 2-fold increase in favorable </text>
<text top="127" left="817" width="130" height="19" font="3">neurologic outcome. </text>
<text top="145" left="817" width="198" height="19" font="3">● A favorable outcome was also </text>
<text top="164" left="817" width="245" height="19" font="3">predicted by a shockable rhythm, lower </text>
<text top="182" left="817" width="188" height="19" font="3">epinephrine dose, and shorter </text>
<text top="200" left="817" width="86" height="19" font="3">resuscitation. </text>
<text top="219" left="817" width="3" height="19" font="3"> </text>
<text top="238" left="125" width="117" height="19" font="3">● Kudenchuk et al.<b> </b></text>
<text top="256" left="125" width="69" height="19" font="3">2013 (125) </text>
<text top="274" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23743237">● </a></text>
<text top="274" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23743237">23743237</a></text>
<text top="274" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23743237"> </a></text>
<text top="292" left="125" width="3" height="19" font="3"> </text>
<text top="311" left="125" width="3" height="19" font="3"> </text>
<text top="237" left="286" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="256" left="286" width="132" height="19" font="3">retrospective, cohort </text>
<text top="274" left="286" width="139" height="19" font="3">of patients with OHCA </text>
<text top="293" left="286" width="116" height="19" font="3">who did or did not </text>
<text top="311" left="286" width="126" height="19" font="3">receive prophylactic </text>
<text top="329" left="286" width="58" height="19" font="3">lidocaine </text>
<text top="347" left="286" width="3" height="19" font="3"> </text>
<text top="366" left="286" width="125" height="19" font="4"><b>Size:</b>   1721 patients </text>
<text top="384" left="286" width="131" height="19" font="3">with OHCA due to VF </text>
<text top="402" left="286" width="39" height="19" font="3">or VT <b> </b></text>
<text top="237" left="443" width="154" height="19" font="4"><b>Inclusion criteria:</b>  OHCA </text>
<text top="256" left="443" width="154" height="19" font="3">due to VF or VT. Age ≥18 </text>
<text top="274" left="443" width="14" height="19" font="3">y  </text>
<text top="292" left="443" width="3" height="19" font="3"> </text>
<text top="311" left="443" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="329" left="443" width="145" height="19" font="3">Missing data points, no </text>
<text top="347" left="443" width="150" height="19" font="3">chance of survival when </text>
<text top="366" left="443" width="120" height="19" font="3">paramedics arrived<b> </b></text>
<text top="238" left="617" width="145" height="19" font="4"><b>1</b>°<b> endpoint:</b>  re-arrest, </text>
<text top="257" left="617" width="171" height="19" font="3">hospital admission, survival </text>
<text top="275" left="617" width="3" height="19" font="3"> </text>
<text top="293" left="617" width="143" height="19" font="4"><b>Results:</b>  1296 patients </text>
<text top="312" left="617" width="134" height="19" font="3">received prophylactic </text>
<text top="330" left="617" width="162" height="19" font="3">lidocaine and 425 did not. </text>
<text top="348" left="617" width="137" height="19" font="3">Prophylactic lidocaine </text>
<text top="367" left="617" width="184" height="19" font="3">reduced re-arrest from VF/VT </text>
<text top="385" left="617" width="185" height="19" font="3">(OR: 0.34; 95% CI: 0.26–0.44); </text>
<text top="403" left="617" width="169" height="19" font="3">non-shockable arrhythmias </text>
<text top="422" left="617" width="182" height="19" font="3">(OR: 0.47;95% CI: 0.29–0.78); </text>
<text top="440" left="617" width="159" height="19" font="3">higher hospital admission </text>
<text top="458" left="617" width="181" height="19" font="3">(OR: 1.88;95% CI, 1.28–2.76); </text>
<text top="476" left="617" width="154" height="19" font="3">and improved survival to </text>
<text top="495" left="617" width="170" height="19" font="3">discharge (OR, 1.49;95% CI: </text>
<text top="513" left="617" width="69" height="19" font="3">1.15–1.95)<b> </b></text>
<text top="238" left="817" width="219" height="19" font="3">● Patients receiving lidocaine had a </text>
<text top="256" left="817" width="246" height="19" font="3">shorter time to a return of spontaneous </text>
<text top="274" left="817" width="155" height="19" font="3">circulation and higher BP </text>
<text top="292" left="817" width="227" height="19" font="3">● Use of prophylactic lidocaine upon </text>
<text top="311" left="817" width="251" height="19" font="3">return to a spontaneous circulation after </text>
<text top="329" left="817" width="252" height="19" font="3">OHCA was associated with less recurrent </text>
<text top="347" left="817" width="240" height="19" font="3">VF/VT and higher rates of admission to </text>
<text top="366" left="817" width="210" height="19" font="3">hospital and survival to discharge. </text>
<text top="384" left="817" width="3" height="19" font="3"> </text>
<text top="532" left="125" width="127" height="19" font="3">● Nademanee et al., </text>
<text top="550" left="125" width="73" height="19" font="3">2000 (126)  </text>
<text top="569" left="125" width="16" height="19" font="3">● <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=10942741"> </a></text>
<text top="569" left="140" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=10942741">10942741</a></text>
<text top="569" left="201" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=10942741"><b> </b></a></text>
<text top="587" left="125" width="3" height="19" font="4"><b> </b></text>
<text top="605" left="125" width="3" height="19" font="3"> </text>
<text top="532" left="286" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="550" left="286" width="88" height="19" font="3">retrospective, </text>
<text top="569" left="286" width="87" height="19" font="3">observational </text>
<text top="587" left="286" width="3" height="19" font="3"> </text>
<text top="605" left="286" width="114" height="19" font="4"><b>Size:</b>    49 patients<b> </b></text>
<text top="532" left="443" width="132" height="19" font="4"><b>Inclusion criteria:</b>  ES </text>
<text top="550" left="443" width="151" height="19" font="3">with recent (72 h–3 mo) </text>
<text top="569" left="443" width="20" height="19" font="3">MI </text>
<text top="587" left="443" width="3" height="19" font="3"> </text>
<text top="605" left="443" width="159" height="19" font="4"><b>Exclusion criteria:</b> MI &lt;72 </text>
<text top="624" left="443" width="11" height="19" font="3">h<b> </b></text>
<text top="533" left="617" width="170" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Effect of beta </text>
<text top="551" left="617" width="135" height="19" font="3">blockade (left stellate </text>
<text top="570" left="617" width="172" height="19" font="3">ganglion blockade, esmolol, </text>
<text top="588" left="617" width="157" height="19" font="3">propranolol) on outcome </text>
<text top="606" left="617" width="59" height="19" font="3">(survival) </text>
<text top="624" left="617" width="3" height="19" font="3"> </text>
<text top="643" left="617" width="177" height="19" font="4"><b>Results:</b>  1-wk mortality rate </text>
<text top="661" left="617" width="148" height="19" font="3">was higher in group not </text>
<text top="679" left="617" width="172" height="19" font="3">treated with beta blockade: </text>
<text top="698" left="617" width="168" height="19" font="3">18 (82%) of the 22 patients </text>
<text top="716" left="617" width="154" height="19" font="3">died, all of refractory VF, </text>
<text top="734" left="617" width="171" height="19" font="3">compared to 6 (22%) of the </text>
<text top="753" left="617" width="133" height="19" font="3">27 patients with beta </text>
<text top="771" left="617" width="172" height="19" font="3">blockade, 3 of refractory VF </text>
<text top="532" left="817" width="233" height="19" font="3">● Sympathetic blockade is superior to </text>
<text top="550" left="817" width="226" height="19" font="3">standard ACLS therapy in treating ES </text>
<text top="569" left="817" width="57" height="19" font="3">patients. </text>
</page>
<page number="63" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">63 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="617" width="156" height="19" font="3">(p&lt;0.0001). Patients who </text>
<text top="127" left="617" width="171" height="19" font="3">survived the initial ES event </text>
<text top="145" left="617" width="184" height="19" font="3">did well over the 1 y followup </text>
<text top="164" left="617" width="171" height="19" font="3">period: Overall survival was </text>
<text top="182" left="617" width="149" height="19" font="3">67% with beta blockade </text>
<text top="200" left="617" width="181" height="19" font="3">compared with 5% without it </text>
<text top="219" left="617" width="73" height="19" font="3">(p&lt;0.0001). </text>
<text top="238" left="125" width="125" height="19" font="3">● Sasson et al. 2010 </text>
<text top="256" left="125" width="35" height="19" font="3">(127) </text>
<text top="274" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20123673">● </a></text>
<text top="274" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20123673">20123673</a></text>
<text top="274" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20123673"> </a></text>
<text top="292" left="125" width="3" height="19" font="3"> </text>
<text top="311" left="125" width="3" height="19" font="3"> </text>
<text top="329" left="125" width="3" height="19" font="3"> </text>
<text top="237" left="286" width="111" height="19" font="4"><b>Study type: </b>Meta-</text>
<text top="256" left="286" width="111" height="19" font="3">analysis OF OHCA </text>
<text top="274" left="286" width="47" height="19" font="3">studies </text>
<text top="292" left="286" width="3" height="19" font="3"> </text>
<text top="311" left="286" width="101" height="19" font="4"><b>Size:</b>  79 studies </text>
<text top="329" left="286" width="113" height="19" font="3">reporting 142,740 </text>
<text top="347" left="286" width="56" height="19" font="3">patients <b> </b></text>
<text top="237" left="443" width="154" height="19" font="4"><b>Inclusion criteria</b>:  OHCA<b> </b></text>
<text top="238" left="617" width="131" height="19" font="4"><b>1</b>°<b> endpoint:</b> survival </text>
<text top="257" left="617" width="3" height="19" font="3"> </text>
<text top="275" left="617" width="172" height="19" font="4"><b>Results:</b> Survival to hospital </text>
<text top="293" left="617" width="160" height="19" font="3">discharge was more likely </text>
<text top="312" left="617" width="138" height="19" font="3">among OHCA patients </text>
<text top="330" left="617" width="158" height="19" font="3">witnessed by a bystander </text>
<text top="348" left="617" width="186" height="19" font="3">(6.4% to 13.5%); witnessed by </text>
<text top="367" left="617" width="133" height="19" font="3">EMS (4.9% to 18.2%), </text>
<text top="385" left="617" width="185" height="19" font="3">received bystander CPR (3.9% </text>
<text top="403" left="617" width="171" height="19" font="3">to 16.1%), or were found in </text>
<text top="422" left="617" width="140" height="19" font="3">VF/VT (14.8% to 23%). </text>
<text top="238" left="817" width="228" height="19" font="3">● Witnessed OHCA and arrest due to </text>
<text top="256" left="817" width="228" height="19" font="3">VF/VT treated with defibrillation had </text>
<text top="274" left="817" width="116" height="19" font="3">improved survival. </text>
<text top="441" left="125" width="123" height="19" font="3">● Buxton et al 1987 </text>
<text top="459" left="125" width="35" height="19" font="3">(128) </text>
<text top="477" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=3578051">● </a></text>
<text top="477" left="137" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=3578051">3578051</a></text>
<text top="477" left="190" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=3578051"> </a></text>
<text top="496" left="125" width="3" height="19" font="3"> </text>
<text top="441" left="286" width="113" height="19" font="4"><b>Study type: </b>single </text>
<text top="459" left="286" width="133" height="19" font="3">center, observational </text>
<text top="513" left="286" width="3" height="19" font="3"> </text>
<text top="531" left="286" width="107" height="19" font="4"><b>Size:</b>  25 patients<b> </b></text>
<text top="441" left="443" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="459" left="443" width="131" height="19" font="3">Sustained VT treated </text>
<text top="477" left="443" width="110" height="19" font="3">with IV verapamil </text>
<text top="495" left="443" width="3" height="19" font="4"><b> </b></text>
<text top="441" left="617" width="132" height="19" font="4"><b>1</b>°<b> endpoint:</b> adverse </text>
<text top="460" left="617" width="96" height="19" font="3">hemodynamics </text>
<text top="478" left="617" width="3" height="19" font="3"> </text>
<text top="496" left="617" width="169" height="19" font="4"><b>Results:</b> 44% of 25 patients </text>
<text top="515" left="617" width="186" height="19" font="3">with sustained VT receiving IV </text>
<text top="533" left="617" width="134" height="19" font="3">verapamil had severe </text>
<text top="551" left="617" width="137" height="19" font="3">hypotension of loss of </text>
<text top="570" left="617" width="94" height="19" font="3">consciousness. </text>
<text top="440" left="817" width="4" height="21" font="0">I</text>
<text top="442" left="821" width="210" height="19" font="3">V verapamil should not be used in </text>
<text top="461" left="817" width="165" height="19" font="3">patients with sustained VT </text>
<text top="589" left="125" width="115" height="19" font="3">● Pellis et al. 2009 </text>
<text top="607" left="125" width="35" height="19" font="3">(129) </text>
<text top="625" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19010581">● </a></text>
<text top="625" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19010581">19010581</a></text>
<text top="625" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19010581"> </a></text>
<text top="643" left="125" width="3" height="19" font="3"> </text>
<text top="662" left="125" width="3" height="19" font="3"> </text>
<text top="588" left="286" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="607" left="286" width="78" height="19" font="3">prospective, </text>
<text top="625" left="286" width="87" height="19" font="3">observational </text>
<text top="643" left="286" width="3" height="19" font="3"> </text>
<text top="662" left="286" width="115" height="19" font="4"><b>Size:</b>  144 patients<b> </b></text>
<text top="588" left="443" width="151" height="19" font="4"><b>Inclusion criteria: </b>OHCA </text>
<text top="607" left="443" width="3" height="19" font="3"> </text>
<text top="625" left="443" width="113" height="19" font="4"><b>Exclusion criteria</b>: </text>
<text top="643" left="443" width="104" height="19" font="3">Inadequate data<b> </b></text>
<text top="589" left="617" width="143" height="19" font="4"><b>1</b>°<b> endpoint:</b>  return of </text>
<text top="608" left="617" width="176" height="19" font="3">spontaneous circulation and </text>
<text top="626" left="617" width="114" height="19" font="3">hospital discharge </text>
<text top="644" left="617" width="3" height="19" font="3"> </text>
<text top="662" left="617" width="165" height="19" font="4"><b>Results:</b>  Precordial thump </text>
<text top="681" left="617" width="140" height="19" font="3">had no effect on heart </text>
<text top="699" left="617" width="165" height="19" font="3">rhythm in 96% of patients. </text>
<text top="718" left="617" width="170" height="19" font="3">with return of spontaneous </text>
<text top="736" left="617" width="180" height="19" font="3">circulation in only 3 patients. </text>
<text top="589" left="817" width="246" height="19" font="3">A pre-cordial thump did not delay other </text>
<text top="607" left="817" width="215" height="19" font="3">aspects of CPR and had no adverse </text>
<text top="625" left="817" width="200" height="19" font="3">effects; but efficacy was lacking. </text>
</page>
<page number="64" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">64 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="137" height="19" font="3">● Volkman et al. 1990 </text>
<text top="127" left="125" width="39" height="19" font="3">(130)  </text>
<text top="145" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=2087859">● </a></text>
<text top="145" left="137" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=2087859">2087859</a></text>
<text top="145" left="190" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=2087859"> </a></text>
<text top="164" left="125" width="3" height="19" font="3"> </text>
<text top="182" left="125" width="3" height="19" font="3"> </text>
<text top="109" left="286" width="116" height="19" font="4"><b>Study type</b>:  single </text>
<text top="127" left="286" width="137" height="19" font="3">center, observational, </text>
<text top="145" left="286" width="129" height="19" font="3">consecutive patients </text>
<text top="200" left="286" width="3" height="19" font="3"> </text>
<text top="218" left="286" width="107" height="19" font="4"><b>Size:</b>  47 patients<b> </b></text>
<text top="109" left="443" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="127" left="443" width="103" height="19" font="3">patients with VT </text>
<text top="109" left="617" width="170" height="19" font="4"><b>1</b>°<b> endpoint:</b> VT conversion </text>
<text top="128" left="617" width="184" height="19" font="3">following a pre-cordial thump </text>
<text top="146" left="617" width="3" height="19" font="3"> </text>
<text top="164" left="617" width="177" height="19" font="4"><b>Results:</b> VT with a heart rate </text>
<text top="183" left="617" width="180" height="19" font="3">≤160 BPM converted in 17 of </text>
<text top="201" left="617" width="169" height="19" font="3">22 cases, and VT &gt;160 bpm </text>
<text top="219" left="617" width="176" height="19" font="3">converted in 3 of 15 cases. 3 </text>
<text top="238" left="617" width="185" height="19" font="3">cases of VF and 7 cases of VFL </text>
<text top="256" left="617" width="107" height="19" font="3">failed to convert. </text>
<text top="109" left="817" width="255" height="19" font="3">A pre-cordial thump converted VT in 77% </text>
<text top="127" left="817" width="257" height="19" font="3">of patients with a rate ≤160 bpm but only </text>
<text top="145" left="817" width="236" height="19" font="3">20% if the rate was faster.  VF and VFL </text>
<text top="164" left="817" width="101" height="19" font="3">did not convert. </text>
<text top="275" left="115" width="3" height="19" font="3"> </text>
<text top="329" left="115" width="731" height="21" font="2"><b>Data Supplement 17. RCTs Secondary Prevention Sudden Death in Ischemic Heart Disease – (Section 7.1.1) </b></text>
<text top="350" left="125" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="369" left="151" width="55" height="19" font="4"><b>Author;  </b></text>
<text top="387" left="128" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="350" left="260" width="88" height="19" font="4"><b>Aim of Study; </b></text>
<text top="369" left="266" width="76" height="19" font="4"><b>Study Type; </b></text>
<text top="387" left="259" width="89" height="19" font="4"><b>Study Size (N) </b></text>
<text top="350" left="388" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="350" left="537" width="123" height="19" font="4"><b>Study Intervention  </b></text>
<text top="369" left="555" width="88" height="19" font="4"><b>(# patients) /  </b></text>
<text top="387" left="539" width="121" height="19" font="4"><b>Study Comparator  </b></text>
<text top="405" left="560" width="75" height="19" font="4"><b>(# patients) </b></text>
<text top="350" left="691" width="135" height="19" font="4"><b>Endpoint and Results </b></text>
<text top="369" left="757" width="3" height="19" font="4"><b> </b></text>
<text top="353" left="870" width="66" height="19" font="4"><b>Relevant 2</b></text>
<text top="350" left="936" width="7" height="20" font="0">°</text>
<text top="353" left="943" width="115" height="19" font="4"><b> Endpoint (if any); </b></text>
<text top="371" left="906" width="116" height="19" font="4"><b>Study Limitations; </b></text>
<text top="389" left="915" width="99" height="19" font="4"><b>Adverse Events </b></text>
<text top="424" left="123" width="47" height="19" font="3">● <b>AVID </b></text>
<text top="443" left="123" width="72" height="19" font="3">● The AVID </text>
<text top="461" left="123" width="82" height="19" font="3">Investigators </text>
<text top="479" left="123" width="30" height="19" font="3">1997</text>
<text top="478" left="154" width="4" height="21" font="0"> </text>
<text top="479" left="157" width="35" height="19" font="3">(131) </text>
<text top="498" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9411221">● </a></text>
<text top="498" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9411221">9411221</a></text>
<text top="498" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9411221"> </a></text>
<text top="516" left="123" width="3" height="19" font="3"> </text>
<text top="424" left="242" width="110" height="19" font="4"><b>Aim:</b>  To examine </text>
<text top="443" left="242" width="82" height="19" font="3">the effect on </text>
<text top="461" left="242" width="111" height="19" font="3">overall survival of </text>
<text top="479" left="242" width="119" height="19" font="3">initial therapy with </text>
<text top="498" left="242" width="59" height="19" font="3">an ICD as </text>
<text top="516" left="242" width="96" height="19" font="3">compared with </text>
<text top="534" left="242" width="94" height="19" font="3">amiodarone or </text>
<text top="552" left="242" width="112" height="19" font="3">sotalol in patients </text>
<text top="571" left="242" width="111" height="19" font="3">resuscitated from </text>
<text top="589" left="242" width="122" height="19" font="3">VF or symptomatic, </text>
<text top="607" left="242" width="111" height="19" font="3">sustained VT with </text>
<text top="626" left="242" width="90" height="19" font="3">hemodynamic </text>
<text top="644" left="242" width="83" height="19" font="3">compromise. </text>
<text top="662" left="242" width="3" height="19" font="3"> </text>
<text top="680" left="242" width="108" height="19" font="4"><b>Study type:</b>   RCT </text>
<text top="699" left="242" width="3" height="19" font="3"> </text>
<text top="717" left="242" width="76" height="19" font="4"><b>Size:</b>    1016 </text>
<text top="735" left="242" width="53" height="19" font="3">patients </text>
<text top="424" left="378" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="443" left="378" width="117" height="19" font="3">patients who were </text>
<text top="461" left="378" width="111" height="19" font="3">resuscitated from </text>
<text top="479" left="378" width="86" height="19" font="3">near-fatal VF; </text>
<text top="498" left="378" width="111" height="19" font="3">sustained VT with </text>
<text top="516" left="378" width="136" height="19" font="3">syncope; or sustained </text>
<text top="534" left="378" width="138" height="19" font="3">VT with an LVEF ≤0.40 </text>
<text top="552" left="378" width="93" height="19" font="3">and symptoms </text>
<text top="571" left="378" width="111" height="19" font="3">suggesting severe </text>
<text top="589" left="378" width="90" height="19" font="3">hemodynamic </text>
<text top="607" left="378" width="83" height="19" font="3">compromise. </text>
<text top="626" left="378" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="644" left="378" width="98" height="19" font="3">arrhythmia was </text>
<text top="662" left="378" width="105" height="19" font="3">judged to have a </text>
<text top="681" left="378" width="75" height="19" font="3">transient or </text>
<text top="699" left="378" width="118" height="19" font="3">correctable cause,  </text>
<text top="717" left="378" width="125" height="19" font="3">excessively high risk </text>
<text top="735" left="378" width="131" height="19" font="3">(life expectancy &lt;1 y, </text>
<text top="754" left="378" width="137" height="19" font="3">class IV HF, awaiting a </text>
<text top="772" left="378" width="122" height="19" font="3">heart transplant, or </text>
<text top="424" left="531" width="85" height="19" font="4"><b>Intervention:</b> </text>
<text top="443" left="531" width="108" height="19" font="3">Therapy with ICD </text>
<text top="461" left="531" width="7" height="19" font="3">  </text>
<text top="479" left="531" width="93" height="19" font="4"><b>Comparator:</b>  <b>  </b></text>
<text top="498" left="531" width="95" height="19" font="3">Antiarrhythmic </text>
<text top="516" left="531" width="122" height="19" font="3">drugs - amiodarone </text>
<text top="534" left="531" width="131" height="19" font="3">or sotalol, (only 2.6% </text>
<text top="552" left="531" width="104" height="19" font="3">received sotalol)<b> </b></text>
<text top="425" left="677" width="88" height="19" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="443" left="677" width="124" height="19" font="3">Overall survival was </text>
<text top="462" left="677" width="161" height="19" font="3">greater with the ICD, with </text>
<text top="480" left="677" width="150" height="19" font="3">unadjusted estimates of </text>
<text top="498" left="677" width="153" height="19" font="3">89.3% as compared with </text>
<text top="517" left="677" width="79" height="19" font="3">82.3% in the </text>
<text top="535" left="677" width="126" height="19" font="3">antiarrhythmic-drug </text>
<text top="553" left="677" width="140" height="19" font="3">group at 1 y, 81.6% vs. </text>
<text top="572" left="677" width="148" height="19" font="3">74.7% at 2 y, and 75.4% </text>
<text top="590" left="677" width="155" height="19" font="3">vs. 64.1% at 3 y (p&lt;0.02). </text>
<text top="608" left="677" width="117" height="19" font="3">The corresponding </text>
<text top="626" left="677" width="142" height="19" font="3">reductions in mortality </text>
<text top="645" left="677" width="163" height="19" font="3">(with 95% CI) with the ICD </text>
<text top="663" left="677" width="146" height="19" font="3">were 39±20%, 27±21%, </text>
<text top="681" left="677" width="82" height="19" font="3">and 31±21%<b>  </b></text>
<text top="424" left="853" width="189" height="19" font="3">● Study terminated early after </text>
<text top="443" left="853" width="191" height="19" font="3">1016 of 1200 patients enrolled </text>
<text top="461" left="853" width="166" height="19" font="3">● 81% of patients had CAD </text>
<text top="479" left="853" width="209" height="19" font="3">● <b>Conclusion:</b> Among survivors of </text>
<text top="498" left="853" width="209" height="19" font="3">VF or sustained VT causing severe </text>
<text top="516" left="853" width="208" height="19" font="3">symptoms, ICD is superior to AAD </text>
<text top="534" left="853" width="173" height="19" font="3">therapy for reducing overall </text>
<text top="552" left="853" width="67" height="19" font="3">mortality.  </text>
<text top="571" left="853" width="3" height="19" font="3"> </text>
<text top="589" left="853" width="3" height="19" font="3"> </text>
</page>
<page number="65" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">65 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="378" width="119" height="19" font="3">requiring a balloon </text>
<text top="127" left="378" width="80" height="19" font="3">pump, other </text>
<text top="145" left="378" width="136" height="19" font="3">mechanical means, or </text>
<text top="164" left="378" width="90" height="19" font="3">inotropic drug </text>
<text top="182" left="378" width="114" height="19" font="3">administration for </text>
<text top="200" left="378" width="90" height="19" font="3">hemodynamic </text>
<text top="219" left="378" width="56" height="19" font="3">support) </text>
<text top="237" left="378" width="137" height="19" font="3">or excessively low risk </text>
<text top="255" left="378" width="103" height="19" font="3">(event occurring </text>
<text top="273" left="378" width="127" height="19" font="3">within 5 d of cardiac </text>
<text top="292" left="378" width="65" height="19" font="3">surgery or </text>
<text top="310" left="378" width="93" height="19" font="3">angioplasty, or </text>
<text top="329" left="378" width="128" height="19" font="3">occurring in-hospital </text>
<text top="347" left="378" width="91" height="19" font="3">&lt;5 d after MI), </text>
<text top="365" left="378" width="56" height="19" font="3">previous </text>
<text top="383" left="378" width="96" height="19" font="3">ICD implant (or </text>
<text top="402" left="378" width="127" height="19" font="3">attempted implant), </text>
<text top="420" left="378" width="96" height="19" font="3">chronic serious </text>
<text top="438" left="378" width="134" height="19" font="3">bacterial infection, or </text>
<text top="457" left="378" width="124" height="19" font="3">were unable to give </text>
<text top="475" left="378" width="41" height="19" font="3">verbal </text>
<text top="493" left="378" width="86" height="19" font="3">assent due to </text>
<text top="512" left="378" width="68" height="19" font="3">neurologic </text>
<text top="530" left="378" width="106" height="19" font="3">impairment, or a </text>
<text top="548" left="378" width="120" height="19" font="3">contraindication to </text>
<text top="566" left="378" width="78" height="19" font="3">amiodarone </text>
<text top="586" left="123" width="44" height="19" font="3">● <b>CIDS </b></text>
<text top="604" left="123" width="95" height="19" font="3">● Conolly et al. </text>
<text top="622" left="123" width="69" height="19" font="3">2000 (132) </text>
<text top="640" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10725290">● </a></text>
<text top="640" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10725290">10725290</a></text>
<text top="640" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10725290"> </a></text>
<text top="659" left="123" width="3" height="19" font="3"> </text>
<text top="585" left="242" width="112" height="19" font="4"><b>Aim:</b>  To compare </text>
<text top="604" left="242" width="113" height="19" font="3">the efficacy of the </text>
<text top="622" left="242" width="51" height="19" font="3">ICD and </text>
<text top="640" left="242" width="122" height="19" font="3">amiodarone for the </text>
<text top="659" left="242" width="86" height="19" font="3">prevention of </text>
<text top="677" left="242" width="107" height="19" font="3">death in patients </text>
<text top="695" left="242" width="86" height="19" font="3">with previous </text>
<text top="714" left="242" width="82" height="19" font="3">sustained VA </text>
<text top="732" left="242" width="3" height="19" font="3"> </text>
<text top="750" left="242" width="105" height="19" font="4"><b>Study type:</b> RCT  </text>
<text top="769" left="242" width="3" height="19" font="3"> </text>
<text top="585" left="378" width="129" height="19" font="4"><b>Inclusion criteria:</b>  in </text>
<text top="604" left="378" width="133" height="19" font="3">the absence of either </text>
<text top="622" left="378" width="88" height="19" font="3">recent AMI or </text>
<text top="640" left="378" width="139" height="19" font="3">electrolyte imbalance, </text>
<text top="659" left="378" width="128" height="19" font="3">they manifested any </text>
<text top="677" left="378" width="123" height="19" font="3">of the following: (1) </text>
<text top="695" left="378" width="124" height="19" font="3">documented VF; (2) </text>
<text top="714" left="378" width="98" height="19" font="3">OHCA requiring </text>
<text top="732" left="378" width="98" height="19" font="3">defibrillation or </text>
<text top="750" left="378" width="110" height="19" font="3">cardioversion; (3) </text>
<text top="769" left="378" width="85" height="19" font="3">documented, </text>
<text top="585" left="531" width="110" height="19" font="4"><b>Intervention:</b> ICD </text>
<text top="604" left="531" width="7" height="19" font="3">  </text>
<text top="622" left="531" width="93" height="19" font="4"><b>Comparator:</b>  <b>  </b></text>
<text top="640" left="531" width="79" height="19" font="3">Amiodarone<b> </b></text>
<text top="586" left="677" width="158" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Death from </text>
<text top="605" left="677" width="67" height="19" font="3">any cause. </text>
<text top="623" left="677" width="164" height="19" font="3">A nonsignificant reduction </text>
<text top="641" left="677" width="145" height="19" font="3">in the risk of death was </text>
<text top="660" left="677" width="142" height="19" font="3">observed with the ICD, </text>
<text top="678" left="677" width="148" height="19" font="3">from 10.2%/y to 8.3%/y </text>
<text top="696" left="677" width="130" height="19" font="3">(RRR 19.7%; 95% CI: -</text>
<text top="714" left="677" width="144" height="19" font="3">7.7%–40%; p=0.142). A </text>
<text top="733" left="677" width="152" height="19" font="3">nonsignificant reduction </text>
<text top="751" left="677" width="149" height="19" font="3">in the risk of arrhythmic </text>
<text top="769" left="677" width="163" height="19" font="3">death was observed, from </text>
<text top="586" left="853" width="180" height="19" font="3">● 82% had ischemic etiology  </text>
<text top="604" left="853" width="181" height="19" font="3">● <b>Conclusions:</b> CIDS provides </text>
<text top="622" left="853" width="212" height="19" font="3">further support for the superiority </text>
<text top="640" left="853" width="211" height="19" font="3">of the ICD over amiodarone in the </text>
<text top="659" left="853" width="165" height="19" font="3">treatment of patients with </text>
<text top="677" left="853" width="180" height="19" font="3">symptomatic sustained VT or </text>
<text top="695" left="853" width="105" height="19" font="3">resuscitated CA.  </text>
<text top="714" left="853" width="3" height="19" font="3"> </text>
<text top="732" left="853" width="3" height="19" font="3"> </text>
<text top="750" left="853" width="3" height="19" font="3"> </text>
<text top="769" left="853" width="3" height="19" font="3"> </text>
</page>
<page number="66" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">66 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="242" width="266" height="19" font="4"><b>Size:</b>    659 patients  sustained VT causing </text>
<text top="127" left="378" width="114" height="19" font="3">syncope; (4) other </text>
<text top="145" left="378" width="85" height="19" font="3">documented, </text>
<text top="164" left="378" width="136" height="19" font="3">sustained VT at a rate </text>
<text top="182" left="378" width="103" height="19" font="3">≥150 beats/min, </text>
<text top="200" left="378" width="139" height="19" font="3">causing presyncope or </text>
<text top="219" left="378" width="117" height="19" font="3">angina in a patient </text>
<text top="237" left="378" width="131" height="19" font="3">with a LVEF ≤35%; or </text>
<text top="255" left="378" width="104" height="19" font="3">(5) unmonitored </text>
<text top="273" left="378" width="84" height="19" font="3">syncope with </text>
<text top="292" left="378" width="74" height="19" font="3">subsequent </text>
<text top="310" left="378" width="113" height="19" font="3">documentation of </text>
<text top="329" left="378" width="122" height="19" font="3">either spontaneous </text>
<text top="347" left="378" width="129" height="19" font="3">VT≥10 s or sustained </text>
<text top="365" left="378" width="134" height="19" font="3">(≥30 s) monomorphic </text>
<text top="383" left="378" width="89" height="19" font="3">VT induced by </text>
<text top="402" left="378" width="83" height="19" font="3">programmed </text>
<text top="420" left="378" width="69" height="19" font="3">ventricular </text>
<text top="438" left="378" width="80" height="19" font="3">stimulation.  </text>
<text top="457" left="378" width="133" height="19" font="4"><b>Exclusion criteria:</b> (1) </text>
<text top="475" left="378" width="118" height="19" font="3">ICD or amiodarone </text>
<text top="493" left="378" width="95" height="19" font="3">not considered </text>
<text top="512" left="378" width="99" height="19" font="3">appropriate, (2) </text>
<text top="530" left="378" width="60" height="19" font="3">excessive </text>
<text top="548" left="378" width="132" height="19" font="3">perioperative risk for </text>
<text top="566" left="378" width="130" height="19" font="3">ICD implantation; (3) </text>
<text top="585" left="378" width="133" height="19" font="3">previous amiodarone </text>
<text top="603" left="378" width="135" height="19" font="3">therapy for ≥6 wk; (4) </text>
<text top="621" left="378" width="94" height="19" font="3">nonarrhythmic </text>
<text top="640" left="378" width="112" height="19" font="3">medical condition </text>
<text top="658" left="378" width="115" height="19" font="3">making 1y survival </text>
<text top="676" left="378" width="132" height="19" font="3">unlikely, and (5) long-</text>
<text top="695" left="378" width="89" height="19" font="3">QT syndrome. </text>
<text top="109" left="677" width="140" height="19" font="3">4.5%/y to 3.0%/y (RRR </text>
<text top="127" left="677" width="135" height="19" font="3">32.8%; 95% CI, -7.2%–</text>
<text top="145" left="677" width="106" height="19" font="3">57.8%; p=0.094). </text>
<text top="164" left="677" width="3" height="19" font="3"> </text>
<text top="182" left="677" width="3" height="19" font="4"><b> </b></text>
</page>
<page number="67" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">67 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="49" height="19" font="3">● <b>CASH </b></text>
<text top="127" left="123" width="78" height="19" font="3">● Kuck et al. </text>
<text top="145" left="123" width="69" height="19" font="3">2000 (133) </text>
<text top="164" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10942742">● </a></text>
<text top="164" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10942742">10942742</a></text>
<text top="164" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10942742"> </a></text>
<text top="182" left="123" width="3" height="19" font="3"> </text>
<text top="109" left="242" width="113" height="19" font="4"><b>Aim:</b>  to study the </text>
<text top="127" left="242" width="109" height="19" font="3">impact on overall </text>
<text top="145" left="242" width="103" height="19" font="3">survival of initial </text>
<text top="164" left="242" width="100" height="19" font="3">therapy with an </text>
<text top="182" left="242" width="106" height="19" font="3">ICD as compared </text>
<text top="200" left="242" width="100" height="19" font="3">with that with 3 </text>
<text top="219" left="242" width="30" height="19" font="3">AAD </text>
<text top="237" left="242" width="3" height="19" font="3"> </text>
<text top="255" left="242" width="108" height="19" font="4"><b>Study type:</b>   RCT </text>
<text top="273" left="242" width="3" height="19" font="3"> </text>
<text top="292" left="242" width="121" height="19" font="4"><b>Size:</b>    288 patients </text>
<text top="109" left="378" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="127" left="378" width="131" height="19" font="3">patients resuscitated </text>
<text top="145" left="378" width="85" height="19" font="3">from CA 2° to </text>
<text top="164" left="378" width="81" height="19" font="3">documented </text>
<text top="182" left="378" width="82" height="19" font="3">sustained VA </text>
<text top="200" left="378" width="3" height="19" font="3"> </text>
<text top="218" left="378" width="129" height="19" font="4"><b>Exclusion criteria:</b>  If </text>
<text top="237" left="378" width="138" height="19" font="3">CA occurred within 72 </text>
<text top="255" left="378" width="125" height="19" font="3">h of an AMI, cardiac </text>
<text top="273" left="378" width="122" height="19" font="3">surgery, electrolyte </text>
<text top="292" left="378" width="107" height="19" font="3">abnormalities, or </text>
<text top="310" left="378" width="123" height="19" font="3">proarrhythmic drug </text>
<text top="329" left="378" width="43" height="19" font="3">effect. </text>
<text top="109" left="531" width="110" height="19" font="4"><b>Intervention:</b> ICD </text>
<text top="127" left="531" width="51" height="19" font="3">therapy </text>
<text top="145" left="531" width="7" height="19" font="3">  </text>
<text top="164" left="531" width="93" height="19" font="4"><b>Comparator:</b>  <b>  </b></text>
<text top="182" left="531" width="81" height="19" font="3">amiodarone, </text>
<text top="200" left="531" width="92" height="19" font="3">metoprolol, or </text>
<text top="219" left="531" width="86" height="19" font="3">propafenone. </text>
<text top="237" left="531" width="91" height="19" font="3">Assignment to </text>
<text top="255" left="531" width="124" height="19" font="3">propafenone was in </text>
<text top="273" left="531" width="132" height="19" font="3">March 1992, after an </text>
<text top="292" left="531" width="99" height="19" font="3">interim analysis </text>
<text top="310" left="531" width="91" height="19" font="3">showed a 61% </text>
<text top="329" left="531" width="99" height="19" font="3">higher all-cause </text>
<text top="347" left="531" width="119" height="19" font="3">mortality rate than </text>
<text top="365" left="531" width="111" height="19" font="3">in 61 ICD patients </text>
<text top="383" left="531" width="126" height="19" font="3">during a followup of </text>
<text top="402" left="531" width="60" height="19" font="3">11.3 mo. <b> </b></text>
<text top="109" left="677" width="85" height="19" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="109" left="761" width="68" height="19" font="14">The 1° end </text>
<text top="128" left="677" width="119" height="19" font="14">point was all-cause </text>
<text top="146" left="677" width="67" height="19" font="14">mortality.  </text>
<text top="165" left="677" width="154" height="19" font="14">Over a mean followup of </text>
<text top="183" left="677" width="131" height="19" font="14">57±34 mo, the death </text>
<text top="201" left="677" width="158" height="19" font="14">rates were 36.4% (95% CI </text>
<text top="219" left="677" width="141" height="19" font="14">26.9% to 46.6%) in the </text>
<text top="238" left="677" width="140" height="19" font="14">ICD and 44.4% (95% CI </text>
<text top="256" left="677" width="141" height="19" font="14">37.2% to 51.8%) in the </text>
<text top="274" left="677" width="151" height="19" font="14">amiodarone/metoprolol </text>
<text top="293" left="677" width="156" height="19" font="14">arm. Overall survival was </text>
<text top="311" left="677" width="117" height="19" font="14">higher, though not </text>
<text top="329" left="677" width="147" height="19" font="14">significantly, in patients </text>
<text top="348" left="677" width="143" height="19" font="14">assigned to ICD than in </text>
<text top="366" left="677" width="141" height="19" font="14">those assigned to drug </text>
<text top="384" left="677" width="160" height="19" font="14">therapy (1-sided p=0.081, </text>
<text top="402" left="677" width="162" height="19" font="14">HR: 0.766; 97.5% CI upper </text>
<text top="421" left="677" width="82" height="19" font="14">bound 1.112)</text>
<text top="421" left="758" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="853" width="12" height="19" font="3">● </text>
<text top="109" left="866" width="171" height="19" font="14">In ICD patients, the percent </text>
<text top="127" left="853" width="199" height="19" font="14">reductions in all-cause mortality </text>
<text top="145" left="853" width="212" height="19" font="14">were 41.9%, 39.3%, 28.4%, 27.7%, </text>
<text top="164" left="853" width="197" height="19" font="14">22.8%, 11.4%, 9.1%, 10.6%, and </text>
<text top="182" left="853" width="178" height="19" font="14">24.7% at y 1 to 9 of followup.</text>
<text top="182" left="1032" width="3" height="19" font="3"> </text>
<text top="200" left="853" width="215" height="19" font="3">● Coronary disease was etiology in </text>
<text top="219" left="853" width="33" height="19" font="3">73%. </text>
<text top="219" left="886" width="167" height="19" font="14">A much larger reduction of </text>
<text top="237" left="853" width="165" height="19" font="14">61%, for SCD was observed</text>
<text top="237" left="1019" width="3" height="19" font="3"> </text>
<text top="255" left="853" width="3" height="19" font="3"> </text>
<text top="273" left="853" width="3" height="19" font="3"> </text>
<text top="440" left="123" width="103" height="19" font="3">● Connolly et al. </text>
<text top="458" left="123" width="69" height="19" font="3">2000 (134) </text>
<text top="476" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11102258">● </a></text>
<text top="476" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11102258">11102258</a></text>
<text top="476" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11102258"> </a></text>
<text top="495" left="123" width="3" height="19" font="4"><b> </b></text>
<text top="440" left="242" width="117" height="19" font="4"><b>Aim:</b> To obtain the </text>
<text top="458" left="242" width="81" height="19" font="3">most precise </text>
<text top="476" left="242" width="96" height="19" font="3">estimate of the </text>
<text top="495" left="242" width="118" height="19" font="3">efficacy of the ICD, </text>
<text top="513" left="242" width="88" height="19" font="3">compared  to  </text>
<text top="531" left="242" width="106" height="19" font="3">amiodarone,  for </text>
<text top="550" left="242" width="118" height="19" font="3">survival in patients </text>
<text top="568" left="242" width="119" height="19" font="3">with malignant VA. </text>
<text top="586" left="242" width="3" height="19" font="3"> </text>
<text top="605" left="242" width="118" height="19" font="4"><b>Study type:</b>   Meta-</text>
<text top="623" left="242" width="100" height="19" font="3">analysis of RCTs </text>
<text top="641" left="242" width="3" height="19" font="3"> </text>
<text top="659" left="242" width="86" height="19" font="4"><b>Size:</b>    3 RCTs </text>
<text top="440" left="378" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="458" left="378" width="33" height="19" font="3">RCTs </text>
<text top="476" left="378" width="135" height="19" font="3">evaluating the ICD vs. </text>
<text top="495" left="378" width="96" height="19" font="3">AAD therapy in </text>
<text top="513" left="378" width="83" height="19" font="3">patients with </text>
<text top="531" left="378" width="126" height="19" font="3">sustained VA or SCD<b> </b></text>
<text top="550" left="378" width="3" height="19" font="4"><b> </b></text>
<text top="440" left="531" width="85" height="19" font="4"><b>Intervention: </b></text>
<text top="458" left="531" width="113" height="19" font="3">ICD (934 patients) </text>
<text top="476" left="531" width="3" height="19" font="4"><b> </b></text>
<text top="495" left="531" width="83" height="19" font="4"><b>Comparator: </b></text>
<text top="513" left="531" width="110" height="19" font="3">Amiodarone (932 </text>
<text top="531" left="531" width="58" height="19" font="3">patients) </text>
<text top="441" left="677" width="150" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Reduction </text>
<text top="459" left="677" width="150" height="19" font="3">in death from any cause </text>
<text top="477" left="677" width="137" height="19" font="3">with the ICD, HR 0.72; </text>
<text top="496" left="677" width="110" height="19" font="3">95% CI 0.60-0.87; </text>
<text top="514" left="677" width="72" height="19" font="3">p=0.0006).  </text>
<text top="532" left="677" width="3" height="19" font="3"> </text>
<text top="550" left="677" width="3" height="19" font="4"><b> </b></text>
<text top="440" left="853" width="106" height="19" font="3">● <b>2° endpoints:</b>   </text>
<text top="458" left="853" width="214" height="19" font="3">Arrhythmic death, HR 0.50 (95% CI </text>
<text top="476" left="853" width="137" height="19" font="3">0.37-0.67; p&lt;0.0001).  </text>
<text top="495" left="853" width="222" height="19" font="3">Survival was extended by a mean of </text>
<text top="513" left="853" width="210" height="19" font="3">4.4 mo by the ICD over a followup </text>
<text top="531" left="853" width="87" height="19" font="3">period of 6 y.  </text>
<text top="550" left="853" width="155" height="19" font="3">● P heterogeneity=0.306 </text>
<text top="568" left="853" width="202" height="19" font="3">Patients with LVEF ≤35% derived </text>
<text top="586" left="853" width="192" height="19" font="3">more benefit from ICD therapy </text>
<text top="605" left="853" width="200" height="19" font="3">than those with more preserved </text>
<text top="623" left="853" width="151" height="19" font="3">left ventricular function. </text>
<text top="679" left="123" width="75" height="19" font="3">● <b>MAVERIC </b></text>
<text top="697" left="123" width="92" height="19" font="3">Lau et al. 2004 </text>
<text top="715" left="123" width="39" height="19" font="3">(135)  </text>
<text top="734" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15172648">● </a></text>
<text top="734" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15172648">15172648</a></text>
<text top="733" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15172648"> </a></text>
<text top="752" left="123" width="3" height="19" font="3"> </text>
<text top="770" left="123" width="3" height="19" font="4"><b> </b></text>
<text top="678" left="242" width="103" height="19" font="4"><b>Aim:</b>  to test the </text>
<text top="697" left="242" width="80" height="19" font="3">possibility of </text>
<text top="715" left="242" width="85" height="19" font="3">prospectively </text>
<text top="734" left="242" width="121" height="19" font="3">identifying patients </text>
<text top="752" left="242" width="118" height="19" font="3">who would benefit </text>
<text top="770" left="242" width="117" height="19" font="3">most ICD by EPS in </text>
<text top="678" left="378" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="697" left="378" width="136" height="19" font="3">survivors of sustained </text>
<text top="715" left="378" width="124" height="19" font="3">VT, VF or SCD in the </text>
<text top="734" left="378" width="131" height="19" font="3">absence of an AMI in </text>
<text top="752" left="378" width="82" height="19" font="3">the last 48 h. </text>
<text top="770" left="378" width="3" height="19" font="3"> </text>
<text top="678" left="531" width="105" height="19" font="4"><b>Intervention:</b> EP-</text>
<text top="697" left="531" width="130" height="19" font="3">guided interventions </text>
<text top="715" left="531" width="96" height="19" font="3">(AAD, coronary </text>
<text top="734" left="531" width="110" height="19" font="3">revascularization, </text>
<text top="752" left="531" width="86" height="19" font="3">and ICD) (106 </text>
<text top="679" left="677" width="152" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Of the 108 </text>
<text top="698" left="677" width="160" height="19" font="3">EP arm patients, 31 (29%) </text>
<text top="716" left="677" width="159" height="19" font="3">received an ICD, 46 (43%) </text>
<text top="734" left="677" width="163" height="19" font="3">received AAD only (mainly </text>
<text top="753" left="677" width="143" height="19" font="3">amiodarone or sotalol) </text>
<text top="771" left="677" width="139" height="19" font="3">and 18 (17%) received </text>
<text top="679" left="853" width="190" height="19" font="3">● 61% of patients had prior MI </text>
<text top="697" left="853" width="201" height="19" font="3">EPS has a minimal impact on the </text>
<text top="715" left="853" width="194" height="19" font="3">diagnosis of patients presented </text>
<text top="734" left="853" width="120" height="19" font="3">with VT, VF or SCD. </text>
<text top="752" left="853" width="220" height="19" font="3">The trial does not support a role for </text>
<text top="770" left="853" width="188" height="19" font="3">EP testing in risk stratification. </text>
</page>
<page number="68" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">68 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="242" width="105" height="19" font="3">the context of 2° </text>
<text top="127" left="242" width="74" height="19" font="3">prevention. </text>
<text top="145" left="242" width="3" height="19" font="3"> </text>
<text top="164" left="242" width="108" height="19" font="4"><b>Study type:</b>   RCT </text>
<text top="182" left="242" width="3" height="19" font="3"> </text>
<text top="200" left="242" width="121" height="19" font="4"><b>Size:</b>    214 patients<b> </b></text>
<text top="109" left="378" width="139" height="19" font="4"><b>Exclusion criteria:</b>  life </text>
<text top="127" left="378" width="130" height="19" font="3">expectancy of &lt;6 mo </text>
<text top="145" left="378" width="72" height="19" font="3">from a non-</text>
<text top="164" left="378" width="125" height="19" font="3">arrhythmic cause or </text>
<text top="182" left="378" width="108" height="19" font="3">child-bearing age<b> </b></text>
<text top="109" left="531" width="125" height="19" font="3">patients assigned to </text>
<text top="127" left="531" width="58" height="19" font="3">this arm) </text>
<text top="145" left="531" width="3" height="19" font="3"> </text>
<text top="164" left="531" width="83" height="19" font="4"><b>Comparator:</b> </text>
<text top="182" left="531" width="81" height="19" font="3">therapy with </text>
<text top="200" left="531" width="108" height="19" font="3">amiodarone (108 </text>
<text top="219" left="531" width="125" height="19" font="3">patients assigned to </text>
<text top="237" left="531" width="58" height="19" font="3">this arm)<b> </b></text>
<text top="109" left="677" width="58" height="19" font="3">coronary </text>
<text top="127" left="677" width="150" height="19" font="3">revascularization but no </text>
<text top="145" left="677" width="115" height="19" font="3">ICD. No significant </text>
<text top="164" left="677" width="153" height="19" font="3">differences in survival or </text>
<text top="182" left="677" width="141" height="19" font="3">arrhythmia recurrence </text>
<text top="200" left="677" width="155" height="19" font="3">existed between the two </text>
<text top="219" left="677" width="157" height="19" font="3">treatment arms after 6 y. </text>
<text top="237" left="677" width="150" height="19" font="3">However, ICD recipients </text>
<text top="255" left="677" width="134" height="19" font="3">had a lower mortality </text>
<text top="273" left="677" width="151" height="19" font="3">than non-ICD recipients, </text>
<text top="292" left="677" width="141" height="19" font="3">regardless of allocated </text>
<text top="310" left="677" width="129" height="19" font="3">treatment (HR=0.54, </text>
<text top="328" left="677" width="69" height="19" font="3">p=0.0391).<b> </b></text>
<text top="347" left="123" width="81" height="19" font="3">● Claro et al. </text>
<text top="366" left="123" width="73" height="19" font="3">2015 (136)  </text>
<text top="384" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26646017">● </a></text>
<text top="384" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26646017">26646017</a></text>
<text top="384" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26646017"> </a></text>
<text top="402" left="123" width="3" height="19" font="3"> </text>
<text top="421" left="123" width="3" height="19" font="3"> </text>
<text top="347" left="242" width="110" height="19" font="4"><b>Aim:</b>  To evaluate </text>
<text top="366" left="242" width="107" height="19" font="3">the effectiveness </text>
<text top="384" left="242" width="114" height="19" font="3">of amiodarone for </text>
<text top="402" left="242" width="119" height="19" font="3">1° or 2° prevention </text>
<text top="421" left="242" width="109" height="19" font="3">of SCD compared </text>
<text top="439" left="242" width="118" height="19" font="3">with placebo or no </text>
<text top="457" left="242" width="121" height="19" font="3">intervention or any </text>
<text top="476" left="242" width="37" height="19" font="3">other </text>
<text top="494" left="242" width="98" height="19" font="3">antiarrhythmic. </text>
<text top="512" left="242" width="3" height="19" font="3"> </text>
<text top="531" left="242" width="117" height="19" font="4"><b>Study type:</b>   meta-</text>
<text top="549" left="242" width="101" height="19" font="3">analyses using a </text>
<text top="567" left="242" width="97" height="19" font="3">random-effects </text>
<text top="586" left="242" width="42" height="19" font="3">model </text>
<text top="604" left="242" width="3" height="19" font="3"> </text>
<text top="622" left="242" width="107" height="19" font="4"><b>Size:</b>    24 studies </text>
<text top="640" left="242" width="122" height="19" font="3">(9,997 participants) </text>
<text top="659" left="242" width="88" height="19" font="3">with 6 studies </text>
<text top="677" left="242" width="94" height="19" font="3">identified as 2° </text>
<text top="695" left="242" width="108" height="19" font="3">prevention trials.<b> </b></text>
<text top="347" left="378" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="366" left="378" width="139" height="19" font="3">Randomized assessing </text>
<text top="384" left="378" width="90" height="19" font="3">the efficacy of </text>
<text top="402" left="378" width="97" height="19" font="3">amiodarone vs. </text>
<text top="421" left="378" width="74" height="19" font="3">placebo, no </text>
<text top="439" left="378" width="136" height="19" font="3">intervention, or other </text>
<text top="457" left="378" width="114" height="19" font="3">antiarrhythmics in </text>
<text top="476" left="378" width="121" height="19" font="3">adults, either for 1° </text>
<text top="494" left="378" width="103" height="19" font="3">prevention or 2° </text>
<text top="512" left="378" width="118" height="19" font="3">prevention of SCD.<b> </b></text>
<text top="347" left="531" width="85" height="19" font="4"><b>Intervention:</b> </text>
<text top="366" left="531" width="79" height="19" font="3">Amiodarone </text>
<text top="384" left="531" width="7" height="19" font="3">  </text>
<text top="402" left="531" width="86" height="19" font="4"><b>Comparator:</b>  </text>
<text top="421" left="531" width="74" height="19" font="3">placebo, no </text>
<text top="439" left="531" width="123" height="19" font="3">intervention, ICD or </text>
<text top="457" left="531" width="37" height="19" font="3">other </text>
<text top="476" left="531" width="100" height="19" font="3">antiarrhythmics<b> </b></text>
<text top="348" left="677" width="124" height="19" font="4"><b>1</b>°<b> endpoint:</b>  For 2° </text>
<text top="367" left="677" width="151" height="19" font="3">prevention, amiodarone </text>
<text top="385" left="677" width="150" height="19" font="3">compared to placebo or </text>
<text top="403" left="677" width="129" height="19" font="3">no intervention (two </text>
<text top="422" left="677" width="157" height="19" font="3">studies, 440 participants) </text>
<text top="440" left="677" width="156" height="19" font="3">appeared to increase the </text>
<text top="458" left="677" width="159" height="19" font="3">risk of SCD (RR: 4.32; 95% </text>
<text top="476" left="677" width="140" height="19" font="3">CI: 0.87–21.49) and all-</text>
<text top="495" left="677" width="126" height="19" font="3">cause mortality (RR: </text>
<text top="513" left="677" width="151" height="19" font="3">3.05;95% CI: 1.33–7.01). </text>
<text top="531" left="677" width="150" height="19" font="3">Compared to other AAD </text>
<text top="550" left="677" width="110" height="19" font="3">(four studies, 839 </text>
<text top="568" left="677" width="158" height="19" font="3">participants) amiodarone </text>
<text top="586" left="677" width="156" height="19" font="3">appeared to increase the </text>
<text top="605" left="677" width="159" height="19" font="3">risk of SCD (RR: 1.40; 95% </text>
<text top="623" left="677" width="142" height="19" font="3">CI: 0.56–3.52; very low </text>
<text top="641" left="677" width="151" height="19" font="3">quality of evidence), but </text>
<text top="660" left="677" width="155" height="19" font="3">there was no effect in all-</text>
<text top="678" left="677" width="160" height="19" font="3">cause mortality (RR: 1.03; </text>
<text top="696" left="677" width="142" height="19" font="3">95% CI: 0.75–1.42; low </text>
<text top="714" left="677" width="112" height="19" font="3">quality evidence).<b> </b></text>
<text top="347" left="853" width="182" height="19" font="3">● <b>Conclusions: </b>With very low </text>
<text top="366" left="853" width="219" height="19" font="3">quality evidence, amiodarone leads </text>
<text top="384" left="853" width="192" height="19" font="3">to a statistically non-significant </text>
<text top="402" left="853" width="206" height="19" font="3">increase in the risk of SCD and all-</text>
<text top="421" left="853" width="207" height="19" font="3">cause mortality (by 33% to 600%) </text>
<text top="439" left="853" width="206" height="19" font="3">when compared to placebo or no </text>
<text top="457" left="853" width="201" height="19" font="3">intervention.  This meta-analysis </text>
<text top="476" left="853" width="212" height="19" font="3">did not effectively rule out benefit </text>
<text top="494" left="853" width="190" height="19" font="3">or harm for 2° prevention with </text>
<text top="512" left="853" width="85" height="19" font="3">amiodarone.  </text>
<text top="531" left="853" width="198" height="19" font="3">● <b>Side effects:</b> Amiodarone was </text>
<text top="549" left="853" width="186" height="19" font="3">associated with an increase in </text>
<text top="567" left="853" width="195" height="19" font="3">pulmonary and thyroid adverse </text>
<text top="586" left="853" width="48" height="19" font="3">events. </text>
<text top="604" left="853" width="203" height="19" font="3">● <b>Limitations:</b> For 2° prevention, </text>
<text top="622" left="853" width="198" height="19" font="3">the evidence is inconsistent and </text>
<text top="640" left="853" width="194" height="19" font="3">the quality of the evidence was </text>
<text top="659" left="853" width="217" height="19" font="3">very low, so the authors concluded </text>
<text top="677" left="853" width="194" height="19" font="3">that there is uncertainty on the </text>
<text top="695" left="853" width="157" height="19" font="3">findings.  There are some </text>
<text top="714" left="853" width="218" height="19" font="3">methodological issues that warrant </text>
<text top="732" left="853" width="209" height="19" font="3">certain caution when interpreting </text>
<text top="750" left="853" width="85" height="19" font="3">these results. </text>
<text top="769" left="115" width="3" height="19" font="3"> </text>
</page>
<page number="69" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">69 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="3" height="19" font="3"> </text>
<text top="162" left="115" width="945" height="21" font="2"><b>Data Supplement 18. Nonrandomized Trials, Observational Studies, and/or Registries for Secondary Prevention Sudden Death in Ischemic </b></text>
<text top="182" left="115" width="212" height="21" font="2"><b>Heart Disease – (Section 7.1.1) </b></text>
<text top="203" left="136" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="221" left="161" width="55" height="19" font="4"><b>Author;  </b></text>
<text top="240" left="139" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="203" left="305" width="88" height="19" font="4"><b>Aim of Study; </b></text>
<text top="221" left="311" width="76" height="19" font="4"><b>Study Type; </b></text>
<text top="240" left="304" width="89" height="19" font="4"><b>Study Size (N) </b></text>
<text top="203" left="468" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="203" left="663" width="135" height="19" font="4"><b>Endpoint and Results </b></text>
<text top="221" left="729" width="3" height="19" font="4"><b> </b></text>
<text top="205" left="870" width="66" height="19" font="4"><b>Relevant 2</b></text>
<text top="203" left="936" width="7" height="20" font="0">°</text>
<text top="205" left="942" width="115" height="19" font="4"><b> Endpoint (if any); </b></text>
<text top="224" left="905" width="116" height="19" font="4"><b>Study Limitations; </b></text>
<text top="242" left="914" width="99" height="19" font="4"><b>Adverse Events </b></text>
<text top="261" left="123" width="112" height="19" font="3">● Raitt et al.<b> </b>2001 </text>
<text top="280" left="123" width="35" height="19" font="3">(137) </text>
<text top="298" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11208684">● </a></text>
<text top="298" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11208684">11208684</a></text>
<text top="298" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11208684"> </a></text>
<text top="316" left="123" width="3" height="19" font="3"> </text>
<text top="261" left="264" width="122" height="19" font="4"><b>Aim:</b>  To determine </text>
<text top="280" left="264" width="161" height="19" font="3">prognostic implications of </text>
<text top="298" left="264" width="60" height="19" font="3">stable VT </text>
<text top="316" left="264" width="3" height="19" font="3"> </text>
<text top="334" left="264" width="167" height="19" font="4"><b>Study type:</b> Observational, </text>
<text top="353" left="264" width="149" height="19" font="3">registry of patients with </text>
<text top="371" left="264" width="151" height="19" font="3">hemodynamically stable </text>
<text top="390" left="264" width="23" height="19" font="3">VT  </text>
<text top="408" left="264" width="3" height="19" font="3"> </text>
<text top="426" left="264" width="35" height="19" font="4"><b>Size:</b>  </text>
<text top="426" left="299" width="133" height="19" font="14">The study population </text>
<text top="444" left="264" width="156" height="19" font="14">consisted of 440 patients </text>
<text top="463" left="264" width="150" height="19" font="14">with stable VT and 1029 </text>
<text top="481" left="264" width="162" height="19" font="14">patients with unstable VT. </text>
<text top="499" left="264" width="159" height="19" font="14">Of the 1029 patients with </text>
<text top="518" left="264" width="131" height="19" font="14">unstable VT, 330 had </text>
<text top="536" left="264" width="144" height="19" font="14">therapy determined by </text>
<text top="554" left="264" width="164" height="19" font="14">randomization in the AVID </text>
<text top="573" left="264" width="163" height="19" font="14">trial: 52% received an ICD, </text>
<text top="591" left="264" width="159" height="19" font="14">47% amiodarone, and 2% </text>
<text top="609" left="264" width="146" height="19" font="14">sotalol. Therapy for the </text>
<text top="627" left="264" width="144" height="19" font="14">remaining 699 patients </text>
<text top="646" left="264" width="156" height="19" font="14">with unstable VT and the </text>
<text top="664" left="264" width="169" height="19" font="14">440 patients with stable VT </text>
<text top="682" left="264" width="142" height="19" font="14">was determined at the </text>
<text top="701" left="264" width="166" height="19" font="14">discretion of the attending </text>
<text top="719" left="264" width="60" height="19" font="14">physician.</text>
<text top="719" left="324" width="3" height="19" font="4"><b> </b></text>
<text top="261" left="447" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="280" left="447" width="8" height="19" font="3">P</text>
<text top="280" left="455" width="135" height="19" font="14">atients with stable VT </text>
<text top="298" left="447" width="156" height="19" font="14">that were not enrolled in </text>
<text top="316" left="447" width="152" height="19" font="14">AVID, were included in a </text>
<text top="334" left="447" width="118" height="19" font="14">registry of patients </text>
<text top="353" left="447" width="141" height="19" font="14">screened for the study.</text>
<text top="353" left="588" width="3" height="19" font="3"> </text>
<text top="371" left="447" width="3" height="19" font="3"> </text>
<text top="389" left="447" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="408" left="447" width="128" height="19" font="14">Patients who had an </text>
<text top="426" left="447" width="162" height="19" font="14">arrhythmia within 5 d of a </text>
<text top="444" left="447" width="140" height="19" font="14">MI, cardiac surgery, or </text>
<text top="463" left="447" width="137" height="19" font="14">coronary intervention </text>
<text top="481" left="447" width="147" height="19" font="14">were excluded, as were </text>
<text top="499" left="447" width="151" height="19" font="14">patients with class IV HF </text>
<text top="518" left="447" width="148" height="19" font="14">or those who were on a </text>
<text top="536" left="447" width="153" height="19" font="14">heart transplant list, had </text>
<text top="554" left="447" width="135" height="19" font="14">a prior ICD implant or </text>
<text top="573" left="447" width="139" height="19" font="14">attempted implant, or </text>
<text top="591" left="447" width="147" height="19" font="14">had a life expectancy of </text>
<text top="609" left="447" width="29" height="19" font="14">&lt;1 y.</text>
<text top="609" left="476" width="3" height="19" font="4"><b> </b></text>
<text top="262" left="622" width="3" height="19" font="14"> </text>
<text top="262" left="626" width="145" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Mortality </text>
<text top="280" left="622" width="3" height="19" font="3"> </text>
<text top="299" left="622" width="182" height="19" font="4"><b>Results:</b>  The mortality in 440 </text>
<text top="317" left="622" width="206" height="19" font="3">patients with stable VT tended to </text>
<text top="335" left="622" width="201" height="19" font="3">be greater than that observed in </text>
<text top="354" left="622" width="186" height="19" font="3">1029 patients presenting with </text>
<text top="372" left="622" width="208" height="19" font="3">unstable VT (33.6% vs. 27.6% at 3 </text>
<text top="390" left="622" width="156" height="19" font="3">y; RR:1.22; p=0.07). After </text>
<text top="409" left="622" width="175" height="19" font="3">adjustment for baseline and </text>
<text top="427" left="622" width="212" height="19" font="3">treatment differences, the RR was </text>
<text top="445" left="622" width="202" height="19" font="3">little changed (RR: 1.25, p=0.06). </text>
<text top="463" left="622" width="3" height="19" font="3"> </text>
<text top="482" left="622" width="3" height="19" font="4"><b> </b></text>
<text top="261" left="852" width="12" height="19" font="3">● </text>
<text top="261" left="864" width="180" height="19" font="14">Sustained VT without serious </text>
<text top="280" left="852" width="173" height="19" font="14">symptoms or hemodynamic </text>
<text top="298" left="852" width="201" height="19" font="14">compromise is associated with a </text>
<text top="316" left="852" width="202" height="19" font="14">high mortality rate and may be a </text>
<text top="334" left="852" width="206" height="19" font="14">marker for a substrate capable of </text>
<text top="353" left="852" width="176" height="19" font="14">producing a more malignant </text>
<text top="371" left="852" width="72" height="19" font="14">arrhythmia.</text>
<text top="371" left="923" width="3" height="19" font="4"><b> </b></text>
</page>
<page number="70" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">70 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="95" height="19" font="3">● Bass EB et al. </text>
<text top="127" left="123" width="69" height="19" font="3">1988 (138) </text>
<text top="145" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3195480">● </a></text>
<text top="145" left="136" width="53" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3195480">3195480</a></text>
<text top="145" left="189" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3195480"> </a></text>
<text top="109" left="264" width="159" height="19" font="4"><b>Study type: </b>retrospective </text>
<text top="127" left="264" width="44" height="19" font="3">cohort </text>
<text top="145" left="264" width="3" height="19" font="4"><b> </b></text>
<text top="164" left="264" width="104" height="19" font="4"><b>Size:</b> 70 patients<b> </b></text>
<text top="109" left="447" width="142" height="19" font="4"><b>Inclusion: </b>unexplained </text>
<text top="127" left="447" width="109" height="19" font="3">syncope EP study </text>
<text top="145" left="447" width="149" height="19" font="3">between April 1981 and </text>
<text top="164" left="447" width="73" height="19" font="3">April 1986. <b> </b></text>
<text top="182" left="447" width="93" height="19" font="4"><b>Exclusion: </b>N/A<b> </b></text>
<text top="109" left="622" width="52" height="19" font="4"><b>Results: </b></text>
<text top="127" left="622" width="210" height="19" font="3">EP study had positive results in 37 </text>
<text top="145" left="622" width="198" height="19" font="3">patients--31 with VT, 3 with SVT </text>
<text top="164" left="622" width="209" height="19" font="3">and 3 with abnormal conduction.  </text>
<text top="182" left="622" width="3" height="19" font="3"> </text>
<text top="200" left="622" width="216" height="19" font="3">No difference in the 3 y recurrence </text>
<text top="219" left="622" width="206" height="19" font="3">rate between the ± studies (32 vs </text>
<text top="237" left="622" width="121" height="19" font="3">24%, respectively).  </text>
<text top="255" left="622" width="3" height="19" font="3"> </text>
<text top="273" left="622" width="209" height="19" font="3">At 3 y, patients + had higher rates </text>
<text top="292" left="622" width="210" height="19" font="3">of SCD than patients with - results </text>
<text top="310" left="622" width="156" height="19" font="3">(48% vs 9%, respectively, </text>
<text top="329" left="622" width="65" height="19" font="3">p&lt;0.002).  </text>
<text top="347" left="622" width="3" height="19" font="3"> </text>
<text top="365" left="622" width="196" height="19" font="3">3 y total mortality rate was also </text>
<text top="383" left="622" width="205" height="19" font="3">higher with + results than among </text>
<text top="402" left="622" width="159" height="19" font="3">those with - (61% vs 15%, </text>
<text top="420" left="622" width="145" height="19" font="3">respectively, p&lt;0.001). <b> </b></text>
<text top="109" left="852" width="171" height="19" font="3">● <b>Conclusion: </b>patients with </text>
<text top="127" left="852" width="186" height="19" font="3">electrophysiologically positive </text>
<text top="145" left="852" width="204" height="19" font="3">results had high rates of SCD and </text>
<text top="164" left="852" width="95" height="19" font="3">total mortality  </text>
<text top="439" left="123" width="112" height="19" font="3">● Owens DK et al. </text>
<text top="457" left="123" width="69" height="19" font="3">2002 (139) </text>
<text top="476" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12228780">● </a></text>
<text top="476" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12228780">12228780</a></text>
<text top="476" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12228780"> </a></text>
<text top="439" left="264" width="151" height="19" font="4"><b>Aim: </b>Evaluated whether </text>
<text top="457" left="264" width="164" height="19" font="3">risk stratification based on </text>
<text top="476" left="264" width="129" height="19" font="3">risk ofSCD alone was </text>
<text top="494" left="264" width="147" height="19" font="3">sufficient to predict the </text>
<text top="512" left="264" width="140" height="19" font="3">effectiveness and cost-</text>
<text top="531" left="264" width="151" height="19" font="3">effectiveness of the ICD. </text>
<text top="439" left="447" width="108" height="19" font="3">Markov model to </text>
<text top="457" left="447" width="109" height="19" font="3">evaluate the cost-</text>
<text top="476" left="447" width="124" height="19" font="3">effectiveness of ICD </text>
<text top="494" left="447" width="147" height="19" font="3">implantation compared </text>
<text top="512" left="447" width="157" height="19" font="3">with empiric amiodarone </text>
<text top="531" left="447" width="138" height="19" font="3">treatment. The model </text>
<text top="549" left="447" width="142" height="19" font="3">incorporated mortality </text>
<text top="567" left="447" width="142" height="19" font="3">rates from sudden and </text>
<text top="586" left="447" width="162" height="19" font="3">nonsudden cardiac death, </text>
<text top="604" left="447" width="136" height="19" font="3">noncardiac death and </text>
<text top="622" left="447" width="153" height="19" font="3">costs for each treatment </text>
<text top="640" left="447" width="157" height="19" font="3">strategy. Model assumed </text>
<text top="659" left="447" width="162" height="19" font="3">that the ICD reduced total </text>
<text top="677" left="447" width="145" height="19" font="3">mortality rates by 25%, </text>
<text top="695" left="447" width="106" height="19" font="3">relative to use of </text>
<text top="714" left="447" width="81" height="19" font="3">amiodarone. </text>
<text top="439" left="622" width="166" height="19" font="4"><b>Results: </b>cost-effectiveness </text>
<text top="457" left="622" width="208" height="19" font="3">becomes unfavorable at both low </text>
<text top="476" left="622" width="194" height="19" font="3">and high total cardiac mortality </text>
<text top="494" left="622" width="41" height="19" font="3">rates.  </text>
<text top="512" left="622" width="159" height="19" font="3">If the annual total cardiac </text>
<text top="531" left="622" width="187" height="19" font="3">mortality rate is 12%, the cost-</text>
<text top="549" left="622" width="187" height="19" font="3">effectiveness of the ICD varies </text>
<text top="567" left="622" width="212" height="19" font="3">from $36,000 per quality-adjusted </text>
<text top="586" left="622" width="204" height="19" font="3">life-year (QALY) gained when the </text>
<text top="604" left="622" width="199" height="19" font="3">ratio of sudden cardiac death to </text>
<text top="622" left="622" width="198" height="19" font="3">nonsudden cardiac death is 4 to </text>
<text top="640" left="622" width="202" height="19" font="3">$116,000 per QALY gained when </text>
<text top="659" left="622" width="102" height="19" font="3">the ratio is 0.25. </text>
<text top="439" left="852" width="217" height="19" font="3">● The cost-effectiveness of ICD use </text>
<text top="457" left="852" width="218" height="19" font="3">relative to amiodarone depends on </text>
<text top="476" left="852" width="217" height="19" font="3">total cardiac mortality rates as well </text>
<text top="494" left="852" width="153" height="19" font="3">as the ratio of sudden to </text>
<text top="512" left="852" width="162" height="19" font="3">nonsudden cardiac death. </text>
<text top="732" left="115" width="4" height="23" font="10"><b> </b></text>
<text top="754" left="115" width="4" height="21" font="0"> </text>
<text top="754" left="331" width="4" height="21" font="2"><b> </b></text>
</page>
<page number="71" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">71 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="900" height="21" font="2"><b>Data Supplement 19. Nonrandomized Trials, Observational Studies, and/or Registries for Coronary Artery Spasm – (Section 7.1.1.1) </b></text>
<text top="129" left="155" width="51" height="19" font="4"><b>Author; </b></text>
<text top="147" left="133" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="129" left="265" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="147" left="294" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="129" left="442" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="129" left="644" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="147" left="656" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="165" left="688" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="129" left="896" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="147" left="924" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="184" left="125" width="108" height="19" font="3">● Ahn et al. 2016 </text>
<text top="203" left="125" width="35" height="19" font="3">(140) </text>
<text top="221" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27386766">● </a></text>
<text top="221" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27386766">27386766</a></text>
<text top="221" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27386766"> </a></text>
<text top="239" left="125" width="3" height="19" font="3"> </text>
<text top="184" left="250" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="203" left="250" width="84" height="19" font="3">retrospective </text>
<text top="221" left="250" width="122" height="19" font="3">multicenter cohort  </text>
<text top="239" left="250" width="3" height="19" font="4"><b> </b></text>
<text top="258" left="250" width="152" height="19" font="4"><b>Size:</b>    188 patients with </text>
<text top="276" left="250" width="80" height="19" font="3">aborted SCD </text>
<text top="294" left="250" width="3" height="19" font="3"> </text>
<text top="313" left="250" width="145" height="19" font="3">Median followup of 7.5 </text>
<text top="331" left="250" width="10" height="19" font="3">y<b> </b></text>
<text top="184" left="418" width="156" height="19" font="3">188 patients with variant </text>
<text top="203" left="418" width="154" height="19" font="3">angina with aborted SCD </text>
<text top="221" left="418" width="147" height="19" font="3">and 1,844 patients with </text>
<text top="239" left="418" width="141" height="19" font="3">variant angina without </text>
<text top="258" left="418" width="167" height="19" font="3">aborted SCD from 13 heart </text>
<text top="276" left="418" width="148" height="19" font="3">centers in South Korea.  </text>
<text top="294" left="418" width="3" height="19" font="3"> </text>
<text top="313" left="418" width="3" height="19" font="3"> </text>
<text top="185" left="599" width="236" height="19" font="4"><b>1</b>°<b> endpoint:</b>  The 1° end point cardiac </text>
<text top="204" left="599" width="39" height="19" font="3">death </text>
<text top="222" left="599" width="3" height="19" font="3"> </text>
<text top="240" left="599" width="233" height="19" font="3">Cardiac death was significantly higher </text>
<text top="258" left="599" width="225" height="19" font="3">in aborted SCD patients (24.1 /1,000 </text>
<text top="277" left="599" width="232" height="19" font="3">patient-y vs. 2.7/ 1,000 patient-y (HR: </text>
<text top="295" left="599" width="205" height="19" font="3">7.26; 95% CI: 4.21-12.5; p&lt;0.001) </text>
<text top="314" left="599" width="3" height="19" font="3"> </text>
<text top="332" left="599" width="225" height="19" font="3">Predictors included family Hx of SCD </text>
<text top="350" left="599" width="239" height="19" font="3">(OR: 3.67; 95% CI: 1.27-10.6; p=0.016), </text>
<text top="368" left="599" width="227" height="19" font="3">multivessel spasm (OR: 2.06; 95% CI: </text>
<text top="387" left="599" width="221" height="19" font="3">1.33-3.19; p=0.001), and LAD artery </text>
<text top="405" left="599" width="220" height="19" font="3">spasm (OR: 1.40; 95% CI: 1.02-1.92; </text>
<text top="423" left="599" width="53" height="19" font="3">p=0.04)  </text>
<text top="442" left="599" width="3" height="19" font="3"> </text>
<text top="460" left="599" width="211" height="19" font="3">A total of 24 aborted SCD patients </text>
<text top="478" left="599" width="83" height="19" font="3">received ICD  </text>
<text top="497" left="599" width="3" height="19" font="3"> </text>
<text top="515" left="599" width="223" height="19" font="3">6 ICD patients experienced VF and 1 </text>
<text top="533" left="599" width="165" height="19" font="3">died due to intractable VF. </text>
<text top="552" left="599" width="3" height="19" font="3"> </text>
<text top="570" left="599" width="201" height="19" font="3">In the aborted SCD patients who </text>
<text top="588" left="599" width="222" height="19" font="3">received an ICD, mortality was 4.3% </text>
<text top="606" left="599" width="241" height="19" font="3">compared with 19.3% of those that did </text>
<text top="625" left="599" width="180" height="19" font="3">not receive an ICD (trend but </text>
<text top="643" left="599" width="139" height="19" font="3">nonsignificant p=0.15) </text>
<text top="184" left="853" width="198" height="19" font="3">● <b>Conclusions:</b> The prognosis of </text>
<text top="203" left="853" width="204" height="19" font="3">patients with variant angina with </text>
<text top="221" left="853" width="172" height="19" font="3">ASCD was worse than other </text>
<text top="239" left="853" width="193" height="19" font="3">patients with variant angina. In </text>
<text top="258" left="853" width="200" height="19" font="3">addition, our findings supported </text>
<text top="276" left="853" width="218" height="19" font="3">ICDs in these high-risk patients as a </text>
<text top="294" left="853" width="188" height="19" font="3">2° prevention because current </text>
<text top="313" left="853" width="176" height="19" font="3">multiple vasodilator therapy </text>
<text top="331" left="853" width="177" height="19" font="3">appeared to be less optimal. </text>
<text top="349" left="853" width="214" height="19" font="3">● <b>Limitations:</b> Retrospective study </text>
<text top="368" left="853" width="198" height="19" font="3">and no accurate information for </text>
<text top="386" left="853" width="194" height="19" font="3">response to medical therapy or </text>
<text top="404" left="853" width="198" height="19" font="3">compliance. This is an ethnically </text>
<text top="423" left="853" width="166" height="19" font="3">homogenous group raising </text>
<text top="441" left="853" width="204" height="19" font="3">questions about extrapolation to </text>
<text top="459" left="853" width="193" height="19" font="3">other ethnicities. It is unknown </text>
<text top="478" left="853" width="173" height="19" font="3">what factors might have led </text>
<text top="496" left="853" width="186" height="19" font="3">physicians to implant an ICD.   </text>
<text top="514" left="853" width="3" height="19" font="4"><b> </b></text>
<text top="662" left="125" width="98" height="19" font="3">● Yamashina et </text>
<text top="682" left="125" width="51" height="19" font="3">al. 2014 </text>
<text top="680" left="176" width="35" height="21" font="0">(141)</text>
<text top="682" left="212" width="7" height="19" font="3">  </text>
<text top="701" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23906527">● </a></text>
<text top="701" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23906527">23906527</a></text>
<text top="701" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23906527"> </a></text>
<text top="719" left="125" width="3" height="19" font="3"> </text>
<text top="662" left="250" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="680" left="250" width="123" height="19" font="3">retrospective single </text>
<text top="699" left="250" width="90" height="19" font="3">center cohort  </text>
<text top="717" left="250" width="3" height="19" font="3"> </text>
<text top="735" left="250" width="128" height="19" font="4"><b>Size:</b>    18 patients in </text>
<text top="754" left="250" width="129" height="19" font="3">Japan between 1992 </text>
<text top="772" left="250" width="63" height="19" font="3">and 2012  </text>
<text top="662" left="418" width="165" height="19" font="3">Resuscitated from CA with </text>
<text top="680" left="418" width="153" height="19" font="3">1) documented VF/VT or </text>
<text top="699" left="418" width="162" height="19" font="3">PEA and 2) the absence of </text>
<text top="717" left="418" width="158" height="19" font="3">significant narrowing due </text>
<text top="735" left="418" width="74" height="19" font="3">to coronary </text>
<text top="754" left="418" width="137" height="19" font="3">atherosclerosis or any </text>
<text top="772" left="418" width="109" height="19" font="3">structural cardiac </text>
<text top="663" left="599" width="186" height="19" font="4"><b>1</b>°<b> endpoint:</b>  recurrent VT/VF </text>
<text top="681" left="599" width="3" height="19" font="3"> </text>
<text top="699" left="599" width="233" height="19" font="4"><b>Results:</b> No recurrent VA, syncope, or </text>
<text top="718" left="599" width="226" height="19" font="3">CA during a mean followup of 67 mo </text>
<text top="736" left="599" width="184" height="19" font="3">(1 of 18 died during the initial </text>
<text top="755" left="599" width="223" height="19" font="3">hospitalization and another cancer). </text>
<text top="773" left="599" width="193" height="19" font="3">All are treated with long-acting </text>
<text top="662" left="853" width="197" height="19" font="3">● <b>Conclusions: </b>Medical therapy </text>
<text top="680" left="853" width="190" height="19" font="3">associated with favorable long-</text>
<text top="699" left="853" width="202" height="19" font="3">term outcomes for patients with </text>
<text top="717" left="853" width="215" height="19" font="3">vasospastic angina associated with </text>
<text top="735" left="853" width="24" height="19" font="3">CA. </text>
</page>
<page number="72" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">72 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="250" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="418" width="140" height="19" font="3">abnormalities possibly </text>
<text top="127" left="418" width="158" height="19" font="3">causing CA; 3) absence of </text>
<text top="145" left="418" width="153" height="19" font="3">identifiable or reversible </text>
<text top="164" left="418" width="134" height="19" font="3">causes of lethal VA 4) </text>
<text top="182" left="418" width="158" height="19" font="3">documented ST elevation </text>
<text top="200" left="418" width="125" height="19" font="3">during chest pain or </text>
<text top="219" left="418" width="155" height="19" font="3">positive provocation test </text>
<text top="109" left="599" width="216" height="19" font="3">CCBs/nitrates and successfully quit </text>
<text top="127" left="599" width="62" height="19" font="3">smoking.  </text>
<text top="145" left="599" width="3" height="19" font="3"> </text>
<text top="164" left="599" width="192" height="19" font="3">6 received ICD – none received </text>
<text top="182" left="599" width="61" height="19" font="3">therapies </text>
<text top="109" left="853" width="217" height="19" font="3">● <b>Limitations:</b> small, retrospective, </text>
<text top="127" left="853" width="193" height="19" font="3">and non-randomized study in a </text>
<text top="145" left="853" width="144" height="19" font="3">single Japanese center. </text>
<text top="164" left="853" width="3" height="19" font="4"><b> </b></text>
<text top="238" left="125" width="104" height="19" font="3">● Eschalier et al. </text>
<text top="256" left="125" width="69" height="19" font="3">2014 (142) </text>
<text top="274" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24373622">● </a></text>
<text top="274" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24373622">24373622</a></text>
<text top="274" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24373622"> </a></text>
<text top="292" left="125" width="3" height="19" font="3"> </text>
<text top="237" left="250" width="111" height="19" font="4"><b>Study type:</b>   case </text>
<text top="256" left="250" width="48" height="19" font="3">reports </text>
<text top="274" left="250" width="3" height="19" font="3"> </text>
<text top="292" left="250" width="110" height="19" font="4"><b>Size:</b>    3 patients. </text>
<text top="238" left="418" width="167" height="19" font="3">Patients with CA related to </text>
<text top="256" left="418" width="168" height="19" font="3">coronary artery vasospasm </text>
<text top="274" left="418" width="3" height="19" font="3"> </text>
<text top="237" left="599" width="225" height="19" font="4"><b>Results:</b> 2/3 patients underwent ICD </text>
<text top="256" left="599" width="231" height="19" font="3">implantation because of recurrent VT </text>
<text top="274" left="599" width="220" height="19" font="3">despite medical therapy.  None had </text>
<text top="292" left="599" width="149" height="19" font="3">ICD shocks in follow-up. </text>
<text top="237" left="853" width="217" height="19" font="4"><b>Conclusions:</b> Very small case series </text>
<text top="256" left="853" width="210" height="19" font="3">demonstrating ICD use in patients </text>
<text top="274" left="853" width="162" height="19" font="3">with coronary vasospasm. </text>
<text top="292" left="853" width="3" height="19" font="3"> </text>
<text top="312" left="125" width="96" height="19" font="3">● Matsue et al. </text>
<text top="330" left="125" width="69" height="19" font="3">2012 (143) </text>
<text top="348" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22840527">● </a></text>
<text top="348" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22840527">22840527</a></text>
<text top="348" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22840527"> </a></text>
<text top="366" left="125" width="3" height="19" font="3"> </text>
<text top="311" left="250" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="330" left="250" width="84" height="19" font="3">retrospective </text>
<text top="348" left="250" width="130" height="19" font="3">observational cohort </text>
<text top="366" left="250" width="3" height="19" font="3"> </text>
<text top="385" left="250" width="144" height="19" font="4"><b>Size:</b>  23 patients. from </text>
<text top="403" left="250" width="128" height="19" font="3">3 Japanese hospitals </text>
<text top="422" left="250" width="3" height="19" font="3"> </text>
<text top="440" left="250" width="139" height="19" font="3">Mean followup period </text>
<text top="458" left="250" width="48" height="19" font="3">of 2.9 y </text>
<text top="312" left="418" width="154" height="19" font="3">23 patients with aborted </text>
<text top="330" left="418" width="112" height="19" font="3">SCD receiving a 2° </text>
<text top="348" left="418" width="133" height="19" font="3">prevention ICD in the </text>
<text top="366" left="418" width="144" height="19" font="3">absence of SHD or CAD </text>
<text top="385" left="418" width="164" height="19" font="3">who had spasm of a major </text>
<text top="403" left="418" width="161" height="19" font="3">epicardial coronary artery </text>
<text top="422" left="418" width="167" height="19" font="3">induced with acetylcholine </text>
<text top="440" left="418" width="62" height="19" font="3">challenge </text>
<text top="458" left="418" width="3" height="19" font="3"> </text>
<text top="476" left="418" width="3" height="19" font="3"> </text>
<text top="311" left="599" width="230" height="19" font="4"><b>Endpoints:</b>  Appropriate ICD therapy, </text>
<text top="330" left="599" width="225" height="19" font="3">sudden CA, or death from all causes  </text>
<text top="348" left="599" width="3" height="19" font="3"> </text>
<text top="366" left="599" width="215" height="19" font="3">26% of patients experienced event </text>
<text top="385" left="599" width="3" height="19" font="3"> </text>
<text top="403" left="599" width="195" height="19" font="3">4 patients had an episode of VF </text>
<text top="422" left="599" width="236" height="19" font="3">appropriately treated by their ICD and </text>
<text top="440" left="599" width="186" height="19" font="3">survived (all but 1 patient was </text>
<text top="458" left="599" width="229" height="19" font="3">compliant with vasodilator therapy).  </text>
<text top="476" left="599" width="229" height="19" font="3">After the first episode of appropriate </text>
<text top="495" left="599" width="229" height="19" font="3">ICD therapy in these 4 patients, none </text>
<text top="513" left="599" width="234" height="19" font="3">received recurrent therapy during the </text>
<text top="531" left="599" width="112" height="19" font="3">limited follow-up. </text>
<text top="550" left="599" width="3" height="19" font="3"> </text>
<text top="568" left="599" width="230" height="19" font="3">1 additional patient survived CA 2° to </text>
<text top="586" left="599" width="165" height="19" font="3">pulseless electrical activity </text>
<text top="605" left="599" width="3" height="19" font="3"> </text>
<text top="312" left="853" width="195" height="19" font="3">● <b>Results: </b>The average time for </text>
<text top="330" left="853" width="209" height="19" font="3">appropriate ICD therapy from ICD </text>
<text top="348" left="853" width="201" height="19" font="3">insertion was about 1 y and only </text>
<text top="366" left="853" width="207" height="19" font="3">2/5 patients with recurrent lethal </text>
<text top="385" left="853" width="216" height="19" font="3">arrhythmia had symptoms of chest </text>
<text top="403" left="853" width="162" height="19" font="3">pain prior to ICD therapy.  </text>
<text top="422" left="853" width="215" height="19" font="3">● <b>Conclusions:</b> These data support </text>
<text top="440" left="853" width="207" height="19" font="3">the use of ICD therapy in patients </text>
<text top="458" left="853" width="198" height="19" font="3">with coronary artery vasospasm </text>
<text top="476" left="853" width="203" height="19" font="3">who have survived an episode of </text>
<text top="495" left="853" width="139" height="19" font="3">life-threatening VT/VF </text>
<text top="513" left="853" width="196" height="19" font="3">● <b>Limitations:</b> Non-randomized </text>
<text top="531" left="853" width="189" height="19" font="3">and relatively small number of </text>
<text top="550" left="853" width="167" height="19" font="3">Japanese patients in only 3 </text>
<text top="568" left="853" width="147" height="19" font="3">cardiovascular centers.  </text>
<text top="586" left="853" width="208" height="19" font="3">● The cohort in the present study </text>
<text top="605" left="853" width="169" height="19" font="3">included only patients with </text>
<text top="623" left="853" width="215" height="19" font="3">coronary vasospasm who had SCD, </text>
<text top="641" left="853" width="186" height="19" font="3">and thus the data shown here </text>
<text top="660" left="853" width="186" height="19" font="3">cannot be extrapolated to the </text>
<text top="678" left="853" width="168" height="19" font="3">whole coronary vasospasm </text>
<text top="696" left="853" width="77" height="19" font="3">population.  </text>
<text top="714" left="853" width="186" height="19" font="3">● Medication compliance was </text>
<text top="733" left="853" width="162" height="19" font="3">evaluated only by medical </text>
<text top="751" left="853" width="203" height="19" font="3">interview with patients, and that </text>
</page>
<page number="73" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">73 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="853" width="209" height="19" font="3">may have caused over-estimation </text>
<text top="127" left="853" width="93" height="19" font="3">of compliance. </text>
<text top="146" left="125" width="88" height="19" font="3">● Takagi et al. </text>
<text top="164" left="125" width="69" height="19" font="3">2011 (144) </text>
<text top="183" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21406685">● </a></text>
<text top="183" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21406685">21406685</a></text>
<text top="183" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21406685"> </a></text>
<text top="201" left="125" width="3" height="19" font="3"> </text>
<text top="146" left="250" width="153" height="19" font="4"><b>Study type:</b>   nationwide </text>
<text top="164" left="250" width="149" height="19" font="3">registry of patients with </text>
<text top="183" left="250" width="117" height="19" font="3">vasospastic angina </text>
<text top="201" left="250" width="3" height="19" font="3"> </text>
<text top="219" left="250" width="137" height="19" font="4"><b>Size:</b>  35 patients with </text>
<text top="238" left="250" width="43" height="19" font="3">OHCA. </text>
<text top="146" left="418" width="162" height="19" font="3">30 men and 5 women had </text>
<text top="164" left="418" width="157" height="19" font="3">OHCA within a registry of </text>
<text top="183" left="418" width="140" height="19" font="3">1429 patients in Japan </text>
<text top="201" left="418" width="147" height="19" font="3">with vasospastic angina </text>
<text top="219" left="418" width="133" height="19" font="3">(definition: an angina </text>
<text top="238" left="418" width="148" height="19" font="3">attack at rest and/or on </text>
<text top="256" left="418" width="156" height="19" font="3">effort, accompanied by a </text>
<text top="274" left="418" width="161" height="19" font="3">transient ECG ST-segment </text>
<text top="293" left="418" width="162" height="19" font="3">elevation or depression of </text>
<text top="311" left="418" width="117" height="19" font="3">&gt;0.1mV or a newly </text>
<text top="329" left="418" width="160" height="19" font="3">appearance of negative U </text>
<text top="347" left="418" width="156" height="19" font="3">wave in at least 2 related </text>
<text top="366" left="418" width="143" height="19" font="3">leads, and/or a total or </text>
<text top="384" left="418" width="152" height="19" font="3">subtotal coronary artery </text>
<text top="402" left="418" width="132" height="19" font="3">narrowing during the </text>
<text top="421" left="418" width="119" height="19" font="3">provocation test of </text>
<text top="439" left="418" width="104" height="19" font="3">coronary spasm, </text>
<text top="457" left="418" width="139" height="19" font="3">accompanied by chest </text>
<text top="476" left="418" width="159" height="19" font="3">pain and/or ischemic ECG </text>
<text top="494" left="418" width="123" height="19" font="3">changes mentioned </text>
<text top="512" left="418" width="49" height="19" font="3">above)  </text>
<text top="531" left="418" width="3" height="19" font="3"> </text>
<text top="549" left="418" width="3" height="19" font="3"> </text>
<text top="567" left="418" width="7" height="19" font="3">  </text>
<text top="147" left="599" width="229" height="19" font="4"><b>1</b>°<b> endpoint:</b>  The 1° end point MACE </text>
<text top="165" left="599" width="223" height="19" font="3">included cardiac death, nonfatal MI, </text>
<text top="183" left="599" width="214" height="19" font="3">hospitalization for unstable angina </text>
<text top="202" left="599" width="229" height="19" font="3">pectoris and HF, and appropriate ICD </text>
<text top="220" left="599" width="219" height="19" font="3">shocks during the follow-up period, </text>
<text top="239" left="599" width="216" height="19" font="3">which began at the date of original </text>
<text top="257" left="599" width="95" height="19" font="3">VSA diagnosis.  </text>
<text top="275" left="599" width="3" height="19" font="3"> </text>
<text top="294" left="599" width="235" height="19" font="4"><b>2</b>°<b> endpoint:</b>  The 2° end point was all-</text>
<text top="312" left="599" width="105" height="19" font="3">cause mortality.  </text>
<text top="331" left="599" width="3" height="19" font="4"><b> </b></text>
<text top="349" left="599" width="56" height="19" font="4"><b>Results:</b>  </text>
<text top="367" left="599" width="208" height="19" font="3">Survival rate free from MACE was </text>
<text top="386" left="599" width="192" height="19" font="3">significantly lower in the OHCA </text>
<text top="404" left="599" width="206" height="19" font="3">survivors compared with the non-</text>
<text top="422" left="599" width="216" height="19" font="3">OHCA patients (72% vs. 92% at 5 y, </text>
<text top="441" left="599" width="230" height="19" font="3">p<i>&lt;</i>0.001).  There was no difference in </text>
<text top="459" left="599" width="197" height="19" font="3">all-cause mortality between the </text>
<text top="477" left="599" width="49" height="19" font="3">groups. </text>
<text top="146" left="853" width="198" height="19" font="3">● <b>Results (continued):</b> In the 35 </text>
<text top="164" left="853" width="173" height="19" font="3">OHCA survivors, 14 patients </text>
<text top="183" left="853" width="213" height="19" font="3">underwent ICD implantation while </text>
<text top="201" left="853" width="198" height="19" font="3">intensively treated with calcium </text>
<text top="219" left="853" width="110" height="19" font="3">channel blockers. </text>
<text top="238" left="853" width="211" height="19" font="3">Appropriate ICD shocks for VF in 2 </text>
<text top="256" left="853" width="195" height="19" font="3">of 14 patients despite intensive </text>
<text top="274" left="853" width="209" height="19" font="3">medical treatment.  SCD occurred </text>
<text top="293" left="853" width="197" height="19" font="3">in 1 patient without an ICD who </text>
<text top="311" left="853" width="213" height="19" font="3">self-discontinued medication prior </text>
<text top="329" left="853" width="113" height="19" font="3">to the fatal event. </text>
<text top="347" left="853" width="172" height="19" font="3">● Rate of cardiac death and </text>
<text top="366" left="853" width="199" height="19" font="3">nonfatal MI in patients in whom </text>
<text top="384" left="853" width="182" height="19" font="3">medications were reduced or </text>
<text top="402" left="853" width="215" height="19" font="3">discontinued (8%, 2 of 25 patients) </text>
<text top="421" left="853" width="215" height="19" font="3">was 10-fold higher than that in the </text>
<text top="439" left="853" width="149" height="19" font="3">patients with continued </text>
<text top="457" left="853" width="188" height="19" font="3">medications (0.7%, 10 of 1404 </text>
<text top="476" left="853" width="122" height="19" font="3">patients, p=0.017).  </text>
<text top="494" left="853" width="191" height="19" font="3">● <b>Limitations:</b> Appropriate ICD </text>
<text top="512" left="853" width="196" height="19" font="3">therapy is used as surrogate for </text>
<text top="531" left="853" width="182" height="19" font="3">sudden death.  Retrospective </text>
<text top="549" left="853" width="210" height="19" font="3">observational study and there the </text>
<text top="567" left="853" width="200" height="19" font="3">association found in the present </text>
<text top="586" left="853" width="212" height="19" font="3">study is not necessarily causal and </text>
<text top="604" left="853" width="197" height="19" font="3">follow-up duration was variable </text>
<text top="622" left="853" width="205" height="19" font="3">possible many arrhythmic events </text>
<text top="640" left="853" width="84" height="19" font="3">were missed. </text>
<text top="660" left="125" width="90" height="19" font="3">● Meisel et al. </text>
<text top="678" left="125" width="73" height="19" font="3">2002 (145)  </text>
<text top="696" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11988204">● </a></text>
<text top="696" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11988204">11988204</a></text>
<text top="696" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11988204"> </a></text>
<text top="714" left="125" width="3" height="19" font="3"> </text>
<text top="659" left="250" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="678" left="250" width="118" height="19" font="3">Retrospective case </text>
<text top="696" left="250" width="149" height="19" font="3">review with multicenter </text>
<text top="714" left="250" width="43" height="19" font="3">survey </text>
<text top="733" left="250" width="3" height="19" font="3"> </text>
<text top="659" left="418" width="135" height="19" font="4"><b>Inclusion criteria:</b>  (1) </text>
<text top="678" left="418" width="152" height="19" font="3">typical chest pain at rest </text>
<text top="696" left="418" width="156" height="19" font="3">associated with transient </text>
<text top="714" left="418" width="165" height="19" font="3">ST-segment elevations not </text>
<text top="733" left="418" width="147" height="19" font="3">present on the baseline </text>
<text top="751" left="418" width="167" height="19" font="3">ECG and disappearing with </text>
<text top="769" left="418" width="105" height="19" font="3">relief of pain; (2) </text>
<text top="659" left="599" width="238" height="19" font="4"><b>Results:</b> All patients were treated with </text>
<text top="678" left="599" width="226" height="19" font="3">maximum tolerated calcium channel </text>
<text top="696" left="599" width="78" height="19" font="3">antagonists. </text>
<text top="714" left="599" width="3" height="19" font="3"> </text>
<text top="733" left="599" width="213" height="19" font="3">Ventricular arrhythmia reoccurred </text>
<text top="751" left="599" width="234" height="19" font="3">after discharge in all patients. Median </text>
<text top="769" left="599" width="240" height="19" font="3">time to the first arrhythmia recurrence </text>
<text top="660" left="853" width="194" height="19" font="3">● <b>Conclusions:</b> VF complicating </text>
<text top="678" left="853" width="180" height="19" font="3">variant angina is a higher risk </text>
<text top="696" left="853" width="211" height="19" font="3">population.  Raises possibility that </text>
<text top="714" left="853" width="175" height="19" font="3">some patients such as those </text>
<text top="733" left="853" width="196" height="19" font="3">remaining symptomatic despite </text>
<text top="751" left="853" width="165" height="19" font="3">medical therapy should be </text>
<text top="769" left="853" width="139" height="19" font="3">considered for an ICD. </text>
</page>
<page number="74" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">74 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="250" width="136" height="19" font="4"><b>Size:</b>    8 patients with </text>
<text top="127" left="250" width="117" height="19" font="3">vasospastic angina </text>
<text top="145" left="250" width="115" height="19" font="3">complicated by VF </text>
<text top="109" left="418" width="100" height="19" font="3">documented VF </text>
<text top="127" left="418" width="136" height="19" font="3">immediately after the </text>
<text top="145" left="418" width="131" height="19" font="3">ischemic episode; (3) </text>
<text top="164" left="418" width="126" height="19" font="3">survival of the index </text>
<text top="182" left="418" width="110" height="19" font="3">episode of VF; (4) </text>
<text top="200" left="418" width="150" height="19" font="3">angiographically normal </text>
<text top="219" left="418" width="158" height="19" font="3">coronary arteries defined </text>
<text top="237" left="418" width="160" height="19" font="3">as patent arteries with no </text>
<text top="255" left="418" width="105" height="19" font="3">irregularities; (5) </text>
<text top="273" left="418" width="156" height="19" font="3">angiographic evidence of </text>
<text top="292" left="418" width="166" height="19" font="3">coronary spasm defined as </text>
<text top="310" left="418" width="140" height="19" font="3">transient narrowing of </text>
<text top="329" left="418" width="167" height="19" font="3">arterial lumen or recurrent </text>
<text top="347" left="418" width="101" height="19" font="3">episodes of ECG </text>
<text top="365" left="418" width="138" height="19" font="3">documented ischemia </text>
<text top="383" left="418" width="149" height="19" font="3">especially if occurring in </text>
<text top="402" left="418" width="115" height="19" font="3">different coronary </text>
<text top="420" left="418" width="115" height="19" font="3">territories; and (6) </text>
<text top="438" left="418" width="153" height="19" font="3">recurrent angina despite </text>
<text top="457" left="418" width="102" height="19" font="3">medical therapy </text>
<text top="475" left="418" width="3" height="19" font="3"> </text>
<text top="493" left="418" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="109" left="599" width="230" height="19" font="3">was 15 mo (range 2-112). An ICD was </text>
<text top="127" left="599" width="233" height="19" font="3">subsequently implanted in 7 patients. </text>
<text top="145" left="599" width="3" height="19" font="3"> </text>
<text top="164" left="599" width="208" height="19" font="3">After ICD implantation, 4 patients </text>
<text top="182" left="599" width="221" height="19" font="3">received appropriate ICD shocks for </text>
<text top="200" left="599" width="217" height="19" font="3">VT/VF.  1 patient died with ICD and </text>
<text top="219" left="599" width="197" height="19" font="3">recurrent chest pain with EMD.  </text>
<text top="237" left="599" width="3" height="19" font="3"> </text>
<text top="255" left="599" width="239" height="19" font="3">1 patient with recurrent VF and no ICD </text>
<text top="273" left="599" width="225" height="19" font="3">had recurrent VF out of hospital and </text>
<text top="292" left="599" width="218" height="19" font="3">subsequent brain damage and died </text>
<text top="310" left="599" width="118" height="19" font="3">several years later. </text>
<text top="329" left="599" width="3" height="19" font="3"> </text>
<text top="109" left="853" width="3" height="19" font="3"> </text>
<text top="512" left="125" width="106" height="19" font="3">● Chevalier et al. </text>
<text top="531" left="125" width="30" height="19" font="3">1998</text>
<text top="529" left="155" width="4" height="21" font="0"> </text>
<text top="531" left="159" width="35" height="19" font="3">(146) </text>
<text top="549" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9426018">● </a></text>
<text top="549" left="137" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9426018">9426018</a></text>
<text top="549" left="190" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9426018"> </a></text>
<text top="567" left="125" width="3" height="19" font="3"> </text>
<text top="512" left="250" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="531" left="250" width="115" height="19" font="3">retrospective case </text>
<text top="549" left="250" width="44" height="19" font="3">review </text>
<text top="567" left="250" width="3" height="19" font="3"> </text>
<text top="585" left="250" width="106" height="19" font="4"><b>Size:</b>   7 patients  </text>
<text top="512" left="418" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="531" left="418" width="125" height="19" font="3">survivors of CA with </text>
<text top="549" left="418" width="124" height="19" font="3">positive ergonovine </text>
<text top="567" left="418" width="104" height="19" font="3">provocation test </text>
<text top="586" left="418" width="3" height="19" font="3"> </text>
<text top="604" left="418" width="135" height="19" font="3">Mean age was 44 y; 3 </text>
<text top="622" left="418" width="160" height="19" font="3">were male and 4 females. </text>
<text top="640" left="418" width="158" height="19" font="3">All of them were habitual </text>
<text top="659" left="418" width="119" height="19" font="3">cigarette smokers.  </text>
<text top="677" left="418" width="3" height="19" font="3"> </text>
<text top="695" left="418" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="512" left="599" width="240" height="19" font="4"><b>Results:</b>  At a mean follow-up 58 mo, 6 </text>
<text top="531" left="599" width="241" height="19" font="3">patients remained free of symptoms. 1 </text>
<text top="549" left="599" width="234" height="19" font="3">patient who continued smoking had a </text>
<text top="567" left="599" width="213" height="19" font="3">new CA despite 10 y after and was </text>
<text top="586" left="599" width="241" height="19" font="3">discovered to have a new LAD and RCA </text>
<text top="604" left="599" width="238" height="19" font="3">stenosis and underwent CABG and ICD </text>
<text top="622" left="599" width="72" height="19" font="3">placement. </text>
<text top="640" left="599" width="3" height="19" font="3"> </text>
<text top="659" left="599" width="3" height="19" font="3"> </text>
<text top="512" left="853" width="211" height="19" font="3">● <b>Conclusions: </b>medical treatment </text>
<text top="531" left="853" width="206" height="19" font="3">with calcium channel antagonists </text>
<text top="549" left="853" width="204" height="19" font="3">appears to be associated with an </text>
<text top="567" left="853" width="218" height="19" font="3">event-free clinical course. Stopping </text>
<text top="586" left="853" width="139" height="19" font="3">smoking is important.  </text>
<text top="604" left="853" width="3" height="19" font="3"> </text>
<text top="714" left="125" width="110" height="19" font="3">● Myerburg et al. </text>
<text top="733" left="125" width="69" height="19" font="3">1992 (147) </text>
<text top="751" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1574091">● </a></text>
<text top="751" left="137" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1574091">1574091</a></text>
<text top="751" left="190" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1574091"> </a></text>
<text top="769" left="125" width="3" height="19" font="3"> </text>
<text top="714" left="250" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="733" left="250" width="128" height="19" font="3">retrospective cohort </text>
<text top="751" left="250" width="3" height="19" font="3"> </text>
<text top="769" left="250" width="96" height="19" font="4"><b>Size:</b> 5 patients </text>
<text top="714" left="418" width="125" height="19" font="4"><b>Inclusion:</b> From 356 </text>
<text top="733" left="418" width="158" height="19" font="3">patients, included were 5 </text>
<text top="751" left="418" width="113" height="19" font="3">survivors of OHCA </text>
<text top="769" left="418" width="151" height="19" font="3">between 1980 and 1991 </text>
<text top="714" left="599" width="229" height="19" font="4"><b>Results:</b>  Titration of calcium channel </text>
<text top="733" left="599" width="227" height="19" font="3">blocking drugs (verapamil, diltiazem, </text>
<text top="751" left="599" width="213" height="19" font="3">or nifedipine) against the ability of </text>
<text top="769" left="599" width="211" height="19" font="3">ergonovine to provoke spasm was </text>
<text top="714" left="853" width="97" height="19" font="3">● <b>Conclusions:  </b></text>
<text top="733" left="853" width="199" height="19" font="3">Silent MI due to coronary artery </text>
<text top="751" left="853" width="213" height="19" font="3">spasm can initiate potentially fatal </text>
</page>
<page number="75" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">75 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="418" width="143" height="19" font="3">without epicardial CAD </text>
<text top="127" left="418" width="99" height="19" font="3">with induced or </text>
<text top="145" left="418" width="115" height="19" font="3">spontaneous focal </text>
<text top="164" left="418" width="161" height="19" font="3">coronary artery spasm (or </text>
<text top="182" left="418" width="37" height="19" font="3">both) </text>
<text top="200" left="418" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="109" left="599" width="210" height="19" font="3">successful in preventing recurrent </text>
<text top="127" left="599" width="177" height="19" font="3">arrhythmias in all 4 patients. </text>
<text top="145" left="599" width="3" height="19" font="3"> </text>
<text top="164" left="599" width="221" height="19" font="3">1/5 patients had a positive EPS with </text>
<text top="182" left="599" width="235" height="19" font="3">ventricular flutter despite propranolol </text>
<text top="200" left="599" width="138" height="19" font="3">so ICD was implanted. </text>
<text top="109" left="853" width="196" height="19" font="3">arrhythmias in patients without </text>
<text top="127" left="853" width="113" height="19" font="3">flow-limiting CAD. </text>
<text top="145" left="853" width="181" height="19" font="3">In patients with OHCA due to </text>
<text top="164" left="853" width="197" height="19" font="3">coronary vasospasm, treatment </text>
<text top="182" left="853" width="186" height="19" font="3">with calcium channel blocking </text>
<text top="200" left="853" width="163" height="19" font="3">agents appears to prevent </text>
<text top="219" left="853" width="142" height="19" font="3">recurrent arrhythmias. </text>
<text top="237" left="853" width="3" height="19" font="3"> </text>
<text top="255" left="853" width="3" height="19" font="3"> </text>
<text top="274" left="115" width="3" height="19" font="3"> </text>
<text top="292" left="115" width="3" height="19" font="3"> </text>
<text top="346" left="115" width="859" height="21" font="2"><b>Data Supplement 20. Nonrandomized Trials, Observational Studies, and/or Registries for Post CABG VT/VF – (Section 7.1.1.2) </b></text>
<text top="368" left="155" width="51" height="19" font="4"><b>Author; </b></text>
<text top="386" left="132" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="368" left="262" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="386" left="291" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="368" left="422" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="368" left="608" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="386" left="621" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="404" left="652" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="368" left="877" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="386" left="905" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="423" left="123" width="86" height="19" font="3">● Saxon et al. </text>
<text top="442" left="123" width="69" height="19" font="3">1995 (148) </text>
<text top="460" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7856540">● </a></text>
<text top="460" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7856540">7856540</a></text>
<text top="460" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7856540"> </a></text>
<text top="478" left="123" width="3" height="19" font="3"> </text>
<text top="423" left="250" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="442" left="250" width="123" height="19" font="3">retrospective single </text>
<text top="460" left="250" width="90" height="19" font="3">center cohort  </text>
<text top="478" left="250" width="3" height="19" font="4"><b> </b></text>
<text top="497" left="250" width="117" height="19" font="4"><b>Size:</b>    17 patients  </text>
<text top="515" left="250" width="3" height="19" font="4"><b> </b></text>
<text top="423" left="411" width="108" height="19" font="3">17 patients UCLA </text>
<text top="442" left="411" width="124" height="19" font="3">medical center with </text>
<text top="460" left="411" width="135" height="19" font="3">new-onset sustatined </text>
<text top="478" left="411" width="128" height="19" font="3">VT/VF within 30 d of </text>
<text top="497" left="411" width="130" height="19" font="3">CABG between 1981-</text>
<text top="515" left="411" width="115" height="19" font="3">1993 compared to </text>
<text top="533" left="411" width="126" height="19" font="3">119 control patients </text>
<text top="552" left="411" width="120" height="19" font="3">1992-1993 without </text>
<text top="570" left="411" width="109" height="19" font="3">VT/VF post-CABG </text>
<text top="588" left="411" width="3" height="19" font="3"> </text>
<text top="423" left="565" width="230" height="19" font="3">VT/VF patients had lower LVEF, more </text>
<text top="442" left="565" width="207" height="19" font="3">likely to have had MI &lt;2 w before </text>
<text top="460" left="565" width="218" height="19" font="3">CABG, graft to chronically occluded </text>
<text top="478" left="565" width="40" height="19" font="3">vessel </text>
<text top="497" left="565" width="3" height="19" font="3"> </text>
<text top="515" left="565" width="201" height="19" font="3">Sustained MMVT 11/17 patients </text>
<text top="533" left="565" width="183" height="19" font="3">(65%) and most (64%) had no </text>
<text top="552" left="565" width="219" height="19" font="3">evidence of peri-op MI.  Those with </text>
<text top="570" left="565" width="178" height="19" font="3">MMVT, 80% inducible at EPS </text>
<text top="588" left="565" width="3" height="19" font="3"> </text>
<text top="607" left="565" width="206" height="19" font="3">Polymorphic VT/VF 6/17 patients </text>
<text top="625" left="565" width="232" height="19" font="3">(35%) and most had peri-op MI (67%) </text>
<text top="643" left="565" width="223" height="19" font="3">and only 2/6 (33%) had inducible VT </text>
<text top="661" left="565" width="44" height="19" font="3">at EPS  </text>
<text top="423" left="816" width="97" height="19" font="3">● <b>Conclusions:</b>  </text>
<text top="442" left="816" width="240" height="19" font="3">New onset MMVT is usually associated </text>
<text top="460" left="816" width="218" height="19" font="3">with old infarct/scarring (and many </text>
<text top="478" left="816" width="108" height="19" font="3">inducible at EPS)  </text>
<text top="497" left="816" width="246" height="19" font="3">● Polymorphic VT/VF usually associated </text>
<text top="515" left="816" width="91" height="19" font="3">with ischemia. </text>
<text top="533" left="816" width="226" height="19" font="3">● Polymorphic VT/VF occurring after </text>
<text top="552" left="816" width="241" height="19" font="3">CABG warrants a therapeutic approach </text>
<text top="570" left="816" width="164" height="19" font="3">targeting treatment of MI. </text>
<text top="588" left="816" width="3" height="19" font="4"><b> </b></text>
<text top="681" left="123" width="97" height="19" font="3">● Ascione et al. </text>
<text top="699" left="123" width="69" height="19" font="3">2004 (149) </text>
<text top="717" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15120824">● </a></text>
<text top="717" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15120824">15120824</a></text>
<text top="717" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15120824"> </a></text>
<text top="735" left="123" width="3" height="19" font="3"> </text>
<text top="754" left="123" width="3" height="19" font="3"> </text>
<text top="680" left="250" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="699" left="250" width="123" height="19" font="3">retrospective single </text>
<text top="717" left="250" width="90" height="19" font="3">center cohort  </text>
<text top="735" left="250" width="3" height="19" font="4"><b> </b></text>
<text top="754" left="250" width="129" height="19" font="4"><b>Size:</b>    4411 patients </text>
<text top="772" left="250" width="111" height="19" font="3">undergoing CABG </text>
<text top="681" left="411" width="129" height="19" font="3">Cases CABG patients </text>
<text top="699" left="411" width="126" height="19" font="3">4/1996-9/2001 with </text>
<text top="717" left="411" width="91" height="19" font="3">VT/VF post-op </text>
<text top="735" left="411" width="134" height="19" font="3">compared to controls </text>
<text top="754" left="411" width="117" height="19" font="3">without.  Assessed </text>
<text top="681" left="565" width="211" height="19" font="3">Factors associated with VT/VF age </text>
<text top="699" left="565" width="203" height="19" font="3">&lt;65 y, female, low BMI, unstable </text>
<text top="717" left="565" width="219" height="19" font="3">angina, reduced LVEF, and need for </text>
<text top="735" left="565" width="104" height="19" font="3">inotrope or IABP </text>
<text top="754" left="565" width="3" height="19" font="3"> </text>
<text top="681" left="816" width="113" height="19" font="3">● <b>Results (cont.):  </b></text>
<text top="699" left="816" width="246" height="19" font="3">5/12 (42%) intraoperative VT/VF died in </text>
<text top="717" left="816" width="231" height="19" font="3">the hospital, as compared with 10/55 </text>
<text top="735" left="816" width="218" height="19" font="3">(18%) with VT/VF in post-op period </text>
<text top="754" left="816" width="245" height="19" font="3">(p=0.08).  Those with post-op VT/VF, 27 </text>
</page>
<page number="76" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">76 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="250" width="130" height="19" font="3">including 69 patients </text>
<text top="127" left="250" width="123" height="19" font="3">with post op VF/VT  </text>
<text top="145" left="250" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="411" width="113" height="19" font="3">factors associated </text>
<text top="127" left="411" width="121" height="19" font="3">with post-op VT/VF </text>
<text top="145" left="411" width="3" height="19" font="3"> </text>
<text top="164" left="411" width="116" height="19" font="3">None of the VT/VF </text>
<text top="182" left="411" width="124" height="19" font="3">patients underwent </text>
<text top="200" left="411" width="100" height="19" font="3">ICD placement.  </text>
<text top="219" left="411" width="3" height="19" font="3"> </text>
<text top="109" left="565" width="198" height="19" font="3">Off-pump CABG associated with </text>
<text top="127" left="565" width="217" height="19" font="3">protective effect (OR: 0.53; 95% CI: </text>
<text top="145" left="565" width="69" height="19" font="3">0.25–1.13) </text>
<text top="164" left="565" width="3" height="19" font="3"> </text>
<text top="182" left="565" width="187" height="19" font="3">Long term survival was similar </text>
<text top="200" left="565" width="209" height="19" font="3">between groups (2 y 98.2% VT/VF </text>
<text top="219" left="565" width="206" height="19" font="3">surviving to discharge vs. 97% for </text>
<text top="237" left="565" width="212" height="19" font="3">control (HR: 0.96; 95% CI: 0.4–2.3) </text>
<text top="109" left="816" width="249" height="19" font="3">(47.4%) had the event within the first 24 </text>
<text top="127" left="816" width="15" height="19" font="3">h. </text>
<text top="145" left="816" width="258" height="19" font="3">● <b>Conclusion:</b> incidence of VT/VF is low in </text>
<text top="164" left="816" width="255" height="19" font="3">patients undergoing CABG but associated </text>
<text top="182" left="816" width="247" height="19" font="3">with high in-hospital mortality.  The late </text>
<text top="200" left="816" width="246" height="19" font="3">survival of those discharged is similar to </text>
<text top="219" left="816" width="57" height="19" font="3">controls. </text>
<text top="256" left="123" width="108" height="19" font="3">● Steinberg et al. </text>
<text top="274" left="123" width="69" height="19" font="3">1999 (150) </text>
<text top="292" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10027813">● </a></text>
<text top="292" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10027813">10027813</a></text>
<text top="292" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10027813"> </a></text>
<text top="311" left="123" width="3" height="19" font="3"> </text>
<text top="256" left="250" width="118" height="19" font="4"><b>Study type:</b> cohort </text>
<text top="274" left="250" width="40" height="19" font="3">study  </text>
<text top="292" left="250" width="3" height="19" font="3"> </text>
<text top="311" left="250" width="107" height="19" font="4"><b>Size:</b> 12 patients  </text>
<text top="256" left="411" width="139" height="19" font="3">Patient with sustained </text>
<text top="274" left="411" width="118" height="19" font="3">post-op VT ≥24 hrs </text>
<text top="292" left="411" width="132" height="19" font="3">but &lt;30 d after CABG </text>
<text top="311" left="411" width="121" height="19" font="3">among consecutive </text>
<text top="329" left="411" width="132" height="19" font="3">patients 382 patients </text>
<text top="347" left="411" width="137" height="19" font="3">undergoing CABG at a </text>
<text top="366" left="411" width="105" height="19" font="3">single institution </text>
<text top="384" left="411" width="3" height="19" font="3"> </text>
<text top="402" left="411" width="127" height="19" font="3">Variables associated </text>
<text top="421" left="411" width="126" height="19" font="3">with the occurrence </text>
<text top="439" left="411" width="131" height="19" font="3">of VT was performed </text>
<text top="256" left="565" width="165" height="19" font="3">Results: 12 patients (3.1%) </text>
<text top="274" left="565" width="226" height="19" font="3">experienced ≥1 episode of sustained </text>
<text top="292" left="565" width="150" height="19" font="3">VT 4.1±4.8 d after CABG </text>
<text top="311" left="565" width="3" height="19" font="3"> </text>
<text top="329" left="565" width="222" height="19" font="3">In 11 /12 patients, no postoperative </text>
<text top="347" left="565" width="202" height="19" font="3">complication explained the VT. 1 </text>
<text top="366" left="565" width="197" height="19" font="3">patient had a perioperative MI.  </text>
<text top="384" left="565" width="3" height="19" font="3"> </text>
<text top="402" left="565" width="209" height="19" font="3">The in-hospital mortality rate was </text>
<text top="421" left="565" width="214" height="19" font="3">25%. Among the 9 survivors, 5 had </text>
<text top="439" left="565" width="194" height="19" font="3">EPS with all inducible sustained </text>
<text top="457" left="565" width="219" height="19" font="3">monomorphic VT (matching clinical </text>
<text top="476" left="565" width="203" height="19" font="3">VT). 3/9 patients received an ICD </text>
<text top="494" left="565" width="225" height="19" font="3">before hospital discharge. Other 6/9 </text>
<text top="512" left="565" width="208" height="19" font="3">patients received chronic therapy </text>
<text top="531" left="565" width="212" height="19" font="3">with AAD (primarily amiodarone).  </text>
<text top="549" left="565" width="3" height="19" font="3"> </text>
<text top="567" left="565" width="221" height="19" font="3">All 9 patients are alive, with a mean </text>
<text top="586" left="565" width="113" height="19" font="3">followup of 2.5 y.  </text>
<text top="604" left="565" width="3" height="19" font="3"> </text>
<text top="622" left="565" width="209" height="19" font="3">2 patients (1 with an ICD and 1 on </text>
<text top="640" left="565" width="231" height="19" font="3">amiodarone) had recurrent VT during </text>
<text top="659" left="565" width="65" height="19" font="3">follow-up. </text>
<text top="256" left="816" width="244" height="19" font="3">● Results (cont.): Patients with VT were </text>
<text top="274" left="816" width="226" height="19" font="3">more likely to have prior MI (92% vs. </text>
<text top="292" left="816" width="245" height="19" font="3">50%, p&lt;0.01), severe CHF (56% vs. 21%, </text>
<text top="311" left="816" width="236" height="19" font="3">p&lt;0.01), and LVEF &lt;0.40 (70% vs. 29%, </text>
<text top="329" left="816" width="57" height="19" font="3">p&lt;0.01).  </text>
<text top="347" left="816" width="242" height="19" font="3">By multivariate analysis, the number of </text>
<text top="366" left="816" width="244" height="19" font="3">bypass grafts across a noncollateralized </text>
<text top="384" left="816" width="236" height="19" font="3">occluded vessel to an infarct zone was </text>
<text top="402" left="816" width="239" height="19" font="3">the only independent factor predicting </text>
<text top="421" left="816" width="23" height="19" font="3">VT. </text>
<text top="439" left="816" width="195" height="19" font="3">● Conclusions: (1) Patients who </text>
<text top="457" left="816" width="221" height="19" font="3">developed VT had a high in-hospital </text>
<text top="476" left="816" width="246" height="19" font="3">mortality rate of 25% (2) However, long-</text>
<text top="494" left="816" width="256" height="19" font="3">term outcome was good (possibly related </text>
<text top="512" left="816" width="245" height="19" font="3">to antiarrhythmic or ICD). (3) predictors </text>
<text top="531" left="816" width="198" height="19" font="3">are MMVT previous MI scar and </text>
<text top="549" left="816" width="228" height="19" font="3">associated severe LV dysfunction. (4) </text>
<text top="567" left="816" width="227" height="19" font="3">Relationship was found between the </text>
<text top="586" left="816" width="254" height="19" font="3">development of VT and the placement of </text>
<text top="604" left="816" width="249" height="19" font="3">a bypass graft across a noncollateralized </text>
<text top="622" left="816" width="232" height="19" font="3">occluded coronary vessel to a chronic </text>
<text top="640" left="816" width="226" height="19" font="3">infarct zone. (5) The development of </text>
<text top="659" left="816" width="204" height="19" font="3">MMVT was typically not due to a </text>
<text top="677" left="816" width="256" height="19" font="3">detectable postoperative complication or </text>
<text top="695" left="816" width="64" height="19" font="3">ischemia.  </text>
<text top="714" left="816" width="3" height="19" font="3"> </text>
<text top="733" left="115" width="3" height="19" font="3"> </text>
</page>
<page number="77" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">77 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="922" height="21" font="2"><b>Data Supplement 21. RCTs and Nonrandomized Trials, Observational Studies, and/or Registries of ICDs Primary Prevention Ventricular </b></text>
<text top="128" left="115" width="625" height="21" font="2"><b>Arrhythmias and Sudden Death in Patients with Ischemic Cardiomyopathy – (Section 7.1.2) </b></text>
<text top="149" left="154" width="39" height="19" font="4"><b>Study </b></text>
<text top="167" left="142" width="64" height="19" font="4"><b>Acronym; </b></text>
<text top="185" left="148" width="55" height="19" font="4"><b>Author;  </b></text>
<text top="204" left="125" width="99" height="19" font="4"><b>Year Published  </b></text>
<text top="149" left="252" width="88" height="19" font="4"><b>Aim of Study; </b></text>
<text top="167" left="258" width="76" height="19" font="4"><b>Study Type; </b></text>
<text top="185" left="251" width="89" height="19" font="4"><b>Study Size (N) </b></text>
<text top="149" left="427" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="149" left="622" width="136" height="19" font="4"><b>Randomized Subjects </b></text>
<text top="149" left="794" width="87" height="19" font="4"><b>Endpoint and </b></text>
<text top="167" left="814" width="48" height="19" font="4"><b>Results </b></text>
<text top="185" left="836" width="3" height="19" font="4"><b> </b></text>
<text top="149" left="957" width="75" height="19" font="4"><b>Conclusion: </b></text>
<text top="223" left="123" width="67" height="19" font="3">● <b>MADIT-I </b></text>
<text top="241" left="123" width="64" height="19" font="3">● Moss et </text>
<text top="260" left="123" width="79" height="19" font="3">al.1996 (42)  </text>
<text top="278" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8960472">● </a></text>
<text top="278" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8960472">8960472</a></text>
<text top="278" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8960472"> </a></text>
<text top="296" left="123" width="3" height="19" font="3"> </text>
<text top="223" left="236" width="110" height="19" font="4"><b>Aim:</b>  To evaluate </text>
<text top="241" left="236" width="55" height="19" font="3">whether </text>
<text top="260" left="236" width="107" height="19" font="3">prophylactic ICD, </text>
<text top="278" left="236" width="112" height="19" font="3">as compared with </text>
<text top="296" left="236" width="82" height="19" font="3">conventional </text>
<text top="314" left="236" width="106" height="19" font="3">medical therapy, </text>
<text top="333" left="236" width="95" height="19" font="3">would improve </text>
<text top="351" left="236" width="106" height="19" font="3">survival in a high-</text>
<text top="370" left="236" width="80" height="19" font="3">risk group of </text>
<text top="388" left="236" width="83" height="19" font="3">patients with </text>
<text top="406" left="236" width="93" height="19" font="3">NSVT, reduced </text>
<text top="424" left="236" width="114" height="19" font="3">LVEF and previous </text>
<text top="443" left="236" width="24" height="19" font="3">MI. </text>
<text top="461" left="236" width="3" height="19" font="3"> </text>
<text top="479" left="236" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="498" left="236" width="75" height="19" font="3">prospective </text>
<text top="516" left="236" width="101" height="19" font="3">multicenter RCT </text>
<text top="534" left="236" width="3" height="19" font="3"> </text>
<text top="552" left="236" width="118" height="19" font="4"><b>Size:</b> 196 patients   </text>
<text top="223" left="368" width="216" height="19" font="4"><b>Inclusion:</b> Previous MI, LVEF ≤35%, </text>
<text top="241" left="368" width="214" height="19" font="3">NSVT, inducible VT at EPS that was </text>
<text top="260" left="368" width="234" height="19" font="3">non-suppressed with IV procainamide </text>
<text top="278" left="368" width="114" height="19" font="3">or equivalent AAD </text>
<text top="296" left="368" width="3" height="19" font="3"> </text>
<text top="314" left="368" width="226" height="19" font="4"><b>Exclusion: </b>previous CA or VT causing </text>
<text top="333" left="368" width="231" height="19" font="3">syncope that was not associated with </text>
<text top="351" left="368" width="213" height="19" font="3">an AMI; symptomatic hypotension </text>
<text top="370" left="368" width="219" height="19" font="3">while in a stable rhythm; and MI &lt;3 </text>
<text top="388" left="368" width="222" height="19" font="3">wk, prior CABG &lt;2 mo or PCI &lt;3 mo, </text>
<text top="406" left="368" width="219" height="19" font="3">as were women of childbearing age </text>
<text top="424" left="368" width="185" height="19" font="3">who were not using medically </text>
<text top="443" left="368" width="218" height="19" font="3">prescribed contraceptives, patients </text>
<text top="461" left="368" width="193" height="19" font="3">with advanced cerebrovascular </text>
<text top="479" left="368" width="222" height="19" font="3">disease, patients with any condition </text>
<text top="498" left="368" width="219" height="19" font="3">other than cardiac disease that was </text>
<text top="516" left="368" width="225" height="19" font="3">associated with a reduced likelihood </text>
<text top="534" left="368" width="238" height="19" font="3">of survival for the duration of the trial, </text>
<text top="553" left="368" width="224" height="19" font="3">and patients who were participating </text>
<text top="571" left="368" width="130" height="19" font="3">in other clinical trials </text>
<text top="223" left="619" width="86" height="19" font="4"><b>Comparator</b>:  </text>
<text top="241" left="619" width="137" height="19" font="3">Control (101 patients) </text>
<text top="260" left="619" width="3" height="19" font="3"> </text>
<text top="278" left="619" width="89" height="19" font="4"><b>Intervention:</b>  </text>
<text top="296" left="619" width="105" height="19" font="3">ICD (95 patients) </text>
<text top="223" left="773" width="125" height="19" font="4"><b>All-cause mortality</b>: </text>
<text top="241" left="773" width="122" height="19" font="3">Control 32% vs. ICD </text>
<text top="260" left="773" width="29" height="19" font="3">13% </text>
<text top="278" left="773" width="99" height="19" font="3">(RRR -59% ARR -</text>
<text top="296" left="773" width="34" height="19" font="3">19%) </text>
<text top="223" left="915" width="155" height="19" font="3">● In patients with a prior </text>
<text top="241" left="915" width="136" height="19" font="3">MI, low EF who are at </text>
<text top="260" left="915" width="98" height="19" font="3">high risk for VT, </text>
<text top="278" left="915" width="130" height="19" font="3">prophylactic therapy </text>
<text top="296" left="915" width="125" height="19" font="3">with an ICD leads to </text>
<text top="314" left="915" width="128" height="19" font="3">improved survival as </text>
<text top="333" left="915" width="96" height="19" font="3">compared with </text>
<text top="351" left="915" width="134" height="19" font="3">conventional medical </text>
<text top="370" left="915" width="55" height="19" font="3">therapy. </text>
<text top="590" left="123" width="90" height="19" font="3">● <b>CABG-Patch </b></text>
<text top="608" left="123" width="70" height="19" font="3">● Bigger et </text>
<text top="627" left="123" width="87" height="19" font="3">al.1997 (151)  </text>
<text top="645" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9371853">● </a></text>
<text top="645" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9371853">9371853</a></text>
<text top="645" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9371853"> </a></text>
<text top="663" left="123" width="3" height="19" font="3"> </text>
<text top="590" left="236" width="110" height="19" font="4"><b>Aim:</b>  To evaluate </text>
<text top="608" left="236" width="106" height="19" font="3">the role of ICD in </text>
<text top="627" left="236" width="86" height="19" font="3">patients after </text>
<text top="645" left="236" width="98" height="19" font="3">CABG with high </text>
<text top="663" left="236" width="68" height="19" font="3">risk of SCD </text>
<text top="681" left="236" width="3" height="19" font="3"> </text>
<text top="700" left="236" width="108" height="19" font="4"><b>Study type:</b>   RCT </text>
<text top="718" left="236" width="3" height="19" font="3"> </text>
<text top="736" left="236" width="118" height="19" font="4"><b>Size:</b> 900 patients   </text>
<text top="590" left="368" width="208" height="19" font="4"><b>Inclusion:</b> Coronary artery bypass </text>
<text top="608" left="368" width="195" height="19" font="3">surgery, EF &lt;36, SAECG positive </text>
<text top="627" left="368" width="3" height="19" font="3"> </text>
<text top="645" left="368" width="227" height="19" font="4"><b>Exclusion:</b> sustained VT/VF, diabetes </text>
<text top="663" left="368" width="202" height="19" font="3">mellitus with poor blood glucose </text>
<text top="681" left="368" width="192" height="19" font="3">control or recurrent infections, </text>
<text top="700" left="368" width="212" height="19" font="3">previous or concomitant aortic- or </text>
<text top="718" left="368" width="209" height="19" font="3">mitral-valve surgery, concomitant </text>
<text top="736" left="368" width="206" height="19" font="3">cerebrovascular surgery, a serum </text>
<text top="755" left="368" width="233" height="19" font="3">creatinine concentration greater than </text>
<text top="773" left="368" width="177" height="19" font="3">3 mg/dl, emergency CABG, a </text>
<text top="590" left="619" width="86" height="19" font="4"><b>Comparator</b>:  </text>
<text top="608" left="619" width="137" height="19" font="3">Control (454 patients) </text>
<text top="627" left="619" width="3" height="19" font="3"> </text>
<text top="645" left="619" width="89" height="19" font="4"><b>Intervention:</b>  </text>
<text top="663" left="619" width="113" height="19" font="3">ICD (446 patients) </text>
<text top="681" left="619" width="3" height="19" font="3"> </text>
<text top="590" left="773" width="125" height="19" font="4"><b>All-cause mortality</b>: </text>
<text top="608" left="773" width="122" height="19" font="3">Control 18% vs. ICD </text>
<text top="627" left="773" width="29" height="19" font="3">18% </text>
<text top="645" left="836" width="3" height="19" font="3"> </text>
<text top="590" left="915" width="107" height="19" font="3">● No evidence of </text>
<text top="608" left="915" width="157" height="19" font="3">improved survival among </text>
<text top="627" left="915" width="117" height="19" font="3">patients with CAD, </text>
<text top="645" left="915" width="116" height="19" font="3">reduced LVEF, and </text>
<text top="663" left="915" width="106" height="19" font="3">abnormal SAECG </text>
<text top="681" left="915" width="137" height="19" font="3">receiving prophylactic </text>
<text top="700" left="915" width="98" height="19" font="3">ICD after CABG  </text>
</page>
<page number="78" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">78 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="368" width="206" height="19" font="3">noncardiovascular condition with </text>
<text top="127" left="368" width="224" height="19" font="3">expected survival of less than 2 y, or </text>
<text top="145" left="368" width="222" height="19" font="3">an inability to attend followup visits </text>
<text top="190" left="123" width="61" height="19" font="3">● <b>MUSTT </b></text>
<text top="209" left="123" width="93" height="19" font="3">● Buxton et al. </text>
<text top="227" left="123" width="62" height="19" font="3">2000 (41) </text>
<text top="245" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10874061">● </a></text>
<text top="245" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10874061">10874061</a></text>
<text top="245" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10874061"> </a></text>
<text top="190" left="236" width="110" height="19" font="4"><b>Aim:</b>  To evaluate </text>
<text top="209" left="236" width="107" height="19" font="3">the usefulness of </text>
<text top="227" left="236" width="71" height="19" font="3">EPS for risk </text>
<text top="245" left="236" width="81" height="19" font="3">stratification </text>
<text top="264" left="236" width="98" height="19" font="3">among patients </text>
<text top="282" left="236" width="63" height="19" font="3">with CAD, </text>
<text top="300" left="236" width="62" height="19" font="3">abnormal </text>
<text top="319" left="236" width="69" height="19" font="3">ventricular </text>
<text top="337" left="236" width="85" height="19" font="3">function, and </text>
<text top="355" left="236" width="36" height="19" font="3">NSVT </text>
<text top="373" left="236" width="3" height="19" font="3"> </text>
<text top="392" left="236" width="108" height="19" font="4"><b>Study type:</b>   RCT </text>
<text top="410" left="236" width="3" height="19" font="3"> </text>
<text top="428" left="236" width="115" height="19" font="4"><b>Size: </b>704 patients  </text>
<text top="190" left="368" width="209" height="19" font="4"><b>Inclusion:</b> CAD, LVEF ≤40%, NSVT, </text>
<text top="209" left="368" width="100" height="19" font="3">inducible at EPS </text>
<text top="227" left="368" width="3" height="19" font="3"> </text>
<text top="245" left="368" width="204" height="19" font="4"><b>Exclusion:</b> H/o of syncope or had </text>
<text top="264" left="368" width="234" height="19" font="3">sustained VT/VF &gt;48 h after the onset </text>
<text top="282" left="368" width="214" height="19" font="3">of AMI, NSVT that occurred only in </text>
<text top="300" left="368" width="220" height="19" font="3">the setting of drug-induced LQTS or </text>
<text top="319" left="368" width="231" height="19" font="3">AMI or that was attributable to acute </text>
<text top="337" left="368" width="224" height="19" font="3">metabolic disorders or drug toxicity, </text>
<text top="355" left="368" width="203" height="19" font="3">or if they had symptomatic NSVT </text>
<text top="190" left="619" width="114" height="19" font="3">If sustained VT/VF </text>
<text top="209" left="619" width="134" height="19" font="3">were induced by EPS, </text>
<text top="227" left="619" width="87" height="19" font="3">patients were </text>
<text top="245" left="619" width="92" height="19" font="3">randomized to </text>
<text top="264" left="619" width="94" height="19" font="3">antiarrhythmic </text>
<text top="282" left="619" width="113" height="19" font="3">therapy, including </text>
<text top="300" left="619" width="137" height="19" font="3">AAD and possible ICD, </text>
<text top="319" left="619" width="118" height="19" font="3">as indicated by the </text>
<text top="337" left="619" width="127" height="19" font="3">results of EP testing, </text>
<text top="355" left="619" width="130" height="19" font="3">or no antiarrhythmic </text>
<text top="374" left="619" width="58" height="19" font="3">therapy.<b> </b> </text>
<text top="392" left="619" width="3" height="19" font="4"><b> </b></text>
<text top="410" left="619" width="86" height="19" font="4"><b>Comparator</b>:  </text>
<text top="428" left="619" width="137" height="19" font="3">Control (353 patients) </text>
<text top="447" left="619" width="103" height="19" font="3">Inducible but no </text>
<text top="465" left="619" width="94" height="19" font="3">antiarrhythmic </text>
<text top="483" left="619" width="3" height="19" font="3"> </text>
<text top="502" left="619" width="89" height="19" font="4"><b>Intervention:</b>  </text>
<text top="520" left="619" width="123" height="19" font="3">Inducible and failed </text>
<text top="538" left="619" width="137" height="19" font="3">suppression with AAD </text>
<text top="557" left="619" width="117" height="19" font="3">and given ICD (161 </text>
<text top="575" left="619" width="58" height="19" font="3">patients) </text>
<text top="190" left="773" width="119" height="19" font="3">Risk of CA or death </text>
<text top="209" left="773" width="104" height="19" font="3">from arrhythmia </text>
<text top="227" left="773" width="122" height="19" font="3">among the patients </text>
<text top="245" left="773" width="85" height="19" font="3">who received </text>
<text top="264" left="773" width="126" height="19" font="3">treatment with ICDs </text>
<text top="282" left="773" width="125" height="19" font="3">was lower than that </text>
<text top="300" left="773" width="122" height="19" font="3">among the patients </text>
<text top="319" left="773" width="121" height="19" font="3">discharged without </text>
<text top="337" left="773" width="112" height="19" font="3">(HR: 0.24; 95% CI: </text>
<text top="355" left="773" width="129" height="19" font="3">0.13–0.45; p&lt;0.001)<b>  </b></text>
<text top="373" left="773" width="132" height="19" font="4"><b>All-cause mortality</b>:   </text>
<text top="392" left="773" width="122" height="19" font="3">Control 55% vs. ICD </text>
<text top="410" left="773" width="29" height="19" font="3">24% </text>
<text top="428" left="773" width="126" height="19" font="3">(RRR -58% and ARR -</text>
<text top="447" left="773" width="34" height="19" font="3">31%) </text>
<text top="190" left="915" width="153" height="19" font="3">● Patients with CAD, left </text>
<text top="209" left="915" width="148" height="19" font="3">ventricular dysfunction, </text>
<text top="227" left="915" width="156" height="19" font="3">and asymptomatic, NSVT </text>
<text top="245" left="915" width="145" height="19" font="3">in whom sustained VAs </text>
<text top="264" left="915" width="149" height="19" font="3">cannot be induced have </text>
<text top="282" left="915" width="149" height="19" font="3">a significantly lower risk </text>
<text top="300" left="915" width="153" height="19" font="3">of SCD and lower overall </text>
<text top="319" left="915" width="135" height="19" font="3">mortality than similar </text>
<text top="337" left="915" width="142" height="19" font="3">patients with inducible </text>
<text top="355" left="915" width="62" height="19" font="3">sustained </text>
<text top="374" left="915" width="114" height="19" font="3">tachyarrhythmias. </text>
<text top="392" left="915" width="141" height="19" font="3">Important to point out </text>
<text top="410" left="915" width="133" height="19" font="3">that receipt of an ICD </text>
<text top="428" left="915" width="127" height="19" font="3">was not randomized </text>
<text top="447" left="915" width="73" height="19" font="3">treatment.  </text>
<text top="594" left="123" width="71" height="19" font="3">● <b>MADIT-II </b></text>
<text top="612" left="123" width="82" height="19" font="3">● Moss et al. </text>
<text top="631" left="123" width="65" height="19" font="3">2002 (44)  </text>
<text top="649" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11907286">● </a></text>
<text top="649" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11907286">11907286</a></text>
<text top="649" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11907286"> </a></text>
<text top="667" left="123" width="3" height="19" font="3"> </text>
<text top="594" left="236" width="110" height="19" font="4"><b>Aim:</b>  To evaluate </text>
<text top="612" left="236" width="111" height="19" font="3">the benefit of ICD </text>
<text top="631" left="236" width="98" height="19" font="3">in patients with </text>
<text top="649" left="236" width="80" height="19" font="3">prior MI and </text>
<text top="667" left="236" width="86" height="19" font="3">reduced LVEF </text>
<text top="685" left="236" width="3" height="19" font="3"> </text>
<text top="704" left="236" width="108" height="19" font="4"><b>Study type:</b>   RCT </text>
<text top="722" left="236" width="3" height="19" font="3"> </text>
<text top="740" left="236" width="126" height="19" font="4"><b>Size: </b>1232 patients   </text>
<text top="594" left="368" width="229" height="19" font="4"><b>Inclusion:</b>  Prior MI (&gt;1 mo), EF ≤30% </text>
<text top="612" left="368" width="3" height="19" font="3"> </text>
<text top="630" left="368" width="229" height="19" font="4"><b>Exclusion:</b> existing indication for ICD; </text>
<text top="649" left="368" width="203" height="19" font="3">NYHA class IV at enrollment; had </text>
<text top="667" left="368" width="235" height="19" font="3">undergone coronary revascularization </text>
<text top="685" left="368" width="169" height="19" font="3">&lt;3 mo; MI &lt;30 d, advanced </text>
<text top="704" left="368" width="232" height="19" font="3">cerebrovascular disease, childbearing </text>
<text top="722" left="368" width="202" height="19" font="3">age and not using contraceptive, </text>
<text top="741" left="368" width="229" height="19" font="3">presence of any condition other than </text>
<text top="759" left="368" width="219" height="19" font="3">cardiac disease that was associated </text>
<text top="777" left="368" width="231" height="19" font="3">with a high likelihood of death during </text>
<text top="594" left="619" width="82" height="19" font="4"><b>Comparator</b>: </text>
<text top="612" left="619" width="137" height="19" font="3">Control (490 patients) </text>
<text top="631" left="619" width="3" height="19" font="3"> </text>
<text top="649" left="619" width="89" height="19" font="4"><b>Intervention:</b>  </text>
<text top="667" left="619" width="113" height="19" font="3">ICD (742 patients) </text>
<text top="685" left="619" width="3" height="19" font="3"> </text>
<text top="594" left="773" width="125" height="19" font="4"><b>All-cause mortality: </b></text>
<text top="612" left="773" width="121" height="19" font="3">control 22% vs. ICD </text>
<text top="631" left="773" width="29" height="19" font="3">16% </text>
<text top="649" left="773" width="126" height="19" font="3">(RRR -28% and ARR -</text>
<text top="667" left="773" width="26" height="19" font="3">6%) </text>
<text top="594" left="915" width="155" height="19" font="3">● In patients with a prior </text>
<text top="612" left="915" width="132" height="19" font="3">MI and advanced left </text>
<text top="631" left="915" width="148" height="19" font="3">ventricular dysfunction, </text>
<text top="649" left="915" width="103" height="19" font="3">prophylactic ICD </text>
<text top="667" left="915" width="136" height="19" font="3">improves survival and </text>
<text top="685" left="915" width="150" height="19" font="3">should be considered as </text>
<text top="704" left="915" width="158" height="19" font="3">a recommended therapy. </text>
</page>
<page number="79" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">79 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="368" width="197" height="19" font="3">the trial, or unwilling to provide </text>
<text top="127" left="368" width="52" height="19" font="3">consent </text>
<text top="174" left="123" width="73" height="19" font="3">● <b>DINAMIT </b></text>
<text top="192" left="123" width="95" height="19" font="3">● Hohnloser et </text>
<text top="211" left="123" width="90" height="19" font="3">al. 2004 (152)  </text>
<text top="229" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15590950">● </a></text>
<text top="229" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15590950">15590950</a></text>
<text top="229" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15590950"> </a></text>
<text top="247" left="123" width="3" height="19" font="3"> </text>
<text top="174" left="236" width="39" height="19" font="4"><b>Aim:</b>   </text>
<text top="192" left="236" width="84" height="19" font="3">To assess the </text>
<text top="211" left="236" width="102" height="19" font="3">benefit of ICD in </text>
<text top="229" left="236" width="83" height="19" font="3">patients with </text>
<text top="248" left="236" width="89" height="19" font="3">recent MI and </text>
<text top="266" left="236" width="89" height="19" font="3">reduced LVEF  </text>
<text top="284" left="236" width="108" height="19" font="4"><b>Study type:</b>   RCT </text>
<text top="302" left="236" width="3" height="19" font="3"> </text>
<text top="320" left="236" width="118" height="19" font="4"><b>Size:</b> 674 patients   </text>
<text top="174" left="368" width="202" height="19" font="4"><b>Inclusion:</b> Recent MI (6-40 d), EF </text>
<text top="192" left="368" width="222" height="19" font="3">≤35%, standard deviation of normal-</text>
<text top="211" left="368" width="226" height="19" font="3">to-normal RR intervals of 70 msec or </text>
<text top="229" left="368" width="238" height="19" font="3">less or a mean RR interval of 750 msec </text>
<text top="248" left="368" width="175" height="19" font="3">or less, mean heart rate ≥80 </text>
<text top="266" left="368" width="66" height="19" font="3">beats/min </text>
<text top="284" left="368" width="3" height="19" font="3"> </text>
<text top="302" left="368" width="216" height="19" font="4"><b>Exclusion:</b> CHF class IV; noncardiac </text>
<text top="321" left="368" width="222" height="19" font="3">disease that limited life expectancy; </text>
<text top="339" left="368" width="228" height="19" font="3">CABG performed since the qualifying </text>
<text top="357" left="368" width="236" height="19" font="3">infarction or planned to be performed </text>
<text top="376" left="368" width="209" height="19" font="3">within 4 wks after randomization; </text>
<text top="394" left="368" width="228" height="19" font="3">three-vessel PCI performed since the </text>
<text top="412" left="368" width="197" height="19" font="3">qualifying infarction; name on a </text>
<text top="431" left="368" width="207" height="19" font="3">waiting list for a heart transplant; </text>
<text top="449" left="368" width="217" height="19" font="3">current, ongoing ICD therapy; prior </text>
<text top="467" left="368" width="179" height="19" font="3">implantation of a permanent </text>
<text top="485" left="368" width="219" height="19" font="3">pacemaker; requirement for an ICD </text>
<text top="504" left="368" width="230" height="19" font="3">(i.e., sustained VT or fibrillation more </text>
<text top="522" left="368" width="181" height="19" font="3">than 48 h after the qualifying </text>
<text top="540" left="368" width="218" height="19" font="3">infarction); low probability that the </text>
<text top="559" left="368" width="235" height="19" font="3">study ICD could be implanted within 7 </text>
<text top="577" left="368" width="226" height="19" font="3">d after randomization; and expected </text>
<text top="595" left="368" width="215" height="19" font="3">poor compliance with the protocol </text>
<text top="174" left="619" width="82" height="19" font="4"><b>Comparator</b>: </text>
<text top="192" left="619" width="137" height="19" font="3">Control (342 patients) </text>
<text top="211" left="619" width="3" height="19" font="3"> </text>
<text top="229" left="619" width="89" height="19" font="4"><b>Intervention:</b>  </text>
<text top="247" left="619" width="113" height="19" font="3">ICD (332 patients) </text>
<text top="174" left="773" width="125" height="19" font="4"><b>All-cause mortality: </b></text>
<text top="192" left="773" width="121" height="19" font="3">control 17% vs. ICD </text>
<text top="211" left="773" width="29" height="19" font="3">19% </text>
<text top="229" left="773" width="3" height="19" font="3"> </text>
<text top="248" left="773" width="3" height="19" font="3"> </text>
<text top="266" left="773" width="79" height="19" font="4"><b>2° outcome:</b> </text>
<text top="284" left="773" width="113" height="19" font="3">arrhythmic death: </text>
<text top="302" left="773" width="121" height="19" font="3">12 ICD group vs. 29 </text>
<text top="321" left="773" width="125" height="19" font="3">in the control group </text>
<text top="339" left="773" width="127" height="19" font="3">(HR ICD group, 0.42; </text>
<text top="357" left="773" width="109" height="19" font="3">95 95% CI 0.22 to </text>
<text top="376" left="773" width="91" height="19" font="3">0.83; p=0.009) </text>
<text top="394" left="773" width="3" height="19" font="3"> </text>
<text top="174" left="915" width="115" height="19" font="3">● Prophylactic ICD </text>
<text top="192" left="915" width="153" height="19" font="3">therapy does not reduce </text>
<text top="211" left="915" width="150" height="19" font="3">overall mortality in high-</text>
<text top="229" left="915" width="140" height="19" font="3">risk patients who have </text>
<text top="248" left="915" width="114" height="19" font="3">recently had a MI. </text>
<text top="266" left="915" width="147" height="19" font="3">● Although ICD therapy </text>
<text top="284" left="915" width="136" height="19" font="3">was associated with a </text>
<text top="302" left="915" width="145" height="19" font="3">reduction in the rate of </text>
<text top="321" left="915" width="157" height="19" font="3">death due to arrhythmia, </text>
<text top="339" left="915" width="131" height="19" font="3">that was offset by an </text>
<text top="357" left="915" width="137" height="19" font="3">increase in the rate of </text>
<text top="376" left="915" width="72" height="19" font="3">death from </text>
<text top="394" left="915" width="142" height="19" font="3">nonarrhythmic causes. </text>
<text top="614" left="123" width="76" height="19" font="3">● <b>SCD-HeFT </b></text>
<text top="633" left="123" width="85" height="19" font="3">● Bardy et al. </text>
<text top="651" left="123" width="65" height="19" font="3">2005 (43)  </text>
<text top="669" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15659722">● </a></text>
<text top="669" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15659722">15659722</a></text>
<text top="669" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15659722"> </a></text>
<text top="614" left="236" width="91" height="19" font="4"><b>Aim:</b>  Evaluate </text>
<text top="633" left="236" width="55" height="19" font="3">whether </text>
<text top="651" left="236" width="105" height="19" font="3">amiodarone or a </text>
<text top="669" left="236" width="91" height="19" font="3">conservatively </text>
<text top="688" left="236" width="83" height="19" font="3">programmed </text>
<text top="706" left="236" width="112" height="19" font="3">shock-only, single-</text>
<text top="724" left="236" width="95" height="19" font="3">lead ICD would </text>
<text top="743" left="236" width="107" height="19" font="3">decrease the risk </text>
<text top="761" left="236" width="113" height="19" font="3">of death from any </text>
<text top="779" left="236" width="103" height="19" font="3">cause in a broad </text>
<text top="614" left="368" width="213" height="19" font="4"><b>Inclusion:</b> NYHA class I-III HF, LVEF </text>
<text top="633" left="368" width="37" height="19" font="3">≤35% </text>
<text top="651" left="368" width="3" height="19" font="3"> </text>
<text top="669" left="368" width="222" height="19" font="4"><b>Exclusion:</b> Age &lt;18 y, unable to give </text>
<text top="688" left="368" width="52" height="19" font="3">consent </text>
<text top="614" left="619" width="100" height="19" font="4"><b>Intervention 1:</b>  </text>
<text top="633" left="619" width="136" height="19" font="3">GDMT plus a ICD (829 </text>
<text top="651" left="619" width="61" height="19" font="3">patients)  </text>
<text top="669" left="619" width="3" height="19" font="4"><b> </b></text>
<text top="687" left="619" width="96" height="19" font="4"><b>Intervention 2:</b> </text>
<text top="706" left="619" width="71" height="19" font="3">GDMT plus </text>
<text top="724" left="619" width="108" height="19" font="3">amiodarone (845 </text>
<text top="743" left="619" width="58" height="19" font="3">patients) </text>
<text top="761" left="619" width="3" height="19" font="3"> </text>
<text top="779" left="619" width="97" height="19" font="4"><b>Comparator 1:</b>  </text>
<text top="614" left="773" width="125" height="19" font="4"><b>All-cause mortality: </b></text>
<text top="633" left="773" width="121" height="19" font="3">control 36% vs. ICD </text>
<text top="651" left="773" width="29" height="19" font="3">29% </text>
<text top="669" left="773" width="129" height="19" font="3">(RRR: -23% and ARR: </text>
<text top="688" left="773" width="31" height="19" font="3">-7%) </text>
<text top="614" left="915" width="149" height="19" font="3">● In patients with NYHA </text>
<text top="633" left="915" width="120" height="19" font="3">class II or III HF and </text>
<text top="651" left="915" width="147" height="19" font="3">LVEF≤35%, amiodarone </text>
<text top="669" left="915" width="143" height="19" font="3">has no favorable effect </text>
<text top="688" left="915" width="128" height="19" font="3">on survival, whereas </text>
<text top="706" left="915" width="142" height="19" font="3">single-lead, shock-only </text>
<text top="724" left="915" width="126" height="19" font="3">ICD therapy reduces </text>
<text top="743" left="915" width="136" height="19" font="3">overall mortality. This </text>
<text top="761" left="915" width="125" height="19" font="3">was the longest and </text>
<text top="779" left="915" width="101" height="19" font="3">largest ICD trial. </text>
</page>
<page number="80" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">80 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="236" width="86" height="19" font="3">population of </text>
<text top="127" left="236" width="115" height="19" font="3">patients with mild-</text>
<text top="145" left="236" width="101" height="19" font="3">to-moderate HF </text>
<text top="164" left="236" width="3" height="19" font="3"> </text>
<text top="182" left="236" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="200" left="236" width="75" height="19" font="3">prospective </text>
<text top="219" left="236" width="101" height="19" font="3">multicenter RCT </text>
<text top="237" left="236" width="3" height="19" font="3"> </text>
<text top="255" left="236" width="126" height="19" font="4"><b>Size:</b> 2521 patients   </text>
<text top="109" left="619" width="122" height="19" font="3">GDMT plus Placebo </text>
<text top="127" left="619" width="89" height="19" font="3">(847 patients) </text>
<text top="145" left="619" width="3" height="19" font="4"><b> </b></text>
<text top="164" left="619" width="3" height="19" font="3"> </text>
<text top="274" left="123" width="39" height="19" font="3">● <b>IRIS</b> </text>
<text top="292" left="123" width="91" height="19" font="3">● Steinbeck et </text>
<text top="311" left="123" width="87" height="19" font="3">al. 2009 (153) </text>
<text top="329" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19812399">● </a></text>
<text top="329" left="136" width="64" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19812399">19812399 </a></text>
<text top="347" left="123" width="3" height="19" font="3"> </text>
<text top="274" left="236" width="65" height="19" font="4"><b>Aim:</b>  Test </text>
<text top="292" left="236" width="108" height="19" font="3">whether patients </text>
<text top="311" left="236" width="102" height="19" font="3">at increased risk </text>
<text top="329" left="236" width="102" height="19" font="3">who are treated </text>
<text top="347" left="236" width="107" height="19" font="3">early with an ICD </text>
<text top="366" left="236" width="91" height="19" font="3">will live longer </text>
<text top="384" left="236" width="99" height="19" font="3">than those who </text>
<text top="402" left="236" width="90" height="19" font="3">receive GDMT </text>
<text top="421" left="236" width="37" height="19" font="3">alone </text>
<text top="439" left="236" width="3" height="19" font="3"> </text>
<text top="457" left="236" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="476" left="236" width="101" height="19" font="3">prospective RCT </text>
<text top="494" left="236" width="3" height="19" font="3"> </text>
<text top="512" left="236" width="118" height="19" font="4"><b>Size:</b> 898 patients   </text>
<text top="274" left="368" width="230" height="19" font="4"><b>Inclusion:</b> Recent MI (5-31 d) plus HR </text>
<text top="292" left="368" width="205" height="19" font="3">&gt;90 bpm and LVEF ≤40% or NSVT </text>
<text top="311" left="368" width="3" height="19" font="3"> </text>
<text top="329" left="368" width="222" height="19" font="4"><b>Exclusion:</b> VAs that occurred before </text>
<text top="347" left="368" width="237" height="19" font="3">the index MI or &gt;48 h after the MI and </text>
<text top="366" left="368" width="224" height="19" font="3">that required treatment, NYHA class </text>
<text top="384" left="368" width="220" height="19" font="3">IV drug-refractory HF, an interval of </text>
<text top="402" left="368" width="91" height="19" font="3">&gt;31 d between</text>
<text top="401" left="459" width="4" height="21" font="0"> </text>
<text top="402" left="463" width="132" height="19" font="3">MI and presentation, </text>
<text top="421" left="368" width="224" height="19" font="3">no ECG documentation within &lt;48 h </text>
<text top="439" left="368" width="198" height="19" font="3">after the onset of chest pain, an </text>
<text top="457" left="368" width="204" height="19" font="3">indication for CABG before study </text>
<text top="476" left="368" width="220" height="19" font="3">entry, a psychiatric disorder, severe </text>
<text top="494" left="368" width="211" height="19" font="3">concomitant disease, a Hx of poor </text>
<text top="512" left="368" width="237" height="19" font="3">compliance with treatment, either the </text>
<text top="531" left="368" width="222" height="19" font="3">inability to participate in this trial or </text>
<text top="549" left="368" width="228" height="19" font="3">current participation in another trial, </text>
<text top="567" left="368" width="207" height="19" font="3">and an unstable clinical condition </text>
<text top="274" left="619" width="82" height="19" font="4"><b>Comparator</b>: </text>
<text top="292" left="619" width="137" height="19" font="3">Control (453 patients) </text>
<text top="311" left="619" width="3" height="19" font="3"> </text>
<text top="329" left="619" width="89" height="19" font="4"><b>Intervention:</b>  </text>
<text top="347" left="619" width="113" height="19" font="3">ICD (445 patients) </text>
<text top="274" left="773" width="125" height="19" font="4"><b>All-cause mortality: </b></text>
<text top="292" left="773" width="126" height="19" font="3">control 23% vs. 22% </text>
<text top="311" left="773" width="3" height="19" font="3"> </text>
<text top="274" left="915" width="115" height="19" font="3">● Prophylactic ICD </text>
<text top="292" left="915" width="143" height="19" font="3">therapy did not reduce </text>
<text top="311" left="915" width="150" height="19" font="3">overall mortality among </text>
<text top="329" left="915" width="138" height="19" font="3">patients with AMI and </text>
<text top="347" left="915" width="127" height="19" font="3">clinical features that </text>
<text top="366" left="915" width="157" height="19" font="3">placed them at increased </text>
<text top="384" left="915" width="29" height="19" font="3">risk. </text>
<text top="586" left="123" width="88" height="19" font="3">● Piccini et al.<b> </b></text>
<text top="605" left="123" width="73" height="19" font="3">2009 (154)  </text>
<text top="623" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19336434">● </a></text>
<text top="623" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19336434">19336434</a></text>
<text top="623" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19336434"> </a></text>
<text top="641" left="123" width="3" height="19" font="4"><b> </b></text>
<text top="660" left="123" width="3" height="19" font="3"> </text>
<text top="678" left="123" width="3" height="19" font="3"> </text>
<text top="696" left="123" width="3" height="19" font="3"> </text>
<text top="586" left="236" width="54" height="19" font="4"><b>Aim:</b>  To </text>
<text top="586" left="291" width="56" height="19" font="11">evaluate </text>
<text top="605" left="236" width="95" height="19" font="11">the cumulative </text>
<text top="623" left="236" width="58" height="19" font="11">evidence </text>
<text top="641" left="236" width="86" height="19" font="11">regarding the </text>
<text top="660" left="236" width="117" height="19" font="11">safety and efficacy </text>
<text top="678" left="236" width="108" height="19" font="11">of amiodarone in </text>
<text top="696" left="236" width="114" height="19" font="11">prevention of SCD </text>
<text top="714" left="236" width="3" height="19" font="4"><b> </b></text>
<text top="733" left="236" width="111" height="19" font="4"><b>Study type:</b> Meta-</text>
<text top="752" left="236" width="84" height="19" font="3">analysis of all </text>
<text top="751" left="321" width="30" height="21" font="0">RCT </text>
<text top="771" left="236" width="115" height="19" font="3">examining the use </text>
<text top="586" left="368" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="586" left="479" width="102" height="19" font="11">Studies in which </text>
<text top="605" left="368" width="180" height="19" font="11">patients were randomized to </text>
<text top="623" left="368" width="223" height="19" font="11">amiodarone and placebo or inactive </text>
<text top="641" left="368" width="117" height="19" font="11">control. Additional </text>
<text top="660" left="368" width="230" height="19" font="11">inclusion criteria included: treatment </text>
<text top="678" left="368" width="191" height="19" font="11">for &gt;30 d, followup &gt;6 mo, and </text>
<text top="696" left="368" width="236" height="19" font="11">availability of all-cause mortality as an </text>
<text top="714" left="368" width="55" height="19" font="11">endpoint</text>
<text top="714" left="424" width="3" height="19" font="3"> </text>
<text top="733" left="368" width="3" height="19" font="3"> </text>
<text top="751" left="368" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="751" left="485" width="48" height="19" font="11">Studies </text>
<text top="587" left="619" width="85" height="19" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="587" left="704" width="31" height="19" font="11">SCD, </text>
<text top="605" left="619" width="90" height="19" font="11">CVD, all-cause </text>
<text top="624" left="619" width="113" height="19" font="11">mortality, and the </text>
<text top="642" left="619" width="115" height="19" font="11">incidences of drug </text>
<text top="660" left="619" width="62" height="19" font="11">toxicities. </text>
<text top="679" left="619" width="3" height="19" font="3"> </text>
<text top="697" left="619" width="135" height="19" font="4"><b>Results:</b>  Amiodarone </text>
<text top="715" left="619" width="90" height="19" font="3">decreased the </text>
<text top="733" left="619" width="105" height="19" font="3">incidence of SCD </text>
<text top="752" left="619" width="121" height="19" font="3">(7.1% vs. 9.7% [OR: </text>
<text top="770" left="619" width="117" height="19" font="3">0.71; 95% CI: 0.61–</text>
<text top="586" left="773" width="89" height="20" font="3">• Amiodarone </text>
<text top="605" left="773" width="116" height="19" font="3">reduces the risk of </text>
<text top="624" left="773" width="101" height="19" font="3">SCD by 29% and </text>
<text top="642" left="773" width="80" height="19" font="3">CVD by 18%, </text>
<text top="660" left="773" width="60" height="19" font="3">however, </text>
<text top="679" left="773" width="128" height="19" font="3">amiodarone therapy </text>
<text top="697" left="773" width="91" height="19" font="3">is neutral with </text>
<text top="715" left="773" width="122" height="19" font="3">respect to all-cause </text>
<text top="734" left="773" width="63" height="19" font="3">mortality  </text>
<text top="752" left="773" width="3" height="19" font="3"> </text>
<text top="586" left="915" width="94" height="19" font="3">● <b>Conclusions:</b> </text>
<text top="605" left="915" width="156" height="19" font="3">Amiodarone reduced the </text>
<text top="623" left="915" width="152" height="19" font="3">risk of SCD but is neutral </text>
<text top="641" left="915" width="152" height="19" font="3">with respect to all-cause </text>
<text top="660" left="915" width="63" height="19" font="3">mortality. </text>
<text top="678" left="915" width="3" height="19" font="3"> </text>
<text top="696" left="915" width="129" height="19" font="3">● Authors suggested </text>
<text top="714" left="915" width="144" height="19" font="3">amiodarone as a viable </text>
<text top="733" left="915" width="137" height="19" font="3">alternative in patients </text>
<text top="751" left="915" width="146" height="19" font="3">who are not eligible for </text>
<text top="769" left="915" width="123" height="19" font="3">or who do not have </text>
</page>
<page number="81" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">81 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="236" width="113" height="19" font="3">of amiodarone vs. </text>
<text top="127" left="236" width="101" height="19" font="3">placebo/control </text>
<text top="145" left="236" width="115" height="19" font="3">for the prevention </text>
<text top="164" left="236" width="50" height="19" font="3">of SCD   </text>
<text top="182" left="236" width="3" height="19" font="3"> </text>
<text top="200" left="236" width="32" height="19" font="4"><b>Size:</b> </text>
<text top="200" left="268" width="56" height="19" font="11">15 trials, </text>
<text top="219" left="236" width="116" height="19" font="11">which randomized </text>
<text top="237" left="236" width="87" height="19" font="11">8,522 patients</text>
<text top="237" left="324" width="3" height="19" font="3"> </text>
<text top="109" left="368" width="228" height="19" font="11">of patients with shock-refractory VA, </text>
<text top="127" left="368" width="228" height="19" font="11">OHCA, patients &lt;18 y, randomization </text>
<text top="145" left="368" width="233" height="19" font="11">to amiodarone vs. a class Ic or class III </text>
<text top="164" left="368" width="238" height="19" font="11">AAD (without a placebo or standard of </text>
<text top="182" left="368" width="213" height="19" font="11">care arm). Studies of patients with </text>
<text top="200" left="368" width="216" height="19" font="11">ICDs were excluded unless used on </text>
<text top="219" left="368" width="69" height="19" font="11">both arms. </text>
<text top="109" left="619" width="122" height="19" font="3">0.84, p&lt;0.001]) and </text>
<text top="127" left="619" width="130" height="19" font="3">cardiovascular death </text>
<text top="145" left="619" width="132" height="19" font="3">(14.0% vs.16.3% [OR: </text>
<text top="164" left="619" width="98" height="19" font="3">0.82;0.71–0.94, </text>
<text top="182" left="619" width="132" height="19" font="3">p=0.004]). There was </text>
<text top="200" left="619" width="124" height="19" font="3">a 1.5% absolute risk </text>
<text top="219" left="619" width="134" height="19" font="3">reduction in all-cause </text>
<text top="237" left="619" width="122" height="19" font="3">mortality which did </text>
<text top="255" left="619" width="121" height="19" font="3">not meet statistical </text>
<text top="273" left="619" width="140" height="19" font="3">significance (p=0.093). </text>
<text top="292" left="619" width="130" height="19" font="3">Amiodarone therapy </text>
<text top="310" left="619" width="126" height="19" font="3">increased the risk of </text>
<text top="329" left="619" width="127" height="19" font="3">pulmonary (2.9% vs. </text>
<text top="347" left="619" width="123" height="19" font="3">1.5% [OR: 1.97;95% </text>
<text top="365" left="619" width="83" height="19" font="3">CI:1.27–3.04, </text>
<text top="383" left="619" width="140" height="19" font="3">p=0.002]), and thyroid </text>
<text top="402" left="619" width="125" height="19" font="3">(3.6% vs. 0.4%; [OR: </text>
<text top="420" left="619" width="117" height="19" font="3">5.68; 95% CI :2.94–</text>
<text top="438" left="619" width="103" height="19" font="3">10.98, p&lt;0.001]) </text>
<text top="457" left="619" width="52" height="19" font="3">toxicity. </text>
<text top="109" left="773" width="101" height="19" font="3">Adverse events: </text>
<text top="127" left="773" width="124" height="19" font="3">associated with a 2- </text>
<text top="145" left="773" width="128" height="19" font="3">and 5-fold increased </text>
<text top="164" left="773" width="110" height="19" font="3">risk of pulmonary </text>
<text top="182" left="773" width="126" height="19" font="3">and thyroid toxicity. </text>
<text top="200" left="773" width="3" height="19" font="3"> </text>
<text top="109" left="915" width="155" height="19" font="3">access to ICD therapy for </text>
<text top="127" left="915" width="145" height="19" font="3">the prevention of SCD.  </text>
<text top="145" left="915" width="3" height="19" font="3"> </text>
<text top="476" left="123" width="81" height="19" font="3">● Claro et al. </text>
<text top="495" left="123" width="34" height="19" font="3">2015 </text>
<text top="494" left="157" width="35" height="21" font="0">(136)</text>
<text top="495" left="192" width="7" height="19" font="3">  </text>
<text top="514" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26646017">● </a></text>
<text top="514" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26646017">26646017</a></text>
<text top="514" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26646017"> </a></text>
<text top="532" left="123" width="3" height="19" font="3"> </text>
<text top="551" left="123" width="3" height="19" font="3"> </text>
<text top="476" left="236" width="110" height="19" font="4"><b>Aim:</b>  To evaluate </text>
<text top="494" left="236" width="107" height="19" font="3">the effectiveness </text>
<text top="512" left="236" width="114" height="19" font="3">of amiodarone for </text>
<text top="531" left="236" width="49" height="19" font="3">1° or 2° </text>
<text top="549" left="236" width="114" height="19" font="3">prevention of SCD </text>
<text top="567" left="236" width="96" height="19" font="3">compared with </text>
<text top="586" left="236" width="87" height="19" font="3">placebo or no </text>
<text top="604" left="236" width="95" height="19" font="3">intervention or </text>
<text top="622" left="236" width="62" height="19" font="3">any other </text>
<text top="640" left="236" width="98" height="19" font="3">antiarrhythmic. </text>
<text top="659" left="236" width="3" height="19" font="3"> </text>
<text top="677" left="236" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="695" left="236" width="91" height="19" font="3">meta-analyses </text>
<text top="714" left="236" width="99" height="19" font="3">using a random-</text>
<text top="732" left="236" width="87" height="19" font="3">effects model </text>
<text top="750" left="236" width="3" height="19" font="3"> </text>
<text top="476" left="368" width="194" height="19" font="4"><b>Inclusion criteria:</b>  Randomized </text>
<text top="494" left="368" width="227" height="19" font="3">assessing the efficacy of amiodarone </text>
<text top="512" left="368" width="230" height="19" font="3">vs. placebo, no intervention, or other </text>
<text top="531" left="368" width="236" height="19" font="3">antiarrhythmics in adults, either for 1° </text>
<text top="549" left="368" width="220" height="19" font="3">prevention or 2° prevention of SCD.<b> </b></text>
<text top="476" left="619" width="85" height="19" font="4"><b>Intervention:</b> </text>
<text top="494" left="619" width="79" height="19" font="3">Amiodarone </text>
<text top="512" left="619" width="7" height="19" font="3">  </text>
<text top="531" left="619" width="141" height="19" font="4"><b>Comparator:</b>  placebo, </text>
<text top="549" left="619" width="126" height="19" font="3">no intervention, ICD </text>
<text top="567" left="619" width="53" height="19" font="3">or other </text>
<text top="586" left="619" width="100" height="19" font="3">antiarrhythmics<b> </b></text>
<text top="476" left="773" width="123" height="19" font="4"><b>1</b>°<b> endpoint:</b>  There </text>
<text top="495" left="773" width="100" height="19" font="3">was a beneficial </text>
<text top="513" left="773" width="69" height="19" font="3">effect with </text>
<text top="531" left="773" width="77" height="19" font="3">amiodarone </text>
<text top="550" left="773" width="121" height="19" font="3">reducing the risk of </text>
<text top="568" left="773" width="105" height="19" font="3">SCD by 12%-34% </text>
<text top="586" left="773" width="125" height="19" font="3">and may reduce the </text>
<text top="605" left="773" width="97" height="19" font="3">risk of all-cause </text>
<text top="623" left="773" width="113" height="19" font="3">mortality by up to </text>
<text top="641" left="773" width="67" height="19" font="3">22% when </text>
<text top="660" left="773" width="96" height="19" font="3">compared with </text>
<text top="678" left="773" width="87" height="19" font="3">placebo or no </text>
<text top="696" left="773" width="120" height="19" font="3">intervention in a 1° </text>
<text top="714" left="773" width="123" height="19" font="3">prevention setting.  </text>
<text top="733" left="773" width="3" height="19" font="3"> </text>
<text top="751" left="773" width="3" height="19" font="3"> </text>
<text top="476" left="915" width="145" height="19" font="3">● <b>Conclusions: </b>There is </text>
<text top="494" left="915" width="157" height="19" font="3">low quality evidence that </text>
<text top="512" left="915" width="153" height="19" font="3">amiodarone reduces the </text>
<text top="531" left="915" width="124" height="19" font="3">risk of SCD and may </text>
<text top="549" left="915" width="129" height="19" font="3">reduce the risk of all-</text>
<text top="567" left="915" width="135" height="19" font="3">cause mortality when </text>
<text top="586" left="915" width="147" height="19" font="3">compared with placebo </text>
<text top="604" left="915" width="156" height="19" font="3">or no intervention in a 1° </text>
<text top="622" left="915" width="123" height="19" font="3">prevention setting.  </text>
<text top="640" left="915" width="3" height="19" font="3"> </text>
<text top="659" left="915" width="158" height="19" font="3">● The evidence regarding </text>
<text top="677" left="915" width="129" height="19" font="3">the comparison with </text>
<text top="695" left="915" width="149" height="19" font="3">other antiarrhythmics is </text>
<text top="714" left="915" width="151" height="19" font="3">of moderate quality and </text>
<text top="732" left="915" width="106" height="19" font="3">goes in the same </text>
<text top="750" left="915" width="65" height="19" font="3">direction.  </text>
<text top="769" left="915" width="3" height="19" font="3"> </text>
</page>
<page number="82" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">82 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="236" width="107" height="19" font="4"><b>Size:</b>    24 studies </text>
<text top="127" left="236" width="42" height="19" font="3">(9,997 </text>
<text top="145" left="236" width="111" height="19" font="3">participants) with </text>
<text top="164" left="236" width="96" height="19" font="3">17 studies with </text>
<text top="182" left="236" width="87" height="19" font="3">8383 patients </text>
<text top="200" left="236" width="78" height="19" font="3">identified as </text>
<text top="219" left="236" width="70" height="19" font="3">relevant 1° </text>
<text top="237" left="236" width="108" height="19" font="3">prevention trials.<b> </b></text>
<text top="109" left="773" width="103" height="19" font="4"><b>Adverse events:</b> </text>
<text top="127" left="773" width="106" height="19" font="3">Amiodarone was </text>
<text top="145" left="773" width="98" height="19" font="3">associated with </text>
<text top="164" left="773" width="113" height="19" font="3">increased adverse </text>
<text top="182" left="773" width="128" height="19" font="3">effects, both thyroid </text>
<text top="200" left="773" width="96" height="19" font="3">and pulmonary </text>
<text top="219" left="773" width="82" height="19" font="3">(based on 12 </text>
<text top="237" left="773" width="81" height="19" font="3">studies), and </text>
<text top="255" left="773" width="103" height="19" font="3">increased risk of </text>
<text top="273" left="773" width="98" height="19" font="3">discontinuation </text>
<text top="292" left="773" width="82" height="19" font="3">(based on 13 </text>
<text top="310" left="773" width="88" height="19" font="3">studies) when </text>
<text top="329" left="773" width="96" height="19" font="3">compared with </text>
<text top="347" left="773" width="55" height="19" font="3">placebo.<b> </b></text>
<text top="109" left="915" width="89" height="19" font="3">● Stresses the </text>
<text top="127" left="915" width="155" height="19" font="3">importance for people in </text>
<text top="145" left="915" width="139" height="19" font="3">low-income countries, </text>
<text top="164" left="915" width="157" height="19" font="3">where an ICD may not be </text>
<text top="182" left="915" width="61" height="19" font="3">available. </text>
<text top="366" left="123" width="94" height="19" font="3">● Owens DK et </text>
<text top="384" left="123" width="87" height="19" font="3">al. 2002 (139) </text>
<text top="402" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12228780">● </a></text>
<text top="402" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12228780">12228780</a></text>
<text top="402" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12228780"> </a></text>
<text top="366" left="236" width="96" height="19" font="4"><b>Aim: </b>Evaluated </text>
<text top="384" left="236" width="80" height="19" font="3">whether risk </text>
<text top="402" left="236" width="81" height="19" font="3">stratification </text>
<text top="421" left="236" width="83" height="19" font="3">based on risk </text>
<text top="439" left="236" width="104" height="19" font="3">ofSCD alone was </text>
<text top="457" left="236" width="76" height="19" font="3">sufficient to </text>
<text top="476" left="236" width="70" height="19" font="3">predict the </text>
<text top="494" left="236" width="110" height="19" font="3">effectiveness and </text>
<text top="512" left="236" width="113" height="19" font="3">cost-effectiveness </text>
<text top="531" left="236" width="68" height="19" font="3">of the ICD. </text>
<text top="366" left="368" width="218" height="19" font="3">Markov model to evaluate the cost-</text>
<text top="384" left="368" width="206" height="19" font="3">effectiveness of ICD implantation </text>
<text top="402" left="368" width="222" height="19" font="3">compared with empiric amiodarone </text>
<text top="421" left="368" width="220" height="19" font="3">treatment. The model incorporated </text>
<text top="439" left="368" width="201" height="19" font="3">mortality rates from sudden and </text>
<text top="457" left="368" width="232" height="19" font="3">nonsudden cardiac death, noncardiac </text>
<text top="476" left="368" width="219" height="19" font="3">death and costs for each treatment </text>
<text top="494" left="368" width="234" height="19" font="3">strategy. Model assumed that the ICD </text>
<text top="512" left="368" width="230" height="19" font="3">reduced total mortality rates by 25%, </text>
<text top="531" left="368" width="188" height="19" font="3">relative to use of amiodarone. </text>
<text top="366" left="619" width="224" height="19" font="4"><b>Results: </b>cost-effectiveness becomes </text>
<text top="384" left="619" width="238" height="19" font="3">unfavorable at both low and high total </text>
<text top="402" left="619" width="148" height="19" font="3">cardiac mortality rates.  </text>
<text top="421" left="619" width="260" height="19" font="3">If the annual total cardiac mortality rate is </text>
<text top="439" left="619" width="273" height="19" font="3">12%, the cost-effectiveness of the ICD varies </text>
<text top="457" left="619" width="266" height="19" font="3">from $36,000 per quality-adjusted life-year </text>
<text top="476" left="619" width="247" height="19" font="3">(QALY) gained when the ratio of sudden </text>
<text top="494" left="619" width="272" height="19" font="3">cardiac death to nonsudden cardiac death is </text>
<text top="512" left="619" width="253" height="19" font="3">4 to $116,000 per QALY gained when the </text>
<text top="531" left="619" width="79" height="19" font="3">ratio is 0.25. </text>
<text top="366" left="915" width="152" height="19" font="3">● The cost-effectiveness </text>
<text top="384" left="915" width="131" height="19" font="3">of ICD use relative to </text>
<text top="402" left="915" width="152" height="19" font="3">amiodarone depends on </text>
<text top="421" left="915" width="138" height="19" font="3">total cardiac mortality </text>
<text top="439" left="915" width="151" height="19" font="3">rates as well as the ratio </text>
<text top="457" left="915" width="152" height="19" font="3">of sudden to nonsudden </text>
<text top="476" left="915" width="90" height="19" font="3">cardiac death. </text>
<text top="550" left="123" width="66" height="19" font="3">● Cantero-</text>
<text top="568" left="123" width="98" height="19" font="3">Pérez EM, et al. </text>
<text top="586" left="123" width="69" height="19" font="3">2013 (155) </text>
<text top="605" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24314988">● </a></text>
<text top="605" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24314988">24314988</a></text>
<text top="605" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24314988"> </a></text>
<text top="550" left="236" width="107" height="19" font="4"><b>Aim:</b> To evaluate </text>
<text top="568" left="236" width="107" height="19" font="3">the effectiveness </text>
<text top="586" left="236" width="118" height="19" font="3">of ICDs for primary </text>
<text top="605" left="236" width="85" height="19" font="3">prevention in </text>
<text top="623" left="236" width="116" height="19" font="3">patients with LVEF </text>
<text top="641" left="236" width="112" height="19" font="3">≤30% included on </text>
<text top="660" left="236" width="60" height="19" font="3">the heart </text>
<text top="678" left="236" width="119" height="19" font="3">transplantation list </text>
<text top="696" left="236" width="3" height="19" font="4"><b> </b></text>
<text top="714" left="236" width="28" height="19" font="4"><b>Size:</b></text>
<text top="713" left="265" width="4" height="21" font="0"> </text>
<text top="714" left="268" width="83" height="19" font="3">Patients who </text>
<text top="733" left="236" width="107" height="19" font="3">received ICDs for </text>
<text top="751" left="236" width="51" height="19" font="3">primary </text>
<text top="769" left="236" width="115" height="19" font="3">prevention (N=28) </text>
<text top="550" left="368" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="568" left="368" width="219" height="19" font="3">Records from patients accepted for </text>
<text top="586" left="368" width="232" height="19" font="3">heart transplantation from January 1, </text>
<text top="605" left="368" width="210" height="19" font="3">2006, to July 30, 2012, and whose </text>
<text top="623" left="368" width="191" height="19" font="3">LVEF was &lt;31% were reviewed </text>
<text top="550" left="619" width="52" height="19" font="4"><b>Results: </b></text>
<text top="568" left="619" width="161" height="19" font="3">Median follow-up of 77 d  </text>
<text top="586" left="619" width="267" height="19" font="3">overall mortality in the ICD group was 7.1% </text>
<text top="605" left="619" width="266" height="19" font="3">(2/28) and in the non-ICD group was 17.6% </text>
<text top="623" left="619" width="105" height="19" font="3">(9/51; p=0.062).  </text>
<text top="641" left="619" width="248" height="19" font="3">Cause of death in patients without ICDs: </text>
<text top="660" left="619" width="173" height="19" font="3">Sudden death (5/9, 55.6%),  </text>
<text top="678" left="619" width="105" height="19" font="3">HF (4/9, 44.4%).  </text>
<text top="696" left="619" width="283" height="19" font="3">Cause of death in patients with ICDs: HFheart  </text>
<text top="550" left="915" width="114" height="19" font="3">● Appropriate ICD </text>
<text top="568" left="915" width="154" height="19" font="3">therapies were recorded </text>
<text top="586" left="915" width="144" height="19" font="3">in 42.9% (12/28) in this </text>
<text top="605" left="915" width="74" height="19" font="3">population. </text>
</page>
<page number="83" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">83 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="236" width="99" height="19" font="3">were compared </text>
<text top="127" left="236" width="83" height="19" font="3">with patients </text>
<text top="145" left="236" width="81" height="19" font="3">without ICDs </text>
<text top="164" left="236" width="45" height="19" font="3">(N=51)<b> </b></text>
<text top="183" left="123" width="94" height="19" font="3">● Fröhlich GM, </text>
<text top="201" left="123" width="64" height="19" font="3">et al. 2013</text>
<text top="199" left="187" width="4" height="21" font="0"> </text>
<text top="219" left="123" width="35" height="19" font="3">(156) </text>
<text top="238" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23813845">● </a></text>
<text top="238" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23813845">23813845</a></text>
<text top="238" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23813845"> </a></text>
<text top="183" left="236" width="29" height="19" font="4"><b>Aim:</b></text>
<text top="181" left="265" width="4" height="21" font="0"> </text>
<text top="183" left="269" width="79" height="19" font="3">To delineate </text>
<text top="201" left="236" width="91" height="19" font="3">the role of ICD </text>
<text top="219" left="236" width="96" height="19" font="3">therapy for the </text>
<text top="238" left="236" width="78" height="19" font="3">primary and </text>
<text top="256" left="236" width="66" height="19" font="3">secondary </text>
<text top="274" left="236" width="114" height="19" font="3">prevention of SCD </text>
<text top="293" left="236" width="104" height="19" font="3">in patients listed </text>
<text top="311" left="236" width="57" height="19" font="3">for heart </text>
<text top="329" left="236" width="98" height="19" font="3">transplantation<b> </b></text>
<text top="347" left="236" width="3" height="19" font="4"><b> </b></text>
<text top="366" left="236" width="83" height="19" font="4"><b>Size:</b> N=1089<b> </b></text>
<text top="183" left="368" width="115" height="19" font="4"><b>Inclusion criteria:  </b></text>
<text top="201" left="368" width="147" height="19" font="3">Patients listed for heart </text>
<text top="219" left="368" width="208" height="19" font="3">transplantation in 2 tertiary heart </text>
<text top="238" left="368" width="225" height="19" font="3">transplant centres were enrolled. Of </text>
<text top="256" left="368" width="227" height="19" font="3">550 patients (51%) on the transplant </text>
<text top="274" left="368" width="98" height="19" font="3">list with an ICD: </text>
<text top="293" left="368" width="197" height="19" font="3">primary prevention ICD: N=216  </text>
<text top="311" left="368" width="211" height="19" font="3">secondary prevention ICD: N=334  </text>
<text top="183" left="619" width="52" height="19" font="4"><b>Results: </b></text>
<text top="201" left="619" width="238" height="19" font="3">Median time on the waiting list = 8 mo </text>
<text top="219" left="619" width="244" height="19" font="3">(estimated 1-year: 88±3% vs. 77±3% vs. </text>
<text top="238" left="619" width="121" height="19" font="3">67±3%; p=0.0001).  </text>
<text top="256" left="619" width="277" height="19" font="3">An independent beneficial effect of ICDs that </text>
<text top="274" left="619" width="263" height="19" font="3">was most pronounced in patients who had </text>
<text top="293" left="619" width="270" height="19" font="3">received an ICD for primary prevention (HR: </text>
<text top="311" left="619" width="204" height="19" font="3">0.4, 95% CI: 0.19–0.85; p=0.016). </text>
<text top="183" left="915" width="124" height="19" font="3">● ICDs appear to be </text>
<text top="201" left="915" width="109" height="19" font="3">associated with a </text>
<text top="219" left="915" width="134" height="19" font="3">reduction in all-cause </text>
<text top="238" left="915" width="127" height="19" font="3">mortality in patients </text>
<text top="256" left="915" width="120" height="19" font="3">implanted with the </text>
<text top="274" left="915" width="141" height="19" font="3">device for primary and </text>
<text top="293" left="915" width="136" height="19" font="3">secondary prevention </text>
<text top="311" left="915" width="119" height="19" font="3">compared to those </text>
<text top="329" left="915" width="98" height="19" font="3">without an ICD. </text>
<text top="385" left="123" width="96" height="19" font="3">● Gandjbakhch </text>
<text top="403" left="123" width="78" height="19" font="3">E, et al. 2016</text>
<text top="402" left="202" width="4" height="21" font="0"> </text>
<text top="422" left="123" width="35" height="19" font="3">(157) </text>
<text top="440" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27344378">● </a></text>
<text top="440" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27344378">27344378</a></text>
<text top="440" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27344378"> </a></text>
<text top="385" left="236" width="107" height="19" font="4"><b>Aim: </b>To evaluate </text>
<text top="403" left="236" width="114" height="19" font="3">the ICD benefit on </text>
<text top="422" left="236" width="74" height="19" font="3">mortality in </text>
<text top="440" left="236" width="111" height="19" font="3">patients with end-</text>
<text top="458" left="236" width="113" height="19" font="3">stage HF listed for </text>
<text top="476" left="236" width="36" height="19" font="3">heart </text>
<text top="495" left="236" width="101" height="19" font="3">transplantation  </text>
<text top="513" left="236" width="3" height="19" font="4"><b> </b></text>
<text top="533" left="236" width="28" height="19" font="4"><b>Size:</b></text>
<text top="531" left="265" width="23" height="21" font="0"> N=</text>
<text top="533" left="287" width="26" height="19" font="3">380 </text>
<text top="552" left="236" width="76" height="19" font="3">consecutive </text>
<text top="570" left="236" width="111" height="19" font="3">patients listed for </text>
<text top="588" left="236" width="36" height="19" font="3">heart </text>
<text top="606" left="236" width="97" height="19" font="3">transplantation </text>
<text top="625" left="236" width="117" height="19" font="3">between 2005 and </text>
<text top="643" left="236" width="109" height="19" font="3">2009 in A tertiary </text>
<text top="661" left="236" width="102" height="19" font="3">heart transplant </text>
<text top="680" left="236" width="46" height="19" font="3">centre <b> </b></text>
<text top="385" left="368" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="403" left="368" width="225" height="19" font="3">Patients with end-stage HF receiving </text>
<text top="422" left="368" width="212" height="19" font="3">an ICD before or within 3 mo after </text>
<text top="440" left="368" width="228" height="19" font="3">being listed for heart transplantation </text>
<text top="385" left="619" width="52" height="19" font="4"><b>Results: </b></text>
<text top="403" left="619" width="268" height="19" font="3">15.6% of patients died while awaiting heart </text>
<text top="422" left="619" width="105" height="19" font="3">transplantation.  </text>
<text top="440" left="619" width="245" height="19" font="3">Non-ICD patients presented more often </text>
<text top="458" left="619" width="180" height="19" font="3">haemodynamic compromise. </text>
<text top="476" left="619" width="277" height="19" font="3">ICD did not remain an independent predictor </text>
<text top="495" left="619" width="58" height="19" font="3">of death. </text>
<text top="513" left="619" width="280" height="19" font="3">Death by haemodynamic compromise (76.3% </text>
<text top="531" left="619" width="269" height="19" font="3">of deaths), which occurred more frequently </text>
<text top="550" left="619" width="256" height="19" font="3">in the non-ICD group (14.7% vs. 5.8%; log-</text>
<text top="568" left="619" width="95" height="19" font="3">rank p=0.002).  </text>
<text top="586" left="619" width="3" height="19" font="3"> </text>
<text top="605" left="619" width="263" height="19" font="3">Unknown/arrhythmic deaths did not differ </text>
<text top="623" left="619" width="267" height="19" font="3">significantly between the two groups (3.9% </text>
<text top="641" left="619" width="168" height="19" font="3">vs. 1.7%; log-rank p=0.21).  </text>
<text top="385" left="915" width="142" height="19" font="3">● Need for mechanical </text>
<text top="403" left="915" width="119" height="19" font="3">circulatory support </text>
<text top="422" left="915" width="109" height="19" font="3">(p&lt;0.001), low EF </text>
<text top="440" left="915" width="88" height="19" font="3">(p=0.001) and </text>
<text top="458" left="915" width="117" height="19" font="3">registration on the </text>
<text top="476" left="915" width="130" height="19" font="3">regular list (p=0.008) </text>
<text top="495" left="915" width="88" height="19" font="3">were the only </text>
<text top="513" left="915" width="147" height="19" font="3">independent predictors </text>
<text top="531" left="915" width="58" height="19" font="3">of death. </text>
<text top="550" left="915" width="9" height="19" font="3">●</text>
<text top="548" left="924" width="4" height="21" font="0"> </text>
<text top="550" left="928" width="73" height="19" font="3">ICD-related </text>
<text top="568" left="915" width="146" height="19" font="3">complications occurred </text>
<text top="586" left="915" width="128" height="19" font="3">in 21.4% of patients, </text>
<text top="605" left="915" width="125" height="19" font="3">mainly as a result of </text>
<text top="623" left="915" width="155" height="19" font="3">postoperative worsening </text>
<text top="641" left="915" width="89" height="19" font="3">of HF (11.9%). </text>
<text top="699" left="123" width="94" height="19" font="3">● Vakil K, et al. </text>
<text top="717" left="123" width="69" height="19" font="3">2016 (158) </text>
<text top="699" left="236" width="116" height="19" font="4"><b>Aim:</b> To assess the </text>
<text top="717" left="236" width="104" height="19" font="3">impact of ICD on </text>
<text top="735" left="236" width="107" height="19" font="3">waitlist mortality </text>
<text top="754" left="236" width="104" height="19" font="3">in patients listed </text>
<text top="699" left="368" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="717" left="368" width="230" height="19" font="3">Adults (age ≥18 y) listed for first-time </text>
<text top="735" left="368" width="192" height="19" font="3">heart transplantation in the US </text>
<text top="754" left="368" width="186" height="19" font="3">between January 1, 1999, and </text>
<text top="772" left="368" width="165" height="19" font="3">September 30, 2014, were </text>
<text top="699" left="619" width="52" height="19" font="4"><b>Results: </b></text>
<text top="717" left="619" width="192" height="19" font="3">Median follow-up of 154 days,  </text>
<text top="735" left="619" width="276" height="19" font="3">3,638 patients (11%) died on the waitlist (9% </text>
<text top="754" left="619" width="231" height="19" font="3">in ICD group vs. 15% in no-ICD group; </text>
<text top="699" left="915" width="9" height="19" font="3">●</text>
<text top="697" left="924" width="4" height="21" font="0"> </text>
<text top="699" left="928" width="116" height="19" font="3">In the subgroup of </text>
<text top="717" left="915" width="145" height="19" font="3">patients with LVAD (N= </text>
<text top="735" left="915" width="159" height="19" font="3">9,478), having an ICD was </text>
<text top="754" left="915" width="116" height="19" font="3">associated with an </text>
<text top="772" left="915" width="135" height="19" font="3">adjusted 19% relative </text>
</page>
<page number="84" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">84 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="236" width="57" height="19" font="3">for heart </text>
<text top="127" left="236" width="98" height="19" font="3">transplantation </text>
<text top="145" left="236" width="3" height="19" font="4"><b> </b></text>
<text top="164" left="236" width="94" height="19" font="4"><b>Size:</b> N=32,599<b> </b></text>
<text top="109" left="368" width="214" height="19" font="3">retrospectively identified from the </text>
<text top="127" left="368" width="212" height="19" font="3">United Network for Organ Sharing </text>
<text top="145" left="368" width="53" height="19" font="3">registry. </text>
<text top="109" left="619" width="260" height="19" font="3">p&lt;0.0001), whereas 63% underwent heart </text>
<text top="127" left="619" width="105" height="19" font="3">transplantation.  </text>
<text top="145" left="619" width="243" height="19" font="3">An ICD at listing was associated with an </text>
<text top="164" left="619" width="272" height="19" font="3">adjusted 13% relative reduction in mortality </text>
<text top="182" left="619" width="188" height="19" font="3">(HR: 0.87; 95% CI: 0.80–0.94).  </text>
<text top="109" left="915" width="137" height="19" font="3">reduction in mortality </text>
<text top="127" left="915" width="146" height="19" font="3">(HR: 0.81; 95% CI: 0.70–</text>
<text top="145" left="915" width="38" height="19" font="3">0.94). </text>
<text top="201" left="115" width="4" height="21" font="0"> </text>
<text top="257" left="115" width="920" height="21" font="2"><b>Data Supplement 22. RCTs Evaluating Treatment and Prevention of Recurrent Ventricular Arrhythmias in Patients with Ischemic Heart </b></text>
<text top="277" left="115" width="170" height="21" font="2"><b>Disease – (Section 7.1.3) </b></text>
<text top="298" left="155" width="39" height="19" font="4"><b>Study </b></text>
<text top="316" left="142" width="64" height="19" font="4"><b>Acronym; </b></text>
<text top="335" left="148" width="55" height="19" font="4"><b>Author;  </b></text>
<text top="353" left="126" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="298" left="258" width="88" height="19" font="4"><b>Aim of Study; </b></text>
<text top="316" left="264" width="76" height="19" font="4"><b>Study Type; </b></text>
<text top="335" left="257" width="89" height="19" font="4"><b>Study Size (N) </b></text>
<text top="298" left="409" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="298" left="583" width="123" height="19" font="4"><b>Study Intervention  </b></text>
<text top="316" left="601" width="88" height="19" font="4"><b>(# patients) /  </b></text>
<text top="335" left="585" width="121" height="19" font="4"><b>Study Comparator  </b></text>
<text top="353" left="606" width="75" height="19" font="4"><b>(# patients) </b></text>
<text top="298" left="742" width="108" height="19" font="4"><b>Endpoint Results </b></text>
<text top="316" left="745" width="102" height="19" font="4"><b>(Absolute Event </b></text>
<text top="335" left="775" width="45" height="19" font="4"><b>Rates,  </b></text>
<text top="353" left="728" width="136" height="19" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="371" left="771" width="49" height="19" font="4"><b>95% CI) </b></text>
<text top="300" left="883" width="66" height="19" font="4"><b>Relevant 2</b></text>
<text top="298" left="948" width="7" height="20" font="0">°</text>
<text top="300" left="955" width="115" height="19" font="4"><b> Endpoint (if any); </b></text>
<text top="319" left="918" width="116" height="19" font="4"><b>Study Limitations; </b></text>
<text top="337" left="927" width="99" height="19" font="4"><b>Adverse Events </b></text>
<text top="390" left="123" width="57" height="19" font="3">● <b>OPTIC</b>  </text>
<text top="409" left="123" width="85" height="19" font="3">● Connolly et </text>
<text top="427" left="123" width="87" height="19" font="3">al. 2006 (159) </text>
<text top="446" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16403928">● </a></text>
<text top="446" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16403928">16403928</a></text>
<text top="445" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16403928"> </a></text>
<text top="390" left="238" width="101" height="19" font="4"><b>Aim:</b> Determine </text>
<text top="409" left="238" width="55" height="19" font="3">whether </text>
<text top="427" left="238" width="125" height="19" font="3">amiodarone plus BB </text>
<text top="446" left="238" width="125" height="19" font="3">or sotalol are better </text>
<text top="464" left="238" width="109" height="19" font="3">than BB alone for </text>
<text top="482" left="238" width="111" height="19" font="3">prevention of ICD </text>
<text top="500" left="238" width="48" height="19" font="3">shocks.<b> </b></text>
<text top="518" left="238" width="3" height="19" font="4"><b> </b></text>
<text top="537" left="238" width="101" height="19" font="4"><b>Study type: </b>RCT </text>
<text top="555" left="238" width="3" height="19" font="4"><b> </b></text>
<text top="574" left="238" width="111" height="19" font="4"><b>Size: </b>412 patients </text>
<text top="390" left="379" width="167" height="19" font="4"><b>Inclusion criteria:  </b>Patients </text>
<text top="409" left="379" width="155" height="19" font="3">who had received an ICD </text>
<text top="427" left="379" width="168" height="19" font="3">within 21 d for inducible or </text>
<text top="446" left="379" width="123" height="19" font="3">spontaneous VT/VF </text>
<text top="464" left="379" width="3" height="19" font="4"><b> </b></text>
<text top="482" left="379" width="167" height="19" font="4"><b>Exclusion criteria:</b> Long QT </text>
<text top="500" left="379" width="151" height="19" font="3">syndrome, corrected QT </text>
<text top="519" left="379" width="159" height="19" font="3">interval of more than 450 </text>
<text top="537" left="379" width="149" height="19" font="3">ms, already receiving or </text>
<text top="555" left="379" width="149" height="19" font="3">recent treatment with a </text>
<text top="574" left="379" width="102" height="19" font="3">class I or class III </text>
<text top="592" left="379" width="136" height="19" font="3">antiarrhythmic agent, </text>
<text top="610" left="379" width="153" height="19" font="3">creatinine clearance less </text>
<text top="629" left="379" width="175" height="19" font="3">than 30 mL/min, AF likely to </text>
<text top="647" left="379" width="155" height="19" font="3">require use of a class I or </text>
<text top="665" left="379" width="141" height="19" font="3">class III antiarrhythmic </text>
<text top="683" left="379" width="144" height="19" font="3">agent, absence of SHD, </text>
<text top="702" left="379" width="106" height="19" font="3">NYHA class IV HF<b> </b></text>
<text top="390" left="573" width="85" height="19" font="4"><b>Intervention: </b></text>
<text top="409" left="573" width="125" height="19" font="3">amiodarone plus BB </text>
<text top="427" left="573" width="61" height="19" font="3">or sotalol<b> </b></text>
<text top="445" left="573" width="7" height="19" font="4"><b>  </b></text>
<text top="464" left="573" width="139" height="19" font="4"><b>Comparator:</b> BB alone </text>
<text top="391" left="727" width="109" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ICD </text>
<text top="409" left="727" width="133" height="19" font="3">shock for any reason. </text>
<text top="428" left="727" width="136" height="19" font="3">Shocks occurred in 41 </text>
<text top="446" left="727" width="103" height="19" font="3">patients (38.5%) </text>
<text top="465" left="727" width="133" height="19" font="3">assigned to BB alone, </text>
<text top="483" left="727" width="124" height="19" font="3">26 (24.3%) assigned </text>
<text top="501" left="727" width="109" height="19" font="3">to sotalol, and 12 </text>
<text top="519" left="727" width="122" height="19" font="3">(10.3%) assigned to </text>
<text top="538" left="727" width="125" height="19" font="3">amiodarone plus BB </text>
<text top="556" left="727" width="112" height="19" font="3">(HR: 0.44; 95% CI: </text>
<text top="574" left="727" width="129" height="19" font="3">0.28–0.68; p&lt;0.001). </text>
<text top="593" left="727" width="3" height="19" font="4"><b> </b></text>
<text top="611" left="727" width="128" height="19" font="4"><b>Safety endpoint:</b> NA </text>
<text top="629" left="727" width="3" height="19" font="4"><b> </b></text>
<text top="390" left="878" width="139" height="19" font="3">● Amiodarone plus BB </text>
<text top="409" left="878" width="194" height="19" font="3">significantly reduced the risk of </text>
<text top="427" left="878" width="191" height="19" font="3">shock compared with BB alone </text>
<text top="446" left="878" width="180" height="19" font="3">(HR: 0.27; 95% CI: 0.14–0.52; </text>
<text top="464" left="878" width="191" height="19" font="3">p&lt;0.001) and sotalol (HR: 0.43; </text>
<text top="482" left="878" width="170" height="19" font="3">95% CI: 0.22–0.85; p=0.02). </text>
<text top="500" left="878" width="195" height="19" font="3">There was a trend for sotalol to </text>
<text top="519" left="878" width="186" height="19" font="3">reduce shocks compared with </text>
<text top="537" left="878" width="176" height="19" font="3">�BB alone (HR: 0.61; 95% CI: </text>
<text top="555" left="878" width="129" height="19" font="3">0.37–1.01; p=0.055). </text>
<text top="574" left="878" width="161" height="19" font="3">● Adverse pulmonary and </text>
<text top="592" left="878" width="118" height="19" font="3">thyroid events and </text>
<text top="610" left="878" width="193" height="19" font="3">symptomatic bradycardia were </text>
<text top="629" left="878" width="192" height="19" font="3">more common among patients </text>
<text top="647" left="878" width="174" height="19" font="3">randomized to amiodarone. </text>
<text top="665" left="878" width="3" height="19" font="3"> </text>
<text top="683" left="878" width="184" height="19" font="3">● <b>Conclusions: </b>Despite use of </text>
<text top="702" left="878" width="184" height="19" font="3">advanced ICD technology and </text>
<text top="720" left="878" width="174" height="19" font="3">treatment with a BB, shocks </text>
<text top="738" left="878" width="171" height="19" font="3">occur commonly in the first </text>
<text top="757" left="878" width="141" height="19" font="3">year after ICD implant. </text>
<text top="775" left="878" width="196" height="19" font="3">Amiodarone plus BB is effective </text>
</page>
<page number="85" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">85 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="878" width="172" height="19" font="3">for preventing these shocks </text>
<text top="127" left="878" width="163" height="19" font="3">and is more effective than </text>
<text top="145" left="878" width="173" height="19" font="3">sotalol but has an increased </text>
<text top="164" left="878" width="172" height="19" font="3">risk of drug-related adverse </text>
<text top="182" left="878" width="52" height="19" font="3">effects.  </text>
<text top="201" left="123" width="97" height="19" font="3">● Pacifico et al. </text>
<text top="219" left="123" width="73" height="19" font="3">1999 (160)  </text>
<text top="238" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10369848">● </a></text>
<text top="238" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10369848">10369848</a></text>
<text top="238" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10369848"> </a></text>
<text top="256" left="123" width="3" height="19" font="3"> </text>
<text top="201" left="238" width="109" height="19" font="4"><b>Aim:</b> Efficacy and </text>
<text top="219" left="238" width="117" height="19" font="3">safety of sotalol to </text>
<text top="238" left="238" width="128" height="19" font="3">prevent shocks from </text>
<text top="256" left="238" width="30" height="19" font="3">ICDs </text>
<text top="274" left="238" width="3" height="19" font="4"><b> </b></text>
<text top="292" left="238" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="311" left="238" width="105" height="19" font="3">prospective, RCT </text>
<text top="329" left="238" width="81" height="19" font="3">double-blind </text>
<text top="347" left="238" width="3" height="19" font="4"><b> </b></text>
<text top="366" left="238" width="111" height="19" font="4"><b>Size:</b> 302 patients<b> </b></text>
<text top="201" left="379" width="176" height="19" font="4"><b>Inclusion criteria: </b>age &gt;18 y, </text>
<text top="219" left="379" width="180" height="19" font="3">life-threatening VT that were </text>
<text top="238" left="379" width="141" height="19" font="3">not due to a reversible </text>
<text top="256" left="379" width="156" height="19" font="3">cause; had received their </text>
<text top="274" left="379" width="160" height="19" font="3">first or a replacement ICD </text>
<text top="293" left="379" width="120" height="19" font="3">within 3 mo before </text>
<text top="311" left="379" width="159" height="19" font="3">enrollment (patients with </text>
<text top="329" left="379" width="162" height="19" font="3">replacement defibrillators </text>
<text top="347" left="379" width="179" height="19" font="3">had to have received at least </text>
<text top="366" left="379" width="131" height="19" font="3">one shock during the </text>
<text top="384" left="379" width="168" height="19" font="3">preceding 6 mo); had a ICD </text>
<text top="402" left="379" width="177" height="19" font="3">that provided tiered therapy </text>
<text top="421" left="379" width="146" height="19" font="3">with EGM and separate </text>
<text top="439" left="379" width="107" height="19" font="3">logging of shocks </text>
<text top="457" left="379" width="3" height="19" font="4"><b> </b></text>
<text top="476" left="379" width="177" height="19" font="4"><b>Exclusion criteria:  i</b>ncessant </text>
<text top="494" left="379" width="135" height="19" font="3">VT; had received AAD </text>
<text top="512" left="379" width="167" height="19" font="3">therapy &lt;5 half-lives of the </text>
<text top="531" left="379" width="168" height="19" font="3">drug before randomization </text>
<text top="549" left="379" width="165" height="19" font="3">in the case of class I and III </text>
<text top="567" left="379" width="160" height="19" font="3">agents (and &lt;3 mo before </text>
<text top="586" left="379" width="177" height="19" font="3">randomization in the case of </text>
<text top="604" left="379" width="144" height="19" font="3">amiodarone); had a QT </text>
<text top="622" left="379" width="159" height="19" font="3">interval of more than 450 </text>
<text top="640" left="379" width="148" height="19" font="3">msec (or a JT interval of </text>
<text top="659" left="379" width="172" height="19" font="3">more than 360 msec) in the </text>
<text top="677" left="379" width="155" height="19" font="3">absence of drug therapy; </text>
<text top="695" left="379" width="133" height="19" font="3">had a LQTS, including </text>
<text top="714" left="379" width="143" height="19" font="3">prolongation of the QT </text>
<text top="732" left="379" width="140" height="19" font="3">interval in response to </text>
<text top="750" left="379" width="172" height="19" font="3">specific drugs; had unstable </text>
<text top="769" left="379" width="171" height="19" font="3">coronary syndromes or had </text>
<text top="201" left="573" width="128" height="19" font="4"><b>Intervention:</b> 160 to </text>
<text top="219" left="573" width="133" height="19" font="3">320 mg of sotalol per </text>
<text top="238" left="573" width="25" height="19" font="3">day </text>
<text top="256" left="573" width="7" height="19" font="4"><b>  </b></text>
<text top="274" left="573" width="83" height="19" font="4"><b>Comparator:</b> </text>
<text top="292" left="573" width="115" height="19" font="3">matching placebo<b>  </b></text>
<text top="202" left="727" width="81" height="19" font="4"><b>1</b>°<b> endpoint:</b> </text>
<text top="220" left="727" width="98" height="19" font="3">Treatment with </text>
<text top="238" left="727" width="71" height="19" font="3">sotalol was </text>
<text top="257" left="727" width="109" height="19" font="3">associated with a </text>
<text top="275" left="727" width="118" height="19" font="3">lower risk of death </text>
<text top="293" left="727" width="137" height="19" font="3">from any cause or the </text>
<text top="312" left="727" width="106" height="19" font="3">delivery of a first </text>
<text top="330" left="727" width="129" height="19" font="3">shock for any reason </text>
<text top="348" left="727" width="106" height="19" font="3">(reduction in risk </text>
<text top="367" left="727" width="118" height="19" font="3">48%; p&lt;0.001; first </text>
<text top="385" left="727" width="135" height="19" font="3">appropriate shock for </text>
<text top="403" left="727" width="116" height="19" font="3">a va or death from </text>
<text top="422" left="727" width="118" height="19" font="3">any cause was also </text>
<text top="440" left="727" width="135" height="19" font="3">reduced (reduction in </text>
<text top="458" left="727" width="123" height="19" font="3">risk, 44%; p=0.007), </text>
<text top="476" left="727" width="3" height="19" font="4"><b> </b></text>
<text top="495" left="727" width="110" height="19" font="4"><b>Safety endpoint:  </b></text>
<text top="513" left="727" width="103" height="19" font="3">Bradycardia was </text>
<text top="531" left="727" width="108" height="19" font="3">more common in </text>
<text top="550" left="727" width="112" height="19" font="3">sotalol group, but </text>
<text top="568" left="727" width="94" height="19" font="3">only 2 patients </text>
<text top="586" left="727" width="133" height="19" font="3">discontinued therapy </text>
<text top="605" left="727" width="96" height="19" font="3">because of it; 3 </text>
<text top="623" left="727" width="100" height="19" font="3">patients in each </text>
<text top="641" left="727" width="89" height="19" font="3">group had HF. </text>
<text top="659" left="727" width="3" height="19" font="4"><b> </b></text>
<text top="201" left="878" width="189" height="19" font="3">● First inappropriate shock for </text>
<text top="219" left="878" width="188" height="19" font="3">a SVT or death from any cause </text>
<text top="238" left="878" width="155" height="19" font="3">was reduced with sotalol </text>
<text top="256" left="878" width="143" height="19" font="3">(reduction in risk, 64%; </text>
<text top="274" left="878" width="61" height="19" font="3">p=0.004). </text>
<text top="292" left="878" width="163" height="19" font="3">● Sotalol also reduced the </text>
<text top="311" left="878" width="189" height="19" font="3">mean frequency of shocks due </text>
<text top="329" left="878" width="148" height="19" font="3">to any cause (1.43±3.53 </text>
<text top="347" left="878" width="172" height="19" font="3">shocks/y, as compared with </text>
<text top="366" left="878" width="161" height="19" font="3">3.89±10.65 in the placebo </text>
<text top="384" left="878" width="105" height="19" font="3">group; p=0.008). </text>
<text top="402" left="878" width="3" height="19" font="3"> </text>
<text top="421" left="878" width="194" height="19" font="3">● <b>Conclusions:</b> Oral sotalol was </text>
<text top="439" left="878" width="195" height="19" font="3">safe and efficacious in reducing </text>
<text top="457" left="878" width="195" height="19" font="3">the risk of death or the delivery </text>
<text top="476" left="878" width="168" height="19" font="3">of a first defibrillator shock </text>
<text top="494" left="878" width="165" height="19" font="3">whether or not ventricular </text>
<text top="512" left="878" width="155" height="19" font="3">function was depressed.  </text>
<text top="531" left="878" width="3" height="19" font="3"> </text>
</page>
<page number="86" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">86 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="379" width="158" height="19" font="3">had an AMI less than two </text>
<text top="127" left="379" width="178" height="19" font="3">weeks before screening; had </text>
<text top="145" left="379" width="164" height="19" font="3">intractable HF (NYHA class </text>
<text top="164" left="379" width="149" height="19" font="3">IV); were candidates for </text>
<text top="182" left="379" width="181" height="19" font="3">heart transplantation; or had </text>
<text top="200" left="379" width="178" height="19" font="3">a medical condition that was </text>
<text top="219" left="379" width="173" height="19" font="3">likely to be fatal in less than </text>
<text top="237" left="379" width="25" height="19" font="3">2 y. </text>
<text top="256" left="123" width="88" height="19" font="3">● Kettering et </text>
<text top="274" left="123" width="87" height="19" font="3">al. 2002 (161) </text>
<text top="292" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12494613">● </a></text>
<text top="292" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12494613">12494613</a></text>
<text top="292" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12494613"> </a></text>
<text top="311" left="123" width="3" height="19" font="3"> </text>
<text top="256" left="238" width="98" height="19" font="4"><b>Aim:</b> Efficacy of </text>
<text top="274" left="238" width="91" height="19" font="3">metoprolol vs. </text>
<text top="292" left="238" width="59" height="19" font="3">sotalol in </text>
<text top="311" left="238" width="69" height="19" font="3">preventing </text>
<text top="329" left="238" width="95" height="19" font="3">recurrent VT in </text>
<text top="347" left="238" width="114" height="19" font="3">patients with ICDs </text>
<text top="366" left="238" width="3" height="19" font="3"> </text>
<text top="384" left="238" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="402" left="238" width="105" height="19" font="3">prospective, RCT </text>
<text top="421" left="238" width="3" height="19" font="4"><b> </b></text>
<text top="439" left="238" width="111" height="19" font="4"><b>Size:</b> 100 patients<b> </b></text>
<text top="256" left="379" width="136" height="19" font="4"><b>Inclusion criteria:</b> ICD </text>
<text top="274" left="379" width="168" height="19" font="3">implanted for sustained VT </text>
<text top="292" left="379" width="35" height="19" font="3">or VF </text>
<text top="311" left="379" width="3" height="19" font="4"><b> </b></text>
<text top="329" left="379" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="347" left="379" width="132" height="19" font="3">Contraindications for </text>
<text top="366" left="379" width="165" height="19" font="3">metoprolol or sotalol; AMI </text>
<text top="384" left="379" width="65" height="19" font="3">within the </text>
<text top="402" left="379" width="165" height="19" font="3">last 4 wk; unstable angina; </text>
<text top="421" left="379" width="178" height="19" font="3">severe concomitant diseases<b> </b></text>
<text top="256" left="573" width="131" height="19" font="4"><b>Intervention: </b>40-480 </text>
<text top="274" left="573" width="99" height="19" font="3">mg sotalol daily </text>
<text top="292" left="573" width="7" height="19" font="4"><b>  </b></text>
<text top="311" left="573" width="128" height="19" font="4"><b>Comparator:</b> 25-200 </text>
<text top="329" left="573" width="126" height="19" font="3">mg daily metoprolol </text>
<text top="347" left="573" width="51" height="19" font="3">tartrate<b> </b></text>
<text top="257" left="727" width="121" height="19" font="4"><b>1</b>°<b> endpoint:</b> VT/VF </text>
<text top="275" left="727" width="129" height="19" font="3">recurrence requiring </text>
<text top="293" left="727" width="126" height="19" font="3">ICD intervention; 33 </text>
<text top="312" left="727" width="112" height="19" font="3">events in patients </text>
<text top="330" left="727" width="79" height="19" font="3">treated with </text>
<text top="348" left="727" width="125" height="19" font="3">metoprolol vs. 30 in </text>
<text top="367" left="727" width="111" height="19" font="3">patients receiving </text>
<text top="385" left="727" width="99" height="19" font="3">sotalol (p=0.68) </text>
<text top="403" left="727" width="3" height="19" font="4"><b> </b></text>
<text top="421" left="727" width="114" height="19" font="4"><b>Adverse Events:</b> 5 </text>
<text top="440" left="727" width="109" height="19" font="3">metoprolol and 6 </text>
<text top="458" left="727" width="97" height="19" font="3">sotalol patients </text>
<text top="476" left="727" width="88" height="19" font="3">required dose </text>
<text top="495" left="727" width="133" height="19" font="3">reduction for fatigue, </text>
<text top="513" left="727" width="80" height="19" font="3">dizziness, HF<b> </b></text>
<text top="256" left="878" width="184" height="19" font="3">● <b>Conclusions:</b>  No significant </text>
<text top="274" left="878" width="194" height="19" font="3">difference in freedom from ICD </text>
<text top="292" left="878" width="190" height="19" font="3">therapies between metoprolol </text>
<text top="311" left="878" width="164" height="19" font="3">and sotalol group (p=0.68) </text>
<text top="329" left="878" width="3" height="19" font="3"> </text>
<text top="347" left="878" width="3" height="19" font="3"> </text>
<text top="532" left="123" width="76" height="19" font="3">● Echt et al. </text>
<text top="550" left="123" width="69" height="19" font="3">1991 (162) </text>
<text top="569" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1900101">● </a></text>
<text top="569" left="136" width="53" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1900101">1900101</a></text>
<text top="569" left="189" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1900101"> </a></text>
<text top="532" left="238" width="111" height="19" font="4"><b>Aim: </b>Examine the </text>
<text top="550" left="238" width="86" height="19" font="3">mortality and </text>
<text top="569" left="238" width="96" height="19" font="3">morbidity after </text>
<text top="587" left="238" width="109" height="19" font="3">randomization to </text>
<text top="605" left="238" width="79" height="19" font="3">encainide or </text>
<text top="624" left="238" width="111" height="19" font="3">flecainide or their </text>
<text top="642" left="238" width="122" height="19" font="3">respective placebo. </text>
<text top="660" left="238" width="3" height="19" font="3"> </text>
<text top="678" left="238" width="101" height="19" font="4"><b>Study type:</b> RCT </text>
<text top="697" left="238" width="3" height="19" font="3"> </text>
<text top="715" left="238" width="119" height="19" font="4"><b>Size:</b> 1498 patients<b> </b></text>
<text top="532" left="379" width="179" height="19" font="4"><b>Inclusion: </b>6 d - 2 y after MI if </text>
<text top="550" left="379" width="161" height="19" font="3">they had an average of ≥6 </text>
<text top="569" left="379" width="140" height="19" font="3">PVCs/h on ambulatory </text>
<text top="587" left="379" width="129" height="19" font="3">electrocardiographic </text>
<text top="605" left="379" width="165" height="19" font="3">monitoring of at least 18 h </text>
<text top="624" left="379" width="170" height="19" font="3">duration, and no runs of VT </text>
<text top="642" left="379" width="149" height="19" font="3">of ≥15 beats at a rate of </text>
<text top="660" left="379" width="174" height="19" font="3">≥120 beats/mim. EF ≤0.55 if </text>
<text top="679" left="379" width="171" height="19" font="3">recruited within 90 d of the </text>
<text top="697" left="379" width="172" height="19" font="3">MI, or EF ≤0.40s if recruited </text>
<text top="715" left="379" width="163" height="19" font="3">90 d or more after the MI. </text>
<text top="733" left="379" width="3" height="19" font="3"> </text>
<text top="752" left="379" width="123" height="19" font="4"><b>Exclusion:</b> as above<b> </b></text>
<text top="532" left="573" width="85" height="19" font="4"><b>Intervention: </b></text>
<text top="550" left="573" width="79" height="19" font="3">encainide or </text>
<text top="569" left="573" width="62" height="19" font="3">flecainide<b> </b></text>
<text top="587" left="573" width="3" height="19" font="4"><b> </b></text>
<text top="605" left="573" width="134" height="19" font="4"><b>Comparator: </b>placebo </text>
<text top="533" left="727" width="81" height="19" font="4"><b>1</b>°<b> endpoint: </b></text>
<text top="551" left="727" width="126" height="19" font="3">arrhythmic death or </text>
<text top="570" left="727" width="86" height="19" font="3">cardiac arrest </text>
<text top="588" left="727" width="3" height="19" font="3"> </text>
<text top="606" left="727" width="83" height="19" font="3">After a mean </text>
<text top="624" left="727" width="137" height="19" font="3">followup of 10 mo, 89 </text>
<text top="643" left="727" width="132" height="19" font="3">patients had died: 59 </text>
<text top="661" left="727" width="110" height="19" font="3">of arrhythmia (43 </text>
<text top="680" left="727" width="128" height="19" font="3">receiving drug vs. 16 </text>
<text top="698" left="727" width="114" height="19" font="3">receiving placebo; </text>
<text top="716" left="727" width="65" height="19" font="3">p=0.0004) </text>
<text top="532" left="878" width="197" height="19" font="3">● <b>Conclusions:</b> Excess of deaths </text>
<text top="550" left="878" width="185" height="19" font="3">due to arrhythmia and deaths </text>
<text top="569" left="878" width="151" height="19" font="3">due to shock after acute </text>
<text top="587" left="878" width="149" height="19" font="3">recurrent MI in patients </text>
<text top="605" left="877" width="158" height="19" font="3">treated with encainide or </text>
<text top="624" left="877" width="177" height="19" font="3">flecainide. Nonlethal events, </text>
<text top="642" left="877" width="142" height="19" font="3">however, were equally </text>
<text top="660" left="877" width="192" height="19" font="3">distributed between the active-</text>
<text top="679" left="877" width="162" height="19" font="3">drug and placebo groups.  </text>
</page>
<page number="87" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">87 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="61" height="19" font="3">● Seidl et </text>
<text top="127" left="123" width="87" height="19" font="3">al.1998 (163)  </text>
<text top="145" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9761084">● </a></text>
<text top="145" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9761084">9761084</a></text>
<text top="145" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9761084"> </a></text>
<text top="164" left="123" width="3" height="19" font="3"> </text>
<text top="182" left="123" width="3" height="19" font="3"> </text>
<text top="109" left="238" width="121" height="19" font="4"><b>Aim:  </b>efficacy of d,l-</text>
<text top="127" left="238" width="71" height="19" font="3">sotalol and </text>
<text top="145" left="238" width="86" height="19" font="3">metoprolol in </text>
<text top="164" left="238" width="69" height="19" font="3">preventing </text>
<text top="182" left="238" width="86" height="19" font="3">recurrence of </text>
<text top="200" left="238" width="70" height="19" font="3">arrhythmic </text>
<text top="219" left="238" width="101" height="19" font="3">events after ICD </text>
<text top="237" left="238" width="85" height="19" font="3">implantation. </text>
<text top="255" left="238" width="3" height="19" font="3"> </text>
<text top="273" left="238" width="81" height="19" font="4"><b>Study type:   </b></text>
<text top="292" left="238" width="105" height="19" font="3">prospective, RCT </text>
<text top="310" left="238" width="3" height="19" font="4"><b> </b></text>
<text top="328" left="238" width="107" height="19" font="4"><b>Size:</b> <b> </b>70 patients<b> </b></text>
<text top="109" left="379" width="167" height="19" font="4"><b>Inclusion criteria:  </b>Patients </text>
<text top="127" left="379" width="157" height="19" font="3">with ICD and Hx of VT/VF </text>
<text top="145" left="379" width="3" height="19" font="4"><b> </b></text>
<text top="164" left="379" width="142" height="19" font="4"><b>Exclusion criteria:</b> AMI </text>
<text top="182" left="379" width="78" height="19" font="3">within 1 wk; </text>
<text top="200" left="379" width="109" height="19" font="3">contraindications </text>
<text top="219" left="379" width="172" height="19" font="3">for BB; Hx of proarrhythmia </text>
<text top="237" left="379" width="128" height="19" font="3">caused by d,l-sotalol </text>
<text top="109" left="573" width="85" height="19" font="4"><b>Intervention: </b></text>
<text top="127" left="573" width="114" height="19" font="3">metoprolol (mean </text>
<text top="145" left="573" width="136" height="19" font="3">dosage 104+37 mg/d) </text>
<text top="164" left="573" width="7" height="19" font="4"><b>  </b></text>
<text top="182" left="573" width="106" height="19" font="4"><b>Comparator</b>:  d,l-</text>
<text top="200" left="573" width="133" height="19" font="3">sotalol (mean dosage </text>
<text top="219" left="573" width="101" height="19" font="3">242± 109 mg/d) </text>
<text top="109" left="727" width="85" height="19" font="4"><b>1</b>°<b> endpoint:  </b></text>
<text top="128" left="727" width="113" height="19" font="3">Actuarial rates for </text>
<text top="146" left="727" width="89" height="19" font="3">absence of VT </text>
<text top="165" left="727" width="134" height="19" font="3">recurrence at 1 and 2 </text>
<text top="183" left="727" width="120" height="19" font="3">y were significantly </text>
<text top="201" left="727" width="81" height="19" font="3">higher in the </text>
<text top="219" left="727" width="111" height="19" font="3">metoprolol group </text>
<text top="238" left="727" width="119" height="19" font="3">compared with the </text>
<text top="256" left="727" width="137" height="19" font="3">d,l-sotalol group (83% </text>
<text top="274" left="727" width="127" height="19" font="3">and 80% vs 57% and </text>
<text top="293" left="727" width="113" height="19" font="3">51%, respectively, </text>
<text top="311" left="727" width="61" height="19" font="3">p=0.016). </text>
<text top="329" left="727" width="3" height="19" font="4"><b> </b></text>
<text top="347" left="727" width="130" height="19" font="4"><b>Safety endpoint:  </b>HF </text>
<text top="366" left="727" width="70" height="19" font="3">led to drug </text>
<text top="384" left="727" width="135" height="19" font="3">discontinuation in 9% </text>
<text top="402" left="727" width="90" height="19" font="3">in each group. </text>
<text top="421" left="727" width="94" height="20" font="3">• 2 episodes of </text>
<text top="440" left="727" width="107" height="19" font="3">proarrhythmia in </text>
<text top="458" left="727" width="87" height="19" font="3">sotalol group. </text>
<text top="109" left="878" width="193" height="19" font="3">● <b>Conclusions:  </b>The recurrence </text>
<text top="127" left="878" width="180" height="19" font="3">rate of VT in patients treated </text>
<text top="145" left="878" width="167" height="19" font="3">with metoprolol was lower </text>
<text top="164" left="878" width="186" height="19" font="3">than in patients treated by d,l-</text>
<text top="182" left="878" width="153" height="19" font="3">sotalol.  No difference in </text>
<text top="200" left="878" width="95" height="19" font="3">overall survival </text>
<text top="219" left="878" width="3" height="19" font="3"> </text>
<text top="237" left="878" width="3" height="19" font="3"> </text>
<text top="255" left="878" width="3" height="19" font="3"> </text>
<text top="477" left="123" width="92" height="19" font="3">● Kuhlkamp et </text>
<text top="496" left="123" width="87" height="19" font="3">al. 1999 (164) </text>
<text top="514" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9935007">● </a></text>
<text top="514" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9935007">9935007</a></text>
<text top="514" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9935007"> </a></text>
<text top="532" left="123" width="3" height="19" font="3"> </text>
<text top="477" left="238" width="88" height="19" font="4"><b>Aim:</b> Evaluate </text>
<text top="496" left="238" width="125" height="19" font="3">efficacy of sotalol in </text>
<text top="514" left="238" width="69" height="19" font="3">preventing </text>
<text top="532" left="238" width="111" height="19" font="3">recurrences of VT </text>
<text top="550" left="238" width="3" height="19" font="4"><b> </b></text>
<text top="569" left="238" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="587" left="238" width="105" height="19" font="3">prospective, RCT </text>
<text top="605" left="238" width="3" height="19" font="4"><b> </b></text>
<text top="624" left="238" width="111" height="19" font="4"><b>Size:</b> 146 patients </text>
<text top="477" left="379" width="164" height="19" font="4"><b>Inclusion criteria:</b> Patients </text>
<text top="496" left="379" width="170" height="19" font="3">with inducible sustained VT </text>
<text top="514" left="379" width="35" height="19" font="3">or VF </text>
<text top="532" left="379" width="3" height="19" font="4"><b> </b></text>
<text top="550" left="379" width="142" height="19" font="4"><b>Exclusion criteria:</b> non-</text>
<text top="569" left="379" width="142" height="19" font="3">syncopal sustained VT; </text>
<text top="587" left="379" width="149" height="19" font="3">contraindications to BB; </text>
<text top="606" left="379" width="158" height="19" font="3">limited projected survival </text>
<text top="624" left="379" width="153" height="19" font="3">due to comorbid disease </text>
<text top="477" left="573" width="138" height="19" font="4"><b>Intervention:</b> Patients </text>
<text top="496" left="573" width="90" height="19" font="3">whose VT was </text>
<text top="514" left="573" width="136" height="19" font="3">suppressed on sotalol </text>
<text top="532" left="573" width="129" height="19" font="3">were treated with it; </text>
<text top="550" left="573" width="115" height="19" font="3">patients whose VT </text>
<text top="569" left="573" width="124" height="19" font="3">was not suppressed </text>
<text top="587" left="573" width="137" height="19" font="3">on sotalol received an </text>
<text top="606" left="573" width="85" height="19" font="3">ICD and were </text>
<text top="624" left="573" width="92" height="19" font="3">randomized to </text>
<text top="642" left="573" width="140" height="19" font="3">treatment with sotalol </text>
<text top="660" left="573" width="130" height="19" font="3">or no antiarrhythmic </text>
<text top="679" left="573" width="51" height="19" font="3">therapy </text>
<text top="697" left="573" width="7" height="19" font="4"><b>  </b></text>
<text top="715" left="573" width="102" height="19" font="4"><b>Comparator:</b> no </text>
<text top="734" left="573" width="101" height="19" font="3">antiarrhythmic<b>   </b></text>
<text top="478" left="727" width="100" height="19" font="4"><b>1</b>°<b> endpoint:</b> 25 </text>
<text top="496" left="727" width="118" height="19" font="3">patients (53.2%) in </text>
<text top="515" left="727" width="79" height="19" font="3">the ICD-only </text>
<text top="533" left="727" width="117" height="19" font="3">group had a VT/VF </text>
<text top="551" left="727" width="85" height="19" font="3">recurrence in </text>
<text top="570" left="727" width="110" height="19" font="3">comparison to 15 </text>
<text top="588" left="727" width="118" height="19" font="3">patients (28.3%) in </text>
<text top="606" left="727" width="134" height="19" font="3">the sotalol group and </text>
<text top="625" left="727" width="136" height="19" font="3">15 patients (32.6%) in </text>
<text top="643" left="727" width="24" height="19" font="3">the </text>
<text top="661" left="727" width="137" height="19" font="3">ICD/sotalol group (p 5 </text>
<text top="680" left="727" width="54" height="19" font="3">0.0013). </text>
<text top="698" left="727" width="3" height="19" font="3"> </text>
<text top="716" left="727" width="110" height="19" font="4"><b>Safety endpoint:  </b></text>
<text top="734" left="727" width="89" height="19" font="3">Intolerance to </text>
<text top="753" left="727" width="96" height="19" font="3">treatment with </text>
<text top="771" left="727" width="99" height="19" font="3">d,lsotalol (overt </text>
<text top="477" left="878" width="193" height="19" font="3">No difference in total mortality </text>
<text top="496" left="878" width="125" height="19" font="3">among the 3 groups </text>
<text top="514" left="878" width="3" height="19" font="3"> </text>
<text top="532" left="878" width="196" height="19" font="4"><b>Conclusion:</b> Sotalol significantly </text>
<text top="550" left="878" width="153" height="19" font="3">reduces the incidence of </text>
<text top="569" left="878" width="188" height="19" font="3">recurrences of sustained VT in </text>
<text top="587" left="878" width="140" height="19" font="3">comparison to no AAD </text>
<text top="606" left="878" width="66" height="19" font="3">treatment </text>
<text top="624" left="878" width="3" height="19" font="3"> </text>
<text top="642" left="878" width="3" height="19" font="3"> </text>
</page>
<page number="88" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">88 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="727" width="93" height="19" font="3">cardiac failure, </text>
<text top="127" left="727" width="83" height="19" font="3">symptomatic </text>
<text top="145" left="727" width="96" height="19" font="3">hypotension or </text>
<text top="164" left="727" width="80" height="19" font="3">Bradycardia) </text>
<text top="195" left="123" width="71" height="19" font="3">● <b>MADIT-II </b></text>
<text top="213" left="123" width="60" height="19" font="4"><b>substudy </b></text>
<text top="232" left="123" width="97" height="19" font="3">● Brodine et al. </text>
<text top="250" left="123" width="69" height="19" font="3">2005 (165) </text>
<text top="268" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16125497">● </a></text>
<text top="268" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16125497">16125497</a></text>
<text top="268" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16125497"> </a></text>
<text top="195" left="238" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="213" left="238" width="91" height="19" font="3">Retrospective, </text>
<text top="232" left="238" width="87" height="19" font="3">observational </text>
<text top="250" left="238" width="3" height="19" font="3"> </text>
<text top="268" left="238" width="111" height="19" font="4"><b>Size:</b> 720 patients </text>
<text top="287" left="238" width="116" height="19" font="3">who received ICDs<b> </b></text>
<text top="195" left="379" width="167" height="19" font="4"><b>Inclusion criteria:</b> ischemic </text>
<text top="213" left="379" width="161" height="19" font="3">cardiomyopathy, EF&lt;30%, </text>
<text top="232" left="379" width="145" height="19" font="3">randomized to ICD arm </text>
<text top="250" left="379" width="3" height="19" font="3"> </text>
<text top="268" left="379" width="166" height="19" font="4"><b>Exclusion criteria:</b> Patients </text>
<text top="287" left="379" width="181" height="19" font="3">who were not randomized to </text>
<text top="305" left="379" width="79" height="19" font="3">ICD therapy <b> </b></text>
<text top="196" left="573" width="85" height="19" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="214" left="573" width="102" height="19" font="3">Appropriate ICD </text>
<text top="232" left="573" width="116" height="19" font="3">therapy for VT/VF; </text>
<text top="251" left="573" width="50" height="19" font="3">survival </text>
<text top="269" left="573" width="3" height="19" font="3"> </text>
<text top="287" left="573" width="123" height="19" font="4"><b>Results:</b>  Patients in </text>
<text top="306" left="573" width="134" height="19" font="3">the top quartile of BB </text>
<text top="324" left="573" width="141" height="19" font="3">doses had a significant </text>
<text top="342" left="573" width="126" height="19" font="3">reduction in the risk </text>
<text top="361" left="573" width="129" height="19" font="3">of VT or VF requiring </text>
<text top="379" left="573" width="140" height="19" font="3">ICD therapy compared </text>
<text top="397" left="573" width="108" height="19" font="3">with patients not </text>
<text top="415" left="573" width="107" height="19" font="3">receiving BB (HR: </text>
<text top="434" left="573" width="132" height="19" font="3">0.48; p=0.02). BB use </text>
<text top="452" left="573" width="122" height="19" font="3">was also associated </text>
<text top="470" left="573" width="96" height="19" font="3">with significant </text>
<text top="489" left="573" width="101" height="19" font="3">improvement in </text>
<text top="507" left="573" width="115" height="19" font="3">survival compared </text>
<text top="525" left="573" width="138" height="19" font="3">with the nonuse of BB </text>
<text top="544" left="573" width="113" height="19" font="3">(HR: 0.4; p&lt;0.01).  </text>
<text top="195" left="727" width="107" height="19" font="3">The frequency of </text>
<text top="213" left="727" width="111" height="19" font="3">inappropriate ICD </text>
<text top="232" left="727" width="98" height="19" font="3">therapy for SVT </text>
<text top="250" left="727" width="127" height="19" font="3">was not significantly </text>
<text top="268" left="727" width="137" height="19" font="3">different among the 3 </text>
<text top="287" left="727" width="111" height="19" font="3">treatment groups </text>
<text top="305" left="727" width="58" height="19" font="3">(p=0.32). </text>
<text top="323" left="727" width="3" height="19" font="3"> </text>
<text top="195" left="878" width="173" height="19" font="3">● <b>Conclusion:</b> Beta blockers </text>
<text top="213" left="878" width="196" height="19" font="3">reduce the risk for VT or VF and </text>
<text top="232" left="878" width="193" height="19" font="3">improve survival in ICD-treated </text>
<text top="250" left="878" width="140" height="19" font="3">patients with ischemic </text>
<text top="268" left="878" width="107" height="19" font="3">cardiomyopathy. </text>
<text top="563" left="123" width="81" height="19" font="3">● <b>SMASH VT </b></text>
<text top="581" left="123" width="88" height="19" font="3">● Reddy et al. </text>
<text top="599" left="123" width="69" height="19" font="3">2007<b> </b>(166) </text>
<text top="618" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18160685">● </a></text>
<text top="618" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18160685">18160685</a></text>
<text top="618" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18160685"> </a></text>
<text top="636" left="123" width="3" height="19" font="3"> </text>
<text top="563" left="238" width="122" height="19" font="4"><b>Aim:</b>  To determine </text>
<text top="581" left="238" width="55" height="19" font="3">whether </text>
<text top="599" left="238" width="79" height="19" font="3">prophylactic </text>
<text top="618" left="238" width="100" height="19" font="3">substrate based </text>
<text top="636" left="238" width="123" height="19" font="3">catheter ablation in </text>
<text top="654" left="238" width="82" height="19" font="3">sinus rhythm </text>
<text top="673" left="238" width="88" height="19" font="3">decreases ICD </text>
<text top="691" left="238" width="117" height="19" font="3">therapies after MI  </text>
<text top="709" left="238" width="3" height="19" font="3"> </text>
<text top="727" left="238" width="108" height="19" font="4"><b>Study type:</b>   RCT </text>
<text top="746" left="238" width="75" height="19" font="3">prospective </text>
<text top="764" left="238" width="3" height="19" font="3"> </text>
<text top="782" left="238" width="115" height="19" font="4"><b>Size:</b>  128 patients </text>
<text top="563" left="379" width="176" height="19" font="4"><b>Inclusion criteria:</b>  age ≥18 y </text>
<text top="581" left="379" width="133" height="19" font="3">with MI at least 1 mo </text>
<text top="599" left="379" width="161" height="19" font="3">previously and a Hx of VF, </text>
<text top="618" left="379" width="168" height="19" font="3">Hemodynamically unstable </text>
<text top="636" left="379" width="124" height="19" font="3">VT, or Syncope with </text>
<text top="654" left="379" width="129" height="19" font="3">inducible VT and ICD </text>
<text top="673" left="379" width="82" height="19" font="3">implantation </text>
<text top="691" left="379" width="3" height="19" font="3"> </text>
<text top="709" left="379" width="113" height="19" font="4"><b>Exclusion criteria: </b></text>
<text top="728" left="379" width="132" height="19" font="3">Treatment with AAD, </text>
<text top="746" left="379" width="170" height="19" font="3">ischemia induced VT/VF, or </text>
<text top="764" left="379" width="115" height="19" font="3">incessant VT or VF </text>
<text top="563" left="573" width="85" height="19" font="4"><b>Intervention:</b> </text>
<text top="581" left="573" width="101" height="19" font="3">Substrate based </text>
<text top="599" left="573" width="124" height="19" font="3">catheter ablation of </text>
<text top="618" left="573" width="101" height="19" font="3">arrhythmogenic </text>
<text top="636" left="573" width="123" height="19" font="3">myocardium during </text>
<text top="654" left="573" width="127" height="19" font="3">sinus rhythm (N=64) </text>
<text top="673" left="573" width="7" height="19" font="3">  </text>
<text top="691" left="573" width="141" height="19" font="4"><b>Comparator:</b> Standard </text>
<text top="709" left="573" width="131" height="19" font="3">ICD follow-up (N=64)<b> </b></text>
<text top="563" left="727" width="77" height="19" font="4"><b>1</b>°<b> endpoint</b> </text>
<text top="582" left="727" width="137" height="19" font="3">After 2 y of follow-up, </text>
<text top="600" left="727" width="85" height="19" font="3">ICD therapies </text>
<text top="618" left="727" width="117" height="19" font="3">occurred in 12% of </text>
<text top="637" left="727" width="129" height="19" font="3">patients randomized </text>
<text top="655" left="727" width="125" height="19" font="3">to catheter ablation </text>
<text top="673" left="727" width="94" height="19" font="3">and 33% in the </text>
<text top="692" left="727" width="112" height="19" font="3">control group (HR </text>
<text top="710" left="727" width="117" height="19" font="3">0.35; CI 0.15–0.78, </text>
<text top="728" left="727" width="58" height="19" font="3">p=0.007)<b> </b></text>
<text top="563" left="878" width="158" height="19" font="3">● Trend towards reduced </text>
<text top="581" left="878" width="152" height="19" font="3">mortality after 2 y in the </text>
<text top="599" left="878" width="168" height="19" font="3">ablation group (9% vs 17%, </text>
<text top="618" left="878" width="50" height="19" font="3">p=0.06) </text>
<text top="636" left="878" width="3" height="19" font="3"> </text>
<text top="654" left="878" width="138" height="19" font="3">● No difference in left </text>
<text top="673" left="878" width="178" height="19" font="3">ventricular function or NYHA </text>
<text top="691" left="878" width="182" height="19" font="3">functional class during follow-</text>
<text top="709" left="878" width="23" height="19" font="3">up. </text>
<text top="728" left="878" width="3" height="19" font="3"> </text>
<text top="746" left="878" width="3" height="19" font="3"> </text>
<text top="764" left="878" width="3" height="19" font="3"> </text>
</page>
<page number="89" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">89 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="64" height="19" font="3">● <b>VANISH</b> </text>
<text top="127" left="123" width="91" height="19" font="3">● Sapp J. et al. </text>
<text top="145" left="123" width="69" height="19" font="3">2016 (167) </text>
<text top="164" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27149033">● </a></text>
<text top="164" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27149033">27149033</a></text>
<text top="164" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27149033"> </a></text>
<text top="109" left="238" width="122" height="19" font="4"><b>Aim:  </b>To determine </text>
<text top="127" left="238" width="110" height="19" font="3">whether catheter </text>
<text top="145" left="238" width="117" height="19" font="3">ablation decreases </text>
<text top="164" left="238" width="100" height="19" font="3">ICD therapies in </text>
<text top="182" left="238" width="83" height="19" font="3">patients with </text>
<text top="200" left="238" width="56" height="19" font="3">ischemic </text>
<text top="219" left="238" width="103" height="19" font="3">cardiomyopathy </text>
<text top="237" left="238" width="112" height="19" font="3">with a Hx of VT or </text>
<text top="255" left="238" width="115" height="19" font="3">VF despite the use </text>
<text top="273" left="238" width="46" height="19" font="3">of AAD </text>
<text top="292" left="238" width="3" height="19" font="3"> </text>
<text top="310" left="238" width="81" height="19" font="4"><b>Study type:   </b></text>
<text top="328" left="238" width="80" height="19" font="3">randomized, </text>
<text top="347" left="238" width="75" height="19" font="3">prospective<b> </b></text>
<text top="365" left="238" width="3" height="19" font="4"><b> </b></text>
<text top="383" left="238" width="115" height="19" font="4"><b>Size: </b> 259 patients </text>
<text top="109" left="379" width="171" height="19" font="4"><b>Inclusion criteria:  </b>Prior MI, </text>
<text top="127" left="379" width="169" height="19" font="3">ICD implantation, at least 1 </text>
<text top="145" left="379" width="129" height="19" font="3">episode of VT during </text>
<text top="164" left="379" width="174" height="19" font="3">treatment with amiodarone </text>
<text top="182" left="379" width="171" height="19" font="3">or another class I or class III </text>
<text top="200" left="379" width="162" height="19" font="3">AAD within the previous 6 </text>
<text top="219" left="379" width="23" height="19" font="3">mo<b> </b></text>
<text top="237" left="379" width="175" height="19" font="4"><b>Exclusion criteria: </b>Failure to </text>
<text top="255" left="379" width="140" height="19" font="3">give informed consent </text>
<text top="109" left="573" width="85" height="19" font="4"><b>Intervention: </b></text>
<text top="127" left="573" width="118" height="19" font="3">Randomized 1:1 to </text>
<text top="145" left="573" width="125" height="19" font="3">catheter ablation or </text>
<text top="164" left="573" width="91" height="19" font="3">escalated AAD </text>
<text top="182" left="573" width="118" height="19" font="3">therapy (escalated-</text>
<text top="200" left="573" width="99" height="19" font="3">therapy group), </text>
<text top="219" left="573" width="53" height="19" font="3">(N=132) </text>
<text top="237" left="573" width="7" height="19" font="4"><b>  </b></text>
<text top="255" left="573" width="86" height="19" font="4"><b>Comparator: </b> </text>
<text top="273" left="573" width="93" height="19" font="3">Escalated drug </text>
<text top="292" left="573" width="134" height="19" font="3">therapy: Amiodarone </text>
<text top="310" left="573" width="140" height="19" font="3">loading then amio 200 </text>
<text top="329" left="573" width="137" height="19" font="3">mg/d (if on Sotalol) or </text>
<text top="347" left="573" width="140" height="19" font="3">Amiodarone reloading </text>
<text top="365" left="573" width="125" height="19" font="3">then 300 mg/d if on </text>
<text top="383" left="573" width="111" height="19" font="3">amiodarone &lt;300 </text>
<text top="402" left="573" width="40" height="19" font="3">mg/d, </text>
<text top="420" left="573" width="89" height="19" font="3">Or addition of </text>
<text top="438" left="573" width="140" height="19" font="3">mexiletine 200 mg TID </text>
<text top="457" left="573" width="120" height="19" font="3">to amiodarone 300 </text>
<text top="475" left="573" width="67" height="19" font="3">mg/d if on </text>
<text top="493" left="573" width="140" height="19" font="3">amiodarone 300 mg/d </text>
<text top="512" left="573" width="53" height="19" font="3">(N=127)<b> </b></text>
<text top="109" left="727" width="77" height="19" font="4"><b>1</b>°<b> endpoint </b></text>
<text top="128" left="727" width="100" height="19" font="3">The 1° outcome </text>
<text top="146" left="727" width="133" height="19" font="3">occurred in 78 of 132 </text>
<text top="165" left="727" width="118" height="19" font="3">patients (59.1%) in </text>
<text top="183" left="727" width="117" height="19" font="3">the ablation group </text>
<text top="201" left="727" width="102" height="19" font="3">and in 87 of 127 </text>
<text top="219" left="727" width="118" height="19" font="3">patients (68.5%) in </text>
<text top="238" left="727" width="137" height="19" font="3">the escalated-therapy </text>
<text top="256" left="727" width="137" height="19" font="3">group. The rate of the </text>
<text top="274" left="727" width="101" height="19" font="3">1° outcome was </text>
<text top="293" left="727" width="129" height="19" font="3">significantly lower in </text>
<text top="311" left="727" width="117" height="19" font="3">the ablation group </text>
<text top="329" left="727" width="132" height="19" font="3">than in the escalated-</text>
<text top="348" left="727" width="90" height="19" font="3">therapy group </text>
<text top="366" left="727" width="89" height="19" font="3">(HR:0.72; 95% </text>
<text top="384" left="727" width="137" height="19" font="3">CI:0.53–0.98; p=0.04)  </text>
<text top="402" left="727" width="3" height="19" font="3"> </text>
<text top="421" left="727" width="121" height="19" font="3">This difference was </text>
<text top="439" left="727" width="103" height="19" font="3">driven by trends </text>
<text top="457" left="727" width="130" height="19" font="3">toward reductions in </text>
<text top="476" left="727" width="126" height="19" font="3">rates of appropriate </text>
<text top="494" left="727" width="127" height="19" font="3">shocks and episodes </text>
<text top="512" left="727" width="78" height="19" font="3">of VT storm<b>  </b></text>
<text top="109" left="878" width="162" height="19" font="3">● VT storm occurred in 32 </text>
<text top="127" left="878" width="195" height="19" font="3">patients (24.2%) in the ablation </text>
<text top="145" left="878" width="187" height="19" font="3">group and 42 patients (33.1%) </text>
<text top="164" left="878" width="191" height="19" font="3">in the escalated-therapy group </text>
<text top="182" left="878" width="176" height="19" font="3">(HR: 0.66; 95% CI: 0.42–0.05 </text>
<text top="200" left="878" width="155" height="19" font="3">p=0.08). Appropriate ICD </text>
<text top="219" left="878" width="188" height="19" font="3">shocks occurred in 50 patients </text>
<text top="237" left="878" width="148" height="19" font="3">(37.9%) and 54 patients </text>
<text top="255" left="878" width="194" height="19" font="3">(42.5%), respectively (HR: 0.77; </text>
<text top="273" left="878" width="170" height="19" font="3">95% CI: 0.53–1.14; p=0.19). </text>
<text top="292" left="878" width="3" height="19" font="3"> </text>
<text top="310" left="878" width="172" height="19" font="3">● 36 patients (27.3%) in the </text>
<text top="329" left="878" width="188" height="19" font="3">ablation group and 35 (27.6%) </text>
<text top="347" left="878" width="191" height="19" font="3">in the escalated-therapy group </text>
<text top="365" left="878" width="176" height="19" font="3">died (HR: 0.96; 95% CI: 0.60–</text>
<text top="383" left="878" width="91" height="19" font="3">1.53; p=0.86).  </text>
<text top="402" left="878" width="3" height="19" font="3"> </text>
<text top="531" left="123" width="90" height="19" font="3">● <b>VTACH Trial </b></text>
<text top="550" left="123" width="85" height="19" font="3">● Kuck KH, et </text>
<text top="568" left="123" width="87" height="19" font="3">al. 2010 (168) </text>
<text top="586" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20109864">● </a></text>
<text top="586" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20109864">20109864</a></text>
<text top="586" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20109864"> </a></text>
<text top="531" left="238" width="86" height="19" font="3">To determine </text>
<text top="550" left="238" width="110" height="19" font="3">whether catheter </text>
<text top="568" left="238" width="105" height="19" font="3">ablation reduces </text>
<text top="586" left="238" width="84" height="19" font="3">the risk of VT </text>
<text top="605" left="238" width="85" height="19" font="3">recurrence in </text>
<text top="623" left="238" width="83" height="19" font="3">patients with </text>
<text top="641" left="238" width="56" height="19" font="3">Ischemic </text>
<text top="660" left="238" width="108" height="19" font="3">Cardiomyopathy, </text>
<text top="678" left="238" width="108" height="19" font="3">stable VT, and an </text>
<text top="696" left="238" width="120" height="19" font="3">ICD compared with </text>
<text top="714" left="238" width="116" height="19" font="3">ICD and continued </text>
<text top="733" left="238" width="107" height="19" font="3">medical Rx alone </text>
<text top="751" left="238" width="72" height="19" font="4"><b>Study Type </b></text>
<text top="769" left="238" width="27" height="19" font="3">RCT </text>
<text top="531" left="379" width="166" height="19" font="4"><b>Inclusion Criteria:</b> Patients </text>
<text top="550" left="379" width="161" height="19" font="3">age 18-80 y with prior MI, </text>
<text top="568" left="379" width="88" height="19" font="3">CAD, clinically </text>
<text top="586" left="379" width="174" height="19" font="3">hemodynamically stable VT, </text>
<text top="605" left="379" width="151" height="19" font="3">reduced LVEF &lt;0.50, ICD </text>
<text top="623" left="379" width="64" height="19" font="3">indication </text>
<text top="641" left="379" width="3" height="19" font="3"> </text>
<text top="659" left="379" width="111" height="19" font="4"><b>Exclusion Criteria </b></text>
<text top="678" left="379" width="177" height="19" font="3">MI or Cardiac Surgery within </text>
<text top="696" left="379" width="176" height="19" font="3">1 mo, LV thrombus, artificial </text>
<text top="714" left="379" width="158" height="19" font="3">heart valve, incessant VT, </text>
<text top="733" left="379" width="173" height="19" font="3">impaired renal function, life </text>
<text top="751" left="379" width="112" height="19" font="3">expectancy &lt;1 y.   </text>
<text top="531" left="573" width="120" height="19" font="4"><b>Study Intervention </b></text>
<text top="550" left="573" width="108" height="19" font="3">ICD plus catheter </text>
<text top="568" left="573" width="87" height="19" font="3">ablation of all </text>
<text top="586" left="573" width="101" height="19" font="3">inducible VTs or </text>
<text top="605" left="573" width="88" height="19" font="3">elimination of </text>
<text top="623" left="573" width="110" height="19" font="3">substrate for non-</text>
<text top="641" left="573" width="78" height="19" font="3">inducible VT </text>
<text top="660" left="573" width="45" height="19" font="3">(N=52) </text>
<text top="678" left="573" width="3" height="19" font="3"> </text>
<text top="696" left="573" width="78" height="19" font="4"><b>Comparator </b></text>
<text top="714" left="573" width="116" height="19" font="3">ICD and continued </text>
<text top="733" left="573" width="102" height="19" font="3">medical therapy </text>
<text top="751" left="573" width="45" height="19" font="3">(N=55)<b> </b></text>
<text top="531" left="727" width="125" height="19" font="3">After 24 mo, 47% of </text>
<text top="550" left="727" width="92" height="19" font="3">patients in the </text>
<text top="568" left="727" width="119" height="19" font="3">ablation group and </text>
<text top="586" left="727" width="132" height="19" font="3">29% of controls were </text>
<text top="605" left="727" width="124" height="19" font="3">free of recurrent VT </text>
<text top="623" left="727" width="104" height="19" font="3">(HR: 0.61;95% CI </text>
<text top="641" left="727" width="129" height="19" font="3">0.37–0.99, p=0.044). </text>
<text top="659" left="727" width="3" height="19" font="4"><b> </b></text>
<text top="531" left="878" width="192" height="19" font="3">● Patients with LVEF &gt;0.30 had </text>
<text top="550" left="878" width="176" height="19" font="3">greater reduction of VT with </text>
<text top="568" left="878" width="162" height="19" font="3">catheter ablation than did </text>
<text top="586" left="878" width="181" height="19" font="3">patients with more severe LV </text>
<text top="605" left="878" width="188" height="19" font="3">dysfunction (freedom from VT </text>
<text top="623" left="878" width="189" height="19" font="3">in 48% with ablation vs 27% of </text>
<text top="641" left="878" width="161" height="19" font="3">controls, (HR:0.47; 95% CI </text>
<text top="660" left="878" width="129" height="19" font="3">0.24–0.88, p=0.016). </text>
<text top="678" left="878" width="3" height="19" font="3"> </text>
<text top="696" left="878" width="176" height="19" font="3">● No difference in VT storm, </text>
<text top="714" left="878" width="170" height="19" font="3">syncope, or death between </text>
<text top="733" left="878" width="136" height="19" font="3">ablation and controls. </text>
<text top="751" left="878" width="3" height="19" font="3"> </text>
<text top="769" left="878" width="3" height="19" font="3"> </text>
</page>
<page number="90" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">90 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="238" width="3" height="19" font="3"> </text>
<text top="127" left="238" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="145" left="238" width="79" height="19" font="3">107 patients </text>
<text top="195" left="123" width="72" height="19" font="3">● <b>CALYPSO </b></text>
<text top="213" left="123" width="86" height="19" font="3">● Al-Khatib S. </text>
<text top="232" left="123" width="67" height="19" font="3">et al. 2015 </text>
<text top="250" left="123" width="35" height="19" font="3">(169) </text>
<text top="268" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25332150">● </a></text>
<text top="268" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25332150">25332150</a></text>
<text top="268" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25332150"> </a></text>
<text top="195" left="238" width="28" height="19" font="4"><b>Aim </b></text>
<text top="213" left="238" width="84" height="19" font="3">Pilot study to </text>
<text top="232" left="238" width="67" height="19" font="3">determine </text>
<text top="250" left="238" width="120" height="19" font="3">feasibility of RCT of </text>
<text top="268" left="238" width="124" height="19" font="3">catheter ablation of </text>
<text top="287" left="238" width="106" height="19" font="3">VT vs. AAD when </text>
<text top="305" left="238" width="104" height="19" font="3">used early in the </text>
<text top="323" left="238" width="113" height="19" font="3">course of patients </text>
<text top="341" left="238" width="90" height="19" font="3">with CAD who </text>
<text top="360" left="238" width="95" height="19" font="3">experience ICD </text>
<text top="378" left="238" width="65" height="19" font="3">therapies. </text>
<text top="396" left="238" width="72" height="19" font="4"><b>Study Type </b></text>
<text top="415" left="238" width="58" height="19" font="3">Pilot RCT </text>
<text top="433" left="238" width="69" height="19" font="4"><b>Study size</b>  </text>
<text top="451" left="238" width="72" height="19" font="3">27 patients </text>
<text top="195" left="379" width="109" height="19" font="4"><b>Inclusion Criteria </b></text>
<text top="213" left="379" width="180" height="19" font="3">Patients with CAD, ICDs, who </text>
<text top="232" left="379" width="179" height="19" font="3">had received &gt;1 ICD shock or </text>
<text top="250" left="379" width="147" height="19" font="3">&gt;3 ATP therapies for VT </text>
<text top="268" left="379" width="3" height="19" font="3"> </text>
<text top="286" left="379" width="111" height="19" font="4"><b>Exclusion Criteria </b></text>
<text top="305" left="379" width="167" height="19" font="3">Present AAD, Incessant VT, </text>
<text top="323" left="379" width="164" height="19" font="3">VT due to reversible cause </text>
<text top="195" left="573" width="81" height="19" font="4"><b>Intervention </b></text>
<text top="213" left="573" width="126" height="19" font="3">Catheter ablation of </text>
<text top="232" left="573" width="64" height="19" font="3">VT (N=13) </text>
<text top="250" left="573" width="3" height="19" font="4"><b> </b></text>
<text top="268" left="573" width="78" height="19" font="4"><b>Comparator </b></text>
<text top="287" left="573" width="71" height="19" font="3">AAD(N=14)<b> </b></text>
<text top="195" left="727" width="76" height="19" font="4"><b>1° Endpoint </b></text>
<text top="213" left="727" width="86" height="19" font="3">Mean time to </text>
<text top="232" left="727" width="137" height="19" font="3">recurrent VT was 75 d </text>
<text top="250" left="727" width="122" height="19" font="3">in ablation arm and </text>
<text top="268" left="727" width="106" height="19" font="3">57 d in AAD arm. </text>
<text top="287" left="727" width="3" height="19" font="3"> </text>
<text top="305" left="727" width="129" height="19" font="3">There were 2 deaths </text>
<text top="323" left="727" width="120" height="19" font="3">in both arms of the </text>
<text top="341" left="727" width="40" height="19" font="3">study<b>  </b></text>
<text top="195" left="878" width="191" height="19" font="3">● Of 243 screened patients, 27 </text>
<text top="213" left="878" width="96" height="19" font="3">were enrolled.  </text>
<text top="232" left="878" width="186" height="19" font="3">● Presently on AAD (88, 41%), </text>
<text top="250" left="877" width="191" height="19" font="3">VT due to reversible cause (23, </text>
<text top="268" left="877" width="170" height="19" font="3">11%), and incessant VT (20, </text>
<text top="287" left="877" width="30" height="19" font="3">9%). </text>
<text top="470" left="122" width="3" height="19" font="3"> </text>
<text top="488" left="115" width="4" height="21" font="2"><b> </b></text>
<text top="544" left="115" width="917" height="21" font="2"><b>Data Supplement 23. Nonrandomized Trials, Observational Studies, and/or Registries of Treatment of Recurrent Arrhythmias in IHD – </b></text>
<text top="565" left="115" width="99" height="21" font="2"><b>(Section 7.1.3)</b></text>
<text top="566" left="213" width="3" height="19" font="3"> </text>
<text top="586" left="130" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="604" left="156" width="51" height="19" font="4"><b>Author; </b></text>
<text top="622" left="133" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="586" left="260" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="604" left="289" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="586" left="443" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="586" left="647" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="604" left="660" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="622" left="691" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="586" left="922" width="77" height="19" font="4"><b>Conclusions </b></text>
<text top="642" left="123" width="89" height="19" font="3">● Blanck et al. </text>
<text top="660" left="123" width="69" height="19" font="3">1993 (170) </text>
<text top="678" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8269297">● </a></text>
<text top="678" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8269297">8269297</a></text>
<text top="678" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8269297"> </a></text>
<text top="696" left="123" width="3" height="19" font="4"><b> </b></text>
<text top="641" left="252" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="660" left="252" width="131" height="19" font="3">Single Center Review </text>
<text top="678" left="252" width="3" height="19" font="3"> </text>
<text top="696" left="252" width="114" height="19" font="4"><b>Size:</b>    48 patients </text>
<text top="641" left="406" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="660" left="406" width="169" height="19" font="3">All patients at single center </text>
<text top="678" left="406" width="181" height="19" font="3">with BBRVT diagnosed at EPS </text>
<text top="696" left="406" width="126" height="19" font="3">between 1980-1992 </text>
<text top="715" left="406" width="54" height="19" font="4"><b>Criteria: </b></text>
<text top="733" left="433" width="159" height="19" font="3">1)  Typical RBBB or LBBB </text>
<text top="751" left="460" width="106" height="19" font="3">QRS morphology </text>
<text top="770" left="460" width="62" height="19" font="3">during VT </text>
<text top="641" left="612" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="660" left="612" width="161" height="19" font="3">45 of 48 patients had SHD </text>
<text top="678" left="612" width="184" height="19" font="3">SHD was NICM in 16 patients, </text>
<text top="696" left="612" width="189" height="19" font="3">ischemic cardiomyopathyin 23 </text>
<text top="715" left="612" width="170" height="19" font="3">patients, V HD in 2 patients </text>
<text top="733" left="612" width="3" height="19" font="3"> </text>
<text top="751" left="612" width="112" height="19" font="3">Mean LVEF 23.2% </text>
<text top="770" left="612" width="3" height="19" font="3"> </text>
<text top="642" left="847" width="221" height="19" font="3">● BBRVT typically occurs in patients </text>
<text top="660" left="847" width="223" height="19" font="3">with SHD from a variety of causes in </text>
<text top="678" left="847" width="171" height="19" font="3">patients with prolonged HV </text>
<text top="696" left="847" width="131" height="19" font="3">conduction intervals. </text>
<text top="715" left="847" width="3" height="19" font="3"> </text>
<text top="733" left="847" width="219" height="19" font="3">● BBRVT is associated with aborted </text>
<text top="751" left="847" width="191" height="19" font="3">SCD, Syncope, and Palpitations </text>
<text top="770" left="847" width="3" height="19" font="3"> </text>
</page>
<page number="91" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">91 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="433" width="157" height="19" font="4"><b>2)  </b>QRS preceded by His </text>
<text top="127" left="460" width="102" height="19" font="3">and appropriate </text>
<text top="145" left="460" width="92" height="19" font="3">bundle branch </text>
<text top="164" left="460" width="59" height="19" font="3">potential<b> </b></text>
<text top="182" left="433" width="146" height="19" font="4"><b>3)  </b>Stable HV, RB-V, or </text>
<text top="200" left="460" width="81" height="19" font="3">LB-V interval<b> </b></text>
<text top="218" left="433" width="159" height="19" font="4"><b>4)  </b>Induction dependent </text>
<text top="237" left="460" width="77" height="19" font="3">on HV delay<b> </b></text>
<text top="255" left="433" width="159" height="19" font="4"><b>5)  </b>Termination by block </text>
<text top="273" left="460" width="42" height="19" font="3">in HPS<b> </b></text>
<text top="292" left="433" width="156" height="19" font="4"><b>6)  </b>Noninducibility after </text>
<text top="310" left="460" width="81" height="19" font="3">RBB ablation<b> </b></text>
<text top="329" left="406" width="7" height="19" font="3">  </text>
<text top="109" left="612" width="131" height="19" font="4"><b>Clinical Presentation </b></text>
<text top="127" left="612" width="125" height="19" font="3">Aborted SCD in 26% </text>
<text top="145" left="612" width="99" height="19" font="3">Syncope in 51% </text>
<text top="164" left="612" width="182" height="19" font="3">Sustained palpitations in 10% </text>
<text top="182" left="612" width="3" height="19" font="3"> </text>
<text top="200" left="612" width="189" height="19" font="3">Mean HV interval in sinus 80.4 </text>
<text top="219" left="612" width="35" height="19" font="3">msec </text>
<text top="237" left="612" width="3" height="19" font="3"> </text>
<text top="255" left="612" width="143" height="19" font="4"><b>QRS morphology in VT </b></text>
<text top="273" left="612" width="121" height="19" font="3">LBBB in 46 patients </text>
<text top="292" left="612" width="115" height="19" font="3">RBBB in 5 patients </text>
<text top="310" left="612" width="218" height="19" font="3">Interfascicular reentry in 2 patients </text>
<text top="329" left="612" width="3" height="19" font="3"> </text>
<text top="347" left="612" width="114" height="19" font="4"><b>Catheter Ablation </b></text>
<text top="365" left="612" width="214" height="19" font="3">Performed in 28 patients targeting </text>
<text top="383" left="612" width="216" height="19" font="3">the RBB in 26 patients and LBB in 2 </text>
<text top="402" left="612" width="53" height="19" font="3">patients </text>
<text top="420" left="612" width="206" height="19" font="3">Successful ablation of VT in 100% </text>
<text top="438" left="612" width="178" height="19" font="3">No Complications observed.  </text>
<text top="109" left="847" width="171" height="19" font="3">● BBRVT is most commonly </text>
<text top="127" left="847" width="171" height="19" font="3">associated with a LBBB QRS </text>
<text top="145" left="847" width="201" height="19" font="3">morphology, and less commonly </text>
<text top="164" left="847" width="202" height="19" font="3">with RBBB or Interfascicular QRS </text>
<text top="182" left="847" width="87" height="19" font="3">morphologies </text>
<text top="200" left="847" width="3" height="19" font="3"> </text>
<text top="219" left="847" width="205" height="19" font="3">● Catheter ablation targeting the </text>
<text top="237" left="847" width="206" height="19" font="3">RBB or LBB is highly effective and </text>
<text top="255" left="847" width="222" height="19" font="3">associated with a low risk of serious </text>
<text top="273" left="847" width="92" height="19" font="3">complications. </text>
<text top="292" left="847" width="3" height="19" font="3"> </text>
<text top="457" left="123" width="108" height="19" font="3">● Brugada J et al. </text>
<text top="476" left="123" width="69" height="19" font="3">2001 (171) </text>
<text top="494" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11216974">● </a></text>
<text top="494" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11216974">11216974</a></text>
<text top="494" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11216974"> </a></text>
<text top="457" left="253" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="476" left="253" width="78" height="19" font="3">prospective <b> </b></text>
<text top="494" left="253" width="3" height="19" font="4"><b> </b></text>
<text top="512" left="253" width="104" height="19" font="4"><b>Size:</b> 61 patients<b> </b></text>
<text top="457" left="406" width="120" height="19" font="4"><b>Inclusion:</b> prior MI, </text>
<text top="476" left="406" width="190" height="19" font="3">spontaneous VA not related to </text>
<text top="494" left="406" width="176" height="19" font="3">an acute ischemic event and </text>
<text top="512" left="406" width="162" height="19" font="3">coronary lesions requiring </text>
<text top="531" left="406" width="107" height="19" font="3">revascularization </text>
<text top="549" left="406" width="3" height="19" font="3"> </text>
<text top="567" left="406" width="90" height="19" font="4"><b>Exclusion:</b> n/a </text>
<text top="586" left="406" width="3" height="19" font="3"> </text>
<text top="604" left="406" width="192" height="19" font="4"><b>Protocol:</b> EP performed before </text>
<text top="622" left="406" width="166" height="19" font="3">and after revascularization<b> </b></text>
<text top="457" left="612" width="217" height="19" font="4"><b>Results: </b>61 patients were inducible </text>
<text top="476" left="612" width="117" height="19" font="3">into sustained VA.  </text>
<text top="494" left="612" width="3" height="19" font="3"> </text>
<text top="512" left="612" width="198" height="19" font="3">After revascularization, 52 of 59 </text>
<text top="531" left="612" width="213" height="19" font="3">patients previously inducible were </text>
<text top="549" left="612" width="193" height="19" font="3">still inducible (group A), and 10 </text>
<text top="567" left="612" width="214" height="19" font="3">patients were noninducible (group </text>
<text top="586" left="612" width="23" height="19" font="3">B).  </text>
<text top="604" left="612" width="3" height="19" font="3"> </text>
<text top="622" left="612" width="181" height="19" font="3">No differences were found in </text>
<text top="640" left="612" width="217" height="19" font="3">clinical, hemodynamic, therapeutic </text>
<text top="659" left="612" width="151" height="19" font="3">and electrophysiological </text>
<text top="677" left="612" width="181" height="19" font="3">characteristics between both </text>
<text top="695" left="612" width="52" height="19" font="3">groups.  </text>
<text top="714" left="612" width="3" height="19" font="3"> </text>
<text top="732" left="612" width="187" height="19" font="3">During 32 +/- 26 mo followup, </text>
<text top="750" left="612" width="197" height="19" font="3">28/52 patients in group A (54%) </text>
<text top="457" left="847" width="219" height="19" font="3">● In patients with VA in the chronic </text>
<text top="476" left="847" width="165" height="19" font="3">phase of MI, probability of </text>
<text top="494" left="847" width="219" height="19" font="3">recurrence is high despite coronary </text>
<text top="512" left="847" width="175" height="19" font="3">artery revascularization, but </text>
<text top="531" left="847" width="204" height="19" font="3">mortality is low if combined with </text>
<text top="549" left="847" width="113" height="19" font="3">appropriate AAD.  </text>
<text top="567" left="847" width="3" height="19" font="3"> </text>
<text top="586" left="847" width="213" height="19" font="3">● Recurrences: lower EF predicted </text>
<text top="604" left="847" width="189" height="19" font="3">higher recurrence rate but not </text>
<text top="622" left="847" width="211" height="19" font="3">ischemia before revascularization, </text>
<text top="640" left="847" width="200" height="19" font="3">amiodarone or BB therapy or EP </text>
<text top="659" left="847" width="218" height="19" font="3">study after revascularization. An EF </text>
<text top="677" left="847" width="160" height="19" font="3">&lt;30% predicted recurrent </text>
<text top="695" left="847" width="221" height="19" font="3">arrhythmic events (p=0.02), but not </text>
<text top="714" left="847" width="187" height="19" font="3">the presence of demonstrable </text>
<text top="732" left="847" width="208" height="19" font="3">ischemia before revascularization </text>
<text top="750" left="847" width="207" height="19" font="3">(p=0.42), amiodarone (p=0.69) or </text>
</page>
<page number="92" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">92 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="612" width="215" height="19" font="3">and 4/10 patients in group B (40%) </text>
<text top="127" left="612" width="206" height="19" font="3">had arrhythmic events (p =0.46).  </text>
<text top="145" left="612" width="3" height="19" font="3"> </text>
<text top="164" left="612" width="197" height="19" font="3">Total mortality was 10% in both </text>
<text top="182" left="612" width="49" height="19" font="3">groups. </text>
<text top="109" left="847" width="193" height="19" font="3">beta-adrenergic blocking agent </text>
<text top="127" left="847" width="109" height="19" font="3">therapy (p=0.53). </text>
<text top="201" left="123" width="116" height="19" font="3">● Sears et al. 1999 </text>
<text top="219" left="123" width="35" height="19" font="3">(172) </text>
<text top="238" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10410293">● </a></text>
<text top="238" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10410293">10410293</a></text>
<text top="238" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10410293"> </a></text>
<text top="201" left="253" width="135" height="19" font="4"><b>Study type:</b> literature </text>
<text top="219" left="253" width="44" height="19" font="3">review<b> </b></text>
<text top="201" left="406" width="170" height="19" font="4"><b>Inclusion: </b>studies assessing </text>
<text top="219" left="406" width="170" height="19" font="3">psychological impact of ICD </text>
<text top="238" left="406" width="74" height="19" font="3">and shocks<b>  </b></text>
<text top="201" left="612" width="184" height="19" font="4"><b>Results:</b>  13-38% of recipients </text>
<text top="219" left="612" width="212" height="19" font="3">experiencing diagnosable levels of </text>
<text top="238" left="612" width="55" height="19" font="3">anxiety.  </text>
<text top="256" left="612" width="3" height="19" font="3"> </text>
<text top="274" left="612" width="212" height="19" font="3">Specific ICD-related concerns such </text>
<text top="293" left="612" width="189" height="19" font="3">as fear of shock, fear of device </text>
<text top="311" left="612" width="221" height="19" font="3">malfunction, fear of death, and fear </text>
<text top="329" left="612" width="182" height="19" font="3">of embarrassment have been </text>
<text top="347" left="612" width="69" height="19" font="3">identified.  </text>
<text top="366" left="612" width="3" height="19" font="4"><b> </b></text>
<text top="384" left="612" width="3" height="19" font="4"><b> </b></text>
<text top="201" left="847" width="174" height="19" font="3">● <b>Conclusions: </b>Psychosocial </text>
<text top="219" left="847" width="228" height="19" font="3">adjustment risk profiles indicate that </text>
<text top="238" left="847" width="223" height="19" font="3">young ICD recipients and those with </text>
<text top="256" left="847" width="225" height="19" font="3">high discharge rates may experience </text>
<text top="274" left="847" width="198" height="19" font="3">the most adjustment difficulties </text>
<text top="403" left="123" width="91" height="19" font="3">● Lopera et al. </text>
<text top="422" left="123" width="69" height="19" font="3">2004 (173) </text>
<text top="440" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15028072">● </a></text>
<text top="440" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15028072">15028072</a></text>
<text top="440" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15028072"> </a></text>
<text top="458" left="123" width="3" height="19" font="4"><b> </b></text>
<text top="476" left="123" width="3" height="19" font="3"> </text>
<text top="403" left="252" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="422" left="252" width="131" height="19" font="3">Single Center Review </text>
<text top="440" left="252" width="3" height="19" font="3"> </text>
<text top="458" left="252" width="114" height="19" font="4"><b>Size:</b>    20 patients </text>
<text top="403" left="406" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="422" left="406" width="146" height="19" font="3">His Bundle, LBB, or RBB </text>
<text top="440" left="406" width="171" height="19" font="3">potential closely associated </text>
<text top="458" left="406" width="131" height="19" font="3">with QRS with any of </text>
<text top="476" left="406" width="88" height="19" font="3">the following: </text>
<text top="495" left="433" width="161" height="19" font="3">1)  H-H interval variation </text>
<text top="513" left="460" width="133" height="19" font="3">preceding similar V-V </text>
<text top="531" left="460" width="111" height="19" font="3">interval variation; </text>
<text top="550" left="433" width="107" height="19" font="3">2)  Anterograde </text>
<text top="568" left="460" width="103" height="19" font="3">activation of the </text>
<text top="586" left="460" width="105" height="19" font="3">bundle branches </text>
<text top="605" left="460" width="121" height="19" font="3">during tachycardia; </text>
<text top="623" left="460" width="20" height="19" font="3">or, </text>
<text top="641" left="433" width="139" height="19" font="3">3)  Abolition of VT by </text>
<text top="660" left="460" width="92" height="19" font="3">bundle branch </text>
<text top="678" left="460" width="57" height="19" font="3">ablation. </text>
<text top="696" left="406" width="3" height="19" font="3"> </text>
<text top="714" left="406" width="153" height="19" font="4"><b>Exclusion criteria:</b>  None </text>
<text top="403" left="612" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="422" left="612" width="174" height="19" font="3">HPS VT induced in 20 of 234 </text>
<text top="440" left="612" width="204" height="19" font="3">consecutive patients referred for </text>
<text top="458" left="612" width="73" height="19" font="3">VT ablation </text>
<text top="476" left="612" width="3" height="19" font="3"> </text>
<text top="495" left="612" width="205" height="19" font="3">NICM: 9 of 81 patients (11%) had </text>
<text top="513" left="612" width="47" height="19" font="3">HPS VT </text>
<text top="531" left="612" width="218" height="19" font="3">ICM:  11 of 153 patients (7.1%) had </text>
<text top="550" left="612" width="47" height="19" font="3">HPS VT </text>
<text top="568" left="612" width="123" height="19" font="3">Mean LVEF 29+17% </text>
<text top="586" left="612" width="208" height="19" font="3"> 2 of 20 patients had normal LVEF </text>
<text top="605" left="612" width="3" height="19" font="3"> </text>
<text top="623" left="612" width="131" height="19" font="4"><b>Clinical Presentation </b></text>
<text top="641" left="612" width="156" height="19" font="3">ICD Shocks in 10 patients </text>
<text top="660" left="612" width="133" height="19" font="3">Syncope in 3 patients </text>
<text top="678" left="612" width="184" height="19" font="3">Other symptoms in 7 patients </text>
<text top="696" left="612" width="3" height="19" font="3"> </text>
<text top="714" left="612" width="213" height="19" font="4"><b>Typical BBRVT</b> in 16 of 20 patients </text>
<text top="733" left="612" width="193" height="19" font="3">(all had LBBB QRS morphology) </text>
<text top="751" left="612" width="150" height="19" font="3">13 of 16 patients BBRVT </text>
<text top="769" left="612" width="170" height="19" font="3">successfully ablated by RBB </text>
<text top="403" left="847" width="197" height="19" font="3">● BBRVT occurs in patients with </text>
<text top="422" left="847" width="152" height="19" font="3">both NICM and ischemic </text>
<text top="440" left="847" width="183" height="19" font="3">cardiomyopathy, usually with </text>
<text top="458" left="847" width="101" height="19" font="3">impaired LVEF.   </text>
<text top="476" left="847" width="3" height="19" font="3"> </text>
<text top="495" left="847" width="171" height="19" font="3">● BBRVT is most commonly </text>
<text top="513" left="847" width="171" height="19" font="3">associated with a LBBB QRS </text>
<text top="531" left="847" width="201" height="19" font="3">morphology, and less commonly </text>
<text top="550" left="847" width="202" height="19" font="3">with RBBB or Interfascicular QRS </text>
<text top="568" left="847" width="87" height="19" font="3">morphologies </text>
<text top="586" left="847" width="3" height="19" font="3"> </text>
<text top="605" left="847" width="205" height="19" font="3">● Catheter ablation targeting the </text>
<text top="623" left="847" width="206" height="19" font="3">RBB or LBB is highly effective and </text>
<text top="641" left="847" width="222" height="19" font="3">associated with a low risk of serious </text>
<text top="660" left="847" width="188" height="19" font="3">complications if only one BB is </text>
<text top="678" left="847" width="196" height="19" font="3">targeted and a higher risk of AV </text>
<text top="696" left="847" width="205" height="19" font="3">block if both BBs are targeted for </text>
<text top="714" left="847" width="57" height="19" font="3">ablation. </text>
<text top="733" left="847" width="3" height="19" font="3"> </text>
</page>
<page number="93" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">93 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="612" width="169" height="19" font="3">ablation and 3 of 16 by LBB </text>
<text top="127" left="612" width="57" height="19" font="3">ablation. </text>
<text top="145" left="612" width="215" height="19" font="3">HV interval prolonged from 70+5.9 </text>
<text top="164" left="612" width="218" height="19" font="3">msec to 83+17 msec after ablation. </text>
<text top="182" left="612" width="3" height="19" font="3"> </text>
<text top="200" left="612" width="211" height="19" font="4"><b>Typical BBRVT and Interfascicular </b></text>
<text top="218" left="612" width="211" height="19" font="4"><b>VT</b> in 2 of 20 patients.  Ablation of </text>
<text top="237" left="612" width="200" height="19" font="3">both the RBB and portion of LBB </text>
<text top="255" left="612" width="191" height="19" font="3">eliminated VT in both patients, </text>
<text top="273" left="612" width="198" height="19" font="3">complicated by AV block in 1 pt. </text>
<text top="292" left="612" width="3" height="19" font="3"> </text>
<text top="310" left="612" width="197" height="19" font="4"><b>Focal Mechanism from BBs</b> in 2 </text>
<text top="328" left="612" width="201" height="19" font="3">patients, one in RBB, one in LBB. </text>
<text top="347" left="612" width="190" height="19" font="3">Ablation eliminated focal VT in </text>
<text top="365" left="612" width="206" height="19" font="3">both patients, complicated by AV </text>
<text top="383" left="612" width="81" height="19" font="3">block in 1 pt. </text>
<text top="402" left="123" width="91" height="19" font="3">● Mehdirad et </text>
<text top="421" left="123" width="83" height="19" font="3">al.1995 (174) </text>
<text top="439" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8771124">● </a></text>
<text top="439" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8771124">8771124</a></text>
<text top="439" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8771124"> </a></text>
<text top="457" left="123" width="3" height="19" font="3"> </text>
<text top="402" left="252" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="421" left="252" width="131" height="19" font="3">Single Center Review </text>
<text top="439" left="252" width="3" height="19" font="3"> </text>
<text top="457" left="252" width="114" height="19" font="4"><b>Size:</b>    16 patients </text>
<text top="402" left="406" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="421" left="406" width="163" height="19" font="3">All patients undergoing RF </text>
<text top="439" left="406" width="176" height="19" font="3">catheter ablation of the RBB </text>
<text top="457" left="406" width="65" height="19" font="3">for BBRVT </text>
<text top="476" left="406" width="3" height="19" font="3"> </text>
<text top="402" left="612" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="421" left="612" width="209" height="19" font="3">HV interval 68+8 msec at baseline </text>
<text top="439" left="612" width="122" height="19" font="3">LVEF mean 31+15% </text>
<text top="457" left="612" width="3" height="19" font="3"> </text>
<text top="476" left="612" width="211" height="19" font="3">RBBB developed in 15/16 patients </text>
<text top="494" left="612" width="114" height="19" font="3">after RBB ablation </text>
<text top="512" left="612" width="156" height="19" font="3">AV block occurred in 1 pt </text>
<text top="531" left="612" width="183" height="19" font="3">After mean of 19±10 mo, one </text>
<text top="549" left="612" width="206" height="19" font="3">patient died suddenly, 2 received </text>
<text top="567" left="612" width="216" height="19" font="3">cardiac transplantation, and 1 died </text>
<text top="586" left="612" width="51" height="19" font="3">of CHF.  </text>
<text top="402" left="847" width="202" height="19" font="3">● Catheter ablation of the RBB is </text>
<text top="421" left="847" width="230" height="19" font="3">effective for the treatment of BBRVT  </text>
<text top="439" left="847" width="3" height="19" font="3"> </text>
<text top="457" left="847" width="167" height="19" font="3">● BBRVT is associated with </text>
<text top="476" left="847" width="219" height="19" font="3">prolonged HV conduction intervals. </text>
<text top="494" left="847" width="3" height="19" font="3"> </text>
<text top="512" left="847" width="216" height="19" font="3">● The medium term followup after </text>
<text top="531" left="847" width="189" height="19" font="3">catheter ablation of the RBB is </text>
<text top="549" left="847" width="118" height="19" font="3">overall quite good. </text>
<text top="605" left="123" width="68" height="19" font="3">● <b>HELP-VT </b></text>
<text top="623" left="123" width="100" height="19" font="3">● Dinov B, et al. </text>
<text top="641" left="123" width="69" height="19" font="3">2014 (175) </text>
<text top="660" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24211823">● </a></text>
<text top="660" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24211823">24211823</a></text>
<text top="660" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24211823"> </a></text>
<text top="605" left="252" width="39" height="19" font="4"><b>Aim:</b>   </text>
<text top="623" left="252" width="109" height="19" font="3">To determine the </text>
<text top="641" left="252" width="93" height="19" font="3">outcome of VT </text>
<text top="660" left="252" width="123" height="19" font="3">catheter ablation in </text>
<text top="678" left="252" width="137" height="19" font="3">patients with NICM to </text>
<text top="696" left="252" width="96" height="19" font="3">those with ICM </text>
<text top="714" left="252" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="733" left="252" width="106" height="19" font="3">Prospective, non-</text>
<text top="751" left="252" width="76" height="19" font="3">randomized </text>
<text top="769" left="252" width="121" height="19" font="4"><b>Size:</b>  227 patients   </text>
<text top="605" left="406" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="623" left="406" width="187" height="19" font="3">Patients with SHD referred for </text>
<text top="641" left="406" width="174" height="19" font="3">catheter ablation of VT with </text>
<text top="660" left="406" width="139" height="19" font="3">either NICM (N=63) or </text>
<text top="678" left="406" width="56" height="19" font="3">ischemic </text>
<text top="696" left="406" width="152" height="19" font="3">cardiomyopathy(N=164) </text>
<text top="714" left="406" width="3" height="19" font="4"><b> </b></text>
<text top="733" left="406" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="751" left="406" width="176" height="19" font="3">Failure of informed consent<b>  </b></text>
<text top="769" left="406" width="3" height="19" font="4"><b> </b></text>
<text top="605" left="612" width="207" height="19" font="4"><b>1</b>°<b> endpoint:</b>  At 1 y follow-up, VT </text>
<text top="624" left="612" width="212" height="19" font="3">free survival was 57% for ischemic </text>
<text top="642" left="612" width="188" height="19" font="3">cardiomyopathyand 40.5% for </text>
<text top="660" left="612" width="199" height="19" font="3">NICM patients (HR: 1.62; 95% CI </text>
<text top="679" left="612" width="181" height="19" font="3">1.12–2.34, p=0.01).  ischemic </text>
<text top="697" left="612" width="218" height="19" font="3">cardiomyopathyrequired epicardial </text>
<text top="715" left="612" width="193" height="19" font="3">ablation in only 2 of 164 (1.2%) </text>
<text top="734" left="612" width="212" height="19" font="3">whereas NICM required epicardial </text>
<text top="752" left="612" width="182" height="19" font="3">ablation in 30.8% (p=0.0001). </text>
<text top="770" left="612" width="3" height="19" font="3"> </text>
<text top="605" left="847" width="92" height="19" font="4"><b>Complications </b></text>
<text top="623" left="847" width="219" height="19" font="3">Complications occurred in 11.1% of </text>
<text top="641" left="847" width="177" height="19" font="3">NICM and 11.1% of ischemic </text>
<text top="660" left="847" width="215" height="19" font="3">cardiomyopathypatients, including </text>
<text top="678" left="847" width="215" height="19" font="3">death in 4.8% of NICM and 3.7% of </text>
<text top="696" left="847" width="162" height="19" font="3">ischemic cardiomyopathy  </text>
<text top="714" left="847" width="3" height="19" font="3"> </text>
<text top="733" left="847" width="3" height="19" font="3"> </text>
</page>
<page number="94" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">94 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="406" width="89" height="19" font="4"><b>Intervention:</b>  </text>
<text top="127" left="406" width="184" height="19" font="3">Catheter ablation for patients </text>
<text top="145" left="406" width="68" height="19" font="3">with NICM </text>
<text top="164" left="406" width="3" height="19" font="4"><b> </b></text>
<text top="182" left="406" width="93" height="19" font="4"><b>Comparator:</b>  <b>  </b></text>
<text top="200" left="406" width="178" height="19" font="3">Catheter ablation in patients </text>
<text top="219" left="406" width="58" height="19" font="3">with ICM </text>
<text top="109" left="612" width="3" height="19" font="3"> </text>
<text top="127" left="612" width="3" height="19" font="4"><b> </b></text>
<text top="238" left="123" width="104" height="19" font="3">● <b>Euro-VT Study </b></text>
<text top="256" left="123" width="105" height="19" font="3">● Tanner H 2010 </text>
<text top="274" left="123" width="35" height="19" font="3">(176) </text>
<text top="293" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19656251">● </a></text>
<text top="293" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19656251">19656251</a></text>
<text top="292" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19656251"> </a></text>
<text top="311" left="123" width="3" height="19" font="3"> </text>
<text top="237" left="252" width="28" height="19" font="4"><b>Aim </b></text>
<text top="256" left="252" width="109" height="19" font="3">To determine the </text>
<text top="274" left="252" width="133" height="19" font="3">safety and efficacy of </text>
<text top="293" left="252" width="103" height="19" font="3">electroanatomic </text>
<text top="311" left="252" width="138" height="19" font="3">mapping and irrigated </text>
<text top="329" left="252" width="127" height="19" font="3">RF catheter ablation </text>
<text top="347" left="252" width="93" height="19" font="3">for VT after MI </text>
<text top="366" left="252" width="3" height="19" font="3"> </text>
<text top="384" left="252" width="76" height="19" font="4"><b>Study Type: </b></text>
<text top="402" left="252" width="107" height="19" font="3">Multicenter, non-</text>
<text top="421" left="252" width="76" height="19" font="3">randomized </text>
<text top="439" left="252" width="3" height="19" font="3"> </text>
<text top="457" left="252" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="476" left="252" width="72" height="19" font="3">63 patients </text>
<text top="494" left="252" width="3" height="19" font="4"><b> </b></text>
<text top="237" left="406" width="109" height="19" font="4"><b>Inclusion Criteria </b></text>
<text top="256" left="406" width="170" height="19" font="3">Drug and device refractory, </text>
<text top="274" left="406" width="175" height="19" font="3">recurrent sustained VT after </text>
<text top="293" left="406" width="24" height="19" font="3">MI. </text>
<text top="311" left="406" width="187" height="19" font="3">&gt;4 episodes of sustained VT in </text>
<text top="329" left="406" width="71" height="19" font="3">prior 6 mo. </text>
<text top="347" left="406" width="3" height="19" font="4"><b> </b></text>
<text top="366" left="406" width="111" height="19" font="4"><b>Exclusion Criteria </b></text>
<text top="384" left="406" width="63" height="19" font="3">Age &lt;18 y </text>
<text top="402" left="406" width="96" height="19" font="3">MI within 2 mo </text>
<text top="421" left="406" width="83" height="19" font="3">LV Thrombus </text>
<text top="439" left="406" width="103" height="19" font="3">Unstable Angina </text>
<text top="457" left="406" width="105" height="19" font="3">Severe AS or MR </text>
<text top="476" left="406" width="177" height="19" font="3">Unwillingness to participate<b>  </b></text>
<text top="494" left="406" width="3" height="19" font="4"><b> </b></text>
<text top="512" left="406" width="81" height="19" font="4"><b>Intervention </b></text>
<text top="531" left="406" width="186" height="19" font="3">Electroanatomic mapping and </text>
<text top="549" left="406" width="139" height="19" font="3">ablation with open-tip </text>
<text top="567" left="406" width="114" height="19" font="3">irrigated catheter. </text>
<text top="238" left="612" width="81" height="19" font="4"><b>1</b>°<b> endpoint: </b></text>
<text top="257" left="612" width="199" height="19" font="3">Acute success with ablation was </text>
<text top="275" left="612" width="207" height="19" font="3">achieved in 83% of mappable VTs </text>
<text top="293" left="612" width="189" height="19" font="3">and 40% of non-mappable VTs </text>
<text top="312" left="612" width="73" height="19" font="3">(p&lt;0.0001). </text>
<text top="330" left="612" width="3" height="19" font="3"> </text>
<text top="348" left="612" width="167" height="19" font="3">During 12mo follow-up, VT </text>
<text top="367" left="612" width="173" height="19" font="3">recurred in 49% of patients. </text>
<text top="385" left="612" width="3" height="19" font="3"> </text>
<text top="403" left="612" width="192" height="19" font="3">The mean number of therapies </text>
<text top="422" left="612" width="179" height="19" font="3">dropped from 60±70 prior to </text>
<text top="440" left="612" width="185" height="19" font="3">ablation to 14±15 in the same </text>
<text top="458" left="612" width="220" height="19" font="3">period of time (6 mo) after ablation </text>
<text top="476" left="612" width="62" height="19" font="3">(p= 0.02). </text>
<text top="495" left="612" width="3" height="19" font="3"> </text>
<text top="513" left="612" width="3" height="19" font="3"> </text>
<text top="237" left="847" width="92" height="19" font="4"><b>Complications </b></text>
<text top="256" left="847" width="201" height="19" font="3">Major complications occurred in </text>
<text top="274" left="847" width="224" height="19" font="3">1.5% and minor complications in 5% </text>
<text top="293" left="847" width="180" height="19" font="3">of patients, particularly groin </text>
<text top="311" left="847" width="199" height="19" font="3">hematomas, with no procedural </text>
<text top="329" left="847" width="49" height="19" font="3">deaths. </text>
<text top="586" left="123" width="102" height="19" font="3">● <b>Post-approval </b></text>
<text top="605" left="123" width="109" height="19" font="4"><b>Thermocool Trial </b></text>
<text top="623" left="123" width="96" height="19" font="3">● Marchlinski F </text>
<text top="641" left="123" width="69" height="19" font="3">2016 (177) </text>
<text top="660" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26868693">● </a></text>
<text top="660" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26868693">26868693</a></text>
<text top="660" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26868693"> </a></text>
<text top="678" left="123" width="3" height="19" font="3"> </text>
<text top="586" left="252" width="28" height="19" font="4"><b>Aim </b></text>
<text top="605" left="252" width="138" height="19" font="3">To evaluate long-term </text>
<text top="623" left="252" width="67" height="19" font="3">safety and </text>
<text top="641" left="252" width="118" height="19" font="3">effectiveness of RF </text>
<text top="660" left="252" width="129" height="19" font="3">catheter ablation for </text>
<text top="678" left="252" width="118" height="19" font="3">VT in patients with </text>
<text top="696" left="252" width="29" height="19" font="3">CAD </text>
<text top="714" left="252" width="3" height="19" font="3"> </text>
<text top="733" left="252" width="76" height="19" font="4"><b>Study Type: </b></text>
<text top="751" left="252" width="107" height="19" font="3">Multicenter, non-</text>
<text top="769" left="252" width="76" height="19" font="3">randomized </text>
<text top="586" left="406" width="109" height="19" font="4"><b>Inclusion Criteria </b></text>
<text top="605" left="406" width="188" height="19" font="3">Patient with coronary disease, </text>
<text top="623" left="406" width="187" height="19" font="3">age ≥18 y and LVEF ≥10% with </text>
<text top="641" left="406" width="143" height="19" font="3">recurrent VT (either ≥4 </text>
<text top="660" left="406" width="178" height="19" font="3">episode documented by ICD, </text>
<text top="678" left="406" width="169" height="19" font="3">≥2 episode documented by </text>
<text top="696" left="406" width="175" height="19" font="3">ECG in patients without ICD, </text>
<text top="714" left="406" width="179" height="19" font="3">incessant VT or symptomatic </text>
<text top="733" left="406" width="163" height="19" font="3">VT despite AAD treatment </text>
<text top="751" left="406" width="3" height="19" font="3"> </text>
<text top="769" left="406" width="111" height="19" font="4"><b>Exclusion Criteria </b></text>
<text top="587" left="612" width="81" height="19" font="4"><b>1</b>°<b> endpoint: </b></text>
<text top="605" left="612" width="155" height="19" font="3">At 6 mo: 62% without VT </text>
<text top="624" left="612" width="212" height="19" font="3">recurrence, proportion of patients </text>
<text top="642" left="612" width="210" height="19" font="3">with ICD shock reduced from 81.2 </text>
<text top="660" left="612" width="216" height="19" font="3">(pre) to 26.8% and ≥50% reduction </text>
<text top="679" left="612" width="223" height="19" font="3">in VT episodes in 63.8% of patients.  </text>
<text top="697" left="612" width="3" height="19" font="3"> </text>
<text top="715" left="612" width="102" height="19" font="4"><b>Safety Endpoint </b></text>
<text top="733" left="612" width="186" height="19" font="3">CV specific AE in 3.9% with no </text>
<text top="752" left="612" width="42" height="19" font="3">stroke </text>
<text top="770" left="612" width="3" height="19" font="3"> </text>
<text top="586" left="847" width="83" height="19" font="3">● <b>Comments </b></text>
<text top="605" left="847" width="209" height="19" font="3">● Reduction in amiodarone usage </text>
<text top="623" left="847" width="119" height="19" font="3">and hospitalization </text>
<text top="641" left="847" width="142" height="19" font="3">● Improvement in QoL </text>
</page>
<page number="95" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">95 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="252" width="3" height="19" font="3"> </text>
<text top="127" left="252" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="145" left="279" width="80" height="19" font="3">249 patients </text>
<text top="164" left="252" width="3" height="19" font="3"> </text>
<text top="109" left="406" width="151" height="19" font="3">Mobile LV thrombus, MI </text>
<text top="127" left="406" width="167" height="19" font="3">within 3 mo, idiopathic VT, </text>
<text top="145" left="406" width="169" height="19" font="3">class IV HF, creatinine ≥2.5, </text>
<text top="164" left="406" width="142" height="19" font="3">recent cardiac surgery, </text>
<text top="182" left="406" width="183" height="19" font="3">unstable angina, severe AS or </text>
<text top="200" left="406" width="28" height="19" font="3">MR. </text>
<text top="219" left="406" width="3" height="19" font="3"> </text>
<text top="237" left="406" width="81" height="19" font="4"><b>Intervention</b> </text>
<text top="255" left="406" width="186" height="19" font="3">Electroanatomic mapping and </text>
<text top="273" left="406" width="139" height="19" font="3">ablation with open-tip </text>
<text top="292" left="406" width="114" height="19" font="3">irrigated catheter. </text>
<text top="311" left="123" width="97" height="19" font="3">● <b>International </b></text>
<text top="329" left="123" width="106" height="19" font="4"><b>VT Collaborative </b></text>
<text top="347" left="123" width="81" height="19" font="4"><b>Group Study </b></text>
<text top="366" left="123" width="91" height="19" font="3">● Tung R 2015 </text>
<text top="384" left="123" width="35" height="19" font="3">(178) </text>
<text top="402" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26031376">● </a></text>
<text top="402" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26031376">26031376</a></text>
<text top="402" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26031376"> </a></text>
<text top="311" left="252" width="119" height="19" font="4"><b>Aim:</b>  to determine </text>
<text top="329" left="252" width="130" height="19" font="3">the association of VT </text>
<text top="347" left="252" width="103" height="19" font="3">recurrence after </text>
<text top="366" left="252" width="130" height="19" font="3">ablation and survival </text>
<text top="384" left="252" width="109" height="19" font="3">in scar related VT </text>
<text top="402" left="252" width="3" height="19" font="3"> </text>
<text top="421" left="252" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="439" left="252" width="75" height="19" font="3">Multicenter </text>
<text top="457" left="252" width="87" height="19" font="3">observational </text>
<text top="476" left="252" width="3" height="19" font="3"> </text>
<text top="494" left="252" width="76" height="19" font="4"><b>Size:</b>    2061 </text>
<text top="311" left="406" width="174" height="19" font="4"><b>Inclusion criteria:</b>  SHD with </text>
<text top="329" left="406" width="167" height="19" font="3">ischemic and non-ischemic </text>
<text top="347" left="406" width="143" height="19" font="3">cardiomyopathies with </text>
<text top="366" left="406" width="135" height="19" font="3">monomorphic VT and </text>
<text top="384" left="406" width="117" height="19" font="3">myocardial scar by </text>
<text top="402" left="406" width="160" height="19" font="3">electroanatomic mapping </text>
<text top="421" left="406" width="3" height="19" font="3"> </text>
<text top="439" left="406" width="186" height="19" font="4"><b>Exclusion criteria:</b>  absence of </text>
<text top="457" left="406" width="161" height="19" font="3">scar on electroanatomical </text>
<text top="476" left="406" width="60" height="19" font="3">mapping<b>  </b></text>
<text top="494" left="406" width="3" height="19" font="4"><b> </b></text>
<text top="512" left="406" width="142" height="19" font="4"><b>Intervention:</b> Catheter </text>
<text top="531" left="406" width="189" height="19" font="3">ablation, either endocardial or </text>
<text top="549" left="406" width="169" height="19" font="3">epicardial, guided by EAM.  </text>
<text top="567" left="406" width="162" height="19" font="3">End point of ablation with </text>
<text top="586" left="406" width="183" height="19" font="3">elimination of all induced VTs<b> </b></text>
<text top="311" left="612" width="88" height="19" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="330" left="612" width="222" height="19" font="3">Freedom from VT recurrence, Heart </text>
<text top="348" left="612" width="221" height="19" font="3">Transplant, or death was 70% at 1 y </text>
<text top="367" left="612" width="65" height="19" font="3">follow-up. </text>
<text top="385" left="612" width="218" height="19" font="3">VT recurred in 55% of patients who </text>
<text top="403" left="612" width="178" height="19" font="3">died vs. 22% of patients who </text>
<text top="422" left="612" width="58" height="19" font="3">survived. </text>
<text top="440" left="612" width="203" height="19" font="3">Transplant free survival was 90% </text>
<text top="458" left="612" width="215" height="19" font="3">for patients without VT recurrence </text>
<text top="476" left="612" width="164" height="19" font="3">and 71% for those with VT </text>
<text top="495" left="612" width="201" height="19" font="3">recurrence (HR: 6.9; 95% CI: 5.3–</text>
<text top="513" left="612" width="87" height="19" font="3">9.0, p&lt;0.001). </text>
<text top="531" left="612" width="3" height="19" font="4"><b> </b></text>
<text top="311" left="847" width="228" height="19" font="3">● Procedural complications occurred </text>
<text top="329" left="847" width="200" height="19" font="3">in 6%, including 2 deaths (0.1%), </text>
<text top="347" left="847" width="191" height="19" font="3">hemopericardium in 1.7%, and </text>
<text top="366" left="847" width="199" height="19" font="3">vascular access complications in </text>
<text top="384" left="847" width="33" height="19" font="3">1.6% </text>
<text top="402" left="847" width="3" height="19" font="3"> </text>
<text top="421" left="847" width="3" height="19" font="3"> </text>
<text top="439" left="847" width="3" height="19" font="3"> </text>
<text top="605" left="123" width="105" height="19" font="3">● <b>Meta-Analysis </b></text>
<text top="623" left="123" width="97" height="19" font="4"><b>of Randomized </b></text>
<text top="641" left="123" width="58" height="19" font="4"><b>and Non-</b></text>
<text top="659" left="123" width="81" height="19" font="4"><b>Randomized </b></text>
<text top="678" left="123" width="111" height="19" font="4"><b>Trials of Catheter </b></text>
<text top="696" left="123" width="98" height="19" font="4"><b>Ablation for VT </b></text>
<text top="714" left="123" width="99" height="19" font="3">● Mallidi J 2011 </text>
<text top="733" left="123" width="35" height="19" font="3">(179) </text>
<text top="751" left="123" width="9" height="19" font="3">●</text>
<text top="750" left="132" width="4" height="21" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21147263"> </a></text>
<text top="751" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21147263">21147263</a></text>
<text top="751" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21147263"> </a></text>
<text top="751" left="231" width="3" height="19" font="3"> </text>
<text top="605" left="252" width="122" height="19" font="4"><b>Aim:</b>  To determine </text>
<text top="623" left="252" width="133" height="19" font="3">the relative risk of VT </text>
<text top="641" left="252" width="138" height="19" font="3">recurrence in patients </text>
<text top="660" left="252" width="128" height="19" font="3">undergoing catheter </text>
<text top="678" left="252" width="119" height="19" font="3">ablation compared </text>
<text top="696" left="252" width="132" height="19" font="3">with medical therapy </text>
<text top="714" left="252" width="3" height="19" font="3"> </text>
<text top="733" left="252" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="751" left="252" width="116" height="19" font="3">Meta-Analysis of 5 </text>
<text top="769" left="252" width="133" height="19" font="3">Trials of VT Ablation   </text>
<text top="605" left="406" width="175" height="19" font="3">PubMed, Embase, Cochrane </text>
<text top="623" left="406" width="181" height="19" font="3">searches of both randomized </text>
<text top="641" left="406" width="171" height="19" font="3">and nonrandomized clinical </text>
<text top="660" left="406" width="193" height="19" font="3">trials of catheter ablation of VT </text>
<text top="678" left="406" width="193" height="19" font="3">compared with a control group </text>
<text top="696" left="406" width="195" height="19" font="3">receiving AAD treatment alone<b>  </b></text>
<text top="714" left="406" width="3" height="19" font="4"><b> </b></text>
<text top="733" left="406" width="89" height="19" font="4"><b>Intervention:</b>  </text>
<text top="751" left="406" width="157" height="19" font="3">Catheter ablation with or </text>
<text top="769" left="406" width="81" height="19" font="3">without AAD </text>
<text top="605" left="612" width="88" height="19" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="624" left="612" width="204" height="19" font="3">VT recurred in 93 of 266 patients </text>
<text top="642" left="612" width="183" height="19" font="3">(35%) after Catheter Ablation </text>
<text top="660" left="612" width="222" height="19" font="3">compared with 105 of 191 (55%) on </text>
<text top="679" left="612" width="210" height="19" font="3">AAD (HR: 0.62; 95% CI: 0.51–0.76, </text>
<text top="697" left="612" width="58" height="19" font="3">p&lt;0.001) </text>
<text top="715" left="612" width="3" height="19" font="3"> </text>
<text top="733" left="612" width="114" height="19" font="4"><b>Safety endpoint:</b>   </text>
<text top="752" left="612" width="195" height="19" font="3">Complications occurred in 6.3% </text>
<text top="770" left="612" width="187" height="19" font="3">after ablation, including death </text>
<text top="605" left="847" width="218" height="19" font="3">● Electrical Storm occurred in 17 of </text>
<text top="623" left="847" width="206" height="19" font="3">116 (15%) after catheter ablation </text>
<text top="641" left="847" width="225" height="19" font="3">and 29 of 119 (25%) on AAD therapy </text>
<text top="660" left="847" width="180" height="19" font="3">(HR: 0.61; 95% CI: 0.36–1.03, </text>
<text top="678" left="847" width="61" height="19" font="3">p&lt;0.066). </text>
<text top="696" left="847" width="3" height="19" font="3"> </text>
<text top="714" left="847" width="190" height="19" font="3">● Mortality occurred in 12% of </text>
<text top="733" left="847" width="212" height="19" font="3">patients treated with ablation and </text>
<text top="751" left="847" width="82" height="19" font="3">14% on AAD. </text>
<text top="769" left="847" width="3" height="19" font="3"> </text>
</page>
<page number="96" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">96 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="252" width="3" height="19" font="3"> </text>
<text top="127" left="252" width="45" height="19" font="4"><b>Size:</b>     </text>
<text top="145" left="252" width="79" height="19" font="3">457 patients </text>
<text top="109" left="406" width="7" height="19" font="3">  </text>
<text top="127" left="406" width="93" height="19" font="4"><b>Comparator:</b>  <b>  </b></text>
<text top="145" left="406" width="78" height="19" font="3">AAD alone.   </text>
<text top="109" left="612" width="222" height="19" font="3">(1%), tamponade (1%) and AV block </text>
<text top="127" left="612" width="42" height="19" font="3">(1.6%) </text>
<text top="195" left="123" width="82" height="19" font="3">● <b>Cooled Tip </b></text>
<text top="213" left="123" width="92" height="19" font="4"><b>Ablation of VT </b></text>
<text top="232" left="123" width="92" height="19" font="3">● Calkins 2000 </text>
<text top="250" left="123" width="35" height="19" font="3">(180) </text>
<text top="268" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10841242">● </a></text>
<text top="268" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10841242">10841242</a></text>
<text top="268" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10841242"> </a></text>
<text top="195" left="252" width="39" height="19" font="4"><b>Aim:</b>   </text>
<text top="213" left="252" width="109" height="19" font="3">To determine the </text>
<text top="232" left="252" width="133" height="19" font="3">safety and efficacy of </text>
<text top="250" left="252" width="124" height="19" font="3">an internally cooled </text>
<text top="268" left="252" width="127" height="19" font="3">RF ablation catheter </text>
<text top="287" left="252" width="131" height="19" font="3">used for VT in SHD in </text>
<text top="305" left="252" width="102" height="19" font="3">patients with &gt;2 </text>
<text top="323" left="252" width="131" height="19" font="3">episodes of VT in the </text>
<text top="341" left="252" width="134" height="19" font="3">prior 2 mo despite &gt;2 </text>
<text top="360" left="252" width="30" height="19" font="3">AAD </text>
<text top="378" left="252" width="3" height="19" font="3"> </text>
<text top="396" left="252" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="415" left="252" width="137" height="19" font="3">Non-Randomized trial </text>
<text top="433" left="252" width="137" height="19" font="3">of Cooled Tip ablation </text>
<text top="451" left="252" width="102" height="19" font="3">catheter for VT   </text>
<text top="470" left="252" width="3" height="19" font="3"> </text>
<text top="488" left="252" width="45" height="19" font="4"><b>Size:</b>     </text>
<text top="506" left="252" width="79" height="19" font="3">147 patients </text>
<text top="195" left="406" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="213" left="406" width="91" height="19" font="3">&gt;2 episodes of </text>
<text top="232" left="406" width="185" height="19" font="3">hemodynamically stable VT in </text>
<text top="250" left="406" width="151" height="19" font="3">previous 2 mo, CAD, ICD </text>
<text top="268" left="406" width="162" height="19" font="3">implantation, failure of &gt;2 </text>
<text top="287" left="406" width="34" height="19" font="3">AAD. </text>
<text top="305" left="406" width="3" height="19" font="4"><b> </b></text>
<text top="323" left="406" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="341" left="406" width="149" height="19" font="3">Failure to give informed </text>
<text top="360" left="406" width="55" height="19" font="3">consent  </text>
<text top="378" left="406" width="3" height="19" font="4"><b> </b></text>
<text top="396" left="406" width="89" height="19" font="4"><b>Intervention:</b>  </text>
<text top="415" left="406" width="169" height="19" font="3">Catheter ablation using the </text>
<text top="433" left="406" width="166" height="19" font="3">Cooled RF catheter system </text>
<text top="451" left="406" width="96" height="19" font="4"><b>Comparator:</b>  <b>   </b></text>
<text top="470" left="406" width="158" height="19" font="3">VT recurrence Hx prior to </text>
<text top="488" left="406" width="53" height="19" font="3">ablation </text>
<text top="196" left="612" width="81" height="19" font="4"><b>1</b>°<b> endpoint: </b></text>
<text top="214" left="612" width="207" height="19" font="3">Acute success with elimination of </text>
<text top="232" left="612" width="161" height="19" font="3">all mappable VTs in 75%,   </text>
<text top="251" left="612" width="3" height="19" font="3"> </text>
<text top="269" left="612" width="208" height="19" font="3">At a mean of 243+153 d of follow-</text>
<text top="287" left="612" width="211" height="19" font="3">up, VT recurred in 46% of patients </text>
<text top="306" left="612" width="3" height="19" font="3"> </text>
<text top="324" left="612" width="156" height="19" font="3">Acute success defined by </text>
<text top="342" left="612" width="212" height="19" font="3">noninduciblity of VT after ablation </text>
<text top="361" left="612" width="183" height="19" font="3">did not predict VT recurrence </text>
<text top="379" left="612" width="3" height="19" font="4"><b> </b></text>
<text top="195" left="847" width="104" height="19" font="3">● <b>Complications </b></text>
<text top="213" left="847" width="184" height="19" font="3">Complications occurred in 8% </text>
<text top="232" left="847" width="145" height="19" font="3">including death in 2.7% </text>
<text top="250" left="847" width="3" height="19" font="3"> </text>
<text top="268" left="847" width="3" height="19" font="3"> </text>
<text top="525" left="123" width="90" height="19" font="3">● <b>Multicenter </b></text>
<text top="543" left="123" width="80" height="19" font="4"><b>ThermoCool </b></text>
<text top="562" left="123" width="73" height="19" font="4"><b>Ventricular </b></text>
<text top="580" left="123" width="78" height="19" font="4"><b>Tachycardia </b></text>
<text top="598" left="123" width="88" height="19" font="4"><b>Ablation Trial</b> </text>
<text top="617" left="123" width="109" height="19" font="3">● Stevenson WG, </text>
<text top="635" left="123" width="103" height="19" font="3">et al. 2008 (181) </text>
<text top="653" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19064682">● </a></text>
<text top="653" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19064682">19064682</a></text>
<text top="653" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19064682"> </a></text>
<text top="525" left="252" width="39" height="19" font="4"><b>Aim:</b>   </text>
<text top="544" left="252" width="109" height="19" font="3">To determine the </text>
<text top="562" left="252" width="91" height="19" font="3">outcome after </text>
<text top="580" left="252" width="124" height="19" font="3">catheter ablation of </text>
<text top="599" left="252" width="19" height="19" font="3">VT </text>
<text top="617" left="252" width="3" height="19" font="4"><b> </b></text>
<text top="635" left="252" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="653" left="252" width="106" height="19" font="3">Non-randomized </text>
<text top="672" left="252" width="3" height="19" font="3"> </text>
<text top="690" left="252" width="42" height="19" font="4"><b>Size:</b>    </text>
<text top="708" left="252" width="79" height="19" font="3">231 patients </text>
<text top="525" left="406" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="544" left="406" width="173" height="19" font="3">&gt;4 episodes of sustained VT </text>
<text top="562" left="406" width="191" height="19" font="3">requiring cardioversion or AAD </text>
<text top="580" left="406" width="175" height="19" font="3">for termination in past 6 mo </text>
<text top="599" left="406" width="182" height="19" font="3">despite ICD or AAD THERAPY, </text>
<text top="617" left="406" width="65" height="19" font="3">age &gt;18 y. </text>
<text top="635" left="406" width="3" height="19" font="3"> </text>
<text top="653" left="406" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="672" left="406" width="159" height="19" font="3">LVEF &lt;0.10, LV thrombus, </text>
<text top="690" left="406" width="188" height="19" font="3">Creatinine &gt;2.5, NYHA Class IV </text>
<text top="708" left="406" width="154" height="19" font="3">CHF, severe AS, unstable </text>
<text top="727" left="406" width="122" height="19" font="3">angina, pregnancy.  </text>
<text top="745" left="406" width="3" height="19" font="3"> </text>
<text top="763" left="406" width="89" height="19" font="4"><b>Intervention:</b>  </text>
<text top="526" left="612" width="88" height="19" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="544" left="612" width="222" height="19" font="3">Freedom from recurrent VT at 6 mo </text>
<text top="563" left="612" width="185" height="19" font="3">follow-up in 123/231 patients </text>
<text top="581" left="612" width="42" height="19" font="3">(53%). </text>
<text top="599" left="612" width="3" height="19" font="3"> </text>
<text top="618" left="612" width="199" height="19" font="3">VT ablation reduced the median </text>
<text top="636" left="612" width="193" height="19" font="3">number of VT episodes in 6 mo </text>
<text top="654" left="612" width="221" height="19" font="3">before ablation from 11.5 to 0 after </text>
<text top="673" left="612" width="123" height="19" font="3">ablation (p&lt;0.0001) </text>
<text top="691" left="612" width="3" height="19" font="3"> </text>
<text top="709" left="612" width="114" height="19" font="4"><b>Safety endpoint:</b>   </text>
<text top="728" left="612" width="188" height="19" font="3">Complications occurred in 7%, </text>
<text top="746" left="612" width="214" height="19" font="3">including 7 patients (3%) who died </text>
<text top="764" left="612" width="198" height="19" font="3">within 3 d of ablation, and groin </text>
<text top="782" left="612" width="140" height="19" font="3">complications in 4.7%. </text>
<text top="525" left="847" width="150" height="19" font="3">● 1 y mortality was 18% </text>
<text top="544" left="847" width="3" height="19" font="3"> </text>
<text top="562" left="847" width="3" height="19" font="3"> </text>
</page>
<page number="97" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">97 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="406" width="164" height="19" font="3">Catheter ablation with the </text>
<text top="127" left="406" width="190" height="19" font="3">BioSense ThermoCool ablation </text>
<text top="145" left="406" width="55" height="19" font="3">catheter </text>
<text top="164" left="406" width="93" height="19" font="4"><b>Comparator:</b>  <b>  </b></text>
<text top="182" left="406" width="163" height="19" font="3">Prior Hx of VT recurrences </text>
<text top="201" left="123" width="108" height="19" font="3">● Steinberg et al. </text>
<text top="219" left="123" width="69" height="19" font="3">1999 (150) </text>
<text top="238" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10027813">● </a></text>
<text top="238" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10027813">10027813</a></text>
<text top="238" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10027813"> </a></text>
<text top="256" left="123" width="3" height="19" font="3"> </text>
<text top="201" left="252" width="118" height="19" font="4"><b>Study type:</b> cohort </text>
<text top="219" left="252" width="40" height="19" font="3">study  </text>
<text top="238" left="252" width="3" height="19" font="3"> </text>
<text top="256" left="252" width="107" height="19" font="4"><b>Size:</b> 12 patients  </text>
<text top="201" left="406" width="171" height="19" font="3">Patient with sustained post-</text>
<text top="219" left="406" width="192" height="19" font="3">operational VT ≥24 h but &lt;30 d </text>
<text top="238" left="406" width="192" height="19" font="3">after CABG among consecutive </text>
<text top="256" left="406" width="132" height="19" font="3">patients 382 patients </text>
<text top="274" left="406" width="175" height="19" font="3">undergoing CABG at a single </text>
<text top="293" left="406" width="66" height="19" font="3">institution </text>
<text top="311" left="406" width="3" height="19" font="3"> </text>
<text top="329" left="406" width="181" height="19" font="3">Variables associated with the </text>
<text top="347" left="406" width="134" height="19" font="3">occurrence of VT was </text>
<text top="366" left="406" width="69" height="19" font="3">performed </text>
<text top="202" left="612" width="195" height="19" font="4"><b>1</b>°<b> endpoint: </b>12 patients (3.1%) </text>
<text top="220" left="612" width="164" height="19" font="3">experienced ≥1 episode of </text>
<text top="238" left="612" width="212" height="19" font="3">sustained VT 4.1±4.8 d after CABG </text>
<text top="257" left="612" width="3" height="19" font="3"> </text>
<text top="275" left="612" width="134" height="19" font="3">In 11 /12 patients, no </text>
<text top="293" left="612" width="170" height="19" font="3">postoperative complication </text>
<text top="312" left="612" width="205" height="19" font="3">explained the VT. 1 patient had a </text>
<text top="330" left="612" width="113" height="19" font="3">perioperative MI.  </text>
<text top="348" left="612" width="3" height="19" font="3"> </text>
<text top="367" left="612" width="209" height="19" font="3">The in-hospital mortality rate was </text>
<text top="385" left="612" width="214" height="19" font="3">25%. Among the 9 survivors, 5 had </text>
<text top="403" left="612" width="194" height="19" font="3">EPS with all inducible sustained </text>
<text top="422" left="612" width="219" height="19" font="3">monomorphic VT (matching clinical </text>
<text top="440" left="612" width="203" height="19" font="3">VT). 3/9 patients received an ICD </text>
<text top="458" left="612" width="200" height="19" font="3">before hospital discharge. Other </text>
<text top="476" left="612" width="181" height="19" font="3">6/9 patients received chronic </text>
<text top="495" left="612" width="174" height="19" font="3">therapy with AAD (primarily </text>
<text top="513" left="612" width="89" height="19" font="3">amiodarone).  </text>
<text top="531" left="612" width="3" height="19" font="3"> </text>
<text top="550" left="612" width="221" height="19" font="3">All 9 patients are alive, with a mean </text>
<text top="568" left="612" width="117" height="19" font="3">follow-up of 2.5 y.  </text>
<text top="586" left="612" width="3" height="19" font="3"> </text>
<text top="605" left="612" width="209" height="19" font="3">2 patients (1 with an ICD and 1 on </text>
<text top="623" left="612" width="189" height="19" font="3">amiodarone) had recurrent VT </text>
<text top="641" left="612" width="104" height="19" font="3">during followup. </text>
<text top="201" left="847" width="210" height="19" font="3">● Results (cont.): Patients with VT </text>
<text top="219" left="847" width="207" height="19" font="3">were more likely to have prior MI </text>
<text top="238" left="847" width="212" height="19" font="3">(92% vs. 50%, p&lt;0.01), severe CHF </text>
<text top="256" left="847" width="199" height="19" font="3">(56% vs. 21%, p&lt;0.01), and LVEF </text>
<text top="274" left="847" width="181" height="19" font="3">&lt;0.40 (70% vs. 29%, p&lt;0.01).  </text>
<text top="292" left="847" width="187" height="19" font="3">● By multivariate analysis, the </text>
<text top="311" left="847" width="203" height="19" font="3">number of bypass grafts across a </text>
<text top="329" left="847" width="224" height="19" font="3">noncollateralized occluded vessel to </text>
<text top="347" left="847" width="174" height="19" font="3">an infarct zone was the only </text>
<text top="366" left="847" width="209" height="19" font="3">independent factor predicting VT. </text>
<text top="384" left="847" width="195" height="19" font="3">● Conclusions: (1) Patients who </text>
<text top="402" left="847" width="221" height="19" font="3">developed VT had a high in-hospital </text>
<text top="421" left="847" width="215" height="19" font="3">mortality rate of 25% (2) However, </text>
<text top="439" left="847" width="183" height="19" font="3">long-term outcome was good </text>
<text top="457" left="847" width="214" height="19" font="3">(possibly related to antiarrhythmic </text>
<text top="476" left="847" width="203" height="19" font="3">or ICD). (3) predictors are MMVT </text>
<text top="494" left="847" width="198" height="19" font="3">previous MI scar and associated </text>
<text top="512" left="847" width="160" height="19" font="3">severe LV dysfunction. (4) </text>
<text top="531" left="847" width="227" height="19" font="3">Relationship was found between the </text>
<text top="549" left="847" width="170" height="19" font="3">development of VT and the </text>
<text top="567" left="847" width="224" height="19" font="3">placement of a bypass graft across a </text>
<text top="586" left="847" width="225" height="19" font="3">noncollateralized occluded coronary </text>
<text top="604" left="847" width="215" height="19" font="3">vessel to a chronic infarct zone. (5) </text>
<text top="622" left="847" width="199" height="19" font="3">The development of MMVT was </text>
<text top="640" left="847" width="200" height="19" font="3">typically not due to a detectable </text>
<text top="659" left="847" width="187" height="19" font="3">postoperative complication or </text>
<text top="677" left="847" width="64" height="19" font="3">ischemia.  </text>
<text top="695" left="847" width="3" height="19" font="3"> </text>
<text top="714" left="115" width="3" height="19" font="3"> </text>
<text top="733" left="115" width="3" height="19" font="3"> </text>
<text top="733" left="331" width="3" height="19" font="3"> </text>
</page>
<page number="98" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">98 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="3" height="19" font="3"> </text>
<text top="162" left="115" width="748" height="21" font="2"><b>Data Supplement 24. Nonrandomized Trials, Observational Studies, and/or Registries of NICM – (Section 7.2) </b></text>
<text top="183" left="151" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="201" left="177" width="51" height="19" font="4"><b>Author; </b></text>
<text top="220" left="155" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="183" left="306" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="201" left="335" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="183" left="483" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="183" left="667" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="201" left="679" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="220" left="711" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="183" left="911" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="201" left="940" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="239" left="130" width="132" height="19" font="3">● Ackerman MJ 2011 </text>
<text top="257" left="130" width="35" height="19" font="3">(182) </text>
<text top="275" left="130" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21810866">● </a></text>
<text top="275" left="142" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21810866">21810866</a></text>
<text top="275" left="203" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21810866"> </a></text>
<text top="239" left="289" width="148" height="19" font="4"><b>Study type:</b>   HRS/EHRA </text>
<text top="257" left="289" width="136" height="19" font="3">consensus statement.<b> </b></text>
<text top="275" left="289" width="3" height="19" font="4"><b> </b></text>
<text top="239" left="461" width="109" height="19" font="3">Expert consensus </text>
<text top="257" left="461" width="159" height="19" font="3">statement on the state of </text>
<text top="275" left="461" width="138" height="19" font="3">genetic testing for the </text>
<text top="294" left="461" width="130" height="19" font="3">channelopathies and </text>
<text top="312" left="461" width="113" height="19" font="3">cardiomyopathies </text>
<text top="330" left="461" width="3" height="19" font="4"><b> </b></text>
<text top="349" left="461" width="114" height="19" font="4"><b>Panel: </b>geneticists, </text>
<text top="367" left="461" width="150" height="19" font="3">arrhythmia specialists     </text>
<text top="385" left="461" width="112" height="19" font="3">Agreement ≥ 84% </text>
<text top="239" left="638" width="204" height="19" font="4"><b>General: Class I: </b>1) sound clinical </text>
<text top="257" left="638" width="148" height="19" font="3">suspicion when positive </text>
<text top="275" left="638" width="144" height="19" font="3">predictive value &gt; 40%, </text>
<text top="294" left="638" width="209" height="19" font="3">signal/noise ratio &gt;10;<b> </b>2) AND/OR </text>
<text top="312" left="638" width="209" height="19" font="3">genetic test result provides either </text>
<text top="330" left="638" width="197" height="19" font="3">diagnostic or prognostic info, or </text>
<text top="349" left="638" width="196" height="19" font="3">influences therapeutic choices.  </text>
<text top="367" left="638" width="185" height="19" font="3">Screening of family members: </text>
<text top="385" left="638" width="206" height="19" font="3">when genetic testing leads to the </text>
<text top="404" left="638" width="193" height="19" font="3">adoption of therapy/protective </text>
<text top="422" left="638" width="202" height="19" font="3">measures/ lifestyle adaptations.<b> </b> </text>
<text top="440" left="638" width="3" height="19" font="3"> </text>
<text top="459" left="638" width="170" height="19" font="3">LQTS: Class I: 1) any pt with </text>
<text top="477" left="638" width="200" height="19" font="3">strong clinical index of suspicion </text>
<text top="495" left="638" width="206" height="19" font="3">for LQTS; 2) any asymptomatic pt </text>
<text top="514" left="638" width="189" height="19" font="3">with QT prolongation on serial </text>
<text top="532" left="638" width="200" height="19" font="3">ECGs:  QTc &gt;480 ms prepuberty; </text>
<text top="550" left="638" width="174" height="19" font="3">&gt;500 ms, adult; 3) Mutation </text>
<text top="568" left="638" width="204" height="19" font="3">specific genetic testing for family </text>
<text top="587" left="638" width="200" height="19" font="3">members and other appropriate </text>
<text top="605" left="638" width="62" height="19" font="3">relatives   </text>
<text top="623" left="638" width="188" height="19" font="3">Class IIb: any asymptomatic pt </text>
<text top="642" left="638" width="186" height="19" font="3">with otherwise idiopathic QTc </text>
<text top="660" left="638" width="200" height="19" font="3">values &gt;460 ms (puberty) or 480 </text>
<text top="678" left="638" width="146" height="19" font="3">ms (183) on serial ECGs </text>
<text top="697" left="638" width="3" height="19" font="3"> </text>
<text top="715" left="638" width="197" height="19" font="3">CPVT: Class I: 1) any pt w strong </text>
<text top="733" left="638" width="173" height="19" font="3">clinical index of suspicion of </text>
<text top="751" left="638" width="42" height="19" font="3">CPVT;  </text>
<text top="239" left="860" width="207" height="19" font="3">● LQTS: Note difference between </text>
<text top="257" left="860" width="207" height="19" font="3">Class I if QTc &gt;480 or 500 ms, and </text>
<text top="275" left="860" width="175" height="19" font="3">Class IIb if QTc &gt;460/480 ms<i> </i></text>
<text top="293" left="860" width="3" height="19" font="5"><i> </i></text>
<text top="311" left="860" width="3" height="19" font="5"><i> </i></text>
<text top="330" left="860" width="3" height="19" font="5"><i> </i></text>
<text top="348" left="860" width="3" height="19" font="5"><i> </i></text>
<text top="366" left="860" width="3" height="19" font="5"><i> </i></text>
<text top="385" left="860" width="3" height="19" font="3"> </text>
</page>
<page number="99" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="589" width="20" height="21" font="0">99 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="638" width="173" height="19" font="3">2) Mutation specific genetic </text>
<text top="127" left="638" width="172" height="19" font="3">testing is recommended for </text>
<text top="145" left="638" width="204" height="19" font="3">family members and appropriate </text>
<text top="164" left="638" width="55" height="19" font="3">relatives </text>
<text top="182" left="638" width="3" height="19" font="3"> </text>
<text top="200" left="638" width="163" height="19" font="3">Brugada: Class I: Mutation </text>
<text top="219" left="638" width="155" height="19" font="3">specific genetic testing is </text>
<text top="237" left="638" width="155" height="19" font="3">recommended for family </text>
<text top="255" left="638" width="163" height="19" font="3">members and appropriate </text>
<text top="273" left="638" width="55" height="19" font="3">relatives </text>
<text top="292" left="638" width="200" height="19" font="4"><b>Class IIa:</b> any pt w strong clinical </text>
<text top="310" left="638" width="155" height="19" font="3">index of suspicion of BrS, </text>
<text top="329" left="638" width="176" height="19" font="3">including with procainamide </text>
<text top="347" left="638" width="62" height="19" font="3">challenge </text>
<text top="365" left="638" width="176" height="19" font="4"><b>Class III:</b> not indicated in the </text>
<text top="383" left="638" width="200" height="19" font="3">setting of an isolated type 2 or 3 </text>
<text top="402" left="638" width="131" height="19" font="3">Brugada ECG pattern </text>
<text top="420" left="638" width="3" height="19" font="3"> </text>
<text top="438" left="638" width="176" height="19" font="4"><b>Short QTS: Class I: </b>Mutation </text>
<text top="457" left="638" width="155" height="19" font="3">specific genetic testing is </text>
<text top="475" left="638" width="155" height="19" font="3">recommended for family </text>
<text top="493" left="638" width="163" height="19" font="3">members and appropriate </text>
<text top="512" left="638" width="55" height="19" font="3">relatives </text>
<text top="530" left="638" width="172" height="19" font="4"><b>Class IIb: </b>any pt with strong </text>
<text top="548" left="638" width="157" height="19" font="3">clinical index of suspicion<b> </b></text>
<text top="566" left="638" width="3" height="19" font="4"><b> </b></text>
<text top="585" left="638" width="197" height="19" font="4"><b>ARVC: Class I: </b>Mutation specific </text>
<text top="603" left="638" width="199" height="19" font="3">genetic testing is recommended </text>
<text top="621" left="638" width="150" height="19" font="3">for family members and </text>
<text top="640" left="638" width="131" height="19" font="3">appropriate relatives </text>
<text top="658" left="638" width="162" height="19" font="4"><b>Class IIa:</b> can be useful for </text>
<text top="676" left="638" width="177" height="19" font="3">patients satisfying task force </text>
<text top="695" left="638" width="112" height="19" font="3">diagnostic criteria </text>
<text top="713" left="638" width="198" height="19" font="4"><b>Class IIb: </b>may be considered for </text>
<text top="731" left="638" width="209" height="19" font="3">patients with possible ACM/ARVC<b> </b></text>
<text top="749" left="638" width="192" height="19" font="4"><b>Class III: </b>not recommended for </text>
<text top="768" left="638" width="202" height="19" font="3">patients with only a single minor </text>
</page>
<page number="100" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">100 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="638" width="192" height="19" font="3">criterion according to the 2010 </text>
<text top="127" left="638" width="110" height="19" font="3">task force criteria </text>
<text top="145" left="638" width="3" height="19" font="3"> </text>
<text top="164" left="638" width="208" height="19" font="4"><b>SCD/SIDS: Class I: 1) </b>Collection of </text>
<text top="182" left="638" width="179" height="19" font="3">tissue sample recommended </text>
<text top="200" left="638" width="173" height="19" font="3">(blood or heart/liver/spleen </text>
<text top="219" left="638" width="172" height="19" font="3">tissue); 2) Mutation specific </text>
<text top="237" left="638" width="199" height="19" font="3">genetic testing is recommended </text>
<text top="255" left="638" width="150" height="19" font="3">for family members and </text>
<text top="273" left="638" width="131" height="19" font="3">appropriate relatives </text>
<text top="292" left="638" width="151" height="19" font="4"><b>Class IIb:</b> testing may be </text>
<text top="310" left="638" width="172" height="19" font="3">considered if circumstantial </text>
<text top="329" left="638" width="199" height="19" font="3">evidence suggests LQTS or CPVT </text>
<text top="347" left="638" width="70" height="19" font="3">specifically </text>
<text top="365" left="638" width="3" height="19" font="4"><b> </b></text>
<text top="383" left="638" width="162" height="19" font="4"><b>ACA/resuscitated: Class I: </b></text>
<text top="402" left="638" width="203" height="19" font="3">Genetic testing should be guided </text>
<text top="420" left="638" width="153" height="19" font="3">by the results of medical </text>
<text top="438" left="638" width="200" height="19" font="3">evaluation and is used for the 1° </text>
<text top="457" left="638" width="173" height="19" font="3">purpose of screening at-risk </text>
<text top="475" left="638" width="194" height="19" font="3">family members for sub-clinical </text>
<text top="493" left="638" width="49" height="19" font="3">disease </text>
<text top="511" left="638" width="202" height="19" font="4"><b>Class III: </b>Routine genetic testing, </text>
<text top="530" left="638" width="200" height="19" font="3">in the absence of a clinical index </text>
<text top="548" left="638" width="156" height="19" font="3">of suspicion for a specific </text>
<text top="566" left="638" width="119" height="19" font="3">cardiomyopathy or </text>
<text top="585" left="638" width="195" height="19" font="3">channelopathy, is not indicated </text>
<text top="603" left="638" width="192" height="19" font="3">for the survivor of unexplained </text>
<text top="621" left="638" width="39" height="19" font="3">OHCA<b> </b></text>
<text top="640" left="638" width="3" height="19" font="4"><b> </b></text>
<text top="658" left="638" width="201" height="19" font="4"><b>HCM: Class I:  1) </b>any pt in whom </text>
<text top="676" left="638" width="149" height="19" font="3">the clinical dx of HCM is </text>
<text top="695" left="638" width="205" height="19" font="3">established.  2) Mutation specific </text>
<text top="713" left="638" width="199" height="19" font="3">genetic testing is recommended </text>
<text top="731" left="638" width="150" height="19" font="3">for family members and </text>
<text top="750" left="638" width="134" height="19" font="3">appropriate relatives  </text>
<text top="768" left="638" width="3" height="19" font="3"> </text>
</page>
<page number="101" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">101 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="638" width="159" height="19" font="4"><b>DCM: Class I: 1) </b>DCM and </text>
<text top="127" left="638" width="185" height="19" font="3">significant cardiac conduction </text>
<text top="145" left="638" width="170" height="19" font="3">disease and/or family Hx of </text>
<text top="164" left="638" width="192" height="19" font="3">premature unexpected sudden </text>
<text top="182" left="638" width="167" height="19" font="3">death. 2) Mutation specific </text>
<text top="200" left="638" width="199" height="19" font="3">genetic testing is recommended </text>
<text top="219" left="638" width="150" height="19" font="3">for family members and </text>
<text top="237" left="638" width="131" height="19" font="3">appropriate relatives </text>
<text top="255" left="638" width="3" height="19" font="3"> </text>
<text top="273" left="638" width="196" height="19" font="4"><b>LVNC: Class I: </b>Mutation specific </text>
<text top="292" left="638" width="199" height="19" font="3">genetic testing is recommended </text>
<text top="310" left="638" width="150" height="19" font="3">for family members and </text>
<text top="329" left="638" width="131" height="19" font="3">appropriate relatives </text>
<text top="347" left="638" width="198" height="19" font="4"><b>Class IIa: </b>can be useful if clinical </text>
<text top="365" left="638" width="155" height="19" font="3">dx of LVNC is established </text>
<text top="383" left="638" width="3" height="19" font="3"> </text>
<text top="401" left="638" width="196" height="19" font="4"><b>PCCD:</b> <b>Class I:</b> Mutation specific </text>
<text top="420" left="638" width="199" height="19" font="3">genetic testing is recommended </text>
<text top="438" left="638" width="150" height="19" font="3">for family members and </text>
<text top="457" left="638" width="131" height="19" font="3">appropriate relatives </text>
<text top="475" left="638" width="197" height="19" font="3"> <b>Class IIb: </b>may be considered as </text>
<text top="493" left="638" width="199" height="19" font="3">part of diagnostic evaluation for </text>
<text top="512" left="638" width="204" height="19" font="3">patients with either isolated CCD </text>
<text top="530" left="638" width="156" height="19" font="3">or CCD with concomitant </text>
<text top="548" left="638" width="155" height="19" font="3">congenital heart disease, </text>
<text top="566" left="638" width="183" height="19" font="3">especially w post family Hx of </text>
<text top="585" left="638" width="36" height="19" font="3">CCD.  </text>
<text top="603" left="638" width="3" height="19" font="4"><b> </b></text>
<text top="622" left="130" width="144" height="19" font="3">● Hershberger RE et al. </text>
<text top="640" left="130" width="69" height="19" font="3">2010 (184) </text>
<text top="659" left="130" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20864896">● </a></text>
<text top="659" left="142" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20864896">20864896</a></text>
<text top="662" left="203" width="4" height="14" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20864896"> </a></text>
<text top="677" left="130" width="3" height="19" font="3"> </text>
<text top="695" left="130" width="3" height="19" font="3"> </text>
<text top="714" left="130" width="3" height="19" font="3"> </text>
<text top="622" left="289" width="132" height="19" font="4"><b>Study type:</b>   This is a </text>
<text top="640" left="289" width="135" height="19" font="3">review on clinical and </text>
<text top="660" left="289" width="102" height="19" font="3">genetic issues in </text>
<text top="658" left="391" width="33" height="21" font="0">DCM</text>
<text top="660" left="424" width="3" height="19" font="4"><b> </b></text>
<text top="622" left="461" width="27" height="19" font="3">N/A </text>
<text top="622" left="638" width="27" height="19" font="3">N/A </text>
<text top="624" left="860" width="77" height="19" font="3">● Idiopathic </text>
<text top="622" left="937" width="33" height="21" font="0">DCM</text>
<text top="624" left="970" width="125" height="19" font="3">, has been shown to </text>
<text top="642" left="860" width="205" height="19" font="3">have a familial basis in 20-35% of </text>
<text top="661" left="860" width="201" height="19" font="3">cases. Genetic studies in familial </text>
<text top="679" left="860" width="225" height="19" font="3">dilated cardiomyopathy have shown </text>
<text top="697" left="860" width="212" height="19" font="3">dramatic locus heterogeneity with </text>
<text top="716" left="860" width="213" height="19" font="3">mutations identified in &gt;30 mostly </text>
<text top="734" left="860" width="219" height="19" font="3">autosomal genes showing primarily </text>
<text top="752" left="860" width="147" height="19" font="3">dominant transmission. </text>
</page>
<page number="102" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">102 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="130" width="144" height="19" font="3">● Piers et al 2013 (185) </text>
<text top="127" left="130" width="12" height="19" font="3">●<a href="http://www.ncbi.nlm.nih.gov/pubmed/24036134"> </a></text>
<text top="127" left="142" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24036134">24036134</a></text>
<text top="127" left="203" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24036134"> </a></text>
<text top="145" left="130" width="3" height="19" font="3"> </text>
<text top="109" left="289" width="159" height="19" font="4"><b>Study type:</b> single center, </text>
<text top="127" left="289" width="87" height="19" font="3">observational </text>
<text top="145" left="289" width="3" height="19" font="3"> </text>
<text top="164" left="289" width="54" height="19" font="4"><b>Size:</b>  45 </text>
<text top="109" left="461" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="127" left="461" width="147" height="19" font="3">Patients with NICM and </text>
<text top="145" left="461" width="153" height="19" font="3">VT treated with catheter </text>
<text top="164" left="461" width="53" height="19" font="3">ablation </text>
<text top="182" left="461" width="3" height="19" font="3"> </text>
<text top="200" left="461" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="109" left="638" width="204" height="19" font="4"><b>1</b>°<b> endpoint:</b>  VT recurrence over </text>
<text top="128" left="638" width="179" height="19" font="3">mean follow up of 25±15 mo </text>
<text top="146" left="638" width="3" height="19" font="3"> </text>
<text top="164" left="638" width="166" height="19" font="4"><b>Results:</b>  VT occurred in 24 </text>
<text top="183" left="638" width="197" height="19" font="3">patients (53%), but the 6 mo VT </text>
<text top="201" left="638" width="198" height="19" font="3">burden was reduced by ≥75% in </text>
<text top="219" left="638" width="36" height="19" font="3">79%.  </text>
<text top="238" left="638" width="200" height="19" font="3">Recurrence rates were low after </text>
<text top="256" left="638" width="180" height="19" font="3">complete procedural success </text>
<text top="274" left="638" width="204" height="19" font="3">(18%), but high after both partial </text>
<text top="293" left="638" width="199" height="19" font="3">success (77%) and failure (73%). </text>
<text top="109" left="860" width="196" height="19" font="3">● VT recurrence is high in NICM </text>
<text top="127" left="860" width="224" height="19" font="3">patients, but significant reduction in </text>
<text top="145" left="860" width="194" height="19" font="3">the frequency of VT episodes is </text>
<text top="164" left="860" width="222" height="19" font="3">observed in the majority of patients </text>
<text top="182" left="860" width="117" height="19" font="3">following ablation. </text>
<text top="200" left="860" width="3" height="19" font="3"> </text>
<text top="219" left="860" width="186" height="19" font="3">● There was a suggestion that </text>
<text top="237" left="860" width="219" height="19" font="3">patients treated with ablation early </text>
<text top="255" left="860" width="235" height="19" font="3">(first VT or VT ICD therapy) had better </text>
<text top="273" left="860" width="206" height="19" font="3">outcome than those treated late. </text>
<text top="312" left="130" width="134" height="19" font="3">● Greulich et al. 2013 </text>
<text top="330" left="130" width="35" height="19" font="3">(186) </text>
<text top="348" left="130" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23498675">● </a></text>
<text top="348" left="142" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23498675">23498675</a></text>
<text top="348" left="203" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23498675"> </a></text>
<text top="367" left="130" width="3" height="19" font="3"> </text>
<text top="311" left="289" width="130" height="19" font="4"><b>Aim:  </b>study aimed to </text>
<text top="330" left="289" width="134" height="19" font="3">demonstrate that the </text>
<text top="348" left="289" width="101" height="19" font="3">presence of late </text>
<text top="367" left="289" width="159" height="19" font="3">gadolinium enhancement </text>
<text top="385" left="289" width="138" height="19" font="3">is a predictor of death </text>
<text top="403" left="289" width="158" height="19" font="3">and other adverse events </text>
<text top="422" left="289" width="98" height="19" font="3">in patients with </text>
<text top="440" left="289" width="83" height="19" font="3">suspected CS<b> </b></text>
<text top="458" left="289" width="3" height="19" font="4"><b> </b></text>
<text top="476" left="289" width="156" height="19" font="4"><b>Study type:</b>   Multicenter </text>
<text top="495" left="289" width="75" height="19" font="3">prospective </text>
<text top="513" left="289" width="3" height="19" font="3"> </text>
<text top="531" left="289" width="118" height="19" font="4"><b>Size:</b>   155 patients </text>
<text top="550" left="289" width="3" height="19" font="4"><b> </b></text>
<text top="311" left="461" width="137" height="19" font="4"><b>Inclusion criteria</b>: 155 </text>
<text top="330" left="461" width="159" height="19" font="3">consecutive patients with </text>
<text top="348" left="461" width="156" height="19" font="3">systemic sarcoidosis who </text>
<text top="367" left="461" width="124" height="19" font="3">underwent CMR for </text>
<text top="385" left="461" width="131" height="19" font="3">workup of suspected </text>
<text top="403" left="461" width="94" height="19" font="3">cardiac sarcoid </text>
<text top="422" left="461" width="158" height="19" font="3">involvement. The median </text>
<text top="440" left="461" width="157" height="19" font="3">follow-up time was 2.6 y. </text>
<text top="458" left="461" width="3" height="19" font="3"> </text>
<text top="476" left="461" width="144" height="19" font="4"><b>Exclusion criteria: </b> N/A<b> </b></text>
<text top="312" left="638" width="196" height="19" font="4"><b>1</b>°<b> endpoint: </b>1° endpoints were </text>
<text top="331" left="638" width="152" height="19" font="3">death, aborted SCD, and </text>
<text top="349" left="638" width="166" height="19" font="3">appropriate ICD discharge. </text>
<text top="367" left="638" width="3" height="19" font="3"> </text>
<text top="386" left="638" width="190" height="19" font="4"><b>Results:</b> LGE was present in 39 </text>
<text top="404" left="638" width="208" height="19" font="3">patients (25.5%). The presence of </text>
<text top="422" left="638" width="206" height="19" font="3">LGE yields a HR of 31.6 for death, </text>
<text top="441" left="638" width="200" height="19" font="3">aborted SCD, or appropriate ICD </text>
<text top="459" left="638" width="184" height="19" font="3">discharge, and of 33.9 for any </text>
<text top="477" left="638" width="153" height="19" font="3">event. This is superior to </text>
<text top="496" left="638" width="200" height="19" font="3">functional or clinical parameters </text>
<text top="514" left="638" width="208" height="19" font="3">such as left LVEF, LV end-diastolic </text>
<text top="532" left="638" width="191" height="19" font="3">volume, or presentation as HF, </text>
<text top="550" left="638" width="207" height="19" font="3">yielding HRs between 0.99 (per % </text>
<text top="569" left="638" width="155" height="19" font="3">increase LVEF) and 1.004 </text>
<text top="587" left="638" width="157" height="19" font="3">(presentation as HF), and </text>
<text top="606" left="638" width="157" height="19" font="3">between 0.94 and 1.2 for </text>
<text top="624" left="638" width="160" height="19" font="3">potentially lethal or other </text>
<text top="642" left="638" width="179" height="19" font="3">adverse events, respectively.<b> </b></text>
<text top="312" left="860" width="208" height="19" font="3">● Could not tell on additional LGE </text>
<text top="330" left="860" width="204" height="19" font="3">parameters due to low numbers. </text>
<text top="661" left="130" width="136" height="19" font="3">● Kuruvilla et al. 2014 </text>
<text top="679" left="130" width="35" height="19" font="3">(187) </text>
<text top="698" left="130" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24363358">● </a></text>
<text top="698" left="142" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24363358">24363358</a></text>
<text top="698" left="203" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24363358"> </a></text>
<text top="661" left="289" width="120" height="19" font="4"><b>Aim:</b>  To assess the </text>
<text top="679" left="289" width="140" height="19" font="3">relation between CMR </text>
<text top="698" left="289" width="144" height="19" font="3">LGE and cardiovascular </text>
<text top="716" left="289" width="116" height="19" font="3">outcomes in NICM </text>
<text top="734" left="289" width="53" height="19" font="3">patients </text>
<text top="753" left="289" width="3" height="19" font="3"> </text>
<text top="661" left="461" width="152" height="19" font="4"><b>Inclusion criteria:</b>  NICM </text>
<text top="679" left="461" width="3" height="19" font="3"> </text>
<text top="698" left="461" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="716" left="461" width="163" height="19" font="3">Ischemic cardiomyopathy, </text>
<text top="734" left="461" width="37" height="19" font="3">HCM<b>  </b></text>
<text top="752" left="461" width="145" height="19" font="4"><b>Intervention:</b> CMR-LGE </text>
<text top="771" left="461" width="152" height="19" font="3">findings and subsequent </text>
<text top="662" left="638" width="198" height="19" font="4"><b>1</b>°<b> endpoint:</b>   Patients with LGE </text>
<text top="680" left="638" width="174" height="19" font="3">had an increased risk of SCA </text>
<text top="699" left="638" width="180" height="19" font="3">events (OR: 5.32; p&lt;0.00001) </text>
<text top="717" left="638" width="184" height="19" font="3">compared with those without </text>
<text top="735" left="638" width="30" height="19" font="3">LGE. </text>
<text top="753" left="638" width="3" height="19" font="3"> </text>
<text top="661" left="860" width="211" height="19" font="3">● Patients with LGE had increased </text>
<text top="679" left="860" width="168" height="19" font="3">overall mortality (OR: 3.27; </text>
<text top="698" left="860" width="181" height="19" font="3">p&lt;0.00001) and increased HF </text>
<text top="716" left="860" width="211" height="19" font="3">hospitalization (OR: 2.91; p=0.02), </text>
<text top="734" left="860" width="228" height="19" font="3">● The annualized event rates for SCA </text>
<text top="753" left="860" width="232" height="19" font="3">was 6.0% in LGE detected patients vs. </text>
<text top="771" left="860" width="235" height="19" font="3">1.2% for those without LGE (p&lt;0.001). </text>
</page>
<page number="103" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">103 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="289" width="118" height="19" font="4"><b>Study type:</b>   Meta-</text>
<text top="127" left="289" width="53" height="19" font="3">Analysis </text>
<text top="145" left="289" width="3" height="19" font="3"> </text>
<text top="164" left="289" width="157" height="19" font="4"><b>Size:</b>  9 studies and 1,488 </text>
<text top="182" left="289" width="53" height="19" font="3">patients </text>
<text top="109" left="461" width="123" height="19" font="3">clinical outcomes in </text>
<text top="127" left="461" width="125" height="19" font="3">patients with NICM  </text>
<text top="145" left="461" width="7" height="19" font="3">  </text>
<text top="164" left="461" width="120" height="19" font="4"><b>Comparator:</b>  <b>  </b>N/A </text>
<text top="201" left="130" width="68" height="19" font="3">● <b>HELP-VT </b></text>
<text top="219" left="130" width="130" height="19" font="3">● Dinov B et al. 2014 </text>
<text top="238" left="130" width="35" height="19" font="3">(175) </text>
<text top="256" left="130" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24211823">● </a></text>
<text top="256" left="142" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24211823">24211823</a></text>
<text top="256" left="203" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24211823"> </a></text>
<text top="274" left="157" width="3" height="19" font="3"> </text>
<text top="292" left="130" width="3" height="19" font="3"> </text>
<text top="201" left="289" width="159" height="19" font="4"><b>Study type:</b> single center, </text>
<text top="219" left="289" width="93" height="19" font="3">observational   </text>
<text top="238" left="289" width="3" height="19" font="3"> </text>
<text top="256" left="289" width="127" height="19" font="4"><b>Size:</b> 227 (63 NICM)  </text>
<text top="201" left="461" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="219" left="461" width="112" height="19" font="3">Patients with SHD </text>
<text top="238" left="461" width="130" height="19" font="3">referred for catheter </text>
<text top="256" left="461" width="159" height="19" font="3">ablation of VT with either </text>
<text top="274" left="461" width="155" height="19" font="3">NICM (N=63) or ischemic </text>
<text top="293" left="461" width="155" height="19" font="3">cardiomyopathy (N=164) </text>
<text top="311" left="461" width="3" height="19" font="4"><b> </b></text>
<text top="329" left="461" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="347" left="461" width="120" height="19" font="3">Failure of informed </text>
<text top="366" left="461" width="52" height="19" font="3">consent </text>
<text top="202" left="638" width="209" height="19" font="4"><b>1</b>°<b> endpoint:</b>  VT free survival at 1 </text>
<text top="220" left="638" width="10" height="19" font="3">y </text>
<text top="238" left="638" width="3" height="19" font="3"> </text>
<text top="257" left="638" width="209" height="19" font="4"><b>Results:</b>  VT free survival 40.5% in </text>
<text top="275" left="638" width="130" height="19" font="3">NICM vs. 57% in ICM </text>
<text top="293" left="638" width="3" height="19" font="3"> </text>
<text top="312" left="638" width="190" height="19" font="3">HR for VT recurrence for NICM </text>
<text top="330" left="638" width="84" height="19" font="3">1.62 (p=0.01) </text>
<text top="348" left="638" width="3" height="19" font="3"> </text>
<text top="201" left="860" width="203" height="19" font="3">● VT free survival worse in NICM </text>
<text top="219" left="860" width="113" height="19" font="3">compared to ICM. </text>
<text top="238" left="860" width="3" height="19" font="3"> </text>
<text top="256" left="860" width="202" height="19" font="3">● Complete noninducibility after </text>
<text top="274" left="860" width="207" height="19" font="3">index procedure predicted better </text>
<text top="293" left="860" width="58" height="19" font="3">outcome </text>
<text top="385" left="130" width="121" height="19" font="3">● Tokuda et al 2012</text>
<text top="383" left="251" width="4" height="21" font="0"> </text>
<text top="403" left="130" width="35" height="19" font="3">(188) </text>
<text top="422" left="130" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22942218">● </a></text>
<text top="422" left="142" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22942218">22942218</a></text>
<text top="422" left="203" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22942218"> </a></text>
<text top="440" left="157" width="3" height="19" font="3"> </text>
<text top="385" left="289" width="116" height="19" font="4"><b>Study type:</b>  single </text>
<text top="403" left="289" width="137" height="19" font="3">center, observational  </text>
<text top="422" left="289" width="3" height="19" font="3"> </text>
<text top="440" left="289" width="68" height="19" font="4"><b>Size:</b>    226 </text>
<text top="385" left="461" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="403" left="461" width="147" height="19" font="3">Patients with NICM and </text>
<text top="422" left="461" width="151" height="19" font="3">sustained monomorphic </text>
<text top="440" left="461" width="149" height="19" font="3">VT referred for catheter </text>
<text top="458" left="461" width="53" height="19" font="3">ablation </text>
<text top="476" left="461" width="3" height="19" font="3"> </text>
<text top="495" left="461" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="385" left="638" width="197" height="19" font="4"><b>1</b>°<b> endpoint:</b>  All cause death or </text>
<text top="404" left="638" width="193" height="19" font="3">heart transplantation following </text>
<text top="422" left="638" width="203" height="19" font="3">ablation; 2° endpoint: composite </text>
<text top="441" left="638" width="192" height="19" font="3">of death, heart transplantation </text>
<text top="459" left="638" width="201" height="19" font="3">and admission for VT recurrence </text>
<text top="477" left="638" width="3" height="19" font="3"> </text>
<text top="495" left="638" width="177" height="19" font="4"><b>Results:</b>  After a mean of 1.4 </text>
<text top="514" left="638" width="126" height="19" font="3">ablation procedures </text>
<text top="532" left="638" width="205" height="19" font="3">1° endpoint (4.4±3.3 y follow-up) </text>
<text top="550" left="638" width="178" height="19" font="3">reached in 66 (29%) patients </text>
<text top="569" left="638" width="198" height="19" font="3">reached the 1° end point: death </text>
<text top="587" left="638" width="197" height="19" font="3">in 50 (21%) and transplant in 16 </text>
<text top="605" left="638" width="31" height="19" font="3">(7%) </text>
<text top="624" left="638" width="3" height="19" font="3"> </text>
<text top="642" left="638" width="202" height="19" font="3">2° endpoint (12 mo): death 10%, </text>
<text top="660" left="638" width="205" height="19" font="3">transplant 3%, VT admission 18% </text>
<text top="679" left="638" width="3" height="19" font="3"> </text>
<text top="385" left="860" width="199" height="19" font="3">● Outcomes of ablation differ in </text>
<text top="403" left="860" width="219" height="19" font="3">individual etiologies of NICM. ARVC </text>
<text top="422" left="860" width="233" height="19" font="3">had better outcomes than DCM for 1° </text>
<text top="440" left="860" width="238" height="19" font="3">(p=0.002) and 2° end points (p=0.004). </text>
<text top="458" left="860" width="227" height="19" font="3">Sarcoidosis had worse outcome than </text>
<text top="476" left="860" width="199" height="19" font="3">DCM for 2° end point (p=0.002). </text>
<text top="698" left="130" width="146" height="19" font="3">● Cantero-Pérez EM, et </text>
<text top="716" left="130" width="87" height="19" font="3">al. 2013 (155) </text>
<text top="734" left="130" width="12" height="19" font="3">●<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24314988"> </a></text>
<text top="734" left="142" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24314988">24314988</a></text>
<text top="734" left="203" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24314988"> </a></text>
<text top="698" left="289" width="131" height="19" font="4"><b>Aim:</b> To evaluate the </text>
<text top="716" left="289" width="151" height="19" font="3">effectiveness of ICDs for </text>
<text top="734" left="289" width="136" height="19" font="3">primary prevention in </text>
<text top="753" left="289" width="153" height="19" font="3">patients with LVEF ≤30% </text>
<text top="698" left="461" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="716" left="461" width="138" height="19" font="3">Records from patients </text>
<text top="734" left="461" width="116" height="19" font="3">accepted for heart </text>
<text top="753" left="461" width="130" height="19" font="3">transplantation from </text>
<text top="771" left="461" width="145" height="19" font="3">January 1, 2006, to July </text>
<text top="698" left="638" width="52" height="19" font="4"><b>Results: </b></text>
<text top="716" left="638" width="161" height="19" font="3">Median follow-up of 77 d  </text>
<text top="734" left="638" width="207" height="19" font="3">overall mortality in the ICD group </text>
<text top="753" left="638" width="194" height="19" font="3">was 7.1% (2/28) and in the non-</text>
<text top="698" left="860" width="209" height="19" font="3">● Appropriate ICD therapies were </text>
<text top="716" left="860" width="203" height="19" font="3">recorded in 42.9% (12/28) in this </text>
<text top="734" left="860" width="74" height="19" font="3">population. </text>
</page>
<page number="104" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">104 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="289" width="135" height="19" font="3">included on the heart </text>
<text top="127" left="289" width="119" height="19" font="3">transplantation list </text>
<text top="145" left="289" width="3" height="19" font="4"><b> </b></text>
<text top="164" left="289" width="28" height="19" font="4"><b>Size:</b></text>
<text top="162" left="317" width="4" height="21" font="0"> </text>
<text top="164" left="321" width="83" height="19" font="3">Patients who </text>
<text top="182" left="289" width="158" height="19" font="3">received ICDs for primary </text>
<text top="200" left="289" width="150" height="19" font="3">prevention (N=28) were </text>
<text top="219" left="289" width="149" height="19" font="3">compared with patients </text>
<text top="237" left="289" width="126" height="19" font="3">without ICDs (N=51)<b> </b></text>
<text top="109" left="461" width="162" height="19" font="3">30, 2012, and whose LVEF </text>
<text top="127" left="461" width="158" height="19" font="3">was &lt;31% were reviewed </text>
<text top="109" left="638" width="172" height="19" font="3">ICD group was 17.6% (9/51; </text>
<text top="127" left="638" width="65" height="19" font="3">p=0.062).  </text>
<text top="145" left="638" width="162" height="19" font="3">Cause of death in patients </text>
<text top="164" left="638" width="85" height="19" font="3">without ICDs: </text>
<text top="182" left="638" width="173" height="19" font="3">Sudden death (5/9, 55.6%),  </text>
<text top="200" left="638" width="105" height="19" font="3">HF (4/9, 44.4%).  </text>
<text top="219" left="638" width="193" height="19" font="3">Cause of death in patients with </text>
<text top="237" left="638" width="90" height="19" font="3">ICDs: HFheart  </text>
<text top="256" left="130" width="128" height="19" font="3">● Fröhlich GM, et al. </text>
<text top="274" left="130" width="30" height="19" font="3">2013</text>
<text top="273" left="160" width="4" height="21" font="0"> </text>
<text top="274" left="164" width="35" height="19" font="3">(156) </text>
<text top="292" left="130" width="12" height="19" font="3">●<a href="https://www.ncbi.nlm.nih.gov/pubmed/23813845"> </a></text>
<text top="292" left="142" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23813845">23813845</a></text>
<text top="292" left="203" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23813845"> </a></text>
<text top="256" left="289" width="29" height="19" font="4"><b>Aim:</b></text>
<text top="254" left="318" width="4" height="21" font="0"> </text>
<text top="256" left="321" width="103" height="19" font="3">To delineate the </text>
<text top="274" left="289" width="139" height="19" font="3">role of ICD therapy for </text>
<text top="292" left="289" width="101" height="19" font="3">the primary and </text>
<text top="311" left="289" width="152" height="19" font="3">secondary prevention of </text>
<text top="329" left="289" width="153" height="19" font="3">SCD in patients listed for </text>
<text top="347" left="289" width="134" height="19" font="3">heart transplantation<b> </b></text>
<text top="366" left="289" width="3" height="19" font="4"><b> </b></text>
<text top="384" left="289" width="83" height="19" font="4"><b>Size:</b> N=1089<b> </b></text>
<text top="256" left="461" width="115" height="19" font="4"><b>Inclusion criteria:  </b></text>
<text top="274" left="461" width="147" height="19" font="3">Patients listed for heart </text>
<text top="292" left="461" width="123" height="19" font="3">transplantation in 2 </text>
<text top="311" left="461" width="151" height="19" font="3">tertiary heart transplant </text>
<text top="329" left="461" width="159" height="19" font="3">centres were enrolled. Of </text>
<text top="347" left="461" width="161" height="19" font="3">550 patients (51%) on the </text>
<text top="366" left="461" width="136" height="19" font="3">transplant list with an </text>
<text top="384" left="461" width="28" height="19" font="3">ICD: </text>
<text top="402" left="461" width="150" height="19" font="3">primary prevention ICD: </text>
<text top="421" left="461" width="47" height="19" font="3">N=216  </text>
<text top="439" left="461" width="136" height="19" font="3">secondary prevention </text>
<text top="457" left="461" width="75" height="19" font="3">ICD: N=334  </text>
<text top="256" left="638" width="52" height="19" font="4"><b>Results: </b></text>
<text top="274" left="638" width="204" height="19" font="3">Median time on the waiting list = </text>
<text top="292" left="638" width="194" height="19" font="3">8 mo (estimated 1-year: 88±3% </text>
<text top="311" left="638" width="205" height="19" font="3">vs. 77±3% vs. 67±3%; p=0.0001).  </text>
<text top="329" left="638" width="203" height="19" font="3">An independent beneficial effect </text>
<text top="347" left="638" width="136" height="19" font="3">of ICDs that was most </text>
<text top="366" left="638" width="202" height="19" font="3">pronounced in patients who had </text>
<text top="384" left="638" width="171" height="19" font="3">received an ICD for primary </text>
<text top="402" left="638" width="174" height="19" font="3">prevention (HR: 0.4, 95% CI: </text>
<text top="421" left="638" width="129" height="19" font="3">0.19–0.85; p=0.016). </text>
<text top="256" left="860" width="233" height="19" font="3">● ICDs appear to be associated with a </text>
<text top="274" left="860" width="208" height="19" font="3">reduction in all-cause mortality in </text>
<text top="292" left="860" width="237" height="19" font="3">patients implanted with the device for </text>
<text top="311" left="860" width="214" height="19" font="3">primary and secondary prevention </text>
<text top="329" left="860" width="217" height="19" font="3">compared to those without an ICD. </text>
<text top="476" left="130" width="144" height="19" font="3">● Gandjbakhch E, et al. </text>
<text top="495" left="130" width="30" height="19" font="3">2016</text>
<text top="493" left="160" width="4" height="21" font="0"> </text>
<text top="495" left="164" width="35" height="19" font="3">(157) </text>
<text top="513" left="130" width="12" height="19" font="3">●<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27344378"> </a></text>
<text top="513" left="142" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27344378">27344378</a></text>
<text top="513" left="203" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27344378"> </a></text>
<text top="476" left="289" width="155" height="19" font="4"><b>Aim: </b>To evaluate the ICD </text>
<text top="495" left="289" width="140" height="19" font="3">benefit on mortality in </text>
<text top="513" left="289" width="147" height="19" font="3">patients with end-stage </text>
<text top="531" left="289" width="113" height="19" font="3">HF listed for heart </text>
<text top="550" left="289" width="101" height="19" font="3">transplantation  </text>
<text top="568" left="289" width="3" height="19" font="4"><b> </b></text>
<text top="587" left="289" width="28" height="19" font="4"><b>Size:</b></text>
<text top="586" left="317" width="23" height="21" font="0"> N=</text>
<text top="588" left="339" width="102" height="19" font="3">380 consecutive </text>
<text top="606" left="289" width="147" height="19" font="3">patients listed for heart </text>
<text top="625" left="289" width="155" height="19" font="3">transplantation between </text>
<text top="643" left="289" width="121" height="19" font="3">2005 and 2009 in A </text>
<text top="661" left="289" width="151" height="19" font="3">tertiary heart transplant </text>
<text top="680" left="289" width="46" height="19" font="3">centre <b> </b></text>
<text top="476" left="461" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="495" left="461" width="147" height="19" font="3">Patients with end-stage </text>
<text top="513" left="461" width="121" height="19" font="3">HF receiving an ICD </text>
<text top="531" left="461" width="137" height="19" font="3">before or within 3 mo </text>
<text top="550" left="461" width="127" height="19" font="3">after being listed for </text>
<text top="568" left="461" width="134" height="19" font="3">heart transplantation </text>
<text top="476" left="638" width="52" height="19" font="4"><b>Results: </b></text>
<text top="495" left="638" width="176" height="19" font="3">15.6% of patients died while </text>
<text top="513" left="638" width="196" height="19" font="3">awaiting heart transplantation.  </text>
<text top="531" left="638" width="209" height="19" font="3">Non-ICD patients presented more </text>
<text top="550" left="638" width="133" height="19" font="3">often haemodynamic </text>
<text top="568" left="638" width="83" height="19" font="3">compromise. </text>
<text top="586" left="638" width="136" height="19" font="3">ICD did not remain an </text>
<text top="605" left="638" width="200" height="19" font="3">independent predictor of death. </text>
<text top="623" left="638" width="155" height="19" font="3">Death by haemodynamic </text>
<text top="641" left="638" width="194" height="19" font="3">compromise (76.3% of deaths), </text>
<text top="660" left="638" width="200" height="19" font="3">which occurred more frequently </text>
<text top="678" left="638" width="195" height="19" font="3">in the non-ICD group (14.7% vs. </text>
<text top="696" left="638" width="155" height="19" font="3">5.8%; log-rank p=0.002).  </text>
<text top="714" left="638" width="3" height="19" font="3"> </text>
<text top="733" left="638" width="202" height="19" font="3">Unknown/arrhythmic deaths did </text>
<text top="751" left="638" width="194" height="19" font="3">not differ significantly between </text>
<text top="476" left="860" width="210" height="19" font="3">● Need for mechanical circulatory </text>
<text top="495" left="860" width="222" height="19" font="3">support (p&lt;0.001), low EF (p=0.001) </text>
<text top="513" left="860" width="211" height="19" font="3">and registration on the regular list </text>
<text top="531" left="860" width="231" height="19" font="3">(p=0.008) were the only independent </text>
<text top="550" left="860" width="124" height="19" font="3">predictors of death. </text>
<text top="568" left="860" width="9" height="19" font="3">●</text>
<text top="566" left="869" width="4" height="21" font="0"> </text>
<text top="568" left="873" width="218" height="19" font="3">ICD-related complications occurred </text>
<text top="586" left="860" width="237" height="19" font="3">in 21.4% of patients, mainly as a result </text>
<text top="605" left="860" width="207" height="19" font="3">of postoperative worsening of HF </text>
<text top="623" left="860" width="54" height="19" font="3">(11.9%). </text>
</page>
<page number="105" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">105 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="638" width="191" height="19" font="3">the two groups (3.9% vs. 1.7%; </text>
<text top="127" left="638" width="111" height="19" font="3">log-rank p=0.21).  </text>
<text top="149" left="130" width="127" height="19" font="3">● Vakil K, et al. 2016 </text>
<text top="168" left="130" width="35" height="19" font="3">(158) </text>
<text top="149" left="289" width="116" height="19" font="4"><b>Aim:</b> To assess the </text>
<text top="168" left="289" width="152" height="19" font="3">impact of ICD on waitlist </text>
<text top="186" left="289" width="127" height="19" font="3">mortality in patients </text>
<text top="204" left="289" width="94" height="19" font="3">listed for heart </text>
<text top="222" left="289" width="98" height="19" font="3">transplantation </text>
<text top="241" left="289" width="3" height="19" font="4"><b> </b></text>
<text top="259" left="289" width="94" height="19" font="4"><b>Size:</b> N=32,599<b> </b></text>
<text top="149" left="461" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="168" left="461" width="149" height="19" font="3">Adults (age ≥18 y) listed </text>
<text top="186" left="461" width="117" height="19" font="3">for first-time heart </text>
<text top="204" left="461" width="156" height="19" font="3">transplantation in the US </text>
<text top="222" left="461" width="160" height="19" font="3">between January 1, 1999, </text>
<text top="241" left="461" width="157" height="19" font="3">and September 30, 2014, </text>
<text top="259" left="461" width="129" height="19" font="3">were retrospectively </text>
<text top="277" left="461" width="119" height="19" font="3">identified from the </text>
<text top="296" left="461" width="163" height="19" font="3">United Network for Organ </text>
<text top="314" left="461" width="102" height="19" font="3">Sharing registry. </text>
<text top="149" left="638" width="52" height="19" font="4"><b>Results: </b></text>
<text top="168" left="638" width="192" height="19" font="3">Median follow-up of 154 days,  </text>
<text top="186" left="638" width="202" height="19" font="3">3,638 patients (11%) died on the </text>
<text top="204" left="638" width="201" height="19" font="3">waitlist (9% in ICD group vs. 15% </text>
<text top="222" left="638" width="172" height="19" font="3">in no-ICD group; p&lt;0.0001), </text>
<text top="241" left="638" width="192" height="19" font="3">whereas 63% underwent heart </text>
<text top="259" left="638" width="105" height="19" font="3">transplantation.  </text>
<text top="277" left="638" width="194" height="19" font="3">An ICD at listing was associated </text>
<text top="296" left="638" width="184" height="19" font="3">with an adjusted 13% relative </text>
<text top="314" left="638" width="200" height="19" font="3">reduction in mortality (HR: 0.87; </text>
<text top="332" left="638" width="124" height="19" font="3">95% CI: 0.80–0.94).  </text>
<text top="149" left="860" width="9" height="19" font="3">●</text>
<text top="148" left="869" width="4" height="21" font="0"> </text>
<text top="149" left="873" width="199" height="19" font="3">In the subgroup of patients with </text>
<text top="168" left="860" width="221" height="19" font="3">LVAD (N= 9,478), having an ICD was </text>
<text top="186" left="860" width="202" height="19" font="3">associated with an adjusted 19% </text>
<text top="204" left="860" width="215" height="19" font="3">relative reduction in mortality (HR: </text>
<text top="222" left="860" width="155" height="19" font="3">0.81; 95% CI: 0.70–0.94). </text>
<text top="351" left="130" width="115" height="19" font="3">● Oloriz et al 2014 </text>
<text top="370" left="130" width="35" height="19" font="3">(189) </text>
<text top="388" left="130" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24785410">● </a></text>
<text top="388" left="142" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24785410">24785410</a></text>
<text top="388" left="203" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24785410"> </a></text>
<text top="406" left="130" width="3" height="19" font="3"> </text>
<text top="351" left="289" width="116" height="19" font="4"><b>Study type:</b>  single </text>
<text top="370" left="289" width="133" height="19" font="3">center, observational </text>
<text top="388" left="289" width="3" height="19" font="3"> </text>
<text top="406" left="289" width="54" height="19" font="4"><b>Size:</b>  87 </text>
<text top="351" left="461" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="370" left="461" width="147" height="19" font="3">Patients with NICM and </text>
<text top="388" left="461" width="115" height="19" font="3">drug refractory VT </text>
<text top="406" left="461" width="132" height="19" font="3">treated with ablation </text>
<text top="425" left="461" width="3" height="19" font="3"> </text>
<text top="443" left="461" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="352" left="638" width="177" height="19" font="4"><b>1</b>°<b> endpoint:</b>  VT recurrence, </text>
<text top="370" left="638" width="155" height="19" font="3">stratified to scar location </text>
<text top="389" left="638" width="187" height="19" font="3">(anteroseptal vs. basal lateral) </text>
<text top="407" left="638" width="196" height="19" font="3">determined by unipolar voltage </text>
<text top="425" left="638" width="57" height="19" font="3">mapping </text>
<text top="444" left="638" width="3" height="19" font="3"> </text>
<text top="462" left="638" width="170" height="19" font="4"><b>Results:</b>  Over a mean 1.5 y </text>
<text top="480" left="638" width="173" height="19" font="3">follow up, VT recurred in 44 </text>
<text top="499" left="638" width="194" height="19" font="3">patients (51%) during a median </text>
<text top="517" left="638" width="196" height="19" font="3">follow-up of 1.5 y. Anteroseptal </text>
<text top="535" left="638" width="196" height="19" font="3">scar was associated with higher </text>
<text top="554" left="638" width="199" height="19" font="3">VT recurrence (74% vs. 25%; log-</text>
<text top="572" left="638" width="88" height="19" font="3">rank p&lt;0.001) </text>
<text top="590" left="638" width="3" height="19" font="3"> </text>
<text top="609" left="638" width="142" height="19" font="3">Death occurred in 15% </text>
<text top="627" left="638" width="3" height="19" font="3"> </text>
<text top="351" left="860" width="192" height="19" font="3">● Multivariate predictors of VT </text>
<text top="370" left="860" width="224" height="19" font="3">recurrence included electrical storm </text>
<text top="388" left="860" width="225" height="19" font="3">(HR: 3.211; p=0.001) and NHYA class </text>
<text top="406" left="860" width="213" height="19" font="3">(HR: 1.608; p=0.018), anteroseptal </text>
<text top="425" left="860" width="206" height="19" font="3">scar pattern (HR: 5.547; p&lt;0.001) </text>
<text top="646" left="130" width="121" height="19" font="3">● Proietti et al 2015</text>
<text top="644" left="251" width="4" height="21" font="0"> </text>
<text top="664" left="130" width="35" height="19" font="3">(190) </text>
<text top="683" left="130" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25488957">● </a></text>
<text top="683" left="142" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25488957">25488957</a></text>
<text top="683" left="203" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25488957"> </a></text>
<text top="701" left="130" width="3" height="19" font="3"> </text>
<text top="646" left="289" width="159" height="19" font="4"><b>Study type:</b> single center, </text>
<text top="664" left="289" width="93" height="19" font="3">observational   </text>
<text top="683" left="289" width="3" height="19" font="3"> </text>
<text top="701" left="289" width="127" height="19" font="4"><b>Size:</b>  142 (55 NICM) </text>
<text top="646" left="461" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="664" left="461" width="139" height="19" font="3">Patients with ischemic </text>
<text top="683" left="461" width="126" height="19" font="3">cardiomyopathyand </text>
<text top="701" left="461" width="112" height="19" font="3">NICM referred for </text>
<text top="719" left="461" width="149" height="19" font="3">catheter ablation for VT </text>
<text top="737" left="461" width="3" height="19" font="3"> </text>
<text top="756" left="461" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="647" left="638" width="177" height="19" font="4"><b>1</b>°<b> endpoint:</b>  VT recurrence, </text>
<text top="665" left="638" width="207" height="19" font="3">determined by ICD interrogations </text>
<text top="683" left="638" width="102" height="19" font="3">over 641±301 d. </text>
<text top="702" left="638" width="3" height="19" font="3"> </text>
<text top="720" left="638" width="197" height="19" font="4"><b>Results:</b>  Recurrent VT occurred </text>
<text top="738" left="638" width="179" height="19" font="3">more frequently in the NICM </text>
<text top="757" left="638" width="195" height="19" font="3">group 51% than in the ischemic </text>
<text top="646" left="860" width="235" height="19" font="3">● Results of substrate guided ablation </text>
<text top="664" left="860" width="227" height="19" font="3">less favorable in NICM than ischemic </text>
<text top="683" left="860" width="156" height="19" font="3">cardiomyopathy patients </text>
</page>
<page number="106" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">106 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="638" width="172" height="19" font="3">cardiomyopathy group 26% </text>
<text top="127" left="638" width="55" height="19" font="3">(p=0.03) </text>
<text top="145" left="638" width="3" height="19" font="3"> </text>
<text top="164" left="638" width="155" height="19" font="3">Acute results (defined by </text>
<text top="182" left="638" width="202" height="19" font="3">response to PES) correlated with </text>
<text top="200" left="638" width="198" height="19" font="3">likelihood of recurrence: for the </text>
<text top="219" left="638" width="178" height="19" font="3">NICM group, recurrence was </text>
<text top="237" left="638" width="187" height="19" font="3">observed in 7, 75 and 100% of </text>
<text top="255" left="638" width="183" height="19" font="3">successful, partially successful</text>
<text top="257" left="821" width="3" height="17" font="7"> </text>
<text top="273" left="638" width="111" height="17" font="7">and failed ablations </text>
<text top="291" left="130" width="127" height="19" font="3">● Haqqani et al 2011</text>
<text top="289" left="257" width="4" height="21" font="0"> </text>
<text top="309" left="130" width="35" height="19" font="3">(191) </text>
<text top="327" left="130" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21392586">● </a></text>
<text top="327" left="142" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21392586">21392586</a></text>
<text top="327" left="203" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21392586"> </a></text>
<text top="346" left="130" width="3" height="19" font="3"> </text>
<text top="291" left="289" width="159" height="19" font="4"><b>Study type:</b> single center, </text>
<text top="309" left="289" width="90" height="19" font="3">observational  </text>
<text top="327" left="289" width="3" height="19" font="3"> </text>
<text top="345" left="289" width="54" height="19" font="4"><b>Size:</b>  31 </text>
<text top="291" left="461" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="309" left="461" width="147" height="19" font="3">Patients with NICM and </text>
<text top="327" left="461" width="153" height="19" font="3">VT treated with catheter </text>
<text top="346" left="461" width="161" height="19" font="3">ablation who had isolated </text>
<text top="364" left="461" width="154" height="19" font="3">intra-septal scar (11.65% </text>
<text top="382" left="461" width="52" height="19" font="3">of total) </text>
<text top="400" left="461" width="3" height="19" font="3"> </text>
<text top="419" left="461" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="291" left="638" width="204" height="19" font="4"><b>1</b>°<b> endpoint:</b>  VT recurrence over </text>
<text top="310" left="638" width="175" height="19" font="3">mean followup of 20±28 mo </text>
<text top="328" left="638" width="3" height="19" font="3"> </text>
<text top="346" left="638" width="205" height="19" font="4"><b>Results:</b>  Following a mean of 1.6 </text>
<text top="365" left="638" width="149" height="19" font="3">ablation procedures, VT </text>
<text top="383" left="638" width="205" height="19" font="3">recurrence was observed in 32%; </text>
<text top="401" left="638" width="167" height="19" font="3">death and heart transplant </text>
<text top="420" left="638" width="157" height="19" font="3">occurred in 26% and 16% </text>
<text top="438" left="638" width="77" height="19" font="3">respectively </text>
<text top="291" left="860" width="218" height="19" font="3">● Isolated septal substrate in NICM </text>
<text top="309" left="860" width="219" height="19" font="3">portended a poor outcome, both in </text>
<text top="327" left="860" width="236" height="19" font="3">terms of VT recurrence and transplant </text>
<text top="346" left="860" width="150" height="19" font="3">free survival in followup </text>
<text top="457" left="130" width="115" height="19" font="3">● Kuhne et al 2010</text>
<text top="455" left="244" width="4" height="21" font="0"> </text>
<text top="475" left="130" width="35" height="19" font="3">(192) </text>
<text top="494" left="130" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20384656">● </a></text>
<text top="494" left="142" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20384656">20384656</a></text>
<text top="494" left="203" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20384656"> </a></text>
<text top="457" left="289" width="159" height="19" font="4"><b>Study type: </b>single center, </text>
<text top="475" left="289" width="97" height="19" font="3">observational    </text>
<text top="494" left="289" width="3" height="19" font="3"> </text>
<text top="512" left="289" width="61" height="19" font="4"><b>Size:</b>  35   </text>
<text top="457" left="461" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="475" left="461" width="147" height="19" font="3">Patients with NICM and </text>
<text top="494" left="461" width="153" height="19" font="3">VT treated with catheter </text>
<text top="512" left="461" width="53" height="19" font="3">ablation </text>
<text top="530" left="461" width="3" height="19" font="3"> </text>
<text top="549" left="461" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="458" left="638" width="204" height="19" font="4"><b>1</b>°<b> endpoint:</b>  VT recurrence over </text>
<text top="476" left="638" width="175" height="19" font="3">mean followup of 18±13 mo </text>
<text top="494" left="638" width="3" height="19" font="3"> </text>
<text top="513" left="638" width="156" height="19" font="4"><b>Results:</b>  Recurrence was </text>
<text top="531" left="638" width="206" height="19" font="3">observed in 57%. In patients who </text>
<text top="549" left="638" width="169" height="19" font="3">had isolated late potentials </text>
<text top="568" left="638" width="199" height="19" font="3">(targeted for ablation), freedom </text>
<text top="586" left="638" width="189" height="19" font="3">from VT and major arrhythmia </text>
<text top="604" left="638" width="169" height="19" font="3">related adverse events was </text>
<text top="623" left="638" width="181" height="19" font="3">improved compared to those </text>
<text top="641" left="638" width="191" height="19" font="3">without identified isolated late </text>
<text top="659" left="638" width="65" height="19" font="3">potentials </text>
<text top="443" left="860" width="3" height="19" font="3"> </text>
<text top="678" left="130" width="107" height="19" font="3">● Cano et al 2009</text>
<text top="677" left="237" width="4" height="21" font="0"> </text>
<text top="678" left="240" width="35" height="19" font="3">(193) </text>
<text top="697" left="130" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19695457">● </a></text>
<text top="697" left="142" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19695457">19695457</a></text>
<text top="697" left="203" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19695457"> </a></text>
<text top="715" left="157" width="3" height="19" font="3"> </text>
<text top="678" left="289" width="159" height="19" font="4"><b>Study type:</b> single center, </text>
<text top="697" left="289" width="97" height="19" font="3">observational    </text>
<text top="715" left="289" width="3" height="19" font="3"> </text>
<text top="733" left="289" width="57" height="19" font="4"><b>Size:</b>  22  </text>
<text top="678" left="461" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="697" left="461" width="147" height="19" font="3">Patients with NICM and </text>
<text top="715" left="461" width="119" height="19" font="3">VT suspected to be </text>
<text top="733" left="461" width="153" height="19" font="3">epicardial in origin (Prior </text>
<text top="752" left="461" width="113" height="19" font="3">failed endocardial </text>
<text top="679" left="638" width="204" height="19" font="4"><b>1</b>°<b> endpoint:</b>  VT recurrence over </text>
<text top="697" left="638" width="171" height="19" font="3">mean follow up of 18±7 mo </text>
<text top="716" left="638" width="161" height="19" font="3">following endocardial and </text>
<text top="734" left="638" width="116" height="19" font="3">epicardial ablation </text>
<text top="752" left="638" width="3" height="19" font="3"> </text>
<text top="678" left="860" width="220" height="19" font="3">● The VT substrate in NICM is often </text>
<text top="697" left="860" width="210" height="19" font="3">more prominent on the epicardial </text>
<text top="715" left="860" width="182" height="19" font="3">than the endocardial surface. </text>
<text top="733" left="860" width="199" height="19" font="3">Epicardial ablation may improve </text>
<text top="752" left="860" width="230" height="19" font="3">outcome in selected patients with VT </text>
<text top="770" left="860" width="141" height="19" font="3">in the setting of NICM. </text>
</page>
<page number="107" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">107 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="461" width="98" height="19" font="3">ablation or ECG </text>
<text top="127" left="461" width="158" height="19" font="3">characteristics during VT) </text>
<text top="145" left="461" width="3" height="19" font="3"> </text>
<text top="164" left="461" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="109" left="638" width="166" height="19" font="4"><b>Results:</b>  Freedom from VT </text>
<text top="127" left="638" width="206" height="19" font="3">recurrence was observed in 15 of </text>
<text top="145" left="638" width="207" height="19" font="3">21 patients in whom any ablation </text>
<text top="164" left="638" width="210" height="19" font="3">was performed, and 14 of 18 with </text>
<text top="182" left="638" width="116" height="19" font="3">epicardial ablation </text>
<text top="201" left="130" width="140" height="19" font="3">● Delacretaz et al 2000</text>
<text top="199" left="270" width="4" height="21" font="0"> </text>
<text top="219" left="130" width="35" height="19" font="3">(194) </text>
<text top="238" left="130" width="9" height="19" font="3">●</text>
<text top="236" left="139" width="4" height="21" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10695454"> </a></text>
<text top="238" left="142" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10695454">10695454</a></text>
<text top="238" left="203" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10695454"> </a></text>
<text top="256" left="157" width="3" height="19" font="3"> </text>
<text top="201" left="289" width="159" height="19" font="4"><b>Study type:</b> single center, </text>
<text top="219" left="289" width="97" height="19" font="3">observational    </text>
<text top="238" left="289" width="3" height="19" font="3"> </text>
<text top="256" left="289" width="61" height="19" font="4"><b>Size:</b>  26   </text>
<text top="201" left="461" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="219" left="461" width="147" height="19" font="3">Patients with NICM and </text>
<text top="238" left="461" width="153" height="19" font="3">VT treated with catheter </text>
<text top="256" left="461" width="53" height="19" font="3">ablation </text>
<text top="274" left="461" width="3" height="19" font="3"> </text>
<text top="292" left="461" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="202" left="638" width="204" height="19" font="4"><b>1</b>°<b> endpoint:</b>  VT recurrence over </text>
<text top="220" left="638" width="175" height="19" font="3">mean followup of 15±12 mo </text>
<text top="238" left="638" width="3" height="19" font="3"> </text>
<text top="257" left="638" width="172" height="19" font="4"><b>Results:</b>  VT recurrence was </text>
<text top="275" left="638" width="184" height="19" font="3">observed in 23%, but differed </text>
<text top="293" left="638" width="206" height="19" font="3">depending on VT mechanism: 40, </text>
<text top="312" left="638" width="179" height="19" font="3">0 and 14% in scar related VT, </text>
<text top="330" left="638" width="170" height="19" font="3">focal VT and bundle branch </text>
<text top="348" left="638" width="133" height="19" font="3">reentry, respectively. </text>
<text top="201" left="860" width="238" height="19" font="3">● Recurrent monomorphic VT in NICM </text>
<text top="219" left="860" width="221" height="19" font="3">can be focal or reentrant; reentrant </text>
<text top="238" left="860" width="211" height="19" font="3">causes can be scar related or 2° to </text>
<text top="256" left="860" width="144" height="19" font="3">bundle branch reentry. </text>
<text top="367" left="115" width="4" height="21" font="0"> </text>
<text top="423" left="115" width="542" height="21" font="2"><b>Data Supplement 25. RCTs Secondary Prevention SCD in NICM – (Section 7.2.1) </b></text>
<text top="444" left="129" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="463" left="154" width="55" height="19" font="4"><b>Author;  </b></text>
<text top="481" left="132" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="444" left="271" width="88" height="19" font="4"><b>Aim of Study; </b></text>
<text top="463" left="277" width="76" height="19" font="4"><b>Study Type; </b></text>
<text top="481" left="271" width="89" height="19" font="4"><b>Study Size (N) </b></text>
<text top="444" left="470" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="444" left="739" width="108" height="19" font="4"><b>Endpoint Results </b></text>
<text top="463" left="721" width="148" height="19" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="481" left="725" width="136" height="19" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="499" left="769" width="49" height="19" font="4"><b>95% CI) </b></text>
<text top="445" left="922" width="152" height="19" font="4"><b>Relevant 2</b>°<b> Endpoint (if </b></text>
<text top="463" left="980" width="35" height="19" font="4"><b>any); </b></text>
<text top="482" left="940" width="116" height="19" font="4"><b>Study Limitations; </b></text>
<text top="500" left="948" width="99" height="19" font="4"><b>Adverse Events </b></text>
<text top="519" left="123" width="47" height="19" font="3">● <b>AVID </b></text>
<text top="537" left="123" width="72" height="19" font="3">● The AVID </text>
<text top="556" left="123" width="82" height="19" font="3">Investigators </text>
<text top="574" left="123" width="30" height="19" font="3">1997</text>
<text top="572" left="154" width="4" height="21" font="0"> </text>
<text top="574" left="157" width="39" height="19" font="3">(131)  </text>
<text top="592" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9411221">● </a></text>
<text top="592" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9411221">9411221</a></text>
<text top="592" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9411221"> </a></text>
<text top="611" left="123" width="3" height="19" font="3"> </text>
<text top="519" left="250" width="110" height="19" font="4"><b>Aim:</b>  To examine </text>
<text top="537" left="250" width="127" height="19" font="3">the effect on overall </text>
<text top="556" left="250" width="103" height="19" font="3">survival of initial </text>
<text top="574" left="250" width="124" height="19" font="3">therapy with an ICD </text>
<text top="592" left="250" width="112" height="19" font="3">as compared with </text>
<text top="611" left="250" width="94" height="19" font="3">amiodarone or </text>
<text top="629" left="250" width="112" height="19" font="3">sotalol in patients </text>
<text top="647" left="250" width="130" height="19" font="3">resuscitated from VF </text>
<text top="666" left="250" width="103" height="19" font="3">or symptomatic, </text>
<text top="684" left="250" width="111" height="19" font="3">sustained VT with </text>
<text top="702" left="250" width="90" height="19" font="3">hemodynamic </text>
<text top="721" left="250" width="83" height="19" font="3">compromise. </text>
<text top="739" left="250" width="3" height="19" font="3"> </text>
<text top="757" left="250" width="108" height="19" font="4"><b>Study type:</b>   RCT </text>
<text top="775" left="250" width="3" height="19" font="3"> </text>
<text top="519" left="393" width="232" height="19" font="4"><b>Inclusion criteria:</b>  patients who were </text>
<text top="537" left="393" width="259" height="19" font="3">resuscitated from near-fatal VF; sustained </text>
<text top="556" left="393" width="254" height="19" font="3">VT with syncope; or sustained VT with an </text>
<text top="574" left="393" width="231" height="19" font="3">LVEF ≤0.40 and symptoms suggesting </text>
<text top="592" left="393" width="217" height="19" font="3">severe hemodynamic compromise. </text>
<text top="611" left="393" width="3" height="19" font="4"><b> </b></text>
<text top="629" left="393" width="257" height="19" font="4"><b>Exclusion criteria:</b> arrhythmia was judged </text>
<text top="647" left="393" width="253" height="19" font="3">to have a transient or correctable cause,  </text>
<text top="666" left="393" width="253" height="19" font="3">excessively high risk (life expectancy &lt;l y, </text>
<text top="684" left="393" width="268" height="19" font="3">class IV CHF, awaiting a heart transplant, or </text>
<text top="702" left="393" width="271" height="19" font="3">requiring a balloon pump, other mechanical </text>
<text top="721" left="393" width="268" height="19" font="3">means, or inotropic drug administration for </text>
<text top="739" left="393" width="146" height="19" font="3">hemodynamic support) </text>
<text top="757" left="393" width="241" height="19" font="3">or excessively low risk (event occurring </text>
<text top="775" left="393" width="269" height="19" font="3">within 5 d of cardiac surgery or angioplasty, </text>
<text top="520" left="679" width="136" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Survival </text>
<text top="538" left="679" width="3" height="19" font="3"> </text>
<text top="556" left="679" width="228" height="19" font="4"><b>Results:</b>  Overall survival was greater </text>
<text top="575" left="679" width="185" height="19" font="3">with the ICD, with unadjusted </text>
<text top="593" left="679" width="179" height="19" font="3">estimates of 89.3 percent, as </text>
<text top="611" left="679" width="205" height="19" font="3">compared with 82.3% in the AAD </text>
<text top="630" left="679" width="218" height="19" font="3">group at 1 y, 81.6% vs 74.7% at 2 y, </text>
<text top="648" left="679" width="219" height="19" font="3">and 75.4% vs 64.1% at 3 y (p&lt;0.02). </text>
<text top="667" left="679" width="200" height="19" font="3">The corresponding reductions in </text>
<text top="685" left="679" width="194" height="19" font="3">mortality (with 95% confidence </text>
<text top="703" left="679" width="210" height="19" font="3">limits) with the ICD were 39±20%, </text>
<text top="721" left="679" width="141" height="19" font="3">27±21%, and 31±21%.<b>  </b></text>
<text top="519" left="921" width="122" height="19" font="3">● Study terminated </text>
<text top="537" left="921" width="150" height="19" font="3">early after 1016 of 1200 </text>
<text top="556" left="921" width="107" height="19" font="3">patients enrolled </text>
<text top="574" left="921" width="137" height="19" font="3">● 81% of patients had </text>
<text top="592" left="921" width="29" height="19" font="3">CAD </text>
<text top="611" left="921" width="3" height="19" font="3"> </text>
</page>
<page number="108" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">108 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="250" width="414" height="19" font="4"><b>Size:</b>    1016 patients  or occurring in-hospital within 5 d after MI), </text>
<text top="127" left="393" width="257" height="19" font="3">had a previous ICD implant (or attempted </text>
<text top="145" left="393" width="272" height="19" font="3">implant), chronic serious bacterial infection, </text>
<text top="164" left="393" width="267" height="19" font="3">or were unable to give verbal assent due to </text>
<text top="182" left="393" width="258" height="19" font="3">neurologic impairment. Contraindications </text>
<text top="200" left="393" width="101" height="19" font="3">to amiodarone.<b>  </b></text>
<text top="218" left="393" width="3" height="19" font="4"><b> </b></text>
<text top="237" left="393" width="193" height="19" font="4"><b>Intervention:</b> Therapy with ICD </text>
<text top="255" left="393" width="7" height="19" font="3">  </text>
<text top="273" left="393" width="265" height="19" font="4"><b>Comparator:</b>  <b>  </b>AAD amiodarone or sotalol, </text>
<text top="292" left="393" width="224" height="19" font="3">but only 2.6% received sotalol, most </text>
<text top="310" left="393" width="133" height="19" font="3">received amiodarone </text>
<text top="329" left="123" width="44" height="19" font="3">● <b>CIDS </b></text>
<text top="347" left="123" width="95" height="19" font="3">● Conolly et al. </text>
<text top="366" left="123" width="69" height="19" font="3">2000 (132) </text>
<text top="384" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10725290">● </a></text>
<text top="384" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10725290">10725290</a></text>
<text top="384" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10725290"> </a></text>
<text top="402" left="123" width="3" height="19" font="3"> </text>
<text top="329" left="250" width="112" height="19" font="4"><b>Aim:</b>  To compare </text>
<text top="347" left="250" width="113" height="19" font="3">the efficacy of the </text>
<text top="366" left="250" width="128" height="19" font="3">ICD and amiodarone </text>
<text top="384" left="250" width="115" height="19" font="3">for the prevention </text>
<text top="402" left="250" width="123" height="19" font="3">of death in patients </text>
<text top="421" left="250" width="86" height="19" font="3">with previous </text>
<text top="439" left="250" width="62" height="19" font="3">sustained </text>
<text top="457" left="250" width="69" height="19" font="3">ventricular </text>
<text top="476" left="250" width="71" height="19" font="3">arrhythmia </text>
<text top="494" left="250" width="3" height="19" font="3"> </text>
<text top="512" left="250" width="105" height="19" font="4"><b>Study type:</b> RCT  </text>
<text top="531" left="250" width="3" height="19" font="3"> </text>
<text top="549" left="250" width="121" height="19" font="4"><b>Size:</b>    659 patients </text>
<text top="329" left="393" width="262" height="19" font="4"><b>Inclusion criteria:</b>  in the absence of either </text>
<text top="347" left="393" width="258" height="19" font="3">recent AMI or electrolyte imbalance, they </text>
<text top="366" left="393" width="221" height="19" font="3">manifested any of the following: (1) </text>
<text top="384" left="393" width="222" height="19" font="3">documented VF; (2) OHCA requiring </text>
<text top="402" left="393" width="208" height="19" font="3">defibrillation or cardioversion; (3) </text>
<text top="421" left="393" width="272" height="19" font="3">documented, sustained VT causing syncope; </text>
<text top="439" left="393" width="249" height="19" font="3">(4) other documented, sustained VT at a </text>
<text top="457" left="393" width="271" height="19" font="3">rate ≥150 beats/min, causing presyncope or </text>
<text top="476" left="393" width="267" height="19" font="3">angina in a patient with a LVEF ≤35%; or (5) </text>
<text top="494" left="393" width="242" height="19" font="3">unmonitored syncope with subsequent </text>
<text top="512" left="393" width="254" height="19" font="3">documentation of either spontaneous VT </text>
<text top="531" left="393" width="267" height="19" font="3">≥10 s or sustained (≥30 s) monomorphic VT </text>
<text top="549" left="393" width="223" height="19" font="3">induced by programmed ventricular </text>
<text top="567" left="393" width="80" height="19" font="3">stimulation.  </text>
<text top="585" left="393" width="3" height="19" font="4"><b> </b></text>
<text top="604" left="393" width="252" height="19" font="4"><b>Exclusion criteria:</b> (1) ICD or amiodarone </text>
<text top="622" left="393" width="255" height="19" font="3">not considered appropriate, (2) excessive </text>
<text top="640" left="393" width="262" height="19" font="3">perioperative risk for ICD implantation; (3) </text>
<text top="659" left="393" width="269" height="19" font="3">previous amiodarone therapy for ≥6 wk; (4) </text>
<text top="677" left="393" width="265" height="19" font="3">nonarrhythmic medical condition making 1 </text>
<text top="695" left="393" width="199" height="19" font="3">y survival unlikely, and (5) LQTS. </text>
<text top="714" left="393" width="3" height="19" font="4"><b> </b></text>
<text top="732" left="393" width="113" height="19" font="4"><b> Intervention:</b> ICD </text>
<text top="750" left="393" width="3" height="19" font="3"> </text>
<text top="769" left="393" width="175" height="19" font="3"> <b>Comparator:</b>  <b>  </b>Amiodarone </text>
<text top="330" left="679" width="225" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Death from any cause. </text>
<text top="348" left="679" width="220" height="19" font="4"><b>Results:</b>  A nonsignificant reduction </text>
<text top="367" left="679" width="205" height="19" font="3">in the risk of death was observed </text>
<text top="385" left="679" width="185" height="19" font="3">with the ICD, from 10.2%/y to </text>
<text top="403" left="679" width="206" height="19" font="3">8.3%/y (RRR: 19.7; 95% CI: -7.7%–</text>
<text top="422" left="679" width="196" height="19" font="3">40%; p=0.142). A nonsignificant </text>
<text top="440" left="679" width="212" height="19" font="3">reduction in the risk of arrhythmic </text>
<text top="458" left="679" width="225" height="19" font="3">death was observed, from 4.5%/y to </text>
<text top="476" left="679" width="217" height="19" font="3">3.0%/y (RRR :32.8%; 95% CI: -7.2%–</text>
<text top="495" left="679" width="106" height="19" font="3">57.8%; p=0.094). </text>
<text top="513" left="679" width="3" height="19" font="3"> </text>
<text top="531" left="679" width="3" height="19" font="4"><b> </b></text>
<text top="329" left="921" width="124" height="19" font="3">● 82% had ischemic </text>
<text top="347" left="921" width="56" height="19" font="3">etiology  </text>
<text top="366" left="921" width="3" height="19" font="3"> </text>
<text top="384" left="921" width="3" height="19" font="3"> </text>
<text top="402" left="921" width="3" height="19" font="3"> </text>
</page>
<page number="109" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">109 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="49" height="19" font="3">● <b>CASH </b></text>
<text top="127" left="123" width="112" height="19" font="3">● Kuck et al. 2000 </text>
<text top="145" left="123" width="35" height="19" font="3">(133) </text>
<text top="164" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10942742">● </a></text>
<text top="164" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10942742">10942742</a></text>
<text top="164" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10942742"> </a></text>
<text top="182" left="123" width="3" height="19" font="3"> </text>
<text top="109" left="250" width="113" height="19" font="4"><b>Aim:</b>  to study the </text>
<text top="127" left="250" width="109" height="19" font="3">impact on overall </text>
<text top="145" left="250" width="103" height="19" font="3">survival of initial </text>
<text top="164" left="250" width="124" height="19" font="3">therapy with an ICD </text>
<text top="182" left="250" width="112" height="19" font="3">as compared with </text>
<text top="200" left="250" width="104" height="19" font="3">that with 3 AAD. </text>
<text top="219" left="250" width="3" height="19" font="3"> </text>
<text top="237" left="250" width="108" height="19" font="4"><b>Study type:</b>   RCT </text>
<text top="255" left="250" width="3" height="19" font="3"> </text>
<text top="273" left="250" width="121" height="19" font="4"><b>Size:</b>    288 patients </text>
<text top="109" left="393" width="246" height="19" font="4"><b>Inclusion criteria:</b>  patients resuscitated </text>
<text top="127" left="393" width="249" height="19" font="3">from CA 2° to documented sustained VA </text>
<text top="145" left="393" width="3" height="19" font="3"> </text>
<text top="164" left="393" width="267" height="19" font="4"><b>Exclusion criteria:</b>  If CA occurred within 72 </text>
<text top="182" left="393" width="246" height="19" font="3">h of an AMI, cardiac surgery, electrolyte </text>
<text top="200" left="393" width="230" height="19" font="3">abnormalities, or proarrhythmic drug </text>
<text top="219" left="393" width="43" height="19" font="3">effect. </text>
<text top="237" left="393" width="3" height="19" font="4"><b> </b></text>
<text top="255" left="393" width="164" height="19" font="4"><b> Intervention:</b> ICD therapy </text>
<text top="273" left="393" width="7" height="19" font="3">  </text>
<text top="292" left="393" width="265" height="19" font="4"><b>Comparator:</b>  <b>  </b>amiodarone, metoprolol, or </text>
<text top="310" left="393" width="260" height="19" font="3">propafenone. Assignment to propafenone </text>
<text top="328" left="393" width="273" height="19" font="3">was in March 1992, after an interim analysis </text>
<text top="347" left="393" width="249" height="19" font="3">showed a 61% higher all-cause mortality </text>
<text top="365" left="393" width="224" height="19" font="3">rate than in 61 ICD patients during a </text>
<text top="383" left="393" width="130" height="19" font="3">followup of 11.3 mo. </text>
<text top="109" left="679" width="85" height="19" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="109" left="764" width="131" height="19" font="14">The 1° end point was </text>
<text top="128" left="679" width="123" height="19" font="14">all-cause mortality.  </text>
<text top="146" left="679" width="56" height="19" font="4"><b>Results:</b>  </text>
<text top="146" left="735" width="159" height="19" font="14">Over a mean follow-up of </text>
<text top="165" left="679" width="199" height="19" font="14">57±34 mo, the death rates were </text>
<text top="183" left="679" width="131" height="19" font="14">36.4% (95% CI: 26.9%</text>
<text top="183" left="810" width="7" height="19" font="3">–</text>
<text top="183" left="818" width="84" height="19" font="14">46.6%) in the </text>
<text top="201" left="679" width="182" height="19" font="14">ICD and 44.4% (95% CI: 37.2%</text>
<text top="201" left="861" width="7" height="19" font="3">–</text>
<text top="219" left="679" width="84" height="19" font="14">51.8%) in the </text>
<text top="238" left="679" width="183" height="19" font="14">amiodarone/metoprolol arm. </text>
<text top="256" left="679" width="217" height="19" font="14">Overall survival was higher, though </text>
<text top="274" left="679" width="227" height="19" font="14">not significantly, in patients assigned </text>
<text top="293" left="679" width="228" height="19" font="14">to ICD than in those assigned to drug </text>
<text top="311" left="679" width="219" height="19" font="14">therapy (HR: 0.766, 97.5% CI:1.112, </text>
<text top="329" left="679" width="58" height="19" font="14">p=0.081).</text>
<text top="329" left="737" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="921" width="12" height="19" font="3">● </text>
<text top="109" left="933" width="120" height="19" font="14">In ICD patients, the </text>
<text top="127" left="921" width="133" height="19" font="14">percent reductions in </text>
<text top="145" left="921" width="150" height="19" font="14">all-cause mortality were </text>
<text top="164" left="921" width="133" height="19" font="14">41.9%, 39.3%, 28.4%, </text>
<text top="182" left="921" width="133" height="19" font="14">27.7%, 22.8%, 11.4%, </text>
<text top="200" left="921" width="148" height="19" font="14">9.1%, 10.6%, and 24.7% </text>
<text top="219" left="921" width="142" height="19" font="14">at 1 y to 9 of follow-up.</text>
<text top="219" left="1063" width="3" height="19" font="3"> </text>
<text top="237" left="921" width="136" height="19" font="3">● CAD was etiology in </text>
<text top="255" left="921" width="29" height="19" font="3">73% </text>
<text top="273" left="921" width="12" height="19" font="3">● </text>
<text top="273" left="933" width="88" height="19" font="14">A much larger </text>
<text top="292" left="921" width="132" height="19" font="14">reduction of 61%, for </text>
<text top="310" left="921" width="111" height="19" font="14">SCD was observed</text>
<text top="310" left="1032" width="3" height="19" font="3"> </text>
<text top="329" left="921" width="3" height="19" font="3"> </text>
<text top="347" left="921" width="3" height="19" font="3"> </text>
<text top="402" left="123" width="83" height="19" font="3">● Desai et al. </text>
<text top="421" left="123" width="69" height="19" font="3">2004 (195) </text>
<text top="439" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15598919">● </a></text>
<text top="439" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15598919">15598919</a></text>
<text top="439" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15598919"> </a></text>
<text top="457" left="123" width="3" height="19" font="4"><b> </b></text>
<text top="402" left="250" width="122" height="19" font="4"><b>Aim:</b>  To determine </text>
<text top="421" left="250" width="130" height="19" font="3">whether ICD therapy </text>
<text top="439" left="250" width="108" height="19" font="3">reduces all-cause </text>
<text top="457" left="250" width="127" height="19" font="3">mortality in patients </text>
<text top="476" left="250" width="72" height="19" font="3">with NICM. </text>
<text top="494" left="250" width="3" height="19" font="3"> </text>
<text top="512" left="250" width="117" height="19" font="4"><b>Study type:</b>   meta-</text>
<text top="531" left="250" width="94" height="19" font="3">analysis of RCT </text>
<text top="549" left="250" width="3" height="19" font="3"> </text>
<text top="567" left="250" width="129" height="19" font="4"><b>Size:</b>    8 randomized </text>
<text top="586" left="250" width="101" height="19" font="3">trials enrolling a </text>
<text top="604" left="250" width="82" height="19" font="3">total of 2146 </text>
<text top="622" left="250" width="121" height="19" font="3">patients with NICM </text>
<text top="640" left="250" width="94" height="19" font="3">were included.<b> </b></text>
<text top="402" left="393" width="256" height="19" font="4"><b>Inclusion criteria:</b>  prospective RCT of ICD </text>
<text top="421" left="393" width="250" height="19" font="3">or combined CRT defibrillator vs medical </text>
<text top="439" left="393" width="261" height="19" font="3">therapy enrolling at least some individuals </text>
<text top="457" left="393" width="271" height="19" font="3">with NICM and reporting all-cause mortality </text>
<text top="476" left="393" width="97" height="19" font="3">as an outcome. </text>
<text top="494" left="393" width="3" height="19" font="4"><b> </b></text>
<text top="512" left="393" width="110" height="19" font="4"><b>Intervention:</b> ICD </text>
<text top="531" left="393" width="7" height="19" font="3">  </text>
<text top="549" left="393" width="199" height="19" font="4"><b>Comparator:</b>  <b>  </b>Medical therapy. </text>
<text top="567" left="393" width="3" height="19" font="4"><b> </b></text>
<text top="403" left="679" width="180" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Two of the 3 2° </text>
<text top="422" left="679" width="169" height="19" font="3">prevention trials presented </text>
<text top="440" left="679" width="219" height="19" font="3">subgroup estimates for ICD efficacy </text>
<text top="458" left="679" width="222" height="19" font="3">in NICM. Pooled analysis of these 2° </text>
<text top="476" left="679" width="205" height="19" font="3">prevention trials (N=256 patients </text>
<text top="495" left="679" width="219" height="19" font="3">with NICM) indicated an equivalent </text>
<text top="513" left="679" width="221" height="19" font="3">to 1 y prevention but nonsignificant </text>
<text top="531" left="679" width="228" height="19" font="3">mortality reduction with ICD therapy </text>
<text top="550" left="679" width="179" height="19" font="3">(RR: 0.69; 95% CI: 0.39–1.24; </text>
<text top="568" left="679" width="57" height="19" font="3">p=0.22).  </text>
<text top="586" left="679" width="3" height="19" font="4"><b> </b></text>
<text top="402" left="921" width="143" height="19" font="3">● Analysis of all 7 trials </text>
<text top="421" left="921" width="138" height="19" font="3">(1° and 2° prevention) </text>
<text top="439" left="921" width="154" height="19" font="3">combined demonstrated </text>
<text top="457" left="921" width="148" height="19" font="3">a statistically significant </text>
<text top="476" left="921" width="151" height="19" font="3">31% overall reduction in </text>
<text top="494" left="921" width="114" height="19" font="3">mortality with ICD </text>
<text top="512" left="921" width="142" height="19" font="3">therapy (RR: 0.69; 95% </text>
<text top="531" left="921" width="148" height="19" font="3">CI: 0.56–0.86; p=0.002). </text>
<text top="549" left="921" width="3" height="19" font="3"> </text>
<text top="660" left="123" width="75" height="19" font="3">● <b>MAVERIC </b></text>
<text top="678" left="123" width="101" height="19" font="3">● Lau et al. 2004</text>
<text top="676" left="224" width="4" height="21" font="0"> </text>
<text top="696" left="123" width="35" height="19" font="3">(135) </text>
<text top="714" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15172648">● </a></text>
<text top="714" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15172648">15172648</a></text>
<text top="714" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15172648"> </a></text>
<text top="733" left="123" width="3" height="19" font="3"> </text>
<text top="751" left="123" width="3" height="19" font="4"><b> </b></text>
<text top="659" left="250" width="103" height="19" font="4"><b>Aim:</b>  to test the </text>
<text top="678" left="250" width="80" height="19" font="3">possibility of </text>
<text top="696" left="250" width="85" height="19" font="3">prospectively </text>
<text top="714" left="250" width="121" height="19" font="3">identifying patients </text>
<text top="733" left="250" width="118" height="19" font="3">who would benefit </text>
<text top="751" left="250" width="117" height="19" font="3">most ICD by EPS in </text>
<text top="659" left="393" width="251" height="19" font="4"><b>Inclusion criteria:</b>  survivors of sustained </text>
<text top="678" left="393" width="231" height="19" font="3">VT, VF or sudden cardiac death in the </text>
<text top="696" left="393" width="213" height="19" font="3">absence of an AMI in the last 48 h. </text>
<text top="714" left="393" width="3" height="19" font="3"> </text>
<text top="733" left="393" width="269" height="19" font="4"><b>Exclusion criteria:</b>  life expectancy of &lt;6 mo </text>
<text top="751" left="393" width="231" height="19" font="3">from a non-arrhythmic cause or child-</text>
<text top="769" left="393" width="75" height="19" font="3">bearing age </text>
<text top="660" left="679" width="162" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Survival and </text>
<text top="679" left="679" width="141" height="19" font="3">arrhythmia recurrence </text>
<text top="697" left="679" width="3" height="19" font="3"> </text>
<text top="715" left="679" width="227" height="19" font="4"><b>Results:</b>  Of the 108 EP arm patients, </text>
<text top="733" left="679" width="216" height="19" font="3">31 (29%) received an ICD, 46 (43%) </text>
<text top="752" left="679" width="163" height="19" font="3">received AAD only (mainly </text>
<text top="770" left="679" width="226" height="19" font="3">amiodarone or sotalol) and 18 (17%) </text>
<text top="660" left="921" width="137" height="19" font="3">● 61% of patients had </text>
<text top="678" left="921" width="53" height="19" font="3">prior MI </text>
<text top="696" left="921" width="125" height="19" font="3">● EPS has a minimal </text>
<text top="714" left="921" width="148" height="19" font="3">impact on the diagnosis </text>
<text top="733" left="921" width="135" height="19" font="3">of patients presented </text>
<text top="751" left="921" width="120" height="19" font="3">with VT, VF or SCD. </text>
</page>
<page number="110" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="16" size="12" family="Times" color="#212121"/>
<text top="803" left="585" width="29" height="21" font="0">110 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="250" width="105" height="19" font="3">the context of 2° </text>
<text top="127" left="250" width="74" height="19" font="3">prevention. </text>
<text top="145" left="250" width="3" height="19" font="3"> </text>
<text top="164" left="250" width="108" height="19" font="4"><b>Study type:</b>   RCT </text>
<text top="182" left="250" width="3" height="19" font="3"> </text>
<text top="200" left="250" width="121" height="19" font="4"><b>Size:</b>    214 patients<b> </b></text>
<text top="109" left="393" width="234" height="19" font="4"><b>Intervention:</b> EP-guided interventions </text>
<text top="127" left="393" width="262" height="19" font="3">(AAD, coronary revascularization, and ICD) </text>
<text top="145" left="393" width="214" height="19" font="3">(106 patients assigned to this arm) </text>
<text top="164" left="393" width="3" height="19" font="3"> </text>
<text top="182" left="393" width="272" height="19" font="4"><b>Comparator:</b> therapy with amiodarone (108 </text>
<text top="200" left="393" width="183" height="19" font="3">patients assigned to this arm)<b> </b></text>
<text top="109" left="679" width="220" height="19" font="3">received coronary revascularization </text>
<text top="127" left="679" width="158" height="19" font="3">but no ICD. No significant </text>
<text top="145" left="679" width="224" height="19" font="3">differences in survival or arrhythmia </text>
<text top="164" left="679" width="209" height="19" font="3">recurrence existed between the 2 </text>
<text top="182" left="679" width="219" height="19" font="3">treatment arms after 6 y. However, </text>
<text top="200" left="679" width="223" height="19" font="3">ICD recipients had a lower mortality </text>
<text top="219" left="679" width="217" height="19" font="3">than non-ICD recipients, regardless </text>
<text top="237" left="679" width="200" height="19" font="3">of allocated treatment (HR:0.54, </text>
<text top="255" left="679" width="69" height="19" font="3">p=0.0391).<b> </b></text>
<text top="109" left="921" width="123" height="19" font="3">● The trial does not </text>
<text top="127" left="921" width="129" height="19" font="3">support a role for EP </text>
<text top="145" left="921" width="84" height="19" font="3">testing in risk </text>
<text top="164" left="921" width="85" height="19" font="3">stratification. </text>
<text top="274" left="123" width="81" height="19" font="3">● Claro et al. </text>
<text top="292" left="123" width="69" height="19" font="3">2015 (136) </text>
<text top="311" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26646017">● </a></text>
<text top="311" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26646017">26646017</a></text>
<text top="311" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26646017"> </a></text>
<text top="329" left="123" width="3" height="19" font="3"> </text>
<text top="347" left="123" width="3" height="19" font="3"> </text>
<text top="274" left="250" width="110" height="19" font="4"><b>Aim:</b>  To evaluate </text>
<text top="292" left="250" width="123" height="19" font="3">the effectiveness of </text>
<text top="311" left="250" width="114" height="19" font="3">amiodarone for 1° </text>
<text top="329" left="250" width="119" height="19" font="3">or 2° prevention of </text>
<text top="347" left="250" width="123" height="19" font="3">SCD compared with </text>
<text top="366" left="250" width="87" height="19" font="3">placebo or no </text>
<text top="384" left="250" width="121" height="19" font="3">intervention or any </text>
<text top="402" left="250" width="37" height="19" font="3">other </text>
<text top="421" left="250" width="98" height="19" font="3">antiarrhythmic. </text>
<text top="439" left="250" width="3" height="19" font="3"> </text>
<text top="457" left="250" width="117" height="19" font="4"><b>Study type:</b>   meta-</text>
<text top="476" left="250" width="101" height="19" font="3">analyses using a </text>
<text top="494" left="250" width="97" height="19" font="3">random-effects </text>
<text top="512" left="250" width="42" height="19" font="3">model </text>
<text top="531" left="250" width="3" height="19" font="3"> </text>
<text top="549" left="250" width="107" height="19" font="4"><b>Size:</b>    24 studies </text>
<text top="567" left="250" width="122" height="19" font="3">(9,997 participants)<b> </b></text>
<text top="274" left="393" width="257" height="19" font="4"><b>Inclusion criteria:</b>  Randomised and quasi-</text>
<text top="292" left="393" width="259" height="19" font="3">randomised trials assessing the efficacy of </text>
<text top="311" left="393" width="271" height="19" font="3">amiodarone vs. placebo, no intervention, or </text>
<text top="329" left="393" width="257" height="19" font="3">other antiarrhythmics in adults, either for </text>
<text top="347" left="393" width="236" height="19" font="3">1° prevention or 2° prevention of SCD. </text>
<text top="366" left="393" width="3" height="19" font="3"> </text>
<text top="384" left="393" width="142" height="19" font="4"><b>Exclusion criteria:</b>  NA<b>  </b></text>
<text top="402" left="393" width="164" height="19" font="4"><b>Intervention:</b> Amiodarone </text>
<text top="421" left="393" width="7" height="19" font="3">  </text>
<text top="439" left="393" width="259" height="19" font="4"><b>Comparator:</b>  placebo, no intervention, or </text>
<text top="457" left="393" width="137" height="19" font="3">other antiarrhythmics<b> </b></text>
<text top="275" left="679" width="183" height="19" font="4"><b>1</b>°<b> endpoint:</b>  SCD and overall </text>
<text top="293" left="679" width="59" height="19" font="3">mortality </text>
<text top="312" left="679" width="3" height="19" font="3"> </text>
<text top="330" left="679" width="169" height="19" font="4"><b>Results:</b>  For 2° prevention, </text>
<text top="348" left="679" width="227" height="19" font="3">amiodarone compared to placebo or </text>
<text top="367" left="679" width="190" height="19" font="3">no intervention (2 studies, 440 </text>
<text top="385" left="679" width="212" height="19" font="3">participants) appeared to increase </text>
<text top="403" left="679" width="202" height="19" font="3">the risk of SCD (RR: 4.32; 95% CI: </text>
<text top="422" left="679" width="219" height="19" font="3">0.87–21.49) and all-cause mortality </text>
<text top="440" left="679" width="172" height="19" font="3">(RR:3.05;95% CI 1.33–7.01). </text>
<text top="458" left="679" width="171" height="19" font="3">However, the quality of the </text>
<text top="476" left="679" width="228" height="19" font="3">evidence was very low. Compared to </text>
<text top="495" left="679" width="203" height="19" font="3">other antiarrhythmics (4 studies, </text>
<text top="513" left="679" width="184" height="19" font="3">839 participants) amiodarone </text>
<text top="531" left="679" width="224" height="19" font="3">appeared to increase the risk of SCD </text>
<text top="550" left="679" width="205" height="19" font="3">(RR:1.40; 95% CI: 0.56–3.52; very </text>
<text top="568" left="679" width="213" height="19" font="3">low quality of evidence), but there </text>
<text top="586" left="679" width="216" height="19" font="3">was no effect in all-cause mortality </text>
<text top="605" left="679" width="204" height="19" font="3">(RR: 1.03; 95% CI: 0.75–1.42; low </text>
<text top="623" left="679" width="112" height="19" font="3">quality evidence).<b> </b></text>
<text top="274" left="921" width="150" height="19" font="3">● For 2° prevention, the </text>
<text top="292" left="921" width="142" height="19" font="3">quality of the evidence </text>
<text top="311" left="921" width="127" height="19" font="3">was very low, so the </text>
<text top="329" left="921" width="145" height="19" font="3">authors concluded that </text>
<text top="347" left="921" width="137" height="19" font="3">there was uncertainty </text>
<text top="366" left="921" width="98" height="19" font="3">on the findings. </text>
<text top="384" left="921" width="118" height="19" font="3">● Amiodarone was </text>
<text top="402" left="921" width="116" height="19" font="3">associated with an </text>
<text top="421" left="921" width="139" height="19" font="3">increase in pulmonary </text>
<text top="439" left="921" width="125" height="19" font="3">and thyroid adverse </text>
<text top="457" left="921" width="48" height="19" font="3">events. </text>
<text top="476" left="921" width="3" height="19" font="3"> </text>
<text top="494" left="921" width="3" height="19" font="3"> </text>
<text top="642" left="123" width="92" height="19" font="3">● <b>OPTIC Study </b></text>
<text top="660" left="123" width="103" height="19" font="3">● Connolly et al. </text>
<text top="680" left="123" width="30" height="19" font="3">2006</text>
<text top="678" left="154" width="39" height="21" font="0"> (159)</text>
<text top="680" left="193" width="3" height="19" font="3"> </text>
<text top="699" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16403928">● </a></text>
<text top="699" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16403928">16403928</a></text>
<text top="699" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16403928"> </a></text>
<text top="717" left="123" width="3" height="19" font="3"> </text>
<text top="642" left="250" width="118" height="19" font="4"><b>Aim:</b> To determine </text>
<text top="660" left="250" width="55" height="19" font="3">whether </text>
<text top="679" left="250" width="125" height="19" font="3">amiodarone plus BB </text>
<text top="697" left="250" width="125" height="19" font="3">or sotalol are better </text>
<text top="715" left="250" width="109" height="19" font="3">than BB alone for </text>
<text top="734" left="250" width="111" height="19" font="3">prevention of ICD </text>
<text top="752" left="250" width="48" height="19" font="3">shocks. </text>
<text top="770" left="250" width="3" height="19" font="3"> </text>
<text top="642" left="393" width="257" height="19" font="4"><b>Inclusion criteria:</b> Patients were eligible if </text>
<text top="660" left="393" width="248" height="19" font="3">they had received an ICD within 21 d for </text>
<text top="679" left="393" width="264" height="19" font="3">inducible or spontaneously occurring VT or </text>
<text top="697" left="393" width="26" height="19" font="3">VF.  </text>
<text top="715" left="393" width="3" height="19" font="3"> </text>
<text top="733" left="393" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="733" left="507" width="157" height="19" font="16">Patients were excluded if </text>
<text top="752" left="393" width="243" height="19" font="16">they had LQTS, corrected QT interval of </text>
<text top="770" left="393" width="249" height="19" font="16">more than 450 millisec, were receiving a </text>
<text top="643" left="679" width="190" height="19" font="4"><b>1</b>°<b> endpoint:</b> ICD shock for any </text>
<text top="661" left="679" width="49" height="19" font="3">reason. </text>
<text top="679" left="679" width="3" height="19" font="3"> </text>
<text top="698" left="679" width="188" height="19" font="4"><b>Results: </b>Shocks occurred in 41 </text>
<text top="716" left="679" width="195" height="19" font="3">patients (38.5%) assigned to BB </text>
<text top="734" left="679" width="182" height="19" font="3">alone, 26 (24.3%) assigned to </text>
<text top="753" left="679" width="215" height="19" font="3">sotalol, and 12 (10.3%) assigned to </text>
<text top="771" left="679" width="219" height="19" font="3">amiodarone plus BB. A reduction in </text>
<text top="642" left="921" width="152" height="19" font="3">● Amiodarone plus BB is </text>
<text top="660" left="921" width="147" height="19" font="3">effective for preventing </text>
<text top="679" left="921" width="120" height="19" font="3">these shocks and is </text>
<text top="697" left="921" width="124" height="19" font="3">more effective than </text>
<text top="715" left="921" width="111" height="19" font="3">sotalol but has an </text>
<text top="734" left="921" width="135" height="19" font="3">increased risk of drug-</text>
<text top="752" left="921" width="143" height="19" font="3">related adverse effects </text>
</page>
<page number="111" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="17" size="17" family="Times" color="#212121"/>
<text top="803" left="585" width="29" height="21" font="0">111 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="250" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="127" left="250" width="105" height="19" font="3">multicenter RCT  </text>
<text top="145" left="250" width="3" height="19" font="3"> </text>
<text top="164" left="250" width="121" height="19" font="4"><b>Size:</b>    412 patients<b> </b></text>
<text top="109" left="393" width="265" height="19" font="16">class I or class III antiarrhythmic agent, had </text>
<text top="127" left="393" width="251" height="19" font="16">received amiodarone or sotalol for more </text>
<text top="145" left="393" width="263" height="19" font="16">than 20 consecutive d at anytime (patients </text>
<text top="164" left="393" width="269" height="19" font="16">who had received &gt;10 d of amiodarone had </text>
<text top="182" left="393" width="266" height="19" font="16">to be taken off amiodarone for 10 d before </text>
<text top="200" left="393" width="97" height="19" font="16">randomization),</text>
<text top="196" left="491" width="4" height="25" font="17"> </text>
<text top="200" left="495" width="141" height="19" font="16">a calculated creatinine </text>
<text top="219" left="393" width="246" height="19" font="16">clearance of less than 30 mL/min (&lt;0.50 </text>
<text top="237" left="393" width="267" height="19" font="16">mL/s), symptomatic AF likely to require use </text>
<text top="255" left="393" width="265" height="19" font="16">of a class I or class III antiarrhythmic agent, </text>
<text top="273" left="393" width="228" height="19" font="16">absence of SHD, contraindications to </text>
<text top="292" left="393" width="272" height="19" font="16">amiodarone or a β-blocker, or NYHA class IV </text>
<text top="310" left="393" width="102" height="19" font="16">symptoms of HF.</text>
<text top="310" left="496" width="7" height="19" font="3">  </text>
<text top="328" left="393" width="259" height="19" font="4"><b>Intervention:</b> amiodarone plus BB, sotalol </text>
<text top="347" left="393" width="37" height="19" font="3">alone </text>
<text top="365" left="393" width="7" height="19" font="3">  </text>
<text top="383" left="393" width="147" height="19" font="4"><b>Comparator:</b>  BB alone.<b> </b></text>
<text top="109" left="679" width="220" height="19" font="3">the risk of shock was observed with </text>
<text top="127" left="679" width="222" height="19" font="3">use of either amiodarone plus BB or </text>
<text top="145" left="679" width="210" height="19" font="3">sotalol vs BB alone (HR: 0.44; 95% </text>
<text top="164" left="679" width="228" height="19" font="3">CI: 0.28–0.68; p&lt;0.001). Amiodarone </text>
<text top="182" left="679" width="226" height="19" font="3">plus BB significantly reduced the risk </text>
<text top="200" left="679" width="207" height="19" font="3">of shock compared with BB alone </text>
<text top="219" left="679" width="180" height="19" font="3">(HR: 0.27; 95% CI: 0.14–0.52; </text>
<text top="237" left="679" width="221" height="19" font="3">p&lt;0.001) and sotalol (HR: 0.43; 95% </text>
<text top="255" left="679" width="217" height="19" font="3">CI: 0.22–0.85; p=0.02). There was a </text>
<text top="273" left="679" width="208" height="19" font="3">trend for sotalol to reduce shocks </text>
<text top="292" left="679" width="182" height="19" font="3">compared with BB alone (HR: </text>
<text top="310" left="679" width="208" height="19" font="3">0.61;95% CI, 0.37–1.01; p=0.055). </text>
<text top="329" left="679" width="144" height="19" font="3">The rates of study drug </text>
<text top="347" left="679" width="228" height="19" font="3">discontinuation at 1y were 18.2% for </text>
<text top="365" left="679" width="217" height="19" font="3">amiodarone, 23.5% for sotalol, and </text>
<text top="383" left="679" width="118" height="19" font="3">5.3% for BB alone. <b> </b></text>
<text top="109" left="921" width="135" height="19" font="3">● Adverse pulmonary </text>
<text top="127" left="921" width="144" height="19" font="3">and thyroid events and </text>
<text top="145" left="921" width="83" height="19" font="3">symptomatic </text>
<text top="164" left="921" width="146" height="19" font="3">bradycardia were more </text>
<text top="182" left="921" width="103" height="19" font="3">common among </text>
<text top="200" left="921" width="146" height="19" font="3">patients randomized to </text>
<text top="219" left="921" width="81" height="19" font="3">amiodarone. </text>
<text top="402" left="123" width="88" height="19" font="3">● Piccini et al.<b> </b></text>
<text top="421" left="123" width="30" height="19" font="3">2009</text>
<text top="419" left="154" width="4" height="21" font="0"> </text>
<text top="421" left="157" width="35" height="19" font="3">(154)<b> </b></text>
<text top="439" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19336434">● </a></text>
<text top="439" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19336434">19336434</a></text>
<text top="439" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19336434"> </a></text>
<text top="457" left="123" width="3" height="19" font="4"><b> </b></text>
<text top="476" left="123" width="3" height="19" font="3"> </text>
<text top="494" left="177" width="3" height="19" font="3"> </text>
<text top="512" left="123" width="3" height="19" font="3"> </text>
<text top="402" left="250" width="54" height="19" font="4"><b>Aim:</b>  To </text>
<text top="402" left="304" width="56" height="19" font="11">evaluate </text>
<text top="421" left="250" width="95" height="19" font="11">the cumulative </text>
<text top="439" left="250" width="58" height="19" font="11">evidence </text>
<text top="457" left="250" width="126" height="19" font="11">regarding the safety </text>
<text top="476" left="250" width="92" height="19" font="11">and efficacy of </text>
<text top="494" left="250" width="92" height="19" font="11">amiodarone in </text>
<text top="512" left="250" width="114" height="19" font="11">prevention of SCD </text>
<text top="531" left="250" width="3" height="19" font="4"><b> </b></text>
<text top="549" left="250" width="111" height="19" font="4"><b>Study type:</b> Meta-</text>
<text top="567" left="250" width="111" height="19" font="3">analysis of all RCT </text>
<text top="586" left="250" width="130" height="19" font="3">examining the use of </text>
<text top="604" left="250" width="97" height="19" font="3">amiodarone vs. </text>
<text top="622" left="250" width="122" height="19" font="3">placebo/control for </text>
<text top="640" left="250" width="110" height="19" font="3">the prevention of </text>
<text top="659" left="250" width="34" height="19" font="3">SCD   </text>
<text top="677" left="250" width="3" height="19" font="3"> </text>
<text top="695" left="250" width="32" height="19" font="4"><b>Size:</b> </text>
<text top="695" left="282" width="96" height="19" font="11">15 trials, which </text>
<text top="714" left="250" width="114" height="19" font="11">randomized 8,522 </text>
<text top="732" left="250" width="50" height="19" font="11">patients</text>
<text top="732" left="300" width="3" height="19" font="3"> </text>
<text top="402" left="393" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="402" left="505" width="155" height="19" font="11">Studies in which patients </text>
<text top="421" left="393" width="231" height="19" font="11">were randomized to amiodarone and </text>
<text top="439" left="393" width="236" height="19" font="11">placebo or inactive control. Additional </text>
<text top="457" left="393" width="251" height="19" font="11">inclusion criteria included: treatment for </text>
<text top="476" left="393" width="259" height="19" font="11">&gt;30 d, follow-up &gt;6 mo, and availability of </text>
<text top="494" left="393" width="206" height="19" font="11">all-cause mortality as an endpoint</text>
<text top="494" left="600" width="3" height="19" font="3"> </text>
<text top="512" left="393" width="3" height="19" font="3"> </text>
<text top="531" left="393" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="531" left="510" width="48" height="19" font="11">Studies </text>
<text top="549" left="393" width="271" height="19" font="11">of patients with shock-refractory VA, OHCA, </text>
<text top="567" left="393" width="202" height="19" font="11">patients &lt;18 y, randomization to </text>
<text top="586" left="393" width="247" height="19" font="11">amiodarone vs. a class Ic or class III AAD </text>
<text top="604" left="393" width="237" height="19" font="11">(without a placebo or standard of care </text>
<text top="622" left="393" width="248" height="19" font="11">arm). Studies of patients with ICDs were </text>
<text top="640" left="393" width="221" height="19" font="11">excluded unless used on both arms. </text>
<text top="403" left="679" width="85" height="19" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="403" left="764" width="121" height="19" font="11">SCD, CVD, all-cause </text>
<text top="422" left="679" width="228" height="19" font="11">mortality, and the incidences of drug </text>
<text top="440" left="679" width="62" height="19" font="11">toxicities. </text>
<text top="458" left="679" width="3" height="19" font="3"> </text>
<text top="476" left="679" width="225" height="19" font="4"><b>Results:</b>  Amiodarone decreased the </text>
<text top="495" left="679" width="214" height="19" font="3">incidence of SCD (7.1 vs. 9.7%; OR: </text>
<text top="513" left="679" width="208" height="19" font="3">0.71; 95% CI: 0.61–0.84; p&lt;0.001) </text>
<text top="531" left="679" width="202" height="19" font="3">and cardiovascular death (14.0% </text>
<text top="550" left="679" width="203" height="19" font="3">vs.16.3%; OR: 0.82; 95% CI: 0.71–</text>
<text top="568" left="679" width="205" height="19" font="3">0.94, p=0.004). There was a 1.5% </text>
<text top="586" left="679" width="215" height="19" font="3">absolute risk reduction in all-cause </text>
<text top="605" left="679" width="181" height="19" font="3">mortality which did not meet </text>
<text top="623" left="679" width="201" height="19" font="3">statistical significance (p=0.093). </text>
<text top="641" left="679" width="216" height="19" font="3">Amiodarone therapy increased the </text>
<text top="660" left="679" width="205" height="19" font="3">risk of pulmonary (2.9% vs. 1.5%; </text>
<text top="678" left="679" width="176" height="19" font="3">OR: 1.97; 95% CI: 1.27–3.04, </text>
<text top="696" left="679" width="193" height="19" font="3">p=0.002), and thyroid (3.6% vs. </text>
<text top="714" left="679" width="220" height="19" font="3">0.4%; OR: 5.68; 95% CI: 2.94–10.98, </text>
<text top="733" left="679" width="109" height="19" font="3">p&lt;0.001) toxicity. </text>
<text top="751" left="679" width="3" height="19" font="3"> </text>
<text top="402" left="921" width="143" height="19" font="3">● Amiodarone reduces </text>
<text top="421" left="921" width="139" height="19" font="3">the risk of SCD by 29% </text>
<text top="439" left="921" width="107" height="19" font="3">and CVD by 18%, </text>
<text top="457" left="921" width="138" height="19" font="3">however, amiodarone </text>
<text top="476" left="921" width="141" height="19" font="3">therapy is neutral with </text>
<text top="494" left="921" width="122" height="19" font="3">respect to all-cause </text>
<text top="512" left="921" width="113" height="19" font="3">mortality and was </text>
<text top="531" left="921" width="140" height="19" font="3">associated with a two- </text>
<text top="549" left="921" width="142" height="19" font="3">and five-fold increased </text>
<text top="567" left="921" width="137" height="19" font="3">risk of pulmonary and </text>
<text top="586" left="921" width="99" height="19" font="3">thyroid toxicity. </text>
<text top="604" left="921" width="129" height="19" font="3">● Authors suggested </text>
<text top="622" left="921" width="144" height="19" font="3">amiodarone as a viable </text>
<text top="640" left="921" width="137" height="19" font="3">alternative in patients </text>
<text top="659" left="921" width="146" height="19" font="3">who are not eligible for </text>
<text top="677" left="921" width="123" height="19" font="3">or who do not have </text>
<text top="695" left="921" width="134" height="19" font="3">access to ICD therapy </text>
<text top="714" left="921" width="131" height="19" font="3">for the prevention of </text>
<text top="732" left="921" width="35" height="19" font="3">SCD.  </text>
<text top="750" left="921" width="3" height="19" font="3"> </text>
<text top="770" left="115" width="4" height="23" font="10"><b> </b></text>
</page>
<page number="112" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">112 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="963" height="21" font="2"><b>Data Supplement 26. Nonrandomized Trials, Observational Studies, and/or Registries of Secondary Prevention SCD in NICM – (Section 7.2.1) </b></text>
<text top="129" left="136" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="147" left="162" width="51" height="19" font="4"><b>Author; </b></text>
<text top="165" left="140" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="129" left="292" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="147" left="321" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="129" left="475" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="129" left="658" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="147" left="670" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="165" left="701" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="129" left="896" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="147" left="924" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="184" left="125" width="112" height="19" font="3">● Raitt et al.<b> </b>2001 </text>
<text top="203" left="125" width="35" height="19" font="3">(137) </text>
<text top="221" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11208684">● </a></text>
<text top="221" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11208684">11208684</a></text>
<text top="221" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11208684"> </a></text>
<text top="239" left="125" width="3" height="19" font="3"> </text>
<text top="258" left="125" width="3" height="19" font="3"> </text>
<text top="184" left="264" width="122" height="19" font="4"><b>Aim:</b>  To determine </text>
<text top="203" left="264" width="161" height="19" font="3">prognostic implications of </text>
<text top="221" left="264" width="60" height="19" font="3">stable VT </text>
<text top="239" left="264" width="3" height="19" font="3"> </text>
<text top="258" left="264" width="167" height="19" font="4"><b>Study type:</b> Observational, </text>
<text top="276" left="264" width="149" height="19" font="3">registry of patients with </text>
<text top="294" left="264" width="174" height="19" font="3">hemodynamically stable VT  </text>
<text top="313" left="264" width="3" height="19" font="3"> </text>
<text top="331" left="264" width="35" height="19" font="4"><b>Size:</b>  </text>
<text top="331" left="299" width="133" height="19" font="14">The study population </text>
<text top="349" left="264" width="156" height="19" font="14">consisted of 440 patients </text>
<text top="368" left="264" width="150" height="19" font="14">with stable VT and 1029 </text>
<text top="386" left="264" width="180" height="19" font="14">patients with unstable VT. Of </text>
<text top="404" left="264" width="141" height="19" font="14">the 1029 patients with </text>
<text top="423" left="264" width="131" height="19" font="14">unstable VT, 330 had </text>
<text top="441" left="264" width="144" height="19" font="14">therapy determined by </text>
<text top="459" left="264" width="164" height="19" font="14">randomization in the AVID </text>
<text top="478" left="264" width="163" height="19" font="14">trial: 52% received an ICD, </text>
<text top="496" left="264" width="159" height="19" font="14">47% amiodarone, and 2% </text>
<text top="514" left="264" width="146" height="19" font="14">sotalol. Therapy for the </text>
<text top="532" left="264" width="175" height="19" font="14">remaining 699 patients with </text>
<text top="551" left="264" width="151" height="19" font="14">unstable VT and the 440 </text>
<text top="569" left="264" width="170" height="19" font="14">patients with stable VT was </text>
<text top="587" left="264" width="178" height="19" font="14">determined at the discretion </text>
<text top="606" left="264" width="162" height="19" font="14">of the attending physician.</text>
<text top="606" left="426" width="3" height="19" font="3"> </text>
<text top="184" left="458" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="203" left="458" width="8" height="19" font="3">P</text>
<text top="203" left="466" width="135" height="19" font="14">atients with stable VT </text>
<text top="221" left="458" width="141" height="19" font="14">that were not enrolled </text>
<text top="239" left="458" width="142" height="19" font="14">in AVID, were included </text>
<text top="258" left="458" width="144" height="19" font="14">in a registry of patients </text>
<text top="276" left="458" width="141" height="19" font="14">screened for the study.</text>
<text top="276" left="599" width="3" height="19" font="3"> </text>
<text top="294" left="458" width="3" height="19" font="3"> </text>
<text top="313" left="458" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="331" left="458" width="128" height="19" font="14">Patients who had an </text>
<text top="349" left="458" width="151" height="19" font="14">arrhythmia within 5 d of </text>
<text top="368" left="458" width="140" height="19" font="14">MI, cardiac surgery, or </text>
<text top="386" left="458" width="137" height="19" font="14">coronary intervention </text>
<text top="404" left="458" width="147" height="19" font="14">were excluded, as were </text>
<text top="423" left="458" width="154" height="19" font="14">patients with NYHA class </text>
<text top="441" left="458" width="153" height="19" font="14">IV HF or those who were </text>
<text top="459" left="458" width="132" height="19" font="14">on a heart transplant </text>
<text top="478" left="458" width="119" height="19" font="14">list, had a prior ICD </text>
<text top="496" left="458" width="135" height="19" font="14">implant or attempted </text>
<text top="514" left="458" width="130" height="19" font="14">implant, or had a life </text>
<text top="532" left="458" width="113" height="19" font="14">expectancy of &lt;1y.</text>
<text top="532" left="572" width="3" height="19" font="3"> </text>
<text top="185" left="626" width="145" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Mortality </text>
<text top="204" left="626" width="3" height="19" font="3"> </text>
<text top="222" left="626" width="182" height="19" font="4"><b>Results:</b>  The mortality in 440 </text>
<text top="240" left="626" width="206" height="19" font="3">patients with stable VT tended to </text>
<text top="258" left="626" width="201" height="19" font="3">be greater than that observed in </text>
<text top="277" left="626" width="186" height="19" font="3">1029 patients presenting with </text>
<text top="295" left="626" width="204" height="19" font="3">unstable VT (33.6% vs 27.6% at 3 </text>
<text top="314" left="626" width="156" height="19" font="3">y; RR:1.22; p=0.07). After </text>
<text top="332" left="626" width="175" height="19" font="3">adjustment for baseline and </text>
<text top="350" left="626" width="212" height="19" font="3">treatment differences, the RR was </text>
<text top="368" left="626" width="199" height="19" font="3">little changed (RR:1.25, p=0.06). </text>
<text top="387" left="626" width="3" height="19" font="3"> </text>
<text top="184" left="854" width="12" height="19" font="3">● </text>
<text top="184" left="866" width="180" height="19" font="14">Sustained VT without serious </text>
<text top="203" left="854" width="173" height="19" font="14">symptoms or hemodynamic </text>
<text top="221" left="854" width="201" height="19" font="14">compromise is associated with a </text>
<text top="239" left="854" width="202" height="19" font="14">high mortality rate and may be a </text>
<text top="258" left="854" width="206" height="19" font="14">marker for a substrate capable of </text>
<text top="276" left="854" width="176" height="19" font="14">producing a more malignant </text>
<text top="294" left="854" width="68" height="19" font="14">arrhythmia</text>
<text top="294" left="921" width="3" height="19" font="3"> </text>
<text top="313" left="854" width="3" height="19" font="3"> </text>
<text top="625" left="125" width="95" height="19" font="3">● Ruwald et al. </text>
<text top="643" left="125" width="69" height="19" font="3">2014 (196) </text>
<text top="661" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24201303">● </a></text>
<text top="661" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24201303">24201303</a></text>
<text top="661" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24201303"> </a></text>
<text top="680" left="125" width="3" height="19" font="3"> </text>
<text top="698" left="125" width="3" height="19" font="3"> </text>
<text top="625" left="264" width="36" height="19" font="4"><b>Aim:</b>  </text>
<text top="625" left="300" width="116" height="19" font="14">to evaluate (1) the </text>
<text top="643" left="264" width="152" height="19" font="14">effects of innovative ICD </text>
<text top="661" left="264" width="167" height="19" font="14">programming with either a </text>
<text top="680" left="264" width="167" height="19" font="14">high-rate cutoff VT zone or </text>
<text top="698" left="264" width="162" height="19" font="14">delayed therapy on risk of </text>
<text top="716" left="264" width="149" height="19" font="14">syncope compared with </text>
<text top="735" left="264" width="173" height="19" font="14">conventional programming; </text>
<text top="753" left="264" width="125" height="19" font="14">(2) the independent </text>
<text top="771" left="264" width="181" height="19" font="14">prognostic factors associated </text>
<text top="625" left="458" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="625" left="573" width="34" height="19" font="14">1500 </text>
<text top="643" left="458" width="105" height="19" font="14">patients from 98 </text>
<text top="661" left="458" width="142" height="19" font="14">hospital centers with a </text>
<text top="680" left="458" width="146" height="19" font="14">1° prevention guideline </text>
<text top="698" left="458" width="146" height="19" font="14">indication to receive an </text>
<text top="716" left="458" width="82" height="19" font="14">ICD or CRT-D.</text>
<text top="716" left="540" width="3" height="19" font="3"> </text>
<text top="735" left="458" width="3" height="19" font="3"> </text>
<text top="753" left="458" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="771" left="458" width="146" height="19" font="14">Patients were excluded </text>
<text top="625" left="626" width="85" height="19" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="625" left="711" width="92" height="19" font="14">Syncope was a </text>
<text top="644" left="626" width="209" height="19" font="14">prespecified safety end point that </text>
<text top="662" left="626" width="198" height="19" font="14">was adjudicated independently. </text>
<text top="680" left="626" width="193" height="19" font="14">Multivariable Cox models were </text>
<text top="699" left="626" width="169" height="19" font="14">used to identify risk factors </text>
<text top="717" left="626" width="194" height="19" font="14">associated with syncope and to </text>
<text top="735" left="626" width="164" height="19" font="14">analyze subsequent risk of </text>
<text top="754" left="626" width="60" height="19" font="14">mortality.</text>
<text top="754" left="686" width="3" height="19" font="3"> </text>
<text top="772" left="626" width="3" height="19" font="3"> </text>
<text top="625" left="854" width="12" height="19" font="3">● </text>
<text top="625" left="866" width="192" height="19" font="14">21 syncopal events (33%) were </text>
<text top="643" left="854" width="220" height="19" font="14">classified as caused by VT or VF and </text>
<text top="661" left="854" width="176" height="19" font="14">4 (6%) as caused by other or </text>
<text top="680" left="854" width="220" height="19" font="14">unspecified arrhythmias, whereas a </text>
<text top="698" left="854" width="183" height="19" font="14">total of 39 events (61%) were </text>
<text top="716" left="854" width="200" height="19" font="14">classified as nonarrhythmogenic.</text>
<text top="716" left="1054" width="3" height="19" font="3"> </text>
<text top="735" left="854" width="19" height="19" font="3">● S</text>
<text top="735" left="873" width="181" height="19" font="14">yncope in HF patients (with a </text>
<text top="753" left="854" width="217" height="19" font="14">defibrillator) is primarily vasovagal, </text>
<text top="771" left="854" width="155" height="19" font="14">orthostatic, or otherwise </text>
</page>
<page number="113" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">113 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="264" width="158" height="19" font="14">with syncope; and (3) the </text>
<text top="127" left="264" width="129" height="19" font="14">association between </text>
<text top="145" left="264" width="135" height="19" font="14">syncope, the cause of </text>
<text top="164" left="264" width="148" height="19" font="14">syncope, and the risk of </text>
<text top="182" left="264" width="175" height="19" font="14">death in patients enrolled in </text>
<text top="200" left="264" width="66" height="19" font="14">MADIT-RIT</text>
<text top="200" left="329" width="3" height="19" font="4"><b> </b></text>
<text top="218" left="264" width="3" height="19" font="4"><b> </b></text>
<text top="237" left="264" width="136" height="19" font="4"><b>Study type:</b> Subgroup </text>
<text top="255" left="264" width="67" height="19" font="3">analysis of </text>
<text top="255" left="330" width="69" height="19" font="14">MADIT-RIT.</text>
<text top="255" left="400" width="3" height="19" font="3"> </text>
<text top="273" left="264" width="3" height="19" font="3"> </text>
<text top="292" left="264" width="156" height="19" font="4"><b>Size: </b> 64 of 1500 patients </text>
<text top="310" left="264" width="122" height="19" font="3">(4.3%) had syncope<b> </b></text>
<text top="109" left="458" width="146" height="19" font="14">if they had experienced </text>
<text top="127" left="458" width="139" height="19" font="14">AF within 1 mo before </text>
<text top="145" left="458" width="128" height="19" font="14">implantation; if they </text>
<text top="164" left="458" width="126" height="19" font="14">previously had been </text>
<text top="182" left="458" width="106" height="19" font="14">implanted with a </text>
<text top="200" left="458" width="147" height="19" font="14">pacemaker, ICD, or CRT-</text>
<text top="219" left="458" width="155" height="19" font="14">D; or if they had a recent </text>
<text top="237" left="458" width="143" height="19" font="14">MI or revascularization </text>
<text top="255" left="458" width="124" height="19" font="14">procedure (within 3 </text>
<text top="273" left="458" width="28" height="19" font="14">mo).</text>
<text top="273" left="486" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="626" width="209" height="19" font="4"><b>Results:</b>  Prognostic factors for all-</text>
<text top="127" left="626" width="171" height="19" font="3">cause syncope included the </text>
<text top="145" left="626" width="131" height="19" font="3">presence of ischemic </text>
<text top="164" left="626" width="211" height="19" font="3">cardiomyopathy (HR: 2.48; 95% CI </text>
<text top="182" left="626" width="206" height="19" font="3">1.42–4.34; p=0.002), previous VA </text>
<text top="200" left="626" width="176" height="19" font="3">(HR: 2.99; 95% CI 1.18–7.59; </text>
<text top="219" left="626" width="194" height="19" font="3">p=0.021), LVEF ≤25% (HR: 1.65; </text>
<text top="237" left="626" width="200" height="19" font="3">95% CI 0.98–2.77; p=0.059), and </text>
<text top="255" left="626" width="193" height="19" font="3">younger age (by 10 y; HR: 1.25; </text>
<text top="273" left="626" width="170" height="19" font="3">95% CI1.00–1.52; p=0.046). </text>
<text top="292" left="626" width="180" height="19" font="3">Syncope was associated with </text>
<text top="310" left="626" width="208" height="19" font="3">increased risk of death regardless </text>
<text top="329" left="626" width="177" height="19" font="3">of its cause (arrhythmogenic </text>
<text top="347" left="626" width="195" height="19" font="3">syncope: HR: 4.51; 95% CI 1.39–</text>
<text top="365" left="626" width="98" height="19" font="3">14.64, p=0.012; </text>
<text top="383" left="626" width="203" height="19" font="3">nonarrhythmogenic syncope: HR </text>
<text top="402" left="626" width="208" height="19" font="3">2.97; 95% CI 1.07–8.28, p=0.038).<b> </b></text>
<text top="109" left="854" width="212" height="19" font="14">nonarrhythmogenic in mechanism </text>
<text top="127" left="854" width="207" height="19" font="14">and underscores the fact that the </text>
<text top="145" left="854" width="205" height="19" font="14">presence of heart disease (in this </text>
<text top="164" left="854" width="211" height="19" font="14">case, ischemic or nonischemic HF) </text>
<text top="182" left="854" width="219" height="19" font="14">does not dictate that syncope has a </text>
<text top="200" left="854" width="85" height="19" font="14">cardiac cause </text>
<text top="219" left="854" width="12" height="19" font="3">● </text>
<text top="219" left="866" width="202" height="19" font="14">Syncope in HF patients is related </text>
<text top="237" left="854" width="213" height="19" font="14">to an increased cardiovascular risk </text>
<text top="255" left="854" width="199" height="19" font="14">profile and is associated with an </text>
<text top="273" left="854" width="208" height="19" font="14">increased risk of death regardless </text>
<text top="292" left="854" width="68" height="19" font="14">of its cause</text>
<text top="292" left="922" width="3" height="19" font="3"> </text>
<text top="421" left="125" width="106" height="19" font="3">● Middlekauff et </text>
<text top="439" left="125" width="68" height="19" font="3">al.1993 (3) </text>
<text top="457" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8417050">● </a></text>
<text top="457" left="137" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8417050">8417050</a></text>
<text top="457" left="190" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8417050"> </a></text>
<text top="476" left="125" width="3" height="19" font="3"> </text>
<text top="421" left="264" width="162" height="19" font="4"><b>Study type:</b> Retrospective </text>
<text top="439" left="264" width="44" height="19" font="3">cohort </text>
<text top="457" left="264" width="3" height="19" font="3"> </text>
<text top="476" left="264" width="176" height="19" font="4"><b>Size:</b>  491 patients with CHF, </text>
<text top="494" left="264" width="146" height="19" font="3">of which 60 had a Hx of </text>
<text top="512" left="264" width="179" height="19" font="3">syncope; the condition had a </text>
<text top="531" left="264" width="157" height="19" font="3">cardiac origin in 29 (48%) </text>
<text top="549" left="264" width="177" height="19" font="3">and was due to other causes </text>
<text top="567" left="264" width="76" height="19" font="3">in 31 (52%).<b> </b></text>
<text top="421" left="458" width="141" height="19" font="4"><b>Inclusion criteria:</b>  491 </text>
<text top="439" left="458" width="129" height="19" font="3">consecutive patients </text>
<text top="457" left="458" width="120" height="19" font="3">with advanced CHF </text>
<text top="476" left="458" width="155" height="19" font="3">(NYHA functional class III </text>
<text top="494" left="458" width="152" height="19" font="3">or IV), no Hx of CA and a </text>
<text top="512" left="458" width="127" height="19" font="3">mean LVEF of 0.20 ± </text>
<text top="531" left="458" width="34" height="19" font="3">0.07.<b> </b></text>
<text top="549" left="458" width="3" height="19" font="3"> </text>
<text top="567" left="458" width="3" height="19" font="3"> </text>
<text top="585" left="458" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="421" left="626" width="145" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Mortality </text>
<text top="440" left="626" width="3" height="19" font="3"> </text>
<text top="458" left="626" width="200" height="19" font="4"><b>Results:</b>  The actuarial incidence </text>
<text top="476" left="626" width="169" height="19" font="3">of sudden death by 1 y was </text>
<text top="495" left="626" width="192" height="19" font="3">significantly greater in patients </text>
<text top="513" left="626" width="204" height="19" font="3">with (45%) than in those without </text>
<text top="531" left="626" width="206" height="19" font="3">(12%, p&lt;0.00001) syncope. In the </text>
<text top="550" left="626" width="202" height="19" font="3">Cox proportional hazards model, </text>
<text top="568" left="626" width="203" height="19" font="3">syncope predicted sudden death </text>
<text top="586" left="626" width="214" height="19" font="3">independent of AF, serum sodium, </text>
<text top="605" left="626" width="163" height="19" font="3">cardiac index, angiotensin-</text>
<text top="623" left="626" width="207" height="19" font="3">converting enzyme inhibition and </text>
<text top="641" left="626" width="199" height="19" font="3">patient age. The actuarial risk of </text>
<text top="660" left="626" width="208" height="19" font="3">sudden death by 1 y was similarly </text>
<text top="678" left="626" width="215" height="19" font="3">high in patients with either cardiac </text>
<text top="696" left="626" width="194" height="19" font="3">syncope or syncope from other </text>
<text top="714" left="626" width="174" height="19" font="3">causes (49% vs. 39%, p=NS).<b> </b></text>
<text top="421" left="854" width="212" height="19" font="3">● Authors concluded that patients </text>
<text top="440" left="854" width="92" height="19" font="3">with advanced </text>
<text top="439" left="946" width="18" height="21" font="0">HF</text>
<text top="440" left="964" width="106" height="19" font="3"> and syncope are </text>
<text top="459" left="854" width="202" height="19" font="3">at especially high risk for sudden </text>
<text top="478" left="854" width="213" height="19" font="3">death regardless of the etiology of </text>
<text top="496" left="854" width="57" height="19" font="3">syncope. </text>
<text top="514" left="854" width="3" height="19" font="3"> </text>
<text top="733" left="125" width="119" height="19" font="3">● Knight et al.1999 </text>
<text top="752" left="125" width="35" height="19" font="3">(197) </text>
<text top="770" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10362200">● </a></text>
<text top="770" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10362200">10362200</a></text>
<text top="770" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10362200"> </a></text>
<text top="733" left="264" width="163" height="19" font="4"><b>Study type:</b> Observational </text>
<text top="752" left="264" width="3" height="19" font="3"> </text>
<text top="770" left="264" width="35" height="19" font="4"><b>Size:</b>  </text>
<text top="770" left="299" width="68" height="19" font="14">14 patients</text>
<text top="770" left="367" width="3" height="19" font="4"><b> </b></text>
<text top="733" left="458" width="107" height="19" font="4"><b>Inclusion criteria</b> </text>
<text top="752" left="458" width="129" height="19" font="3">consecutive patients </text>
<text top="770" left="458" width="108" height="19" font="3">who had a NICM, </text>
<text top="734" left="626" width="145" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Mortality </text>
<text top="753" left="626" width="3" height="19" font="3"> </text>
<text top="733" left="854" width="12" height="19" font="3">● </text>
<text top="733" left="866" width="168" height="19" font="14">The authors conclude that t</text>
<text top="733" left="1034" width="19" height="19" font="3">he </text>
<text top="752" left="854" width="207" height="19" font="3">high incidence of appropriate ICD </text>
<text top="770" left="854" width="181" height="19" font="3">shocks and the association of </text>
</page>
<page number="114" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">114 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="3" height="19" font="3"> </text>
<text top="109" left="458" width="132" height="19" font="3">unexplained syncope </text>
<text top="127" left="458" width="92" height="19" font="3">and a negative </text>
<text top="145" left="458" width="138" height="19" font="3">electrophysiology test </text>
<text top="164" left="458" width="127" height="19" font="3">and who underwent </text>
<text top="182" left="458" width="75" height="19" font="3">defibrillator </text>
<text top="200" left="458" width="141" height="19" font="3">implantation (Syncope </text>
<text top="219" left="458" width="141" height="19" font="3">Group).19 consecutive </text>
<text top="238" left="458" width="94" height="19" font="3">patients with a </text>
<text top="237" left="552" width="38" height="21" font="0">NICM</text>
<text top="238" left="590" width="3" height="19" font="3"> </text>
<text top="257" left="458" width="121" height="19" font="3">and a CA who were </text>
<text top="275" left="458" width="114" height="19" font="3">treated with a ICD </text>
<text top="294" left="458" width="152" height="19" font="3">(Arrest Group) served as </text>
<text top="312" left="458" width="104" height="19" font="3">a control group.  </text>
<text top="330" left="458" width="3" height="19" font="3"> </text>
<text top="348" left="458" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="367" left="458" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="626" width="183" height="19" font="4"><b>Results:</b>  Seven of 14 patients </text>
<text top="127" left="626" width="173" height="19" font="3">(50%) in the Syncope Group </text>
<text top="145" left="626" width="196" height="19" font="3">received appropriate shocks for </text>
<text top="164" left="626" width="189" height="19" font="3">VA during a mean follow-up of </text>
<text top="182" left="626" width="209" height="19" font="3">24±13 mo, compared with 8 of 19 </text>
<text top="200" left="626" width="213" height="19" font="3">patients (42%) in the Arrest Group </text>
<text top="219" left="626" width="210" height="19" font="3">during a mean follow-up of 45±40 </text>
<text top="237" left="626" width="74" height="19" font="3">mo (p=0.1).<b> </b></text>
<text top="109" left="854" width="217" height="19" font="3">recurrent syncope with VA support </text>
<text top="127" left="854" width="189" height="19" font="3">the treatment of patients with </text>
<text top="145" left="854" width="207" height="19" font="3">NICM unexplained syncope and a </text>
<text top="164" left="854" width="194" height="19" font="3">negative electrophysiology test </text>
<text top="182" left="854" width="59" height="19" font="3">with ICD. </text>
<text top="200" left="854" width="3" height="19" font="3"> </text>
<text top="386" left="125" width="93" height="19" font="3">● Brilakis et al. </text>
<text top="404" left="125" width="69" height="19" font="3">2001 (198) </text>
<text top="423" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11816631">● </a></text>
<text top="423" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11816631">11816631</a></text>
<text top="423" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11816631"> </a></text>
<text top="441" left="125" width="3" height="19" font="3"> </text>
<text top="386" left="264" width="163" height="19" font="4"><b>Study type:</b> Observational </text>
<text top="404" left="264" width="3" height="19" font="3"> </text>
<text top="423" left="264" width="35" height="19" font="4"><b>Size:</b>  </text>
<text top="423" left="299" width="68" height="19" font="14">54 patients</text>
<text top="423" left="367" width="3" height="19" font="4"><b> </b></text>
<text top="386" left="458" width="115" height="19" font="4"><b>Inclusion criteria: </b> </text>
<text top="404" left="458" width="118" height="19" font="3">Between 1990 and </text>
<text top="423" left="458" width="123" height="19" font="3">1998, 54 (mean age </text>
<text top="441" left="458" width="120" height="19" font="3">67±11 y, 76% men) </text>
<text top="459" left="458" width="149" height="19" font="3">patients presented with </text>
<text top="478" left="458" width="121" height="19" font="3">IDCM and syncope. </text>
<text top="496" left="458" width="3" height="19" font="3"> </text>
<text top="514" left="458" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="386" left="626" width="209" height="19" font="4"><b>Results:</b> An EPS was done in 37 of </text>
<text top="404" left="626" width="210" height="19" font="3">the 54 patients. In the 17 patients </text>
<text top="423" left="626" width="209" height="19" font="3">who received an ICD, incidence of </text>
<text top="441" left="626" width="194" height="19" font="3">appropriate shocks at 1 and 3 y </text>
<text top="459" left="626" width="211" height="19" font="3">was 47% and 74%, respectively, in </text>
<text top="478" left="626" width="144" height="19" font="3">the inducible sustained </text>
<text top="496" left="626" width="207" height="19" font="3">monomorphic VT group, and 40% </text>
<text top="514" left="626" width="178" height="19" font="3">and 40%, respectively, in the </text>
<text top="532" left="626" width="211" height="19" font="3">group without inducible sustained </text>
<text top="551" left="626" width="186" height="19" font="3">monomorphic VT (p=0.29, log-</text>
<text top="569" left="626" width="62" height="19" font="3">rank test)<b> </b></text>
<text top="386" left="854" width="12" height="19" font="3">● </text>
<text top="386" left="866" width="163" height="19" font="14">The authors conclude that </text>
<text top="404" left="854" width="152" height="19" font="3">programmed ventricular </text>
<text top="423" left="854" width="189" height="19" font="3">stimulation is not useful in risk </text>
<text top="441" left="854" width="218" height="19" font="3">stratification of patients with IDCM </text>
<text top="459" left="854" width="172" height="19" font="3">and syncope and may delay </text>
<text top="478" left="854" width="173" height="19" font="3">necessary ICD implantation. </text>
<text top="588" left="125" width="103" height="19" font="3">● Fonarow et al. </text>
<text top="606" left="125" width="69" height="19" font="3">2000 (199) </text>
<text top="625" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10760339">● </a></text>
<text top="625" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10760339">10760339</a></text>
<text top="625" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10760339"> </a></text>
<text top="643" left="125" width="3" height="19" font="3"> </text>
<text top="588" left="264" width="163" height="19" font="4"><b>Study type:</b> Observational </text>
<text top="606" left="264" width="3" height="19" font="3"> </text>
<text top="625" left="264" width="115" height="19" font="4"><b>Size:</b>  147 patients<b> </b></text>
<text top="588" left="458" width="141" height="19" font="4"><b>Inclusion criteria: </b> 147 </text>
<text top="606" left="458" width="119" height="19" font="3">patients with Hx of </text>
<text top="625" left="458" width="152" height="19" font="3">syncope and no prior Hx </text>
<text top="643" left="458" width="133" height="19" font="3">of sustained VT or CA </text>
<text top="661" left="458" width="100" height="19" font="3">were identified. </text>
<text top="680" left="458" width="100" height="19" font="3">Outcomes were </text>
<text top="698" left="458" width="129" height="19" font="3">compared for the 25 </text>
<text top="716" left="458" width="144" height="19" font="3">patients managed with </text>
<text top="735" left="458" width="149" height="19" font="3">an ICD and 122 patients </text>
<text top="753" left="458" width="90" height="19" font="3">managed with </text>
<text top="588" left="626" width="207" height="19" font="4"><b>Results:</b> During a mean follow-up </text>
<text top="606" left="626" width="199" height="19" font="3">of 22 mo, there were 31 deaths, </text>
<text top="625" left="626" width="187" height="19" font="3">18 sudden, in patients treated </text>
<text top="643" left="626" width="168" height="19" font="3">with conventional therapy, </text>
<text top="661" left="626" width="185" height="19" font="3">whereas there were 2 deaths, </text>
<text top="680" left="626" width="203" height="19" font="3">none sudden, in patients treated </text>
<text top="698" left="626" width="211" height="19" font="3">with an ICD. An appropriate shock </text>
<text top="716" left="626" width="166" height="19" font="3">occurred in 40% of the ICD </text>
<text top="735" left="626" width="201" height="19" font="3">patients. Actuarial survival at 2 y </text>
<text top="753" left="626" width="200" height="19" font="3">was 84.9% with ICD therapy and </text>
<text top="588" left="854" width="215" height="19" font="3">● The authors conclude in patients </text>
<text top="606" left="854" width="213" height="19" font="3">with nonischemic cardiomyopathy </text>
<text top="625" left="854" width="220" height="19" font="3">and syncope, therapy with an ICD is </text>
<text top="643" left="854" width="186" height="19" font="3">associated with a reduction in </text>
<text top="661" left="854" width="218" height="19" font="3">sudden death and an improvement </text>
<text top="680" left="854" width="113" height="19" font="3">in overall survival. </text>
</page>
<page number="115" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">115 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="458" width="134" height="19" font="3">conventional medical </text>
<text top="127" left="458" width="55" height="19" font="3">therapy. </text>
<text top="145" left="458" width="3" height="19" font="3"> </text>
<text top="164" left="458" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="182" left="458" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="626" width="205" height="19" font="3">66.9% with conventional therapy </text>
<text top="127" left="626" width="58" height="19" font="3">(p=0.04).<b> </b></text>
<text top="201" left="125" width="12" height="19" font="3">● </text>
<text top="201" left="137" width="99" height="19" font="16">Olshansky et al. </text>
<text top="219" left="125" width="69" height="19" font="16">2008 (200) </text>
<text top="238" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18371559">● </a></text>
<text top="238" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18371559">18371559</a></text>
<text top="238" left="198" width="3" height="19" font="16"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18371559"> </a></text>
<text top="256" left="125" width="3" height="19" font="3"> </text>
<text top="274" left="125" width="3" height="19" font="3"> </text>
<text top="293" left="125" width="3" height="19" font="3"> </text>
<text top="311" left="125" width="3" height="19" font="3"> </text>
<text top="201" left="264" width="136" height="19" font="4"><b>Study type:</b> Subgroup </text>
<text top="219" left="264" width="162" height="19" font="3">analysis of SCD-HeFT trial. </text>
<text top="238" left="264" width="3" height="19" font="3"> </text>
<text top="256" left="264" width="115" height="19" font="4"><b>Size:</b>  472 patients<b> </b></text>
<text top="201" left="458" width="115" height="19" font="4"><b>Inclusion criteria: </b> </text>
<text top="219" left="458" width="154" height="19" font="3">Patients in the SCD-HeFT </text>
<text top="238" left="458" width="115" height="19" font="3">trial who reported </text>
<text top="256" left="458" width="135" height="19" font="3">syncope prior of after </text>
<text top="274" left="458" width="96" height="19" font="3">randomization. </text>
<text top="292" left="458" width="3" height="19" font="3"> </text>
<text top="311" left="458" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="329" left="458" width="3" height="19" font="4"><b> </b></text>
<text top="202" left="626" width="213" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Outcomes, including </text>
<text top="220" left="626" width="213" height="19" font="3">mortality, ICD discharges and SCD. </text>
<text top="238" left="626" width="3" height="19" font="3"> </text>
<text top="257" left="626" width="56" height="19" font="4"><b>Results:</b>  </text>
<text top="257" left="682" width="139" height="19" font="16">In SCD-HeFT, 162 (6%) </text>
<text top="275" left="626" width="177" height="19" font="16">patients had syncope before </text>
<text top="293" left="626" width="187" height="19" font="16">randomization, 356 (14%) had </text>
<text top="312" left="626" width="179" height="19" font="16">syncope after randomization </text>
<text top="330" left="626" width="157" height="19" font="16">(similar incidence in each </text>
<text top="348" left="626" width="214" height="19" font="16">randomized arm), and 46 (2%) had </text>
<text top="367" left="626" width="157" height="19" font="16">syncope before and after </text>
<text top="385" left="626" width="191" height="19" font="16">randomization. In the ICD arm, </text>
<text top="403" left="626" width="160" height="19" font="16">syncope, before and after </text>
<text top="422" left="626" width="191" height="19" font="16">randomization, was associated </text>
<text top="440" left="626" width="198" height="19" font="16">with appropriate ICD discharges </text>
<text top="458" left="626" width="135" height="19" font="16">(HR: 1.75;95% CI: 1.10</text>
<text top="458" left="761" width="7" height="19" font="3">–</text>
<text top="458" left="768" width="34" height="19" font="16">2.80, </text>
<text top="476" left="626" width="183" height="19" font="16">p=0.019 and HR: 2.91;95% CI: </text>
<text top="495" left="626" width="26" height="19" font="16">1.89</text>
<text top="495" left="652" width="7" height="19" font="3">–</text>
<text top="495" left="660" width="175" height="19" font="16">4.47, p=0.001, respectively). </text>
<text top="513" left="626" width="177" height="19" font="16">Post-randomization syncope </text>
<text top="531" left="626" width="212" height="19" font="16">predicted total and cardiovascular </text>
<text top="550" left="626" width="177" height="19" font="16">death (HR: 1.41; 95% CI: 1.13</text>
<text top="550" left="803" width="7" height="19" font="3">–</text>
<text top="568" left="626" width="201" height="19" font="16">1.76, p=0.002 and HR: 1.55; 95% </text>
<text top="586" left="626" width="46" height="19" font="16">CI: 1.19</text>
<text top="586" left="672" width="7" height="19" font="3">–</text>
<text top="586" left="679" width="91" height="19" font="16">2.02, p=0.001, </text>
<text top="605" left="626" width="167" height="19" font="16">respectively). The elevated </text>
<text top="623" left="626" width="170" height="19" font="16">relative risk of mortality for </text>
<text top="641" left="626" width="204" height="19" font="16">syncope vs. nonsyncope patients </text>
<text top="660" left="626" width="194" height="19" font="16">did not vary significantly across </text>
<text top="678" left="626" width="191" height="19" font="16">treatment arms (ICD, HR: 1.54; </text>
<text top="696" left="626" width="75" height="19" font="16">95% CI: 1.04</text>
<text top="696" left="701" width="7" height="19" font="3">–</text>
<text top="696" left="708" width="115" height="19" font="16">2.27; amiodarone, </text>
<text top="714" left="626" width="134" height="19" font="16">HR: 1.33; 95% CI: 0.91</text>
<text top="714" left="760" width="7" height="19" font="3">–</text>
<text top="714" left="767" width="61" height="19" font="16">1.93; and </text>
<text top="733" left="626" width="189" height="19" font="16">placebo, HR: 1.39; 95% CI: 0.96</text>
<text top="733" left="815" width="7" height="19" font="3">–</text>
<text top="751" left="626" width="201" height="19" font="16">2.02, test for difference p=0.86). </text>
<text top="201" left="854" width="12" height="19" font="3">● </text>
<text top="201" left="866" width="178" height="19" font="16">Syncope was common in the </text>
<text top="219" left="854" width="168" height="19" font="16">SCD-HeFT population. Post-</text>
<text top="238" left="854" width="173" height="19" font="16">randomization syncope was </text>
<text top="256" left="854" width="201" height="19" font="16">associated with increased risk of </text>
<text top="274" left="854" width="211" height="19" font="16">all-cause mortality, cardiovascular </text>
<text top="293" left="854" width="170" height="19" font="16">mortality, and SCD (despite </text>
<text top="311" left="854" width="199" height="19" font="16">randomization to an ICD). Those </text>
<text top="329" left="854" width="192" height="19" font="16">patients randomized to an ICD, </text>
<text top="347" left="854" width="219" height="19" font="16">who had syncope, were more likely </text>
<text top="366" left="854" width="208" height="19" font="16">to receive appropriate ICD shocks </text>
<text top="384" left="854" width="204" height="19" font="16">than those without syncope; yet, </text>
<text top="402" left="854" width="195" height="19" font="16">did not protect patients against </text>
<text top="421" left="854" width="188" height="19" font="16">recurrent syncope and did not </text>
<text top="439" left="854" width="199" height="19" font="16">protect against the risk of death.</text>
<text top="439" left="1052" width="3" height="19" font="3"> </text>
<text top="770" left="115" width="3" height="19" font="3"> </text>
</page>
<page number="116" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">116 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="525" height="21" font="2"><b>Data Supplement 27. RCTs Primary Prevention SCD in NICM – (Section 7.2.2) </b></text>
<text top="129" left="127" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="147" left="153" width="55" height="19" font="4"><b>Author;  </b></text>
<text top="165" left="131" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="129" left="268" width="88" height="19" font="4"><b>Aim of Study; </b></text>
<text top="147" left="274" width="76" height="19" font="4"><b>Study Type; </b></text>
<text top="165" left="267" width="89" height="19" font="4"><b>Study Size (N) </b></text>
<text top="129" left="405" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="129" left="562" width="123" height="19" font="4"><b>Study Intervention  </b></text>
<text top="147" left="579" width="88" height="19" font="4"><b>(# patients) /  </b></text>
<text top="165" left="563" width="121" height="19" font="4"><b>Study Comparator  </b></text>
<text top="184" left="584" width="75" height="19" font="4"><b>(# patients) </b></text>
<text top="129" left="732" width="108" height="19" font="4"><b>Endpoint Results </b></text>
<text top="147" left="714" width="148" height="19" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="165" left="718" width="136" height="19" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="184" left="761" width="49" height="19" font="4"><b>95% CI) </b></text>
<text top="129" left="883" width="190" height="19" font="4"><b>Relevant  2</b>°<b> Endpoint (if any); </b></text>
<text top="148" left="920" width="116" height="19" font="4"><b>Study Limitations; </b></text>
<text top="166" left="929" width="99" height="19" font="4"><b>Adverse Events </b></text>
<text top="203" left="123" width="44" height="19" font="3">● <b>CAT  </b></text>
<text top="221" left="123" width="68" height="19" font="3">● Bänsch D</text>
<text top="221" left="192" width="2" height="12" font="15"> </text>
<text top="221" left="194" width="34" height="19" font="3">et al. </text>
<text top="239" left="123" width="69" height="19" font="3">2002 (201) </text>
<text top="258" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=11914254">● </a></text>
<text top="258" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=11914254">11914254</a></text>
<text top="258" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=11914254"> </a></text>
<text top="276" left="123" width="3" height="19" font="3"> </text>
<text top="294" left="123" width="3" height="19" font="4"><b> </b></text>
<text top="313" left="123" width="10" height="19" font="3">   </text>
<text top="203" left="247" width="111" height="19" font="4"><b>Aim:</b>  Multicenter </text>
<text top="221" left="247" width="87" height="19" font="3">RCT of ICD vs. </text>
<text top="239" left="247" width="83" height="19" font="3">conventional </text>
<text top="258" left="247" width="115" height="19" font="3">Therapy in NIDCM </text>
<text top="276" left="247" width="3" height="19" font="3"> </text>
<text top="294" left="247" width="108" height="19" font="4"><b>Study type:</b>   RCT </text>
<text top="313" left="247" width="3" height="19" font="3"> </text>
<text top="331" left="247" width="121" height="19" font="4"><b>Size:</b>    104 patients </text>
<text top="203" left="390" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="221" left="390" width="133" height="19" font="3">Recent onset of DCM </text>
<text top="239" left="390" width="150" height="19" font="3">(≤9 mo) and an EF ≤30% </text>
<text top="258" left="390" width="85" height="19" font="3">and class II-III </text>
<text top="276" left="390" width="3" height="19" font="3"> </text>
<text top="294" left="390" width="150" height="19" font="4"><b>Exclusion criteria:</b>  CAD, </text>
<text top="313" left="390" width="108" height="19" font="3">excessive alcohol </text>
<text top="331" left="390" width="115" height="19" font="3">intake, prior MI or </text>
<text top="349" left="390" width="78" height="19" font="3">myocarditis. </text>
<text top="203" left="553" width="110" height="19" font="4"><b>Intervention:</b> ICD </text>
<text top="221" left="553" width="45" height="19" font="3">(N=50) </text>
<text top="239" left="553" width="3" height="19" font="3"> </text>
<text top="258" left="553" width="93" height="19" font="4"><b>Comparator:</b>  <b>  </b></text>
<text top="276" left="553" width="135" height="19" font="3">Conventional therapy </text>
<text top="294" left="553" width="45" height="19" font="3">(N=54)<b> </b></text>
<text top="203" left="703" width="153" height="19" font="4"><b>1</b>°<b> endpoint:</b>  The 1° end </text>
<text top="222" left="703" width="149" height="19" font="3">point of the trial was all-</text>
<text top="240" left="703" width="141" height="19" font="3">cause mortality at 1 y.  </text>
<text top="258" left="703" width="3" height="19" font="3"> </text>
<text top="277" left="703" width="160" height="20" font="3">• Cumulative survival was </text>
<text top="296" left="703" width="160" height="19" font="3">92%, 86%, and 73% in the </text>
<text top="314" left="703" width="129" height="19" font="3">ICD treatment group </text>
<text top="333" left="703" width="156" height="19" font="3">vs. 93%, 80%, and 68% in </text>
<text top="351" left="703" width="158" height="19" font="3">the control group after 2, </text>
<text top="369" left="703" width="143" height="19" font="3">4, and 6 y, respectively </text>
<text top="388" left="703" width="114" height="19" font="3">(log rank p=0.554) </text>
<text top="406" left="703" width="10" height="19" font="3">   </text>
<text top="424" left="703" width="3" height="19" font="4"><b> </b></text>
<text top="203" left="882" width="182" height="19" font="3">● Enrollment was terminated </text>
<text top="221" left="882" width="158" height="19" font="3">early because the interim </text>
<text top="239" left="882" width="154" height="19" font="3">analysis showed that the </text>
<text top="258" left="882" width="189" height="19" font="3">overall1 y mortality rate for all </text>
<text top="276" left="882" width="175" height="19" font="3">patients was only 5.6%, well </text>
<text top="294" left="882" width="174" height="19" font="3">below the assumed value of </text>
<text top="313" left="882" width="36" height="19" font="3">30%.  </text>
<text top="331" left="882" width="135" height="19" font="3">● Because the overall </text>
<text top="349" left="882" width="192" height="19" font="3">mortality rate was too low, the </text>
<text top="368" left="882" width="181" height="19" font="3">study was stopped for futility </text>
<text top="386" left="882" width="175" height="19" font="3">after the pilot phase. Even if </text>
<text top="404" left="882" width="151" height="19" font="3">1,348 patients had been </text>
<text top="423" left="882" width="180" height="19" font="3">included, as initially planned, </text>
<text top="441" left="882" width="159" height="19" font="3">the trial would have been </text>
<text top="459" left="882" width="98" height="19" font="3">underpowered. </text>
<text top="478" left="882" width="3" height="19" font="3"> </text>
<text top="497" left="123" width="84" height="19" font="3">● <b>AMIOVIRT </b> </text>
<text top="515" left="123" width="86" height="19" font="3">● Strickberger</text>
<text top="513" left="210" width="4" height="21" font="0"> </text>
<text top="515" left="213" width="16" height="19" font="3">et </text>
<text top="533" left="123" width="87" height="19" font="3">al.<b> </b>2003 (202) </text>
<text top="552" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12767651?dopt=Citation">● </a></text>
<text top="552" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12767651?dopt=Citation">12767651</a></text>
<text top="552" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12767651?dopt=Citation"> </a></text>
<text top="570" left="123" width="3" height="19" font="3"> </text>
<text top="497" left="247" width="111" height="19" font="4"><b>Aim:</b>  Multicenter </text>
<text top="515" left="247" width="87" height="19" font="3">RCT of ICD vs. </text>
<text top="533" left="247" width="78" height="19" font="3">amiodarone </text>
<text top="552" left="247" width="115" height="19" font="3">Therapy in NIDCM </text>
<text top="570" left="247" width="62" height="19" font="3">and NSVT </text>
<text top="588" left="247" width="3" height="19" font="3"> </text>
<text top="606" left="247" width="111" height="19" font="4"><b>Study type: </b>RCT    </text>
<text top="625" left="247" width="3" height="19" font="3"> </text>
<text top="643" left="247" width="121" height="19" font="4"><b>Size:</b>    103 patients </text>
<text top="497" left="390" width="132" height="19" font="4"><b>Inclusion criteria:</b>  EF </text>
<text top="515" left="390" width="131" height="19" font="3">≤0.35, asymptomatic </text>
<text top="533" left="390" width="133" height="19" font="3">NSVT, NYHA class I to </text>
<text top="552" left="390" width="18" height="19" font="3">III. </text>
<text top="570" left="390" width="3" height="19" font="3"> </text>
<text top="588" left="390" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="606" left="390" width="140" height="19" font="3">Syncope, pregnancy, a </text>
<text top="625" left="390" width="120" height="19" font="3">contraindication to </text>
<text top="643" left="390" width="94" height="19" font="3">amiodarone or </text>
<text top="661" left="390" width="121" height="19" font="3">ICD or concomitant </text>
<text top="680" left="390" width="133" height="19" font="3">therapy with a Class I </text>
<text top="698" left="390" width="30" height="19" font="3">AAD </text>
<text top="497" left="553" width="110" height="19" font="4"><b>Intervention:</b> ICD </text>
<text top="515" left="553" width="45" height="19" font="3">(N=51) </text>
<text top="533" left="553" width="7" height="19" font="3">  </text>
<text top="551" left="553" width="86" height="19" font="4"><b>Comparator:</b>  </text>
<text top="570" left="553" width="131" height="19" font="3">Amiodarone (N=52)<b>   </b></text>
<text top="497" left="703" width="119" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Total </text>
<text top="516" left="703" width="60" height="19" font="3">Mortality </text>
<text top="534" left="703" width="3" height="19" font="3"> </text>
<text top="553" left="703" width="152" height="20" font="3">• Survival at 1 y (90% vs. </text>
<text top="571" left="703" width="135" height="19" font="3">96%) and 3 y (88% vs. </text>
<text top="590" left="703" width="143" height="19" font="3">87%) was similar in the </text>
<text top="608" left="703" width="128" height="19" font="3">amiodarone and ICD </text>
<text top="626" left="703" width="122" height="19" font="3">groups respectively </text>
<text top="645" left="703" width="51" height="19" font="3">(p=0.8).<b> </b></text>
<text top="497" left="882" width="169" height="19" font="3">● Trial terminated early for </text>
<text top="515" left="882" width="175" height="19" font="3">futility in view of lower than </text>
<text top="533" left="882" width="123" height="19" font="3">expected mortality. </text>
<text top="552" left="882" width="189" height="19" font="3">● With the observed mortality </text>
<text top="570" left="882" width="174" height="19" font="3">rates, approximately 12,000 </text>
<text top="588" left="882" width="161" height="19" font="3">patients would have been </text>
<text top="606" left="882" width="191" height="19" font="3">required to achieve a power of </text>
<text top="625" left="882" width="33" height="19" font="3">80%. </text>
<text top="643" left="882" width="3" height="19" font="3"> </text>
<text top="661" left="882" width="3" height="19" font="3"> </text>
<text top="680" left="882" width="3" height="19" font="3"> </text>
<text top="698" left="882" width="3" height="19" font="3"> </text>
</page>
<page number="117" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">117 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="76" height="19" font="3">● <b>DEFINITE  </b></text>
<text top="127" left="123" width="105" height="19" font="3">● Kadish A, et al. </text>
<text top="145" left="123" width="69" height="19" font="3">2004 (203) </text>
<text top="164" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15152060">● </a></text>
<text top="164" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15152060">15152060</a></text>
<text top="164" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15152060"> </a></text>
<text top="109" left="247" width="111" height="19" font="4"><b>Aim:</b>  Multicenter </text>
<text top="127" left="247" width="87" height="19" font="3">RCT of ICD vs. </text>
<text top="145" left="247" width="108" height="19" font="3">standard medical </text>
<text top="164" left="247" width="112" height="19" font="3">therapy in NIDCM </text>
<text top="182" left="247" width="101" height="19" font="3">and ambient VA </text>
<text top="200" left="247" width="3" height="19" font="3"> </text>
<text top="218" left="247" width="108" height="19" font="4"><b>Study type:</b>   RCT </text>
<text top="237" left="247" width="3" height="19" font="3"> </text>
<text top="255" left="247" width="121" height="19" font="4"><b>Size:</b>    458 patients </text>
<text top="109" left="390" width="132" height="19" font="4"><b>Inclusion criteria:</b>  EF </text>
<text top="127" left="390" width="140" height="19" font="3">≤35%, and &gt;10 PVCs/h </text>
<text top="145" left="390" width="56" height="19" font="3">or NSVT. </text>
<text top="164" left="390" width="3" height="19" font="3"> </text>
<text top="182" left="390" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="200" left="390" width="86" height="19" font="3">NYHA class IV </text>
<text top="219" left="390" width="71" height="19" font="3">HF, familial </text>
<text top="237" left="390" width="103" height="19" font="3">cardiomyopathy </text>
<text top="255" left="390" width="146" height="19" font="3">associated with sudden </text>
<text top="273" left="390" width="80" height="19" font="3">death, acute </text>
<text top="292" left="390" width="91" height="19" font="3">myocarditis or </text>
<text top="310" left="390" width="103" height="19" font="3">congenital heart </text>
<text top="328" left="390" width="52" height="19" font="3">disease. </text>
<text top="109" left="553" width="110" height="19" font="4"><b>Intervention:</b> ICD </text>
<text top="127" left="553" width="53" height="19" font="3">(N=229) </text>
<text top="145" left="553" width="3" height="19" font="3"> </text>
<text top="164" left="553" width="93" height="19" font="4"><b>Comparator:</b>  <b>  </b></text>
<text top="182" left="553" width="135" height="19" font="3">Conventional therapy </text>
<text top="200" left="553" width="53" height="19" font="3">(N=229)<b> </b></text>
<text top="109" left="703" width="119" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Total </text>
<text top="128" left="703" width="60" height="19" font="3">Mortality </text>
<text top="146" left="703" width="3" height="19" font="3"> </text>
<text top="165" left="703" width="163" height="19" font="3">Fewer patients died in the </text>
<text top="183" left="703" width="134" height="19" font="3">ICD group than in the </text>
<text top="201" left="703" width="158" height="19" font="3">Control group (28 vs. 40), </text>
<text top="219" left="703" width="128" height="19" font="3">but the difference in </text>
<text top="238" left="703" width="155" height="19" font="3">survival was NS (p=0.08)<b> </b> </text>
<text top="256" left="703" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="882" width="189" height="19" font="3">● There were 3 sudden deaths </text>
<text top="127" left="882" width="167" height="19" font="3">from arrhythmia in the ICD </text>
<text top="145" left="882" width="174" height="19" font="3">group, as compared with 14 </text>
<text top="164" left="882" width="83" height="19" font="3">deaths in the </text>
<text top="182" left="882" width="183" height="19" font="3">● Control group (HR: 0.20; 95 </text>
<text top="200" left="882" width="159" height="19" font="3">% CI: 0.06–0.71; p=0.006) </text>
<text top="219" left="909" width="3" height="19" font="3"> </text>
<text top="347" left="123" width="76" height="19" font="3">● <b>SCD-HeFT </b></text>
<text top="366" left="123" width="85" height="19" font="3">● Bardy et al. </text>
<text top="384" left="123" width="30" height="19" font="3">2005</text>
<text top="383" left="154" width="4" height="21" font="0"> </text>
<text top="384" left="157" width="28" height="19" font="3">(43) </text>
<text top="402" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15659722">● </a></text>
<text top="402" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15659722">15659722</a></text>
<text top="402" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15659722"> </a></text>
<text top="421" left="123" width="3" height="19" font="3"> </text>
<text top="439" left="123" width="3" height="19" font="3"> </text>
<text top="347" left="247" width="111" height="19" font="4"><b>Aim:</b>  Multicenter </text>
<text top="366" left="247" width="83" height="19" font="3">RCT of ICD vs </text>
<text top="384" left="247" width="97" height="19" font="3">amiodarone vs. </text>
<text top="402" left="247" width="101" height="19" font="3">optimal medical </text>
<text top="421" left="247" width="51" height="19" font="3">therapy </text>
<text top="439" left="247" width="3" height="19" font="3"> </text>
<text top="457" left="247" width="108" height="19" font="4"><b>Study type:</b>  RCT  </text>
<text top="476" left="247" width="3" height="19" font="3"> </text>
<text top="494" left="247" width="79" height="19" font="4"><b>Size:</b>    2,521 </text>
<text top="512" left="247" width="53" height="19" font="3">patients </text>
<text top="347" left="390" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="366" left="390" width="100" height="19" font="3">Ischemic or non </text>
<text top="384" left="390" width="132" height="19" font="3">ischemic DCM, NYHA </text>
<text top="402" left="390" width="120" height="19" font="3">class II or III HF and </text>
<text top="421" left="390" width="69" height="19" font="3">LVEF ≤35% </text>
<text top="439" left="390" width="3" height="19" font="3"> </text>
<text top="457" left="390" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="347" left="553" width="85" height="19" font="4"><b>Intervention:</b> </text>
<text top="366" left="553" width="131" height="19" font="3">Amiodarone (N=845) </text>
<text top="384" left="553" width="131" height="19" font="3">ICD therapy (N= 829) </text>
<text top="402" left="553" width="7" height="19" font="3">  </text>
<text top="421" left="553" width="93" height="19" font="4"><b>Comparator:</b>  <b>  </b></text>
<text top="439" left="553" width="103" height="19" font="3">Optimal medical </text>
<text top="457" left="553" width="103" height="19" font="3">therapy (N=847) </text>
<text top="348" left="703" width="88" height="19" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="367" left="703" width="156" height="19" font="3">After a median follow-up </text>
<text top="385" left="703" width="152" height="19" font="3">of 4 y, the mortality rate </text>
<text top="403" left="703" width="162" height="19" font="3">was 22% in the ICD group, </text>
<text top="422" left="703" width="145" height="19" font="3">28% in the amiodarone </text>
<text top="440" left="703" width="137" height="19" font="3">group, and 29% in the </text>
<text top="458" left="703" width="118" height="19" font="3">control group. This </text>
<text top="476" left="703" width="128" height="19" font="3">resulted in a 22% RR </text>
<text top="495" left="703" width="132" height="19" font="3">reduction and a 7.2% </text>
<text top="513" left="703" width="158" height="19" font="3">absolute risk reduction in </text>
<text top="531" left="703" width="155" height="19" font="3">the all-cause mortality in </text>
<text top="550" left="703" width="104" height="19" font="3">the ICD group as </text>
<text top="568" left="703" width="160" height="19" font="3">compared with optimized </text>
<text top="586" left="703" width="139" height="19" font="3">medical therapy alone </text>
<text top="605" left="703" width="62" height="19" font="3">(p=0.007)<b> </b></text>
<text top="347" left="882" width="162" height="19" font="3">● Amiodarone showed no </text>
<text top="366" left="882" width="112" height="19" font="3">benefit in survival </text>
<text top="384" left="882" width="177" height="19" font="3">● Non-ischemic DCM 48% of </text>
<text top="402" left="882" width="47" height="19" font="3">cohort. </text>
<text top="421" left="882" width="180" height="19" font="3">● Similar benefit ischemic vs. </text>
<text top="439" left="882" width="88" height="19" font="3">non-ischemic. </text>
<text top="457" left="882" width="3" height="19" font="3"> </text>
<text top="476" left="882" width="3" height="19" font="3"> </text>
<text top="624" left="123" width="98" height="19" font="3">● <b>COMPANION </b></text>
<text top="642" left="123" width="96" height="19" font="3">● Bristow et al. </text>
<text top="660" left="123" width="69" height="19" font="3">2004 (204) </text>
<text top="679" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15152059">● </a></text>
<text top="679" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15152059">15152059</a></text>
<text top="679" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15152059"> </a></text>
<text top="697" left="123" width="3" height="19" font="3"> </text>
<text top="624" left="247" width="111" height="19" font="4"><b>Aim:</b>  Multicenter </text>
<text top="642" left="247" width="117" height="19" font="3">RCT of CRT vs. CRT-</text>
<text top="660" left="247" width="97" height="19" font="3">D vs. optimized </text>
<text top="679" left="247" width="102" height="19" font="3">medical therapy </text>
<text top="697" left="247" width="3" height="19" font="3"> </text>
<text top="715" left="247" width="108" height="19" font="4"><b>Study type:</b>   RCT </text>
<text top="733" left="247" width="3" height="19" font="3"> </text>
<text top="752" left="247" width="79" height="19" font="4"><b>Size:</b>    1,520 </text>
<text top="770" left="247" width="53" height="19" font="3">patients </text>
<text top="624" left="390" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="642" left="390" width="138" height="19" font="3">1,520 Ischemic or non </text>
<text top="660" left="390" width="132" height="19" font="3">ischemic DCM, NYHA </text>
<text top="679" left="390" width="115" height="19" font="3">class III or IV, LVEF </text>
<text top="697" left="390" width="125" height="19" font="3">≤35% and QRS &gt;120 </text>
<text top="715" left="390" width="35" height="19" font="3">msec </text>
<text top="733" left="390" width="3" height="19" font="3"> </text>
<text top="752" left="390" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="624" left="553" width="89" height="19" font="4"><b>Intervention:</b>  </text>
<text top="642" left="553" width="93" height="19" font="3">CRT-D (N=595) </text>
<text top="660" left="553" width="117" height="19" font="3">CRT Pacer (N=617) </text>
<text top="679" left="553" width="3" height="19" font="3"> </text>
<text top="697" left="553" width="135" height="19" font="4"><b>Comparator:</b> Optimal </text>
<text top="715" left="553" width="102" height="19" font="3">medical therapy </text>
<text top="733" left="553" width="53" height="19" font="3">(N=308) </text>
<text top="624" left="703" width="153" height="19" font="4"><b>1</b>°<b> endpoint:</b>  The 1° end </text>
<text top="643" left="703" width="156" height="19" font="3">point was a composite of </text>
<text top="661" left="703" width="148" height="19" font="3">death or hospitalization </text>
<text top="680" left="703" width="88" height="19" font="3">for any cause. </text>
<text top="698" left="703" width="154" height="19" font="3">CRT-P decreased the risk </text>
<text top="716" left="703" width="147" height="19" font="3">of the 1° end point (HR: </text>
<text top="734" left="703" width="154" height="19" font="3">0.81; p=0.014), as did CT-</text>
<text top="753" left="703" width="130" height="19" font="3">D (HR: 0.80; p=0.01). </text>
<text top="624" left="882" width="176" height="19" font="3">● A CRT pacemaker reduced </text>
<text top="642" left="882" width="182" height="19" font="3">the risk of the 2° end point of </text>
<text top="660" left="882" width="182" height="19" font="3">death from any cause by 24% </text>
<text top="679" left="882" width="129" height="19" font="3">(p=0.059), and a CRT </text>
<text top="697" left="882" width="150" height="19" font="3">pacemaker–defibrillator </text>
<text top="715" left="882" width="149" height="19" font="3">reduced the risk by 36% </text>
<text top="734" left="882" width="62" height="19" font="3">(p=0.003) </text>
<text top="752" left="882" width="186" height="19" font="3">● Non ischemic 44% of cohort </text>
<text top="770" left="882" width="3" height="19" font="3"> </text>
</page>
<page number="118" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">118 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="83" height="19" font="3">● Desai et al. </text>
<text top="127" left="123" width="69" height="19" font="3">2004 (195) </text>
<text top="145" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=15598919">● </a></text>
<text top="145" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=15598919">15598919</a></text>
<text top="145" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=15598919"> </a></text>
<text top="164" left="123" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="247" width="122" height="19" font="4"><b>Aim:</b>  To determine </text>
<text top="127" left="247" width="79" height="19" font="3">whether ICD </text>
<text top="145" left="247" width="121" height="19" font="3">therapy reduces all-</text>
<text top="164" left="247" width="112" height="19" font="3">cause mortality in </text>
<text top="182" left="247" width="125" height="19" font="3">patients with NICM. </text>
<text top="200" left="247" width="3" height="19" font="3"> </text>
<text top="218" left="247" width="110" height="19" font="4"><b>Study type: </b>meta-</text>
<text top="237" left="247" width="100" height="19" font="3">analysis of RCTs </text>
<text top="255" left="247" width="3" height="19" font="3"> </text>
<text top="273" left="247" width="75" height="19" font="4"><b>Size:</b> 8 RCTs </text>
<text top="292" left="247" width="116" height="19" font="3">enrolling a total of </text>
<text top="310" left="247" width="117" height="19" font="3">2146 patients with </text>
<text top="329" left="247" width="72" height="19" font="3">NICM were </text>
<text top="347" left="247" width="104" height="19" font="3">included. 7 trials </text>
<text top="365" left="247" width="118" height="19" font="3">reported subgroup </text>
<text top="383" left="247" width="108" height="19" font="3">estimates for ICD </text>
<text top="402" left="247" width="103" height="19" font="3">efficacy in NICM<b> </b></text>
<text top="109" left="390" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="127" left="390" width="148" height="19" font="3">prospective RCTs of ICD </text>
<text top="145" left="390" width="128" height="19" font="3">or combined cardiac </text>
<text top="164" left="390" width="113" height="19" font="3">resynchronization </text>
<text top="182" left="390" width="77" height="19" font="3">therapy and </text>
<text top="200" left="390" width="141" height="19" font="3">defibrillator (CRT-D) vs </text>
<text top="219" left="390" width="102" height="19" font="3">medical therapy </text>
<text top="237" left="390" width="142" height="19" font="3">enrolling at least some </text>
<text top="255" left="390" width="136" height="19" font="3">individuals with NICM </text>
<text top="273" left="390" width="144" height="19" font="3">and reporting all-cause </text>
<text top="292" left="390" width="94" height="19" font="3">mortality as an </text>
<text top="310" left="390" width="58" height="19" font="3">outcome </text>
<text top="328" left="390" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="553" width="110" height="19" font="4"><b>Intervention:</b> ICD </text>
<text top="127" left="553" width="7" height="19" font="3">  </text>
<text top="145" left="553" width="93" height="19" font="4"><b>Comparator:</b>  <b>  </b></text>
<text top="164" left="553" width="103" height="19" font="3">Medical therapy<b> </b></text>
<text top="109" left="703" width="125" height="19" font="4"><b>1</b>°<b> endpoint:</b> Five 1° </text>
<text top="128" left="703" width="161" height="19" font="3">prevention trials enrolling </text>
<text top="146" left="703" width="155" height="19" font="3">1854 patients with NICM </text>
<text top="165" left="703" width="146" height="19" font="3">were identified; pooled </text>
<text top="183" left="703" width="127" height="19" font="3">analysis suggested a </text>
<text top="201" left="703" width="143" height="19" font="3">significant reduction in </text>
<text top="219" left="703" width="137" height="19" font="3">total mortality among </text>
<text top="238" left="703" width="146" height="19" font="3">patients randomized to </text>
<text top="256" left="703" width="149" height="19" font="3">ICD or CRT-D vs medical </text>
<text top="274" left="703" width="161" height="19" font="3">therapy (RR: 0.69; 95% CI: </text>
<text top="293" left="703" width="129" height="19" font="3">0.55–0.87; p=0.002). </text>
<text top="311" left="703" width="123" height="19" font="3">Mortality reduction </text>
<text top="329" left="703" width="160" height="19" font="3">remained significant even </text>
<text top="348" left="703" width="162" height="19" font="3">after elimination of CRT-D </text>
<text top="366" left="703" width="44" height="19" font="3">trials.   </text>
<text top="384" left="703" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="882" width="141" height="20" font="3">• Analysis of all 7 trials </text>
<text top="128" left="882" width="165" height="19" font="3">combined demonstrated a </text>
<text top="146" left="882" width="166" height="19" font="3">statistically significant 31% </text>
<text top="165" left="882" width="181" height="19" font="3">overall reduction in mortality </text>
<text top="183" left="882" width="168" height="19" font="3">with ICD therapy (RR: 0.69; </text>
<text top="201" left="882" width="178" height="19" font="3">95% CI: 0.56–0.86; p=0.002). </text>
<text top="219" left="882" width="3" height="19" font="3"> </text>
<text top="421" left="123" width="65" height="19" font="3">● <b>DANISH </b></text>
<text top="439" left="123" width="99" height="19" font="3">● Kober L, et al. </text>
<text top="457" left="123" width="69" height="19" font="3">2016 (205) </text>
<text top="476" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27571011">● </a></text>
<text top="476" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27571011">27571011</a></text>
<text top="476" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27571011"> </a></text>
<text top="421" left="247" width="110" height="19" font="4"><b>Aim:</b>  To evaluate </text>
<text top="439" left="247" width="87" height="19" font="3">the benefit of </text>
<text top="457" left="247" width="124" height="19" font="3">prophylactic ICDs in </text>
<text top="476" left="247" width="83" height="19" font="3">patients with </text>
<text top="494" left="247" width="109" height="19" font="3">systolic HF that is </text>
<text top="512" left="247" width="96" height="19" font="3">not due to CAD </text>
<text top="531" left="247" width="3" height="19" font="3"> </text>
<text top="549" left="247" width="111" height="19" font="4"><b>Study type</b>: RCT    </text>
<text top="567" left="247" width="3" height="19" font="3"> </text>
<text top="585" left="247" width="129" height="19" font="4"><b>Size:</b>    1116 patients </text>
<text top="421" left="390" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="439" left="390" width="137" height="19" font="3">Symptomatic patients </text>
<text top="457" left="390" width="137" height="19" font="3">(NYHA class II or III, or </text>
<text top="476" left="390" width="124" height="19" font="3">NYHA class IV if CRT </text>
<text top="494" left="390" width="115" height="19" font="3">was planned) with </text>
<text top="512" left="390" width="80" height="19" font="3">nonischemic </text>
<text top="531" left="390" width="146" height="19" font="3">systolic HF (LVEF ≤35%) </text>
<text top="549" left="390" width="139" height="19" font="3">and an increased level </text>
<text top="567" left="390" width="115" height="19" font="3">(&gt;200 pg/mL) of N-</text>
<text top="586" left="390" width="119" height="19" font="3">terminal pro–brain </text>
<text top="604" left="390" width="144" height="19" font="3">natriuretic peptide (NT-</text>
<text top="622" left="390" width="58" height="19" font="3">proBNP). </text>
<text top="640" left="390" width="3" height="19" font="3"> </text>
<text top="659" left="390" width="117" height="19" font="4"><b>Exclusion criteria</b>:  </text>
<text top="677" left="390" width="109" height="19" font="3">Patients who had </text>
<text top="695" left="390" width="106" height="19" font="3">permanent atrial </text>
<text top="714" left="390" width="107" height="19" font="3">fibrillation with a </text>
<text top="732" left="390" width="110" height="19" font="3">resting heart rate </text>
<text top="750" left="390" width="74" height="19" font="3">higher than </text>
<text top="421" left="553" width="110" height="19" font="4"><b>Intervention</b>: ICD </text>
<text top="439" left="553" width="53" height="19" font="3">(N=556) </text>
<text top="457" left="553" width="7" height="19" font="3">  </text>
<text top="476" left="553" width="127" height="19" font="4"><b>Comparator:</b>   Usual </text>
<text top="494" left="553" width="134" height="19" font="3">care for CHF (N=560)  </text>
<text top="421" left="703" width="158" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Death from </text>
<text top="440" left="703" width="71" height="19" font="3">any cause.  </text>
<text top="458" left="703" width="3" height="19" font="3"> </text>
<text top="476" left="703" width="156" height="19" font="3">After a median follow-up </text>
<text top="495" left="703" width="156" height="19" font="3">period of 67.6 mo, the 1° </text>
<text top="513" left="703" width="157" height="19" font="3">outcome had occurred in </text>
<text top="531" left="703" width="144" height="19" font="3">120 patients (21.6%) in </text>
<text top="550" left="703" width="155" height="19" font="3">the ICD group and in 131 </text>
<text top="568" left="703" width="141" height="19" font="3">patients (23.4%) in the </text>
<text top="586" left="703" width="150" height="19" font="3">control group (HR: 0.87; </text>
<text top="605" left="703" width="116" height="19" font="3">95% CI: 0.68–1.12; </text>
<text top="623" left="703" width="54" height="19" font="3">p=0.28). </text>
<text top="421" left="882" width="189" height="20" font="3">• SCD (a 2° outcome) occurred </text>
<text top="440" left="882" width="192" height="19" font="3">in 24 patients (4.3%) in the ICD </text>
<text top="458" left="882" width="152" height="19" font="3">group and in 46 patients </text>
<text top="476" left="882" width="167" height="19" font="3">(8.2%) in the control group </text>
<text top="495" left="882" width="180" height="19" font="3">(HR: 0.50; 95% CI: 0.31–0.82; </text>
<text top="513" left="882" width="58" height="19" font="3">p=0.005) </text>
<text top="531" left="882" width="191" height="20" font="3">• 58% of patients received CRT </text>
<text top="550" left="882" width="159" height="19" font="3">system, which could have </text>
<text top="569" left="882" width="161" height="19" font="3">influenced overall results. </text>
<text top="587" left="882" width="176" height="20" font="3">• Younger patients did show </text>
<text top="606" left="882" width="101" height="19" font="3">survival benefit. </text>
<text top="625" left="882" width="3" height="19" font="3"> </text>
<text top="643" left="882" width="3" height="19" font="3"> </text>
</page>
<page number="119" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">119 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="390" width="134" height="19" font="3">100 beats per minute </text>
<text top="127" left="390" width="149" height="19" font="3">or renal failure that was </text>
<text top="145" left="390" width="116" height="19" font="3">being treated with </text>
<text top="164" left="390" width="51" height="19" font="3">dialysis. </text>
<text top="231" left="115" width="963" height="21" font="2"><b>Data Supplement 28. Nonrandomized Trials, Observational Studies, and/or Registries of Primary Prevention of SCD in NICM – (Section 7.2.2) </b></text>
<text top="252" left="140" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="270" left="166" width="51" height="19" font="4"><b>Author; </b></text>
<text top="288" left="143" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="252" left="276" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="270" left="305" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="252" left="460" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="252" left="662" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="270" left="674" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="288" left="705" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="252" left="896" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="270" left="924" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="307" left="125" width="70" height="19" font="3">● <b>Marburg </b></text>
<text top="326" left="125" width="107" height="19" font="4"><b>Cardiomyopathy </b></text>
<text top="344" left="125" width="42" height="19" font="4"><b>Study  </b></text>
<text top="363" left="125" width="125" height="19" font="3">● Grimm et al. 2003 </text>
<text top="381" left="125" width="35" height="19" font="3">(206) </text>
<text top="399" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14623812">● </a></text>
<text top="399" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14623812">14623812</a></text>
<text top="399" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14623812"> </a></text>
<text top="417" left="125" width="3" height="19" font="3"> </text>
<text top="436" left="125" width="3" height="19" font="3"> </text>
<text top="307" left="271" width="118" height="19" font="4"><b>Aim: </b>To determine </text>
<text top="326" left="271" width="24" height="19" font="3">the </text>
<text top="344" left="271" width="97" height="19" font="3">clinical value of </text>
<text top="363" left="271" width="134" height="19" font="3">potential noninvasive </text>
<text top="381" left="271" width="96" height="19" font="3">arrhythmia risk </text>
<text top="399" left="271" width="125" height="19" font="3">predictors in a large </text>
<text top="417" left="271" width="122" height="19" font="3">patient cohort with </text>
<text top="436" left="271" width="24" height="19" font="3">IDC </text>
<text top="454" left="271" width="3" height="19" font="4"><b> </b></text>
<text top="472" left="271" width="3" height="19" font="4"><b> </b></text>
<text top="491" left="271" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="509" left="271" width="74" height="19" font="3">Prospective </text>
<text top="527" left="271" width="86" height="19" font="3">observational </text>
<text top="546" left="271" width="115" height="19" font="3">monocenter study </text>
<text top="564" left="271" width="3" height="19" font="3"> </text>
<text top="582" left="271" width="111" height="19" font="4"><b>Size:</b> 343 patients </text>
<text top="307" left="419" width="169" height="19" font="4"><b>Inclusion criteria:</b> Men and </text>
<text top="326" left="419" width="180" height="19" font="3">women with IDC between 16 </text>
<text top="344" left="419" width="191" height="19" font="3">and 70 y of age and LVEF &lt;45% </text>
<text top="363" left="419" width="196" height="19" font="3">and a LV end-diastolic diameter </text>
<text top="381" left="419" width="188" height="19" font="3">&gt;56 mm by echocardiography. </text>
<text top="399" left="419" width="3" height="19" font="3"> </text>
<text top="417" left="419" width="144" height="19" font="4"><b>Exclusion criteria:</b>  CHF </text>
<text top="436" left="419" width="201" height="19" font="3">NYHA functional class IV; a Hx of </text>
<text top="454" left="419" width="195" height="19" font="3">sustained VT or VF); an episode </text>
<text top="472" left="419" width="189" height="19" font="3">of unexplained syncope within </text>
<text top="491" left="419" width="181" height="19" font="3">the previous 12 mo; class I or </text>
<text top="509" left="419" width="193" height="19" font="3">class III AAD therapy that could </text>
<text top="527" left="419" width="192" height="19" font="3">not be withdrawn for at least 5 </text>
<text top="546" left="419" width="171" height="19" font="3">drug half-lives; amiodarone </text>
<text top="564" left="419" width="183" height="19" font="3">therapy within the previous 6 </text>
<text top="582" left="419" width="180" height="19" font="3">mo; pacemaker dependency; </text>
<text top="600" left="419" width="187" height="19" font="3">CAD diagnosed by evidence of </text>
<text top="619" left="419" width="176" height="19" font="3">any coronary artery stenosis </text>
<text top="637" left="419" width="200" height="19" font="3">&gt;50% by angiography; or a Hx of </text>
<text top="655" left="419" width="127" height="19" font="3">MI, systemic arterial </text>
<text top="674" left="419" width="127" height="19" font="3">hypertension, active </text>
<text top="692" left="419" width="201" height="19" font="3">myocarditis, alcohol abuse, drug </text>
<text top="710" left="419" width="172" height="19" font="3">dependency, severe liver or </text>
<text top="729" left="419" width="196" height="19" font="3">kidney disease, thyroid disease, </text>
<text top="747" left="419" width="159" height="19" font="3">malignancies, or systemic </text>
<text top="765" left="419" width="58" height="19" font="3">diseases. </text>
<text top="308" left="633" width="193" height="19" font="4"><b>1</b>°<b> endpoint:</b>  During 52±21 mo </text>
<text top="327" left="633" width="191" height="19" font="3">of follow-up, major arrhythmic </text>
<text top="345" left="633" width="171" height="19" font="3">events were observed in 46 </text>
<text top="363" left="633" width="202" height="19" font="3">patients (13%), including sudden </text>
<text top="382" left="633" width="199" height="19" font="3">cardiac death in 23 patients and </text>
<text top="400" left="633" width="202" height="19" font="3">sustained VT or VF in another 23 </text>
<text top="418" left="633" width="53" height="19" font="3">patients </text>
<text top="436" left="633" width="3" height="19" font="3"> </text>
<text top="455" left="633" width="154" height="19" font="4"><b>Results:</b>  On multivariate </text>
<text top="473" left="633" width="168" height="19" font="3">analysis, LVEF was the only </text>
<text top="491" left="633" width="161" height="19" font="3">significant arrhythmia risk </text>
<text top="510" left="633" width="192" height="19" font="3">predictor in patients with sinus </text>
<text top="528" left="633" width="206" height="19" font="3">rhythm, with a relative risk of 2.3 </text>
<text top="546" left="633" width="194" height="19" font="3">per 10% decrease of LVEF (95% </text>
<text top="565" left="633" width="196" height="19" font="3">CI: 1.5–3.3; p=0.0001). NSVT on </text>
<text top="583" left="633" width="178" height="19" font="3">Holter was associated with a </text>
<text top="601" left="633" width="198" height="19" font="3">trend toward higher arrhythmia </text>
<text top="620" left="633" width="181" height="19" font="3">risk (RR: 1.7; 95% CI: 0.9–3.3; </text>
<text top="638" left="633" width="207" height="19" font="3">p=0.11), whereas BB therapy was </text>
<text top="656" left="633" width="193" height="19" font="3">associated with a trend toward </text>
<text top="674" left="633" width="189" height="19" font="3">lower arrhythmia risk (RR: 0.6; </text>
<text top="693" left="633" width="155" height="19" font="3">95% CI: 0.3–1.2; p=0.13). </text>
<text top="711" left="633" width="3" height="19" font="3"> </text>
<text top="307" left="854" width="213" height="19" font="3">● Non invasive tests such as signal-</text>
<text top="326" left="854" width="158" height="19" font="3">averaged ECG, baroreflex </text>
<text top="344" left="854" width="200" height="19" font="3">sensitivity, heart rate variability, </text>
<text top="363" left="854" width="217" height="19" font="3">and T-wave alternans did not seem </text>
<text top="381" left="854" width="198" height="19" font="3">to be helpful for arrhythmia risk </text>
<text top="399" left="854" width="85" height="19" font="3">stratification. </text>
<text top="417" left="854" width="3" height="19" font="3"> </text>
</page>
<page number="120" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">120 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="119" height="19" font="3">● Goldberger et al. </text>
<text top="127" left="125" width="30" height="19" font="3">2014</text>
<text top="126" left="155" width="4" height="21" font="0"> </text>
<text top="127" left="159" width="39" height="19" font="3">(207)  </text>
<text top="145" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24445228">● </a></text>
<text top="145" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24445228">24445228</a></text>
<text top="145" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24445228"> </a></text>
<text top="164" left="125" width="3" height="19" font="3"> </text>
<text top="109" left="271" width="111" height="19" font="4"><b>Aim: </b> To estimate </text>
<text top="127" left="271" width="117" height="19" font="3">performance of 12 </text>
<text top="145" left="271" width="82" height="19" font="3">common risk </text>
<text top="164" left="271" width="124" height="19" font="3">stratification test as </text>
<text top="182" left="271" width="81" height="19" font="3">predictors of </text>
<text top="200" left="271" width="129" height="19" font="3">arrhythmic events in </text>
<text top="219" left="271" width="130" height="19" font="3">patients with DNICM </text>
<text top="237" left="271" width="3" height="19" font="4"><b> </b></text>
<text top="255" left="271" width="117" height="19" font="4"><b>Study type:</b>   meta-</text>
<text top="273" left="271" width="85" height="19" font="3">analysis of 12 </text>
<text top="292" left="271" width="125" height="19" font="3">commonly reported </text>
<text top="310" left="271" width="106" height="19" font="3">risk stratification </text>
<text top="329" left="271" width="131" height="19" font="3">tests as predictors of </text>
<text top="347" left="271" width="114" height="19" font="3">arrhythmic events </text>
<text top="365" left="271" width="3" height="19" font="3"> </text>
<text top="383" left="271" width="107" height="19" font="4"><b>Size:</b>    45 studies </text>
<text top="402" left="271" width="94" height="19" font="3">enrolling 6,088 </text>
<text top="420" left="271" width="53" height="19" font="3">patients </text>
<text top="109" left="419" width="180" height="19" font="4"><b>Inclusion criteria:</b>  45 studies </text>
<text top="127" left="419" width="197" height="19" font="3">involving human subjects of the </text>
<text top="145" left="419" width="163" height="19" font="3">following tests: baroreflex </text>
<text top="164" left="419" width="132" height="19" font="3">sensitivity, heart rate </text>
<text top="182" left="419" width="138" height="19" font="3">turbulence, heart rate </text>
<text top="200" left="419" width="167" height="19" font="3">variability, LV end-diastolic </text>
<text top="219" left="419" width="107" height="19" font="3">dimension, LVEF, </text>
<text top="237" left="419" width="194" height="19" font="3">electrophysiologic study, NSVT, </text>
<text top="255" left="419" width="137" height="19" font="3">LBBB, signal-averaged </text>
<text top="273" left="419" width="195" height="19" font="3">electrocardiogram, fragmented </text>
<text top="292" left="419" width="187" height="19" font="3">QRS, QRS-T angle, and T-wave </text>
<text top="310" left="419" width="61" height="19" font="3">alternans </text>
<text top="328" left="419" width="3" height="19" font="3"> </text>
<text top="347" left="419" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="109" left="633" width="205" height="19" font="4"><b>Results:</b>  Test sensitivities ranged </text>
<text top="127" left="633" width="134" height="19" font="3">from 28.8% to 91.0%, </text>
<text top="145" left="633" width="164" height="19" font="3">specificities from 36.2% to </text>
<text top="164" left="633" width="197" height="19" font="3">87.1%, and odds ratios from 1.5 </text>
<text top="182" left="633" width="206" height="19" font="3">to 6.7. Odds ratio was highest for </text>
<text top="200" left="633" width="193" height="19" font="3">fragmented QRS and TWA (OR: </text>
<text top="219" left="633" width="173" height="19" font="3">6.73 and 4.66; 95% CI: 3.85–</text>
<text top="237" left="633" width="132" height="19" font="3">11.76 and 2.55–8.53, </text>
<text top="255" left="633" width="201" height="19" font="3">respectively) and lowest for QRS </text>
<text top="273" left="633" width="206" height="19" font="3">duration (OR: 1.51; 95% CI: 1.13– </text>
<text top="292" left="633" width="183" height="19" font="3">2.01). None of the autonomic </text>
<text top="310" left="633" width="205" height="19" font="3">tests (heart rate variability, heart </text>
<text top="329" left="633" width="168" height="19" font="3">rate turbulence, baroreflex </text>
<text top="347" left="633" width="169" height="19" font="3">sensitivity) were significant </text>
<text top="365" left="633" width="152" height="19" font="3">predictors of arrhythmic </text>
<text top="383" left="633" width="68" height="19" font="3">outcomes. </text>
<text top="402" left="633" width="3" height="19" font="3"> </text>
<text top="109" left="854" width="171" height="19" font="3">● Techniques incorporating </text>
<text top="127" left="854" width="143" height="19" font="3">functional parameters, </text>
<text top="145" left="854" width="182" height="19" font="3">depolarization abnormalities, </text>
<text top="164" left="854" width="206" height="19" font="3">repolarization abnormalities, and </text>
<text top="182" left="854" width="203" height="19" font="3">arrhythmic markers provide only </text>
<text top="200" left="854" width="176" height="19" font="3">modest risk stratification for </text>
<text top="219" left="854" width="202" height="19" font="3">sudden cardiac death in patients </text>
<text top="238" left="854" width="30" height="19" font="3">with </text>
<text top="237" left="885" width="42" height="21" font="0">NICM.</text>
<text top="238" left="926" width="3" height="19" font="3"> </text>
<text top="257" left="854" width="165" height="19" font="3">● At best, the OR for any 1 </text>
<text top="275" left="854" width="208" height="19" font="3">predictor is generally in the range </text>
<text top="294" left="854" width="158" height="19" font="3">of 2 to 4, precluding their </text>
<text top="312" left="854" width="159" height="19" font="3">usefulness in isolation for </text>
<text top="330" left="854" width="169" height="19" font="3">individual patient decisions </text>
<text top="439" left="125" width="102" height="19" font="3">● Anselme et al. </text>
<text top="457" left="125" width="69" height="19" font="3">2013 (208) </text>
<text top="476" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23811080">● </a></text>
<text top="476" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23811080">23811080</a></text>
<text top="476" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23811080"> </a></text>
<text top="494" left="125" width="3" height="19" font="3"> </text>
<text top="439" left="271" width="117" height="19" font="4"><b>Aim:</b> To evaluate a </text>
<text top="457" left="271" width="69" height="19" font="3">strategy of </text>
<text top="476" left="271" width="118" height="19" font="3">prophylactic ICD in </text>
<text top="494" left="271" width="101" height="19" font="3">LMNA mutation </text>
<text top="512" left="271" width="80" height="19" font="3">carriers with </text>
<text top="531" left="271" width="112" height="19" font="3">significant cardiac </text>
<text top="549" left="271" width="132" height="19" font="3">conduction disorders<b> </b></text>
<text top="567" left="271" width="3" height="19" font="4"><b> </b></text>
<text top="585" left="271" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="604" left="271" width="113" height="19" font="3">Prospective single </text>
<text top="622" left="271" width="129" height="19" font="3">center observational </text>
<text top="640" left="271" width="3" height="19" font="3"> </text>
<text top="659" left="271" width="113" height="19" font="4"><b>Size:</b>    47 patients </text>
<text top="677" left="271" width="71" height="19" font="3">with LMNA </text>
<text top="695" left="271" width="66" height="19" font="3">mutations </text>
<text top="439" left="419" width="197" height="19" font="4"><b>Inclusion criteria</b> ICD implant at </text>
<text top="457" left="419" width="198" height="19" font="3">any time during follow-up when </text>
<text top="476" left="419" width="125" height="19" font="3">any of the following </text>
<text top="494" left="419" width="144" height="19" font="3">prespecified significant </text>
<text top="512" left="419" width="159" height="19" font="3">conduction disorders was </text>
<text top="531" left="419" width="186" height="19" font="3">encountered: (1) requirement </text>
<text top="549" left="419" width="162" height="19" font="3">for permanent ventricular </text>
<text top="567" left="419" width="183" height="19" font="3">pacing for bradycardia; (2) PR </text>
<text top="586" left="419" width="163" height="19" font="3">interval &gt;0.24 s and either </text>
<text top="604" left="419" width="195" height="19" font="3">complete LBBB (LBBB) or NSVT; </text>
<text top="622" left="419" width="187" height="19" font="3">(3) patients already implanted </text>
<text top="640" left="419" width="127" height="19" font="3">with a pacemaker at </text>
<text top="659" left="419" width="172" height="19" font="3">presentation to our center.  </text>
<text top="677" left="419" width="3" height="19" font="3"> </text>
<text top="695" left="419" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="440" left="633" width="171" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Malignant VA </text>
<text top="458" left="633" width="3" height="19" font="3"> </text>
<text top="476" left="633" width="206" height="19" font="4"><b>Results:</b>  ICD was implanted in 21 </text>
<text top="495" left="633" width="186" height="19" font="3">out of the 47 patients. Among </text>
<text top="513" left="633" width="188" height="19" font="3">ICD recipients, no patient died </text>
<text top="531" left="633" width="195" height="19" font="3">suddenly and 11 (52%) patients </text>
<text top="550" left="633" width="207" height="19" font="3">required appropriate ICD therapy </text>
<text top="568" left="633" width="199" height="19" font="3">during a median follow-up of 62 </text>
<text top="586" left="633" width="202" height="19" font="3">mo. LVEF was ≥45% in 9 patients </text>
<text top="605" left="633" width="199" height="19" font="3">at the time of the event. Among </text>
<text top="623" left="633" width="147" height="19" font="3">the 10 patients without </text>
<text top="641" left="633" width="186" height="19" font="3">malignant VA, device memory </text>
<text top="660" left="633" width="188" height="19" font="3">recorded NSVT in 8 (80%). The </text>
<text top="678" left="633" width="140" height="19" font="3">presence of significant </text>
<text top="696" left="633" width="183" height="19" font="3">conduction disorders was the </text>
<text top="714" left="633" width="156" height="19" font="3">only factor related to the </text>
<text top="733" left="633" width="202" height="19" font="3">occurrence of malignant VA (HR: </text>
<text top="751" left="633" width="158" height="19" font="3">5.20; 95% CI: 1.14–23.53; </text>
<text top="769" left="633" width="54" height="19" font="3">p=0.03). </text>
<text top="439" left="854" width="163" height="19" font="3">● Life-threatening VAs are </text>
<text top="457" left="854" width="197" height="19" font="3">common in patients with LMNA </text>
<text top="476" left="854" width="204" height="19" font="3">mutations and significant cardiac </text>
<text top="494" left="854" width="213" height="19" font="3">conduction disorders, even if LVEF </text>
<text top="512" left="854" width="77" height="19" font="3">is preserved </text>
<text top="531" left="854" width="3" height="19" font="3"> </text>
</page>
<page number="121" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">121 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="129" height="19" font="3">● van Rijsingen et al. </text>
<text top="127" left="125" width="69" height="19" font="3">2012 (209) </text>
<text top="145" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22281253">● </a></text>
<text top="145" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22281253">22281253</a></text>
<text top="145" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22281253"> </a></text>
<text top="164" left="125" width="3" height="19" font="3"> </text>
<text top="109" left="271" width="128" height="19" font="4"><b>Aim:</b> The purpose of </text>
<text top="127" left="271" width="106" height="19" font="3">this study was to </text>
<text top="145" left="271" width="92" height="19" font="3">determine risk </text>
<text top="164" left="271" width="121" height="19" font="3">factors that predict </text>
<text top="182" left="271" width="100" height="19" font="3">malignant VA in </text>
<text top="200" left="271" width="126" height="19" font="3">Lamin A/C mutation </text>
<text top="219" left="271" width="49" height="19" font="3">carriers<b> </b></text>
<text top="237" left="271" width="3" height="19" font="4"><b> </b></text>
<text top="255" left="271" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="273" left="271" width="79" height="19" font="3">Multicenter, </text>
<text top="292" left="271" width="84" height="19" font="3">retrospective </text>
<text top="310" left="271" width="51" height="19" font="3">analysis </text>
<text top="328" left="271" width="3" height="19" font="3"> </text>
<text top="347" left="271" width="111" height="19" font="4"><b>Size:</b> 269 patients </text>
<text top="109" left="419" width="172" height="19" font="4"><b>Inclusion criteria:</b> Mutation </text>
<text top="127" left="419" width="186" height="19" font="3">carriers older than 15 y of age </text>
<text top="145" left="419" width="170" height="19" font="3">with a previously published </text>
<text top="164" left="419" width="172" height="19" font="3">pathogenic <i>LMNA </i>mutation </text>
<text top="182" left="419" width="183" height="19" font="3">with cardiac involvement and </text>
<text top="200" left="419" width="194" height="19" font="3">persons with a newly identified </text>
<text top="218" left="419" width="193" height="20" font="5"><i>LMNA </i>mutation with clinical or </text>
<text top="237" left="419" width="125" height="19" font="3">family evidence of a </text>
<text top="255" left="419" width="163" height="19" font="3">laminopathy with possible </text>
<text top="273" left="419" width="130" height="19" font="3">cardiac involvement. </text>
<text top="292" left="419" width="3" height="19" font="3"> </text>
<text top="310" left="419" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="109" left="633" width="175" height="19" font="4"><b>1</b>°<b> endpoint:</b>  First occurring </text>
<text top="128" left="633" width="171" height="19" font="3">MVA. MVA were defined as </text>
<text top="146" left="633" width="200" height="19" font="3">appropriate ICD treatment, CPR, </text>
<text top="165" left="633" width="44" height="19" font="3">or SCD </text>
<text top="183" left="633" width="3" height="19" font="3"> </text>
<text top="201" left="633" width="184" height="19" font="4"><b>Results:</b>  At median follow-up </text>
<text top="219" left="633" width="186" height="19" font="3">period of 43 mo (interquartile </text>
<text top="238" left="633" width="179" height="19" font="3">range: 17–101 mo), 48 (18%) </text>
<text top="256" left="633" width="168" height="19" font="3">persons experienced a first </text>
<text top="274" left="633" width="186" height="19" font="3">episode of MVA. Independent </text>
<text top="293" left="633" width="198" height="19" font="3">risk factors for MVA were NSVT, </text>
<text top="311" left="633" width="181" height="19" font="3">LVEF &lt;45% at the first clinical </text>
<text top="329" left="633" width="168" height="19" font="3">contact, male sex, and non-</text>
<text top="348" left="633" width="151" height="19" font="3">missense mutations (ins-</text>
<text top="366" left="633" width="173" height="19" font="3">del/truncating or mutations </text>
<text top="384" left="633" width="205" height="19" font="3">affecting splicing). MVA occurred </text>
<text top="402" left="633" width="201" height="19" font="3">only in persons with at least 2 of </text>
<text top="421" left="633" width="188" height="19" font="3">these risk factors. There was a </text>
<text top="439" left="633" width="174" height="19" font="3">cumulative risk for MVA per </text>
<text top="457" left="633" width="133" height="19" font="3">additional risk factor. </text>
<text top="109" left="854" width="216" height="19" font="3">● Carriers of <i>LMNA </i>mutations with </text>
<text top="127" left="854" width="220" height="19" font="3">a high risk of MVA can be identified </text>
<text top="145" left="854" width="150" height="19" font="3">using these risk factors.  </text>
<text top="164" left="854" width="201" height="19" font="3">● Conduction disturbances were </text>
<text top="182" left="854" width="184" height="19" font="3">not a risk factor in this study.  </text>
<text top="200" left="854" width="201" height="19" font="3">● The 4 independent risk factors </text>
<text top="219" left="854" width="210" height="19" font="3">were NSVT, LVEF &lt;45% at the first </text>
<text top="237" left="854" width="213" height="19" font="3">clinical contact, male sex, and non-</text>
<text top="255" left="854" width="179" height="19" font="3">missense mutations (ins-del/ </text>
<text top="273" left="854" width="205" height="19" font="3">truncating or mutations affecting </text>
<text top="292" left="854" width="57" height="19" font="3">splicing). </text>
<text top="310" left="854" width="3" height="19" font="3"> </text>
<text top="476" left="125" width="125" height="19" font="3">● Pasotti et al. 2008 </text>
<text top="495" left="125" width="35" height="19" font="3">(210) </text>
<text top="513" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18926329">● </a></text>
<text top="513" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18926329">18926329</a></text>
<text top="513" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18926329"> </a></text>
<text top="531" left="125" width="3" height="19" font="3"> </text>
<text top="550" left="125" width="3" height="19" font="3"> </text>
<text top="476" left="271" width="126" height="19" font="4"><b>Aim:</b> The aim of this </text>
<text top="495" left="271" width="130" height="19" font="3">study was to analyze </text>
<text top="513" left="271" width="130" height="19" font="3">the long-term follow-</text>
<text top="531" left="271" width="81" height="19" font="3">up of dilated </text>
<text top="550" left="271" width="128" height="19" font="3">cardiolaminopathies </text>
<text top="568" left="271" width="98" height="19" font="3">in patients with </text>
<text top="586" left="271" width="78" height="19" font="3">LAMIN gene </text>
<text top="605" left="271" width="66" height="19" font="3">mutations<b> </b></text>
<text top="623" left="271" width="3" height="19" font="4"><b> </b></text>
<text top="641" left="271" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="660" left="271" width="87" height="19" font="3">Retrospective </text>
<text top="678" left="271" width="86" height="19" font="3">observational </text>
<text top="696" left="271" width="113" height="19" font="3">longitudinal study </text>
<text top="714" left="271" width="3" height="19" font="3"> </text>
<text top="733" left="271" width="104" height="19" font="4"><b>Size:</b> 94 patients </text>
<text top="476" left="419" width="130" height="19" font="4"><b>Inclusion criteria:</b> 27 </text>
<text top="495" left="419" width="181" height="19" font="3">consecutive families in which </text>
<text top="512" left="419" width="156" height="20" font="5"><i>LMNA </i>gene defects were </text>
<text top="531" left="419" width="183" height="19" font="3">identified in the probands, all </text>
<text top="550" left="419" width="196" height="19" font="3">sharing the DCM phenotype. Of </text>
<text top="568" left="419" width="201" height="19" font="3">the 164 family members, 94 had </text>
<text top="586" left="419" width="140" height="19" font="3">LMNA gene mutations </text>
<text top="605" left="419" width="3" height="19" font="3"> </text>
<text top="623" left="419" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="477" left="633" width="202" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Events were death </text>
<text top="496" left="633" width="196" height="19" font="3">from any cause, death from HF, </text>
<text top="514" left="633" width="195" height="19" font="3">heart transplantation, and SCD, </text>
<text top="532" left="633" width="159" height="19" font="3">including appropriate ICD </text>
<text top="550" left="633" width="85" height="19" font="3">interventions </text>
<text top="569" left="633" width="3" height="19" font="3"> </text>
<text top="587" left="633" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="606" left="633" width="136" height="20" font="3">• 60 of 94 (64%) were </text>
<text top="625" left="633" width="202" height="19" font="3">phenotypically affected whereas </text>
<text top="643" left="633" width="166" height="19" font="3">34 were only genotypically </text>
<text top="661" left="633" width="58" height="19" font="3">affected. </text>
<text top="680" left="633" width="206" height="20" font="3">• Of the 60 patients, 40 had DCM </text>
<text top="699" left="633" width="172" height="19" font="3">with AVB, 12 had DCM with </text>
<text top="717" left="633" width="200" height="19" font="3">VT/VF, 6 had DCM with AVB and </text>
<text top="735" left="633" width="174" height="19" font="3">EDMD2, and 2 had AVB plus </text>
<text top="753" left="633" width="57" height="19" font="3">EDMD2.  </text>
<text top="476" left="854" width="205" height="19" font="3">● Authors concluded that dilated </text>
<text top="495" left="854" width="218" height="19" font="3">cardiomyopathies caused by <i>LMNA </i></text>
<text top="513" left="854" width="213" height="19" font="3">gene defects are highly penetrant, </text>
<text top="531" left="854" width="195" height="19" font="3">adult onset, malignant diseases </text>
<text top="550" left="854" width="219" height="19" font="3">characterized by a high rate HF and </text>
<text top="568" left="854" width="179" height="19" font="3">life-threatening arrhythmias. </text>
<text top="586" left="854" width="186" height="19" font="3">● Neither AVB nor pacemaker </text>
<text top="605" left="854" width="186" height="19" font="3">implantation turned out to be </text>
<text top="623" left="854" width="133" height="19" font="3">predictors of events.  </text>
<text top="641" left="854" width="196" height="19" font="3">● NYHA class III to IV and highly </text>
<text top="660" left="854" width="55" height="19" font="3">dynamic </text>
<text top="678" left="854" width="215" height="19" font="3">● Competitive sports for 10 y were </text>
<text top="696" left="854" width="195" height="19" font="3">independent predictors of total </text>
<text top="714" left="854" width="48" height="19" font="3">events. </text>
<text top="733" left="854" width="3" height="19" font="3"> </text>
</page>
<page number="122" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">122 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="633" width="205" height="20" font="3">•During a median of 57 mo there </text>
<text top="128" left="633" width="163" height="19" font="3">were 49 events in 43 DCM </text>
<text top="146" left="633" width="57" height="19" font="3">patients. </text>
<text top="165" left="633" width="194" height="20" font="3">•The events were related to HF </text>
<text top="184" left="633" width="185" height="19" font="3">(15 heart transplants, 1 death </text>
<text top="202" left="633" width="191" height="19" font="3">from end-stage HF) and VA (15 </text>
<text top="220" left="633" width="178" height="19" font="3">SCDs and 12 appropriate ICD </text>
<text top="238" left="633" width="93" height="19" font="3">interventions). </text>
<text top="258" left="125" width="107" height="19" font="3">● van Berlo et al.<b> </b></text>
<text top="276" left="125" width="69" height="19" font="3">2005 (211) </text>
<text top="294" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=15551023">● </a></text>
<text top="294" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=15551023">15551023</a></text>
<text top="294" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=15551023"> </a></text>
<text top="312" left="125" width="3" height="19" font="3"> </text>
<text top="257" left="271" width="107" height="19" font="4"><b>Aim:</b> To evaluate </text>
<text top="276" left="271" width="102" height="19" font="3">common clinical </text>
<text top="294" left="271" width="107" height="19" font="3">characteristics of </text>
<text top="312" left="271" width="121" height="19" font="3">patients with lamin </text>
<text top="331" left="271" width="125" height="19" font="3">A/C gene mutations </text>
<text top="349" left="271" width="106" height="19" font="3">that cause either </text>
<text top="367" left="271" width="135" height="19" font="3">isolated DCM or DCM </text>
<text top="386" left="271" width="116" height="19" font="3">in association with </text>
<text top="404" left="271" width="109" height="19" font="3">skeletal muscular </text>
<text top="422" left="271" width="68" height="19" font="3">dystrophy.<b> </b></text>
<text top="441" left="271" width="3" height="19" font="4"><b> </b></text>
<text top="459" left="271" width="111" height="19" font="4"><b>Study type:</b> Meta-</text>
<text top="477" left="271" width="101" height="19" font="3">analysis (pooled </text>
<text top="496" left="271" width="35" height="19" font="3">data) </text>
<text top="514" left="271" width="3" height="19" font="3"> </text>
<text top="532" left="271" width="123" height="19" font="4"><b>Size:</b> 299 carriers of </text>
<text top="550" left="271" width="129" height="19" font="3">lamin A/C mutations </text>
<text top="257" left="419" width="133" height="19" font="4"><b>Inclusion criteria:</b>  21 </text>
<text top="276" left="419" width="178" height="19" font="3">publications between March </text>
<text top="294" left="419" width="197" height="19" font="3">1999 and March 2002 reporting </text>
<text top="312" left="419" width="162" height="19" font="3">lamin A/C gene mutations </text>
<text top="331" left="419" width="3" height="19" font="3"> </text>
<text top="349" left="419" width="173" height="19" font="4"><b>Exclusion criteria:</b>   Patients </text>
<text top="367" left="419" width="121" height="19" font="3">with familial partial </text>
<text top="386" left="419" width="193" height="19" font="3">lipodystrophy, progeria, axonal </text>
<text top="404" left="419" width="199" height="19" font="3">neuropathy and mandibuloacral </text>
<text top="422" left="419" width="188" height="19" font="3">dysplasia caused by mutations </text>
<text top="441" left="419" width="169" height="19" font="3">in the lamin A/C gene were </text>
<text top="459" left="419" width="58" height="19" font="3">excluded </text>
<text top="258" left="633" width="189" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Arrhythmias and </text>
<text top="277" left="633" width="87" height="19" font="3">sudden death </text>
<text top="295" left="633" width="3" height="19" font="3"> </text>
<text top="313" left="633" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="332" left="633" width="178" height="20" font="3">• Cardiac dysrhythmias were </text>
<text top="351" left="633" width="203" height="19" font="3">reported in 92% of patients after </text>
<text top="369" left="633" width="202" height="19" font="3">the age of 30 y; HF was reported </text>
<text top="387" left="633" width="167" height="19" font="3">in 64% after the age of 50.  </text>
<text top="406" left="633" width="205" height="20" font="3">• 76 of the reported 299 patients </text>
<text top="425" left="633" width="209" height="19" font="3">(25%) died at a mean age of 46 y.  </text>
<text top="443" left="633" width="183" height="20" font="3">• Sudden death was the most </text>
<text top="462" left="633" width="179" height="19" font="3">frequently reported mode of </text>
<text top="480" left="633" width="195" height="19" font="3">death (46%) in both the cardiac </text>
<text top="499" left="633" width="146" height="19" font="3">and the neuromuscular </text>
<text top="517" left="633" width="73" height="19" font="3">phenotype. </text>
<text top="258" left="854" width="216" height="19" font="3">● Authors conclude that carriers of </text>
<text top="276" left="854" width="203" height="19" font="3">lamin A/C mutations carry a high </text>
<text top="294" left="854" width="132" height="19" font="3">risk of sudden death. </text>
<text top="312" left="854" width="205" height="19" font="3">● Presence of pacemaker did not </text>
<text top="331" left="854" width="186" height="19" font="3">protect against sudden death. </text>
<text top="349" left="854" width="3" height="19" font="3"> </text>
<text top="570" left="125" width="122" height="19" font="3">● Piccini et al.<b> </b>2009 </text>
<text top="588" left="125" width="35" height="19" font="3">(154)<b> </b></text>
<text top="606" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19336434">● </a></text>
<text top="606" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19336434">19336434</a></text>
<text top="606" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19336434"> </a></text>
<text top="624" left="125" width="3" height="19" font="4"><b> </b></text>
<text top="643" left="125" width="3" height="19" font="3"> </text>
<text top="661" left="179" width="3" height="19" font="3"> </text>
<text top="679" left="125" width="3" height="19" font="3"> </text>
<text top="569" left="271" width="54" height="19" font="4"><b>Aim:</b>  To </text>
<text top="570" left="325" width="80" height="19" font="11">evaluate the </text>
<text top="588" left="271" width="129" height="19" font="11">cumulative evidence </text>
<text top="606" left="271" width="126" height="19" font="11">regarding the safety </text>
<text top="624" left="271" width="92" height="19" font="11">and efficacy of </text>
<text top="643" left="271" width="92" height="19" font="11">amiodarone in </text>
<text top="661" left="271" width="114" height="19" font="11">prevention of SCD </text>
<text top="679" left="271" width="3" height="19" font="4"><b> </b></text>
<text top="698" left="271" width="111" height="19" font="4"><b>Study type:</b> Meta-</text>
<text top="717" left="271" width="84" height="19" font="3">analysis of all </text>
<text top="716" left="355" width="30" height="21" font="0">RCT </text>
<text top="736" left="271" width="130" height="19" font="3">examining the use of </text>
<text top="755" left="271" width="97" height="19" font="3">amiodarone vs. </text>
<text top="773" left="271" width="122" height="19" font="3">placebo/control for </text>
<text top="569" left="419" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="570" left="530" width="62" height="19" font="11">Studies in </text>
<text top="588" left="419" width="127" height="19" font="11">which patients were </text>
<text top="606" left="419" width="196" height="19" font="11">randomized to amiodarone and </text>
<text top="624" left="419" width="170" height="19" font="11">placebo or inactive control. </text>
<text top="643" left="419" width="66" height="19" font="11">Additional </text>
<text top="661" left="419" width="164" height="19" font="11">inclusion criteria included: </text>
<text top="679" left="419" width="190" height="19" font="11">treatment for &gt;30 d, follow-up </text>
<text top="698" left="419" width="175" height="19" font="11">&gt;6 mo, and availability of all-</text>
<text top="716" left="419" width="188" height="19" font="11">cause mortality as an endpoint</text>
<text top="716" left="607" width="3" height="19" font="3"> </text>
<text top="734" left="419" width="3" height="19" font="3"> </text>
<text top="752" left="419" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="753" left="536" width="48" height="19" font="11">Studies </text>
<text top="570" left="633" width="85" height="19" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="570" left="718" width="121" height="19" font="11">SCD, CVD, all-cause </text>
<text top="589" left="633" width="196" height="19" font="11">mortality, and the incidences of </text>
<text top="607" left="633" width="93" height="19" font="11">drug toxicities. </text>
<text top="625" left="633" width="3" height="19" font="3"> </text>
<text top="644" left="633" width="201" height="19" font="4"><b>Results:</b>  Amiodarone decreased </text>
<text top="662" left="633" width="175" height="19" font="3">the incidence of SCD [7.1 vs. </text>
<text top="680" left="633" width="175" height="19" font="3">9.7%; OR: 0.71; 95% CI 0.61–</text>
<text top="699" left="633" width="118" height="19" font="3">0.84; p&lt;0.001] and </text>
<text top="717" left="633" width="168" height="19" font="3">cardiovascular death (CVD) </text>
<text top="735" left="633" width="195" height="19" font="3">[14.0% vs.16.3%; OR: 0.82; 95% </text>
<text top="753" left="633" width="183" height="19" font="3">CI 0.71–0.94, p=0.004]. There </text>
<text top="772" left="633" width="152" height="19" font="3">was a 1.5% absolute risk </text>
<text top="570" left="854" width="207" height="19" font="3">● Amiodarone reduces the risk of </text>
<text top="588" left="854" width="181" height="19" font="3">SCD by 29% and CVD by 18%, </text>
<text top="606" left="854" width="202" height="19" font="3">however, amiodarone therapy is </text>
<text top="624" left="854" width="200" height="19" font="3">neutral with respect to all-cause </text>
<text top="643" left="854" width="211" height="19" font="3">mortality and was associated with </text>
<text top="661" left="854" width="195" height="19" font="3">a 2- and 5-fold increased risk of </text>
<text top="680" left="854" width="195" height="19" font="3">pulmonary and thyroid toxicity. </text>
<text top="698" left="854" width="207" height="19" font="3">● Authors suggested amiodarone </text>
<text top="716" left="854" width="204" height="19" font="3">as a viable alternative in patients </text>
<text top="734" left="854" width="211" height="19" font="3">who are not eligible for or who do </text>
<text top="753" left="854" width="212" height="19" font="3">not have access to ICD therapy for </text>
<text top="771" left="854" width="145" height="19" font="3">the prevention of SCD.  </text>
</page>
<page number="123" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">123 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="271" width="110" height="19" font="3">the prevention of </text>
<text top="127" left="271" width="34" height="19" font="3">SCD   </text>
<text top="145" left="271" width="3" height="19" font="3"> </text>
<text top="164" left="271" width="32" height="19" font="4"><b>Size:</b> </text>
<text top="164" left="302" width="96" height="19" font="11">15 trials, which </text>
<text top="182" left="271" width="114" height="19" font="11">randomized 8,522 </text>
<text top="200" left="271" width="50" height="19" font="11">patients</text>
<text top="200" left="321" width="3" height="19" font="3"> </text>
<text top="109" left="419" width="139" height="19" font="11">of patients with shock-</text>
<text top="127" left="419" width="185" height="19" font="11">refractory VA, OHCA, patients </text>
<text top="145" left="419" width="149" height="19" font="11">&lt;18 y, randomization to </text>
<text top="164" left="419" width="170" height="19" font="11">amiodarone vs. a class Ic or </text>
<text top="182" left="419" width="195" height="19" font="11">class III AAD (without a placebo </text>
<text top="200" left="419" width="155" height="19" font="11">or standard of care arm). </text>
<text top="219" left="419" width="177" height="19" font="11">Studies of patients with ICDs </text>
<text top="237" left="419" width="186" height="19" font="11">were excluded unless used on </text>
<text top="255" left="419" width="69" height="19" font="11">both arms. </text>
<text top="109" left="633" width="194" height="19" font="3">reduction in all-cause mortality </text>
<text top="127" left="633" width="183" height="19" font="3">which did not meet statistical </text>
<text top="145" left="633" width="140" height="19" font="3">significance (p=0.093). </text>
<text top="164" left="633" width="192" height="19" font="3">Amiodarone therapy increased </text>
<text top="182" left="633" width="191" height="19" font="3">the risk of pulmonary [2.9% vs. </text>
<text top="200" left="633" width="175" height="19" font="3">1.5%; OR: 1.97; 95% CI 1.27–</text>
<text top="219" left="633" width="206" height="19" font="3">3.04, p=0.002], and thyroid [3.6% </text>
<text top="237" left="633" width="195" height="19" font="3">vs. 0.4%; OR: 5.68; 95% CI 2.94–</text>
<text top="255" left="633" width="150" height="19" font="3">10.98, p&lt;0.001] toxicity. </text>
<text top="273" left="633" width="3" height="19" font="3"> </text>
<text top="109" left="854" width="3" height="19" font="3"> </text>
<text top="292" left="125" width="82" height="19" font="3">● <b>WEARIT-II  </b></text>
<text top="311" left="125" width="126" height="19" font="3">● Kutyifa et al. 2015 </text>
<text top="329" left="125" width="35" height="19" font="3">(212) </text>
<text top="347" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26316618?dopt=Citation">● </a></text>
<text top="347" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26316618?dopt=Citation">26316618</a></text>
<text top="347" left="198" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26316618?dopt=Citation"><b> </b></a></text>
<text top="366" left="125" width="3" height="19" font="3"> </text>
<text top="292" left="271" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="311" left="271" width="89" height="19" font="3">Observational </text>
<text top="329" left="271" width="3" height="19" font="3"> </text>
<text top="347" left="271" width="76" height="19" font="4"><b>Size:</b>   2000  </text>
<text top="292" left="419" width="187" height="19" font="4"><b>Inclusion criteria:</b>  All patients </text>
<text top="311" left="419" width="131" height="19" font="3">with LifeVest offered </text>
<text top="329" left="419" width="183" height="19" font="3">patients with LVEF and a high </text>
<text top="347" left="419" width="190" height="19" font="3">risk for SCD after MI, following </text>
<text top="366" left="419" width="199" height="19" font="3">coronary revascularization, with </text>
<text top="384" left="419" width="196" height="19" font="3">a new-onset dilated NICM, with </text>
<text top="402" left="419" width="134" height="19" font="3">high risk for SCD until </text>
<text top="421" left="419" width="187" height="19" font="3">stabilization, or with inherited </text>
<text top="439" left="419" width="168" height="19" font="3">or congenital heart disease </text>
<text top="457" left="419" width="167" height="19" font="4"><b>Exclusion criteria:</b>  refused </text>
<text top="476" left="419" width="52" height="19" font="3">consent </text>
<text top="293" left="633" width="88" height="19" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="312" left="633" width="3" height="19" font="3"> </text>
<text top="330" left="633" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="348" left="633" width="200" height="19" font="3">805 patients (40%) had ischemic </text>
<text top="367" left="633" width="186" height="19" font="3">cardiomyopathy, 927 patients </text>
<text top="385" left="633" width="144" height="19" font="3">(46%) had nonischemic </text>
<text top="403" left="633" width="197" height="19" font="3">cardiomyopathy, and 268 (14%) </text>
<text top="422" left="633" width="184" height="19" font="3">patients were diagnosed with </text>
<text top="440" left="633" width="179" height="19" font="3">congenital or inherited heart </text>
<text top="458" left="633" width="49" height="19" font="3">disease </text>
<text top="476" left="633" width="184" height="19" font="3">The median age was 62 y; the </text>
<text top="495" left="633" width="168" height="19" font="3">median LVEF was 25%. The </text>
<text top="513" left="633" width="194" height="19" font="3">median WCD wear time was 90 </text>
<text top="531" left="633" width="197" height="19" font="3">d, with median daily use of 22.5 </text>
<text top="550" left="633" width="15" height="19" font="3">h. </text>
<text top="292" left="854" width="163" height="19" font="3">● There was a total of 120 </text>
<text top="311" left="854" width="131" height="19" font="3">sustained ventricular </text>
<text top="329" left="854" width="216" height="19" font="3">tachyarrhythmias in 41 patients, of </text>
<text top="347" left="854" width="202" height="19" font="3">whom 54% received appropriate </text>
<text top="366" left="854" width="179" height="19" font="3">WCD shock. Only 10 patients </text>
<text top="384" left="854" width="218" height="19" font="3">(0.5%) received inappropriate WCD </text>
<text top="402" left="854" width="55" height="19" font="3">therapy. </text>
<text top="421" left="854" width="214" height="19" font="3">● The rate of sustained ventricular </text>
<text top="439" left="854" width="211" height="19" font="3">tachyarrhythmias by 3 mo was 3% </text>
<text top="457" left="854" width="185" height="19" font="3">among patients with ischemic </text>
<text top="476" left="854" width="129" height="19" font="3">cardiomyopathy and </text>
<text top="494" left="854" width="217" height="19" font="3">congenital/inherited heart disease, </text>
<text top="512" left="854" width="173" height="19" font="3">and 1% among nonischemic </text>
<text top="531" left="854" width="111" height="19" font="3">patients (p=0.02). </text>
<text top="549" left="854" width="189" height="19" font="3">● 90 sustained VT events in 22 </text>
<text top="567" left="854" width="178" height="19" font="3">patients were withheld from </text>
<text top="586" left="854" width="206" height="19" font="3">therapy, whereas 30 events in 22 </text>
<text top="604" left="854" width="181" height="19" font="3">patients required WCD shock </text>
<text top="622" left="854" width="198" height="19" font="3">therapy owing to hemodynamic </text>
<text top="640" left="854" width="186" height="19" font="3">instability (corresponding to 5 </text>
<text top="659" left="854" width="160" height="19" font="3">events per 100 patient y). </text>
<text top="677" left="854" width="209" height="19" font="3">● All patients who required shock </text>
<text top="695" left="854" width="208" height="19" font="3">delivery had their VT/VF episodes </text>
<text top="714" left="854" width="201" height="19" font="3">successfully terminated with the </text>
<text top="732" left="854" width="69" height="19" font="3">first shock. </text>
<text top="750" left="854" width="187" height="19" font="3">● 10 patients (0.5%, 2 per 100 </text>
<text top="769" left="854" width="210" height="19" font="3">patient-y) had inappropriate WCD </text>
</page>
<page number="124" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">124 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="854" width="179" height="19" font="3">therapy during the follow-up </text>
<text top="127" left="854" width="155" height="19" font="3">because of ECG artifacts. </text>
<text top="145" left="854" width="191" height="19" font="3">● Inappropriate shocks did not </text>
<text top="164" left="854" width="103" height="19" font="3">induce VT or VF. </text>
<text top="183" left="125" width="116" height="19" font="3">● Singh et al. 2015 </text>
<text top="201" left="125" width="35" height="19" font="3">(213) </text>
<text top="219" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26670060">● </a></text>
<text top="219" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26670060">26670060</a></text>
<text top="219" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26670060"> </a></text>
<text top="238" left="125" width="3" height="19" font="3"> </text>
<text top="183" left="271" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="201" left="271" width="125" height="19" font="3">observational single </text>
<text top="219" left="271" width="43" height="19" font="3">center </text>
<text top="238" left="271" width="3" height="19" font="3"> </text>
<text top="256" left="271" width="118" height="19" font="4"><b>Size:</b> 691 (254 new </text>
<text top="274" left="271" width="120" height="19" font="3">NICM and 271 new </text>
<text top="292" left="271" width="28" height="19" font="3">ICM </text>
<text top="183" left="419" width="134" height="19" font="4"><b>Inclusion criteria:</b>  All </text>
<text top="201" left="419" width="197" height="19" font="3">consecutive patients prescribed </text>
<text top="219" left="419" width="182" height="19" font="3">a WCD between June 1, 2004 </text>
<text top="238" left="419" width="152" height="19" font="3">and May 30, 2015 at the </text>
<text top="256" left="419" width="152" height="19" font="3">hospitals comprising the </text>
<text top="274" left="419" width="199" height="19" font="3">University of Pittsburgh Medical </text>
<text top="293" left="419" width="159" height="19" font="3">Center to which access to </text>
<text top="311" left="419" width="164" height="19" font="3">clinical data was available. </text>
<text top="329" left="419" width="3" height="19" font="3"> </text>
<text top="347" left="419" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="366" left="419" width="190" height="19" font="3">Patients with an explanted ICD </text>
<text top="384" left="419" width="186" height="19" font="3">awaiting reimplantation, prior </text>
<text top="402" left="419" width="198" height="19" font="3">cardiac arrest unrelated to AMI, </text>
<text top="421" left="419" width="162" height="19" font="3">or elevated risk of SCD for </text>
<text top="439" left="419" width="163" height="19" font="3">reasons other than ICM or </text>
<text top="457" left="419" width="42" height="19" font="3">NICM. </text>
<text top="183" left="633" width="196" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Appropriate WCD </text>
<text top="202" left="633" width="51" height="19" font="3">therapy </text>
<text top="220" left="633" width="3" height="19" font="3"> </text>
<text top="238" left="633" width="203" height="19" font="4"><b>Results:</b>  During 56.7 patient-y, 0 </text>
<text top="257" left="633" width="165" height="19" font="3">NICM patients received an </text>
<text top="275" left="633" width="148" height="19" font="3">appropriate WCD shock </text>
<text top="293" left="633" width="3" height="19" font="3"> </text>
<text top="312" left="633" width="190" height="19" font="3">During 46.7 patient-y, 6 (2.2%) </text>
<text top="330" left="633" width="56" height="19" font="3">ischemic </text>
<text top="348" left="633" width="208" height="19" font="3">cardiomyopathypatients received </text>
<text top="367" left="633" width="147" height="19" font="3">an appropriate shock; 5 </text>
<text top="385" left="633" width="171" height="19" font="3">survived the episode, and 4 </text>
<text top="403" left="633" width="185" height="19" font="3">survived to hospital discharge </text>
<text top="183" left="854" width="132" height="19" font="3">● Single center study </text>
<text top="201" left="854" width="3" height="19" font="3"> </text>
<text top="476" left="125" width="110" height="19" font="3">● Uyei et al. 2014 </text>
<text top="495" left="125" width="35" height="19" font="3">(214) </text>
<text top="513" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24893969">● </a></text>
<text top="513" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24893969">24893969</a></text>
<text top="513" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24893969"> </a></text>
<text top="531" left="128" width="3" height="19" font="3"> </text>
<text top="476" left="271" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="495" left="271" width="114" height="19" font="3">Systematic review </text>
<text top="513" left="271" width="3" height="19" font="3"> </text>
<text top="531" left="271" width="3" height="19" font="3"> </text>
<text top="550" left="271" width="32" height="19" font="4"><b>Size:</b> </text>
<text top="476" left="419" width="27" height="19" font="3">N/A </text>
<text top="477" left="633" width="112" height="19" font="4"><b>1</b>°<b> endpoint:</b>  N/A </text>
<text top="496" left="633" width="3" height="19" font="3"> </text>
<text top="514" left="633" width="149" height="19" font="4"><b>Results:</b>  It appears that </text>
<text top="532" left="633" width="160" height="19" font="3">wearable defibrillator use </text>
<text top="550" left="633" width="115" height="19" font="3">compared with no </text>
<text top="569" left="633" width="175" height="19" font="3">defibrillator use reduces the </text>
<text top="587" left="633" width="170" height="19" font="3">chance of VT/VF associated </text>
<text top="605" left="633" width="162" height="19" font="3">deaths by an absolute risk </text>
<text top="624" left="633" width="195" height="19" font="3">reduction of approximately 1%, </text>
<text top="642" left="633" width="129" height="19" font="3">achieved by averting </text>
<text top="660" left="633" width="202" height="19" font="3">approximately 4/5th of all VT/VF </text>
<text top="679" left="633" width="116" height="19" font="3">associated deaths. </text>
<text top="476" left="854" width="210" height="19" font="3">● The quality of evidence was low </text>
<text top="495" left="854" width="205" height="19" font="3">to very low quality, such that our </text>
<text top="513" left="854" width="166" height="19" font="3">confidence in the reported </text>
<text top="531" left="854" width="115" height="19" font="3">estimates is weak. </text>
<text top="550" left="854" width="3" height="19" font="3"> </text>
<text top="698" left="125" width="105" height="19" font="3">● Al-Khatib et al. </text>
<text top="716" left="125" width="107" height="19" font="3">JAMA Cardiology </text>
<text top="734" left="125" width="30" height="19" font="3">2017</text>
<text top="733" left="155" width="4" height="21" font="0"> </text>
<text top="734" left="159" width="35" height="19" font="3">(215) </text>
<text top="753" left="125" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28355432">● </a></text>
<text top="753" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28355432">28355432</a></text>
<text top="753" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28355432"> </a></text>
<text top="771" left="125" width="3" height="19" font="3"> </text>
<text top="698" left="271" width="110" height="19" font="4"><b>Study type:</b> meta-</text>
<text top="716" left="271" width="100" height="19" font="3">analysis of RCTs </text>
<text top="734" left="271" width="3" height="19" font="3"> </text>
<text top="752" left="271" width="90" height="19" font="4"><b>Size: </b>N=1,874<b> </b> </text>
<text top="698" left="419" width="131" height="19" font="4"><b>Inclusion criteria:</b>  1° </text>
<text top="716" left="419" width="199" height="19" font="3">prevention ICDs in patients with </text>
<text top="734" left="419" width="38" height="19" font="3">NICM </text>
<text top="753" left="419" width="3" height="19" font="3"> </text>
<text top="771" left="419" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="698" left="633" width="201" height="19" font="4"><b>1</b>°<b> endpoint:</b>  all-cause mortality </text>
<text top="717" left="633" width="3" height="19" font="3"> </text>
<text top="735" left="633" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="753" left="633" width="188" height="19" font="3">Pooling data with fixed and RE </text>
<text top="772" left="633" width="176" height="19" font="3">models from these 4 studies </text>
<text top="698" left="854" width="219" height="20" font="3">• 1° prevention ICDs are efficacious </text>
<text top="717" left="854" width="203" height="19" font="3">at reducing all-cause mortality in </text>
<text top="735" left="854" width="121" height="19" font="3">patients with NICM </text>
</page>
<page number="125" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">125 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="10" height="19" font="3">   </text>
<text top="109" left="419" width="27" height="19" font="3">CRT </text>
<text top="127" left="419" width="195" height="19" font="3">Antiarrhythmic medication arm </text>
<text top="145" left="419" width="3" height="19" font="3"> </text>
<text top="109" left="633" width="204" height="19" font="3">showed a significant reduction in </text>
<text top="127" left="633" width="190" height="19" font="3">all-cause mortality with an ICD </text>
<text top="145" left="633" width="192" height="19" font="3">(HR: 0.75; 95% CI 0.61-0.93, p= </text>
<text top="164" left="633" width="74" height="19" font="3">0.008; p for </text>
<text top="182" left="633" width="139" height="19" font="3">heterogeneity=0.873)  </text>
<text top="237" left="115" width="937" height="21" font="2"><b>Data Supplement 29. RCTs and Nonrandomized Trials, Observational Studies, and/or Registries of Treatment of Recurrent VA in Patients </b></text>
<text top="257" left="115" width="194" height="21" font="2"><b>With NICM – (Section 7.2.3) </b></text>
<text top="278" left="130" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="296" left="155" width="51" height="19" font="4"><b>Author; </b></text>
<text top="315" left="133" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="278" left="262" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="296" left="291" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="278" left="443" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="278" left="644" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="296" left="656" width="126" height="19" font="4"><b>(P values; OR or RR; </b></text>
<text top="315" left="688" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="278" left="887" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="296" left="916" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="334" left="123" width="92" height="19" font="3">● <b>OPTIC Study </b></text>
<text top="352" left="123" width="103" height="19" font="3">● Connolly et al. </text>
<text top="370" left="123" width="69" height="19" font="3">2006 (159) </text>
<text top="389" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16403928">● </a></text>
<text top="389" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16403928">16403928</a></text>
<text top="389" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16403928"> </a></text>
<text top="407" left="123" width="3" height="19" font="3"> </text>
<text top="334" left="251" width="118" height="19" font="4"><b>Aim:</b> To determine </text>
<text top="352" left="251" width="133" height="19" font="3">whether amiodarone </text>
<text top="370" left="251" width="132" height="19" font="3">plus BB or sotalol are </text>
<text top="389" left="251" width="130" height="19" font="3">better than BB alone </text>
<text top="407" left="251" width="132" height="19" font="3">for prevention of ICD </text>
<text top="425" left="251" width="48" height="19" font="3">shocks. </text>
<text top="444" left="251" width="3" height="19" font="3"> </text>
<text top="462" left="251" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="480" left="251" width="105" height="19" font="3">multicenter RCT  </text>
<text top="499" left="251" width="3" height="19" font="3"> </text>
<text top="517" left="251" width="121" height="19" font="4"><b>Size:</b>    412 patients<b> </b></text>
<text top="334" left="410" width="164" height="19" font="4"><b>Inclusion criteria:</b> Patients </text>
<text top="352" left="410" width="150" height="19" font="3">were eligible if they had </text>
<text top="370" left="410" width="170" height="19" font="3">received an ICD within 21 d </text>
<text top="389" left="410" width="97" height="19" font="3">for inducible or </text>
<text top="407" left="410" width="172" height="19" font="3">spontaneously occurring VT </text>
<text top="425" left="410" width="42" height="19" font="3">or VF.  </text>
<text top="444" left="410" width="3" height="19" font="3"> </text>
<text top="462" left="410" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="462" left="523" width="53" height="19" font="16">Patients </text>
<text top="480" left="410" width="161" height="19" font="16">were excluded if they had </text>
<text top="499" left="410" width="186" height="19" font="16">LQTS, corrected QT interval of </text>
<text top="517" left="410" width="180" height="19" font="16">more than 450 millisec, were </text>
<text top="535" left="410" width="172" height="19" font="16">receiving a class I or class III </text>
<text top="554" left="410" width="162" height="19" font="16">antiarrhythmic agent, had </text>
<text top="572" left="410" width="149" height="19" font="16">received amiodarone or </text>
<text top="590" left="410" width="151" height="19" font="16">sotalol for more than 20 </text>
<text top="608" left="410" width="175" height="19" font="16">consecutive days at anytime </text>
<text top="627" left="410" width="169" height="19" font="16">(patients who had received </text>
<text top="645" left="410" width="173" height="19" font="16">&gt;10 d of amiodarone had to </text>
<text top="663" left="410" width="175" height="19" font="16">be taken off amiodarone for </text>
<text top="682" left="410" width="167" height="19" font="16">10d before randomization),</text>
<text top="677" left="577" width="4" height="25" font="17"> </text>
<text top="682" left="581" width="11" height="19" font="16">a </text>
<text top="700" left="410" width="130" height="19" font="16">calculated creatinine </text>
<text top="718" left="410" width="154" height="19" font="16">clearance of less than 30 </text>
<text top="737" left="410" width="134" height="19" font="16">mL/min (&lt;0.50 mL/s), </text>
<text top="755" left="410" width="153" height="19" font="16">symptomatic AF likely to </text>
<text top="773" left="410" width="155" height="19" font="16">require use of a class I or </text>
<text top="334" left="609" width="190" height="19" font="4"><b>1</b>°<b> endpoint:</b> ICD shock for any </text>
<text top="353" left="609" width="49" height="19" font="3">reason. </text>
<text top="371" left="609" width="3" height="19" font="3"> </text>
<text top="389" left="609" width="188" height="19" font="4"><b>Results: </b>Shocks occurred in 41 </text>
<text top="408" left="609" width="195" height="19" font="3">patients (38.5%) assigned to BB </text>
<text top="426" left="609" width="182" height="19" font="3">alone, 26 (24.3%) assigned to </text>
<text top="444" left="609" width="215" height="19" font="3">sotalol, and 12 (10.3%) assigned to </text>
<text top="463" left="609" width="219" height="19" font="3">amiodarone plus BB. A reduction in </text>
<text top="481" left="609" width="220" height="19" font="3">the risk of shock was observed with </text>
<text top="499" left="609" width="206" height="19" font="3">use of either amiodarone plus BB </text>
<text top="518" left="609" width="197" height="19" font="3">or sotalol vs BB alone (HR: 0.44; </text>
<text top="536" left="609" width="178" height="19" font="3">95% CI: 0.28–0.68; p&lt;0.001). </text>
<text top="554" left="609" width="203" height="19" font="3">Amiodarone plus BB significantly </text>
<text top="573" left="609" width="156" height="19" font="3">reduced the risk of shock </text>
<text top="591" left="609" width="216" height="19" font="3">compared with BB alone (HR: 0.27; </text>
<text top="609" left="609" width="201" height="19" font="3">95% CI: 0.14–0.52; p&lt;0.001) and </text>
<text top="627" left="609" width="190" height="19" font="3">sotalol (HR: 0.43; 95% CI: 0.22–</text>
<text top="646" left="609" width="201" height="19" font="3">0.85; p=0.02). There was a trend </text>
<text top="664" left="609" width="171" height="19" font="3">for sotalol to reduce shocks </text>
<text top="682" left="609" width="182" height="19" font="3">compared with BB alone (HR: </text>
<text top="701" left="609" width="208" height="19" font="3">0.61;95% CI, 0.37–1.01; p=0.055). </text>
<text top="719" left="609" width="144" height="19" font="3">The rates of study drug </text>
<text top="737" left="609" width="207" height="19" font="3">discontinuation at 1y were 18.2% </text>
<text top="756" left="609" width="212" height="19" font="3">for amiodarone, 23.5% for sotalol, </text>
<text top="774" left="609" width="145" height="19" font="3">and 5.3% for BB alone. <b> </b></text>
<text top="334" left="843" width="209" height="19" font="3">● Amiodarone plus BB is effective </text>
<text top="352" left="843" width="211" height="19" font="3">for preventing these shocks and is </text>
<text top="370" left="843" width="217" height="19" font="3">more effective than sotalol but has </text>
<text top="389" left="843" width="201" height="19" font="3">an increased risk of drug-related </text>
<text top="407" left="843" width="96" height="19" font="3">adverse effects </text>
<text top="425" left="843" width="209" height="19" font="3">● Adverse pulmonary and thyroid </text>
<text top="444" left="843" width="153" height="19" font="3">events and symptomatic </text>
<text top="462" left="843" width="203" height="19" font="3">bradycardia were more common </text>
<text top="480" left="843" width="191" height="19" font="3">among patients randomized to </text>
<text top="499" left="843" width="81" height="19" font="3">amiodarone. </text>
</page>
<page number="126" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">126 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="410" width="183" height="19" font="16">class III antiarrhythmic agent, </text>
<text top="127" left="410" width="102" height="19" font="16">absence of SHD, </text>
<text top="145" left="410" width="126" height="19" font="16">contraindications to </text>
<text top="164" left="410" width="186" height="19" font="16">amiodarone or a β-blocker, or </text>
<text top="182" left="410" width="169" height="19" font="16">NYHA class IV symptoms of </text>
<text top="200" left="410" width="20" height="19" font="16">HF.</text>
<text top="200" left="430" width="7" height="19" font="3">  </text>
<text top="218" left="410" width="163" height="19" font="4"><b>Intervention:</b> amiodarone </text>
<text top="237" left="410" width="133" height="19" font="3">plus BB, sotalol alone </text>
<text top="255" left="410" width="7" height="19" font="3">  </text>
<text top="273" left="410" width="147" height="19" font="4"><b>Comparator:</b>  BB alone.<b> </b></text>
<text top="292" left="123" width="97" height="19" font="3">● <b>International </b></text>
<text top="311" left="123" width="106" height="19" font="4"><b>VT Collaborative </b></text>
<text top="329" left="123" width="81" height="19" font="4"><b>Group Study </b></text>
<text top="347" left="123" width="91" height="19" font="3">● Tung R 2015 </text>
<text top="366" left="123" width="35" height="19" font="3">(178) </text>
<text top="292" left="251" width="143" height="19" font="4"><b>Aim:</b>  to determine the </text>
<text top="311" left="251" width="106" height="19" font="3">association of VT </text>
<text top="329" left="251" width="103" height="19" font="3">recurrence after </text>
<text top="347" left="251" width="144" height="19" font="3">ablation and survival in </text>
<text top="366" left="251" width="94" height="19" font="3">scar related VT </text>
<text top="384" left="251" width="3" height="19" font="3"> </text>
<text top="402" left="251" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="421" left="251" width="75" height="19" font="3">Multicenter </text>
<text top="439" left="251" width="87" height="19" font="3">observational </text>
<text top="457" left="251" width="3" height="19" font="3"> </text>
<text top="476" left="251" width="76" height="19" font="4"><b>Size:</b>    2061 </text>
<text top="292" left="410" width="174" height="19" font="4"><b>Inclusion criteria:</b>  SHD with </text>
<text top="311" left="410" width="169" height="19" font="3">Ischemic and Non-Ischemic </text>
<text top="329" left="410" width="143" height="19" font="3">cardiomyopathies with </text>
<text top="347" left="410" width="135" height="19" font="3">monomorphic VT and </text>
<text top="366" left="410" width="117" height="19" font="3">myocardial scar by </text>
<text top="384" left="410" width="160" height="19" font="3">electroanatomic mapping </text>
<text top="402" left="410" width="3" height="19" font="3"> </text>
<text top="421" left="410" width="186" height="19" font="4"><b>Exclusion criteria:</b>  absence of </text>
<text top="439" left="410" width="161" height="19" font="3">scar on electroanatomical </text>
<text top="457" left="410" width="60" height="19" font="3">mapping<b>  </b></text>
<text top="476" left="410" width="3" height="19" font="4"><b> </b></text>
<text top="494" left="410" width="142" height="19" font="4"><b>Intervention:</b> Catheter </text>
<text top="512" left="410" width="172" height="19" font="3">ablation, either endocardial </text>
<text top="531" left="410" width="186" height="19" font="3">or epicardial, guided by EAM.  </text>
<text top="549" left="410" width="162" height="19" font="3">End point of ablation with </text>
<text top="567" left="410" width="183" height="19" font="3">elimination of all induced VTs<b> </b></text>
<text top="586" left="410" width="3" height="19" font="3"> </text>
<text top="293" left="609" width="88" height="19" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="312" left="609" width="184" height="19" font="3">Freedom from VT recurrence, </text>
<text top="330" left="609" width="192" height="19" font="3">Heart Transplant, or death was </text>
<text top="348" left="609" width="132" height="19" font="3">70% at 1 y follow-up. </text>
<text top="367" left="609" width="218" height="19" font="3">VT recurred in 55% of patients who </text>
<text top="385" left="609" width="178" height="19" font="3">died vs. 22% of patients who </text>
<text top="403" left="609" width="58" height="19" font="3">survived. </text>
<text top="422" left="609" width="203" height="19" font="3">Transplant free survival was 90% </text>
<text top="440" left="609" width="215" height="19" font="3">for patients without VT recurrence </text>
<text top="458" left="609" width="164" height="19" font="3">and 71% for those with VT </text>
<text top="476" left="609" width="219" height="19" font="3">recurrence (HR 6.9; 95% CI 5.3–9.0, </text>
<text top="495" left="609" width="61" height="19" font="3">p&lt;0.001). </text>
<text top="513" left="609" width="3" height="19" font="4"><b> </b></text>
<text top="292" left="843" width="170" height="19" font="3">● Procedural complications </text>
<text top="311" left="843" width="212" height="19" font="3">occurred in 6%, including 2 deaths </text>
<text top="329" left="843" width="210" height="19" font="3">(0.1%), hemopericardium in 1.7%, </text>
<text top="347" left="843" width="225" height="19" font="3">and vascular access complications in </text>
<text top="366" left="843" width="33" height="19" font="3">1.6% </text>
<text top="384" left="843" width="3" height="19" font="3"> </text>
<text top="402" left="843" width="3" height="19" font="3"> </text>
<text top="421" left="843" width="3" height="19" font="3"> </text>
<text top="605" left="123" width="68" height="19" font="3">● <b>HELP-VT </b></text>
<text top="623" left="123" width="85" height="19" font="3">● Dinov 2014 </text>
<text top="641" left="123" width="35" height="19" font="3">(175) </text>
<text top="660" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24211823">● </a></text>
<text top="660" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24211823">24211823</a></text>
<text top="660" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24211823"> </a></text>
<text top="678" left="123" width="3" height="19" font="3"> </text>
<text top="696" left="123" width="3" height="19" font="3"> </text>
<text top="605" left="251" width="39" height="19" font="4"><b>Aim:</b>   </text>
<text top="623" left="251" width="109" height="19" font="3">To determine the </text>
<text top="641" left="251" width="93" height="19" font="3">outcome of VT </text>
<text top="660" left="251" width="123" height="19" font="3">catheter ablation in </text>
<text top="678" left="251" width="137" height="19" font="3">patients with NICM to </text>
<text top="696" left="251" width="124" height="19" font="3">those with Ischemic </text>
<text top="714" left="251" width="142" height="19" font="3">Cardiomyopathy (ICM) </text>
<text top="733" left="251" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="751" left="251" width="106" height="19" font="3">Prospective, non-</text>
<text top="769" left="251" width="76" height="19" font="3">randomized </text>
<text top="605" left="410" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="623" left="410" width="166" height="19" font="3">Patients with SHD referred </text>
<text top="641" left="410" width="164" height="19" font="3">for catheter ablation of VT </text>
<text top="660" left="410" width="169" height="19" font="3">with either NICM (N=63) or </text>
<text top="678" left="410" width="56" height="19" font="3">ischemic </text>
<text top="696" left="410" width="152" height="19" font="3">cardiomyopathy(N=164) </text>
<text top="714" left="410" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="733" left="410" width="172" height="19" font="3">Failure of informed consent </text>
<text top="751" left="410" width="89" height="19" font="4"><b>Intervention:</b>  </text>
<text top="605" left="609" width="204" height="19" font="4"><b>1</b>°<b> endpoint:</b>  At 1y follow-up, VT </text>
<text top="624" left="609" width="212" height="19" font="3">free survival was 57% for ischemic </text>
<text top="642" left="609" width="188" height="19" font="3">cardiomyopathyand 40.5% for </text>
<text top="660" left="609" width="203" height="19" font="3">NICM patients (HR: 1.62; 95% CI: </text>
<text top="679" left="609" width="181" height="19" font="3">1.12–2.34, p=0.01).  ischemic </text>
<text top="697" left="609" width="218" height="19" font="3">cardiomyopathyrequired epicardial </text>
<text top="715" left="609" width="193" height="19" font="3">ablation in only 2 of 164 (1.2%) </text>
<text top="734" left="609" width="212" height="19" font="3">whereas NICM required epicardial </text>
<text top="752" left="609" width="182" height="19" font="3">ablation in 30.8% (p=0.0001). </text>
<text top="770" left="609" width="3" height="19" font="3"> </text>
<text top="605" left="843" width="104" height="19" font="3">● <b>Complications </b></text>
<text top="623" left="843" width="219" height="19" font="3">Complications occurred in 11.1% of </text>
<text top="641" left="843" width="177" height="19" font="3">NICM and 11.1% of ischemic </text>
<text top="660" left="843" width="215" height="19" font="3">cardiomyopathypatients, including </text>
<text top="678" left="843" width="215" height="19" font="3">death in 4.8% of NICM and 3.7% of </text>
<text top="696" left="843" width="162" height="19" font="3">ischemic cardiomyopathy  </text>
<text top="714" left="843" width="3" height="19" font="3"> </text>
<text top="733" left="843" width="3" height="19" font="3"> </text>
</page>
<page number="127" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">127 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="251" width="121" height="19" font="4"><b>Size:</b>  227 patients   </text>
<text top="109" left="410" width="134" height="19" font="3"> Catheter ablation for </text>
<text top="127" left="410" width="121" height="19" font="3">patients with NICM </text>
<text top="145" left="410" width="93" height="19" font="4"><b>Comparator:</b>  <b>  </b></text>
<text top="164" left="410" width="178" height="19" font="3">Catheter ablation in patients </text>
<text top="182" left="410" width="86" height="19" font="3">with ischemic </text>
<text top="200" left="410" width="103" height="19" font="3">cardiomyopathy </text>
<text top="109" left="609" width="3" height="19" font="3"> </text>
<text top="127" left="609" width="3" height="19" font="4"><b> </b></text>
<text top="219" left="115" width="4" height="23" font="10"><b> </b></text>
<text top="277" left="115" width="969" height="21" font="2"><b>Data Supplement 30. Nonrandomized Trials, Observational Studies, and/or Registries of Arrhythmogenic Right Ventricular Cardiomyopathy – </b></text>
<text top="297" left="115" width="89" height="21" font="2"><b>(Section 7.3) </b></text>
<text top="318" left="146" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="336" left="172" width="51" height="19" font="4"><b>Author; </b></text>
<text top="355" left="150" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="318" left="265" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="336" left="294" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="318" left="408" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="318" left="612" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="336" left="624" width="126" height="19" font="4"><b>(P values; OR or RR; </b></text>
<text top="355" left="656" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="318" left="891" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="336" left="920" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="374" left="118" width="109" height="19" font="3">● Quarta G, et al. </text>
<text top="392" left="118" width="96" height="19" font="3">Circ 2011 (216) </text>
<text top="411" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21606390">● </a></text>
<text top="411" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21606390">21606390</a></text>
<text top="411" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21606390"> </a></text>
<text top="429" left="118" width="3" height="19" font="4"><b> </b></text>
<text top="447" left="145" width="3" height="19" font="3"> </text>
<text top="374" left="263" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="392" left="263" width="100" height="19" font="3">national cohort  </text>
<text top="411" left="263" width="3" height="19" font="3"> </text>
<text top="429" left="263" width="68" height="19" font="4"><b>Size:</b>    255<b> </b></text>
<text top="374" left="405" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="392" left="405" width="107" height="19" font="3">100 families with </text>
<text top="411" left="405" width="100" height="19" font="3">ARVC evaluated </text>
<text top="429" left="405" width="69" height="19" font="3">2003-2009 </text>
<text top="447" left="405" width="3" height="19" font="3"> </text>
<text top="465" left="405" width="107" height="19" font="3">first degree: 210  </text>
<text top="484" left="405" width="115" height="19" font="3">second degree: 45 </text>
<text top="502" left="405" width="3" height="19" font="3"> </text>
<text top="520" left="405" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="539" left="405" width="31" height="19" font="3">N/A <b> </b></text>
<text top="375" left="545" width="269" height="19" font="4"><b>1</b>°<b> endpoint:</b>  <b>Familial evaluation for ARVC</b>; </text>
<text top="393" left="545" width="274" height="19" font="3">followup 3.4±1.6 y.  Deceased proband in 51 </text>
<text top="411" left="545" width="51" height="19" font="3">families </text>
<text top="430" left="545" width="3" height="19" font="3"> </text>
<text top="448" left="545" width="286" height="19" font="4"><b>Results:</b> in 88% of deceased: dx of ARVC made </text>
<text top="466" left="545" width="67" height="19" font="3">at autopsy </text>
<text top="485" left="545" width="238" height="19" font="3">SCD most common in young: 31% died </text>
<text top="503" left="545" width="106" height="19" font="3">between 14-20 y </text>
<text top="521" left="545" width="275" height="19" font="3">Definite or probable gene mutations; 58% of </text>
<text top="540" left="545" width="196" height="19" font="3">families, 73% of living probands </text>
<text top="558" left="545" width="249" height="19" font="3">42% of first degree relatives had disease </text>
<text top="576" left="545" width="69" height="19" font="3">expression </text>
<text top="595" left="545" width="226" height="19" font="3">62% of gene carriers had phenotypic </text>
<text top="613" left="545" width="69" height="19" font="3">expression </text>
<text top="631" left="545" width="284" height="19" font="3">Progressive disease expression beyond age 40 </text>
<text top="649" left="545" width="44" height="19" font="3">in 50%<b> </b></text>
<text top="374" left="844" width="199" height="19" font="3">● &gt;50% probands died suddenly </text>
<text top="392" left="844" width="213" height="19" font="3">● Desmosomal gene complexity in </text>
<text top="411" left="844" width="211" height="19" font="3">10% of relatives, assoc with 5-fold </text>
<text top="429" left="844" width="220" height="19" font="3">increased risk of disease expression </text>
<text top="669" left="118" width="98" height="19" font="3">● Kapplinger JD </text>
<text top="687" left="118" width="102" height="19" font="3">JACC 2011 (217) </text>
<text top="705" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21636032">● </a></text>
<text top="705" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21636032">21636032</a></text>
<text top="705" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21636032"> </a></text>
<text top="723" left="118" width="7" height="19" font="3">  </text>
<text top="742" left="118" width="3" height="19" font="4"><b> </b></text>
<text top="760" left="145" width="3" height="19" font="3"> </text>
<text top="668" left="263" width="115" height="19" font="4"><b>Study type:</b>  Multi-</text>
<text top="687" left="263" width="125" height="19" font="3">center Netherlands, </text>
<text top="705" left="263" width="88" height="19" font="3">retrospective  </text>
<text top="723" left="263" width="3" height="19" font="3"> </text>
<text top="742" left="263" width="122" height="19" font="4"><b>Size:</b>    93 probands </text>
<text top="760" left="263" width="106" height="19" font="3">and 427 controls<b> </b></text>
<text top="668" left="405" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="687" left="405" width="116" height="19" font="3">ARVC patients and </text>
<text top="705" left="405" width="89" height="19" font="3">427 unrelated </text>
<text top="723" left="405" width="102" height="19" font="3">healthy controls </text>
<text top="742" left="405" width="3" height="19" font="3"> </text>
<text top="669" left="545" width="239" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Determine prevalence of </text>
<text top="688" left="545" width="269" height="19" font="3">background “noise” in ARVC genetic testing </text>
<text top="706" left="545" width="3" height="19" font="3"> </text>
<text top="724" left="545" width="266" height="19" font="4"><b>Results:</b> Mutations present in 58% of ARVC </text>
<text top="742" left="545" width="125" height="19" font="3">and 16% of controls </text>
<text top="761" left="545" width="251" height="19" font="3">Radical mutations: 43% of ARVC, vs 0.5% </text>
<text top="779" left="545" width="53" height="19" font="3">controls </text>
<text top="669" left="844" width="179" height="19" font="3">● Radical mutations are high-</text>
<text top="687" left="844" width="177" height="19" font="3">probablility ARVC associated </text>
<text top="705" left="844" width="66" height="19" font="3">mutations </text>
<text top="723" left="844" width="207" height="19" font="3">● R Missense mutation should be </text>
<text top="742" left="844" width="187" height="19" font="3">interpreted in context of race, </text>
<text top="760" left="844" width="177" height="19" font="3">ethnicity, mutation location, </text>
<text top="778" left="844" width="219" height="19" font="3">sequence conservation; more likely </text>
</page>
<page number="128" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="18" size="12" family="Times" color="#2e74b5"/>
<text top="803" left="585" width="29" height="21" font="0">128 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="405" width="104" height="19" font="3">Tested for PKP2, </text>
<text top="127" left="405" width="110" height="19" font="3">DSP, DSG2, DSC2, </text>
<text top="145" left="405" width="53" height="19" font="3">TEME43 </text>
<text top="164" left="405" width="3" height="19" font="3"> </text>
<text top="182" left="405" width="125" height="19" font="3">Added data from 82 </text>
<text top="200" left="405" width="120" height="19" font="3">patients in ARVD/C </text>
<text top="219" left="405" width="96" height="19" font="3">Registry in USA </text>
<text top="237" left="405" width="3" height="19" font="3"> </text>
<text top="255" left="405" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="273" left="405" width="27" height="19" font="3">N/A<b> </b></text>
<text top="109" left="545" width="261" height="19" font="3">Missense mutations: 21% of ARVC, 16% of </text>
<text top="127" left="545" width="53" height="19" font="3">controls<b> </b></text>
<text top="145" left="545" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="844" width="226" height="19" font="3">positive if Caucasian, within DSP and </text>
<text top="127" left="844" width="198" height="19" font="3">DSG2 hotspot, and conserved in </text>
<text top="145" left="844" width="146" height="19" font="3">PKP2 and DSG2 residue </text>
<text top="164" left="844" width="228" height="19" font="3">● R Background mutation rate = 16% </text>
<text top="182" left="844" width="115" height="19" font="3">(vs 5% for LQT1-3) </text>
<text top="292" left="118" width="121" height="19" font="3">● Bhonsale A, et al. </text>
<text top="311" left="118" width="96" height="19" font="3">CAE 2013 (218) </text>
<text top="329" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23671136">● </a></text>
<text top="329" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23671136">23671136</a></text>
<text top="329" left="191" width="3" height="19" font="18"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23671136"><b> </b></a></text>
<text top="347" left="118" width="3" height="19" font="3"> </text>
<text top="292" left="263" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="311" left="263" width="3" height="19" font="3"> </text>
<text top="329" left="263" width="68" height="19" font="4"><b>Size:</b>    215<b> </b></text>
<text top="292" left="405" width="115" height="19" font="4"><b>Inclusion criteria:</b> <b> </b></text>
<text top="311" left="405" width="120" height="19" font="3">ARVC patients with </text>
<text top="329" left="405" width="116" height="19" font="3">positive genotype: </text>
<text top="347" left="405" width="81" height="19" font="3">desmosomal </text>
<text top="366" left="405" width="109" height="19" font="3">mutation carriers </text>
<text top="384" left="405" width="64" height="19" font="3">PKP2 85% </text>
<text top="402" left="405" width="110" height="19" font="3">53% males, mean </text>
<text top="421" left="405" width="83" height="19" font="3">age 32 ±18 y  </text>
<text top="439" left="405" width="122" height="19" font="3">Presentation VT/VF </text>
<text top="457" left="405" width="29" height="19" font="3">23% </text>
<text top="476" left="405" width="3" height="19" font="3"> </text>
<text top="494" left="405" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="512" left="405" width="27" height="19" font="3">N/A<b> </b></text>
<text top="293" left="545" width="241" height="19" font="4"><b>1</b>°<b> endpoint:</b> Risk stratification in ARVC </text>
<text top="312" left="545" width="264" height="19" font="3">genotype positive: sustained VT, SCD/ADA, </text>
<text top="330" left="545" width="142" height="19" font="3">appropriate ICD shock  </text>
<text top="348" left="545" width="117" height="19" font="3">Mean followup 7 y </text>
<text top="367" left="545" width="3" height="19" font="3"> </text>
<text top="385" left="545" width="112" height="19" font="4"><b>Results:</b>  40% ACE </text>
<text top="403" left="545" width="281" height="19" font="3">ECG: high risk ≥3 inverted precordial T waves; </text>
<text top="422" left="545" width="274" height="19" font="3">intermediate risk = T wave inversion in leads </text>
<text top="440" left="545" width="248" height="19" font="3">V1, V2 + late depol; low risk = 02 T wave </text>
<text top="458" left="545" width="202" height="19" font="3">inversion without depol changes </text>
<text top="476" left="545" width="253" height="19" font="3">PVC count on holter higher in arrhythmic </text>
<text top="495" left="545" width="128" height="19" font="3">outcomes, p&lt;0.0001 </text>
<text top="513" left="545" width="266" height="19" font="3">Event free survival lowest among probands </text>
<text top="531" left="545" width="272" height="19" font="3">p&lt;0.001, and symptomatic patients p&lt;0.001 </text>
<text top="550" left="545" width="280" height="19" font="3">Incremental risk: Proband, HR: 7.7; ≥3 T wave </text>
<text top="568" left="545" width="251" height="19" font="3">inversions, HR: 4.2; male gender, HR: 1.8 </text>
<text top="292" left="844" width="190" height="19" font="3">● ARVC desmosomal mutation </text>
<text top="311" left="844" width="163" height="19" font="3">carriers risk stratification:  </text>
<text top="329" left="844" width="165" height="19" font="3">● High risk: ECG ≥3 T wave </text>
<text top="347" left="844" width="210" height="19" font="3">inversions, Holter, proband status </text>
<text top="366" left="844" width="201" height="19" font="3">● Increasing PVC’s on holter c/w </text>
<text top="384" left="844" width="186" height="19" font="3">arrhythmic events, &gt; 760 PVC’ </text>
<text top="402" left="844" width="187" height="19" font="3">● “Benign” ECG conferred low </text>
<text top="421" left="844" width="95" height="19" font="3">arrhythmic risk </text>
<text top="439" left="844" width="3" height="19" font="3"> </text>
<text top="587" left="118" width="112" height="19" font="3">● Marcus FI, et al. </text>
<text top="605" left="118" width="102" height="19" font="3">JACC 2013 (219) </text>
<text top="624" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23500315">● </a></text>
<text top="624" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23500315">23500315</a></text>
<text top="624" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23500315"> </a></text>
<text top="587" left="263" width="255" height="19" font="3">Review paper for physicians summarizing </text>
<text top="605" left="263" width="113" height="19" font="3">genetics of ARVC   </text>
<text top="624" left="263" width="3" height="19" font="3"> </text>
<text top="642" left="263" width="54" height="19" font="3">5 genes: </text>
<text top="660" left="486" width="3" height="19" font="3"> </text>
<text top="678" left="486" width="3" height="19" font="4"><b> </b></text>
<text top="697" left="486" width="3" height="19" font="4"><b> </b></text>
<text top="715" left="486" width="3" height="19" font="4"><b> </b></text>
<text top="733" left="486" width="3" height="19" font="4"><b> </b></text>
<text top="752" left="486" width="3" height="19" font="4"><b> </b></text>
<text top="661" left="272" width="190" height="19" font="3">Plakophilin- 2             73-78% </text>
<text top="680" left="272" width="190" height="19" font="3">Desmoglein -2                10-13% </text>
<text top="699" left="272" width="175" height="19" font="3">Desmocollin-2                4-6% </text>
<text top="718" left="272" width="93" height="19" font="3">Desmoplakin    </text>
<text top="718" left="413" width="34" height="19" font="3">3-8% </text>
<text top="737" left="272" width="65" height="19" font="3">Junctional </text>
<text top="756" left="272" width="88" height="19" font="3">plakoglobin     </text>
<text top="737" left="413" width="34" height="19" font="3">1-4% </text>
<text top="587" left="545" width="270" height="19" font="3">ARVC: aut dominant, Desmosomes: cardiac, </text>
<text top="605" left="545" width="58" height="19" font="3">skin, hair </text>
<text top="624" left="545" width="280" height="19" font="3">30-50% of patients with ARVC have abnormal </text>
<text top="642" left="544" width="284" height="19" font="3">gene, range 26-58%, highest in clinical familial </text>
<text top="660" left="544" width="252" height="19" font="3">disease.  20-30% family Hx sudden death </text>
<text top="679" left="544" width="3" height="19" font="3"> </text>
<text top="697" left="544" width="281" height="19" font="3">Negative genetic tesing ≠ no disease, as &gt;50% </text>
<text top="715" left="544" width="143" height="19" font="3">gene negative to date.  </text>
<text top="733" left="545" width="237" height="19" font="3">Abnormal gene = risk, but not disease; </text>
<text top="752" left="545" width="275" height="19" font="3">modified by additional gene modifiers, virus, </text>
<text top="770" left="545" width="55" height="19" font="3">athletics </text>
<text top="587" left="844" width="201" height="19" font="3">● Proband may not benefit from </text>
<text top="605" left="844" width="229" height="19" font="3">gene testing, does not alter therapy.  </text>
<text top="624" left="844" width="216" height="19" font="3"> Patients with &gt;1 gene abnormality </text>
<text top="642" left="844" width="190" height="19" font="3">may have more severe course; </text>
<text top="660" left="844" width="74" height="19" font="3">earlier ICD.  </text>
<text top="679" left="844" width="200" height="19" font="3">● Benefits genetic testing ARVC: </text>
<text top="697" left="844" width="230" height="19" font="3">understand cause of disease, identify </text>
<text top="715" left="844" width="187" height="19" font="3">family members at risk, family </text>
<text top="734" left="844" width="174" height="19" font="3">planning, limited prognostic </text>
<text top="752" left="844" width="80" height="19" font="3">information. </text>
</page>
<page number="129" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">129 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="263" width="79" height="19" font="3">Cost ~$5400 </text>
<text top="109" left="545" width="283" height="19" font="3">PKP2 may require a second mutation to cause </text>
<text top="127" left="545" width="257" height="19" font="3">disease. The second mutation may not be </text>
<text top="145" left="545" width="275" height="19" font="3">tested in relatives, leading to false negative.  </text>
<text top="164" left="545" width="265" height="19" font="3">~48% of patients with ARVC have at least 2 </text>
<text top="182" left="545" width="285" height="19" font="3">different mutations; these patients have more </text>
<text top="200" left="544" width="99" height="19" font="3">severe disease.  </text>
<text top="219" left="544" width="281" height="19" font="3">Truly abnormal gene should not be present in </text>
<text top="237" left="544" width="106" height="19" font="3">&gt;1:400 controls;  </text>
<text top="255" left="544" width="260" height="19" font="3">However, 1:200 Finnish have desmosomal </text>
<text top="273" left="544" width="265" height="19" font="3">mutation of ARVC; 6% of Asians carry PKP2 </text>
<text top="292" left="544" width="76" height="19" font="3">mutations.   </text>
<text top="310" left="544" width="285" height="19" font="3">“the interpretation of genetic results for ARVC </text>
<text top="329" left="544" width="269" height="19" font="3">is not an exact science and is more complex </text>
<text top="347" left="544" width="279" height="19" font="3">than for other heart disorders caused by only </text>
<text top="365" left="544" width="281" height="19" font="3">a single gene and for which most patients will </text>
<text top="383" left="544" width="218" height="19" font="3">have an abnormal gene identified”. </text>
<text top="401" left="545" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="844" width="203" height="19" font="3">● For gene carriers: Recommend </text>
<text top="127" left="844" width="207" height="19" font="3">cardiac eval beginning at 10-12 y: </text>
<text top="145" left="844" width="204" height="19" font="3">ECG, SAECG, echo, holter, ± CMR </text>
<text top="164" left="844" width="210" height="19" font="3">● Evaluate q 2 y between 10-20 y; </text>
<text top="182" left="844" width="213" height="19" font="3">then every 5 y, may stop at age 50-</text>
<text top="200" left="844" width="36" height="19" font="3">60 y.  </text>
<text top="421" left="118" width="117" height="19" font="3">● Bhonsale A et al. </text>
<text top="439" left="118" width="103" height="19" font="3">Eur Heart J 2015 </text>
<text top="457" left="118" width="35" height="19" font="3">(220) </text>
<text top="476" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25616645">● </a></text>
<text top="476" left="130" width="64" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25616645">25616645 </a></text>
<text top="476" left="195" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25616645"> </a></text>
<text top="421" left="263" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="439" left="263" width="87" height="19" font="3">Retrospective </text>
<text top="457" left="263" width="122" height="19" font="3">multicenter, Dutch, </text>
<text top="476" left="263" width="23" height="19" font="3">US  </text>
<text top="494" left="263" width="3" height="19" font="3"> </text>
<text top="512" left="263" width="68" height="19" font="4"><b>Size:</b> 577   <b> </b></text>
<text top="421" left="405" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="439" left="405" width="114" height="19" font="3">Genotype positive </text>
<text top="457" left="405" width="107" height="19" font="3">desmosomal and </text>
<text top="476" left="405" width="109" height="19" font="3">non-desmosomal </text>
<text top="494" left="405" width="124" height="19" font="3">mutations in ARVC.  </text>
<text top="512" left="405" width="67" height="19" font="3">PKP2 80%  </text>
<text top="531" left="405" width="3" height="19" font="3"> </text>
<text top="549" left="405" width="111" height="19" font="3">Males 55%, mean </text>
<text top="567" left="405" width="110" height="19" font="3">age 35±17 y.  541 </text>
<text top="586" left="405" width="104" height="19" font="3">presenting alive: </text>
<text top="604" left="405" width="116" height="19" font="3">Presentation SCD= </text>
<text top="622" left="405" width="22" height="19" font="3">6% </text>
<text top="640" left="405" width="98" height="19" font="3">41% probands.  </text>
<text top="659" left="405" width="3" height="19" font="3"> </text>
<text top="677" left="405" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="695" left="405" width="97" height="19" font="3">non-genotyped </text>
<text top="714" left="405" width="38" height="19" font="3">ARVD<b> </b></text>
<text top="421" left="545" width="271" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Impact of genotype on clinical </text>
<text top="440" left="545" width="247" height="19" font="3">course in ARVC mutation carriers. Mean </text>
<text top="458" left="545" width="101" height="19" font="3">followup 6±7 y.  </text>
<text top="476" left="545" width="3" height="19" font="3"> </text>
<text top="495" left="545" width="283" height="19" font="4"><b>Results:</b>  Presentation with SCD were younger </text>
<text top="513" left="545" width="274" height="19" font="3">(median 23 y) than those presenting with VT </text>
<text top="531" left="545" width="110" height="19" font="3">(36 y) (p&lt;0.001).   </text>
<text top="550" left="545" width="261" height="19" font="3">Death 2%, transplant 2%; Sustained VT/VF </text>
<text top="568" left="545" width="185" height="19" font="3">30%, LVEF &lt; 55 14%; CHF 5%.  </text>
<text top="586" left="545" width="240" height="19" font="3">Compound mutations:  earlier onset of </text>
<text top="605" left="545" width="285" height="19" font="3">symptoms, higher incidence VT/VF. PKP2 least </text>
<text top="623" left="545" width="177" height="19" font="3">ventricular dysfunction, 9%;  </text>
<text top="641" left="545" width="3" height="19" font="3"> </text>
<text top="660" left="545" width="247" height="19" font="3">Desmoplakin (DSP) mutations had more </text>
<text top="678" left="545" width="285" height="19" font="3">ventricular dysfunction/HF than PKP2 carriers: </text>
<text top="696" left="544" width="265" height="19" font="3">40% ventricular dysfunction; more likely to </text>
<text top="714" left="544" width="190" height="19" font="3">present with SCD (11% of SCD) </text>
<text top="733" left="544" width="3" height="19" font="3"> </text>
<text top="751" left="545" width="284" height="19" font="3">Male gender higher arrhythmic outcome, 53% </text>
<text top="769" left="545" width="45" height="19" font="3">vs 29% </text>
<text top="421" left="844" width="224" height="19" font="3">● Among ARVC patients with known </text>
<text top="439" left="844" width="219" height="19" font="3">genotype: specific genotype affects </text>
<text top="457" left="844" width="164" height="19" font="3">clinical course and disease </text>
<text top="476" left="844" width="73" height="19" font="3">expression. </text>
<text top="494" left="844" width="219" height="19" font="3">● Gene specific variation in SCD, LV </text>
<text top="512" left="844" width="102" height="19" font="3">dysfunction, HF. </text>
<text top="531" left="844" width="229" height="19" font="3">● Males worse outcome:  more likely </text>
<text top="549" left="844" width="225" height="19" font="3">to be probands, symptomatic earlier </text>
<text top="567" left="844" width="176" height="19" font="3">and more severe arrhythmic </text>
<text top="586" left="844" width="73" height="19" font="3">expression. </text>
<text top="604" left="844" width="213" height="19" font="3">● Phenotypic variability—modifier </text>
<text top="622" left="844" width="204" height="19" font="3">genes/environmental influences. </text>
</page>
<page number="130" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">130 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="118" width="122" height="19" font="3">● Rigato I et al. Circ </text>
<text top="127" left="118" width="110" height="19" font="3">CV Genetics 2013 </text>
<text top="145" left="118" width="35" height="19" font="3">(221) </text>
<text top="164" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24070718">● </a></text>
<text top="164" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24070718">24070718</a></text>
<text top="164" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24070718"> </a></text>
<text top="109" left="263" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="127" left="263" width="74" height="19" font="3">Prospective </text>
<text top="145" left="263" width="99" height="19" font="3">Observational    </text>
<text top="164" left="263" width="3" height="19" font="3"> </text>
<text top="182" left="263" width="68" height="19" font="4"><b>Size:</b>  134  <b> </b></text>
<text top="109" left="405" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="127" left="405" width="115" height="19" font="3">Desmosomal gene </text>
<text top="145" left="405" width="115" height="19" font="3">mutations carriers </text>
<text top="164" left="405" width="115" height="19" font="3">Desmoplakin 39%, </text>
<text top="182" left="405" width="115" height="19" font="3">plakophilin 2 34%, </text>
<text top="200" left="405" width="118" height="19" font="3">desmoglein 2 26%, </text>
<text top="219" left="405" width="113" height="19" font="3">desmocolliln 2 1% </text>
<text top="237" left="405" width="84" height="19" font="3">16% complex </text>
<text top="255" left="405" width="65" height="19" font="3">genotype: </text>
<text top="273" left="405" width="86" height="19" font="3">compound or </text>
<text top="292" left="405" width="55" height="19" font="3">dignenic </text>
<text top="310" left="405" width="97" height="19" font="3">heterozygosity  </text>
<text top="329" left="405" width="3" height="19" font="3"> </text>
<text top="347" left="405" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="365" left="405" width="27" height="19" font="3">N/A<b> </b></text>
<text top="109" left="545" width="245" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ARVC gene carriers risk of </text>
<text top="128" left="545" width="128" height="19" font="3">arrhythmic outcome </text>
<text top="146" left="545" width="3" height="19" font="3"> </text>
<text top="164" left="545" width="258" height="19" font="4"><b>Results:</b>  Median observation 39 y (22-52) </text>
<text top="183" left="545" width="187" height="19" font="3">16% major arrhythmic events. </text>
<text top="201" left="545" width="155" height="19" font="3">Independent predictors:  </text>
<text top="219" left="545" width="259" height="19" font="3">Multiple desmosomal gene mutations HR: </text>
<text top="238" left="545" width="193" height="19" font="3">3.71; 95 CI:1.54–8.92, p=0.003. </text>
<text top="256" left="544" width="256" height="19" font="3">Male gender HR: 2.76; 95% CI: 1.19–6.41, </text>
<text top="274" left="544" width="49" height="19" font="3">p=0.02. </text>
<text top="109" left="844" width="220" height="19" font="3">● Multiple DS gene mutation status </text>
<text top="127" left="844" width="206" height="19" font="3">was powerful predictor for major </text>
<text top="145" left="844" width="118" height="19" font="3">arrhythmic events. </text>
<text top="164" left="844" width="3" height="19" font="3"> </text>
<text top="182" left="844" width="3" height="19" font="3"> </text>
<text top="384" left="118" width="119" height="19" font="3">● Groeneweg JA et </text>
<text top="402" left="118" width="120" height="19" font="3">al. Circ CV Genetics </text>
<text top="421" left="118" width="69" height="19" font="3">2015 (222) </text>
<text top="439" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25820315">● </a></text>
<text top="439" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25820315">25820315</a></text>
<text top="439" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25820315"> </a></text>
<text top="384" left="263" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="402" left="263" width="84" height="19" font="3">retrospective </text>
<text top="421" left="263" width="125" height="19" font="3">multicenter, Europe </text>
<text top="439" left="263" width="55" height="19" font="3">and USA </text>
<text top="457" left="263" width="3" height="19" font="3"> </text>
<text top="476" left="263" width="76" height="19" font="4"><b>Size:</b>  1001  <b> </b></text>
<text top="384" left="405" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="402" left="405" width="93" height="19" font="3">ARVC patients  </text>
<text top="421" left="405" width="94" height="19" font="3">Probands 44%, </text>
<text top="439" left="405" width="102" height="19" font="3">family members </text>
<text top="457" left="405" width="36" height="19" font="3">56%.  </text>
<text top="476" left="405" width="120" height="19" font="3">Probands: 416/439 </text>
<text top="494" left="405" width="123" height="19" font="3">presented alive (5% </text>
<text top="512" left="405" width="105" height="19" font="3">presented SCD).  </text>
<text top="531" left="405" width="3" height="19" font="3"> </text>
<text top="549" left="405" width="76" height="19" font="3">Overall 63% </text>
<text top="567" left="405" width="115" height="19" font="3">mutation positive<b>:</b> </text>
<text top="586" left="405" width="67" height="19" font="3">PKP2 46%. </text>
<text top="604" left="405" width="108" height="19" font="3">Family members: </text>
<text top="622" left="405" width="89" height="19" font="3">73% mutation </text>
<text top="640" left="405" width="56" height="19" font="3">carriers.  </text>
<text top="659" left="405" width="3" height="19" font="3"> </text>
<text top="677" left="405" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="695" left="405" width="27" height="19" font="3">N/A<b> </b></text>
<text top="385" left="545" width="250" height="19" font="4"><b>1</b>°<b> endpoint:</b> outcomes of ARVC patients </text>
<text top="403" left="545" width="128" height="19" font="3">median followup 7 y </text>
<text top="422" left="545" width="3" height="19" font="3"> </text>
<text top="440" left="545" width="265" height="19" font="4"><b>Results:</b>  Sustained VT developed in 72% of </text>
<text top="458" left="545" width="68" height="19" font="3">probands.  </text>
<text top="476" left="545" width="274" height="19" font="3">Probands with positive mutations presented </text>
<text top="495" left="545" width="98" height="19" font="3">at younger age. </text>
<text top="513" left="545" width="233" height="19" font="3">Mortality 6%, transplantation 4%, not </text>
<text top="531" left="545" width="230" height="19" font="3">different based on mutation status in </text>
<text top="550" left="545" width="68" height="19" font="3">probands.  </text>
<text top="568" left="545" width="241" height="19" font="3">Family members: 1/3 developed ARVC. </text>
<text top="586" left="545" width="239" height="19" font="3">Sustained VT 8%, cardiac mortality 2%. </text>
<text top="605" left="545" width="3" height="19" font="3"> </text>
<text top="623" left="545" width="241" height="19" font="3">Mutations in family members modified </text>
<text top="641" left="545" width="266" height="19" font="3">course: 8x increase in VT, increased cardiac </text>
<text top="660" left="545" width="67" height="19" font="3">mortality.  </text>
<text top="678" left="545" width="272" height="19" font="3">ICD improved survival in index patients: SCD </text>
<text top="696" left="545" width="161" height="19" font="3">0.6% vs 16% without ICD. <b> </b></text>
<text top="384" left="844" width="160" height="19" font="3">● ARVC: 10% death/heart </text>
<text top="402" left="844" width="189" height="19" font="3">transplantation during median </text>
<text top="421" left="844" width="79" height="19" font="3">followup 7y. </text>
<text top="439" left="844" width="232" height="19" font="3">● Probands: Mutations altered age of </text>
<text top="457" left="844" width="166" height="19" font="3">disease expression but not </text>
<text top="476" left="844" width="68" height="19" font="3">outcomes. </text>
<text top="494" left="844" width="184" height="19" font="3">● Family members:  mutation </text>
<text top="512" left="844" width="220" height="19" font="3">carriers had more VA and increased </text>
<text top="531" left="844" width="114" height="19" font="3">cardiac mortality.  </text>
</page>
<page number="131" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">131 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="118" width="118" height="19" font="3">● te Riele AS, et al. </text>
<text top="127" left="118" width="94" height="19" font="3">EHJ 2016 (223) </text>
<text top="145" left="118" width="9" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26314686">●</a></text>
<text top="145" left="127" width="64" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26314686"> 26314686</a></text>
<text top="145" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26314686"> </a></text>
<text top="109" left="263" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="127" left="263" width="75" height="19" font="3">Multicenter </text>
<text top="145" left="263" width="95" height="19" font="3">retrospective    </text>
<text top="164" left="263" width="3" height="19" font="3"> </text>
<text top="182" left="263" width="68" height="19" font="4"><b>Size:</b>    274<b> </b></text>
<text top="109" left="405" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="127" left="405" width="76" height="19" font="3">First degree </text>
<text top="145" left="405" width="108" height="19" font="3">relatives of ARVC </text>
<text top="164" left="405" width="55" height="19" font="3">proband </text>
<text top="182" left="405" width="92" height="19" font="3">46% male, age </text>
<text top="200" left="405" width="51" height="19" font="3">36±19 y </text>
<text top="219" left="405" width="3" height="19" font="3"> </text>
<text top="237" left="405" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="255" left="405" width="31" height="19" font="3">N/A <b> </b></text>
<text top="109" left="545" width="279" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ARVC first degree relatives: risk </text>
<text top="128" left="545" width="161" height="19" font="3">of ARVC dx and outcomes </text>
<text top="146" left="545" width="155" height="19" font="3">Mean followup 6.7±3.7 y </text>
<text top="165" left="544" width="3" height="19" font="3"> </text>
<text top="183" left="545" width="189" height="19" font="4"><b>Results:</b>  35% developed ARVC </text>
<text top="201" left="545" width="270" height="19" font="3">Risk of ARVC dx: sibling, HR: 3.11; p&lt;0 .001,  </text>
<text top="219" left="544" width="258" height="19" font="3">symptoms, p&lt;0.001, pathogenic mutation </text>
<text top="238" left="544" width="155" height="19" font="3">p&lt;0.001, female, p=0.01. </text>
<text top="256" left="545" width="223" height="19" font="3">8% developed sustained VA: neither </text>
<text top="274" left="545" width="275" height="19" font="3">relatedness to proband nor malignant family </text>
<text top="293" left="545" width="252" height="19" font="3">Hx were predictive of arrhythmic events. </text>
<text top="109" left="844" width="212" height="19" font="3">● ARVC first degree relatives’ with </text>
<text top="127" left="844" width="163" height="19" font="3">increased likelihood of dx: </text>
<text top="145" left="844" width="188" height="19" font="3">symptoms, sibling, pathogenic </text>
<text top="164" left="844" width="159" height="19" font="3">mutation, female gender. </text>
<text top="182" left="844" width="189" height="19" font="3">● Malignant family Hx was not </text>
<text top="200" left="844" width="212" height="19" font="3">associated with arrhythmic events<b> </b></text>
<text top="312" left="118" width="124" height="19" font="3">● Kamath GS, et al., </text>
<text top="330" left="118" width="90" height="19" font="3">HR 2011 (224) </text>
<text top="348" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20933608">● </a></text>
<text top="348" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20933608">20933608</a></text>
<text top="348" left="191" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20933608"><b> </b></a></text>
<text top="311" left="263" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="330" left="263" width="123" height="19" font="3">retrospective single </text>
<text top="348" left="263" width="50" height="19" font="3">center   </text>
<text top="367" left="263" width="3" height="19" font="3"> </text>
<text top="385" left="263" width="61" height="19" font="4"><b>Size:</b> 87   <b> </b></text>
<text top="311" left="405" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="330" left="405" width="98" height="19" font="3">ARVC probands </text>
<text top="348" left="405" width="122" height="19" font="3">compared with 103 </text>
<text top="367" left="405" width="53" height="19" font="3">controls </text>
<text top="385" left="405" width="3" height="19" font="3"> </text>
<text top="403" left="405" width="125" height="19" font="3">Mean age 37 y, 54% </text>
<text top="422" left="405" width="33" height="19" font="3">male </text>
<text top="440" left="405" width="3" height="19" font="3"> </text>
<text top="458" left="405" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="476" left="405" width="27" height="19" font="3">N/A<b> </b></text>
<text top="312" left="545" width="264" height="19" font="4"><b>1</b>°<b> endpoint:</b> SAECG abnormalities in ARVC </text>
<text top="331" left="545" width="254" height="19" font="3">Abnormal: fQRSD ≥114 ms, LASD &gt;38 ms, </text>
<text top="349" left="545" width="97" height="19" font="3">RMS-40 &lt;20 µV </text>
<text top="367" left="545" width="3" height="19" font="3"> </text>
<text top="386" left="545" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="404" left="545" width="273" height="19" font="3">SAECG sensitivity/specificity: 1-criteria 69%/ </text>
<text top="422" left="545" width="285" height="19" font="3">92%; 2-criteria 47%/95%; 3-criteria 33%/100%<b> </b></text>
<text top="312" left="844" width="229" height="19" font="3">● SAECG: using 1/3 criteria increased </text>
<text top="330" left="844" width="227" height="19" font="3">sensitivity and maintained specificity </text>
<text top="348" left="844" width="202" height="19" font="3">● SAECG correlated with disease </text>
<text top="367" left="844" width="174" height="19" font="3">severity on CMR, but not VT </text>
<text top="496" left="118" width="116" height="19" font="3">● Marcus FI, et al., </text>
<text top="514" left="118" width="96" height="19" font="3">Circ 1982 (225) </text>
<text top="532" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7053899">● </a></text>
<text top="532" left="130" width="53" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7053899">7053899</a></text>
<text top="532" left="184" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7053899"> </a></text>
<text top="495" left="263" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="514" left="263" width="43" height="19" font="3">center </text>
<text top="532" left="263" width="3" height="19" font="3"> </text>
<text top="550" left="263" width="61" height="19" font="4"><b>Size:</b>    22<b> </b></text>
<text top="495" left="405" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="514" left="405" width="90" height="19" font="3">22 adults with </text>
<text top="532" left="405" width="100" height="19" font="3">recurrent VT w/ </text>
<text top="550" left="405" width="74" height="19" font="3">LBBB 21/22 </text>
<text top="569" left="405" width="96" height="19" font="3">Mean age 39 y, </text>
<text top="587" left="405" width="74" height="19" font="3">Males 2.7:1 </text>
<text top="605" left="405" width="3" height="19" font="3"> </text>
<text top="624" left="405" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="642" left="405" width="27" height="19" font="3">N/A<b> </b></text>
<text top="496" left="545" width="284" height="19" font="4"><b>1</b>°<b> endpoint:</b> right ventricular abnormalities in </text>
<text top="515" left="545" width="37" height="19" font="3">ARVC </text>
<text top="533" left="545" width="3" height="19" font="3"> </text>
<text top="551" left="545" width="273" height="19" font="4"><b>Results:</b>  inverted T waves right precordium, </text>
<text top="570" left="545" width="253" height="19" font="3">cardiac enlargement, delayed ventricular </text>
<text top="588" left="545" width="65" height="19" font="3">potentials </text>
<text top="606" left="545" width="194" height="19" font="3">RV dysplasia– inferior, apical or </text>
<text top="624" left="545" width="283" height="19" font="3">diaphragmatic-diagnosed with angiography. 1 </text>
<text top="643" left="545" width="46" height="19" font="3">death.  </text>
<text top="496" left="844" width="226" height="19" font="3">● Characterize RV pathology in LBBB </text>
<text top="514" left="844" width="19" height="19" font="3">VT </text>
<text top="532" left="844" width="220" height="19" font="3">● Consider dx in patients with VT of </text>
<text top="550" left="844" width="220" height="19" font="3">unknown cause, particularly if LBBB </text>
<text top="569" left="844" width="49" height="19" font="3">pattern </text>
<text top="587" left="844" width="3" height="19" font="3"> </text>
<text top="662" left="118" width="111" height="19" font="3">● Corrado D et al. </text>
<text top="680" left="118" width="102" height="19" font="3">JACC 1997 (226) </text>
<text top="698" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9362410">● </a></text>
<text top="698" left="130" width="53" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9362410">9362410</a></text>
<text top="698" left="184" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9362410"><b> </b></a></text>
<text top="662" left="263" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="680" left="263" width="84" height="19" font="3">retrospective </text>
<text top="698" left="263" width="78" height="19" font="3">multicenter  </text>
<text top="717" left="263" width="3" height="19" font="3"> </text>
<text top="735" left="263" width="54" height="19" font="4"><b>Size:</b>  42 </text>
<text top="753" left="263" width="10" height="19" font="3">  <b> </b></text>
<text top="662" left="405" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="680" left="405" width="101" height="19" font="3">Pathologic dx of </text>
<text top="698" left="405" width="121" height="19" font="3">ARVC at autopsy or </text>
<text top="717" left="405" width="102" height="19" font="3">heart transplant </text>
<text top="735" left="405" width="126" height="19" font="3">Mean age 29.6±18 y </text>
<text top="753" left="405" width="53" height="19" font="3">(9–65 y) </text>
<text top="772" left="405" width="3" height="19" font="3"> </text>
<text top="662" left="545" width="224" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ARVC clinic-pathologic </text>
<text top="681" left="545" width="94" height="19" font="3">manifestations </text>
<text top="699" left="545" width="3" height="19" font="3"> </text>
<text top="718" left="545" width="277" height="19" font="4"><b>Results:</b> 80% died suddenly: 47% of SCD died </text>
<text top="736" left="545" width="97" height="19" font="3">during exertion </text>
<text top="754" left="545" width="188" height="19" font="3">SCD first symptom in 35%.        </text>
<text top="773" left="545" width="64" height="19" font="3">CHF 24%   </text>
<text top="662" left="844" width="214" height="19" font="3">● LV involvement in 76% of ARVC:  </text>
<text top="680" left="844" width="112" height="19" font="3">● age dependent, </text>
<text top="698" left="844" width="177" height="19" font="3">● more severe cardiomegaly </text>
<text top="717" left="844" width="77" height="19" font="3">● More CHF </text>
<text top="735" left="844" width="143" height="19" font="3">● Prior syncope in 26% </text>
<text top="753" left="844" width="184" height="19" font="3">● SCD exercise related in 47% </text>
</page>
<page number="132" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">132 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="405" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="127" left="405" width="31" height="19" font="3">N/A <b> </b></text>
<text top="109" left="545" width="84" height="19" font="3">Syncope 26% </text>
<text top="127" left="545" width="144" height="19" font="3">Exercise related in 64% </text>
<text top="145" left="545" width="191" height="19" font="3">LV fibrofatty involvement 76%  </text>
<text top="164" left="545" width="181" height="19" font="3">Isolated RV involvement 24% </text>
<text top="183" left="118" width="102" height="19" font="3">● Link MS ert al. </text>
<text top="201" left="118" width="102" height="19" font="3">JACC 2014 (227) </text>
<text top="219" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25011714">● </a></text>
<text top="219" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25011714">25011714</a></text>
<text top="219" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25011714"> </a></text>
<text top="183" left="263" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="201" left="263" width="111" height="19" font="3">Prospective multi-</text>
<text top="219" left="263" width="46" height="19" font="3">center  </text>
<text top="238" left="263" width="101" height="19" font="3">North American </text>
<text top="256" left="263" width="92" height="19" font="3">ARVC Registry  </text>
<text top="274" left="263" width="3" height="19" font="3"> </text>
<text top="292" left="263" width="61" height="19" font="4"><b>Size:</b>  137<b> </b></text>
<text top="183" left="405" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="201" left="405" width="90" height="19" font="3">ARVC patients </text>
<text top="219" left="405" width="122" height="19" font="3">enrolled in registry  </text>
<text top="238" left="405" width="3" height="19" font="3"> </text>
<text top="256" left="405" width="118" height="19" font="3">79% (108 patients) </text>
<text top="274" left="405" width="89" height="19" font="3">received ICD’s </text>
<text top="293" left="405" width="3" height="19" font="3"> </text>
<text top="311" left="405" width="64" height="19" font="3">Mean age </text>
<text top="329" left="405" width="126" height="19" font="3">enrollment 40±14 y. </text>
<text top="347" left="405" width="103" height="19" font="3">Prior symptoms, </text>
<text top="366" left="405" width="118" height="19" font="3">sustained VT or CA </text>
<text top="384" left="405" width="29" height="19" font="3">41% </text>
<text top="402" left="405" width="3" height="19" font="3"> </text>
<text top="421" left="405" width="3" height="19" font="3"> </text>
<text top="439" left="405" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="457" left="405" width="27" height="19" font="3">N/A<b> </b></text>
<text top="183" left="545" width="262" height="19" font="4"><b>1</b>°<b> endpoint</b>:  Sustained VA in ARVC during </text>
<text top="202" left="545" width="116" height="19" font="3">followup 3.3±1.7 y </text>
<text top="220" left="545" width="3" height="19" font="3"> </text>
<text top="238" left="545" width="272" height="19" font="4"><b>Results:</b> 44% (48 patients) had 502 episodes </text>
<text top="257" left="545" width="243" height="19" font="3">of sustained VT: 97% monomorphic VT. </text>
<text top="275" left="545" width="140" height="19" font="3">Inapprop shocks 17%.  </text>
<text top="293" left="545" width="232" height="19" font="3">Independent predictors sust VT: prior </text>
<text top="312" left="545" width="266" height="19" font="3">spontaneous VT, inferior T wave inversion.  </text>
<text top="330" left="545" width="258" height="19" font="3">Independent predictor life threatening VT </text>
<text top="348" left="545" width="232" height="19" font="3">(rate ≥240bpm or VF): younger age at </text>
<text top="367" left="545" width="78" height="19" font="3">enrollment.  </text>
<text top="385" left="545" width="239" height="19" font="3">ATP successfully terminated 92% of VT </text>
<text top="403" left="545" width="281" height="19" font="3"> Patients without ICD implantation: no SCD or </text>
<text top="422" left="545" width="120" height="19" font="3">SVT -followup 2.4 y </text>
<text top="183" left="844" width="216" height="19" font="3">● ARVC predictors of VT: sustained </text>
<text top="201" left="844" width="192" height="19" font="3">VT prior to ICD, inferior T wave </text>
<text top="219" left="844" width="228" height="19" font="3">inversion, younger age at enrollment </text>
<text top="238" left="844" width="172" height="19" font="3">● 48% received ICD therapy </text>
<text top="256" left="844" width="227" height="19" font="3">● Recommend programming ATP for </text>
<text top="274" left="844" width="209" height="19" font="3">termination of VT: successful 92% </text>
<text top="293" left="844" width="205" height="19" font="3">● Syncope, family Hx SCD did not </text>
<text top="311" left="844" width="122" height="19" font="3">predict ICD therapy </text>
<text top="476" left="118" width="111" height="19" font="3">● Corrado D et al. </text>
<text top="495" left="118" width="96" height="19" font="3">Circ 2015 (228) </text>
<text top="513" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26216213">● </a></text>
<text top="513" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26216213">26216213</a></text>
<text top="513" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26216213"> </a></text>
<text top="531" left="118" width="3" height="19" font="4"><b> </b></text>
<text top="476" left="263" width="150" height="19" font="3">International Task Force </text>
<text top="495" left="263" width="3" height="19" font="3"> </text>
<text top="513" left="263" width="238" height="19" font="3">Treatment of ARVC: International Task </text>
<text top="531" left="263" width="155" height="19" font="3">Force Recommendations<b> </b></text>
<text top="476" left="545" width="283" height="19" font="3">No<b> </b>competitive or endurance sports; AAD’s as </text>
<text top="495" left="545" width="269" height="19" font="3">adjunct in patients w frequent AICD shocks; </text>
<text top="513" left="545" width="284" height="19" font="3">BB for patients with recurrent VT, appropriate </text>
<text top="531" left="545" width="249" height="19" font="3">ICD rx, or ICD therapy for SVT; epicardial </text>
<text top="550" left="545" width="255" height="19" font="3">ablation for patients who fail endocardial </text>
<text top="568" left="545" width="233" height="19" font="3">approach; ICD for patients with hemo </text>
<text top="586" left="545" width="166" height="19" font="3">unstable sustained VT/ VF. </text>
<text top="605" left="545" width="3" height="19" font="3"> </text>
<text top="623" left="545" width="271" height="19" font="3">EPS for suspected ARVC; restrict athletics to </text>
<text top="641" left="545" width="234" height="19" font="3">low intensity; BB for all ARVC patients </text>
<text top="660" left="545" width="276" height="19" font="3">irrespective of arrhythmias; cath ablation for </text>
<text top="678" left="545" width="245" height="19" font="3">recurrent VT fail meds other than amio. </text>
<text top="696" left="545" width="3" height="19" font="3"> </text>
<text top="714" left="545" width="259" height="19" font="3">Vstim for risk stratification asymptomatic; </text>
<text top="733" left="545" width="269" height="19" font="3">endocardial voltage mapping; restrict comp </text>
<text top="751" left="545" width="238" height="19" font="3">sports in phenotype neg patients; cath </text>
<text top="769" left="545" width="257" height="19" font="3">ablation without ICD for selected patients </text>
<text top="476" left="844" width="126" height="19" font="3">● ICD implantation:  </text>
<text top="495" left="844" width="232" height="19" font="3">● Hemodynamically unstable sust VT, </text>
<text top="513" left="844" width="226" height="19" font="3">or VF; severe systolic dysfunction RV </text>
<text top="531" left="844" width="97" height="19" font="3">or LVEF ≤ 35%;  </text>
<text top="550" left="844" width="227" height="19" font="3">● Hemodynamically stable sustained </text>
<text top="568" left="844" width="221" height="19" font="3">VT; unexplained syncope; mod vent </text>
<text top="586" left="844" width="225" height="19" font="3">dysfunction RV EF= 36-40% or LVEF= </text>
<text top="605" left="844" width="105" height="19" font="3">36-45%; or NSVT </text>
<text top="623" left="844" width="123" height="19" font="3">● Minor risk factors </text>
<text top="641" left="844" width="220" height="19" font="3">● Prophylactic ICD in asymptomatic </text>
<text top="660" left="844" width="189" height="19" font="3">patients with no risk factors of </text>
<text top="678" left="844" width="135" height="19" font="3">healthy gene carriers.<b> </b></text>
</page>
<page number="133" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">133 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="545" width="244" height="19" font="3">with drug refractory hemo stable single </text>
<text top="127" left="545" width="100" height="19" font="3">morphology VT. </text>
<text top="145" left="545" width="3" height="19" font="3"> </text>
<text top="164" left="545" width="281" height="19" font="3">No BB for healthy gene carriers; cath ablation </text>
<text top="182" left="545" width="265" height="19" font="3">as alternative to ICD for prevention of SCD. </text>
<text top="201" left="118" width="111" height="19" font="3">● Corrado D et al. </text>
<text top="219" left="118" width="96" height="19" font="3">Circ 2003 (229) </text>
<text top="238" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=14638546">● </a></text>
<text top="238" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=14638546">14638546</a></text>
<text top="237" left="191" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=14638546"><b> </b></a></text>
<text top="201" left="263" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="219" left="263" width="74" height="19" font="3">multicenter </text>
<text top="238" left="263" width="88" height="19" font="3">retrospective  </text>
<text top="256" left="263" width="3" height="19" font="3"> </text>
<text top="274" left="263" width="68" height="19" font="4"><b>Size:</b>    132<b> </b></text>
<text top="201" left="405" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="219" left="405" width="120" height="19" font="3">ARVC patients with </text>
<text top="238" left="405" width="24" height="19" font="3">ICD </text>
<text top="256" left="405" width="93" height="19" font="3">Mean age 40 y </text>
<text top="274" left="405" width="72" height="19" font="3">70% males  </text>
<text top="293" left="405" width="121" height="19" font="3">ICD indication: ACA </text>
<text top="311" left="405" width="114" height="19" font="3">10%, sustained VT </text>
<text top="329" left="405" width="120" height="19" font="3">62%, syncope 16%; </text>
<text top="347" left="405" width="96" height="19" font="3">nonsust VT 9%; </text>
<text top="366" left="405" width="82" height="19" font="3">family Hx 3% </text>
<text top="384" left="405" width="3" height="19" font="3"> </text>
<text top="402" left="405" width="106" height="19" font="3">83% on AA drugs </text>
<text top="421" left="405" width="74" height="19" font="3">prior to ICD </text>
<text top="439" left="405" width="3" height="19" font="3"> </text>
<text top="457" left="405" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="476" left="405" width="27" height="19" font="3">N/A<b> </b></text>
<text top="202" left="545" width="266" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ARVC appropriate ICD shocks </text>
<text top="220" left="545" width="138" height="19" font="3">Mean followup 39 mo </text>
<text top="238" left="544" width="3" height="19" font="3"> </text>
<text top="257" left="545" width="258" height="19" font="4"><b>Results:</b>  Approp shocks 48%, comps 14%, </text>
<text top="275" left="545" width="132" height="19" font="3">inapprop shocks 16% </text>
<text top="293" left="545" width="269" height="19" font="3">84% underwent PES: 69% inducible sust VT: </text>
<text top="312" left="545" width="283" height="19" font="3">neither sensitive nor specific: 51% no appropr </text>
<text top="330" left="545" width="263" height="19" font="3">shock, 54% of non-inducible had approp rx </text>
<text top="348" left="545" width="229" height="19" font="3">Syncope: 21 patients: none died, one </text>
<text top="367" left="545" width="229" height="19" font="3">underwent OHT; 38% approp shocks; </text>
<text top="385" left="545" width="280" height="19" font="3">multivariate analysis p=0.07 for approp shock </text>
<text top="403" left="545" width="272" height="19" font="4"><b>Independent predictors of VF: </b>ACA, VT with </text>
<text top="422" left="545" width="274" height="19" font="3">hemodynamic compromise, younger age, LV </text>
<text top="440" left="545" width="79" height="19" font="3">involvement<b> </b></text>
<text top="201" left="844" width="158" height="19" font="3">● 48% approp ICD shocks </text>
<text top="219" left="844" width="193" height="19" font="3">● Predictors: ACA, unstable VT, </text>
<text top="238" left="844" width="156" height="19" font="3">younger age, lower LVEF  </text>
<text top="256" left="844" width="228" height="19" font="3">● PES not predictive of approp shock </text>
<text top="274" left="844" width="228" height="19" font="3">● Syncope not statistically important </text>
<text top="293" left="844" width="179" height="19" font="3">as risk factor in multivariable </text>
<text top="311" left="844" width="55" height="19" font="3">analysis. </text>
<text top="329" left="844" width="226" height="19" font="3">● 4 patients implanted due to family </text>
<text top="347" left="844" width="165" height="19" font="3">Hx SCD: no approp shocks  </text>
<text top="495" left="118" width="104" height="19" font="3">● Piccini JP et al<b>. </b></text>
<text top="513" left="118" width="122" height="19" font="3">Heart Rhythm 2005 </text>
<text top="531" left="118" width="35" height="19" font="3">(230) </text>
<text top="550" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16253908">● </a></text>
<text top="550" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16253908">16253908</a></text>
<text top="550" left="191" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16253908"><b> </b></a></text>
<text top="495" left="263" width="119" height="19" font="4"><b>Study type:</b>   single </text>
<text top="513" left="263" width="127" height="19" font="3">center retrospective </text>
<text top="531" left="263" width="3" height="19" font="3"> </text>
<text top="550" left="263" width="64" height="19" font="4"><b>Size: </b>67    <b> </b></text>
<text top="495" left="405" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="513" left="405" width="83" height="19" font="3">Patients with </text>
<text top="531" left="405" width="125" height="19" font="3">definite or probable </text>
<text top="550" left="405" width="101" height="19" font="3">ARVC with ICD’s </text>
<text top="568" left="405" width="119" height="19" font="3">Mean age 36±14 y; </text>
<text top="586" left="405" width="63" height="19" font="3">52% male </text>
<text top="605" left="405" width="119" height="19" font="3">1° prevention 42%, </text>
<text top="623" left="405" width="45" height="19" font="3">2° 58% </text>
<text top="641" left="405" width="119" height="19" font="3">Sustained VT: 52%, </text>
<text top="660" left="405" width="115" height="19" font="3">syncope 36%, ACA </text>
<text top="678" left="405" width="32" height="19" font="3">58/5 </text>
<text top="696" left="405" width="3" height="19" font="3"> </text>
<text top="714" left="405" width="3" height="19" font="3"> </text>
<text top="733" left="405" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="751" left="405" width="27" height="19" font="3">N/A </text>
<text top="769" left="405" width="3" height="19" font="4"><b> </b></text>
<text top="495" left="545" width="196" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ARVC clinical + EP </text>
<text top="514" left="545" width="266" height="19" font="3">characteristics that predict appropriate ICD </text>
<text top="532" left="545" width="51" height="19" font="3">shocks.  </text>
<text top="550" left="545" width="155" height="19" font="3">Mean followup 4.4±2.9 y </text>
<text top="569" left="544" width="3" height="19" font="3"> </text>
<text top="587" left="545" width="253" height="19" font="4"><b>Results:</b>  Appropriate shocks in 94% of 2° </text>
<text top="605" left="545" width="271" height="19" font="3">prevention, 39% of 1° prevention (p=0.001), </text>
<text top="624" left="545" width="74" height="19" font="3">overall 66% </text>
<text top="642" left="545" width="225" height="19" font="3">approp shocks:  Definite ARVC: 73%; </text>
<text top="660" left="545" width="92" height="19" font="3">probable:33%  </text>
<text top="679" left="545" width="213" height="19" font="3">Overall 21% received shock for life </text>
<text top="697" left="545" width="284" height="19" font="3">threatening VT/VF &gt;240 bpm; no difference in </text>
<text top="715" left="545" width="172" height="19" font="3">1° or 2° prevention patients </text>
<text top="734" left="544" width="283" height="19" font="3">EPS did not predict ICD approp use in patients </text>
<text top="752" left="544" width="117" height="19" font="3">with 1° prevention </text>
<text top="770" left="545" width="247" height="19" font="3">All patients with VF had inducible VT/VF </text>
<text top="495" left="844" width="198" height="19" font="3">● Multivariate predictor approp </text>
<text top="513" left="844" width="204" height="19" font="3">shock: sustained VT/VF, OR:11.4; </text>
<text top="531" left="844" width="60" height="19" font="3">p=0.015;  </text>
<text top="550" left="844" width="164" height="19" font="3">● NSVT, OR: 6.29, p=0.051 </text>
<text top="568" left="844" width="214" height="19" font="3">● EPS did not predict ICD shocks in </text>
<text top="586" left="844" width="194" height="19" font="3">patients with 1° prevention ICD </text>
<text top="605" left="844" width="209" height="19" font="3">● Further research to identify low </text>
<text top="623" left="844" width="210" height="19" font="3">risk patients who do not need ICD </text>
<text top="641" left="844" width="68" height="19" font="3">placement </text>
<text top="660" left="844" width="228" height="19" font="3">● Syncope not statistically significant<b> </b></text>
</page>
<page number="134" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">134 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="545" width="250" height="19" font="3">Syncope: 43% approp shocks, 22% no rx, </text>
<text top="127" left="545" width="49" height="19" font="3">p=0.08  </text>
<text top="284" left="118" width="117" height="19" font="3">● Bhonsale A et al. </text>
<text top="303" left="118" width="102" height="19" font="3">JACC 2011 (231) </text>
<text top="321" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21939834">● </a></text>
<text top="321" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21939834">21939834</a></text>
<text top="321" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21939834"> </a></text>
<text top="284" left="263" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="303" left="263" width="126" height="19" font="3">Retrospective single </text>
<text top="321" left="263" width="50" height="19" font="3">center   </text>
<text top="339" left="263" width="3" height="19" font="3"> </text>
<text top="357" left="263" width="61" height="19" font="4"><b>Size:</b>    84<b> </b></text>
<text top="284" left="405" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="303" left="405" width="127" height="19" font="3">Definite or probable </text>
<text top="321" left="405" width="91" height="19" font="3">ARVC with ICD </text>
<text top="339" left="405" width="119" height="19" font="3">implantation for 1° </text>
<text top="357" left="405" width="74" height="19" font="3">prevention  </text>
<text top="376" left="405" width="72" height="19" font="3">63 patients </text>
<text top="394" left="405" width="113" height="19" font="3">genotyped: 43% + </text>
<text top="412" left="405" width="81" height="19" font="3">desmosomal </text>
<text top="431" left="405" width="66" height="19" font="3">mutations </text>
<text top="449" left="405" width="3" height="19" font="3"> </text>
<text top="467" left="405" width="116" height="19" font="3">76% symptomatic, </text>
<text top="486" left="405" width="108" height="19" font="3">63% &gt;1000 PVC’s </text>
<text top="504" left="405" width="60" height="19" font="3">on holter </text>
<text top="522" left="405" width="3" height="19" font="3"> </text>
<text top="541" left="405" width="91" height="19" font="3">Syncope: 27%  </text>
<text top="559" left="405" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="577" left="405" width="27" height="19" font="3">N/A<b> </b></text>
<text top="285" left="545" width="254" height="19" font="4"><b>1</b>°<b> endpoint</b>:  Incidence and predictors of </text>
<text top="303" left="545" width="275" height="19" font="3">appropriate ICD shocks for ARVC undergoing </text>
<text top="322" left="545" width="132" height="19" font="3">ICD for 1° prevention </text>
<text top="340" left="545" width="159" height="19" font="3">Mean followup 4.7±3.4 y. </text>
<text top="358" left="544" width="3" height="19" font="3"> </text>
<text top="376" left="545" width="205" height="19" font="4"><b>Results:</b>  48% approp ICD shocks. </text>
<text top="395" left="545" width="279" height="19" font="3">Predictors: Multivariable analysis: Positive VT </text>
<text top="413" left="545" width="263" height="19" font="3">inducibility at PES, HR: 4.5; 95% CI: 1.4–15, </text>
<text top="431" left="544" width="285" height="19" font="3">p=0.013), clinical nonsust VT, HR:10.5; 95% CI: </text>
<text top="450" left="544" width="261" height="19" font="3">2.4–46.2, p=0.002); PVC’s &gt;1000/24 h, HR: </text>
<text top="468" left="544" width="148" height="19" font="3">3.48; proband, HR:1.62. </text>
<text top="486" left="544" width="3" height="19" font="3"> </text>
<text top="505" left="544" width="265" height="19" font="3">Syncope: approp shocks 9%/y. 25% approp </text>
<text top="523" left="544" width="207" height="19" font="3">shocks, vs 30% no approp shocks  </text>
<text top="541" left="544" width="271" height="19" font="3">Recent syncope &lt;6 mo: 63% appropr shocks </text>
<text top="560" left="544" width="150" height="19" font="3">vs 20% remote, p=0.046 </text>
<text top="284" left="844" width="222" height="20" font="3">•<b>  </b>48% ARVC patients undergoing 1° </text>
<text top="303" left="844" width="203" height="19" font="3">prevention ICD received appropr </text>
<text top="322" left="844" width="44" height="19" font="3">shocks </text>
<text top="340" left="844" width="230" height="19" font="3">Approp shocks: proband, inducible at </text>
<text top="358" left="844" width="182" height="19" font="3">EPS, clinical nonsust VT, PVCs </text>
<text top="377" left="844" width="85" height="19" font="3">&gt;1000/24 hrs </text>
<text top="395" left="844" width="3" height="19" font="3"> </text>
<text top="413" left="844" width="206" height="19" font="3">● Syncope NS predictor, HR: 0.91 </text>
<text top="431" left="844" width="3" height="19" font="3"> </text>
<text top="450" left="844" width="215" height="19" font="3">● Non-inducible: 1/20 appropr ICD </text>
<text top="468" left="844" width="38" height="19" font="3">shock </text>
<text top="486" left="844" width="3" height="19" font="3"> </text>
<text top="505" left="844" width="3" height="19" font="4"><b> </b></text>
<text top="596" left="118" width="125" height="19" font="3">● Dalal D et al. JACC </text>
<text top="615" left="118" width="69" height="19" font="3">2007 (232) </text>
<text top="633" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17662396">● </a></text>
<text top="633" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17662396">17662396</a></text>
<text top="633" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17662396"> </a></text>
<text top="596" left="263" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="615" left="263" width="123" height="19" font="3">retrospective single </text>
<text top="633" left="263" width="46" height="19" font="3">center  </text>
<text top="651" left="263" width="3" height="19" font="3"> </text>
<text top="669" left="263" width="64" height="19" font="4"><b>Size: </b>24    <b> </b></text>
<text top="596" left="405" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="615" left="405" width="90" height="19" font="3">ARVC patients </text>
<text top="633" left="405" width="126" height="19" font="3">undergoing ablation </text>
<text top="651" left="405" width="75" height="19" font="3">at Hopkins.  </text>
<text top="669" left="405" width="3" height="19" font="3"> </text>
<text top="688" left="405" width="111" height="19" font="3">Mean age 36±9 y, </text>
<text top="706" left="405" width="69" height="19" font="3">46% males </text>
<text top="724" left="405" width="3" height="19" font="3"> </text>
<text top="743" left="405" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="761" left="405" width="27" height="19" font="3">N/A<b> </b></text>
<text top="597" left="545" width="265" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Efficacy of ablation for ARVC. </text>
<text top="615" left="545" width="142" height="19" font="3">Mean followup 32 mo. </text>
<text top="634" left="545" width="3" height="19" font="3"> </text>
<text top="652" left="545" width="266" height="19" font="4"><b>Results:</b>  48 procedures. 46% eliminated all </text>
<text top="670" left="545" width="78" height="19" font="3">inducible VT </text>
<text top="688" left="545" width="253" height="19" font="3">Recurrence: overall 85%. One procedural </text>
<text top="707" left="545" width="281" height="19" font="3">death 4%. VT recurrence free survival: 50% at </text>
<text top="725" left="545" width="230" height="19" font="3">5 mos, 25% at 14 mo. Did not vary by </text>
<text top="744" left="545" width="227" height="19" font="3">procedural success, mapping, repeat </text>
<text top="762" left="545" width="80" height="19" font="3">procedures. <b> </b></text>
<text top="596" left="844" width="201" height="19" font="3">● High rate of recurrent VT after </text>
<text top="615" left="844" width="111" height="19" font="3">ablation for ARVC </text>
<text top="633" left="844" width="197" height="19" font="3">● “diffuse cardiomyopathy with </text>
<text top="651" left="844" width="180" height="19" font="3">evolving electrical substrate” </text>
<text top="669" left="844" width="3" height="19" font="3"> </text>
<text top="688" left="844" width="3" height="19" font="4"><b> </b></text>
</page>
<page number="135" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="19" size="12" family="Times" color="#0070c0"/>
<text top="803" left="585" width="29" height="21" font="0">135 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="118" width="107" height="19" font="3">● Garcia FC et al. </text>
<text top="127" left="118" width="96" height="19" font="3">Circ 2009 (233) </text>
<text top="145" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19620503">● </a></text>
<text top="145" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19620503">19620503</a></text>
<text top="145" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19620503"> </a></text>
<text top="109" left="263" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="127" left="263" width="123" height="19" font="3">retrospective single </text>
<text top="145" left="263" width="43" height="19" font="3">center </text>
<text top="164" left="263" width="3" height="19" font="3"> </text>
<text top="182" left="263" width="57" height="19" font="4"><b>Size:</b>   13<b> </b></text>
<text top="109" left="405" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="127" left="405" width="90" height="19" font="3">ARVC patients </text>
<text top="145" left="405" width="73" height="19" font="3">undergoing </text>
<text top="164" left="405" width="116" height="19" font="3">epicardial ablation </text>
<text top="182" left="405" width="70" height="19" font="3">after failed </text>
<text top="200" left="405" width="75" height="19" font="3">endocardial </text>
<text top="219" left="405" width="73" height="19" font="3">ablation VT </text>
<text top="237" left="405" width="3" height="19" font="3"> </text>
<text top="255" left="405" width="113" height="19" font="4"><b>Exclusion criteria: </b></text>
<text top="273" left="405" width="34" height="19" font="3">N/A  <b> </b></text>
<text top="109" left="545" width="239" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Endocardial vs epicardial </text>
<text top="128" left="545" width="105" height="19" font="3">ablation in ARVC </text>
<text top="146" left="545" width="3" height="19" font="3"> </text>
<text top="164" left="545" width="190" height="19" font="4"><b>Results:</b>  27 VT’s in 13 patients </text>
<text top="183" left="545" width="237" height="19" font="3">85% epi ablation opposite endocardial </text>
<text top="201" left="545" width="84" height="19" font="3">ablation sites </text>
<text top="219" left="545" width="220" height="19" font="3">77% no VT with 18±13 mo followup </text>
<text top="109" left="844" width="213" height="19" font="3">● Epicardial ablation in ARVC after </text>
<text top="127" left="844" width="225" height="19" font="3">failed endocardial ablation results in </text>
<text top="145" left="844" width="66" height="19" font="3">VT control </text>
<text top="164" left="844" width="3" height="19" font="3"> </text>
<text top="182" left="844" width="3" height="19" font="3"> </text>
<text top="292" left="118" width="127" height="19" font="3">● Philips B et al. Circ </text>
<text top="311" left="118" width="89" height="19" font="3">AE 2012 (234) </text>
<text top="329" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22492430">● </a></text>
<text top="329" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22492430">22492430</a></text>
<text top="329" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22492430"> </a></text>
<text top="292" left="263" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="311" left="263" width="87" height="19" font="3">Retrospective </text>
<text top="329" left="263" width="81" height="19" font="3">multicenter   </text>
<text top="347" left="263" width="3" height="19" font="3"> </text>
<text top="366" left="263" width="61" height="19" font="4"><b>Size:</b>   87 <b> </b></text>
<text top="292" left="405" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="311" left="405" width="90" height="19" font="3">ARVC patients </text>
<text top="329" left="405" width="126" height="19" font="3">undergoing ablation </text>
<text top="347" left="405" width="103" height="19" font="3">1992-2011 at 80 </text>
<text top="366" left="405" width="56" height="19" font="3">centers.  </text>
<text top="384" left="405" width="119" height="19" font="3">Mean age 33±11 y, </text>
<text top="402" left="405" width="63" height="19" font="3">53% male </text>
<text top="421" left="405" width="67" height="19" font="3">50% failed </text>
<text top="439" left="405" width="75" height="19" font="3">endocardial </text>
<text top="457" left="405" width="53" height="19" font="3">ablation </text>
<text top="476" left="405" width="3" height="19" font="3"> </text>
<text top="494" left="405" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="512" left="405" width="27" height="19" font="3">N/A<b> </b></text>
<text top="293" left="545" width="250" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ARVC Efficacy of epicardial </text>
<text top="312" left="545" width="92" height="19" font="3">ablation of VT<b>.</b> </text>
<text top="330" left="545" width="3" height="19" font="3"> </text>
<text top="348" left="545" width="261" height="19" font="4"><b>Results:</b>  175 ablations in 87 patients: 53% </text>
<text top="367" left="545" width="120" height="19" font="3">repeat procedures. </text>
<text top="385" left="545" width="195" height="19" font="3">27% recurrent VT; VT reduction </text>
<text top="403" left="545" width="288" height="19" font="3">Freedom from VT at 1, 5, 10y: 47%, 21%, 15%.  </text>
<text top="422" left="545" width="284" height="19" font="3">Epicardial ablation: freedom from VT at 1, 5 y: </text>
<text top="440" left="545" width="66" height="19" font="3">64%, 45%  </text>
<text top="458" left="545" width="281" height="19" font="3">Burden of VT reduced irrespective of ablation </text>
<text top="476" left="545" width="110" height="19" font="3">strategy: p&lt;0.001 </text>
<text top="495" left="545" width="264" height="19" font="3">Complications: 2.3% major: death; delayed </text>
<text top="513" left="545" width="249" height="19" font="3">MI/occlusion RCA. Related to pericardial </text>
<text top="531" left="545" width="50" height="19" font="3">access.  </text>
<text top="292" left="844" width="215" height="19" font="3">● Epicardial ablation of VT in ARVC </text>
<text top="311" left="844" width="230" height="19" font="3">associated with high recurrence rate, </text>
<text top="329" left="844" width="146" height="19" font="3">but reduces VT burden. </text>
<text top="347" left="844" width="184" height="19" font="3">● Majority of VT circuits were </text>
<text top="366" left="844" width="67" height="19" font="3">epicardial. </text>
<text top="384" left="844" width="3" height="19" font="3"> </text>
<text top="402" left="844" width="3" height="19" font="3"> </text>
<text top="421" left="844" width="3" height="19" font="3"> </text>
<text top="550" left="118" width="111" height="19" font="3">● Bai R, et al. CAE </text>
<text top="569" left="118" width="69" height="19" font="3">2011 (235) </text>
<text top="587" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21665983">● </a></text>
<text top="587" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21665983">21665983</a></text>
<text top="587" left="191" width="3" height="19" font="19"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21665983"> </a></text>
<text top="605" left="118" width="3" height="19" font="4"><b> </b></text>
<text top="624" left="145" width="3" height="19" font="3"> </text>
<text top="550" left="263" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="569" left="263" width="75" height="19" font="3">Multicenter </text>
<text top="587" left="263" width="75" height="19" font="3">prospective </text>
<text top="605" left="263" width="3" height="19" font="3"> </text>
<text top="624" left="263" width="61" height="19" font="4"><b>Size:</b>  49  <b> </b></text>
<text top="550" left="405" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="569" left="405" width="114" height="19" font="3">Consecutive ARVC </text>
<text top="587" left="405" width="126" height="19" font="3">patients undergoing </text>
<text top="605" left="405" width="53" height="19" font="3">ablation </text>
<text top="624" left="405" width="47" height="19" font="3">All sust </text>
<text top="642" left="405" width="113" height="19" font="3">monomorphic VT; </text>
<text top="660" left="405" width="91" height="19" font="3">all with AICD’s </text>
<text top="679" left="405" width="3" height="19" font="3"> </text>
<text top="697" left="405" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="715" left="405" width="27" height="19" font="3">N/A<b> </b></text>
<text top="551" left="545" width="262" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Comparison of outcomes for </text>
<text top="570" left="545" width="221" height="19" font="3">ARVC ablation, endocardial vs endo-</text>
<text top="588" left="545" width="283" height="19" font="3">epicardial: non-inducibility of VT with isuprel.  </text>
<text top="606" left="545" width="81" height="19" font="3">Followup 3 y </text>
<text top="624" left="545" width="3" height="19" font="3"> </text>
<text top="643" left="545" width="274" height="19" font="4"><b>Results:</b> Freedom from VA or ICD therapies:  </text>
<text top="661" left="545" width="256" height="19" font="3">Endocardial: 52%, endo-epi 85%, p=0.029<b> </b></text>
<text top="679" left="544" width="3" height="19" font="4"><b> </b></text>
<text top="550" left="844" width="218" height="19" font="3">● Combined endocardial-epicardial </text>
<text top="569" left="844" width="221" height="19" font="3">ablation approach in ARVC achieves </text>
<text top="587" left="844" width="202" height="19" font="3">longer term freedom from VA or </text>
<text top="605" left="844" width="48" height="19" font="3">shocks. </text>
<text top="624" left="844" width="226" height="19" font="3">● Patients with frequent PVC’s more </text>
<text top="642" left="844" width="160" height="19" font="3">likely to have recurrences </text>
<text top="734" left="118" width="117" height="19" font="3">● Berruezo A et al. </text>
<text top="753" left="118" width="115" height="19" font="3">Circ AE 2012 (236) </text>
<text top="771" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22205683">● </a></text>
<text top="771" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22205683">22205683</a></text>
<text top="771" left="191" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22205683"><b> </b></a></text>
<text top="734" left="263" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="753" left="263" width="123" height="19" font="3">retrospective single </text>
<text top="771" left="263" width="46" height="19" font="3">center  </text>
<text top="734" left="405" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="753" left="405" width="90" height="19" font="3">ARVC patients </text>
<text top="771" left="405" width="118" height="19" font="3">undergoing endo + </text>
<text top="735" left="545" width="284" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ARVC patients: recurrence of VT </text>
<text top="753" left="545" width="198" height="19" font="3">after ablation endo + epicardial  </text>
<text top="772" left="545" width="3" height="19" font="3"> </text>
<text top="734" left="844" width="181" height="19" font="3">● ARVC combined endo + epi </text>
<text top="753" left="844" width="203" height="19" font="3">ablation reveals wider substrate, </text>
<text top="771" left="844" width="212" height="19" font="3">with good short/mid-term success<b> </b></text>
</page>
<page number="136" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">136 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="263" width="3" height="19" font="3"> </text>
<text top="127" left="263" width="61" height="19" font="4"><b>Size:</b>    11<b> </b></text>
<text top="109" left="405" width="116" height="19" font="3">epicardial ablation </text>
<text top="127" left="405" width="35" height="19" font="3">of VT </text>
<text top="145" left="405" width="3" height="19" font="3"> </text>
<text top="164" left="405" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="182" left="405" width="27" height="19" font="3">N/A<b> </b></text>
<text top="109" left="545" width="267" height="19" font="4"><b>Results:</b>  ablation eliminated all clinical and </text>
<text top="127" left="545" width="71" height="19" font="3">induced VT </text>
<text top="145" left="545" width="158" height="19" font="3">64% continued on sotalol </text>
<text top="164" left="545" width="232" height="19" font="3">9% VT recurrence with median 11 mo </text>
<text top="182" left="545" width="57" height="19" font="3">followup<b> </b></text>
<text top="109" left="844" width="3" height="19" font="3"> </text>
<text top="127" left="844" width="3" height="19" font="3"> </text>
<text top="201" left="118" width="105" height="19" font="3">● Philips B Heart </text>
<text top="219" left="118" width="117" height="19" font="3">Rhythm 2015(237) </text>
<text top="238" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25530221">● </a></text>
<text top="238" left="130" width="68" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25530221">25530221  </a></text>
<text top="238" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25530221"> </a></text>
<text top="201" left="263" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="219" left="263" width="123" height="19" font="3">retrospective single </text>
<text top="238" left="263" width="46" height="19" font="3">center  </text>
<text top="256" left="263" width="3" height="19" font="3"> </text>
<text top="274" left="263" width="61" height="19" font="4"><b>Size:</b>  30  <b> </b></text>
<text top="201" left="405" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="219" left="405" width="110" height="19" font="3">ARVC undergoing </text>
<text top="238" left="405" width="116" height="19" font="3">epicardial ablation </text>
<text top="256" left="405" width="117" height="19" font="3">at tertiary center<b> </b>   </text>
<text top="274" left="405" width="3" height="19" font="3"> </text>
<text top="292" left="405" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="311" left="405" width="27" height="19" font="3">N/A<b> </b></text>
<text top="202" left="545" width="278" height="19" font="4"><b>1</b>°<b> endpoint: </b>Safety and efficacy of epicardial </text>
<text top="220" left="545" width="225" height="19" font="3">ablation at tertiary center for ARVC   </text>
<text top="238" left="545" width="3" height="19" font="3"> </text>
<text top="257" left="545" width="237" height="19" font="4"><b>Results:</b>  VT circuits: 69% on epicardial </text>
<text top="275" left="545" width="269" height="19" font="3">surface, most sub-tricuspid.  VT recurrence: </text>
<text top="293" left="545" width="33" height="19" font="3">27%. </text>
<text top="312" left="545" width="185" height="19" font="3">Reduced VT burden (p&lt;0.001) </text>
<text top="330" left="544" width="212" height="19" font="3">VT free survival at 1,2 y: 76%, 70% </text>
<text top="348" left="545" width="267" height="19" font="3">Complications: 3.3%, pericarditis. Fluoro 82 </text>
<text top="367" left="545" width="82" height="19" font="3">min (40-135) </text>
<text top="201" left="844" width="220" height="19" font="3">● Epicardial ablation for VT in ARVC </text>
<text top="219" left="844" width="135" height="19" font="3">safe in tertiary center </text>
<text top="238" left="844" width="196" height="19" font="3">● Freedom from VT 70% at 2 y.  </text>
<text top="256" left="844" width="134" height="19" font="3">● Reduces VT burden </text>
<text top="274" left="844" width="3" height="19" font="3"> </text>
<text top="386" left="118" width="124" height="19" font="3">● Santangeli P et al. </text>
<text top="404" left="118" width="115" height="19" font="3">Circ AE 2015 (238) </text>
<text top="422" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26546346">● </a></text>
<text top="422" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26546346">26546346</a></text>
<text top="422" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26546346"> </a></text>
<text top="386" left="263" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="404" left="263" width="126" height="19" font="3">Retrospective single </text>
<text top="422" left="263" width="46" height="19" font="3">center  </text>
<text top="441" left="263" width="3" height="19" font="3"> </text>
<text top="459" left="263" width="61" height="19" font="4"><b>Size:</b>    62<b> </b></text>
<text top="386" left="405" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="404" left="405" width="90" height="19" font="3">ARVC patients </text>
<text top="422" left="405" width="126" height="19" font="3">undergoing ablation </text>
<text top="441" left="405" width="101" height="19" font="3">Endo + epi: 63% </text>
<text top="459" left="405" width="3" height="19" font="3"> </text>
<text top="477" left="405" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="496" left="405" width="31" height="19" font="3">N/A <b> </b></text>
<text top="386" left="545" width="242" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ARVC ablation outcomes, </text>
<text top="405" left="545" width="128" height="19" font="3">followup 56±44 mos </text>
<text top="423" left="545" width="240" height="19" font="3">Epicardial ablation if failed endocardial </text>
<text top="441" left="545" width="53" height="19" font="3">ablation </text>
<text top="460" left="545" width="3" height="19" font="3"> </text>
<text top="478" left="545" width="280" height="19" font="4"><b>Results:</b>  VT recurrence: 29%; VT free survival </text>
<text top="496" left="545" width="29" height="19" font="3">71% </text>
<text top="515" left="545" width="119" height="19" font="3">64% on BB or no rx </text>
<text top="386" left="844" width="231" height="19" font="3">● ARVC VT ablation outcomes ‘good’; </text>
<text top="404" left="844" width="133" height="19" font="3">most have VT control </text>
<text top="422" left="844" width="3" height="19" font="3"> </text>
<text top="441" left="844" width="3" height="19" font="3"> </text>
<text top="534" left="118" width="107" height="19" font="3">● James CA et al. </text>
<text top="552" left="118" width="102" height="19" font="3">JACC 2013 (239) </text>
<text top="570" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23871885">● </a></text>
<text top="570" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23871885">23871885</a></text>
<text top="570" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23871885"> </a></text>
<text top="534" left="263" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="552" left="263" width="127" height="19" font="3">center retrospective </text>
<text top="570" left="263" width="3" height="19" font="3"> </text>
<text top="588" left="263" width="61" height="19" font="4"><b>Size:</b>  87  <b> </b></text>
<text top="534" left="405" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="552" left="405" width="90" height="19" font="3">ARVC patients </text>
<text top="570" left="405" width="115" height="19" font="3">interviewed about </text>
<text top="589" left="405" width="115" height="19" font="3">exercise from 10 y </text>
<text top="607" left="405" width="45" height="19" font="3">of age. </text>
<text top="625" left="405" width="115" height="19" font="3">Mean age 44±18 y </text>
<text top="643" left="405" width="3" height="19" font="3"> </text>
<text top="662" left="405" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="680" left="405" width="31" height="19" font="3">N/A <b> </b></text>
<text top="534" left="545" width="241" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ARVC exercise and VT/VF </text>
<text top="553" left="545" width="3" height="19" font="3"> </text>
<text top="571" left="545" width="244" height="19" font="4"><b>Results:</b>  Endurance athletes developed </text>
<text top="589" left="545" width="270" height="19" font="3">symptoms at younger age (30±13 y) vs 40 y, </text>
<text top="608" left="545" width="53" height="19" font="3">p=0.05;  </text>
<text top="626" left="545" width="122" height="19" font="3">Increasing exercise  </text>
<text top="644" left="545" width="279" height="19" font="3">Lower lifetime survival free of VT/VF p=0.013 </text>
<text top="534" left="844" width="217" height="19" font="3">● Endurance and frequent exercise </text>
<text top="552" left="844" width="197" height="19" font="3">increase the risk of VT/VF, HF in </text>
<text top="570" left="844" width="94" height="19" font="3">ARVC patients. </text>
<text top="589" left="844" width="3" height="19" font="3"> </text>
<text top="607" left="844" width="3" height="19" font="3"> </text>
<text top="699" left="118" width="114" height="19" font="3">● Sawant AC et al. </text>
<text top="717" left="118" width="104" height="19" font="3">JAHA 2014 (240) </text>
<text top="736" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25516436">● </a></text>
<text top="736" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25516436">25516436</a></text>
<text top="736" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25516436"> </a></text>
<text top="699" left="263" width="119" height="19" font="4"><b>Study type:</b>   single </text>
<text top="717" left="263" width="127" height="19" font="3">center retrospective </text>
<text top="736" left="263" width="3" height="19" font="3"> </text>
<text top="754" left="263" width="61" height="19" font="4"><b>Size:</b>   82 <b> </b></text>
<text top="699" left="405" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="717" left="405" width="90" height="19" font="3">ARVC patients </text>
<text top="736" left="405" width="92" height="19" font="3">interviewed re </text>
<text top="754" left="405" width="53" height="19" font="3">exercise </text>
<text top="700" left="545" width="266" height="19" font="4"><b>1</b>°<b> endpoint:</b> ARVC: exercise and impact on </text>
<text top="718" left="545" width="244" height="19" font="3">desmosomal and gene-elusive patients  </text>
<text top="737" left="545" width="3" height="19" font="3"> </text>
<text top="699" left="844" width="221" height="19" font="3">● Gene-elusive non-familial ARVC is </text>
<text top="717" left="844" width="182" height="19" font="3">assoc with very high intensity </text>
<text top="736" left="844" width="53" height="19" font="3">exercise </text>
<text top="754" left="844" width="212" height="19" font="3">● Recommend exercise restriction </text>
<text top="773" left="844" width="3" height="19" font="3"> </text>
</page>
<page number="137" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">137 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="405" width="82" height="19" font="3">Desmosomal </text>
<text top="127" left="405" width="88" height="19" font="3">mutations: 39 </text>
<text top="145" left="405" width="101" height="19" font="3">Gene-elusive 43 </text>
<text top="164" left="405" width="3" height="19" font="3"> </text>
<text top="182" left="405" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="200" left="405" width="27" height="19" font="3">N/A<b> </b></text>
<text top="109" left="545" width="241" height="19" font="4"><b>Results:</b>  all gene-elusive patients were </text>
<text top="127" left="545" width="267" height="19" font="3">endurance athletes; more intense exerscie, </text>
<text top="145" left="545" width="53" height="19" font="3">p&lt;0.001 </text>
<text top="164" left="545" width="255" height="19" font="3">Family Hx more often neg in gene-elusive </text>
<text top="182" left="545" width="249" height="19" font="3">Gene-elusive patients with most intense </text>
<text top="200" left="545" width="259" height="19" font="3">exercise had younger age at presentation, </text>
<text top="219" left="545" width="287" height="19" font="3">p=0.025, shorter survival free of VEA, p=0.002  </text>
<text top="238" left="118" width="115" height="19" font="3">● Ruwald AC et al. </text>
<text top="256" left="118" width="94" height="19" font="3">EHJ 2015 (241) </text>
<text top="274" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25896080">● </a></text>
<text top="274" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25896080">25896080</a></text>
<text top="274" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25896080"> </a></text>
<text top="237" left="263" width="113" height="19" font="4"><b>Study type: </b>North </text>
<text top="256" left="263" width="94" height="19" font="3">Americal ARVC </text>
<text top="274" left="263" width="120" height="19" font="3">registry, 18 centers </text>
<text top="293" left="263" width="72" height="19" font="3">US, Canada </text>
<text top="311" left="263" width="3" height="19" font="3"> </text>
<text top="329" left="263" width="119" height="19" font="4"><b>Size:</b> 108 probands<b> </b></text>
<text top="237" left="405" width="100" height="19" font="4"><b>Inclusion: </b>ARVC </text>
<text top="256" left="405" width="121" height="19" font="3">Registry probands.  </text>
<text top="274" left="405" width="3" height="19" font="4"><b> </b></text>
<text top="292" left="405" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="311" left="405" width="120" height="19" font="3">Age &lt;12 y; ICD &gt;2 y </text>
<text top="329" left="405" width="119" height="19" font="3">before enrollment; </text>
<text top="347" left="405" width="113" height="19" font="3">unknown exercise </text>
<text top="366" left="405" width="94" height="19" font="3">level before dx<b> </b></text>
<text top="238" left="545" width="271" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ARVC exercise and VT/VF/SCD </text>
<text top="257" left="545" width="78" height="19" font="3">followup 3 y </text>
<text top="275" left="545" width="248" height="19" font="4"><b>Results:</b>  Patients in competitive sports:  </text>
<text top="293" left="545" width="266" height="19" font="3">Younger at age of Dx, 71% inducible VT/VF, </text>
<text top="312" left="545" width="151" height="19" font="3">increased risk death/VT.<b> </b></text>
<text top="238" left="844" width="229" height="19" font="3">● Competitive sports associated with </text>
<text top="256" left="844" width="214" height="19" font="3">HR: 2.05 for VTA/death and earlier </text>
<text top="274" left="844" width="194" height="19" font="3">presentation of symptoms, c/w </text>
<text top="293" left="844" width="186" height="19" font="3">recreational sports or inactive </text>
<text top="385" left="118" width="118" height="19" font="3">● Sawant AC Heart </text>
<text top="403" left="118" width="120" height="19" font="3">Rhythm 2016 (242)<b> </b></text>
<text top="422" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26321091">● </a></text>
<text top="422" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26321091">26321091</a></text>
<text top="422" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26321091"> </a></text>
<text top="385" left="263" width="117" height="19" font="4"><b>Study type:</b>  Single </text>
<text top="403" left="263" width="134" height="19" font="3">center retrospective   </text>
<text top="422" left="263" width="3" height="19" font="3"> </text>
<text top="440" left="263" width="61" height="19" font="4"><b>Size:</b>  28  <b> </b></text>
<text top="385" left="405" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="403" left="405" width="110" height="19" font="3">ARVC first degree </text>
<text top="422" left="405" width="71" height="19" font="3">relatives of </text>
<text top="440" left="405" width="126" height="19" font="3">probands with PKP2 </text>
<text top="458" left="405" width="124" height="19" font="3">mutation, interview </text>
<text top="476" left="405" width="104" height="19" font="3">re exercise since </text>
<text top="495" left="405" width="111" height="19" font="3">age 10 y; exercise </text>
<text top="513" left="405" width="46" height="19" font="3">vs AHA </text>
<text top="531" left="405" width="115" height="19" font="3">recommendations </text>
<text top="550" left="405" width="107" height="19" font="3">to restrict to 390-</text>
<text top="568" left="405" width="92" height="19" font="3">650 MET-HR/y </text>
<text top="586" left="405" width="3" height="19" font="3"> </text>
<text top="605" left="405" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="623" left="405" width="31" height="19" font="3">N/A <b> </b></text>
<text top="385" left="545" width="242" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ARVC and outcomes with </text>
<text top="404" left="545" width="184" height="19" font="3">exercise intensity (MET-HR/y) </text>
<text top="422" left="545" width="3" height="19" font="3"> </text>
<text top="441" left="545" width="274" height="19" font="4"><b>Results:</b>  After adjusting for age, sex, family;  </text>
<text top="459" left="545" width="279" height="19" font="3">participation in endurance athletics, (OR: 7.4, </text>
<text top="477" left="545" width="262" height="19" font="3">p=0.03), higher intensity exercise (OR: 4.2, </text>
<text top="496" left="545" width="277" height="19" font="3">p=0.004) were associated with dx of ARVCD.  </text>
<text top="514" left="545" width="3" height="19" font="3"> </text>
<text top="532" left="545" width="273" height="19" font="3">Family members restricting exercise to ≤650 </text>
<text top="550" left="545" width="263" height="19" font="3">MET-Hr/yr (AHA upper limits) were sig less </text>
<text top="569" left="544" width="283" height="19" font="3">likely to have ARVC dx (OR: 0.07, p=0.002); no </text>
<text top="587" left="544" width="40" height="19" font="3">VT/VF </text>
<text top="605" left="544" width="3" height="19" font="3"> </text>
<text top="624" left="545" width="257" height="19" font="3">(AHA/AC Sports Med recommend healthy </text>
<text top="642" left="545" width="276" height="19" font="3">adults participate in minimum, 450-750 MET-</text>
<text top="660" left="545" width="204" height="19" font="3">min weekly =390–650 MET-Hr/y) </text>
<text top="385" left="844" width="228" height="19" font="3">● Recommend restricting unaffected </text>
<text top="403" left="844" width="223" height="19" font="3">desmosomal mutation carriers from </text>
<text top="422" left="844" width="182" height="19" font="3">endurance and high-intensity </text>
<text top="440" left="844" width="170" height="19" font="3">athletics, but not from AHA </text>
<text top="458" left="844" width="208" height="19" font="3">recommended minimum levels of </text>
<text top="476" left="844" width="167" height="19" font="3">exercise for heatlhy adults  </text>
<text top="495" left="844" width="3" height="19" font="3"> </text>
<text top="513" left="844" width="3" height="19" font="3"> </text>
<text top="679" left="118" width="118" height="19" font="3">● Saberniak J et al. </text>
<text top="698" left="118" width="110" height="19" font="3">Eur J Heart F 2014</text>
<text top="696" left="228" width="4" height="21" font="0"> </text>
<text top="716" left="118" width="35" height="21" font="0">(243)</text>
<text top="717" left="153" width="3" height="19" font="3"> </text>
<text top="736" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25319773">● </a></text>
<text top="736" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25319773">25319773</a></text>
<text top="736" left="191" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25319773"><b> </b></a></text>
<text top="679" left="263" width="119" height="19" font="4"><b>Study type:</b>   single </text>
<text top="698" left="263" width="46" height="19" font="3">center  </text>
<text top="716" left="263" width="3" height="19" font="3"> </text>
<text top="734" left="263" width="68" height="19" font="4"><b>Size:</b>    110<b> </b></text>
<text top="679" left="405" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="698" left="405" width="124" height="19" font="3">ARVC probands and </text>
<text top="716" left="405" width="111" height="19" font="3">mutation positive </text>
<text top="734" left="405" width="102" height="19" font="3">family members </text>
<text top="753" left="405" width="3" height="19" font="3"> </text>
<text top="680" left="545" width="285" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ARVC assess exercise ventricular </text>
<text top="698" left="545" width="154" height="19" font="3">function with echo, CMR </text>
<text top="717" left="545" width="277" height="19" font="3">Athlete: intensity ≥6 METS, duration ≥4 h/wk </text>
<text top="735" left="545" width="281" height="19" font="4"><b>Results:</b>  Function reduced in athletes’ vs non-</text>
<text top="753" left="545" width="232" height="19" font="3">athletes by echo and MRI, all p&lt;0.01.  </text>
<text top="679" left="844" width="206" height="19" font="3">● ARVC athletes showed reduced </text>
<text top="698" left="844" width="230" height="19" font="3">biventricular function compared with </text>
<text top="716" left="844" width="219" height="19" font="3">non-athletes and mutation-positive </text>
<text top="734" left="844" width="102" height="19" font="3">family members </text>
</page>
<page number="138" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">138 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="405" width="115" height="19" font="3">Genotyping in 100 </text>
<text top="127" left="405" width="53" height="19" font="3">patients </text>
<text top="145" left="405" width="89" height="19" font="3">75% mutation </text>
<text top="164" left="405" width="115" height="19" font="3">positive, PKP 91%, </text>
<text top="182" left="405" width="112" height="19" font="3">Syncope 44%, ICD </text>
<text top="200" left="405" width="29" height="19" font="3">47% </text>
<text top="219" left="405" width="3" height="19" font="3"> </text>
<text top="237" left="405" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="255" left="405" width="27" height="19" font="3">N/A<b> </b></text>
<text top="109" left="545" width="267" height="19" font="3">METs x min/wk correlated with reduced RV </text>
<text top="127" left="545" width="144" height="19" font="3">and LV function p&lt;0.01 </text>
<text top="145" left="545" width="266" height="19" font="3">LVEF by MRI reduced in athletes, index and </text>
<text top="164" left="545" width="102" height="19" font="3">family members </text>
<text top="182" left="545" width="279" height="19" font="3">Exercise induced VA in 37% of patients, more </text>
<text top="200" left="545" width="248" height="19" font="3">likely in athletes p&lt;0.001 and in those w </text>
<text top="219" left="544" width="267" height="19" font="3">increased duration exercise ≥2.5 h/wk x 6 y </text>
<text top="237" left="545" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="844" width="217" height="19" font="3">● Amount and intensity of exercise </text>
<text top="127" left="844" width="217" height="19" font="3">was assoc with impaired LV and RV </text>
<text top="145" left="844" width="54" height="19" font="3">function </text>
<text top="164" left="844" width="211" height="19" font="3">● Exercise aggravates, accelerates </text>
<text top="182" left="844" width="197" height="19" font="3">myocardial dysfunction in ARVC </text>
<text top="274" left="118" width="123" height="19" font="3">● Sen-Chowdry S et </text>
<text top="292" left="118" width="120" height="19" font="3">al. JACC 2008 (244) </text>
<text top="311" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19095136">● </a></text>
<text top="311" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19095136">19095136</a></text>
<text top="311" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19095136"> </a></text>
<text top="274" left="263" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="292" left="263" width="86" height="19" font="3">observational </text>
<text top="311" left="263" width="47" height="19" font="3">cohort  </text>
<text top="329" left="263" width="3" height="19" font="3"> </text>
<text top="347" left="263" width="61" height="19" font="4"><b>Size:</b>    42<b> </b></text>
<text top="274" left="405" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="292" left="405" width="104" height="19" font="3">ARVC patients w </text>
<text top="311" left="405" width="114" height="19" font="3">clinical suggestion </text>
<text top="329" left="405" width="117" height="19" font="3">of LV involvement: </text>
<text top="347" left="405" width="119" height="19" font="3">one or more: RBBB </text>
<text top="366" left="405" width="77" height="19" font="3">morphology </text>
<text top="384" left="405" width="126" height="19" font="3">arrhythmia, isolated </text>
<text top="402" left="405" width="102" height="19" font="3">(infero) lateral T </text>
<text top="421" left="405" width="99" height="19" font="3">wave inversion, </text>
<text top="439" left="405" width="123" height="19" font="3">proven family dx LV </text>
<text top="457" left="405" width="117" height="19" font="3">ARVC or idiopathic </text>
<text top="476" left="405" width="118" height="19" font="3">myocardial fibrosis </text>
<text top="494" left="405" width="3" height="19" font="3"> </text>
<text top="512" left="405" width="79" height="19" font="3">Clinical eval: </text>
<text top="531" left="405" width="109" height="19" font="3">includes CMR (41 </text>
<text top="549" left="405" width="62" height="19" font="3">patients): </text>
<text top="567" left="405" width="85" height="19" font="3">consensus &gt;2 </text>
<text top="586" left="405" width="90" height="19" font="3">readers; echo, </text>
<text top="604" left="405" width="97" height="19" font="3">holter, exercise </text>
<text top="622" left="405" width="90" height="19" font="3">test, mutation </text>
<text top="640" left="405" width="62" height="19" font="3">screening </text>
<text top="659" left="405" width="3" height="19" font="3"> </text>
<text top="677" left="405" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="695" left="405" width="98" height="19" font="3">HCM, ischemia, </text>
<text top="714" left="405" width="99" height="19" font="3">other structural </text>
<text top="732" left="405" width="127" height="19" font="3">heart/lung/systemic </text>
<text top="750" left="405" width="49" height="19" font="3">disease<b> </b></text>
<text top="275" left="545" width="224" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ARVC presenting as LV </text>
<text top="293" left="545" width="266" height="19" font="3">dominant arrhythmogenic cardiomyopathy </text>
<text top="312" left="545" width="140" height="19" font="3">(LDAC): CMR &amp; clinical </text>
<text top="330" left="545" width="3" height="19" font="3"> </text>
<text top="348" left="545" width="269" height="19" font="4"><b>Results:</b>  Desmosomal mutations present in </text>
<text top="367" left="545" width="206" height="19" font="3">45% of probands, 33% of families </text>
<text top="385" left="545" width="267" height="19" font="3">Arrhythmia of RBBB morphology exceeding </text>
<text top="403" left="545" width="206" height="19" font="3">degree of ventricular dysfunction </text>
<text top="422" left="545" width="200" height="19" font="3">distinguished ARVC from dilated </text>
<text top="440" left="545" width="103" height="19" font="3">cardiomyopathy </text>
<text top="458" left="545" width="3" height="19" font="3"> </text>
<text top="476" left="545" width="244" height="19" font="3">CMR: 88% RV segmental dil and/or wall </text>
<text top="495" left="545" width="240" height="19" font="3">motion abnormality; 27% low RVEF; LV </text>
<text top="513" left="545" width="262" height="19" font="3">involvement 34% dilation or decreased EF. </text>
<text top="531" left="544" width="3" height="19" font="3"> </text>
<text top="550" left="544" width="204" height="19" font="3">LV late gadolinium enhancement </text>
<text top="568" left="544" width="266" height="19" font="3">Inflammatory myocarditis on genetic basis: </text>
<text top="586" left="544" width="149" height="19" font="3">10% prior “myocarditis”<b> </b></text>
<text top="274" left="844" width="223" height="19" font="3">● LV dominant ARVC subtype under-</text>
<text top="292" left="844" width="73" height="19" font="3">recognized  </text>
<text top="311" left="844" width="221" height="19" font="3">● Unexplained T wave inversion V5, </text>
<text top="329" left="844" width="87" height="19" font="3">V6± V4, I, aVL </text>
<text top="347" left="844" width="165" height="19" font="3">● VT of RBBB morphology, </text>
<text top="366" left="844" width="100" height="19" font="3">● LV aneurysms </text>
<text top="384" left="844" width="174" height="19" font="3">● LV dilation and/or systolic </text>
<text top="402" left="844" width="176" height="19" font="3">impairment with arrhythmic </text>
<text top="421" left="844" width="82" height="19" font="3">presentation </text>
<text top="439" left="844" width="214" height="19" font="3">● Extensive LGE of LV myocardium </text>
<text top="457" left="844" width="224" height="19" font="3">● “inflammatory myocarditis part of </text>
<text top="476" left="844" width="102" height="19" font="3">nat Hx of ARVC” </text>
</page>
<page number="139" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">139 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="118" width="107" height="19" font="3">● Vermes E et al. </text>
<text top="127" left="118" width="104" height="19" font="3">JACC CV Imaging </text>
<text top="145" left="118" width="69" height="19" font="3">2011 (245)<b> </b></text>
<text top="164" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21414577">● </a></text>
<text top="164" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21414577">21414577</a></text>
<text top="164" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21414577"> </a></text>
<text top="109" left="263" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="127" left="263" width="84" height="19" font="3">retrospective </text>
<text top="145" left="263" width="86" height="19" font="3">cohort, single </text>
<text top="164" left="263" width="43" height="19" font="3">center </text>
<text top="182" left="263" width="3" height="19" font="3"> </text>
<text top="200" left="263" width="68" height="19" font="4"><b>Size:</b>   294 <b> </b></text>
<text top="109" left="405" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="127" left="405" width="107" height="19" font="3">Patients referred </text>
<text top="145" left="405" width="125" height="19" font="3">for ARVC evaluation </text>
<text top="164" left="405" width="122" height="19" font="3">by CMR 2005–2010 </text>
<text top="182" left="405" width="3" height="19" font="3"> </text>
<text top="200" left="405" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="219" left="405" width="31" height="19" font="3">N/A <b> </b></text>
<text top="109" left="545" width="259" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Compare ARVC CMR criteria </text>
<text top="128" left="545" width="276" height="19" font="3">from 1994–2010; also, assessed 134 patients </text>
<text top="146" left="544" width="247" height="19" font="3">with full diagnostic evaluation for ARVC  </text>
<text top="165" left="545" width="3" height="19" font="3"> </text>
<text top="183" left="545" width="271" height="19" font="3">Results:  original CMR criteria: 23.5% major; </text>
<text top="201" left="545" width="146" height="19" font="3">using 2010: 6.5% major </text>
<text top="219" left="545" width="273" height="19" font="3">Of 69 patients with major criteria 1994, only </text>
<text top="238" left="545" width="175" height="19" font="3">23% had major criteria 2010 </text>
<text top="256" left="545" width="274" height="19" font="3">Of 172 with minor---only 1.1% minor criteria </text>
<text top="274" left="545" width="34" height="19" font="3">2010 </text>
<text top="293" left="545" width="3" height="19" font="3"> </text>
<text top="311" left="545" width="275" height="19" font="3">Also, assessed 10 patients with proven ARVC </text>
<text top="329" left="545" width="155" height="19" font="3">on complete evaluation:  </text>
<text top="348" left="545" width="255" height="19" font="3">4/10 met major criteria, none met minor  </text>
<text top="366" left="544" width="253" height="19" font="3">Specificity for major/minor criteria: 1994-</text>
<text top="384" left="545" width="143" height="19" font="3">78/39%; 2010: 94/96% </text>
<text top="402" left="545" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="844" width="197" height="19" font="3">● 2010 criteria reduced major + </text>
<text top="127" left="844" width="213" height="19" font="3">minor CMR criteria: from 23.5% to </text>
<text top="145" left="844" width="33" height="19" font="3">6.5% </text>
<text top="164" left="844" width="3" height="19" font="3"> </text>
<text top="182" left="844" width="183" height="19" font="3">● new TFC for CMR improved </text>
<text top="200" left="844" width="207" height="19" font="3">specificity, but may have reduced </text>
<text top="219" left="844" width="64" height="19" font="3">sensitivity </text>
<text top="422" left="118" width="114" height="19" font="3">● te Riele AS et al. </text>
<text top="440" left="118" width="89" height="19" font="3">JCE 2013(246)<b> </b></text>
<text top="458" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23889974">● </a></text>
<text top="458" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23889974">23889974</a></text>
<text top="458" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23889974"> </a></text>
<text top="421" left="263" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="440" left="263" width="74" height="19" font="3">multicenter </text>
<text top="458" left="263" width="88" height="19" font="3">retrospective: </text>
<text top="476" left="263" width="82" height="19" font="3">international </text>
<text top="495" left="263" width="86" height="19" font="3">registry ARVC </text>
<text top="513" left="263" width="3" height="19" font="3"> </text>
<text top="531" left="263" width="61" height="19" font="4"><b>Size:</b>    80<b> </b></text>
<text top="421" left="405" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="440" left="405" width="97" height="19" font="3">ARVC mutation </text>
<text top="458" left="405" width="104" height="19" font="3">positive patients </text>
<text top="476" left="405" width="109" height="19" font="3">undergoing CMR, </text>
<text top="495" left="405" width="29" height="19" font="3">EPS. </text>
<text top="513" left="405" width="113" height="19" font="3">CMR 74, EPS in 11 </text>
<text top="531" left="405" width="53" height="19" font="3">patients </text>
<text top="550" left="405" width="64" height="19" font="3">PKP2 83% </text>
<text top="568" left="405" width="3" height="19" font="3"> </text>
<text top="586" left="405" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="605" left="405" width="31" height="19" font="3">N/A <b> </b></text>
<text top="422" left="545" width="240" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ARVC electro-anatomical </text>
<text top="441" left="545" width="126" height="19" font="3">correlates CMR, EPS </text>
<text top="459" left="545" width="117" height="19" font="3">Mean followup 6 y </text>
<text top="477" left="545" width="3" height="19" font="3"> </text>
<text top="495" left="545" width="260" height="19" font="4"><b>Results:</b>  CMR: abnl RV 96%, biventricular: </text>
<text top="514" left="545" width="110" height="19" font="3">52%, LV only: 4%. </text>
<text top="532" left="545" width="3" height="19" font="3"> </text>
<text top="550" left="545" width="285" height="19" font="3">ACE 41%: VT 67%, approp ICD shock 23%, ACA </text>
<text top="569" left="545" width="36" height="19" font="3">10%.  </text>
<text top="587" left="545" width="257" height="19" font="3">Arrhythmia free survival lower in patients </text>
<text top="606" left="545" width="211" height="19" font="3">with more abnormal RV segments </text>
<text top="624" left="545" width="227" height="19" font="3">24 patients with advanced structural </text>
<text top="642" left="545" width="246" height="19" font="3">abnormalities: 1,5, 10 y arrhythmia free </text>
<text top="660" left="545" width="153" height="19" font="3">survival= 57%, 42%, 35% </text>
<text top="679" left="545" width="257" height="19" font="3">EPS: scar more extensive in epicardium vs </text>
<text top="697" left="545" width="278" height="19" font="3">endocardium, p&lt;0.0001; scar map correlated </text>
<text top="715" left="545" width="129" height="19" font="3">with CMR locations:  </text>
<text top="734" left="545" width="284" height="19" font="3">RV epicardial scar subtricuspid 100%, RV basal </text>
<text top="752" left="545" width="110" height="19" font="3">anterior wall 64% </text>
<text top="422" left="844" width="232" height="19" font="3">● CMR: basal inferior (94%) and basal </text>
<text top="440" left="844" width="227" height="19" font="3">anterior RV (87%) and posterolateral </text>
<text top="458" left="844" width="216" height="19" font="3">LV involvement (80% subepicardial </text>
<text top="476" left="844" width="96" height="19" font="3">fat infiltration). </text>
<text top="495" left="844" width="226" height="19" font="3">● RV apex involved only in advanced </text>
<text top="513" left="844" width="52" height="19" font="3">disease. </text>
<text top="531" left="844" width="190" height="19" font="3">● Epicardial delayed activation </text>
<text top="550" left="844" width="228" height="19" font="3">particularly in perivalvar RV area and </text>
<text top="568" left="844" width="116" height="19" font="3">LV posterolat wall. </text>
<text top="586" left="844" width="198" height="19" font="3">● RVOT involved late in disease. </text>
</page>
<page number="140" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">140 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="545" width="261" height="19" font="3">Ablation successful in 18/19 VT: 84% were </text>
<text top="127" left="545" width="181" height="19" font="3">from RV; no VT from RV apex </text>
<text top="146" left="118" width="114" height="19" font="3">● te Riele AS et al. </text>
<text top="164" left="118" width="102" height="19" font="3">JACC 2013 (247) </text>
<text top="183" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23810894">● </a></text>
<text top="183" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23810894">23810894</a></text>
<text top="183" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23810894"> </a></text>
<text top="146" left="263" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="164" left="263" width="124" height="19" font="3">prospective registry </text>
<text top="183" left="263" width="43" height="19" font="3">based  </text>
<text top="201" left="263" width="3" height="19" font="3"> </text>
<text top="219" left="263" width="61" height="19" font="4"><b>Size:</b>  69  <b> </b></text>
<text top="146" left="405" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="164" left="405" width="97" height="19" font="3">ARVC mutation </text>
<text top="183" left="405" width="101" height="19" font="3">carriers without </text>
<text top="201" left="405" width="82" height="19" font="3">sustained VA </text>
<text top="219" left="405" width="3" height="19" font="3"> </text>
<text top="238" left="405" width="107" height="19" font="3">78%: first degree </text>
<text top="256" left="405" width="59" height="19" font="3">relatives  </text>
<text top="274" left="405" width="64" height="19" font="3">83% PKP2 </text>
<text top="293" left="405" width="66" height="19" font="3">mutations </text>
<text top="311" left="405" width="3" height="19" font="3"> </text>
<text top="329" left="405" width="115" height="19" font="3">Mean age 27±15 y </text>
<text top="347" left="405" width="3" height="19" font="3"> </text>
<text top="366" left="405" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="384" left="405" width="100" height="19" font="3">ARVC with prior </text>
<text top="402" left="405" width="82" height="19" font="3">sustained VA<b> </b></text>
<text top="147" left="545" width="230" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ARVC mutation carriers </text>
<text top="165" left="545" width="260" height="19" font="3">undergoing risk stratification: incremental </text>
<text top="183" left="545" width="166" height="19" font="3">value of ECG, Holter, CMR. </text>
<text top="202" left="545" width="120" height="19" font="3"> Mean followup 6 y </text>
<text top="220" left="545" width="3" height="19" font="3"> </text>
<text top="238" left="545" width="226" height="19" font="4"><b>Results:</b>  78% holter; ECG, CMR in all </text>
<text top="257" left="545" width="217" height="19" font="3">68% asymptomatic at presentation </text>
<text top="275" left="545" width="262" height="19" font="3">Abnormal ECG: 57%, abnormal Holter 26% </text>
<text top="293" left="545" width="264" height="19" font="3">(PVC’s &gt;500/24 h, or nonsust VT &gt;100 bpm </text>
<text top="312" left="545" width="271" height="19" font="3">Abnormal CMR 30% patients with abnormal </text>
<text top="330" left="545" width="283" height="19" font="3">ECG/Holter: 48% had abnormal CMR, vs 4% in </text>
<text top="348" left="545" width="267" height="19" font="3">patients with normal ECG/Holter, p&lt;0.0001 </text>
<text top="367" left="545" width="233" height="19" font="3">Only 1 pt with normal ECG/holter had </text>
<text top="385" left="545" width="98" height="19" font="3">abnormal CMR. </text>
<text top="403" left="545" width="269" height="19" font="3">Development of sust VA: 16% mean time to </text>
<text top="422" left="545" width="104" height="19" font="3">arrhythmia 4.5 y </text>
<text top="440" left="545" width="247" height="19" font="3">All patients with sust VA presented with </text>
<text top="458" left="545" width="256" height="19" font="3">electrical abnormalities; all had abnormal </text>
<text top="476" left="545" width="36" height="19" font="3">CMR. </text>
<text top="495" left="545" width="7" height="19" font="3">  </text>
<text top="513" left="545" width="237" height="19" font="3"> Patients with both electrical and CMR </text>
<text top="531" left="545" width="226" height="19" font="3">abnormalities: higher VA, p &lt;0.0001: </text>
<text top="550" left="545" width="287" height="19" font="3">arrhythmia free survival at 1,5,10 y: 89%, 54%, </text>
<text top="568" left="545" width="36" height="19" font="3">36%.  </text>
<text top="586" left="545" width="3" height="19" font="4"><b> </b></text>
<text top="146" left="844" width="231" height="19" font="3">● Presence of mutation alone did not </text>
<text top="164" left="844" width="146" height="19" font="3">confer arrhythmia risk.  </text>
<text top="183" left="844" width="182" height="19" font="3">● ECG &amp; holter abnormalities </text>
<text top="201" left="844" width="162" height="19" font="3">preceded detectable CMR </text>
<text top="219" left="844" width="199" height="19" font="3">abnormalities in ARVC mutation </text>
<text top="238" left="844" width="49" height="19" font="3">carriers </text>
<text top="256" left="844" width="194" height="19" font="3">● ECG PLUS CMR abnormalities </text>
<text top="274" left="844" width="148" height="19" font="3">identify high risk group; </text>
<text top="293" left="844" width="151" height="19" font="3">●<b>?</b> ICD for 1° prevention </text>
<text top="311" left="844" width="208" height="19" font="3">● “Evaluation of cardiac structure </text>
<text top="329" left="844" width="219" height="19" font="3">and function using CMR is probably </text>
<text top="347" left="844" width="195" height="19" font="3">not necessary in the absence of </text>
<text top="366" left="844" width="206" height="19" font="3">baseline electrical abnormalities” </text>
<text top="384" left="844" width="3" height="19" font="3"> </text>
<text top="605" left="118" width="86" height="19" font="3">● Liu T et al. J </text>
<text top="624" left="118" width="107" height="19" font="3">Cardiovasc magn </text>
<text top="642" left="118" width="110" height="19" font="3">Reson 2014 (248) </text>
<text top="660" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24996808">● </a></text>
<text top="660" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24996808">24996808</a></text>
<text top="660" left="191" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24996808"><b> </b></a></text>
<text top="605" left="263" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="624" left="263" width="135" height="19" font="3">retrospective cohort   </text>
<text top="642" left="263" width="3" height="19" font="3"> </text>
<text top="660" left="263" width="68" height="19" font="4"><b>Size:</b>    968 </text>
<text top="678" left="263" width="3" height="19" font="4"><b> </b></text>
<text top="605" left="405" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="624" left="405" width="107" height="19" font="3">patients referred </text>
<text top="642" left="405" width="122" height="19" font="3">1995-2010 for CMR </text>
<text top="660" left="405" width="75" height="19" font="3">with clinical </text>
<text top="679" left="405" width="119" height="19" font="3">suspicion of ARVC   </text>
<text top="697" left="405" width="109" height="19" font="3">If quantitative RV </text>
<text top="715" left="405" width="122" height="19" font="3">measures not avail, </text>
<text top="734" left="405" width="76" height="19" font="3">repeat CMR </text>
<text top="752" left="405" width="69" height="19" font="3">performed </text>
<text top="770" left="405" width="93" height="19" font="3">Mean age 42 y </text>
<text top="606" left="545" width="272" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ARVC: effect of revised TFC on </text>
<text top="624" left="545" width="179" height="19" font="3">CMR criteria vs 1994 criteria. </text>
<text top="643" left="545" width="3" height="19" font="3"> </text>
<text top="661" left="545" width="261" height="19" font="4"><b>Results:</b>  2010 criteria reduced no. of total </text>
<text top="679" left="545" width="284" height="19" font="3">patients meeting diagnostic CMR criteria from </text>
<text top="698" left="545" width="274" height="19" font="3">~23% to 2.6%: 2.2% met major criteria, 0.4% </text>
<text top="716" left="545" width="68" height="19" font="3">met minor </text>
<text top="734" left="545" width="237" height="19" font="3">CMR identified alternatic dx in 9.2% of </text>
<text top="753" left="545" width="249" height="19" font="3">patients, and 4.4% of dx were “potential </text>
<text top="605" left="844" width="214" height="19" font="3">● 2010 criteria reduced number of </text>
<text top="624" left="844" width="204" height="19" font="3">total patients meeting diagnostic </text>
<text top="642" left="844" width="79" height="19" font="3">CMR criteria </text>
<text top="660" left="844" width="217" height="19" font="3">● Only 2.6% met diagnostic criteria </text>
<text top="679" left="844" width="52" height="19" font="3">on CMR </text>
<text top="697" left="844" width="225" height="19" font="3">● More objective, quantified criteria </text>
<text top="715" left="844" width="120" height="19" font="3">in ARVC dx by CMR </text>
</page>
<page number="141" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">141 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="405" width="69" height="19" font="3">Males 52% </text>
<text top="127" left="405" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="145" left="405" width="27" height="19" font="3">N/A<b> </b></text>
<text top="109" left="545" width="217" height="19" font="3">mimics” af ARVC-sarcoidosis, other </text>
<text top="127" left="545" width="117" height="19" font="3">cardiomyopathies. </text>
<text top="145" left="545" width="3" height="19" font="4"><b> </b></text>
<text top="164" left="118" width="109" height="19" font="3">● Marcus FI et al. </text>
<text top="183" left="118" width="96" height="19" font="3">Circ 2010 (249) </text>
<text top="201" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20172911">● </a></text>
<text top="201" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20172911">20172911</a></text>
<text top="201" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20172911"> </a></text>
<text top="219" left="118" width="3" height="19" font="4"><b> </b></text>
<text top="164" left="263" width="238" height="19" font="3">Modifications of Task Force criteria for </text>
<text top="183" left="263" width="37" height="19" font="3">ARVC </text>
<text top="201" left="263" width="3" height="19" font="3"> </text>
<text top="219" left="263" width="7" height="19" font="3"> <b> </b></text>
<text top="165" left="545" width="255" height="19" font="4"><b>1</b>°<b> endpoint</b>: Quantification, specificity of </text>
<text top="183" left="545" width="153" height="19" font="3">ARVC diagnostic criteria. </text>
<text top="202" left="545" width="3" height="19" font="3"> </text>
<text top="220" left="545" width="244" height="19" font="3">Structural, ECG, arrhythmic and genetic </text>
<text top="239" left="545" width="210" height="19" font="3">features as major and minor, with </text>
<text top="257" left="545" width="128" height="19" font="3">quantitative criteria. </text>
<text top="275" left="545" width="3" height="19" font="3"> </text>
<text top="293" left="545" width="267" height="19" font="3">SAECG: fQRS fQRSD &gt;114 ms, LASD ≥38 ms, </text>
<text top="312" left="545" width="275" height="19" font="3">RMS-40 ≤20 µV, terminal activation duration </text>
<text top="330" left="545" width="138" height="19" font="3">QRS ≥55 ms V1,2, or 3 </text>
<text top="348" left="545" width="159" height="19" font="3">See major criteria at right </text>
<text top="367" left="545" width="255" height="19" font="3">Dx: 2 major, or 1 major plus 2 minor, or 4 </text>
<text top="385" left="545" width="175" height="19" font="3">minor from different groups </text>
<text top="403" left="545" width="3" height="19" font="3"> </text>
<text top="422" left="545" width="188" height="19" font="3">RV fat not part of CMR criteria </text>
<text top="440" left="545" width="3" height="19" font="3"> </text>
<text top="458" left="545" width="213" height="19" font="3">Added mutation status in proband </text>
<text top="476" left="545" width="3" height="19" font="3"> </text>
<text top="164" left="844" width="99" height="19" font="3">● Major criteria </text>
<text top="183" left="844" width="198" height="19" font="3">● Dysfunction: echo, MRI, angio </text>
<text top="201" left="844" width="179" height="19" font="3">regional dyskinesia, akinesia, </text>
<text top="219" left="844" width="231" height="19" font="3">dyssynchrony AND dilation; echo FAC </text>
<text top="238" left="844" width="44" height="19" font="3">≤33%,  </text>
<text top="256" left="844" width="206" height="19" font="3">● CMR RVEF ≤40%; RVEDVI ≥100–</text>
<text top="274" left="844" width="59" height="19" font="3">110 ml/m</text>
<text top="274" left="903" width="5" height="12" font="15">2</text>
<text top="274" left="908" width="157" height="19" font="3"> (Female/male); localized </text>
<text top="292" left="844" width="217" height="19" font="3">RV aneurysms or severe segmental </text>
<text top="311" left="844" width="54" height="19" font="3">dilatiom </text>
<text top="329" left="844" width="189" height="19" font="3">● Tissue bx: residual myocytes </text>
<text top="347" left="844" width="224" height="19" font="3">&lt;60%● ECG Repol: age &gt;14 y: Twave </text>
<text top="366" left="844" width="156" height="19" font="3">inversion V1, V2, and V3; </text>
<text top="384" left="844" width="192" height="19" font="3">● Depolarization: epsilon V1-3; </text>
<text top="402" left="844" width="206" height="19" font="3">● Arrhythmia: nonsust/sust VT of </text>
<text top="421" left="844" width="119" height="19" font="3">LBBB, superior axis </text>
<text top="439" left="844" width="222" height="19" font="3">● Family hx: ARVC confirmed in first </text>
<text top="457" left="844" width="208" height="19" font="3">degree relative by TFC, surgery or </text>
<text top="476" left="844" width="218" height="19" font="3">autopsy; or pathogenic mutation in </text>
<text top="494" left="844" width="55" height="19" font="3">proband<b> </b></text>
<text top="513" left="118" width="111" height="19" font="3">● Corrado D et al. </text>
<text top="531" left="118" width="60" height="19" font="3">Circ 2010 </text>
<text top="550" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20823389">● </a></text>
<text top="550" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20823389">20823389</a></text>
<text top="550" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20823389"> </a></text>
<text top="513" left="263" width="81" height="19" font="4"><b>Study type</b>:   </text>
<text top="531" left="263" width="75" height="19" font="3">Multicenter </text>
<text top="550" left="263" width="88" height="19" font="3">retrospective  </text>
<text top="568" left="263" width="3" height="19" font="3"> </text>
<text top="586" left="263" width="68" height="19" font="4"><b>Size: </b>   106 </text>
<text top="605" left="263" width="3" height="19" font="3"> </text>
<text top="513" left="411" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="531" left="411" width="112" height="19" font="3">consecutive ARVC </text>
<text top="550" left="411" width="108" height="19" font="3">patients with ICD </text>
<text top="568" left="411" width="103" height="19" font="3">implanted for 1° </text>
<text top="586" left="411" width="70" height="19" font="3">prevention </text>
<text top="605" left="411" width="93" height="19" font="3">Mean age 36 y </text>
<text top="623" left="411" width="69" height="19" font="3">Males 67% </text>
<text top="641" left="411" width="84" height="19" font="3">Syncope 39% </text>
<text top="660" left="411" width="110" height="19" font="3">NSVT 53%, family </text>
<text top="678" left="411" width="76" height="19" font="3">Hx SCD 46% </text>
<text top="696" left="411" width="3" height="19" font="3"> </text>
<text top="714" left="411" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="733" left="411" width="101" height="19" font="3">Prior sust VT/VF </text>
<text top="514" left="545" width="273" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ARVC appropr ICD shocks in 1° </text>
<text top="532" left="545" width="70" height="19" font="3">prevention </text>
<text top="550" left="545" width="138" height="19" font="3">Mean followup 58 mo </text>
<text top="569" left="544" width="3" height="19" font="3"> </text>
<text top="587" left="545" width="243" height="19" font="4"><b>Results:</b>  approp shocks: 24%; inapprop </text>
<text top="605" left="545" width="153" height="19" font="3">shocks 19%; comps 17%  </text>
<text top="624" left="545" width="234" height="19" font="3">PES: performed in 60% of patients: 40 </text>
<text top="642" left="544" width="278" height="19" font="3">patients (60%) inducible. 65% did not receive </text>
<text top="660" left="544" width="235" height="19" font="3">approp therapy; of non-inducible 30% </text>
<text top="679" left="544" width="282" height="19" font="3">received approp rx. PES PPV 35%, neg PV 70% </text>
<text top="697" left="544" width="281" height="19" font="3">Syncope: 43% approp shocks, 4 had recurrent </text>
<text top="715" left="544" width="176" height="19" font="3">syncope without arrhythmia </text>
<text top="513" left="844" width="225" height="19" font="3">● Overall group had high arrhythmic </text>
<text top="531" left="844" width="29" height="19" font="3">risk: </text>
<text top="550" left="844" width="7" height="19" font="3">  </text>
<text top="568" left="844" width="220" height="19" font="3"> Univariate analysis: approp shocks: </text>
<text top="586" left="844" width="172" height="19" font="3">younger, syncope, NSVT, LV </text>
<text top="605" left="844" width="75" height="19" font="3">dysfunction </text>
<text top="623" left="844" width="3" height="19" font="3"> </text>
<text top="641" left="844" width="206" height="19" font="3">● Multivar analysis: syncope only </text>
<text top="660" left="844" width="175" height="19" font="3">predictor, HR: 3.16, p=0.005 </text>
<text top="678" left="844" width="3" height="19" font="3"> </text>
<text top="696" left="844" width="191" height="19" font="3">● No pt with ICD implanted for </text>
<text top="714" left="844" width="191" height="19" font="3">family Hx only had appropriate </text>
<text top="733" left="844" width="44" height="19" font="3">shocks </text>
<text top="752" left="118" width="120" height="19" font="3">● Marcus GM et al. </text>
<text top="770" left="118" width="67" height="19" font="3">JACC 2009 </text>
<text top="752" left="263" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="770" left="263" width="124" height="19" font="3">Retrospective multi-</text>
<text top="752" left="411" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="770" left="411" width="105" height="19" font="3">ARVC patients in </text>
<text top="752" left="545" width="282" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Suppression of VEA on AA meds </text>
<text top="771" left="545" width="51" height="19" font="3">in ARVC </text>
<text top="752" left="844" width="201" height="19" font="3">● Overall BB not associated with </text>
<text top="770" left="844" width="179" height="19" font="3">increase or decrease in VEA;  </text>
</page>
<page number="142" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">142 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19660690">● </a></text>
<text top="109" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19660690">19660690</a></text>
<text top="109" left="191" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19660690"><b> </b></a></text>
<text top="109" left="263" width="82" height="19" font="3">center North </text>
<text top="127" left="263" width="98" height="19" font="3">American ARVC </text>
<text top="145" left="263" width="52" height="19" font="3">Registry </text>
<text top="164" left="263" width="3" height="19" font="3"> </text>
<text top="182" left="263" width="61" height="19" font="4"><b>Size:</b>    95 </text>
<text top="109" left="411" width="118" height="19" font="3">Registry treatment </text>
<text top="127" left="411" width="102" height="19" font="3">with ICD and AA </text>
<text top="145" left="411" width="37" height="19" font="3">drugs </text>
<text top="164" left="411" width="3" height="19" font="3"> </text>
<text top="182" left="411" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="200" left="411" width="27" height="19" font="3">N/A<b> </b></text>
<text top="109" left="545" width="3" height="19" font="3"> </text>
<text top="127" left="545" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="145" left="545" width="279" height="19" font="3">BB: used in 61%, (58 patients): no increase or </text>
<text top="164" left="545" width="276" height="19" font="3">decrease in VEA; atenolol (20 patients) assoc </text>
<text top="182" left="545" width="260" height="19" font="3">with decreased risk VEA, HR: 0.25; 95% CI: </text>
<text top="200" left="545" width="125" height="19" font="3">0.08–0.80, p=0.018. </text>
<text top="219" left="545" width="275" height="19" font="3">Sotalol 38 patients: increased risk ICD shock; </text>
<text top="237" left="545" width="285" height="19" font="3">in high dose 320 mg (6 patients) VEA HR: 14.0; </text>
<text top="255" left="545" width="158" height="19" font="3">95%CI: 1.6–125, p=0.018. </text>
<text top="273" left="545" width="269" height="19" font="3">Amio (10 patients) lower risk VEA, HR: 0.25; </text>
<text top="292" left="545" width="116" height="19" font="3">95% CI: 0.07–0.95.<b> </b></text>
<text top="109" left="844" width="219" height="19" font="3">Atenolol associated with decreased </text>
<text top="127" left="844" width="53" height="19" font="3">risk VEA </text>
<text top="145" left="844" width="3" height="19" font="3"> </text>
<text top="164" left="844" width="207" height="19" font="3">● Sotalol increased risk ICD shock </text>
<text top="182" left="844" width="130" height="19" font="3">Amio lower risk VEA  </text>
<text top="311" left="118" width="119" height="19" font="3">● Hershberger RE J </text>
<text top="329" left="118" width="125" height="19" font="3">Card Fail 2009 (250) </text>
<text top="347" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19254666">● </a></text>
<text top="347" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19254666">19254666</a></text>
<text top="347" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19254666"> </a></text>
<text top="366" left="118" width="3" height="19" font="3"> </text>
<text top="384" left="118" width="3" height="19" font="3"> </text>
<text top="311" left="263" width="245" height="19" font="3"> Genetic evaluation of Cardiomyopathy  </text>
<text top="329" left="263" width="3" height="19" font="3"> </text>
<text top="347" left="263" width="3" height="19" font="3"> </text>
<text top="311" left="545" width="271" height="19" font="3">Guideline restricts the indication for genetic </text>
<text top="329" left="545" width="231" height="19" font="3">testing to that of facilitation of family </text>
<text top="347" left="545" width="255" height="19" font="3">screening and management. Ie, Testing is </text>
<text top="366" left="545" width="277" height="19" font="3">used for risk stratification of family members </text>
<text top="384" left="545" width="248" height="19" font="3">who have little or no clinical evidence of </text>
<text top="402" left="545" width="177" height="19" font="3">disease. Recommendations:  </text>
<text top="421" left="545" width="3" height="19" font="3"> </text>
<text top="439" left="545" width="265" height="19" font="3">Careful family Hx for ≥3 generations, for all </text>
<text top="457" left="545" width="60" height="19" font="3">patients.  </text>
<text top="476" left="545" width="3" height="19" font="3"> </text>
<text top="494" left="545" width="273" height="19" font="3">Clinical screening recommended at intervals </text>
<text top="512" left="545" width="261" height="19" font="3">for asymptomatic at-risk relatives who are </text>
<text top="531" left="545" width="116" height="19" font="3">mutation carriers;  </text>
<text top="549" left="545" width="3" height="19" font="3"> </text>
<text top="567" left="545" width="247" height="19" font="3">Clinical screening for asymptomatic first </text>
<text top="586" left="545" width="280" height="19" font="3">degree relatives when genetic testing has not </text>
<text top="604" left="545" width="275" height="19" font="3">been performed/or mutation not identified.  </text>
<text top="622" left="545" width="3" height="19" font="3"> </text>
<text top="640" left="545" width="282" height="19" font="3">Genetic screening for Fabry disease in all men </text>
<text top="659" left="545" width="195" height="19" font="3">w unexplained cardiac disease.  </text>
<text top="677" left="545" width="3" height="19" font="3"> </text>
<text top="695" left="545" width="223" height="19" font="3">Referral to centers expert in genetic </text>
<text top="714" left="545" width="263" height="19" font="3">evaluation and family based management. </text>
<text top="732" left="545" width="3" height="19" font="3"> </text>
<text top="311" left="844" width="194" height="19" font="3">● Details of clinical screening &amp; </text>
<text top="329" left="844" width="99" height="19" font="3">intervals given:  </text>
<text top="347" left="844" width="137" height="19" font="3">● SAECG in ARVC only </text>
<text top="366" left="844" width="96" height="19" font="3">● CMR in ARVC </text>
<text top="384" left="844" width="3" height="19" font="3"> </text>
<text top="402" left="844" width="200" height="19" font="3">● Childhood: screening intervals </text>
<text top="421" left="844" width="181" height="19" font="3">specified relative to ages and </text>
<text top="439" left="844" width="100" height="19" font="3">mutation status </text>
<text top="457" left="844" width="3" height="19" font="3"> </text>
<text top="476" left="844" width="182" height="19" font="3">● Especially LMNA mutations </text>
</page>
<page number="143" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">143 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="545" width="245" height="19" font="3">Genetic testing for the one most clearly </text>
<text top="127" left="545" width="279" height="19" font="3">affected person in a family to facilitate family </text>
<text top="145" left="544" width="180" height="19" font="3">screening and management.  </text>
<text top="164" left="545" width="3" height="19" font="3"> </text>
<text top="182" left="545" width="271" height="19" font="3">ICD may be considered before the LVEF falls </text>
<text top="200" left="545" width="284" height="19" font="3">below 35% in patients with CM and significant </text>
<text top="219" left="545" width="251" height="19" font="3">arrhythmia or known risk of arrhythmia.  </text>
<text top="250" left="118" width="130" height="19" font="3">● Marcus FI et al. HR </text>
<text top="269" left="118" width="34" height="19" font="3">2009 </text>
<text top="287" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19560088">● </a></text>
<text top="287" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19560088">19560088</a></text>
<text top="287" left="191" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19560088"><b> </b></a></text>
<text top="250" left="263" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="269" left="263" width="75" height="19" font="3">Multicenter </text>
<text top="287" left="263" width="91" height="19" font="3">retrospective   </text>
<text top="305" left="263" width="3" height="19" font="3"> </text>
<text top="324" left="263" width="72" height="19" font="4"><b>Size:</b>   108   </text>
<text top="342" left="263" width="3" height="19" font="3"> </text>
<text top="250" left="411" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="269" left="411" width="101" height="19" font="3">North American </text>
<text top="287" left="411" width="104" height="19" font="3">ARVC/D Registry </text>
<text top="305" left="411" width="61" height="19" font="3">probands </text>
<text top="324" left="411" width="63" height="19" font="3">57% male </text>
<text top="342" left="411" width="116" height="19" font="3">Mean age at dx 38 </text>
<text top="360" left="411" width="10" height="19" font="3">y </text>
<text top="379" left="411" width="105" height="19" font="3">34% competitive </text>
<text top="397" left="411" width="53" height="19" font="3">athletes </text>
<text top="415" left="411" width="100" height="19" font="3">Symptoms: ~ all </text>
<text top="434" left="411" width="84" height="19" font="3">Syncope 21% </text>
<text top="452" left="411" width="53" height="19" font="3">VA 70%  </text>
<text top="470" left="411" width="111" height="19" font="3">Sustained VT 35% </text>
<text top="489" left="411" width="93" height="19" font="3">Genotype: 100 </text>
<text top="507" left="411" width="86" height="19" font="3">patients: 33% </text>
<text top="525" left="411" width="89" height="19" font="3">positive: PKP2 </text>
<text top="543" left="411" width="94" height="19" font="3">present in 22% </text>
<text top="562" left="411" width="3" height="19" font="3"> </text>
<text top="580" left="411" width="3" height="19" font="3"> </text>
<text top="598" left="411" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="617" left="411" width="27" height="19" font="3">N/A<b> </b></text>
<text top="251" left="545" width="259" height="19" font="4"><b>1</b>°<b> endpoint:</b> <b> </b>Study ARVC clinical eval and </text>
<text top="270" left="545" width="247" height="19" font="3">diagnostic utility of 7 tests: ECG, SAECG, </text>
<text top="288" left="545" width="257" height="19" font="3">holter, echo, MRI, RV angio, biopsy in 108 </text>
<text top="306" left="545" width="268" height="19" font="3">probands referred to core center. Followup </text>
<text top="325" left="545" width="87" height="19" font="3">mean 27 mo.  </text>
<text top="343" left="545" width="3" height="19" font="3"> </text>
<text top="361" left="545" width="234" height="19" font="4"><b>Results:</b> 78% of probands classified as </text>
<text top="379" left="545" width="154" height="19" font="3">affected after evaluation </text>
<text top="398" left="545" width="269" height="19" font="3">Biopsy performed in 59%: should not target </text>
<text top="416" left="545" width="238" height="19" font="3">septum but should target RV free wall; </text>
<text top="434" left="545" width="189" height="19" font="3">sarcoidosis found in 3 patients </text>
<text top="453" left="544" width="280" height="19" font="3"> 15% viral infection: Parvovirus 4; enterovirus </text>
<text top="471" left="544" width="253" height="19" font="3">not fou<b>nd: </b> ARVC may predispose to viral </text>
<text top="489" left="544" width="216" height="19" font="3">myocarditis and accelerate disease </text>
<text top="508" left="544" width="75" height="19" font="3">progression </text>
<text top="526" left="544" width="3" height="19" font="4"><b> </b></text>
<text top="544" left="545" width="267" height="19" font="3">Among 86 patients referred with diagnosis, </text>
<text top="562" left="544" width="229" height="19" font="3">23% did not meet TFC, reclassified as </text>
<text top="581" left="544" width="267" height="19" font="3">borderline, or not ARVC (2 patients)-mainly </text>
<text top="599" left="544" width="284" height="19" font="3">due to CMR interpretation at referring vs core </text>
<text top="617" left="545" width="148" height="19" font="3">lab-only 63% confirmed </text>
<text top="250" left="844" width="193" height="19" font="3">● Biopsy and CMR least helpful </text>
<text top="269" left="844" width="232" height="19" font="3">● Diagnostic eval favors: ECG, SAECG, </text>
<text top="287" left="844" width="94" height="19" font="3">echo, RV angio </text>
<text top="305" left="844" width="220" height="19" font="3">● Recommend minimum diagnostic </text>
<text top="324" left="844" width="36" height="19" font="3">eval:  </text>
<text top="342" left="844" width="219" height="19" font="3">ECG, SAECG, Holter, echo, RV angio </text>
<text top="360" left="844" width="3" height="19" font="3"> </text>
<text top="379" left="844" width="224" height="19" font="3">Diagnostic performance of CMR and </text>
<text top="397" left="844" width="228" height="19" font="3">biopsy was less than with other tests </text>
<text top="415" left="844" width="3" height="19" font="4"><b> </b></text>
<text top="434" left="844" width="3" height="19" font="3"> </text>
<text top="636" left="118" width="129" height="19" font="3">● Choudhary N et al. </text>
<text top="655" left="118" width="57" height="19" font="3">JCE 2016 </text>
<text top="673" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26840461">● </a></text>
<text top="673" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26840461">26840461</a></text>
<text top="673" left="191" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26840461"><b> </b></a></text>
<text top="636" left="263" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="655" left="263" width="79" height="19" font="3">Multicenter  </text>
<text top="673" left="263" width="68" height="19" font="4"><b>Size:</b>    125 </text>
<text top="691" left="263" width="3" height="19" font="3"> </text>
<text top="636" left="411" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="655" left="411" width="112" height="19" font="3">ARVC probands in </text>
<text top="673" left="411" width="101" height="19" font="3">North American </text>
<text top="691" left="411" width="89" height="19" font="3">ARVC Registry </text>
<text top="710" left="411" width="69" height="19" font="3">Males 56% </text>
<text top="728" left="411" width="87" height="19" font="3">109 genotype </text>
<text top="746" left="411" width="45" height="19" font="3">testing </text>
<text top="765" left="411" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="783" left="411" width="31" height="19" font="3">N/A  </text>
<text top="637" left="545" width="274" height="19" font="3"> <b>1</b>°<b> endpoint:</b>  Presentation, outcomes ARVC </text>
<text top="656" left="545" width="64" height="19" font="3">by gender </text>
<text top="674" left="545" width="138" height="19" font="3">Mean followup 37 mo </text>
<text top="692" left="544" width="3" height="19" font="3"> </text>
<text top="711" left="545" width="248" height="19" font="4"><b>Results:</b> ACE more likely in “affected” vs </text>
<text top="729" left="545" width="83" height="19" font="3">“borderline”  </text>
<text top="747" left="545" width="201" height="19" font="3"> ICD VT/VF or SCD: no difference </text>
<text top="766" left="545" width="280" height="19" font="3">Fast VT/VF or death in women trend to lower </text>
<text top="784" left="545" width="83" height="19" font="3">risk, HR: 0.41 </text>
<text top="636" left="844" width="205" height="19" font="3">● No major gender differences in </text>
<text top="655" left="844" width="67" height="19" font="3">outcomes  </text>
<text top="673" left="844" width="215" height="19" font="3">● Women highest risk age: 31-40 y </text>
<text top="691" left="844" width="223" height="19" font="3">● ARVC females: increased PVC’s on </text>
<text top="710" left="844" width="186" height="19" font="3">Holter, 2200 vs 1089, p=0.016 </text>
<text top="728" left="844" width="207" height="19" font="3">● SAECG: ACE in females-equal in </text>
<text top="746" left="844" width="189" height="19" font="3">patients w or w/out abnl SAEC </text>
<text top="765" left="844" width="210" height="19" font="3">● In males, ACE more likely if abnl </text>
<text top="783" left="844" width="44" height="19" font="3">SAECG </text>
</page>
<page number="144" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">144 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="545" width="266" height="19" font="3">Males: Increase in Abnormal SAECG 81% vs </text>
<text top="127" left="545" width="268" height="19" font="3">48%, p&lt;0.001, inducible VT/VF 60% vs 40%, </text>
<text top="145" left="545" width="53" height="19" font="3">p=0.026 </text>
<text top="164" left="545" width="3" height="19" font="3"> </text>
<text top="182" left="545" width="278" height="19" font="3">Overall VT/VF shocks: 27% women, 41% men </text>
<text top="200" left="545" width="261" height="19" font="3">Genotype positive: 38%, of positive: PKP-2 </text>
<text top="219" left="544" width="151" height="19" font="3">71%; genotype = gender </text>
<text top="237" left="544" width="120" height="19" font="3"> ≥2 mutations:   8% </text>
<text top="255" left="545" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="844" width="199" height="19" font="3">● cardiac events not different in </text>
<text top="127" left="844" width="184" height="19" font="3">genotype positive vs negative </text>
<text top="274" left="118" width="115" height="19" font="3">● Saguner AM AJC </text>
<text top="292" left="118" width="34" height="19" font="3">2013 </text>
<text top="311" left="118" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23103200">● </a></text>
<text top="311" left="130" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23103200">23103200</a></text>
<text top="311" left="191" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23103200"> </a></text>
<text top="274" left="263" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="292" left="263" width="113" height="19" font="3">Prospective single </text>
<text top="311" left="263" width="53" height="19" font="3">center    </text>
<text top="329" left="263" width="3" height="19" font="3"> </text>
<text top="347" left="263" width="61" height="19" font="4"><b>Size:</b> 62    </text>
<text top="366" left="263" width="7" height="19" font="3">  </text>
<text top="274" left="411" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="292" left="411" width="90" height="19" font="3">ARVC patients </text>
<text top="311" left="411" width="109" height="19" font="3">undergoing EPS    </text>
<text top="329" left="411" width="87" height="19" font="4"><b>NOTE</b> prior to </text>
<text top="347" left="411" width="37" height="19" font="3">study </text>
<text top="366" left="411" width="100" height="19" font="3">39% had clinical </text>
<text top="384" left="411" width="111" height="19" font="3">hemodynamically </text>
<text top="402" left="411" width="106" height="19" font="3">compromised VT </text>
<text top="421" left="411" width="116" height="19" font="3">or VF; 32% sust VT </text>
<text top="439" left="411" width="73" height="19" font="3">stable; 50% </text>
<text top="457" left="411" width="58" height="19" font="3">syncope; </text>
<text top="476" left="411" width="99" height="19" font="3">NYHA Class II-III </text>
<text top="494" left="411" width="37" height="19" font="3">31%;  </text>
<text top="512" left="411" width="113" height="19" font="3">LVEF &lt;50% in 24% </text>
<text top="531" left="411" width="98" height="19" font="3">RV FAC &lt;33% in </text>
<text top="549" left="411" width="29" height="19" font="3">48% </text>
<text top="567" left="411" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="586" left="411" width="31" height="19" font="3">N/A <b> </b></text>
<text top="275" left="545" width="281" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ARVC utility of V-stim to predict </text>
<text top="293" left="545" width="210" height="19" font="3">outcomes: positive EP = sustained </text>
<text top="312" left="545" width="281" height="19" font="3">monomorphic VT only, triple VEST, =/- isuprel </text>
<text top="330" left="545" width="256" height="19" font="4"><b>Results:</b>  55% sustained monomorphic VT </text>
<text top="348" left="545" width="284" height="19" font="3">inducible at PES correlated with increased risk </text>
<text top="367" left="545" width="109" height="19" font="3">adverse outcome </text>
<text top="385" left="545" width="3" height="19" font="3"> </text>
<text top="403" left="545" width="253" height="19" font="3">Inducibility of sust monomorphic VT (HR: </text>
<text top="422" left="545" width="231" height="19" font="3">2.52; 95% CI:1.03–6.16, p=0.043) and </text>
<text top="440" left="545" width="218" height="19" font="3">nonadherence to meds and activity </text>
<text top="458" left="545" width="244" height="19" font="3">restrictions (HR: 2.34; 95% CI: 1.1–4.99, </text>
<text top="476" left="545" width="58" height="19" font="3">p=0.028) </text>
<text top="495" left="545" width="119" height="19" font="3">PPV 65%, NPV 71% </text>
<text top="513" left="545" width="280" height="19" font="3">Anti-tach pacing successfully terminated VT &gt; </text>
<text top="531" left="545" width="81" height="19" font="3">90% of cases </text>
<text top="274" left="844" width="188" height="19" font="3">● study included symptomatic </text>
<text top="292" left="844" width="225" height="19" font="3">patients with clinical VT/VF/syncope </text>
<text top="311" left="844" width="170" height="19" font="3">and ventricular dysfunction </text>
<text top="329" left="844" width="3" height="19" font="3"> </text>
<text top="347" left="844" width="230" height="19" font="3">● Cannot identify how many patients </text>
<text top="366" left="844" width="202" height="19" font="3">were asymptomatic with normal </text>
<text top="384" left="844" width="124" height="19" font="3">ventricular function </text>
<text top="604" left="115" width="4" height="23" font="10"><b> </b></text>
<text top="626" left="115" width="4" height="21" font="0"> </text>
<text top="626" left="331" width="4" height="21" font="2"><b> </b></text>
</page>
<page number="145" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="20" size="14" family="Times" color="#0000ff"/>
<text top="803" left="585" width="29" height="21" font="0">145 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="918" height="21" font="2"><b>Data Supplement 31. Nonrandomized Trials, Observational Studies, and/or Registries of Hypertrophic Cardiomyopathy – (Section 7.4) </b></text>
<text top="129" left="145" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="147" left="171" width="51" height="19" font="4"><b>Author; </b></text>
<text top="165" left="148" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="129" left="303" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="147" left="332" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="129" left="480" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="129" left="642" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="147" left="654" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="165" left="686" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="129" left="874" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="147" left="903" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="184" left="125" width="124" height="19" font="3">● Maron et al.<b> </b>2000 </text>
<text top="203" left="125" width="35" height="19" font="3">(251)<b> </b></text>
<text top="221" left="125" width="12" height="19" font="3">●<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10666426"> </a></text>
<text top="221" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10666426">10666426</a></text>
<text top="221" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10666426"> </a></text>
<text top="239" left="125" width="3" height="19" font="3"> </text>
<text top="184" left="281" width="169" height="19" font="4"><b>Study type:</b>  Retrospective, </text>
<text top="203" left="281" width="168" height="19" font="3">multicenter, observational  </text>
<text top="221" left="281" width="3" height="19" font="3"> </text>
<text top="239" left="281" width="121" height="19" font="4"><b>Size:</b>    128 patients<b> </b></text>
<text top="184" left="464" width="145" height="19" font="4"><b>Inclusion criteria:</b> HCM </text>
<text top="203" left="464" width="144" height="19" font="3">patients at high risk for </text>
<text top="221" left="464" width="134" height="19" font="3">SCD treated with ICD  </text>
<text top="239" left="464" width="3" height="19" font="3"> </text>
<text top="258" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="276" left="464" width="104" height="19" font="3">Inadequate data<b> </b></text>
<text top="185" left="628" width="147" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ICD shock </text>
<text top="204" left="628" width="88" height="19" font="3">from VT or VF </text>
<text top="222" left="628" width="3" height="19" font="3"> </text>
<text top="240" left="628" width="170" height="19" font="4"><b>Results:</b>  At 3.1 y follow up, </text>
<text top="258" left="628" width="109" height="19" font="3">the ICD delivered </text>
<text top="277" left="628" width="171" height="19" font="3">appropriate therapy in 23% </text>
<text top="295" left="628" width="161" height="19" font="3">of patients (7%/y). 25% of </text>
<text top="314" left="628" width="98" height="19" font="3">patients had an </text>
<text top="332" left="628" width="129" height="19" font="3">inappropriate shock. </text>
<text top="350" left="628" width="160" height="19" font="3">Therapy for 1° prevention </text>
<text top="368" left="628" width="166" height="19" font="3">patients was 5%/y; and for </text>
<text top="387" left="628" width="132" height="19" font="3">2° prevention 11%/y.<b> </b></text>
<text top="184" left="820" width="170" height="19" font="3">● VT or VF are the principal </text>
<text top="203" left="820" width="171" height="19" font="3">mechanisms of SCD in HCM </text>
<text top="221" left="820" width="232" height="19" font="3">● ICDs are highly effective in high risk </text>
<text top="239" left="820" width="53" height="19" font="3">patients </text>
<text top="258" left="820" width="3" height="19" font="3"> </text>
<text top="406" left="125" width="116" height="19" font="3">● Christiaans et al. </text>
<text top="424" left="125" width="69" height="19" font="3">2009 (252) </text>
<text top="442" left="125" width="12" height="19" font="3">●<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19533783"> </a></text>
<text top="442" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19533783">19533783</a></text>
<text top="442" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19533783"> </a></text>
<text top="406" left="281" width="164" height="19" font="4"><b>Study type:</b> observational, </text>
<text top="424" left="281" width="81" height="19" font="3">single center </text>
<text top="442" left="281" width="3" height="19" font="3"> </text>
<text top="461" left="281" width="111" height="19" font="4"><b>Size:</b> 143 patients<b> </b></text>
<text top="406" left="464" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="424" left="464" width="150" height="19" font="3">Predictively tested HCM </text>
<text top="442" left="464" width="109" height="19" font="3">mutation carriers </text>
<text top="461" left="464" width="75" height="19" font="3">followed by </text>
<text top="479" left="464" width="88" height="19" font="3">questionnaire </text>
<text top="497" left="464" width="3" height="19" font="3"> </text>
<text top="516" left="464" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="534" left="464" width="103" height="19" font="3">inadequate data </text>
<text top="407" left="628" width="154" height="19" font="4"><b>1</b>°<b> endpoint:</b> satisfaction </text>
<text top="425" left="628" width="147" height="19" font="3">with genetic counseling </text>
<text top="443" left="628" width="3" height="19" font="3"> </text>
<text top="461" left="628" width="171" height="19" font="4"><b>Results:</b> Genetic counseling </text>
<text top="480" left="628" width="159" height="19" font="3">was valued positively and </text>
<text top="498" left="628" width="172" height="19" font="3">only 4 carriers would rather </text>
<text top="516" left="628" width="161" height="19" font="3">not have known that they </text>
<text top="535" left="628" width="152" height="19" font="3">were a mutation carrier. </text>
<text top="406" left="820" width="222" height="19" font="3">● The majority of genetic carriers of </text>
<text top="424" left="820" width="201" height="19" font="3">HCM gene(s) were satisfied with </text>
<text top="442" left="820" width="117" height="19" font="3">genetic counseling </text>
<text top="461" left="820" width="224" height="19" font="3">● Receiving information by mail was </text>
<text top="479" left="820" width="74" height="19" font="3">satisfactory </text>
<text top="497" left="820" width="3" height="19" font="3"> </text>
<text top="554" left="125" width="130" height="19" font="3">● Hamang et al 2012 </text>
<text top="572" left="125" width="35" height="19" font="3">(253)<b> </b></text>
<text top="590" left="125" width="12" height="19" font="3">●<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21773878"> </a></text>
<text top="590" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21773878">21773878</a></text>
<text top="589" left="198" width="4" height="21" font="20"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21773878"> </a></text>
<text top="609" left="125" width="3" height="19" font="3"> </text>
<text top="554" left="281" width="153" height="19" font="4"><b>Study type:</b> Prospective, </text>
<text top="572" left="281" width="166" height="19" font="3">multi-center observational </text>
<text top="590" left="281" width="37" height="19" font="3">study </text>
<text top="609" left="281" width="3" height="19" font="3"> </text>
<text top="627" left="281" width="115" height="19" font="4"><b>Size:</b>  126 patients<b> </b></text>
<text top="554" left="464" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="572" left="464" width="123" height="19" font="3">Norwegian patients </text>
<text top="590" left="464" width="146" height="19" font="3">with a clinical diagnosis </text>
<text top="609" left="464" width="139" height="19" font="3">or genetic risk of HCM </text>
<text top="627" left="464" width="110" height="19" font="3">attending genetic </text>
<text top="645" left="464" width="69" height="19" font="3">counseling </text>
<text top="664" left="464" width="3" height="19" font="3"> </text>
<text top="682" left="464" width="113" height="19" font="4"><b>Exclusion criteria: </b></text>
<text top="700" left="464" width="103" height="19" font="3">inadequate data </text>
<text top="554" left="628" width="170" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Development </text>
<text top="573" left="628" width="152" height="19" font="3">of heart-focused anxiety </text>
<text top="591" left="628" width="3" height="19" font="3"> </text>
<text top="609" left="628" width="154" height="19" font="4"><b>Results:  </b>1 y of follow-up </text>
<text top="628" left="628" width="175" height="19" font="3">questionnaires after genetic </text>
<text top="646" left="628" width="170" height="19" font="3">counseling.  Patients with a </text>
<text top="665" left="628" width="154" height="19" font="3">clinical diagnosis of HCM </text>
<text top="683" left="628" width="154" height="19" font="3">compared to genetic risk </text>
<text top="701" left="628" width="134" height="19" font="3">had higher avoidance </text>
<text top="719" left="628" width="126" height="19" font="3">(p&lt;0.002), attention </text>
<text top="738" left="628" width="116" height="19" font="3">(p&lt;0.005) and fear </text>
<text top="756" left="628" width="66" height="19" font="3">(p&lt;0.007). </text>
<text top="554" left="820" width="227" height="19" font="3">● Patients with a clinical diagnosis of </text>
<text top="572" left="820" width="209" height="19" font="3">HCM receiving genetic counseling </text>
<text top="590" left="820" width="196" height="19" font="3">continue to experience anxiety. </text>
<text top="609" left="820" width="234" height="19" font="3">● Patients with a genetic risk for HCM </text>
<text top="627" left="820" width="220" height="19" font="3">had less anxiety if they experienced </text>
<text top="645" left="820" width="220" height="19" font="3">satisfaction with genetic counseling </text>
</page>
<page number="146" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">146 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="85" height="19" font="3">●Bos JM et al </text>
<text top="127" left="125" width="69" height="19" font="3">2014 (254) </text>
<text top="145" left="125" width="12" height="19" font="3">●<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24793961"> </a></text>
<text top="145" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24793961">24793961</a></text>
<text top="145" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24793961"> </a></text>
<text top="163" left="125" width="4" height="21" font="20"> </text>
<text top="184" left="125" width="3" height="19" font="3"> </text>
<text top="109" left="281" width="160" height="19" font="4"><b>Study type:</b> Single center, </text>
<text top="127" left="281" width="167" height="19" font="3">observational data registry </text>
<text top="145" left="281" width="3" height="19" font="3"> </text>
<text top="164" left="281" width="122" height="19" font="4"><b>Size:</b>  1053 patients<b> </b></text>
<text top="109" left="464" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="127" left="464" width="151" height="19" font="3">Established clinical HCM </text>
<text top="145" left="464" width="60" height="19" font="3">diagnosis </text>
<text top="164" left="464" width="3" height="19" font="3"> </text>
<text top="182" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="200" left="464" width="104" height="19" font="3">Inadequate data </text>
<text top="109" left="628" width="135" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Genetic </text>
<text top="128" left="628" width="100" height="19" font="3">testing for HCM </text>
<text top="146" left="628" width="3" height="19" font="3"> </text>
<text top="164" left="628" width="173" height="19" font="4"><b>Results:</b>  1053 patients with </text>
<text top="183" left="628" width="146" height="19" font="3">clinical HCM (mean age </text>
<text top="201" left="628" width="142" height="19" font="3">44.4±19 y) had genetic </text>
<text top="219" left="628" width="158" height="19" font="3">testing evaluating 9 HCM-</text>
<text top="238" left="628" width="149" height="19" font="3">associated myofilament </text>
<text top="256" left="628" width="178" height="19" font="3">genes.  34% were positive or </text>
<text top="274" left="628" width="115" height="19" font="3">a HCM mutation. . </text>
<text top="109" left="820" width="230" height="19" font="3">● Predictors of a positive genetic test </text>
<text top="127" left="820" width="211" height="19" font="3">were reverse curve morphological </text>
<text top="145" left="820" width="227" height="19" font="3">subtype, age &lt;45 y, LV wall thickness </text>
<text top="164" left="820" width="223" height="19" font="3">≥20 mm, family history of HCM, and </text>
<text top="182" left="820" width="219" height="19" font="3">family history of SCD. Hypertension </text>
<text top="200" left="820" width="119" height="19" font="3">was not predictive. </text>
<text top="219" left="820" width="240" height="19" font="3">● A positive genetic test was predicted </text>
<text top="237" left="820" width="165" height="19" font="3">in 6% of patients with only </text>
<text top="255" left="820" width="199" height="19" font="3">hypertension and 80% with all 5 </text>
<text top="273" left="820" width="117" height="19" font="3">predictor markers. </text>
<text top="293" left="125" width="114" height="19" font="3">● O’Mahony et al. </text>
<text top="312" left="125" width="69" height="19" font="3">2014 (255) </text>
<text top="330" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24126876">● </a></text>
<text top="330" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24126876">24126876</a></text>
<text top="330" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24126876"> </a></text>
<text top="348" left="125" width="3" height="19" font="3"> </text>
<text top="293" left="281" width="142" height="19" font="4"><b>Study type:</b> Prognostic </text>
<text top="312" left="281" width="135" height="19" font="3">model derived from a </text>
<text top="330" left="281" width="163" height="19" font="3">retrospective, multicenter </text>
<text top="348" left="281" width="156" height="19" font="3">longitudinal cohort study </text>
<text top="367" left="281" width="137" height="19" font="3">Clinical risk prediction </text>
<text top="385" left="281" width="142" height="19" font="3">model for SCD in HCM  </text>
<text top="403" left="281" width="3" height="19" font="3"> </text>
<text top="421" left="281" width="126" height="19" font="4"><b>Size:</b>  3,675 patients<b> </b></text>
<text top="293" left="464" width="145" height="19" font="4"><b>Inclusion criteria: </b>HCM </text>
<text top="312" left="464" width="53" height="19" font="3">patients </text>
<text top="330" left="464" width="3" height="19" font="3"> </text>
<text top="348" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="367" left="464" width="103" height="19" font="3">inadequate data<b> </b></text>
<text top="294" left="628" width="129" height="19" font="4"><b>1</b>°<b> endpoint:</b>  SCD or </text>
<text top="312" left="628" width="138" height="19" font="3">appropriate ICD shock </text>
<text top="331" left="628" width="3" height="19" font="3"> </text>
<text top="349" left="628" width="167" height="19" font="4"><b>Results:</b>  Median follow-up </text>
<text top="367" left="628" width="154" height="19" font="3">5.7 y; 5% of patients had </text>
<text top="386" left="628" width="132" height="19" font="3">SCD/ICD shock. 8 pre-</text>
<text top="404" left="628" width="158" height="19" font="3">specified predictors were </text>
<text top="422" left="628" width="152" height="19" font="3">associated with SCD/ICD </text>
<text top="441" left="628" width="157" height="19" font="3">shock at 15% significance </text>
<text top="459" left="628" width="163" height="19" font="3">level. Model developed to </text>
<text top="477" left="628" width="170" height="19" font="3">estimate probability of SCD </text>
<text top="496" left="628" width="153" height="19" font="3">at 5 y.  For every 16 ICDs </text>
<text top="514" left="628" width="174" height="19" font="3">implanted in patients with a </text>
<text top="532" left="628" width="176" height="19" font="3">≥4% 5-y SCD risk, potentially </text>
<text top="550" left="628" width="113" height="19" font="3">1 pt will be saved.<b> </b></text>
<text top="293" left="820" width="221" height="19" font="3">● Risk modifiers for SCD used in the </text>
<text top="312" left="820" width="207" height="19" font="3">model were age, maximal LV wall </text>
<text top="330" left="820" width="204" height="19" font="3">thickness, left atrial diameter, LV </text>
<text top="348" left="820" width="217" height="19" font="3">outflow tract gradient, family Hx of </text>
<text top="367" left="820" width="171" height="19" font="3">SCD, non-sustained VT, and </text>
<text top="385" left="820" width="132" height="19" font="3">unexplained syncope </text>
<text top="403" left="820" width="216" height="19" font="3">● This is the first validated SCD risk </text>
<text top="422" left="820" width="212" height="19" font="3">prediction model for patients with </text>
<text top="440" left="820" width="172" height="19" font="3">HCM and provides accurate </text>
<text top="458" left="820" width="195" height="19" font="3">individualized estimates for the </text>
<text top="476" left="820" width="193" height="19" font="3">probability of SCD using clinical </text>
<text top="495" left="820" width="78" height="19" font="3">parameters. </text>
<text top="570" left="125" width="119" height="19" font="3">● Elliott et al. 1999 </text>
<text top="588" left="125" width="35" height="19" font="3">(256) </text>
<text top="606" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10334430">● </a></text>
<text top="606" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10334430">10334430</a></text>
<text top="606" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10334430"> </a></text>
<text top="624" left="125" width="3" height="19" font="3"> </text>
<text top="569" left="281" width="159" height="19" font="4"><b>Study type:</b> single center, </text>
<text top="588" left="281" width="87" height="19" font="3">observational </text>
<text top="606" left="281" width="128" height="19" font="3">Survival after SCD or </text>
<text top="624" left="281" width="133" height="19" font="3">sustained VT in HCM: </text>
<text top="643" left="281" width="156" height="19" font="3">treated with amiodarone </text>
<text top="661" left="281" width="41" height="19" font="3">or ICD<b> </b></text>
<text top="680" left="281" width="3" height="19" font="3"> </text>
<text top="698" left="281" width="107" height="19" font="4"><b>Size:</b>  16 patients<b> </b></text>
<text top="569" left="464" width="145" height="19" font="4"><b>Inclusion criteria: </b>HCM </text>
<text top="588" left="464" width="111" height="19" font="3">patients surviving </text>
<text top="606" left="464" width="113" height="19" font="3">resuscitated VF or </text>
<text top="624" left="464" width="138" height="19" font="3">syncopal sustained VT </text>
<text top="643" left="464" width="3" height="19" font="3"> </text>
<text top="661" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="679" left="464" width="103" height="19" font="3">inadequate data<b> </b></text>
<text top="570" left="628" width="164" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Survival free </text>
<text top="589" left="628" width="177" height="19" font="3">from SCD or appropriate ICD </text>
<text top="607" left="628" width="38" height="19" font="3">shock </text>
<text top="625" left="628" width="3" height="19" font="3"> </text>
<text top="644" left="628" width="139" height="19" font="4"><b>Results:</b>  8 patients on </text>
<text top="662" left="628" width="170" height="19" font="3">amiodarone and 6 received </text>
<text top="680" left="628" width="147" height="19" font="3">an ICD. Mean follow-up </text>
<text top="699" left="628" width="131" height="19" font="3">6.1±4 y 2 patients on </text>
<text top="717" left="628" width="173" height="19" font="3">amiodarone with SCD and 3 </text>
<text top="735" left="628" width="155" height="19" font="3">patients had appropriate </text>
<text top="753" left="628" width="66" height="19" font="3">ICD shock.<b> </b></text>
<text top="570" left="820" width="188" height="19" font="3">● ICD therapy was better than </text>
<text top="588" left="820" width="224" height="19" font="3">amiodarone at preventing recurrent </text>
<text top="606" left="820" width="27" height="19" font="3">SCD </text>
<text top="624" left="820" width="175" height="19" font="3">● Small numbers and purely </text>
<text top="643" left="820" width="191" height="19" font="3">observational without controls </text>
<text top="661" left="820" width="61" height="19" font="3">reported. </text>
</page>
<page number="147" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">147 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="124" height="19" font="3">● Maron et al. 2007 </text>
<text top="127" left="125" width="35" height="19" font="3">(257) </text>
<text top="145" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=17652294">● </a></text>
<text top="145" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=17652294">17652294</a></text>
<text top="145" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=17652294"> </a></text>
<text top="164" left="125" width="3" height="19" font="3"> </text>
<text top="182" left="125" width="3" height="19" font="3"> </text>
<text top="109" left="281" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="127" left="281" width="169" height="19" font="3">Retrospective, multicenter, </text>
<text top="145" left="281" width="49" height="19" font="3">registry </text>
<text top="164" left="281" width="168" height="19" font="3">ICD to prevent SCD in HCM </text>
<text top="182" left="281" width="121" height="19" font="4"><b>Size:</b>   506 patients  </text>
<text top="109" left="464" width="148" height="19" font="4"><b>Inclusion criteria:</b>  HCM </text>
<text top="127" left="464" width="144" height="19" font="3">patients at high risk for </text>
<text top="145" left="464" width="131" height="19" font="3">SCD treated with ICD </text>
<text top="164" left="464" width="3" height="19" font="3"> </text>
<text top="182" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="200" left="464" width="104" height="19" font="3">Inadequate data </text>
<text top="109" left="628" width="147" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ICD shock </text>
<text top="128" left="628" width="88" height="19" font="3">from VT or VF </text>
<text top="146" left="628" width="3" height="19" font="3"> </text>
<text top="164" left="628" width="111" height="19" font="4"><b>Results:</b>  20% had </text>
<text top="183" left="628" width="157" height="19" font="3">appropriate treatment of </text>
<text top="201" left="628" width="156" height="19" font="3">VT/VF: 10.6% per y for 2° </text>
<text top="219" left="628" width="163" height="19" font="3">prevention and 3.6%/y for </text>
<text top="238" left="628" width="151" height="19" font="3">1° prevention.  Time to 1</text>
<text top="237" left="779" width="7" height="12" font="15">st</text>
<text top="238" left="786" width="3" height="19" font="3"> </text>
<text top="256" left="628" width="173" height="19" font="3">appropriate shock was 10 y. </text>
<text top="274" left="628" width="166" height="19" font="3">Appropriate discharge was </text>
<text top="293" left="628" width="172" height="19" font="3">similar in patients with 1, 2, </text>
<text top="311" left="628" width="152" height="19" font="3">or 3 risk factors (p=0.77) </text>
<text top="109" left="820" width="231" height="19" font="3">● ICDs are highly effective in high risk </text>
<text top="127" left="820" width="53" height="19" font="3">patients </text>
<text top="145" left="820" width="225" height="19" font="3">● One death due to VT/VF when ICD </text>
<text top="164" left="820" width="108" height="19" font="3">failed to function </text>
<text top="182" left="820" width="204" height="19" font="3">● Inappropriate shocks in 27% of </text>
<text top="200" left="820" width="53" height="19" font="3">patients </text>
<text top="219" left="820" width="237" height="19" font="3">● A single modifier of high risk for SCD </text>
<text top="237" left="820" width="189" height="19" font="3">may be sufficient to justify ICD </text>
<text top="255" left="820" width="68" height="19" font="3">placement </text>
<text top="330" left="125" width="114" height="19" font="3">● Lin G et al.<b> </b>2009 </text>
<text top="348" left="125" width="35" height="19" font="3">(258) </text>
<text top="367" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19282314">● </a></text>
<text top="367" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19282314">19282314</a></text>
<text top="367" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19282314"> </a></text>
<text top="385" left="125" width="3" height="19" font="3"> </text>
<text top="403" left="125" width="3" height="19" font="3"> </text>
<text top="330" left="281" width="169" height="19" font="4"><b>Study type:</b>  Retrospective, </text>
<text top="348" left="281" width="138" height="19" font="3">single center, registry  </text>
<text top="367" left="281" width="116" height="19" font="3">Complications and </text>
<text top="385" left="281" width="155" height="19" font="3">inappropriate ICD shocks </text>
<text top="403" left="281" width="101" height="19" font="3">in HCM patients </text>
<text top="422" left="281" width="3" height="19" font="3"> </text>
<text top="440" left="281" width="118" height="19" font="4"><b>Size:</b>  181 patients  </text>
<text top="330" left="464" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="348" left="464" width="117" height="19" font="3">Patients with HCM </text>
<text top="367" left="464" width="86" height="19" font="3">receiving ICD  </text>
<text top="385" left="464" width="3" height="19" font="3"> </text>
<text top="403" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="422" left="464" width="104" height="19" font="3">Inadequate data </text>
<text top="331" left="628" width="172" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Inappropriate </text>
<text top="349" left="628" width="113" height="19" font="3">shocks and device </text>
<text top="367" left="628" width="88" height="19" font="3">complications </text>
<text top="386" left="628" width="3" height="19" font="3"> </text>
<text top="404" left="628" width="155" height="19" font="4"><b>Results:</b>  Mean follow up </text>
<text top="422" left="628" width="169" height="19" font="3">4.92 y. 36% of patients had </text>
<text top="441" left="628" width="144" height="19" font="3">complications and 23% </text>
<text top="459" left="628" width="169" height="19" font="3">inappropriate shocks (5.3% </text>
<text top="477" left="628" width="164" height="19" font="3">per y). Appropriate shocks </text>
<text top="496" left="628" width="38" height="19" font="3">4%/y. </text>
<text top="330" left="820" width="213" height="19" font="3">● Inappropriate shocks and device </text>
<text top="348" left="820" width="225" height="19" font="3">complications are significant in HCM </text>
<text top="367" left="820" width="155" height="19" font="3">patients receiving an ICD </text>
<text top="385" left="820" width="233" height="19" font="3">● Younger patients and those with AF </text>
<text top="403" left="820" width="181" height="19" font="3">more likely to have problems </text>
<text top="515" left="125" width="117" height="19" font="3">● Syska et al. 2010 </text>
<text top="533" left="125" width="35" height="19" font="3">(259) </text>
<text top="551" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20132378">● </a></text>
<text top="551" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20132378">20132378</a></text>
<text top="551" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20132378"> </a></text>
<text top="570" left="125" width="3" height="19" font="3"> </text>
<text top="588" left="125" width="3" height="19" font="3"> </text>
<text top="515" left="281" width="165" height="19" font="4"><b>Study type:</b> Retrospective, </text>
<text top="533" left="281" width="129" height="19" font="3">observational, single </text>
<text top="551" left="281" width="50" height="19" font="3">center   </text>
<text top="570" left="281" width="164" height="19" font="3">Efficacy and complications </text>
<text top="588" left="281" width="139" height="19" font="3">of ICD therapy in HCM </text>
<text top="606" left="281" width="3" height="19" font="3"> </text>
<text top="624" left="281" width="115" height="19" font="4"><b>Size:</b>  104 patients </text>
<text top="515" left="464" width="145" height="19" font="4"><b>Inclusion criteria:</b> HCM </text>
<text top="533" left="464" width="144" height="19" font="3">patients at high risk for </text>
<text top="551" left="464" width="147" height="19" font="3">VT/VF treated with ICD  </text>
<text top="570" left="464" width="3" height="19" font="3"> </text>
<text top="588" left="464" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="606" left="464" width="107" height="19" font="3">Inadequate data  </text>
<text top="515" left="628" width="160" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ICD therapy </text>
<text top="534" left="628" width="163" height="19" font="3">and relation to clinical risk </text>
<text top="552" left="628" width="43" height="19" font="3">profile </text>
<text top="570" left="628" width="3" height="19" font="3"> </text>
<text top="588" left="628" width="170" height="19" font="4"><b>Results:</b>  Average follow up </text>
<text top="607" left="628" width="109" height="19" font="3">4.6 y. 53.8% of 2° </text>
<text top="625" left="628" width="123" height="19" font="3">prevention patients </text>
<text top="644" left="628" width="149" height="19" font="3">received an appropriate </text>
<text top="662" left="628" width="150" height="19" font="3">therapy and 16.7% of 1° </text>
<text top="680" left="628" width="127" height="19" font="3">prevention patients. </text>
<text top="699" left="628" width="94" height="19" font="3">Complications: </text>
<text top="717" left="628" width="131" height="19" font="3">inappropriate shocks </text>
<text top="735" left="628" width="158" height="19" font="3">(33.7%), lead dysfunction </text>
<text top="753" left="628" width="143" height="19" font="3">(12.5%), and infections </text>
<text top="772" left="628" width="46" height="19" font="3">(4.8%). </text>
<text top="515" left="820" width="209" height="19" font="3">● ICD therapy is effective in HCM, </text>
<text top="533" left="820" width="205" height="19" font="3">although the complication rate is </text>
<text top="551" left="820" width="69" height="19" font="3">significant. </text>
<text top="570" left="820" width="227" height="19" font="3">● 1, 2, or more risk modifiers did not </text>
<text top="588" left="820" width="208" height="19" font="3">predict appropriate ICD therapies </text>
<text top="606" left="820" width="3" height="19" font="3"> </text>
</page>
<page number="148" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">148 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="114" height="19" font="3">● O’Mahony et al. </text>
<text top="127" left="125" width="69" height="19" font="3">2012 (260) </text>
<text top="145" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21757459">● </a></text>
<text top="145" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21757459">21757459</a></text>
<text top="145" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21757459"> </a></text>
<text top="164" left="125" width="3" height="19" font="3"> </text>
<text top="182" left="125" width="3" height="19" font="3"> </text>
<text top="109" left="281" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="127" left="281" width="91" height="19" font="3">Retrospective, </text>
<text top="145" left="281" width="129" height="19" font="3">observational, single </text>
<text top="164" left="281" width="94" height="19" font="3">center, cohort  </text>
<text top="182" left="281" width="164" height="19" font="3">Efficacy and complications </text>
<text top="200" left="281" width="139" height="19" font="3">of ICD therapy in HCM </text>
<text top="219" left="281" width="3" height="19" font="3"> </text>
<text top="237" left="281" width="115" height="19" font="4"><b>Size:</b>  334 patients </text>
<text top="109" left="464" width="145" height="19" font="4"><b>Inclusion criteria:</b> HCM </text>
<text top="127" left="464" width="144" height="19" font="3">patients at high risk for </text>
<text top="145" left="464" width="151" height="19" font="3">VT/VF treated with ICD   </text>
<text top="164" left="464" width="3" height="19" font="3"> </text>
<text top="182" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="200" left="464" width="104" height="19" font="3">Inadequate data </text>
<text top="109" left="628" width="160" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ICD therapy </text>
<text top="128" left="628" width="114" height="19" font="3">and complications </text>
<text top="146" left="628" width="3" height="19" font="3"> </text>
<text top="164" left="628" width="146" height="19" font="4"><b>Results:</b>  8% of patients </text>
<text top="183" left="628" width="175" height="19" font="3">received appropriate shocks </text>
<text top="201" left="628" width="160" height="19" font="3">(2.3%/y).  16% of patients </text>
<text top="219" left="628" width="142" height="19" font="3">received inappropriate </text>
<text top="238" left="628" width="158" height="19" font="3">shocks (4.6%/y). 18% had </text>
<text top="256" left="628" width="138" height="19" font="3">implant complications </text>
<text top="274" left="628" width="137" height="19" font="3">(5.1%/y) and 30% had </text>
<text top="293" left="628" width="131" height="19" font="3">inappropriate shocks </text>
<text top="311" left="628" width="59" height="19" font="3">(8.6%/y). </text>
<text top="109" left="820" width="196" height="19" font="3">● HCM patients with an ICD are </text>
<text top="127" left="820" width="214" height="19" font="3">exposed to frequent inappropriate </text>
<text top="145" left="820" width="212" height="19" font="3">shocks and implant complications  </text>
<text top="164" left="820" width="3" height="19" font="3"> </text>
<text top="330" left="125" width="135" height="19" font="3">● Melacini et al.<b> </b>2007 </text>
<text top="348" left="125" width="35" height="19" font="3">(261) </text>
<text top="367" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=17502652">● </a></text>
<text top="367" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=17502652">17502652</a></text>
<text top="367" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=17502652"> </a></text>
<text top="385" left="125" width="3" height="19" font="3"> </text>
<text top="403" left="125" width="3" height="19" font="3"> </text>
<text top="330" left="281" width="165" height="19" font="4"><b>Study type:</b> Retrospective, </text>
<text top="348" left="281" width="85" height="19" font="3">single center, </text>
<text top="367" left="281" width="93" height="19" font="3">observational   </text>
<text top="385" left="281" width="169" height="19" font="3">Pharmacological treatment </text>
<text top="403" left="281" width="143" height="19" font="3">to prevent SCD in HCM<b> </b></text>
<text top="422" left="281" width="3" height="19" font="3"> </text>
<text top="440" left="281" width="115" height="19" font="4"><b>Size:</b>  173 patients </text>
<text top="330" left="464" width="148" height="19" font="4"><b>Inclusion criteria:</b>  HCM </text>
<text top="348" left="464" width="102" height="19" font="3">patients on AAD </text>
<text top="367" left="464" width="3" height="19" font="3"> </text>
<text top="385" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="403" left="464" width="104" height="19" font="3">Inadequate data </text>
<text top="331" left="628" width="176" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Risk of sudden </text>
<text top="349" left="628" width="39" height="19" font="3">death </text>
<text top="367" left="628" width="3" height="19" font="3"> </text>
<text top="386" left="628" width="154" height="19" font="4"><b>Results:</b>  10% of patients </text>
<text top="404" left="628" width="171" height="19" font="3">had SCD over an average of </text>
<text top="422" left="628" width="172" height="19" font="3">62 mo: 20% on amiodarone </text>
<text top="441" left="628" width="150" height="19" font="3">(6/30), 9% on verapamil </text>
<text top="459" left="628" width="158" height="19" font="3">(4/46) and BB (7/76), and </text>
<text top="477" left="628" width="126" height="19" font="3">0% on sotalol (0/21) </text>
<text top="330" left="820" width="233" height="19" font="3">● Medical treatment is not absolutely </text>
<text top="348" left="820" width="233" height="19" font="3">protective against risk of SCD in HCM. </text>
<text top="367" left="820" width="3" height="19" font="3"> </text>
<text top="496" left="125" width="143" height="19" font="3">● McKenna et al. 1985 </text>
<text top="515" left="125" width="35" height="19" font="3">(262) </text>
<text top="533" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/4039188">● </a></text>
<text top="533" left="137" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/4039188">4039188</a></text>
<text top="533" left="190" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/4039188"> </a></text>
<text top="551" left="125" width="3" height="19" font="4"><b> </b></text>
<text top="496" left="281" width="159" height="19" font="4"><b>Study type:</b> single center, </text>
<text top="515" left="281" width="87" height="19" font="3">observational </text>
<text top="533" left="281" width="143" height="19" font="3">Improved survival with </text>
<text top="551" left="281" width="152" height="19" font="3">amiodarone in HCM and </text>
<text top="570" left="281" width="19" height="19" font="3">VT </text>
<text top="588" left="281" width="3" height="19" font="3"> </text>
<text top="606" left="281" width="107" height="19" font="4"><b>Size:</b>  86 patients<b> </b></text>
<text top="496" left="464" width="148" height="19" font="4"><b>Inclusion criteria:</b>  HCM </text>
<text top="515" left="464" width="139" height="19" font="3">patients with NSVT on </text>
<text top="533" left="464" width="42" height="19" font="3">Holter </text>
<text top="551" left="464" width="3" height="19" font="3"> </text>
<text top="569" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="588" left="464" width="103" height="19" font="3">inadequate data<b> </b></text>
<text top="497" left="628" width="177" height="19" font="4"><b>1</b>°<b> endpoint:</b>  SCD, recurrent </text>
<text top="515" left="628" width="19" height="19" font="3">VT </text>
<text top="534" left="628" width="3" height="19" font="3"> </text>
<text top="552" left="628" width="167" height="19" font="4"><b>Results:</b> 24 patients during </text>
<text top="570" left="628" width="157" height="19" font="3">1976-1977 had NSVT and </text>
<text top="589" left="628" width="172" height="19" font="3">received conventional AAD: </text>
<text top="607" left="628" width="172" height="19" font="3">7 patients had SCD during 3 </text>
<text top="625" left="628" width="147" height="19" font="3">y follow-up. 21 patients </text>
<text top="644" left="628" width="168" height="19" font="3">from 1978-1979 with NSVT </text>
<text top="662" left="628" width="156" height="19" font="3">received amiodarone: no </text>
<text top="680" left="628" width="178" height="19" font="3">SCD on amiodarone during 3 </text>
<text top="699" left="628" width="76" height="19" font="3">y follow-up.<b> </b></text>
<text top="496" left="820" width="191" height="19" font="3">● Amiodarone was better than </text>
<text top="515" left="820" width="181" height="19" font="3">conventional medications for </text>
<text top="533" left="820" width="108" height="19" font="3">preventing SCD.   </text>
<text top="551" left="820" width="3" height="19" font="3"> </text>
<text top="570" left="820" width="237" height="19" font="3">Study design was purely observational </text>
<text top="588" left="820" width="3" height="19" font="3"> </text>
<text top="718" left="125" width="129" height="19" font="3">● Olivotto et al.1999 </text>
<text top="736" left="125" width="35" height="19" font="3">(263) </text>
<text top="754" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=10362212">● </a></text>
<text top="754" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=10362212">10362212</a></text>
<text top="754" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=10362212"> </a></text>
<text top="773" left="125" width="3" height="19" font="3"> </text>
<text top="718" left="281" width="156" height="19" font="4"><b>Study type:</b>  Prospective, </text>
<text top="736" left="281" width="171" height="19" font="3">single center observational  </text>
<text top="754" left="281" width="3" height="19" font="3"> </text>
<text top="718" left="464" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="736" left="464" width="147" height="19" font="3">Patients with HCM who </text>
<text top="754" left="464" width="124" height="19" font="3">underwent exercise </text>
<text top="773" left="464" width="49" height="19" font="3">testing  </text>
<text top="718" left="628" width="145" height="19" font="4"><b>1</b>°<b> endpoint:</b> Mortality  </text>
<text top="737" left="628" width="3" height="19" font="3"> </text>
<text top="755" left="628" width="130" height="19" font="4"><b>Results:</b>  22% had an </text>
<text top="773" left="628" width="156" height="19" font="3">abnormal BP response (9 </text>
<text top="718" left="820" width="216" height="19" font="3">● An abnormal BP response during </text>
<text top="736" left="820" width="227" height="19" font="3">exercise in HCM was associated with </text>
<text top="754" left="820" width="79" height="19" font="3">CV mortality </text>
</page>
<page number="149" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">149 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="3" height="19" font="3"> </text>
<text top="109" left="281" width="139" height="19" font="3">Prognostic value of BP </text>
<text top="127" left="281" width="169" height="19" font="3">response during exercise in </text>
<text top="145" left="281" width="34" height="19" font="3">HCM<b> </b></text>
<text top="164" left="281" width="3" height="19" font="3"> </text>
<text top="182" left="281" width="115" height="19" font="4"><b>Size:</b>  128 patients </text>
<text top="109" left="464" width="3" height="19" font="3"> </text>
<text top="127" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="145" left="464" width="104" height="19" font="3">Inadequate data </text>
<text top="109" left="628" width="162" height="19" font="3">with hypotension, 19 with </text>
<text top="127" left="628" width="156" height="19" font="3">failed BP rise).   4.7±3.7 y </text>
<text top="145" left="628" width="174" height="19" font="3">follow up, 7% died (3 SCD, 6 </text>
<text top="164" left="628" width="133" height="19" font="3">HF).  An abnormal BP </text>
<text top="182" left="628" width="121" height="19" font="3">response predicted </text>
<text top="200" left="628" width="128" height="19" font="3">increased risk for CV </text>
<text top="219" left="628" width="164" height="19" font="3">mortality (OR: 4.5; 95% CI: </text>
<text top="237" left="628" width="68" height="19" font="3">1.1–20.1).  </text>
<text top="109" left="820" width="214" height="19" font="3">● However, the positive predictive </text>
<text top="127" left="820" width="183" height="19" font="3">value was only 14%. Negative </text>
<text top="145" left="820" width="130" height="19" font="3">predictive value 95% </text>
<text top="164" left="820" width="3" height="19" font="3"> </text>
<text top="256" left="125" width="121" height="19" font="3">● Sadoul et al.1997 </text>
<text top="274" left="125" width="35" height="19" font="3">(264) </text>
<text top="292" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=9386166">● </a></text>
<text top="292" left="137" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=9386166">9386166</a></text>
<text top="292" left="190" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=9386166"> </a></text>
<text top="311" left="125" width="3" height="19" font="3"> </text>
<text top="329" left="125" width="3" height="19" font="3"> </text>
<text top="256" left="281" width="156" height="19" font="4"><b>Study type:</b>  Prospective, </text>
<text top="274" left="281" width="171" height="19" font="3">single center observational  </text>
<text top="292" left="281" width="139" height="19" font="3">Prognostic value of BP </text>
<text top="311" left="281" width="169" height="19" font="3">response during exercise in </text>
<text top="329" left="281" width="34" height="19" font="3">HCM </text>
<text top="347" left="281" width="3" height="19" font="3"> </text>
<text top="366" left="281" width="121" height="19" font="4"><b>Size:</b>   161 patients  </text>
<text top="256" left="464" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="274" left="464" width="147" height="19" font="3">Patients with HCM who </text>
<text top="292" left="464" width="124" height="19" font="3">underwent exercise </text>
<text top="311" left="464" width="45" height="19" font="3">testing </text>
<text top="329" left="464" width="3" height="19" font="3"> </text>
<text top="347" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="366" left="464" width="104" height="19" font="3">Inadequate data </text>
<text top="257" left="628" width="145" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Mortality </text>
<text top="275" left="628" width="3" height="19" font="3"> </text>
<text top="293" left="628" width="130" height="19" font="4"><b>Results:</b>  37% had an </text>
<text top="312" left="628" width="144" height="19" font="3">abnormal BP response. </text>
<text top="330" left="628" width="173" height="19" font="3">During 44±22 mo follow up, </text>
<text top="348" left="628" width="175" height="19" font="3">SCD occurred in 12 patients: </text>
<text top="367" left="628" width="168" height="19" font="3">3% in normal BP group and </text>
<text top="385" left="628" width="125" height="19" font="3">15% in abnormal BP </text>
<text top="403" left="628" width="102" height="19" font="3">response group. </text>
<text top="256" left="820" width="193" height="19" font="3">● A normal BP response during </text>
<text top="274" left="820" width="204" height="19" font="3">exercise identifies low risk young </text>
<text top="292" left="820" width="121" height="19" font="3">patients with HCM. </text>
<text top="311" left="820" width="216" height="19" font="3">● An abnormal response had a low </text>
<text top="329" left="820" width="227" height="19" font="3">(15%) positive predictive value and a </text>
<text top="347" left="820" width="172" height="19" font="3">high (97%) predictive value. </text>
<text top="366" left="820" width="3" height="19" font="3"> </text>
<text top="422" left="125" width="125" height="19" font="3">● Sorajja et al. 2006 </text>
<text top="441" left="125" width="35" height="19" font="3">(265) </text>
<text top="459" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16762758">● </a></text>
<text top="459" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16762758">16762758</a></text>
<text top="459" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16762758"> </a></text>
<text top="477" left="125" width="3" height="19" font="3"> </text>
<text top="495" left="125" width="3" height="19" font="4"><b> </b></text>
<text top="422" left="281" width="160" height="19" font="4"><b>Study type:</b> Single center, </text>
<text top="441" left="281" width="164" height="19" font="3">retrospective, longitudinal </text>
<text top="459" left="281" width="66" height="19" font="3">data base. </text>
<text top="477" left="281" width="3" height="19" font="3"> </text>
<text top="496" left="281" width="140" height="19" font="3">Clinical implications of </text>
<text top="514" left="281" width="146" height="19" font="3">massive hypertrophy in </text>
<text top="532" left="281" width="34" height="19" font="3">HCM<b> </b></text>
<text top="550" left="281" width="3" height="19" font="3"> </text>
<text top="569" left="281" width="115" height="19" font="4"><b>Size:</b>  107 patients </text>
<text top="422" left="464" width="145" height="19" font="4"><b>Inclusion criteria: </b>HCM </text>
<text top="441" left="464" width="141" height="19" font="3">patients with LVH ≥ 30 </text>
<text top="459" left="464" width="27" height="19" font="3">mm </text>
<text top="477" left="464" width="3" height="19" font="3"> </text>
<text top="495" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="514" left="464" width="103" height="19" font="3">inadequate data </text>
<text top="423" left="628" width="136" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Survival </text>
<text top="441" left="628" width="3" height="19" font="3"> </text>
<text top="460" left="628" width="144" height="19" font="4"><b>Results:</b>  10-y outcome </text>
<text top="478" left="628" width="169" height="19" font="3">assessed. Survival less than </text>
<text top="496" left="628" width="169" height="19" font="3">general population (77% vs </text>
<text top="515" left="628" width="156" height="19" font="3">95%, p&lt;0.001). SCD most </text>
<text top="533" left="628" width="171" height="19" font="3">common cause of mortality </text>
<text top="551" left="628" width="171" height="19" font="3">in younger patients (overall </text>
<text top="570" left="628" width="84" height="19" font="3">survival 80%) </text>
<text top="422" left="820" width="235" height="19" font="3">● Patients with HCM and massive LVH </text>
<text top="441" left="820" width="235" height="19" font="3">are at increased risk of SCD, especially </text>
<text top="459" left="820" width="83" height="19" font="3">in the young. </text>
<text top="477" left="820" width="3" height="19" font="3"> </text>
<text top="589" left="125" width="113" height="19" font="3">● Maki et al. 1998 </text>
<text top="607" left="125" width="35" height="19" font="3">(266) </text>
<text top="625" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9761089">● </a></text>
<text top="625" left="137" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9761089">9761089</a></text>
<text top="625" left="190" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9761089"> </a></text>
<text top="643" left="125" width="3" height="19" font="3"> </text>
<text top="588" left="281" width="159" height="19" font="4"><b>Study type:</b> single center, </text>
<text top="607" left="281" width="151" height="19" font="3">retrospective, data base </text>
<text top="625" left="281" width="51" height="19" font="3">analysis </text>
<text top="643" left="281" width="157" height="19" font="3">Hemodynamic predictors </text>
<text top="662" left="281" width="92" height="19" font="3">of SCD in HCM </text>
<text top="680" left="281" width="3" height="19" font="4"><b> </b></text>
<text top="698" left="281" width="115" height="19" font="4"><b>Size:</b>  309 patients<b> </b></text>
<text top="588" left="464" width="115" height="19" font="4"><b>Inclusion criteria: </b> </text>
<text top="607" left="464" width="117" height="19" font="3">Patients with HCM </text>
<text top="625" left="464" width="3" height="19" font="3"> </text>
<text top="643" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="662" left="464" width="104" height="19" font="3">Inadequate data<b> </b></text>
<text top="589" left="628" width="112" height="19" font="4"><b>1</b>°<b> endpoint:</b>  SCD </text>
<text top="608" left="628" width="3" height="19" font="3"> </text>
<text top="626" left="628" width="179" height="19" font="4"><b>Results:</b>  Mean follow-up 9.4 </text>
<text top="644" left="628" width="164" height="19" font="3">y; SCD in 9%. Independent </text>
<text top="663" left="628" width="154" height="19" font="3">predictors of SCD were a </text>
<text top="681" left="628" width="171" height="19" font="3">smaller difference between </text>
<text top="699" left="628" width="155" height="19" font="3">peak and rest SBP during </text>
<text top="718" left="628" width="145" height="19" font="3">exercise (p=0.006), and </text>
<text top="736" left="628" width="143" height="19" font="3">higher LV outflow tract </text>
<text top="754" left="628" width="153" height="19" font="3">pressure gradient at rest </text>
<text top="773" left="628" width="167" height="19" font="3">(p=0.003). Exercise-related </text>
<text top="589" left="820" width="225" height="19" font="3">● Patients with exercise-related SCD </text>
<text top="607" left="820" width="189" height="19" font="3">were younger and had smaller </text>
<text top="625" left="820" width="201" height="19" font="3">increases in SBP during exercise. </text>
</page>
<page number="150" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">150 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="628" width="133" height="19" font="3">SCD in 8 patients and </text>
<text top="127" left="628" width="178" height="19" font="3">exercise-unrelated SCD in 20 </text>
<text top="145" left="628" width="174" height="19" font="3">patients (mean age 28 vs 47 </text>
<text top="164" left="628" width="68" height="19" font="3">y, p&lt;0.05).<b> </b></text>
<text top="183" left="125" width="119" height="19" font="3">● Elliott et al. 2006 </text>
<text top="201" left="125" width="35" height="19" font="3">(267) </text>
<text top="219" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16754630">● </a></text>
<text top="219" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16754630">16754630</a></text>
<text top="219" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16754630"> </a></text>
<text top="238" left="125" width="3" height="19" font="3"> </text>
<text top="183" left="281" width="160" height="19" font="4"><b>Study type:</b> Single center, </text>
<text top="201" left="281" width="151" height="19" font="3">retrospective, data base </text>
<text top="219" left="281" width="103" height="19" font="3">LV outflow track </text>
<text top="238" left="281" width="167" height="19" font="3">obstruction and SCD risk in </text>
<text top="256" left="281" width="34" height="19" font="3">HCM </text>
<text top="274" left="281" width="3" height="19" font="3"> </text>
<text top="292" left="281" width="115" height="19" font="4"><b>Size:</b>  917 patients<b> </b></text>
<text top="183" left="464" width="145" height="19" font="4"><b>Inclusion criteria: </b>HCM </text>
<text top="201" left="464" width="102" height="19" font="3">patients with LV </text>
<text top="219" left="464" width="138" height="19" font="3">outflow tract gradient </text>
<text top="238" left="464" width="64" height="19" font="3">measured </text>
<text top="256" left="464" width="3" height="19" font="3"> </text>
<text top="274" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="292" left="464" width="103" height="19" font="3">inadequate data<b> </b></text>
<text top="183" left="628" width="112" height="19" font="4"><b>1</b>°<b> endpoint:</b>  SCD </text>
<text top="202" left="628" width="3" height="19" font="3"> </text>
<text top="220" left="628" width="138" height="19" font="4"><b>Results:</b> 31.4% had LV </text>
<text top="238" left="628" width="167" height="19" font="3">outflow tract gradient ≥ 30 </text>
<text top="257" left="628" width="169" height="19" font="3">mmHg, followed median of </text>
<text top="275" left="628" width="175" height="19" font="3">61 mo, 5.9% had SCD, VF, or </text>
<text top="293" left="628" width="160" height="19" font="3">appropriate ICD shock. LV </text>
<text top="312" left="628" width="164" height="19" font="3">outflow tract gradient ≥30 </text>
<text top="330" left="628" width="142" height="19" font="3">mmHg associated with </text>
<text top="348" left="628" width="165" height="19" font="3">reduced survival free from </text>
<text top="367" left="628" width="178" height="19" font="3">SCD and ICD shock (91.4% vs </text>
<text top="385" left="628" width="102" height="19" font="3">95.7%. p=0.004)<b> </b></text>
<text top="183" left="820" width="241" height="19" font="3">● LV outflow tract gradient ≥ 30 mmHg </text>
<text top="201" left="820" width="228" height="19" font="3">was an independent risk modifier for </text>
<text top="219" left="820" width="184" height="19" font="3">SCD/ICD shock with a 2.4-fold </text>
<text top="238" left="820" width="195" height="19" font="3">(p=0.003) increase in the risk of </text>
<text top="256" left="820" width="244" height="19" font="3">SCD/ICD shock that is increased if other </text>
<text top="274" left="820" width="163" height="19" font="3">risk modifiers are present. </text>
<text top="292" left="820" width="3" height="19" font="3"> </text>
<text top="311" left="820" width="219" height="19" font="3">● Risk of SCD/ICD shock low (0.37% </text>
<text top="329" left="820" width="232" height="19" font="3">annual risk) if the only risk modifier is </text>
<text top="347" left="820" width="236" height="19" font="3">an increased LV outflow tract gradient </text>
<text top="404" left="125" width="114" height="19" font="3">● Monserrat et al. </text>
<text top="422" left="125" width="69" height="19" font="3">2003 (268) </text>
<text top="441" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=12957435">● </a></text>
<text top="441" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=12957435">12957435</a></text>
<text top="441" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=12957435"> </a></text>
<text top="459" left="125" width="3" height="19" font="3"> </text>
<text top="477" left="125" width="3" height="19" font="3"> </text>
<text top="404" left="281" width="169" height="19" font="4"><b>Study type:</b>  Retrospective, </text>
<text top="422" left="281" width="85" height="19" font="3">single center, </text>
<text top="441" left="281" width="90" height="19" font="3">observational  </text>
<text top="459" left="281" width="150" height="19" font="3">NSVT and risk for SCD in </text>
<text top="477" left="281" width="128" height="19" font="3">young HCM patients<b> </b></text>
<text top="496" left="281" width="3" height="19" font="3"> </text>
<text top="514" left="281" width="111" height="19" font="4"><b>Size:</b> 531 patients </text>
<text top="404" left="464" width="145" height="19" font="4"><b>Inclusion criteria:</b> HCM </text>
<text top="422" left="464" width="147" height="19" font="3">with Holter monitoring  </text>
<text top="441" left="464" width="3" height="19" font="3"> </text>
<text top="459" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="477" left="464" width="104" height="19" font="3">Inadequate data </text>
<text top="405" left="628" width="134" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Sudden </text>
<text top="423" left="628" width="86" height="19" font="3">cardiac death </text>
<text top="441" left="628" width="3" height="19" font="3"> </text>
<text top="460" left="628" width="159" height="19" font="4"><b>Results:</b> 19.6% had NSVT. </text>
<text top="478" left="628" width="168" height="19" font="3">Mean follow up 70±40 mo. </text>
<text top="496" left="628" width="176" height="19" font="3">32 died from SCD, 21 had an </text>
<text top="515" left="628" width="109" height="19" font="3">ICD placed with 4 </text>
<text top="533" left="628" width="174" height="19" font="3">appropriate shocks.  The OR </text>
<text top="551" left="628" width="137" height="19" font="3">of SCD in HCM 30 y or </text>
<text top="570" left="628" width="164" height="19" font="3">younger was 4.35 (95% CI: </text>
<text top="588" left="628" width="137" height="19" font="3">1.54–12.28; p=0.006); </text>
<text top="606" left="628" width="179" height="19" font="3">compared with 2.16 (95% CI: </text>
<text top="624" left="628" width="178" height="19" font="3">0.82–5.96; p=0.1) in patients </text>
<text top="643" left="628" width="99" height="19" font="3">older than 30 y. </text>
<text top="404" left="820" width="180" height="20" font="3">• NSVT was associates with a </text>
<text top="423" left="820" width="215" height="19" font="3">substantial increased risk of SCD in </text>
<text top="441" left="820" width="161" height="19" font="3">young patients with HCM  </text>
<text top="460" left="820" width="224" height="20" font="3">• No relationship between duration, </text>
<text top="479" left="820" width="228" height="19" font="3">frequency and rate of NSVT runs and </text>
<text top="497" left="820" width="99" height="19" font="3">adverse events. </text>
<text top="515" left="820" width="3" height="19" font="3"> </text>
<text top="662" left="125" width="123" height="19" font="3">● Spirito et al.<b> </b>2000 </text>
<text top="680" left="125" width="35" height="19" font="3">(269) </text>
<text top="698" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=10853000">● </a></text>
<text top="698" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=10853000">10853000</a></text>
<text top="698" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=10853000"> </a></text>
<text top="717" left="125" width="3" height="19" font="3"> </text>
<text top="735" left="125" width="3" height="19" font="3"> </text>
<text top="662" left="281" width="169" height="19" font="4"><b>Study type:</b>  Retrospective, </text>
<text top="680" left="281" width="85" height="19" font="3">single center, </text>
<text top="698" left="281" width="90" height="19" font="3">observational  </text>
<text top="717" left="281" width="137" height="19" font="3">LVH and risk of SCD in </text>
<text top="735" left="281" width="37" height="19" font="3">HCM  </text>
<text top="753" left="281" width="3" height="19" font="3"> </text>
<text top="772" left="281" width="121" height="19" font="4"><b>Size:</b>    480 patients<b> </b></text>
<text top="662" left="464" width="148" height="19" font="4"><b>Inclusion criteria:</b>  HCM </text>
<text top="680" left="464" width="53" height="19" font="3">patients </text>
<text top="698" left="464" width="3" height="19" font="3"> </text>
<text top="717" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="735" left="464" width="104" height="19" font="3">Inadequate data<b> </b></text>
<text top="662" left="628" width="109" height="19" font="4"><b>1</b>°<b> endpoint:</b> SCD </text>
<text top="681" left="628" width="3" height="19" font="3"> </text>
<text top="699" left="628" width="170" height="19" font="4"><b>Results:</b>  23 patients (4.8%) </text>
<text top="718" left="628" width="174" height="19" font="3">had SCD with a mean follow </text>
<text top="736" left="628" width="165" height="19" font="3">up of 6.5 y. The risk of SCD </text>
<text top="754" left="628" width="121" height="19" font="3">increased with wall </text>
<text top="773" left="628" width="174" height="19" font="3">thickness: 0 per 1,000 pt y if </text>
<text top="662" left="820" width="205" height="19" font="3">● The cumulative risk of SCD was </text>
<text top="680" left="820" width="234" height="19" font="3">nearly 0 for a wall thickness of 19 mm </text>
<text top="698" left="820" width="243" height="19" font="3">or less; and was 40% The sudden death </text>
<text top="717" left="820" width="218" height="19" font="3">risk in HCM was increased for a left </text>
<text top="735" left="820" width="236" height="19" font="3">ventricular wall thickness of 30 mm or </text>
<text top="753" left="820" width="40" height="19" font="3">more. </text>
<text top="772" left="820" width="3" height="19" font="3"> </text>
</page>
<page number="151" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">151 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="628" width="162" height="19" font="3">15 mm or less, to 18.2 per </text>
<text top="127" left="628" width="174" height="19" font="3">1,000 pt y if 30 mm or more </text>
<text top="145" left="628" width="118" height="19" font="3">(95% CI: 7.3–37.6). </text>
<text top="164" left="125" width="119" height="19" font="3">● Elliott et al.<b> </b>2001 </text>
<text top="183" left="125" width="35" height="19" font="3">(270) </text>
<text top="201" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=11273061">● </a></text>
<text top="201" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=11273061">11273061</a></text>
<text top="201" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=11273061"> </a></text>
<text top="219" left="125" width="3" height="19" font="3"> </text>
<text top="238" left="125" width="3" height="19" font="3"> </text>
<text top="164" left="281" width="169" height="19" font="4"><b>Study type:</b>  Retrospective, </text>
<text top="183" left="281" width="85" height="19" font="3">single center, </text>
<text top="201" left="281" width="90" height="19" font="3">observational  </text>
<text top="219" left="281" width="150" height="19" font="3">Severe hypertrophy and </text>
<text top="238" left="281" width="76" height="19" font="3">SCD in HCM<b> </b></text>
<text top="256" left="281" width="3" height="19" font="3"> </text>
<text top="274" left="281" width="121" height="19" font="4"><b>Size:</b>   630 patients <b> </b></text>
<text top="164" left="464" width="148" height="19" font="4"><b>Inclusion criteria:</b>  HCM </text>
<text top="183" left="464" width="53" height="19" font="3">patients </text>
<text top="201" left="464" width="3" height="19" font="3"> </text>
<text top="219" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="238" left="464" width="104" height="19" font="3">Inadequate data<b> </b></text>
<text top="165" left="628" width="134" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Sudden </text>
<text top="183" left="628" width="86" height="19" font="3">cardiac death </text>
<text top="202" left="628" width="3" height="19" font="3"> </text>
<text top="220" left="628" width="170" height="19" font="4"><b>Results:</b>  39 patients (6.2%) </text>
<text top="238" left="628" width="170" height="19" font="3">had SCD or appropriate ICD </text>
<text top="257" left="628" width="126" height="19" font="3">shock; 10 had a wall </text>
<text top="275" left="628" width="178" height="19" font="3">thickness of 30 mm or more. </text>
<text top="293" left="628" width="169" height="19" font="3">Wall thickness of 30 mm or </text>
<text top="312" left="628" width="115" height="19" font="3">more had a higher </text>
<text top="330" left="628" width="171" height="19" font="3">probability of SCD or shock: </text>
<text top="348" left="628" width="171" height="19" font="3">(RR: 2.07; 95% CI: 1.0–4.25; </text>
<text top="367" left="628" width="58" height="19" font="3">p=0.049) </text>
<text top="164" left="820" width="230" height="19" font="3">● A wall thickness in HCM of 30+ mm </text>
<text top="183" left="820" width="157" height="19" font="3">was associated with SCD. </text>
<text top="201" left="820" width="245" height="19" font="3">● Most sudden deaths occur in patients </text>
<text top="219" left="820" width="245" height="19" font="3">with a thickness less than 30 mm so the </text>
<text top="238" left="820" width="195" height="19" font="3">presence of other risk factors is </text>
<text top="256" left="820" width="65" height="19" font="3">important </text>
<text top="274" left="820" width="3" height="19" font="3"> </text>
<text top="386" left="125" width="119" height="19" font="3">● Elliott et al.<b> </b>2000 </text>
<text top="404" left="125" width="35" height="19" font="3">(271) </text>
<text top="422" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=11127463">● </a></text>
<text top="422" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=11127463">11127463</a></text>
<text top="422" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=11127463"> </a></text>
<text top="441" left="125" width="3" height="19" font="3"> </text>
<text top="459" left="125" width="3" height="19" font="3"> </text>
<text top="386" left="281" width="169" height="19" font="4"><b>Study type:</b>  Retrospective, </text>
<text top="404" left="281" width="85" height="19" font="3">single center, </text>
<text top="422" left="281" width="90" height="19" font="3">observational  </text>
<text top="441" left="281" width="170" height="19" font="3">Risk factors for SCD in HCM<b> </b></text>
<text top="459" left="281" width="3" height="19" font="3"> </text>
<text top="477" left="281" width="121" height="19" font="4"><b>Size:</b>    368 patients<b> </b></text>
<text top="386" left="464" width="148" height="19" font="4"><b>Inclusion criteria:</b>  HCM </text>
<text top="404" left="464" width="53" height="19" font="3">patients </text>
<text top="422" left="464" width="3" height="19" font="3"> </text>
<text top="441" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="459" left="464" width="104" height="19" font="3">Inadequate data<b> </b></text>
<text top="386" left="628" width="134" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Sudden </text>
<text top="405" left="628" width="86" height="19" font="3">cardiac death </text>
<text top="423" left="628" width="3" height="19" font="3"> </text>
<text top="441" left="628" width="181" height="19" font="4"><b>Results:</b> Follow up 3.6±2.5 y.  </text>
<text top="460" left="628" width="159" height="19" font="3">The SCD free survival was </text>
<text top="478" left="628" width="174" height="19" font="3">95% with 0 risk factors, 93% </text>
<text top="496" left="628" width="178" height="19" font="3">for 1, 82% for 2, and 36% for </text>
<text top="515" left="628" width="154" height="19" font="3">3. Six y SCD risk was 72% </text>
<text top="533" left="628" width="160" height="19" font="3">(95% CI: 56%–88%) for 2+ </text>
<text top="551" left="628" width="160" height="19" font="3">risk factors and 94% (95% </text>
<text top="570" left="628" width="150" height="19" font="3">CI: 91%–98%) for 1 or 0. </text>
<text top="386" left="820" width="221" height="19" font="3">● Risk factors for SCD include NSVT, </text>
<text top="404" left="820" width="233" height="19" font="3">syncope, exercise BP response, family </text>
<text top="422" left="820" width="188" height="19" font="3">Hx of SCD, left ventricular wall </text>
<text top="441" left="820" width="60" height="19" font="3">thickness </text>
<text top="459" left="820" width="238" height="19" font="3">● 2 or more risk factors had a high risk </text>
<text top="477" left="820" width="49" height="19" font="3">for SCD </text>
<text top="496" left="820" width="3" height="19" font="3"> </text>
<text top="589" left="125" width="111" height="19" font="3">● Ackerman et al.<b> </b></text>
<text top="607" left="125" width="69" height="19" font="3">2002 (272) </text>
<text top="625" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12084606">● </a></text>
<text top="625" left="137" width="64" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12084606">12084606 </a></text>
<text top="643" left="125" width="3" height="19" font="6"> </text>
<text top="662" left="125" width="3" height="19" font="3"> </text>
<text top="588" left="281" width="125" height="19" font="4"><b>Study type:</b> Genetic </text>
<text top="607" left="281" width="162" height="19" font="3">analysis in unrelated HCM </text>
<text top="625" left="281" width="60" height="19" font="3">patients   </text>
<text top="643" left="281" width="146" height="19" font="3">Malignant mutations in </text>
<text top="662" left="281" width="34" height="19" font="3">HCM<b> </b></text>
<text top="680" left="281" width="3" height="19" font="3"> </text>
<text top="698" left="281" width="115" height="19" font="4"><b>Size:</b>  293 patients<b> </b></text>
<text top="588" left="464" width="148" height="19" font="4"><b>Inclusion criteria:</b>  HCM </text>
<text top="607" left="464" width="140" height="19" font="3">patients consenting to </text>
<text top="625" left="464" width="99" height="19" font="3">genetic analysis </text>
<text top="643" left="464" width="3" height="19" font="3"> </text>
<text top="662" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="680" left="464" width="104" height="19" font="3">Inadequate data<b> </b></text>
<text top="589" left="628" width="135" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Genetic </text>
<text top="608" left="628" width="87" height="19" font="3">abnormalities </text>
<text top="626" left="628" width="3" height="19" font="3"> </text>
<text top="644" left="628" width="145" height="19" font="4"><b>Results:</b>  4 beta myosin </text>
<text top="663" left="628" width="129" height="19" font="3">heavy chain and one </text>
<text top="681" left="628" width="160" height="19" font="3">troponin T gene mutation </text>
<text top="699" left="628" width="137" height="19" font="3">assessed. 3 of the 293 </text>
<text top="718" left="628" width="157" height="19" font="3">patients had one of the 5 </text>
<text top="736" left="628" width="160" height="19" font="3">mutations and all 3 &lt;25 y. </text>
<text top="589" left="820" width="229" height="19" font="3">● There is profound heterogeneity in </text>
<text top="607" left="820" width="34" height="19" font="3">HCM </text>
<text top="625" left="820" width="236" height="19" font="3">● Only1% of unrelated individuals had </text>
<text top="643" left="820" width="224" height="19" font="3">one of the 5 “malignant” mutations. </text>
<text top="755" left="125" width="119" height="19" font="3">● Lopes et al. 2013 </text>
<text top="773" left="125" width="35" height="19" font="3">(273) </text>
<text top="755" left="281" width="298" height="19" font="4"><b>Study type:</b> Meta-analysis    <b>Inclusion criteria:</b>  </text>
<text top="773" left="464" width="115" height="19" font="3">Studies evaluating </text>
<text top="756" left="628" width="132" height="19" font="4"><b>1</b>°<b> endpoint:</b> Genetic </text>
<text top="774" left="628" width="63" height="19" font="3">mutation  </text>
<text top="755" left="820" width="217" height="19" font="3">● HCM is a heterogeneous disease. </text>
</page>
<page number="152" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">152 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23674365">● </a></text>
<text top="109" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23674365">23674365</a></text>
<text top="109" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23674365"> </a></text>
<text top="127" left="125" width="3" height="19" font="3"> </text>
<text top="145" left="125" width="3" height="19" font="3"> </text>
<text top="109" left="281" width="152" height="19" font="3">Meta-analysis of genetic </text>
<text top="127" left="281" width="114" height="19" font="3">mutations in HCM<b> </b></text>
<text top="145" left="281" width="3" height="19" font="3"> </text>
<text top="164" left="281" width="135" height="19" font="4"><b>Size:</b>  18 publications, </text>
<text top="182" left="281" width="91" height="19" font="3">2,459 patients<b> </b></text>
<text top="109" left="464" width="128" height="19" font="3">genetic mutations in </text>
<text top="127" left="464" width="34" height="19" font="3">HCM </text>
<text top="145" left="464" width="3" height="19" font="3"> </text>
<text top="164" left="464" width="149" height="19" font="4"><b>Exclusion criteria:</b>  Poor </text>
<text top="182" left="464" width="80" height="19" font="3">study design<b> </b></text>
<text top="109" left="628" width="3" height="19" font="3"> </text>
<text top="127" left="628" width="158" height="19" font="4"><b>Results:</b>  Sarcomere gene </text>
<text top="145" left="628" width="158" height="19" font="3">mutation associated with </text>
<text top="164" left="628" width="152" height="19" font="3">younger age (p&lt;0.0005), </text>
<text top="182" left="628" width="109" height="19" font="3">family Hx of HCM </text>
<text top="200" left="628" width="177" height="19" font="3">(p&lt;0.0005), family Hx of SCD </text>
<text top="219" left="628" width="172" height="19" font="3">(p&lt;0.0005) and greater wall </text>
<text top="237" left="628" width="118" height="19" font="3">thickness (p=0.03). </text>
<text top="109" left="820" width="191" height="19" font="3">● The establishment of precise </text>
<text top="127" left="820" width="213" height="19" font="3">genotype-phenotype relationships </text>
<text top="145" left="820" width="153" height="19" font="3">could not be established </text>
<text top="164" left="820" width="3" height="19" font="3"> </text>
<text top="256" left="125" width="141" height="19" font="3">● Bos et al. 2010 (274) </text>
<text top="274" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21059440">● </a></text>
<text top="274" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21059440">21059440</a></text>
<text top="274" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21059440"> </a></text>
<text top="292" left="125" width="3" height="19" font="3"> </text>
<text top="311" left="125" width="3" height="19" font="3"> </text>
<text top="256" left="281" width="157" height="19" font="4"><b>Study type:</b>  Multicenter, </text>
<text top="274" left="281" width="133" height="19" font="3">consecutive patients, </text>
<text top="292" left="281" width="141" height="19" font="3">prospective data base, </text>
<text top="311" left="281" width="90" height="19" font="3">observational  </text>
<text top="329" left="281" width="164" height="19" font="3">Family Hx and SCD in HCM<b> </b></text>
<text top="347" left="281" width="3" height="19" font="3"> </text>
<text top="366" left="281" width="118" height="19" font="4"><b>Size:</b>  177 patients <b> </b></text>
<text top="256" left="464" width="148" height="19" font="4"><b>Inclusion criteria:</b>  HCM </text>
<text top="274" left="464" width="110" height="19" font="3">patients with and </text>
<text top="292" left="464" width="138" height="19" font="3">without a family Hx of </text>
<text top="311" left="464" width="50" height="19" font="3">SCD in 1</text>
<text top="311" left="514" width="7" height="12" font="15">st</text>
<text top="311" left="521" width="49" height="19" font="3"> degree </text>
<text top="329" left="464" width="141" height="19" font="3">relatives who received </text>
<text top="347" left="464" width="47" height="19" font="3">an ICD. </text>
<text top="366" left="464" width="3" height="19" font="3"> </text>
<text top="384" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="402" left="464" width="104" height="19" font="3">Inadequate data<b> </b></text>
<text top="257" left="628" width="129" height="19" font="4"><b>1</b>°<b> endpoint:</b>  SCD or </text>
<text top="275" left="628" width="162" height="19" font="3">appropriate ICD discharge </text>
<text top="293" left="628" width="3" height="19" font="3"> </text>
<text top="311" left="628" width="168" height="19" font="4"><b>Results:</b>  4.6±3 y follow up, </text>
<text top="330" left="628" width="155" height="19" font="3">25 patients (14%) had an </text>
<text top="348" left="628" width="158" height="19" font="3">appropriate ICD therapy.  </text>
<text top="367" left="628" width="170" height="19" font="3">Patients with a family Hx of </text>
<text top="385" left="628" width="172" height="19" font="3">SCD experience ICDs shocks </text>
<text top="403" left="628" width="171" height="19" font="3">at a rate (3.7/100 person-y) </text>
<text top="422" left="628" width="144" height="19" font="3">similar to patients with </text>
<text top="440" left="628" width="163" height="19" font="3">other risk factors (3.1/100 </text>
<text top="458" left="628" width="35" height="19" font="3">pt y). </text>
<text top="256" left="820" width="189" height="19" font="3">●  Patients receiving ICD for 1° </text>
<text top="274" left="820" width="226" height="19" font="3">prevention because of a family Hx of </text>
<text top="292" left="820" width="233" height="19" font="3">SCD whether as an isolated risk factor </text>
<text top="311" left="820" width="205" height="19" font="3">or combined with other markers, </text>
<text top="329" left="820" width="221" height="19" font="3">experience rates of appropriate ICD </text>
<text top="347" left="820" width="235" height="19" font="3">discharge comparable to that of other </text>
<text top="366" left="820" width="74" height="19" font="3">risk factors. </text>
<text top="384" left="820" width="3" height="19" font="3"> </text>
<text top="477" left="125" width="123" height="19" font="3">● Spirito et al. 2009 </text>
<text top="496" left="125" width="35" height="19" font="3">(275) </text>
<text top="514" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19307481">● </a></text>
<text top="514" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19307481">19307481</a></text>
<text top="514" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19307481"> </a></text>
<text top="532" left="125" width="3" height="19" font="3"> </text>
<text top="550" left="125" width="3" height="19" font="3"> </text>
<text top="477" left="281" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="496" left="281" width="167" height="19" font="3">Observational, prospective </text>
<text top="514" left="281" width="98" height="19" font="3">data base entry </text>
<text top="532" left="281" width="164" height="19" font="3">Syncope and risk of SCD in </text>
<text top="550" left="281" width="34" height="19" font="3">HCM<b> </b></text>
<text top="569" left="281" width="3" height="19" font="3"> </text>
<text top="587" left="281" width="133" height="19" font="4"><b>Size:</b>   1,511 patients <b> </b></text>
<text top="477" left="464" width="148" height="19" font="4"><b>Inclusion criteria:</b>  HCM </text>
<text top="496" left="464" width="53" height="19" font="3">patients </text>
<text top="514" left="464" width="3" height="19" font="3"> </text>
<text top="532" left="464" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="550" left="464" width="107" height="19" font="3">Inadequate data <b> </b></text>
<text top="478" left="628" width="164" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Relationship </text>
<text top="496" left="628" width="165" height="19" font="3">between syncope and SCD </text>
<text top="515" left="628" width="3" height="19" font="3"> </text>
<text top="533" left="628" width="173" height="19" font="4"><b>Results:</b>  205 patients (14%) </text>
<text top="551" left="628" width="175" height="19" font="3">had unexplained or neurally-</text>
<text top="570" left="628" width="171" height="19" font="3">mediated syncope.  5.6±5.2 </text>
<text top="588" left="628" width="146" height="19" font="3">y follow up, 74 patients </text>
<text top="606" left="628" width="177" height="19" font="3">(4.9%) had SCD. Relative risk </text>
<text top="624" left="628" width="153" height="19" font="3">of SCD was 1.78 (95% CI: </text>
<text top="643" left="628" width="132" height="19" font="3">0.88–3.51; p=0.08) in </text>
<text top="661" left="628" width="158" height="19" font="3">unexplained syncope and </text>
<text top="680" left="628" width="147" height="19" font="3">0.91 (95% CI: 0.0– 3.83; </text>
<text top="698" left="628" width="172" height="19" font="3">p=1.0) in neurally-mediated </text>
<text top="716" left="628" width="57" height="19" font="3">syncope. </text>
<text top="477" left="820" width="209" height="19" font="3">● Unexplained syncope was a risk </text>
<text top="496" left="820" width="137" height="19" font="3">factor for SCD in HCM </text>
<text top="514" left="820" width="189" height="19" font="3">●  Patients ≤40 y with syncope </text>
<text top="532" left="820" width="224" height="19" font="3">occurring &gt;5 y before evaluation did </text>
<text top="550" left="820" width="213" height="19" font="3">not show an increased risk of SCD. </text>
<text top="569" left="820" width="233" height="19" font="3">● Neurally mediated syncope was not </text>
<text top="587" left="820" width="108" height="19" font="3">predictive of SCD </text>
<text top="605" left="820" width="3" height="19" font="3"> </text>
<text top="735" left="125" width="124" height="19" font="3">● Maron et al. 2009 </text>
<text top="753" left="125" width="35" height="19" font="3">(276) </text>
<text top="772" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19221222">● </a></text>
<text top="772" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19221222">19221222</a></text>
<text top="772" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19221222"> </a></text>
<text top="735" left="281" width="169" height="19" font="4"><b>Study type:</b>  Retrospective, </text>
<text top="753" left="281" width="80" height="19" font="3">registry data </text>
<text top="735" left="464" width="107" height="19" font="4"><b>Inclusion criteria </b></text>
<text top="753" left="464" width="114" height="19" font="3">Athletes who died </text>
<text top="772" left="464" width="58" height="19" font="3">suddenly </text>
<text top="736" left="628" width="166" height="19" font="4"><b>1</b>°<b> endpoint:</b>  cause of SCD </text>
<text top="754" left="628" width="3" height="19" font="3"> </text>
<text top="735" left="820" width="225" height="19" font="3">● Athletes confined to United States </text>
<text top="753" left="820" width="237" height="19" font="3">● CVD was found in 54% of the deaths </text>
</page>
<page number="153" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">153 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="3" height="19" font="3"> </text>
<text top="109" left="281" width="150" height="19" font="3">Sudden deaths in young </text>
<text top="127" left="281" width="133" height="19" font="3">competitive athletes.<b> </b></text>
<text top="145" left="281" width="3" height="19" font="3"> </text>
<text top="164" left="281" width="126" height="19" font="4"><b>Size:</b>  1,866 patients<b> </b></text>
<text top="109" left="464" width="3" height="19" font="3"> </text>
<text top="127" left="464" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="145" left="464" width="103" height="19" font="3">inadequate data<b> </b></text>
<text top="109" left="628" width="168" height="19" font="4"><b>Results:</b>  Average age 19±6 </text>
<text top="127" left="628" width="135" height="19" font="3">y.  The most common </text>
<text top="145" left="628" width="156" height="19" font="3">cardiovascular cause was </text>
<text top="164" left="628" width="75" height="19" font="3">HCM (36%) <b> </b></text>
<text top="109" left="820" width="234" height="19" font="3">● HCM was the most common finding </text>
<text top="127" left="820" width="244" height="19" font="3">in young athletes experiencing SCD due </text>
<text top="145" left="820" width="116" height="19" font="3">to a cardiac cause. </text>
<text top="183" left="125" width="112" height="19" font="3">● Kuck et al. 1988 </text>
<text top="201" left="125" width="35" height="19" font="3">(277) </text>
<text top="219" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3280318">● </a></text>
<text top="219" left="137" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3280318">3280318</a></text>
<text top="219" left="190" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3280318"> </a></text>
<text top="237" left="125" width="3" height="19" font="4"><b> </b></text>
<text top="183" left="281" width="168" height="19" font="4"><b>Study type:</b>  observational, </text>
<text top="201" left="281" width="161" height="19" font="3">single center, consecutive </text>
<text top="219" left="281" width="121" height="19" font="3">Role of PVS in HCM </text>
<text top="238" left="281" width="3" height="19" font="3"> </text>
<text top="256" left="281" width="103" height="19" font="4"><b>Size</b>: 54 patients<b> </b></text>
<text top="183" left="464" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="201" left="464" width="109" height="19" font="3">symptomatic and </text>
<text top="219" left="464" width="143" height="19" font="3">asymptomatic patients </text>
<text top="238" left="464" width="64" height="19" font="3">with HCM </text>
<text top="256" left="464" width="3" height="19" font="3"> </text>
<text top="274" left="464" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="292" left="464" width="103" height="19" font="3">inadequate data<b> </b></text>
<text top="183" left="628" width="175" height="19" font="4"><b>1</b>°<b> endpoint:</b>  results of PVS  </text>
<text top="202" left="628" width="3" height="19" font="3"> </text>
<text top="220" left="628" width="176" height="19" font="4"><b>Results</b> 11 symptomatic and </text>
<text top="238" left="628" width="165" height="19" font="3">43 asymptomatic patients. </text>
<text top="257" left="628" width="166" height="19" font="3">33% of had inducible rabid </text>
<text top="275" left="628" width="106" height="19" font="3">monomorphic or </text>
<text top="293" left="628" width="126" height="19" font="3">polymorphic VT, VF.<b> </b></text>
<text top="183" left="820" width="204" height="19" font="3">● PVS induced VA in 33% of both </text>
<text top="201" left="820" width="233" height="19" font="3">symptomatic and asymptomatic HCM </text>
<text top="219" left="820" width="57" height="19" font="3">patients. </text>
<text top="238" left="820" width="3" height="19" font="3"> </text>
<text top="256" left="820" width="3" height="19" font="3"> </text>
<text top="312" left="125" width="141" height="19" font="3">● Zhu et al. 1998 (278) </text>
<text top="331" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9474693">● </a></text>
<text top="331" left="137" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9474693">9474693</a></text>
<text top="331" left="190" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9474693"> </a></text>
<text top="349" left="125" width="3" height="19" font="3"> </text>
<text top="312" left="281" width="168" height="19" font="4"><b>Study type:</b>  observational, </text>
<text top="331" left="281" width="161" height="19" font="3">single center, consecutive </text>
<text top="349" left="281" width="121" height="19" font="3">Role of PVS in HCM </text>
<text top="367" left="281" width="3" height="19" font="3"> </text>
<text top="386" left="281" width="103" height="19" font="4"><b>Size</b>: 53 patients<b> </b></text>
<text top="312" left="464" width="145" height="19" font="4"><b>Inclusion criteria: </b>HCM </text>
<text top="331" left="464" width="138" height="19" font="3">patients with no Hx of </text>
<text top="349" left="464" width="27" height="19" font="3">SCD </text>
<text top="367" left="464" width="3" height="19" font="3"> </text>
<text top="386" left="464" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="404" left="464" width="103" height="19" font="3">inadequate data<b> </b></text>
<text top="313" left="628" width="171" height="19" font="4"><b>1</b>°<b> endpoint:</b>  results of PVS </text>
<text top="332" left="628" width="151" height="19" font="3">and long term follow-up </text>
<text top="350" left="628" width="3" height="19" font="3"> </text>
<text top="368" left="628" width="115" height="19" font="4"><b>Results: </b>Sustained </text>
<text top="386" left="628" width="134" height="19" font="3">polymorphic VT or VF </text>
<text top="405" left="628" width="142" height="19" font="3">induced in 35%.  Mean </text>
<text top="423" left="628" width="149" height="19" font="3">follow-up 47±31 mo: no </text>
<text top="441" left="628" width="178" height="19" font="3">events (VT, VF, or ICD shock) </text>
<text top="460" left="628" width="128" height="19" font="3">in 34 patients with a </text>
<text top="478" left="628" width="174" height="19" font="3">negative PVS, 3 events in 19 </text>
<text top="496" left="628" width="165" height="19" font="3">patients with positive PVS.<b> </b></text>
<text top="312" left="820" width="155" height="19" font="3">● Sustained polymorphic </text>
<text top="331" left="820" width="235" height="19" font="3">VT/VFinducible in 1/3 of patients with </text>
<text top="349" left="820" width="245" height="19" font="3">HCM with a low subsequent event rate. </text>
<text top="367" left="820" width="3" height="19" font="3"> </text>
<text top="386" left="820" width="3" height="19" font="3"> </text>
<text top="515" left="125" width="116" height="19" font="3">● Christiaans et al. </text>
<text top="534" left="125" width="69" height="19" font="3">2010 (279) </text>
<text top="552" left="125" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20019025">● </a></text>
<text top="552" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20019025">20019025</a></text>
<text top="552" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20019025"> </a></text>
<text top="515" left="281" width="164" height="19" font="4"><b>Study type:</b> observational, </text>
<text top="534" left="281" width="165" height="19" font="3">single center, registry data </text>
<text top="552" left="281" width="99" height="19" font="3">The yield of risk </text>
<text top="570" left="281" width="144" height="19" font="3">stratification for SCD in </text>
<text top="589" left="281" width="142" height="19" font="3">HCM myosin-binding C </text>
<text top="607" left="281" width="146" height="19" font="3">gene mutation carriers; </text>
<text top="625" left="281" width="119" height="19" font="3">focus on predictive </text>
<text top="644" left="281" width="62" height="19" font="3">screening<b> </b></text>
<text top="662" left="281" width="3" height="19" font="3"> </text>
<text top="680" left="281" width="111" height="19" font="4"><b>Size:</b> 245 patients<b> </b></text>
<text top="515" left="464" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="534" left="464" width="141" height="19" font="3">Asymptomatic carriers </text>
<text top="552" left="464" width="122" height="19" font="3">of an MYBPC3 gene </text>
<text top="570" left="464" width="60" height="19" font="3">mutation </text>
<text top="589" left="464" width="3" height="19" font="3"> </text>
<text top="607" left="464" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="625" left="464" width="103" height="19" font="3">inadequate data<b> </b></text>
<text top="516" left="628" width="157" height="19" font="4"><b>1</b>°<b> endpoint:</b> diagnosis of </text>
<text top="534" left="628" width="159" height="19" font="3">HCM, long-term outcome </text>
<text top="553" left="628" width="3" height="19" font="3"> </text>
<text top="571" left="628" width="163" height="19" font="4"><b>Results:</b>  Clinical HCM was </text>
<text top="589" left="628" width="141" height="19" font="3">diagnosed in 53 of 235 </text>
<text top="608" left="628" width="166" height="19" font="3">mutation carriers (22.6%).  </text>
<text top="626" left="628" width="166" height="19" font="3">Women were affected less </text>
<text top="644" left="628" width="151" height="19" font="3">than men (15% and 32% </text>
<text top="663" left="628" width="153" height="19" font="3">respectively, p=0.003)25 </text>
<text top="681" left="628" width="161" height="19" font="3">carriers (11%) with one or </text>
<text top="699" left="628" width="155" height="19" font="3">more risk factors for SCD </text>
<text top="718" left="628" width="172" height="19" font="3">and manifest HCM could be </text>
<text top="736" left="628" width="93" height="19" font="3">at risk for SCD.<b> </b></text>
<text top="515" left="820" width="228" height="19" font="3">● At first cardiac evaluation 22.6% of </text>
<text top="534" left="820" width="240" height="19" font="3">asymptomatic carriers were diagnosed </text>
<text top="552" left="820" width="64" height="19" font="3">with HCM </text>
<text top="570" left="820" width="236" height="19" font="3">● Risk factors for SCD were frequently </text>
<text top="589" left="820" width="242" height="19" font="3">present and 11% of carriers could be at </text>
<text top="607" left="820" width="77" height="19" font="3">risk for SCD. </text>
<text top="625" left="820" width="218" height="19" font="3">● Predictive genetic testing in HCM </text>
<text top="644" left="820" width="181" height="19" font="3">families and frequent cardiac </text>
<text top="662" left="820" width="221" height="19" font="3">evaluation for the presence of HCM </text>
<text top="680" left="820" width="221" height="19" font="3">and risk factors for SCD are justified </text>
<text top="698" left="820" width="122" height="19" font="3">until advanced age. </text>
<text top="755" left="125" width="133" height="19" font="3">● Olivotto et al. 2008 </text>
<text top="773" left="125" width="35" height="19" font="3">(280) </text>
<text top="755" left="281" width="153" height="19" font="4"><b>Study type:</b> Multicenter, </text>
<text top="773" left="281" width="122" height="19" font="3">prospective, cohort </text>
<text top="755" left="464" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="773" left="464" width="148" height="19" font="3">Unrelated patients with </text>
<text top="756" left="628" width="126" height="19" font="4"><b>1</b>°<b> endpoint:</b> clinical </text>
<text top="774" left="628" width="161" height="19" font="3">outcomes related to HCM </text>
<text top="755" left="820" width="213" height="19" font="3">● Screening for sarcomere protein </text>
<text top="773" left="820" width="218" height="19" font="3">gene mutations in HCM identifies a </text>
</page>
<page number="154" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">154 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="12" height="19" font="3">●<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18533079"> </a></text>
<text top="109" left="137" width="64" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18533079">18533079 </a></text>
<text top="127" left="125" width="3" height="19" font="6"> </text>
<text top="145" left="125" width="3" height="19" font="3"> </text>
<text top="109" left="281" width="163" height="19" font="3">Myofilament protein gene </text>
<text top="127" left="281" width="148" height="19" font="3">mutation screening and </text>
<text top="145" left="281" width="157" height="19" font="3">outcome of patients with </text>
<text top="164" left="281" width="34" height="19" font="3">HCM<b> </b></text>
<text top="182" left="281" width="3" height="19" font="3"> </text>
<text top="200" left="281" width="115" height="19" font="4"><b>Size:</b>  203 patients<b> </b></text>
<text top="109" left="464" width="112" height="19" font="3">HCM with genetic </text>
<text top="127" left="464" width="130" height="19" font="3">testing of the 8 HCM-</text>
<text top="145" left="464" width="122" height="19" font="3">susceptibility genes </text>
<text top="164" left="464" width="3" height="19" font="3"> </text>
<text top="182" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="200" left="464" width="103" height="19" font="3">inadequate data<b> </b></text>
<text top="109" left="628" width="3" height="19" font="3"> </text>
<text top="127" left="628" width="167" height="19" font="4"><b>Results:</b>  Mean follow-up 4 </text>
<text top="145" left="628" width="139" height="19" font="3">y. 62% of patients had </text>
<text top="164" left="628" width="153" height="19" font="3">mutations (Myofilament-</text>
<text top="182" left="628" width="145" height="19" font="3">positive HCM) and 38% </text>
<text top="200" left="628" width="179" height="19" font="3">were myofilament-negative.  </text>
<text top="219" left="628" width="134" height="19" font="3">Myofilament-positive </text>
<text top="237" left="628" width="177" height="19" font="3">patients at increased risk for </text>
<text top="255" left="628" width="173" height="19" font="3">CV death, stroke, Class III or </text>
<text top="273" left="628" width="166" height="19" font="3">IV HF (25% vs 7% HR: 4.27; </text>
<text top="292" left="628" width="58" height="19" font="3">p=0.008)<b> </b></text>
<text top="109" left="820" width="200" height="19" font="3">broad subgroup of patients with </text>
<text top="127" left="820" width="242" height="19" font="3">increased propensity toward long-term </text>
<text top="145" left="820" width="241" height="19" font="3">impairment of LV function and adverse </text>
<text top="164" left="820" width="58" height="19" font="3">outcome </text>
<text top="182" left="820" width="228" height="19" font="3">● These findings were irrespective of </text>
<text top="200" left="820" width="233" height="19" font="3">the myofilament (thick, intermediate, </text>
<text top="219" left="820" width="107" height="19" font="3">or thin) involved. </text>
<text top="311" left="125" width="119" height="19" font="3">● Ingles et al. 2013 </text>
<text top="329" left="125" width="35" height="19" font="3">(281) </text>
<text top="347" left="125" width="12" height="19" font="3">●<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23598715"> </a></text>
<text top="347" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23598715">23598715</a></text>
<text top="347" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23598715"> </a></text>
<text top="311" left="281" width="153" height="19" font="4"><b>Study type:</b> Multicenter, </text>
<text top="329" left="281" width="151" height="19" font="3">retrospective, data base </text>
<text top="347" left="281" width="51" height="19" font="3">analysis </text>
<text top="366" left="281" width="128" height="19" font="3">Clinical predictors of </text>
<text top="384" left="281" width="157" height="19" font="3">genetic testing outcomes </text>
<text top="402" left="281" width="48" height="19" font="3">in HCM<b> </b></text>
<text top="421" left="281" width="3" height="19" font="3"> </text>
<text top="439" left="281" width="115" height="19" font="4"><b>Size:</b>  265 patients<b> </b></text>
<text top="311" left="464" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="329" left="464" width="151" height="19" font="3">Probands with HCM and </text>
<text top="347" left="464" width="93" height="19" font="3">genetic testing </text>
<text top="366" left="464" width="3" height="19" font="3"> </text>
<text top="384" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="402" left="464" width="103" height="19" font="3">inadequate data<b> </b></text>
<text top="311" left="628" width="176" height="19" font="4"><b>1</b>°<b> endpoint:</b> Identify clinical </text>
<text top="330" left="628" width="158" height="19" font="3">variables that can predict </text>
<text top="348" left="628" width="140" height="19" font="3">probands with HCM in </text>
<text top="367" left="628" width="124" height="19" font="3">whom a pathogenic </text>
<text top="385" left="628" width="165" height="19" font="3">mutation will be identified </text>
<text top="403" left="628" width="3" height="19" font="3"> </text>
<text top="421" left="628" width="127" height="19" font="4"><b>Results:</b>  52% of 265 </text>
<text top="440" left="628" width="154" height="19" font="3">patients had at least one </text>
<text top="458" left="628" width="158" height="19" font="3">mutation.  Detection rate </text>
<text top="476" left="628" width="151" height="19" font="3">was higher with positive </text>
<text top="495" left="628" width="132" height="19" font="3">family Hx (72 vs 29%, </text>
<text top="513" left="628" width="143" height="19" font="3">p&lt;0.0001) and positive </text>
<text top="531" left="628" width="176" height="19" font="3">family Hx of SCD (89 vs 59%, </text>
<text top="550" left="628" width="72" height="19" font="3">p&lt;0.0001). <b> </b></text>
<text top="311" left="820" width="243" height="19" font="3">● Family Hx is a key clinical predictor of </text>
<text top="329" left="820" width="221" height="19" font="3">a positive genetic diagnosis and has </text>
<text top="347" left="820" width="237" height="19" font="3">direct clinical relevance, particularly in </text>
<text top="366" left="820" width="237" height="19" font="3">the pretest genetic counseling setting. </text>
<text top="384" left="820" width="204" height="19" font="3">● Multivariate analysis identified </text>
<text top="402" left="820" width="204" height="19" font="3">female gender, increased LV wall </text>
<text top="421" left="820" width="221" height="19" font="3">thickness, family Hx of SCD as being </text>
<text top="439" left="820" width="238" height="19" font="3">associated with the greatest chance of </text>
<text top="457" left="820" width="176" height="19" font="3">identifying a gene mutation. </text>
<text top="569" left="125" width="121" height="19" font="3">● Jensen et al 2013 </text>
<text top="587" left="125" width="35" height="19" font="3">(282) </text>
<text top="605" left="125" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23197161">● </a></text>
<text top="605" left="137" width="64" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23197161">23197161 </a></text>
<text top="624" left="125" width="3" height="19" font="6"> </text>
<text top="642" left="125" width="3" height="19" font="3"> </text>
<text top="569" left="281" width="159" height="19" font="4"><b>Study type:</b> single center, </text>
<text top="587" left="281" width="121" height="19" font="3">observational, data </text>
<text top="605" left="281" width="49" height="19" font="3">registry </text>
<text top="624" left="281" width="137" height="19" font="3">Penetrance of HCM in </text>
<text top="642" left="281" width="169" height="19" font="3">children and adolescents: a </text>
<text top="660" left="281" width="144" height="19" font="3">12-y follow-up study of </text>
<text top="679" left="281" width="133" height="19" font="3">clinical screening and </text>
<text top="697" left="281" width="158" height="19" font="3">predictive genetic testing<b> </b></text>
<text top="715" left="281" width="3" height="19" font="3"> </text>
<text top="733" left="281" width="167" height="19" font="4"><b>Size:</b>  90 probands and 361 </text>
<text top="752" left="281" width="55" height="19" font="3">relatives<b> </b></text>
<text top="569" left="464" width="145" height="19" font="4"><b>Inclusion criteria:</b> HCM </text>
<text top="587" left="464" width="112" height="19" font="3">patients and their </text>
<text top="605" left="464" width="131" height="19" font="3">relatives with clinical </text>
<text top="624" left="464" width="88" height="19" font="3">screening and </text>
<text top="642" left="464" width="112" height="19" font="3">predictive genetic </text>
<text top="660" left="464" width="45" height="19" font="3">testing </text>
<text top="679" left="464" width="3" height="19" font="3"> </text>
<text top="697" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="715" left="464" width="103" height="19" font="3">inadequate data<b> </b></text>
<text top="569" left="628" width="174" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Penetrance of </text>
<text top="588" left="628" width="153" height="19" font="3">HCM of child relatives of </text>
<text top="606" left="628" width="117" height="19" font="3">patients with HCM </text>
<text top="624" left="628" width="3" height="19" font="3"> </text>
<text top="643" left="628" width="139" height="19" font="4"><b>Results:</b>  After a mean </text>
<text top="661" left="628" width="161" height="19" font="3">follow-up of 12 y, 2 of the </text>
<text top="679" left="628" width="174" height="19" font="3">36 (6%; 95% CI: 2-18) at-risk </text>
<text top="698" left="628" width="152" height="19" font="3">child relatives who were </text>
<text top="716" left="628" width="141" height="19" font="3">phenotype negative at </text>
<text top="734" left="628" width="169" height="19" font="3">conclusion developed HCM </text>
<text top="753" left="628" width="175" height="19" font="3">phenotype at 26 and 28 y of </text>
<text top="771" left="628" width="29" height="19" font="3">age.<b> </b></text>
<text top="569" left="820" width="176" height="19" font="3">● The penetrance of HCM in </text>
<text top="587" left="820" width="230" height="19" font="3">phenotype-negative child relatives at </text>
<text top="605" left="820" width="245" height="19" font="3">risk of developing HCM was 6% after 12 </text>
<text top="624" left="820" width="92" height="19" font="3">y of follow-up. </text>
<text top="642" left="820" width="239" height="19" font="3">● The finding of phenotype conversion </text>
<text top="660" left="820" width="214" height="19" font="3">in the mid-20s warrants continued </text>
<text top="679" left="820" width="160" height="19" font="3">screening into adulthood. </text>
<text top="697" left="820" width="232" height="19" font="3">● 42% of the child relatives were non-</text>
<text top="715" left="820" width="230" height="19" font="3">carriers, and repeat clinical follow-up </text>
<text top="734" left="820" width="245" height="19" font="3">could be safely limited to the remaining </text>
<text top="752" left="820" width="57" height="19" font="3">children. </text>
</page>
<page number="155" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">155 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="122" height="19" font="3">● Bos JM et al 2013 </text>
<text top="127" left="125" width="35" height="19" font="3">(274) </text>
<text top="145" left="125" width="9" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24793961">●</a></text>
<text top="145" left="134" width="64" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24793961"> 24793961</a></text>
<text top="145" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24793961"> </a></text>
<text top="164" left="125" width="3" height="19" font="6"> </text>
<text top="182" left="125" width="3" height="19" font="6"> </text>
<text top="200" left="125" width="3" height="19" font="3"> </text>
<text top="109" left="281" width="160" height="19" font="4"><b>Study type:</b> Single center, </text>
<text top="127" left="281" width="167" height="19" font="3">observational data registry </text>
<text top="145" left="281" width="130" height="19" font="3">Characterization of a </text>
<text top="164" left="281" width="158" height="19" font="3">phenotype-based genetic </text>
<text top="182" left="281" width="150" height="19" font="3">test prediction score for </text>
<text top="200" left="281" width="146" height="19" font="3">unrelated patients with </text>
<text top="219" left="281" width="34" height="19" font="3">HCM </text>
<text top="237" left="281" width="122" height="19" font="4"><b>Size:</b>  1053 patients<b> </b></text>
<text top="109" left="464" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="127" left="464" width="151" height="19" font="3">Established clinical HCM </text>
<text top="145" left="464" width="60" height="19" font="3">diagnosis </text>
<text top="164" left="464" width="3" height="19" font="3"> </text>
<text top="182" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="200" left="464" width="104" height="19" font="3">Inadequate data<b> </b></text>
<text top="109" left="628" width="138" height="19" font="4"><b>1</b>°<b> endpoint:</b>   Genetic </text>
<text top="128" left="628" width="100" height="19" font="3">testing for HCM </text>
<text top="146" left="628" width="3" height="19" font="3"> </text>
<text top="164" left="628" width="173" height="19" font="4"><b>Results:</b>  1053 patients with </text>
<text top="183" left="628" width="176" height="19" font="3">clinical HCM (mean age 44.4 </text>
<text top="201" left="628" width="164" height="19" font="3">± 19 y) had genetic testing </text>
<text top="219" left="628" width="112" height="19" font="3">evaluating 9 HCM-</text>
<text top="238" left="628" width="149" height="19" font="3">associated myofilament </text>
<text top="256" left="628" width="174" height="19" font="3">genes. 34% were positive or </text>
<text top="274" left="628" width="115" height="19" font="3">a HCM mutation. .<b> </b></text>
<text top="109" left="820" width="230" height="19" font="3">● Predictors of a positive genetic test </text>
<text top="127" left="820" width="211" height="19" font="3">were reverse curve morphological </text>
<text top="145" left="820" width="224" height="19" font="3">subtype, age &lt;45y, LV wall thickness </text>
<text top="164" left="820" width="234" height="19" font="3">≥20mm, family Hx of HCM, and family </text>
<text top="182" left="820" width="203" height="19" font="3">Hx of SCD. Hypertension was not </text>
<text top="200" left="820" width="68" height="19" font="3">predictive. </text>
<text top="219" left="820" width="8" height="20" font="0">•</text>
<text top="221" left="827" width="234" height="19" font="3">  A positive genetic test was predicted </text>
<text top="239" left="820" width="165" height="19" font="3">in 6% of patients with only </text>
<text top="258" left="820" width="199" height="19" font="3">hypertension and 80% with all 5 </text>
<text top="276" left="820" width="117" height="19" font="3">predictor markers. </text>
<text top="295" left="125" width="142" height="19" font="3">● Girolami F et al 2010 </text>
<text top="313" left="125" width="35" height="19" font="3">(283) </text>
<text top="332" left="125" width="12" height="19" font="3">●<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20359594"> </a></text>
<text top="332" left="137" width="64" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20359594">20359594 </a></text>
<text top="350" left="125" width="3" height="19" font="6"> </text>
<text top="368" left="125" width="3" height="19" font="3"> </text>
<text top="295" left="281" width="157" height="19" font="4"><b>Study type:</b>  Multicenter, </text>
<text top="313" left="281" width="167" height="19" font="3">observational data registry </text>
<text top="332" left="281" width="127" height="19" font="3">Clinical features and </text>
<text top="350" left="281" width="107" height="19" font="3">outcome of HCM </text>
<text top="368" left="281" width="134" height="19" font="3">associated with triple </text>
<text top="386" left="281" width="149" height="19" font="3">sarcomere protein gene </text>
<text top="405" left="281" width="66" height="19" font="3">mutations </text>
<text top="423" left="281" width="3" height="19" font="3"> </text>
<text top="441" left="281" width="115" height="19" font="4"><b>Size:</b>  488 patients<b> </b></text>
<text top="295" left="464" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="313" left="464" width="128" height="19" font="3">Patients with clinical </text>
<text top="332" left="464" width="106" height="19" font="3">HCM undergoing </text>
<text top="350" left="464" width="93" height="19" font="3">genetic testing </text>
<text top="368" left="464" width="3" height="19" font="3"> </text>
<text top="386" left="464" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="405" left="464" width="104" height="19" font="3">Inadequate data<b> </b></text>
<text top="295" left="628" width="170" height="19" font="4"><b>1</b>°<b> endpoint:</b>  The presence </text>
<text top="314" left="628" width="153" height="19" font="3">of triple sarcomere gene </text>
<text top="332" left="628" width="69" height="19" font="3">mutations  </text>
<text top="351" left="628" width="3" height="19" font="3"> </text>
<text top="369" left="628" width="163" height="19" font="4"><b>Results:</b>  Of 488 unrelated </text>
<text top="387" left="628" width="138" height="19" font="3">index HCM patients, 4 </text>
<text top="406" left="628" width="170" height="19" font="3">(0.8%) had triple mutations </text>
<text top="424" left="628" width="178" height="19" font="3">and significant events during </text>
<text top="442" left="628" width="64" height="19" font="3">follow up.<b> </b></text>
<text top="295" left="820" width="242" height="19" font="3">● 4 patients with HCM (0.8% of cohort) </text>
<text top="313" left="820" width="229" height="19" font="3">had triple sarcomere gene mutations </text>
<text top="332" left="820" width="244" height="19" font="3">● The clinical outcome in the 4 patients </text>
<text top="350" left="820" width="215" height="19" font="3">included resuscitated SCD in 1; ICD </text>
<text top="368" left="820" width="238" height="19" font="3">implantation due to risk factors in all 4 </text>
<text top="386" left="820" width="217" height="19" font="3">with appropriate shocks in 2; and 3 </text>
<text top="405" left="820" width="211" height="19" font="3">progressed to end-stage HCM by 4</text>
<text top="404" left="1031" width="8" height="12" font="15">th</text>
<text top="405" left="1039" width="3" height="19" font="3"> </text>
<text top="423" left="820" width="196" height="19" font="3">decade with transplant in 1 and </text>
<text top="441" left="820" width="153" height="19" font="3">biventricular pacing in 2. </text>
<text top="461" left="125" width="119" height="19" font="3">● Hershberger RE J </text>
<text top="480" left="125" width="125" height="19" font="3">Card Fail 2009 (250) </text>
<text top="498" left="125" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19254666">● </a></text>
<text top="498" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19254666">19254666</a></text>
<text top="498" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19254666"> </a></text>
<text top="516" left="125" width="3" height="19" font="3"> </text>
<text top="534" left="125" width="3" height="19" font="3"> </text>
<text top="461" left="281" width="7" height="19" font="3">  </text>
<text top="461" left="464" width="134" height="19" font="3">Genetic evaluation of </text>
<text top="480" left="464" width="108" height="19" font="3">Cardiomyopathy  </text>
<text top="498" left="464" width="3" height="19" font="3"> </text>
<text top="516" left="464" width="3" height="19" font="3"> </text>
<text top="461" left="628" width="138" height="19" font="3">Guideline restricts the </text>
<text top="480" left="628" width="178" height="19" font="3">indication for genetic testing </text>
<text top="498" left="628" width="145" height="19" font="3">to that of facilitation of </text>
<text top="516" left="628" width="129" height="19" font="3">family screening and </text>
<text top="534" left="628" width="167" height="19" font="3">management. Ie, Testing is </text>
<text top="553" left="628" width="175" height="19" font="3">used for risk stratification of </text>
<text top="571" left="628" width="165" height="19" font="3">family members who have </text>
<text top="589" left="628" width="170" height="19" font="3">little or no clinical evidence </text>
<text top="608" left="628" width="68" height="19" font="3">of disease. </text>
<text top="626" left="628" width="125" height="19" font="3">Recommendations:  </text>
<text top="644" left="628" width="3" height="19" font="3"> </text>
<text top="663" left="628" width="147" height="19" font="3">Careful family Hx for ≥3 </text>
<text top="681" left="628" width="179" height="19" font="3">generations, for all patients.  </text>
<text top="699" left="628" width="3" height="19" font="3"> </text>
<text top="717" left="628" width="109" height="19" font="3">Clinical screening </text>
<text top="736" left="628" width="164" height="19" font="3">recommended at intervals </text>
<text top="754" left="628" width="152" height="19" font="3">for asymptomatic at-risk </text>
<text top="461" left="820" width="194" height="19" font="3">● Details of clinical screening &amp; </text>
<text top="480" left="820" width="99" height="19" font="3">intervals given:  </text>
<text top="498" left="820" width="125" height="19" font="3">SAECG in ARVC only </text>
<text top="516" left="820" width="84" height="19" font="3">CMR in ARVC </text>
<text top="534" left="820" width="3" height="19" font="3"> </text>
<text top="553" left="820" width="200" height="19" font="3">● Childhood: screening intervals </text>
<text top="571" left="820" width="241" height="19" font="3">specified relative to ages and mutation </text>
<text top="589" left="820" width="40" height="19" font="3">status </text>
<text top="608" left="820" width="3" height="19" font="3"> </text>
<text top="626" left="820" width="182" height="19" font="3">● Especially LMNA mutations </text>
</page>
<page number="156" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">156 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="628" width="168" height="19" font="3">relatives who are mutation </text>
<text top="127" left="628" width="57" height="19" font="3">carriers;  </text>
<text top="145" left="628" width="3" height="19" font="3"> </text>
<text top="164" left="628" width="130" height="19" font="3">Clinical screening for </text>
<text top="182" left="628" width="163" height="19" font="3">asymptomatic first degree </text>
<text top="200" left="628" width="141" height="19" font="3">relatives when genetic </text>
<text top="219" left="628" width="128" height="19" font="3">testing has not been </text>
<text top="237" left="628" width="172" height="19" font="3">performed/or mutation not </text>
<text top="255" left="628" width="69" height="19" font="3">identified.  </text>
<text top="273" left="628" width="3" height="19" font="3"> </text>
<text top="292" left="628" width="171" height="19" font="3">Genetic screening for Fabry </text>
<text top="310" left="628" width="126" height="19" font="3">disease in all men w </text>
<text top="329" left="628" width="181" height="19" font="3">unexplained cardiac disease.  </text>
<text top="347" left="628" width="3" height="19" font="3"> </text>
<text top="365" left="628" width="175" height="19" font="3">Referral to centers expert in </text>
<text top="383" left="628" width="142" height="19" font="3">genetic evaluation and </text>
<text top="402" left="628" width="169" height="19" font="3">family based management. </text>
<text top="420" left="628" width="3" height="19" font="3"> </text>
<text top="438" left="628" width="167" height="19" font="3">Genetic testing for the one </text>
<text top="457" left="628" width="177" height="19" font="3">most clearly affected person </text>
<text top="475" left="628" width="139" height="19" font="3">in a family to facilitate </text>
<text top="493" left="628" width="129" height="19" font="3">family screening and </text>
<text top="512" left="628" width="92" height="19" font="3">management.  </text>
<text top="530" left="628" width="3" height="19" font="3"> </text>
<text top="548" left="628" width="143" height="19" font="3">ICD may be considered </text>
<text top="566" left="628" width="169" height="19" font="3">before the LVEF falls below </text>
<text top="585" left="628" width="178" height="19" font="3">35% in patients with CM and </text>
<text top="603" left="628" width="153" height="19" font="3">significant arrhythmia or </text>
<text top="621" left="628" width="164" height="19" font="3">known risk of arrhythmia.  </text>
<text top="640" left="125" width="142" height="19" font="3">● Klues HG, et al. 1995 </text>
<text top="659" left="125" width="35" height="19" font="3">(284) </text>
<text top="677" left="125" width="12" height="19" font="3">●<a href="https://www.ncbi.nlm.nih.gov/pubmed/7594106"> </a></text>
<text top="677" left="137" width="53" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7594106">7594106</a></text>
<text top="677" left="190" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7594106"> </a></text>
<text top="642" left="281" width="29" height="19" font="4"><b>Aim:</b></text>
<text top="640" left="310" width="12" height="21" font="0"> T</text>
<text top="642" left="322" width="80" height="19" font="3">o achieve an </text>
<text top="661" left="281" width="160" height="19" font="3">understanding of the true </text>
<text top="679" left="281" width="168" height="19" font="3">structural heterogeneity of </text>
<text top="697" left="281" width="34" height="19" font="3">HCM </text>
<text top="715" left="281" width="3" height="19" font="3"> </text>
<text top="734" left="281" width="32" height="19" font="4"><b>Size: </b></text>
<text top="752" left="281" width="96" height="19" font="3">N=600 patients </text>
<text top="640" left="464" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="659" left="464" width="101" height="19" font="3">Patients with LV </text>
<text top="677" left="464" width="79" height="19" font="3">hypertrophy </text>
<text top="640" left="628" width="52" height="19" font="4"><b>Results: </b></text>
<text top="659" left="628" width="158" height="19" font="3">LV wall thickness = 15–52 </text>
<text top="677" left="628" width="127" height="19" font="3">mm (mean 22.3±5).  </text>
<text top="695" left="628" width="120" height="19" font="3">Various patterns of </text>
<text top="714" left="628" width="172" height="19" font="3">asymmetric LV hypertrophy </text>
<text top="732" left="628" width="96" height="19" font="3">were identified </text>
<text top="750" left="628" width="140" height="19" font="3">Hypertrophy involved: </text>
<text top="640" left="820" width="190" height="19" font="3">● In HCM the distribution ofLV </text>
<text top="659" left="820" width="198" height="19" font="3">hypertrophy is characteristically </text>
<text top="677" left="820" width="173" height="19" font="3">asymmetric and particularly </text>
<text top="695" left="820" width="224" height="19" font="3">heterogeneous, encompassing most </text>
<text top="714" left="820" width="245" height="19" font="3">possible patterns of wall thickening and </text>
<text top="732" left="820" width="237" height="19" font="3">with no single morphologic expression </text>
<text top="750" left="820" width="180" height="19" font="3">considered typical or classic.  </text>
</page>
<page number="157" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">157 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="628" width="166" height="19" font="3">2 left ventricular segments </text>
<text top="127" left="628" width="147" height="19" font="3">(228 patients [38%]) or  </text>
<text top="145" left="628" width="164" height="19" font="3">≥3 segments (202 patients </text>
<text top="164" left="628" width="46" height="19" font="3">[34%])  </text>
<text top="182" left="628" width="162" height="19" font="3">1 segment in a substantial </text>
<text top="200" left="628" width="151" height="19" font="3">number of patients (170 </text>
<text top="219" left="628" width="50" height="19" font="3">[28%]).  </text>
<text top="237" left="628" width="3" height="19" font="3"> </text>
<text top="255" left="628" width="167" height="19" font="3">The anterior portion of the </text>
<text top="273" left="628" width="123" height="19" font="3">ventricular septum: </text>
<text top="292" left="628" width="152" height="19" font="3">most frequently showed </text>
<text top="310" left="628" width="151" height="19" font="3">thickening (573 patients </text>
<text top="329" left="628" width="97" height="19" font="3">[96%]), and the </text>
<text top="347" left="628" width="124" height="19" font="3">predominant site of </text>
<text top="365" left="628" width="128" height="19" font="3">hypertrophy in most </text>
<text top="383" left="628" width="137" height="19" font="3">patients (492 patients </text>
<text top="402" left="628" width="50" height="19" font="3">[83%]).  </text>
<text top="109" left="820" width="229" height="19" font="3">● A greater extent of LV hypertrophy </text>
<text top="127" left="820" width="230" height="19" font="3">was associated with younger age and </text>
<text top="145" left="820" width="209" height="19" font="3">more marked mitral valve systolic </text>
<text top="164" left="820" width="177" height="19" font="3">anterior motion and outflow </text>
<text top="182" left="820" width="236" height="19" font="3">obstruction but showed no relation to </text>
<text top="200" left="820" width="208" height="19" font="3">either magnitude of symptoms or </text>
<text top="219" left="820" width="50" height="19" font="3">gender. </text>
<text top="421" left="125" width="118" height="19" font="3">● Adabag AS, et al. </text>
<text top="439" left="125" width="35" height="19" font="3">(285) </text>
<text top="457" left="125" width="12" height="19" font="3">●<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17126660"> </a></text>
<text top="457" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17126660">17126660</a></text>
<text top="457" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17126660"> </a></text>
<text top="421" left="281" width="142" height="19" font="4"><b>Aim:</b> To determine the </text>
<text top="439" left="281" width="135" height="19" font="3">clinical circumstances </text>
<text top="457" left="281" width="126" height="19" font="3">under which HCM is </text>
<text top="476" left="281" width="62" height="19" font="3">identified </text>
<text top="494" left="281" width="3" height="19" font="3"> </text>
<text top="512" left="281" width="75" height="19" font="4"><b>Size:</b> N=711 </text>
<text top="421" left="464" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="439" left="464" width="116" height="19" font="3">HCM patients who </text>
<text top="457" left="464" width="147" height="19" font="3">underwent a diagnostic </text>
<text top="476" left="464" width="113" height="19" font="3">echocardiography </text>
<text top="421" left="628" width="172" height="19" font="4"><b>1</b>°<b> endpoint: </b>Clincail trigger </text>
<text top="440" left="628" width="3" height="19" font="3"> </text>
<text top="458" left="628" width="52" height="19" font="4"><b>Results: </b></text>
<text top="476" left="628" width="173" height="19" font="3">HCM was initially suspected </text>
<text top="495" left="628" width="139" height="19" font="3">only after the onset of </text>
<text top="513" left="628" width="167" height="19" font="3">cardiac symptoms or acute </text>
<text top="531" left="628" width="132" height="19" font="3">cardiac events in 384 </text>
<text top="550" left="628" width="57" height="19" font="3">patients. </text>
<text top="568" left="628" width="3" height="19" font="3"> </text>
<text top="586" left="628" width="159" height="19" font="3">In 327 patients, HCM was </text>
<text top="605" left="628" width="159" height="19" font="3">recognized while patients </text>
<text top="623" left="628" width="128" height="19" font="3">were asymptomatic: </text>
<text top="641" left="628" width="143" height="19" font="3">225 by routine medical </text>
<text top="660" left="628" width="81" height="19" font="3">evaluations,  </text>
<text top="678" left="628" width="137" height="19" font="3">27 of whom HCM was </text>
<text top="696" left="628" width="113" height="19" font="3">recognized during </text>
<text top="714" left="628" width="102" height="19" font="3">preparticipation </text>
<text top="733" left="628" width="106" height="19" font="3">examinations for </text>
<text top="751" left="628" width="171" height="19" font="3">competitive sports or other </text>
<text top="769" left="628" width="65" height="19" font="3">activities.  </text>
<text top="421" left="820" width="230" height="19" font="3">● Patients with extreme hypertrophy </text>
<text top="439" left="820" width="230" height="19" font="3">(wall thickness ≥30 mm) and those at </text>
<text top="457" left="820" width="232" height="19" font="3">high risk for sudden death were more </text>
<text top="476" left="820" width="232" height="19" font="3">often asymptomatic and identified by </text>
<text top="494" left="820" width="239" height="19" font="3">routine or family screenings (p&lt;0.0001 </text>
<text top="512" left="820" width="168" height="19" font="3">and p=0.004, respectively). </text>
</page>
<page number="158" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">158 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="628" width="174" height="19" font="3">Women, older patients (age </text>
<text top="127" left="628" width="164" height="19" font="3">≥50 years), and those with </text>
<text top="145" left="628" width="167" height="19" font="3">outflow obstruction at rest </text>
<text top="164" left="628" width="171" height="19" font="3">(gradient ≥30 mm Hg) were </text>
<text top="182" left="628" width="152" height="19" font="3">more likely suspected to </text>
<text top="200" left="628" width="139" height="19" font="3">have HCM by virtue of </text>
<text top="219" left="628" width="174" height="19" font="3">cardiac symptoms or events </text>
<text top="237" left="628" width="77" height="19" font="3">(p&lt;0.0001).  </text>
<text top="257" left="125" width="114" height="19" font="3">● Afonso LC, et al. </text>
<text top="276" left="125" width="34" height="19" font="3">2008 </text>
<text top="294" left="125" width="12" height="19" font="3">●<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19356516"> </a></text>
<text top="294" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19356516">19356516</a></text>
<text top="294" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19356516"> </a></text>
<text top="257" left="281" width="157" height="19" font="4"><b>Aim: </b>To profile the utility </text>
<text top="276" left="281" width="159" height="19" font="3">and pitfalls of established </text>
<text top="294" left="281" width="116" height="19" font="3">echocardiographic </text>
<text top="312" left="281" width="163" height="19" font="3">modalities and discuss the </text>
<text top="330" left="281" width="134" height="19" font="3">evolving role of novel </text>
<text top="349" left="281" width="167" height="19" font="3">echocardiographic imaging </text>
<text top="367" left="281" width="154" height="19" font="3">modalities such as tissue </text>
<text top="385" left="281" width="149" height="19" font="3">Doppler, Doppler-based </text>
<text top="404" left="281" width="170" height="19" font="3">strain, 2-dimensional strain </text>
<text top="422" left="281" width="165" height="19" font="3">(speckle tracking imaging), </text>
<text top="440" left="281" width="168" height="19" font="3">and 3-dimensional imaging </text>
<text top="459" left="281" width="166" height="19" font="3">in the assessment of HCM.<b> </b></text>
<text top="257" left="464" width="3" height="19" font="4"><b> </b></text>
<text top="257" left="628" width="3" height="19" font="4"><b> </b></text>
<text top="257" left="820" width="208" height="19" font="3">● At the time of this paper, tissue </text>
<text top="276" left="820" width="242" height="19" font="3">Doppler-derived strain and 2D strain or </text>
<text top="294" left="820" width="215" height="19" font="3">speckle tracking imaging represent </text>
<text top="312" left="820" width="169" height="19" font="3">robust and rapidly evolving </text>
<text top="330" left="820" width="229" height="19" font="3">technologies that have advanced our </text>
<text top="349" left="820" width="232" height="19" font="3">understanding of regional myocardial </text>
<text top="367" left="820" width="123" height="19" font="3">mechanics in HCM.  </text>
<text top="385" left="820" width="236" height="19" font="3">● Ongoing refinements and additional </text>
<text top="404" left="820" width="223" height="19" font="3">research will define the incremental </text>
<text top="422" left="820" width="190" height="19" font="3">role and clinical utility of these </text>
<text top="440" left="820" width="221" height="19" font="3">promising techniques, including the </text>
<text top="459" left="820" width="229" height="19" font="3">identification of preclinical disease in </text>
<text top="477" left="820" width="168" height="19" font="3">carriers of HCM mutations, </text>
<text top="495" left="820" width="228" height="19" font="3">improvement of diagnostic accuracy, </text>
<text top="514" left="820" width="240" height="19" font="3">risk stratification, planning therapeutic </text>
<text top="532" left="820" width="234" height="19" font="3">strategies, and monitoring treatment. </text>
<text top="551" left="115" width="4" height="21" font="2"><b> </b></text>
<text top="571" left="115" width="4" height="21" font="0"> </text>
<text top="571" left="331" width="4" height="21" font="2"><b> </b></text>
</page>
<page number="159" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">159 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="791" height="21" font="2"><b>Data Supplement 32. Nonrandomized Trials, Observational Studies, and/or Registries of Myocarditis – (Section 7.5) </b></text>
<text top="129" left="149" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="147" left="175" width="51" height="19" font="4"><b>Author; </b></text>
<text top="165" left="152" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="129" left="299" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="147" left="328" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="129" left="469" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="129" left="640" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="147" left="653" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="165" left="684" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="129" left="880" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="147" left="908" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="184" left="125" width="124" height="19" font="3">● Cooper et al.1997 </text>
<text top="203" left="125" width="35" height="19" font="3">(286) </text>
<text top="221" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9197214">● </a></text>
<text top="221" left="137" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9197214">9197214</a></text>
<text top="221" left="190" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9197214"> </a></text>
<text top="239" left="125" width="3" height="19" font="3"> </text>
<text top="184" left="289" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="203" left="289" width="90" height="19" font="3">observational, </text>
<text top="221" left="289" width="147" height="19" font="3">multicenter data base    </text>
<text top="239" left="289" width="143" height="19" font="3">Natural Hx of giant-cell </text>
<text top="258" left="289" width="74" height="19" font="3">myocarditis </text>
<text top="276" left="289" width="3" height="19" font="3"> </text>
<text top="294" left="289" width="110" height="19" font="4"><b>Size:</b>  63 patients  </text>
<text top="184" left="447" width="151" height="19" font="4"><b>Inclusion criteria:</b>  Giant </text>
<text top="203" left="447" width="99" height="19" font="3">cell myocarditis </text>
<text top="221" left="447" width="3" height="19" font="3"> </text>
<text top="239" left="447" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="258" left="447" width="103" height="19" font="3">inadequate data </text>
<text top="185" left="623" width="135" height="19" font="4"><b>1</b>°<b> endpoint:</b>  survival </text>
<text top="204" left="623" width="3" height="19" font="3"> </text>
<text top="222" left="623" width="158" height="19" font="4"><b>Results:</b>  Rate of death or </text>
<text top="240" left="623" width="178" height="19" font="3">cardiac transplantation 89%; </text>
<text top="258" left="623" width="170" height="19" font="3">median survival from onset </text>
<text top="277" left="623" width="135" height="19" font="3">of symptoms 5.5 mo.  </text>
<text top="295" left="623" width="3" height="19" font="3"> </text>
<text top="184" left="822" width="227" height="19" font="3">● Giant cell myocarditis is often fatal </text>
<text top="203" left="822" width="109" height="19" font="3">due to HF and VA </text>
<text top="221" left="822" width="3" height="19" font="3"> </text>
<text top="314" left="125" width="137" height="19" font="3">● Kandolin et al.<b> </b>2013 </text>
<text top="333" left="125" width="35" height="19" font="3">(287) </text>
<text top="351" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23149495">● </a></text>
<text top="351" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23149495">23149495</a></text>
<text top="351" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23149495"> </a></text>
<text top="369" left="125" width="3" height="19" font="3"> </text>
<text top="314" left="289" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="333" left="289" width="90" height="19" font="3">observational, </text>
<text top="351" left="289" width="127" height="19" font="3">retrospective, single </text>
<text top="369" left="289" width="46" height="19" font="3">center  </text>
<text top="388" left="289" width="136" height="19" font="3">Management of giant-</text>
<text top="406" left="289" width="129" height="19" font="3">cell myocarditis with </text>
<text top="424" left="289" width="128" height="19" font="3">immunosuppression </text>
<text top="442" left="289" width="3" height="19" font="3"> </text>
<text top="461" left="289" width="114" height="19" font="4"><b>Size:</b>   32 patients  </text>
<text top="314" left="447" width="150" height="19" font="4"><b>Inclusion criteria:</b>  giant-</text>
<text top="333" left="447" width="147" height="19" font="3">cell myocarditis treated </text>
<text top="351" left="447" width="158" height="19" font="3">with immunosuppression </text>
<text top="369" left="447" width="3" height="19" font="3"> </text>
<text top="387" left="447" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="406" left="447" width="152" height="19" font="3">inadequate data, unable </text>
<text top="424" left="447" width="41" height="19" font="3">to use </text>
<text top="442" left="447" width="128" height="19" font="3">immunosuppression </text>
<text top="315" left="623" width="135" height="19" font="4"><b>1</b>°<b> endpoint:</b>  survival </text>
<text top="333" left="623" width="3" height="19" font="3"> </text>
<text top="352" left="623" width="153" height="19" font="4"><b>Results:</b>  Transplant-free </text>
<text top="370" left="623" width="176" height="19" font="3">survival 69% at 1 y, 58% at 2 </text>
<text top="388" left="623" width="110" height="19" font="3">y, 52% at 5y. 59% </text>
<text top="407" left="623" width="161" height="19" font="3">experienced sustained VA </text>
<text top="425" left="623" width="141" height="19" font="3">during follow up and 3 </text>
<text top="443" left="623" width="181" height="19" font="3">received ICD shocks for VT or </text>
<text top="462" left="623" width="23" height="19" font="3">VF. </text>
<text top="480" left="623" width="3" height="19" font="3"> </text>
<text top="314" left="822" width="195" height="19" font="3">● 2/3 of patients with giant-cell </text>
<text top="333" left="822" width="239" height="19" font="3">myocarditis are free from severe HF or </text>
<text top="351" left="822" width="244" height="19" font="3">transplantation on immunosuppression </text>
<text top="369" left="822" width="246" height="19" font="3">● 59% experience life-threatening VT or </text>
<text top="388" left="822" width="19" height="19" font="3">VF </text>
<text top="406" left="822" width="3" height="19" font="3"> </text>
<text top="499" left="125" width="126" height="19" font="3">● Maleszewski et al. </text>
<text top="517" left="125" width="69" height="19" font="3">2015 (288) </text>
<text top="535" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25882774">● </a></text>
<text top="535" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25882774">25882774</a></text>
<text top="535" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25882774"> </a></text>
<text top="554" left="128" width="3" height="19" font="3"> </text>
<text top="499" left="289" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="517" left="289" width="88" height="19" font="3">retrospective, </text>
<text top="535" left="289" width="90" height="19" font="3">observational, </text>
<text top="554" left="289" width="144" height="19" font="3">multicenter data base   </text>
<text top="572" left="289" width="112" height="19" font="3">Long-term risks in </text>
<text top="590" left="289" width="133" height="19" font="3">giant cell myocarditis<b> </b></text>
<text top="609" left="289" width="3" height="19" font="3"> </text>
<text top="627" left="289" width="114" height="19" font="4"><b>Size:</b>  26 patients   </text>
<text top="499" left="447" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="517" left="447" width="143" height="19" font="3">Patients with giant-cell </text>
<text top="535" left="447" width="161" height="19" font="3">myocarditis surviving &gt;1 y </text>
<text top="554" left="447" width="87" height="19" font="3">without heart </text>
<text top="572" left="447" width="98" height="19" font="3">transplantation </text>
<text top="590" left="447" width="3" height="19" font="3"> </text>
<text top="609" left="447" width="113" height="19" font="4"><b>Exclusion criteria: </b></text>
<text top="627" left="447" width="162" height="19" font="3">inadequate data, need for </text>
<text top="645" left="447" width="104" height="19" font="3">transplantation   </text>
<text top="500" left="623" width="164" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Survival free </text>
<text top="518" left="623" width="142" height="19" font="3">from death, transplant </text>
<text top="536" left="623" width="3" height="19" font="3"> </text>
<text top="554" left="623" width="183" height="19" font="4"><b>Results:</b>  mean age 54.6±13.9 </text>
<text top="573" left="623" width="178" height="19" font="3">y, follow up 5.5 y starting 1 y </text>
<text top="591" left="623" width="160" height="19" font="3">after diagnosis. 12% died; </text>
<text top="609" left="623" width="170" height="19" font="3">19% transplanted; 23% had </text>
<text top="628" left="623" width="150" height="19" font="3">19 episodes of VT or VF  </text>
<text top="646" left="623" width="3" height="19" font="3"> </text>
<text top="499" left="822" width="224" height="19" font="3">● The risk of disease recurrence and </text>
<text top="517" left="822" width="191" height="19" font="3">progression is high in giant-cell </text>
<text top="535" left="822" width="154" height="19" font="3">myocarditis treated with </text>
<text top="554" left="822" width="128" height="19" font="3">immunosuppression </text>
<text top="572" left="822" width="241" height="19" font="3">● Life-threatening VT or VF occurred in </text>
<text top="590" left="822" width="246" height="19" font="3">23% of patients during long-term follow </text>
<text top="609" left="822" width="19" height="19" font="3">up </text>
<text top="627" left="822" width="3" height="19" font="3"> </text>
<text top="665" left="125" width="125" height="19" font="3">● <b>WEARIT/BIROAD</b>  </text>
<text top="684" left="125" width="136" height="19" font="3">● Feldman et al. 2004 </text>
<text top="702" left="125" width="35" height="19" font="3">(289) </text>
<text top="720" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14720148">● </a></text>
<text top="720" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14720148">14720148</a></text>
<text top="720" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14720148"> </a></text>
<text top="665" left="289" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="684" left="289" width="134" height="19" font="3">Prospective registries </text>
<text top="702" left="289" width="98" height="19" font="3">were combined </text>
<text top="720" left="289" width="126" height="19" font="3">Use of the wearable </text>
<text top="739" left="289" width="83" height="19" font="3">defibrillator. <b> </b></text>
<text top="757" left="289" width="3" height="19" font="3"> </text>
<text top="775" left="289" width="121" height="19" font="4"><b>Size:</b>    289 patients </text>
<text top="665" left="447" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="684" left="447" width="146" height="19" font="3">symptomatic HF and EF </text>
<text top="702" left="447" width="115" height="19" font="3">&lt;0.30 (WEARIT) or </text>
<text top="720" left="447" width="144" height="19" font="3">patients at high risk for </text>
<text top="739" left="447" width="142" height="19" font="3">SCD after MI or bypass </text>
<text top="757" left="447" width="109" height="19" font="3">surgery (BIROAD) </text>
<text top="775" left="447" width="3" height="19" font="3"> </text>
<text top="666" left="623" width="160" height="19" font="4"><b>1</b>°<b> endpoint:</b>  appropriate </text>
<text top="684" left="623" width="155" height="19" font="3">shock form the wearable </text>
<text top="703" left="623" width="76" height="19" font="3">defibrillator </text>
<text top="721" left="623" width="3" height="19" font="3"> </text>
<text top="739" left="623" width="181" height="19" font="4"><b>Results:</b>  4 mo follow up. 6 of </text>
<text top="758" left="623" width="151" height="19" font="3">8 defibrillation attempts </text>
<text top="776" left="623" width="167" height="19" font="3">successful; 6 inappropriate </text>
<text top="665" left="822" width="201" height="19" font="3">● The wearable defibrillator was </text>
<text top="684" left="822" width="250" height="19" font="3">successful in defibrillating 75% of events </text>
<text top="702" left="822" width="234" height="19" font="3">● 24% of patients did not tolerate the </text>
<text top="720" left="822" width="43" height="19" font="3">device </text>
<text top="739" left="822" width="3" height="19" font="3"> </text>
</page>
<page number="160" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="21" size="12" family="Times" color="#2a2a2a"/>
<text top="803" left="585" width="29" height="21" font="0">160 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="447" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="127" left="447" width="103" height="19" font="3">inadequate data </text>
<text top="109" left="623" width="181" height="19" font="3">shocks. 6 SCD during study: 5 </text>
<text top="127" left="623" width="182" height="19" font="3">not wearing and 1 incorrectly </text>
<text top="145" left="623" width="164" height="19" font="3">wearing device. 68 did not </text>
<text top="164" left="623" width="81" height="19" font="3">tolerate vest </text>
<text top="182" left="623" width="3" height="19" font="3"> </text>
<text top="201" left="125" width="141" height="19" font="3">● Kao et al. 2012 (290) </text>
<text top="219" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23234574">● </a></text>
<text top="219" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23234574">23234574</a></text>
<text top="219" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23234574"> </a></text>
<text top="238" left="125" width="3" height="19" font="3"> </text>
<text top="201" left="289" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="219" left="289" width="78" height="19" font="3">multicenter, </text>
<text top="238" left="289" width="124" height="19" font="3">prospective registry </text>
<text top="256" left="289" width="138" height="19" font="3">Wearable defibrillator </text>
<text top="274" left="289" width="34" height="19" font="3">in HF<b> </b></text>
<text top="293" left="289" width="3" height="19" font="3"> </text>
<text top="311" left="289" width="117" height="19" font="4"><b>Size:</b>    82 patients  </text>
<text top="201" left="447" width="134" height="19" font="4"><b>Inclusion criteria:</b>  HF </text>
<text top="219" left="447" width="108" height="19" font="3">patients awaiting </text>
<text top="238" left="447" width="147" height="19" font="3">transplantation, dilated </text>
<text top="256" left="447" width="123" height="19" font="3">cardiomyopathy, or </text>
<text top="274" left="447" width="117" height="19" font="3">receiving inotropic </text>
<text top="293" left="447" width="65" height="19" font="3">medicines </text>
<text top="311" left="447" width="3" height="19" font="3"> </text>
<text top="329" left="447" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="347" left="447" width="103" height="19" font="3">inadequate data </text>
<text top="202" left="623" width="172" height="19" font="4"><b>1</b>°<b> endpoint:</b>  sudden death </text>
<text top="220" left="623" width="3" height="19" font="3"> </text>
<text top="238" left="623" width="173" height="19" font="4"><b>Results:</b>  75±58 d follow up. </text>
<text top="257" left="623" width="166" height="19" font="3">No episodes of sudden CA. </text>
<text top="275" left="623" width="3" height="19" font="3"> </text>
<text top="201" left="822" width="234" height="19" font="3">● The event rate was too low to allow </text>
<text top="219" left="822" width="249" height="19" font="3">assessment of the wearable defibrillator </text>
<text top="238" left="849" width="3" height="19" font="3"> </text>
<text top="366" left="115" width="4" height="23" font="10"><b> </b></text>
<text top="424" left="115" width="841" height="21" font="2"><b>Data Supplement 33. Nonrandomized Trials, Observational Studies, and/or Registries of Cardiac Sarcoidosis – (Section 7.6) </b></text>
<text top="445" left="123" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="464" left="149" width="51" height="19" font="4"><b>Author; </b></text>
<text top="482" left="126" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="445" left="251" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="464" left="281" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="445" left="423" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="445" left="637" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="464" left="649" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="482" left="681" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="445" left="896" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="464" left="925" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="501" left="116" width="93" height="19" font="3">● Naruse et al. </text>
<text top="519" left="116" width="69" height="19" font="3">2014 (291) </text>
<text top="538" left="116" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24837644">● </a></text>
<text top="538" left="129" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24837644">24837644</a></text>
<text top="538" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24837644"> </a></text>
<text top="556" left="116" width="3" height="19" font="3"> </text>
<text top="501" left="245" width="101" height="19" font="4"><b>Aim:  </b>This study </text>
<text top="519" left="245" width="116" height="19" font="3">sought to describe </text>
<text top="538" left="245" width="122" height="19" font="3">both clinical and EP </text>
<text top="556" left="245" width="118" height="19" font="3">characteristics and </text>
<text top="574" left="245" width="80" height="19" font="3">outcomes of </text>
<text top="593" left="245" width="134" height="19" font="3">systematic treatment </text>
<text top="611" left="245" width="96" height="19" font="3">approach to VT </text>
<text top="629" left="245" width="120" height="19" font="3">associated with CS. </text>
<text top="648" left="245" width="3" height="19" font="4"><b> </b></text>
<text top="666" left="245" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="684" left="245" width="129" height="19" font="3">center observational </text>
<text top="703" left="245" width="3" height="19" font="3"> </text>
<text top="721" left="245" width="114" height="19" font="4"><b>Size:</b>    37 patients<b> </b></text>
<text top="501" left="395" width="133" height="19" font="4"><b>Inclusion criteria:</b>  37 </text>
<text top="519" left="395" width="152" height="19" font="3">consecutive patients (11 </text>
<text top="538" left="395" width="161" height="19" font="3">men; age, 56±11 y) with a </text>
<text top="556" left="395" width="157" height="19" font="3">diagnosis of sustained VT </text>
<text top="574" left="395" width="167" height="19" font="3">associated with CS. Clinical </text>
<text top="593" left="395" width="139" height="19" font="3">effects of a systematic </text>
<text top="611" left="395" width="126" height="19" font="3">treatment approach </text>
<text top="629" left="395" width="161" height="19" font="3">including medical therapy </text>
<text top="648" left="395" width="109" height="19" font="3">(both steroid and </text>
<text top="666" left="395" width="161" height="19" font="3">antiarrhythmic agents), in </text>
<text top="684" left="395" width="102" height="19" font="3">association with </text>
<text top="703" left="395" width="151" height="19" font="3">radiofrequency catheter </text>
<text top="721" left="395" width="159" height="19" font="3">ablation, were evaluated. </text>
<text top="739" left="395" width="3" height="19" font="3"> </text>
<text top="757" left="395" width="144" height="19" font="4"><b>Exclusion criteria:  </b>N/A<b> </b></text>
<text top="502" left="583" width="85" height="19" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="502" left="668" width="133" height="19" font="21">freedom from any VT </text>
<text top="520" left="583" width="3" height="19" font="4"><b> </b></text>
<text top="538" left="583" width="233" height="19" font="4"><b>Results: </b>During a 39 mo follow-up, 23 </text>
<text top="557" left="583" width="232" height="19" font="3">(62%) patients were free from any VT </text>
<text top="575" left="583" width="252" height="19" font="3">episodes with medical therapy. Fourteen </text>
<text top="593" left="583" width="256" height="19" font="3">patients who experienced VT recurrences </text>
<text top="612" left="583" width="241" height="19" font="3">even while on drug therapy underwent </text>
<text top="630" left="583" width="254" height="19" font="3">radiofrequency catheter ablation. After a </text>
<text top="648" left="583" width="218" height="19" font="3">33 mo follow-up subsequent to the </text>
<text top="667" left="583" width="254" height="19" font="3">radiofrequency catheter ablation, 6 of 14 </text>
<text top="685" left="583" width="250" height="19" font="3">patients experienced VT recurrence. The </text>
<text top="703" left="583" width="250" height="19" font="3">number of VTs sustained during EPS was </text>
<text top="722" left="583" width="253" height="19" font="3">higher in the patients with VT recurrence </text>
<text top="740" left="583" width="257" height="19" font="3">than in those without (3.7±1.4 vs 1.9±0.8; </text>
<text top="758" left="583" width="54" height="19" font="3">p&lt;0.01).<b> </b></text>
<text top="501" left="855" width="3" height="19" font="3"> </text>
</page>
<page number="161" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">161 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="116" width="107" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Takaya%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25529542">● Takaya Y,</a> et al. </text>
<text top="127" left="116" width="69" height="19" font="3">2015 (292) </text>
<text top="145" left="116" width="95" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25529542">● Am J Cardiol. </a></text>
<text top="164" left="116" width="78" height="19" font="3">2015 Feb 15 </text>
<text top="182" left="116" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25529542">● </a></text>
<text top="182" left="129" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25529542">25529542</a></text>
<text top="180" left="189" width="4" height="21" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25529542"> </a></text>
<text top="109" left="245" width="90" height="19" font="4"><b>Aim: </b>to assess </text>
<text top="127" left="245" width="132" height="19" font="3">outcomes in patients </text>
<text top="145" left="245" width="131" height="19" font="3">with AVB as an initial </text>
<text top="164" left="245" width="104" height="19" font="3">manifestation of </text>
<text top="182" left="245" width="117" height="19" font="3">cardiac sarcoidosis </text>
<text top="200" left="245" width="133" height="19" font="3">compared with those </text>
<text top="219" left="245" width="117" height="19" font="3">in patients with VT </text>
<text top="237" left="245" width="69" height="19" font="3">and/or HF. </text>
<text top="235" left="314" width="4" height="21" font="0"> </text>
<text top="255" left="245" width="3" height="19" font="4"><b> </b></text>
<text top="273" left="245" width="119" height="19" font="4"><b>Study type:</b>   single </text>
<text top="292" left="245" width="129" height="19" font="3">center observational </text>
<text top="310" left="245" width="3" height="19" font="3"> </text>
<text top="328" left="245" width="83" height="19" font="4"><b>Size:</b>    53 pts<b> </b></text>
<text top="109" left="395" width="142" height="19" font="4"><b>Inclusion criteria: </b>Fifty-</text>
<text top="127" left="395" width="165" height="19" font="3">three consecutive patients </text>
<text top="145" left="395" width="151" height="19" font="3">with cardiac sarcoidosis, </text>
<text top="164" left="395" width="162" height="19" font="3">who had high-degree AVB </text>
<text top="182" left="395" width="145" height="19" font="3">(N=22) or VT and/or HF </text>
<text top="200" left="395" width="137" height="19" font="3">(N=31), were enrolled </text>
<text top="219" left="395" width="3" height="19" font="3"> </text>
<text top="237" left="395" width="141" height="19" font="4"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="109" left="583" width="222" height="19" font="4"><b>1</b>°<b> endpoint:</b>  major adverse cardiac </text>
<text top="128" left="583" width="218" height="19" font="3">events, including cardiac death, VF, </text>
<text top="146" left="583" width="249" height="19" font="3">sustained VT, and hospitalization for HF. </text>
<text top="165" left="583" width="3" height="19" font="3"> </text>
<text top="183" left="583" width="253" height="19" font="4"><b>Results:</b>  Over a median follow-up period </text>
<text top="201" left="583" width="255" height="19" font="3">of 34 mo, the outcomes of major adverse </text>
<text top="219" left="583" width="234" height="19" font="3">cardiac events were better in patients </text>
<text top="238" left="583" width="250" height="19" font="3">with high-degree AVB than in those with </text>
<text top="256" left="583" width="234" height="19" font="3">VT and/or HF (log-rank test, p=0.046). </text>
<text top="274" left="583" width="251" height="19" font="3">However, this difference was due mainly </text>
<text top="293" left="583" width="238" height="19" font="3">to HF hospitalization. The outcomes of </text>
<text top="311" left="583" width="231" height="19" font="3">fatal cardiac events, including cardiac </text>
<text top="329" left="583" width="210" height="19" font="3">death, VF, and sustained VT, were </text>
<text top="348" left="583" width="241" height="19" font="3">comparable between the 2 groups (log-</text>
<text top="366" left="583" width="114" height="19" font="3">rank test, p=0.877<b> </b></text>
<text top="109" left="855" width="194" height="20" font="3">• Positive myocardial uptake of </text>
<text top="109" left="1048" width="12" height="12" font="15">67 </text>
<text top="128" left="855" width="36" height="19" font="3">Ga or </text>
<text top="128" left="891" width="12" height="12" font="15">18 </text>
<text top="128" left="903" width="152" height="19" font="3">F-FDG disappeared after </text>
<text top="146" left="855" width="210" height="19" font="3">the initiation of steroid treatment </text>
<text top="165" left="855" width="192" height="19" font="3">in all patients, and high-degree </text>
<text top="183" left="855" width="202" height="19" font="3">AVB recovered in some patients, </text>
<text top="201" left="855" width="203" height="19" font="3">indicating that steroid treatment </text>
<text top="219" left="855" width="190" height="19" font="3">was effective but might not be </text>
<text top="238" left="855" width="205" height="19" font="3">sufficient for preventing the fatal </text>
<text top="256" left="855" width="189" height="19" font="3">cardiac events in patients with </text>
<text top="274" left="855" width="109" height="19" font="3">high-degree AVB. </text>
<text top="293" left="855" width="3" height="19" font="3"> </text>
<text top="385" left="116" width="103" height="19" font="3">● Kandolin et al. </text>
<text top="403" left="116" width="69" height="19" font="3">2015 (293) </text>
<text top="422" left="116" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25527698">● </a></text>
<text top="422" left="129" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25527698">25527698</a></text>
<text top="422" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25527698"> </a></text>
<text top="440" left="116" width="3" height="19" font="3"> </text>
<text top="385" left="245" width="98" height="19" font="4"><b>Aim:</b> assess the </text>
<text top="403" left="245" width="90" height="19" font="3">epidemiology, </text>
<text top="422" left="245" width="121" height="19" font="3">characteristics, and </text>
<text top="440" left="245" width="107" height="19" font="3">outcome of CS in </text>
<text top="458" left="245" width="48" height="19" font="3">Finland </text>
<text top="476" left="245" width="3" height="19" font="4"><b> </b></text>
<text top="495" left="245" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="513" left="245" width="87" height="19" font="3">Retrospective </text>
<text top="531" left="245" width="3" height="19" font="3"> </text>
<text top="550" left="245" width="118" height="19" font="4"><b>Size:</b>   110 patients<b> </b></text>
<text top="385" left="395" width="149" height="19" font="4"><b>Inclusion criteria:</b>  adult </text>
<text top="403" left="395" width="136" height="19" font="3">(&gt;18y of age) patients </text>
<text top="422" left="395" width="96" height="19" font="3">diagnosed with </text>
<text top="440" left="395" width="167" height="19" font="3">histologically confirmed CS </text>
<text top="458" left="395" width="154" height="19" font="3">in Finland between 1988 </text>
<text top="476" left="395" width="150" height="19" font="3">and 2012. A total of 110 </text>
<text top="495" left="395" width="174" height="19" font="3">patients (71 women) 51±9 y </text>
<text top="513" left="395" width="146" height="19" font="3">of age (mean±SD) were </text>
<text top="531" left="395" width="163" height="19" font="3">found and followed up for </text>
<text top="550" left="395" width="168" height="19" font="3">outcome events to the end </text>
<text top="568" left="395" width="53" height="19" font="3">of 2013. </text>
<text top="586" left="395" width="3" height="19" font="3"> </text>
<text top="605" left="395" width="141" height="19" font="4"><b>Exclusion criteria: </b>N/A </text>
<text top="386" left="583" width="219" height="19" font="4"><b>1</b>°<b> endpoint: </b>serious cardiovascular </text>
<text top="404" left="583" width="44" height="19" font="3">events </text>
<text top="422" left="583" width="3" height="19" font="3"> </text>
<text top="441" left="583" width="217" height="19" font="4"><b>Results:</b> Altogether, 102 of the 110 </text>
<text top="459" left="583" width="234" height="19" font="3">patients received immunosuppressive </text>
<text top="477" left="583" width="228" height="19" font="3">therapy, and 56 received an ICD. Left </text>
<text top="496" left="583" width="246" height="19" font="3">ventricular function was impaired (LVEF </text>
<text top="514" left="583" width="242" height="19" font="3">&lt;50%) in 65 patients (59%) at diagnosis </text>
<text top="532" left="583" width="238" height="19" font="3">and showed no overall change over 12 </text>
<text top="550" left="583" width="246" height="19" font="3">mo of steroid therapy. During follow-up </text>
<text top="569" left="583" width="227" height="19" font="3">(median, 6.6 y), 10 patients died of a </text>
<text top="587" left="583" width="231" height="19" font="3">cardiac cause, 11 patients underwent </text>
<text top="606" left="583" width="251" height="19" font="3">transplantation, and another 11 patients </text>
<text top="624" left="583" width="206" height="19" font="3">suffered an aborted SCD. The KM </text>
<text top="642" left="583" width="179" height="19" font="3">estimates for 1-, 5-, and 10-y </text>
<text top="660" left="583" width="258" height="19" font="3">transplantation-free cardiac survival were </text>
<text top="679" left="583" width="241" height="19" font="3">97%, 90%, and 83%, respectively. HF at </text>
<text top="697" left="583" width="234" height="19" font="3">presentation predicted poor outcome </text>
<text top="715" left="583" width="193" height="19" font="3">(log-rank p=0.0001) with a 10 y </text>
<text top="734" left="583" width="240" height="19" font="3">transplantation-free cardiac survival of </text>
<text top="752" left="583" width="63" height="19" font="3">only 53%.<b> </b></text>
<text top="385" left="855" width="172" height="19" font="3">● With current therapy, the </text>
<text top="403" left="855" width="190" height="19" font="3">prognosis of CS appears better </text>
<text top="422" left="855" width="189" height="19" font="3">than generally considered, but </text>
<text top="440" left="855" width="196" height="19" font="3">patients presenting with HF still </text>
<text top="458" left="855" width="191" height="19" font="3">have poor long-term outcome. </text>
<text top="476" left="855" width="197" height="19" font="3">● Steroids appeared to stabilize </text>
<text top="495" left="855" width="191" height="19" font="3">disease but not reverse it. 10-y </text>
<text top="513" left="855" width="199" height="19" font="3">estimate of transplantation-free </text>
<text top="531" left="855" width="216" height="19" font="3">cardiac survival was as high as 91% </text>
<text top="550" left="855" width="198" height="19" font="3">in patients who were diagnosed </text>
<text top="568" left="855" width="137" height="19" font="3">clinically and received </text>
<text top="586" left="855" width="216" height="19" font="3">contemporary immunosuppressive </text>
<text top="605" left="855" width="124" height="19" font="3">and device therapy. </text>
<text top="623" left="855" width="193" height="19" font="3">● EF &lt;35% was most important </text>
<text top="641" left="855" width="139" height="19" font="3">predictor of outcomes </text>
</page>
<page number="162" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">162 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="116" width="87" height="19" font="3">● Yazaki et al. </text>
<text top="127" left="116" width="69" height="19" font="3">2001 (294) </text>
<text top="145" left="116" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11703997">● </a></text>
<text top="145" left="129" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11703997">11703997</a></text>
<text top="145" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11703997"> </a></text>
<text top="164" left="116" width="3" height="19" font="3"> </text>
<text top="182" left="116" width="3" height="19" font="3"> </text>
<text top="109" left="245" width="118" height="19" font="4"><b>Aim:</b> To determine </text>
<text top="127" left="245" width="89" height="19" font="3">the significant </text>
<text top="145" left="245" width="81" height="19" font="3">predictors of </text>
<text top="164" left="245" width="102" height="19" font="3">mortality and to </text>
<text top="182" left="245" width="131" height="19" font="3">assess the efficacy of </text>
<text top="200" left="245" width="94" height="19" font="3">corticosteroids </text>
<text top="218" left="245" width="3" height="19" font="4"><b> </b></text>
<text top="237" left="245" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="255" left="245" width="84" height="19" font="3">retrospective </text>
<text top="273" left="245" width="128" height="19" font="3">multicenter in Japan </text>
<text top="292" left="245" width="3" height="19" font="3"> </text>
<text top="310" left="245" width="110" height="19" font="4"><b>Size:</b>   95 patients<b> </b></text>
<text top="109" left="395" width="133" height="19" font="4"><b>Inclusion criteria:</b>  95 </text>
<text top="127" left="395" width="165" height="19" font="3">Japanese patients with CS. </text>
<text top="145" left="395" width="160" height="19" font="3">Twenty of the 95 patients </text>
<text top="164" left="395" width="120" height="19" font="3">had never received </text>
<text top="182" left="395" width="139" height="19" font="3">corticosteroid therapy </text>
<text top="200" left="395" width="174" height="19" font="3">because the sarcoidosis had </text>
<text top="219" left="395" width="168" height="19" font="3">not been diagnosed before </text>
<text top="237" left="395" width="151" height="19" font="3">their deaths; sarcoidosis </text>
<text top="255" left="395" width="171" height="19" font="3">was proved at autospy. The </text>
<text top="273" left="395" width="157" height="19" font="3">other 75 patients treated </text>
<text top="292" left="395" width="159" height="19" font="3">with corticosteroids were </text>
<text top="310" left="395" width="147" height="19" font="3">classified into 2 cohorts </text>
<text top="329" left="395" width="149" height="19" font="3">according to initial LVEF </text>
<text top="347" left="395" width="154" height="19" font="3">obtained by contrast left </text>
<text top="365" left="395" width="123" height="19" font="3">ventriculography or </text>
<text top="383" left="395" width="149" height="19" font="3">echocardiography: LVEF </text>
<text top="402" left="395" width="167" height="19" font="3">≥50% (N=39) or LVEF &lt;50% </text>
<text top="420" left="395" width="31" height="19" font="3">(36). </text>
<text top="438" left="395" width="3" height="19" font="3"> </text>
<text top="457" left="395" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="109" left="583" width="226" height="19" font="4"><b>1</b>°<b> endpoint:</b>  predictors of mortality<b> </b></text>
<text top="128" left="583" width="3" height="19" font="4"><b> </b></text>
<text top="146" left="583" width="254" height="19" font="4"><b>Results:</b> During the mean follow-up of 68 </text>
<text top="165" left="583" width="256" height="19" font="3">mo, 29 patients (73%) died of CHF and 11 </text>
<text top="183" left="583" width="232" height="19" font="3">(27%) experienced sudden death. KM </text>
<text top="201" left="583" width="250" height="19" font="3">survival curves showed 5-y survival rates </text>
<text top="219" left="583" width="233" height="19" font="3">of 75% in the steroid-treated patients </text>
<text top="238" left="583" width="257" height="19" font="3">and of 89% in patients with a LVEF ≥ 50%, </text>
<text top="256" left="583" width="249" height="19" font="3">whereas there was only 10% 5 y survival </text>
<text top="274" left="583" width="230" height="19" font="3">rate in autopsy subjects. Multivariate </text>
<text top="293" left="583" width="248" height="19" font="3">analysis identified NYHA functional class </text>
<text top="311" left="583" width="245" height="19" font="3">HR: 7.72 per class I increase, p=0.0008), </text>
<text top="329" left="583" width="234" height="19" font="3">left ventricular end-diastolic diameter </text>
<text top="348" left="583" width="246" height="19" font="3">(HR: 2.60/10 mm increase, p=0.02), and </text>
<text top="366" left="583" width="210" height="19" font="3">sustained VT (HR: 7.20, p=0.03) as </text>
<text top="384" left="583" width="226" height="19" font="3">independent predictors of mortality.<b> </b></text>
<text top="109" left="855" width="183" height="19" font="3">● Authors concluded that the </text>
<text top="127" left="855" width="214" height="19" font="3">severity of HF was one of the most </text>
<text top="145" left="855" width="212" height="19" font="3">significant independent predictors </text>
<text top="164" left="855" width="170" height="19" font="3">of mortality for CS. Starting </text>
<text top="182" left="855" width="162" height="19" font="3">corticosteroids before the </text>
<text top="200" left="855" width="210" height="19" font="3">occurrence of systolic dysfunction </text>
<text top="219" left="855" width="190" height="19" font="3">resulted in an excellent clinical </text>
<text top="237" left="855" width="58" height="19" font="3">outcome </text>
<text top="476" left="116" width="96" height="19" font="3">● Aizer A, et al. </text>
<text top="494" left="116" width="69" height="19" font="3">2005 (295) </text>
<text top="512" left="116" width="95" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16018857">● Am J Cardiol. </a></text>
<text top="531" left="116" width="37" height="19" font="3">2005  </text>
<text top="549" left="116" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16018857">● </a></text>
<text top="549" left="129" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16018857">16018857</a></text>
<text top="549" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16018857"> </a></text>
<text top="476" left="245" width="130" height="19" font="4"><b>Aim:</b> To evaluate the </text>
<text top="494" left="245" width="54" height="19" font="3">utility of </text>
<text top="512" left="245" width="83" height="19" font="3">programmed </text>
<text top="531" left="245" width="69" height="19" font="3">ventricular </text>
<text top="549" left="245" width="135" height="19" font="3">stimulation to predict </text>
<text top="567" left="245" width="112" height="19" font="3">future arrhythmic </text>
<text top="586" left="245" width="112" height="19" font="3">events in patients </text>
<text top="604" left="245" width="77" height="19" font="3">with cardiac </text>
<text top="622" left="245" width="70" height="19" font="3">sarcoidosis<b> </b></text>
<text top="640" left="245" width="3" height="19" font="4"><b> </b></text>
<text top="659" left="245" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="677" left="245" width="46" height="19" font="3">center  </text>
<text top="695" left="245" width="3" height="19" font="3"> </text>
<text top="714" left="245" width="79" height="19" font="4"><b>Size:</b>   32 pts<b> </b></text>
<text top="476" left="395" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="494" left="395" width="161" height="19" font="3">Consecutive patients with </text>
<text top="512" left="395" width="117" height="19" font="3">cardiac sarcoidosis </text>
<text top="531" left="395" width="154" height="19" font="3">underwent programmed </text>
<text top="549" left="395" width="145" height="19" font="3">ventricular stimulation. </text>
<text top="567" left="395" width="165" height="19" font="3">Patients with spontaneous </text>
<text top="586" left="395" width="137" height="19" font="3">or inducible sustained </text>
<text top="604" left="395" width="146" height="19" font="3">ventricular arrhythmias </text>
<text top="622" left="395" width="140" height="19" font="3">(N=12) underwent ICD </text>
<text top="640" left="395" width="58" height="19" font="3">insertion </text>
<text top="659" left="395" width="3" height="19" font="3"> </text>
<text top="677" left="395" width="135" height="19" font="4"><b>Exclusion criteria: </b>NA<b> </b></text>
<text top="476" left="583" width="258" height="19" font="4"><b>1</b>°<b> endpoint: </b>appropriate ICD therapies or </text>
<text top="495" left="583" width="87" height="19" font="3">sudden death </text>
<text top="513" left="583" width="3" height="19" font="3"> </text>
<text top="531" left="583" width="212" height="19" font="4"><b>Results: </b>5 of 6 patients (83%) with </text>
<text top="550" left="583" width="213" height="19" font="3">spontaneous sustained ventricular </text>
<text top="568" left="583" width="233" height="19" font="3">arrhythmias and 4 of 6 patients (67%) </text>
<text top="586" left="583" width="247" height="19" font="3">without spontaneous but with inducible </text>
<text top="605" left="583" width="208" height="19" font="3">sustained ventricular arrhythmias </text>
<text top="623" left="583" width="256" height="19" font="3">received appropriate ICD therapy. 2 of 20 </text>
<text top="641" left="583" width="252" height="19" font="3">patients (10%) with neither spontaneous </text>
<text top="660" left="583" width="215" height="19" font="3">nor inducible sustained ventricular </text>
<text top="678" left="583" width="217" height="19" font="3">arrhythmias experienced sustained </text>
<text top="696" left="583" width="254" height="19" font="3">ventricular arrhythmias or sudden death. </text>
<text top="714" left="583" width="225" height="19" font="3">Programmed ventricular stimulation </text>
<text top="733" left="583" width="251" height="19" font="3">predicted subsequent arrhythmic events </text>
<text top="751" left="583" width="230" height="19" font="3">in the entire population (relative HR:  </text>
<text top="769" left="583" width="253" height="19" font="3">4.47; 95% CI: 1.30–15.39) and in patients </text>
<text top="476" left="855" width="218" height="20" font="3">• Most patients had syncope, NSVT </text>
<text top="495" left="855" width="217" height="19" font="3">or presysncope and mean EF in the </text>
<text top="513" left="855" width="86" height="19" font="3">inducible was </text>
<text top="513" left="941" width="61" height="19" font="21">33.2±17.0</text>
<text top="513" left="1002" width="3" height="19" font="3"> </text>
</page>
<page number="163" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="22" size="12" family="Times" color="#4f4f4f"/>
<text top="803" left="585" width="29" height="21" font="0">163 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="583" width="229" height="19" font="3">who presented without spontaneous </text>
<text top="127" left="583" width="208" height="19" font="3">sustained ventricular arrhythmias </text>
<text top="145" left="583" width="241" height="19" font="3">(relative HR: 6.97; 95% CI: 1.27–38.27).<b> </b></text>
<text top="164" left="116" width="110" height="19" font="3">● Mehta D., et al. </text>
<text top="183" left="116" width="69" height="19" font="3">2011 (296) </text>
<text top="201" left="116" width="101" height="19" font="3">● Circ Arrhythm </text>
<text top="219" left="116" width="93" height="19" font="3">Electrophysiol. </text>
<text top="238" left="116" width="34" height="19" font="3">2011 </text>
<text top="256" left="116" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21193539">● </a></text>
<text top="256" left="129" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21193539">21193539</a></text>
<text top="256" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21193539"> </a></text>
<text top="164" left="245" width="118" height="19" font="4"><b>Aim:  to </b>assess the </text>
<text top="183" left="245" width="135" height="19" font="3">value of programmed </text>
<text top="201" left="245" width="136" height="19" font="3">electric stimulation of </text>
<text top="219" left="245" width="136" height="19" font="3">the ventricle (PES) for </text>
<text top="238" left="245" width="120" height="19" font="3">risk stratification in </text>
<text top="256" left="245" width="83" height="19" font="3">patients with </text>
<text top="274" left="245" width="74" height="19" font="3">sarcoidosis <b> </b></text>
<text top="292" left="245" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="311" left="245" width="112" height="19" font="3">center 1998-2008 </text>
<text top="329" left="245" width="3" height="19" font="3"> </text>
<text top="347" left="245" width="79" height="19" font="4"><b>Size:</b>   76 pts </text>
<text top="164" left="395" width="164" height="19" font="4"><b>Inclusion criteria</b>: Patients </text>
<text top="183" left="395" width="121" height="19" font="3">with biopsy-proven </text>
<text top="201" left="395" width="151" height="19" font="3">systemic sarcoidosis but </text>
<text top="219" left="395" width="165" height="19" font="3">without cardiac symptoms </text>
<text top="238" left="395" width="130" height="19" font="3">who had evidence of </text>
<text top="256" left="395" width="162" height="19" font="3">cardiac sarcoidosis on PET </text>
<text top="274" left="395" width="139" height="19" font="3">or CMR were included </text>
<text top="292" left="395" width="3" height="19" font="3"> </text>
<text top="311" left="395" width="146" height="19" font="4"><b>Exclusion criteria: </b>prior </text>
<text top="329" left="395" width="131" height="19" font="3">history of ventricular </text>
<text top="347" left="395" width="118" height="19" font="3">arrhythmias or ICD </text>
<text top="165" left="583" width="228" height="19" font="4"><b>1</b>°<b> endpoint: </b>survival and arrhythmic </text>
<text top="183" left="583" width="48" height="19" font="3">events. </text>
<text top="202" left="583" width="3" height="19" font="3"> </text>
<text top="220" left="583" width="239" height="19" font="4"><b>Results:</b> Eight (11%) were inducible for </text>
<text top="238" left="583" width="247" height="19" font="3">sustained VA and received an ICD. None </text>
<text top="257" left="583" width="241" height="19" font="3">of the noninducible patients received a </text>
<text top="275" left="583" width="245" height="19" font="3">defibrillator. LVEF was lower in patients </text>
<text top="293" left="583" width="198" height="19" font="3">with inducible VA (36.4±4.2% vs </text>
<text top="312" left="583" width="217" height="19" font="3">55.8±1.5%, p&lt;0.05). Over a median </text>
<text top="330" left="583" width="232" height="19" font="3">follow-up of 5 y, 6 of 8 patients in the </text>
<text top="348" left="583" width="247" height="19" font="3">group with inducible VA had VA or died, </text>
<text top="367" left="583" width="240" height="19" font="3">compared with 1 death in the negative </text>
<text top="385" left="583" width="39" height="19" font="3">group </text>
<text top="165" left="855" width="10" height="20" font="3">• </text>
<text top="165" left="865" width="194" height="19" font="14">Authors mention that based on </text>
<text top="183" left="855" width="179" height="19" font="14">present clinical indications, a </text>
<text top="202" left="855" width="204" height="19" font="14">significant proportion of patients </text>
<text top="220" left="855" width="201" height="19" font="14">with CS and LVEF of &lt;35% would </text>
<text top="239" left="855" width="214" height="19" font="14">qualify for ICD implantation. There </text>
<text top="257" left="855" width="211" height="19" font="14">are no data to guide management </text>
<text top="275" left="855" width="217" height="19" font="14">of patients with minimal or mild LV </text>
<text top="293" left="855" width="206" height="19" font="14">dysfunction who lack evidence of </text>
<text top="312" left="855" width="204" height="19" font="14">VA or conduction system disease.</text>
<text top="312" left="1059" width="3" height="19" font="3"> </text>
<text top="404" left="116" width="103" height="19" font="3">● Coleman et al. </text>
<text top="422" left="116" width="69" height="19" font="3">2016 (297) </text>
<text top="441" left="116" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27450877">● </a></text>
<text top="441" left="129" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27450877">27450877</a></text>
<text top="441" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27450877"> </a></text>
<text top="459" left="116" width="3" height="19" font="3"> </text>
<text top="404" left="245" width="101" height="19" font="4"><b>Aim:  </b>This study </text>
<text top="422" left="245" width="125" height="19" font="3">sought to perform a </text>
<text top="441" left="245" width="113" height="19" font="3">systematic review </text>
<text top="459" left="245" width="130" height="19" font="3">and meta-analysis to </text>
<text top="477" left="245" width="97" height="19" font="3">understand the </text>
<text top="496" left="245" width="120" height="19" font="3">prognostic value of </text>
<text top="514" left="245" width="122" height="19" font="3">myocardial scarring </text>
<text top="532" left="245" width="127" height="19" font="3">as evidenced by late </text>
<text top="550" left="245" width="71" height="19" font="3">gadolinium </text>
<text top="569" left="245" width="123" height="19" font="3">enhancement (298) </text>
<text top="587" left="245" width="118" height="19" font="3">on CMR imaging in </text>
<text top="605" left="245" width="128" height="19" font="3">patients with known </text>
<text top="624" left="245" width="104" height="19" font="3">or suspected CS. </text>
<text top="642" left="245" width="3" height="19" font="4"><b> </b></text>
<text top="660" left="245" width="117" height="19" font="4"><b>Study type:</b>   Meta </text>
<text top="679" left="245" width="55" height="19" font="3">analysis  </text>
<text top="697" left="245" width="3" height="19" font="3"> </text>
<text top="715" left="245" width="104" height="19" font="4"><b>Size:</b> Ten studies </text>
<text top="733" left="245" width="94" height="19" font="3">were included, </text>
<text top="752" left="245" width="116" height="19" font="3">involving a total of </text>
<text top="770" left="245" width="83" height="19" font="3">760 patients.<b> </b></text>
<text top="404" left="395" width="159" height="19" font="4"><b>Inclusion criteria</b>: Studies </text>
<text top="422" left="395" width="173" height="19" font="3">were considered eligible for </text>
<text top="441" left="395" width="69" height="19" font="3">inclusion if </text>
<text top="459" left="395" width="171" height="19" font="3">CMR was used to assess for </text>
<text top="477" left="395" width="155" height="19" font="3">myocardial scarring from </text>
<text top="496" left="395" width="163" height="19" font="3">biopsy-proven or clinically </text>
<text top="514" left="395" width="154" height="19" font="3">suspected sarcoidosis; in </text>
<text top="532" left="395" width="171" height="19" font="3">cohorts of &gt;5 patients; with </text>
<text top="550" left="395" width="112" height="19" font="3">&gt;1 y of prognostic </text>
<text top="569" left="395" width="155" height="19" font="3">follow-up data, including </text>
<text top="587" left="395" width="159" height="19" font="3">event data for ventricular </text>
<text top="605" left="395" width="158" height="19" font="3">arrhythmia, SCD, aborted </text>
<text top="624" left="395" width="131" height="19" font="3">cardiac death and/or </text>
<text top="642" left="395" width="165" height="19" font="3">appropriate ICD discharge, </text>
<text top="660" left="395" width="138" height="19" font="3">hospital admission for </text>
<text top="679" left="395" width="139" height="19" font="3">congestive HF, cardiac </text>
<text top="697" left="395" width="142" height="19" font="3">mortality, and allcause </text>
<text top="715" left="395" width="63" height="19" font="3">mortality. </text>
<text top="734" left="395" width="3" height="19" font="3"> </text>
<text top="752" left="395" width="161" height="19" font="4"><b>Exclusion criteria:</b> Studies </text>
<text top="770" left="395" width="167" height="19" font="3">with populations known to </text>
<text top="405" left="583" width="235" height="19" font="4"><b>1</b>°<b> endpoint: </b>all-cause mortality and a </text>
<text top="423" left="583" width="242" height="19" font="3">composite outcome of arrhythmogenic </text>
<text top="441" left="583" width="192" height="19" font="3">events plus all-cause mortality. </text>
<text top="460" left="583" width="3" height="19" font="3"> </text>
<text top="478" left="583" width="246" height="19" font="4"><b>Results:</b> The average EF was 57.8±9.1%. </text>
<text top="496" left="583" width="251" height="19" font="3">Patients with LGE had higher odds for all-</text>
<text top="515" left="583" width="238" height="19" font="3">cause mortality (OR: 3.06; p&lt;0.03) and </text>
<text top="533" left="583" width="240" height="19" font="3">higher odds of the composite outcome </text>
<text top="551" left="583" width="213" height="19" font="3">(OR: 10.74; p&lt;0.00001) than those </text>
<text top="570" left="583" width="236" height="19" font="3">without LGE. Patients with LGE had an </text>
<text top="588" left="583" width="238" height="19" font="3">increased annualized event rate of the </text>
<text top="606" left="583" width="227" height="19" font="3">composite outcome (11.9% vs. 1.1%; </text>
<text top="624" left="583" width="69" height="19" font="3">p&lt;0.0001).<b> </b></text>
<text top="404" left="855" width="40" height="19" font="3">● This </text>
<text top="404" left="895" width="145" height="19" font="22">analysis shows that the </text>
<text top="422" left="855" width="216" height="19" font="22">presence of LGE in sarcoid patients </text>
<text top="441" left="855" width="218" height="19" font="22">with normal or near-normal LVEF is </text>
<text top="459" left="855" width="181" height="19" font="22">prognostically significant and </text>
<text top="477" left="855" width="208" height="19" font="22">greatly increases the likelihood of </text>
<text top="496" left="855" width="95" height="19" font="22">adverse events.</text>
<text top="496" left="950" width="3" height="19" font="3"> </text>
</page>
<page number="164" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">164 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="395" width="78" height="19" font="3">have CAD or </text>
<text top="127" left="395" width="129" height="19" font="3">cardiomyopathies of </text>
<text top="145" left="395" width="127" height="19" font="3">nonsarcoid etiology.<b> </b></text>
<text top="164" left="116" width="103" height="19" font="3">● Murtagh et al. </text>
<text top="183" left="116" width="30" height="19" font="3">2016</text>
<text top="181" left="146" width="4" height="21" font="0"> </text>
<text top="183" left="150" width="35" height="19" font="3">(299) </text>
<text top="201" left="116" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26763280">● </a></text>
<text top="201" left="129" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26763280">26763280</a></text>
<text top="201" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26763280"> </a></text>
<text top="219" left="116" width="3" height="19" font="3"> </text>
<text top="164" left="245" width="129" height="19" font="4"><b>Aim:  </b>The aim of this </text>
<text top="183" left="245" width="80" height="19" font="3">study was to </text>
<text top="201" left="245" width="112" height="19" font="3">establish whether </text>
<text top="219" left="245" width="89" height="19" font="3">CMR with LGE </text>
<text top="238" left="245" width="127" height="19" font="3">imaging can be used </text>
<text top="256" left="245" width="87" height="19" font="3">to risk stratify </text>
<text top="274" left="245" width="128" height="19" font="3">patients with known </text>
<text top="293" left="245" width="78" height="19" font="3">extracardiac </text>
<text top="311" left="245" width="97" height="19" font="3">sarcoidosis and </text>
<text top="329" left="245" width="97" height="19" font="3">preserved LVEF </text>
<text top="347" left="245" width="53" height="19" font="3">(&gt;50%).  </text>
<text top="366" left="245" width="3" height="19" font="3"> </text>
<text top="384" left="245" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="402" left="245" width="131" height="19" font="3">center retrospective  </text>
<text top="421" left="245" width="3" height="19" font="3"> </text>
<text top="439" left="245" width="118" height="19" font="4"><b>Size:</b>   205 patients </text>
<text top="457" left="245" width="3" height="19" font="3"> </text>
<text top="164" left="395" width="137" height="19" font="4"><b>Inclusion criteria</b>: 205 </text>
<text top="183" left="395" width="153" height="19" font="3">patients with LVEF &gt;50% </text>
<text top="201" left="395" width="175" height="19" font="3">and extracardiac sarcoidosis </text>
<text top="219" left="395" width="101" height="19" font="3">who underwent </text>
<text top="238" left="395" width="151" height="19" font="3">cardiovascular magnetic </text>
<text top="256" left="395" width="114" height="19" font="3">resonance for LGE </text>
<text top="274" left="395" width="68" height="19" font="3">evaluation </text>
<text top="292" left="395" width="3" height="19" font="3"> </text>
<text top="311" left="395" width="141" height="19" font="4"><b>Exclusion criteria: </b>N/A </text>
<text top="165" left="583" width="184" height="19" font="4"><b>1</b>°<b> endpoint:</b>  death or any VT<b> </b></text>
<text top="183" left="583" width="3" height="19" font="4"><b> </b></text>
<text top="202" left="583" width="3" height="19" font="4"><b> </b></text>
<text top="220" left="583" width="249" height="19" font="4"><b>Results: </b>Forty-one of 205 patients (20%) </text>
<text top="238" left="583" width="241" height="19" font="3">had LGE; 12 of 205 (6%) died or had VT </text>
<text top="257" left="583" width="256" height="19" font="3">during follow-up; of these, 10 (83%) were </text>
<text top="275" left="583" width="248" height="19" font="3">in the LGE+ group. In the LGE+ group (1) </text>
<text top="293" left="583" width="244" height="19" font="3">the rate of death/VT/y was &gt;20× higher </text>
<text top="312" left="583" width="220" height="19" font="3">than LGE- (4.9 vs. 0.2%, p&lt;0.01); (2) </text>
<text top="330" left="583" width="251" height="19" font="3">death/VT were associated with a greater </text>
<text top="348" left="583" width="246" height="19" font="3">burden of LGE (14±11 vs. 5±5%, p&lt;0.01) </text>
<text top="367" left="583" width="239" height="19" font="3">and right ventricular dysfunction (right </text>
<text top="385" left="583" width="257" height="19" font="3">ventricular EF 45±12 vs. 53±28%, p=0.04). </text>
<text top="403" left="583" width="230" height="19" font="3">LGE burden was the best predictor of </text>
<text top="422" left="583" width="213" height="19" font="3">death/VT (area under the receiver-</text>
<text top="440" left="583" width="254" height="19" font="3">operating characteristics curve, 0.80); for </text>
<text top="458" left="583" width="231" height="19" font="3">every 1% increase of LGE burden, the </text>
<text top="476" left="583" width="227" height="19" font="3">hazard of death/VT increased by 8%.<b> </b></text>
<text top="164" left="855" width="178" height="19" font="3">● The burden of LGE and the </text>
<text top="183" left="855" width="209" height="19" font="3">severity of RV dysfunction further </text>
<text top="201" left="855" width="179" height="19" font="3">refine the risk of death/VT in </text>
<text top="219" left="855" width="102" height="19" font="3">patients with CS </text>
<text top="496" left="116" width="106" height="19" font="3">● Crawford et al. </text>
<text top="514" left="116" width="30" height="19" font="3">2014</text>
<text top="512" left="146" width="4" height="21" font="0"> </text>
<text top="514" left="150" width="35" height="19" font="3">(300) </text>
<text top="532" left="116" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25266311">● </a></text>
<text top="532" left="129" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25266311">25266311</a></text>
<text top="532" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25266311"> </a></text>
<text top="550" left="116" width="3" height="19" font="3"> </text>
<text top="495" left="245" width="94" height="19" font="4"><b>Aim:  </b>to assess </text>
<text top="514" left="245" width="106" height="19" font="3">whether delayed </text>
<text top="532" left="245" width="136" height="19" font="3">enhancement (DE) on </text>
<text top="550" left="245" width="108" height="19" font="3">MRI is associated </text>
<text top="569" left="245" width="126" height="19" font="3">with VT/VF or death </text>
<text top="587" left="245" width="116" height="19" font="3">in patients with CS </text>
<text top="605" left="245" width="96" height="19" font="3">and LVEF&gt;35%. </text>
<text top="624" left="245" width="3" height="19" font="4"><b> </b></text>
<text top="642" left="245" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="660" left="245" width="87" height="19" font="3">Retrospective </text>
<text top="679" left="245" width="84" height="19" font="3">analysis from </text>
<text top="697" left="245" width="124" height="19" font="3">multicenter registry </text>
<text top="715" left="245" width="3" height="19" font="3"> </text>
<text top="733" left="245" width="110" height="19" font="4"><b>Size:</b>   51 patients </text>
<text top="752" left="245" width="3" height="19" font="4"><b> </b></text>
<text top="495" left="395" width="169" height="19" font="4"><b>Inclusion criteria</b>: Fifty-one </text>
<text top="514" left="395" width="160" height="19" font="3">patients with CS and LVEF </text>
<text top="532" left="395" width="160" height="19" font="3">&gt;35% underwent DE-MRI. </text>
<text top="550" left="395" width="160" height="19" font="3">DE was assessed by visual </text>
<text top="569" left="395" width="170" height="19" font="3">scoring and quantified with </text>
<text top="587" left="395" width="129" height="19" font="3">the full-width at half-</text>
<text top="605" left="395" width="146" height="19" font="3">maximum method. The </text>
<text top="624" left="395" width="165" height="19" font="3">patients were followed for </text>
<text top="642" left="395" width="91" height="19" font="3">48.0±20.2 mo. </text>
<text top="660" left="395" width="3" height="19" font="3"> </text>
<text top="678" left="395" width="141" height="19" font="4"><b>Exclusion criteria: </b>N/A </text>
<text top="496" left="583" width="180" height="19" font="4"><b>1</b>°<b> endpoint:</b>  death or VT/VF<b> </b></text>
<text top="515" left="583" width="3" height="19" font="4"><b> </b></text>
<text top="533" left="583" width="3" height="19" font="4"><b> </b></text>
<text top="551" left="583" width="255" height="19" font="4"><b>Results:</b> Twenty-two of 51 patients (63%) </text>
<text top="570" left="583" width="252" height="19" font="3">had DE. Forty patients had no prior Hx of </text>
<text top="588" left="583" width="250" height="19" font="3">VT (1° prevention cohort). Among those, </text>
<text top="606" left="583" width="241" height="19" font="3">3 patients developed VT and 2 patients </text>
<text top="624" left="583" width="219" height="19" font="3">died. DE was associated with risk of </text>
<text top="643" left="583" width="254" height="19" font="3">VT/VF or death (p=0.0032 for any DE and </text>
<text top="661" left="583" width="237" height="19" font="3">p&lt;0.0001 for right ventricular DE). The </text>
<text top="680" left="583" width="256" height="19" font="3">positive predictive values of the presence </text>
<text top="698" left="583" width="211" height="19" font="3">of any DE, multifocal DE, and right </text>
<text top="716" left="583" width="222" height="19" font="3">ventricular DE for death or VT/VF at </text>
<text top="734" left="583" width="258" height="19" font="3">mean follow-up of 48 mo were 22%, 48%, </text>
<text top="753" left="583" width="147" height="19" font="3">and 100%, respectively.<b> </b></text>
<text top="496" left="855" width="194" height="19" font="3">● A cut-off value of ≥9 involved </text>
<text top="514" left="855" width="210" height="19" font="3">segments separated patients with </text>
<text top="532" left="855" width="216" height="19" font="3">and without future VTs, suggesting </text>
<text top="550" left="855" width="188" height="19" font="3">that a threshold effect may be </text>
<text top="569" left="855" width="158" height="19" font="3">present. Right ventricular </text>
<text top="587" left="855" width="156" height="19" font="3">involvement seems to be </text>
<text top="605" left="855" width="159" height="19" font="3">particularly important for </text>
<text top="624" left="855" width="156" height="19" font="3">arrhythmogenesis; it was </text>
<text top="642" left="855" width="206" height="19" font="3">predictive of adverse events in 1° </text>
<text top="660" left="855" width="194" height="19" font="3">prevention patients and for the </text>
<text top="679" left="855" width="216" height="19" font="3">group as a whole. Patients without </text>
<text top="697" left="855" width="200" height="19" font="3">DE on MRI have a low risk of VT. </text>
</page>
<page number="165" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">165 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="116" width="101" height="19" font="3">● Greulich et al. </text>
<text top="127" left="116" width="30" height="19" font="3">2013</text>
<text top="126" left="146" width="4" height="21" font="0"> </text>
<text top="127" left="150" width="35" height="19" font="3">(186) </text>
<text top="145" left="116" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23498675">● </a></text>
<text top="145" left="129" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23498675">23498675</a></text>
<text top="145" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23498675"> </a></text>
<text top="164" left="116" width="3" height="19" font="3"> </text>
<text top="109" left="245" width="130" height="19" font="4"><b>Aim:  </b>study aimed to </text>
<text top="127" left="245" width="134" height="19" font="3">demonstrate that the </text>
<text top="145" left="245" width="101" height="19" font="3">presence of late </text>
<text top="164" left="245" width="71" height="19" font="3">gadolinium </text>
<text top="182" left="245" width="136" height="19" font="3">enhancement (298) is </text>
<text top="200" left="245" width="125" height="19" font="3">a predictor of death </text>
<text top="219" left="245" width="114" height="19" font="3">and other adverse </text>
<text top="237" left="245" width="112" height="19" font="3">events in patients </text>
<text top="255" left="245" width="114" height="19" font="3">with suspected CS<b> </b></text>
<text top="273" left="245" width="3" height="19" font="4"><b> </b></text>
<text top="292" left="245" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="310" left="245" width="75" height="19" font="3">Multicenter </text>
<text top="328" left="245" width="75" height="19" font="3">prospective </text>
<text top="347" left="245" width="3" height="19" font="3"> </text>
<text top="365" left="245" width="118" height="19" font="4"><b>Size:</b>   155 patients </text>
<text top="109" left="395" width="137" height="19" font="4"><b>Inclusion criteria</b>: 155 </text>
<text top="127" left="395" width="159" height="19" font="3">consecutive patients with </text>
<text top="145" left="395" width="156" height="19" font="3">systemic sarcoidosis who </text>
<text top="164" left="395" width="174" height="19" font="3">underwent CMR for workup </text>
<text top="182" left="395" width="128" height="19" font="3">of suspected cardiac </text>
<text top="200" left="395" width="157" height="19" font="3">sarcoid involvement. The </text>
<text top="219" left="395" width="169" height="19" font="3">median follow-up time was </text>
<text top="237" left="395" width="36" height="19" font="3">2.6 y. </text>
<text top="255" left="395" width="3" height="19" font="3"> </text>
<text top="273" left="395" width="144" height="19" font="4"><b>Exclusion criteria: </b> N/A<b> </b></text>
<text top="109" left="583" width="239" height="19" font="4"><b>1</b>°<b> endpoint: </b>1° endpoints were death, </text>
<text top="128" left="583" width="209" height="19" font="3">aborted SCD, and appropriate ICD </text>
<text top="146" left="583" width="65" height="19" font="3">discharge. </text>
<text top="165" left="583" width="3" height="19" font="3"> </text>
<text top="183" left="583" width="243" height="19" font="4"><b>Results:</b> LGE was present in 39 patients </text>
<text top="201" left="583" width="256" height="19" font="3">(25.5%). The presence of LGE yields a Cox </text>
<text top="219" left="583" width="218" height="19" font="3">HR: 31.6 for death, aborted SCD, or </text>
<text top="238" left="583" width="238" height="19" font="3">appropriate ICD discharge, and of 33.9 </text>
<text top="256" left="583" width="199" height="19" font="3">for any event. This is superior to </text>
<text top="274" left="583" width="248" height="19" font="3">functional or clinical parameters such as </text>
<text top="293" left="583" width="205" height="19" font="3">LVEF, LV end-diastolic volume, or </text>
<text top="311" left="583" width="256" height="19" font="3">presentation as HF, yielding HRs between </text>
<text top="329" left="583" width="228" height="19" font="3">0.99 (per % increase LVEF) and 1.004 </text>
<text top="348" left="583" width="244" height="19" font="3">(presentation as HF), and between 0.94 </text>
<text top="366" left="583" width="230" height="19" font="3">and 1.2 for potentially lethal or other </text>
<text top="384" left="583" width="179" height="19" font="3">adverse events, respectively.<b> </b></text>
<text top="109" left="855" width="208" height="19" font="3">● Could not tell on additional LGE </text>
<text top="127" left="855" width="204" height="19" font="3">parameters due to low numbers. </text>
<text top="403" left="116" width="113" height="19" font="3">● Blankstein et al. </text>
<text top="422" left="116" width="30" height="19" font="3">2014</text>
<text top="420" left="146" width="4" height="21" font="0"> </text>
<text top="422" left="150" width="35" height="19" font="3">(301) </text>
<text top="440" left="116" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24140661">● </a></text>
<text top="440" left="129" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24140661">24140661</a></text>
<text top="440" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24140661"> </a></text>
<text top="458" left="116" width="3" height="19" font="3"> </text>
<text top="403" left="245" width="91" height="19" font="4"><b>Aim:  </b>to relate </text>
<text top="422" left="245" width="122" height="19" font="3">imaging findings on </text>
<text top="440" left="245" width="112" height="19" font="3">positron emission </text>
<text top="458" left="245" width="129" height="19" font="3">tomography (PET) to </text>
<text top="476" left="245" width="98" height="19" font="3">adverse cardiac </text>
<text top="495" left="245" width="112" height="19" font="3">events in patients </text>
<text top="513" left="245" width="75" height="19" font="3">referred for </text>
<text top="531" left="245" width="128" height="19" font="3">evaluation of known </text>
<text top="550" left="245" width="104" height="19" font="3">or suspected CS. </text>
<text top="568" left="245" width="3" height="19" font="3"> </text>
<text top="586" left="245" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="605" left="245" width="129" height="19" font="3">center observational </text>
<text top="623" left="245" width="3" height="19" font="3"> </text>
<text top="641" left="245" width="115" height="19" font="4"><b>Size:</b>  118 patients </text>
<text top="659" left="245" width="3" height="19" font="4"><b> </b></text>
<text top="403" left="395" width="114" height="19" font="4"><b>Inclusion criteria</b>:  </text>
<text top="422" left="395" width="159" height="19" font="3">consecutive patients with </text>
<text top="440" left="395" width="151" height="19" font="3">no Hx of CAD, who were </text>
<text top="458" left="395" width="140" height="19" font="3">referred for PET, using </text>
<text top="476" left="395" width="175" height="19" font="3">(18)F-fluorodeoxyglucose to </text>
<text top="495" left="395" width="174" height="19" font="3">assess for inflammation and </text>
<text top="513" left="395" width="172" height="19" font="3">rubidium-82 to evaluate for </text>
<text top="531" left="395" width="143" height="19" font="3">perfusion defects (PD), </text>
<text top="550" left="395" width="150" height="19" font="3">following a high-fat/low-</text>
<text top="568" left="395" width="129" height="19" font="3">carbohydrate diet to </text>
<text top="586" left="395" width="175" height="19" font="3">suppress normal myocardial </text>
<text top="605" left="395" width="95" height="19" font="3">glucose uptake </text>
<text top="623" left="395" width="3" height="19" font="3"> </text>
<text top="641" left="395" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="404" left="583" width="161" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Death or VT<b> </b></text>
<text top="422" left="583" width="3" height="19" font="4"><b> </b></text>
<text top="441" left="583" width="232" height="19" font="4"><b>Results: </b>Among the 118 patients (age </text>
<text top="459" left="583" width="248" height="19" font="3">52±11 y; 57% males; mean EF: 47±16%), </text>
<text top="477" left="583" width="240" height="19" font="3">47 (40%) had normal and 71 (60%) had </text>
<text top="496" left="583" width="233" height="19" font="3">abnormal cardiac PET findings. Over a </text>
<text top="514" left="583" width="252" height="19" font="3">median follow-up of 1.5 y, there were 31 </text>
<text top="532" left="583" width="213" height="19" font="3">(26%) adverse events (27 VT and 8 </text>
<text top="550" left="583" width="213" height="19" font="3">deaths). Cardiac PET findings were </text>
<text top="569" left="583" width="228" height="19" font="3">predictive of AE, and the presence of </text>
<text top="587" left="583" width="230" height="19" font="3">both a PD and abnormal FDG (29% of </text>
<text top="606" left="583" width="231" height="19" font="3">patients) was associated with HR:3.9; </text>
<text top="624" left="583" width="232" height="19" font="3">p&lt;0.01 and remained significant after </text>
<text top="642" left="583" width="234" height="19" font="3">adjusting for LVEF and clinical criteria. </text>
<text top="660" left="583" width="207" height="19" font="3">Extra-cardiac FDG uptake (26% of </text>
<text top="679" left="583" width="230" height="19" font="3">patients) was not associated with AE.<b> </b></text>
<text top="403" left="855" width="213" height="19" font="3">● Conclusion was that presence of </text>
<text top="422" left="855" width="220" height="19" font="3">focal PD and FDG uptake on cardiac </text>
<text top="440" left="855" width="197" height="19" font="3">PET identifies patients at higher </text>
<text top="458" left="855" width="119" height="19" font="3">risk of death or VT. </text>
<text top="698" left="116" width="109" height="19" font="3">● Kron et al. 2013</text>
<text top="696" left="225" width="4" height="21" font="0"> </text>
<text top="716" left="116" width="35" height="19" font="3">(302) </text>
<text top="734" left="116" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23002195">● </a></text>
<text top="734" left="129" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23002195">23002195</a></text>
<text top="734" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23002195"> </a></text>
<text top="753" left="116" width="3" height="19" font="3"> </text>
<text top="771" left="116" width="3" height="19" font="3"> </text>
<text top="698" left="245" width="128" height="19" font="4"><b>Aim: </b>to evaluate the </text>
<text top="716" left="245" width="133" height="19" font="3">efficacy and safety of </text>
<text top="734" left="245" width="129" height="19" font="3">ICDs in patients with </text>
<text top="753" left="245" width="18" height="19" font="3">CS </text>
<text top="771" left="245" width="3" height="19" font="4"><b> </b></text>
<text top="698" left="395" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="716" left="395" width="159" height="19" font="3">consecutive patients with </text>
<text top="734" left="395" width="122" height="19" font="3">CS and an ICD at 13 </text>
<text top="753" left="395" width="114" height="19" font="3">academic centers. </text>
<text top="698" left="583" width="235" height="19" font="4"><b>1</b>°<b> endpoint:</b>  appropriate ICD therapy<b> </b></text>
<text top="717" left="583" width="3" height="19" font="3"> </text>
<text top="735" left="583" width="3" height="19" font="3"> </text>
<text top="753" left="583" width="211" height="19" font="4"><b>Results: </b>Over a mean follow-up of </text>
<text top="772" left="583" width="226" height="19" font="3">4.2±4.0 y, 85 of 234 (36.2%) patients </text>
<text top="698" left="855" width="200" height="19" font="3">● Patients receiving appropriate </text>
<text top="716" left="855" width="201" height="19" font="3">therapies were more likely to be </text>
<text top="734" left="855" width="216" height="19" font="3">male, have a Hx of syncope, have a </text>
<text top="753" left="855" width="196" height="19" font="3">lower LVEF, a 2° prevention ICD </text>
<text top="771" left="855" width="64" height="19" font="3">indication </text>
</page>
<page number="166" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">166 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="245" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="127" left="245" width="74" height="19" font="3">multicentre </text>
<text top="145" left="245" width="115" height="19" font="3">retrospective data </text>
<text top="164" left="245" width="48" height="19" font="3">review  </text>
<text top="182" left="245" width="3" height="19" font="3"> </text>
<text top="200" left="245" width="118" height="19" font="4"><b>Size:</b>   235 patients </text>
<text top="219" left="245" width="124" height="19" font="3">from 13 institutions </text>
<text top="109" left="395" width="156" height="19" font="3">147 patients (62.6%) had </text>
<text top="127" left="395" width="168" height="19" font="3">their devices implanted for </text>
<text top="145" left="395" width="141" height="19" font="3">1° prevention while 88 </text>
<text top="164" left="395" width="137" height="19" font="3">patients (37.5%) were </text>
<text top="182" left="395" width="103" height="19" font="3">implanted for 2° </text>
<text top="200" left="395" width="165" height="19" font="3">prevention, including 7 for </text>
<text top="219" left="395" width="123" height="19" font="3">VF (3.0%), 63 for VT </text>
<text top="237" left="395" width="173" height="19" font="3">(26.8%), and 18 for syncope </text>
<text top="255" left="395" width="162" height="19" font="3">presumed to be due to an </text>
<text top="273" left="395" width="117" height="19" font="3">arrhythmia (7.7%). </text>
<text top="292" left="395" width="3" height="19" font="3"> </text>
<text top="310" left="395" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="109" left="583" width="225" height="19" font="3">received an appropriate ICD therapy </text>
<text top="127" left="583" width="244" height="19" font="3">(shocks and/or anti-tachycardia pacing) </text>
<text top="145" left="583" width="211" height="19" font="3">and 67 of 226 (29.7%) received an </text>
<text top="164" left="583" width="118" height="19" font="3">appropriate shock. </text>
<text top="109" left="855" width="159" height="19" font="3">● Most patients receiving </text>
<text top="127" left="855" width="214" height="19" font="3">appropriate therapies had an LVEF </text>
<text top="145" left="855" width="208" height="19" font="3">&gt;35%, suggesting that CS patients </text>
<text top="164" left="855" width="204" height="19" font="3">with mild or moderately reduced </text>
<text top="182" left="855" width="162" height="19" font="3">LVEF may be at risk for VA </text>
<text top="329" left="116" width="99" height="19" font="3">● Mohsen et al. </text>
<text top="347" left="116" width="30" height="19" font="3">2014</text>
<text top="346" left="146" width="4" height="21" font="0"> </text>
<text top="347" left="150" width="35" height="19" font="3">(303) </text>
<text top="366" left="116" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24433308">● </a></text>
<text top="366" left="129" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24433308">24433308</a></text>
<text top="366" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24433308"> </a></text>
<text top="384" left="116" width="3" height="19" font="3"> </text>
<text top="329" left="245" width="126" height="19" font="4"><b>Aim:  </b>to identify the </text>
<text top="347" left="245" width="105" height="19" font="3">predictors of life-</text>
<text top="366" left="245" width="110" height="19" font="3">threatening VA in </text>
<text top="384" left="245" width="128" height="19" font="3">patients with CS and </text>
<text top="402" left="245" width="123" height="19" font="3">to evaluate the role </text>
<text top="421" left="245" width="104" height="19" font="3">of the ICD in this </text>
<text top="439" left="245" width="121" height="19" font="3">patient population.<b> </b></text>
<text top="457" left="245" width="3" height="19" font="4"><b> </b></text>
<text top="476" left="245" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="494" left="245" width="74" height="19" font="3">multicentre </text>
<text top="512" left="245" width="115" height="19" font="3">retrospective data </text>
<text top="531" left="245" width="44" height="19" font="3">review </text>
<text top="549" left="245" width="7" height="19" font="3">  </text>
<text top="567" left="245" width="114" height="19" font="4"><b>Size:</b>   32 patients. </text>
<text top="586" left="245" width="133" height="19" font="3">84% received the ICD </text>
<text top="604" left="245" width="92" height="19" font="3">for symptoms. </text>
<text top="329" left="395" width="167" height="19" font="4"><b>Inclusion criteria:</b>  Patients </text>
<text top="347" left="395" width="121" height="19" font="3">with biopsy-proven </text>
<text top="366" left="395" width="151" height="19" font="3">systemic sarcoidosis but </text>
<text top="384" left="395" width="165" height="19" font="3">without cardiac symptoms </text>
<text top="402" left="395" width="167" height="19" font="3">who had evidence of CS on </text>
<text top="421" left="395" width="112" height="19" font="3">positron emission </text>
<text top="439" left="395" width="162" height="19" font="3">tomography (PET) or CMR </text>
<text top="457" left="395" width="90" height="19" font="3">were included </text>
<text top="476" left="395" width="3" height="19" font="3"> </text>
<text top="494" left="395" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="330" left="583" width="235" height="19" font="4"><b>1</b>°<b> endpoint:</b>  appropriate ICD therapy<b> </b></text>
<text top="348" left="583" width="3" height="19" font="4"><b> </b></text>
<text top="367" left="583" width="3" height="19" font="4"><b> </b></text>
<text top="385" left="583" width="232" height="19" font="4"><b>Results:</b> The mean LVEF was 41±18%. </text>
<text top="403" left="583" width="241" height="19" font="3">Thirty patients received an ICD. Twelve </text>
<text top="422" left="583" width="216" height="19" font="3">patients (36.3%) had sustained VA. </text>
<text top="440" left="583" width="228" height="19" font="3">Eleven patients received appropriate </text>
<text top="458" left="583" width="207" height="19" font="3">therapies and 9 patients received </text>
<text top="476" left="583" width="257" height="19" font="3">inappropriate shocks, representing 36.7% </text>
<text top="495" left="583" width="205" height="19" font="3">and 30.0% of the ICD population, </text>
<text top="513" left="583" width="219" height="19" font="3">respectively. Patients who received </text>
<text top="531" left="583" width="249" height="19" font="3">appropriate ICD therapies were younger </text>
<text top="550" left="583" width="255" height="19" font="3">with mean age 47.4±7.8, and had a lower </text>
<text top="568" left="583" width="254" height="19" font="3">mean LVEF 33.0±12.0 compared to those </text>
<text top="586" left="583" width="209" height="19" font="3">who did not receive ICD therapies </text>
<text top="605" left="583" width="225" height="19" font="3">(p=0.0301 and 0.0341, respectively). </text>
<text top="329" left="855" width="194" height="19" font="3">● CS is strongly associated with </text>
<text top="347" left="855" width="158" height="19" font="3">malignant VA. No specific </text>
<text top="366" left="855" width="113" height="19" font="3">predictors of such </text>
<text top="384" left="855" width="209" height="19" font="3">tachyarrhythmias emerged, other </text>
<text top="402" left="855" width="185" height="19" font="3">than young age and low LVEF. </text>
<text top="421" left="855" width="187" height="19" font="3">● Over 2/3 received ICD for 2° </text>
<text top="439" left="855" width="70" height="19" font="3">prevention </text>
<text top="457" left="855" width="3" height="19" font="3"> </text>
<text top="624" left="116" width="98" height="19" font="3">● Schuller et al. </text>
<text top="642" left="116" width="30" height="19" font="3">2012</text>
<text top="640" left="146" width="4" height="21" font="0"> </text>
<text top="642" left="150" width="35" height="19" font="3">(304) </text>
<text top="660" left="116" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22812589">● </a></text>
<text top="660" left="129" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22812589">22812589</a></text>
<text top="660" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22812589"> </a></text>
<text top="624" left="245" width="109" height="19" font="4"><b>Aim:  </b>identify the </text>
<text top="642" left="245" width="88" height="19" font="3">incidence and </text>
<text top="660" left="245" width="131" height="19" font="3">characteristics of ICD </text>
<text top="679" left="245" width="128" height="19" font="3">therapies in patients </text>
<text top="697" left="245" width="49" height="19" font="3">with CS<b> </b></text>
<text top="715" left="245" width="3" height="19" font="4"><b> </b></text>
<text top="733" left="245" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="752" left="245" width="74" height="19" font="3">multicentre </text>
<text top="770" left="245" width="87" height="19" font="3">observational </text>
<text top="624" left="395" width="168" height="19" font="4"><b>Inclusion criteria:</b>  Patients </text>
<text top="642" left="395" width="118" height="19" font="3">with CS and an ICD </text>
<text top="660" left="395" width="135" height="19" font="3">implanted for 1° or 2° </text>
<text top="679" left="395" width="134" height="19" font="3">prevention of sudden </text>
<text top="697" left="395" width="173" height="19" font="3">death. Additionally, authors </text>
<text top="715" left="395" width="171" height="19" font="3">included a comparison with </text>
<text top="734" left="395" width="152" height="19" font="3">historical controls of ICD </text>
<text top="752" left="395" width="157" height="19" font="3">therapy rates reported in </text>
<text top="770" left="395" width="169" height="19" font="3">clinical trials evaluating the </text>
<text top="624" left="583" width="187" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Any ICD therapy<b> </b></text>
<text top="643" left="583" width="3" height="19" font="4"><b> </b></text>
<text top="661" left="583" width="258" height="19" font="4"><b>Results:</b> Of the 112 CS subjects identified, </text>
<text top="679" left="583" width="200" height="19" font="3">36 (32.1%) received appropriate </text>
<text top="698" left="583" width="221" height="19" font="3">therapies VT over a mean follow-up </text>
<text top="716" left="583" width="255" height="19" font="3">period of 29.2 mo. VT storm (&gt;3 episodes </text>
<text top="734" left="583" width="208" height="19" font="3">in 24 h) occurred in 16 (14.2%) CS </text>
<text top="753" left="583" width="205" height="19" font="3">subjects. Inappropriate therapies </text>
<text top="771" left="583" width="216" height="19" font="3">occurred in 13 CS subjects (11.6%). </text>
<text top="624" left="855" width="209" height="19" font="3">● Appropriate ICD therapies were </text>
<text top="642" left="855" width="195" height="19" font="3">higher than in historical control </text>
<text top="660" left="855" width="3" height="19" font="3"> </text>
</page>
<page number="167" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">167 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="245" width="3" height="19" font="3"> </text>
<text top="127" left="245" width="114" height="19" font="4"><b>Size:</b>   32 patients. </text>
<text top="145" left="245" width="133" height="19" font="3">84% received the ICD </text>
<text top="164" left="245" width="92" height="19" font="3">for symptoms.<b> </b></text>
<text top="109" left="395" width="174" height="19" font="3">ICD for 1° and 2° prevention </text>
<text top="127" left="395" width="107" height="19" font="3">of sudden death. </text>
<text top="145" left="395" width="3" height="19" font="3"> </text>
<text top="164" left="395" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="109" left="583" width="241" height="19" font="3">Covariates associated with appropriate </text>
<text top="127" left="583" width="236" height="19" font="3">ICD therapies included LVEF &lt;55% (OR </text>
<text top="145" left="583" width="256" height="19" font="3">6.52; 95% CI: 2.43–17.5), right ventricular </text>
<text top="164" left="583" width="221" height="19" font="3">dysfunction (OR: 6.73; 95% CI: 2.69–</text>
<text top="182" left="583" width="231" height="19" font="3">16.8), and symptomatic HF (OR: 4.33; </text>
<text top="200" left="583" width="121" height="19" font="3">95% CI: 1.86–10.1).<b> </b></text>
<text top="219" left="116" width="112" height="19" font="3">● Yodogawa et al. </text>
<text top="238" left="116" width="30" height="19" font="3">2011</text>
<text top="236" left="146" width="4" height="21" font="0"> </text>
<text top="238" left="150" width="35" height="19" font="3">(305) </text>
<text top="256" left="116" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21496164">● </a></text>
<text top="256" left="129" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21496164">21496164</a></text>
<text top="256" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21496164"> </a></text>
<text top="219" left="245" width="132" height="19" font="4"><b>Aim:  </b>to evaluate<b> </b>the </text>
<text top="238" left="245" width="66" height="19" font="3">efficacy of </text>
<text top="256" left="245" width="88" height="19" font="3">corticosteroid </text>
<text top="274" left="245" width="104" height="19" font="3">therapy VA in CS<b> </b></text>
<text top="292" left="245" width="3" height="19" font="4"><b> </b></text>
<text top="311" left="245" width="114" height="19" font="4"><b>Study type:</b> Single </text>
<text top="329" left="245" width="129" height="19" font="3">center observational </text>
<text top="347" left="245" width="3" height="19" font="3"> </text>
<text top="366" left="245" width="104" height="19" font="4"><b>Size: </b>31 patients<b> </b></text>
<text top="219" left="395" width="168" height="19" font="4"><b>Inclusion criteria:</b>  Patients </text>
<text top="238" left="395" width="137" height="19" font="3">presenting premature </text>
<text top="256" left="395" width="148" height="19" font="3">ventricular contractions </text>
<text top="274" left="395" width="124" height="19" font="3">(PVCs ≥300/d) were </text>
<text top="293" left="395" width="135" height="19" font="3">investigated. All were </text>
<text top="311" left="395" width="135" height="19" font="3">treated with steroids. </text>
<text top="329" left="395" width="3" height="19" font="3"> </text>
<text top="347" left="395" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="220" left="583" width="228" height="19" font="4"><b>1</b>°<b> endpoint:</b>  PVCs and NSVT burden </text>
<text top="238" left="583" width="204" height="19" font="3">before and after steroid therapy. </text>
<text top="257" left="583" width="3" height="19" font="4"><b> </b></text>
<text top="275" left="583" width="254" height="19" font="4"><b>Results: </b>The group with less advanced LV </text>
<text top="293" left="583" width="231" height="19" font="3">dysfunction patients (EF ≥35%, N=17) </text>
<text top="312" left="583" width="218" height="19" font="3">showed significant reduction in the </text>
<text top="330" left="583" width="227" height="19" font="3">number of PVCs (from 1820±2969 to </text>
<text top="348" left="583" width="190" height="19" font="3">742±1425, p=0.048) and in the </text>
<text top="367" left="583" width="220" height="19" font="3">prevalence of NSVT (from 41 to 6%, </text>
<text top="385" left="583" width="252" height="19" font="3">p=0.039). Late potentials on SAECG were </text>
<text top="403" left="583" width="197" height="19" font="3">abolished in 3 patients. The less </text>
<text top="422" left="583" width="256" height="19" font="3">advanced LV dysfunction group showed a </text>
<text top="440" left="583" width="254" height="19" font="3">significantly higher prevalence of gallium-</text>
<text top="458" left="583" width="246" height="19" font="3">67 uptake compared with the advanced </text>
<text top="476" left="583" width="258" height="19" font="3">LV dysfunction group (EF &lt;35 %, N=14). In </text>
<text top="495" left="583" width="236" height="19" font="3">the advanced LV dysfunction patients, </text>
<text top="513" left="583" width="242" height="19" font="3">there were no significant differences in </text>
<text top="531" left="583" width="115" height="19" font="3">these parameters. </text>
<text top="219" left="855" width="215" height="19" font="3">● Steroid therapy may be effective </text>
<text top="239" left="855" width="21" height="19" font="3">for </text>
<text top="237" left="876" width="19" height="21" font="0">VA</text>
<text top="239" left="895" width="165" height="19" font="3"> in the early stage, but less </text>
<text top="258" left="855" width="157" height="19" font="3">effective in the late stage </text>
<text top="550" left="116" width="78" height="19" font="3">● Segawa et </text>
<text top="569" left="116" width="83" height="19" font="3">al.2016 (306) </text>
<text top="587" left="116" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27301264">● </a></text>
<text top="587" left="129" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27301264">27301264</a></text>
<text top="587" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27301264"> </a></text>
<text top="605" left="116" width="3" height="19" font="3"> </text>
<text top="550" left="245" width="108" height="19" font="4"><b>Aim:  </b>to evaluate </text>
<text top="569" left="245" width="102" height="19" font="3">time course and </text>
<text top="587" left="245" width="115" height="19" font="3">factors correlating </text>
<text top="605" left="245" width="83" height="19" font="3">with VT after </text>
<text top="624" left="245" width="95" height="19" font="3">introduction of </text>
<text top="642" left="245" width="88" height="19" font="3">corticosteroid </text>
<text top="660" left="245" width="119" height="19" font="3">therapy in patients </text>
<text top="679" left="245" width="130" height="19" font="3">with CS remain to be </text>
<text top="697" left="245" width="71" height="19" font="3">elucidated. </text>
<text top="715" left="245" width="3" height="19" font="3"> </text>
<text top="733" left="245" width="114" height="19" font="4"><b>Study type:</b> Single </text>
<text top="752" left="245" width="129" height="19" font="3">center observational </text>
<text top="770" left="245" width="3" height="19" font="3"> </text>
<text top="550" left="395" width="168" height="19" font="4"><b>Inclusion criteria:</b>  Patients </text>
<text top="569" left="395" width="166" height="19" font="3">presenting with CS treated </text>
<text top="587" left="395" width="86" height="19" font="3">with steroids. </text>
<text top="605" left="395" width="3" height="19" font="3"> </text>
<text top="624" left="395" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="551" left="583" width="172" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Sustained VA. </text>
<text top="569" left="583" width="3" height="19" font="4"><b> </b></text>
<text top="588" left="583" width="245" height="19" font="4"><b>Results:</b> During a mean follow-up of 5.5 </text>
<text top="606" left="583" width="183" height="19" font="3">y, 20 out of 68 patients (29%) </text>
<text top="624" left="583" width="210" height="19" font="3">experienced VTs after initiation of </text>
<text top="643" left="583" width="244" height="19" font="3">corticosteroid therapy, especially in the </text>
<text top="661" left="583" width="210" height="19" font="3">first 12 mo in 14 patients (70%). A </text>
<text top="680" left="583" width="220" height="19" font="3">multivariable analysis revealed that </text>
<text top="698" left="583" width="214" height="19" font="3">positive gallium scintigraphy had a </text>
<text top="716" left="583" width="221" height="19" font="3">significant correlation with VTs (HR: </text>
<text top="734" left="583" width="242" height="19" font="3">11.33; 95% CI: 3.22–39.92; p&lt;0.001), in </text>
<text top="753" left="583" width="249" height="19" font="3">addition to reduced LVEF (HR: 0.94; 95% </text>
<text top="771" left="583" width="234" height="19" font="3">CI: 0.90–0.97; p=0.001). Furthermore, </text>
<text top="550" left="855" width="201" height="19" font="3">● These results indicate that VTs </text>
<text top="569" left="855" width="218" height="19" font="3">and electric storm frequently occur </text>
<text top="587" left="855" width="211" height="19" font="3">in the first 12mo after initiation of </text>
<text top="605" left="855" width="218" height="19" font="3">corticosteroid therapy, presumably </text>
<text top="624" left="855" width="155" height="19" font="3">because of inflammatory </text>
<text top="642" left="855" width="200" height="19" font="3">conditions, and that the positive </text>
<text top="660" left="855" width="214" height="19" font="3">gallium scintigraphy is a significant </text>
<text top="679" left="855" width="209" height="19" font="3">and independent predictor of VTs </text>
</page>
<page number="168" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="23" size="14" family="Times" color="#4f4f4f"/>
<text top="803" left="585" width="29" height="21" font="0">168 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="245" width="104" height="19" font="4"><b>Size: </b>68 patients<b> </b></text>
<text top="109" left="583" width="251" height="19" font="3">electrical storm was noted in 10 patients </text>
<text top="127" left="583" width="212" height="19" font="3">(14.7%), 8 within the first 12mo of </text>
<text top="145" left="583" width="234" height="19" font="3">treatment, whereas the recurrence of </text>
<text top="164" left="583" width="204" height="19" font="3">electric storm was relatively less.<b> </b></text>
<text top="182" left="115" width="4" height="21" font="0"> </text>
<text top="203" left="115" width="4" height="21" font="0"> </text>
<text top="259" left="115" width="967" height="21" font="2"><b>Data Supplement 34. Nonrandomized Trials, Observational Studies, and/or Registries of Other Infiltrative Cardiomyopathies – (Section 7.6.1) </b></text>
<text top="280" left="146" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="298" left="172" width="51" height="19" font="4"><b>Author; </b></text>
<text top="316" left="149" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="280" left="294" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="298" left="323" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="280" left="463" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="280" left="636" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="298" left="649" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="316" left="680" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="280" left="879" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="298" left="908" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="336" left="125" width="106" height="19" font="3">● Varr et al. 2014</text>
<text top="334" left="230" width="4" height="21" font="0"> </text>
<text top="336" left="234" width="35" height="19" font="3">(307) </text>
<text top="354" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24121001">● </a></text>
<text top="354" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24121001">24121001</a></text>
<text top="354" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24121001"> </a></text>
<text top="372" left="125" width="3" height="19" font="3"> </text>
<text top="335" left="283" width="133" height="19" font="4"><b>Aim: </b>To test whether </text>
<text top="354" left="283" width="108" height="19" font="3">there is a specific </text>
<text top="372" left="283" width="139" height="19" font="3">population of patients </text>
<text top="390" left="283" width="77" height="19" font="3">with cardiac </text>
<text top="409" left="283" width="131" height="19" font="3">amyloidosis at risk of </text>
<text top="427" left="283" width="125" height="19" font="3">SCD owing to VA (vs </text>
<text top="446" left="283" width="108" height="19" font="3">EMD) who would </text>
<text top="464" left="283" width="101" height="19" font="3">benefit from ICD</text>
<text top="462" left="384" width="4" height="21" font="23"> </text>
<text top="464" left="388" width="3" height="19" font="4"><b> </b></text>
<text top="482" left="283" width="3" height="19" font="4"><b> </b></text>
<text top="500" left="283" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="519" left="283" width="137" height="19" font="3">Retrospective registry </text>
<text top="537" left="283" width="111" height="19" font="3">Database analysis </text>
<text top="555" left="283" width="3" height="19" font="3"> </text>
<text top="574" left="283" width="57" height="19" font="4"><b>Size:</b>   31<b> </b></text>
<text top="335" left="443" width="137" height="19" font="4"><b>Inclusion criteria: </b>The<b> </b></text>
<text top="354" left="443" width="109" height="19" font="3">Stanford Amyloid </text>
<text top="372" left="443" width="129" height="19" font="3">Center’s database to </text>
<text top="390" left="443" width="151" height="19" font="3">identify all patients with </text>
<text top="409" left="443" width="126" height="19" font="3">AL or ATTR who had </text>
<text top="427" left="443" width="121" height="19" font="3">ambulatory cardiac </text>
<text top="446" left="443" width="158" height="19" font="3">monitoring. This included </text>
<text top="464" left="443" width="109" height="19" font="3">patients who had </text>
<text top="482" left="443" width="154" height="19" font="3">undergone interrogation </text>
<text top="500" left="443" width="146" height="19" font="3">of an ICD or pacemaker </text>
<text top="519" left="443" width="120" height="19" font="3">and those who had </text>
<text top="537" left="443" width="160" height="19" font="3">ambulatory monitoring in </text>
<text top="555" left="443" width="137" height="19" font="3">the outpatient setting </text>
<text top="574" left="443" width="123" height="19" font="3">with either a Holter </text>
<text top="592" left="443" width="125" height="19" font="3">monitor or Ziopatch </text>
<text top="610" left="443" width="144" height="19" font="3">(iRhythm technologies, </text>
<text top="629" left="443" width="118" height="19" font="3">San Francisco, CA). </text>
<text top="647" left="443" width="3" height="19" font="3"> </text>
<text top="665" left="443" width="113" height="19" font="4"><b>Exclusion criteria: </b></text>
<text top="683" left="443" width="130" height="19" font="3">patients who did not </text>
<text top="702" left="443" width="107" height="19" font="3">have any form of </text>
<text top="720" left="443" width="134" height="19" font="3">telemetry monitoring </text>
<text top="738" left="443" width="54" height="19" font="3">available</text>
<text top="737" left="496" width="4" height="21" font="23"> </text>
<text top="738" left="500" width="3" height="19" font="4"><b> </b></text>
<text top="336" left="617" width="105" height="19" font="4"><b>1</b>°<b> endpoint:</b>  VA<b> </b></text>
<text top="354" left="617" width="3" height="19" font="4"><b> </b></text>
<text top="373" left="617" width="176" height="19" font="4"><b>Results:</b>  NSVT was common </text>
<text top="391" left="617" width="190" height="19" font="3">and occurred in 23 of 31 (74%) </text>
<text top="409" left="617" width="174" height="19" font="3">patients. Sustained VT or VF </text>
<text top="428" left="617" width="156" height="19" font="3">occurred in 6 of 31 (19%) </text>
<text top="446" left="617" width="144" height="19" font="3">patients over the study </text>
<text top="465" left="617" width="183" height="19" font="3">period. Of the 6 patients with </text>
<text top="483" left="617" width="129" height="19" font="3">VT/VF, 1 patient had </text>
<text top="501" left="617" width="182" height="19" font="3">spontaneous resolution of VT </text>
<text top="519" left="617" width="160" height="19" font="3">before the delivery of ICD </text>
<text top="538" left="617" width="156" height="19" font="3">therapy. The remaining 5 </text>
<text top="556" left="617" width="164" height="19" font="3">patients had ICD therapies </text>
<text top="574" left="617" width="173" height="19" font="3">used, either antitachycardia </text>
<text top="593" left="617" width="181" height="19" font="3">pacing (ATP) or defibrillation. </text>
<text top="611" left="617" width="125" height="19" font="3">All patients had had </text>
<text top="629" left="617" width="185" height="19" font="3">documented NSVT before ICD </text>
<text top="648" left="617" width="116" height="19" font="3">therapy for VT/VF.<b> </b></text>
<text top="336" left="820" width="228" height="19" font="3">● Of the 6 patients who received ICD </text>
<text top="354" left="820" width="227" height="19" font="3">therapies, 4 died within 18 mo and 3 </text>
<text top="372" left="820" width="188" height="19" font="3">received the ICD initially for 1° </text>
<text top="390" left="820" width="78" height="19" font="3">prevention.  </text>
<text top="409" left="820" width="242" height="19" font="3">● The authors proposed criteria for ICD </text>
<text top="427" left="820" width="50" height="19" font="3">implant </text>
<text top="446" left="820" width="231" height="19" font="3">● That included syncope, VT or NSVT. </text>
<text top="757" left="125" width="126" height="19" font="3">● Kristen et al. 2008 </text>
<text top="776" left="125" width="35" height="19" font="3">(308) </text>
<text top="757" left="283" width="131" height="19" font="4"><b>Aim: </b>to test whether </text>
<text top="776" left="283" width="147" height="19" font="3">prophylactic placement </text>
<text top="757" left="443" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="776" left="443" width="83" height="19" font="3">patients with </text>
<text top="758" left="617" width="144" height="19" font="4"><b>1</b>°<b> endpoint:</b>  mortality </text>
<text top="777" left="617" width="3" height="19" font="3"> </text>
<text top="757" left="820" width="243" height="19" font="3">● Authors concluded that patients with </text>
<text top="776" left="820" width="254" height="19" font="3">cardiac amyloidosis predominantly die as </text>
</page>
<page number="169" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">169 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18242546">● </a></text>
<text top="109" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18242546">18242546</a></text>
<text top="109" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18242546"> </a></text>
<text top="127" left="125" width="3" height="19" font="3"> </text>
<text top="145" left="125" width="3" height="19" font="3"> </text>
<text top="109" left="283" width="138" height="19" font="3">of an ICD reduces SCD </text>
<text top="127" left="283" width="145" height="19" font="3">in patients with cardiac </text>
<text top="145" left="283" width="75" height="19" font="3">amyloidosis<b> </b></text>
<text top="164" left="283" width="3" height="19" font="4"><b> </b></text>
<text top="182" left="283" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="200" left="283" width="129" height="19" font="3">center observational </text>
<text top="219" left="283" width="3" height="19" font="3"> </text>
<text top="237" left="283" width="61" height="19" font="4"><b>Size:</b>    19 </text>
<text top="109" left="443" width="129" height="19" font="3">histologically proven </text>
<text top="127" left="443" width="148" height="19" font="3">cardiac amyloidosis and </text>
<text top="145" left="443" width="144" height="19" font="3">risk of sudden death as </text>
<text top="164" left="443" width="154" height="19" font="3">demonstrated by a Hx of </text>
<text top="182" left="443" width="99" height="19" font="3">syncope and/or </text>
<text top="200" left="443" width="141" height="19" font="3">ventricular extra beats </text>
<text top="219" left="443" width="118" height="19" font="3">(Lown grade IVa or </text>
<text top="237" left="443" width="47" height="19" font="3">higher) </text>
<text top="255" left="443" width="3" height="19" font="3"> </text>
<text top="273" left="443" width="141" height="19" font="4"><b>Exclusion criteria</b>: N/A </text>
<text top="109" left="617" width="148" height="19" font="4"><b>Results:</b>  During a mean </text>
<text top="127" left="617" width="160" height="19" font="3">follow-up of 811±151 d, 2 </text>
<text top="145" left="617" width="164" height="19" font="3">patients with sustained VT </text>
<text top="164" left="617" width="176" height="19" font="3">were successfully treated by </text>
<text top="182" left="617" width="134" height="19" font="3">the ICD. Two patients </text>
<text top="200" left="617" width="107" height="19" font="3">underwent heart </text>
<text top="219" left="617" width="139" height="19" font="3">transplantation, and 7 </text>
<text top="237" left="617" width="126" height="19" font="3">patients died due to </text>
<text top="255" left="617" width="115" height="19" font="3">electromechanical </text>
<text top="273" left="617" width="129" height="19" font="3">dissociation (N=6) or </text>
<text top="292" left="617" width="123" height="19" font="3">glioblastoma (N=1). </text>
<text top="109" left="820" width="180" height="19" font="3">a result of electromechanical </text>
<text top="127" left="820" width="227" height="19" font="3">dissociation and other diagnoses not </text>
<text top="145" left="820" width="215" height="19" font="3">amenable to ICD therapy. Selected </text>
<text top="164" left="820" width="235" height="19" font="3">patients with cardiac amyloidosis may </text>
<text top="182" left="820" width="177" height="19" font="3">benefit from ICD placement. </text>
<text top="200" left="820" width="3" height="19" font="3"> </text>
<text top="311" left="125" width="120" height="19" font="3">● Lubitz et al. 2008 </text>
<text top="329" left="125" width="35" height="19" font="3">(309) </text>
<text top="347" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18634918">● </a></text>
<text top="347" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18634918">18634918</a></text>
<text top="347" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18634918"> </a></text>
<text top="366" left="125" width="3" height="19" font="3"> </text>
<text top="384" left="125" width="3" height="19" font="3"> </text>
<text top="311" left="283" width="128" height="19" font="4"><b>Study type:</b>   Review </text>
<text top="330" left="283" width="62" height="19" font="3">Article on </text>
<text top="329" left="345" width="30" height="21" font="0">SCD </text>
<text top="330" left="375" width="15" height="19" font="3">in </text>
<text top="349" left="283" width="66" height="19" font="3">infiltrative </text>
<text top="368" left="283" width="117" height="19" font="3">cardiomyopathies: </text>
<text top="386" left="283" width="74" height="19" font="3">sarcoidosis, </text>
<text top="404" left="283" width="83" height="19" font="3">scleroderma, </text>
<text top="423" left="283" width="79" height="19" font="3">amyloidosis, </text>
<text top="441" left="283" width="116" height="19" font="3">hemachromatosis. </text>
<text top="459" left="283" width="3" height="19" font="3"> </text>
<text top="477" left="283" width="64" height="19" font="4"><b>Size:</b>    NA </text>
<text top="311" left="443" width="118" height="19" font="4"><b>Inclusion criteria:   </b></text>
<text top="329" left="443" width="108" height="19" font="3">Review article on </text>
<text top="347" left="443" width="66" height="19" font="3">infiltrative </text>
<text top="366" left="443" width="132" height="19" font="3">cardiomyopathis and </text>
<text top="384" left="443" width="139" height="19" font="3">sudden death. Studies </text>
<text top="402" left="443" width="150" height="19" font="3">related to sudden death </text>
<text top="421" left="443" width="113" height="19" font="3">and sudden death </text>
<text top="439" left="443" width="104" height="19" font="3">prevention were </text>
<text top="457" left="443" width="73" height="19" font="3">discussed.   </text>
<text top="476" left="443" width="3" height="19" font="3"> </text>
<text top="494" left="443" width="141" height="19" font="4"><b>Exclusion criteria: </b>N/A </text>
<text top="311" left="617" width="106" height="19" font="4"><b>1</b>°<b> endpoint:</b>  NA </text>
<text top="330" left="617" width="3" height="19" font="4"><b> </b></text>
<text top="348" left="617" width="181" height="19" font="4"><b>Results:</b>  It is difficult to draw </text>
<text top="367" left="617" width="148" height="19" font="3">substantive conclusions </text>
<text top="385" left="617" width="186" height="19" font="3">regarding the appropriate risk </text>
<text top="403" left="617" width="174" height="19" font="3">stratification and therapy of </text>
<text top="422" left="617" width="173" height="19" font="3">patients with the infiltrative </text>
<text top="440" left="617" width="145" height="19" font="3">cardiomyopathies. Few </text>
<text top="458" left="617" width="186" height="19" font="3">studies are prospective, many </text>
<text top="476" left="617" width="147" height="19" font="3">use different diagnostic </text>
<text top="495" left="617" width="161" height="19" font="3">criteria, and therapies are </text>
<text top="513" left="617" width="119" height="19" font="3">rarely randomized. </text>
<text top="531" left="617" width="188" height="19" font="3">Furthermore, sample sizes are </text>
<text top="550" left="617" width="163" height="19" font="3">small, studies are typically </text>
<text top="568" left="617" width="135" height="19" font="3">single center, and the </text>
<text top="586" left="617" width="154" height="19" font="3">heterogeneity of disease </text>
<text top="605" left="617" width="180" height="19" font="3">manifestations may preclude </text>
<text top="623" left="617" width="177" height="19" font="3">the generalization of results. </text>
<text top="641" left="617" width="172" height="19" font="3">Patients in high-risk groups, </text>
<text top="660" left="617" width="131" height="19" font="3">especially those with </text>
<text top="678" left="617" width="153" height="19" font="3">significantly reduced left </text>
<text top="696" left="617" width="171" height="19" font="3">ventricular function may be </text>
<text top="714" left="617" width="187" height="19" font="3">best treated with prophylactic </text>
<text top="733" left="617" width="28" height="19" font="3">ICD. </text>
<text top="311" left="820" width="236" height="19" font="3">● Data on sudden death prevention in </text>
<text top="329" left="820" width="235" height="19" font="3">diseases other than sarcoidosis is very </text>
<text top="347" left="820" width="36" height="19" font="3">scant </text>
<text top="366" left="820" width="3" height="19" font="3"> </text>
<text top="384" left="820" width="3" height="19" font="3"> </text>
<text top="751" left="115" width="4" height="21" font="2"><b> </b></text>
</page>
<page number="170" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">170 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="969" height="21" font="2"><b>Data Supplement 35. Nonrandomized Trials, Observational Studies, and/or Registries of Use of ICD and WCD in Patients with HFrEF - (Section </b></text>
<text top="128" left="115" width="43" height="21" font="2"><b>7.8.1) </b></text>
<text top="180" left="153" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="199" left="178" width="51" height="19" font="4"><b>Author; </b></text>
<text top="217" left="156" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="180" left="307" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="199" left="336" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="180" left="467" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="180" left="638" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="199" left="650" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="217" left="682" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="180" left="883" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="199" left="912" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="236" left="123" width="148" height="19" font="3">● Gandjbakhch E, et al.  </text>
<text top="255" left="123" width="69" height="19" font="3">2016 (157) </text>
<text top="273" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27344378">● </a></text>
<text top="273" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27344378">27344378</a></text>
<text top="273" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27344378"> </a></text>
<text top="291" left="123" width="3" height="19" font="3"> </text>
<text top="236" left="297" width="119" height="19" font="4"><b>Study type:</b>   single </text>
<text top="255" left="297" width="127" height="19" font="3">center retrospective </text>
<text top="273" left="297" width="123" height="19" font="3">observational study </text>
<text top="291" left="297" width="3" height="19" font="3"> </text>
<text top="309" left="297" width="121" height="19" font="4"><b>Size:</b>    380 patients </text>
<text top="328" left="297" width="90" height="19" font="3">(122 with ICD)<b> </b></text>
<text top="236" left="455" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="255" left="455" width="129" height="19" font="3">consecutive patients </text>
<text top="273" left="455" width="94" height="19" font="3">listed for heart </text>
<text top="291" left="455" width="124" height="19" font="3">transplantation at 1 </text>
<text top="309" left="455" width="128" height="19" font="3">center.  ICD patients </text>
<text top="328" left="455" width="102" height="19" font="3">characterized as </text>
<text top="346" left="455" width="128" height="19" font="3">having ICD before or </text>
<text top="365" left="455" width="109" height="19" font="3">within 3 mo after </text>
<text top="383" left="455" width="131" height="19" font="3">being listed for heart </text>
<text top="401" left="455" width="66" height="19" font="3">transplant </text>
<text top="419" left="455" width="3" height="19" font="3"> </text>
<text top="437" left="455" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="237" left="612" width="145" height="19" font="4"><b>1</b>°<b> endpoint:</b>   all-cause </text>
<text top="255" left="612" width="59" height="19" font="3">mortality </text>
<text top="274" left="612" width="3" height="19" font="3"> </text>
<text top="292" left="612" width="201" height="19" font="4"><b>Results:</b>   Patients with ICD were </text>
<text top="310" left="612" width="190" height="19" font="3">less likely to die on the waiting </text>
<text top="329" left="612" width="203" height="19" font="3">list (8.3% ICD patients and 19.0% </text>
<text top="347" left="612" width="198" height="19" font="3">non-ICD, p=0.001).  However, in </text>
<text top="365" left="612" width="201" height="19" font="3">multivariable model, ICD did not </text>
<text top="384" left="612" width="146" height="19" font="3">remain an independent </text>
<text top="402" left="612" width="63" height="19" font="3">predictor. </text>
<text top="420" left="612" width="3" height="19" font="3"> </text>
<text top="438" left="612" width="190" height="19" font="3">ICD-related complications 21% </text>
<text top="457" left="612" width="192" height="19" font="3">of patients of which 11.9% was </text>
<text top="475" left="612" width="157" height="19" font="3">post-op worsening of HF. </text>
<text top="493" left="612" width="3" height="19" font="3"> </text>
<text top="512" left="612" width="3" height="19" font="4"><b> </b></text>
<text top="236" left="828" width="230" height="19" font="3">● <b>Conclusion:</b> Patients with ICD were </text>
<text top="255" left="828" width="236" height="19" font="3">less likely to die on the waiting list but </text>
<text top="273" left="828" width="241" height="19" font="3">this did not appear in the multivariable </text>
<text top="291" left="828" width="236" height="19" font="3">model to be independently associated </text>
<text top="309" left="828" width="94" height="19" font="3">with mortality. </text>
<text top="531" left="123" width="128" height="19" font="3">● Frohlich GM, et al. </text>
<text top="549" left="123" width="107" height="19" font="3">Heart 2013 (156) </text>
<text top="567" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23813845">● </a></text>
<text top="567" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23813845">23813845</a></text>
<text top="567" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23813845"> </a></text>
<text top="586" left="123" width="3" height="19" font="3"> </text>
<text top="604" left="123" width="7" height="19" font="3">. </text>
<text top="531" left="297" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="549" left="297" width="84" height="19" font="3">retrospective </text>
<text top="567" left="297" width="123" height="19" font="3">observational study </text>
<text top="586" left="297" width="3" height="19" font="3"> </text>
<text top="604" left="297" width="69" height="19" font="4"><b>Size:</b>  1089 </text>
<text top="622" left="297" width="129" height="19" font="3">consecutive patients </text>
<text top="641" left="297" width="94" height="19" font="3">listed for heart </text>
<text top="659" left="297" width="113" height="19" font="3">transplantation of </text>
<text top="677" left="297" width="135" height="19" font="3">which 550 (51%) with </text>
<text top="696" left="297" width="140" height="19" font="3">ICD (216 1° and 334 2° </text>
<text top="714" left="297" width="141" height="19" font="3">prevention indcations) </text>
<text top="531" left="455" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="549" left="455" width="129" height="19" font="3">consecutive patients </text>
<text top="567" left="455" width="94" height="19" font="3">listed for heart </text>
<text top="586" left="455" width="139" height="19" font="3">transplantation in two </text>
<text top="604" left="455" width="98" height="19" font="3">tertiary centers </text>
<text top="622" left="455" width="3" height="19" font="3"> </text>
<text top="641" left="455" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="531" left="612" width="145" height="19" font="4"><b>1</b>°<b> endpoint:</b>   all-cause </text>
<text top="550" left="612" width="59" height="19" font="3">mortality </text>
<text top="568" left="612" width="3" height="19" font="3"> </text>
<text top="586" left="612" width="195" height="19" font="4"><b>Results:</b>   estimated 1 y survival </text>
<text top="605" left="612" width="178" height="19" font="3">88% ICD vs. 77% without ICD </text>
<text top="623" left="612" width="80" height="19" font="3">(p=0.0001).   </text>
<text top="641" left="612" width="3" height="19" font="3"> </text>
<text top="660" left="612" width="181" height="19" font="3">Model adjustment suggested </text>
<text top="678" left="612" width="184" height="19" font="3">ICD independently associated </text>
<text top="696" left="612" width="192" height="19" font="3">with survival most pronounced </text>
<text top="715" left="612" width="175" height="19" font="3">for those with 1° prevention </text>
<text top="733" left="612" width="168" height="19" font="3">indication (HR: 0.4; 95% CI: </text>
<text top="751" left="612" width="126" height="19" font="3">0.19–0.85; p=0.016) </text>
<text top="770" left="612" width="3" height="19" font="3"> </text>
<text top="531" left="828" width="198" height="19" font="3">● Conclusion: ICD appears to be </text>
<text top="549" left="828" width="242" height="19" font="3">associated with a reduction in all-cause </text>
<text top="567" left="828" width="230" height="19" font="3">mortality compared to those without </text>
<text top="586" left="828" width="155" height="19" font="3">an ICD on the waiting list </text>
<text top="604" left="828" width="3" height="19" font="3"> </text>
</page>
<page number="171" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">171 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="155" height="19" font="3">● Sandner SE, et al. 2001 </text>
<text top="127" left="123" width="35" height="19" font="3">(310) </text>
<text top="145" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11568051">● </a></text>
<text top="145" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11568051">11568051</a></text>
<text top="145" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11568051"> </a></text>
<text top="109" left="297" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="127" left="297" width="87" height="19" font="3">Retrospective </text>
<text top="145" left="297" width="123" height="19" font="3">observational study </text>
<text top="164" left="297" width="3" height="19" font="3"> </text>
<text top="182" left="297" width="140" height="19" font="4"><b>Size:</b>    854 patients on </text>
<text top="200" left="297" width="114" height="19" font="3">the waiting list for </text>
<text top="219" left="297" width="133" height="19" font="3">heart transplant (102 </text>
<text top="237" left="297" width="112" height="19" font="3">patients with ICD, </text>
<text top="255" left="297" width="124" height="19" font="3">11.9%).  All patients </text>
<text top="273" left="297" width="116" height="19" font="3">had ICD implanted </text>
<text top="292" left="297" width="104" height="19" font="3">before listing for </text>
<text top="310" left="297" width="66" height="19" font="3">transplant </text>
<text top="109" left="455" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="127" left="455" width="130" height="19" font="3">Consecutive patients </text>
<text top="145" left="455" width="94" height="19" font="3">listed for heart </text>
<text top="164" left="455" width="140" height="19" font="3">transplant 1/1992 and </text>
<text top="182" left="455" width="47" height="19" font="3">3/2000 </text>
<text top="200" left="455" width="3" height="19" font="3"> </text>
<text top="218" left="455" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="237" left="455" width="27" height="19" font="3">N/A </text>
<text top="255" left="455" width="3" height="19" font="3"> </text>
<text top="273" left="455" width="144" height="19" font="3">Patient demographics:  </text>
<text top="292" left="455" width="137" height="19" font="3">Indication for ICD was </text>
<text top="310" left="455" width="73" height="19" font="3">SCA (63%),  </text>
<text top="329" left="455" width="3" height="19" font="3"> </text>
<text top="347" left="455" width="114" height="19" font="3">60% non-ischemic </text>
<text top="365" left="455" width="56" height="19" font="3">etiology  </text>
<text top="383" left="455" width="3" height="19" font="3"> </text>
<text top="402" left="455" width="140" height="19" font="3">Only 24% overall were </text>
<text top="420" left="455" width="39" height="19" font="3">on BB </text>
<text top="109" left="612" width="194" height="19" font="4"><b>1</b>°<b> endpoint and results:</b>   Total </text>
<text top="128" left="612" width="165" height="19" font="3">mortality while waiting for </text>
<text top="146" left="612" width="189" height="19" font="3">transplant was 13.2% with ICD </text>
<text top="165" left="612" width="201" height="19" font="3">and 25.8% without ICD (p=0.03). </text>
<text top="183" left="612" width="3" height="19" font="3"> </text>
<text top="201" left="612" width="203" height="19" font="3">Rate of 12 mo sudden death was </text>
<text top="219" left="612" width="186" height="19" font="3">20% in the non-ICD group and </text>
<text top="238" left="612" width="128" height="19" font="3">0% in the ICD group. </text>
<text top="256" left="612" width="3" height="19" font="3"> </text>
<text top="274" left="612" width="193" height="19" font="3">Cox proportional hazard model </text>
<text top="293" left="612" width="145" height="19" font="3">showed absence of ICD </text>
<text top="311" left="612" width="160" height="19" font="3">associated with increased </text>
<text top="329" left="612" width="177" height="19" font="3">mortality and sudden death. </text>
<text top="348" left="612" width="3" height="19" font="3"> </text>
<text top="109" left="828" width="211" height="19" font="3">● Limitations: retrospective, older </text>
<text top="127" left="828" width="224" height="19" font="3">study with MADIT I and MUSTT type </text>
<text top="145" left="828" width="219" height="19" font="3">indications for ICD and ICD patients </text>
<text top="164" left="828" width="202" height="19" font="3">were highly selected introducing </text>
<text top="182" left="828" width="205" height="19" font="3">confounding and baseline clinical </text>
<text top="200" left="828" width="228" height="19" font="3">variables were not comparable.  Low </text>
<text top="219" left="828" width="64" height="19" font="3">use of BB. </text>
<text top="237" left="828" width="238" height="19" font="3">● Conclusions: supports the use of ICD </text>
<text top="255" left="828" width="218" height="19" font="3">for improving survival to transplant </text>
<text top="439" left="123" width="133" height="19" font="3">● Kao AC, et al. 2012  </text>
<text top="457" left="123" width="35" height="19" font="3">(290) </text>
<text top="476" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23234574">● </a></text>
<text top="476" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23234574">23234574</a></text>
<text top="476" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23234574"> </a></text>
<text top="439" left="297" width="81" height="19" font="4"><b>Study type:   </b></text>
<text top="457" left="297" width="88" height="19" font="3">Observational </text>
<text top="476" left="297" width="118" height="19" font="3">multicenter cohort </text>
<text top="494" left="297" width="37" height="19" font="3">study<b> </b></text>
<text top="512" left="297" width="3" height="19" font="4"><b> </b></text>
<text top="531" left="297" width="61" height="19" font="4"><b>Size: </b>   82<b> </b></text>
<text top="439" left="455" width="97" height="19" font="4"><b>Inclusion: </b>WCD </text>
<text top="459" left="455" width="89" height="19" font="3">prescribed for </text>
<text top="457" left="544" width="40" height="21" font="0">either</text>
<text top="459" left="584" width="3" height="19" font="3"> </text>
<text top="478" left="454" width="104" height="19" font="3">listed for cardiac </text>
<text top="496" left="454" width="101" height="19" font="3">transplantation, </text>
<text top="514" left="454" width="142" height="19" font="3">diagnosed with dilated </text>
<text top="532" left="454" width="123" height="19" font="3">cardiomyopathy, or </text>
<text top="551" left="454" width="117" height="19" font="3">receiving inotropic </text>
<text top="569" left="454" width="82" height="19" font="3">medications.<b> </b></text>
<text top="587" left="455" width="3" height="19" font="4"><b> </b></text>
<text top="606" left="455" width="132" height="19" font="3">Mean age 56.8±13.2, </text>
<text top="624" left="455" width="127" height="19" font="3">and 72% were male. </text>
<text top="642" left="455" width="138" height="19" font="3">Most patients (98.8%) </text>
<text top="661" left="455" width="131" height="19" font="3">were diagnosed with </text>
<text top="679" left="455" width="118" height="19" font="3">DCM with a low EF </text>
<text top="697" left="455" width="125" height="19" font="3">(&lt;40%) and 12 were </text>
<text top="716" left="455" width="104" height="19" font="3">listed for cardiac </text>
<text top="734" left="455" width="101" height="19" font="3">transplantation.<b> </b></text>
<text top="752" left="455" width="3" height="19" font="4"><b> </b></text>
<text top="439" left="612" width="168" height="19" font="3">Device worn for 75±58 d. 4 </text>
<text top="457" left="612" width="172" height="19" font="3">patients were on inotropes. </text>
<text top="476" left="612" width="187" height="19" font="3">There were no sudden cardiac </text>
<text top="494" left="612" width="173" height="19" font="3">arrests or deaths during the </text>
<text top="512" left="612" width="44" height="19" font="3">study.  </text>
<text top="531" left="612" width="3" height="19" font="3"> </text>
<text top="549" left="612" width="182" height="19" font="3">41.5% of patients were much </text>
<text top="567" left="612" width="194" height="19" font="3">improved after WCD use, while </text>
<text top="586" left="612" width="177" height="19" font="3">34.1% went on to receive an </text>
<text top="604" left="612" width="28" height="19" font="3">ICD. </text>
<text top="439" left="828" width="215" height="19" font="3">● <b>Conclusions: </b>WCD monitored HF </text>
<text top="457" left="828" width="221" height="19" font="3">patients until further assessment of </text>
<text top="476" left="828" width="217" height="19" font="3">risk. The leading reasons for end of </text>
<text top="494" left="828" width="243" height="19" font="3">WCD use were improvement in LVEF or </text>
<text top="512" left="828" width="200" height="19" font="3">ICD implantation if there was no </text>
<text top="531" left="828" width="203" height="19" font="3">significant improvement in LVEF. </text>
</page>
<page number="172" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">172 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="567" left="115" width="4" height="21" font="0"> </text>
<text top="587" left="115" width="4" height="21" font="0"> </text>
<text top="587" left="331" width="4" height="21" font="2"><b> </b></text>
<text top="109" left="123" width="153" height="19" font="3">● Opreanu M et al. 2015 </text>
<text top="127" left="123" width="35" height="19" font="3">(311) </text>
<text top="145" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26094085">● </a></text>
<text top="145" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26094085">26094085</a></text>
<text top="145" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26094085"> </a></text>
<text top="164" left="123" width="3" height="19" font="3"> </text>
<text top="109" left="297" width="143" height="19" font="4"><b>Study type:</b>  registry of </text>
<text top="127" left="297" width="108" height="19" font="3">patients awaiting </text>
<text top="145" left="297" width="133" height="19" font="3">heart transplant with </text>
<text top="164" left="297" width="34" height="19" font="3">WCD </text>
<text top="182" left="297" width="3" height="19" font="3"> </text>
<text top="200" left="297" width="115" height="19" font="4"><b>Size: </b>121 patients  </text>
<text top="219" left="297" width="3" height="19" font="3"> </text>
<text top="237" left="297" width="145" height="19" font="3">Patient Demographics:  </text>
<text top="255" left="297" width="137" height="19" font="3">consisting of 83 (69%) </text>
<text top="273" left="297" width="114" height="19" font="3">men and 38 (31%) </text>
<text top="292" left="297" width="142" height="19" font="3">women. The mean age </text>
<text top="310" left="297" width="139" height="19" font="3">was 44±18 y. Mean EF </text>
<text top="329" left="297" width="120" height="19" font="3">was 25 ± 15%. Non-</text>
<text top="347" left="297" width="56" height="19" font="3">ischemic </text>
<text top="365" left="297" width="144" height="19" font="3">cardiomyopathy (CMP) </text>
<text top="383" left="297" width="119" height="19" font="3">was the underlying </text>
<text top="402" left="297" width="132" height="19" font="3">diagnosis in 67 (55%) </text>
<text top="420" left="297" width="131" height="19" font="3">patients, whereas 21 </text>
<text top="438" left="297" width="118" height="19" font="3">(17%) patients had </text>
<text top="457" left="297" width="133" height="19" font="3">ischemic CMP and 33 </text>
<text top="475" left="297" width="133" height="19" font="3">(27%) had a mixed or </text>
<text top="493" left="297" width="137" height="19" font="3">uncharacterized CMP. </text>
<text top="512" left="297" width="134" height="19" font="3">NYHA Class III HF was </text>
<text top="530" left="297" width="121" height="19" font="3">present in 32% and </text>
<text top="548" left="297" width="132" height="19" font="3">34% were in Class IV. </text>
<text top="109" left="455" width="120" height="19" font="4"><b>Inclusion:</b>  patients </text>
<text top="127" left="455" width="91" height="19" font="3">awaiting heart </text>
<text top="145" left="455" width="130" height="19" font="3">transplant with WCD </text>
<text top="109" left="612" width="193" height="19" font="3">The patients wore the WCD for </text>
<text top="127" left="612" width="154" height="19" font="3">an average of 127±392 d </text>
<text top="145" left="612" width="199" height="19" font="3">(median 39d) with average daily </text>
<text top="164" left="612" width="174" height="19" font="3">use of 17±7 h (median 20h). </text>
<text top="182" left="612" width="179" height="19" font="3">Seven patients (6%) received </text>
<text top="200" left="612" width="189" height="19" font="3">appropriate WCD shocks. Fifty-</text>
<text top="219" left="612" width="185" height="19" font="3">one patients (42%) ended use </text>
<text top="237" left="612" width="184" height="19" font="3">after ICD implantation and 13 </text>
<text top="255" left="612" width="187" height="19" font="3">patients (11%) after HT. There </text>
<text top="273" left="612" width="132" height="19" font="3">were 11 deaths (9%). </text>
<text top="292" left="612" width="3" height="19" font="3"> </text>
<text top="109" left="828" width="97" height="19" font="3">● <b>Conclusions:</b>  </text>
<text top="107" left="926" width="4" height="21" font="0"> </text>
<text top="109" left="929" width="77" height="19" font="3">A significant </text>
<text top="127" left="828" width="218" height="19" font="3">proportion of patients on the heart </text>
<text top="145" left="828" width="217" height="19" font="3">transplant waiting list will have VA. </text>
<text top="164" left="828" width="246" height="19" font="3">WCD use in this registry associated with </text>
<text top="182" left="828" width="227" height="19" font="3">a high compliance and efficacy and a </text>
<text top="200" left="828" width="236" height="19" font="3">low complication rate, suggesting that </text>
<text top="219" left="828" width="245" height="19" font="3">the WCD is a reasonable bridge therapy </text>
<text top="237" left="828" width="241" height="19" font="3">for preventing SCD in patients awaiting </text>
<text top="255" left="828" width="24" height="19" font="3">HT. </text>
</page>
<page number="173" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">173 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="816" height="21" font="2"><b>Data Supplement 36. Nonrandomized Trials, Observational Studies, and/or Registries Related to LVAD – (Section 7.8.3) </b></text>
<text top="129" left="132" width="157" height="19" font="4"><b>Study Acronym; Author;  </b></text>
<text top="147" left="161" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="129" left="340" width="88" height="19" font="4"><b>Aim of Study; </b></text>
<text top="147" left="345" width="76" height="19" font="4"><b>Study Type; </b></text>
<text top="165" left="339" width="89" height="19" font="4"><b>Study Size (N) </b></text>
<text top="129" left="499" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="129" left="691" width="123" height="19" font="4"><b>Study Intervention  </b></text>
<text top="147" left="709" width="88" height="19" font="4"><b>(# patients) /  </b></text>
<text top="165" left="693" width="121" height="19" font="4"><b>Study Comparator  </b></text>
<text top="184" left="714" width="75" height="19" font="4"><b>(# patients) </b></text>
<text top="129" left="912" width="108" height="19" font="4"><b>Endpoint Results </b></text>
<text top="147" left="894" width="148" height="19" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="165" left="899" width="136" height="19" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="184" left="942" width="49" height="19" font="4"><b>95% CI) </b></text>
<text top="203" left="123" width="142" height="19" font="3">● Vakil, et al.  JACCCEP </text>
<text top="221" left="123" width="69" height="19" font="3">2016 (312) </text>
<text top="239" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27395347">● </a></text>
<text top="239" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27395347">27395347</a></text>
<text top="239" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27395347"> </a></text>
<text top="258" left="123" width="3" height="19" font="4"><b> </b></text>
<text top="203" left="307" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="221" left="307" width="138" height="19" font="3">retrospective national </text>
<text top="239" left="307" width="49" height="19" font="3">registry </text>
<text top="258" left="307" width="3" height="19" font="3"> </text>
<text top="276" left="307" width="144" height="19" font="4"><b>Size:</b>    32,599 patients  </text>
<text top="294" left="307" width="3" height="19" font="3"> </text>
<text top="313" left="307" width="3" height="19" font="4"><b> </b></text>
<text top="203" left="473" width="157" height="19" font="4"><b>Inclusion criteria:</b>  Adults </text>
<text top="221" left="473" width="157" height="19" font="3">(age ≥18 y) listed for first-</text>
<text top="239" left="473" width="135" height="19" font="3">time HT in the United </text>
<text top="258" left="473" width="163" height="19" font="3">States between January 1, </text>
<text top="276" left="473" width="157" height="19" font="3">1999, and September 30, </text>
<text top="294" left="473" width="167" height="19" font="3">2014, were retrospectively </text>
<text top="313" left="473" width="163" height="19" font="3">identified from the United </text>
<text top="331" left="473" width="167" height="19" font="3">Network for Organ Sharing </text>
<text top="349" left="473" width="57" height="19" font="3">registry.  </text>
<text top="368" left="473" width="3" height="19" font="3"> </text>
<text top="386" left="473" width="169" height="19" font="3">Median follow-up of 154 d, </text>
<text top="404" left="473" width="38" height="19" font="3">3,638<b> </b></text>
<text top="203" left="658" width="186" height="19" font="4"><b>1</b>°<b> endpoint:</b> all-cause waitlist </text>
<text top="222" left="658" width="63" height="19" font="3">mortality. </text>
<text top="240" left="658" width="3" height="19" font="3"> </text>
<text top="258" left="658" width="177" height="19" font="4"><b>Results:</b> 9% died on the wait </text>
<text top="277" left="658" width="163" height="19" font="3">list in ICD group vs. 15% in </text>
<text top="295" left="658" width="161" height="19" font="3">no-ICD group (p&lt;0.0001),  </text>
<text top="314" left="658" width="3" height="19" font="3"> </text>
<text top="332" left="658" width="127" height="19" font="3">An ICD at listing was </text>
<text top="350" left="658" width="145" height="19" font="3">associated reduction in </text>
<text top="368" left="658" width="171" height="19" font="3">mortality (HR: 0.87; 95% CI: </text>
<text top="387" left="658" width="76" height="19" font="3">0.80–0.94).  </text>
<text top="405" left="658" width="3" height="19" font="3"> </text>
<text top="423" left="658" width="169" height="19" font="3">In the subgroup of patients </text>
<text top="442" left="658" width="178" height="19" font="3">with LVAD (N=9,478), having </text>
<text top="460" left="658" width="168" height="19" font="3">an ICD was associated with </text>
<text top="478" left="658" width="186" height="19" font="3">relative reduction in mortality </text>
<text top="497" left="658" width="180" height="19" font="3">(HR: 0.81; 95% CI 0.70–0.94).<b> </b></text>
<text top="203" left="858" width="88" height="19" font="3">● <b>Conclusion:</b> </text>
<text top="201" left="946" width="4" height="21" font="0"> </text>
<text top="203" left="950" width="76" height="19" font="3">ICD use was </text>
<text top="221" left="858" width="210" height="19" font="3">associated with improved survival </text>
<text top="239" left="858" width="209" height="19" font="3">on the HT waitlist in patients with </text>
<text top="258" left="858" width="110" height="19" font="3">or without LVADs<b> </b></text>
<text top="551" left="115" width="924" height="21" font="2"><b>Data Supplement 37. Nonrandomized Trials, Observational Studies, and/or Registries Related to ICD Use After Heart Transplantation – </b></text>
<text top="571" left="115" width="102" height="21" font="2"><b>(Section 7.8.4) </b></text>
<text top="593" left="139" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="611" left="165" width="55" height="19" font="4"><b>Author;  </b></text>
<text top="629" left="143" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="593" left="311" width="88" height="19" font="4"><b>Aim of Study; </b></text>
<text top="611" left="316" width="76" height="19" font="4"><b>Study Type; </b></text>
<text top="629" left="310" width="89" height="19" font="4"><b>Study Size (N) </b></text>
<text top="593" left="472" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="593" left="633" width="208" height="19" font="4"><b>Study Intervention (# patients) /  </b></text>
<text top="611" left="639" width="192" height="19" font="4"><b>Study Comparator (# patients) </b></text>
<text top="593" left="912" width="108" height="19" font="4"><b>Endpoint Results </b></text>
<text top="611" left="894" width="148" height="19" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="629" left="874" width="185" height="19" font="4"><b>P values; OR or RR; &amp; 95% CI) </b></text>
<text top="648" left="123" width="107" height="19" font="3">● Tsai et al. 2009 </text>
<text top="667" left="123" width="35" height="19" font="3">(313) </text>
<text top="685" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19808340">● </a></text>
<text top="685" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19808340">19808340</a></text>
<text top="685" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19808340"> </a></text>
<text top="703" left="123" width="3" height="19" font="3"> </text>
<text top="648" left="270" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="667" left="270" width="147" height="19" font="3">Retrospective cohort of </text>
<text top="685" left="270" width="142" height="19" font="3">Heart Tx. Patients with </text>
<text top="703" left="270" width="135" height="19" font="3">ICDs across 5 centers. </text>
<text top="722" left="270" width="69" height="19" font="3">1995-2005 </text>
<text top="740" left="270" width="3" height="19" font="3"> </text>
<text top="648" left="451" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="667" left="451" width="119" height="19" font="3">Patients with heart </text>
<text top="685" left="451" width="128" height="19" font="3">transplants and ICDs </text>
<text top="703" left="451" width="3" height="19" font="3"> </text>
<text top="722" left="451" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="649" left="626" width="160" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Descriptive: </text>
<text top="667" left="626" width="192" height="19" font="3">Indications for ICDs and shocks </text>
<text top="686" left="626" width="174" height="19" font="3">(appropriate/inappropriate) </text>
<text top="704" left="626" width="3" height="19" font="3"> </text>
<text top="722" left="626" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="741" left="626" width="122" height="19" font="3"> indications for ICD  </text>
<text top="759" left="626" width="209" height="19" font="3">1)  severe allograft vasculopathy </text>
<text top="777" left="653" width="52" height="19" font="3">(N=12),  </text>
<text top="648" left="858" width="154" height="19" font="3">● Use of ICDs after heart </text>
<text top="667" left="858" width="146" height="19" font="3">transplantation may be </text>
<text top="685" left="858" width="200" height="19" font="3">appropriate in selected high-risk </text>
<text top="703" left="858" width="60" height="19" font="3">patients.  </text>
<text top="722" left="858" width="201" height="19" font="3">● Very small number, no control </text>
<text top="740" left="858" width="138" height="19" font="3">group, Pre-SCD-HeFT.  </text>
</page>
<page number="174" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">174 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="270" width="152" height="19" font="4"><b>Size:</b>    36 (2612 patients </text>
<text top="127" left="270" width="164" height="19" font="3">with heart transplants, 36, </text>
<text top="145" left="270" width="65" height="19" font="3">with ICDs) </text>
<text top="109" left="626" width="203" height="19" font="3">2)  unexplained syncope (N=9),  </text>
<text top="127" left="626" width="126" height="19" font="3">3)  Hx of CA (N=8),  </text>
<text top="145" left="626" width="208" height="19" font="3">4)  severe LV dysfunction (N=7).  </text>
<text top="164" left="625" width="3" height="19" font="3"> </text>
<text top="182" left="625" width="198" height="19" font="3">Shocks: 22 shocks in 10 patients </text>
<text top="200" left="625" width="45" height="19" font="3">(28%),  </text>
<text top="219" left="626" width="211" height="19" font="3">Appropriate: 8 patients/12 shocks </text>
<text top="237" left="626" width="192" height="19" font="3">(100% - allograft vasculopathy) </text>
<text top="255" left="626" width="213" height="19" font="3">Inappropriate: 3 patients of whom </text>
<text top="273" left="626" width="199" height="19" font="3">8 (80%) received 12 appropriate </text>
<text top="292" left="626" width="198" height="19" font="3">shocks for either rapid VT or VF. </text>
<text top="310" left="626" width="176" height="19" font="3">The shocks were effective in </text>
<text top="329" left="626" width="99" height="19" font="3">terminating the </text>
<text top="347" left="626" width="215" height="19" font="3">VA in all cases. Three (8%) patients </text>
<text top="365" left="626" width="212" height="19" font="3">received 10 inappropriate shocks.  </text>
<text top="384" left="123" width="111" height="19" font="3">● McDowell et al. </text>
<text top="402" left="123" width="69" height="19" font="3">2009 (314) </text>
<text top="421" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19632584?dopt=Citation">● </a></text>
<text top="421" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19632584?dopt=Citation">19632584</a></text>
<text top="421" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19632584?dopt=Citation"> </a></text>
<text top="439" left="123" width="3" height="19" font="3"> </text>
<text top="384" left="270" width="141" height="19" font="4"><b>Study type:</b>   Survey of </text>
<text top="402" left="270" width="122" height="19" font="3">transplant program </text>
<text top="421" left="270" width="162" height="19" font="3">directors.  Asked about all </text>
<text top="439" left="270" width="168" height="19" font="3">transplant patients with an </text>
<text top="457" left="270" width="28" height="19" font="3">ICD  </text>
<text top="476" left="270" width="3" height="19" font="3"> </text>
<text top="494" left="270" width="134" height="19" font="4"><b>Size:</b> 44 patients with </text>
<text top="512" left="270" width="163" height="19" font="3">heart transplants with ICD </text>
<text top="384" left="451" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="402" left="451" width="148" height="19" font="3">Survey responses about </text>
<text top="421" left="451" width="159" height="19" font="3">heart transplant patients. </text>
<text top="439" left="451" width="63" height="19" font="3">With ICDs </text>
<text top="457" left="451" width="3" height="19" font="3"> </text>
<text top="476" left="451" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="385" left="626" width="153" height="19" font="4"><b>1</b>°<b> endpoint:</b> Indication,  </text>
<text top="403" left="626" width="3" height="19" font="3"> </text>
<text top="421" left="626" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="440" left="626" width="143" height="19" font="3">Indication for implant* </text>
<text top="458" left="626" width="173" height="20" font="3">•  1° VT/VF arrest 6 (13.3) </text>
<text top="477" left="626" width="203" height="20" font="3">•  Unexplained syncope 3 (6.7) </text>
<text top="497" left="626" width="198" height="20" font="3">•  CAV with LV dysfunction 20 </text>
<text top="516" left="652" width="39" height="19" font="3">(44.4) </text>
<text top="534" left="626" width="211" height="20" font="3">•  CAV without LV dysfunction 3 </text>
<text top="553" left="652" width="31" height="19" font="3">(6.7) </text>
<text top="571" left="626" width="213" height="20" font="3">•  Non-specific graft dysfunction </text>
<text top="590" left="652" width="50" height="19" font="3">5 (11.1) </text>
<text top="609" left="625" width="169" height="20" font="3">•  High-grade arrhythmia </text>
<text top="628" left="652" width="93" height="19" font="3">determined by </text>
<text top="646" left="625" width="205" height="20" font="3">•  Non-invasive monitor 3 (6.7) </text>
<text top="665" left="625" width="159" height="19" font="3">Patients with appropriate </text>
<text top="683" left="625" width="168" height="19" font="3">therapies 6 (13.6); Total 19 </text>
<text top="702" left="626" width="170" height="19" font="3">Patients with inappropriate </text>
<text top="720" left="626" width="156" height="19" font="3">therapies 3 (6.8) Total 15 </text>
<text top="384" left="858" width="177" height="19" font="3">● Most common reason was </text>
<text top="402" left="858" width="187" height="19" font="3">allograft vasculopathy with LV </text>
<text top="421" left="858" width="75" height="19" font="3">dysfunction </text>
<text top="739" left="123" width="126" height="19" font="3">● Neylon et al. 2016 </text>
<text top="757" left="123" width="35" height="19" font="3">(315) </text>
<text top="776" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26856670?dopt=Citation">● </a></text>
<text top="776" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26856670?dopt=Citation">26856670</a></text>
<text top="776" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26856670?dopt=Citation"> </a></text>
<text top="739" left="270" width="163" height="19" font="4"><b>Study type:</b>   Single center </text>
<text top="757" left="270" width="126" height="19" font="3">review of transplant </text>
<text top="776" left="270" width="114" height="19" font="3">patients with ICDs </text>
<text top="739" left="451" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="740" left="626" width="156" height="19" font="4"><b>1</b>°<b> endpoint:</b> Descriptive  </text>
<text top="758" left="626" width="3" height="19" font="3"> </text>
<text top="776" left="626" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="739" left="858" width="188" height="19" font="3">● ICDs in transplant patients – </text>
<text top="757" left="858" width="82" height="19" font="3">inconclusive. </text>
</page>
<page number="175" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">175 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="270" width="3" height="19" font="3"> </text>
<text top="127" left="270" width="104" height="19" font="4"><b>Size:</b> 10 patients </text>
<text top="109" left="451" width="147" height="19" font="3">Review of all transplant </text>
<text top="127" left="451" width="114" height="19" font="3">patients with ICDs </text>
<text top="145" left="451" width="155" height="19" font="3">between 1983 and 2012. </text>
<text top="164" left="451" width="3" height="19" font="3"> </text>
<text top="182" left="451" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="109" left="626" width="213" height="20" font="3">•  Allograft vasculopathy in 8/10 </text>
<text top="128" left="626" width="116" height="20" font="3">•  1/10 shocked, </text>
<text top="147" left="626" width="86" height="20" font="3">•  1/10 ATP </text>
<text top="201" left="115" width="4" height="21" font="0"> </text>
<text top="257" left="115" width="937" height="21" font="2"><b>Data Supplement 38. Nonrandomized Trials, Observational Studies, and/or Registries Evaluating the Risk of Sudden Death or Ventricular </b></text>
<text top="277" left="115" width="480" height="21" font="2"><b>Arrhythmias in Patients with Neuromuscular Disorders – (Section 7.8) </b></text>
<text top="298" left="124" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="316" left="150" width="51" height="19" font="4"><b>Author; </b></text>
<text top="334" left="127" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="298" left="274" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="316" left="303" width="70" height="19" font="4"><b>Study Size  </b></text>
<text top="298" left="448" width="142" height="19" font="4"><b>Study Size (N); Patient </b></text>
<text top="316" left="483" width="72" height="19" font="4"><b>Population </b></text>
<text top="298" left="635" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="316" left="647" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="334" left="679" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="298" left="883" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="316" left="912" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="353" left="123" width="100" height="19" font="3">● Tanawuttiwat </text>
<text top="371" left="123" width="82" height="19" font="3">T, et al. 2017 </text>
<text top="390" left="123" width="35" height="19" font="3">(316) </text>
<text top="408" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27829084">● </a></text>
<text top="408" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27829084">27829084</a></text>
<text top="408" left="196" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27829084"> </a></text>
<text top="353" left="241" width="163" height="19" font="4"><b>Study type:</b> Observational </text>
<text top="371" left="241" width="182" height="19" font="3">retrospective cohort referred </text>
<text top="390" left="241" width="153" height="19" font="3">for risk stratification at a </text>
<text top="408" left="241" width="131" height="19" font="3">single referral center<b> </b></text>
<text top="426" left="241" width="3" height="19" font="4"><b> </b></text>
<text top="444" left="241" width="111" height="19" font="4"><b>Size:</b> 155 patients<b> </b></text>
<text top="353" left="445" width="141" height="19" font="4"><b>Inclusion criteria:</b>  136 </text>
<text top="371" left="445" width="143" height="19" font="3">patients with DM1 and </text>
<text top="390" left="445" width="135" height="19" font="3">28 patients with DM2 </text>
<text top="408" left="445" width="99" height="19" font="3">with genetically </text>
<text top="426" left="445" width="126" height="19" font="3">confirmed diagnosis </text>
<text top="445" left="445" width="108" height="19" font="3">and baseline ECG </text>
<text top="463" left="445" width="141" height="19" font="3">between January 1997 </text>
<text top="481" left="445" width="110" height="19" font="3">and August 2014.<b> </b></text>
<text top="500" left="445" width="3" height="19" font="4"><b> </b></text>
<text top="518" left="445" width="117" height="19" font="4"><b>Exclusion criteria:  </b></text>
<text top="536" left="445" width="144" height="19" font="3">Exclusion of ECG’s with </text>
<text top="555" left="445" width="119" height="19" font="3">paced or non-sinus </text>
<text top="573" left="445" width="48" height="19" font="3">rhythm<b> </b></text>
<text top="353" left="606" width="154" height="19" font="4"><b>1° endpoint:</b> Conduction </text>
<text top="371" left="606" width="207" height="19" font="3">abnormalities were defined as PR </text>
<text top="390" left="606" width="196" height="19" font="3">of at least 240 msec and QRS of </text>
<text top="408" left="606" width="109" height="19" font="3">at least 120 msec<b> </b></text>
<text top="426" left="606" width="3" height="19" font="4"><b> </b></text>
<text top="444" left="606" width="207" height="19" font="4"><b>Results:</b> In DM1, incidences of PR </text>
<text top="463" left="606" width="208" height="19" font="3">≥240 ms and QRS ≥120 ms during </text>
<text top="481" left="606" width="190" height="19" font="3">a mean 5.54 y were 19.2% and </text>
<text top="500" left="606" width="128" height="19" font="3">11.7%, respectively. <b> </b></text>
<text top="518" left="606" width="3" height="19" font="4"><b> </b></text>
<text top="536" left="606" width="195" height="19" font="3">In contrast, DM2 patients there </text>
<text top="555" left="606" width="125" height="19" font="3">were no incident PR </text>
<text top="573" left="606" width="183" height="19" font="3">abnormalities, despite similar </text>
<text top="591" left="606" width="197" height="19" font="3">incidence of QRS abnormalities. </text>
<text top="609" left="606" width="3" height="19" font="3"> </text>
<text top="628" left="606" width="181" height="19" font="3">An incident 10 ms increase in </text>
<text top="646" left="606" width="209" height="19" font="3">QRS duration was associated with </text>
<text top="664" left="606" width="162" height="19" font="3">3.5% decrease in EF in the </text>
<text top="683" left="605" width="199" height="19" font="3">subsequent year (−3.45; 95% CI: </text>
<text top="701" left="606" width="144" height="19" font="3">−4.87–−2.03; p&lt;0.001).<b> </b></text>
<text top="353" left="828" width="221" height="19" font="3">● Prevalence of critically prognostic </text>
<text top="371" left="828" width="241" height="19" font="3">conduction abnormalities &gt;20% and LV </text>
<text top="390" left="828" width="243" height="19" font="3">dysfunction &gt; 10% (defined LVEF &lt;55%) </text>
<text top="408" left="828" width="240" height="19" font="3">● Incident QRS prolongation &gt; 10 ms is </text>
<text top="426" left="828" width="237" height="19" font="3">associated with decreased LV function </text>
<text top="445" left="828" width="135" height="19" font="3">the subsequent year.  </text>
<text top="463" left="828" width="246" height="19" font="3">● Supports serial ECG examinations and </text>
<text top="481" left="828" width="185" height="19" font="3">symptom / QRS prolongation–</text>
<text top="500" left="828" width="224" height="19" font="3">prompted evaluation of LV function. </text>
<text top="518" left="828" width="215" height="19" font="3">● Limitations include retrospective </text>
<text top="536" left="828" width="243" height="19" font="3">design with potential for selection bias, </text>
<text top="555" left="828" width="223" height="19" font="3">differential clinical follow-up among </text>
<text top="573" left="828" width="71" height="19" font="3">subgroups. </text>
<text top="720" left="123" width="94" height="19" font="3">● Merino et al. </text>
<text top="738" left="123" width="69" height="19" font="3">1998 (317) </text>
<text top="756" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9714111">● </a></text>
<text top="756" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9714111">9714111</a></text>
<text top="756" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9714111"> </a></text>
<text top="775" left="123" width="3" height="19" font="3"> </text>
<text top="720" left="241" width="120" height="19" font="4"><b>Aim</b>:  To assess the </text>
<text top="738" left="241" width="185" height="19" font="3">mechanism of sustained VT in </text>
<text top="756" left="241" width="125" height="19" font="3">myotonic dystrophy </text>
<text top="775" left="241" width="3" height="19" font="3"> </text>
<text top="720" left="445" width="144" height="19" font="4"><b>Inclusion:</b>  Consecutive </text>
<text top="738" left="445" width="144" height="19" font="3">patients with myotonic </text>
<text top="756" left="445" width="91" height="19" font="3">dystrophy and </text>
<text top="720" left="606" width="112" height="19" font="4"><b>1</b>°<b> endpoint:</b>  N/A </text>
<text top="739" left="606" width="3" height="19" font="3"> </text>
<text top="757" left="606" width="203" height="19" font="4"><b>Results:</b>  Clinical tachycardia was </text>
<text top="775" left="606" width="205" height="19" font="3">inducible in all patients and were </text>
<text top="720" left="828" width="231" height="19" font="3">● Summary – A high clinical suspicion </text>
<text top="738" left="828" width="236" height="19" font="3">for bundle-branch reentry tachycardia </text>
<text top="756" left="828" width="215" height="19" font="3">is reasonable in patients with wide </text>
</page>
<page number="176" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">176 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="241" width="148" height="19" font="4"><b>Study type:</b>  Case series </text>
<text top="127" left="241" width="3" height="19" font="4"><b> </b></text>
<text top="145" left="241" width="99" height="19" font="4"><b>Size:</b>  6 patients </text>
<text top="108" left="445" width="135" height="19" font="3">sustained VT referred </text>
<text top="127" left="445" width="46" height="19" font="3">for EPS </text>
<text top="145" left="445" width="3" height="19" font="4"><b> </b></text>
<text top="163" left="445" width="93" height="19" font="4"><b>Exclusion:</b> N/A </text>
<text top="108" left="606" width="193" height="19" font="3">bundle branch reentry.  VT was </text>
<text top="127" left="606" width="199" height="19" font="3">no longer inducible after bundle </text>
<text top="145" left="606" width="175" height="19" font="3">branch ablation except for a </text>
<text top="163" left="606" width="186" height="19" font="3">nonclinically documented and </text>
<text top="182" left="606" width="168" height="19" font="3">NSVT in a patient with SHD </text>
<text top="108" left="828" width="216" height="19" font="3">complex tachycardia and myotonic </text>
<text top="127" left="828" width="65" height="19" font="3">dystrophy </text>
<text top="145" left="828" width="239" height="19" font="3">● Limitations – small case series.  Does </text>
<text top="163" left="828" width="201" height="19" font="3">not prove a link between bundle </text>
<text top="182" left="828" width="222" height="19" font="3">branch reentry and sudden death in </text>
<text top="200" left="828" width="95" height="19" font="3">this population </text>
<text top="218" left="828" width="3" height="19" font="3"> </text>
<text top="237" left="123" width="91" height="19" font="3">● Diegoli et al. </text>
<text top="255" left="123" width="30" height="19" font="3">2011</text>
<text top="254" left="153" width="4" height="21" font="0"> </text>
<text top="255" left="157" width="35" height="19" font="3">(318) </text>
<text top="273" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21851881">● </a></text>
<text top="273" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21851881">21851881</a></text>
<text top="273" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21851881"> </a></text>
<text top="292" left="123" width="3" height="19" font="3"> </text>
<text top="237" left="241" width="188" height="19" font="4"><b>Aim</b>: To describe the outcome </text>
<text top="255" left="241" width="145" height="19" font="3">of patients with dilated </text>
<text top="273" left="241" width="156" height="19" font="3">cardiomyopathy and DYS </text>
<text top="292" left="241" width="48" height="19" font="3">defects </text>
<text top="310" left="241" width="3" height="19" font="3"> </text>
<text top="328" left="241" width="157" height="19" font="4"><b>Study type:</b> Cohort study </text>
<text top="347" left="241" width="3" height="19" font="3"> </text>
<text top="365" left="241" width="161" height="19" font="4"><b>Size:</b> 34 patients with DYS </text>
<text top="383" left="241" width="48" height="19" font="3">defects </text>
<text top="401" left="241" width="3" height="19" font="4"><b> </b></text>
<text top="237" left="445" width="121" height="19" font="4"><b>Inclusion: </b>1/1995 – </text>
<text top="255" left="445" width="144" height="19" font="3">12/2009, screened DYS </text>
<text top="273" left="445" width="137" height="19" font="3">in 436 unrelated male </text>
<text top="292" left="445" width="127" height="19" font="3">probands diagnosed </text>
<text top="310" left="445" width="128" height="19" font="3">with DCM who were </text>
<text top="329" left="445" width="57" height="19" font="3">male sex </text>
<text top="347" left="445" width="3" height="19" font="3"> </text>
<text top="365" left="445" width="121" height="19" font="4"><b>Exclusion:</b> females, </text>
<text top="383" left="445" width="131" height="19" font="3">families with male to </text>
<text top="402" left="445" width="114" height="19" font="3">male transmission<b> </b></text>
<text top="237" left="606" width="112" height="19" font="4"><b>1</b>°<b> endpoint:</b>  N/A </text>
<text top="256" left="606" width="3" height="19" font="3"> </text>
<text top="274" left="606" width="166" height="19" font="4"><b>Results:</b> Of the 34 affected </text>
<text top="293" left="606" width="192" height="19" font="3">patients, 8 patients underwent </text>
<text top="311" left="606" width="192" height="19" font="3">heart transplant and 8 patients </text>
<text top="329" left="606" width="172" height="19" font="3">received an ICD (indications </text>
<text top="348" left="606" width="203" height="19" font="3">depressed LVEF).  There were no </text>
<text top="366" left="606" width="203" height="19" font="3">appropriate interventions during </text>
<text top="384" left="606" width="193" height="19" font="3">a median follow-up 14 mo (IQR </text>
<text top="402" left="606" width="69" height="19" font="3">5–25 mo).  </text>
<text top="237" left="828" width="238" height="19" font="3">● DYS-related DCM is characterized by </text>
<text top="255" left="828" width="211" height="19" font="3">severe impairment of LV function, </text>
<text top="273" left="828" width="173" height="19" font="3">marked LV dilation, and low </text>
<text top="292" left="828" width="222" height="19" font="3">arrhythmogenic risk; the only factor </text>
<text top="310" left="828" width="238" height="19" font="3">that impacts survival seems to be end- </text>
<text top="329" left="828" width="59" height="19" font="3">stage HF. </text>
<text top="347" left="828" width="234" height="19" font="3">● Limitations: relatively small number </text>
<text top="365" left="828" width="245" height="19" font="3">of patients and short follow-up, referral </text>
<text top="383" left="828" width="47" height="19" font="3">center. </text>
<text top="421" left="123" width="102" height="19" font="3">● Anselme et al. </text>
<text top="439" left="123" width="69" height="19" font="3">2013 (208) </text>
<text top="458" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23811080">● </a></text>
<text top="458" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23811080">23811080</a></text>
<text top="458" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23811080"> </a></text>
<text top="476" left="123" width="3" height="19" font="3"> </text>
<text top="421" left="241" width="186" height="19" font="4"><b>Aim:</b> To evaluate a strategy of </text>
<text top="439" left="241" width="185" height="19" font="3">prophylactic ICD implantation </text>
<text top="458" left="241" width="187" height="19" font="3">in lamin A/C mutation carriers </text>
<text top="476" left="241" width="143" height="19" font="3">with significant cardiac </text>
<text top="494" left="241" width="132" height="19" font="3">conduction disorders </text>
<text top="513" left="241" width="3" height="19" font="3"> </text>
<text top="531" left="241" width="160" height="19" font="4"><b>Study type:</b> Cohort study, </text>
<text top="549" left="241" width="81" height="19" font="3">single center </text>
<text top="568" left="241" width="3" height="19" font="3"> </text>
<text top="586" left="241" width="104" height="19" font="4"><b>Size: </b>47 patients </text>
<text top="421" left="445" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="440" left="445" width="111" height="20" font="3">• LMNA mutation </text>
<text top="459" left="445" width="139" height="19" font="3">carriers seen between </text>
<text top="477" left="445" width="121" height="19" font="3">3/1999 and 4/2009 </text>
<text top="495" left="445" width="124" height="20" font="3">• 47 patients (mean </text>
<text top="514" left="445" width="134" height="19" font="3">age 38±11 y; 26 men) </text>
<text top="533" left="445" width="142" height="19" font="3">with LMNA mutation.   </text>
<text top="551" left="445" width="94" height="20" font="3">• 21 (45%) had </text>
<text top="570" left="445" width="138" height="19" font="3">significant conduction </text>
<text top="588" left="445" width="131" height="19" font="3">disorders (defined as </text>
<text top="607" left="445" width="135" height="19" font="3">bradycardia requiring </text>
<text top="625" left="445" width="117" height="19" font="3">pacemaker or a PR </text>
<text top="643" left="445" width="147" height="19" font="3">interval of &gt;240 ms and </text>
<text top="662" left="445" width="135" height="19" font="3">either complete LBBB </text>
<text top="680" left="445" width="139" height="19" font="3">or NSVT) and received </text>
<text top="698" left="445" width="114" height="19" font="3">a prophylactic ICD </text>
<text top="717" left="445" width="3" height="19" font="3"> </text>
<text top="735" left="445" width="141" height="19" font="4"><b>Exclusion criteria</b>: N/A </text>
<text top="422" left="606" width="112" height="19" font="4"><b>1</b>°<b> endpoint:</b>  N/A </text>
<text top="440" left="606" width="3" height="19" font="3"> </text>
<text top="459" left="606" width="63" height="19" font="4"><b>Results:</b>    </text>
<text top="477" left="606" width="199" height="20" font="3">• In those with ICD, 11/21 (52%) </text>
<text top="496" left="606" width="177" height="19" font="3">had appropriate ICD therapy </text>
<text top="514" left="606" width="199" height="19" font="3">during a median follow-up of 62 </text>
<text top="533" left="606" width="23" height="19" font="3">mo </text>
<text top="551" left="606" width="206" height="20" font="3">• LVEF was ≥45% in 9/11 patients </text>
<text top="570" left="606" width="157" height="19" font="3">with appropriate therapy </text>
<text top="589" left="606" width="177" height="20" font="3">• The presence of significant </text>
<text top="608" left="606" width="144" height="19" font="3">conduction disorders is </text>
<text top="626" left="606" width="183" height="19" font="3">associated with malignant VA </text>
<text top="644" left="606" width="188" height="19" font="3">(HR: 5.20; 95% CI: 1.14–23.53; </text>
<text top="662" left="606" width="50" height="19" font="3">p=0.03) </text>
<text top="421" left="828" width="235" height="19" font="3">● Life-threatening VAs are common in </text>
<text top="439" left="828" width="239" height="19" font="3">patients with lamin A/C mutations and </text>
<text top="458" left="828" width="185" height="19" font="3">significant cardiac conduction </text>
<text top="476" left="828" width="225" height="19" font="3">disorders, even if LVEF is preserved.  </text>
<text top="494" left="828" width="217" height="19" font="3">● ICD is an effective treatment and </text>
<text top="513" left="828" width="221" height="19" font="3">should be considered in this patient </text>
<text top="531" left="828" width="74" height="19" font="3">population. </text>
<text top="549" left="828" width="3" height="19" font="3"> </text>
<text top="568" left="828" width="3" height="19" font="3"> </text>
<text top="586" left="828" width="3" height="19" font="3"> </text>
<text top="604" left="828" width="3" height="19" font="3"> </text>
<text top="623" left="828" width="3" height="19" font="3"> </text>
<text top="641" left="828" width="3" height="19" font="3"> </text>
<text top="659" left="828" width="3" height="19" font="3"> </text>
<text top="678" left="828" width="3" height="19" font="3"> </text>
</page>
<page number="177" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">177 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="123" width="96" height="19" font="3">● van Rijsingen </text>
<text top="127" left="123" width="30" height="19" font="3">et al.</text>
<text top="125" left="153" width="4" height="21" font="0"> </text>
<text top="127" left="157" width="69" height="19" font="3">2012 (209) </text>
<text top="145" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22281253">● </a></text>
<text top="145" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22281253">22281253</a></text>
<text top="145" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22281253"> </a></text>
<text top="163" left="123" width="3" height="19" font="3"> </text>
<text top="182" left="123" width="3" height="19" font="3"> </text>
<text top="108" left="241" width="171" height="19" font="4"><b>Aim:</b> To identify risk factors </text>
<text top="127" left="241" width="181" height="19" font="3">that predict malignant VAs in </text>
<text top="145" left="241" width="172" height="19" font="3">lamin A/C mutation carriers </text>
<text top="163" left="241" width="3" height="19" font="3"> </text>
<text top="182" left="241" width="123" height="19" font="4"><b>Study type:</b> Cohort, </text>
<text top="200" left="241" width="74" height="19" font="3">multicenter </text>
<text top="218" left="241" width="3" height="19" font="3"> </text>
<text top="236" left="241" width="111" height="19" font="4"><b>Size:</b> 269 patients </text>
<text top="108" left="445" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="127" left="445" width="134" height="19" font="3">Pathogenic lamin A/C </text>
<text top="145" left="445" width="109" height="19" font="3">mutation carriers </text>
<text top="163" left="445" width="117" height="19" font="3">between 2000 and </text>
<text top="182" left="445" width="34" height="19" font="3">2010 </text>
<text top="200" left="445" width="3" height="19" font="3"> </text>
<text top="218" left="445" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="237" left="445" width="145" height="20" font="3">•  Patients ≤15 y of age </text>
<text top="256" left="445" width="140" height="20" font="3">•  Median follow up of </text>
<text top="275" left="445" width="42" height="19" font="3">43 mo </text>
<text top="109" left="606" width="174" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Occurrence of </text>
<text top="127" left="606" width="91" height="19" font="3">malignant VAs </text>
<text top="146" left="606" width="3" height="19" font="3"> </text>
<text top="164" left="606" width="63" height="19" font="4"><b>Results:</b>    </text>
<text top="182" left="606" width="208" height="20" font="3">• 48 (18%) had malignant VAs (11 </text>
<text top="201" left="606" width="190" height="19" font="3">successful CPR, 25 appropriate </text>
<text top="220" left="606" width="169" height="19" font="3">ICD treatment, and 12 died </text>
<text top="238" left="606" width="63" height="19" font="3">suddenly) </text>
<text top="257" left="606" width="205" height="20" font="3">• Risk factors for VAs were NSVT, </text>
<text top="276" left="606" width="188" height="19" font="3">LVEF &lt;45%, male sex, and non-</text>
<text top="294" left="606" width="151" height="19" font="3">missense mutations (ins-</text>
<text top="312" left="606" width="173" height="19" font="3">del/truncating or mutations </text>
<text top="330" left="606" width="192" height="19" font="3">affecting splicing). VA occurred </text>
<text top="349" left="606" width="201" height="19" font="3">only in persons with at least 2 of </text>
<text top="367" left="606" width="111" height="19" font="3">these risk factors. </text>
<text top="108" left="828" width="225" height="19" font="3">● Patients with lamin A/C mutations </text>
<text top="127" left="828" width="229" height="19" font="3">with ≥2 risk factors may benefit from </text>
<text top="145" left="828" width="103" height="19" font="3">prophylactic ICD </text>
<text top="163" left="828" width="3" height="19" font="3"> </text>
<text top="182" left="828" width="3" height="19" font="3"> </text>
<text top="200" left="828" width="3" height="19" font="3"> </text>
<text top="218" left="828" width="3" height="19" font="3"> </text>
<text top="386" left="123" width="93" height="19" font="3">● Meune et al. </text>
<text top="404" left="123" width="69" height="19" font="3">2006 (319) </text>
<text top="422" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=16407522">● </a></text>
<text top="422" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=16407522">16407522</a></text>
<text top="422" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=16407522"> </a></text>
<text top="441" left="123" width="3" height="19" font="3"> </text>
<text top="459" left="123" width="3" height="19" font="3"> </text>
<text top="386" left="241" width="185" height="19" font="4"><b>Aim:</b> To assess whether ICD is </text>
<text top="404" left="241" width="186" height="19" font="3">beneficial for 1° prevention of </text>
<text top="422" left="241" width="189" height="19" font="3">SCD in patients with lamin A/C </text>
<text top="441" left="241" width="129" height="19" font="3">gene mutations with </text>
<text top="459" left="241" width="172" height="19" font="3">preserved LVEF referred for </text>
<text top="477" left="241" width="161" height="19" font="3">pacing due to presence of </text>
<text top="496" left="241" width="182" height="19" font="3">progressive conduction delay </text>
<text top="514" left="241" width="46" height="19" font="3">or SND </text>
<text top="532" left="241" width="3" height="19" font="3"> </text>
<text top="551" left="241" width="163" height="19" font="4"><b>Study type:</b>   Cohort study </text>
<text top="569" left="241" width="3" height="19" font="3"> </text>
<text top="587" left="241" width="114" height="19" font="4"><b>Size:</b>    19 patients </text>
<text top="606" left="241" width="3" height="19" font="3"> </text>
<text top="624" left="241" width="3" height="19" font="3"> </text>
<text top="386" left="445" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="404" left="445" width="132" height="19" font="3">Lamin A/C mutations </text>
<text top="422" left="445" width="145" height="19" font="3">associated with cardiac </text>
<text top="441" left="445" width="120" height="19" font="3">conduction defects </text>
<text top="459" left="445" width="3" height="19" font="3"> </text>
<text top="477" left="445" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="496" left="445" width="137" height="20" font="3">• 19 patients received </text>
<text top="515" left="445" width="89" height="19" font="3">ICD (Muscular </text>
<text top="533" left="445" width="128" height="19" font="3">phenotype: 9 Emery-</text>
<text top="551" left="445" width="129" height="19" font="3">Dreifuss, 8 DCM plus </text>
<text top="570" left="445" width="135" height="19" font="3">conduction disease, 1 </text>
<text top="588" left="445" width="87" height="19" font="3">Limb-girdle, 1 </text>
<text top="606" left="445" width="104" height="19" font="3">shoulder-muscle </text>
<text top="625" left="445" width="83" height="19" font="3">amyotrophy) </text>
<text top="643" left="445" width="138" height="20" font="3">• Mean age 41.7±13.4 </text>
<text top="662" left="445" width="10" height="19" font="3">y </text>
<text top="681" left="445" width="102" height="20" font="3">• Sex: 73% Male </text>
<text top="700" left="445" width="144" height="20" font="3">• Mean LVEF 58%±12% </text>
<text top="386" left="606" width="168" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Not specified </text>
<text top="405" left="606" width="3" height="19" font="4"><b> </b></text>
<text top="423" left="606" width="63" height="19" font="4"><b>Results:</b>    </text>
<text top="442" left="606" width="136" height="20" font="3">• 8/19 (42%) received </text>
<text top="461" left="606" width="151" height="19" font="3">appropriate ICD therapy </text>
<text top="479" left="606" width="149" height="20" font="3">• Follow up 33.9±21 mo </text>
<text top="498" left="606" width="170" height="20" font="3">• No factor (including LVEF, </text>
<text top="517" left="606" width="188" height="19" font="3">spontaneous or induced VA or </text>
<text top="535" left="606" width="169" height="19" font="3">drug therapy) predicted VA </text>
<text top="554" left="606" width="44" height="19" font="3">events </text>
<text top="572" left="606" width="188" height="20" font="3">• LVEF not reduced in patients </text>
<text top="591" left="606" width="144" height="19" font="3">receiving ICD therapies </text>
<text top="609" left="606" width="3" height="19" font="3"> </text>
<text top="628" left="606" width="3" height="19" font="3"> </text>
<text top="646" left="606" width="3" height="19" font="3"> </text>
<text top="664" left="606" width="3" height="19" font="3"> </text>
<text top="386" left="828" width="149" height="19" font="3">● 1 inappropriate shock </text>
<text top="404" left="828" width="246" height="19" font="3">● Summary: ICD rather than pacemaker </text>
<text top="422" left="828" width="232" height="19" font="3">should be considered in patients with </text>
<text top="441" left="828" width="221" height="19" font="3">conduction disorders and lamin A/C </text>
<text top="459" left="828" width="60" height="19" font="3">mutation </text>
<text top="719" left="123" width="92" height="19" font="3">● Pasotti et al. </text>
<text top="737" left="123" width="69" height="19" font="3">2008 (210) </text>
<text top="755" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18926329">● </a></text>
<text top="755" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18926329">18926329</a></text>
<text top="755" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18926329"> </a></text>
<text top="774" left="123" width="3" height="19" font="3"> </text>
<text top="719" left="241" width="190" height="19" font="4"><b>Aim:</b> The aim of this study was </text>
<text top="737" left="241" width="153" height="19" font="3">to analyze the long-term </text>
<text top="755" left="241" width="123" height="19" font="3">follow-up of dilated </text>
<text top="774" left="241" width="143" height="19" font="3">cardiolaminopathies in </text>
<text top="719" left="445" width="130" height="19" font="4"><b>Inclusion criteria:</b> 27 </text>
<text top="737" left="445" width="141" height="19" font="3">consecutive families in </text>
<text top="755" left="445" width="114" height="19" font="3">which <i>LMNA </i>gene </text>
<text top="774" left="445" width="144" height="19" font="3">defects were identified </text>
<text top="720" left="606" width="202" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Events were death </text>
<text top="738" left="606" width="196" height="19" font="3">from any cause, death from HF, </text>
<text top="756" left="606" width="195" height="19" font="3">heart transplantation, and SCD, </text>
<text top="719" left="828" width="205" height="19" font="3">● Authors concluded that dilated </text>
<text top="737" left="828" width="218" height="19" font="3">cardiomyopathies caused by <i>LMNA </i></text>
<text top="755" left="828" width="213" height="19" font="3">gene defects are highly penetrant, </text>
<text top="774" left="828" width="195" height="19" font="3">adult onset, malignant diseases </text>
</page>
<page number="178" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">178 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="123" width="3" height="19" font="3"> </text>
<text top="108" left="241" width="183" height="19" font="3">patients with Lamin A/C gene </text>
<text top="127" left="241" width="66" height="19" font="3">mutations<b> </b></text>
<text top="145" left="241" width="3" height="19" font="4"><b> </b></text>
<text top="163" left="241" width="162" height="19" font="4"><b>Study type:</b> Retrospective </text>
<text top="182" left="241" width="162" height="19" font="3">observational longitudinal </text>
<text top="200" left="241" width="37" height="19" font="3">study </text>
<text top="218" left="241" width="3" height="19" font="3"> </text>
<text top="236" left="241" width="104" height="19" font="4"><b>Size:</b> 94 patients </text>
<text top="108" left="445" width="121" height="19" font="3">in the probands, all </text>
<text top="127" left="445" width="105" height="19" font="3">sharing the DCM </text>
<text top="145" left="445" width="141" height="19" font="3">phenotype. Of the 164 </text>
<text top="163" left="445" width="124" height="19" font="3">family members, 94 </text>
<text top="182" left="445" width="100" height="19" font="3">had LMNA gene </text>
<text top="200" left="445" width="66" height="19" font="3">mutations </text>
<text top="218" left="445" width="3" height="19" font="3"> </text>
<text top="236" left="445" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="108" left="606" width="159" height="19" font="3">including appropriate ICD </text>
<text top="127" left="606" width="85" height="19" font="3">interventions </text>
<text top="145" left="606" width="3" height="19" font="3"> </text>
<text top="163" left="606" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="182" left="606" width="136" height="20" font="3">• 60 of 94 (64%) were </text>
<text top="201" left="606" width="202" height="19" font="3">phenotypically affected whereas </text>
<text top="219" left="606" width="166" height="19" font="3">34 were only genotypically </text>
<text top="237" left="606" width="58" height="19" font="3">affected. </text>
<text top="256" left="606" width="206" height="20" font="3">• Of the 60 patients, 40 had DCM </text>
<text top="275" left="606" width="172" height="19" font="3">with AVB, 12 had DCM with </text>
<text top="293" left="606" width="193" height="19" font="3">VT/fibrillation, 6 had DCM with </text>
<text top="311" left="606" width="201" height="19" font="3">AVB and EDMD2, and 2 had AVB </text>
<text top="330" left="606" width="85" height="19" font="3">plus EDMD2.  </text>
<text top="348" left="606" width="205" height="20" font="3">•During a median of 57 mo there </text>
<text top="367" left="606" width="163" height="19" font="3">were 49 events in 43 DCM </text>
<text top="385" left="606" width="57" height="19" font="3">patients. </text>
<text top="404" left="606" width="194" height="20" font="3">•The events were related to HF </text>
<text top="423" left="606" width="185" height="19" font="3">(15 heart transplants, 1 death </text>
<text top="441" left="606" width="191" height="19" font="3">from end-stage HF) and VA (15 </text>
<text top="459" left="606" width="178" height="19" font="3">SCDs and 12 appropriate ICD </text>
<text top="478" left="606" width="93" height="19" font="3">interventions). </text>
<text top="108" left="828" width="234" height="19" font="3">characterized by a high rate of HF and </text>
<text top="127" left="828" width="179" height="19" font="3">life-threatening arrhythmias. </text>
<text top="145" left="828" width="3" height="19" font="3"> </text>
<text top="496" left="123" width="89" height="19" font="3">● van Berlo et </text>
<text top="515" left="123" width="87" height="19" font="3">al.<b> </b>2005 (211) </text>
<text top="533" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=15551023">● </a></text>
<text top="533" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=15551023">15551023</a></text>
<text top="533" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=15551023"> </a></text>
<text top="551" left="123" width="3" height="19" font="3"> </text>
<text top="496" left="241" width="164" height="19" font="4"><b>Aim:</b> To evaluate common </text>
<text top="515" left="241" width="152" height="19" font="3">clinical characteristics of </text>
<text top="533" left="241" width="180" height="19" font="3">patients with lamin A/C gene </text>
<text top="551" left="241" width="172" height="19" font="3">mutations that cause either </text>
<text top="570" left="241" width="150" height="19" font="3">isolated DCM or DCM in </text>
<text top="588" left="241" width="152" height="19" font="3">association with skeletal </text>
<text top="606" left="241" width="128" height="19" font="3">muscular dystrophy.<b> </b></text>
<text top="624" left="241" width="3" height="19" font="4"><b> </b></text>
<text top="643" left="241" width="162" height="19" font="4"><b>Study type:</b> Meta-analysis </text>
<text top="661" left="241" width="86" height="19" font="3">(pooled data) </text>
<text top="679" left="241" width="3" height="19" font="3"> </text>
<text top="698" left="241" width="123" height="19" font="4"><b>Size:</b> 299 carriers of </text>
<text top="716" left="241" width="129" height="19" font="3">lamin A/C mutations </text>
<text top="496" left="445" width="133" height="19" font="4"><b>Inclusion criteria:</b>  21 </text>
<text top="515" left="445" width="135" height="19" font="3">publications between </text>
<text top="533" left="445" width="43" height="19" font="3">March </text>
<text top="551" left="445" width="137" height="19" font="3">1999 and March 2002 </text>
<text top="570" left="445" width="123" height="19" font="3">reporting lamin A/C </text>
<text top="588" left="445" width="99" height="19" font="3">gene mutations </text>
<text top="606" left="445" width="3" height="19" font="3"> </text>
<text top="624" left="445" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="643" left="445" width="131" height="19" font="3">Patients with familial </text>
<text top="661" left="445" width="134" height="19" font="3">partial lipodystrophy, </text>
<text top="680" left="445" width="102" height="19" font="3">progeria, axonal </text>
<text top="698" left="445" width="101" height="19" font="3">neuropathy and </text>
<text top="716" left="445" width="98" height="19" font="3">mandibuloacral </text>
<text top="734" left="445" width="123" height="19" font="3">dysplasia caused by </text>
<text top="753" left="445" width="141" height="19" font="3">mutations in the lamin </text>
<text top="497" left="606" width="189" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Arrhythmias and </text>
<text top="516" left="606" width="87" height="19" font="3">sudden death </text>
<text top="534" left="606" width="3" height="19" font="3"> </text>
<text top="552" left="606" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="571" left="606" width="178" height="20" font="3">• Cardiac dysrhythmias were </text>
<text top="589" left="606" width="203" height="19" font="3">reported in 92% of patients after </text>
<text top="608" left="606" width="193" height="19" font="3">30 y of age; HF was reported in </text>
<text top="626" left="606" width="139" height="19" font="3">64% after 50 y of age.  </text>
<text top="645" left="606" width="205" height="20" font="3">• 76 of the reported 299 patients </text>
<text top="664" left="606" width="193" height="19" font="3">(25%) died at a mean of 46 y of </text>
<text top="682" left="606" width="32" height="19" font="3">age.  </text>
<text top="700" left="606" width="183" height="20" font="3">• Sudden death was the most </text>
<text top="719" left="606" width="179" height="19" font="3">frequently reported mode of </text>
<text top="738" left="606" width="195" height="19" font="3">death (46%) in both the cardiac </text>
<text top="756" left="606" width="146" height="19" font="3">and the neuromuscular </text>
<text top="774" left="606" width="73" height="19" font="3">phenotype. </text>
<text top="496" left="828" width="216" height="19" font="3">● Authors conclude that carriers of </text>
<text top="515" left="828" width="244" height="19" font="3">lamin A/C mutations carry a high risk of </text>
<text top="533" left="828" width="91" height="19" font="3">sudden death. </text>
<text top="551" left="828" width="205" height="19" font="3">● Presence of pacemaker did not </text>
<text top="570" left="828" width="186" height="19" font="3">protect against sudden death. </text>
<text top="588" left="828" width="3" height="19" font="3"> </text>
</page>
<page number="179" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">179 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="445" width="93" height="19" font="3">A/C gene were </text>
<text top="127" left="445" width="58" height="19" font="3">excluded </text>
<text top="145" left="123" width="94" height="19" font="3">● Lallemand et </text>
<text top="164" left="123" width="48" height="19" font="3">al. 2012</text>
<text top="162" left="171" width="4" height="21" font="0"> </text>
<text top="164" left="175" width="35" height="19" font="3">(320) </text>
<text top="182" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22038543">● </a></text>
<text top="182" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22038543">22038543</a></text>
<text top="182" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22038543"> </a></text>
<text top="200" left="123" width="3" height="19" font="3"> </text>
<text top="219" left="123" width="3" height="19" font="3"> </text>
<text top="145" left="241" width="191" height="19" font="4"><b>Aim:</b> To analyze the natural Hx </text>
<text top="164" left="241" width="170" height="19" font="3">and predictors of change in </text>
<text top="182" left="241" width="177" height="19" font="3">infra-Hisian conduction time </text>
<text top="200" left="241" width="140" height="19" font="3">in myotonic dystrophy </text>
<text top="219" left="241" width="185" height="19" font="3">patients with normal baseline </text>
<text top="237" left="241" width="29" height="19" font="3">EPS  </text>
<text top="255" left="241" width="3" height="19" font="4"><b> </b></text>
<text top="273" left="241" width="157" height="19" font="4"><b>Study type:</b> Cohort study </text>
<text top="292" left="241" width="3" height="19" font="3"> </text>
<text top="310" left="241" width="111" height="19" font="4"><b>Size:</b> 127 patients </text>
<text top="145" left="445" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="164" left="445" width="143" height="19" font="3">Patients with muscular </text>
<text top="182" left="445" width="139" height="19" font="3">dystrophy of which 25 </text>
<text top="200" left="445" width="128" height="19" font="3">underwent a second </text>
<text top="219" left="445" width="146" height="19" font="3">EPS for new symptoms, </text>
<text top="237" left="445" width="122" height="19" font="3">new AV conduction </text>
<text top="255" left="445" width="138" height="19" font="3">abnormalities on ECG, </text>
<text top="273" left="445" width="124" height="19" font="3">changes on SA-ECG, </text>
<text top="292" left="445" width="114" height="19" font="3">ord asymptomatic </text>
<text top="310" left="445" width="136" height="19" font="3">patients &gt;60 mo from </text>
<text top="329" left="445" width="53" height="19" font="3">first EPS </text>
<text top="347" left="445" width="3" height="19" font="3"> </text>
<text top="365" left="445" width="144" height="19" font="4"><b>Exclusion criteria: </b> N/A </text>
<text top="146" left="606" width="112" height="19" font="4"><b>1</b>°<b> endpoint:</b>  N/A </text>
<text top="165" left="606" width="3" height="19" font="3"> </text>
<text top="183" left="606" width="169" height="19" font="4"><b>Results:</b>   Mean HV interval </text>
<text top="201" left="606" width="197" height="19" font="3">increased between the baseline </text>
<text top="219" left="606" width="110" height="19" font="3">and follow-up EP  </text>
<text top="238" left="606" width="209" height="20" font="3">• Study – 52.1±1.6 ms to 61.4±2.2 </text>
<text top="257" left="606" width="25" height="19" font="3">ms. </text>
<text top="275" left="606" width="175" height="20" font="3">• Predictors of increased HV </text>
<text top="294" left="606" width="191" height="19" font="3">interval were change in resting </text>
<text top="312" left="606" width="198" height="19" font="3">ECG and SA-ECG (QRSd ≥100 ms </text>
<text top="331" left="606" width="172" height="19" font="3">or low amplitude signal &lt;40 </text>
<text top="349" left="606" width="72" height="19" font="3">microvolts) </text>
<text top="368" left="606" width="173" height="20" font="3">• 5 patients with HV ≥70 ms </text>
<text top="387" left="606" width="205" height="19" font="3">received prophylactic pacemaker </text>
<text top="145" left="828" width="225" height="19" font="3">● In patients with normal initial EPS, </text>
<text top="164" left="828" width="230" height="19" font="3">changes in the resting ECG and/or SA-</text>
<text top="182" left="828" width="188" height="19" font="3">ECG on annual follow-up were </text>
<text top="200" left="828" width="233" height="19" font="3">associated with change in infra-Hisian </text>
<text top="219" left="828" width="72" height="19" font="3">conduction </text>
<text top="237" left="828" width="3" height="19" font="3"> </text>
<text top="255" left="828" width="3" height="19" font="3"> </text>
<text top="273" left="828" width="3" height="19" font="3"> </text>
<text top="292" left="828" width="3" height="19" font="3"> </text>
<text top="310" left="828" width="3" height="19" font="3"> </text>
<text top="329" left="828" width="3" height="19" font="3"> </text>
<text top="347" left="828" width="3" height="19" font="3"> </text>
<text top="365" left="828" width="3" height="19" font="3"> </text>
<text top="405" left="123" width="89" height="19" font="3">● Wahbi et al. </text>
<text top="424" left="123" width="69" height="19" font="3">2012 (321) </text>
<text top="442" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22453570">● </a></text>
<text top="442" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22453570">22453570</a></text>
<text top="442" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22453570"> </a></text>
<text top="460" left="123" width="3" height="19" font="3"> </text>
<text top="478" left="123" width="3" height="19" font="3"> </text>
<text top="405" left="241" width="173" height="19" font="4"><b>Aim:</b> To determine whether </text>
<text top="424" left="241" width="182" height="19" font="3">an invasive strategy based on </text>
<text top="442" left="241" width="130" height="19" font="3">EPS and prophylactic </text>
<text top="460" left="241" width="182" height="19" font="3">pacemaker is associated with </text>
<text top="478" left="241" width="160" height="19" font="3">longer survival in patients </text>
<text top="497" left="241" width="160" height="19" font="3">presenting with myotonic </text>
<text top="515" left="241" width="133" height="19" font="3">dystrophy type 1 and </text>
<text top="533" left="241" width="180" height="19" font="3">infranodal conduction delays </text>
<text top="552" left="241" width="168" height="19" font="3">compared to a noninvasive </text>
<text top="570" left="241" width="157" height="19" font="3">strategy using propensity </text>
<text top="588" left="241" width="79" height="19" font="3">adjustments </text>
<text top="607" left="241" width="3" height="19" font="3"> </text>
<text top="625" left="241" width="157" height="19" font="4"><b>Study type:</b> Cohort study </text>
<text top="643" left="241" width="3" height="19" font="3"> </text>
<text top="661" left="241" width="111" height="19" font="4"><b>Size: </b>486 patients </text>
<text top="405" left="445" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="424" left="445" width="137" height="19" font="3">Genetically confirmed </text>
<text top="442" left="445" width="125" height="19" font="3">myotonic dystrophy </text>
<text top="460" left="445" width="146" height="19" font="3">type 1 with PR &gt;200 ms </text>
<text top="478" left="445" width="129" height="19" font="3">and/or QRS &gt;100 ms </text>
<text top="497" left="445" width="121" height="19" font="3">between 1/2000 to </text>
<text top="515" left="445" width="55" height="19" font="3">12/2009 </text>
<text top="533" left="445" width="3" height="19" font="3"> </text>
<text top="552" left="445" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="570" left="445" width="3" height="19" font="3"> </text>
<text top="588" left="445" width="3" height="19" font="3"> </text>
<text top="406" left="606" width="202" height="19" font="4"><b>1</b>°<b> endpoint:</b>  All-cause mortality </text>
<text top="424" left="606" width="3" height="19" font="3"> </text>
<text top="443" left="606" width="63" height="19" font="4"><b>Results:</b>    </text>
<text top="461" left="606" width="113" height="19" font="3">341 (70.2%) - EPS  </text>
<text top="479" left="606" width="165" height="19" font="3">compared to 145 (29.8%) - </text>
<text top="498" left="606" width="129" height="19" font="3">noninvasive strategy </text>
<text top="516" left="606" width="3" height="19" font="3"> </text>
<text top="534" left="606" width="190" height="20" font="3">• Median follow-up 7.4 y (322) </text>
<text top="553" left="606" width="205" height="20" font="3">• 50 patients died in EPS strategy </text>
<text top="572" left="606" width="43" height="19" font="3">group  </text>
<text top="591" left="606" width="163" height="19" font="3">30 died in the noninvasive </text>
<text top="609" left="606" width="204" height="19" font="3">strategy group (HR: 0.74; 95% CI: </text>
<text top="627" left="606" width="118" height="19" font="3">0.47–1.16; p=0.19) </text>
<text top="646" left="606" width="180" height="20" font="3">• Difference attributable to a </text>
<text top="665" left="606" width="166" height="19" font="3">lower incidence of SCD (10 </text>
<text top="683" left="606" width="198" height="19" font="3">patients invasive strategy group </text>
<text top="701" left="606" width="167" height="19" font="3">vs. 16 patients noninvasive </text>
<text top="720" left="606" width="203" height="19" font="3">strategy group, HR: 0.24; 95% CI: </text>
<text top="738" left="606" width="130" height="19" font="3">0.10–0.56; p=0.001]) </text>
<text top="405" left="828" width="236" height="19" font="3">● In patients with myotonic dystrophy </text>
<text top="424" left="828" width="196" height="19" font="3">type 1, an invasive strategy was </text>
<text top="442" left="828" width="213" height="19" font="3">associated with a higher rate of 9y </text>
<text top="460" left="828" width="221" height="19" font="3">survival than a noninvasive strategy </text>
<text top="478" left="828" width="3" height="19" font="3"> </text>
<text top="497" left="828" width="3" height="19" font="3"> </text>
<text top="515" left="828" width="3" height="19" font="3"> </text>
<text top="533" left="828" width="3" height="19" font="3"> </text>
</page>
<page number="180" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">180 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="123" width="100" height="19" font="3">● Ha et al. 2012 </text>
<text top="127" left="123" width="35" height="19" font="3">(323) </text>
<text top="145" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22385162">● </a></text>
<text top="145" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22385162">22385162</a></text>
<text top="145" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22385162"> </a></text>
<text top="163" left="123" width="3" height="19" font="3"> </text>
<text top="182" left="123" width="3" height="19" font="3"> </text>
<text top="108" left="241" width="175" height="19" font="4"><b>Aim:</b> To define predictors of </text>
<text top="127" left="241" width="182" height="19" font="3">cardiac conduction disease in </text>
<text top="145" left="241" width="179" height="19" font="3">myotonic dystrophy patients </text>
<text top="163" left="241" width="3" height="19" font="3"> </text>
<text top="182" left="241" width="160" height="19" font="4"><b>Study type:</b> Cohort study, </text>
<text top="200" left="241" width="83" height="19" font="3">single-center </text>
<text top="218" left="241" width="3" height="19" font="3"> </text>
<text top="236" left="241" width="111" height="19" font="4"><b>Size:</b> 211 patients </text>
<text top="108" left="445" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="127" left="445" width="143" height="19" font="3">Patients with DM1 and </text>
<text top="145" left="445" width="118" height="19" font="3">25 DM2 after 2003 </text>
<text top="163" left="445" width="3" height="19" font="3"> </text>
<text top="182" left="445" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="200" left="445" width="3" height="19" font="3"> </text>
<text top="109" left="606" width="112" height="19" font="4"><b>1</b>°<b> endpoint:</b>  N/A </text>
<text top="127" left="606" width="3" height="19" font="3"> </text>
<text top="146" left="606" width="56" height="19" font="4"><b>Results:</b>  </text>
<text top="164" left="606" width="139" height="19" font="3">• Follow-up 57±46 mo </text>
<text top="182" left="606" width="3" height="19" font="3"> </text>
<text top="201" left="606" width="199" height="19" font="3">• A severe ECG abnormality was </text>
<text top="219" left="606" width="196" height="19" font="3">defined as a PR interval of ≥240 </text>
<text top="237" left="606" width="193" height="19" font="3">ms or QRS duration of ≥120 ms </text>
<text top="256" left="606" width="10" height="19" font="3">   </text>
<text top="274" left="606" width="160" height="20" font="3">• Severe ECG abnormality </text>
<text top="293" left="606" width="196" height="19" font="3">present in 24% of DM1 patients </text>
<text top="311" left="606" width="158" height="19" font="3">and 17% of DM2 patients </text>
<text top="330" left="606" width="202" height="20" font="3">• Pacemaker or ICD implanted in </text>
<text top="349" left="606" width="207" height="19" font="3">14% of all patients, including 65% </text>
<text top="367" left="606" width="171" height="19" font="3">of patients with severe ECG </text>
<text top="385" left="606" width="94" height="19" font="3">abnormalities.  </text>
<text top="404" left="606" width="178" height="20" font="3">• 13 patients died (1.16%/y), </text>
<text top="423" left="606" width="191" height="19" font="3">including 3 sudden (2 of whom </text>
<text top="441" left="606" width="108" height="19" font="3">had pacemakers) </text>
<text top="108" left="828" width="235" height="19" font="3">● Despite identification of conduction </text>
<text top="127" left="828" width="201" height="19" font="3">disease and prophylactic pacing, </text>
<text top="145" left="828" width="240" height="19" font="3">mortality remains high in patients with </text>
<text top="163" left="828" width="243" height="19" font="3">a severe ECG abnormality (most deaths </text>
<text top="182" left="828" width="231" height="19" font="3">non-sudden, suggesting that a severe </text>
<text top="200" left="828" width="242" height="19" font="3">ECG abnormality is also general marker </text>
<text top="218" left="828" width="190" height="19" font="3">of risk for all-cause mortality.)  </text>
<text top="237" left="828" width="228" height="19" font="3">● Of 3 patients who died suddenly, 2 </text>
<text top="255" left="828" width="214" height="19" font="3">had pacemakers, suggesting that a </text>
<text top="273" left="828" width="206" height="19" font="3">severe ECG abnormality does not </text>
<text top="291" left="828" width="230" height="19" font="3">simply predict sudden death from AV </text>
<text top="310" left="828" width="36" height="19" font="3">block </text>
<text top="328" left="828" width="3" height="19" font="3"> </text>
<text top="460" left="123" width="96" height="19" font="3">● Laurent et al. </text>
<text top="478" left="123" width="66" height="19" font="3">2011(324) </text>
<text top="496" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20227121">● </a></text>
<text top="496" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20227121">20227121</a></text>
<text top="496" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20227121"> </a></text>
<text top="515" left="123" width="3" height="19" font="3"> </text>
<text top="533" left="123" width="3" height="19" font="3"> </text>
<text top="460" left="241" width="173" height="19" font="4"><b>Aim:</b> To determine whether </text>
<text top="478" left="241" width="176" height="19" font="3">implantation of prophylactic </text>
<text top="496" left="241" width="146" height="19" font="3">pacemaker in myotonic </text>
<text top="515" left="241" width="169" height="19" font="3">dystrophy patients with HV </text>
<text top="533" left="241" width="184" height="19" font="3">interval ≥70 lowers the risk of </text>
<text top="551" left="241" width="135" height="19" font="3">sudden death (due to </text>
<text top="570" left="241" width="122" height="19" font="3">complete AV block) </text>
<text top="588" left="241" width="3" height="19" font="3"> </text>
<text top="606" left="241" width="157" height="19" font="4"><b>Study type:</b> Cohort study </text>
<text top="625" left="241" width="3" height="19" font="3"> </text>
<text top="643" left="241" width="111" height="19" font="4"><b>Size:</b> 100 patients </text>
<text top="460" left="445" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="478" left="445" width="137" height="19" font="3">Genetically confirmed </text>
<text top="496" left="445" width="124" height="19" font="3">MD1 between 1994 </text>
<text top="515" left="445" width="114" height="19" font="3">and 2008 at single </text>
<text top="533" left="445" width="66" height="19" font="3">institution </text>
<text top="551" left="445" width="3" height="19" font="3"> </text>
<text top="570" left="445" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="588" left="445" width="139" height="20" font="3">• Infantile form of MD </text>
<text top="607" left="445" width="144" height="20" font="3">• 100 patients enrolled </text>
<text top="626" left="445" width="141" height="19" font="3">and 49 implanted with </text>
<text top="645" left="445" width="113" height="19" font="3">pacemaker for HV </text>
<text top="663" left="445" width="76" height="19" font="3">interval ≥70 </text>
<text top="681" left="445" width="110" height="20" font="3">• Mean follow up </text>
<text top="700" left="445" width="65" height="19" font="3">74±39 mo </text>
<text top="719" left="445" width="129" height="20" font="3">• 46% had 1 or more </text>
<text top="738" left="445" width="133" height="19" font="3">Groh criteria (rhythm </text>
<text top="756" left="445" width="126" height="19" font="3">other than sinus, PR </text>
<text top="774" left="445" width="146" height="19" font="3">≥240 ms, QRS ≥120 ms, </text>
<text top="461" left="606" width="199" height="19" font="4"><b>1</b>°<b> endpoint:</b> All-cause mortality </text>
<text top="479" left="606" width="3" height="19" font="3"> </text>
<text top="497" left="606" width="56" height="19" font="4"><b>Results:</b>  </text>
<text top="516" left="606" width="206" height="20" font="3">• 10 deaths (9 respiratory failure, </text>
<text top="535" left="606" width="189" height="19" font="3">1 sudden). 1 SCD occurred in a </text>
<text top="553" left="606" width="205" height="19" font="3">patient with pacemaker who had </text>
<text top="571" left="606" width="199" height="19" font="3">no spontaneous VT suggesting a </text>
<text top="590" left="606" width="174" height="19" font="3">non-cardiac etiology for this </text>
<text top="608" left="606" width="42" height="19" font="3">event. </text>
<text top="626" left="606" width="170" height="20" font="3">• 1/51 with HV interval &lt;70 </text>
<text top="645" left="606" width="185" height="19" font="3">developed complete AV block </text>
<text top="664" left="606" width="184" height="20" font="3">• 19/49 patients with HV ≥ 70 </text>
<text top="683" left="606" width="124" height="19" font="3">developed AV block </text>
<text top="460" left="828" width="229" height="19" font="3">● Implantation of a pacemaker when </text>
<text top="478" left="828" width="225" height="19" font="3">HV interval ≥70 seemed to identify a </text>
<text top="496" left="828" width="223" height="19" font="3">population likely to progress to high </text>
<text top="515" left="828" width="200" height="19" font="3">grade AV block.  A higher rate of </text>
<text top="533" left="828" width="195" height="19" font="3">sudden death would have been </text>
<text top="551" left="828" width="237" height="19" font="3">expected based on previous studies of </text>
<text top="570" left="828" width="239" height="19" font="3">comparable populations, implying that </text>
<text top="588" left="828" width="235" height="19" font="3">prophylactic pacemaker implantation, </text>
<text top="606" left="828" width="208" height="19" font="3">based on these criteria, may have </text>
<text top="625" left="828" width="191" height="19" font="3">prevented some deaths due to </text>
<text top="643" left="828" width="57" height="19" font="3">asystole. </text>
</page>
<page number="181" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">181 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="445" width="8" height="19" font="3">2</text>
<text top="108" left="452" width="10" height="12" font="15">nd</text>
<text top="108" left="462" width="28" height="19" font="3"> or 3</text>
<text top="108" left="490" width="9" height="12" font="15">rd</text>
<text top="108" left="498" width="70" height="19" font="3"> degree AV </text>
<text top="127" left="445" width="40" height="19" font="3">block) </text>
<text top="145" left="123" width="92" height="19" font="3">● Bhakta et al. </text>
<text top="164" left="123" width="69" height="19" font="3">2011 (325) </text>
<text top="182" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22035077">● </a></text>
<text top="182" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22035077">22035077</a></text>
<text top="182" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22035077"> </a></text>
<text top="200" left="123" width="3" height="19" font="3"> </text>
<text top="219" left="123" width="3" height="19" font="3"> </text>
<text top="145" left="241" width="177" height="19" font="4"><b>Aim:</b> To assess implant rates </text>
<text top="164" left="241" width="188" height="19" font="3">and indications for pacemaker </text>
<text top="182" left="241" width="161" height="19" font="3">and ICDs and outcomes in </text>
<text top="200" left="241" width="120" height="19" font="3">patients with DM1  </text>
<text top="219" left="241" width="3" height="19" font="3"> </text>
<text top="237" left="241" width="160" height="19" font="4"><b>Study type:</b> Cohort study, </text>
<text top="255" left="241" width="74" height="19" font="3">multicenter </text>
<text top="273" left="241" width="3" height="19" font="3"> </text>
<text top="292" left="241" width="111" height="19" font="4"><b>Size:</b> 406 patients </text>
<text top="145" left="445" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="164" left="445" width="137" height="19" font="3">Genetically confirmed </text>
<text top="182" left="445" width="33" height="19" font="3">DM1 </text>
<text top="200" left="445" width="3" height="19" font="3"> </text>
<text top="218" left="445" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="237" left="445" width="3" height="19" font="3"> </text>
<text top="255" left="445" width="3" height="19" font="3"> </text>
<text top="273" left="445" width="3" height="19" font="3"> </text>
<text top="146" left="606" width="112" height="19" font="4"><b>1</b>°<b> endpoint:</b>  N/A </text>
<text top="165" left="606" width="3" height="19" font="3"> </text>
<text top="183" left="606" width="63" height="19" font="4"><b>Results:</b>    </text>
<text top="201" left="606" width="122" height="19" font="3">Follow up 9.5±3.2 y </text>
<text top="219" left="606" width="205" height="19" font="3">46 (11.3%) received a pacemaker </text>
<text top="238" left="606" width="130" height="19" font="3">and 21 (5.2%) an ICD </text>
<text top="256" left="606" width="208" height="19" font="3">Devices were primarily implanted </text>
<text top="274" left="606" width="183" height="19" font="3">for asymptomatic conduction </text>
<text top="293" left="606" width="170" height="19" font="3">abnormalities or LV systolic </text>
<text top="311" left="606" width="75" height="19" font="3">dysfunction </text>
<text top="329" left="606" width="3" height="19" font="3"> </text>
<text top="348" left="606" width="172" height="19" font="3">7 (15.2%) pacemakers were </text>
<text top="366" left="606" width="187" height="19" font="3">implanted for third-degree AV </text>
<text top="384" left="606" width="188" height="19" font="3">block and 6 (28.6%) ICDs were </text>
<text top="402" left="606" width="113" height="19" font="3">implanted for VAs </text>
<text top="421" left="606" width="185" height="19" font="3">5 (10.9%) pacemaker patients </text>
<text top="439" left="606" width="199" height="19" font="3">underwent upgrade to an ICD (3 </text>
<text top="457" left="606" width="198" height="19" font="3">for LV systolic dysfunction, 1 for </text>
<text top="476" left="606" width="162" height="19" font="3">VAs, and 1 for progressive </text>
<text top="494" left="606" width="132" height="19" font="3">conduction disease).  </text>
<text top="512" left="606" width="180" height="19" font="3">17 (27.4%) of the 62 patients </text>
<text top="531" left="606" width="185" height="19" font="3">with devices were pacemaker-</text>
<text top="549" left="606" width="172" height="19" font="3">dependent at last follow-up </text>
<text top="567" left="606" width="165" height="19" font="3">3 (14.3%) ICD patients had </text>
<text top="586" left="606" width="137" height="19" font="3">appropriate therapies </text>
<text top="604" left="606" width="192" height="19" font="3">24 (52.2%) pacemaker patients </text>
<text top="622" left="606" width="194" height="19" font="3">died including 13 of respiratory </text>
<text top="640" left="606" width="183" height="19" font="3">failure and 7 of sudden death </text>
<text top="659" left="606" width="168" height="19" font="3">7 (33.3%) ICD patients died </text>
<text top="677" left="606" width="199" height="19" font="3">including 2 of respiratory failure </text>
<text top="696" left="606" width="195" height="19" font="3">and 3 of sudden death (1 death </text>
<text top="714" left="606" width="151" height="19" font="3">was documented due to </text>
<text top="732" left="606" width="152" height="19" font="3">inappropriate therapies) </text>
<text top="145" left="828" width="203" height="19" font="3">● Adult DM1 patients commonly </text>
<text top="164" left="828" width="188" height="19" font="3">receive pacemakers and ICDs.  </text>
<text top="182" left="828" width="205" height="19" font="3">● The risk of SCD in patients with </text>
<text top="200" left="828" width="238" height="19" font="3">pacemakers suggests that the ICD may </text>
<text top="219" left="828" width="245" height="19" font="3">warranted but SCD was still observed in </text>
<text top="237" left="828" width="249" height="19" font="3">ICD patients raising uncertainty benefit.  </text>
<text top="255" left="828" width="208" height="19" font="3">● DM1 patients are at high risk of </text>
<text top="273" left="828" width="185" height="19" font="3">respiratory failure. Therefore, </text>
<text top="292" left="828" width="222" height="19" font="3">pacemaker or ICDs in asymptomatic </text>
<text top="310" left="828" width="237" height="19" font="3">patients moderate conduction disease </text>
<text top="329" left="828" width="194" height="19" font="3">and also severe skeletal muscle </text>
<text top="347" left="828" width="187" height="19" font="3">involvement may not improve </text>
<text top="365" left="828" width="68" height="19" font="3">outcomes. </text>
</page>
<page number="182" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">182 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="123" width="103" height="19" font="3">● Nazarian et al. </text>
<text top="127" left="123" width="69" height="19" font="3">2011 (326) </text>
<text top="145" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20946286">● </a></text>
<text top="145" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20946286">20946286</a></text>
<text top="145" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20946286"> </a></text>
<text top="163" left="123" width="3" height="19" font="3"> </text>
<text top="182" left="123" width="3" height="19" font="3"> </text>
<text top="108" left="241" width="153" height="19" font="4"><b>Aim:</b> To characterize the </text>
<text top="127" left="241" width="183" height="19" font="3">trends and predictors of time-</text>
<text top="145" left="241" width="166" height="19" font="3">dependent ECG changes in </text>
<text top="163" left="241" width="117" height="19" font="3">patients with DM1 </text>
<text top="182" left="241" width="3" height="19" font="3"> </text>
<text top="200" left="241" width="160" height="19" font="4"><b>Study type:</b> Cohort study, </text>
<text top="218" left="241" width="81" height="19" font="3">single center </text>
<text top="237" left="241" width="3" height="19" font="3"> </text>
<text top="255" left="241" width="104" height="19" font="4"><b>Size:</b> 70 patients </text>
<text top="108" left="445" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="127" left="445" width="116" height="19" font="3">Patients with DM1 </text>
<text top="145" left="445" width="140" height="19" font="3">baseline ECG and then </text>
<text top="163" left="445" width="110" height="19" font="3">routine follow-up </text>
<text top="182" left="445" width="3" height="19" font="3"> </text>
<text top="200" left="445" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="218" left="445" width="136" height="20" font="3">• History of second or </text>
<text top="237" left="445" width="139" height="19" font="3">third degree AV block, </text>
<text top="256" left="445" width="139" height="19" font="3">VAs, resuscitated SCD, </text>
<text top="274" left="445" width="136" height="19" font="3">or persistent supraVA </text>
<text top="292" left="445" width="137" height="20" font="3">• Mean follow-up 956 </text>
<text top="311" left="445" width="11" height="19" font="3">d </text>
<text top="330" left="445" width="138" height="20" font="3">• Clinical predictors of </text>
<text top="349" left="445" width="120" height="19" font="3">conduction disease </text>
<text top="367" left="445" width="109" height="19" font="3">progression were </text>
<text top="385" left="445" width="92" height="19" font="3">assessed using </text>
<text top="404" left="445" width="128" height="19" font="3">multivariate analysis </text>
<text top="109" left="606" width="208" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Time dependent PR </text>
<text top="127" left="606" width="170" height="19" font="3">or QRS prolongation during </text>
<text top="146" left="606" width="62" height="19" font="3">follow-up </text>
<text top="164" left="606" width="3" height="19" font="3"> </text>
<text top="182" left="606" width="63" height="19" font="4"><b>Results:</b>    </text>
<text top="201" left="606" width="173" height="20" font="3">• Age, h/o AF or flutter, and </text>
<text top="220" left="606" width="178" height="19" font="3">number of cytosine-thymine-</text>
<text top="238" left="606" width="173" height="19" font="3">guanine (CTG) repeats were </text>
<text top="256" left="606" width="203" height="19" font="3">predictors of time-dependent PR </text>
<text top="275" left="606" width="140" height="19" font="3">and QRS prolongation  </text>
<text top="293" left="606" width="199" height="20" font="3">• Lower LVEF associated greater </text>
<text top="312" left="606" width="104" height="19" font="3">QRS progression </text>
<text top="108" left="828" width="241" height="19" font="3">● Patients with DM1 can develop rapid </text>
<text top="127" left="828" width="249" height="19" font="3">changes in cardiac conduction intervals.  </text>
<text top="145" left="828" width="223" height="19" font="3">● AF or flutter, older age, and larger </text>
<text top="163" left="828" width="227" height="19" font="3">CTG expansions predict greater time-</text>
<text top="182" left="828" width="194" height="19" font="3">dependent PR and QRS interval </text>
<text top="200" left="828" width="223" height="19" font="3">prolongation and warrant particular </text>
<text top="218" left="828" width="237" height="19" font="3">attention in the arrhythmic evaluation </text>
<text top="237" left="828" width="191" height="19" font="3">of this high-risk patient subset. </text>
<text top="255" left="828" width="3" height="19" font="3"> </text>
<text top="273" left="828" width="3" height="19" font="3"> </text>
<text top="291" left="828" width="3" height="19" font="3"> </text>
<text top="422" left="123" width="92" height="19" font="3">● Bhakta et al. </text>
<text top="441" left="123" width="30" height="19" font="3">2010</text>
<text top="439" left="153" width="4" height="21" font="0"> </text>
<text top="441" left="157" width="35" height="19" font="3">(327) </text>
<text top="459" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21146669">● </a></text>
<text top="459" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21146669">21146669</a></text>
<text top="459" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21146669"> </a></text>
<text top="477" left="123" width="3" height="19" font="3"> </text>
<text top="496" left="123" width="3" height="19" font="3"> </text>
<text top="422" left="241" width="187" height="19" font="4"><b>Aim:</b> To assess the prevalence </text>
<text top="441" left="241" width="163" height="19" font="3">of conduction disease and </text>
<text top="459" left="241" width="186" height="19" font="3">LVEF in population of patients </text>
<text top="477" left="241" width="63" height="19" font="3">with DM1 </text>
<text top="496" left="241" width="3" height="19" font="3"> </text>
<text top="514" left="241" width="159" height="19" font="4"><b>Study type:</b> cohort study, </text>
<text top="532" left="241" width="74" height="19" font="3">multicenter </text>
<text top="551" left="241" width="3" height="19" font="3"> </text>
<text top="569" left="241" width="111" height="19" font="4"><b>Size:</b> 406 patients </text>
<text top="422" left="445" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="441" left="445" width="147" height="19" font="3">Patients with DM1 with </text>
<text top="459" left="445" width="128" height="19" font="3">confirmed abnormal </text>
<text top="477" left="445" width="133" height="19" font="3">CTG repeat sequence </text>
<text top="496" left="445" width="132" height="19" font="3">(one or both alleles ≥ </text>
<text top="514" left="445" width="73" height="19" font="3">38 repeats) </text>
<text top="532" left="445" width="3" height="19" font="3"> </text>
<text top="551" left="445" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="569" left="445" width="106" height="19" font="3">Patients &lt;18 y or </text>
<text top="587" left="445" width="115" height="19" font="3">unconfirmed DM1 </text>
<text top="606" left="445" width="117" height="19" font="3">diagnosis as above </text>
<text top="624" left="445" width="7" height="19" font="3">  </text>
<text top="423" left="606" width="112" height="19" font="4"><b>1</b>°<b> endpoint:</b>  N/A </text>
<text top="442" left="606" width="3" height="19" font="3"> </text>
<text top="460" left="606" width="63" height="19" font="4"><b>Results:</b>    </text>
<text top="478" left="606" width="196" height="19" font="3">Cardiac imaging was performed </text>
<text top="496" left="606" width="95" height="19" font="3">on 180 (44.3%) </text>
<text top="515" left="606" width="3" height="19" font="3"> </text>
<text top="533" left="606" width="163" height="20" font="3">• Prevalence of LV systolic </text>
<text top="552" left="606" width="204" height="19" font="3">dysfunction and HF in 41 (10.1%) </text>
<text top="570" left="606" width="151" height="19" font="3">of 406 (risk factors were </text>
<text top="589" left="606" width="183" height="19" font="3">increasing age, male sex, ECG </text>
<text top="607" left="606" width="163" height="19" font="3">conduction abnormalities, </text>
<text top="625" left="606" width="187" height="19" font="3">presence of atrial and VA, and </text>
<text top="644" left="606" width="119" height="19" font="3">implanted devices) </text>
<text top="662" left="606" width="183" height="20" font="3">• Presence of decreased LVEF </text>
<text top="681" left="606" width="182" height="19" font="3">was associated with all-cause </text>
<text top="699" left="606" width="195" height="19" font="3">death (RR: 3.9; 95% CI: 2.3–6.4; </text>
<text top="718" left="606" width="198" height="19" font="3">p&lt;0.001) and cardiac death (RR: </text>
<text top="736" left="606" width="197" height="19" font="3">5.7; 95% CI: 2.6–12.4; p&lt;0.001). </text>
<text top="422" left="828" width="220" height="19" font="3">● There is a notable incidence of LV </text>
<text top="441" left="828" width="221" height="19" font="3">systolic dysfunction and HF exists in </text>
<text top="459" left="828" width="124" height="19" font="3">patients with DM1.  </text>
<text top="477" left="828" width="230" height="19" font="3">● The presence of LVSD/HF in DM1 is </text>
<text top="496" left="828" width="230" height="19" font="3">significantly associated with all-cause </text>
<text top="514" left="828" width="116" height="19" font="3">and cardiac death. </text>
<text top="532" left="828" width="3" height="19" font="3"> </text>
<text top="551" left="828" width="3" height="19" font="3"> </text>
<text top="569" left="828" width="3" height="19" font="3"> </text>
<text top="587" left="828" width="3" height="19" font="3"> </text>
<text top="606" left="828" width="3" height="19" font="3"> </text>
<text top="624" left="828" width="3" height="19" font="3"> </text>
<text top="642" left="828" width="3" height="19" font="3"> </text>
</page>
<page number="183" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">183 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="123" width="80" height="19" font="3">● Groh et al. </text>
<text top="127" left="123" width="30" height="19" font="3">2008</text>
<text top="125" left="153" width="4" height="21" font="0"> </text>
<text top="127" left="157" width="35" height="19" font="3">(328) </text>
<text top="145" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=18565861">● </a></text>
<text top="145" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=18565861">18565861</a></text>
<text top="145" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=18565861"> </a></text>
<text top="163" left="123" width="3" height="19" font="3"> </text>
<text top="182" left="123" width="3" height="19" font="3"> </text>
<text top="108" left="241" width="180" height="19" font="4"><b>Aim:</b> To identify whether the </text>
<text top="127" left="241" width="184" height="19" font="3">ECG is useful for prediction of </text>
<text top="145" left="241" width="184" height="19" font="3">SCD risk in patients with DM1 </text>
<text top="163" left="241" width="3" height="19" font="3"> </text>
<text top="182" left="241" width="160" height="19" font="4"><b>Study type:</b> Cohort study, </text>
<text top="200" left="241" width="74" height="19" font="3">multicenter </text>
<text top="218" left="241" width="3" height="19" font="3"> </text>
<text top="236" left="241" width="111" height="19" font="4"><b>Size:</b> 406 patients </text>
<text top="108" left="445" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="127" left="445" width="137" height="19" font="3">Genetically confirmed </text>
<text top="145" left="445" width="120" height="19" font="3">DM1 (only patients </text>
<text top="163" left="445" width="121" height="19" font="3">with abnormal CTG </text>
<text top="182" left="445" width="131" height="19" font="3">repeat sequence ≥38 </text>
<text top="200" left="445" width="54" height="19" font="3">repeats) </text>
<text top="218" left="445" width="3" height="19" font="3"> </text>
<text top="236" left="445" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="255" left="445" width="3" height="19" font="3"> </text>
<text top="109" left="606" width="112" height="19" font="4"><b>1</b>°<b> endpoint:</b>  N/A </text>
<text top="127" left="606" width="3" height="19" font="3"> </text>
<text top="146" left="606" width="63" height="19" font="4"><b>Results:</b>    </text>
<text top="164" left="606" width="207" height="19" font="3">• Defined: Severe abnormality on </text>
<text top="182" left="606" width="198" height="19" font="3">ECG includes rhythm other than </text>
<text top="201" left="606" width="208" height="19" font="3">sinus, PR interval ≥ 240 ms, QRS ≥ </text>
<text top="219" left="606" width="202" height="19" font="3">120 ms, or 2nd or 3rd degree AV </text>
<text top="237" left="606" width="36" height="19" font="3">block </text>
<text top="256" left="606" width="205" height="19" font="3">• 96/406 had severe abnormality </text>
<text top="274" left="606" width="194" height="19" font="3">on ECG – 9 received ICD and 23 </text>
<text top="292" left="606" width="77" height="19" font="3">pacemakers </text>
<text top="311" left="606" width="3" height="19" font="3"> </text>
<text top="329" left="606" width="189" height="20" font="3">• Follow-up 5.7 y during which </text>
<text top="348" left="606" width="189" height="19" font="3">81/406 (20%) died (27 SCD, 32 </text>
<text top="366" left="606" width="204" height="19" font="3">respiratory failure, 5 non-sudden </text>
<text top="385" left="606" width="192" height="19" font="3">cardiac deaths, 17 deaths from </text>
<text top="403" left="606" width="85" height="19" font="3">other causes) </text>
<text top="421" left="606" width="178" height="20" font="3">• Of the 27 SCD, 17 had post-</text>
<text top="440" left="606" width="198" height="19" font="3">collapse rhythm documented of </text>
<text top="459" left="606" width="148" height="19" font="3">which only 9 was VT/VF </text>
<text top="477" left="606" width="208" height="20" font="3">• Severe abnormality on ECG (RR: </text>
<text top="496" left="606" width="200" height="19" font="3">3.3; CI: 1.25–8.78) and diagnosis </text>
<text top="514" left="606" width="183" height="19" font="3">of atrial tachyarrhythmia (RR: </text>
<text top="533" left="606" width="210" height="19" font="3">5.18; CI: 2.28–11.77) predictive of </text>
<text top="551" left="606" width="185" height="19" font="3">sudden death in patients with </text>
<text top="569" left="606" width="33" height="19" font="3">DM1 </text>
<text top="588" left="606" width="185" height="20" font="3">• Rates of prophylactic pacing </text>
<text top="607" left="606" width="209" height="19" font="3">increased during the study period </text>
<text top="625" left="606" width="170" height="19" font="3">and we not associated with </text>
<text top="643" left="606" width="144" height="19" font="3">decreased rates of SCD </text>
<text top="108" left="828" width="243" height="19" font="3">● Patients with DM1 are at high risk for </text>
<text top="127" left="828" width="235" height="19" font="3">sudden death (up to 1/3 of deaths are </text>
<text top="145" left="828" width="53" height="19" font="3">sudden) </text>
<text top="163" left="828" width="236" height="19" font="3">● Severe abnormality on ECG (RR: 3.3; </text>
<text top="182" left="828" width="219" height="19" font="3">95% CI: 1.25–8.78) and diagnosis of </text>
<text top="200" left="828" width="231" height="19" font="3">atrial tachyarrhythmia (RR: 5.18; 95% </text>
<text top="218" left="828" width="224" height="19" font="3">CI: 2.28–11.77) predictive of sudden </text>
<text top="237" left="828" width="170" height="19" font="3">death in patients with DM1 </text>
<text top="255" left="828" width="209" height="19" font="3">● Severe abnormality on ECG PPV </text>
<text top="273" left="828" width="240" height="19" font="3">12.1% and NPV 97.1% for prediction of </text>
<text top="291" left="828" width="27" height="19" font="3">SCD </text>
<text top="310" left="828" width="3" height="19" font="3"> </text>
<text top="328" left="828" width="3" height="19" font="3"> </text>
<text top="346" left="828" width="3" height="19" font="3"> </text>
<text top="662" left="123" width="104" height="19" font="3">● Laforêt P et al. </text>
<text top="680" left="123" width="69" height="19" font="3">1998 (329) </text>
<text top="699" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=9818880">● </a></text>
<text top="699" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=9818880">9818880</a></text>
<text top="699" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=9818880"> </a></text>
<text top="717" left="123" width="3" height="19" font="3"> </text>
<text top="735" left="123" width="3" height="19" font="3"> </text>
<text top="662" left="241" width="189" height="19" font="4"><b>Aim:</b> Evaluate the incidence of </text>
<text top="680" left="241" width="141" height="19" font="3">cardiac involvement in </text>
<text top="699" left="241" width="190" height="19" font="3">facioscapulohumeral muscular </text>
<text top="717" left="241" width="65" height="19" font="3">dystrophy<b> </b></text>
<text top="735" left="241" width="3" height="19" font="4"><b> </b></text>
<text top="753" left="241" width="162" height="19" font="4"><b>Study type:</b> Cohort, single </text>
<text top="772" left="241" width="43" height="19" font="3">center </text>
<text top="662" left="445" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="680" left="445" width="116" height="19" font="3">Patients exhibiting </text>
<text top="699" left="445" width="135" height="19" font="3">clinical and molecular </text>
<text top="717" left="445" width="70" height="19" font="3">features of </text>
<text top="735" left="445" width="130" height="19" font="3">facioscapulohumeral </text>
<text top="753" left="445" width="127" height="19" font="3">muscular dystrophy  </text>
<text top="772" left="445" width="3" height="19" font="3"> </text>
<text top="663" left="606" width="112" height="19" font="4"><b>1</b>°<b> endpoint:</b>  N/A </text>
<text top="681" left="606" width="3" height="19" font="3"> </text>
<text top="699" left="606" width="150" height="19" font="4"><b>Results:</b>   5 patients had </text>
<text top="718" left="606" width="207" height="19" font="3">conduction defects or arrhythmia </text>
<text top="736" left="606" width="188" height="19" font="3">(IVCD or AF/flutter induced by </text>
<text top="754" left="606" width="206" height="19" font="3">EPS), 1 case of AV block requiring </text>
<text top="662" left="828" width="210" height="19" font="3">●  Patients with FSHMD may have </text>
<text top="680" left="828" width="127" height="19" font="3">cardiac involvement.</text>
<text top="679" left="955" width="8" height="21" font="0">  </text>
<text top="699" left="828" width="171" height="19" font="3">● Significant clinical cardiac </text>
<text top="717" left="828" width="235" height="19" font="3">involvement is rather rare in this form </text>
<text top="735" left="828" width="192" height="19" font="3">of muscular dystrophy, specific </text>
<text top="753" left="828" width="153" height="19" font="3">monitoring or treatment </text>
<text top="772" left="828" width="245" height="19" font="3">recommendations are not well defined. </text>
</page>
<page number="184" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">184 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="241" width="3" height="19" font="3"> </text>
<text top="127" left="241" width="111" height="19" font="4"><b>Size: </b>100 patients </text>
<text top="108" left="445" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="127" left="445" width="3" height="19" font="3"> </text>
<text top="108" left="606" width="204" height="19" font="3">pacemaker, 1 case of VT possibly </text>
<text top="127" left="606" width="169" height="19" font="3">related to co-existing ARVC </text>
<text top="108" left="828" width="218" height="19" font="3">● Discussion of arrhythmia- related </text>
<text top="127" left="828" width="133" height="19" font="3">symptoms and yearly </text>
<text top="145" left="828" width="180" height="19" font="3">electrocardiograms has been </text>
<text top="163" left="828" width="97" height="19" font="3">recommended. </text>
<text top="182" left="123" width="95" height="19" font="3">● Stevenson et </text>
<text top="200" left="123" width="87" height="19" font="3">al. 1990 (330) </text>
<text top="219" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=2299071">● </a></text>
<text top="219" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=2299071">2299071</a></text>
<text top="219" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=2299071"> </a></text>
<text top="237" left="123" width="3" height="19" font="3"> </text>
<text top="255" left="123" width="3" height="19" font="3"> </text>
<text top="182" left="241" width="165" height="19" font="4"><b>Aim:</b> Evaluate incidence of </text>
<text top="200" left="241" width="141" height="19" font="3">cardiac involvement in </text>
<text top="219" left="241" width="136" height="19" font="3">fascioscapulohumeral </text>
<text top="237" left="241" width="124" height="19" font="3">muscular dystrophy<b> </b></text>
<text top="255" left="241" width="3" height="19" font="4"><b> </b></text>
<text top="273" left="241" width="160" height="19" font="4"><b>Study type:</b> cohort, single </text>
<text top="292" left="241" width="43" height="19" font="3">center </text>
<text top="310" left="241" width="3" height="19" font="3"> </text>
<text top="328" left="241" width="104" height="19" font="4"><b>Size:</b> 30 patients </text>
<text top="182" left="445" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="200" left="445" width="83" height="19" font="3">Patients with </text>
<text top="219" left="445" width="136" height="19" font="3">fascioscapulohumeral </text>
<text top="237" left="445" width="124" height="19" font="3">muscular dystrophy </text>
<text top="255" left="445" width="135" height="19" font="3">(autosomal dominant </text>
<text top="273" left="445" width="76" height="19" font="3">inheritance, </text>
<text top="292" left="445" width="121" height="19" font="3">characteristic facial </text>
<text top="310" left="445" width="83" height="19" font="3">involvement, </text>
<text top="329" left="445" width="103" height="19" font="3">scapular/deltoid </text>
<text top="347" left="445" width="120" height="19" font="3">muscle weakness &gt; </text>
<text top="365" left="445" width="93" height="19" font="3">biceps/triceps, </text>
<text top="383" left="445" width="140" height="19" font="3">myopathic changes on </text>
<text top="402" left="445" width="97" height="19" font="3">biopsy or EMG) </text>
<text top="420" left="445" width="3" height="19" font="3"> </text>
<text top="438" left="445" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="457" left="445" width="125" height="19" font="3">Elbow contractures, </text>
<text top="475" left="445" width="124" height="19" font="3">absence of scapular </text>
<text top="493" left="445" width="134" height="19" font="3">winging, and X-linked </text>
<text top="512" left="445" width="55" height="19" font="3">heredity </text>
<text top="530" left="445" width="3" height="19" font="3"> </text>
<text top="183" left="606" width="206" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Evidence of cardiac </text>
<text top="201" left="606" width="79" height="19" font="3">involvement </text>
<text top="219" left="606" width="3" height="19" font="3"> </text>
<text top="237" left="606" width="63" height="19" font="4"><b>Results:</b>    </text>
<text top="256" left="606" width="197" height="19" font="3">• 30/30 had 12-lead ECG, 22/30 </text>
<text top="274" left="606" width="152" height="19" font="3">had 24 hr Holter, 15 had </text>
<text top="293" left="606" width="204" height="19" font="3">echocardiogram, 10 patients had </text>
<text top="311" left="606" width="84" height="19" font="3">12 EP studies </text>
<text top="329" left="606" width="3" height="19" font="3"> </text>
<text top="348" left="606" width="178" height="20" font="3">• P wave abnormalities were </text>
<text top="367" left="606" width="99" height="19" font="3">common (60%)  </text>
<text top="385" left="606" width="204" height="20" font="3">• AF or Aflutter induced at EPS in </text>
<text top="404" left="606" width="40" height="19" font="3">10/12 </text>
<text top="423" left="606" width="201" height="20" font="3">• Evidence of abnormal AV node </text>
<text top="442" left="606" width="155" height="19" font="3">conduction or infranodal </text>
<text top="460" left="606" width="183" height="19" font="3">conduction present on EPS or </text>
<text top="478" left="606" width="141" height="19" font="3">ECG in 27% of patients </text>
<text top="497" left="606" width="196" height="20" font="3">• Sinus node function abnormal </text>
<text top="516" left="606" width="79" height="19" font="3">in 3 patients </text>
<text top="182" left="828" width="187" height="19" font="3">● Evidence supporting cardiac </text>
<text top="200" left="828" width="211" height="19" font="3">involvement in this condition with </text>
<text top="219" left="828" width="213" height="19" font="3">minority of cases having abnormal </text>
<text top="237" left="828" width="236" height="19" font="3">sinus node function or AV conduction. </text>
<text top="584" left="115" width="11" height="23" font="10"><b>D</b></text>
<text top="586" left="126" width="641" height="21" font="2"><b>ata Supplement 39. Nonrandomized Trials Related to Cardiac Channelopathies – (Section 7.9) </b></text>
<text top="607" left="131" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="625" left="156" width="51" height="19" font="4"><b>Author; </b></text>
<text top="644" left="134" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="607" left="283" width="39" height="19" font="4"><b>Study </b></text>
<text top="625" left="259" width="86" height="19" font="4"><b>Type/Design; </b></text>
<text top="644" left="269" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="625" left="393" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="607" left="617" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="625" left="630" width="126" height="19" font="4"><b>(P values; OR or RR; </b></text>
<text top="644" left="661" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="616" left="891" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="635" left="919" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="663" left="123" width="112" height="19" font="3">● Costa J et al.<b> </b>HR </text>
<text top="681" left="123" width="69" height="19" font="3">2012 (331) </text>
<text top="699" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22293141">● </a></text>
<text top="699" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22293141">22293141</a></text>
<text top="699" left="197" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22293141"><b> </b></a></text>
<text top="663" left="253" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="681" left="253" width="74" height="19" font="3">multicenter </text>
<text top="699" left="253" width="3" height="19" font="3"> </text>
<text top="718" left="253" width="76" height="19" font="4"><b>Size:</b>    1051<b> </b></text>
<text top="663" left="365" width="149" height="19" font="4"><b>Inclusion criteria:</b>  LQT1 </text>
<text top="681" left="365" width="131" height="19" font="3">gentoype, age 0-40 y </text>
<text top="699" left="365" width="3" height="19" font="3"> </text>
<text top="718" left="365" width="120" height="19" font="4"><b>Exclusion criteria:</b>  <b> </b></text>
<text top="664" left="555" width="255" height="19" font="4"><b>1</b>°<b> endpoint:  LQT1 gender and mutation </b></text>
<text top="682" left="555" width="215" height="19" font="4"><b>specific risk</b> stratification ACA/SCD </text>
<text top="700" left="555" width="3" height="19" font="3"> </text>
<text top="719" left="555" width="150" height="19" font="4"><b>Results:</b>  Increased risk:  </text>
<text top="737" left="555" width="244" height="19" font="3">Age 0-13 y: males; &gt;13, Males =females </text>
<text top="755" left="555" width="251" height="19" font="3">Loop mutations: HR: 2.7 for females, not </text>
<text top="774" left="555" width="39" height="19" font="3">males </text>
<text top="663" left="843" width="213" height="19" font="3">● Combined assessment of clinical </text>
<text top="681" left="843" width="213" height="19" font="3">and mutation location can identify </text>
<text top="699" left="843" width="210" height="19" font="3">gender specific risk factors for life-</text>
<text top="718" left="843" width="119" height="19" font="3">threatening events </text>
<text top="736" left="843" width="3" height="19" font="3"> </text>
<text top="755" left="843" width="3" height="19" font="3"> </text>
</page>
<page number="185" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">185 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="555" width="266" height="19" font="3">Time-dependent syncope increased risk for </text>
<text top="127" left="555" width="98" height="19" font="3">males, HR: 4.73 </text>
<text top="145" left="555" width="224" height="19" font="3">QTc ≥500 ms: higher risk for women </text>
<text top="230" left="123" width="87" height="19" font="3">● Bai R, et al.  </text>
<text top="249" left="123" width="96" height="19" font="3">CAE 2009 (332) </text>
<text top="267" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19808439">● </a></text>
<text top="267" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19808439">19808439</a></text>
<text top="267" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19808439"> </a></text>
<text top="230" left="254" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="249" left="254" width="74" height="19" font="3">Sigle center </text>
<text top="267" left="254" width="91" height="19" font="3">retrospective   </text>
<text top="285" left="254" width="3" height="19" font="3"> </text>
<text top="303" left="254" width="76" height="19" font="4"><b>Size:</b>   1394 <b> </b></text>
<text top="230" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="249" left="367" width="137" height="19" font="3">consecutive probands </text>
<text top="267" left="367" width="167" height="19" font="3">referred with confirmed or </text>
<text top="285" left="367" width="147" height="19" font="3">suspected LQTS, BrS, or </text>
<text top="303" left="367" width="169" height="19" font="3">CPVT, or idiopathic VF/ACA </text>
<text top="322" left="367" width="3" height="19" font="3"> </text>
<text top="340" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="231" left="555" width="253" height="19" font="4"><b>1</b>°<b> endpoint:  </b>Yield of genetic testing and </text>
<text top="249" left="555" width="32" height="19" font="3">cost  </text>
<text top="268" left="555" width="3" height="19" font="3"> </text>
<text top="286" left="555" width="274" height="19" font="4"><b>Results:</b> Yield and cost in US $ per diagnosis: </text>
<text top="304" left="555" width="120" height="19" font="3">LQTS: 40%, $13402 </text>
<text top="323" left="555" width="109" height="19" font="3">Br S: 8%, $33,148 </text>
<text top="341" left="555" width="117" height="19" font="3">CPVT: 35%, $9170  </text>
<text top="359" left="555" width="169" height="19" font="3">Idiopathic VF: 9%, $71,430 <b> </b></text>
<text top="230" left="843" width="214" height="19" font="3">● Yield in LQTS higher if confirmed </text>
<text top="249" left="843" width="101" height="19" font="3">dx present: 64% </text>
<text top="267" left="843" width="222" height="19" font="3">● Yield in BrS increased if type 1 BrS </text>
<text top="285" left="843" width="165" height="19" font="3">ECG with AV block present </text>
<text top="303" left="843" width="215" height="19" font="3">● Yield in CPVT increased in males, </text>
<text top="322" left="843" width="220" height="19" font="3">prior CA, or confirmed bidirectional </text>
<text top="340" left="843" width="69" height="19" font="3">VT present </text>
<text top="358" left="843" width="196" height="19" font="3">● LQTS, CPVT reasonable cost if </text>
<text top="377" left="843" width="147" height="19" font="3">strong clinical suspicion </text>
<text top="395" left="843" width="147" height="19" font="3">● BrS less cost effective </text>
<text top="413" left="843" width="206" height="19" font="3">● Idiopathic VF ineffective, costly </text>
<text top="432" left="123" width="101" height="19" font="3">● Gehi AK, et al. </text>
<text top="451" left="123" width="93" height="19" font="3">JCE 2006 (333) </text>
<text top="469" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16836701">● </a></text>
<text top="469" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16836701">16836701</a></text>
<text top="469" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16836701"> </a></text>
<text top="487" left="123" width="3" height="19" font="4"><b> </b></text>
<text top="506" left="123" width="3" height="19" font="3"> </text>
<text top="432" left="254" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="451" left="254" width="92" height="19" font="3">Meta-analysis: </text>
<text top="469" left="254" width="78" height="19" font="3">retrieved 30 </text>
<text top="487" left="254" width="75" height="19" font="3">prospective </text>
<text top="506" left="254" width="66" height="19" font="3">studies on </text>
<text top="524" left="254" width="85" height="19" font="3">Brugada ECG<b>  </b></text>
<text top="542" left="254" width="3" height="19" font="4"><b> </b></text>
<text top="560" left="254" width="79" height="19" font="4"><b> Size:</b>    1545<b> </b></text>
<text top="432" left="367" width="141" height="19" font="4"><b>Inclusion: </b>Publications </text>
<text top="451" left="367" width="115" height="19" font="3">1/1990-3/2005 on </text>
<text top="469" left="367" width="172" height="19" font="3">prognosis of patients with a </text>
<text top="487" left="367" width="86" height="19" font="3">Brugada ECG: </text>
<text top="506" left="367" width="169" height="19" font="3">Prospective cohort studies, </text>
<text top="524" left="367" width="165" height="19" font="3">&gt;10 subjects, primary data </text>
<text top="542" left="367" width="132" height="19" font="3">on syncope, SCD, ICD </text>
<text top="561" left="367" width="173" height="19" font="3">shocks; followup &gt;6 mo and </text>
<text top="579" left="367" width="94" height="19" font="3">&gt;90% followup </text>
<text top="597" left="367" width="3" height="19" font="3"> </text>
<text top="615" left="367" width="150" height="19" font="4"><b>Exclusions: </b>non-English; </text>
<text top="634" left="367" width="170" height="19" font="3">presence of cardiac disease<b> </b></text>
<text top="433" left="555" width="238" height="19" font="4"><b>1</b>°<b> endpoint:</b> Identify risk predictors of </text>
<text top="451" left="555" width="242" height="19" font="3">adverse natural history in patients with </text>
<text top="470" left="555" width="82" height="19" font="3">Brugada ECG </text>
<text top="488" left="555" width="3" height="19" font="3"> </text>
<text top="506" left="555" width="59" height="19" font="4"><b> Results:  </b></text>
<text top="525" left="555" width="274" height="19" font="3">Risk increased with prior hx syncope or ACA, </text>
<text top="543" left="555" width="234" height="19" font="3">spont type 1 Br ECG, and male gender </text>
<text top="561" left="555" width="3" height="19" font="4"><b> </b></text>
<text top="579" left="555" width="205" height="19" font="4"><b> NOT sig risk factors:</b> Fam hx SCD </text>
<text top="598" left="555" width="271" height="19" font="3">SCN5A mutation, or inducibility by PES: (not </text>
<text top="616" left="555" width="256" height="19" font="3">a risk factor but heterogeneity of studies) </text>
<text top="634" left="555" width="3" height="19" font="4"><b> </b></text>
<text top="432" left="843" width="214" height="19" font="3">● BrS ACE risk increased with prior </text>
<text top="451" left="843" width="155" height="19" font="3">syncope or SCD, RR: 3.24 </text>
<text top="469" left="843" width="110" height="19" font="3">● Males, RR: 3.47 </text>
<text top="487" left="843" width="175" height="19" font="3">● Spont type 1 ECG RR: 4.65 </text>
<text top="506" left="843" width="3" height="19" font="3"> </text>
<text top="654" left="123" width="110" height="19" font="3">● Kim JA et al. HR </text>
<text top="672" left="123" width="69" height="19" font="3">2010 (334) </text>
<text top="690" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20850565">● </a></text>
<text top="690" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20850565">20850565</a></text>
<text top="690" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20850565"> </a></text>
<text top="653" left="253" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="672" left="253" width="81" height="19" font="3">multicenter   </text>
<text top="690" left="253" width="88" height="19" font="3">retrospective  </text>
<text top="709" left="253" width="3" height="19" font="3"> </text>
<text top="727" left="253" width="68" height="19" font="4"><b>Size:</b>   634 <b> </b></text>
<text top="653" left="365" width="175" height="19" font="4"><b>Inclusion criteria:</b>  genotype </text>
<text top="672" left="365" width="45" height="19" font="3">+ LQT2 </text>
<text top="690" left="365" width="3" height="19" font="3"> </text>
<text top="709" left="365" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="654" left="555" width="228" height="19" font="4"><b>1</b>°<b> endpoint:</b>  LQT2 genotype: trigger </text>
<text top="673" left="555" width="199" height="19" font="3">specific risk factors for SCD/ACA </text>
<text top="691" left="555" width="3" height="19" font="3"> </text>
<text top="709" left="555" width="251" height="19" font="4"><b>Results:</b>  arousal 44%, exercise 13%, non-</text>
<text top="728" left="555" width="155" height="19" font="3">exercie/non-arousal 43% </text>
<text top="746" left="555" width="250" height="19" font="3">Risk for arousal: female &gt;13 y, pore-loop </text>
<text top="764" left="555" width="60" height="19" font="3">mutation </text>
<text top="654" left="843" width="209" height="19" font="3">● Pore-loop mutations assoc with </text>
<text top="672" left="843" width="96" height="19" font="3">arousal events; </text>
<text top="690" left="843" width="216" height="19" font="3">● BB not significanty protective for </text>
<text top="709" left="843" width="69" height="19" font="3">this subset </text>
<text top="727" left="843" width="3" height="19" font="3"> </text>
<text top="745" left="843" width="3" height="19" font="3"> </text>
</page>
<page number="186" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">186 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="555" width="260" height="19" font="3">Non-pore loop assoc with exercise events, </text>
<text top="127" left="555" width="51" height="19" font="3">HR:6.84 </text>
<text top="145" left="555" width="268" height="19" font="3">Beta-bl reduced risk for exercise events but </text>
<text top="164" left="555" width="203" height="19" font="3">not arousal/non-exercise events  </text>
<text top="183" left="123" width="103" height="19" font="3">● Migdalovich D </text>
<text top="201" left="123" width="88" height="19" font="3">et al. HR 2011 </text>
<text top="219" left="123" width="35" height="19" font="3">(335)<b> </b></text>
<text top="238" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21440677">● </a></text>
<text top="238" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21440677">21440677</a></text>
<text top="238" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21440677"> </a></text>
<text top="183" left="253" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="201" left="253" width="74" height="19" font="3">multicenter </text>
<text top="219" left="253" width="91" height="19" font="3">retrospective   </text>
<text top="238" left="253" width="3" height="19" font="3"> </text>
<text top="256" left="253" width="72" height="19" font="4"><b>Size:</b>  1166 <b> </b></text>
<text top="183" left="365" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="201" left="365" width="96" height="19" font="3">LQT2 genotype </text>
<text top="219" left="365" width="3" height="19" font="3"> </text>
<text top="237" left="365" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="183" left="555" width="254" height="19" font="4"><b>1</b>°<b> endpoint:</b>  LQT2 genotype vs outcome </text>
<text top="202" left="555" width="131" height="19" font="3">ACA/SCD by age 40 y </text>
<text top="220" left="555" width="236" height="19" font="3">Pore-loop vs non-pore loop mutations </text>
<text top="238" left="555" width="3" height="19" font="3"> </text>
<text top="257" left="555" width="263" height="19" font="4"><b>Results:</b>  women w LQT2 much higher risk: </text>
<text top="275" left="555" width="84" height="19" font="3">26% vs. men; </text>
<text top="293" left="555" width="256" height="19" font="3">For women, no sig difference in mutation </text>
<text top="312" left="555" width="25" height="19" font="3">site </text>
<text top="330" left="555" width="156" height="19" font="3">Risk similar at age &lt;13 y;  </text>
<text top="348" left="555" width="247" height="19" font="3">Age &gt;13 y, females HR: 2.23 ACA/SCD vs </text>
<text top="367" left="555" width="39" height="19" font="3">males </text>
<text top="385" left="555" width="219" height="19" font="3">Males: pore loop mutations &gt;2-fold </text>
<text top="403" left="555" width="87" height="19" font="3">increased risk </text>
<text top="422" left="555" width="255" height="19" font="3">Increased risk: QTc ≥ 500 msec (males 2x, </text>
<text top="440" left="555" width="150" height="19" font="3">females 4-fold increase) </text>
<text top="458" left="555" width="233" height="19" font="3">Highest risk: 5.3/1000 patient-y: prior </text>
<text top="476" left="555" width="271" height="19" font="3">syncope plus QTc ≥ 500 ms, pore loop male, </text>
<text top="495" left="555" width="168" height="19" font="3">or female &gt;13 y old, HR: 17 </text>
<text top="513" left="555" width="131" height="19" font="3">BB: 61% reduced risk </text>
<text top="183" left="843" width="228" height="19" font="3">● Women w LQT2 much higher risk v </text>
<text top="201" left="843" width="31" height="19" font="3">men </text>
<text top="219" left="843" width="211" height="19" font="3">● Overall, pore loop mutations sig </text>
<text top="238" left="843" width="223" height="19" font="3">increased risk ACA, SCD, greater risk </text>
<text top="256" left="843" width="128" height="19" font="3">for males vs females </text>
<text top="274" left="843" width="218" height="19" font="3">● Pore loop mutations LQT2 males, </text>
<text top="293" left="843" width="131" height="19" font="3">HR:2.18 for ACA/SCD </text>
<text top="311" left="843" width="7" height="19" font="3">  </text>
<text top="532" left="123" width="98" height="19" font="3">● Ackerman MJ </text>
<text top="550" left="123" width="69" height="19" font="3">2011 (182) </text>
<text top="569" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21810866">● </a></text>
<text top="569" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21810866">21810866</a></text>
<text top="569" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21810866"> </a></text>
<text top="532" left="253" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="550" left="253" width="67" height="19" font="3">HRS/EHRA </text>
<text top="569" left="253" width="66" height="19" font="3">consensus </text>
<text top="587" left="253" width="70" height="19" font="3">statement.<b> </b></text>
<text top="605" left="253" width="3" height="19" font="4"><b> </b></text>
<text top="532" left="365" width="175" height="19" font="3">Expert consensus statement </text>
<text top="550" left="365" width="141" height="19" font="3">on the state of genetic </text>
<text top="569" left="365" width="90" height="19" font="3">testing for the </text>
<text top="587" left="365" width="130" height="19" font="3">channelopathies and </text>
<text top="605" left="365" width="113" height="19" font="3">cardiomyopathies </text>
<text top="624" left="365" width="3" height="19" font="4"><b> </b></text>
<text top="642" left="365" width="114" height="19" font="4"><b>Panel: </b>geneticists, </text>
<text top="660" left="365" width="150" height="19" font="3">arrhythmia specialists     </text>
<text top="679" left="365" width="112" height="19" font="3">Agreement ≥ 84% </text>
<text top="532" left="555" width="263" height="19" font="4"><b>General:</b> Class I: 1) sound clinical suspicion </text>
<text top="550" left="555" width="233" height="19" font="3">when positive predictive value &gt; 40%, </text>
<text top="569" left="555" width="257" height="19" font="3">signal/noise ratio &gt;10; 2) AND/OR genetic </text>
<text top="587" left="555" width="243" height="19" font="3">test result provides either diagnostic or </text>
<text top="605" left="555" width="255" height="19" font="3">prognostic info, or influences therapeutic </text>
<text top="624" left="555" width="56" height="19" font="3">choices.  </text>
<text top="642" left="555" width="270" height="19" font="3">Screening of family members: when genetic </text>
<text top="660" left="555" width="195" height="19" font="3">testing leads to the adoption of </text>
<text top="679" left="555" width="238" height="19" font="3">therapy/protective measures/ lifestyle </text>
<text top="697" left="555" width="83" height="19" font="3">adaptations.  </text>
<text top="715" left="555" width="3" height="19" font="3"> </text>
<text top="733" left="555" width="258" height="19" font="3">LQTS: Class I: 1) any pt with strong clinical </text>
<text top="752" left="555" width="212" height="19" font="3">index of suspicion for LQTS; 2) any </text>
<text top="770" left="555" width="259" height="19" font="3">asymptomatic pt with QT prolongation on </text>
<text top="532" left="843" width="207" height="19" font="3">● LQTS: Note difference between </text>
<text top="550" left="843" width="207" height="19" font="3">Class I if QTc &gt;480 or 500 ms, and </text>
<text top="569" left="843" width="178" height="19" font="3">Class IIb if QTc &gt; 460/480 ms<i> </i></text>
<text top="586" left="843" width="3" height="19" font="5"><i> </i></text>
<text top="605" left="843" width="3" height="19" font="5"><i> </i></text>
<text top="623" left="843" width="3" height="19" font="5"><i> </i></text>
<text top="641" left="843" width="3" height="19" font="5"><i> </i></text>
<text top="659" left="843" width="3" height="19" font="5"><i> </i></text>
<text top="679" left="843" width="3" height="19" font="3"> </text>
</page>
<page number="187" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">187 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="555" width="269" height="19" font="3">serial ECGs:  QTc &gt;480 ms prepuberty; &gt;500 </text>
<text top="127" left="555" width="237" height="19" font="3">ms, adult; 3) Mutation specific genetic </text>
<text top="145" left="555" width="232" height="19" font="3">testing for family members and other </text>
<text top="164" left="555" width="138" height="19" font="3">appropriate relatives   </text>
<text top="182" left="555" width="219" height="19" font="3">Class IIb: any asymptomatic pt with </text>
<text top="200" left="555" width="252" height="19" font="3">otherwise idiopathic QTc values &gt;460 ms </text>
<text top="219" left="555" width="214" height="19" font="3">(puberty) or 480 ms on serial ECGs </text>
<text top="237" left="555" width="3" height="19" font="3"> </text>
<text top="255" left="555" width="242" height="19" font="3">CPVT: Class I: 1) any pt w strong clinical </text>
<text top="273" left="555" width="171" height="19" font="3">index of suspicion of CPVT;  </text>
<text top="292" left="555" width="231" height="19" font="3">2) Mutation specific genetic testing is </text>
<text top="310" left="555" width="242" height="19" font="3">recommended for family members and </text>
<text top="329" left="555" width="131" height="19" font="3">appropriate relatives </text>
<text top="347" left="555" width="3" height="19" font="3"> </text>
<text top="365" left="555" width="260" height="19" font="3">Brugada: Class I: Mutation specific genetic </text>
<text top="383" left="555" width="274" height="19" font="3">testing is recommended for family members </text>
<text top="402" left="555" width="157" height="19" font="3">and appropriate relatives </text>
<text top="420" left="555" width="251" height="19" font="3">Class IIa: any pt w strong clinical index of </text>
<text top="438" left="555" width="192" height="19" font="3">suspicion of BrS, including with </text>
<text top="457" left="555" width="149" height="19" font="3">procainamide challenge </text>
<text top="475" left="555" width="254" height="19" font="3">Class III: not indicated in the setting of an </text>
<text top="493" left="555" width="252" height="19" font="3">isolated type 2 or 3 Brugada ECG pattern </text>
<text top="512" left="555" width="3" height="19" font="3"> </text>
<text top="530" left="555" width="270" height="19" font="3">Short QTS: Class I: Mutation specific genetic </text>
<text top="548" left="555" width="274" height="19" font="3">testing is recommended for family members </text>
<text top="566" left="555" width="157" height="19" font="3">and appropriate relatives </text>
<text top="585" left="555" width="268" height="19" font="3">Class IIb: any pt with strong clinical index of </text>
<text top="603" left="555" width="60" height="19" font="3">suspicion </text>
<text top="621" left="555" width="3" height="19" font="3"> </text>
<text top="640" left="555" width="243" height="19" font="3">ARVC: Class I: Mutation specific genetic </text>
<text top="658" left="555" width="274" height="19" font="3">testing is recommended for family members </text>
<text top="676" left="555" width="157" height="19" font="3">and appropriate relatives </text>
<text top="695" left="555" width="275" height="19" font="3">Class IIa: can be useful for patients satisfying </text>
<text top="713" left="555" width="175" height="19" font="3">task force diagnostic criteria </text>
<text top="731" left="555" width="250" height="19" font="3">Class IIb: may be considered for patients </text>
<text top="750" left="555" width="156" height="19" font="3">with possible ACM/ARVC </text>
</page>
<page number="188" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">188 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="555" width="274" height="19" font="3">Class III: not recommended for patients with </text>
<text top="127" left="555" width="253" height="19" font="3">only a single minor criterion according to </text>
<text top="145" left="555" width="168" height="19" font="3">the 2010 task force criteria </text>
<text top="164" left="555" width="3" height="19" font="3"> </text>
<text top="182" left="555" width="243" height="19" font="3">SCD/SIDS: Class I: 1) Collection of tissue </text>
<text top="200" left="555" width="200" height="19" font="3">sample recommended (blood or </text>
<text top="219" left="555" width="238" height="19" font="3">heart/liver/spleen tissue); 2) Mutation </text>
<text top="237" left="555" width="269" height="19" font="3">specific genetic testing is recommended for </text>
<text top="255" left="555" width="259" height="19" font="3">family members and appropriate relatives </text>
<text top="273" left="555" width="232" height="19" font="3">Class IIb: testing may be considered if </text>
<text top="292" left="555" width="254" height="19" font="3">circumstantial evidence suggests LQTS or </text>
<text top="310" left="555" width="105" height="19" font="3">CPVT specifically </text>
<text top="329" left="555" width="3" height="19" font="3"> </text>
<text top="347" left="555" width="254" height="19" font="3">ACA/resuscitated: Class I: Genetic testing </text>
<text top="365" left="555" width="261" height="19" font="3">should be guided by the results of medical </text>
<text top="383" left="555" width="269" height="19" font="3">evaluation and is used for the 1° purpose of </text>
<text top="402" left="555" width="253" height="19" font="3">screening at-risk family members for sub-</text>
<text top="420" left="555" width="93" height="19" font="3">clinical disease </text>
<text top="438" left="555" width="239" height="19" font="3">Class III: Routine genetic testing, in the </text>
<text top="457" left="555" width="269" height="19" font="3">absence of a clinical index of suspicion for a </text>
<text top="475" left="555" width="266" height="19" font="3">specific cardiomyopathy or channelopathy, </text>
<text top="493" left="555" width="210" height="19" font="3">is not indicated for the survivor of </text>
<text top="512" left="555" width="118" height="19" font="3">unexplained OHCA </text>
<text top="530" left="555" width="3" height="19" font="3"> </text>
<text top="548" left="555" width="268" height="19" font="3">HCM: Class I:  1) any pt in whom the clinical </text>
<text top="566" left="555" width="236" height="19" font="3">dx of HCM is established.  2) Mutation </text>
<text top="585" left="555" width="269" height="19" font="3">specific genetic testing is recommended for </text>
<text top="603" left="555" width="263" height="19" font="3">family members and appropriate relatives  </text>
<text top="621" left="555" width="3" height="19" font="3"> </text>
<text top="640" left="555" width="270" height="19" font="3">DCM: Class I: 1) DCM and significant cardiac </text>
<text top="658" left="555" width="242" height="19" font="3">conduction disease and/or family Hx of </text>
<text top="676" left="555" width="250" height="19" font="3">premature unexpected sudden death. 2) </text>
<text top="695" left="555" width="215" height="19" font="3">Mutation specific genetic testing is </text>
<text top="713" left="555" width="242" height="19" font="3">recommended for family members and </text>
<text top="731" left="555" width="131" height="19" font="3">appropriate relatives </text>
<text top="750" left="555" width="3" height="19" font="3"> </text>
</page>
<page number="189" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">189 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="555" width="242" height="19" font="3">LVNC: Class I: Mutation specific genetic </text>
<text top="127" left="555" width="274" height="19" font="3">testing is recommended for family members </text>
<text top="145" left="555" width="157" height="19" font="3">and appropriate relatives </text>
<text top="164" left="555" width="266" height="19" font="3">Class IIa: can be useful if clinical dx of LVNC </text>
<text top="182" left="555" width="85" height="19" font="3">is established </text>
<text top="200" left="555" width="3" height="19" font="3"> </text>
<text top="219" left="555" width="243" height="19" font="3">PCCD: Class I: Mutation specific genetic </text>
<text top="237" left="555" width="274" height="19" font="3">testing is recommended for family members </text>
<text top="255" left="555" width="157" height="19" font="3">and appropriate relatives </text>
<text top="273" left="555" width="240" height="19" font="3"> Class IIb: may be considered as part of </text>
<text top="292" left="555" width="238" height="19" font="3">diagnostic evaluation for patients with </text>
<text top="310" left="555" width="196" height="19" font="3">either isolated CCD or CCD with </text>
<text top="329" left="555" width="236" height="19" font="3">concomitant congenital heart disease, </text>
<text top="347" left="555" width="219" height="19" font="3">especially w post family Hx of CCD.  </text>
<text top="365" left="555" width="3" height="19" font="3"> </text>
<text top="384" left="123" width="111" height="19" font="3">● Nannenberg EA </text>
<text top="402" left="123" width="102" height="19" font="3">Circ CV Genetics </text>
<text top="421" left="123" width="69" height="19" font="3">2012 (336) </text>
<text top="439" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22373669">● </a></text>
<text top="439" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22373669">22373669</a></text>
<text top="439" left="197" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22373669"><b> </b></a></text>
<text top="384" left="253" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="402" left="253" width="87" height="19" font="3">Retrospective </text>
<text top="421" left="253" width="85" height="19" font="3">single center, </text>
<text top="439" left="253" width="82" height="19" font="3">Netherlands  </text>
<text top="457" left="253" width="3" height="19" font="3"> </text>
<text top="476" left="253" width="76" height="19" font="4"><b>Size:</b>    1170<b> </b></text>
<text top="384" left="365" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="402" left="365" width="125" height="19" font="3">Genotype positive 6 </text>
<text top="421" left="365" width="130" height="19" font="3">inherited arrhythmia </text>
<text top="439" left="365" width="158" height="19" font="3">syndromes analyzed with </text>
<text top="457" left="365" width="169" height="19" font="3">Family Tree Mortality Ratio </text>
<text top="476" left="365" width="55" height="19" font="3">(FTMR):  </text>
<text top="494" left="365" width="116" height="19" font="3">LQT1,2,3; Brugada </text>
<text top="512" left="365" width="162" height="19" font="3">Syndrome, SCN5A overlap </text>
<text top="531" left="365" width="135" height="19" font="3">syndrome (LQT3, BrS, </text>
<text top="549" left="365" width="163" height="19" font="3">conduction disease); RYR2 </text>
<text top="567" left="365" width="42" height="19" font="3">CPVT.  </text>
<text top="586" left="365" width="3" height="19" font="3"> </text>
<text top="604" left="365" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="385" left="555" width="228" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Using FTMR method to </text>
<text top="403" left="555" width="265" height="19" font="3">achieve Standardized Mortality Ratio(SMR) </text>
<text top="422" left="555" width="218" height="19" font="3">(observed to expected mortality by </text>
<text top="440" left="555" width="263" height="19" font="3">genotype and age in inherited arrhythmias </text>
<text top="458" left="555" width="3" height="19" font="3"> </text>
<text top="476" left="555" width="264" height="19" font="4"><b>Results:</b>  LQTS1: in first 10 y of life SMR 2.9 </text>
<text top="495" left="555" width="58" height="19" font="3">(1.5–5.1) </text>
<text top="513" left="555" width="231" height="19" font="3">LQTS2: age 30-39 y, SMR 4.0 (1.1–10) </text>
<text top="531" left="555" width="239" height="19" font="3">LQTS3: age 15-19 y, SMR 5.8(1.2–16.9) </text>
<text top="550" left="555" width="268" height="19" font="3">SCN5A overlap syndrome: 20-39 y, SMR 3.8 </text>
<text top="568" left="555" width="58" height="19" font="3">(2.5–5.7) </text>
<text top="586" left="555" width="228" height="19" font="3">CPVT: age 20-39 y, SMR 3.0 (1.3–6.0) </text>
<text top="605" left="555" width="266" height="19" font="3">BrS: 40-59 y, SMR 1.79 (1.2–2.4), especially </text>
<text top="623" left="555" width="39" height="19" font="3">males<b> </b></text>
<text top="384" left="843" width="220" height="19" font="3">● Identify age ranges of highest risk </text>
<text top="402" left="843" width="209" height="19" font="3">for specified inherited arrhythmia </text>
<text top="421" left="843" width="70" height="19" font="3">syndromes </text>
<text top="439" left="843" width="213" height="19" font="3">● Asymptomatic patients over age </text>
<text top="457" left="843" width="161" height="19" font="3">ranges may not require rx </text>
<text top="476" left="843" width="3" height="19" font="3"> </text>
<text top="642" left="123" width="91" height="19" font="3">● Kimbrough J<b> </b></text>
<text top="660" left="123" width="96" height="19" font="3">Circ 2001 (337)<b> </b></text>
<text top="679" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11479253">● </a></text>
<text top="679" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11479253">11479253</a></text>
<text top="678" left="197" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11479253"><b> </b></a></text>
<text top="697" left="123" width="7" height="19" font="3">  </text>
<text top="642" left="253" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="660" left="253" width="87" height="19" font="3">Retrospective </text>
<text top="679" left="253" width="83" height="19" font="3">multi-center  </text>
<text top="697" left="253" width="3" height="19" font="3"> </text>
<text top="715" left="253" width="68" height="19" font="4"><b>Size:</b>    791<b> </b></text>
<text top="642" left="365" width="168" height="19" font="4"><b>Inclusion criteria:</b>  791 first </text>
<text top="660" left="365" width="177" height="19" font="3">degree relatives of 211 LQTS </text>
<text top="679" left="365" width="61" height="19" font="3">probands </text>
<text top="697" left="365" width="3" height="19" font="3"> </text>
<text top="715" left="365" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="643" left="555" width="217" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Risk of ACE for family </text>
<text top="661" left="555" width="200" height="19" font="3">members of proband with LQTS<b> </b> </text>
<text top="679" left="555" width="3" height="19" font="3"> </text>
<text top="698" left="555" width="269" height="19" font="4"><b>Results:</b>  Severity of proband symptoms did </text>
<text top="716" left="555" width="265" height="19" font="3">not significantly influence family member’s </text>
<text top="734" left="555" width="263" height="19" font="3">symptoms, although more likely to receive </text>
<text top="753" left="555" width="27" height="19" font="3">BB.  </text>
<text top="642" left="843" width="196" height="19" font="3">● Affected female parents have </text>
<text top="660" left="843" width="188" height="19" font="3">increased risk of cardiac event </text>
<text top="679" left="843" width="102" height="19" font="3">before age 40 y. </text>
<text top="697" left="843" width="225" height="19" font="3">● Severity of proband symptoms did </text>
<text top="715" left="843" width="200" height="19" font="3">not significantly influence family </text>
<text top="734" left="843" width="135" height="19" font="3">members’ symptoms. </text>
</page>
<page number="190" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="24" size="12" family="Times" color="#5b9bd5"/>
<text top="803" left="585" width="29" height="21" font="0">190 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="555" width="219" height="19" font="3">Female gender and duration of QTc </text>
<text top="127" left="555" width="135" height="19" font="3">important risk factors </text>
<text top="208" left="123" width="88" height="19" font="3">● Kaufman ES </text>
<text top="226" left="123" width="89" height="19" font="3">Heart Rhythm </text>
<text top="245" left="123" width="69" height="19" font="3">2008 (338) </text>
<text top="263" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18534367">● </a></text>
<text top="263" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18534367">18534367</a></text>
<text top="263" left="197" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18534367"><b> </b></a></text>
<text top="208" left="253" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="226" left="253" width="87" height="19" font="3">Retrospective </text>
<text top="245" left="253" width="53" height="19" font="3">registry: </text>
<text top="263" left="253" width="83" height="19" font="3">International </text>
<text top="281" left="253" width="90" height="19" font="3">LQTS Registry  </text>
<text top="300" left="253" width="3" height="19" font="3"> </text>
<text top="318" left="253" width="69" height="19" font="4"><b>Size:</b>  1915<b> </b></text>
<text top="208" left="365" width="171" height="19" font="4"><b>Inclusion criteria:</b>   Patients </text>
<text top="226" left="365" width="141" height="19" font="3">with QTc ≥450 msec in </text>
<text top="245" left="365" width="162" height="19" font="3">registry, who had a sibling </text>
<text top="263" left="365" width="58" height="19" font="3">with SCD </text>
<text top="281" left="365" width="3" height="19" font="3"> </text>
<text top="299" left="365" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="209" left="555" width="261" height="19" font="4"><b>1</b>°<b> endpoint:  </b>risk of death in LQTS when a </text>
<text top="227" left="555" width="235" height="19" font="3">sibling has died: ACA, SCD, or syncope </text>
<text top="245" left="555" width="3" height="19" font="3"> </text>
<text top="264" left="555" width="236" height="19" font="4"><b>Results:</b>  270 patients with sibling SCD </text>
<text top="282" left="555" width="243" height="19" font="3">Sibling death did not correlate with risk </text>
<text top="300" left="555" width="59" height="19" font="3">ACA/SCD </text>
<text top="319" left="555" width="231" height="19" font="3">Was associated with increased risk of </text>
<text top="337" left="555" width="54" height="19" font="3">syncope </text>
<text top="355" left="555" width="266" height="19" font="3">Associations with increased risk death: QTc </text>
<text top="373" left="555" width="176" height="19" font="3">≥530 msec, syncope, gender<b> </b></text>
<text top="208" left="843" width="216" height="19" font="3">● SCD of sibling did not predict risk </text>
<text top="226" left="843" width="100" height="19" font="3">of death or ACA </text>
<text top="245" left="843" width="228" height="19" font="3">● Did correlate with increased risk of </text>
<text top="263" left="843" width="83" height="19" font="3">syncope ~6% </text>
<text top="281" left="843" width="204" height="19" font="3">● Hx of syncope, QTc≥ 530 msec, </text>
<text top="300" left="843" width="189" height="19" font="3">female gender correlated with </text>
<text top="318" left="843" width="146" height="19" font="3">increased risk ACA/SCD </text>
<text top="393" left="123" width="115" height="19" font="3">● Wedekind H Eur </text>
<text top="411" left="123" width="104" height="19" font="3">J Ped 2009 (339) </text>
<text top="429" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19101729">● </a></text>
<text top="429" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19101729">19101729</a></text>
<text top="429" left="197" width="3" height="19" font="24"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19101729"><b> </b></a></text>
<text top="447" left="123" width="3" height="19" font="4"><b> </b></text>
<text top="392" left="253" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="411" left="253" width="87" height="19" font="3">Retrospective </text>
<text top="429" left="253" width="81" height="19" font="3">single center </text>
<text top="447" left="253" width="3" height="19" font="3"> </text>
<text top="466" left="253" width="61" height="19" font="4"><b>Size:</b>   83 <b> </b></text>
<text top="392" left="365" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="411" left="365" width="114" height="19" font="3">Genotype positive </text>
<text top="429" left="365" width="169" height="19" font="4"><b>probands</b>, age ≤16 y LQTS:  </text>
<text top="447" left="365" width="90" height="19" font="3">89% LQT1, 2,3 </text>
<text top="466" left="365" width="136" height="19" font="3">Mean QTc 510±74 ms </text>
<text top="484" left="365" width="153" height="19" font="3">61% symptoms: syncope </text>
<text top="502" left="365" width="152" height="19" font="3">49%, ACA 33%, SCD 18% </text>
<text top="521" left="365" width="95" height="19" font="3">78% with BB rx </text>
<text top="539" left="365" width="3" height="19" font="3"> </text>
<text top="557" left="365" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="393" left="555" width="251" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Recurrent syncope, ACA or </text>
<text top="412" left="555" width="274" height="19" font="3">SCD after dx LQTS.  Mean followup 5.9±4.7 y </text>
<text top="430" left="555" width="3" height="19" font="3"> </text>
<text top="448" left="555" width="201" height="19" font="4"><b>Results:</b>  92% treated: Followup: </text>
<text top="467" left="555" width="266" height="19" font="3">Propranolol 79%, atenolol 20%, metoprolol </text>
<text top="485" left="555" width="269" height="19" font="3">12%, bisoprolol 8%, pindolol 2%; mexiletine </text>
<text top="503" left="555" width="25" height="19" font="3">4%  </text>
<text top="522" left="555" width="116" height="19" font="3">ICD 8%, pacer 5%.  </text>
<text top="540" left="555" width="267" height="19" font="3">31% recurrent symptoms: 14% ACA or SCD; </text>
<text top="558" left="555" width="83" height="19" font="3">syncope 86% </text>
<text top="577" left="555" width="274" height="19" font="3">Significant predictors: QTc &gt;500 ms (HR: 2.9; </text>
<text top="595" left="555" width="263" height="19" font="3">95% CI: 1.2–7.3 p=0.02); prior syncope HR: </text>
<text top="613" left="555" width="264" height="19" font="3">4.04; 95% CI: 1.1–15, ACA HR:11.7; 95% CI: </text>
<text top="631" left="555" width="113" height="19" font="3">3.1–43.4, p&lt;0.001 </text>
<text top="393" left="843" width="213" height="19" font="3">● Risk predictors: QTc &gt; 500 msec, </text>
<text top="411" left="843" width="132" height="19" font="3">prior syncope or ACA </text>
<text top="429" left="843" width="204" height="19" font="3">● LQT2 highest rate SCD vs other </text>
<text top="447" left="843" width="3" height="19" font="3"> </text>
<text top="466" left="843" width="3" height="19" font="3"> </text>
<text top="651" left="123" width="94" height="19" font="3">● Goldenberg I<b> </b></text>
<text top="669" left="123" width="102" height="19" font="3">JACC 2011 (340)<b> </b></text>
<text top="687" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21185501">● </a></text>
<text top="687" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21185501">21185501</a></text>
<text top="687" left="197" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21185501"><b> </b></a></text>
<text top="650" left="253" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="669" left="253" width="75" height="19" font="3">Multicenter </text>
<text top="687" left="253" width="82" height="19" font="3">international </text>
<text top="705" left="253" width="53" height="19" font="3">registry, </text>
<text top="724" left="253" width="88" height="19" font="3">retrospective  </text>
<text top="742" left="253" width="3" height="19" font="3"> </text>
<text top="760" left="253" width="68" height="19" font="4"><b>Size:</b>  469  <b> </b></text>
<text top="650" left="365" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="669" left="365" width="155" height="19" font="3">Genotyped patients with </text>
<text top="687" left="365" width="125" height="19" font="3">LQTS: 3386 patients </text>
<text top="705" left="365" width="135" height="19" font="3">Normal QTc: ≤440 ms </text>
<text top="724" left="365" width="148" height="19" font="3">Prolonged QTc &gt;440 ms </text>
<text top="742" left="365" width="131" height="19" font="3">Unaffected: negative </text>
<text top="760" left="365" width="61" height="19" font="3">genotype </text>
<text top="779" left="365" width="3" height="19" font="3"> </text>
<text top="651" left="555" width="273" height="19" font="4"><b>1</b>°<b> endpoint:</b>  LQTS with normal QTc: risk for </text>
<text top="670" left="555" width="104" height="19" font="3">ACE: ACA or SCD </text>
<text top="688" left="555" width="3" height="19" font="3"> </text>
<text top="706" left="555" width="250" height="19" font="4"><b>Results:</b> <b> </b>Normal QTc =14% of total LQTS </text>
<text top="724" left="555" width="112" height="19" font="3">patients in study.  </text>
<text top="743" left="555" width="262" height="19" font="3">Normal QTc risk ACA/SCD =4%, lower than </text>
<text top="761" left="555" width="266" height="19" font="3">those with prolonged QTc (15%) but higher </text>
<text top="779" left="555" width="227" height="19" font="3">than genotype neg family members.  </text>
<text top="651" left="843" width="210" height="19" font="3">● Genotype positive patients with </text>
<text top="669" left="843" width="188" height="19" font="3">normal QTc =25% of genotype </text>
<text top="687" left="843" width="108" height="19" font="3">positive patients. </text>
<text top="705" left="843" width="213" height="19" font="3">● 4% ACA/SCD with normal QTc vs </text>
<text top="724" left="843" width="134" height="19" font="3">15% if prolonged QTc </text>
<text top="742" left="843" width="3" height="19" font="4"><b> </b></text>
</page>
<page number="191" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">191 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="365" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="109" left="555" width="246" height="19" font="3">Increased risk: mutation characteristics; </text>
<text top="127" left="555" width="214" height="19" font="3">LQT1 vs LQTS 2, HR: 9.88; p=0.03;   </text>
<text top="145" left="555" width="267" height="19" font="3">Duration of QTc and gender important only </text>
<text top="164" left="555" width="180" height="19" font="3">in those with prolonged QTc. </text>
<text top="221" left="123" width="104" height="19" font="3">● Tester DJ JACC </text>
<text top="240" left="123" width="30" height="19" font="3">2006</text>
<text top="238" left="154" width="4" height="21" font="0"> </text>
<text top="240" left="157" width="35" height="19" font="3">(341) </text>
<text top="258" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16487842">● </a></text>
<text top="258" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16487842">16487842</a></text>
<text top="258" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16487842"> </a></text>
<text top="221" left="253" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="240" left="253" width="84" height="19" font="3">retrospective </text>
<text top="258" left="253" width="88" height="19" font="3">single center   </text>
<text top="276" left="253" width="3" height="19" font="3"> </text>
<text top="295" left="253" width="68" height="19" font="4"><b>Size:</b>  541  <b> </b></text>
<text top="221" left="365" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="240" left="365" width="129" height="19" font="3">consecutive patients </text>
<text top="258" left="365" width="169" height="19" font="3">undergoing Genetic testing </text>
<text top="276" left="365" width="106" height="19" font="3">LQTS  1997-2004 </text>
<text top="295" left="365" width="3" height="19" font="3"> </text>
<text top="313" left="365" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="222" left="555" width="260" height="19" font="4"><b>1</b>°<b> endpoint:</b>  yield of LQTS genetic testing </text>
<text top="240" left="555" width="126" height="19" font="3">vs. clinical genotype </text>
<text top="259" left="555" width="3" height="19" font="3"> </text>
<text top="277" left="555" width="234" height="19" font="4"><b>Results:</b>  50% positive genotype. Yield </text>
<text top="295" left="555" width="222" height="19" font="3">correlated with duration of QTc and </text>
<text top="314" left="555" width="160" height="19" font="3">phenotype:  0%: QTc&lt;400 </text>
<text top="332" left="555" width="185" height="19" font="3">62%: QTc &gt;480 ms (p&lt;0.0001) </text>
<text top="350" left="555" width="198" height="19" font="3">Schwartz score ≥4: 72% positive<b> </b></text>
<text top="221" left="843" width="226" height="19" font="3">● Genotype results more likely to be </text>
<text top="240" left="843" width="208" height="19" font="3">positive with QTc &gt;480ms or with </text>
<text top="258" left="843" width="137" height="19" font="3">higher Schwartz score </text>
<text top="276" left="843" width="3" height="19" font="3"> </text>
<text top="370" left="123" width="85" height="19" font="3">● Priori S Circ </text>
<text top="388" left="123" width="69" height="19" font="3">2002 (342) </text>
<text top="406" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11901046">● </a></text>
<text top="406" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11901046">11901046</a></text>
<text top="406" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11901046"> </a></text>
<text top="369" left="253" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="388" left="253" width="75" height="19" font="3">Multicenter </text>
<text top="406" left="253" width="88" height="19" font="3">retrospective  </text>
<text top="424" left="253" width="3" height="19" font="3"> </text>
<text top="443" left="253" width="68" height="19" font="4"><b>Size:</b>   200 <b> </b></text>
<text top="369" left="365" width="169" height="19" font="4"><b>Inclusion criteria:</b>  Brugada </text>
<text top="388" left="365" width="164" height="19" font="3">S with ECG changes, spont </text>
<text top="406" left="365" width="107" height="19" font="3">(51%) or induced </text>
<text top="424" left="365" width="91" height="19" font="3">130 probands  </text>
<text top="443" left="365" width="3" height="19" font="3"> </text>
<text top="461" left="365" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="370" left="555" width="265" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Brugada risk stratification for </text>
<text top="389" left="555" width="27" height="19" font="3">SCD </text>
<text top="407" left="555" width="128" height="19" font="3">PES performed in 86 </text>
<text top="425" left="555" width="3" height="19" font="3"> </text>
<text top="443" left="555" width="267" height="19" font="4"><b>Results:</b> SCN5A identified in 22% probands, </text>
<text top="462" left="555" width="147" height="19" font="3">46% of family members </text>
<text top="480" left="555" width="227" height="19" font="3">Risk analysis: gender; ECG, family hx, </text>
<text top="498" left="555" width="170" height="19" font="3">mutation status, symptoms </text>
<text top="517" left="555" width="256" height="19" font="3">Syncope without ST elevation on baseline </text>
<text top="535" left="555" width="95" height="19" font="3">ECG: not a risk  </text>
<text top="553" left="555" width="254" height="19" font="3">Syncope AND ST elevation: increased risk </text>
<text top="572" left="555" width="139" height="19" font="3">SCD, HR: 6.4; p &lt;0.002<b> </b></text>
<text top="370" left="843" width="186" height="19" font="3">● Multivariable risk predictor: </text>
<text top="388" left="843" width="226" height="19" font="3">spontaneous ST elevation V1-V3 and </text>
<text top="406" left="843" width="89" height="19" font="3">Hx of syncope </text>
<text top="424" left="843" width="218" height="19" font="3">● Syncope without spontaneous ST </text>
<text top="443" left="843" width="159" height="19" font="3">elevation not a risk factor </text>
<text top="461" left="843" width="126" height="19" font="3">● PES not predictive </text>
<text top="479" left="843" width="174" height="19" font="3">● Mutation carriers without </text>
<text top="498" left="843" width="127" height="19" font="3">phenotype: low risk  </text>
<text top="591" left="123" width="62" height="19" font="3">● <b>FINGER </b></text>
<text top="609" left="123" width="94" height="19" font="3">● Probst V Circ </text>
<text top="627" left="123" width="69" height="19" font="3">2010 (343) </text>
<text top="646" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20100972">● </a></text>
<text top="646" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20100972">20100972</a></text>
<text top="646" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20100972"> </a></text>
<text top="591" left="253" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="609" left="253" width="80" height="19" font="3">Multi-center </text>
<text top="627" left="253" width="72" height="19" font="3">registry, 11 </text>
<text top="646" left="253" width="63" height="19" font="3">centers in </text>
<text top="664" left="253" width="47" height="19" font="3">Europe </text>
<text top="682" left="253" width="3" height="19" font="3"> </text>
<text top="700" left="253" width="76" height="19" font="4"><b>Size:</b>   1029 <b> </b></text>
<text top="591" left="365" width="169" height="19" font="4"><b>Inclusion criteria:</b>  Brugada </text>
<text top="609" left="365" width="65" height="19" font="3">Syndrome </text>
<text top="627" left="365" width="155" height="19" font="3"> ECG spont (45%) or with </text>
<text top="646" left="365" width="97" height="19" font="3">drug challenge. </text>
<text top="664" left="365" width="130" height="19" font="3">Median 45 y (35-55). </text>
<text top="682" left="365" width="160" height="19" font="3">Hx ACA 6%, syncope 30%, </text>
<text top="701" left="365" width="150" height="19" font="3">asymptomatic 64% (654 </text>
<text top="719" left="365" width="65" height="19" font="3">patients).  </text>
<text top="737" left="365" width="132" height="19" font="3">SCN5A positive 22%.  </text>
<text top="755" left="365" width="3" height="19" font="3"> </text>
<text top="774" left="365" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="591" left="555" width="211" height="19" font="4"><b>1</b>°<b> endpoint:</b> ACE outcomes in BrS </text>
<text top="610" left="555" width="3" height="19" font="3"> </text>
<text top="628" left="555" width="224" height="19" font="4"><b>Results:</b> PES performed in 62%: 41% </text>
<text top="646" left="555" width="248" height="19" font="3">positive, higher in symptomatic patients </text>
<text top="665" left="555" width="128" height="19" font="3">46% vs 37%, p=0.02. </text>
<text top="683" left="555" width="225" height="19" font="3">PES performed in 369 asymptomatic </text>
<text top="701" left="555" width="235" height="19" font="3">patients: 37% positive (137/369); 85% </text>
<text top="720" left="555" width="256" height="19" font="3">(117/137) inducible asyx patients had ICD </text>
<text top="738" left="555" width="65" height="19" font="3">implanted </text>
<text top="756" left="555" width="262" height="19" font="3">ICD’s implanted: 433/1029 patients (42%): </text>
<text top="775" left="555" width="269" height="19" font="3">of 433: 54 ACA (12.5%), 208 syncope (48%), </text>
<text top="591" left="843" width="212" height="19" font="3">● Low event rate in asymptomatic </text>
<text top="609" left="843" width="106" height="19" font="3">patients 0.5%/y.  </text>
<text top="627" left="843" width="226" height="19" font="3">● Inducibility w PES or family Hx SCD </text>
<text top="646" left="843" width="226" height="19" font="3">or SCN5A mutation not predictors of </text>
<text top="664" left="843" width="27" height="19" font="3">ACE </text>
<text top="682" left="843" width="228" height="19" font="3">● Predictors of ACE: symptoms, ACA, </text>
<text top="701" left="843" width="229" height="19" font="3">syncope, presence of ICD, spont type </text>
<text top="719" left="843" width="43" height="19" font="3">1 ECG. </text>
<text top="737" left="843" width="206" height="19" font="3">● Among asymptomatic patients: </text>
<text top="755" left="843" width="219" height="19" font="3">37% positive PES; of these 85% had </text>
<text top="774" left="843" width="97" height="19" font="3">ICD implanted.  </text>
</page>
<page number="192" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">192 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="555" width="213" height="19" font="3">171 asymptomatic (39%). 118/171 </text>
<text top="127" left="555" width="236" height="19" font="3">asymptomatic patients with ICD (69%) </text>
<text top="145" left="555" width="192" height="19" font="3">implanted due to positive EPS.  </text>
<text top="164" left="555" width="3" height="19" font="3"> </text>
<text top="182" left="555" width="234" height="19" font="3">ACE 51: approp ICD shocks 44, SCD 7.  </text>
<text top="200" left="555" width="263" height="19" font="3">Mean ACE rate 1.6%/y:  7.7% in patients w </text>
<text top="219" left="555" width="234" height="19" font="3">Hx ACA;1.9% w prior syncope; 0.5% in </text>
<text top="237" left="555" width="96" height="19" font="3">asymp patients </text>
<text top="255" left="555" width="264" height="19" font="3">Predictors: symptoms (p&lt;0.001):  ACA (HR: </text>
<text top="273" left="555" width="275" height="19" font="3">11; 95% CI: 4.8–24.3, p&lt;0.001), syncope (HR: </text>
<text top="292" left="555" width="191" height="19" font="3">3.4; 95% CI 1.6–7.4, p=0.002),   </text>
<text top="310" left="555" width="271" height="19" font="3">ICD implantation (HR: 3.9; 95% CI: 1.4–10.6, </text>
<text top="329" left="555" width="65" height="19" font="3">p=0.007).  </text>
<text top="347" left="555" width="243" height="19" font="3">spont type 1 ECG (HR: 1.8;95% CI: 1.03–</text>
<text top="365" left="555" width="91" height="19" font="3">3.33, p=0.04);  </text>
<text top="383" left="555" width="273" height="19" font="3">NOT predictive: gender, family Hx SCD, +PES </text>
<text top="402" left="555" width="221" height="19" font="3">(p=0.48), presence SCN5A mutation </text>
<text top="109" left="843" width="223" height="19" font="3">● ICD implantation in asymptomatic </text>
<text top="127" left="843" width="161" height="19" font="3">patients was significant in </text>
<text top="145" left="843" width="227" height="19" font="3">multivariable analysis as predictor of </text>
<text top="164" left="843" width="196" height="19" font="3">ACE: HR:10.1; 95% CI: 1.7–58.7, </text>
<text top="182" left="843" width="57" height="19" font="3">p=0.01).  </text>
<text top="200" left="843" width="231" height="19" font="3">● No independent predictive value of </text>
<text top="219" left="843" width="215" height="19" font="3">PES (p=0.09), males (p=0.42, spont </text>
<text top="237" left="843" width="204" height="19" font="3">type 1 ECG (p=0.38) age (p=0.97) </text>
<text top="421" left="123" width="92" height="19" font="3">● Moss AJ Circ </text>
<text top="439" left="123" width="66" height="19" font="3">2000(344)<b> </b></text>
<text top="457" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10673253">● </a></text>
<text top="457" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10673253">10673253</a></text>
<text top="457" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10673253"> </a></text>
<text top="421" left="253" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="439" left="253" width="87" height="19" font="3">Retrospective </text>
<text top="457" left="253" width="87" height="19" font="3">observational </text>
<text top="476" left="253" width="3" height="19" font="3"> </text>
<text top="494" left="253" width="68" height="19" font="4"><b>Size:</b> 869   <b> </b></text>
<text top="421" left="365" width="149" height="19" font="4"><b>Inclusion criteria:</b>  LQTS </text>
<text top="439" left="365" width="175" height="19" font="3">registry, Rochester, patients </text>
<text top="457" left="365" width="165" height="19" font="3">treatment w BB age &lt;41 y, </text>
<text top="476" left="365" width="161" height="19" font="3">80% syncope or ACA prior </text>
<text top="494" left="365" width="169" height="19" font="3">to rx. Atenolol, metoprolol, </text>
<text top="512" left="365" width="135" height="19" font="3">nadolol, propranolol.  </text>
<text top="531" left="365" width="154" height="19" font="3">139/869 genotyped: LQT </text>
<text top="549" left="365" width="174" height="19" font="3">1(69), LQT 2 (42), LQT 3 (28) </text>
<text top="567" left="365" width="175" height="19" font="4"><b>Exclusion criteria:</b> age &gt;41 y </text>
<text top="586" left="365" width="47" height="19" font="3">start rx<b> </b></text>
<text top="421" left="555" width="266" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Recurrent CE on b-bl in LQTS<b> </b> </text>
<text top="440" left="555" width="3" height="19" font="3"> </text>
<text top="458" left="555" width="264" height="19" font="4"><b>Results:</b> B-Bl significantly reduce risk LQT 1 </text>
<text top="476" left="555" width="41" height="19" font="3">and 2; </text>
<text top="495" left="555" width="107" height="19" font="3"> LQT 3: no effect  </text>
<text top="513" left="555" width="231" height="19" font="3"> For symptomatic patients, HR 5.8 for </text>
<text top="531" left="555" width="207" height="19" font="3">recurrent CE: 32% ACE within 5 y. </text>
<text top="550" left="555" width="148" height="19" font="3">Prior syncope: HR: 3.1.   </text>
<text top="568" left="555" width="235" height="19" font="3">Prior ACA, HR: 12.9 for ACA or sudden </text>
<text top="586" left="555" width="161" height="19" font="3">death: 14% recurrent CA.<b>  </b></text>
<text top="421" left="843" width="220" height="20" font="3">•  For LQT 1 and 2, BB reduce risk </text>
<text top="440" left="843" width="204" height="20" font="3">•  Highly symptomatic patients </text>
<text top="459" left="870" width="185" height="19" font="3">prior to treatment at high risk </text>
<text top="477" left="870" width="133" height="19" font="3">for recurrent events.  </text>
<text top="496" left="843" width="189" height="20" font="3">•  LQT 3 patients: BB did not </text>
<text top="515" left="870" width="70" height="19" font="3">reduce risk </text>
<text top="605" left="123" width="115" height="19" font="3">● Zareba JCE 2003 </text>
<text top="624" left="123" width="35" height="19" font="3">(345) </text>
<text top="642" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12741701">● </a></text>
<text top="642" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12741701">12741701</a></text>
<text top="642" left="197" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12741701"><b> </b></a></text>
<text top="605" left="253" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="624" left="253" width="82" height="19" font="3">Single center </text>
<text top="642" left="253" width="85" height="19" font="3">retrospective </text>
<text top="660" left="253" width="3" height="19" font="3"> </text>
<text top="678" left="253" width="68" height="19" font="4"><b>Size:125</b>    <b> </b></text>
<text top="605" left="365" width="175" height="19" font="4"><b>Inclusion criteria:</b>  125 LQTS </text>
<text top="624" left="365" width="118" height="19" font="3">patients with ICD’s </text>
<text top="642" left="365" width="160" height="19" font="3">compared with LQTS with </text>
<text top="660" left="365" width="167" height="19" font="3">similar risk and no ICD. ICD </text>
<text top="679" left="365" width="144" height="19" font="3">Indications: 54 ACA, 19 </text>
<text top="697" left="365" width="165" height="19" font="3">recurrent syncope on b-bl; </text>
<text top="715" left="365" width="141" height="19" font="3">52 “other” (syncope; + </text>
<text top="734" left="365" width="92" height="19" font="3">family Hx SCD) </text>
<text top="752" left="365" width="3" height="19" font="3"> </text>
<text top="770" left="365" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="606" left="555" width="248" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Mortality of LQTS patients </text>
<text top="624" left="555" width="165" height="19" font="3">treated with/without ICD:  </text>
<text top="643" left="555" width="257" height="19" font="3">73 patients with syncope on treatment or </text>
<text top="661" left="555" width="268" height="19" font="3">prior ACA and ICD compared with 161 LQTS </text>
<text top="680" left="555" width="225" height="19" font="3">patients without ICD (89 ACA, 72 rec </text>
<text top="698" left="555" width="104" height="19" font="3">syncope on b-bl) </text>
<text top="716" left="555" width="3" height="19" font="3"> </text>
<text top="734" left="555" width="264" height="19" font="4"><b>Results:</b>  Deaths:  ICD 1.3% (1 pt), followup </text>
<text top="753" left="555" width="240" height="19" font="3">av 3 y, vs. 16% (26 patients) in non-ICD </text>
<text top="771" left="555" width="216" height="19" font="3">patients during 8 y mean followup. </text>
<text top="605" left="843" width="225" height="19" font="3">● Prior ACA or recurrent syncope on </text>
<text top="624" left="843" width="225" height="19" font="3">b-bl treatment assoc with significant </text>
<text top="642" left="843" width="199" height="19" font="3">mortality without ICD during 8 y </text>
<text top="660" left="843" width="57" height="19" font="3">followup </text>
<text top="679" left="843" width="3" height="19" font="3"> </text>
</page>
<page number="193" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">193 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="113" height="19" font="3">● Monnig G Heart </text>
<text top="127" left="123" width="85" height="19" font="3">Rhythm 2005 </text>
<text top="145" left="123" width="35" height="19" font="3">(346) </text>
<text top="164" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15840474">● </a></text>
<text top="164" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15840474">15840474</a></text>
<text top="164" left="197" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15840474"><b> </b></a></text>
<text top="109" left="253" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="127" left="253" width="81" height="19" font="3">single center </text>
<text top="145" left="253" width="85" height="19" font="3">retrospective </text>
<text top="164" left="253" width="3" height="19" font="3"> </text>
<text top="182" left="253" width="61" height="19" font="4"><b>Size:</b>    27<b> </b></text>
<text top="109" left="365" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="127" left="365" width="172" height="19" font="3">symptomatic <b>LQTS patients </b></text>
<text top="145" left="365" width="155" height="19" font="3">undergoing ICD implant.  </text>
<text top="164" left="365" width="148" height="19" font="3">Mean QTc 540±64; 85% </text>
<text top="182" left="365" width="133" height="19" font="3">famle, 63% ACA, 33% </text>
<text top="200" left="365" width="165" height="19" font="3">recurrent syncope on b-bl, </text>
<text top="219" left="365" width="141" height="19" font="3">4% “severe phenotype </text>
<text top="237" left="365" width="169" height="19" font="3">81 genotype pos: LQT 1 28, </text>
<text top="255" left="365" width="167" height="19" font="3">LQT2 39; LQT3 1, LQT5 13.  </text>
<text top="273" left="365" width="3" height="19" font="3"> </text>
<text top="292" left="365" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="109" left="555" width="264" height="19" font="4"><b>1</b>°<b> endpoint:</b>  LQTS Appropriate ICD shocks </text>
<text top="128" left="555" width="163" height="19" font="3">or death during followup.  </text>
<text top="146" left="555" width="3" height="19" font="3"> </text>
<text top="164" left="555" width="223" height="19" font="4"><b>Results:</b>  Mean followup 65±34 mo.  </text>
<text top="183" left="555" width="154" height="19" font="3">Death 1 pt, non-cardiac.  </text>
<text top="201" left="555" width="261" height="19" font="3">Approp shocks: 37%; 30% multiple shocks. </text>
<text top="219" left="555" width="267" height="19" font="3">Logistic regression: QTc &gt;500 ms, prior ACA </text>
<text top="238" left="555" width="71" height="19" font="3">predictive.  </text>
<text top="256" left="555" width="262" height="19" font="3">Shocks reduced from av 7.1 to 0.75 shocks </text>
<text top="274" left="555" width="267" height="19" font="3">annually by adding b-bl, increased rate anti-</text>
<text top="293" left="555" width="252" height="19" font="3">brady pacing, rate smoothing algorithm.  </text>
<text top="109" left="843" width="214" height="19" font="3">● Predictors of approp ICD shocks: </text>
<text top="127" left="843" width="161" height="19" font="3">QTc &gt;500 msec, prior ACA </text>
<text top="145" left="843" width="205" height="19" font="3">● Approp shocks reduced by anti-</text>
<text top="164" left="843" width="229" height="19" font="3">brady pacing, b-bl rx, rate-smoothing </text>
<text top="182" left="843" width="3" height="19" font="3"> </text>
<text top="200" left="843" width="3" height="19" font="3"> </text>
<text top="312" left="123" width="106" height="19" font="3">● Hayashi M Circ </text>
<text top="330" left="123" width="69" height="19" font="3">2009 (347) </text>
<text top="348" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19398665">● </a></text>
<text top="348" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19398665">19398665</a></text>
<text top="348" left="197" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19398665"><b> </b></a></text>
<text top="311" left="253" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="330" left="253" width="81" height="19" font="3">single center </text>
<text top="348" left="253" width="95" height="19" font="3">retrospective    </text>
<text top="367" left="253" width="3" height="19" font="3"> </text>
<text top="385" left="253" width="68" height="19" font="4"><b>Size:</b>  101  <b> </b></text>
<text top="311" left="365" width="165" height="19" font="4"><b>Inclusion criteria:</b> CPVT 50 </text>
<text top="330" left="365" width="124" height="19" font="3">probands, 51 family </text>
<text top="348" left="365" width="164" height="19" font="3">members, age at dx 15±10 </text>
<text top="367" left="365" width="17" height="19" font="3">y.  </text>
<text top="385" left="365" width="120" height="19" font="3">Symptoms 60% (61 </text>
<text top="403" left="365" width="173" height="19" font="3">patients), all probands, 22% </text>
<text top="422" left="365" width="102" height="19" font="3">family members </text>
<text top="440" left="365" width="174" height="19" font="3">93% symptomatic &lt;21 y old  </text>
<text top="458" left="365" width="176" height="19" font="3">77% detection of mutations: </text>
<text top="476" left="365" width="79" height="19" font="3">RYR2 CASQ2 </text>
<text top="495" left="365" width="3" height="19" font="3"> </text>
<text top="513" left="365" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="312" left="555" width="219" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ACE in CPVT patients: </text>
<text top="331" left="555" width="240" height="19" font="3">syncope, ACA, approp ICD shocks, SCD  </text>
<text top="349" left="555" width="3" height="19" font="3"> </text>
<text top="367" left="555" width="146" height="19" font="4"><b>Results:</b>  followup 7.9 y </text>
<text top="386" left="555" width="275" height="19" font="3">8 y total event rate 32% total, 27% with b-bl, </text>
<text top="404" left="555" width="274" height="19" font="3">58% without b-bl. 8 y event ACA/SCD 13% (8 </text>
<text top="422" left="555" width="58" height="19" font="3">patients) </text>
<text top="441" left="555" width="273" height="19" font="3">Increased risk: Absence BB HR: 5.54; 95% CI: </text>
<text top="459" left="555" width="251" height="19" font="3">1.17–16.15, p=0.003), Hx ACA HR: 13.01; </text>
<text top="477" left="555" width="264" height="19" font="3">95% CI: 2.48–68.21, p=0.002); younger age </text>
<text top="496" left="555" width="263" height="19" font="3">at dx (HR: 0.54/decade; 95% CI: 0.33–0.89, </text>
<text top="514" left="555" width="50" height="19" font="3">p=0.02) </text>
<text top="532" left="555" width="266" height="19" font="3">32% with events on b-blockers did not take </text>
<text top="550" left="555" width="176" height="19" font="3">meds on day of event.            </text>
<text top="569" left="555" width="112" height="19" font="3">Nadolol: ACE 19% </text>
<text top="569" left="693" width="3" height="19" font="3"> </text>
<text top="312" left="843" width="217" height="19" font="3">● Higher risk for lack of BB, Hx ACA </text>
<text top="330" left="843" width="221" height="19" font="3">● Prior syncope not associated with </text>
<text top="348" left="843" width="87" height="19" font="3">increased risk </text>
<text top="367" left="843" width="3" height="19" font="3"> </text>
<text top="385" left="843" width="3" height="19" font="3"> </text>
<text top="588" left="123" width="89" height="19" font="3">● Delise P EHJ </text>
<text top="606" left="123" width="66" height="19" font="3">2011(348) </text>
<text top="624" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20978016">● </a></text>
<text top="624" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20978016">20978016</a></text>
<text top="624" left="197" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20978016"><b> </b></a></text>
<text top="588" left="253" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="606" left="253" width="83" height="19" font="3">Multi- center </text>
<text top="624" left="253" width="81" height="19" font="3">prospective   </text>
<text top="643" left="253" width="3" height="19" font="3"> </text>
<text top="661" left="253" width="68" height="19" font="4"><b>Size:</b>    320<b> </b></text>
<text top="588" left="365" width="158" height="19" font="4"><b>Inclusion criteria:</b>  Type 1 </text>
<text top="606" left="365" width="169" height="19" font="4"><b>Brugada ECG: </b>spontaneous </text>
<text top="624" left="365" width="154" height="19" font="3">54%, drug-induced 46%.  </text>
<text top="643" left="365" width="3" height="19" font="3"> </text>
<text top="661" left="365" width="108" height="19" font="3">Median age 43 y. </text>
<text top="680" left="365" width="69" height="19" font="3">Males 81% </text>
<text top="698" left="365" width="3" height="19" font="3"> </text>
<text top="716" left="365" width="124" height="19" font="3">Asymptomatic 66%, </text>
<text top="734" left="365" width="83" height="19" font="3">syncope 33% </text>
<text top="753" left="365" width="3" height="19" font="3"> </text>
<text top="771" left="365" width="85" height="19" font="3">NO prior ACA </text>
<text top="588" left="555" width="272" height="19" font="4"><b>1</b>°<b> endpoint:</b> <b> </b>predictors in Brugada S of ACE </text>
<text top="607" left="555" width="219" height="19" font="3">(approp ICD shocks, sudden death)  </text>
<text top="625" left="555" width="3" height="19" font="3"> </text>
<text top="644" left="555" width="260" height="19" font="4"><b>Results:</b>  Median followup 40 mos (IQR 20-</text>
<text top="662" left="555" width="23" height="19" font="3">67) </text>
<text top="680" left="555" width="255" height="19" font="3">5.3 % MACE (17 patients): VF on ICD (14), </text>
<text top="699" left="555" width="95" height="19" font="3">sudden death3 </text>
<text top="717" left="555" width="252" height="19" font="3">MACE occurred in 10.4% of symptomatic </text>
<text top="735" left="555" width="218" height="19" font="3">and 2.8% of asymptomatic patients </text>
<text top="753" left="555" width="62" height="19" font="3">(p=0.004) </text>
<text top="772" left="555" width="229" height="19" font="3">ICD’s implanted in 34%(110 patients) </text>
<text top="588" left="843" width="215" height="19" font="3">● Combining 2 or more risk factors </text>
<text top="606" left="843" width="177" height="19" font="3">was useful risk stratification: </text>
<text top="625" left="870" width="180" height="20" font="3">•  Spontaneous type 1 ECG </text>
<text top="644" left="870" width="180" height="20" font="3">•  Family Hx sudden death, </text>
<text top="663" left="897" width="134" height="19" font="3">syncope, positive PES </text>
<text top="681" left="816" width="3" height="19" font="3"> </text>
<text top="699" left="843" width="207" height="19" font="3">● MACE occurred only in patients </text>
<text top="718" left="843" width="208" height="19" font="3">with 2 or more risk factors. MACE </text>
<text top="736" left="843" width="80" height="19" font="3">event rates:  </text>
<text top="754" left="870" width="201" height="20" font="3">•  3.0%/pt/yr in symptomatic,  </text>
<text top="774" left="870" width="201" height="20" font="3">•  0.8%/pt/yr in asymptomatic </text>
</page>
<page number="194" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">194 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="365" width="3" height="19" font="3"> </text>
<text top="127" left="365" width="3" height="19" font="3"> </text>
<text top="145" left="365" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="109" left="555" width="273" height="19" font="3">PES performed in 245 (76%): positive in 50% </text>
<text top="127" left="555" width="260" height="19" font="3">of symptomatic and 32% of asymptomatic </text>
<text top="145" left="555" width="60" height="19" font="3">patients.  </text>
<text top="164" left="555" width="218" height="19" font="3">MACE in 14% of positive PES, 0% of </text>
<text top="182" left="555" width="273" height="19" font="3">negative, 5.3% of no EPS: positive predictive </text>
<text top="200" left="555" width="236" height="19" font="3">values 14%, negative pred value 100% </text>
<text top="219" left="555" width="231" height="19" font="3">VF occurred in 15.5% of patients with </text>
<text top="237" left="555" width="260" height="19" font="3">inducible VF using doubles, 8.6% of triples </text>
<text top="255" left="555" width="272" height="19" font="3">Combination of risk factors most significant: </text>
<text top="273" left="555" width="221" height="19" font="3">spont ECG, family Hx sudden death, </text>
<text top="292" left="555" width="273" height="19" font="3">syncope, positive EPS: no events occurred in </text>
<text top="310" left="555" width="263" height="19" font="3">patients without any of above or with only </text>
<text top="329" left="555" width="98" height="19" font="3">one risk factor.  </text>
<text top="347" left="555" width="258" height="19" font="3">Spontaneous type 1 ECG: if additional risk </text>
<text top="365" left="555" width="181" height="19" font="3">factors, 30% MACE (p&lt;0.001) </text>
<text top="109" left="816" width="3" height="19" font="3"> </text>
<text top="127" left="843" width="220" height="19" font="3">● PES can be useful in patients with </text>
<text top="145" left="843" width="197" height="19" font="3">spontaneous type 1 ECG and no </text>
<text top="164" left="843" width="222" height="19" font="3">other risk factors; may be helpful to </text>
<text top="182" left="843" width="153" height="19" font="3">identify low risk patients </text>
<text top="384" left="123" width="95" height="19" font="3">● Hiraoka M JE </text>
<text top="402" left="123" width="69" height="19" font="3">2013 (349) </text>
<text top="421" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23702150">● </a></text>
<text top="421" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23702150">23702150</a></text>
<text top="421" left="197" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23702150"><b> </b></a></text>
<text top="384" left="253" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="402" left="253" width="74" height="19" font="3">Prospective </text>
<text top="421" left="253" width="88" height="19" font="3">single center   </text>
<text top="439" left="253" width="3" height="19" font="3"> </text>
<text top="457" left="253" width="61" height="19" font="4"><b>Size:</b>    69<b> </b></text>
<text top="384" left="365" width="169" height="19" font="4"><b>Inclusion criteria:</b>  Brugada </text>
<text top="402" left="365" width="149" height="19" font="3">S patients ages 18–35 y  </text>
<text top="421" left="365" width="108" height="19" font="3">Mean age 30±6 y </text>
<text top="439" left="365" width="3" height="19" font="3"> </text>
<text top="457" left="365" width="114" height="19" font="3">No genetic testing </text>
<text top="476" left="365" width="3" height="19" font="3"> </text>
<text top="494" left="365" width="3" height="19" font="3"> </text>
<text top="512" left="365" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="385" left="555" width="266" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Brugada S ages 18-35 y at dx, </text>
<text top="403" left="555" width="143" height="19" font="3">outcomes of VF or SCD </text>
<text top="422" left="555" width="137" height="19" font="3">Followup 43±27 mos.  </text>
<text top="440" left="555" width="3" height="19" font="3"> </text>
<text top="458" left="555" width="258" height="19" font="4"><b>Results:</b>  Based on presenting symptoms:  </text>
<text top="476" left="555" width="262" height="19" font="3">VF 42%, syncope 12%, asymptomatic 2.5% </text>
<text top="495" left="555" width="266" height="19" font="3">Not predictive: gender, family Hx SCD, abnl </text>
<text top="513" left="555" width="262" height="19" font="3">SAECG, spontaneous vs drug-induced ECG, </text>
<text top="531" left="555" width="100" height="19" font="3">inducible VT/VF </text>
<text top="550" left="555" width="3" height="19" font="3"> </text>
<text top="568" left="555" width="212" height="19" font="3">All ages 460 patients symptoms at </text>
<text top="586" left="555" width="169" height="19" font="3">presentation vs outcomes:  </text>
<text top="605" left="555" width="262" height="19" font="3">VF 8.4%/y, Syncope 1.7%/y, asymptomatic </text>
<text top="623" left="555" width="46" height="19" font="3">0.3%/y </text>
<text top="641" left="555" width="3" height="19" font="4"><b> </b></text>
<text top="384" left="843" width="227" height="19" font="3">● Brugada outcomes in young adults </text>
<text top="402" left="843" width="159" height="19" font="3">vs presenting symptoms:  </text>
<text top="421" left="843" width="226" height="19" font="3">● Events: VF 11.2% /y, syncope 3.3% </text>
<text top="439" left="843" width="150" height="19" font="3">y, asymptomatic 0.7%/y </text>
<text top="457" left="843" width="3" height="19" font="3"> </text>
<text top="476" left="843" width="3" height="19" font="3"> </text>
<text top="494" left="843" width="3" height="19" font="3"> </text>
<text top="660" left="123" width="72" height="19" font="3">● <b>PRELUDE</b> </text>
<text top="679" left="123" width="106" height="19" font="3">● Priori SG et al.  </text>
<text top="697" left="123" width="67" height="19" font="3">JACC 2012 </text>
<text top="715" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22192666">● </a></text>
<text top="715" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22192666">22192666</a></text>
<text top="715" left="197" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22192666"><b> </b></a></text>
<text top="660" left="253" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="679" left="253" width="74" height="19" font="3">Prospective </text>
<text top="697" left="253" width="53" height="19" font="3">registry  </text>
<text top="715" left="253" width="3" height="19" font="3"> </text>
<text top="733" left="253" width="68" height="19" font="4"><b>Size:</b>   308 <b> </b></text>
<text top="660" left="365" width="167" height="19" font="4"><b>Inclusion criteria:</b>  Age &gt;18 </text>
<text top="679" left="365" width="145" height="19" font="3">y, BrS type 1 ECG spont </text>
<text top="697" left="365" width="146" height="19" font="3">(56%, 171/308) or drug-</text>
<text top="715" left="365" width="176" height="19" font="3">induced, without prior ACA;  </text>
<text top="733" left="365" width="3" height="19" font="3"> </text>
<text top="661" left="555" width="268" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Predictive accuracy of PES for </text>
<text top="679" left="555" width="243" height="19" font="3">sustained VT/VF or approp ICD shock in </text>
<text top="698" left="555" width="58" height="19" font="3">Brugada. </text>
<text top="716" left="555" width="3" height="19" font="3"> </text>
<text top="734" left="555" width="237" height="19" font="4"><b>Results: </b>PES performed at enrollment; </text>
<text top="753" left="555" width="136" height="19" font="3">followup every 6 mo.  </text>
<text top="771" left="555" width="123" height="19" font="3">Mean age 45±12 y.  </text>
<text top="660" left="843" width="186" height="19" font="3">● PES did not predict high risk </text>
<text top="679" left="843" width="218" height="19" font="3">● Predictors: spontaneous type BrS </text>
<text top="697" left="843" width="202" height="19" font="3">ECG and symptoms; f-QRS, VERP </text>
<text top="715" left="843" width="69" height="19" font="3">&lt;200 msec </text>
<text top="734" left="843" width="225" height="19" font="3">VERP &lt;200 msec was predictive: this </text>
<text top="752" left="843" width="226" height="19" font="3">data would only be obtained at EPS.  </text>
</page>
<page number="195" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">195 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="365" width="169" height="19" font="3">21% with prior syncope (65 </text>
<text top="127" left="365" width="157" height="19" font="3">patients: 16/65 {25%} &gt; 1 </text>
<text top="145" left="365" width="65" height="19" font="3">syncope).  </text>
<text top="164" left="365" width="3" height="19" font="3"> </text>
<text top="182" left="365" width="141" height="19" font="3">SCN5A positive 20% of </text>
<text top="200" left="365" width="102" height="19" font="3">tested patients.  </text>
<text top="219" left="365" width="3" height="19" font="3"> </text>
<text top="237" left="365" width="154" height="19" font="3">(f-QRS =2 or more spikes </text>
<text top="255" left="365" width="150" height="19" font="3">within QRS leads V1-V3: </text>
<text top="273" left="365" width="88" height="19" font="3">present 8.1%) </text>
<text top="292" left="365" width="3" height="19" font="3"> </text>
<text top="310" left="365" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="109" left="555" width="221" height="19" font="3">Cardiac arrest 4.5% (14/308), 13/14 </text>
<text top="127" left="555" width="185" height="19" font="3">resuscitated with ICD, EMS 1.  </text>
<text top="145" left="555" width="245" height="19" font="3">PES positive in 41% (126/308); of these: </text>
<text top="164" left="555" width="238" height="19" font="3">single stimulation 5.5%, double 44.5%, </text>
<text top="182" left="555" width="78" height="19" font="3">triples 50%.  </text>
<text top="200" left="555" width="243" height="19" font="3">ICD’s implanted in 137 patients (78% of </text>
<text top="219" left="555" width="269" height="19" font="3">inducible patients {98/126} and 21% of non-</text>
<text top="237" left="555" width="179" height="19" font="3">inducible patients {39/182}.   </text>
<text top="255" left="555" width="153" height="19" font="3">Annual event rate 1.5%:  </text>
<text top="273" left="555" width="3" height="19" font="3"> </text>
<text top="292" left="555" width="262" height="19" font="3">Multivariable predictors: spont type 1 ECG </text>
<text top="310" left="555" width="261" height="19" font="3">and Hx of syncope (HR: 4.20; 95% CI: 1.38–</text>
<text top="329" left="555" width="269" height="19" font="3">12.79, p=0.012), Ventricular ERP &lt;200 msec </text>
<text top="347" left="555" width="249" height="19" font="3">(HR: 3.91; 95% CI: 1.03–12.79, p=0.045), </text>
<text top="365" left="555" width="260" height="19" font="3"> QRS fractionation (HR: 4.94, 95% CI: 1.54–</text>
<text top="383" left="555" width="95" height="19" font="3">15.8, p=0.007). </text>
<text top="402" left="555" width="3" height="19" font="3"> </text>
<text top="420" left="555" width="261" height="19" font="3"> Positive PES not predictive (HR: 1.03; 95% </text>
<text top="438" left="555" width="137" height="19" font="3">CI: 0.34–3.16, p=0.96) </text>
<text top="109" left="843" width="216" height="19" font="3">● NOTE that + PES used in decision </text>
<text top="127" left="843" width="205" height="19" font="3">to implant ICD’s: 13/137 patients </text>
<text top="145" left="843" width="219" height="19" font="3">(9.5%) with ICD’s were resuscitated </text>
<text top="164" left="843" width="59" height="19" font="3">with ICD. </text>
<text top="182" left="843" width="3" height="19" font="3"> </text>
<text top="200" left="843" width="224" height="19" font="3">Note 1/14 patients with VF had only </text>
<text top="219" left="843" width="186" height="19" font="3">spont type 1 ECG and no prior </text>
<text top="237" left="843" width="200" height="19" font="3">syncope, neg family hx, neg EPS, </text>
<text top="255" left="843" width="183" height="19" font="3">VERP &gt;200 msec but + SCN5A </text>
<text top="273" left="843" width="231" height="19" font="3">mutation and received ICD after EPS.  </text>
<text top="292" left="843" width="210" height="19" font="3">Only 1 pt without ICD had ACA: pt </text>
<text top="310" left="843" width="199" height="19" font="3">had spont type 1 ECG, VRP &lt;200 </text>
<text top="329" left="843" width="105" height="19" font="3">msec, and fQRS.  </text>
<text top="457" left="123" width="97" height="19" font="3">● Wilde A et al. </text>
<text top="476" left="123" width="60" height="19" font="3">Circ 2016 </text>
<text top="494" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27566755">● </a></text>
<text top="494" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27566755">27566755</a></text>
<text top="494" left="197" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27566755"><b> </b></a></text>
<text top="457" left="253" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="476" left="253" width="74" height="19" font="3">multicenter </text>
<text top="494" left="253" width="87" height="19" font="3">observational </text>
<text top="512" left="253" width="3" height="19" font="3"> </text>
<text top="531" left="253" width="68" height="19" font="4"><b>Size:</b>   391 <b> </b></text>
<text top="457" left="365" width="149" height="19" font="4"><b>Inclusion criteria:</b>  LQT3 </text>
<text top="476" left="365" width="153" height="19" font="3">SCN5A mutation carriers </text>
<text top="494" left="365" width="3" height="19" font="3"> </text>
<text top="512" left="365" width="115" height="19" font="3">In 8%, first cardiac </text>
<text top="531" left="365" width="125" height="19" font="3">symptom: ACA, SCD </text>
<text top="549" left="365" width="3" height="19" font="3"> </text>
<text top="567" left="365" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="586" left="365" width="167" height="19" font="3">symptoms during first year </text>
<text top="604" left="365" width="119" height="19" font="3">of life-12 patients;  </text>
<text top="622" left="365" width="175" height="19" font="3">Lost to followup after age 1: </text>
<text top="640" left="365" width="68" height="19" font="3">3 patients; </text>
<text top="659" left="365" width="163" height="19" font="3"> Patients with 2 mutations<b> </b></text>
<text top="458" left="555" width="272" height="19" font="4"><b>1</b>°<b> endpoint:</b>  LQT3 ACE outcomes: syncope, </text>
<text top="476" left="555" width="60" height="19" font="3">ACA, SCD </text>
<text top="495" left="555" width="128" height="19" font="3">Median followup 7 y </text>
<text top="513" left="555" width="3" height="19" font="3"> </text>
<text top="531" left="555" width="261" height="19" font="4"><b>Results:</b>  Rx: B-bl 29%; LCSD 2%; pacer 5%; </text>
<text top="550" left="555" width="61" height="19" font="3">ICD 18%.  </text>
<text top="568" left="555" width="247" height="19" font="3">Time dependent increase in ACE: by age </text>
<text top="586" left="555" width="275" height="19" font="3">40yrs, ~40% with ACE. ~ 50% of ACE =ACA or </text>
<text top="605" left="555" width="27" height="19" font="3">SCD </text>
<text top="623" left="555" width="3" height="19" font="3"> </text>
<text top="641" left="555" width="263" height="19" font="3">B-blocker rx: 83% risk reduction in females </text>
<text top="660" left="555" width="265" height="19" font="3">(p=0.015); 49% risk reduction in males (not </text>
<text top="678" left="555" width="234" height="19" font="3">sig; too few events in males to assess) </text>
<text top="696" left="555" width="140" height="19" font="3">BB not pro-arrhythmic </text>
<text top="714" left="555" width="191" height="19" font="3">3% died on BB during followup </text>
<text top="733" left="555" width="244" height="19" font="3">Multivariate risk factors: QTc, syncope:  </text>
<text top="457" left="843" width="107" height="19" font="3">● High risk LQT3: </text>
<text top="476" left="843" width="58" height="19" font="3">Females; </text>
<text top="494" left="843" width="138" height="19" font="3">syncope, QTc 450-490 </text>
<text top="512" left="843" width="7" height="19" font="3">  </text>
<text top="531" left="843" width="193" height="19" font="3">● Hx of syncope—doubled risk  </text>
<text top="549" left="843" width="3" height="19" font="3"> </text>
<text top="567" left="843" width="210" height="20" font="3">• BB therapy significantly reduced </text>
<text top="586" left="843" width="209" height="19" font="3">risk for ACE, especially in females  </text>
<text top="605" left="843" width="3" height="19" font="3"> </text>
<text top="623" left="843" width="225" height="19" font="3">Mutation type/location did not have </text>
<text top="641" left="843" width="136" height="19" font="3">sig effect on outcome </text>
<text top="660" left="843" width="3" height="19" font="3"> </text>
</page>
<page number="196" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">196 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="555" width="244" height="19" font="3">Each 10 msec increase in QTc up to 500 </text>
<text top="127" left="555" width="259" height="19" font="3">msec associated with 19% increase in ACE </text>
<text top="145" left="555" width="226" height="19" font="3">(no further risk with QTc &gt;500 msec) </text>
<text top="164" left="123" width="101" height="19" font="3">● Probst V et al. </text>
<text top="183" left="123" width="108" height="19" font="3">Circ CV Gen 2009 </text>
<text top="201" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20031634">● </a></text>
<text top="201" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20031634">20031634</a></text>
<text top="201" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20031634"> </a></text>
<text top="164" left="253" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="183" left="253" width="74" height="19" font="3">multicenter </text>
<text top="201" left="253" width="91" height="19" font="3">retrospective   </text>
<text top="219" left="253" width="3" height="19" font="3"> </text>
<text top="237" left="253" width="68" height="19" font="4"><b>Size:</b>   115 <b> </b></text>
<text top="164" left="365" width="135" height="19" font="4"><b>Inclusion criteria:</b> BrS </text>
<text top="183" left="365" width="140" height="19" font="3">families with at least 5 </text>
<text top="201" left="365" width="163" height="19" font="3">family members genotype </text>
<text top="219" left="365" width="44" height="19" font="3">carries </text>
<text top="238" left="365" width="3" height="19" font="3"> </text>
<text top="256" left="365" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="165" left="555" width="220" height="19" font="4"><b>1</b>°<b> endpoint:</b>  BrS assoc with SCN5A </text>
<text top="183" left="555" width="3" height="19" font="3"> </text>
<text top="202" left="555" width="218" height="19" font="4"><b>Results:</b>  BrS ECG present in 47% of </text>
<text top="220" left="555" width="109" height="19" font="3">mutation carriers </text>
<text top="238" left="555" width="253" height="19" font="3">Mutation carriers had longer PR and QRS </text>
<text top="257" left="555" width="59" height="19" font="3">intervals  </text>
<text top="275" left="555" width="263" height="19" font="3">SCN5A mutations are not directly causal of </text>
<text top="293" left="555" width="94" height="19" font="3">Br pattern ECG </text>
<text top="311" left="555" width="3" height="19" font="4"><b> </b></text>
<text top="164" left="843" width="175" height="19" font="3">● Poor genotype phenotype </text>
<text top="183" left="843" width="163" height="19" font="3">correlation for BrS SCN5A  </text>
<text top="201" left="843" width="3" height="19" font="3"> </text>
<text top="219" left="843" width="3" height="19" font="3"> </text>
<text top="331" left="123" width="94" height="19" font="3">● Crotti L et al. </text>
<text top="349" left="123" width="62" height="19" font="3">ACC 2012 </text>
<text top="367" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22840528">● </a></text>
<text top="367" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22840528">22840528</a></text>
<text top="367" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22840528"> </a></text>
<text top="331" left="253" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="349" left="253" width="75" height="19" font="3">Multicenter </text>
<text top="367" left="253" width="85" height="19" font="3">retrospective </text>
<text top="386" left="253" width="68" height="19" font="4"><b>Size:</b>  129  <b> </b></text>
<text top="331" left="365" width="138" height="19" font="4"><b>Inclusion criteria: </b>BrS <b> </b></text>
<text top="331" left="555" width="256" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Genotype results Brugada S </text>
<text top="350" left="555" width="3" height="19" font="3"> </text>
<text top="368" left="555" width="211" height="19" font="4"><b>Results:</b>  20% putative pathogenic </text>
<text top="386" left="555" width="268" height="19" font="3">mutations, (95% in SCN5A; 5% other genes) </text>
<text top="405" left="555" width="261" height="19" font="3">Yield similar with type 1 Brugada ECG only </text>
<text top="423" left="555" width="238" height="19" font="3">(23%) and those with symptoms (17%) </text>
<text top="441" left="555" width="242" height="19" font="3">Prolonged PQ interval &gt; 200 msec: 38% </text>
<text top="460" left="555" width="255" height="19" font="3">positive vs 11% if PQ &lt; 200 ms, (OR 8, 1.5-</text>
<text top="478" left="555" width="23" height="19" font="3">16) </text>
<text top="331" left="843" width="222" height="19" font="3">● Brugada: no genotype/phenotype </text>
<text top="349" left="843" width="71" height="19" font="3">correlation </text>
<text top="367" left="843" width="3" height="19" font="5"><i> </i></text>
<text top="497" left="123" width="113" height="19" font="3">● Risgaard B et al. </text>
<text top="515" left="123" width="101" height="19" font="3">Clin Genet 2013 </text>
<text top="534" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23414114">● </a></text>
<text top="534" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23414114">23414114</a></text>
<text top="534" left="197" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23414114"><b> </b></a></text>
<text top="497" left="253" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="515" left="253" width="44" height="19" font="3">Exome </text>
<text top="534" left="253" width="73" height="19" font="3">Sequencing </text>
<text top="552" left="253" width="81" height="19" font="3">Project (ESP) </text>
<text top="570" left="253" width="61" height="19" font="3">analysis    </text>
<text top="589" left="253" width="3" height="19" font="3"> </text>
<text top="607" left="253" width="76" height="19" font="4"><b>Size:</b>    6258<b> </b></text>
<text top="497" left="365" width="165" height="19" font="4"><b>Inclusion criteria:</b>  Genetic </text>
<text top="515" left="365" width="122" height="19" font="3">variants of Brugada </text>
<text top="534" left="365" width="160" height="19" font="3">Syndrome searched for in </text>
<text top="552" left="365" width="75" height="19" font="3">exome data </text>
<text top="570" left="365" width="3" height="19" font="3"> </text>
<text top="588" left="365" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="498" left="555" width="221" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Identify prevalence of </text>
<text top="516" left="555" width="251" height="19" font="3">mutations associated with BrS in general </text>
<text top="534" left="555" width="45" height="19" font="3">exome </text>
<text top="553" left="555" width="231" height="19" font="3">BrS prevalence ~ 1:2000 to 1:100,000 </text>
<text top="571" left="555" width="3" height="19" font="3"> </text>
<text top="589" left="555" width="269" height="19" font="4"><b>Results:</b>  10% of variants identified in ESP, a </text>
<text top="608" left="555" width="111" height="19" font="3">frequency of 1:23 </text>
<text top="626" left="555" width="3" height="19" font="4"><b> </b></text>
<text top="497" left="843" width="215" height="19" font="3">● ~10% of variants associated with </text>
<text top="515" left="843" width="204" height="19" font="3">BrS are present in Exome, raising </text>
<text top="534" left="843" width="193" height="19" font="3">doubt about monogenic role in </text>
<text top="552" left="843" width="126" height="19" font="3">pathogenicity of BrS </text>
<text top="570" left="843" width="220" height="19" font="3">● Recommend using Exome data to </text>
<text top="589" left="843" width="170" height="19" font="3">establish gene frequency in </text>
<text top="607" left="843" width="70" height="19" font="3">population </text>
<text top="645" left="115" width="4" height="21" font="0"> </text>
<text top="701" left="115" width="624" height="21" font="2"><b>Data Supplement 40. Nonrandomized Trials Related to Congenital LQTS – (Section 7.9.1.1.) </b></text>
<text top="722" left="135" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="740" left="160" width="51" height="19" font="4"><b>Author; </b></text>
<text top="759" left="152" width="96" height="19" font="4"><b>Year Published</b> </text>
<text top="722" left="295" width="39" height="19" font="4"><b>Study </b></text>
<text top="740" left="271" width="86" height="19" font="4"><b>Type/Design; </b></text>
<text top="759" left="281" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="740" left="401" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="722" left="619" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="740" left="631" width="126" height="19" font="4"><b>(P values; OR or RR; </b></text>
<text top="759" left="663" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="731" left="893" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="749" left="935" width="80" height="19" font="4"><b>Comment(s)</b> </text>
</page>
<page number="197" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">197 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="103" height="19" font="3">● Garson AJ Circ </text>
<text top="127" left="123" width="69" height="19" font="3">1993 (350) </text>
<text top="145" left="123" width="9" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=%208099317">●</a></text>
<text top="145" left="132" width="57" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=%208099317"> 8099317</a></text>
<text top="144" left="189" width="4" height="21" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=%208099317"> </a></text>
<text top="109" left="262" width="81" height="19" font="4"><b>Study type:   </b></text>
<text top="127" left="262" width="87" height="19" font="3">Retrospective </text>
<text top="145" left="262" width="74" height="19" font="3">multicenter </text>
<text top="164" left="262" width="3" height="19" font="3"> </text>
<text top="182" left="262" width="68" height="19" font="4"><b>Size:</b>   287 <b> </b></text>
<text top="109" left="379" width="141" height="19" font="4"><b>Inclusion criteria</b>:  Age </text>
<text top="127" left="379" width="105" height="19" font="3">&lt;21y, QTc &gt;0.44, </text>
<text top="145" left="379" width="135" height="19" font="3">unexplained syncope, </text>
<text top="164" left="379" width="162" height="19" font="3">seizures, ACA triggered by </text>
<text top="182" left="379" width="145" height="19" font="3">emotion or exercise, or </text>
<text top="200" left="379" width="101" height="19" font="3">family Hx LQTS.  </text>
<text top="219" left="379" width="145" height="19" font="3">Mean age presentation </text>
<text top="237" left="379" width="33" height="19" font="3">8.8 y </text>
<text top="255" left="379" width="99" height="19" font="3">61% symptoms  </text>
<text top="273" left="379" width="105" height="19" font="3">9% ACA was first </text>
<text top="292" left="379" width="61" height="19" font="3">symptom </text>
<text top="310" left="379" width="3" height="19" font="4"><b> </b></text>
<text top="328" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="109" left="555" width="265" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ACA or SCD for LQTS children </text>
<text top="128" left="555" width="167" height="19" font="3">during Mean followup 5 y.  </text>
<text top="146" left="555" width="3" height="19" font="3"> </text>
<text top="164" left="555" width="259" height="19" font="4"><b>Results</b>:  Rx 68% BB, 8% other meds, LCSD </text>
<text top="183" left="555" width="72" height="19" font="3">2%, ICD 1% </text>
<text top="201" left="555" width="256" height="19" font="3">Med treatment effective for symptoms in </text>
<text top="219" left="555" width="138" height="19" font="3">76%, and for VEA 60% </text>
<text top="238" left="555" width="269" height="19" font="3">Symptoms in first mo of life high risk group: </text>
<text top="256" left="555" width="67" height="19" font="3">16% died.  </text>
<text top="274" left="555" width="276" height="19" font="3">Asymptomatic patients with normal QTc and </text>
<text top="293" left="555" width="273" height="19" font="3">positive family Hx may be low risk group (no </text>
<text top="311" left="555" width="121" height="19" font="3">genotyping results) </text>
<text top="329" left="555" width="225" height="19" font="3">Predictors highest risk: symptoms at </text>
<text top="348" left="555" width="203" height="19" font="3">presentation, propranolol failure<b> </b></text>
<text top="109" left="848" width="222" height="19" font="3">● QTc at presentation &gt;0.60 highest </text>
<text top="127" left="848" width="64" height="19" font="3">risk group </text>
<text top="145" left="848" width="155" height="19" font="3">● no difference between </text>
<text top="164" left="848" width="155" height="19" font="3">propranolol and atenolol </text>
<text top="182" left="848" width="227" height="19" font="3">● consider prophylactic treatment in </text>
<text top="200" left="848" width="201" height="19" font="3">asymptomatic patients with QTc </text>
<text top="219" left="848" width="37" height="19" font="3">&gt;0.44 </text>
<text top="237" left="848" width="3" height="19" font="3"> </text>
<text top="367" left="123" width="105" height="19" font="3">● Hobbs<b> </b>JB et al. </text>
<text top="385" left="123" width="107" height="19" font="3">JAMA 2006 (351) </text>
<text top="403" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16968849">● </a></text>
<text top="403" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16968849">16968849</a></text>
<text top="403" left="196" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16968849"><b> </b></a></text>
<text top="367" left="262" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="385" left="262" width="87" height="19" font="3">Retrospective </text>
<text top="403" left="262" width="74" height="19" font="3">multicenter </text>
<text top="422" left="262" width="3" height="19" font="3"> </text>
<text top="440" left="262" width="76" height="19" font="4"><b>Size:</b>    2772<b> </b></text>
<text top="367" left="379" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="385" left="379" width="126" height="19" font="3">Adolescents in LQTS </text>
<text top="403" left="379" width="157" height="19" font="3">Registry alive at age 10 y, </text>
<text top="422" left="379" width="142" height="19" font="3">followed until age 20 y </text>
<text top="440" left="379" width="3" height="19" font="3"> </text>
<text top="458" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="367" left="555" width="278" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ACA or SCD in adolescents with </text>
<text top="386" left="555" width="34" height="19" font="3">LQTS </text>
<text top="404" left="555" width="3" height="19" font="3"> </text>
<text top="422" left="555" width="220" height="19" font="4"><b>Results:</b>  81 patients w ACA, 45 SCD </text>
<text top="441" left="555" width="252" height="19" font="3">Significant risk factors: recent syncope in </text>
<text top="459" left="555" width="267" height="19" font="3">prior 2 y, HR: 11.7; QTc ≥ 530 msec HR: 2.3; </text>
<text top="477" left="555" width="258" height="19" font="3">males age 10-12 y, HR: 4; males = females </text>
<text top="496" left="555" width="82" height="19" font="3">ages 13–20 y </text>
<text top="514" left="555" width="259" height="19" font="3">Beta blocker therapy ↓by 64% in patients </text>
<text top="532" left="555" width="145" height="19" font="3">with syncope in last 2 y </text>
<text top="367" left="848" width="211" height="19" font="3">● Risk factors: syncope, QTc ≥ 530 </text>
<text top="385" left="848" width="155" height="19" font="3">msec, males age 10–12 y </text>
<text top="403" left="848" width="3" height="19" font="3"> </text>
<text top="422" left="848" width="3" height="19" font="3"> </text>
<text top="440" left="848" width="3" height="19" font="3"> </text>
<text top="551" left="123" width="94" height="19" font="3">● Goldenberg I<b> </b></text>
<text top="570" left="123" width="102" height="19" font="3">JACC 2011 (340)<b> </b></text>
<text top="588" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21185501">● </a></text>
<text top="588" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21185501">21185501</a></text>
<text top="588" left="196" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21185501"><b> </b></a></text>
<text top="551" left="262" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="570" left="262" width="75" height="19" font="3">Multicenter </text>
<text top="588" left="262" width="82" height="19" font="3">international </text>
<text top="606" left="262" width="53" height="19" font="3">registry, </text>
<text top="624" left="262" width="88" height="19" font="3">retrospective  </text>
<text top="643" left="262" width="3" height="19" font="3"> </text>
<text top="661" left="262" width="68" height="19" font="4"><b>Size:</b>  469  <b> </b></text>
<text top="551" left="379" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="570" left="379" width="155" height="19" font="3">Genotyped patients with </text>
<text top="588" left="379" width="125" height="19" font="3">LQTS: 3386 patients </text>
<text top="606" left="379" width="135" height="19" font="3">Normal QTc: ≤440 ms </text>
<text top="624" left="379" width="148" height="19" font="3">Prolonged QTc &gt;440 ms </text>
<text top="643" left="379" width="131" height="19" font="3">Unaffected: negative </text>
<text top="661" left="379" width="61" height="19" font="3">genotype </text>
<text top="680" left="379" width="3" height="19" font="3"> </text>
<text top="698" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="552" left="555" width="273" height="19" font="4"><b>1</b>°<b> endpoint:</b>  LQTS with normal QTc: risk for </text>
<text top="570" left="555" width="104" height="19" font="3">ACE: ACA or SCD </text>
<text top="589" left="555" width="3" height="19" font="3"> </text>
<text top="607" left="555" width="250" height="19" font="4"><b>Results:</b> <b> </b>Normal QTc =14% of total LQTS </text>
<text top="625" left="555" width="112" height="19" font="3">patients in study.  </text>
<text top="644" left="555" width="262" height="19" font="3">Normal QTc risk ACA/SCD =4%, lower than </text>
<text top="662" left="555" width="266" height="19" font="3">those with prolonged QTc (15%) but higher </text>
<text top="680" left="555" width="227" height="19" font="3">than genotype neg family members.  </text>
<text top="699" left="555" width="246" height="19" font="3">Increased risk: mutation characteristics; </text>
<text top="717" left="555" width="214" height="19" font="3">LQT1 vs LQTS 2, HR: 9.88; p=0.03;   </text>
<text top="735" left="555" width="267" height="19" font="3">Duration of QTc and gender important only </text>
<text top="753" left="555" width="180" height="19" font="3">in those with prolonged QTc. </text>
<text top="551" left="848" width="210" height="19" font="3">● Genotype positive patients with </text>
<text top="570" left="848" width="188" height="19" font="3">normal QTc =25% of genotype </text>
<text top="588" left="848" width="108" height="19" font="3">positive patients. </text>
<text top="606" left="848" width="213" height="19" font="3">● 4% ACA/SCD with normal QTc vs </text>
<text top="624" left="848" width="134" height="19" font="3">15% if prolonged QTc </text>
<text top="643" left="848" width="3" height="19" font="4"><b> </b></text>
</page>
<page number="198" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="25" size="12" family="Times" color="#5b9bd5"/>
<text top="803" left="585" width="29" height="21" font="0">198 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="106" height="19" font="3">● Priori SG NEJM </text>
<text top="127" left="123" width="69" height="19" font="3">2003 (352) </text>
<text top="145" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12736279">● </a></text>
<text top="145" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12736279">12736279</a></text>
<text top="145" left="196" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12736279"> </a></text>
<text top="109" left="262" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="127" left="262" width="91" height="19" font="3">Retrospective  </text>
<text top="145" left="262" width="3" height="19" font="3"> </text>
<text top="164" left="262" width="68" height="19" font="4"><b>Size:</b>  647  <b> </b></text>
<text top="109" left="379" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="127" left="379" width="132" height="19" font="3">Genotyped patients:  </text>
<text top="145" left="379" width="135" height="19" font="3">LQT1 60%, LQT2 32%, </text>
<text top="164" left="379" width="155" height="19" font="3">LQT3 8%, mean followup </text>
<text top="182" left="379" width="29" height="19" font="3">28 y </text>
<text top="200" left="379" width="3" height="19" font="3"> </text>
<text top="218" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="109" left="555" width="274" height="19" font="4"><b>1</b>°<b> endpoint:</b>  LQTS risk of ACE age &lt;40 y and </text>
<text top="128" left="555" width="201" height="19" font="3">before rx: syncope, ACA, sudden </text>
<text top="146" left="555" width="83" height="19" font="3">deathbefore  </text>
<text top="165" left="555" width="3" height="19" font="3"> </text>
<text top="183" left="555" width="251" height="19" font="4"><b>Results:</b>  Incidence ACE: LQT1 30%, LQT2 </text>
<text top="201" left="555" width="234" height="19" font="3">46%, LQT3 42%.    13% ACA or sudden </text>
<text top="219" left="555" width="140" height="19" font="3">deathbefore age 40 y,  </text>
<text top="238" left="555" width="172" height="19" font="3">Events highest among LQT2 </text>
<text top="256" left="555" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="848" width="151" height="19" font="3">● Genetic locus and QTc </text>
<text top="127" left="848" width="152" height="19" font="3">independent risk factors </text>
<text top="145" left="848" width="224" height="19" font="3">● QTc risk factor for LQT1 and LQT2, </text>
<text top="164" left="848" width="59" height="19" font="3">not LQT3 </text>
<text top="182" left="848" width="12" height="19" font="3">● </text>
<text top="275" left="123" width="123" height="19" font="3">● Wedekind H Eur J </text>
<text top="293" left="123" width="96" height="19" font="3">Ped 2009 (339) </text>
<text top="312" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19101729">● </a></text>
<text top="312" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19101729">19101729</a></text>
<text top="312" left="196" width="3" height="19" font="25"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19101729"> </a></text>
<text top="330" left="123" width="3" height="19" font="3"> </text>
<text top="275" left="262" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="293" left="262" width="87" height="19" font="3">Retrospective </text>
<text top="312" left="262" width="81" height="19" font="3">single center </text>
<text top="330" left="262" width="3" height="19" font="3"> </text>
<text top="348" left="262" width="61" height="19" font="4"><b>Size:</b>   83 <b> </b></text>
<text top="275" left="379" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="293" left="379" width="114" height="19" font="3">Genotype positive </text>
<text top="312" left="379" width="126" height="19" font="3">probands, age ≤16 y </text>
<text top="330" left="379" width="132" height="19" font="3">LQTS:  89% LQT1, 2,3 </text>
<text top="348" left="379" width="136" height="19" font="3">Mean QTc 510±74 ms </text>
<text top="367" left="379" width="153" height="19" font="3">61% symptoms: syncope </text>
<text top="385" left="379" width="152" height="19" font="3">49%, ACA 33%, SCD 18% </text>
<text top="403" left="379" width="95" height="19" font="3">78% with BB rx </text>
<text top="422" left="379" width="3" height="19" font="3"> </text>
<text top="440" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="276" left="555" width="278" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Recurrent syncope, ACA or SCD </text>
<text top="294" left="555" width="247" height="19" font="3">after dx LQTS.  Mean followup 5.9±4.7 y </text>
<text top="312" left="555" width="3" height="19" font="3"> </text>
<text top="331" left="555" width="277" height="19" font="4"><b>Results:</b>  92% treated: Followup: Propranolol </text>
<text top="349" left="555" width="224" height="19" font="3">79%, atenolol 20%, metoprolol 12%, </text>
<text top="367" left="555" width="261" height="19" font="3">bisoprolol 8%, pindolol 2%; mexiletine 4%  </text>
<text top="386" left="555" width="116" height="19" font="3">ICD 8%, pacer 5%.  </text>
<text top="404" left="555" width="267" height="19" font="3">31% recurrent symptoms: 14% ACA or SCD; </text>
<text top="422" left="555" width="83" height="19" font="3">syncope 86% </text>
<text top="441" left="555" width="271" height="19" font="3">Significant predictors: QTc &gt;500 ms, p=0.02, </text>
<text top="459" left="555" width="264" height="19" font="3">HR: 2.9; 95% CI: 1.2–7.3; prior syncope HR: </text>
<text top="477" left="555" width="267" height="19" font="3">4.04; 95% CI: 1.1–15, ACA HR: 11.7; 95% CI: </text>
<text top="496" left="555" width="113" height="19" font="3">3.1–43.4, p&lt;0.001<b> </b></text>
<text top="275" left="848" width="209" height="19" font="3">● Risk predictors: QTc &gt;500 msec, </text>
<text top="293" left="848" width="132" height="19" font="3">prior syncope or ACA </text>
<text top="312" left="848" width="204" height="19" font="3">● LQT2 highest rate SCD vs other </text>
<text top="330" left="848" width="3" height="19" font="3"> </text>
<text top="348" left="848" width="3" height="19" font="3"> </text>
<text top="515" left="123" width="120" height="19" font="3">● Jons C et al. JACC </text>
<text top="533" left="123" width="69" height="19" font="3">2010 (353)<b> </b></text>
<text top="551" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20170817">● </a></text>
<text top="551" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20170817">20170817</a></text>
<text top="551" left="196" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20170817"> </a></text>
<text top="515" left="262" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="533" left="262" width="87" height="19" font="3">Retrospective </text>
<text top="551" left="262" width="83" height="19" font="3">International </text>
<text top="570" left="262" width="90" height="19" font="3">LQTS Registry  </text>
<text top="588" left="262" width="3" height="19" font="3"> </text>
<text top="606" left="262" width="76" height="19" font="4"><b>Size:</b>    1059<b> </b></text>
<text top="515" left="379" width="148" height="19" font="4"><b>Inclusion criteria:</b>  LQTS </text>
<text top="533" left="379" width="156" height="19" font="3">patients, QTc ≥ 450 msec </text>
<text top="551" left="379" width="128" height="19" font="3">with syncope as first </text>
<text top="570" left="379" width="67" height="19" font="3">symptoms </text>
<text top="588" left="379" width="84" height="19" font="3">20% with ICD </text>
<text top="606" left="379" width="106" height="19" font="3">52 patients LCSD </text>
<text top="624" left="379" width="3" height="19" font="3"> </text>
<text top="643" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="515" left="555" width="257" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Risk of ACE in LQTS patients </text>
<text top="534" left="555" width="84" height="19" font="3">with syncope </text>
<text top="552" left="555" width="229" height="19" font="3">Severe = ACA, approp ICD shock, SCD </text>
<text top="570" left="555" width="3" height="19" font="3"> </text>
<text top="588" left="555" width="264" height="19" font="4"><b>Results:</b>  Lowest risk in patients with single </text>
<text top="607" left="555" width="228" height="19" font="3">syncope before rx; intermediate risk: </text>
<text top="625" left="555" width="218" height="19" font="3">multiple syncope before rx, HR: 1.8 </text>
<text top="644" left="555" width="242" height="19" font="3">Higher risk: syncope after BB rx: HR:3.6 </text>
<text top="662" left="555" width="269" height="19" font="3">p&lt;0.001. Does not state how many patients </text>
<text top="680" left="555" width="60" height="19" font="3">died/aca. </text>
<text top="515" left="848" width="192" height="19" font="3">● Recurrent syncope during BB </text>
<text top="533" left="848" width="220" height="19" font="3">treatment assoc with increased risk </text>
<text top="551" left="848" width="121" height="19" font="3">of recurrent events<b> </b></text>
<text top="570" left="848" width="213" height="19" font="3">●BB failure highest in children and </text>
<text top="588" left="848" width="51" height="19" font="3">females </text>
<text top="699" left="123" width="110" height="19" font="3">● Barsheshet Circ </text>
<text top="718" left="123" width="69" height="19" font="3">2012 (354) </text>
<text top="736" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22456477">● </a></text>
<text top="736" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22456477">22456477</a></text>
<text top="736" left="196" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22456477"> </a></text>
<text top="699" left="262" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="718" left="262" width="87" height="19" font="3">Retrospective </text>
<text top="736" left="262" width="87" height="19" font="3">observational </text>
<text top="754" left="262" width="3" height="19" font="3"> </text>
<text top="699" left="379" width="149" height="19" font="4"><b>Inclusion criteria:</b>  LQT1 </text>
<text top="718" left="379" width="126" height="19" font="3">genotyped patients, </text>
<text top="736" left="379" width="147" height="19" font="3">mutations KCNQ1, ages </text>
<text top="754" left="379" width="56" height="19" font="3">birth-40  </text>
<text top="773" left="379" width="3" height="19" font="3"> </text>
<text top="700" left="555" width="272" height="19" font="4"><b>1</b>°<b> endpoint:  </b>Risk for ACA/SCD vs. mutation </text>
<text top="718" left="555" width="102" height="19" font="3">location in LQT1 </text>
<text top="737" left="555" width="3" height="19" font="3"> </text>
<text top="755" left="555" width="227" height="19" font="4"><b>Results:</b>  105 events: 27 ACA, 78 SCD </text>
<text top="699" left="848" width="174" height="19" font="3">● LQT1 patients with C-loop </text>
<text top="718" left="848" width="180" height="19" font="3">mutations are at high risk for </text>
<text top="736" left="848" width="208" height="19" font="3">ACA/SCD, and derive pronounced </text>
<text top="754" left="848" width="156" height="19" font="3">benefit from b-blocker rx </text>
<text top="773" left="848" width="3" height="19" font="3"> </text>
</page>
<page number="199" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">199 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="262" width="68" height="19" font="4"><b>Size:</b>    860 </text>
<text top="127" left="262" width="53" height="19" font="3">patients </text>
<text top="109" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="109" left="555" width="274" height="19" font="3">C-loop mutations highest risk (HR: 2.75; 95% </text>
<text top="127" left="555" width="144" height="19" font="3">CI: 1.29–5.86, p=0.009) </text>
<text top="145" left="555" width="274" height="19" font="3">B-bl treatment sig greater risk reduction in C </text>
<text top="164" left="555" width="279" height="19" font="3">loop mutations (HR: 0.12; 95% CI:  0.02–0.73, </text>
<text top="182" left="555" width="278" height="19" font="3">p=0.02) vs all other mutations (HR: 0.82; 95% </text>
<text top="200" left="555" width="137" height="19" font="3">CI: 0.31–2.13, p=0.68) </text>
<text top="219" left="555" width="257" height="19" font="3">C-loop mutations showed sig reduction in </text>
<text top="237" left="555" width="218" height="19" font="3">channel activation in response to b-</text>
<text top="255" left="555" width="141" height="19" font="3">adrenergic stimulation </text>
<text top="109" left="848" width="3" height="19" font="3"> </text>
<text top="127" left="848" width="3" height="19" font="3"> </text>
<text top="274" left="123" width="114" height="19" font="3">● Vincent GM Circ </text>
<text top="292" left="123" width="30" height="19" font="3">2009</text>
<text top="291" left="153" width="4" height="21" font="0"> </text>
<text top="292" left="157" width="35" height="19" font="3">(355) </text>
<text top="311" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19118258">● </a></text>
<text top="311" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19118258">19118258</a></text>
<text top="311" left="196" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19118258"> </a></text>
<text top="274" left="262" width="81" height="19" font="3"> <b>Study type:</b>  </text>
<text top="292" left="262" width="87" height="19" font="3">Retrospective </text>
<text top="311" left="262" width="93" height="19" font="3">observational   </text>
<text top="329" left="262" width="3" height="19" font="3"> </text>
<text top="347" left="262" width="58" height="19" font="4"><b>Size: </b>216<b> </b></text>
<text top="366" left="262" width="17" height="19" font="3">     </text>
<text top="274" left="379" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="292" left="379" width="162" height="19" font="3">Genotype + LQT1 patients </text>
<text top="311" left="379" width="137" height="19" font="3">treatment with BB for </text>
<text top="329" left="379" width="129" height="19" font="3">minimum 2 y (unless </text>
<text top="347" left="379" width="107" height="19" font="3">CA/SCD), median </text>
<text top="366" left="379" width="140" height="19" font="3">followup 10 y. Median </text>
<text top="384" left="379" width="114" height="19" font="3">age 26 y (4–76 y);  </text>
<text top="402" left="379" width="149" height="19" font="3">73% symptomatic; prior </text>
<text top="421" left="379" width="149" height="19" font="3">CA in 12% (26 patients). </text>
<text top="439" left="379" width="136" height="19" font="3">Mean QTc 495±48 ms </text>
<text top="457" left="379" width="3" height="19" font="3"> </text>
<text top="476" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="275" left="555" width="279" height="19" font="4"><b>1</b>°<b> endpoint:</b> ACE (syncope, CA, SCD) in LQT 1 </text>
<text top="293" left="555" width="116" height="19" font="3">treatment with BB </text>
<text top="312" left="555" width="3" height="19" font="3"> </text>
<text top="330" left="555" width="182" height="19" font="4"><b>Results:</b>  75% asymptomatic.  </text>
<text top="348" left="555" width="64" height="19" font="3">ACE 25%.  </text>
<text top="367" left="555" width="259" height="19" font="3">5.5% CA/SCD (12 patients) after rx:  11/12 </text>
<text top="385" left="555" width="256" height="19" font="3">non-compliant or on QT prolonging med.  </text>
<text top="403" left="555" width="261" height="19" font="3">None of 26 patients with prior CA had SCD </text>
<text top="422" left="555" width="153" height="19" font="3">on beta-bl, one had CA.   </text>
<text top="440" left="555" width="272" height="19" font="3">Risk for CE reduced to 0.06 CE/y (0.05–0.07) </text>
<text top="458" left="555" width="3" height="19" font="3"> </text>
<text top="274" left="848" width="213" height="19" font="3">● Risk for CA in compliant patients </text>
<text top="292" left="848" width="208" height="19" font="3">&lt;&lt;&lt; non-compliant (OR:0.03; 95% </text>
<text top="311" left="848" width="152" height="19" font="3">CI: 0.003–0.22, p=0.001) </text>
<text top="329" left="848" width="209" height="19" font="3">● Beta-bl meds approp treatment </text>
<text top="347" left="848" width="217" height="19" font="3">for asxy patients, and symptomatic </text>
<text top="366" left="848" width="186" height="19" font="3">patients who have not had CA </text>
<text top="384" left="848" width="97" height="19" font="3">before b-bl rx.   </text>
<text top="402" left="848" width="195" height="19" font="3">● Risk of CA/SCD on beta bl not </text>
<text top="421" left="848" width="206" height="19" font="3">assoc with baseline QTc nor prior </text>
<text top="439" left="848" width="93" height="19" font="3">syx nor gender </text>
<text top="457" left="848" width="210" height="19" font="3">● LQT1 patients with prior CA had </text>
<text top="476" left="848" width="169" height="19" font="3">very low risk CA/SCD on BB<b> </b></text>
<text top="495" left="123" width="125" height="19" font="3">● Moss AJ Circ 2000 </text>
<text top="513" left="123" width="35" height="19" font="3">(344)<b> </b></text>
<text top="531" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10673253">● </a></text>
<text top="531" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10673253">10673253</a></text>
<text top="531" left="196" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10673253"> </a></text>
<text top="495" left="262" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="513" left="262" width="87" height="19" font="3">Retrospective </text>
<text top="531" left="262" width="87" height="19" font="3">observational </text>
<text top="550" left="262" width="3" height="19" font="3"> </text>
<text top="568" left="262" width="68" height="19" font="4"><b>Size:</b> 869   <b> </b></text>
<text top="495" left="379" width="149" height="19" font="4"><b>Inclusion criteria:</b>  LQTS </text>
<text top="513" left="379" width="122" height="19" font="3">registry, Rochester, </text>
<text top="531" left="379" width="152" height="19" font="3">patients treatment w BB </text>
<text top="550" left="379" width="148" height="19" font="3">age &lt;41 y, 80% syncope </text>
<text top="568" left="379" width="114" height="19" font="3">or ACA prior to rx. </text>
<text top="586" left="379" width="134" height="19" font="3">Atenolol, metoprolol, </text>
<text top="605" left="379" width="135" height="19" font="3">nadolol, propranolol.  </text>
<text top="623" left="379" width="154" height="19" font="3">139/869 genotyped: LQT </text>
<text top="641" left="379" width="147" height="19" font="3">1(69), LQT 2 (42), LQT 3 </text>
<text top="660" left="379" width="28" height="19" font="3">(28) </text>
<text top="678" left="379" width="138" height="19" font="4"><b>Exclusion criteria:</b> age </text>
<text top="696" left="379" width="83" height="19" font="3">&gt;41 y start rx<b> </b></text>
<text top="495" left="555" width="266" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Recurrent CE on b-bl in LQTS<b> </b> </text>
<text top="514" left="555" width="3" height="19" font="3"> </text>
<text top="532" left="555" width="264" height="19" font="4"><b>Results:</b> B-Bl significantly reduce risk LQT 1 </text>
<text top="550" left="555" width="41" height="19" font="3">and 2; </text>
<text top="569" left="555" width="107" height="19" font="3"> LQT 3: no effect  </text>
<text top="587" left="555" width="231" height="19" font="3"> For symptomatic patients, HR 5.8 for </text>
<text top="605" left="555" width="207" height="19" font="3">recurrent CE: 32% ACE within 5 y. </text>
<text top="624" left="555" width="148" height="19" font="3">Prior syncope: HR: 3.1.   </text>
<text top="642" left="555" width="278" height="19" font="3">Prior ACA, HR: 12.9 for ACA or sudden death: </text>
<text top="660" left="555" width="118" height="19" font="3">14% recurrent CA.<b>  </b></text>
<text top="495" left="848" width="205" height="19" font="3">● For LQT 1 and 2, BB reduce risk </text>
<text top="513" left="848" width="223" height="19" font="3">● Highly symptomatic patients prior </text>
<text top="531" left="848" width="173" height="19" font="3">to treatment at high risk for </text>
<text top="550" left="848" width="112" height="19" font="3">recurrent events.  </text>
<text top="568" left="848" width="220" height="19" font="3">● LQT 3 patients: BB did not reduce </text>
<text top="586" left="848" width="25" height="19" font="3">risk </text>
</page>
<page number="200" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">200 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="124" height="19" font="3">● Abu-Zeitone JACC </text>
<text top="127" left="123" width="69" height="19" font="3">2014 (356) </text>
<text top="145" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25257637">● </a></text>
<text top="145" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25257637">25257637</a></text>
<text top="145" left="196" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25257637"> </a></text>
<text top="109" left="262" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="127" left="262" width="87" height="19" font="3">Retrospective </text>
<text top="145" left="262" width="74" height="19" font="3">multicenter </text>
<text top="164" left="262" width="3" height="19" font="3"> </text>
<text top="182" left="262" width="79" height="19" font="4"><b>Size:</b>    1530  </text>
<text top="109" left="379" width="118" height="19" font="4"><b>Inclusion criteria:</b> <b> </b> </text>
<text top="127" left="379" width="155" height="19" font="3">Patients in LQTS registry, </text>
<text top="145" left="379" width="154" height="19" font="3">Rochester, NY treatment </text>
<text top="164" left="379" width="147" height="19" font="3">with BB: atenolol (441), </text>
<text top="182" left="379" width="111" height="19" font="3">metoprolol (151), </text>
<text top="200" left="379" width="114" height="19" font="3">propranolol (679), </text>
<text top="219" left="379" width="153" height="19" font="3">nadolol (259), age &lt;40 y, </text>
<text top="237" left="379" width="52" height="19" font="3">no AICD </text>
<text top="255" left="379" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="273" left="379" width="137" height="19" font="3">simultaneous use of 2 </text>
<text top="292" left="379" width="86" height="19" font="3">beta Blockers </text>
<text top="109" left="555" width="261" height="19" font="4"><b>1</b>°<b> endpoint:</b>  First cardiac event: syncope, </text>
<text top="128" left="555" width="218" height="19" font="3">CA, sudden deathafter starting b-bl </text>
<text top="146" left="555" width="3" height="19" font="3"> </text>
<text top="164" left="555" width="271" height="19" font="4"><b>Results:</b>  LQT 1: risk reduction 57% any b-bl, </text>
<text top="183" left="555" width="148" height="19" font="3">no differential efficacy.  </text>
<text top="201" left="555" width="223" height="19" font="3">LQT2: nadolol only med with sig risk </text>
<text top="219" left="555" width="122" height="19" font="3">reduction (HR: 0.4)  </text>
<text top="238" left="555" width="3" height="19" font="3"> </text>
<text top="109" left="848" width="185" height="19" font="3">● All BB reduce risk of events, </text>
<text top="127" left="848" width="120" height="19" font="3">without difference  </text>
<text top="145" left="848" width="176" height="19" font="3">● In LQT 2 nadolol appeared </text>
<text top="164" left="848" width="118" height="19" font="3">superior (HR: 0.40) </text>
<text top="182" left="848" width="224" height="19" font="3">● For patients with recurrent events </text>
<text top="200" left="848" width="226" height="19" font="3">on beta-bl, propranolol offered least </text>
<text top="219" left="848" width="132" height="19" font="3">protection (HR: 0.52) </text>
<text top="237" left="848" width="3" height="19" font="3"> </text>
<text top="311" left="123" width="118" height="19" font="3">● Goldenberg I JCE </text>
<text top="329" left="123" width="69" height="19" font="3">2010 (357) </text>
<text top="347" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20233272">● </a></text>
<text top="347" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20233272">20233272</a></text>
<text top="347" left="196" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20233272"><b> </b></a></text>
<text top="311" left="262" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="329" left="262" width="87" height="19" font="3">Retrospective </text>
<text top="347" left="262" width="87" height="19" font="3">observational </text>
<text top="366" left="262" width="80" height="19" font="3">Multi-center </text>
<text top="384" left="262" width="3" height="19" font="3"> </text>
<text top="402" left="262" width="76" height="19" font="4"><b>Size:</b>    1393<b> </b></text>
<text top="311" left="379" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="329" left="379" width="141" height="19" font="3">Genotyped LQT1 (971) </text>
<text top="347" left="379" width="149" height="19" font="3">and LQT2 (422) patients </text>
<text top="366" left="379" width="131" height="19" font="3">in International LQTS </text>
<text top="384" left="379" width="156" height="19" font="3">registry. Ages Birth-40 y.  </text>
<text top="402" left="379" width="3" height="19" font="3"> </text>
<text top="421" left="379" width="143" height="19" font="3">ICD 129 patients (LQT1 </text>
<text top="439" left="379" width="139" height="19" font="3">50, 9%; LQT2 79, 19%) </text>
<text top="457" left="379" width="3" height="19" font="3"> </text>
<text top="476" left="379" width="144" height="19" font="3">LCSD 31 patients, LQT1 </text>
<text top="494" left="379" width="82" height="19" font="3">3%, LQT2 4% </text>
<text top="512" left="379" width="3" height="19" font="3"> </text>
<text top="531" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="311" left="555" width="235" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Age related, gender and </text>
<text top="330" left="555" width="228" height="19" font="3">genotype specific risk factors for ACE </text>
<text top="348" left="555" width="236" height="19" font="3">(syncope, approp shock, ACA, or SCD)  </text>
<text top="367" left="555" width="215" height="19" font="4"><b>Results:</b>  ACE LQT1 39%, LQT2 46% </text>
<text top="385" left="555" width="83" height="19" font="3">Risk for ACE:  </text>
<text top="403" left="555" width="253" height="20" font="3">•  Ages 0–14 y, LQT1 genotype vs LQT2 </text>
<text top="422" left="582" width="241" height="19" font="3">(HR: 1.49; 95% CI: 1.14–1.93, p&lt;0.003); </text>
<text top="441" left="582" width="223" height="19" font="3">males vs females (HR: 1.31, p=0.04)  </text>
<text top="459" left="555" width="263" height="20" font="3">•  Ages 15–40 y, LQT2 vs LQT1, (HR 1.67; </text>
<text top="478" left="582" width="249" height="19" font="3">95% CI: 1.31–2.13, p&lt;0.001); females vs. </text>
<text top="496" left="582" width="214" height="19" font="3">males HR: 2.58; 95% CI: 1.90–3.49, </text>
<text top="515" left="582" width="58" height="19" font="3">p&lt;0.001) </text>
<text top="533" left="555" width="270" height="20" font="3">•  QTC≥500 msec at increased risk in both </text>
<text top="552" left="582" width="243" height="19" font="3">age groups: 0–14 y, HR: 2.3 (p&lt;0.0001); </text>
<text top="570" left="582" width="197" height="19" font="3">age 15–40 y, HR: 2.22 (p&lt;0.001) </text>
<text top="589" left="555" width="268" height="20" font="3">•  Treatment in LQT1: atenolol decreased </text>
<text top="608" left="582" width="200" height="19" font="3">risk HR: 0.23; 95% CI: 0.08–0.67, </text>
<text top="626" left="582" width="225" height="19" font="3">p=0.008) nadolol was not associated </text>
<text top="644" left="582" width="242" height="19" font="3">with sig risk reduction<i> </i>(HR: 0.4; 95% CI: </text>
<text top="663" left="582" width="118" height="19" font="3">0.14–1.16, p=0.09) </text>
<text top="681" left="555" width="275" height="20" font="3">•  Treatment in LQT2: nadolol reduced risk </text>
<text top="700" left="582" width="237" height="19" font="3">(HR: 0.13; 95% CI:  0.03–0.62, p=0.01); </text>
<text top="719" left="582" width="246" height="19" font="3">atenolol did not (HR: 0.69; 95% CI: 0.32–</text>
<text top="737" left="582" width="84" height="19" font="3">1.49, p=0.34) </text>
<text top="755" left="555" width="239" height="20" font="3">•  ACA or SCD rarely occurred during </text>
<text top="774" left="582" width="143" height="19" font="3">treatment with beta-bl </text>
<text top="311" left="848" width="207" height="19" font="3">● B-blockers reduced risk in LQT1 </text>
<text top="329" left="848" width="41" height="19" font="3">and 2: </text>
<text top="352" left="880" width="9" height="12" font="3">o</text>
<text top="351" left="889" width="4" height="14" font="3"> </text>
<text top="347" left="907" width="148" height="19" font="3">LQT1 atenolol &gt; nadolol </text>
<text top="371" left="880" width="9" height="12" font="3">o</text>
<text top="369" left="889" width="4" height="14" font="3"> </text>
<text top="366" left="907" width="148" height="19" font="3">LQT2 nadolol &gt; atenolol </text>
<text top="384" left="848" width="3" height="19" font="3"> </text>
<text top="402" left="848" width="184" height="19" font="3">● ACA/SCD rarely occurred as </text>
<text top="421" left="848" width="197" height="19" font="3">presenting symptom in patients </text>
<text top="439" left="848" width="123" height="19" font="3">treatment with b-bl </text>
<text top="457" left="848" width="223" height="19" font="3">● QTc ≥ 500 msec increased risk HR: </text>
<text top="476" left="848" width="49" height="19" font="3">2.2–2.3 </text>
<text top="494" left="848" width="203" height="19" font="3">● Syncope during b-bl treatment </text>
<text top="512" left="848" width="213" height="19" font="3">assoc with increased risk ACA/SCD </text>
<text top="531" left="848" width="222" height="19" font="3">● Recommend BB therapy routinely </text>
<text top="549" left="848" width="185" height="19" font="3">to all high-risk LQT1 and LQT2 </text>
<text top="567" left="848" width="214" height="19" font="3">patients without contraindications </text>
<text top="586" left="848" width="59" height="19" font="3">as first rx </text>
<text top="604" left="848" width="226" height="19" font="3">● 1° AICD therapy recommended for </text>
<text top="622" left="848" width="191" height="19" font="3">those with syncope during b-bl </text>
<text top="640" left="848" width="51" height="19" font="3">therapy </text>
</page>
<page number="201" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">201 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="555" width="237" height="20" font="3">•   Patients with syncope during b-bl </text>
<text top="128" left="582" width="244" height="19" font="3">treatment had rel high rate subsequent </text>
<text top="146" left="582" width="202" height="19" font="3">ADA/SCD (&gt;1 event per 100 pt-y. </text>
<text top="311" left="123" width="100" height="19" font="3">● Sauer AJ JACC </text>
<text top="330" left="123" width="69" height="19" font="3">2007 (358) </text>
<text top="348" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17239714">● </a></text>
<text top="348" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17239714">17239714</a></text>
<text top="348" left="196" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17239714"><b> </b></a></text>
<text top="311" left="262" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="330" left="262" width="88" height="19" font="3">retrospective <b> </b></text>
<text top="348" left="262" width="3" height="19" font="4"><b> </b></text>
<text top="366" left="262" width="3" height="19" font="4"><b> </b></text>
<text top="384" left="262" width="3" height="19" font="4"><b> </b></text>
<text top="403" left="262" width="58" height="19" font="4"><b>Size: </b>812<b> </b></text>
<text top="311" left="379" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="330" left="379" width="148" height="19" font="3">Genotype positive LQTS </text>
<text top="348" left="379" width="100" height="19" font="3">adults ≥18 y old </text>
<text top="366" left="379" width="83" height="19" font="3">8% prior ACA </text>
<text top="384" left="379" width="3" height="19" font="3"> </text>
<text top="403" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="312" left="555" width="230" height="19" font="4"><b>1</b>°<b> endpoint:</b> ACE: syncope, ACA, SCD </text>
<text top="330" left="555" width="189" height="19" font="3">between ages 18-40 y in LQTS  </text>
<text top="349" left="555" width="3" height="19" font="3"> </text>
<text top="367" left="555" width="275" height="19" font="4"><b>Results:</b>  Risk predictors: ACA or SCD: female </text>
<text top="385" left="555" width="254" height="19" font="3">gender HR: 32.68; QTc ≥500 ms HR: 3.34; </text>
<text top="404" left="555" width="266" height="19" font="3">QTc ≥550 msec HR: 6.35; syncope after age </text>
<text top="422" left="555" width="84" height="19" font="3">18y, HR: 5.10 </text>
<text top="440" left="555" width="272" height="19" font="3">LQT2 33% recurrent ACE. LQT1 highest prior </text>
<text top="458" left="555" width="80" height="19" font="3">events 34%.  </text>
<text top="477" left="555" width="257" height="19" font="3">BB reduced risk ACA, SCD by 60%; highest </text>
<text top="495" left="555" width="261" height="19" font="3">benefit in QTc ≥500 msec, LQT1 and LQT2. </text>
<text top="311" left="848" width="206" height="19" font="3">● Highest risk: females, QTc &gt;500 </text>
<text top="330" left="848" width="179" height="19" font="3">msec, syncope after age 18 y </text>
<text top="348" left="848" width="114" height="19" font="3">● LQT2 higher risk </text>
<text top="366" left="848" width="8" height="20" font="0">•</text>
<text top="368" left="855" width="213" height="19" font="3"> QTc ≤499 msec did not contribute </text>
<text top="387" left="848" width="159" height="19" font="3">to higher risk lethal event </text>
<text top="514" left="123" width="94" height="19" font="3">● Steinberg C J </text>
<text top="532" left="123" width="123" height="19" font="3">Interv Card EP 2016 </text>
<text top="551" left="123" width="35" height="19" font="3">(359) </text>
<text top="569" left="123" width="9" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2027394160">●</a></text>
<text top="569" left="132" width="64" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2027394160"> 27394160</a></text>
<text top="569" left="196" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2027394160"> </a></text>
<text top="514" left="262" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="532" left="262" width="84" height="19" font="3">retrospective </text>
<text top="551" left="262" width="44" height="19" font="3">cohort </text>
<text top="569" left="262" width="3" height="19" font="3"> </text>
<text top="587" left="262" width="68" height="19" font="4"><b>Size:</b>    114<b> </b></text>
<text top="514" left="379" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="532" left="379" width="149" height="19" font="3">Genotype positive LQT1 </text>
<text top="551" left="379" width="128" height="19" font="3">(62%) or LQT2 (38%) </text>
<text top="569" left="379" width="143" height="19" font="3">treated with bisoprolol </text>
<text top="587" left="379" width="118" height="19" font="3">52%, (59 patients), </text>
<text top="606" left="379" width="105" height="19" font="3">nadolol 14%, (16 </text>
<text top="624" left="379" width="161" height="19" font="3">patients) or atenolol 34%, </text>
<text top="642" left="379" width="84" height="19" font="3">(39 patients)  </text>
<text top="661" left="379" width="81" height="19" font="3">59% females </text>
<text top="679" left="379" width="3" height="19" font="4"><b> </b></text>
<text top="697" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="515" left="555" width="206" height="19" font="4"><b>1</b>°<b> endpoint:</b>  syncope, SCD, ACA, </text>
<text top="533" left="555" width="265" height="19" font="3">documented polymorphic VT LQT1 or 2, on </text>
<text top="552" left="555" width="20" height="19" font="3">BB </text>
<text top="570" left="555" width="244" height="19" font="3"> Median followup 3 y for bisoprolol and </text>
<text top="588" left="555" width="204" height="19" font="3">nadolol; 6 y for atenolol (p=0.03) </text>
<text top="607" left="555" width="3" height="19" font="3"> </text>
<text top="625" left="555" width="276" height="19" font="4"><b>Results:</b>  Symptoms: 29%: syncope 27%, ACA </text>
<text top="643" left="555" width="253" height="19" font="3">3.5%, documented VT; ICD’s 7%.  Dosing: </text>
<text top="661" left="555" width="272" height="19" font="3">bisoprolol 5 mg, nadolol 65–80 mg, atenolol </text>
<text top="680" left="555" width="41" height="19" font="3">55 mg </text>
<text top="698" left="555" width="238" height="19" font="3">Nadolol patients highest proportion of </text>
<text top="716" left="555" width="204" height="19" font="3">probands vs bisoprolol (p=0.007) </text>
<text top="735" left="555" width="265" height="19" font="3">QTc shortening greater with bisoprolol and </text>
<text top="753" left="555" width="268" height="19" font="3">nadolol, vs. atenolol; QTc reduction greater </text>
<text top="771" left="555" width="269" height="19" font="3">in nadolol vs. atenolol, similar to bisoprolol  </text>
<text top="514" left="848" width="162" height="19" font="3">● Bisoprolol (selective b-1 </text>
<text top="532" left="848" width="192" height="19" font="3">antagonist) well-tolerated, and </text>
<text top="551" left="848" width="202" height="19" font="3">shortened QTc similar to nadolol </text>
<text top="569" left="848" width="218" height="19" font="3">● not powered to assess difference </text>
<text top="587" left="848" width="34" height="19" font="3">in BB </text>
<text top="606" left="848" width="3" height="19" font="3"> </text>
</page>
<page number="202" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">202 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="555" width="232" height="19" font="3">Cumulative incidence ACE 0.5%/pt-y.  </text>
<text top="127" left="555" width="253" height="19" font="3">ACA in one pt on bisoprolol; syncope in 2 </text>
<text top="145" left="555" width="235" height="19" font="3">patients with atenolol; no events with </text>
<text top="164" left="555" width="49" height="19" font="3">nadolol </text>
<text top="182" left="555" width="246" height="19" font="3">NO difference events bisoprolol 0.4% vs </text>
<text top="200" left="555" width="131" height="19" font="3">other b-blocker 0.6% </text>
<text top="219" left="123" width="111" height="19" font="3">● Nannenberg EA </text>
<text top="238" left="123" width="102" height="19" font="3">Circ CV Genetics </text>
<text top="256" left="123" width="69" height="19" font="3">2012 (336) </text>
<text top="274" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22373669">● </a></text>
<text top="274" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22373669">22373669</a></text>
<text top="274" left="196" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22373669"><b> </b></a></text>
<text top="219" left="262" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="238" left="262" width="87" height="19" font="3">Retrospective </text>
<text top="256" left="262" width="85" height="19" font="3">single center, </text>
<text top="274" left="262" width="82" height="19" font="3">Netherlands  </text>
<text top="292" left="262" width="3" height="19" font="3"> </text>
<text top="311" left="262" width="45" height="19" font="4"><b>Size:</b>    <b> </b></text>
<text top="219" left="379" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="238" left="379" width="125" height="19" font="3">Genotype positive 6 </text>
<text top="256" left="379" width="130" height="19" font="3">inherited arrhythmia </text>
<text top="274" left="379" width="158" height="19" font="3">syndromes analyzed with </text>
<text top="293" left="379" width="134" height="19" font="3">Family Tree Mortality </text>
<text top="311" left="379" width="90" height="19" font="3">Ratio (FTMR):  </text>
<text top="329" left="379" width="116" height="19" font="3">LQT1,2,3; Brugada </text>
<text top="347" left="379" width="113" height="19" font="3">Syndrome, SCN5A </text>
<text top="366" left="379" width="157" height="19" font="3">overlap syndrome (LQT3, </text>
<text top="384" left="379" width="156" height="19" font="3">BrS, conduction disease); </text>
<text top="402" left="379" width="77" height="19" font="3">RYR2 CPVT.  </text>
<text top="421" left="379" width="3" height="19" font="3"> </text>
<text top="439" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="220" left="555" width="278" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Using FTMR method to achieve </text>
<text top="238" left="555" width="215" height="19" font="3">Standardized Mortality Ratio(SMR) </text>
<text top="257" left="555" width="279" height="19" font="3">(observed to expected mortality by genotype </text>
<text top="275" left="555" width="202" height="19" font="3">and age in inherited arrhythmias </text>
<text top="293" left="555" width="3" height="19" font="3"> </text>
<text top="311" left="555" width="264" height="19" font="4"><b>Results:</b>  LQTS1: in first 10 y of life SMR 2.9 </text>
<text top="330" left="555" width="58" height="19" font="3">(1.5–5.1) </text>
<text top="348" left="555" width="231" height="19" font="3">LQTS2: age 30-39 y, SMR 4.0 (1.1–10) </text>
<text top="367" left="555" width="239" height="19" font="3">LQTS3: age 15-19 y, SMR 5.8(1.2–16.9) </text>
<text top="385" left="555" width="268" height="19" font="3">SCN5A overlap syndrome: 20-39 y, SMR 3.8 </text>
<text top="403" left="555" width="58" height="19" font="3">(2.5–5.7) </text>
<text top="422" left="555" width="228" height="19" font="3">CPVT: age 20-39 y, SMR 3.0 (1.3–6.0) </text>
<text top="440" left="555" width="266" height="19" font="3">BrS: 40-59 y, SMR 1.79 (1.2–2.4), especially </text>
<text top="458" left="555" width="39" height="19" font="3">males<b> </b></text>
<text top="219" left="848" width="220" height="19" font="3">● Identify age ranges of highest risk </text>
<text top="238" left="848" width="209" height="19" font="3">for specified inherited arrhythmia </text>
<text top="256" left="848" width="70" height="19" font="3">syndromes </text>
<text top="274" left="848" width="213" height="19" font="3">● Asymptomatic patients over age </text>
<text top="292" left="848" width="161" height="19" font="3">ranges may not require rx </text>
<text top="311" left="848" width="3" height="19" font="3"> </text>
<text top="477" left="123" width="122" height="19" font="3">● Villain E<b> </b>EHJ 2004 </text>
<text top="496" left="123" width="35" height="19" font="3">(360)<b> </b></text>
<text top="514" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15321698">● </a></text>
<text top="514" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15321698">15321698</a></text>
<text top="514" left="196" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15321698"><b> </b></a></text>
<text top="477" left="262" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="496" left="262" width="84" height="19" font="3">retrospective </text>
<text top="514" left="262" width="81" height="19" font="3">single center </text>
<text top="532" left="262" width="3" height="19" font="3"> </text>
<text top="550" left="262" width="68" height="19" font="4"><b>Size:</b>    122<b> </b></text>
<text top="477" left="379" width="149" height="19" font="4"><b>Inclusion criteria:</b>  LQTS </text>
<text top="496" left="379" width="146" height="19" font="3">in pt &lt;18 y treated with </text>
<text top="514" left="379" width="143" height="19" font="3">BB, dx 1984-2002; 86% </text>
<text top="532" left="379" width="93" height="19" font="3">genotype pos.  </text>
<text top="550" left="379" width="155" height="19" font="3">26 patients dx in first mo </text>
<text top="569" left="379" width="159" height="19" font="3">of life; for others, median </text>
<text top="587" left="379" width="76" height="19" font="3">age 6y at dx </text>
<text top="605" left="379" width="112" height="19" font="3">54% symptomatic </text>
<text top="624" left="379" width="61" height="19" font="3">probands </text>
<text top="642" left="379" width="3" height="19" font="3"> </text>
<text top="660" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="478" left="555" width="259" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ACA or SCD in LQTS patients </text>
<text top="496" left="555" width="243" height="19" font="3">&lt;18yr old during followup median 7.5 y </text>
<text top="515" left="555" width="3" height="19" font="3"> </text>
<text top="533" left="555" width="187" height="19" font="4"><b>Results:</b>  BB:  nadolol 50 mg/m</text>
<text top="533" left="742" width="5" height="12" font="15">2</text>
<text top="533" left="747" width="83" height="19" font="3">/d given bid;  </text>
<text top="551" left="555" width="244" height="19" font="3">Propranolol 3-5 mg/kg/d, acebutolol 10 </text>
<text top="570" left="555" width="258" height="19" font="3">mg/kg/d., atenolol 50 mg/d, bisoprolol 10 </text>
<text top="588" left="555" width="47" height="19" font="3">mg/d.   </text>
<text top="606" left="555" width="269" height="19" font="3">Monitored at least yearly with ecg, exercise </text>
<text top="624" left="555" width="260" height="19" font="3">test and/or holter, goal peak HR &lt;130-150 </text>
<text top="643" left="555" width="38" height="19" font="3">bpm.  </text>
<text top="661" left="555" width="228" height="19" font="3">Symptomatic patients w longer QTc.  </text>
<text top="680" left="555" width="211" height="19" font="3">3 neonates died; one pt died after </text>
<text top="698" left="555" width="160" height="19" font="3">pacemaker implantation.  </text>
<text top="716" left="555" width="234" height="19" font="3">One pt died after meds discontinued.  </text>
<text top="734" left="555" width="263" height="19" font="3">4.5% recurrent syncope. Cumulative event-</text>
<text top="753" left="555" width="107" height="19" font="3">free survival 94% </text>
<text top="477" left="848" width="200" height="19" font="3">● BB highly effective in children, </text>
<text top="496" left="848" width="122" height="19" font="3">particularly in LQT1 </text>
<text top="514" left="848" width="188" height="19" font="3">● Double mutations or LQT2,3 </text>
<text top="532" left="848" width="71" height="19" font="3">higher risk  </text>
<text top="550" left="848" width="180" height="19" font="3">● no LQT1 patient died while </text>
<text top="569" left="848" width="78" height="19" font="3">receiving BB </text>
</page>
<page number="203" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">203 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="116" height="19" font="3">● Moltedo JM Ped </text>
<text top="127" left="123" width="116" height="19" font="3">Cardiol 2011 (361) </text>
<text top="145" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20960185">● </a></text>
<text top="145" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20960185">20960185</a></text>
<text top="145" left="196" width="3" height="19" font="25"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20960185"> </a></text>
<text top="164" left="123" width="3" height="19" font="3"> </text>
<text top="109" left="262" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="127" left="262" width="95" height="19" font="3">retrospective    </text>
<text top="145" left="262" width="3" height="19" font="3"> </text>
<text top="164" left="262" width="61" height="19" font="4"><b>Size:</b>    57<b> </b></text>
<text top="109" left="379" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="127" left="379" width="141" height="19" font="3">Pediatric patients with </text>
<text top="145" left="379" width="113" height="19" font="3">LQTS treated with </text>
<text top="164" left="379" width="61" height="19" font="3">atenolol.  </text>
<text top="182" left="379" width="159" height="19" font="3">Genotyping not available  </text>
<text top="200" left="379" width="3" height="19" font="3"> </text>
<text top="218" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="109" left="555" width="271" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Death, recurrent symptoms in </text>
<text top="128" left="555" width="243" height="19" font="3">young LQT1 ps treatment with atenolol </text>
<text top="146" left="555" width="159" height="19" font="3">during followup 5.4±4.5 y </text>
<text top="165" left="555" width="3" height="19" font="3"> </text>
<text top="183" left="555" width="269" height="19" font="4"><b>Results:</b>  Mean age dx 9 ±6 y, 60% females.  </text>
<text top="201" left="555" width="153" height="19" font="3">Mean QTc 521± 54 msec </text>
<text top="219" left="555" width="266" height="19" font="3">Mean dose atenolol 1.5±0.5 mg/kg/d twice </text>
<text top="238" left="555" width="272" height="19" font="3">daily; dose titrated to achieve peak HR &lt;150 </text>
<text top="256" left="555" width="174" height="19" font="3">bpm on holter and exercise. </text>
<text top="274" left="555" width="258" height="19" font="3"> + family Hx sudden death22%. ICD’s 10%  </text>
<text top="293" left="555" width="273" height="19" font="3">Symptoms 42%: VT: 18%, syncope 10%, ACA </text>
<text top="311" left="555" width="271" height="19" font="3">7%, AV block 4%. One death, non-compliant </text>
<text top="329" left="555" width="74" height="19" font="3">with meds.  </text>
<text top="348" left="555" width="242" height="19" font="3">Recurrent symptoms: 8%, 4 patients: ¾ </text>
<text top="366" left="555" width="262" height="19" font="3">received ICD. All patients with recurrences </text>
<text top="384" left="555" width="126" height="19" font="3">had QTc &gt; 500 msec </text>
<text top="402" left="555" width="256" height="19" font="3">6% side effects (1 pt) or inadequate heart </text>
<text top="421" left="555" width="197" height="19" font="3">rate control—change b-blocker  </text>
<text top="109" left="848" width="194" height="19" font="3">● Atenolol in twice daily dosing </text>
<text top="127" left="848" width="196" height="19" font="3">effective in pediatric patients in </text>
<text top="145" left="848" width="100" height="19" font="3">reducing events </text>
<text top="164" left="848" width="184" height="19" font="3">● Assessing adequacy of beta-</text>
<text top="182" left="848" width="184" height="19" font="3">blockade by blunting peak HR </text>
<text top="200" left="848" width="93" height="19" font="3">recommended </text>
<text top="219" left="848" width="202" height="19" font="3">● Recurrent syncope occurred in </text>
<text top="237" left="848" width="179" height="19" font="3">patients with QTc &gt;500 msec<b> </b></text>
<text top="440" left="123" width="87" height="19" font="3">● Schwartz et </text>
<text top="458" left="123" width="83" height="19" font="3">al.2004 (362) </text>
<text top="476" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15051644">● </a></text>
<text top="476" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15051644">15051644</a></text>
<text top="476" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15051644"> </a></text>
<text top="495" left="100" width="3" height="19" font="3"> </text>
<text top="513" left="123" width="3" height="19" font="3"> </text>
<text top="440" left="262" width="96" height="19" font="4"><b>Aim: </b> To<b> </b>assess </text>
<text top="458" left="262" width="88" height="19" font="3">the long-term </text>
<text top="476" left="262" width="100" height="19" font="3">efficacy of LCSD </text>
<text top="495" left="262" width="81" height="19" font="3">in a group of </text>
<text top="513" left="262" width="55" height="19" font="3">high-risk </text>
<text top="531" left="262" width="57" height="19" font="3">patients.<b> </b></text>
<text top="550" left="262" width="3" height="19" font="4"><b> </b></text>
<text top="568" left="262" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="586" left="262" width="75" height="19" font="3">Multicenter </text>
<text top="605" left="262" width="90" height="19" font="3">global registry </text>
<text top="623" left="262" width="3" height="19" font="3"> </text>
<text top="641" left="262" width="68" height="19" font="4"><b>Size:</b>    147 </text>
<text top="660" left="262" width="53" height="19" font="3">patients </text>
<text top="440" left="379" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="440" left="494" width="26" height="19" font="14">162 </text>
<text top="458" left="379" width="117" height="19" font="14">LQTS patients who </text>
<text top="476" left="379" width="162" height="19" font="14">underwent LCSD between </text>
<text top="495" left="379" width="128" height="19" font="14">1970 and 2002 were </text>
<text top="513" left="379" width="152" height="19" font="14">identified. Among them, </text>
<text top="531" left="379" width="113" height="19" font="14">15 underwent left </text>
<text top="550" left="379" width="124" height="19" font="14">stellectomy that we </text>
<text top="568" left="379" width="148" height="19" font="14">regarded as inadequate </text>
<text top="586" left="379" width="104" height="19" font="14">denervation and </text>
<text top="605" left="379" width="133" height="19" font="14">therefore insufficient </text>
<text top="623" left="379" width="157" height="19" font="14">therapy. Accordingly, the </text>
<text top="641" left="379" width="133" height="19" font="14">analysis is on the 147 </text>
<text top="660" left="379" width="154" height="19" font="14">patients who underwent </text>
<text top="678" left="379" width="30" height="19" font="14">LCSD</text>
<text top="678" left="410" width="3" height="19" font="3"> </text>
<text top="696" left="379" width="3" height="19" font="3"> </text>
<text top="714" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="441" left="555" width="85" height="19" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="441" left="640" width="188" height="19" font="14">Cardiac events and on survival </text>
<text top="459" left="555" width="131" height="19" font="14">free of cardiac events</text>
<text top="459" left="686" width="3" height="19" font="3"> </text>
<text top="477" left="555" width="3" height="19" font="3"> </text>
<text top="495" left="555" width="218" height="19" font="4"><b>Results:</b>  Their QT interval was very </text>
<text top="514" left="555" width="244" height="19" font="3">prolonged (QTc, 543±65 ms); 99% were </text>
<text top="532" left="555" width="249" height="19" font="3">symptomatic; 48% had a CA; and 75% of </text>
<text top="550" left="555" width="198" height="19" font="3">those treated with BB remained </text>
<text top="569" left="555" width="275" height="19" font="3">symptomatic. The average follow-up periods </text>
<text top="587" left="555" width="255" height="19" font="3">between first CE and LCSD and post-LCSD </text>
<text top="606" left="555" width="272" height="19" font="3">were 4.6 and 7.8 y, respectively. After LCSD, </text>
<text top="624" left="555" width="240" height="19" font="3">46% remained asymptomatic. Syncope </text>
<text top="642" left="555" width="257" height="19" font="3">occurred in 31%, ACA in 16%, and sudden </text>
<text top="660" left="555" width="275" height="19" font="3">death in 7%. The mean yearly number of CEs </text>
<text top="679" left="555" width="240" height="19" font="3">per patient dropped by 91% (p&lt;0.001). </text>
<text top="697" left="555" width="276" height="19" font="3">Among 74 patients with only syncope before </text>
<text top="715" left="555" width="274" height="19" font="3">LCSD, all types of CEs decreased significantly </text>
<text top="734" left="555" width="267" height="19" font="3">as in the entire group, and a post-LCSD QTc </text>
<text top="752" left="555" width="227" height="19" font="3">&lt;500 ms predicted very low risk. The </text>
<text top="770" left="555" width="270" height="19" font="3">percentage of patients with &gt;5 CEs declined </text>
<text top="440" left="848" width="12" height="19" font="3">● </text>
<text top="440" left="860" width="155" height="19" font="14">LCSD is associated with a </text>
<text top="458" left="848" width="167" height="19" font="14">significant reduction in the </text>
<text top="476" left="848" width="201" height="19" font="14">incidence of ACA and syncope in </text>
<text top="495" left="848" width="180" height="19" font="14">high-risk LQTS patients when </text>
<text top="513" left="848" width="202" height="19" font="14">compared with pre-LCSD events. </text>
<text top="531" left="848" width="183" height="19" font="14">However, LCSD is not entirely </text>
<text top="550" left="848" width="188" height="19" font="14">effective in preventing cardiac </text>
<text top="568" left="848" width="204" height="19" font="14">events including SCD during long-</text>
<text top="586" left="848" width="102" height="19" font="14">term follow-up.  </text>
<text top="605" left="848" width="12" height="19" font="3">● </text>
<text top="605" left="860" width="212" height="19" font="14">The study population included the </text>
<text top="623" left="848" width="186" height="19" font="14">vast majority of LQTS patients </text>
<text top="641" left="848" width="185" height="19" font="14">treated with LCSD worldwide. </text>
<text top="660" left="848" width="203" height="19" font="3">● Among 51 genotyped patients, </text>
<text top="678" left="848" width="203" height="19" font="3">LCSD appeared more effective in </text>
<text top="696" left="848" width="153" height="19" font="3">LQT1 and LQT3 patients. </text>
<text top="714" left="848" width="3" height="19" font="3"> </text>
</page>
<page number="204" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">204 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="555" width="276" height="19" font="3">from 55% to 8% (p&lt;0.001). In 5 patients with </text>
<text top="127" left="555" width="261" height="19" font="3">preoperative implantable defibrillator and </text>
<text top="145" left="555" width="268" height="19" font="3">multiple discharges, the post-LCSD count of </text>
<text top="164" left="555" width="256" height="19" font="3">shocks decreased by 95% (p=0.02) from a </text>
<text top="182" left="555" width="238" height="19" font="3">median number of 25 to 0 per patient. </text>
<text top="201" left="123" width="85" height="19" font="3">● Bos JM Circ </text>
<text top="219" left="123" width="95" height="19" font="3">Arrhythm Elect </text>
<text top="238" left="123" width="69" height="19" font="3">2013 (363) </text>
<text top="256" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23728945">● </a></text>
<text top="256" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23728945">23728945</a></text>
<text top="256" left="196" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23728945"><b> </b></a></text>
<text top="201" left="262" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="219" left="262" width="82" height="19" font="3">Single center </text>
<text top="238" left="262" width="85" height="19" font="3">retrospective </text>
<text top="256" left="262" width="3" height="19" font="3"> </text>
<text top="274" left="262" width="61" height="19" font="4"><b>Size:</b> 52   <b> </b></text>
<text top="201" left="379" width="145" height="19" font="4"><b>Inclusion criteria: </b>LQTS </text>
<text top="219" left="379" width="163" height="19" font="3">patients undergoing LCSD  </text>
<text top="238" left="379" width="138" height="19" font="3">2005-2010, mean QTc </text>
<text top="256" left="379" width="91" height="19" font="3">528±74 msec;  </text>
<text top="274" left="379" width="123" height="19" font="3">33% 1° prevention.  </text>
<text top="292" left="379" width="130" height="19" font="3">Mean age 14.1±10 y. </text>
<text top="311" left="379" width="3" height="19" font="3"> </text>
<text top="329" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="202" left="555" width="266" height="19" font="4"><b>1</b>°<b> endpoint:</b>  LCSD for LQTS: ACE: syncope, </text>
<text top="220" left="555" width="214" height="19" font="3">ACA, SCD, approp ICD shock for VF </text>
<text top="238" left="555" width="95" height="19" font="3">F/U 3.6±1.3 y.   </text>
<text top="257" left="555" width="3" height="19" font="3"> </text>
<text top="275" left="555" width="268" height="19" font="4"><b>Results:</b>  23% recurrent ACE (not specified). </text>
<text top="293" left="555" width="177" height="19" font="3">15% no reduction in events.  </text>
<text top="312" left="555" width="3" height="19" font="3"> </text>
<text top="330" left="555" width="216" height="19" font="3">No recurrence in patients with b-bl </text>
<text top="348" left="555" width="238" height="19" font="3">intolerance as indication (vs. recurrent </text>
<text top="367" left="555" width="209" height="19" font="3">events). (0/12 vs 17/40, p&lt;0.001)  </text>
<text top="385" left="555" width="185" height="19" font="3">Ptosis: 8%, pneumothorax 6% </text>
<text top="201" left="848" width="211" height="20" font="3">•  23% recurrent ACE after LCSD </text>
<text top="220" left="848" width="3" height="19" font="3"> </text>
<text top="238" left="848" width="3" height="19" font="3"> </text>
<text top="257" left="848" width="3" height="19" font="3"> </text>
<text top="404" left="123" width="100" height="19" font="3">● Schneider, HE </text>
<text top="422" left="123" width="97" height="19" font="3">Clin Res Cardiol </text>
<text top="441" left="123" width="69" height="19" font="3">2013 (364) </text>
<text top="459" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22821214">● </a></text>
<text top="459" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22821214">22821214</a></text>
<text top="459" left="196" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22821214"> </a></text>
<text top="404" left="262" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="422" left="262" width="87" height="19" font="3">Retrospective </text>
<text top="441" left="262" width="81" height="19" font="3">single center </text>
<text top="459" left="262" width="3" height="19" font="3"> </text>
<text top="477" left="262" width="61" height="19" font="4"><b>Size:</b>  10  <b> </b></text>
<text top="404" left="379" width="156" height="19" font="4"><b>Inclusion criteria:</b>  LQT 5, </text>
<text top="422" left="379" width="141" height="19" font="3">CPVT 5, with recurrent </text>
<text top="441" left="379" width="149" height="19" font="3">syncope, VT, ICD shocks </text>
<text top="459" left="379" width="91" height="19" font="3">or ACA on BB.  </text>
<text top="477" left="379" width="164" height="19" font="3">Mean age 14 y (3.9–42 y).  </text>
<text top="496" left="379" width="145" height="19" font="3">2 ICD pre-surg; 6 ICD at </text>
<text top="514" left="379" width="41" height="19" font="3">LSCD.  </text>
<text top="532" left="379" width="3" height="19" font="4"><b> </b></text>
<text top="550" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="569" left="379" width="3" height="19" font="4"><b> </b></text>
<text top="405" left="555" width="237" height="19" font="4"><b>1</b>°<b> endpoint:</b>  LCSD for LQT, CPVT: ACE </text>
<text top="423" left="555" width="272" height="19" font="3">LOS 3-9 d; followup median 2.3 y (0.6–3.9 y) </text>
<text top="441" left="555" width="3" height="19" font="3"> </text>
<text top="460" left="555" width="3" height="19" font="3"> </text>
<text top="478" left="555" width="253" height="19" font="4"><b>Results:</b>  Decrease in arrhythmia burden, </text>
<text top="496" left="555" width="27" height="19" font="3">ACE </text>
<text top="515" left="555" width="153" height="19" font="3">No ICD discharges for VT </text>
<text top="533" left="555" width="62" height="19" font="3">ACA: 10% </text>
<text top="551" left="555" width="272" height="19" font="3">Horner syndrome 70%, 20% pleural effusion </text>
<text top="404" left="848" width="184" height="19" font="3">● Reduction in ICD discharges </text>
<text top="422" left="848" width="71" height="19" font="3">● 10% ACA </text>
<text top="441" left="848" width="153" height="19" font="3">● Minor comps frequent </text>
<text top="459" left="848" width="3" height="19" font="3"> </text>
<text top="588" left="123" width="116" height="19" font="3">● Collura CA Heart </text>
<text top="606" left="123" width="120" height="19" font="3">Rhythm 2009 (365) </text>
<text top="624" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19467503">● </a></text>
<text top="624" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19467503">19467503</a></text>
<text top="624" left="196" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19467503"> </a></text>
<text top="588" left="262" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="606" left="262" width="81" height="19" font="3">single center </text>
<text top="624" left="262" width="91" height="19" font="3">retrospective   </text>
<text top="643" left="262" width="3" height="19" font="3"> </text>
<text top="661" left="262" width="61" height="19" font="4"><b>Size:</b>    20<b> </b></text>
<text top="588" left="379" width="148" height="19" font="4"><b>Inclusion criteria:</b>  LCSD </text>
<text top="606" left="379" width="111" height="19" font="3">2005-2008, video-</text>
<text top="624" left="379" width="120" height="19" font="3">assisted. Mean age </text>
<text top="643" left="379" width="133" height="19" font="3">9.1±9.7 y, (2mo-42 y) </text>
<text top="661" left="379" width="156" height="19" font="3">LQTS 12 geno +, 4 geno – </text>
<text top="679" left="379" width="77" height="19" font="3">LQT; CPVT 2 </text>
<text top="698" left="379" width="3" height="19" font="4"><b> </b></text>
<text top="716" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="588" left="555" width="270" height="19" font="4"><b>1</b>°<b> endpoint:</b>  LCSD for LQTS and CPVT: ACE  </text>
<text top="607" left="555" width="137" height="19" font="3">followup mean 17 mo </text>
<text top="625" left="555" width="3" height="19" font="3"> </text>
<text top="643" left="555" width="277" height="19" font="4"><b>Results:</b>  2° prev: ICD shocks eliminated 72%; </text>
<text top="662" left="555" width="97" height="19" font="3">18% ineffective </text>
<text top="680" left="555" width="268" height="19" font="3">2° prev 11, mean QTc 549 msec; 1° 9, mean </text>
<text top="698" left="555" width="96" height="19" font="3">QTc 480 msec.  </text>
<text top="588" left="848" width="188" height="19" font="3">● LCSD reduced shocks in 72% </text>
<text top="606" left="848" width="168" height="19" font="3">during short term followup </text>
<text top="624" left="848" width="110" height="19" font="3">● 18% ineffective </text>
<text top="643" left="848" width="3" height="19" font="3"> </text>
<text top="661" left="848" width="3" height="19" font="3"> </text>
<text top="735" left="123" width="107" height="19" font="3">● Hofferberth SC </text>
<text top="753" left="123" width="96" height="19" font="3">JTCS 2014(366) </text>
<text top="772" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24268954">● </a></text>
<text top="772" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24268954">24268954</a></text>
<text top="772" left="196" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24268954"> </a></text>
<text top="735" left="262" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="753" left="262" width="81" height="19" font="3">single center </text>
<text top="772" left="262" width="85" height="19" font="3">retrospective </text>
<text top="735" left="379" width="148" height="19" font="4"><b>Inclusion criteria:</b>  LCSD </text>
<text top="753" left="379" width="125" height="19" font="3">2000-2011. LQTS 13 </text>
<text top="736" left="555" width="274" height="19" font="4"><b>1</b>°<b> endpoint:</b> ACE after LCSD: LQTS, CPVT, VF </text>
<text top="754" left="555" width="226" height="19" font="3">Median followup 28 mo, (4–131 mo) </text>
<text top="773" left="555" width="3" height="19" font="3"> </text>
<text top="735" left="848" width="207" height="19" font="3">● LCSD recommended in patients </text>
<text top="753" left="848" width="223" height="19" font="3">with recurrent symptoms refractory </text>
<text top="772" left="848" width="53" height="19" font="3">to meds </text>
</page>
<page number="205" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">205 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="262" width="3" height="19" font="3"> </text>
<text top="127" left="262" width="61" height="19" font="4"><b>Size:</b>    24<b> </b></text>
<text top="109" left="379" width="154" height="19" font="3">(median age 8 y), CPVT 9 </text>
<text top="127" left="379" width="157" height="19" font="3">(age 17 y), VF 2 (age 23).  </text>
<text top="145" left="379" width="3" height="19" font="4"><b> </b></text>
<text top="164" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="109" left="555" width="212" height="19" font="4"><b>Results:</b>  73% marked reduction in </text>
<text top="127" left="555" width="259" height="19" font="3">arrhythmia burden; 55% arrhythmia free.  </text>
<text top="145" left="555" width="161" height="19" font="3">27% persistent symptoms </text>
<text top="109" left="848" width="202" height="19" font="3">● 27% recurrent symptoms, non-</text>
<text top="127" left="848" width="72" height="19" font="3">responders </text>
<text top="183" left="123" width="78" height="19" font="3">● Chattha IS </text>
<text top="201" left="123" width="122" height="19" font="3">Heart Rhythm 2010 </text>
<text top="219" left="123" width="35" height="19" font="3">(367) </text>
<text top="238" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20226272">● </a></text>
<text top="238" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20226272">20226272</a></text>
<text top="238" left="196" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20226272"> </a></text>
<text top="183" left="263" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="201" left="263" width="87" height="19" font="3">Retrospective </text>
<text top="219" left="263" width="88" height="19" font="3">single center   </text>
<text top="238" left="263" width="3" height="19" font="3"> </text>
<text top="256" left="263" width="54" height="19" font="4"><b>Size:</b>  75<b> </b></text>
<text top="183" left="379" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="201" left="379" width="152" height="19" font="3">Exercise testing done on </text>
<text top="219" left="379" width="64" height="19" font="3">3 groups:  </text>
<text top="238" left="379" width="156" height="19" font="3">LQT1, LQT2, and controls </text>
<text top="256" left="379" width="7" height="19" font="3">  </text>
<text top="274" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="183" left="555" width="263" height="19" font="4"><b>1</b>°<b> endpoint:</b> Genotypic specific changes in </text>
<text top="202" left="555" width="111" height="19" font="3">QTc with exercise </text>
<text top="220" left="555" width="3" height="19" font="3"> </text>
<text top="238" left="555" width="156" height="19" font="4"><b>Results:</b>  Changes in QTc: </text>
<text top="257" left="555" width="279" height="19" font="3">LQT1: longer corrected QTc at peak and early </text>
<text top="275" left="555" width="57" height="19" font="3">recovery </text>
<text top="293" left="555" width="227" height="19" font="3">LQT2: QTc increased during recovery </text>
<text top="312" left="555" width="232" height="19" font="3">Controls: normal QTc during recovery<b> </b></text>
<text top="183" left="848" width="211" height="19" font="3">● End of recovery QTc &gt;445 msec, </text>
<text top="201" left="848" width="175" height="19" font="3">usually at 4 min of recovery, </text>
<text top="219" left="848" width="197" height="19" font="3">distinguished 92% of LQTS from </text>
<text top="238" left="848" width="53" height="19" font="3">controls </text>
<text top="256" left="848" width="214" height="19" font="3">● Start of recovery QTc &gt;460 msec </text>
<text top="274" left="848" width="225" height="19" font="3">correctly identified 80% of LQT1 and </text>
<text top="293" left="848" width="80" height="19" font="3">92% of LQT2 </text>
<text top="331" left="123" width="119" height="19" font="3">● Aziz PF CAE 2011 </text>
<text top="349" left="123" width="35" height="19" font="3">(368) </text>
<text top="367" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21956039">● </a></text>
<text top="367" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21956039">21956039</a></text>
<text top="367" left="196" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21956039"><b> </b></a></text>
<text top="331" left="262" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="349" left="262" width="82" height="19" font="3">Single center </text>
<text top="367" left="262" width="91" height="19" font="3">retrospective   </text>
<text top="386" left="262" width="3" height="19" font="3"> </text>
<text top="404" left="262" width="65" height="19" font="4"><b>Size:</b>   158<b> </b></text>
<text top="331" left="379" width="153" height="19" font="4"><b>Inclusion criteria:</b>  LQT1, </text>
<text top="349" left="379" width="118" height="19" font="3">LQT2, and controls </text>
<text top="367" left="379" width="107" height="19" font="3">undergoing cycle </text>
<text top="386" left="379" width="121" height="19" font="3">ergometer exercise </text>
<text top="404" left="379" width="45" height="19" font="3">testing </text>
<text top="422" left="379" width="3" height="19" font="3"> </text>
<text top="441" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="331" left="555" width="275" height="19" font="4"><b>1</b>°<b> endpoint:</b>  QTc changes during exercise in </text>
<text top="350" left="555" width="34" height="19" font="3">LQTS<b> </b></text>
<text top="368" left="555" width="271" height="19" font="4"><b>Results:</b>  LQT1 and LQT2 with sig increase in </text>
<text top="386" left="555" width="134" height="19" font="3">QTc during recovery.  </text>
<text top="405" left="555" width="276" height="19" font="3">Recovery delta QTc- (7 min-1 min) &gt; 30 msec </text>
<text top="423" left="555" width="97" height="19" font="3">predicted LQT2 </text>
<text top="441" left="555" width="3" height="19" font="4"><b> </b></text>
<text top="331" left="848" width="174" height="19" font="3">● QTc &gt;460 msec at 7min of </text>
<text top="349" left="848" width="221" height="19" font="3">recovery predicted LQT1 or LQT2 vs </text>
<text top="367" left="848" width="210" height="19" font="3">controls with 96% sensitivity, 86% </text>
<text top="386" left="848" width="132" height="19" font="3">specificity, 91% PPV.  </text>
<text top="460" left="123" width="116" height="19" font="3">● Laksman ZW JCE </text>
<text top="479" left="123" width="69" height="19" font="3">2013 (369) </text>
<text top="497" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23691991">● </a></text>
<text top="497" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23691991">23691991</a></text>
<text top="497" left="196" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23691991"> </a></text>
<text top="460" left="262" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="479" left="262" width="82" height="19" font="3">Single center </text>
<text top="497" left="262" width="91" height="19" font="3">retrospective   </text>
<text top="515" left="262" width="3" height="19" font="3"> </text>
<text top="534" left="262" width="65" height="19" font="4"><b>Size:</b>   123<b> </b></text>
<text top="460" left="379" width="146" height="19" font="4"><b>Inclusion criteria:</b> LQT1 </text>
<text top="479" left="379" width="126" height="19" font="3">patients undergoing </text>
<text top="497" left="379" width="162" height="19" font="3">exercise testing; 28% with </text>
<text top="515" left="379" width="112" height="19" font="3">C-loop mutations  </text>
<text top="534" left="379" width="3" height="19" font="3"> </text>
<text top="552" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="461" left="555" width="245" height="19" font="4"><b>1</b>°<b> endpoint:</b>  LQT1 patients undergoing </text>
<text top="480" left="555" width="251" height="19" font="3">exercise: assess QTc and response to BB <b> </b></text>
<text top="498" left="555" width="241" height="19" font="4"><b>Results:</b>  no difference in QTc response </text>
<text top="516" left="555" width="224" height="19" font="3">based on mutation location in LQT1; </text>
<text top="534" left="555" width="256" height="19" font="3">however, BB did not reduce QTc in c-loop </text>
<text top="553" left="555" width="113" height="19" font="3">mutation patients </text>
<text top="571" left="555" width="3" height="19" font="4"><b> </b></text>
<text top="460" left="848" width="172" height="19" font="3">● LQT1 patients with c-loop </text>
<text top="479" left="848" width="224" height="19" font="3">mutations did not increase QTc with </text>
<text top="497" left="848" width="56" height="19" font="3">exercise  </text>
<text top="515" left="848" width="215" height="19" font="3">● BB reduced supine, standing and </text>
<text top="534" left="848" width="116" height="19" font="3">peak exercise QTc  </text>
<text top="590" left="123" width="92" height="19" font="3">● Sy RW Heart </text>
<text top="608" left="123" width="120" height="19" font="3">Rhythm 2011 (370) </text>
<text top="627" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21315846">● </a></text>
<text top="627" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21315846">21315846</a></text>
<text top="627" left="196" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21315846"><b> </b></a></text>
<text top="590" left="262" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="608" left="262" width="81" height="19" font="3">single center </text>
<text top="627" left="262" width="88" height="19" font="3">retrospective  </text>
<text top="645" left="262" width="95" height="19" font="3">33% presented </text>
<text top="663" left="262" width="36" height="19" font="3">&lt;21 y </text>
<text top="682" left="262" width="3" height="19" font="3"> </text>
<text top="700" left="262" width="61" height="19" font="4"><b>Size:</b> 27   <b> </b></text>
<text top="590" left="379" width="133" height="19" font="4"><b>Inclusion criteria:</b>  27 </text>
<text top="608" left="379" width="119" height="19" font="3">patients with CPVT </text>
<text top="627" left="379" width="104" height="19" font="3">Median age 35 y </text>
<text top="645" left="379" width="75" height="19" font="3">65% female </text>
<text top="663" left="379" width="140" height="19" font="3">CA 33%, syncope 56%, </text>
<text top="682" left="379" width="119" height="19" font="3">asymptomatic 11% </text>
<text top="700" left="379" width="151" height="19" font="3">ICD’s in 15 patients with </text>
<text top="718" left="379" width="151" height="19" font="3">CA or recurrent syncope </text>
<text top="737" left="379" width="93" height="19" font="3">on b-blockers;  </text>
<text top="755" left="379" width="3" height="19" font="3"> </text>
<text top="773" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="591" left="555" width="249" height="19" font="4"><b>1</b>°<b> endpoint:</b>  CPVT outcomes<b>:</b> recurrent </text>
<text top="609" left="555" width="213" height="19" font="3">syncope, death or appropr shocks  </text>
<text top="628" left="555" width="3" height="19" font="3"> </text>
<text top="646" left="555" width="169" height="19" font="4"><b>Results:</b>  followup 6.2±5.7y </text>
<text top="664" left="555" width="229" height="19" font="3">63% exercise induced, 83% adrenalin </text>
<text top="683" left="555" width="249" height="19" font="3">induced; polymorphic VT more common </text>
<text top="701" left="555" width="115" height="19" font="3">than bidirectional. </text>
<text top="719" left="555" width="238" height="19" font="3">SVT in 26%, (AF in 3, focal LA tach in 1) </text>
<text top="737" left="555" width="114" height="19" font="3">caused ICD shocks </text>
<text top="590" left="848" width="218" height="19" font="3">● SVT occurred frequently (AF) and </text>
<text top="608" left="848" width="118" height="19" font="3">caused ICD shocks  </text>
<text top="627" left="848" width="174" height="19" font="3">●  Patients presenting &lt;21 y </text>
<text top="645" left="848" width="197" height="19" font="3">appeared to have increased risk </text>
<text top="663" left="848" width="139" height="19" font="3">death during followup </text>
<text top="682" left="848" width="213" height="19" font="3">● Two deaths despite medications </text>
<text top="700" left="848" width="112" height="19" font="3">and ICD therapies </text>
<text top="718" left="848" width="3" height="19" font="3"> </text>
</page>
<page number="206" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">206 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="555" width="273" height="19" font="3">2 deaths, both in patients with ICD’s: one VF </text>
<text top="127" left="555" width="239" height="19" font="3">triggered by inappropriate shocks; one </text>
<text top="145" left="555" width="217" height="19" font="3">incessant VT not-responding to ICD </text>
<text top="164" left="555" width="272" height="19" font="3">4 appropr shocks; 19% inappropriate shocks </text>
<text top="182" left="555" width="249" height="19" font="3">5 y risk ACE on b-blockers 4.9% all CPVT, </text>
<text top="200" left="555" width="138" height="19" font="3">5.8% for RYR2 carriers<b> </b></text>
<text top="219" left="123" width="120" height="19" font="3">● Spazzolini C JACC </text>
<text top="239" left="123" width="30" height="19" font="3">2009</text>
<text top="237" left="153" width="39" height="21" font="0"> (371)</text>
<text top="239" left="192" width="3" height="19" font="3"> </text>
<text top="258" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19695463">● </a></text>
<text top="258" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19695463">19695463</a></text>
<text top="258" left="196" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19695463"><b> </b></a></text>
<text top="219" left="262" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="238" left="262" width="87" height="19" font="3">Retrospective </text>
<text top="256" left="262" width="83" height="19" font="3">International </text>
<text top="274" left="262" width="90" height="19" font="3">LQTS Registry  </text>
<text top="292" left="262" width="3" height="19" font="3"> </text>
<text top="311" left="262" width="68" height="19" font="4"><b>Size:</b>   212 <b> </b></text>
<text top="219" left="379" width="148" height="19" font="4"><b>Inclusion criteria:</b>  LQTS </text>
<text top="238" left="379" width="154" height="19" font="3">patients with ECG during </text>
<text top="256" left="379" width="96" height="19" font="3">first year of life </text>
<text top="274" left="379" width="3" height="19" font="3"> </text>
<text top="292" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="220" left="555" width="278" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Outcome of LQTS patients with </text>
<text top="238" left="555" width="119" height="19" font="3">ACA during infancy </text>
<text top="257" left="555" width="3" height="19" font="3"> </text>
<text top="275" left="555" width="269" height="19" font="4"><b>Results:</b>  70 patients events &lt;1y: 20 SCD, 16 </text>
<text top="293" left="555" width="108" height="19" font="3">ACA, 34 syncope. </text>
<text top="312" left="555" width="229" height="19" font="3">Risk of ACE: HR &lt;100, QTc ≥500 msec </text>
<text top="330" left="555" width="254" height="19" font="3">ACA in first year: HR: 23.4 for ACA/SCD in </text>
<text top="348" left="555" width="60" height="19" font="3">first 10y.  </text>
<text top="367" left="555" width="274" height="19" font="3">BB reduced risk in patients with syncope but </text>
<text top="385" left="555" width="83" height="19" font="3">not ACA/SCD </text>
<text top="220" left="848" width="218" height="20" font="3">• ACA in first year of life are at very </text>
<text top="238" left="848" width="203" height="19" font="3">high risk of subsequent ACA/SCD </text>
<text top="257" left="848" width="140" height="19" font="3">during next 10 y of life </text>
<text top="275" left="848" width="3" height="19" font="3"> </text>
<text top="294" left="848" width="195" height="20" font="3">• BB not effective in preventing </text>
<text top="312" left="848" width="219" height="19" font="3">SCD/ACA in patients with prior ACA </text>
<text top="404" left="123" width="125" height="19" font="3">● Zhang C, et al. JCE </text>
<text top="422" left="123" width="69" height="19" font="3">2015 (372) </text>
<text top="441" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26149510">● </a></text>
<text top="441" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26149510">26149510</a></text>
<text top="441" left="196" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26149510"> </a></text>
<text top="404" left="262" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="422" left="262" width="76" height="19" font="3">LQT registry </text>
<text top="441" left="262" width="88" height="19" font="3">retrospective  </text>
<text top="459" left="262" width="3" height="19" font="3"> </text>
<text top="477" left="262" width="68" height="19" font="4"><b>Size:</b> 548   <b> </b></text>
<text top="404" left="379" width="148" height="19" font="4"><b>Inclusion criteria:</b>  LQTS </text>
<text top="422" left="379" width="156" height="19" font="3">patients 1979-2003, with </text>
<text top="441" left="379" width="160" height="19" font="3">followup to 2015, treated </text>
<text top="459" left="379" width="92" height="19" font="3">with Attention </text>
<text top="477" left="379" width="127" height="19" font="3">deficit/hyperactivity </text>
<text top="496" left="379" width="103" height="19" font="3">disorder (ADHD) </text>
<text top="514" left="379" width="78" height="19" font="3">medications </text>
<text top="532" left="379" width="3" height="19" font="3"> </text>
<text top="550" left="379" width="154" height="19" font="4"><b>Exclusion criteria:</b>  other </text>
<text top="569" left="379" width="149" height="19" font="3">LQT; patients with ICD’s<b> </b></text>
<text top="405" left="555" width="263" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Identify major ACE (syncope, </text>
<text top="423" left="555" width="262" height="19" font="3">ACA, SCD) in patients with LQTS treatment </text>
<text top="441" left="555" width="235" height="19" font="3">with ADHD meds; mean followup 7.9y </text>
<text top="460" left="555" width="3" height="19" font="3"> </text>
<text top="478" left="555" width="272" height="19" font="4"><b>Results:</b>  62% cumulative probablility of ACE </text>
<text top="496" left="555" width="269" height="19" font="3">in ADHD group, vs 28% in non-ADHD group. </text>
<text top="515" left="555" width="278" height="19" font="3">Time dependent use increased risk, HR: 3.07, </text>
<text top="533" left="555" width="241" height="19" font="3">p=0.03; increased riks in males, HR: 6.8<b> </b></text>
<text top="551" left="555" width="3" height="19" font="4"><b> </b></text>
<text top="404" left="848" width="196" height="19" font="3">● ADHD meds-stimulant or non-</text>
<text top="422" left="848" width="166" height="19" font="3">stimulants-associated with </text>
<text top="441" left="848" width="164" height="19" font="3">increased risk majory ACE, </text>
<text top="459" left="848" width="126" height="19" font="3">particularly in mlaes </text>
<text top="477" left="848" width="3" height="19" font="3"> </text>
<text top="496" left="848" width="3" height="19" font="3"> </text>
<text top="514" left="848" width="3" height="19" font="3"> </text>
<text top="588" left="123" width="114" height="19" font="3">● Choy et al. 1997 </text>
<text top="606" left="123" width="35" height="19" font="3">(373) </text>
<text top="624" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9337183">● </a></text>
<text top="624" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9337183">9337183</a></text>
<text top="624" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9337183"> </a></text>
<text top="643" left="123" width="3" height="19" font="3"> </text>
<text top="661" left="123" width="7" height="19" font="3">  </text>
<text top="588" left="262" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="606" left="262" width="82" height="19" font="3">Double-blind </text>
<text top="624" left="262" width="91" height="19" font="3">comparison of </text>
<text top="643" left="262" width="66" height="19" font="3">potassium </text>
<text top="661" left="262" width="85" height="19" font="3">infusion after </text>
<text top="679" left="262" width="87" height="19" font="3">quinidine and </text>
<text top="698" left="262" width="51" height="19" font="3">placebo </text>
<text top="716" left="262" width="92" height="19" font="3">sequentially in </text>
<text top="734" left="262" width="68" height="19" font="3">12 healthy </text>
<text top="753" left="262" width="57" height="19" font="3">subjects. </text>
<text top="588" left="379" width="160" height="19" font="4"><b>Inclusion criteria: </b>healthy </text>
<text top="606" left="379" width="135" height="19" font="3">subjects (12) and CHF </text>
<text top="624" left="379" width="151" height="19" font="3">(mean EF 17%) with age-</text>
<text top="643" left="379" width="161" height="19" font="3">matched controls without </text>
<text top="661" left="379" width="28" height="19" font="3">CHF </text>
<text top="679" left="379" width="3" height="19" font="3"> </text>
<text top="698" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="716" left="379" width="3" height="19" font="3"> </text>
<text top="588" left="555" width="264" height="19" font="4"><b>1</b>°<b> endpoint: </b>Effect on QTUc from KCl after </text>
<text top="607" left="555" width="132" height="19" font="3">quinidine or placebo. </text>
<text top="625" left="555" width="3" height="19" font="3"> </text>
<text top="643" left="555" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="662" left="555" width="262" height="19" font="3">KCl was IV, 0.5 mEq/kg (to maximum of 40 </text>
<text top="680" left="555" width="207" height="19" font="3">meEq) over 60-70 min resulted in </text>
<text top="698" left="555" width="273" height="19" font="3">normalization of quinidine-induced and CHF-</text>
<text top="717" left="555" width="160" height="19" font="3">related QTU prolongation </text>
<text top="588" left="848" width="207" height="20" font="3">• “Potentially arrhythmogenic QT </text>
<text top="607" left="848" width="191" height="19" font="3">abnormalities during quinidine </text>
<text top="625" left="848" width="219" height="19" font="3">treatment and in CHF can be nearly </text>
<text top="644" left="848" width="215" height="19" font="3">normalized by modest elevation of </text>
<text top="662" left="848" width="114" height="19" font="3">serum potassium” </text>
</page>
<page number="207" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">207 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="262" width="89" height="19" font="3">Also, study on </text>
<text top="127" left="262" width="98" height="19" font="3">QTU in patients </text>
<text top="145" left="262" width="84" height="19" font="3">with CHF and </text>
<text top="164" left="262" width="83" height="19" font="3">age-matched </text>
<text top="182" left="262" width="83" height="19" font="3">controls who </text>
<text top="200" left="262" width="86" height="19" font="3">receive IV KCl </text>
<text top="219" left="262" width="3" height="19" font="3"> </text>
<text top="237" left="262" width="54" height="19" font="4"><b>Size:  </b>12 </text>
<text top="255" left="262" width="91" height="19" font="3">healthy, 8 CHF </text>
<text top="273" left="262" width="66" height="19" font="3">plus 8 age-</text>
<text top="292" left="262" width="57" height="19" font="3">matched </text>
<text top="310" left="262" width="53" height="19" font="3">controls </text>
<text top="329" left="123" width="99" height="19" font="3">● Kannankeril P </text>
<text top="347" left="123" width="94" height="19" font="3">Pharmacol Rev </text>
<text top="366" left="123" width="69" height="19" font="3">2010 (374) </text>
<text top="384" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21079043">● </a></text>
<text top="384" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21079043">21079043</a></text>
<text top="384" left="196" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21079043"> </a></text>
<text top="329" left="263" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="347" left="263" width="47" height="19" font="3">Review </text>
<text top="366" left="263" width="3" height="19" font="3"> </text>
<text top="384" left="263" width="66" height="19" font="4"><b>Size:</b>   N/A<b> </b></text>
<text top="329" left="379" width="139" height="19" font="4"><b>Inclusion criteria:</b> N/A </text>
<text top="347" left="379" width="3" height="19" font="3"> </text>
<text top="366" left="379" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="330" left="555" width="112" height="19" font="4"><b>1</b>°<b> endpoint:</b>  N/A<b> </b></text>
<text top="348" left="555" width="83" height="19" font="4"><b>Results:</b>  N/A </text>
<text top="367" left="555" width="3" height="19" font="3"> </text>
<text top="385" left="555" width="240" height="19" font="3">Lists drugs associated with torsades de </text>
<text top="403" left="555" width="49" height="19" font="3">pointes </text>
<text top="422" left="555" width="3" height="19" font="3"> </text>
<text top="440" left="555" width="258" height="19" font="3">Genetic background-polymorphisms- may </text>
<text top="458" left="555" width="108" height="19" font="3">contribute to risk </text>
<text top="476" left="555" width="3" height="19" font="3"> </text>
<text top="495" left="555" width="3" height="19" font="4"><b> </b></text>
<text top="329" left="848" width="179" height="19" font="3">● Associated factors for drug </text>
<text top="347" left="848" width="169" height="19" font="3">induced LQTS; bradycardia, </text>
<text top="366" left="848" width="215" height="19" font="3">hypokalemia; hypomagnesemia by </text>
<text top="384" left="848" width="216" height="19" font="3">modulating L-type calcium channel </text>
<text top="402" left="848" width="54" height="19" font="3">function </text>
<text top="421" left="848" width="216" height="19" font="3">● Drugs prolonging QT: block rapid </text>
<text top="439" left="848" width="193" height="19" font="3">component of delayed rectifier </text>
<text top="457" left="848" width="139" height="19" font="3">potassium current, IKr </text>
<text top="513" left="115" width="4" height="21" font="2"><b> </b></text>
<text top="570" left="115" width="895" height="21" font="2"><b>Data Supplement 41. Nonrandomized Trials Related to Catecholaminergic Polymorphic Ventricular Tachycardia – (Section 7.9.1.2.) </b></text>
<text top="591" left="131" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="609" left="157" width="51" height="19" font="4"><b>Author; </b></text>
<text top="627" left="134" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="591" left="284" width="39" height="19" font="4"><b>Study </b></text>
<text top="609" left="260" width="86" height="19" font="4"><b>Type/Design; </b></text>
<text top="627" left="270" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="609" left="394" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="591" left="618" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="609" left="630" width="126" height="19" font="4"><b>(P values; OR or RR; </b></text>
<text top="627" left="662" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="600" left="891" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="618" left="919" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="647" left="123" width="106" height="19" font="3">● Hayashi M Circ </text>
<text top="665" left="123" width="69" height="19" font="3">2009 (347) </text>
<text top="683" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19398665">● </a></text>
<text top="683" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19398665">19398665</a></text>
<text top="683" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19398665"> </a></text>
<text top="646" left="254" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="665" left="254" width="81" height="19" font="3">single center </text>
<text top="683" left="254" width="95" height="19" font="3">retrospective    </text>
<text top="702" left="254" width="3" height="19" font="3"> </text>
<text top="720" left="254" width="68" height="19" font="4"><b>Size:</b>  101  <b> </b></text>
<text top="646" left="365" width="165" height="19" font="4"><b>Inclusion criteria:</b> CPVT 50 </text>
<text top="665" left="365" width="124" height="19" font="3">probands, 51 family </text>
<text top="683" left="365" width="164" height="19" font="3">members, age at dx 15±10 </text>
<text top="702" left="365" width="17" height="19" font="3">y.  </text>
<text top="720" left="365" width="120" height="19" font="3">Symptoms 60% (61 </text>
<text top="738" left="365" width="173" height="19" font="3">patients), all probands, 22% </text>
<text top="757" left="365" width="102" height="19" font="3">family members </text>
<text top="775" left="365" width="174" height="19" font="3">93% symptomatic &lt;21 y old  </text>
<text top="647" left="556" width="219" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ACE in CPVT patients: </text>
<text top="666" left="556" width="240" height="19" font="3">syncope, ACA, approp ICD shocks, SCD  </text>
<text top="684" left="556" width="3" height="19" font="3"> </text>
<text top="702" left="556" width="146" height="19" font="4"><b>Results:</b>  followup 7.9 y </text>
<text top="721" left="556" width="275" height="19" font="3">8 y total event rate 32% total, 27% with b-bl, </text>
<text top="739" left="556" width="274" height="19" font="3">58% without b-bl. 8 y event ACA/SCD 13% (8 </text>
<text top="757" left="556" width="58" height="19" font="3">patients) </text>
<text top="647" left="844" width="217" height="19" font="3">● Higher risk for lack of BB, Hx ACA </text>
<text top="665" left="844" width="221" height="19" font="3">● Prior syncope not associated with </text>
<text top="683" left="844" width="87" height="19" font="3">increased risk </text>
<text top="702" left="844" width="3" height="19" font="3"> </text>
<text top="720" left="957" width="3" height="19" font="4"><b> </b></text>
</page>
<page number="208" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">208 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="365" width="176" height="19" font="3">77% detection of mutations: </text>
<text top="127" left="365" width="79" height="19" font="3">RYR2 CASQ2 </text>
<text top="145" left="365" width="3" height="19" font="3"> </text>
<text top="164" left="365" width="148" height="19" font="4"><b>Exclusion criteria:</b>   N/A<b> </b></text>
<text top="109" left="556" width="273" height="19" font="3">Increased risk: Absence BB HR: 5.54; 95% CI: </text>
<text top="127" left="556" width="251" height="19" font="3">1.17–16.15, p=0.003), Hx ACA HR: 13.01; </text>
<text top="145" left="556" width="264" height="19" font="3">95% CI: 2.48–68.21, p=0.002); younger age </text>
<text top="164" left="556" width="263" height="19" font="3">at dx (HR: 0.54/decade; 95% CI: 0.33–0.89, </text>
<text top="182" left="556" width="50" height="19" font="3">p=0.02) </text>
<text top="200" left="556" width="266" height="19" font="3">32% with events on b-blockers did not take </text>
<text top="219" left="556" width="176" height="19" font="3">meds on day of event.            </text>
<text top="237" left="556" width="112" height="19" font="3">Nadolol: ACE 19% </text>
<text top="237" left="718" width="3" height="19" font="4"><b> </b></text>
<text top="256" left="123" width="108" height="19" font="3">● Roston TM Circ </text>
<text top="274" left="123" width="118" height="19" font="3">Arrh EP 2015 (375) </text>
<text top="292" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25713214">● </a></text>
<text top="292" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25713214">25713214</a></text>
<text top="292" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25713214"> </a></text>
<text top="256" left="254" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="274" left="254" width="74" height="19" font="3">multicenter </text>
<text top="292" left="254" width="84" height="19" font="3">retrospective </text>
<text top="311" left="254" width="47" height="19" font="3">cohort  </text>
<text top="329" left="254" width="3" height="19" font="3"> </text>
<text top="347" left="254" width="68" height="19" font="4"><b>Size:</b>  226  <b> </b></text>
<text top="256" left="365" width="176" height="19" font="4"><b>Inclusion criteria:</b>  age &lt;19 y </text>
<text top="274" left="365" width="83" height="19" font="3">dx with CPVT </text>
<text top="292" left="365" width="143" height="19" font="3">Symptomatic 78%; 211 </text>
<text top="311" left="365" width="140" height="19" font="3">treatment with meds:  </text>
<text top="329" left="365" width="100" height="19" font="3">B-blockers: 91% </text>
<text top="347" left="365" width="70" height="19" font="3">AICD: 54%  </text>
<text top="366" left="365" width="148" height="19" font="3">Flecainide 24%, calcium </text>
<text top="384" left="365" width="109" height="19" font="3">channel blockers  </text>
<text top="402" left="365" width="59" height="19" font="3">LCSD 8%  </text>
<text top="421" left="365" width="3" height="19" font="3"> </text>
<text top="439" left="365" width="151" height="19" font="4"><b>Exclusion criteria:</b>  N/A  <b> </b></text>
<text top="257" left="556" width="258" height="19" font="4"><b>1</b>°<b> endpoint:</b> ACE during followup in CPVT </text>
<text top="275" left="556" width="192" height="19" font="3">Treatment failure: syncope, CA </text>
<text top="293" left="556" width="3" height="19" font="3"> </text>
<text top="311" left="556" width="260" height="19" font="4"><b>Results:</b>  Median followup 3.5y (1.4–5.3 y) </text>
<text top="330" left="556" width="268" height="19" font="3">Deaths 3% (6 patients): 2 patients receiving </text>
<text top="348" left="556" width="248" height="19" font="3">b-blocker; one previously asymptomatic </text>
<text top="367" left="556" width="276" height="19" font="3">B-blockers: 25% recurrent events; 2% deaths </text>
<text top="385" left="556" width="259" height="19" font="3">Flecainide: 38% persistent VA, 16% failure </text>
<text top="403" left="556" width="226" height="19" font="3">(non-complaince, suboptimal dose);  </text>
<text top="422" left="556" width="268" height="19" font="3">LCSD: 18 patients:  16% complications; 67% </text>
<text top="440" left="556" width="255" height="19" font="3">asymptomatic after rx; 11% recurrent VT, </text>
<text top="458" left="556" width="78" height="19" font="3">5% CA (1 pt) </text>
<text top="476" left="556" width="237" height="19" font="3">ICD: electrical storm 18%; 46% approp </text>
<text top="495" left="556" width="212" height="19" font="3">shocks, 22% inappropriate shocks; </text>
<text top="513" left="556" width="117" height="19" font="3">complications 23%<b> </b></text>
<text top="256" left="844" width="201" height="19" font="3">● CPVT 25% recurrent events on </text>
<text top="274" left="844" width="195" height="19" font="3">BB—compliant, non-compliant, </text>
<text top="292" left="844" width="116" height="19" font="3">inadequate dosing </text>
<text top="311" left="844" width="192" height="19" font="3">● High complications with ICDs </text>
<text top="329" left="871" width="3" height="19" font="3"> </text>
<text top="532" left="123" width="78" height="19" font="3">● Chattha IS </text>
<text top="550" left="123" width="89" height="19" font="3">Heart Rhythm </text>
<text top="569" left="123" width="69" height="19" font="3">2010 (367) </text>
<text top="587" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20226272">● </a></text>
<text top="587" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20226272">20226272</a></text>
<text top="587" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20226272"> </a></text>
<text top="532" left="254" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="550" left="254" width="87" height="19" font="3">Retrospective </text>
<text top="569" left="254" width="88" height="19" font="3">single center   </text>
<text top="587" left="254" width="3" height="19" font="3"> </text>
<text top="605" left="254" width="54" height="19" font="4"><b>Size:</b>  75<b> </b></text>
<text top="532" left="365" width="168" height="19" font="4"><b>Inclusion criteria:</b>  Exercise </text>
<text top="550" left="365" width="163" height="19" font="3">testing done on 3 groups:  </text>
<text top="569" left="365" width="156" height="19" font="3">LQT1, LQT2, and controls </text>
<text top="587" left="365" width="7" height="19" font="3">  </text>
<text top="605" left="365" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="533" left="556" width="263" height="19" font="4"><b>1</b>°<b> endpoint:</b> Genotypic specific changes in </text>
<text top="551" left="556" width="111" height="19" font="3">QTc with exercise </text>
<text top="570" left="556" width="3" height="19" font="3"> </text>
<text top="588" left="556" width="156" height="19" font="4"><b>Results:</b>  Changes in QTc: </text>
<text top="606" left="556" width="245" height="19" font="3">LQT1: longer corrected QTc at peak and </text>
<text top="624" left="556" width="90" height="19" font="3">early recovery </text>
<text top="643" left="556" width="227" height="19" font="3">LQT2: QTc increased during recovery </text>
<text top="661" left="556" width="232" height="19" font="3">Controls: normal QTc during recovery<b> </b></text>
<text top="532" left="844" width="211" height="19" font="3">● End of recovery QTc &gt;445 msec, </text>
<text top="550" left="844" width="175" height="19" font="3">usually at 4 min of recovery, </text>
<text top="569" left="844" width="197" height="19" font="3">distinguished 92% of LQTS from </text>
<text top="587" left="844" width="53" height="19" font="3">controls </text>
<text top="605" left="844" width="214" height="19" font="3">● Start of recovery QTc &gt;460 msec </text>
<text top="624" left="844" width="225" height="19" font="3">correctly identified 80% of LQT1 and </text>
<text top="642" left="844" width="80" height="19" font="3">92% of LQT2 </text>
<text top="680" left="123" width="110" height="19" font="3">● Wilde AA NEJM </text>
<text top="698" left="123" width="66" height="19" font="3">2008(376) </text>
<text top="717" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18463378">● </a></text>
<text top="717" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18463378">18463378</a></text>
<text top="717" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18463378"> </a></text>
<text top="680" left="254" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="698" left="254" width="82" height="19" font="3">Single center </text>
<text top="717" left="254" width="93" height="19" font="3">observational   </text>
<text top="735" left="254" width="3" height="19" font="3"> </text>
<text top="753" left="254" width="53" height="19" font="4"><b>Size:</b>    3<b> </b></text>
<text top="680" left="365" width="149" height="19" font="4"><b>Inclusion criteria:</b> <b> </b>CPVT </text>
<text top="698" left="365" width="146" height="19" font="3">patients, treatment BB, </text>
<text top="717" left="365" width="160" height="19" font="3">multiple ICD shocks: LCSD </text>
<text top="735" left="365" width="69" height="19" font="3">performed </text>
<text top="753" left="365" width="100" height="19" font="3">RYR2 mutations </text>
<text top="772" left="365" width="3" height="19" font="3"> </text>
<text top="681" left="556" width="268" height="19" font="4"><b>1</b>°<b> endpoint:</b>  CPVT patients and LCSD: ACE  </text>
<text top="699" left="556" width="139" height="19" font="3">after ICD implantation </text>
<text top="718" left="556" width="3" height="19" font="3"> </text>
<text top="736" left="556" width="208" height="19" font="4"><b>Results:</b>  no symptoms after LCSD </text>
<text top="754" left="556" width="3" height="19" font="4"><b> </b></text>
<text top="680" left="844" width="184" height="19" font="3">● LCSD does not preclude ICD </text>
<text top="698" left="844" width="82" height="19" font="3">implantation </text>
<text top="717" left="844" width="196" height="19" font="3">● LCSD Reduced symptoms and </text>
<text top="735" left="844" width="44" height="19" font="3">shocks </text>
</page>
<page number="209" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">209 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="365" width="148" height="19" font="4"><b>Exclusion criteria:</b>   N/A<b> </b></text>
<text top="109" left="844" width="189" height="19" font="3">● LCSD recommended in CPVT </text>
<text top="127" left="844" width="197" height="19" font="3">patients with symptoms on b-bl </text>
<text top="145" left="844" width="51" height="19" font="3">therapy </text>
<text top="164" left="123" width="94" height="19" font="3">● Li J ATS 2008 </text>
<text top="183" left="123" width="35" height="19" font="3">(377) </text>
<text top="201" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19022016">● </a></text>
<text top="201" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19022016">19022016</a></text>
<text top="201" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19022016"> </a></text>
<text top="164" left="254" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="183" left="254" width="82" height="19" font="3">Single center </text>
<text top="201" left="254" width="85" height="19" font="3">retrospective </text>
<text top="219" left="254" width="3" height="19" font="3"> </text>
<text top="237" left="254" width="61" height="19" font="4"><b>Size:</b>    11<b> </b></text>
<text top="164" left="365" width="133" height="19" font="4"><b>Inclusion criteria:</b>  11 </text>
<text top="183" left="365" width="170" height="19" font="3">patients LCSD for LQT 2002-</text>
<text top="201" left="365" width="158" height="19" font="3">2007, BB not tolerated or </text>
<text top="219" left="365" width="157" height="19" font="3">refractory; followup time </text>
<text top="238" left="365" width="78" height="19" font="3">37±26 mos.  </text>
<text top="256" left="365" width="148" height="19" font="4"><b>Exclusion criteria:</b>   N/A<b> </b></text>
<text top="165" left="556" width="252" height="19" font="4"><b>1</b>°<b> endpoint:</b>  LQTS treatment with LCSD: </text>
<text top="183" left="556" width="64" height="19" font="3">outcomes </text>
<text top="202" left="556" width="3" height="19" font="3"> </text>
<text top="220" left="556" width="181" height="19" font="4"><b>Results:</b>  7/11 no symptoms;  </text>
<text top="238" left="583" width="184" height="19" font="3">2  recurrent syncope; 1 SCD </text>
<text top="257" left="556" width="3" height="19" font="4"><b> </b></text>
<text top="164" left="844" width="213" height="19" font="3">● LCSD reduced syncopal episodes </text>
<text top="183" left="844" width="55" height="19" font="3">by 82%;  </text>
<text top="201" left="844" width="110" height="19" font="3">● Mortality: 9.1% </text>
<text top="276" left="123" width="116" height="19" font="3">● Collura CA Heart </text>
<text top="294" left="123" width="85" height="19" font="3">Rhythm 2009 </text>
<text top="312" left="123" width="35" height="19" font="3">(365) </text>
<text top="331" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19467503">● </a></text>
<text top="331" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19467503">19467503</a></text>
<text top="331" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19467503"> </a></text>
<text top="276" left="254" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="294" left="254" width="81" height="19" font="3">single center </text>
<text top="312" left="254" width="91" height="19" font="3">retrospective   </text>
<text top="331" left="254" width="3" height="19" font="3"> </text>
<text top="349" left="254" width="61" height="19" font="4"><b>Size:</b>    20<b> </b></text>
<text top="276" left="365" width="148" height="19" font="4"><b>Inclusion criteria:</b>  LCSD </text>
<text top="294" left="365" width="166" height="19" font="3">2005-2008, video-assisted. </text>
<text top="312" left="365" width="166" height="19" font="3">Mean age 9.1±9.7 y, (2mo–</text>
<text top="331" left="365" width="30" height="19" font="3">42y) </text>
<text top="349" left="365" width="156" height="19" font="3">LQTS 12 geno +, 4 geno – </text>
<text top="367" left="365" width="77" height="19" font="3">LQT; CPVT 2 </text>
<text top="386" left="365" width="148" height="19" font="4"><b>Exclusion criteria:</b>   N/A<b> </b></text>
<text top="276" left="556" width="270" height="19" font="4"><b>1</b>°<b> endpoint:</b>  LCSD for LQTS and CPVT: ACE  </text>
<text top="295" left="556" width="143" height="19" font="3">followup mean 17 mos </text>
<text top="313" left="556" width="3" height="19" font="3"> </text>
<text top="331" left="556" width="244" height="19" font="4"><b>Results:</b>  2° prev: ICD shocks eliminated </text>
<text top="350" left="556" width="33" height="19" font="3">72%; </text>
<text top="368" left="556" width="97" height="19" font="3">18% ineffective </text>
<text top="386" left="556" width="268" height="19" font="3">2° prev 11, mean QTc 549 msec; 1° 9, mean </text>
<text top="405" left="556" width="96" height="19" font="3">QTc 480 msec. <b> </b></text>
<text top="276" left="844" width="188" height="19" font="3">● LCSD reduced shocks in 72% </text>
<text top="294" left="844" width="168" height="19" font="3">during short term followup </text>
<text top="312" left="817" width="3" height="19" font="3"> </text>
<text top="331" left="844" width="110" height="19" font="3">● 18% ineffective </text>
<text top="349" left="871" width="3" height="19" font="3"> </text>
<text top="367" left="871" width="3" height="19" font="3"> </text>
<text top="424" left="123" width="96" height="19" font="3">● Schneider HE </text>
<text top="442" left="123" width="97" height="19" font="3">Clin Res Cardiol </text>
<text top="460" left="123" width="69" height="19" font="3">2013 (364)<b> </b></text>
<text top="479" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22821214">● </a></text>
<text top="479" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22821214">22821214</a></text>
<text top="479" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22821214"> </a></text>
<text top="424" left="254" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="442" left="254" width="87" height="19" font="3">Retrospective </text>
<text top="460" left="254" width="81" height="19" font="3">single center </text>
<text top="479" left="254" width="3" height="19" font="3"> </text>
<text top="497" left="254" width="61" height="19" font="4"><b>Size:</b>  10  <b> </b></text>
<text top="424" left="365" width="156" height="19" font="4"><b>Inclusion criteria:</b>  LQT 5, </text>
<text top="442" left="365" width="141" height="19" font="3">CPVT 5, with recurrent </text>
<text top="460" left="365" width="165" height="19" font="3">syncope, VT, ICD shocks or </text>
<text top="479" left="365" width="75" height="19" font="3">ACA on BB.  </text>
<text top="497" left="365" width="164" height="19" font="3">Mean age 14 y (3.9–42 y).  </text>
<text top="515" left="365" width="145" height="19" font="3">2 ICD pre-surg; 6 ICD at </text>
<text top="534" left="365" width="41" height="19" font="3">LSCD.  </text>
<text top="552" left="365" width="148" height="19" font="4"><b>Exclusion criteria:</b>   N/A </text>
<text top="570" left="365" width="3" height="19" font="4"><b> </b></text>
<text top="425" left="556" width="237" height="19" font="4"><b>1</b>°<b> endpoint:</b>  LCSD for LQT, CPVT: ACE </text>
<text top="443" left="556" width="271" height="19" font="3">LOS 3–9 d; followup median 2.3y (0.6–3.9 y) </text>
<text top="461" left="556" width="3" height="19" font="3"> </text>
<text top="480" left="556" width="3" height="19" font="3"> </text>
<text top="498" left="556" width="253" height="19" font="4"><b>Results:</b>  Decrease in arrhythmia burden, </text>
<text top="516" left="556" width="27" height="19" font="3">ACE </text>
<text top="534" left="556" width="153" height="19" font="3">No ICD discharges for VT </text>
<text top="553" left="556" width="62" height="19" font="3">ACA: 10% </text>
<text top="571" left="556" width="272" height="19" font="3">Horner syndrome 70%, 20% pleural effusion<b> </b></text>
<text top="424" left="844" width="184" height="19" font="3">● Reduction in ICD discharges </text>
<text top="442" left="844" width="71" height="19" font="3">● 10% ACA </text>
<text top="460" left="844" width="153" height="19" font="3">● Minor comps frequent </text>
<text top="479" left="871" width="3" height="19" font="3"> </text>
<text top="590" left="123" width="107" height="19" font="3">● Hofferberth SC </text>
<text top="608" left="123" width="100" height="19" font="3">JTCS 2014 (366) </text>
<text top="627" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24268954">● </a></text>
<text top="627" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24268954">24268954</a></text>
<text top="627" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24268954"> </a></text>
<text top="590" left="254" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="608" left="254" width="81" height="19" font="3">single center </text>
<text top="627" left="254" width="85" height="19" font="3">retrospective </text>
<text top="645" left="254" width="3" height="19" font="3"> </text>
<text top="663" left="254" width="61" height="19" font="4"><b>Size:</b>    24<b> </b></text>
<text top="590" left="365" width="148" height="19" font="4"><b>Inclusion criteria:</b>  LCSD </text>
<text top="608" left="365" width="125" height="19" font="3">2000-2011. LQTS 13 </text>
<text top="627" left="365" width="154" height="19" font="3">(median age 8 y), CPVT 9 </text>
<text top="645" left="365" width="167" height="19" font="3">(age 17 y), VF 2 (age 23 y).  </text>
<text top="663" left="365" width="148" height="19" font="4"><b>Exclusion criteria:</b>   N/A<b> </b></text>
<text top="591" left="556" width="274" height="19" font="4"><b>1</b>°<b> endpoint:</b> ACE after LCSD: LQTS, CPVT, VF </text>
<text top="609" left="556" width="223" height="19" font="3">Median followup 28mo, (4–131 mo) </text>
<text top="628" left="556" width="3" height="19" font="3"> </text>
<text top="646" left="556" width="212" height="19" font="4"><b>Results:</b>  73% marked reduction in </text>
<text top="664" left="556" width="259" height="19" font="3">arrhythmia burden; 55% arrhythmia free.  </text>
<text top="683" left="556" width="161" height="19" font="3">27% persistent symptoms<b> </b></text>
<text top="590" left="844" width="207" height="19" font="3">● LCSD recommended in patients </text>
<text top="608" left="844" width="223" height="19" font="3">with recurrent symptoms refractory </text>
<text top="627" left="844" width="53" height="19" font="3">to meds </text>
<text top="645" left="844" width="202" height="19" font="3">● 27% recurrent symptoms, non-</text>
<text top="663" left="844" width="72" height="19" font="3">responders </text>
<text top="702" left="123" width="109" height="19" font="3">● Van der Werf C </text>
<text top="720" left="123" width="102" height="19" font="3">JACC 2011 (378) </text>
<text top="738" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21616285">● </a></text>
<text top="738" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21616285">21616285</a></text>
<text top="738" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21616285"> </a></text>
<text top="702" left="254" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="720" left="254" width="74" height="19" font="3">multicenter </text>
<text top="738" left="254" width="95" height="19" font="3">retrospective    </text>
<text top="757" left="254" width="3" height="19" font="3"> </text>
<text top="775" left="254" width="61" height="19" font="4"><b>Size:</b>  33  <b> </b></text>
<text top="702" left="365" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="720" left="365" width="151" height="19" font="3">Flecainide treatment for </text>
<text top="738" left="365" width="147" height="19" font="3">genotype positive CPVT </text>
<text top="757" left="365" width="130" height="19" font="3">patients, 8 European </text>
<text top="775" left="365" width="157" height="19" font="3">centers prior to 12/2009; </text>
<text top="702" left="556" width="264" height="19" font="4"><b>1</b>°<b> endpoint:</b>  reduction of VA in CPVT with<b> </b></text>
<text top="721" left="556" width="257" height="19" font="3">flecainide during exercise testing. Median </text>
<text top="739" left="556" width="96" height="19" font="3">followup 20mo </text>
<text top="757" left="556" width="3" height="19" font="3"> </text>
<text top="757" left="644" width="3" height="19" font="3"> </text>
<text top="702" left="844" width="222" height="19" font="3">● Flecainide suppresses VA in CPVT, </text>
<text top="720" left="844" width="65" height="19" font="3">up to 76% </text>
<text top="738" left="871" width="3" height="19" font="3"> </text>
</page>
<page number="210" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">210 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="662" left="115" width="4" height="21" font="0"> </text>
<text top="682" left="115" width="4" height="21" font="0"> </text>
<text top="682" left="331" width="4" height="21" font="2"><b> </b></text>
<text top="109" left="365" width="3" height="19" font="3"> </text>
<text top="127" left="365" width="148" height="19" font="4"><b>Exclusion criteria:</b>   N/A<b> </b></text>
<text top="109" left="556" width="243" height="19" font="4"><b>Results:</b>  Median age 25 y (7–68y); 73% </text>
<text top="127" left="556" width="51" height="19" font="3">females </text>
<text top="145" left="556" width="209" height="19" font="3">29/33 underwent exercise testing </text>
<text top="164" left="556" width="258" height="19" font="3">Median dose flecainide in responders 150 </text>
<text top="182" left="556" width="114" height="19" font="3">mg (100–300mg).  </text>
<text top="200" left="556" width="247" height="19" font="3">76% partial or complete suppression VA </text>
<text top="219" left="556" width="272" height="19" font="3">with exercise (p&lt;0.001); no worsening of VA </text>
<text top="237" left="556" width="255" height="19" font="3">Appropr ICD shock in 1 pt, low serum flec </text>
<text top="255" left="556" width="32" height="19" font="3">level<b> </b></text>
<text top="274" left="123" width="92" height="19" font="3">● Watanabe H </text>
<text top="292" left="123" width="89" height="19" font="3">Heart Rhythm </text>
<text top="311" left="123" width="69" height="19" font="3">2013 (379) </text>
<text top="329" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23286974">● </a></text>
<text top="329" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23286974">23286974</a></text>
<text top="329" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23286974"> </a></text>
<text top="274" left="254" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="292" left="254" width="82" height="19" font="3">Single center </text>
<text top="311" left="254" width="95" height="19" font="3">retrospective    </text>
<text top="329" left="254" width="3" height="19" font="3"> </text>
<text top="347" left="254" width="61" height="19" font="4"><b>Size:</b>   12 <b> </b></text>
<text top="274" left="365" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="292" left="365" width="154" height="19" font="3">Genotype negative CPVT </text>
<text top="311" left="365" width="153" height="19" font="3">with VA, syncope or ACA </text>
<text top="329" left="365" width="3" height="19" font="3"> </text>
<text top="347" left="365" width="148" height="19" font="4"><b>Exclusion criteria:</b>   N/A<b> </b></text>
<text top="275" left="556" width="221" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Flecainide efficacy for </text>
<text top="293" left="556" width="242" height="19" font="3">suppressing VA in CPVT during exercise </text>
<text top="312" left="556" width="45" height="19" font="3">testing </text>
<text top="330" left="556" width="194" height="19" font="4"><b>Results:</b>  Mean followup 48 mo </text>
<text top="348" left="556" width="222" height="19" font="3">Reduced arrhythmias 8/12 patients, </text>
<text top="367" left="556" width="119" height="19" font="3">prevented VA 7/12 </text>
<text top="385" left="556" width="196" height="19" font="3">2/12 ACA/SCD, non-compliance<b> </b></text>
<text top="274" left="844" width="190" height="19" font="3">● Flecainide suppressed VA on </text>
<text top="292" left="844" width="211" height="19" font="3">exercise testing in 75% of patients </text>
<text top="311" left="844" width="3" height="19" font="3"> </text>
<text top="404" left="123" width="84" height="19" font="3">● Priori S circ </text>
<text top="422" left="123" width="66" height="19" font="3">2002(342) </text>
<text top="441" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12093772">● </a></text>
<text top="441" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12093772">12093772</a></text>
<text top="441" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12093772"> </a></text>
<text top="404" left="254" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="422" left="254" width="74" height="19" font="3">multicenter </text>
<text top="441" left="254" width="85" height="19" font="3">retrospective </text>
<text top="459" left="254" width="3" height="19" font="3"> </text>
<text top="477" left="254" width="68" height="19" font="4"><b>Size:</b>    148<b> </b></text>
<text top="404" left="365" width="149" height="19" font="4"><b>Inclusion criteria:</b>  CPVT </text>
<text top="422" left="365" width="159" height="19" font="3">probands (30) underwent </text>
<text top="441" left="365" width="169" height="19" font="3">genotyping; and 118 family </text>
<text top="459" left="365" width="120" height="19" font="3">members screened </text>
<text top="477" left="365" width="3" height="19" font="3"> </text>
<text top="495" left="365" width="148" height="19" font="4"><b>Exclusion criteria:</b>   N/A<b> </b></text>
<text top="405" left="556" width="231" height="19" font="4"><b>1</b>°<b> endpoint:</b>  CPVT genotype RyR2 vs </text>
<text top="423" left="556" width="58" height="19" font="3">outcome </text>
<text top="441" left="556" width="3" height="19" font="3"> </text>
<text top="460" left="556" width="212" height="19" font="4"><b>Results:</b>  RyR2 identified in 47% of </text>
<text top="478" left="556" width="274" height="19" font="3">probands, and 9 family members, 4 clinically </text>
<text top="496" left="556" width="36" height="19" font="3">silent </text>
<text top="515" left="556" width="224" height="19" font="3">71% of gene positive were de novo;  </text>
<text top="533" left="556" width="272" height="19" font="3">29% familial: of familial, 75% asymptomatic, </text>
<text top="551" left="556" width="261" height="19" font="3">55% VA on exercise test; 44% no syx or VA </text>
<text top="570" left="556" width="118" height="19" font="3">on exercise testing </text>
<text top="588" left="556" width="219" height="19" font="3">RyR2: events at younger age, males </text>
<text top="606" left="556" width="116" height="19" font="3">increased syncope </text>
<text top="624" left="556" width="258" height="19" font="3">Genotype positivity did not correlate with </text>
<text top="643" left="556" width="117" height="19" font="3">VA, SCD, beta-bl rx<b> </b></text>
<text top="404" left="844" width="208" height="19" font="3">● Genotype positive RyR2 did not </text>
<text top="422" left="844" width="220" height="19" font="3">correlate with VA, SCD, or response </text>
<text top="441" left="844" width="36" height="19" font="3">to BB </text>
<text top="459" left="844" width="3" height="19" font="3"> </text>
<text top="477" left="844" width="3" height="19" font="3"> </text>
</page>
<page number="211" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="26" size="12" family="Times" color="#4f81bd"/>
<text top="803" left="585" width="29" height="21" font="0">211 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="641" height="21" font="2"><b>Data Supplement 42. Nonrandomized Trials Related to Brugada Syndrome – (Secction7.9.1.3) </b></text>
<text top="131" left="143" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="149" left="169" width="51" height="19" font="4"><b>Author; </b></text>
<text top="167" left="146" width="96" height="19" font="4"><b>Year Published</b> </text>
<text top="140" left="279" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="158" left="308" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="149" left="437" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="131" left="647" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="149" left="660" width="126" height="19" font="4"><b>(P values; OR or RR; </b></text>
<text top="167" left="691" width="63" height="19" font="4"><b>&amp; 95% CI)</b> </text>
<text top="140" left="907" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="158" left="935" width="80" height="19" font="4"><b>Comment(s)</b> </text>
<text top="189" left="123" width="125" height="19" font="3">● Gehi AK, et al. JCE </text>
<text top="207" left="123" width="69" height="19" font="3">2006 (333) </text>
<text top="226" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16836701">● </a></text>
<text top="226" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16836701">16836701</a></text>
<text top="226" left="197" width="3" height="19" font="26"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16836701"> </a></text>
<text top="244" left="123" width="3" height="19" font="3"> </text>
<text top="262" left="123" width="3" height="19" font="3"> </text>
<text top="189" left="278" width="118" height="19" font="4"><b>Study type:</b>   Meta-</text>
<text top="207" left="278" width="114" height="19" font="3">analysis: retrieved </text>
<text top="226" left="278" width="93" height="19" font="3">30 prospective </text>
<text top="244" left="278" width="120" height="19" font="3">studies on Brugada </text>
<text top="262" left="278" width="32" height="19" font="3">ECG<b>  </b></text>
<text top="280" left="278" width="3" height="19" font="4"><b> </b></text>
<text top="299" left="278" width="76" height="19" font="4"><b>Size:</b>    1545<b> </b></text>
<text top="189" left="417" width="141" height="19" font="4"><b>Inclusion: </b>Publications </text>
<text top="207" left="417" width="115" height="19" font="3">1/1990-3/2005 on </text>
<text top="226" left="417" width="131" height="19" font="3">prognosis of patients </text>
<text top="244" left="417" width="127" height="19" font="3">with a Brugada ECG: </text>
<text top="262" left="417" width="118" height="19" font="3">Prospective cohort </text>
<text top="280" left="417" width="134" height="19" font="3">studies, &gt;10 subjects, </text>
<text top="299" left="417" width="158" height="19" font="3">primary data on syncope, </text>
<text top="317" left="417" width="104" height="19" font="3">SCD, ICD shocks; </text>
<text top="335" left="417" width="125" height="19" font="3">followup &gt;6 mo and </text>
<text top="354" left="417" width="94" height="19" font="3">&gt;90% followup </text>
<text top="372" left="417" width="3" height="19" font="3"> </text>
<text top="390" left="417" width="150" height="19" font="4"><b>Exclusions: </b>non-English; </text>
<text top="409" left="417" width="122" height="19" font="3">presence of cardiac </text>
<text top="427" left="417" width="49" height="19" font="3">disease<b> </b></text>
<text top="190" left="590" width="238" height="19" font="4"><b>1</b>°<b> endpoint:</b> Identify risk predictors of </text>
<text top="208" left="590" width="242" height="19" font="3">adverse natural history in patients with </text>
<text top="226" left="590" width="82" height="19" font="3">Brugada ECG </text>
<text top="245" left="590" width="3" height="19" font="3"> </text>
<text top="263" left="590" width="59" height="19" font="4"><b> Results:  </b></text>
<text top="281" left="590" width="241" height="19" font="3">Risk increased with prior hx syncope or </text>
<text top="300" left="590" width="265" height="19" font="3">ACA, spontaneous type 1 Br ECG, and male </text>
<text top="318" left="590" width="46" height="19" font="3">gender </text>
<text top="336" left="590" width="3" height="19" font="4"><b> </b></text>
<text top="354" left="590" width="205" height="19" font="4"><b> NOT sig risk factors:</b> Fam hx SCD </text>
<text top="373" left="590" width="242" height="19" font="3">SCN5A mutation, or inducibility by PES: </text>
<text top="391" left="590" width="233" height="19" font="3">(not a risk factor but heterogeneity of </text>
<text top="410" left="590" width="51" height="19" font="3">studies) </text>
<text top="428" left="590" width="3" height="19" font="4"><b> </b></text>
<text top="189" left="869" width="184" height="19" font="3">● BrS ACE risk increased with  </text>
<text top="207" left="869" width="188" height="19" font="3">prior syncope or SCD, RR: 3.24 </text>
<text top="226" left="869" width="110" height="19" font="3">● Males, RR: 3.47 </text>
<text top="244" left="868" width="193" height="19" font="3">● Spontaneous type 1 ECG, RR: </text>
<text top="262" left="868" width="30" height="19" font="3">4.65 </text>
<text top="280" left="868" width="3" height="19" font="3"> </text>
<text top="447" left="123" width="131" height="19" font="3">● Somani R, et al. HR </text>
<text top="465" left="123" width="69" height="19" font="3">2014 (380) </text>
<text top="483" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24657429">● </a></text>
<text top="483" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24657429">24657429</a></text>
<text top="483" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24657429"> </a></text>
<text top="447" left="278" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="465" left="278" width="75" height="19" font="3">Multicenter </text>
<text top="483" left="278" width="75" height="19" font="3">prospective<b> </b></text>
<text top="502" left="278" width="3" height="19" font="4"><b> </b></text>
<text top="520" left="278" width="58" height="19" font="4"><b>Size: 174 </b></text>
<text top="447" left="417" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="465" left="417" width="103" height="19" font="3">CASPER study of </text>
<text top="483" left="417" width="115" height="19" font="3">probands and first </text>
<text top="502" left="417" width="117" height="19" font="3">degree relatives of </text>
<text top="520" left="417" width="127" height="19" font="3">Unexplained cardiac </text>
<text top="538" left="417" width="146" height="19" font="3">arrest, SCD &lt;60 y, VT or </text>
<text top="557" left="417" width="92" height="19" font="3">VF undergoing </text>
<text top="575" left="417" width="102" height="19" font="3">cardioversion or </text>
<text top="593" left="417" width="139" height="19" font="3">defibrillation, syncope </text>
<text top="612" left="417" width="130" height="19" font="3">with polymorphic VT<b> </b></text>
<text top="630" left="417" width="3" height="19" font="4"><b> </b></text>
<text top="648" left="417" width="113" height="19" font="4"><b>Exclusion criteria: </b></text>
<text top="667" left="417" width="140" height="19" font="3">decreased LVEF, HCM, </text>
<text top="685" left="417" width="152" height="19" font="3">CHD, overt Brugada ECG </text>
<text top="703" left="417" width="146" height="19" font="3">pattern, prolonged QTc<b> </b></text>
<text top="448" left="590" width="256" height="19" font="4"><b>1</b>°<b> endpoint: </b>Provocation of Brugada ECG </text>
<text top="466" left="590" width="234" height="19" font="3">with procainamide infusion 15 mg/kg, </text>
<text top="484" left="590" width="98" height="19" font="3">maximum 1 gm<b> </b></text>
<text top="502" left="590" width="3" height="19" font="4"><b> </b></text>
<text top="521" left="590" width="156" height="19" font="4"><b>Results: </b>Mean age 47 yrs </text>
<text top="539" left="590" width="260" height="19" font="3">Procainamide: increased HR, prolongation </text>
<text top="557" left="590" width="40" height="19" font="3">of QT. </text>
<text top="576" left="590" width="249" height="19" font="3">Brugada ECG provoked in 12/174 = 6.9% </text>
<text top="594" left="590" width="244" height="19" font="3">10/12 pts with ECG changes had SCN5A </text>
<text top="612" left="590" width="63" height="19" font="3">mutation. </text>
<text top="447" left="869" width="213" height="19" font="3">● Procainamide infusion provoked </text>
<text top="465" left="869" width="195" height="19" font="3">Brugada ECG changes in ~7% of </text>
<text top="483" left="869" width="124" height="19" font="3">CASPER population. </text>
<text top="722" left="123" width="125" height="19" font="3">● Mizusawa Y, et al. </text>
<text top="741" left="123" width="90" height="19" font="3">HR 2016 (381) </text>
<text top="759" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27033637">● </a></text>
<text top="759" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27033637">27033637</a></text>
<text top="759" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27033637"> </a></text>
<text top="722" left="278" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="741" left="278" width="74" height="19" font="3">multicenter </text>
<text top="759" left="278" width="85" height="19" font="3">retrospective </text>
<text top="777" left="278" width="3" height="19" font="3"> </text>
<text top="722" left="417" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="741" left="417" width="152" height="19" font="3">Brugada S pts with fever </text>
<text top="759" left="417" width="147" height="19" font="3">88 asymptomatic (79%) </text>
<text top="777" left="417" width="133" height="19" font="3">26% SCN5A mutation </text>
<text top="723" left="590" width="261" height="19" font="4"><b>1</b>°<b> endpoint:</b> compare effects of fever and </text>
<text top="741" left="590" width="108" height="19" font="3">drugs on BrS ECG </text>
<text top="760" left="590" width="239" height="19" font="3">Subgroup of asymptomatc pts, (N=52), </text>
<text top="778" left="590" width="74" height="19" font="3">serial ECG’s </text>
<text top="722" left="869" width="161" height="19" font="3">● 3 aymptomatic patients </text>
<text top="741" left="869" width="158" height="19" font="3">developed VF/SCA during </text>
<text top="759" left="869" width="198" height="19" font="3">followup; 1/3 with spontaneous </text>
<text top="777" left="869" width="59" height="19" font="3">BrS ECG,  </text>
</page>
<page number="212" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">212 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="278" width="68" height="19" font="4"><b>Size:</b>    112<b> </b></text>
<text top="109" left="417" width="93" height="19" font="3">Mean age 46 y </text>
<text top="127" left="417" width="69" height="19" font="3">76% males </text>
<text top="145" left="417" width="3" height="19" font="4"><b> </b></text>
<text top="164" left="417" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="182" left="417" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="590" width="57" height="19" font="3">followup </text>
<text top="127" left="590" width="208" height="19" font="4"><b>Results: </b>fever shortened PR, drug </text>
<text top="145" left="590" width="202" height="19" font="3">challenge prolonged PR and QRS </text>
<text top="164" left="590" width="3" height="19" font="3"> </text>
<text top="182" left="590" width="232" height="19" font="3">Drug challenge in 36 pts: ajmaline 24, </text>
<text top="200" left="590" width="159" height="19" font="3">pilsicainide 7, flecainide 5<b> </b></text>
<text top="109" left="869" width="3" height="19" font="3"> </text>
<text top="127" left="869" width="170" height="19" font="3">● Paper is hard to interpret </text>
<text top="219" left="123" width="62" height="19" font="3">● <b>FINGER </b></text>
<text top="238" left="123" width="127" height="19" font="3">● Probst V Circ 2010 </text>
<text top="256" left="123" width="35" height="19" font="3">(343) </text>
<text top="274" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20100972">● </a></text>
<text top="274" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20100972">20100972</a></text>
<text top="274" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20100972"> </a></text>
<text top="219" left="278" width="118" height="19" font="4"><b>Study type:</b>   Multi-</text>
<text top="238" left="278" width="115" height="19" font="3">center registry, 11 </text>
<text top="256" left="278" width="110" height="19" font="3">centers in Europe </text>
<text top="274" left="278" width="3" height="19" font="3"> </text>
<text top="292" left="278" width="76" height="19" font="4"><b>Size:</b>   1029 <b> </b></text>
<text top="219" left="417" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="238" left="417" width="119" height="19" font="3">Brugada Syndrome </text>
<text top="256" left="417" width="155" height="19" font="3"> ECG spont (45%) or with </text>
<text top="274" left="417" width="97" height="19" font="3">drug challenge. </text>
<text top="293" left="417" width="130" height="19" font="3">Median 45 y (35-55). </text>
<text top="311" left="417" width="160" height="19" font="3">Hx ACA 6%, syncope 30%, </text>
<text top="329" left="417" width="150" height="19" font="3">asymptomatic 64% (654 </text>
<text top="347" left="417" width="65" height="19" font="3">patients).  </text>
<text top="366" left="417" width="132" height="19" font="3">SCN5A positive 22%.  </text>
<text top="384" left="417" width="3" height="19" font="3"> </text>
<text top="402" left="417" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="220" left="590" width="211" height="19" font="4"><b>1</b>°<b> endpoint:</b> ACE outcomes in BrS </text>
<text top="238" left="590" width="3" height="19" font="3"> </text>
<text top="257" left="590" width="224" height="19" font="4"><b>Results:</b> PES performed in 62%: 41% </text>
<text top="275" left="590" width="248" height="19" font="3">positive, higher in symptomatic patients </text>
<text top="293" left="590" width="128" height="19" font="3">46% vs 37%, p=0.02. </text>
<text top="312" left="590" width="225" height="19" font="3">PES performed in 369 asymptomatic </text>
<text top="330" left="590" width="235" height="19" font="3">patients: 37% positive (137/369); 85% </text>
<text top="348" left="590" width="256" height="19" font="3">(117/137) inducible asyx patients had ICD </text>
<text top="367" left="590" width="65" height="19" font="3">implanted </text>
<text top="385" left="590" width="262" height="19" font="3">ICD’s implanted: 433/1029 patients (42%): </text>
<text top="403" left="590" width="227" height="19" font="3">of 433: 54 ACA (12.5%), 208 syncope </text>
<text top="422" left="590" width="255" height="19" font="3">(48%), 171 asymptomatic (39%). 118/171 </text>
<text top="440" left="590" width="236" height="19" font="3">asymptomatic patients with ICD (69%) </text>
<text top="458" left="590" width="192" height="19" font="3">implanted due to positive EPS.  </text>
<text top="476" left="590" width="3" height="19" font="3"> </text>
<text top="495" left="590" width="234" height="19" font="3">ACE 51: approp ICD shocks 44, SCD 7.  </text>
<text top="513" left="590" width="263" height="19" font="3">Mean ACE rate 1.6%/y:  7.7% in patients w </text>
<text top="531" left="590" width="234" height="19" font="3">Hx ACA;1.9% w prior syncope; 0.5% in </text>
<text top="550" left="590" width="96" height="19" font="3">asymp patients </text>
<text top="568" left="590" width="264" height="19" font="3">Predictors: symptoms (p&lt;0.001):  ACA (HR: </text>
<text top="586" left="590" width="246" height="19" font="3">11; 95% CI: 4.8–24.3, p&lt;0.001), syncope </text>
<text top="605" left="590" width="221" height="19" font="3">(HR: 3.4; 95% CI 1.6–7.4, p=0.002),   </text>
<text top="623" left="590" width="237" height="19" font="3">ICD implantation (HR: 3.9; 95% CI: 1.4–</text>
<text top="641" left="590" width="98" height="19" font="3">10.6, p=0.007).  </text>
<text top="660" left="590" width="243" height="19" font="3">spont type 1 ECG (HR: 1.8;95% CI: 1.03–</text>
<text top="678" left="590" width="91" height="19" font="3">3.33, p=0.04);  </text>
<text top="696" left="590" width="240" height="19" font="3">NOT predictive: gender, family Hx SCD, </text>
<text top="714" left="590" width="254" height="19" font="3">+PES (p=0.48), presence SCN5A mutation </text>
<text top="219" left="869" width="212" height="19" font="3">● Low event rate in asymptomatic </text>
<text top="238" left="869" width="106" height="19" font="3">patients 0.5%/y.  </text>
<text top="256" left="869" width="199" height="19" font="3">● Inducibility w PES or family Hx </text>
<text top="274" left="869" width="172" height="19" font="3">SCD or SCN5A mutation not </text>
<text top="293" left="869" width="109" height="19" font="3">predictors of ACE </text>
<text top="311" left="869" width="196" height="19" font="3">● Predictors of ACE: symptoms, </text>
<text top="329" left="869" width="193" height="19" font="3">ACA, syncope, presence of ICD, </text>
<text top="347" left="869" width="111" height="19" font="3">spont type 1 ECG. </text>
<text top="366" left="869" width="206" height="19" font="3">● Among asymptomatic patients: </text>
<text top="384" left="869" width="192" height="19" font="3">37% positive PES; of these 85% </text>
<text top="402" left="869" width="123" height="19" font="3">had ICD implanted.  </text>
<text top="421" left="869" width="133" height="19" font="3">● ICD implantation in </text>
<text top="439" left="869" width="170" height="19" font="3">asymptomatic patients was </text>
<text top="457" left="869" width="164" height="19" font="3">significant in multivariable </text>
<text top="476" left="869" width="174" height="19" font="3">analysis as predictor of ACE: </text>
<text top="494" left="869" width="164" height="19" font="3">HR:10.1; 95% CI: 1.7–58.7, </text>
<text top="512" left="869" width="57" height="19" font="3">p=0.01).  </text>
<text top="531" left="869" width="179" height="19" font="3">● No independent predictive </text>
<text top="549" left="869" width="175" height="19" font="3">value of PES (p=0.09), males </text>
<text top="567" left="869" width="161" height="19" font="3">(p=0.42, spont type 1 ECG </text>
<text top="586" left="869" width="134" height="19" font="3">(p=0.38) age (p=0.97) </text>
<text top="733" left="123" width="128" height="19" font="3">● Hiraoka M JE 2013 </text>
<text top="752" left="123" width="35" height="19" font="3">(349) </text>
<text top="770" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23702150">● </a></text>
<text top="770" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23702150">23702150</a></text>
<text top="770" left="197" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23702150"><b> </b></a></text>
<text top="733" left="278" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="752" left="278" width="113" height="19" font="3">Prospective single </text>
<text top="770" left="278" width="50" height="19" font="3">center   </text>
<text top="733" left="417" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="752" left="417" width="148" height="19" font="3">Brugada S patients ages </text>
<text top="770" left="417" width="55" height="19" font="3">18–35 y  </text>
<text top="734" left="590" width="244" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Brugada S ages 18-35 y at </text>
<text top="753" left="590" width="164" height="19" font="3">dx, outcomes of VF or SCD </text>
<text top="771" left="590" width="137" height="19" font="3">Followup 43±27 mos.  </text>
<text top="733" left="869" width="186" height="19" font="3">● Brugada outcomes in young </text>
<text top="752" left="869" width="203" height="19" font="3">adults’ vs presenting symptoms:  </text>
</page>
<page number="213" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">213 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="278" width="3" height="19" font="3"> </text>
<text top="127" left="278" width="61" height="19" font="4"><b>Size:</b>    69<b> </b></text>
<text top="109" left="417" width="108" height="19" font="3">Mean age 30±6 y </text>
<text top="127" left="417" width="3" height="19" font="3"> </text>
<text top="145" left="417" width="114" height="19" font="3">No genetic testing </text>
<text top="164" left="417" width="3" height="19" font="3"> </text>
<text top="182" left="417" width="3" height="19" font="3"> </text>
<text top="200" left="417" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="109" left="590" width="3" height="19" font="3"> </text>
<text top="127" left="590" width="258" height="19" font="4"><b>Results:</b>  Based on presenting symptoms:  </text>
<text top="145" left="590" width="262" height="19" font="3">VF 42%, syncope 12%, asymptomatic 2.5% </text>
<text top="164" left="590" width="236" height="19" font="3">Not predictive: gender, family Hx SCD, </text>
<text top="182" left="590" width="260" height="19" font="3">abnl SAECG, spontaneous vs drug-induced </text>
<text top="200" left="590" width="131" height="19" font="3">ECG, inducible VT/VF </text>
<text top="219" left="590" width="3" height="19" font="3"> </text>
<text top="237" left="590" width="212" height="19" font="3">All ages 460 patients symptoms at </text>
<text top="255" left="590" width="169" height="19" font="3">presentation vs outcomes:  </text>
<text top="273" left="590" width="262" height="19" font="3">VF 8.4%/y, Syncope 1.7%/y, asymptomatic </text>
<text top="292" left="590" width="46" height="19" font="3">0.3%/y </text>
<text top="310" left="590" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="869" width="190" height="19" font="3">● Events: VF 11.2%/y, syncope </text>
<text top="127" left="869" width="185" height="19" font="3">3.3%/y, asymptomatic 0.7%/y </text>
<text top="145" left="869" width="3" height="19" font="3"> </text>
<text top="164" left="869" width="3" height="19" font="3"> </text>
<text top="182" left="869" width="3" height="19" font="3"> </text>
<text top="329" left="123" width="72" height="19" font="3">● <b>PRELUDE</b> </text>
<text top="347" left="123" width="138" height="19" font="3">● Priori SG et al.  JACC </text>
<text top="366" left="123" width="69" height="19" font="3">2012 (382) </text>
<text top="384" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22192666">● </a></text>
<text top="384" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22192666">22192666</a></text>
<text top="384" left="197" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22192666"><b> </b></a></text>
<text top="329" left="278" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="347" left="278" width="127" height="19" font="3">Prospective registry  </text>
<text top="366" left="278" width="3" height="19" font="3"> </text>
<text top="384" left="278" width="68" height="19" font="4"><b>Size:</b>   308 <b> </b></text>
<text top="329" left="417" width="141" height="19" font="4"><b>Inclusion criteria:</b>  Age </text>
<text top="347" left="417" width="133" height="19" font="3">&gt;18 y, BrS type 1 ECG </text>
<text top="366" left="417" width="151" height="19" font="3">spont (56%, 171/308) or </text>
<text top="384" left="417" width="140" height="19" font="3">drug-induced, without </text>
<text top="402" left="417" width="69" height="19" font="3">prior ACA;  </text>
<text top="421" left="417" width="3" height="19" font="3"> </text>
<text top="439" left="417" width="146" height="19" font="3">21% with prior syncope </text>
<text top="457" left="417" width="159" height="19" font="3">(65 patients: 16/65 {25%} </text>
<text top="476" left="417" width="84" height="19" font="3">&gt;1 syncope).  </text>
<text top="494" left="417" width="3" height="19" font="3"> </text>
<text top="512" left="417" width="141" height="19" font="3">SCN5A positive 20% of </text>
<text top="531" left="417" width="102" height="19" font="3">tested patients.  </text>
<text top="549" left="417" width="3" height="19" font="3"> </text>
<text top="567" left="417" width="157" height="19" font="3">(f-QRS = 2 or more spikes </text>
<text top="586" left="417" width="150" height="19" font="3">within QRS leads V1-V3: </text>
<text top="604" left="417" width="88" height="19" font="3">present 8.1%) </text>
<text top="622" left="417" width="3" height="19" font="3"> </text>
<text top="640" left="417" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="330" left="590" width="247" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Predictive accuracy of PES </text>
<text top="348" left="590" width="265" height="19" font="3">for sustained VT/VF or approp ICD shock in </text>
<text top="367" left="590" width="64" height="19" font="3">Brugada S </text>
<text top="385" left="590" width="3" height="19" font="3"> </text>
<text top="403" left="590" width="237" height="19" font="4"><b>Results: </b>PES performed at enrollment; </text>
<text top="422" left="590" width="136" height="19" font="3">followup every 6 mo.  </text>
<text top="440" left="590" width="123" height="19" font="3">Mean age 45±12 y.  </text>
<text top="458" left="590" width="221" height="19" font="3">Cardiac arrest 4.5% (14/308), 13/14 </text>
<text top="476" left="590" width="185" height="19" font="3">resuscitated with ICD, EMS 1.  </text>
<text top="495" left="590" width="249" height="19" font="3"> PES positive in 41% (126/308); of these: </text>
<text top="513" left="590" width="238" height="19" font="3">single stimulation 5.5%, double 44.5%, </text>
<text top="531" left="590" width="78" height="19" font="3">triples 50%.  </text>
<text top="550" left="590" width="247" height="19" font="3"> ICD’s implanted in 137 patients (78% of </text>
<text top="568" left="590" width="240" height="19" font="3">inducible patients {98/126} and 21% of </text>
<text top="586" left="590" width="208" height="19" font="3">non-inducible patients {39/182}.   </text>
<text top="605" left="590" width="153" height="19" font="3">Annual event rate 1.5%:  </text>
<text top="623" left="590" width="3" height="19" font="4"><b> </b></text>
<text top="641" left="590" width="262" height="19" font="3">Multivariable predictors: spont type 1 ECG </text>
<text top="660" left="590" width="261" height="19" font="3">and Hx of syncope (HR: 4.20; 95% CI: 1.38–</text>
<text top="678" left="590" width="237" height="19" font="3">12.79, p=0.012), Ventricular ERP &lt; 200 </text>
<text top="696" left="590" width="222" height="19" font="3">msec (HR: 3.91; 95% CI: 1.03–12.79, </text>
<text top="714" left="590" width="61" height="19" font="3">p=0.045), </text>
<text top="733" left="590" width="260" height="19" font="3"> QRS fractionation (HR: 4.94’ 95% CI: 1.54–</text>
<text top="751" left="590" width="95" height="19" font="3">15.8, p=0.007). </text>
<text top="769" left="590" width="3" height="19" font="3"> </text>
<text top="329" left="869" width="184" height="20" font="3">•<b> </b>PES did not predict high risk </text>
<text top="348" left="869" width="192" height="20" font="3">• Predictors: spontaneous type </text>
<text top="367" left="869" width="191" height="19" font="3">BrS ecg AND symptoms; f-QRS, </text>
<text top="386" left="869" width="104" height="19" font="3">VERP &lt;200 msec </text>
<text top="404" left="869" width="199" height="19" font="3">VERP &lt;200 msec was predictive: </text>
<text top="422" left="869" width="204" height="19" font="3">this data would only be obtained </text>
<text top="441" left="869" width="48" height="19" font="3">at EPS.  </text>
<text top="459" left="869" width="213" height="20" font="3">• NOTE that + PES used in decision </text>
<text top="478" left="869" width="205" height="19" font="3">to implant ICD’s: 13/137 patients </text>
<text top="496" left="869" width="141" height="19" font="3">(9.5%) with ICD’s were </text>
<text top="515" left="869" width="137" height="19" font="3">resuscitated with ICD. </text>
<text top="533" left="869" width="3" height="19" font="3"> </text>
<text top="551" left="869" width="194" height="19" font="3">Note 1/14 patients with VF had </text>
<text top="570" left="868" width="183" height="19" font="3">only spont type 1 ECG and no </text>
<text top="588" left="868" width="204" height="19" font="3">prior syncope, neg family hx, neg </text>
<text top="606" left="868" width="212" height="19" font="3">EPS, VERP &gt;200 msec but + SCN5A </text>
<text top="625" left="868" width="199" height="19" font="3">mutation and received ICD after </text>
<text top="643" left="868" width="33" height="19" font="3">EPS.  </text>
<text top="661" left="868" width="210" height="19" font="3">Only 1 pt without ICD had ACA: pt </text>
<text top="680" left="868" width="203" height="19" font="3">had spont type 1 ECG, VRP &lt; 200 </text>
<text top="698" left="868" width="105" height="19" font="3">msec, and fQRS.  </text>
</page>
<page number="214" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">214 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="590" width="258" height="19" font="3">Positive PES not predictive (HR: 1.03; 95% </text>
<text top="127" left="590" width="144" height="19" font="3">CI: 0.34–3.16, p = 0.96) </text>
<text top="146" left="123" width="118" height="19" font="3">● Casado-Arroyo<b> </b>R </text>
<text top="164" left="123" width="102" height="19" font="3">JACC 2016 (383)<b> </b></text>
<text top="183" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27491905">● </a></text>
<text top="183" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27491905">27491905</a></text>
<text top="183" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27491905"> </a></text>
<text top="146" left="278" width="117" height="19" font="4"><b>Study type:</b>  Single </text>
<text top="164" left="278" width="43" height="19" font="3">center </text>
<text top="183" left="278" width="88" height="19" font="3">retrospective  </text>
<text top="201" left="278" width="3" height="19" font="3"> </text>
<text top="219" left="278" width="68" height="19" font="4"><b>Size:</b>    447<b> </b></text>
<text top="146" left="417" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="164" left="417" width="159" height="19" font="3">Compare BrS early period </text>
<text top="183" left="417" width="130" height="19" font="3">≤2002 vs. 2003-2014 </text>
<text top="201" left="417" width="63" height="19" font="3">Early: 165 </text>
<text top="219" left="417" width="70" height="19" font="3">Latter: 282 </text>
<text top="238" left="417" width="134" height="19" font="3">ICD’s: 48% early, 44% </text>
<text top="256" left="417" width="37" height="19" font="3">latter </text>
<text top="274" left="417" width="3" height="19" font="3"> </text>
<text top="292" left="417" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="147" left="590" width="257" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Long term trends Brugada S </text>
<text top="165" left="590" width="29" height="19" font="3">EPS  </text>
<text top="183" left="590" width="3" height="19" font="3"> </text>
<text top="202" left="590" width="208" height="19" font="4"><b>Results:</b>  Early group more severe </text>
<text top="220" left="590" width="70" height="19" font="3">phenotype </text>
<text top="238" left="590" width="218" height="19" font="3">ACA 12% early, 4.6% latter, p =.005 </text>
<text top="257" left="590" width="213" height="19" font="3">PES positive 34% early, 19% latter, </text>
<text top="275" left="590" width="53" height="19" font="3">p&lt;0.001 </text>
<text top="293" left="590" width="260" height="19" font="3">Spontaneous type 1 ECG: early 50%, latter </text>
<text top="312" left="590" width="94" height="19" font="3">26%, p=0.0002 </text>
<text top="330" left="590" width="217" height="19" font="3">Recurrent VA: early 19%, latter 5%, </text>
<text top="348" left="590" width="53" height="19" font="3">p=0.007 </text>
<text top="367" left="590" width="3" height="19" font="4"><b> </b></text>
<text top="146" left="869" width="195" height="19" font="3">● Brugada s: changes over time </text>
<text top="164" left="869" width="194" height="19" font="3">● Decrease in ACA over time as </text>
<text top="183" left="869" width="82" height="19" font="3">presentation </text>
<text top="201" left="869" width="190" height="19" font="3">● PES predictive in early group </text>
<text top="219" left="869" width="89" height="19" font="3">but not latter  </text>
<text top="386" left="123" width="122" height="19" font="3">● Belhassen B et al, </text>
<text top="404" left="123" width="96" height="19" font="3">CAE 2015 (384) </text>
<text top="422" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26354972">● </a></text>
<text top="422" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26354972">26354972</a></text>
<text top="422" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26354972"> </a></text>
<text top="386" left="278" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="404" left="278" width="123" height="19" font="3">retrospective single </text>
<text top="422" left="278" width="46" height="19" font="3">center  </text>
<text top="441" left="278" width="3" height="19" font="3"> </text>
<text top="459" left="278" width="61" height="19" font="4"><b>Size:</b>    96<b> </b></text>
<text top="386" left="417" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="404" left="417" width="117" height="19" font="3">Brugada S patients </text>
<text top="422" left="417" width="125" height="19" font="3">undergoing PES and </text>
<text top="441" left="417" width="129" height="19" font="3">treated with Class IA </text>
<text top="459" left="417" width="37" height="19" font="3">drugs </text>
<text top="477" left="417" width="115" height="19" font="3">Mean age 39±16 y </text>
<text top="496" left="417" width="69" height="19" font="3">88% males </text>
<text top="514" left="417" width="3" height="19" font="3"> </text>
<text top="532" left="417" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="386" left="590" width="261" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Brugada S outcomes treated </text>
<text top="405" left="590" width="84" height="19" font="3">with IA drugs<b> </b></text>
<text top="423" left="590" width="168" height="19" font="3">Mean followup 113±71 mo </text>
<text top="441" left="590" width="3" height="19" font="3"> </text>
<text top="460" left="590" width="234" height="19" font="4"><b>Results:</b>  Prior ACA 10, syncope 27, 59 </text>
<text top="478" left="590" width="90" height="19" font="3">asymptomatic </text>
<text top="496" left="590" width="235" height="19" font="3">PES: VF induced in 69% (100% of prior </text>
<text top="515" left="590" width="180" height="19" font="3">ACA, 74% of syncope, 61% of </text>
<text top="533" left="590" width="231" height="19" font="3">asymptomatic), PES RVA and RVOT in </text>
<text top="551" left="590" width="139" height="19" font="3">most, ≤3 extrastimuli.  </text>
<text top="570" left="590" width="255" height="19" font="3">PES positive in 77% males, 9% females; in </text>
<text top="588" left="590" width="261" height="19" font="3">88% with spont ECG vs 59% without spont </text>
<text top="606" left="590" width="35" height="19" font="3">ECG.  </text>
<text top="624" left="590" width="231" height="19" font="3">Tested (60 patients) w quinidine (54), </text>
<text top="643" left="590" width="170" height="19" font="3">disopyramide (2), both (4).  </text>
<text top="661" left="590" width="257" height="19" font="3">Quinidine prevented re-induction of VF in </text>
<text top="680" left="590" width="153" height="19" font="3">90%<b>;</b> disopyramide 50%  </text>
<text top="698" left="590" width="215" height="19" font="3">30  Patients with neg PES were not </text>
<text top="716" left="590" width="226" height="19" font="3">treated: all remained asymptomatic. </text>
<text top="734" left="590" width="235" height="19" font="3">ICD implanted in 20 patients after PES </text>
<text top="753" left="590" width="189" height="19" font="3">(30% of inducible VF patients): </text>
<text top="771" left="590" width="197" height="19" font="3">complications 55% of patients.   </text>
<text top="386" left="869" width="171" height="19" font="3">● Brugada S: Class IA meds: </text>
<text top="404" left="869" width="162" height="19" font="3">● No deaths on quinidine; </text>
<text top="422" left="869" width="189" height="19" font="3">40% of ACA patients remained </text>
<text top="441" left="869" width="165" height="19" font="3">arrhythmia free off AAD (3 </text>
<text top="459" left="869" width="178" height="19" font="3">treatment with quinidine for </text>
<text top="477" left="869" width="202" height="19" font="3">many years then discontinued rx </text>
<text top="496" left="869" width="114" height="19" font="3">● 38% side effects<b> </b></text>
</page>
<page number="215" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">215 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="590" width="183" height="19" font="3">4 died of non-cardiac causes.  </text>
<text top="127" left="590" width="235" height="19" font="3">Recurrent syncope: vasovagal 10, non-</text>
<text top="145" left="590" width="89" height="19" font="3">arrhythmic 2.  </text>
<text top="164" left="590" width="257" height="19" font="3">2/96 had recurrent arrhythmia: both with </text>
<text top="182" left="590" width="241" height="19" font="3">prior ACA<b>; </b>both discontinued quinidine </text>
<text top="200" left="590" width="124" height="19" font="3">and had VF storms. <b> </b></text>
<text top="219" left="123" width="135" height="19" font="3">● Nademanee K et al. </text>
<text top="238" left="123" width="92" height="19" font="3">Circ 2011(385) </text>
<text top="256" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21403098">● </a></text>
<text top="256" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21403098">21403098</a></text>
<text top="256" left="197" width="3" height="19" font="18"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21403098"><b> </b></a></text>
<text top="219" left="278" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="238" left="278" width="126" height="19" font="3">Retrospective single </text>
<text top="256" left="278" width="43" height="19" font="3">center </text>
<text top="274" left="278" width="3" height="19" font="3"> </text>
<text top="292" left="278" width="53" height="19" font="4"><b>Size:</b> 9   <b> </b></text>
<text top="219" left="417" width="126" height="19" font="4"><b>Inclusion criteria:</b>  <b>9 </b></text>
<text top="238" left="417" width="111" height="19" font="3">Brugada patients, </text>
<text top="256" left="417" width="113" height="19" font="3">symptomatic with </text>
<text top="274" left="417" width="83" height="19" font="3">recurrent VF  </text>
<text top="292" left="417" width="3" height="19" font="3"> </text>
<text top="311" left="417" width="155" height="19" font="3">median 4 episodes/mon; </text>
<text top="329" left="417" width="155" height="19" font="3">median age 38 y; all with </text>
<text top="347" left="417" width="34" height="19" font="3">ICD’s </text>
<text top="366" left="417" width="3" height="19" font="3"> </text>
<text top="384" left="417" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="220" left="590" width="237" height="19" font="4"><b>1</b>°<b> endpoint:</b>  mapping and ablation of </text>
<text top="238" left="590" width="106" height="19" font="3">RVOT in Brugada </text>
<text top="257" left="590" width="3" height="19" font="3"> </text>
<text top="275" left="590" width="206" height="19" font="4"><b>Results:</b>  Anterior aspect of RVOT </text>
<text top="293" left="590" width="236" height="19" font="3">epicardium with late fractionate egms </text>
<text top="312" left="590" width="240" height="19" font="3">Ablation successful in 78% (7/9) VF not </text>
<text top="330" left="590" width="263" height="19" font="3">inducible, normalization of Brugada ECG in </text>
<text top="348" left="590" width="29" height="19" font="3">89% </text>
<text top="367" left="590" width="255" height="19" font="3">Followup 20±6 mo, no recurrent VT/VF in </text>
<text top="385" left="590" width="222" height="19" font="3">all patients off meds (except one on </text>
<text top="403" left="590" width="82" height="19" font="3">amiodarone) </text>
<text top="219" left="869" width="129" height="19" font="3">● BrS shows delayed </text>
<text top="238" left="869" width="209" height="19" font="3">repolarization over anterior RVOT </text>
<text top="256" left="869" width="79" height="19" font="3">epicardium.  </text>
<text top="274" left="869" width="191" height="19" font="3">● Ablation normalizes ECG and </text>
<text top="292" left="869" width="92" height="19" font="3">reduces VT/VF<b> </b></text>
<text top="311" left="869" width="3" height="19" font="3"> </text>
<text top="422" left="123" width="137" height="19" font="3">● Sunsaneewitaykul B </text>
<text top="441" left="123" width="126" height="19" font="3">et al. JCE 2012 (386) </text>
<text top="459" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22988965">● </a></text>
<text top="459" left="136" width="68" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22988965">22988965  </a></text>
<text top="459" left="203" width="3" height="19" font="18"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22988965"><b> </b></a></text>
<text top="422" left="278" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="441" left="278" width="126" height="19" font="3">Retrospective single </text>
<text top="459" left="278" width="43" height="19" font="3">center </text>
<text top="477" left="278" width="3" height="19" font="3"> </text>
<text top="495" left="278" width="57" height="19" font="4"><b>Size:</b>   10<b> </b></text>
<text top="422" left="417" width="138" height="19" font="4"><b>Inclusion criteria:</b>  BrS<b> </b></text>
<text top="441" left="417" width="158" height="19" font="3">patient’s EP mapping and </text>
<text top="459" left="417" width="147" height="19" font="3">ablation. between 8/07-</text>
<text top="477" left="417" width="40" height="19" font="3">12/08 </text>
<text top="496" left="417" width="146" height="19" font="3"> VF storm (4) and no VF </text>
<text top="514" left="417" width="63" height="19" font="3">storm (6)  </text>
<text top="532" left="417" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="423" left="590" width="230" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Ablation of zone of late </text>
<text top="441" left="590" width="116" height="19" font="3">activation in RVOT </text>
<text top="460" left="590" width="3" height="19" font="3"> </text>
<text top="478" left="590" width="258" height="19" font="4"><b>Results:</b>   Patients with VF storm: ablation </text>
<text top="496" left="590" width="244" height="19" font="3">modified Brugada ECG in 75% (3/4) and </text>
<text top="515" left="590" width="250" height="19" font="3">suppressed VF in all 4 during followup of </text>
<text top="533" left="590" width="185" height="19" font="3">12–30 mo. RBBB in ¼ patients </text>
<text top="422" left="869" width="206" height="19" font="3">● Ablation of late activation zone </text>
<text top="441" left="869" width="197" height="19" font="3">in RVOT may suppress VF storm </text>
<text top="459" left="869" width="161" height="19" font="3">and reduce VF recurrence </text>
<text top="552" left="123" width="141" height="19" font="3">● Zhang<b> </b>et al.<b> </b>HR 2016 </text>
<text top="570" left="123" width="35" height="19" font="3">(387)<b> </b></text>
<text top="589" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27453126">● </a></text>
<text top="589" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27453126">27453126</a></text>
<text top="589" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27453126"> </a></text>
<text top="552" left="278" width="110" height="19" font="4"><b>Study type:</b>   Two </text>
<text top="570" left="278" width="43" height="19" font="3">center </text>
<text top="589" left="278" width="88" height="19" font="3">retrospective  </text>
<text top="607" left="278" width="3" height="19" font="3"> </text>
<text top="625" left="278" width="61" height="19" font="4"><b>Size:</b>    11<b> </b></text>
<text top="552" left="417" width="138" height="19" font="4"><b>Inclusion criteria:</b>  BrS </text>
<text top="570" left="417" width="121" height="19" font="3">patients, 9 spont, 2 </text>
<text top="589" left="417" width="52" height="19" font="3">induced </text>
<text top="607" left="417" width="3" height="19" font="3"> </text>
<text top="625" left="417" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="553" left="590" width="222" height="19" font="4"><b>1</b>°<b> endpoint:  </b>Brugada mapping and </text>
<text top="571" left="590" width="179" height="19" font="3">ablation of RVOT epicardium </text>
<text top="589" left="590" width="3" height="19" font="3"> </text>
<text top="608" left="590" width="253" height="19" font="4"><b>Results:</b>  Normalization of spont Brugada </text>
<text top="626" left="590" width="109" height="19" font="3">ECG pattern in all </text>
<text top="644" left="590" width="194" height="19" font="3">73% free of VT/VF at 25±11 mo<b> </b></text>
<text top="552" left="869" width="212" height="19" font="3">● Ablation epicardial RVOT results </text>
<text top="570" left="869" width="200" height="19" font="3">in normalization of Brugada ECG </text>
<text top="589" left="869" width="118" height="19" font="3">and reduces VT/VF </text>
<text top="607" left="869" width="188" height="19" font="3">● ICD needed despite ablation </text>
<text top="663" left="123" width="138" height="19" font="3">● Brugada J et al.  Circ </text>
<text top="682" left="123" width="92" height="19" font="3">A E 2015 (388) </text>
<text top="700" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26291334">● </a></text>
<text top="700" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26291334">26291334</a></text>
<text top="700" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26291334"> </a></text>
<text top="663" left="278" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="682" left="278" width="82" height="19" font="3">Single center </text>
<text top="700" left="278" width="85" height="19" font="3">retrospective </text>
<text top="718" left="278" width="61" height="19" font="4"><b>Size:</b>    14<b> </b></text>
<text top="663" left="417" width="142" height="19" font="4"><b>Inclusion criteria:</b>  BrS, </text>
<text top="682" left="417" width="144" height="19" font="3">spont ECG, median age </text>
<text top="700" left="417" width="29" height="19" font="3">39 y </text>
<text top="718" left="417" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="664" left="590" width="231" height="19" font="4"><b>1</b>°<b> endpoint:</b> <b> </b>Epicardial mapping and </text>
<text top="683" left="590" width="159" height="19" font="3">ablation RVOT in Brugada </text>
<text top="701" left="590" width="248" height="19" font="4"><b>Results:</b>  Ablation resolved spontaneous </text>
<text top="719" left="590" width="82" height="19" font="3">Brugada ECG </text>
<text top="737" left="590" width="127" height="19" font="3">5 mo, no recurrence<b> </b></text>
<text top="663" left="869" width="157" height="19" font="3">● Ablation may eliminate </text>
<text top="682" left="869" width="213" height="19" font="3">spontaneous Brugada ECG pattern </text>
<text top="700" left="869" width="3" height="19" font="3"> </text>
</page>
<page number="216" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">216 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="105" height="19" font="3">● McNamara DA<b> </b></text>
<text top="127" left="123" width="134" height="19" font="3">● Cochrane Database </text>
<text top="145" left="123" width="123" height="19" font="3">Syst Rev 2015 (389) </text>
<text top="164" left="123" width="3" height="19" font="3"> </text>
<text top="109" left="278" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="127" left="278" width="126" height="19" font="3">Cochrane search for </text>
<text top="145" left="278" width="125" height="19" font="3">randomized trials of </text>
<text top="164" left="278" width="91" height="19" font="3">ICD vs medical </text>
<text top="182" left="278" width="88" height="19" font="3">treatment ion </text>
<text top="200" left="278" width="94" height="19" font="3">channelopathy </text>
<text top="219" left="278" width="3" height="19" font="3"> </text>
<text top="237" left="278" width="61" height="19" font="4"><b>Size:</b>  86  <b> </b></text>
<text top="109" left="417" width="107" height="19" font="4"><b>nclusion criteria: </b></text>
<text top="127" left="417" width="117" height="19" font="4"><b>patients </b>&gt;18 y, ion </text>
<text top="145" left="417" width="108" height="19" font="3">channelopathies, </text>
<text top="164" left="417" width="133" height="19" font="3">randomized to ICD vs </text>
<text top="182" left="417" width="143" height="19" font="3">medical rx, identified 2 </text>
<text top="200" left="417" width="159" height="19" font="3">studies including Brugada </text>
<text top="219" left="417" width="53" height="19" font="3">patients </text>
<text top="237" left="417" width="3" height="19" font="3"> </text>
<text top="255" left="417" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="109" left="590" width="248" height="19" font="4"><b>1</b>°<b> endpoint:</b>  All-cause mortality, ACE in </text>
<text top="128" left="590" width="74" height="19" font="3">BrS and ICD<b> </b></text>
<text top="146" left="590" width="3" height="19" font="4"><b> </b></text>
<text top="164" left="590" width="233" height="19" font="4"><b>Results:</b>  2 studies identified, Brugada </text>
<text top="183" left="590" width="163" height="19" font="3">Syndrome, same authors.  </text>
<text top="201" left="590" width="246" height="19" font="3">ICD: assoc with decreased risk mortality </text>
<text top="219" left="590" width="178" height="19" font="3">RR: 0.11; 95% CI: 0.01–0.83)  </text>
<text top="238" left="590" width="260" height="19" font="3">Adverse events higher in ICD: 28% vs 10%, </text>
<text top="256" left="590" width="175" height="19" font="3">RR: 2.44; 95% CI: 0.92–6.44) </text>
<text top="274" left="590" width="245" height="19" font="3">Non-fatal ACE higher in ICD: 26% vs 0%, </text>
<text top="293" left="590" width="175" height="19" font="3">RR: 11.4; 95% CI: 1.57–83.3)<b> </b></text>
<text top="109" left="869" width="207" height="19" font="3">● Decreased mortality in patients </text>
<text top="127" left="869" width="199" height="19" font="3">randomized to ICD in BrS: 9-fold </text>
<text top="145" left="869" width="62" height="19" font="3">reduction </text>
<text top="164" left="869" width="3" height="19" font="3"> </text>
<text top="182" left="869" width="183" height="19" font="3">● Brugada patients with prior </text>
<text top="200" left="869" width="180" height="19" font="3">ACA:  ICD treatment reduced </text>
<text top="219" left="869" width="59" height="19" font="3">mortality </text>
<text top="237" left="869" width="3" height="19" font="4"><b> </b></text>
<text top="312" left="123" width="122" height="19" font="3">● Delise P et al. EHJ </text>
<text top="330" left="123" width="69" height="19" font="3">2011 (348) </text>
<text top="348" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20978016">● </a></text>
<text top="348" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20978016">20978016</a></text>
<text top="348" left="197" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20978016"><b> </b></a></text>
<text top="311" left="278" width="118" height="19" font="4"><b>Study type:</b>  Multi- </text>
<text top="330" left="278" width="124" height="19" font="3">center prospective   </text>
<text top="348" left="278" width="3" height="19" font="3"> </text>
<text top="367" left="278" width="68" height="19" font="4"><b>Size:</b>    320<b> </b></text>
<text top="311" left="417" width="158" height="19" font="4"><b>Inclusion criteria:</b>  Type 1 </text>
<text top="330" left="417" width="86" height="19" font="3">Brugada ECG: </text>
<text top="348" left="417" width="148" height="19" font="3">spontaneous 54%, drug-</text>
<text top="367" left="417" width="89" height="19" font="3">induced 46%.  </text>
<text top="385" left="417" width="3" height="19" font="3"> </text>
<text top="403" left="417" width="108" height="19" font="3">Median age 43 y. </text>
<text top="422" left="417" width="69" height="19" font="3">Males 81% </text>
<text top="440" left="417" width="3" height="19" font="3"> </text>
<text top="458" left="417" width="124" height="19" font="3">Asymptomatic 66%, </text>
<text top="476" left="417" width="83" height="19" font="3">syncope 33% </text>
<text top="495" left="417" width="3" height="19" font="3"> </text>
<text top="513" left="417" width="83" height="19" font="3">No prior ACA </text>
<text top="531" left="417" width="3" height="19" font="3"> </text>
<text top="550" left="417" width="3" height="19" font="3"> </text>
<text top="568" left="417" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="312" left="590" width="245" height="19" font="4"><b>1</b>°<b> endpoint:</b> <b> </b>predictors in Brugada S of </text>
<text top="331" left="590" width="247" height="19" font="3">ACE (approp ICD shocks, sudden death)  </text>
<text top="349" left="590" width="3" height="19" font="3"> </text>
<text top="367" left="590" width="241" height="19" font="4"><b>Results:</b>  Median followup 40 mos (IQR </text>
<text top="386" left="590" width="46" height="19" font="3">20–67) </text>
<text top="404" left="590" width="255" height="19" font="3">5.3 % MACE (17 patients): VF on ICD (14), </text>
<text top="422" left="590" width="95" height="19" font="3">sudden death3 </text>
<text top="441" left="590" width="252" height="19" font="3">MACE occurred in 10.4% of symptomatic </text>
<text top="459" left="590" width="218" height="19" font="3">and 2.8% of asymptomatic patients </text>
<text top="477" left="590" width="62" height="19" font="3">(p=0.004) </text>
<text top="496" left="590" width="229" height="19" font="3">ICD’s implanted in 34%(110 patients) </text>
<text top="514" left="590" width="244" height="19" font="3">PES performed in 245 (76%): positive in </text>
<text top="532" left="590" width="200" height="19" font="3">50% of symptomatic and 32% of </text>
<text top="550" left="590" width="150" height="19" font="3">asymptomatic patients.  </text>
<text top="569" left="590" width="218" height="19" font="3">MACE in 14% of positive PES, 0% of </text>
<text top="587" left="590" width="208" height="19" font="3">negative, 5.3% of no EPS: positive </text>
<text top="606" left="590" width="263" height="19" font="3">predictive values 14%, negative pred value </text>
<text top="624" left="590" width="37" height="19" font="3">100% </text>
<text top="642" left="590" width="231" height="19" font="3">VF occurred in 15.5% of patients with </text>
<text top="660" left="590" width="260" height="19" font="3">inducible VF using doubles, 8.6% of triples </text>
<text top="679" left="590" width="202" height="19" font="3">Combination of risk factors most </text>
<text top="697" left="590" width="248" height="19" font="3">significant: spont ECG, family Hx sudden </text>
<text top="715" left="590" width="243" height="19" font="3">death, syncope, positive EPS: no events </text>
<text top="734" left="590" width="258" height="19" font="3">occurred in patients without any of above </text>
<text top="752" left="590" width="175" height="19" font="3">or with only one risk factor.  </text>
<text top="312" left="869" width="197" height="19" font="3">● Combining ≥2 risk factors was </text>
<text top="330" left="869" width="150" height="19" font="3">useful risk stratification: </text>
<text top="348" left="869" width="153" height="19" font="3">Spontaneous type 1 ECG </text>
<text top="367" left="869" width="210" height="19" font="3">Family Hx sudden death, syncope, </text>
<text top="385" left="869" width="76" height="19" font="3">positive PES </text>
<text top="403" left="869" width="207" height="19" font="3">● MACE occurred only in patients </text>
<text top="422" left="869" width="119" height="19" font="3">with ≥2 risk factors </text>
<text top="440" left="869" width="132" height="19" font="3">● MACE event rates:  </text>
<text top="458" left="868" width="174" height="19" font="3">3.0%/pt/yr in symptomatic,  </text>
<text top="476" left="868" width="174" height="19" font="3">0.8%/pt/yr in asymptomatic </text>
<text top="495" left="868" width="190" height="19" font="3">● PES can be useful in patients </text>
<text top="513" left="868" width="209" height="19" font="3">with spontaneous type 1 ECG and </text>
<text top="531" left="868" width="178" height="19" font="3">no other risk factors; may be </text>
<text top="550" left="868" width="162" height="19" font="3">helpful to identify low risk </text>
<text top="568" left="868" width="53" height="19" font="3">patients </text>
</page>
<page number="217" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">217 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="590" width="258" height="19" font="3">Spontaneous type 1 ECG: if additional risk </text>
<text top="127" left="590" width="181" height="19" font="3">factors, 30% MACE (p&lt;0.001) </text>
<text top="146" left="123" width="118" height="19" font="3">● Sieira J et al. Circ </text>
<text top="164" left="123" width="138" height="19" font="3">Arrhyth EP 2015 (390) </text>
<text top="183" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26215662">● </a></text>
<text top="183" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26215662">26215662</a></text>
<text top="183" left="197" width="3" height="19" font="24"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26215662"><b> </b></a></text>
<text top="201" left="123" width="3" height="19" font="3"> </text>
<text top="146" left="278" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="164" left="278" width="43" height="19" font="3">center </text>
<text top="183" left="278" width="85" height="19" font="3">retrospective </text>
<text top="201" left="278" width="3" height="19" font="3"> </text>
<text top="219" left="278" width="68" height="19" font="4"><b>Size:</b>   363 <b> </b></text>
<text top="146" left="417" width="115" height="19" font="4"><b>Inclusion criteria:</b> <b> </b></text>
<text top="164" left="417" width="144" height="19" font="3">Asymptomatic patients </text>
<text top="183" left="417" width="135" height="19" font="3">type 1 BrS ECG, spont </text>
<text top="201" left="417" width="144" height="19" font="3">(11%) or drug-induced. </text>
<text top="219" left="417" width="134" height="19" font="3"> Mean age 40.9±17 y, </text>
<text top="238" left="417" width="76" height="19" font="3">55% males.  </text>
<text top="256" left="417" width="150" height="19" font="3">321 patients underwent </text>
<text top="274" left="417" width="33" height="19" font="3">PES.<b>  </b></text>
<text top="293" left="417" width="152" height="19" font="3">22%<b> </b>genotype + SCN5A.  </text>
<text top="311" left="417" width="3" height="19" font="3"> </text>
<text top="329" left="417" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="147" left="590" width="217" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Event-free survival in </text>
<text top="165" left="590" width="71" height="19" font="3">Brugada S.  </text>
<text top="183" left="590" width="168" height="19" font="3">Mean followup 73±59 mo.  </text>
<text top="202" left="590" width="3" height="19" font="3"> </text>
<text top="220" left="590" width="261" height="19" font="4"><b>Results:</b>  PES positive in 10% (32 patients)  </text>
<text top="238" left="590" width="224" height="19" font="3">ICD’s implanted 17% (61 patients), 6 </text>
<text top="257" left="590" width="66" height="19" font="3">approp rx. </text>
<text top="275" left="590" width="244" height="19" font="3">Event free survival: 99% 1 y, 96% at 5 y, </text>
<text top="293" left="590" width="137" height="19" font="3">95.4% at 10 and 15 y.  </text>
<text top="312" left="590" width="241" height="19" font="3">Arrhythmic events: 9, annual incidence </text>
<text top="330" left="590" width="33" height="19" font="3">0.5% </text>
<text top="348" left="590" width="239" height="19" font="3">Multivariate analysis: Positive PES only </text>
<text top="367" left="590" width="256" height="19" font="3">significant predictor (HR: 9.1, 95% CI: 1.8–</text>
<text top="385" left="590" width="84" height="19" font="3">46.8, p&lt;0.01) </text>
<text top="146" left="869" width="157" height="19" font="3">● Brugada S: Positive PES </text>
<text top="164" left="869" width="199" height="19" font="3">predictor of adverse events, HR: </text>
<text top="183" left="869" width="26" height="19" font="3">9.1. </text>
<text top="201" left="869" width="203" height="19" font="3">● Event free survival 95.4% at 10 </text>
<text top="219" left="869" width="55" height="19" font="3">and 15 y </text>
<text top="238" left="869" width="3" height="19" font="3"> </text>
<text top="256" left="869" width="3" height="19" font="4"><b> </b></text>
<text top="404" left="123" width="129" height="19" font="3">● Konigstein M et al. </text>
<text top="422" left="123" width="122" height="19" font="3">Heart Rhythm 2016 </text>
<text top="441" left="123" width="35" height="19" font="3">(391) </text>
<text top="459" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27131070">● </a></text>
<text top="459" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27131070">27131070</a></text>
<text top="459" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27131070"> </a></text>
<text top="404" left="278" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="422" left="278" width="74" height="19" font="3">multicenter </text>
<text top="441" left="278" width="85" height="19" font="3">retrospective </text>
<text top="459" left="278" width="3" height="19" font="3"> </text>
<text top="477" left="278" width="61" height="19" font="4"><b>Size:</b>    74<b> </b></text>
<text top="404" left="417" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="422" left="417" width="141" height="19" font="3">Brugada database non-</text>
<text top="441" left="417" width="132" height="19" font="3">cardiac drug-induced </text>
<text top="459" left="417" width="143" height="19" font="3">Brugada patients; each </text>
<text top="477" left="417" width="144" height="19" font="3">with 5 healthy controls </text>
<text top="496" left="417" width="119" height="19" font="3">Mean age 39±16 y. </text>
<text top="514" left="417" width="69" height="19" font="3">77% males </text>
<text top="532" left="417" width="3" height="19" font="3"> </text>
<text top="550" left="417" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="405" left="590" width="242" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Outcomes of non-cardiac </text>
<text top="423" left="590" width="108" height="19" font="3">drug-induced BrS </text>
<text top="441" left="590" width="3" height="19" font="3"> </text>
<text top="460" left="590" width="256" height="19" font="4"><b>Results:</b> By definition: “spontaneous type </text>
<text top="478" left="590" width="49" height="19" font="3">1” ECG: </text>
<text top="496" left="590" width="203" height="19" font="3">49% psychotropic meds (lithium, </text>
<text top="515" left="590" width="252" height="19" font="3">amitriptyline), 27% anesthetic/analgesic, </text>
<text top="533" left="590" width="211" height="19" font="3">24% other; of total, 20% propofol  </text>
<text top="551" left="590" width="243" height="19" font="3">occurred predominantly in adult males, </text>
<text top="570" left="590" width="262" height="19" font="3">frequently due to drug toxicity, occurs late </text>
<text top="588" left="590" width="155" height="19" font="3">after onset of treatment  </text>
<text top="606" left="590" width="258" height="19" font="3">Off-drug ECG’s: 33% type IIC Brugada ECG<b> </b></text>
<text top="404" left="869" width="204" height="19" font="3">● Non-cardiac drug induced type </text>
<text top="422" left="869" width="97" height="19" font="3">1 Brugada ECG: </text>
<text top="441" left="869" width="141" height="19" font="3">● 26% VF/pulseless VT </text>
<text top="459" left="868" width="113" height="19" font="3">● 13.5% mortality<b> </b></text>
<text top="625" left="123" width="134" height="19" font="3">● Sroubek J et al. Circ </text>
<text top="643" left="123" width="69" height="19" font="3">2016 (392) </text>
<text top="662" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26797467">● </a></text>
<text top="662" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26797467">26797467</a></text>
<text top="662" left="197" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26797467"><b> </b></a></text>
<text top="680" left="123" width="3" height="19" font="4"><b> </b></text>
<text top="625" left="278" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="643" left="278" width="114" height="19" font="3">Systematic review </text>
<text top="662" left="278" width="123" height="19" font="3">and pooled analysis </text>
<text top="680" left="278" width="90" height="19" font="3">of prospective </text>
<text top="698" left="278" width="86" height="19" font="3">observational </text>
<text top="717" left="278" width="50" height="19" font="3">studies  </text>
<text top="735" left="278" width="3" height="19" font="4"><b> </b></text>
<text top="753" left="278" width="100" height="19" font="4"><b>Size:   </b>8 studies, </text>
<text top="772" left="278" width="87" height="19" font="3">1312 patients<b> </b></text>
<text top="625" left="417" width="138" height="19" font="4"><b>Inclusion criteria</b>:  BrS </text>
<text top="643" left="417" width="133" height="19" font="3">patients without ACA </text>
<text top="662" left="417" width="126" height="19" font="3">who underwent PES </text>
<text top="680" left="417" width="156" height="19" font="3">Mean age 44.9 ±13.3 yrs; </text>
<text top="698" left="417" width="134" height="19" font="3">79% male; 53% spont </text>
<text top="717" left="417" width="70" height="19" font="3">type 1 ECG<b> </b></text>
<text top="735" left="417" width="3" height="19" font="3"> </text>
<text top="753" left="417" width="121" height="19" font="3">Prior Syncope 33%; </text>
<text top="772" left="417" width="3" height="19" font="4"><b> </b></text>
<text top="626" left="590" width="259" height="19" font="4"><b>1</b>°<b> endpoint:</b>  CA or appropriate ICD shock </text>
<text top="644" left="590" width="86" height="19" font="3">in Brugada S.  </text>
<text top="662" left="590" width="3" height="19" font="4"><b> </b></text>
<text top="681" left="590" width="258" height="19" font="4"><b>Results:  </b>PES induced sust VEA (40%).with </text>
<text top="699" left="590" width="241" height="19" font="3">up to triple extrastimuli in 527 patients </text>
<text top="718" left="590" width="223" height="19" font="3">(2%, single; double 18%; triples 28% </text>
<text top="736" left="590" width="255" height="19" font="3"> AICD’s implanted in 576 patients: 77% of </text>
<text top="754" left="590" width="234" height="19" font="3">ICD implanted in PES positive patients </text>
<text top="625" left="869" width="187" height="19" font="3">● Positive PES associated with </text>
<text top="643" left="869" width="157" height="19" font="3">increased risk ACE during </text>
<text top="662" left="869" width="179" height="19" font="3">followup; induction with 1–2 </text>
<text top="680" left="869" width="174" height="19" font="3">extrastimuli associated with </text>
<text top="698" left="869" width="74" height="19" font="3">higher risk.  </text>
<text top="717" left="869" width="196" height="19" font="3">● Specificity of induction as risk </text>
<text top="735" left="869" width="192" height="19" font="3">predictor decreased with triple </text>
<text top="753" left="869" width="33" height="19" font="3">VEST </text>
</page>
<page number="218" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">218 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="417" width="144" height="19" font="4"><b>Exclusion criteria:  </b>N/A<b> </b></text>
<text top="109" left="590" width="220" height="19" font="3">65 patients experienced ACE during </text>
<text top="127" left="590" width="263" height="19" font="3">median followup 38 mo: 5 CA, appropriate </text>
<text top="145" left="590" width="88" height="19" font="3">ICD shock 60.  </text>
<text top="164" left="590" width="262" height="19" font="3">Positive PES assoc with increased risk ACE: </text>
<text top="182" left="590" width="240" height="19" font="3">HR: 2.66, 95% CI: 1.44–4.92, p &lt;0.001); </text>
<text top="200" left="590" width="252" height="19" font="3">greatest risk in those induced with single </text>
<text top="219" left="590" width="250" height="19" font="3">(HR: 1.99, 95% CI: 0.52–7.68, p=0.32); or </text>
<text top="237" left="590" width="233" height="19" font="3">double extrastimuli (HR: 2.55, 95% CI: </text>
<text top="255" left="590" width="254" height="19" font="3">1.34–4.88, p=0.005), vs. triples (HR: 2.08, </text>
<text top="273" left="590" width="166" height="19" font="3">95% CI: 0.98–4.39, p=0.06) </text>
<text top="292" left="590" width="232" height="19" font="3">Clinical variables useful: annual event </text>
<text top="310" left="590" width="257" height="19" font="3">rates for no syncope, drug induced type 1 </text>
<text top="329" left="590" width="250" height="19" font="3">ECG: 0.27% (95% CI: 0.07–0.68); Positive </text>
<text top="347" left="590" width="232" height="19" font="3">syncope and spont type 1 ECG 3.22%; </text>
<text top="365" left="590" width="117" height="19" font="3">(95% CI: 2.23–4.5)  </text>
<text top="383" left="590" width="258" height="19" font="3">Highest risk: + syncope, spont type 1 ECG: </text>
<text top="402" left="590" width="227" height="19" font="3">neg PES HR: 2.55; 95% CI: 1.58–3.89; </text>
<text top="420" left="590" width="244" height="19" font="3"> positive PES HR: 5.6; 95% CI: 2.98–9.58 </text>
<text top="438" left="590" width="221" height="19" font="3">Annual incidence rates of CA or VT:  </text>
<text top="457" left="590" width="252" height="19" font="3">Asymptomatic, spont type 1 ECG: annual </text>
<text top="475" left="590" width="251" height="19" font="3">events 1.04 (95% CI: 0.61–1.67): positive </text>
<text top="493" left="590" width="262" height="19" font="3">PES 1.70 (95% CI: 0.73–3.35); negative PES </text>
<text top="512" left="590" width="152" height="19" font="3">0.78 (95% CI: 0.36–1.47) </text>
<text top="530" left="590" width="260" height="19" font="3">Asymptomatic, drug ind ECG: overall 0.27, </text>
<text top="548" left="590" width="257" height="19" font="3">neg PES 0.23 (95% CI: 0.05–0.68), pos PES </text>
<text top="566" left="590" width="152" height="19" font="3">0.45 (95% CI: 0.01–2.49) </text>
<text top="585" left="590" width="240" height="19" font="3">Spont type 1 ECG:  asymptomatic, with </text>
<text top="603" left="590" width="240" height="19" font="3">neg PES: annual event incidence 0.78% </text>
<text top="621" left="590" width="259" height="19" font="3">(95% CI: 0.36–1.47); pos PES 1.70 (95% CI: </text>
<text top="640" left="590" width="76" height="19" font="3">0.73–3.35).  </text>
<text top="658" left="590" width="258" height="19" font="3">Prior syncope and neg PES 2.55% (95% CI: </text>
<text top="676" left="590" width="232" height="19" font="3">1.58–3.89); Positive PES 5.60 (95% CI: </text>
<text top="695" left="590" width="69" height="19" font="3">2.98–9.58) </text>
<text top="713" left="590" width="240" height="19" font="3">Drug induced ECG: asymptomatic:  neg </text>
<text top="731" left="590" width="243" height="19" font="3">PES 0.23% (95% CI: 0.05–0.68); positive </text>
<text top="750" left="590" width="214" height="19" font="3">PES 0.45 (95% CI: 0.01–2.49); prior </text>
<text top="768" left="590" width="244" height="19" font="3">syncope and negative PES 1.29 (95% CI: </text>
<text top="109" left="869" width="192" height="19" font="3">● Negative PES did not identify </text>
<text top="127" left="869" width="119" height="19" font="3">low risk individuals<i> </i></text>
<text top="145" left="869" width="212" height="19" font="3">● Annual event rates varied based </text>
<text top="164" left="869" width="200" height="19" font="3">on syncope, spontaneous type 1 </text>
<text top="182" left="869" width="139" height="19" font="3">ECG, and positive PES: </text>
<text top="200" left="869" width="188" height="19" font="3">● Asymptomatic patients with </text>
<text top="219" left="869" width="204" height="19" font="3">spont type ECG and positive PES: </text>
<text top="237" left="869" width="209" height="19" font="3">annual incidence 1.70 (0.73–3.35) </text>
<text top="255" left="869" width="213" height="19" font="3">● Aymptomatic patients with drug </text>
<text top="273" left="869" width="162" height="19" font="3">ind ECG and + PES: annual </text>
<text top="292" left="869" width="165" height="19" font="3">incidence 0.45 (0.01–2.49) </text>
<text top="310" left="869" width="170" height="19" font="3">● Clinical factors important </text>
<text top="329" left="869" width="188" height="19" font="3">determinants of risk: syncope; </text>
<text top="347" left="869" width="108" height="19" font="3">spont type 1 ECG </text>
<text top="365" left="869" width="188" height="19" font="3">● Asymptomatic patients with </text>
<text top="383" left="869" width="202" height="19" font="3">drug induced ECG patterns: “PES </text>
<text top="402" left="869" width="146" height="19" font="3">may not be warranted” </text>
<text top="420" left="869" width="153" height="19" font="3">● Symptomatic patients: </text>
<text top="438" left="868" width="198" height="19" font="3">increased risk with positive PES, </text>
<text top="457" left="868" width="172" height="19" font="3">but risk exists with neg PES: </text>
<text top="475" left="868" width="212" height="19" font="3">higher if spont type 1 ECG: ? value </text>
<text top="493" left="868" width="45" height="19" font="3">of  PES </text>
</page>
<page number="219" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">219 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="590" width="232" height="19" font="3">0.52–2.67); positive PES 1.96 (95% CI: </text>
<text top="127" left="590" width="69" height="19" font="3">0.40–5.73)<b> </b></text>
<text top="146" left="123" width="129" height="19" font="3">● Sieira J et al. Heart </text>
<text top="164" left="123" width="69" height="19" font="3">2016 (393) </text>
<text top="183" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26740482">● </a></text>
<text top="183" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26740482">26740482</a></text>
<text top="183" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26740482"> </a></text>
<text top="201" left="123" width="3" height="19" font="3"> </text>
<text top="146" left="278" width="117" height="19" font="4"><b>Study type:</b>  Single </text>
<text top="164" left="278" width="43" height="19" font="3">center </text>
<text top="183" left="278" width="85" height="19" font="3">retrospective </text>
<text top="201" left="278" width="3" height="19" font="3"> </text>
<text top="219" left="278" width="68" height="19" font="4"><b>Size:</b>   228 <b> </b></text>
<text top="146" left="417" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="164" left="417" width="110" height="19" font="3">Women with BrS, </text>
<text top="183" left="417" width="124" height="19" font="3">spontaneous 8%, or </text>
<text top="201" left="417" width="52" height="19" font="3">induced </text>
<text top="219" left="417" width="3" height="19" font="3"> </text>
<text top="237" left="417" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="147" left="590" width="217" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Brugada outcomes in </text>
<text top="165" left="590" width="190" height="19" font="3">women, mean followup 73 mo </text>
<text top="183" left="590" width="3" height="19" font="3"> </text>
<text top="202" left="590" width="197" height="19" font="4"><b>Results:</b>  Mean age 41.5± 17.3 y </text>
<text top="220" left="590" width="229" height="19" font="3">women = 42% of Brugada population </text>
<text top="238" left="590" width="241" height="19" font="3">Spontaneous type 1 ECG 7.9% vs males </text>
<text top="257" left="590" width="78" height="19" font="3">23%, p&lt;0.01 </text>
<text top="275" left="590" width="249" height="19" font="3">ICD implanted in 28%, event rate 0.7%/y </text>
<text top="293" left="590" width="89" height="19" font="3">vs 1.9% males<b> </b></text>
<text top="146" left="869" width="97" height="19" font="3">● BrS Females:  </text>
<text top="164" left="869" width="186" height="19" font="3">● Less severe than males, less </text>
<text top="183" left="869" width="108" height="19" font="3">spont type 1 ECG </text>
<text top="201" left="869" width="168" height="19" font="3">● Event rate 0.7%/y (males </text>
<text top="219" left="869" width="50" height="19" font="3">1.9%/y) </text>
<text top="238" left="869" width="167" height="19" font="3">Higher risk: prior ACA, SND<b> </b></text>
<text top="312" left="123" width="119" height="19" font="3">● Priori S et al. Circ </text>
<text top="331" left="123" width="69" height="19" font="3">2002 (394) </text>
<text top="349" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11901046">● </a></text>
<text top="349" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11901046">11901046</a></text>
<text top="349" left="197" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11901046"><b> </b></a></text>
<text top="312" left="278" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="331" left="278" width="75" height="19" font="3">Multicenter </text>
<text top="349" left="278" width="88" height="19" font="3">retrospective  </text>
<text top="367" left="278" width="3" height="19" font="3"> </text>
<text top="386" left="278" width="68" height="19" font="4"><b>Size:</b>   200 <b> </b></text>
<text top="312" left="417" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="331" left="417" width="123" height="19" font="3">Brugada S with ECG </text>
<text top="349" left="417" width="150" height="19" font="3">changes, spont (51%) or </text>
<text top="367" left="417" width="52" height="19" font="3">induced </text>
<text top="386" left="417" width="3" height="19" font="3"> </text>
<text top="404" left="417" width="91" height="19" font="3">130 probands  </text>
<text top="422" left="417" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="313" left="590" width="265" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Brugada risk stratification for </text>
<text top="332" left="590" width="27" height="19" font="3">SCD </text>
<text top="350" left="590" width="128" height="19" font="3">PES performed in 86 </text>
<text top="368" left="590" width="3" height="19" font="3"> </text>
<text top="386" left="590" width="203" height="19" font="4"><b>Results:</b> SCN5A identified in 22% </text>
<text top="405" left="590" width="212" height="19" font="3">probands, 46% of family members </text>
<text top="423" left="590" width="227" height="19" font="3">Risk analysis: gender; ECG, family hx, </text>
<text top="441" left="590" width="170" height="19" font="3">mutation status, symptoms </text>
<text top="460" left="590" width="256" height="19" font="3">Syncope without ST elevation on baseline </text>
<text top="478" left="590" width="95" height="19" font="3">ECG: not a risk  </text>
<text top="496" left="590" width="254" height="19" font="3">Syncope AND ST elevation: increased risk </text>
<text top="515" left="590" width="135" height="19" font="3">SCD, HR: 6.4, p&lt;0.002<b> </b></text>
<text top="312" left="869" width="186" height="19" font="3">● Multivariable risk predictor: </text>
<text top="331" left="869" width="200" height="19" font="3">spontaneous ST elevation V1-V3 </text>
<text top="349" left="869" width="115" height="19" font="3">and Hx of syncope </text>
<text top="367" left="869" width="200" height="19" font="3">● Syncope without spontaneous </text>
<text top="386" left="869" width="177" height="19" font="3">ST elevation not a risk factor </text>
<text top="404" left="869" width="126" height="19" font="3">● PES not predictive </text>
<text top="422" left="869" width="161" height="19" font="3">Mutation carriers without </text>
<text top="441" left="869" width="127" height="19" font="3">phenotype: low risk  </text>
<text top="534" left="123" width="131" height="19" font="3">● Fauchier L et al. IJC </text>
<text top="552" left="123" width="30" height="19" font="3">2013</text>
<text top="550" left="154" width="4" height="21" font="0"> </text>
<text top="552" left="157" width="35" height="19" font="3">(395)<b> </b></text>
<text top="570" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23642819">● </a></text>
<text top="570" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23642819">23642819</a></text>
<text top="570" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23642819"> </a></text>
<text top="534" left="278" width="117" height="19" font="4"><b>Study type:</b>   meta-</text>
<text top="552" left="278" width="55" height="19" font="3">analysis  </text>
<text top="570" left="278" width="3" height="19" font="3"> </text>
<text top="588" left="278" width="76" height="19" font="4"><b>Size:</b>    1789<b> </b></text>
<text top="534" left="417" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="552" left="417" width="117" height="19" font="3">Brugada S patients </text>
<text top="570" left="417" width="98" height="19" font="3">undergoing PES </text>
<text top="589" left="417" width="148" height="19" font="3">ACA 11%, syncope 31%, </text>
<text top="607" left="417" width="119" height="19" font="3">asymptomatic 57% </text>
<text top="625" left="417" width="3" height="19" font="3"> </text>
<text top="643" left="417" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="534" left="590" width="247" height="19" font="4"><b>1</b>°<b> endpoint:</b>  utility of PES in Brugada S: </text>
<text top="553" left="590" width="248" height="19" font="3">adverse event = sust VT/VF, appropriate </text>
<text top="571" left="590" width="158" height="19" font="3">ICD shock, sudden death) </text>
<text top="589" left="590" width="3" height="19" font="3"> </text>
<text top="608" left="590" width="254" height="19" font="4"><b>Results:</b>  Inducible VT/VF associated with </text>
<text top="626" left="590" width="243" height="19" font="3">higher risk arrhythmic event in patients </text>
<text top="644" left="590" width="229" height="19" font="3">with prior syncope (OR: 3.30, 95% CI: </text>
<text top="663" left="590" width="264" height="19" font="3">1.68–6.51, p=0.0006) and in asymptomatic </text>
<text top="681" left="590" width="233" height="19" font="3">patients (OR: 4.62, 95% CI: 2.14–9.97, </text>
<text top="699" left="590" width="65" height="19" font="3">p&lt;0.0001)<b> </b></text>
<text top="534" left="869" width="195" height="20" font="3">• Inducibility of VT in Brugada S </text>
<text top="553" left="868" width="153" height="19" font="3">patients with syncope or </text>
<text top="571" left="868" width="188" height="19" font="3">asymptomatic may identify an </text>
<text top="590" left="868" width="177" height="19" font="3">increased risk of subsequent </text>
<text top="608" left="868" width="44" height="19" font="3">events<b> </b></text>
<text top="718" left="123" width="130" height="19" font="3">● Rodriguez-Manero </text>
<text top="737" left="123" width="139" height="19" font="3">M et al. Heart Rhythm </text>
<text top="755" left="123" width="30" height="19" font="3">2016</text>
<text top="753" left="154" width="4" height="21" font="0"> </text>
<text top="755" left="157" width="35" height="19" font="3">(396) </text>
<text top="773" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26538325">●<b> </b></a></text>
<text top="773" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26538325">26538325</a></text>
<text top="773" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26538325"> </a></text>
<text top="718" left="278" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="737" left="278" width="120" height="19" font="3">retrospective multi </text>
<text top="755" left="278" width="43" height="19" font="3">center </text>
<text top="773" left="278" width="3" height="19" font="3"> </text>
<text top="718" left="417" width="138" height="19" font="4"><b>Inclusion criteria:</b>  BrS </text>
<text top="737" left="417" width="160" height="19" font="3">patients with implantable </text>
<text top="755" left="417" width="24" height="19" font="3">ICD </text>
<text top="773" left="417" width="69" height="19" font="3">1993-2014 </text>
<text top="719" left="590" width="232" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ICD usage and comps in </text>
<text top="737" left="590" width="68" height="19" font="3">Brugada S. </text>
<text top="756" left="590" width="166" height="19" font="3">followup mean 69 ± 54 mo </text>
<text top="774" left="590" width="234" height="19" font="4"><b>Results:</b>  13.7% at least one approp rx </text>
<text top="718" left="869" width="31" height="19" font="3">BrS:  </text>
<text top="737" left="869" width="160" height="19" font="3">● ICD approp use in ~14% </text>
<text top="755" left="869" width="170" height="19" font="3">● Monomorphic VT in 4.2% </text>
</page>
<page number="220" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">220 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="278" width="68" height="19" font="4"><b>Size:</b>   834 <b> </b></text>
<text top="109" left="417" width="126" height="19" font="3">mean age 45±13.9 y </text>
<text top="127" left="417" width="79" height="19" font="3">24% women </text>
<text top="145" left="417" width="3" height="19" font="3"> </text>
<text top="164" left="417" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="182" left="417" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="590" width="239" height="19" font="3">Monomorphic VT recorded in 4.2% (35 </text>
<text top="127" left="590" width="250" height="19" font="3">patients), sensitive to anti-tach pacing in </text>
<text top="145" left="590" width="29" height="19" font="3">43% </text>
<text top="164" left="590" width="245" height="19" font="3">Monomorphic VT from RVOT 6, LVOT 2, </text>
<text top="182" left="590" width="207" height="19" font="3">BBR 2 successfully ablated in 80% </text>
<text top="109" left="869" width="210" height="19" font="3">● Successful ablation in 80% of 10 </text>
<text top="127" left="869" width="186" height="19" font="3">patients with outflow tract VT </text>
<text top="201" left="123" width="127" height="19" font="3">● Sacher F et al. Circ </text>
<text top="219" left="123" width="30" height="19" font="3">2013</text>
<text top="218" left="154" width="4" height="21" font="0"> </text>
<text top="219" left="157" width="35" height="19" font="3">(397)<b> </b></text>
<text top="238" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23995538">● </a></text>
<text top="238" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23995538">23995538</a></text>
<text top="237" left="197" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23995538"><b> </b></a></text>
<text top="201" left="278" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="219" left="278" width="87" height="19" font="3">Retrospective </text>
<text top="238" left="278" width="79" height="19" font="3">multi-center </text>
<text top="256" left="278" width="3" height="19" font="3"> </text>
<text top="274" left="278" width="68" height="19" font="4"><b>Size:</b>  378  <b> </b></text>
<text top="201" left="417" width="138" height="19" font="4"><b>Inclusion criteria:</b>  BrS </text>
<text top="219" left="417" width="108" height="19" font="3">patients with ICD </text>
<text top="238" left="417" width="115" height="19" font="3">Mean age 46±13 y </text>
<text top="256" left="417" width="134" height="19" font="3">ACA 31, syncope 181, </text>
<text top="274" left="417" width="116" height="19" font="3">asymptomatic 166 </text>
<text top="293" left="417" width="3" height="19" font="3"> </text>
<text top="311" left="417" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="202" left="590" width="215" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ICD outcomes in BrS<b>,</b> </text>
<text top="220" left="590" width="160" height="19" font="3">followup mean 77±42 mo </text>
<text top="238" left="590" width="3" height="19" font="3"> </text>
<text top="257" left="590" width="209" height="19" font="4"><b>Results:</b>  appropriate shocks 12%, </text>
<text top="275" left="590" width="224" height="19" font="3">Shock rates highest for ACA patients </text>
<text top="293" left="590" width="248" height="19" font="3">(48%), syncope 19%, 12% asymptomatic </text>
<text top="312" left="590" width="236" height="19" font="3">Inaapropriate shocks 24%; due to lead </text>
<text top="330" left="590" width="250" height="19" font="3">failure, SVT, T wave oversensing or sinus </text>
<text top="348" left="590" width="138" height="19" font="3">tach. Lead failure 29% </text>
<text top="201" left="869" width="166" height="19" font="3">● Approp ICD shocks more </text>
<text top="219" left="869" width="190" height="19" font="3">prevalent in symptomatic BrS;  </text>
<text top="238" left="869" width="171" height="19" font="3">Asymptomatic patients had </text>
<text top="256" left="869" width="126" height="19" font="3">approp shocks 1%/y </text>
<text top="274" left="869" width="180" height="19" font="3">● Optimal programming may </text>
<text top="293" left="869" width="148" height="19" font="3">reduce inapprop shocks </text>
<text top="311" left="869" width="163" height="19" font="3">● Lead failure a significant </text>
<text top="329" left="869" width="55" height="19" font="3">problem </text>
<text top="367" left="123" width="115" height="19" font="3">● Rosso R et al. Isr </text>
<text top="386" left="123" width="108" height="19" font="3">Med Assoc J 2008</text>
<text top="384" left="231" width="4" height="21" font="0"> </text>
<text top="404" left="123" width="35" height="19" font="3">(398) </text>
<text top="422" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18669142">● </a></text>
<text top="422" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18669142">18669142</a></text>
<text top="422" left="197" width="3" height="19" font="24"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18669142"><b> </b></a></text>
<text top="441" left="123" width="3" height="19" font="3"> </text>
<text top="367" left="278" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="386" left="278" width="121" height="19" font="3">retrospective multi-</text>
<text top="404" left="278" width="117" height="19" font="3">center, 12 centers, </text>
<text top="422" left="278" width="69" height="19" font="3">1994-2007 </text>
<text top="441" left="278" width="3" height="19" font="3"> </text>
<text top="459" left="278" width="61" height="19" font="4"><b>Size:</b>  59  <b> </b></text>
<text top="367" left="417" width="138" height="19" font="4"><b>Inclusion criteria:</b>  BrS </text>
<text top="386" left="417" width="108" height="19" font="3">patients with ICD </text>
<text top="404" left="417" width="104" height="19" font="3">Mean age 44.1 y </text>
<text top="422" left="417" width="3" height="19" font="3"> </text>
<text top="441" left="417" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="368" left="590" width="264" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Followup efficacy and comps </text>
<text top="386" left="590" width="116" height="19" font="3">of ICD in Brugada;  </text>
<text top="405" left="590" width="122" height="19" font="3">followup 45±35 mo </text>
<text top="423" left="590" width="3" height="19" font="3"> </text>
<text top="441" left="590" width="219" height="19" font="4"><b>Results:</b>  Symptoms 71%: ACA 19%, </text>
<text top="460" left="590" width="179" height="19" font="3">syncope 53%, inducible VF in </text>
<text top="478" left="590" width="264" height="19" font="3">asymptomatic patients 24%, family Hx SCD </text>
<text top="496" left="590" width="37" height="19" font="3">0.5%. </text>
<text top="515" left="590" width="239" height="19" font="3">Appropriate shocks 8.4%, all with prior </text>
<text top="533" left="590" width="29" height="19" font="3">ACA </text>
<text top="551" left="590" width="74" height="19" font="3">Comps 32% </text>
<text top="570" left="590" width="161" height="19" font="3">Inappropriate shocks 27% </text>
<text top="588" left="590" width="251" height="19" font="3">Psych problems 13.5%, mainly related to </text>
<text top="606" left="590" width="131" height="19" font="3">inappropriate shocks </text>
<text top="367" left="869" width="192" height="19" font="3">● Appropriate shocks occurred </text>
<text top="386" left="869" width="211" height="19" font="3">only in symptomatic patients with </text>
<text top="404" left="869" width="62" height="19" font="3">prior ACA </text>
<text top="422" left="869" width="195" height="19" font="3">● VF inducibility did not predict </text>
<text top="441" left="869" width="91" height="19" font="3">approp shocks </text>
<text top="459" left="869" width="154" height="19" font="3">● High complication rate </text>
<text top="477" left="869" width="3" height="19" font="3"> </text>
<text top="625" left="123" width="131" height="19" font="3">● Conte G et al. JACC </text>
<text top="643" left="123" width="30" height="19" font="3">2015</text>
<text top="642" left="154" width="4" height="21" font="0"> </text>
<text top="643" left="157" width="35" height="19" font="3">(399) </text>
<text top="662" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25744005">● </a></text>
<text top="662" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25744005">25744005</a></text>
<text top="662" left="197" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25744005"><b> </b></a></text>
<text top="625" left="278" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="643" left="278" width="113" height="19" font="3">Prospective single </text>
<text top="662" left="278" width="43" height="19" font="3">center </text>
<text top="680" left="278" width="3" height="19" font="3"> </text>
<text top="698" left="278" width="68" height="19" font="4"><b>Size:</b>   176 <b> </b></text>
<text top="625" left="417" width="135" height="19" font="4"><b>Inclusion criteria: </b>BrS </text>
<text top="643" left="417" width="124" height="19" font="3">patients with ICD’s   </text>
<text top="662" left="417" width="3" height="19" font="3"> </text>
<text top="680" left="417" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="626" left="590" width="246" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Long term followup ICD in </text>
<text top="644" left="590" width="187" height="19" font="3">BrS, mean followup 84±57 mo </text>
<text top="663" left="590" width="3" height="19" font="3"> </text>
<text top="681" left="590" width="207" height="19" font="4"><b>Results:</b>  Spontaneous VA in 17%. </text>
<text top="699" left="590" width="179" height="19" font="3">Appropriate shocks 15.9%      </text>
<text top="718" left="590" width="172" height="19" font="3">Inappropriate shocks 18.7% </text>
<text top="736" left="590" width="131" height="19" font="3">Electrical storm 2.3% </text>
<text top="754" left="590" width="248" height="19" font="3">SCN5A mutation (22%) did not correlate </text>
<text top="773" left="590" width="122" height="19" font="3">with approp shocks </text>
<text top="625" left="869" width="202" height="19" font="3">● ACA and VT inducibility on EPS </text>
<text top="643" left="869" width="198" height="19" font="3">were multi-variate predictors of </text>
<text top="662" left="869" width="120" height="19" font="3">appropriate shocks </text>
<text top="680" left="869" width="206" height="19" font="3">● Appropriate shocks occurred in </text>
<text top="698" left="868" width="188" height="19" font="3">13% of asymptomatic patients </text>
</page>
<page number="221" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">221 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="138" height="19" font="3">● Miyazaki S et al. AJC </text>
<text top="127" left="123" width="69" height="19" font="3">2013 (400) </text>
<text top="145" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23433764">● </a></text>
<text top="145" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23433764">23433764</a></text>
<text top="145" left="197" width="3" height="19" font="24"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23433764"><b> </b></a></text>
<text top="164" left="123" width="3" height="19" font="3"> </text>
<text top="109" left="278" width="116" height="19" font="4"><b>Study type:</b>  single </text>
<text top="127" left="278" width="43" height="19" font="3">center </text>
<text top="145" left="278" width="88" height="19" font="3">retrospective  </text>
<text top="164" left="278" width="3" height="19" font="3"> </text>
<text top="182" left="278" width="61" height="19" font="4"><b>Size:</b>    41<b> </b></text>
<text top="109" left="417" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="127" left="417" width="148" height="19" font="3">Brugada S patients with </text>
<text top="145" left="417" width="24" height="19" font="3">ICD </text>
<text top="164" left="417" width="115" height="19" font="3">Mean age 48±12 y </text>
<text top="182" left="417" width="69" height="19" font="3">93% males </text>
<text top="200" left="417" width="3" height="19" font="3"> </text>
<text top="218" left="417" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="109" left="590" width="237" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Brugada S ICD outcomes </text>
<text top="128" left="590" width="149" height="19" font="3">Median followup 76 mo </text>
<text top="146" left="590" width="3" height="19" font="3"> </text>
<text top="164" left="590" width="265" height="19" font="4"><b>Results:</b> Complications 37%: device related </text>
<text top="183" left="590" width="212" height="19" font="3">20%, inappropriate shocks in 24%  </text>
<text top="201" left="590" width="155" height="19" font="3">Appropriate shocks: 12% </text>
<text top="109" left="869" width="125" height="19" font="3">● Brugada S + ICD’s: </text>
<text top="127" left="869" width="122" height="19" font="3">Complications 37%  </text>
<text top="145" left="869" width="3" height="19" font="3"> </text>
<text top="238" left="123" width="106" height="19" font="3">● Takaqi M et al. </text>
<text top="256" left="123" width="89" height="19" font="3">Heart Rhythm </text>
<text top="274" left="123" width="66" height="19" font="3">2014(401) </text>
<text top="292" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24981871">● </a></text>
<text top="292" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24981871">24981871</a></text>
<text top="292" left="197" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24981871"><b> </b></a></text>
<text top="237" left="278" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="256" left="278" width="123" height="19" font="3">retrospective single </text>
<text top="274" left="278" width="53" height="19" font="3">center    </text>
<text top="292" left="278" width="3" height="19" font="3"> </text>
<text top="311" left="278" width="68" height="19" font="4"><b>Size:</b>   213 <b> </b></text>
<text top="237" left="417" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="256" left="417" width="117" height="19" font="3">Brugada S patients </text>
<text top="274" left="417" width="97" height="19" font="3">undergoing ICD </text>
<text top="293" left="417" width="89" height="19" font="3">implantation, <b> </b></text>
<text top="311" left="417" width="115" height="19" font="3">Mean age 53±14 y </text>
<text top="329" left="417" width="69" height="19" font="3">Males 93% </text>
<text top="347" left="417" width="3" height="19" font="3"> </text>
<text top="366" left="417" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="238" left="590" width="256" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ACE documented VT or SCD </text>
<text top="257" left="590" width="134" height="19" font="3">in Brugada S with ICD </text>
<text top="275" left="590" width="161" height="19" font="3">Mean followup 60±31 mo </text>
<text top="293" left="590" width="3" height="19" font="3"> </text>
<text top="311" left="590" width="198" height="19" font="4"><b>Results:</b> indications classified as </text>
<text top="330" left="590" width="251" height="19" font="3"> IIa (66): spontaneous type 1 ECG and Hx </text>
<text top="348" left="590" width="137" height="19" font="3">of cardiac syncope, or </text>
<text top="367" left="590" width="258" height="19" font="3"> IIb (147): spont or drug induced type ECG </text>
<text top="385" left="590" width="158" height="19" font="3">and inducible VF by PES.   </text>
<text top="403" left="590" width="187" height="19" font="3">Event rates:   IIa 12%, 2.2%/y;  </text>
<text top="422" left="590" width="139" height="19" font="3"> IIb 3%, 0.5%/y p=0.01<b> </b></text>
<text top="238" left="869" width="195" height="19" font="3">● ICD implantation in Brugada:  </text>
<text top="256" left="869" width="168" height="19" font="3">● Higher events in IIa vs IIb </text>
<text top="274" left="869" width="196" height="19" font="3">● Spontaneous type 1 ECG AND </text>
<text top="293" left="869" width="183" height="19" font="3">syncope useful for identifying </text>
<text top="311" left="869" width="111" height="19" font="3">intermediate risk  </text>
<text top="440" left="115" width="4" height="21" font="0"> </text>
<text top="496" left="115" width="791" height="21" font="2"><b>Data Supplement 43. Nonrandomized Trials Related to Early Repolarization “J-wave” Syndrome – (Secction 7.9.1.4) </b></text>
<text top="520" left="138" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="538" left="163" width="51" height="19" font="4"><b>Author; </b></text>
<text top="556" left="141" width="96" height="19" font="4"><b>Year Published</b> </text>
<text top="520" left="318" width="39" height="19" font="4"><b>Study </b></text>
<text top="538" left="294" width="86" height="19" font="4"><b>Type/Design; </b></text>
<text top="556" left="304" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="538" left="434" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="520" left="642" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="538" left="654" width="126" height="19" font="4"><b>(P values; OR or RR; </b></text>
<text top="556" left="686" width="63" height="19" font="4"><b>&amp; 95% CI)</b> </text>
<text top="529" left="898" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="547" left="926" width="80" height="19" font="4"><b>Comment(s)</b> </text>
<text top="578" left="116" width="129" height="19" font="3">● Rosso R et al.<b> </b>JACC </text>
<text top="596" left="116" width="69" height="19" font="3">2008 (398)<b> </b></text>
<text top="614" left="116" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18926326">● </a></text>
<text top="614" left="129" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18926326">18926326</a></text>
<text top="614" left="189" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18926326"><b> </b></a></text>
<text top="578" left="275" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="596" left="275" width="87" height="19" font="3">Retrospective </text>
<text top="614" left="275" width="85" height="19" font="3">single center  </text>
<text top="633" left="275" width="3" height="19" font="3"> </text>
<text top="651" left="275" width="61" height="19" font="4"><b>Size:</b>    45<b> </b></text>
<text top="578" left="412" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="596" left="412" width="136" height="19" font="3">Idiopathic VF patients </text>
<text top="614" left="412" width="122" height="19" font="3">compared with 123 </text>
<text top="633" left="412" width="131" height="19" font="3">age/gender matched </text>
<text top="651" left="412" width="60" height="19" font="3">controls.  </text>
<text top="669" left="412" width="148" height="19" font="3">Mean age 38±15 y, 71% </text>
<text top="688" left="412" width="33" height="19" font="3">male </text>
<text top="706" left="412" width="134" height="19" font="3">2/45 dx with Brugada </text>
<text top="724" left="412" width="3" height="19" font="3"> </text>
<text top="742" left="412" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="578" left="590" width="247" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Assess frequency of ER on </text>
<text top="597" left="590" width="97" height="19" font="3">ECG vs controls </text>
<text top="615" left="590" width="3" height="19" font="3"> </text>
<text top="633" left="590" width="232" height="19" font="4"><b>Results:</b>  ER more common among VF </text>
<text top="652" left="590" width="188" height="19" font="3">patients, 42% vs 13%, p=0.001 </text>
<text top="670" left="590" width="246" height="19" font="3">J point elev in inferior leads: 27% vs 8%, </text>
<text top="688" left="590" width="53" height="19" font="3">p=0.006 </text>
<text top="707" left="590" width="227" height="19" font="3">J point elev in leads I-aVL 13% vs 1%, </text>
<text top="725" left="590" width="53" height="19" font="3">p=0.009 </text>
<text top="743" left="590" width="210" height="19" font="3">J point elev in V4-V6 equal among </text>
<text top="762" left="590" width="121" height="19" font="3">groups, 6.7 vs 7.3% </text>
<text top="578" left="858" width="195" height="19" font="3">● J point elevation occurs more </text>
<text top="596" left="858" width="164" height="19" font="3">frequently in idiopathic VF </text>
<text top="614" left="858" width="187" height="19" font="3">patients than healthy controls </text>
<text top="633" left="858" width="214" height="19" font="3">● Athletes intermediate frequency </text>
<text top="651" left="858" width="177" height="19" font="3">of J point elevation between </text>
<text top="669" left="858" width="197" height="19" font="3">normal adults and idiopathic VF </text>
<text top="688" left="858" width="53" height="19" font="3">patients </text>
<text top="706" left="858" width="191" height="19" font="3">● ST segment elevation or QRS </text>
<text top="724" left="858" width="188" height="19" font="3">slurring did not add diagnostic </text>
<text top="743" left="858" width="42" height="19" font="3">values </text>
</page>
<page number="222" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">222 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="590" width="227" height="19" font="3">Males more often had J point elev vs </text>
<text top="127" left="590" width="242" height="19" font="3">females; young athletes more frequent </text>
<text top="145" left="590" width="238" height="19" font="3">than controls but less than VF patients </text>
<text top="164" left="590" width="3" height="19" font="4"><b> </b></text>
<text top="183" left="116" width="131" height="19" font="3">● Haissaguerre M, et </text>
<text top="201" left="116" width="120" height="19" font="3">al. JACC 2009 (402) </text>
<text top="219" left="116" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19215837">● </a></text>
<text top="219" left="129" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19215837">19215837</a></text>
<text top="219" left="189" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19215837"><b> </b></a></text>
<text top="183" left="275" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="201" left="275" width="118" height="19" font="3">multicenter cohort </text>
<text top="219" left="275" width="3" height="19" font="3"> </text>
<text top="237" left="275" width="68" height="19" font="4"><b>Size:</b>    122<b> </b></text>
<text top="183" left="412" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="201" left="412" width="141" height="19" font="3">Idiopathic VF survivors </text>
<text top="219" left="412" width="127" height="19" font="3">with ER assessed for </text>
<text top="238" left="412" width="80" height="19" font="3">recurrent VF </text>
<text top="256" left="412" width="3" height="19" font="3"> </text>
<text top="274" left="412" width="106" height="19" font="3">All pts had AICDs </text>
<text top="293" left="412" width="65" height="19" font="3">implanted </text>
<text top="311" left="412" width="3" height="19" font="3"> </text>
<text top="329" left="412" width="158" height="19" font="3">Mean age of diagnosis 39 </text>
<text top="347" left="412" width="10" height="19" font="3">y </text>
<text top="366" left="412" width="3" height="19" font="3"> </text>
<text top="384" left="412" width="120" height="19" font="4"><b>Exclusion criteria:</b>  <b> </b></text>
<text top="183" left="590" width="243" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Recurrent VF &gt;3 episodes </text>
<text top="202" left="590" width="3" height="19" font="3"> </text>
<text top="220" left="590" width="234" height="19" font="4"><b>Results:</b> overall 27% with multiple (&gt;3 </text>
<text top="238" left="590" width="157" height="19" font="3">episodes) of recurrent VF<b> </b></text>
<text top="257" left="590" width="206" height="19" font="3">Inducible VF 28% in entire cohort </text>
<text top="275" left="590" width="212" height="19" font="3">Pts with &gt;3 episodes recurrent VF: </text>
<text top="293" left="590" width="247" height="19" font="3">inducible VF 48%, p&lt;0.01, prior syncope </text>
<text top="312" left="590" width="253" height="19" font="3">58%, p&lt;0.001 compared with pts with &lt;3 </text>
<text top="330" left="590" width="186" height="19" font="3">episodes of recurrent VF. Anti-</text>
<text top="348" left="590" width="242" height="19" font="3">arrhythmic meds not highly effective in </text>
<text top="367" left="590" width="153" height="19" font="3">preventing recurrent VF  </text>
<text top="385" left="590" width="176" height="19" font="3">1 death due to refractory VF </text>
<text top="183" left="858" width="189" height="19" font="3">● Recurrent VF high: 40% with </text>
<text top="201" left="858" width="133" height="19" font="3">mult episodes in 27% </text>
<text top="219" left="858" width="199" height="19" font="3">● Meds not effective other than </text>
<text top="238" left="858" width="197" height="19" font="3">quinidine or hydroquinindine (9 </text>
<text top="256" left="858" width="27" height="19" font="3">pts) </text>
<text top="404" left="116" width="126" height="19" font="3">● Tikkanen JT ET AL. </text>
<text top="422" left="116" width="107" height="19" font="3">NEJM 2009 (403) </text>
<text top="441" left="116" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19917913">● </a></text>
<text top="441" left="129" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19917913">19917913</a></text>
<text top="441" left="189" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19917913"> </a></text>
<text top="404" left="275" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="422" left="275" width="84" height="19" font="3">retrospective </text>
<text top="441" left="275" width="112" height="19" font="3">community based </text>
<text top="459" left="275" width="112" height="19" font="3">screen of ECG’s in </text>
<text top="477" left="275" width="117" height="19" font="3">Finnish population </text>
<text top="496" left="275" width="69" height="19" font="3">1962-1972 </text>
<text top="514" left="275" width="3" height="19" font="3"> </text>
<text top="532" left="275" width="83" height="19" font="4"><b>Size:</b>    10864<b> </b></text>
<text top="404" left="412" width="152" height="19" font="4"><b>Inclusion criteria:</b>  ECG’s </text>
<text top="422" left="412" width="122" height="19" font="3">obtained in general </text>
<text top="441" left="412" width="133" height="19" font="3">population reviewed, </text>
<text top="459" left="412" width="3" height="19" font="3"> </text>
<text top="477" left="412" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="405" left="590" width="253" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Death from cardiac causes; </text>
<text top="423" left="590" width="215" height="19" font="3">2°: death from any cause and from </text>
<text top="441" left="590" width="233" height="19" font="3">arrhythmia before end of 2007; mean </text>
<text top="460" left="590" width="116" height="19" font="3">followup 30±11 y.  </text>
<text top="478" left="590" width="3" height="19" font="3"> </text>
<text top="496" left="590" width="230" height="19" font="4"><b>Results:</b>  Prevalence J point elev of at </text>
<text top="515" left="590" width="244" height="19" font="3">least 0.1 mV: 5.8%: inferior leads 3.5 %, </text>
<text top="533" left="590" width="247" height="19" font="3">70% male; Lateral leads 2.4%, 58% male </text>
<text top="551" left="590" width="250" height="19" font="3">J point elev at least 0.2 mV inferior leads </text>
<text top="570" left="590" width="112" height="19" font="3">0.3%, lateral 0.3% </text>
<text top="588" left="590" width="255" height="19" font="3">Cardiac death: ER patients (RR: 1.28, 95% </text>
<text top="606" left="590" width="254" height="19" font="3">CI: 1.04–1.59, p=0.03); arrhythmia death  </text>
<text top="624" left="590" width="232" height="19" font="3">J point elev 0.2 mV: cardiac death RR: </text>
<text top="643" left="590" width="199" height="19" font="3">2.98, 95% CI: 1.85–4.92, p=0.01; </text>
<text top="661" left="590" width="249" height="19" font="3">arrhythmic death RR: 2.92, 95% CI: 1.45–</text>
<text top="680" left="590" width="79" height="19" font="3">5.89, p=0.01 </text>
<text top="698" left="590" width="247" height="19" font="3">QTc (RR: 1.2, 95% CI: 1.02–1.42, p=0.03) </text>
<text top="716" left="589" width="232" height="19" font="3">and LVH (RR: 1.16, 95% CI: 1.05–1.27, </text>
<text top="734" left="590" width="219" height="19" font="3">p=0.004) weaker predictors cardiac </text>
<text top="753" left="590" width="39" height="19" font="3">death </text>
<text top="404" left="858" width="195" height="19" font="3">● ER pattern in inferior leads of </text>
<text top="422" left="858" width="157" height="19" font="3">ECG is associated with an </text>
<text top="441" left="858" width="175" height="19" font="3">increased risk of death from </text>
<text top="459" left="858" width="185" height="19" font="3">cardiac causes in middle-aged </text>
<text top="477" left="858" width="41" height="19" font="3">adults </text>
<text top="496" left="858" width="206" height="19" font="3">● ER transmural heterogeneity in </text>
<text top="514" left="858" width="208" height="19" font="3">vent repolarization, increases risk </text>
<text top="532" left="858" width="147" height="19" font="3">during cardiac ischemia </text>
</page>
<page number="223" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="27" size="12" family="Times" color="#4f81bd"/>
<text top="803" left="585" width="29" height="21" font="0">223 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="116" width="111" height="19" font="3">● Sinner<b> </b>MF et al. </text>
<text top="127" left="116" width="122" height="19" font="3">Heart Rhythm 2012 </text>
<text top="145" left="116" width="35" height="19" font="3">(404)<b> </b></text>
<text top="164" left="116" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22683750">● </a></text>
<text top="164" left="129" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22683750">22683750</a></text>
<text top="164" left="189" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22683750"> </a></text>
<text top="109" left="275" width="92" height="19" font="4"><b>Study type:</b>   3 </text>
<text top="127" left="275" width="112" height="19" font="3">community based </text>
<text top="145" left="275" width="78" height="19" font="3">ECG cohorts </text>
<text top="164" left="275" width="76" height="19" font="4"><b>Size:</b>   7482 <b> </b></text>
<text top="109" left="412" width="141" height="19" font="4"><b>Inclusion criteria:</b>  452 </text>
<text top="127" left="412" width="102" height="19" font="3">patients with ER </text>
<text top="145" left="412" width="157" height="19" font="3">underwent genome wide </text>
<text top="164" left="412" width="118" height="19" font="3">association studies </text>
<text top="182" left="412" width="148" height="19" font="4"><b>Exclusion criteria:</b> N/A  <b> </b></text>
<text top="109" left="590" width="238" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Combined meta-analysis </text>
<text top="128" left="590" width="251" height="19" font="3">failed to reach genome wide significance </text>
<text top="146" left="590" width="3" height="19" font="3"> </text>
<text top="164" left="590" width="141" height="19" font="4"><b>Results:</b>  ER: 70% male </text>
<text top="183" left="590" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="858" width="174" height="19" font="3">● Unable to reliably identify </text>
<text top="127" left="858" width="217" height="19" font="3">genetic variants predisposing to ER </text>
<text top="145" left="858" width="3" height="19" font="3"> </text>
<text top="164" left="858" width="3" height="19" font="3"> </text>
<text top="202" left="116" width="143" height="19" font="3">● Adhikarla C et al. AJC </text>
<text top="220" left="116" width="69" height="19" font="3">2011 (405) </text>
<text top="238" left="116" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21907947">● </a></text>
<text top="238" left="129" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21907947">21907947</a></text>
<text top="238" left="189" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21907947"> </a></text>
<text top="202" left="275" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="220" left="275" width="93" height="19" font="4"><b>retrospective </b>  </text>
<text top="238" left="275" width="120" height="19" font="3">Screening ECG’s on </text>
<text top="257" left="275" width="96" height="19" font="3">veterans for ER </text>
<text top="275" left="275" width="57" height="19" font="3">1987-99  </text>
<text top="293" left="275" width="3" height="19" font="3"> </text>
<text top="311" left="275" width="83" height="19" font="4"><b>Size:</b>    29281<b> </b></text>
<text top="202" left="412" width="144" height="19" font="4"><b>Inclusion criteria:</b>  ER &gt; </text>
<text top="220" left="412" width="150" height="19" font="3">0.1 mV with ST segment </text>
<text top="238" left="412" width="124" height="19" font="3">elevation, J wave as </text>
<text top="257" left="412" width="163" height="19" font="3">upward defection, slurs as </text>
<text top="275" left="412" width="102" height="19" font="3">delay on R wave </text>
<text top="293" left="412" width="134" height="19" font="3">downstroke: first 250 </text>
<text top="312" left="412" width="150" height="19" font="3">patients selected. Mean </text>
<text top="330" left="412" width="55" height="19" font="3">42±10 y  </text>
<text top="348" left="412" width="3" height="19" font="3"> </text>
<text top="367" left="412" width="154" height="19" font="4"><b>Exclusion criteria:</b>  other </text>
<text top="385" left="412" width="116" height="19" font="3">ECG abnormalities<b> </b></text>
<text top="202" left="590" width="232" height="19" font="4"><b>1</b>°<b> endpoint:</b>  assess changes in ER on </text>
<text top="221" left="590" width="160" height="19" font="3">ECG during 10 y followup  </text>
<text top="239" left="590" width="3" height="19" font="3"> </text>
<text top="257" left="590" width="237" height="19" font="4"><b>Results:</b>  122/244 patients had second </text>
<text top="276" left="590" width="32" height="19" font="3">ECG<b>  </b></text>
<text top="294" left="590" width="256" height="19" font="3">ER persisted in 38%<b>;</b> most no longer filled </text>
<text top="312" left="590" width="54" height="19" font="3">criteria.  </text>
<text top="331" left="590" width="3" height="19" font="4"><b> </b></text>
<text top="202" left="858" width="194" height="19" font="3">● ER pattern lost in over half of </text>
<text top="220" left="858" width="177" height="19" font="3">young male cohort over 10 y </text>
<text top="238" left="858" width="173" height="19" font="3">period, not related to death </text>
<text top="257" left="858" width="3" height="19" font="3"> </text>
<text top="404" left="116" width="128" height="19" font="3">● Siebermair J, et al. </text>
<text top="422" left="116" width="130" height="19" font="3">Europace 2016 (406) </text>
<text top="441" left="116" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26759124">● </a></text>
<text top="441" left="129" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26759124">26759124</a></text>
<text top="441" left="189" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26759124"> </a></text>
<text top="459" left="116" width="3" height="19" font="3"> </text>
<text top="404" left="275" width="117" height="19" font="4"><b>Study type:</b>  Single </text>
<text top="422" left="275" width="43" height="19" font="3">center </text>
<text top="441" left="275" width="85" height="19" font="3">retrospective </text>
<text top="459" left="275" width="3" height="19" font="3"> </text>
<text top="477" left="275" width="61" height="19" font="4"><b>Size:</b>    35<b> </b></text>
<text top="404" left="412" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="422" left="412" width="141" height="19" font="3">Idiopathic VF survivors </text>
<text top="441" left="412" width="147" height="19" font="3">assessed for ER and ICD </text>
<text top="459" left="412" width="127" height="19" font="3">interventions during </text>
<text top="477" left="412" width="144" height="19" font="3">follow-up median 8.8 y </text>
<text top="496" left="412" width="3" height="19" font="3"> </text>
<text top="514" left="412" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="405" left="590" width="244" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Appropriate VF shocks on </text>
<text top="423" left="590" width="241" height="19" font="3">ICD in idiopathic VF pts; compare ER to </text>
<text top="441" left="590" width="47" height="19" font="3">non-ER </text>
<text top="460" left="590" width="3" height="19" font="3"> </text>
<text top="478" left="590" width="239" height="19" font="4"><b>Results:</b> overall 43% recurrent VF after </text>
<text top="496" left="590" width="100" height="19" font="3">median 6.6 yrs.  </text>
<text top="515" left="590" width="231" height="19" font="3">VF more frequent in ER patients: (HR: </text>
<text top="533" left="590" width="188" height="19" font="3">3.9, 95% CI: 1.4–11.0, p=0.01)  </text>
<text top="551" left="590" width="256" height="19" font="3">40% inappropriate shocks: 66% due to AF </text>
<text top="404" left="858" width="158" height="19" font="3">● Recurrent VF high: 43% </text>
<text top="422" left="858" width="171" height="19" font="3">● Recurrent VF higher in ER </text>
<text top="441" left="858" width="53" height="19" font="3">patients </text>
<text top="459" left="858" width="216" height="19" font="3">● High incidence AF in VF survivors </text>
<text top="477" left="858" width="3" height="19" font="3"> </text>
<text top="570" left="116" width="138" height="19" font="3">●Cheng YJ, et al. JAHA </text>
<text top="589" left="116" width="34" height="19" font="3">2016 </text>
<text top="607" left="116" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27671315">● </a></text>
<text top="607" left="129" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27671315">27671315</a></text>
<text top="607" left="189" width="3" height="19" font="27"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27671315"><b> </b></a></text>
<text top="625" left="116" width="3" height="19" font="3"> </text>
<text top="570" left="275" width="114" height="19" font="4"><b>Study type:</b>  meta-</text>
<text top="589" left="275" width="51" height="19" font="3">analysis </text>
<text top="607" left="275" width="3" height="19" font="3"> </text>
<text top="625" left="275" width="107" height="19" font="4"><b>Size:</b>    16 studies </text>
<text top="643" left="275" width="111" height="19" font="3">including 334,524 </text>
<text top="662" left="275" width="115" height="19" font="3">patients identified<b> </b></text>
<text top="570" left="412" width="161" height="19" font="4"><b>Inclusion criteria:</b>  studies </text>
<text top="589" left="412" width="161" height="19" font="3">assessing link between ER </text>
<text top="607" left="412" width="145" height="19" font="3">and risk of SCA, cardiac </text>
<text top="625" left="412" width="158" height="19" font="3">death, and eath from any </text>
<text top="644" left="412" width="38" height="19" font="3">cause </text>
<text top="662" left="412" width="3" height="19" font="3"> </text>
<text top="680" left="412" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="571" left="590" width="245" height="19" font="4"><b>1</b>°<b> endpoint:</b>  risk of SCA, cardiac death, </text>
<text top="589" left="590" width="234" height="19" font="3">death any cause associated with early </text>
<text top="608" left="590" width="185" height="19" font="3">repolarization pattern on ECG </text>
<text top="626" left="590" width="3" height="19" font="3"> </text>
<text top="644" left="590" width="241" height="19" font="4"><b>Results:</b> Increased risk of SCA (RR:2.18, </text>
<text top="663" left="590" width="233" height="19" font="3">95% CI: 1.29–3.68), and cardiac death </text>
<text top="681" left="590" width="247" height="19" font="3">(RR: 1.48, 95% CI: 1.06–2.07) in patients </text>
<text top="699" left="590" width="160" height="19" font="3">with early repolarization.  </text>
<text top="718" left="590" width="238" height="19" font="3">Increased risk predominantly in Asians </text>
<text top="736" left="590" width="240" height="19" font="3">and whites but not African Americans.  </text>
<text top="754" left="590" width="207" height="19" font="3">J-point elevation in inferior leads, </text>
<text top="773" left="590" width="244" height="19" font="3">notching configuration, and harizaontal </text>
<text top="570" left="858" width="202" height="19" font="3">● Early repolarization associated </text>
<text top="589" left="858" width="181" height="19" font="3">with absolute risk increase of </text>
<text top="607" left="858" width="207" height="19" font="3">139.6 additional SCAs/100,000 pt </text>
<text top="625" left="858" width="207" height="19" font="3">y and responsible for 7.3% of SCA </text>
<text top="644" left="858" width="126" height="19" font="3">in general poulation </text>
</page>
<page number="224" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">224 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="590" width="224" height="19" font="3">or descending ST segement connote </text>
<text top="127" left="590" width="74" height="19" font="3">higher risk. <b> </b></text>
<text top="146" left="116" width="120" height="19" font="3">● Tikkanen JT et al. </text>
<text top="164" left="116" width="115" height="19" font="3">Circ AE 2012 (407) </text>
<text top="183" left="116" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22730409">● </a></text>
<text top="183" left="129" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22730409">22730409</a></text>
<text top="183" left="189" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22730409"><b> </b></a></text>
<text top="146" left="275" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="164" left="275" width="87" height="19" font="3">Retrospective </text>
<text top="183" left="275" width="110" height="19" font="3">population based </text>
<text top="201" left="275" width="3" height="19" font="3"> </text>
<text top="219" left="275" width="72" height="19" font="4"><b>Size:</b>  432   <b> </b></text>
<text top="146" left="412" width="115" height="19" font="4"><b>Inclusion criteria:  </b></text>
<text top="164" left="412" width="120" height="19" font="3">Prevalence of ER in </text>
<text top="183" left="412" width="134" height="19" font="3">Baseline ECG’s of 432 </text>
<text top="201" left="412" width="155" height="19" font="3">consecutive cases of SCD </text>
<text top="219" left="412" width="100" height="19" font="3">due to ischemia </text>
<text top="238" left="412" width="122" height="19" font="3">compared with 532 </text>
<text top="256" left="412" width="112" height="19" font="3">survivors of acute </text>
<text top="274" left="412" width="94" height="19" font="3">ischemic event </text>
<text top="292" left="412" width="3" height="19" font="3"> </text>
<text top="311" left="412" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="147" left="590" width="248" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Prevalence of ER in SCD vs </text>
<text top="165" left="590" width="169" height="19" font="3">survivors of acute ischemia </text>
<text top="183" left="590" width="3" height="19" font="3"> </text>
<text top="202" left="590" width="229" height="19" font="4"><b>Results:</b>  Prevalence ER ≥0.1 mV in at </text>
<text top="220" left="590" width="254" height="19" font="3">least 2 inf or lateral leads: 14.4% cases vs </text>
<text top="238" left="590" width="93" height="19" font="3">7.9% controls.  </text>
<text top="257" left="590" width="221" height="19" font="3">ER with horizontal or descending ST </text>
<text top="275" left="590" width="244" height="19" font="3">segment assoc with SCD 10.2% vs 5.3%, </text>
<text top="293" left="590" width="212" height="19" font="3">p=0.004; ER with ascending ST NS. </text>
<text top="312" left="590" width="248" height="19" font="3">SCD patients younger, more often male, </text>
<text top="330" left="589" width="209" height="19" font="3">smokers, lower BMI, elevated HR, </text>
<text top="348" left="589" width="191" height="19" font="3">prolonged QRS complex, lower </text>
<text top="367" left="589" width="151" height="19" font="3">prevalence of Hx of CVD </text>
<text top="385" left="590" width="3" height="19" font="3"> </text>
<text top="146" left="858" width="204" height="19" font="3">● Higher prevalence of ER in SCD </text>
<text top="164" left="858" width="214" height="19" font="3">ischemic patients than in survivors </text>
<text top="183" left="858" width="149" height="19" font="3">of acute coronary event </text>
<text top="201" left="858" width="187" height="19" font="3">● ER increases vulnerability to </text>
<text top="219" left="858" width="182" height="19" font="3">fatal arrhythmia during acute </text>
<text top="238" left="858" width="128" height="19" font="3">myocardial ischemia </text>
<text top="256" left="858" width="3" height="19" font="3"> </text>
<text top="274" left="858" width="3" height="19" font="3"> </text>
<text top="404" left="116" width="115" height="19" font="3">● Junttila MJ et al. </text>
<text top="422" left="116" width="122" height="19" font="3">Heart Rhythm 2014 </text>
<text top="441" left="116" width="35" height="19" font="3">(408)<b> </b></text>
<text top="459" left="116" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24858812">● </a></text>
<text top="459" left="129" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24858812">24858812</a></text>
<text top="459" left="189" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24858812"> </a></text>
<text top="404" left="275" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="422" left="275" width="114" height="19" font="3">Community based </text>
<text top="441" left="275" width="84" height="19" font="3">ECG’s Finnish </text>
<text top="459" left="275" width="112" height="19" font="3">population, mean </text>
<text top="477" left="275" width="58" height="19" font="3">44±8 yrs  </text>
<text top="496" left="275" width="3" height="19" font="3"> </text>
<text top="514" left="275" width="87" height="19" font="4"><b>Size:</b>  10,846  <b> </b></text>
<text top="404" left="412" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="422" left="412" width="160" height="19" font="3">arrhythmic outcomes and </text>
<text top="441" left="412" width="159" height="19" font="3">cardiac deaths in patients </text>
<text top="459" left="412" width="141" height="19" font="3">with ER on community </text>
<text top="477" left="412" width="62" height="19" font="3">screening </text>
<text top="496" left="412" width="3" height="19" font="3"> </text>
<text top="514" left="412" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="405" left="590" width="206" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Sustained VT or VF, </text>
<text top="423" left="590" width="252" height="19" font="3">arrhythmic death, non-arrhythmic cardia </text>
<text top="441" left="590" width="225" height="19" font="3">death, AF, CHF, CAD; mean followup </text>
<text top="460" left="590" width="51" height="19" font="3">30±11 y </text>
<text top="478" left="590" width="3" height="19" font="3"> </text>
<text top="496" left="590" width="231" height="19" font="4"><b>Results:</b>  Inferior ER 3.5% prevalence: </text>
<text top="515" left="590" width="248" height="19" font="3">predicted VF-VT events (N=108), HR: 2.2 </text>
<text top="533" left="590" width="253" height="19" font="3">(1.1–4.5, p=0.03), not not nonarrhythmic </text>
<text top="551" left="590" width="167" height="19" font="3">cardiac death, CHF, or CAD </text>
<text top="570" left="590" width="254" height="19" font="3">Inferior ER predicted arrhythmic death in </text>
<text top="588" left="590" width="240" height="19" font="3">cases without other QRS abnormalities </text>
<text top="606" left="590" width="246" height="19" font="3">(HR: 1.68, 95% CI: 1.1–2.58, p=0.02) but </text>
<text top="624" left="590" width="171" height="19" font="3">not in those with coexisting </text>
<text top="643" left="590" width="237" height="19" font="3">abnormalities in QRS morphology (HR: </text>
<text top="661" left="590" width="192" height="19" font="3">1.3, 95% CI: 0.86–1.96, p=0.22) </text>
<text top="404" left="858" width="197" height="19" font="3">● Inferior ER without other QRS </text>
<text top="422" left="858" width="193" height="19" font="3">morphology changes predicted </text>
<text top="441" left="858" width="203" height="19" font="3">occurrence of VT-VF but not non-</text>
<text top="459" left="858" width="161" height="19" font="3">arrhythmic cardiac events </text>
<text top="477" left="858" width="194" height="19" font="3">● Suggests ER sign of increased </text>
<text top="496" left="858" width="165" height="19" font="3">vulnerability to ventricular </text>
<text top="514" left="858" width="110" height="19" font="3">tachyarrhythmias </text>
<text top="680" left="115" width="4" height="21" font="0"> </text>
<text top="700" left="115" width="4" height="21" font="0"> </text>
<text top="700" left="331" width="4" height="21" font="2"><b> </b></text>
</page>
<page number="225" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">225 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="650" height="21" font="2"><b>Data Supplement 44. Nonrandomized Trials Related to Short-QT Syndrome – (Secction 7.9.1.5) </b></text>
<text top="129" left="140" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="147" left="166" width="51" height="19" font="4"><b>Author; </b></text>
<text top="165" left="143" width="96" height="19" font="4"><b>Year Published</b> </text>
<text top="138" left="273" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="156" left="302" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="147" left="438" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="129" left="648" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="147" left="661" width="126" height="19" font="4"><b>(P values; OR or RR; </b></text>
<text top="165" left="692" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="138" left="905" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="156" left="934" width="80" height="19" font="4"><b>Comment(s)</b> </text>
<text top="184" left="125" width="125" height="19" font="3">● Gaita F et al. JACC </text>
<text top="203" left="125" width="69" height="19" font="3">2004 (409)<b> </b></text>
<text top="221" left="125" width="12" height="19" font="3">●<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15093889"> </a></text>
<text top="221" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15093889">15093889</a></text>
<text top="221" left="198" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15093889"><b> </b></a></text>
<text top="184" left="271" width="119" height="19" font="4"><b>Study type:</b>   single </text>
<text top="203" left="271" width="127" height="19" font="3">center retrospective </text>
<text top="221" left="271" width="3" height="19" font="3"> </text>
<text top="239" left="271" width="53" height="19" font="4"><b>Size:</b>    6<b> </b></text>
<text top="184" left="413" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="203" left="413" width="167" height="19" font="3">Symptomatic patients with </text>
<text top="221" left="413" width="165" height="19" font="3">QTc &lt;380 undergoing drug </text>
<text top="239" left="413" width="164" height="19" font="3">testing. One prior ACA age </text>
<text top="258" left="413" width="28" height="19" font="3">6 y.  </text>
<text top="276" left="413" width="153" height="19" font="3">PES 5 adult patients: 4/5 </text>
<text top="294" left="413" width="85" height="19" font="3">inducible VF.  </text>
<text top="313" left="413" width="148" height="19" font="3">5 adults received ICD’s.  </text>
<text top="331" left="413" width="3" height="19" font="3"> </text>
<text top="349" left="413" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="185" left="595" width="240" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Prolongation of QTc with </text>
<text top="204" left="595" width="78" height="19" font="3">medications </text>
<text top="222" left="595" width="3" height="19" font="3"> </text>
<text top="240" left="595" width="222" height="19" font="4"><b>Results:</b>  Flecainid, sotalol, ibutilide, </text>
<text top="258" left="595" width="146" height="19" font="3">hydroquinidine tested.  </text>
<text top="277" left="595" width="246" height="19" font="3">Only hydroquinidine prlonged QTc from </text>
<text top="295" left="595" width="235" height="19" font="3">263±12 to 363±25, prolonged VERP to </text>
<text top="314" left="595" width="196" height="19" font="3">≥200 msec, and no VF induced.  </text>
<text top="184" left="865" width="203" height="19" font="3">● Hydroquinidine prolonged QTc </text>
<text top="203" left="865" width="201" height="19" font="3">and resulted in non-inducible VF </text>
<text top="221" left="865" width="215" height="19" font="3">● use dependent block fast inward </text>
<text top="239" left="865" width="214" height="19" font="3">Na, blocks rapid IKr and IKs, IKATP, </text>
<text top="258" left="865" width="27" height="19" font="3">Ito.  </text>
<text top="276" left="865" width="3" height="19" font="3"> </text>
<text top="368" left="125" width="118" height="19" font="3">● Giustetto C et al. </text>
<text top="387" left="125" width="86" height="19" font="3">EHJ 2006 (51) </text>
<text top="405" left="125" width="12" height="19" font="3">●<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16926178"> </a></text>
<text top="405" left="137" width="64" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16926178">16926178 </a></text>
<text top="405" left="201" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16926178"> </a></text>
<text top="368" left="271" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="387" left="271" width="126" height="19" font="3">Retrospective single </text>
<text top="405" left="271" width="43" height="19" font="3">center </text>
<text top="423" left="271" width="3" height="19" font="3"> </text>
<text top="441" left="271" width="61" height="19" font="4"><b>Size:</b>    29<b> </b></text>
<text top="368" left="413" width="151" height="19" font="4"><b>Inclusion criteria:</b>  Short </text>
<text top="387" left="413" width="122" height="19" font="3">QTc ≤340 msec and </text>
<text top="405" left="413" width="149" height="19" font="3">personal or family Hx of </text>
<text top="423" left="413" width="96" height="19" font="3">CA. 73% males. </text>
<text top="442" left="413" width="3" height="19" font="3"> </text>
<text top="460" left="413" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="369" left="595" width="228" height="19" font="4"><b>1</b>°<b> endpoint:</b>  outcomes with AICD or </text>
<text top="388" left="595" width="96" height="19" font="3">hydroquinidine </text>
<text top="406" left="595" width="3" height="19" font="3"> </text>
<text top="424" left="595" width="229" height="19" font="4"><b>Results:</b> Median age dx 30 yrs (4-80); </text>
<text top="442" left="595" width="255" height="19" font="3">62% symptomatic: syncope 24%, AF 31%. </text>
<text top="461" left="595" width="236" height="19" font="3">34% ACA (10 patients); 2/10 had CA in </text>
<text top="479" left="595" width="257" height="19" font="3">infancy. In 28% ACA was initial symptom.  </text>
<text top="497" left="595" width="255" height="19" font="3">AICD implanted in 14; 10 hydroquinidine. </text>
<text top="516" left="595" width="236" height="19" font="3">Median followup 23 mo (9-49), one pt </text>
<text top="534" left="595" width="229" height="19" font="3">with appropriate ICD shock. No pt on </text>
<text top="552" left="595" width="231" height="19" font="3">hydroquinidine had SCD or syncope.   </text>
<text top="571" left="595" width="3" height="19" font="3"> </text>
<text top="589" left="595" width="215" height="19" font="3">PES 18/29: VERP 140-180 msec. VF </text>
<text top="607" left="595" width="204" height="19" font="3">induced in 61% (11/18); 3/6 with </text>
<text top="626" left="595" width="208" height="19" font="3">documented VF had inducible VF: </text>
<text top="644" left="595" width="234" height="19" font="3">sensitivity 50%. AERP CL 600: 120-180 </text>
<text top="662" left="595" width="93" height="19" font="3">ms, mean 157. </text>
<text top="368" left="865" width="217" height="19" font="3">● Short QTS may be a cause of SCD </text>
<text top="387" left="865" width="62" height="19" font="3">in infancy </text>
<text top="405" left="865" width="3" height="19" font="3"> </text>
<text top="423" left="865" width="158" height="19" font="3">● Hydroquinidine may be </text>
<text top="442" left="865" width="199" height="19" font="3">proposed in children or patients </text>
<text top="460" left="865" width="130" height="19" font="3">not suitable for AICD </text>
<text top="478" left="865" width="3" height="19" font="3"> </text>
<text top="497" left="865" width="119" height="19" font="3">PES sensitivity 50% </text>
<text top="515" left="865" width="3" height="19" font="3"> </text>
<text top="533" left="865" width="3" height="19" font="3"> </text>
<text top="681" left="125" width="115" height="19" font="3">● Gollob MH et al. </text>
<text top="699" left="125" width="102" height="19" font="3">JACC 2011 (410) </text>
<text top="718" left="125" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21310316">● </a></text>
<text top="718" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21310316">21310316</a></text>
<text top="718" left="198" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21310316"><b> </b></a></text>
<text top="681" left="271" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="699" left="271" width="113" height="19" font="3">Medline database </text>
<text top="718" left="271" width="47" height="19" font="3">search  </text>
<text top="736" left="271" width="3" height="19" font="3"> </text>
<text top="754" left="271" width="61" height="19" font="4"><b>Size:</b>   61 <b> </b></text>
<text top="681" left="413" width="159" height="19" font="4"><b>Inclusion criteria:</b>  review </text>
<text top="699" left="413" width="169" height="19" font="3">details of reported cases of </text>
<text top="718" left="413" width="35" height="19" font="3">SQTS </text>
<text top="736" left="413" width="3" height="19" font="3"> </text>
<text top="754" left="413" width="142" height="19" font="4"><b>Exclusion criteria:</b> non-</text>
<text top="773" left="413" width="102" height="19" font="3">English journals <b> </b></text>
<text top="682" left="595" width="239" height="19" font="4"><b>1</b>°<b> endpoint:</b>  review reported cases of </text>
<text top="700" left="595" width="191" height="19" font="3">Short QTS: 61 cases worldwide </text>
<text top="719" left="595" width="3" height="19" font="3"> </text>
<text top="737" left="595" width="244" height="19" font="4"><b>Results:</b>  Increased in males: 75% mean </text>
<text top="755" left="595" width="198" height="19" font="3">QTc 397 msec, 248–381 msec in </text>
<text top="774" left="595" width="126" height="19" font="3">symptomatic cases.  </text>
<text top="681" left="865" width="178" height="20" font="3">• Gollob criteria for SQTS, ≥4 </text>
<text top="700" left="865" width="106" height="19" font="3">points very likely </text>
<text top="719" left="865" width="202" height="20" font="3">• QTc duration &lt;370, &lt;350, &lt;330 </text>
<text top="738" left="865" width="154" height="19" font="3">J point-Tpeak &lt;120 msec </text>
<text top="756" left="865" width="155" height="19" font="3">Clinical hx: ACA, SCD, AF, </text>
<text top="774" left="865" width="136" height="19" font="3">unexplained syncope; </text>
</page>
<page number="226" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">226 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="595" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="865" width="172" height="19" font="3">Family hx; Genotype results </text>
<text top="128" left="125" width="118" height="19" font="3">● Giustetto C et al. </text>
<text top="146" left="125" width="94" height="19" font="3">JACC 2011 (53) </text>
<text top="164" left="125" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21798421">● </a></text>
<text top="164" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21798421">21798421</a></text>
<text top="164" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21798421"> </a></text>
<text top="128" left="271" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="146" left="271" width="121" height="19" font="3">retrospective multi-</text>
<text top="164" left="271" width="46" height="19" font="3">center  </text>
<text top="183" left="271" width="3" height="19" font="3"> </text>
<text top="201" left="271" width="64" height="19" font="4"><b>Size: </b>53    <b> </b></text>
<text top="128" left="413" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="146" left="413" width="119" height="19" font="3">European Short QT </text>
<text top="164" left="413" width="164" height="19" font="3">Registry<b> patients </b>with QTc </text>
<text top="183" left="413" width="166" height="19" font="3">≤360 msec with Hx sudden </text>
<text top="201" left="413" width="136" height="19" font="3">death, ACA, syncope;  </text>
<text top="219" left="413" width="144" height="19" font="3">patients with QTc ≤340 </text>
<text top="238" left="413" width="142" height="19" font="3">msec included without </text>
<text top="256" left="413" width="74" height="19" font="3">symptoms.  </text>
<text top="274" left="413" width="76" height="19" font="3">75% males.  </text>
<text top="293" left="413" width="151" height="19" font="3">Family Hx SCD/CA (11).   </text>
<text top="311" left="413" width="160" height="19" font="3">Genotype positive 23% of </text>
<text top="329" left="413" width="132" height="19" font="3">probands:  HERG in 4 </text>
<text top="347" left="413" width="128" height="19" font="3">families (N588K in 2, </text>
<text top="366" left="413" width="147" height="19" font="3">T6181 in 2; CACNB2b in </text>
<text top="384" left="413" width="72" height="19" font="3">one family) </text>
<text top="402" left="413" width="11" height="19" font="3">.  </text>
<text top="421" left="413" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="128" left="595" width="247" height="19" font="4"><b>1</b>°<b> endpoint:</b> syncope, CA or approp ICD </text>
<text top="147" left="595" width="82" height="19" font="3">shocks SQTS  </text>
<text top="165" left="595" width="3" height="19" font="3"> </text>
<text top="183" left="595" width="222" height="19" font="4"><b>Results:</b>  Mean Followup 64±27 mo. </text>
<text top="202" left="595" width="213" height="19" font="3">Median age 26 y (IQR 17–39). 62% </text>
<text top="220" left="595" width="256" height="19" font="3">symptomatic: 32% with ACA (13 patients) </text>
<text top="239" left="595" width="226" height="19" font="3">or sudden death(4), syncope 8, AF 6, </text>
<text top="257" left="595" width="61" height="19" font="3">palps 13.  </text>
<text top="275" left="595" width="139" height="19" font="3">Age at CA 3 mos–62 y. </text>
<text top="293" left="595" width="239" height="19" font="3"> Males:  &gt;90% of CA occurred between </text>
<text top="312" left="595" width="67" height="19" font="3">14-40 yrs.  </text>
<text top="330" left="595" width="251" height="19" font="3">Prevalence CA males 35%, females 30%.  </text>
<text top="348" left="595" width="207" height="19" font="3">AICD in 24, hydroquinidine in 12.  </text>
<text top="367" left="595" width="218" height="19" font="3">11/12 with prior CA received ICD: 2 </text>
<text top="385" left="595" width="253" height="19" font="3">approp ICD shocks. 58% complications of </text>
<text top="403" left="595" width="220" height="19" font="3">ICD,<b> </b>inapprop shocks due to T wave </text>
<text top="422" left="595" width="115" height="19" font="3">oversensing 4/14.  </text>
<text top="440" left="595" width="253" height="19" font="3">PES: 28 patients.<b> </b>VERP CL 600-500: mean </text>
<text top="458" left="595" width="251" height="19" font="3">166 msec. AERP 166 msec. VF induced in </text>
<text top="476" left="595" width="234" height="19" font="3">16/28: 3/28 with prior CA = sensitivity </text>
<text top="495" left="595" width="105" height="19" font="3">37%, NPVs 58%. <b> </b></text>
<text top="513" left="595" width="211" height="19" font="3">Overall event rate 3.3%/y: 4.9% in </text>
<text top="531" left="595" width="170" height="19" font="3">patients without AA drugs.  </text>
<text top="550" left="595" width="195" height="19" font="3">Asymptomatic patients: 27. ICD </text>
<text top="568" left="595" width="222" height="19" font="3">implanted in 9 due to + family Hx or </text>
<text top="586" left="595" width="231" height="19" font="3">induced VF. Two long term quinidine. </text>
<text top="605" left="595" width="219" height="19" font="3">One syncope; 2 nonsust VT on ICD.  </text>
<text top="128" left="865" width="205" height="19" font="3">● SQTS assoc with SCD in all ages </text>
<text top="146" left="865" width="212" height="19" font="3">● Symptomatic patients have high </text>
<text top="164" left="865" width="216" height="19" font="3">risk of recurrent arrhythmic events </text>
<text top="183" left="865" width="148" height="19" font="3">●  Patients treated with </text>
<text top="201" left="865" width="177" height="19" font="3">Hydroquinidine did not have </text>
<text top="219" left="865" width="114" height="19" font="3">arrhythmic events </text>
<text top="238" left="865" width="180" height="19" font="3">● Asymptomatic patients: no </text>
<text top="256" left="865" width="98" height="19" font="3">CA/ICD shocks.  </text>
<text top="274" left="865" width="122" height="19" font="3">● PES not sensitive <b> </b></text>
<text top="624" left="125" width="114" height="19" font="3">● Villafane J et al.  </text>
<text top="642" left="125" width="102" height="19" font="3">JACC 2013 (411) </text>
<text top="660" left="125" width="12" height="19" font="3">●<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23375927"> </a></text>
<text top="660" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23375927">23375927</a></text>
<text top="660" left="198" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23375927"><b> </b></a></text>
<text top="624" left="271" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="642" left="271" width="75" height="19" font="3">Multicenter </text>
<text top="660" left="271" width="88" height="19" font="3">retrospective  </text>
<text top="679" left="271" width="3" height="19" font="3"> </text>
<text top="697" left="271" width="57" height="19" font="4"><b>Size:</b> 25  <b> </b></text>
<text top="624" left="413" width="168" height="19" font="4"><b>Inclusion criteria:</b>  patients </text>
<text top="642" left="413" width="152" height="19" font="3">&lt;21 y old with short QTc </text>
<text top="660" left="413" width="76" height="19" font="3">&lt;360 msec.  </text>
<text top="679" left="413" width="107" height="19" font="3">Median age 15 y  </text>
<text top="697" left="413" width="3" height="19" font="3"> </text>
<text top="715" left="413" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="624" left="595" width="230" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ACE in short QT; Assess </text>
<text top="643" left="595" width="80" height="19" font="3">Gollob score </text>
<text top="661" left="595" width="121" height="19" font="3">Mean followup 6 y. </text>
<text top="679" left="595" width="219" height="19" font="4"><b>Results:</b>  Symptoms 56%: ACA 24%, </text>
<text top="698" left="595" width="83" height="19" font="3">syncope 16% </text>
<text top="716" left="595" width="221" height="19" font="3">84% personal or family Hx ACA/SCD </text>
<text top="734" left="595" width="101" height="19" font="3">24% genotype + </text>
<text top="753" left="595" width="191" height="19" font="3">AICD 11: 2 approp shocks; 64% </text>
<text top="771" left="595" width="131" height="19" font="3">inappropriate shocks </text>
<text top="624" left="865" width="169" height="19" font="3">● modified Gollob score &gt;5 </text>
<text top="642" left="865" width="178" height="19" font="3">associated with likely clinical </text>
<text top="660" left="865" width="44" height="19" font="3">events </text>
<text top="679" left="865" width="203" height="19" font="3">● High rate inappropriate shocks </text>
<text top="697" left="865" width="3" height="19" font="3"> </text>
<text top="715" left="865" width="3" height="19" font="3"> </text>
</page>
<page number="227" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">227 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="595" width="182" height="19" font="3">10 patients med rx: quinidine </text>
<text top="127" left="595" width="226" height="19" font="3">Gollob score &lt;5 remained event free </text>
<text top="145" left="595" width="211" height="19" font="3">(excluding patients for symptoms) </text>
<text top="164" left="125" width="117" height="19" font="3">● Mazzanti A et al. </text>
<text top="183" left="125" width="102" height="19" font="3">JACC 2014 (412)<b> </b></text>
<text top="201" left="125" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24291113">● </a></text>
<text top="201" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24291113">24291113</a></text>
<text top="201" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24291113"> </a></text>
<text top="164" left="271" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="183" left="271" width="56" height="19" font="3">Registry  </text>
<text top="201" left="271" width="3" height="19" font="3"> </text>
<text top="219" left="271" width="61" height="19" font="4"><b>Size:</b>  73  <b> </b></text>
<text top="164" left="413" width="151" height="19" font="4"><b>Inclusion criteria:</b>  Short </text>
<text top="183" left="413" width="155" height="19" font="3">QTS: asymptomatic ≤340 </text>
<text top="201" left="413" width="139" height="19" font="3">msec, or QTc 340–360 </text>
<text top="219" left="413" width="156" height="19" font="3">msec Plus ACA, family Hx </text>
<text top="238" left="413" width="139" height="19" font="3">SCD or family Hx SQTS </text>
<text top="256" left="413" width="128" height="19" font="3">53% symptomatic at </text>
<text top="274" left="413" width="49" height="19" font="3">referral </text>
<text top="292" left="413" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="165" left="595" width="250" height="19" font="4"><b>1</b>°<b> endpoint:</b>  SQTS patients followed for </text>
<text top="183" left="595" width="91" height="19" font="3">median 56 mo </text>
<text top="202" left="595" width="3" height="19" font="3"> </text>
<text top="220" left="595" width="234" height="19" font="4"><b>Results:</b> 84% male Mean age 26±15 y, </text>
<text top="238" left="595" width="240" height="19" font="3">QTc 329±22 msec. 40% presented with </text>
<text top="257" left="595" width="142" height="19" font="3">ACA, range 1 mo–41 y. </text>
<text top="275" left="595" width="161" height="19" font="3">CA during sleep 83%, 17% </text>
<text top="293" left="595" width="115" height="19" font="3">emotion/exertion  </text>
<text top="312" left="595" width="204" height="19" font="3">Rate CA 4% first yr of life, 1.3%/y </text>
<text top="330" left="595" width="110" height="19" font="3">between 20-40 y. </text>
<text top="348" left="595" width="239" height="19" font="3">Probability first occurrence CA by 40 y: </text>
<text top="367" left="595" width="36" height="19" font="3">41%.  </text>
<text top="385" left="595" width="208" height="19" font="3">ACA only predictor of recurrence: </text>
<text top="403" left="595" width="83" height="19" font="3">p&lt;0.0000001<b> </b></text>
<text top="164" left="865" width="210" height="19" font="3">● SQTS highly lethal at young age  </text>
<text top="183" left="865" width="154" height="19" font="3">● 11% genotype positive </text>
<text top="201" left="865" width="212" height="19" font="3">● Prior ACA predicts recurrent CA: </text>
<text top="219" left="865" width="213" height="19" font="3">recommend ICD for these patients </text>
<text top="238" left="865" width="210" height="19" font="3">● Gollob score did not predict risk </text>
<text top="422" left="125" width="114" height="19" font="3">● Iribarren C et al. </text>
<text top="441" left="125" width="103" height="19" font="3">Ann Noninv ECG </text>
<text top="459" left="125" width="69" height="19" font="3">2014 (413) </text>
<text top="477" left="125" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24829126">● </a></text>
<text top="477" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24829126">24829126</a></text>
<text top="477" left="198" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24829126"><b> </b></a></text>
<text top="422" left="271" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="441" left="271" width="91" height="19" font="3">Retrospective  </text>
<text top="459" left="271" width="3" height="19" font="3"> </text>
<text top="477" left="271" width="76" height="19" font="4"><b>Size:</b>    1026<b> </b></text>
<text top="422" left="413" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="441" left="413" width="162" height="19" font="3">Screened 6,387,070 ECG’s </text>
<text top="459" left="413" width="168" height="19" font="3">in population of 1.7 million </text>
<text top="477" left="413" width="168" height="19" font="3">persons for QTc ≤300 msec </text>
<text top="496" left="413" width="3" height="19" font="3"> </text>
<text top="514" left="413" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="423" left="595" width="238" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Prevalence, risk of death </text>
<text top="441" left="595" width="231" height="19" font="3">associated with Short QT during 8.3 y </text>
<text top="460" left="595" width="106" height="19" font="3">median followup </text>
<text top="478" left="595" width="3" height="19" font="3"> </text>
<text top="496" left="595" width="224" height="19" font="4"><b>Results:</b>  Prevalence 2.7/100,000<b>,</b> or </text>
<text top="515" left="595" width="108" height="19" font="3">1/141,935 ECG’s. </text>
<text top="533" left="595" width="254" height="19" font="3">Associations: age &gt;65 y, AA race, prior Hx </text>
<text top="551" left="595" width="137" height="19" font="3">VA, COPD, ST changes </text>
<text top="570" left="595" width="209" height="19" font="3">QTc ≤300 msec assoc w increased </text>
<text top="588" left="595" width="217" height="19" font="3">mortality: HR: 2.6 (95% CI: 1.9–3.7) </text>
<text top="422" left="865" width="162" height="19" font="3">● QTc ≤300 msec: 2.6 fold </text>
<text top="441" left="865" width="126" height="19" font="3">increased risk death </text>
<text top="459" left="865" width="3" height="19" font="3"> </text>
<text top="477" left="865" width="3" height="19" font="3"> </text>
<text top="607" left="125" width="112" height="19" font="3">● Guerrier K et al. </text>
<text top="625" left="125" width="109" height="19" font="3">Circ Arrh EP 2015 </text>
<text top="643" left="125" width="35" height="19" font="3">(414) </text>
<text top="662" left="125" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26386018">● </a></text>
<text top="662" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26386018">26386018</a></text>
<text top="662" left="198" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26386018"><b> </b></a></text>
<text top="607" left="271" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="625" left="271" width="127" height="19" font="3">center retrospective </text>
<text top="643" left="271" width="3" height="19" font="3"> </text>
<text top="662" left="271" width="45" height="19" font="4"><b>Size:</b>    <b> </b></text>
<text top="607" left="413" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="625" left="413" width="154" height="19" font="3">Screened 272, 504 ECG’s </text>
<text top="643" left="413" width="150" height="19" font="3">&lt;21 y for QTc≤340 msec </text>
<text top="662" left="413" width="3" height="19" font="3"> </text>
<text top="680" left="413" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="608" left="595" width="251" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Prevalence short QTc ≤340 </text>
<text top="626" left="595" width="210" height="19" font="3">msec in patients &lt;21 y old, deaths </text>
<text top="644" left="595" width="3" height="19" font="3"> </text>
<text top="662" left="595" width="239" height="19" font="4"><b>Results:</b>  Prevalence 0.05%, 76% males </text>
<text top="681" left="595" width="236" height="19" font="3">Females shorter QTc 312 vs 323 msec, </text>
<text top="699" left="595" width="45" height="19" font="3">p=0.03 </text>
<text top="718" left="595" width="180" height="19" font="3">2 deaths: respiratory; dilated </text>
<text top="736" left="595" width="103" height="19" font="3">cardiomyopathy </text>
<text top="607" left="865" width="215" height="19" font="3">● Short QTc ≤340 msec prevalence </text>
<text top="625" left="865" width="114" height="19" font="3">0.05% in &lt;21 y old </text>
<text top="643" left="865" width="3" height="19" font="3"> </text>
<text top="662" left="865" width="164" height="19" font="3">● Short QT rare, increased </text>
<text top="680" left="865" width="125" height="19" font="3">prevalence in males </text>
<text top="698" left="865" width="3" height="19" font="3"> </text>
</page>
<page number="228" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">228 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="114" height="19" font="3">● Bun SS et al. JCE </text>
<text top="127" left="125" width="69" height="19" font="3">2012 (415) </text>
<text top="145" left="125" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22493951">● </a></text>
<text top="145" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22493951">22493951</a></text>
<text top="145" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22493951"> </a></text>
<text top="109" left="271" width="108" height="19" font="4"><b>Study type:</b>  case </text>
<text top="127" left="271" width="45" height="19" font="3">report  </text>
<text top="145" left="271" width="3" height="19" font="3"> </text>
<text top="164" left="271" width="53" height="19" font="4"><b>Size:</b>  1  <b> </b></text>
<text top="109" left="413" width="166" height="19" font="4"><b>Inclusion criteria:</b>  28 y old </text>
<text top="127" left="413" width="165" height="19" font="3">ACA while asleep, QTc 320 </text>
<text top="145" left="413" width="129" height="19" font="3">msec, admitted with </text>
<text top="164" left="413" width="132" height="19" font="3">electrical storm, 8 VF </text>
<text top="182" left="413" width="82" height="19" font="3">arrests while </text>
<text top="200" left="413" width="137" height="19" font="3">sedated/hypothermia </text>
<text top="219" left="413" width="3" height="19" font="3"> </text>
<text top="237" left="413" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="109" left="595" width="248" height="19" font="4"><b>1</b>°<b> endpoint:</b>  treatment electrical storm </text>
<text top="128" left="595" width="78" height="19" font="3">in short QTS </text>
<text top="146" left="595" width="3" height="19" font="3"> </text>
<text top="164" left="595" width="248" height="19" font="4"><b>Results:</b>  isoproterenol infusion resulted </text>
<text top="183" left="595" width="97" height="19" font="3">in sinus rhythm </text>
<text top="201" left="595" width="3" height="19" font="4"><b> </b></text>
<text top="219" left="595" width="3" height="19" font="4"><b> </b></text>
<text top="237" left="595" width="3" height="19" font="4"><b> </b></text>
<text top="256" left="595" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="865" width="152" height="19" font="3">● Case report efficacy of </text>
<text top="127" left="865" width="214" height="19" font="3">isoproterenol in treating recurrent </text>
<text top="145" left="865" width="90" height="19" font="3">VF in short QT </text>
<text top="164" left="865" width="3" height="19" font="3"> </text>
<text top="275" left="125" width="128" height="19" font="3">● Dhutia H et al. Br J </text>
<text top="293" left="125" width="107" height="19" font="3">Sports Med 2016 </text>
<text top="312" left="125" width="35" height="19" font="3">(416) </text>
<text top="330" left="125" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26400956">● </a></text>
<text top="330" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26400956">26400956</a></text>
<text top="330" left="198" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26400956"><b> </b></a></text>
<text top="275" left="271" width="113" height="19" font="4"><b>Study type:</b> single </text>
<text top="293" left="271" width="134" height="19" font="3">center retrospective   </text>
<text top="312" left="271" width="3" height="19" font="3"> </text>
<text top="330" left="271" width="104" height="19" font="4"><b>Size:</b>    screening </text>
<text top="348" left="271" width="98" height="19" font="3">18,825 patients<b> </b></text>
<text top="275" left="413" width="165" height="19" font="4"><b>Inclusion criteria:</b>  Healthy </text>
<text top="293" left="413" width="128" height="19" font="3">people ages 14–35 y </text>
<text top="312" left="413" width="165" height="19" font="3">undergoing screening with </text>
<text top="330" left="413" width="72" height="19" font="3">hx, PE, ECG </text>
<text top="348" left="413" width="3" height="19" font="3"> </text>
<text top="367" left="413" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="276" left="595" width="256" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Prevalence and significance </text>
<text top="294" left="595" width="214" height="19" font="3">of short QTS among healthy young </text>
<text top="312" left="595" width="69" height="19" font="3">individuals </text>
<text top="331" left="595" width="3" height="19" font="3"> </text>
<text top="349" left="595" width="211" height="19" font="4"><b>Results:</b>  QTc ≤320 msec: 0.1%, 26 </text>
<text top="367" left="595" width="53" height="19" font="3">patients </text>
<text top="386" left="595" width="209" height="19" font="3">                QTc ≤330 msec: 0.2%, 44 </text>
<text top="404" left="595" width="53" height="19" font="3">patients </text>
<text top="422" left="595" width="225" height="19" font="3">                QTc &lt;380 msec: 7.9%, 1478 </text>
<text top="441" left="595" width="53" height="19" font="3">patients </text>
<text top="459" left="595" width="232" height="19" font="3">                QTc &lt;390 msec: 15.8%, 2973 </text>
<text top="477" left="595" width="53" height="19" font="3">patients </text>
<text top="496" left="595" width="186" height="19" font="3">Followup 5.3±1.2 y, no deaths </text>
<text top="275" left="865" width="209" height="19" font="3">● Males, Afro-Caribbean ethnicity </text>
<text top="293" left="865" width="189" height="19" font="3">had strongest association with </text>
<text top="312" left="865" width="56" height="19" font="3">short QT </text>
<text top="330" left="865" width="207" height="19" font="3">● Short QTc ≤320 msec: excellent </text>
<text top="348" left="865" width="205" height="19" font="3">medium term prognosis in young </text>
<text top="367" left="865" width="53" height="19" font="3">patients </text>
<text top="385" left="865" width="189" height="19" font="3">● Recommend using QTc ≤320<b> </b></text>
<text top="403" left="865" width="195" height="19" font="4"><b>msec</b> to prevent over-diagnosis </text>
<text top="514" left="115" width="4" height="21" font="0"> </text>
<text top="534" left="115" width="4" height="21" font="0"> </text>
<text top="555" left="115" width="4" height="21" font="0"> </text>
<text top="611" left="115" width="598" height="21" font="2"><b>Data Supplement 45.  RCTs Related to VA in the Structurally Normal Heart – (Section 8) </b></text>
<text top="632" left="119" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="650" left="145" width="55" height="19" font="4"><b>Author;  </b></text>
<text top="668" left="122" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="632" left="269" width="88" height="19" font="4"><b>Aim of Study; </b></text>
<text top="650" left="275" width="76" height="19" font="4"><b>Study Type; </b></text>
<text top="668" left="268" width="89" height="19" font="4"><b>Study Size (N) </b></text>
<text top="632" left="407" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="632" left="560" width="136" height="19" font="4"><b>Study Intervention (# </b></text>
<text top="650" left="593" width="72" height="19" font="4"><b>patients) /  </b></text>
<text top="668" left="561" width="133" height="19" font="4"><b>Study Comparator (# </b></text>
<text top="687" left="598" width="59" height="19" font="4"><b>patients) </b></text>
<text top="632" left="756" width="108" height="19" font="4"><b>Endpoint Results </b></text>
<text top="650" left="738" width="148" height="19" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="668" left="728" width="165" height="19" font="4"><b>P values; OR or RR; &amp; 95% </b></text>
<text top="687" left="800" width="20" height="19" font="4"><b>CI) </b></text>
<text top="633" left="915" width="152" height="19" font="4"><b>Relevant 2</b>°<b> Endpoint (if </b></text>
<text top="651" left="974" width="35" height="19" font="4"><b>any); </b></text>
<text top="669" left="933" width="116" height="19" font="4"><b>Study Limitations; </b></text>
<text top="687" left="942" width="99" height="19" font="4"><b>Adverse Events </b></text>
<text top="707" left="119" width="74" height="19" font="3">● Ling et al. </text>
<text top="725" left="119" width="69" height="19" font="3">2014 (417) </text>
<text top="743" left="119" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24523413">● </a></text>
<text top="743" left="131" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24523413">24523413</a></text>
<text top="743" left="192" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24523413"> </a></text>
<text top="761" left="119" width="3" height="19" font="4"><b> </b></text>
<text top="707" left="235" width="133" height="19" font="4"><b>Aim:</b>  to compare the </text>
<text top="725" left="235" width="66" height="19" font="3">efficacy of </text>
<text top="743" left="235" width="151" height="19" font="3">radiofrequency catheter </text>
<text top="762" left="235" width="117" height="19" font="3">ablation (RFCA) vs. </text>
<text top="707" left="404" width="118" height="19" font="4"><b>Inclusion criteria</b>:   </text>
<text top="725" left="404" width="20" height="19" font="3">(1) </text>
<text top="743" left="404" width="57" height="19" font="3">frequent </text>
<text top="762" left="404" width="116" height="19" font="3">symptomatic VPBs </text>
<text top="780" left="404" width="94" height="19" font="3">from the RVOT </text>
<text top="707" left="543" width="162" height="19" font="4"><b>Intervention:</b>  RF catheter </text>
<text top="725" left="543" width="107" height="19" font="3">ablation of RVOT </text>
<text top="743" left="543" width="89" height="19" font="4"><b>Comparator:</b>   </text>
<text top="762" left="543" width="95" height="19" font="3">Antiarrhythmic </text>
<text top="780" left="543" width="85" height="19" font="3">medications<b>   </b></text>
<text top="707" left="726" width="153" height="19" font="4"><b>1</b>°<b> endpoint:</b>  The 1° end </text>
<text top="726" left="726" width="148" height="19" font="3">point was recurrence of </text>
<text top="744" left="726" width="141" height="19" font="3">RVOT VPBs at a rate of </text>
<text top="707" left="907" width="154" height="19" font="3">● RF Catheter ablation is </text>
<text top="725" left="907" width="154" height="19" font="3">more effective than AAD </text>
<text top="743" left="907" width="159" height="19" font="3">for treatment of frequent </text>
<text top="762" left="907" width="149" height="19" font="3">premature beats arising </text>
<text top="780" left="907" width="98" height="19" font="3">from the RVOT. </text>
</page>
<page number="229" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">229 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="235" width="133" height="19" font="3">AAD for treatment of </text>
<text top="127" left="235" width="140" height="19" font="3">patients with frequent </text>
<text top="145" left="235" width="138" height="19" font="3">ventricular premature </text>
<text top="164" left="235" width="149" height="19" font="3">beats (VPBs) originating </text>
<text top="182" left="235" width="89" height="19" font="3">from the right </text>
<text top="200" left="235" width="152" height="19" font="3">ventricular outflow tract </text>
<text top="219" left="235" width="50" height="19" font="3">(RVOT). </text>
<text top="237" left="235" width="3" height="19" font="3"> </text>
<text top="255" left="235" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="273" left="235" width="105" height="19" font="3">Prospective, RCT </text>
<text top="292" left="235" width="3" height="19" font="3"> </text>
<text top="310" left="235" width="121" height="19" font="4"><b>Size:</b>    330 patients </text>
<text top="109" left="404" width="119" height="19" font="3">documented by 12-</text>
<text top="127" left="404" width="29" height="19" font="3">lead </text>
<text top="145" left="404" width="77" height="19" font="3">ECG to have </text>
<text top="164" left="404" width="125" height="19" font="3">inferior axis and left </text>
<text top="182" left="404" width="93" height="19" font="3">bundle-branch </text>
<text top="200" left="404" width="108" height="19" font="3">block (LBBB) QRS </text>
<text top="219" left="404" width="77" height="19" font="3">morphology </text>
<text top="237" left="404" width="119" height="19" font="3">(2) &gt;6000 VPBs per </text>
<text top="255" left="404" width="87" height="19" font="3">24h on Holter </text>
<text top="273" left="404" width="75" height="19" font="3">monitoring. </text>
<text top="292" left="404" width="3" height="19" font="3"> </text>
<text top="310" left="404" width="120" height="19" font="4"><b>Exclusion criteria</b>:   </text>
<text top="328" left="404" width="119" height="19" font="3">(1) the presence of </text>
<text top="347" left="404" width="65" height="19" font="3">non-RVOT </text>
<text top="365" left="404" width="93" height="19" font="3">origin for VPBs </text>
<text top="383" left="404" width="107" height="19" font="3">indicated by an S </text>
<text top="402" left="404" width="103" height="19" font="3">wave in lead I, R-</text>
<text top="420" left="404" width="91" height="19" font="3">wave duration </text>
<text top="438" left="404" width="97" height="19" font="3">index in V1 and </text>
<text top="457" left="404" width="100" height="19" font="3">V2≥0.5, and R/S </text>
<text top="475" left="404" width="101" height="19" font="3">wave amplitude </text>
<text top="493" left="404" width="97" height="19" font="3">index in V1 and </text>
<text top="512" left="404" width="69" height="19" font="3">V2≥0.311;  </text>
<text top="530" left="404" width="106" height="19" font="3">(2) previous AAD </text>
<text top="548" left="404" width="58" height="19" font="3">therapy;  </text>
<text top="566" left="404" width="119" height="19" font="3">(3) evidence of any </text>
<text top="585" left="404" width="62" height="19" font="3">structural </text>
<text top="603" left="404" width="89" height="19" font="3">heart disease; </text>
<text top="621" left="404" width="124" height="19" font="3">(4) hyperthyroidism </text>
<text top="640" left="404" width="85" height="19" font="3">or electrolyte </text>
<text top="658" left="404" width="83" height="19" font="3">disturbance;  </text>
<text top="676" left="404" width="51" height="19" font="3">(5) drug </text>
<text top="695" left="404" width="55" height="19" font="3">toxicity;  </text>
<text top="713" left="404" width="76" height="19" font="3">(6) diabetes </text>
<text top="731" left="404" width="59" height="19" font="3">mellitus;  </text>
<text top="750" left="404" width="126" height="19" font="3">(7) BP&gt;165/100 mm </text>
<text top="768" left="404" width="24" height="19" font="3">Hg; </text>
<text top="109" left="726" width="120" height="19" font="3">≥300 beats per day </text>
<text top="127" left="726" width="129" height="19" font="3">documented by 24 h </text>
<text top="145" left="726" width="159" height="19" font="3">Holter monitoring. The 2° </text>
<text top="164" left="726" width="124" height="19" font="3">variables of interest </text>
<text top="182" left="726" width="150" height="19" font="3">including the number of </text>
<text top="200" left="726" width="109" height="19" font="3">VPBs, the burden </text>
<text top="219" left="726" width="145" height="19" font="3">of VPBs (the number of </text>
<text top="237" left="726" width="100" height="19" font="3">VPBs/ total QRS </text>
<text top="255" left="726" width="144" height="19" font="3">complexes×100%), and </text>
<text top="273" left="726" width="142" height="19" font="3">LVEF at each follow-up </text>
<text top="292" left="726" width="160" height="19" font="3">time point were collected </text>
<text top="310" left="726" width="3" height="19" font="3"> </text>
<text top="329" left="726" width="147" height="19" font="3">During the 1y follow-up </text>
<text top="347" left="726" width="75" height="19" font="3">period, VPB </text>
<text top="365" left="726" width="97" height="19" font="3">recurrence was </text>
<text top="383" left="726" width="129" height="19" font="3">significantly lower in </text>
<text top="402" left="726" width="146" height="19" font="3">patients randomized to </text>
<text top="420" left="726" width="154" height="19" font="3">RFCA group (32 patients, </text>
<text top="438" left="726" width="165" height="19" font="3">19.4%) vs. AAD group (146 </text>
<text top="457" left="726" width="158" height="19" font="3">patients, 88.6%; p&lt;0.001, </text>
<text top="475" left="726" width="164" height="19" font="3">log-rank test). In a Poisson </text>
<text top="493" left="726" width="142" height="19" font="3">generalized estimating </text>
<text top="512" left="726" width="131" height="19" font="3">equations regression </text>
<text top="530" left="726" width="81" height="19" font="3">model, RFCA </text>
<text top="548" left="726" width="136" height="19" font="3">was associated with a </text>
<text top="566" left="726" width="145" height="19" font="3">greater decrease in the </text>
<text top="585" left="726" width="163" height="19" font="3">burden of VPBs (incidence </text>
<text top="603" left="726" width="155" height="19" font="3">rate ratio: 0.105; 95% CI: </text>
<text top="621" left="726" width="141" height="19" font="3">0.104–0.105; p&lt;0.001) </text>
<text top="640" left="726" width="155" height="19" font="3">compared with AAD. In a </text>
<text top="658" left="726" width="160" height="19" font="3">liner GEE model, the LVEF </text>
<text top="676" left="726" width="97" height="19" font="3">had a tendency </text>
<text top="695" left="726" width="127" height="19" font="3">to increase after the </text>
<text top="713" left="726" width="158" height="19" font="3">treatment in both groups </text>
<text top="731" left="726" width="166" height="19" font="3">(coefficient, 0.584; 95% CI: </text>
<text top="750" left="726" width="144" height="19" font="3">0.467–0.702; p&lt;0.001).<b> </b></text>
<text top="109" left="907" width="3" height="19" font="3"> </text>
<text top="127" left="907" width="3" height="19" font="3"> </text>
</page>
<page number="230" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">230 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="404" width="86" height="19" font="3">(8) significant </text>
<text top="127" left="404" width="125" height="19" font="3">impairment of renal </text>
<text top="145" left="404" width="62" height="19" font="3">function;  </text>
<text top="164" left="404" width="121" height="19" font="3">(9) QT interval&gt;450 </text>
<text top="182" left="404" width="113" height="19" font="3">ms in the absence </text>
<text top="200" left="404" width="109" height="19" font="3">of bundle-branch </text>
<text top="219" left="404" width="47" height="19" font="3">block;   </text>
<text top="237" left="404" width="114" height="19" font="3">(10) significant AV </text>
<text top="255" left="404" width="120" height="19" font="3">conduction disease </text>
<text top="273" left="404" width="99" height="19" font="3">and left or right </text>
<text top="292" left="404" width="93" height="19" font="3">bundle-branch </text>
<text top="310" left="404" width="36" height="19" font="3">block </text>
<text top="329" left="119" width="102" height="19" font="3">● Krittayaphong </text>
<text top="347" left="119" width="95" height="19" font="3">et al. 2002 (94) </text>
<text top="366" left="119" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12486439?dopt=Citation">● </a></text>
<text top="366" left="131" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12486439?dopt=Citation">12486439</a></text>
<text top="366" left="192" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12486439?dopt=Citation"><b> </b></a></text>
<text top="329" left="235" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="347" left="235" width="27" height="19" font="3">RCT </text>
<text top="366" left="235" width="3" height="19" font="3"> </text>
<text top="384" left="235" width="142" height="19" font="4"><b>Aim:</b> To determine the </text>
<text top="402" left="235" width="134" height="19" font="3">efficacy of atenolol in </text>
<text top="421" left="235" width="105" height="19" font="3">the treatment of </text>
<text top="439" left="235" width="136" height="19" font="3">symptomatic VA from </text>
<text top="457" left="235" width="133" height="19" font="3">RVOT compared with </text>
<text top="476" left="235" width="51" height="19" font="3">placebo </text>
<text top="494" left="235" width="3" height="19" font="3"> </text>
<text top="512" left="235" width="50" height="19" font="4"><b>Size:</b> 52<b> </b></text>
<text top="329" left="404" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="347" left="404" width="89" height="19" font="3">VA with LBBB, </text>
<text top="366" left="404" width="75" height="19" font="3">inferior axis </text>
<text top="384" left="404" width="85" height="19" font="3">morphology.  </text>
<text top="402" left="404" width="109" height="19" font="3">Symptomatic (VA </text>
<text top="421" left="404" width="94" height="19" font="3">disturbed their </text>
<text top="439" left="404" width="94" height="19" font="3">daily activities) </text>
<text top="457" left="404" width="3" height="19" font="3"> </text>
<text top="476" left="404" width="113" height="19" font="4"><b>Exclusion criteria</b> <b> </b></text>
<text top="494" left="404" width="33" height="19" font="3">SHD.<b> </b></text>
<text top="329" left="543" width="85" height="19" font="4"><b>Intervention: </b></text>
<text top="347" left="543" width="148" height="19" font="3">Atenolol 50-100mg/day </text>
<text top="366" left="543" width="3" height="19" font="3"> </text>
<text top="384" left="543" width="144" height="19" font="4"><b>Comparator:</b>  <b>  </b>Placebo </text>
<text top="402" left="626" width="3" height="19" font="4"><b> </b></text>
<text top="330" left="726" width="88" height="19" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="348" left="726" width="131" height="19" font="3">Atenolol significantly </text>
<text top="367" left="726" width="132" height="19" font="3">decreased PVC count </text>
<text top="385" left="726" width="140" height="19" font="3">(p=0.001) and average </text>
<text top="403" left="726" width="126" height="19" font="3">heart rate (p&lt;0.001) </text>
<text top="422" left="726" width="140" height="19" font="3">compared to placebo.  </text>
<text top="440" left="726" width="164" height="19" font="3">Both placebo and atenolol </text>
<text top="458" left="726" width="127" height="19" font="3">decreased symptom </text>
<text top="476" left="726" width="72" height="19" font="3">frequency.  </text>
<text top="495" left="809" width="3" height="19" font="4"><b> </b></text>
<text top="329" left="907" width="142" height="19" font="3">● BB may be useful for </text>
<text top="347" left="907" width="147" height="19" font="3">patients with RVOT and </text>
<text top="366" left="907" width="107" height="19" font="3">symptomatic VA. </text>
<text top="384" left="907" width="3" height="19" font="3"> </text>
<text top="531" left="115" width="4" height="21" font="0"> </text>
<text top="587" left="115" width="911" height="21" font="2"><b>Data Supplement 46.  Nonrandomized Trials, Observational Studies, and/or Registries Related to Outflow Tract and AV Annular VA – </b></text>
<text top="607" left="115" width="89" height="21" font="2"><b>(Section 8.1) </b></text>
<text top="628" left="149" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="647" left="175" width="51" height="19" font="4"><b>Author; </b></text>
<text top="665" left="153" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="628" left="300" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="647" left="329" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="628" left="467" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="628" left="640" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="647" left="652" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="665" left="683" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="628" left="884" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="647" left="912" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="684" left="125" width="143" height="19" font="3">● Liao et al. 2015 (418) </text>
<text top="703" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26670064">● </a></text>
<text top="703" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26670064">26670064</a></text>
<text top="703" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26670064"> </a></text>
<text top="721" left="125" width="3" height="19" font="3"> </text>
<text top="684" left="290" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="703" left="290" width="84" height="19" font="3">Single Center </text>
<text top="721" left="290" width="89" height="19" font="3">Observational </text>
<text top="739" left="290" width="3" height="19" font="3"> </text>
<text top="757" left="290" width="42" height="19" font="4"><b>Size:</b>    </text>
<text top="776" left="290" width="75" height="19" font="3">24 patients  </text>
<text top="684" left="447" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="703" left="447" width="147" height="19" font="3">Patients with idiopathic </text>
<text top="721" left="447" width="89" height="19" font="3">VAs that were </text>
<text top="739" left="447" width="125" height="19" font="3">successfully ablated </text>
<text top="757" left="447" width="126" height="19" font="3">within the pulmonic </text>
<text top="776" left="447" width="107" height="19" font="3">valve sinus cusps </text>
<text top="684" left="620" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="703" left="620" width="157" height="19" font="3">Among 244 patients with </text>
<text top="721" left="620" width="164" height="19" font="3">LBBB and inferior QRS axis </text>
<text top="739" left="620" width="158" height="19" font="3">VAs, 24 patients required </text>
<text top="757" left="620" width="179" height="19" font="3">ablation within the pulmonic </text>
<text top="776" left="620" width="75" height="19" font="3">sinus cusps. </text>
<text top="684" left="823" width="255" height="19" font="3">● Right ventricular outflow tract VAs may </text>
<text top="703" left="823" width="227" height="19" font="3">require ablation within the pulmonic </text>
<text top="721" left="823" width="110" height="19" font="3">valve sinus cusps. </text>
</page>
<page number="231" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">231 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="447" width="3" height="19" font="3"> </text>
<text top="127" left="447" width="151" height="19" font="4"><b>Exclusion criteria:</b>  none </text>
<text top="109" left="620" width="185" height="19" font="3">Successful ablation within the </text>
<text top="127" left="620" width="176" height="19" font="3">right PV sinus in 10 patients, </text>
<text top="145" left="620" width="138" height="19" font="3">the left sinus in 8, and </text>
<text top="164" left="620" width="117" height="19" font="3">anterior sinus in 6. </text>
<text top="182" left="620" width="184" height="19" font="3">There were no complications. </text>
<text top="201" left="125" width="131" height="19" font="3">● Morady et al. 1990 </text>
<text top="219" left="125" width="35" height="19" font="3">(419) </text>
<text top="238" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2242533">● </a></text>
<text top="238" left="137" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2242533">2242533</a></text>
<text top="238" left="190" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2242533"> </a></text>
<text top="256" left="125" width="3" height="19" font="3"> </text>
<text top="201" left="290" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="219" left="290" width="131" height="19" font="3">Center observational </text>
<text top="238" left="290" width="3" height="19" font="3"> </text>
<text top="256" left="290" width="114" height="19" font="4"><b>Size:</b>    10 patients </text>
<text top="201" left="447" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="219" left="447" width="130" height="19" font="3">Consecutive patients </text>
<text top="238" left="447" width="133" height="19" font="3">undergoing DC Shock </text>
<text top="256" left="447" width="124" height="19" font="3">catheter ablation of </text>
<text top="274" left="447" width="56" height="19" font="3">RVOT VT </text>
<text top="293" left="447" width="3" height="19" font="3"> </text>
<text top="311" left="447" width="151" height="19" font="4"><b>Exclusion criteria:</b>  none </text>
<text top="201" left="620" width="183" height="19" font="4"><b>Results:</b>  DC shock ablation in </text>
<text top="219" left="620" width="166" height="19" font="3">the RVOT rendered 9 of 10 </text>
<text top="238" left="620" width="158" height="19" font="3">patients free of VT over a </text>
<text top="256" left="620" width="184" height="19" font="3">mean follow-up of 33+18 mo. </text>
<text top="274" left="620" width="184" height="19" font="3">There were no complications. </text>
<text top="292" left="620" width="3" height="19" font="3"> </text>
<text top="311" left="620" width="3" height="19" font="3"> </text>
<text top="201" left="823" width="237" height="19" font="3">● RVOT VT can be successfully ablated </text>
<text top="219" left="823" width="253" height="19" font="3">with DC shock ablation with high efficacy </text>
<text top="238" left="823" width="144" height="19" font="3">and low complications. </text>
<text top="330" left="125" width="132" height="19" font="3">● Yamada et al. 2008 </text>
<text top="348" left="125" width="35" height="19" font="3">(420) </text>
<text top="366" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18598894">● </a></text>
<text top="366" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18598894">18598894</a></text>
<text top="366" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18598894"> </a></text>
<text top="385" left="125" width="3" height="19" font="4"><b> </b></text>
<text top="330" left="290" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="348" left="290" width="133" height="19" font="3">Center Observational </text>
<text top="366" left="290" width="3" height="19" font="3"> </text>
<text top="385" left="290" width="121" height="19" font="4"><b>Size:</b>    265 patients </text>
<text top="330" left="447" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="348" left="447" width="91" height="19" font="3">Idiopathic VAs </text>
<text top="366" left="447" width="128" height="19" font="3">undergoing catheter </text>
<text top="385" left="447" width="53" height="19" font="3">ablation </text>
<text top="403" left="447" width="3" height="19" font="3"> </text>
<text top="422" left="447" width="129" height="19" font="3">44 patients with VAs </text>
<text top="440" left="447" width="130" height="19" font="3">mapped and ablated </text>
<text top="458" left="447" width="152" height="19" font="3">within the aortic sinuses </text>
<text top="330" left="620" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="348" left="620" width="149" height="19" font="3">Left coronary cusp in 24 </text>
<text top="366" left="620" width="107" height="19" font="3">patients (54.5%), </text>
<text top="385" left="620" width="157" height="19" font="3">Right coronary cusp in 14 </text>
<text top="403" left="620" width="107" height="19" font="3">patients (31.8%), </text>
<text top="422" left="620" width="173" height="19" font="3">Right-Left cusp junction in 5 </text>
<text top="440" left="620" width="133" height="19" font="3">patients (11.4%), and </text>
<text top="458" left="620" width="161" height="19" font="3">Noncoronary cusp in 1 pt. </text>
<text top="476" left="620" width="3" height="19" font="3"> </text>
<text top="495" left="620" width="189" height="19" font="3">Successful catheter ablation in </text>
<text top="513" left="620" width="143" height="19" font="3">44/44 patients (100%). </text>
<text top="531" left="620" width="113" height="19" font="3">No complications. </text>
<text top="550" left="620" width="3" height="19" font="3"> </text>
<text top="330" left="823" width="251" height="19" font="3">● The aortic valve sinuses are a common </text>
<text top="348" left="823" width="257" height="19" font="3">location of outflow tract arrhythmias that </text>
<text top="366" left="823" width="255" height="19" font="3">can be effectively and safely ablated with </text>
<text top="385" left="823" width="71" height="19" font="3">RF current. </text>
<text top="569" left="125" width="135" height="19" font="3">● Yamada et al. 2010  </text>
<text top="587" left="125" width="35" height="19" font="3">(421) </text>
<text top="605" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20855374">● </a></text>
<text top="605" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20855374">20855374</a></text>
<text top="605" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20855374"> </a></text>
<text top="624" left="125" width="3" height="19" font="4"><b> </b></text>
<text top="569" left="290" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="587" left="290" width="84" height="19" font="3">Single Center </text>
<text top="605" left="290" width="89" height="19" font="3">Observational </text>
<text top="624" left="290" width="3" height="19" font="3"> </text>
<text top="642" left="290" width="114" height="19" font="4"><b>Size:</b>    27 patients </text>
<text top="569" left="447" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="587" left="447" width="149" height="19" font="3">Among 221 consecutive </text>
<text top="605" left="447" width="102" height="19" font="3">patients with LV </text>
<text top="624" left="447" width="113" height="19" font="3">Idiopathic VAs, 27 </text>
<text top="642" left="447" width="159" height="19" font="3">patients had VAs mapped </text>
<text top="660" left="447" width="119" height="19" font="3">and ablated on the </text>
<text top="679" left="447" width="108" height="19" font="3">Summit of the LV </text>
<text top="697" left="447" width="3" height="19" font="3"> </text>
<text top="715" left="447" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="569" left="620" width="59" height="19" font="4"><b>Results:   </b></text>
<text top="587" left="620" width="176" height="19" font="3">Successful ablation from the </text>
<text top="605" left="620" width="150" height="19" font="3">Great Cardiac Vein in 14 </text>
<text top="624" left="620" width="185" height="19" font="3">patients and on the epicardial </text>
<text top="642" left="620" width="135" height="19" font="3">surface of the LV in 4. </text>
<text top="660" left="620" width="133" height="19" font="3">In 5 patients ablation </text>
<text top="679" left="620" width="180" height="19" font="3">abandoned because of origin </text>
<text top="697" left="620" width="190" height="19" font="3">in the inaccessible region.  In 4 </text>
<text top="715" left="620" width="179" height="19" font="3">patients ablation abandoned </text>
<text top="734" left="620" width="155" height="19" font="3">due to close proximity to </text>
<text top="752" left="620" width="165" height="19" font="3">epicardial coronary artery. </text>
<text top="770" left="620" width="3" height="19" font="3"> </text>
<text top="569" left="823" width="246" height="19" font="3">● LV summit VAs may be ablated within </text>
<text top="587" left="823" width="231" height="19" font="3">the GCV or inferior to the GCV on the </text>
<text top="605" left="823" width="247" height="19" font="3">epicardial surface, though sites superior </text>
<text top="624" left="823" width="221" height="19" font="3">to the GCV are often inaccessible to </text>
<text top="642" left="823" width="57" height="19" font="3">ablation. </text>
</page>
<page number="232" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">232 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="150" height="19" font="3">● Mountantonakis et al. </text>
<text top="127" left="125" width="69" height="19" font="3">2010 (422) </text>
<text top="145" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20855374">● </a></text>
<text top="145" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20855374">20855374</a></text>
<text top="145" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20855374"> </a></text>
<text top="164" left="125" width="3" height="19" font="3"> </text>
<text top="109" left="290" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="127" left="290" width="133" height="19" font="3">Center Observational </text>
<text top="145" left="290" width="3" height="19" font="3"> </text>
<text top="164" left="290" width="114" height="19" font="4"><b>Size:</b>    47 patients </text>
<text top="109" left="447" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="127" left="447" width="149" height="19" font="3">Among 511 consecutive </text>
<text top="145" left="447" width="140" height="19" font="3">patients with non-scar </text>
<text top="164" left="447" width="149" height="19" font="3">related VAs, 47 patients </text>
<text top="182" left="447" width="158" height="19" font="3">were found to have a site </text>
<text top="200" left="447" width="120" height="19" font="3">of origin within the </text>
<text top="219" left="447" width="156" height="19" font="3">Coronary Venous System </text>
<text top="237" left="447" width="40" height="19" font="3">(CVS). </text>
<text top="255" left="447" width="3" height="19" font="3"> </text>
<text top="273" left="447" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="109" left="620" width="59" height="19" font="4"><b>Results:   </b></text>
<text top="127" left="620" width="187" height="19" font="3">Twenty-five (53%) were in the </text>
<text top="145" left="620" width="187" height="19" font="3">great cardiac vein, 19 (40%) in </text>
<text top="164" left="620" width="175" height="19" font="3">the anterior interventricular </text>
<text top="182" left="620" width="181" height="19" font="3">vein, and 3(7%) in the middle </text>
<text top="200" left="620" width="80" height="19" font="3">cardiac vein. </text>
<text top="219" left="620" width="177" height="19" font="3">Successful ablation achieved </text>
<text top="237" left="620" width="171" height="19" font="3">in 17 of 18 (94%) ablated at </text>
<text top="255" left="620" width="184" height="19" font="3">the earliest CVS site and in 16 </text>
<text top="273" left="620" width="138" height="19" font="3">of 29 (55%) ablated at </text>
<text top="292" left="620" width="189" height="19" font="3">adjacent CVS or non-CVS sites. </text>
<text top="109" left="823" width="239" height="19" font="3">● Although ablation at the earliest CVS </text>
<text top="127" left="823" width="197" height="19" font="3">site is effective, it is often (62%) </text>
<text top="145" left="823" width="244" height="19" font="3">precluded, mainly because of proximity </text>
<text top="164" left="823" width="255" height="19" font="3">to coronary arteries. Ablation at adjacent </text>
<text top="182" left="823" width="248" height="19" font="3">CVS and non-CVS sites can be successful </text>
<text top="200" left="823" width="251" height="19" font="3">in 55% of these anatomically challenging </text>
<text top="219" left="823" width="255" height="19" font="3">cases, for an overall ablation success rate </text>
<text top="237" left="823" width="49" height="19" font="3">of 70%. </text>
<text top="311" left="125" width="127" height="19" font="3">● Doppalapudi et al. </text>
<text top="329" left="125" width="69" height="19" font="3">2009 (423) </text>
<text top="347" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19121799">● </a></text>
<text top="347" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19121799">19121799</a></text>
<text top="347" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19121799"> </a></text>
<text top="311" left="290" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="329" left="290" width="84" height="19" font="3">Single Center </text>
<text top="347" left="290" width="89" height="19" font="3">Observational </text>
<text top="366" left="290" width="3" height="19" font="3"> </text>
<text top="384" left="290" width="106" height="19" font="4"><b>Size:</b>    4 patients </text>
<text top="311" left="447" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="329" left="447" width="157" height="19" font="11">Among 340 patients with </text>
<text top="347" left="447" width="158" height="19" font="11">idiopathic VT referred for </text>
<text top="366" left="447" width="120" height="19" font="11">ablation, four were </text>
<text top="384" left="447" width="140" height="19" font="11">identified with VT that </text>
<text top="402" left="447" width="121" height="19" font="11">was mapped to the </text>
<text top="421" left="447" width="145" height="19" font="11">epicardium at the crux. </text>
<text top="439" left="447" width="3" height="19" font="11"> </text>
<text top="457" left="447" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="311" left="620" width="59" height="19" font="4"><b>Results:   </b></text>
<text top="329" left="620" width="170" height="19" font="3">VT was sustained and rapid </text>
<text top="347" left="620" width="184" height="19" font="3">(mean cycle length 264 msec) </text>
<text top="366" left="620" width="139" height="19" font="3">in all patients and was </text>
<text top="384" left="620" width="168" height="19" font="3">associated with syncope or </text>
<text top="402" left="620" width="175" height="19" font="3">presyncope in three. VT was </text>
<text top="421" left="620" width="166" height="19" font="3">induced with programmed </text>
<text top="439" left="620" width="182" height="19" font="3">stimulation or burst pacing in </text>
<text top="457" left="620" width="162" height="19" font="3">all 4 patients but required </text>
<text top="476" left="620" width="153" height="19" font="3">isoproterenol infusion in </text>
<text top="494" left="620" width="40" height="19" font="3">three. </text>
<text top="311" left="823" width="207" height="19" font="3">Idiopathic VT may arise by a focal </text>
<text top="329" left="823" width="242" height="19" font="3">mechanism from the epicardium at the </text>
<text top="347" left="823" width="239" height="19" font="3">crux in close proximity to the posterior </text>
<text top="366" left="823" width="202" height="19" font="3">descending coronary artery. This </text>
<text top="384" left="823" width="181" height="19" font="3">syndrome can result in rapid, </text>
<text top="402" left="823" width="250" height="19" font="3">catecholamine-sensitive VT and requires </text>
<text top="421" left="823" width="205" height="19" font="3">careful attention to the posterior </text>
<text top="439" left="823" width="213" height="19" font="3">descending coronary artery during </text>
<text top="457" left="823" width="57" height="19" font="3">ablation. </text>
<text top="513" left="125" width="142" height="19" font="3">● Konstantinidou et al. </text>
<text top="531" left="125" width="69" height="19" font="3">2011 (424) </text>
<text top="550" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21307021">● </a></text>
<text top="550" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21307021">21307021</a></text>
<text top="550" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21307021"> </a></text>
<text top="513" left="290" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="531" left="290" width="84" height="19" font="3">Single Center </text>
<text top="550" left="290" width="89" height="19" font="3">Observational </text>
<text top="568" left="290" width="3" height="19" font="3"> </text>
<text top="586" left="290" width="114" height="19" font="4"><b>Size:</b>    13 patients </text>
<text top="513" left="447" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="531" left="447" width="140" height="19" font="11">13 patients presenting </text>
<text top="550" left="447" width="133" height="19" font="11">with VT suggestive of </text>
<text top="568" left="447" width="72" height="19" font="11">RVOT origin</text>
<text top="568" left="519" width="87" height="19" font="3"> with ablation </text>
<text top="586" left="447" width="124" height="19" font="3">guided by Magnetic </text>
<text top="605" left="447" width="72" height="19" font="3">Navigation  </text>
<text top="623" left="447" width="3" height="19" font="3"> </text>
<text top="641" left="447" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="513" left="620" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="531" left="620" width="176" height="19" font="11">The RVOT was reached in all </text>
<text top="550" left="620" width="170" height="19" font="11">patients utilized solely with </text>
<text top="568" left="620" width="24" height="19" font="11">the </text>
<text top="568" left="644" width="129" height="19" font="3">Magnetic Navigation </text>
<text top="586" left="620" width="44" height="19" font="3">System</text>
<text top="586" left="664" width="110" height="19" font="11">. Successful RVOT </text>
<text top="605" left="620" width="188" height="19" font="11">ablation was achieved in (135) </text>
<text top="623" left="620" width="107" height="19" font="11">(92.3%) patients. </text>
<text top="641" left="620" width="172" height="19" font="11">No Complications occurred. </text>
<text top="660" left="620" width="170" height="19" font="11">During a mean follow-up of </text>
<text top="678" left="620" width="116" height="19" font="11">252+211 d, clinical </text>
<text top="696" left="620" width="168" height="19" font="11">arrhythmia recurrence was </text>
<text top="714" left="620" width="162" height="19" font="11">observed in 1 of 13 (7.7%) </text>
<text top="733" left="620" width="57" height="19" font="11">patients. </text>
<text top="751" left="620" width="3" height="19" font="3"> </text>
<text top="513" left="823" width="12" height="19" font="3">● </text>
<text top="513" left="836" width="197" height="19" font="11">RVOT access is feasible with the </text>
<text top="531" left="823" width="174" height="19" font="3">Magnetic Navigation System</text>
<text top="531" left="997" width="81" height="19" font="11">, while RVOT </text>
<text top="550" left="823" width="250" height="19" font="11">mapping and ablation appear to be safe, </text>
<text top="568" left="823" width="116" height="19" font="11">fast, and effective. </text>
<text top="586" left="823" width="3" height="19" font="11"> </text>
<text top="605" left="823" width="3" height="19" font="3"> </text>
</page>
<page number="233" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">233 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="130" height="19" font="3">● Ouyang et al. 2002 </text>
<text top="127" left="125" width="35" height="19" font="3">(425) </text>
<text top="145" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11823089">● </a></text>
<text top="145" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11823089">11823089</a></text>
<text top="145" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11823089"> </a></text>
<text top="164" left="125" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="288" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="127" left="288" width="84" height="19" font="3">Single Center </text>
<text top="145" left="288" width="89" height="19" font="3">Observational </text>
<text top="164" left="288" width="3" height="19" font="3"> </text>
<text top="182" left="288" width="114" height="19" font="4"><b>Size:</b>    15 patients </text>
<text top="109" left="447" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="127" left="447" width="130" height="19" font="3">Consecutive patients </text>
<text top="145" left="447" width="146" height="19" font="3">with VAs from the right </text>
<text top="164" left="447" width="152" height="19" font="3">ventricular outflow tract </text>
<text top="182" left="447" width="103" height="19" font="3">or aortic sinuses </text>
<text top="200" left="447" width="3" height="19" font="3"> </text>
<text top="218" left="447" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="109" left="619" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="127" left="619" width="185" height="19" font="3">The RVOT was site of origin in </text>
<text top="145" left="619" width="176" height="19" font="3">7 patients and aortic sinuses </text>
<text top="164" left="619" width="83" height="19" font="3">in 8 patients. </text>
<text top="182" left="619" width="169" height="19" font="3"> The left coronary cusp was </text>
<text top="200" left="619" width="156" height="19" font="3">the site of origin in 5 of 7 </text>
<text top="219" left="619" width="135" height="19" font="3">patients and the right </text>
<text top="237" left="619" width="142" height="19" font="3">coronary cusp in 2 of 7 </text>
<text top="255" left="619" width="183" height="19" font="3">patients with aortic sinus VAs </text>
<text top="109" left="823" width="252" height="19" font="3">● VAs may arise in either the right or left </text>
<text top="127" left="823" width="228" height="19" font="3">ventricular outflow tracts and can be </text>
<text top="145" left="823" width="189" height="19" font="3">safely ablated with RF current. </text>
<text top="274" left="125" width="148" height="19" font="3">● Tada et al. 2005 (426) </text>
<text top="292" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15766824">● </a></text>
<text top="292" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15766824">15766824</a></text>
<text top="292" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15766824"> </a></text>
<text top="311" left="125" width="3" height="19" font="3"> </text>
<text top="274" left="288" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="292" left="288" width="133" height="19" font="3">Center Observational </text>
<text top="311" left="288" width="3" height="19" font="3"> </text>
<text top="329" left="288" width="114" height="19" font="4"><b>Size:</b>    19 patients </text>
<text top="274" left="447" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="292" left="447" width="130" height="19" font="3">Consecutive patients </text>
<text top="311" left="447" width="151" height="19" font="3">with VAs mapped to the </text>
<text top="329" left="447" width="126" height="19" font="3">mitral valve annulus </text>
<text top="347" left="447" width="3" height="19" font="3"> </text>
<text top="366" left="447" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="274" left="619" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="292" left="619" width="157" height="19" font="3">Among 352 patients with </text>
<text top="311" left="619" width="170" height="19" font="3">idiopathic VAs, 19 (5%) had </text>
<text top="329" left="619" width="127" height="19" font="3">mitral annular VAs.   </text>
<text top="347" left="619" width="180" height="19" font="3">11 (58%) originated from the </text>
<text top="366" left="619" width="178" height="19" font="3">anterolateral mitral annulus, </text>
<text top="384" left="619" width="167" height="19" font="3">2 from the posterior mitral </text>
<text top="402" left="619" width="149" height="19" font="3">annulus, and 6 from the </text>
<text top="421" left="619" width="186" height="19" font="3">posteroseptal mitral annulus.  </text>
<text top="439" left="619" width="177" height="19" font="3">Successful ablation achieved </text>
<text top="457" left="619" width="161" height="19" font="3">in 19/19 patients (100%).  </text>
<text top="476" left="619" width="173" height="19" font="3">No complications observed. </text>
<text top="494" left="619" width="3" height="19" font="3"> </text>
<text top="512" left="619" width="164" height="19" font="3">Over a follow-up period of </text>
<text top="531" left="619" width="158" height="19" font="3">21+15 mo, there were no </text>
<text top="549" left="619" width="151" height="19" font="3">recurrences of VAs after </text>
<text top="567" left="619" width="57" height="19" font="3">ablation. </text>
<text top="274" left="823" width="244" height="19" font="3">● VAs may arise from the anterolateral, </text>
<text top="292" left="823" width="241" height="19" font="3">posterior, and posteroseptal regions of </text>
<text top="311" left="823" width="251" height="19" font="3">the mitral annulus and can be effectively </text>
<text top="329" left="823" width="216" height="19" font="3">and safely ablated with RF current. </text>
<text top="586" left="125" width="148" height="19" font="3">● Tada et al. 2008 (427) </text>
<text top="605" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18313601">● </a></text>
<text top="605" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18313601">18313601</a></text>
<text top="605" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18313601"> </a></text>
<text top="586" left="288" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="605" left="288" width="133" height="19" font="3">Center Observational </text>
<text top="623" left="288" width="3" height="19" font="3"> </text>
<text top="641" left="288" width="110" height="19" font="4"><b>Size:</b>   12 patients </text>
<text top="586" left="447" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="605" left="447" width="134" height="19" font="3">Cases of VAs mapped </text>
<text top="623" left="447" width="141" height="19" font="3">and ablated within the </text>
<text top="641" left="447" width="122" height="19" font="3">Pulmonary Artery.   </text>
<text top="660" left="447" width="3" height="19" font="3"> </text>
<text top="678" left="447" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="586" left="619" width="59" height="19" font="4"><b>Results:   </b></text>
<text top="605" left="619" width="183" height="19" font="3">Among 276 patients with VAs </text>
<text top="623" left="619" width="169" height="19" font="3">referred for RF ablation, 12 </text>
<text top="641" left="619" width="180" height="19" font="3">patients were identified with </text>
<text top="660" left="619" width="171" height="19" font="3">a successful site of catheter </text>
<text top="678" left="619" width="189" height="19" font="3">ablation within the pulmonary </text>
<text top="696" left="619" width="51" height="19" font="3">artery.   </text>
<text top="714" left="619" width="3" height="19" font="3"> </text>
<text top="733" left="619" width="185" height="19" font="3">All 12 patients had attempted </text>
<text top="751" left="619" width="187" height="19" font="3">ablation within the RVOT with </text>
<text top="586" left="823" width="252" height="19" font="3">● A site of origin in the Pulmonary artery </text>
<text top="605" left="823" width="248" height="19" font="3">should be suspected when mapping and </text>
<text top="623" left="823" width="229" height="19" font="3">ablation of apparent RVOT VAs is not </text>
<text top="641" left="823" width="230" height="19" font="3">successful within the RVOT.  Ablation </text>
<text top="660" left="823" width="243" height="19" font="3">within the pulmonary artery is safe and </text>
<text top="678" left="823" width="65" height="19" font="3">effectifve. </text>
</page>
<page number="234" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">234 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="619" width="125" height="19" font="3">a change in the QRS </text>
<text top="127" left="619" width="174" height="19" font="3">morphology after ablation.   </text>
<text top="145" left="619" width="177" height="19" font="3">A characteristic prepotential </text>
<text top="164" left="619" width="151" height="19" font="3">was recorded within the </text>
<text top="182" left="619" width="142" height="19" font="3">pulmonary artery in all </text>
<text top="200" left="619" width="142" height="19" font="3">patients.  Ablation was </text>
<text top="219" left="619" width="130" height="19" font="3">successful within the </text>
<text top="237" left="619" width="164" height="19" font="3">pulmonary artery in 12/12 </text>
<text top="255" left="619" width="180" height="19" font="3">patients (100%).  There were </text>
<text top="273" left="619" width="111" height="19" font="3">no complications. </text>
<text top="292" left="619" width="173" height="19" font="3">No recurrences of VAs were </text>
<text top="310" left="619" width="163" height="19" font="3">observed over a follow-up </text>
<text top="328" left="619" width="127" height="19" font="3">period of 27+13 mo. </text>
<text top="347" left="125" width="148" height="19" font="3">● Tada et al. 2007 (428) </text>
<text top="366" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18313601">● </a></text>
<text top="366" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18313601">18313601</a></text>
<text top="366" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18313601"> </a></text>
<text top="384" left="125" width="3" height="19" font="3"> </text>
<text top="347" left="288" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="366" left="288" width="133" height="19" font="3">Center Observational </text>
<text top="384" left="288" width="3" height="19" font="3"> </text>
<text top="402" left="288" width="114" height="19" font="4"><b>Size:</b>    38 patients </text>
<text top="347" left="447" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="366" left="447" width="130" height="19" font="3">Consecutive patients </text>
<text top="384" left="447" width="121" height="19" font="3">with idiopathic VAs </text>
<text top="402" left="447" width="149" height="19" font="3">mapped and ablated on </text>
<text top="421" left="447" width="135" height="19" font="3">the tricuspid annulus  </text>
<text top="439" left="447" width="3" height="19" font="3"> </text>
<text top="457" left="447" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="347" left="619" width="52" height="19" font="4"><b>Results: </b></text>
<text top="366" left="619" width="149" height="19" font="3">Among 454 consecutive </text>
<text top="384" left="619" width="177" height="19" font="3">patients with idiopathic VAs, </text>
<text top="402" left="619" width="176" height="19" font="3">38 patients (8%) were found </text>
<text top="421" left="619" width="188" height="19" font="3">to originate from the tricuspid </text>
<text top="439" left="619" width="62" height="19" font="3">annulus.   </text>
<text top="457" left="619" width="180" height="19" font="3">28 (74%) originated from the </text>
<text top="476" left="619" width="166" height="19" font="3">septal tricuspid annulus 10 </text>
<text top="494" left="619" width="148" height="19" font="3">(26%) from the freewall </text>
<text top="512" left="619" width="136" height="19" font="3">portion of the annuls. </text>
<text top="531" left="619" width="179" height="19" font="3">Catheter ablation eliminated </text>
<text top="549" left="619" width="178" height="19" font="3">90% of freewall VAs but only </text>
<text top="567" left="619" width="142" height="19" font="3">57% of septal tricuspid </text>
<text top="586" left="619" width="84" height="19" font="3">annular VAs.  </text>
<text top="604" left="619" width="184" height="19" font="3">There were no complications. </text>
<text top="622" left="619" width="3" height="19" font="3"> </text>
<text top="347" left="823" width="250" height="19" font="3">● Tricuspid annular VAs are not rare and </text>
<text top="366" left="823" width="255" height="19" font="3">ablation has a higher efficacy for freewall </text>
<text top="384" left="823" width="107" height="19" font="3">than septal sites. </text>
<text top="641" left="125" width="135" height="19" font="3">● Kamioka et al. 2015 </text>
<text top="660" left="125" width="35" height="19" font="3">(429) </text>
<text top="678" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25633492">● </a></text>
<text top="678" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25633492">25633492</a></text>
<text top="678" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25633492"> </a></text>
<text top="641" left="288" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="660" left="288" width="84" height="19" font="3">Single Center </text>
<text top="678" left="288" width="89" height="19" font="3">Observational </text>
<text top="696" left="288" width="114" height="19" font="4"><b>Size:</b>    34 patients </text>
<text top="641" left="447" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="660" left="447" width="130" height="19" font="3">Consecutive patients </text>
<text top="678" left="447" width="91" height="19" font="3">with LVOT Vas </text>
<text top="696" left="447" width="3" height="19" font="3"> </text>
<text top="714" left="447" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="641" left="619" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="660" left="619" width="152" height="19" font="3">Twelve patients had VAs </text>
<text top="678" left="619" width="173" height="19" font="3">mapped in the Aortic cusps, </text>
<text top="696" left="619" width="151" height="19" font="3">and 22 patients had VAs </text>
<text top="714" left="619" width="158" height="19" font="3">mapped below the Aortic </text>
<text top="733" left="619" width="39" height="19" font="3">valve. </text>
<text top="641" left="823" width="258" height="19" font="3">● LVOT VAs may arise above or below the </text>
<text top="660" left="823" width="244" height="19" font="3">aortic valve. Prepotentials are recorded </text>
<text top="678" left="823" width="237" height="19" font="3">at the site of successful ablation in the </text>
<text top="696" left="823" width="258" height="19" font="3">majority of patients with origin within the </text>
<text top="714" left="823" width="231" height="19" font="3">aortic sinuses but are rarely recorded </text>
<text top="733" left="823" width="149" height="19" font="3">below the aortic valve.   </text>
</page>
<page number="235" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">235 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="619" width="163" height="19" font="3">Pre-potentials recorded in </text>
<text top="127" left="619" width="173" height="19" font="3">91% of Aortic Sinus VAs and </text>
<text top="145" left="619" width="171" height="19" font="3">13% below the aortic valve. </text>
<text top="164" left="619" width="3" height="19" font="3"> </text>
<text top="182" left="619" width="166" height="19" font="3">VAs successfully ablated in </text>
<text top="200" left="619" width="139" height="19" font="3">34/34 patients (100%) </text>
<text top="219" left="125" width="117" height="19" font="3">● Nagashima et al. </text>
<text top="238" left="125" width="69" height="19" font="3">2014 (430) </text>
<text top="256" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25110163">● </a></text>
<text top="256" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25110163">25110163</a></text>
<text top="256" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25110163"> </a></text>
<text top="219" left="288" width="143" height="19" font="4"><b>Study type:</b>  Single Site </text>
<text top="238" left="288" width="90" height="19" font="3">observational  </text>
<text top="256" left="288" width="3" height="19" font="3"> </text>
<text top="274" left="288" width="114" height="19" font="4"><b>Size:</b>    30 patients </text>
<text top="219" left="447" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="238" left="447" width="159" height="19" font="3">30 patients with VAs with </text>
<text top="256" left="447" width="139" height="19" font="3">early activation within </text>
<text top="274" left="447" width="141" height="19" font="3">the Great Cardiac Vein </text>
<text top="293" left="447" width="42" height="19" font="3">(GCV). </text>
<text top="311" left="447" width="3" height="19" font="3"> </text>
<text top="329" left="447" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="219" left="619" width="59" height="19" font="4"><b>Results:   </b></text>
<text top="238" left="619" width="167" height="19" font="3">Angiography in 27 patients </text>
<text top="256" left="619" width="154" height="19" font="3">showed earliest GCV site </text>
<text top="274" left="619" width="164" height="19" font="3">within 5 mm of a coronary </text>
<text top="293" left="619" width="116" height="19" font="3">artery in 20 (74%). </text>
<text top="311" left="619" width="189" height="19" font="3">Ablation was performed in the </text>
<text top="329" left="619" width="142" height="19" font="3">GCV in 15 patients and </text>
<text top="347" left="619" width="167" height="19" font="3">abolished VA in 8. Ablation </text>
<text top="366" left="619" width="167" height="19" font="3">was attempted at adjacent </text>
<text top="384" left="619" width="175" height="19" font="3">non-GCV sites in 19 patients </text>
<text top="402" left="619" width="188" height="19" font="3">and abolished VA in 5 patients </text>
<text top="421" left="619" width="165" height="19" font="3">(4 from the left ventricular </text>
<text top="439" left="619" width="178" height="19" font="3">endocardium and 1 from the </text>
<text top="457" left="619" width="121" height="19" font="3">left coronary cusp). </text>
<text top="476" left="619" width="3" height="19" font="3"> </text>
<text top="494" left="619" width="178" height="19" font="3">After a median of 2.8 mo, 13 </text>
<text top="512" left="619" width="187" height="19" font="3">patients remained free of VA.  </text>
<text top="531" left="619" width="186" height="19" font="3">Major complications occurred </text>
<text top="549" left="619" width="141" height="19" font="3">in 4 patients, including </text>
<text top="567" left="619" width="155" height="19" font="3">coronary injury requiring </text>
<text top="586" left="619" width="57" height="19" font="3">stenting. </text>
<text top="219" left="823" width="216" height="19" font="3">● Ablation within the GCV requires </text>
<text top="238" left="823" width="223" height="19" font="3">careful attention to the proximity of </text>
<text top="256" left="823" width="242" height="19" font="3">coronary arteries with the potential for </text>
<text top="274" left="823" width="147" height="19" font="3">coronary arterial injury. </text>
<text top="605" left="125" width="132" height="19" font="3">● Yamada et al. 2015 </text>
<text top="623" left="125" width="35" height="19" font="3">(431) </text>
<text top="641" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25637597">● </a></text>
<text top="641" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25637597">25637597</a></text>
<text top="641" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25637597"> </a></text>
<text top="660" left="125" width="3" height="19" font="3"> </text>
<text top="605" left="288" width="117" height="19" font="4"><b>Study type:</b>  Single </text>
<text top="623" left="288" width="131" height="19" font="3">Center observational </text>
<text top="641" left="288" width="40" height="19" font="3">study  </text>
<text top="660" left="288" width="3" height="19" font="3"> </text>
<text top="678" left="288" width="114" height="19" font="4"><b>Size:</b>    64 patients </text>
<text top="605" left="447" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="623" left="447" width="147" height="19" font="3">64 consecutive patients </text>
<text top="641" left="447" width="113" height="19" font="3">with symptomatic </text>
<text top="660" left="447" width="151" height="19" font="3">idiopathic sustained VTs </text>
<text top="678" left="447" width="118" height="19" font="3">(VTs) (N=14), NSVT </text>
<text top="696" left="447" width="134" height="19" font="3">(N=15), or premature </text>
<text top="714" left="447" width="149" height="19" font="3">ventricular contractions </text>
<text top="733" left="447" width="131" height="19" font="3">(PVCs) (N=35), which </text>
<text top="751" left="447" width="109" height="19" font="3">presumed origins </text>
<text top="769" left="447" width="155" height="19" font="3">identified in the AMC, LV </text>
<text top="605" left="619" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="623" left="619" width="141" height="19" font="3">Among 64 patients, 14 </text>
<text top="641" left="619" width="180" height="19" font="3">patients were identified with </text>
<text top="660" left="619" width="174" height="19" font="3">intramural foci between the </text>
<text top="678" left="619" width="183" height="19" font="3">endocardium and epicardium </text>
<text top="696" left="619" width="179" height="19" font="3">which required sequential or </text>
<text top="714" left="619" width="140" height="19" font="3">simultaneous irrigated </text>
<text top="733" left="619" width="151" height="19" font="3">unipolar radiofrequency </text>
<text top="751" left="619" width="185" height="19" font="3">ablation from the endocardial </text>
<text top="605" left="823" width="244" height="19" font="3">● LVOT VAs originating from intramural </text>
<text top="623" left="823" width="214" height="19" font="3">foci could usually be eliminated by </text>
<text top="641" left="823" width="218" height="19" font="3">sequential unipolar radiofrequency </text>
<text top="660" left="823" width="206" height="19" font="3">ablation and sometimes required </text>
<text top="678" left="823" width="227" height="19" font="3">simultaneous ablation from both the </text>
<text top="696" left="823" width="206" height="19" font="3">endocardial and epicardial sides.  </text>
</page>
<page number="236" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">236 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="447" width="138" height="19" font="3">summit, or intramural </text>
<text top="127" left="447" width="112" height="19" font="3">sites between the </text>
<text top="145" left="447" width="111" height="19" font="3">endocardium and </text>
<text top="164" left="447" width="76" height="19" font="3">epicardium. </text>
<text top="182" left="447" width="3" height="19" font="3"> </text>
<text top="200" left="447" width="148" height="19" font="4"><b>Exclusion criteria:</b>   N/A </text>
<text top="219" left="447" width="10" height="19" font="3">   </text>
<text top="109" left="619" width="177" height="19" font="3">and epicardial sides for their </text>
<text top="127" left="619" width="83" height="19" font="3">elimination.   </text>
<text top="145" left="619" width="167" height="19" font="3">Simultaneous ablation was </text>
<text top="164" left="619" width="160" height="19" font="3">most likely to be required </text>
<text top="182" left="619" width="173" height="19" font="3">when the distance between </text>
<text top="200" left="619" width="188" height="19" font="3">the endocardial and epicardial </text>
<text top="219" left="619" width="184" height="19" font="3">ablation sites was &gt;8 mm and </text>
<text top="237" left="619" width="173" height="19" font="3">the earliest local ventricular </text>
<text top="255" left="619" width="184" height="19" font="3">activation time relative to the </text>
<text top="273" left="619" width="186" height="19" font="3">QRS onset during the VAs was </text>
<text top="292" left="619" width="183" height="19" font="3">&lt;30 ms at both ablation sites. </text>
<text top="311" left="125" width="139" height="19" font="3">● Hai et al. 2015 (432) </text>
<text top="329" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25637597">● </a></text>
<text top="329" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25637597">25637597</a></text>
<text top="329" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25637597"> </a></text>
<text top="311" left="288" width="117" height="19" font="4"><b>Study type:</b>  Single </text>
<text top="329" left="288" width="131" height="19" font="3">Center observational </text>
<text top="347" left="288" width="40" height="19" font="3">study  </text>
<text top="366" left="288" width="3" height="19" font="3"> </text>
<text top="384" left="288" width="114" height="19" font="4"><b>Size:</b>    21 patients </text>
<text top="311" left="447" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="329" left="447" width="102" height="19" font="3">All patients who </text>
<text top="347" left="447" width="135" height="19" font="3">underwent successful </text>
<text top="366" left="447" width="150" height="19" font="3">catheter ablation of VAs </text>
<text top="384" left="447" width="114" height="19" font="3">at the Aortomitral </text>
<text top="402" left="447" width="108" height="19" font="3">Continuity (AMS) </text>
<text top="421" left="447" width="3" height="19" font="3"> </text>
<text top="439" left="447" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="457" left="447" width="10" height="19" font="3">   </text>
<text top="311" left="619" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="329" left="619" width="122" height="19" font="3">Among 21 patients, </text>
<text top="347" left="619" width="153" height="19" font="3">prepotentials (PPs) were </text>
<text top="366" left="619" width="163" height="19" font="3">found at the ablation sites </text>
<text top="384" left="619" width="190" height="19" font="3">preceding the ventricular EGM </text>
<text top="402" left="619" width="153" height="19" font="3">during arrhythmias in 13 </text>
<text top="421" left="619" width="172" height="19" font="3">(61.9%) patients and during </text>
<text top="439" left="619" width="158" height="19" font="3">sinus rhythm in 7 (53.8%) </text>
<text top="457" left="619" width="57" height="19" font="3">patients. </text>
<text top="476" left="619" width="183" height="19" font="3">VAs with PPs were associated </text>
<text top="494" left="619" width="159" height="19" font="3">with a significantly higher </text>
<text top="512" left="619" width="132" height="19" font="3">burden of premature </text>
<text top="531" left="619" width="179" height="19" font="3">ventricular complexes (PVCs; </text>
<text top="549" left="619" width="173" height="19" font="3">26.1±10.9% vs. 14.9±10.1%, </text>
<text top="567" left="619" width="171" height="19" font="3">p=0.03), shorter ventricular </text>
<text top="586" left="619" width="133" height="19" font="3">EGM to QRS intervals </text>
<text top="604" left="619" width="172" height="19" font="3">(9.0±28.5 msec vs. 33.1±8.8 </text>
<text top="622" left="619" width="163" height="19" font="3">msec, p=0.03), lower pace </text>
<text top="640" left="619" width="146" height="19" font="3">map scores (8.7±1.6 vs. </text>
<text top="659" left="619" width="158" height="19" font="3">11.4±0.8, p=0.001), and a </text>
<text top="677" left="619" width="158" height="19" font="3">trend toward shorter V-H </text>
<text top="695" left="619" width="183" height="19" font="3">intervals during VA (32.1± 8.6 </text>
<text top="714" left="619" width="158" height="19" font="3">msec vs. 76.3±11.1 msec, </text>
<text top="732" left="619" width="186" height="19" font="3">p=0.06) as compared to those </text>
<text top="750" left="619" width="74" height="19" font="3">without PP. </text>
<text top="311" left="823" width="248" height="19" font="3">● Specific identification and targeting of </text>
<text top="329" left="823" width="243" height="19" font="3">PPs when ablating VAs at the AMC may </text>
<text top="347" left="823" width="177" height="19" font="3">improve procedural success. </text>
<text top="366" left="823" width="3" height="19" font="3"> </text>
<text top="384" left="823" width="3" height="19" font="3"> </text>
</page>
<page number="237" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">237 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="132" height="19" font="3">● Yamada et al. 2010 </text>
<text top="127" left="125" width="35" height="19" font="3">(433) </text>
<text top="145" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19804552">● </a></text>
<text top="145" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19804552">19804552</a></text>
<text top="145" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19804552"> </a></text>
<text top="164" left="125" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="288" width="117" height="19" font="4"><b>Study type:  </b>Single </text>
<text top="127" left="288" width="131" height="19" font="3">Center observational </text>
<text top="145" left="288" width="40" height="19" font="3">study  </text>
<text top="164" left="288" width="3" height="19" font="4"><b> </b></text>
<text top="182" left="288" width="114" height="19" font="4"><b>Size</b>:    21 patients<b> </b></text>
<text top="109" left="447" width="118" height="19" font="4"><b>Inclusion criteria:   </b></text>
<text top="127" left="447" width="102" height="19" font="3">All patients who </text>
<text top="145" left="447" width="135" height="19" font="3">underwent successful </text>
<text top="164" left="447" width="150" height="19" font="3">catheter ablation of VAs </text>
<text top="182" left="447" width="114" height="19" font="3">at the Aortomitral </text>
<text top="200" left="447" width="108" height="19" font="3">Continuity (AMS) </text>
<text top="219" left="447" width="3" height="19" font="3"> </text>
<text top="237" left="447" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="255" left="447" width="10" height="19" font="4"><b>   </b></text>
<text top="109" left="619" width="59" height="19" font="4"><b>Results:   </b></text>
<text top="127" left="619" width="147" height="19" font="3">48 consecutive patients </text>
<text top="145" left="619" width="138" height="19" font="3">undergoing successful </text>
<text top="164" left="619" width="188" height="19" font="3">catheter ablation of idiopathic </text>
<text top="182" left="619" width="176" height="19" font="3">VAs originating from the left </text>
<text top="200" left="619" width="170" height="19" font="3">coronary cusp (LCC, N= 29), </text>
<text top="219" left="619" width="179" height="19" font="3">aortomitral continuity (AMC, </text>
<text top="237" left="619" width="178" height="19" font="3">N=10) and great cardiac vein </text>
<text top="255" left="619" width="168" height="19" font="3">or anterior interventricular </text>
<text top="273" left="619" width="146" height="19" font="3">cardiac vein (Epi, N= 9). </text>
<text top="292" left="619" width="165" height="19" font="3">An S wave in lead V5 or V6 </text>
<text top="310" left="619" width="169" height="19" font="3">occurred significantly more </text>
<text top="329" left="619" width="188" height="19" font="3">often during both the VAs and </text>
<text top="347" left="619" width="164" height="19" font="3">pacing from the AMC than </text>
<text top="365" left="619" width="180" height="19" font="3">during that from the LCC and </text>
<text top="383" left="619" width="188" height="19" font="3">Epi (p&lt;0.05 vs.  p=0.0001). For </text>
<text top="402" left="619" width="165" height="19" font="3">discriminating whether VA </text>
<text top="420" left="619" width="137" height="19" font="3">origins can be ablated </text>
<text top="438" left="619" width="179" height="19" font="3">endocardially or epicardially, </text>
<text top="457" left="619" width="190" height="19" font="3">the maximum deflection index </text>
<text top="475" left="619" width="170" height="19" font="3">(MDI = the shortest time to </text>
<text top="493" left="619" width="168" height="19" font="3">the maximum deflection in </text>
<text top="512" left="619" width="151" height="19" font="3">any precordial lead/QRS </text>
<text top="530" left="619" width="184" height="19" font="3">duration) was reliable for VAs </text>
<text top="548" left="619" width="183" height="19" font="3">arising from the AMC (100%), </text>
<text top="566" left="619" width="173" height="19" font="3">but was less reliable for LCC </text>
<text top="585" left="619" width="181" height="19" font="3">(73%) and Epi (67%) VAs. In 3 </text>
<text top="603" left="619" width="179" height="19" font="3">(33%) of the Epi VAs, the site </text>
<text top="621" left="619" width="183" height="19" font="3">of an excellent pace map was </text>
<text top="640" left="619" width="186" height="19" font="3">located transmurally opposite </text>
<text top="658" left="619" width="183" height="19" font="3">to the successful ablation site </text>
<text top="676" left="619" width="141" height="19" font="3">(LCC = 1 and AMC = 2).<b> </b></text>
<text top="109" left="823" width="195" height="19" font="3">● The MDI has limited value for </text>
<text top="127" left="823" width="198" height="19" font="3">discriminating endocardial from </text>
<text top="145" left="823" width="246" height="19" font="3">epicardial VA origins in sites adjacent to </text>
<text top="164" left="823" width="235" height="19" font="3">the LSOV probably due to preferential </text>
<text top="182" left="823" width="225" height="19" font="3">conduction, intramural VA origins or </text>
<text top="200" left="823" width="147" height="19" font="3">myocardium in contact  </text>
<text top="219" left="823" width="84" height="19" font="3">with the LCC. </text>
<text top="695" left="115" width="4" height="21" font="0"> </text>
<text top="715" left="115" width="4" height="21" font="0"> </text>
<text top="715" left="331" width="4" height="21" font="2"><b> </b></text>
</page>
<page number="238" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">238 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="959" height="21" font="2"><b>Data Supplement 47.  Nonrandomized Trials, Observational Studies, and/or Registries of Catheter Ablation in Papillary Muscle VA - (Section </b></text>
<text top="128" left="115" width="30" height="21" font="2"><b>8.2) </b></text>
<text top="149" left="148" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="167" left="173" width="51" height="19" font="4"><b>Author; </b></text>
<text top="185" left="151" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="149" left="295" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="167" left="325" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="149" left="462" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="149" left="635" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="167" left="647" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="185" left="679" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="149" left="878" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="167" left="907" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="205" left="125" width="127" height="19" font="3">● Doppalapudi et al. </text>
<text top="223" left="125" width="69" height="19" font="3">2008 (434) </text>
<text top="241" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19808390">● </a></text>
<text top="241" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19808390">19808390</a></text>
<text top="241" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19808390"> </a></text>
<text top="259" left="125" width="3" height="19" font="4"><b> </b></text>
<text top="278" left="125" width="3" height="19" font="4"><b> </b></text>
<text top="296" left="125" width="3" height="19" font="4"><b> </b></text>
<text top="205" left="286" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="223" left="286" width="115" height="19" font="3">Site Observational </text>
<text top="241" left="286" width="3" height="19" font="3"> </text>
<text top="259" left="286" width="106" height="19" font="4"><b>Size:</b>    9 patients </text>
<text top="205" left="442" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="223" left="442" width="113" height="19" font="3">VT mapped to the </text>
<text top="241" left="442" width="115" height="19" font="3">Posterior Papillary </text>
<text top="260" left="442" width="105" height="19" font="3">Muscle of the LV </text>
<text top="278" left="442" width="3" height="19" font="3"> </text>
<text top="296" left="442" width="151" height="19" font="4"><b>Exclusion criteria:</b>  none </text>
<text top="205" left="615" width="160" height="19" font="3">Among 290 patients  with </text>
<text top="223" left="615" width="179" height="19" font="3">idiopathic VAs, 7 were found </text>
<text top="241" left="615" width="126" height="19" font="3">to have origin in the </text>
<text top="260" left="615" width="120" height="19" font="3">Posteromedial PM. </text>
<text top="278" left="615" width="161" height="19" font="3">All patients had RBBB and </text>
<text top="296" left="615" width="121" height="19" font="3">Superior QRS axis.   </text>
<text top="314" left="615" width="127" height="19" font="3">No patient had SHD. </text>
<text top="333" left="615" width="156" height="19" font="3">VT had focal mechanism, </text>
<text top="351" left="615" width="172" height="19" font="3">sensitive to catecholamines </text>
<text top="370" left="615" width="3" height="19" font="3"> </text>
<text top="388" left="615" width="177" height="19" font="4"><b>Results:</b>  Successful catheter </text>
<text top="406" left="615" width="190" height="19" font="3">ablation in all patients without </text>
<text top="424" left="615" width="92" height="19" font="3">complications. </text>
<text top="443" left="615" width="3" height="19" font="3"> </text>
<text top="205" left="818" width="239" height="19" font="3">● Posteromedial papillary muscle VT is </text>
<text top="223" left="818" width="223" height="19" font="3">catecholamine sensitive with a focal </text>
<text top="241" left="818" width="203" height="19" font="3">mechanism that is amendable to </text>
<text top="260" left="818" width="250" height="19" font="3">catheter ablation. Catheter stability may </text>
<text top="278" left="818" width="244" height="19" font="3">be difficult and multiple RF applications </text>
<text top="296" left="818" width="129" height="19" font="3">are usually required. </text>
<text top="314" left="818" width="3" height="19" font="3"> </text>
<text top="462" left="125" width="132" height="19" font="3">● Yamada et al. 2010 </text>
<text top="480" left="125" width="35" height="19" font="3">(435) </text>
<text top="498" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20558848">● </a></text>
<text top="498" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20558848">20558848</a></text>
<text top="498" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20558848"> </a></text>
<text top="517" left="125" width="3" height="19" font="4"><b> </b></text>
<text top="462" left="286" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="480" left="286" width="115" height="19" font="3">Site Observational </text>
<text top="498" left="286" width="3" height="19" font="3"> </text>
<text top="517" left="286" width="114" height="19" font="4"><b>Size:</b>    19 patients </text>
<text top="462" left="442" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="480" left="442" width="113" height="19" font="3">VT mapped to the </text>
<text top="498" left="442" width="108" height="19" font="3">Posteromedial or </text>
<text top="517" left="442" width="140" height="19" font="3">Anterolateral Papillary </text>
<text top="535" left="442" width="111" height="19" font="3">Muscles of the LV </text>
<text top="553" left="442" width="3" height="19" font="3"> </text>
<text top="572" left="442" width="3" height="19" font="3"> </text>
<text top="590" left="442" width="151" height="19" font="4"><b>Exclusion criteria:</b>  none </text>
<text top="462" left="615" width="149" height="19" font="3">Among 159 consecutive </text>
<text top="480" left="615" width="174" height="19" font="3">patients with idiopathic VAs </text>
<text top="498" left="615" width="180" height="19" font="3">mapped to the LV, the site of </text>
<text top="517" left="615" width="104" height="19" font="3">origin was in the </text>
<text top="535" left="615" width="176" height="19" font="3">Posteromedial PM in 12 and </text>
<text top="553" left="615" width="169" height="19" font="3">the Anterolateral PM in 7.   </text>
<text top="572" left="615" width="3" height="19" font="3"> </text>
<text top="590" left="615" width="175" height="19" font="4"><b>Results:</b>  Successful ablation </text>
<text top="608" left="615" width="139" height="19" font="3">was achieved in 19/19 </text>
<text top="627" left="615" width="143" height="19" font="3">patients.  Multiple QRS </text>
<text top="645" left="615" width="182" height="19" font="3">morphologies were observed </text>
<text top="663" left="615" width="165" height="19" font="3">in 47% of patients and in 7 </text>
<text top="681" left="615" width="158" height="19" font="3">patients ablation on both </text>
<text top="700" left="615" width="132" height="19" font="3">sides of the PM were </text>
<text top="718" left="615" width="172" height="19" font="3">required.  No complications </text>
<text top="736" left="615" width="98" height="19" font="3">were observed. </text>
<text top="755" left="615" width="166" height="19" font="3">Recurrence of PM VAs was </text>
<text top="773" left="615" width="164" height="19" font="3">observed in 2/19 patients. </text>
<text top="462" left="818" width="240" height="19" font="3">● VT of focal origin may occur in either </text>
<text top="480" left="818" width="238" height="19" font="3">the posteromedial of the anterolateral </text>
<text top="498" left="818" width="241" height="19" font="3">PMs of the LV.  Catheter ablation often </text>
<text top="517" left="818" width="244" height="19" font="3">requires multiple RF applications over a </text>
<text top="535" left="818" width="222" height="19" font="3">wide area suggesting an origin deep </text>
<text top="553" left="818" width="93" height="19" font="3">within the PM. </text>
<text top="572" left="818" width="214" height="19" font="3">● The recurrence risk after initially </text>
<text top="590" left="818" width="226" height="19" font="3">successful ablation is higher than for </text>
<text top="608" left="818" width="216" height="19" font="3">many other forms of idiopathic VT. </text>
</page>
<page number="239" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">239 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="615" width="3" height="19" font="3"> </text>
<text top="128" left="125" width="145" height="19" font="3">● Yokokawa et al. 2010 </text>
<text top="146" left="125" width="35" height="19" font="3">(436) </text>
<text top="164" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20637311">● </a></text>
<text top="164" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20637311">20637311</a></text>
<text top="164" left="198" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20637311"><b> </b></a></text>
<text top="183" left="125" width="3" height="19" font="3"> </text>
<text top="128" left="286" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="146" left="286" width="115" height="19" font="3">Site Observational </text>
<text top="164" left="286" width="3" height="19" font="3"> </text>
<text top="183" left="286" width="114" height="19" font="4"><b>Size:</b>    40 patients </text>
<text top="128" left="442" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="146" left="442" width="113" height="19" font="3">VT mapped to the </text>
<text top="164" left="442" width="108" height="19" font="3">Posteromedial or </text>
<text top="183" left="442" width="139" height="19" font="3">anterolateral Papillary </text>
<text top="201" left="442" width="111" height="19" font="3">Muscles of the LV </text>
<text top="219" left="442" width="3" height="19" font="3"> </text>
<text top="237" left="442" width="153" height="19" font="4"><b>Exclusion criteria:</b>  None </text>
<text top="128" left="615" width="48" height="19" font="4"><b>Results </b></text>
<text top="146" left="615" width="147" height="19" font="3">40 consecutive patients </text>
<text top="164" left="615" width="54" height="19" font="3">referred </text>
<text top="183" left="615" width="173" height="19" font="3">for ablation of symptomatic </text>
<text top="201" left="615" width="138" height="19" font="3">premature ventricular </text>
<text top="219" left="615" width="68" height="19" font="3">complexes </text>
<text top="238" left="615" width="151" height="19" font="3">(PVCs) (N=19) or VT (VT) </text>
<text top="256" left="615" width="157" height="19" font="3">(N=21) originating from a </text>
<text top="274" left="615" width="159" height="19" font="3">Papillary muscle in the LV </text>
<text top="293" left="615" width="123" height="19" font="3">(N=32) or RV (N=8). </text>
<text top="311" left="615" width="3" height="19" font="3"> </text>
<text top="329" left="615" width="186" height="19" font="3">Antiarrhythmic drugs failed to </text>
<text top="347" left="615" width="187" height="19" font="3">control the VAs in 24 patients. </text>
<text top="366" left="615" width="171" height="19" font="3">20 of 40 patients (50%) had </text>
<text top="384" left="615" width="176" height="19" font="3">SHD: prior MI in 10 patients, </text>
<text top="402" left="615" width="178" height="19" font="3">dilated cardiomyopathy in 9, </text>
<text top="421" left="615" width="103" height="19" font="3">and VHD in 1 pt. </text>
<text top="439" left="615" width="3" height="19" font="3"> </text>
<text top="457" left="615" width="185" height="19" font="3">Catheter ablation was acutely </text>
<text top="476" left="615" width="186" height="19" font="3">successful in 33 of 40 patients </text>
<text top="494" left="615" width="42" height="19" font="3">(83%). </text>
<text top="512" left="615" width="3" height="19" font="3"> </text>
<text top="531" left="615" width="109" height="19" font="3">Pleomorphic QRS </text>
<text top="549" left="615" width="162" height="19" font="3">morphologies observed in </text>
<text top="567" left="615" width="97" height="19" font="3">31/40 patients. </text>
<text top="586" left="615" width="148" height="19" font="3">By MRI, the mass of the </text>
<text top="604" left="615" width="152" height="19" font="3">arrhythmogenic PM was </text>
<text top="622" left="615" width="184" height="19" font="3">greater in patients with failed </text>
<text top="640" left="615" width="166" height="19" font="3">than successful ablations.   </text>
<text top="659" left="615" width="179" height="19" font="3">In follow-up, the PVC burden </text>
<text top="677" left="615" width="176" height="19" font="3">was reduced from 15%+11% </text>
<text top="695" left="615" width="151" height="19" font="3">to 3%+3%; p&lt;0.01) after </text>
<text top="714" left="615" width="122" height="19" font="3">successful ablation. </text>
<text top="128" left="818" width="221" height="19" font="3">● VAs may originate in the papillary </text>
<text top="146" left="818" width="253" height="19" font="3">muscles of both the LV and the RV.  PVCs </text>
<text top="164" left="818" width="224" height="19" font="3">from the papillary muscles are often </text>
<text top="183" left="818" width="91" height="19" font="3">pleomorphic.   </text>
<text top="201" left="818" width="245" height="19" font="3">● Catheter ablation is successful in over </text>
<text top="219" left="818" width="237" height="19" font="3">80% of cases, with greater mass of the </text>
<text top="238" left="818" width="255" height="19" font="3">papillary muscle predicting lower efficacy </text>
<text top="256" left="818" width="76" height="19" font="3">of ablation.  </text>
<text top="733" left="125" width="140" height="19" font="3">● Crawford et al. 2010 </text>
<text top="751" left="125" width="35" height="19" font="3">(437) </text>
<text top="769" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20206325">● </a></text>
<text top="769" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20206325">20206325</a></text>
<text top="769" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20206325"> </a></text>
<text top="733" left="286" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="751" left="286" width="113" height="19" font="3">Site observational </text>
<text top="769" left="286" width="3" height="19" font="3"> </text>
<text top="733" left="442" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="733" left="615" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="751" left="615" width="181" height="19" font="11">A total of 15 distinct PAP VAs </text>
<text top="769" left="615" width="180" height="19" font="11">was mapped to the posterior </text>
<text top="733" left="818" width="12" height="19" font="3">● </text>
<text top="733" left="831" width="225" height="19" font="11">PVCs and VT may originate in the RV </text>
<text top="751" left="818" width="203" height="19" font="11">PAPs. Radiofrequency ablation is </text>
<text top="769" left="818" width="180" height="19" font="11">effective in eliminating these </text>
</page>
<page number="240" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">240 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="3" height="19" font="3"> </text>
<text top="109" left="286" width="106" height="19" font="4"><b>Size:</b>    8 patients </text>
<text top="109" left="442" width="120" height="19" font="3">VAs mapped to the </text>
<text top="127" left="442" width="147" height="19" font="3">papillary muscles in the </text>
<text top="145" left="442" width="92" height="19" font="3">right ventricle. </text>
<text top="164" left="442" width="3" height="19" font="3"> </text>
<text top="182" left="442" width="151" height="19" font="4"><b>Exclusion criteria:</b>  none </text>
<text top="109" left="615" width="151" height="19" font="11">(N=3), anterior (N=4), or </text>
<text top="127" left="615" width="81" height="19" font="11">septal (N=8). </text>
<text top="145" left="615" width="3" height="19" font="11"> </text>
<text top="164" left="615" width="177" height="19" font="11">Successful ablation achieved </text>
<text top="182" left="615" width="100" height="19" font="11">in all 8 patients. </text>
<text top="200" left="615" width="182" height="19" font="11">The PVC burden was reduced </text>
<text top="219" left="615" width="186" height="19" font="11">from 17%+20% preablation to </text>
<text top="237" left="615" width="151" height="19" font="11">0.6%+0.8% postablation.</text>
<text top="237" left="766" width="3" height="19" font="3"> </text>
<text top="109" left="818" width="173" height="19" font="11">arrhythmias with low risk of </text>
<text top="127" left="818" width="88" height="19" font="11">complications.</text>
<text top="127" left="907" width="3" height="19" font="3"> </text>
<text top="256" left="125" width="142" height="19" font="3">● Ban et al. 2013 (438) </text>
<text top="274" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24385992">● </a></text>
<text top="274" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24385992">24385992</a></text>
<text top="274" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24385992"> </a></text>
<text top="292" left="125" width="3" height="19" font="3"> </text>
<text top="256" left="286" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="274" left="286" width="115" height="19" font="3">Site Observational </text>
<text top="292" left="286" width="3" height="19" font="3"> </text>
<text top="311" left="286" width="114" height="19" font="4"><b>Size:</b>    12 patients </text>
<text top="256" left="442" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="274" left="442" width="157" height="19" font="3">Among 284 patients with </text>
<text top="292" left="442" width="90" height="19" font="3">idiopathic VAs </text>
<text top="311" left="442" width="149" height="19" font="3">undergoing ablation, 12 </text>
<text top="329" left="442" width="149" height="19" font="3">patients were identified </text>
<text top="347" left="442" width="159" height="19" font="3">with VAs originating from </text>
<text top="366" left="442" width="148" height="19" font="3">the Papillary Muscles of </text>
<text top="384" left="442" width="53" height="19" font="3">the LV.   </text>
<text top="256" left="615" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="274" left="615" width="174" height="19" font="3">Successful catheter ablation </text>
<text top="292" left="615" width="187" height="19" font="3">was achieved in 7 of 8 (87.5%) </text>
<text top="311" left="615" width="179" height="19" font="3">patients with high amplitude </text>
<text top="329" left="615" width="171" height="19" font="3">electrograms at the earliest </text>
<text top="347" left="615" width="87" height="19" font="3">site of origin.  </text>
<text top="366" left="615" width="146" height="19" font="3">The 4 patients with low </text>
<text top="384" left="615" width="170" height="19" font="3">amplitude and fractionated </text>
<text top="402" left="615" width="186" height="19" font="3">electrograms had recurrences </text>
<text top="421" left="615" width="139" height="19" font="3">of VAs after ablation.   </text>
<text top="439" left="615" width="3" height="19" font="3"> </text>
<text top="457" left="615" width="153" height="19" font="3">The mean duration from </text>
<text top="476" left="615" width="189" height="19" font="3">onset to peak downstroke (Δt) </text>
<text top="494" left="615" width="175" height="19" font="3">on the unipolar electrogram </text>
<text top="512" left="615" width="184" height="19" font="3">was significantly longer in the </text>
<text top="531" left="615" width="174" height="19" font="3">successful group than in the </text>
<text top="549" left="615" width="189" height="19" font="3">recurrence group (58±8 ms vs. </text>
<text top="567" left="615" width="156" height="19" font="3">37±9 ms, p=0.04). A slow </text>
<text top="586" left="615" width="163" height="19" font="3">downstroke &gt;50 ms of the </text>
<text top="604" left="615" width="183" height="19" font="3">initial Q wave on the unipolar </text>
<text top="622" left="615" width="178" height="19" font="3">electrogram at ablation sites </text>
<text top="640" left="615" width="131" height="19" font="3">was also significantly </text>
<text top="659" left="615" width="163" height="19" font="3">associated with successful </text>
<text top="677" left="615" width="167" height="19" font="3">outcome (85.7% vs. 25.0%, </text>
<text top="695" left="615" width="54" height="19" font="3">p=0.03). </text>
<text top="714" left="615" width="3" height="19" font="3"> </text>
<text top="256" left="818" width="234" height="19" font="3">● In PMVT, a high-amplitude, discrete </text>
<text top="274" left="818" width="252" height="19" font="3">potential before the QRS and slow down-</text>
<text top="292" left="818" width="211" height="19" font="3">stroke of the initial Q wave on the </text>
<text top="311" left="818" width="255" height="19" font="3">unipolar electrogram at ablation sites are </text>
<text top="329" left="818" width="233" height="19" font="3">related to favorable outcome after RF </text>
<text top="347" left="818" width="112" height="19" font="3">catheter ablation. </text>
</page>
<page number="241" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">241 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="939" height="21" font="2"><b>Data Supplement 48.  Nonrandomized Trials, Observational Studies, and/or Registries Related to Interfascicular Reentrant VT (Belhassen </b></text>
<text top="128" left="115" width="185" height="21" font="2"><b>Tachycardia)- (Section 8.3) </b></text>
<text top="149" left="147" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="167" left="173" width="51" height="19" font="4"><b>Author; </b></text>
<text top="185" left="150" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="149" left="295" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="167" left="324" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="149" left="462" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="149" left="634" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="167" left="646" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="185" left="678" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="149" left="877" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="167" left="906" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="205" left="125" width="130" height="19" font="3">● Nogami et al. 2000 </text>
<text top="223" left="125" width="35" height="19" font="3">(439) </text>
<text top="241" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10987604">● </a></text>
<text top="241" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10987604">10987604</a></text>
<text top="241" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10987604"> </a></text>
<text top="205" left="285" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="223" left="285" width="75" height="19" font="3">Multicenter </text>
<text top="241" left="285" width="89" height="19" font="3">Observational </text>
<text top="259" left="285" width="3" height="19" font="4"><b> </b></text>
<text top="278" left="285" width="114" height="19" font="4"><b>Size:</b>    20 patients </text>
<text top="205" left="442" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="223" left="442" width="147" height="19" font="3">20 consecutive patients </text>
<text top="241" left="442" width="152" height="19" font="3">with verapamil-sensitive </text>
<text top="260" left="442" width="43" height="19" font="3">left VT </text>
<text top="278" left="442" width="136" height="19" font="3">exhibiting a RBBB and </text>
<text top="296" left="442" width="140" height="19" font="3">left-axis deviation QRS </text>
<text top="314" left="442" width="119" height="19" font="3">who underwent RF </text>
<text top="333" left="442" width="60" height="19" font="3">ablation.  </text>
<text top="351" left="442" width="3" height="19" font="3"> </text>
<text top="369" left="442" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="388" left="442" width="36" height="19" font="3">None </text>
<text top="205" left="615" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="223" left="615" width="137" height="19" font="3">Sustained VT could be </text>
<text top="241" left="615" width="153" height="19" font="3">induced by programmed </text>
<text top="260" left="615" width="135" height="19" font="3">electrical stimulation, </text>
<text top="278" left="615" width="185" height="19" font="3">entrained by rapid ventricular </text>
<text top="296" left="615" width="163" height="19" font="3">pacing, and terminated by </text>
<text top="314" left="615" width="160" height="19" font="3">verapamil in all patients.   </text>
<text top="333" left="615" width="183" height="19" font="3">Two discrete potentials could </text>
<text top="351" left="615" width="188" height="19" font="3">be recorded on the LV septum </text>
<text top="370" left="615" width="168" height="19" font="3">with antegrade conduction </text>
<text top="388" left="615" width="123" height="19" font="3">(P1) and retrograde </text>
<text top="406" left="615" width="103" height="19" font="3">conduction (P2). </text>
<text top="424" left="615" width="181" height="19" font="3">RF current applied to the exit </text>
<text top="443" left="615" width="183" height="19" font="3">site of P1 terminated VT in all </text>
<text top="461" left="615" width="60" height="19" font="3">patients.  </text>
<text top="479" left="615" width="175" height="19" font="3">The interval between the LV </text>
<text top="498" left="615" width="128" height="19" font="3">and the P1 potential </text>
<text top="516" left="615" width="171" height="19" font="3">demonstrated decremental </text>
<text top="534" left="615" width="162" height="19" font="3">conduction and verapamil </text>
<text top="553" left="615" width="68" height="19" font="3">sensitivity. </text>
<text top="205" left="817" width="249" height="19" font="3">● Verapamil sensitive idiopathic LV VT is </text>
<text top="223" left="817" width="215" height="19" font="3">a reentrant tachycardia involving a </text>
<text top="241" left="817" width="241" height="19" font="3">discrete longitudinal pathway in the LV </text>
<text top="260" left="817" width="247" height="19" font="3">septum and retrograde conduction over </text>
<text top="278" left="817" width="218" height="19" font="3">the His Purkinje network.  Catheter </text>
<text top="296" left="817" width="237" height="19" font="3">ablation is highly successful with a low </text>
<text top="314" left="817" width="136" height="19" font="3">risk of complications.  </text>
<text top="572" left="125" width="136" height="19" font="3">● Liu et al. 2015 (440) </text>
<text top="590" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10987604">● </a></text>
<text top="590" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10987604">10987604</a></text>
<text top="590" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10987604"> </a></text>
<text top="608" left="125" width="3" height="19" font="3"> </text>
<text top="572" left="285" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="590" left="285" width="84" height="19" font="3">Single Center </text>
<text top="608" left="285" width="89" height="19" font="3">Observational </text>
<text top="627" left="285" width="3" height="19" font="3"> </text>
<text top="645" left="285" width="125" height="19" font="4"><b>Size:</b>    120 patients  </text>
<text top="572" left="442" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="590" left="442" width="130" height="19" font="3">Consecutive patients </text>
<text top="608" left="442" width="155" height="19" font="3">with Idiopathic fascicular </text>
<text top="627" left="442" width="147" height="19" font="3">VT undergoing catheter </text>
<text top="645" left="442" width="60" height="19" font="3">ablation.  </text>
<text top="663" left="442" width="3" height="19" font="4"><b> </b></text>
<text top="681" left="442" width="113" height="19" font="4"><b>Exclusion criteri</b>a: </text>
<text top="700" left="442" width="40" height="19" font="3">None  </text>
<text top="572" left="615" width="59" height="19" font="4"><b>Results:   </b></text>
<text top="590" left="615" width="174" height="19" font="3">120 patients with idiopathic </text>
<text top="608" left="615" width="151" height="19" font="3">fascicular VT (mean age, </text>
<text top="627" left="615" width="160" height="19" font="3">29.3±12.7 y; 82% men; all </text>
<text top="645" left="615" width="103" height="19" font="3">with normal EF). </text>
<text top="663" left="615" width="157" height="19" font="3">Catheter ablation acutely </text>
<text top="681" left="615" width="148" height="19" font="3">successful in 117 of 120 </text>
<text top="700" left="615" width="182" height="19" font="3">patients. Over median follow-</text>
<text top="718" left="615" width="182" height="19" font="3">up of 55.7 mo, VT recurred in </text>
<text top="736" left="615" width="185" height="19" font="3">17 patients, all successfully re-</text>
<text top="755" left="615" width="53" height="19" font="3">ablated. </text>
<text top="572" left="817" width="223" height="19" font="3">Ablation of FVT guided by activation </text>
<text top="590" left="817" width="217" height="19" font="3">mapping is associated with a single </text>
<text top="608" left="817" width="255" height="19" font="3">procedural success rate of 80.3% without </text>
<text top="627" left="817" width="98" height="19" font="3">the use of AAD. </text>
<text top="645" left="817" width="3" height="19" font="3"> </text>
<text top="663" left="817" width="245" height="19" font="3">23 patients (20%) developed new onset </text>
<text top="681" left="817" width="241" height="19" font="3">LPF block, whereas 67 patients (58.3%) </text>
<text top="700" left="817" width="245" height="19" font="3">exhibited rightward shift in their frontal </text>
<text top="718" left="817" width="180" height="19" font="3">axis compared with baseline. </text>
<text top="736" left="817" width="237" height="19" font="3">There were no complications from the </text>
<text top="755" left="817" width="71" height="19" font="3">procedure. </text>
</page>
<page number="242" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">242 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="136" height="19" font="3">● Lin et al. 2005 (441) </text>
<text top="127" left="125" width="12" height="19" font="3">●<a href="http://www.ncbi.nlm.nih.gov/pubmed/26386017"> </a></text>
<text top="127" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26386017">26386017</a></text>
<text top="127" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26386017"> </a></text>
<text top="145" left="125" width="3" height="19" font="3"> </text>
<text top="109" left="285" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="127" left="285" width="84" height="19" font="3">Single Center </text>
<text top="145" left="285" width="89" height="19" font="3">Observational </text>
<text top="164" left="285" width="3" height="19" font="3"> </text>
<text top="182" left="285" width="114" height="19" font="4"><b>Size:</b>    15 patients </text>
<text top="109" left="442" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="127" left="442" width="130" height="19" font="3">Consecutive patients </text>
<text top="145" left="442" width="155" height="19" font="3">with idiopathic fascicular </text>
<text top="164" left="442" width="147" height="19" font="3">VT undergoing catheter </text>
<text top="182" left="442" width="53" height="19" font="3">ablation </text>
<text top="200" left="442" width="3" height="19" font="3"> </text>
<text top="218" left="442" width="124" height="19" font="4"><b>Exclusion criteria:</b>    </text>
<text top="237" left="442" width="27" height="19" font="3">N/A </text>
<text top="109" left="615" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="127" left="615" width="149" height="19" font="3">Among 15 patients with </text>
<text top="145" left="615" width="159" height="19" font="3">idiopathic fascicular VT, 6 </text>
<text top="164" left="615" width="164" height="19" font="3">(40%) had VT that was not </text>
<text top="182" left="615" width="173" height="19" font="3">inducible with programmed </text>
<text top="200" left="615" width="189" height="19" font="3">stimulation and isoproterenol. </text>
<text top="219" left="615" width="166" height="19" font="3">For these patients, a linear </text>
<text top="237" left="615" width="110" height="19" font="3">lesion was placed </text>
<text top="255" left="615" width="185" height="19" font="3">perpendicular to the long axis </text>
<text top="273" left="615" width="187" height="19" font="3">of the ventricle approximately </text>
<text top="292" left="615" width="180" height="19" font="3">midway from the base to the </text>
<text top="310" left="615" width="180" height="19" font="3">apex in the region of the mid </text>
<text top="329" left="615" width="146" height="19" font="3">to mid-inferior septum. </text>
<text top="347" left="615" width="183" height="19" font="3">Left posterior fascicular block </text>
<text top="365" left="615" width="177" height="19" font="3">developed in 2 of 6 patients. </text>
<text top="383" left="615" width="180" height="19" font="3">No spontaneous arrhythmias </text>
<text top="402" left="615" width="178" height="19" font="3">occurred during follow-up to </text>
<text top="420" left="615" width="165" height="19" font="3">16±8 mo (range 6–30 mo). </text>
<text top="109" left="817" width="244" height="19" font="3">● A linear ablation lesion perpendicular </text>
<text top="127" left="817" width="243" height="19" font="3">to the long axis of the LV across the left </text>
<text top="145" left="817" width="247" height="19" font="3">side of the interventricular septum is an </text>
<text top="164" left="817" width="237" height="19" font="3">effective ablation strategy for patients </text>
<text top="182" left="817" width="244" height="19" font="3">with idiopathic fascicular VT that is non-</text>
<text top="200" left="817" width="66" height="19" font="3">inducible.  </text>
<text top="439" left="115" width="4" height="21" font="2"><b> </b></text>
<text top="495" left="115" width="968" height="21" font="2"><b>Data Supplement 49. Nonrandomized Trials, Observational Studies, and/or Registries Related to Idiopathic Polymorphic VT/VF - (Section 8.5) </b></text>
<text top="516" left="139" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="534" left="165" width="51" height="19" font="4"><b>Author; </b></text>
<text top="553" left="143" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="516" left="273" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="534" left="302" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="516" left="441" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="516" left="627" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="534" left="639" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="553" left="671" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="516" left="884" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="534" left="912" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="572" left="130" width="111" height="19" font="3">● Haïssaguerre et </text>
<text top="590" left="130" width="87" height="19" font="3">al. 2002 (442) </text>
<text top="608" left="130" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11879868">● </a></text>
<text top="608" left="142" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11879868">11879868</a></text>
<text top="608" left="203" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11879868"> </a></text>
<text top="572" left="265" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="590" left="265" width="82" height="19" font="3">Multi-Center </text>
<text top="608" left="265" width="89" height="19" font="3">Observational </text>
<text top="627" left="265" width="3" height="19" font="3"> </text>
<text top="645" left="265" width="114" height="19" font="4"><b>Size:</b>    16 patients </text>
<text top="572" left="420" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="590" left="420" width="102" height="19" font="3">16 patients with </text>
<text top="608" left="420" width="162" height="19" font="3">idiopathic VF treated with </text>
<text top="627" left="420" width="108" height="19" font="3">catheter ablation </text>
<text top="645" left="420" width="3" height="19" font="3"> </text>
<text top="663" left="420" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="572" left="595" width="51" height="19" font="3">Results: </text>
<text top="590" left="595" width="185" height="19" font="3">16 patients with idiopathic VF </text>
<text top="608" left="595" width="198" height="19" font="3">triggered by short coupled PVCs </text>
<text top="627" left="595" width="207" height="19" font="3">(mean 300 msec).  The mean PVC </text>
<text top="645" left="595" width="186" height="19" font="3">frequency per day was 9618.   </text>
<text top="663" left="595" width="185" height="19" font="3">The initiating focus was in the </text>
<text top="682" left="595" width="164" height="19" font="3">RVOT in 4 patients, the RV </text>
<text top="700" left="595" width="178" height="19" font="3">Purkinje in 4 patients, the LV </text>
<text top="718" left="595" width="194" height="19" font="3">Purkinje in 7 patients, and both </text>
<text top="737" left="595" width="194" height="19" font="3">the RV and LV Purkinje in 1 pt.   </text>
<text top="572" left="823" width="257" height="19" font="3">● Idiopathic VF is often triggered by short </text>
<text top="590" left="823" width="220" height="19" font="3">coupled PVCs from the RVOT or the </text>
<text top="608" left="823" width="251" height="19" font="3">Purkinje system.  The initiating focus can </text>
<text top="627" left="823" width="240" height="19" font="3">be successfully ablated with low risk of </text>
<text top="645" left="823" width="95" height="19" font="3">complications.  </text>
</page>
<page number="243" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">243 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="595" width="206" height="19" font="3">Initially successful ablation of the </text>
<text top="127" left="595" width="180" height="19" font="3">triggering PVC focus in 16/16 </text>
<text top="145" left="595" width="64" height="19" font="3">patients.   </text>
<text top="164" left="595" width="173" height="19" font="3">Long term freedom from VF </text>
<text top="182" left="595" width="157" height="19" font="3">observed in 13 patients.   </text>
<text top="201" left="130" width="74" height="19" font="3">● <b>VALIANT  </b></text>
<text top="219" left="130" width="103" height="19" font="3">● Solomon et al. </text>
<text top="238" left="130" width="62" height="19" font="3">2005 (30) </text>
<text top="256" left="130" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15972864">● </a></text>
<text top="256" left="142" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15972864">15972864</a></text>
<text top="256" left="203" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15972864"> </a></text>
<text top="274" left="130" width="7" height="19" font="3">  </text>
<text top="201" left="265" width="135" height="19" font="4"><b>Aim:</b>  To evaluate risk </text>
<text top="219" left="265" width="135" height="19" font="3">and predictors of SCD </text>
<text top="238" left="265" width="118" height="19" font="3">in patients post MI </text>
<text top="256" left="265" width="124" height="19" font="3">with left ventricular </text>
<text top="274" left="265" width="140" height="19" font="3">dysfunction and/or HF </text>
<text top="292" left="265" width="3" height="19" font="3"> </text>
<text top="311" left="265" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="329" left="265" width="141" height="19" font="3">Observational study of </text>
<text top="347" left="265" width="132" height="19" font="3">patients enrolled in a </text>
<text top="366" left="265" width="27" height="19" font="3">RCT </text>
<text top="384" left="265" width="3" height="19" font="3"> </text>
<text top="402" left="265" width="127" height="19" font="4"><b>Size:</b> 14,609 patients</text>
<text top="401" left="391" width="4" height="21" font="0"> </text>
<text top="201" left="420" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="219" left="420" width="128" height="19" font="3">Patients with first or </text>
<text top="238" left="420" width="148" height="19" font="3">subsequent MI with HF, </text>
<text top="256" left="420" width="145" height="19" font="3">LV dysfunction, or both </text>
<text top="274" left="420" width="3" height="19" font="3"> </text>
<text top="292" left="420" width="156" height="19" font="4"><b>Exclusion criteria:</b>  ICD in </text>
<text top="311" left="420" width="85" height="19" font="3">place prior to </text>
<text top="329" left="420" width="89" height="19" font="3">randomization</text>
<text top="328" left="509" width="4" height="21" font="0"> </text>
<text top="201" left="595" width="204" height="19" font="4"><b>Intervention:</b> Analysis of rates of </text>
<text top="219" left="595" width="207" height="19" font="3">SCD. Evaluation of EF determined </text>
<text top="238" left="595" width="192" height="19" font="3">by echocardiography as well as </text>
<text top="256" left="595" width="115" height="19" font="3">other parameters. </text>
<text top="274" left="595" width="7" height="19" font="3">  </text>
<text top="292" left="595" width="124" height="19" font="4"><b>Comparator:</b>  <b>   </b>N/A </text>
<text top="311" left="595" width="199" height="19" font="4"><b>1</b>°<b> endpoint:</b>  The risk of sudden </text>
<text top="330" left="595" width="212" height="19" font="3">deathwas greatest in the first 30 d </text>
<text top="348" left="595" width="190" height="19" font="3">after MI: 1.4% per mo, 95% CI: </text>
<text top="367" left="595" width="179" height="19" font="3">1.2%–1.6% and decreased to </text>
<text top="385" left="595" width="185" height="19" font="3">0.14% per mo 95% CI:  0.11%–</text>
<text top="403" left="595" width="208" height="19" font="3">0.18% after 2 y after MI.  Patients </text>
<text top="422" left="595" width="173" height="19" font="3">with LVEF &lt;30% were at the </text>
<text top="440" left="595" width="127" height="19" font="3">greatest risk for SCD </text>
<text top="458" left="595" width="4" height="21" font="0"> </text>
<text top="201" left="823" width="232" height="19" font="3">● Each 5% lower LVEF was associated </text>
<text top="219" left="823" width="236" height="19" font="3">with a 21% increase in adjusted risk of </text>
<text top="238" left="823" width="180" height="19" font="3">SCD or CA with resuscitation. </text>
<text top="256" left="823" width="4" height="21" font="0"> </text>
<text top="479" left="130" width="119" height="19" font="3">● Linzer et al. 1990 </text>
<text top="497" left="130" width="28" height="19" font="3">(25) </text>
<text top="516" left="130" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2371954">● </a></text>
<text top="516" left="142" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2371954">2371954</a></text>
<text top="516" left="195" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2371954"> </a></text>
<text top="534" left="130" width="3" height="19" font="3"> </text>
<text top="552" left="130" width="3" height="19" font="3"> </text>
<text top="571" left="157" width="3" height="19" font="3"> </text>
<text top="479" left="265" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="497" left="265" width="87" height="19" font="3">observational </text>
<text top="516" left="265" width="3" height="19" font="3"> </text>
<text top="534" left="265" width="50" height="19" font="4"><b>Size:</b> 57 </text>
<text top="479" left="420" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="497" left="420" width="141" height="19" font="3">Syncope with negative </text>
<text top="516" left="420" width="42" height="19" font="3">Holter </text>
<text top="534" left="420" width="3" height="19" font="3"> </text>
<text top="552" left="420" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="571" left="420" width="109" height="19" font="3">Patients who had </text>
<text top="589" left="420" width="70" height="19" font="3">undergone </text>
<text top="607" left="420" width="148" height="19" font="3">electrophysiology study </text>
<text top="480" left="595" width="204" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Monitor up to 1mo </text>
<text top="498" left="595" width="64" height="19" font="3">with Loop </text>
<text top="516" left="595" width="3" height="19" font="3"> </text>
<text top="535" left="595" width="178" height="19" font="4"><b>Results:</b>  arrhythmia was the </text>
<text top="553" left="595" width="191" height="19" font="3">cause of symptoms (diagnostic </text>
<text top="571" left="595" width="175" height="19" font="3">yield 25%; 95% CI: 14–38%). </text>
<text top="590" left="595" width="179" height="19" font="3">VT (1 patient), high grade AV </text>
<text top="608" left="595" width="36" height="19" font="3">block </text>
<text top="626" left="595" width="180" height="19" font="3">(2 patients), supraventricular </text>
<text top="645" left="595" width="145" height="19" font="3">tachycardia (1 patient), </text>
<text top="663" left="595" width="209" height="19" font="3">asystole or junctional bradycardia </text>
<text top="681" left="595" width="206" height="19" font="3">from neutrally mediated syncope </text>
<text top="699" left="595" width="194" height="19" font="3">(3 patients) and normal cardiac </text>
<text top="718" left="595" width="158" height="19" font="3">rhythms (the remaining 7 </text>
<text top="736" left="595" width="62" height="19" font="3">patients). </text>
<text top="479" left="823" width="256" height="19" font="3">● 25% yield for syncope Dx after negative </text>
<text top="497" left="823" width="42" height="19" font="3">Holter </text>
<text top="516" left="823" width="162" height="19" font="3">● VT/VF uncommon (1 pt) </text>
<text top="755" left="130" width="116" height="19" font="3">● Noda et al. 2005 </text>
<text top="774" left="130" width="35" height="19" font="3">(443) </text>
<text top="755" left="265" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="774" left="265" width="133" height="19" font="3">Center Observational </text>
<text top="755" left="420" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="755" left="595" width="59" height="19" font="4"><b>Results:   </b></text>
<text top="755" left="823" width="232" height="19" font="3">● PVCs from the RVOT may trigger VF </text>
<text top="774" left="823" width="252" height="19" font="3">when the coupling interval is short (&lt;320 </text>
</page>
<page number="244" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">244 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="130" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16198845">● </a></text>
<text top="109" left="142" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16198845">16198845</a></text>
<text top="109" left="203" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16198845"> </a></text>
<text top="109" left="265" width="3" height="19" font="3"> </text>
<text top="127" left="265" width="114" height="19" font="4"><b>Size:</b>    16 patients </text>
<text top="109" left="420" width="128" height="19" font="3">16 patients who had </text>
<text top="127" left="420" width="116" height="19" font="3">documented VF or </text>
<text top="145" left="420" width="152" height="19" font="3">syncope out of a total of </text>
<text top="164" left="420" width="147" height="19" font="3">101 patients with RVOT </text>
<text top="182" left="420" width="154" height="19" font="3">VAs undergoing catheter </text>
<text top="200" left="420" width="57" height="19" font="3">ablation  </text>
<text top="109" left="595" width="164" height="19" font="3">Holter monitoring showed </text>
<text top="127" left="595" width="204" height="19" font="3">frequent PVCs with LBBB inferior </text>
<text top="145" left="595" width="178" height="19" font="3">QRS axis with mean coupling </text>
<text top="164" left="595" width="164" height="19" font="3">interval of 245+ 28 msec.   </text>
<text top="182" left="595" width="211" height="19" font="3">RF ablation targeting the initiating </text>
<text top="200" left="595" width="191" height="19" font="3">PVC focus acutely successful in </text>
<text top="219" left="595" width="103" height="19" font="3">16/16 patients.   </text>
<text top="237" left="595" width="191" height="19" font="3">Over mean follow-up period of </text>
<text top="255" left="595" width="179" height="19" font="3">54±39 mo, no recurrences of </text>
<text top="273" left="595" width="93" height="19" font="3">syncope or VF. </text>
<text top="292" left="595" width="3" height="19" font="3"> </text>
<text top="109" left="823" width="223" height="19" font="3">msec). The long term outcome after </text>
<text top="127" left="823" width="204" height="19" font="3">ablation of the triggering focus is </text>
<text top="145" left="823" width="62" height="19" font="3">excellent. </text>
<text top="311" left="130" width="111" height="19" font="3">● Haissaguerre et </text>
<text top="329" left="130" width="87" height="19" font="3">al. 2002 (444) </text>
<text top="347" left="130" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12186801">● </a></text>
<text top="347" left="142" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12186801">12186801</a></text>
<text top="347" left="203" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12186801"> </a></text>
<text top="311" left="265" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="329" left="265" width="75" height="19" font="3">Multicenter </text>
<text top="347" left="265" width="89" height="19" font="3">Observational </text>
<text top="366" left="265" width="114" height="19" font="4"><b>Size:</b>    27 patients </text>
<text top="311" left="420" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="329" left="420" width="145" height="19" font="3">27 patients undergoing </text>
<text top="347" left="420" width="124" height="19" font="3">catheter ablation of </text>
<text top="366" left="420" width="134" height="19" font="3">idiopathic VF without </text>
<text top="384" left="420" width="29" height="19" font="3">SHD </text>
<text top="311" left="595" width="59" height="19" font="4"><b>Results:   </b></text>
<text top="329" left="595" width="188" height="19" font="3">Premature beats were elicited </text>
<text top="347" left="595" width="181" height="19" font="3">from the Purkinje conducting </text>
<text top="366" left="595" width="194" height="19" font="3">system in 23 patients: from the </text>
<text top="385" left="595" width="24" height="19" font="3">left </text>
<text top="384" left="619" width="73" height="21" font="0">ventricular</text>
<text top="385" left="692" width="90" height="19" font="3"> septum in 10, </text>
<text top="404" left="595" width="213" height="19" font="3">from the anterior right ventricle in </text>
<text top="423" left="595" width="195" height="19" font="3">9, and from both in 4, and from </text>
<text top="441" left="595" width="144" height="19" font="3">the RVOT in 4 patients. </text>
<text top="459" left="595" width="186" height="19" font="3">The interval from the Purkinje </text>
<text top="478" left="595" width="158" height="19" font="3">potential to the following </text>
<text top="496" left="595" width="209" height="19" font="3">myocardial activation varied from </text>
<text top="514" left="595" width="212" height="19" font="3">10–150 ms during premature beat </text>
<text top="532" left="595" width="183" height="19" font="3">but was 11±5 ms during sinus </text>
<text top="551" left="595" width="183" height="19" font="3">rhythm, indicating location at </text>
<text top="569" left="595" width="201" height="19" font="3">peripheral Purkinje arborization. </text>
<text top="587" left="595" width="182" height="19" font="3">The accuracy of mapping was </text>
<text top="606" left="595" width="210" height="19" font="3">confirmed by acute elimination of </text>
<text top="624" left="595" width="180" height="19" font="3">premature beats during local </text>
<text top="642" left="595" width="207" height="19" font="3">radiofrequency delivery. During a </text>
<text top="661" left="595" width="164" height="19" font="3">follow-up of 24±28 mo, 24 </text>
<text top="679" left="595" width="207" height="19" font="3">patients (89%) had no recurrence </text>
<text top="699" left="595" width="16" height="19" font="3">of </text>
<text top="697" left="611" width="17" height="21" font="0">VF</text>
<text top="699" left="628" width="86" height="19" font="3"> without drug </text>
<text top="311" left="823" width="214" height="19" font="3">● Idiopathic VF can be successfully </text>
<text top="329" left="823" width="243" height="19" font="3">ablated by targeting the initiating focus </text>
<text top="347" left="823" width="253" height="19" font="3">which is usually in the Purkinje system or </text>
<text top="366" left="823" width="41" height="19" font="3">RVOT. </text>
<text top="718" left="130" width="122" height="19" font="3">● Van Herendael et </text>
<text top="736" left="130" width="87" height="19" font="3">al. 2014 (445) </text>
<text top="755" left="130" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24398086">● </a></text>
<text top="755" left="142" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24398086">24398086</a></text>
<text top="755" left="203" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24398086"> </a></text>
<text top="718" left="265" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="736" left="265" width="133" height="19" font="3">Center Observational </text>
<text top="755" left="265" width="3" height="19" font="3"> </text>
<text top="773" left="265" width="114" height="19" font="4"><b>Size:</b>    30 patients </text>
<text top="718" left="420" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="736" left="420" width="150" height="19" font="3">30 patients from among </text>
<text top="755" left="420" width="109" height="19" font="3">1132 consecutive </text>
<text top="773" left="420" width="126" height="19" font="3">patients undergoing </text>
<text top="718" left="595" width="59" height="19" font="4"><b>Results:   </b></text>
<text top="736" left="595" width="209" height="19" font="3">In 21 patients, VF/PMVT occurred </text>
<text top="755" left="595" width="206" height="19" font="3">in the setting of cardiomyopathy; </text>
<text top="773" left="595" width="171" height="19" font="3">in 9 patients, VF/PMVT was </text>
<text top="718" left="823" width="228" height="19" font="3">● Catheter ablation of VPD-triggered </text>
<text top="736" left="823" width="209" height="19" font="3">VF/PMVT is highly successful. Left </text>
<text top="755" left="823" width="235" height="19" font="3">ventricular outflow tract and papillary </text>
<text top="773" left="823" width="249" height="19" font="3">muscles are common and are previously </text>
</page>
<page number="245" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">245 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="420" width="150" height="19" font="3">catheter ablation of VAs </text>
<text top="127" left="420" width="70" height="19" font="3">of all types </text>
<text top="109" left="595" width="177" height="19" font="3">idiopathic. The origin of VPD </text>
<text top="127" left="595" width="181" height="19" font="3">trigger was from the Purkinje </text>
<text top="145" left="595" width="207" height="19" font="3">network in 9, papillary muscles in </text>
<text top="164" left="595" width="206" height="19" font="3">8, left ventricular outflow tract in </text>
<text top="182" left="595" width="189" height="19" font="3">9, and other low-voltage areas </text>
<text top="200" left="595" width="209" height="19" font="3">unrelated to Purkinje activity in 4. </text>
<text top="219" left="595" width="167" height="19" font="3">Acute VPD elimination was </text>
<text top="237" left="595" width="187" height="19" font="3">achieved in 26 patients (87%), </text>
<text top="255" left="595" width="163" height="19" font="3">with a decrease in VPDs in </text>
<text top="273" left="595" width="158" height="19" font="3">another 3 patients (97%). </text>
<text top="292" left="595" width="208" height="19" font="3">During median follow-up of 418 d </text>
<text top="310" left="595" width="185" height="19" font="3">(interquartile range [IQR] 144-</text>
<text top="329" left="595" width="177" height="19" font="3">866), 5 patients developed a </text>
<text top="347" left="595" width="174" height="19" font="3">VF/PMVT recurrence after a </text>
<text top="365" left="595" width="99" height="19" font="3">median of 34 d. </text>
<text top="109" left="823" width="224" height="19" font="3">unrecognized sites of origin of these </text>
<text top="127" left="823" width="258" height="19" font="3">triggers in patients with and without SHD. </text>
<text top="384" left="130" width="119" height="19" font="3">● Sadek et al. 2015 </text>
<text top="402" left="130" width="39" height="19" font="3">(446)  </text>
<text top="421" left="130" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25240695">● </a></text>
<text top="421" left="142" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25240695">25240695</a></text>
<text top="421" left="203" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25240695"> </a></text>
<text top="439" left="130" width="7" height="19" font="4"><b>  </b></text>
<text top="384" left="265" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="402" left="265" width="84" height="19" font="3">Single Center </text>
<text top="421" left="265" width="89" height="19" font="3">Observationa. </text>
<text top="439" left="265" width="114" height="19" font="4"><b>Size:</b>    10 patients </text>
<text top="384" left="420" width="118" height="19" font="4"><b>Inclusion criteria:   </b></text>
<text top="402" left="420" width="129" height="19" font="3">10 patients with VAs </text>
<text top="421" left="420" width="139" height="19" font="3">mapped to moderator </text>
<text top="439" left="420" width="93" height="19" font="3">band in the RV </text>
<text top="457" left="420" width="128" height="19" font="3">undergoing catheter </text>
<text top="476" left="420" width="53" height="19" font="3">ablation </text>
<text top="384" left="595" width="59" height="19" font="4"><b>Results:   </b></text>
<text top="402" left="595" width="212" height="19" font="3">VF was the clinical arrhythmia in 7 </text>
<text top="421" left="595" width="214" height="19" font="3">patients and monomorphic VT in 3 </text>
<text top="439" left="595" width="64" height="19" font="3">patients.   </text>
<text top="457" left="595" width="3" height="19" font="3"> </text>
<text top="476" left="595" width="183" height="19" font="3">Six patients required a repeat </text>
<text top="494" left="595" width="74" height="19" font="3">procedure.  </text>
<text top="512" left="595" width="214" height="19" font="3">After mean follow-up of 21.5±11.6 </text>
<text top="531" left="595" width="176" height="19" font="3">mo, all patients were free of </text>
<text top="549" left="595" width="210" height="19" font="3">sustained VAs, with only 1 patient </text>
<text top="567" left="595" width="177" height="19" font="3">requiring AAD therapy and 1 </text>
<text top="586" left="595" width="195" height="19" font="3">patient having isolated PVCs no </text>
<text top="604" left="595" width="212" height="19" font="3">longer inducing VF. There were no </text>
<text top="622" left="595" width="162" height="19" font="3">procedural complications. </text>
<text top="384" left="823" width="234" height="19" font="3">● VAs originating from the moderator </text>
<text top="402" left="823" width="227" height="19" font="3">band may present with VF.  Catheter </text>
<text top="421" left="823" width="238" height="19" font="3">ablation is effective, though the risk of </text>
<text top="439" left="823" width="249" height="19" font="3">requiring more than one procedure may </text>
<text top="457" left="823" width="185" height="19" font="3">be higher than for other sites. </text>
<text top="641" left="130" width="106" height="20" font="3">•<b> </b>Tester DJ et al.  </text>
<text top="660" left="130" width="105" height="19" font="3">Mayo Clinic Proc </text>
<text top="679" left="130" width="69" height="19" font="3">2011 (447) </text>
<text top="697" left="130" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21964171">● </a></text>
<text top="697" left="142" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21964171">21964171</a></text>
<text top="697" left="203" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21964171"><b> </b></a></text>
<text top="641" left="265" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="660" left="265" width="123" height="19" font="3">retrospective single </text>
<text top="678" left="265" width="46" height="19" font="3">center  </text>
<text top="696" left="265" width="3" height="19" font="3"> </text>
<text top="714" left="265" width="61" height="19" font="4"><b>Size:</b> 35   <b> </b></text>
<text top="641" left="420" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="660" left="420" width="141" height="19" font="3">Unexplained drowning </text>
<text top="678" left="420" width="122" height="19" font="3">patients 1988-2010 </text>
<text top="696" left="420" width="158" height="19" font="3">molecular autopsy, mean </text>
<text top="714" left="420" width="149" height="19" font="3">age 17±12 y (4-69 y). 28 </text>
<text top="733" left="420" width="155" height="19" font="3">swimming (age 15.7 y), 7 </text>
<text top="751" left="420" width="146" height="19" font="3">bathtub (age 23 y). PCR </text>
<text top="642" left="595" width="192" height="19" font="4"><b>1</b>°<b> endpoint:</b> <b> </b>genetic mutation </text>
<text top="660" left="595" width="187" height="19" font="3">yield in unexplained drowning </text>
<text top="679" left="595" width="46" height="19" font="3">victims </text>
<text top="697" left="595" width="3" height="19" font="3"> </text>
<text top="715" left="595" width="206" height="19" font="4"><b>Results:</b>  23% positive mutations, </text>
<text top="733" left="595" width="178" height="19" font="3">8/28 swimming, 0/7 bathtub </text>
<text top="752" left="595" width="176" height="19" font="3">Pos family Hx 43%: syncope, </text>
<text top="770" left="595" width="190" height="19" font="3">seizures, CA, near-drowning or </text>
<text top="641" left="823" width="224" height="19" font="3">● Recommend genetic screening for </text>
<text top="660" left="823" width="218" height="19" font="3">unexplained drowning, especially if </text>
<text top="678" left="823" width="258" height="19" font="3">positive family Hx of drowning, prolonged </text>
<text top="696" left="823" width="27" height="19" font="3">QTc </text>
<text top="714" left="823" width="3" height="19" font="3"> </text>
</page>
<page number="246" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">246 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="420" width="159" height="19" font="3">DNA sequencing for LQTS </text>
<text top="127" left="420" width="62" height="19" font="3">1-3, RYR2 </text>
<text top="145" left="420" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="164" left="420" width="27" height="19" font="3">N/A<b> </b></text>
<text top="109" left="595" width="214" height="19" font="3">drowning. Among 11 patients with </text>
<text top="127" left="595" width="186" height="19" font="3">positive personal or family hx, </text>
<text top="145" left="595" width="114" height="19" font="3">64% gene positive </text>
<text top="243" left="130" width="118" height="19" font="3">● Tzimas I et al.<b> </b>Int </text>
<text top="261" left="130" width="108" height="19" font="3">J Legal Med 2016 </text>
<text top="280" left="130" width="35" height="19" font="3">(448)<b> </b></text>
<text top="298" left="130" width="12" height="19" font="3">●<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27460199"> </a></text>
<text top="298" left="142" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27460199">27460199</a></text>
<text top="298" left="203" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27460199"><b> </b></a></text>
<text top="243" left="265" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="261" left="265" width="91" height="19" font="3">retrospective   </text>
<text top="280" left="265" width="3" height="19" font="3"> </text>
<text top="298" left="265" width="68" height="19" font="4"><b>Size:</b>    171<b> </b></text>
<text top="243" left="420" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="261" left="420" width="158" height="19" font="3">Genotyping performed in </text>
<text top="280" left="420" width="147" height="19" font="3">corpses found in water: </text>
<text top="298" left="420" width="166" height="19" font="3">drowning, unclear deaths.  </text>
<text top="316" left="420" width="3" height="19" font="3"> </text>
<text top="335" left="420" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="244" left="595" width="212" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Testing mutations in </text>
<text top="262" left="595" width="188" height="19" font="3">19 variants in drowning/water </text>
<text top="280" left="595" width="99" height="19" font="3">related deaths.  </text>
<text top="299" left="595" width="3" height="19" font="3"> </text>
<text top="317" left="595" width="212" height="19" font="4"><b>Results:</b>  one SNP of KCNQ1 noted </text>
<text top="335" left="595" width="128" height="19" font="3">NOS1AP significance </text>
<text top="243" left="823" width="234" height="19" font="3">● NOS1AP mutation of KCNq1 may be </text>
<text top="261" left="823" width="192" height="19" font="3">significant in drowning victims. </text>
<text top="280" left="823" width="224" height="19" font="3">● Recommend molecular autopsy in </text>
<text top="298" left="823" width="166" height="19" font="3">unexplained water deaths.<b> </b></text>
<text top="354" left="130" width="108" height="19" font="3">● Anderson JH et </text>
<text top="373" left="130" width="92" height="19" font="3">al. Circ CV Gen </text>
<text top="391" left="130" width="69" height="19" font="3">2016 (449) </text>
<text top="409" left="130" width="12" height="19" font="3">●<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27114410"> </a></text>
<text top="409" left="142" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27114410">27114410</a></text>
<text top="409" left="203" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27114410"> </a></text>
<text top="354" left="265" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="373" left="265" width="123" height="19" font="3">retrospective single </text>
<text top="391" left="265" width="50" height="19" font="3">center   </text>
<text top="409" left="265" width="3" height="19" font="3"> </text>
<text top="428" left="265" width="61" height="19" font="4"><b>Size:</b>    32<b> </b></text>
<text top="354" left="420" width="115" height="19" font="4"><b>Inclusion criteria:  </b></text>
<text top="373" left="420" width="138" height="19" font="3">Exertion related SUDY </text>
<text top="391" left="420" width="119" height="19" font="3">decedents (sudden </text>
<text top="409" left="420" width="132" height="19" font="3">unexplained death in </text>
<text top="428" left="420" width="49" height="19" font="3">young)  </text>
<text top="446" left="420" width="72" height="19" font="3">ages 1-19 y </text>
<text top="464" left="420" width="151" height="19" font="3">Mean age 11±5 y Family </text>
<text top="483" left="420" width="155" height="19" font="3">Hx SCD age &lt;50 y in 10%  </text>
<text top="501" left="420" width="3" height="19" font="3"> </text>
<text top="519" left="420" width="152" height="19" font="3">Molecular autopsy 1998-</text>
<text top="537" left="420" width="38" height="19" font="3">2010. </text>
<text top="556" left="420" width="140" height="19" font="3">DNA sequencing (PCR) </text>
<text top="574" left="420" width="161" height="19" font="3">followed by whole-exome </text>
<text top="593" left="420" width="73" height="19" font="3">sequencing </text>
<text top="611" left="420" width="3" height="19" font="3"> </text>
<text top="629" left="420" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="355" left="595" width="181" height="19" font="4"><b>1</b>°<b> endpoint:</b>  yield of genetic </text>
<text top="373" left="595" width="210" height="19" font="3">testing in decedents with exercise </text>
<text top="392" left="595" width="134" height="19" font="3">related sudden death </text>
<text top="410" left="595" width="3" height="19" font="3"> </text>
<text top="428" left="595" width="213" height="19" font="4"><b>Results:</b>  PCR DNA testing putative </text>
<text top="447" left="595" width="184" height="19" font="3">mutation in 34% (11 patients, </text>
<text top="465" left="595" width="84" height="19" font="3">LQTS, CPVT).  </text>
<text top="483" left="595" width="209" height="19" font="3">Subsequent WES performed in 21 </text>
<text top="502" left="595" width="154" height="19" font="3">patients, yield 3/21, 14% </text>
<text top="520" left="595" width="181" height="19" font="3">(calmodulin 2, PKP2 1-ARVC). </text>
<text top="538" left="595" width="160" height="19" font="3">Calmodulin deaths 2, 5 y.  </text>
<text top="557" left="595" width="3" height="19" font="4"><b> </b></text>
<text top="575" left="595" width="187" height="19" font="3">Yield higher among decedents </text>
<text top="593" left="595" width="186" height="19" font="3">aged 1–10 y (91%) vs. 11–19 y </text>
<text top="612" left="595" width="106" height="19" font="3">(19%), p=0.0001 <b> </b></text>
<text top="354" left="823" width="256" height="19" font="3">● In decedents with exertion related <b>SUD </b></text>
<text top="373" left="823" width="150" height="19" font="3">&lt;20 y, overall yield 44%, </text>
<text top="391" left="823" width="214" height="19" font="3">● Yield higher in probands   &lt;11 y.  </text>
<text top="409" left="823" width="3" height="19" font="3"> </text>
<text top="648" left="130" width="98" height="19" font="3">● Wang D et al. </text>
<text top="667" left="130" width="95" height="19" font="3">Forensic Sci Int </text>
<text top="685" left="130" width="69" height="19" font="3">2014 (450)<b> </b></text>
<text top="703" left="130" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24631775">● </a></text>
<text top="703" left="142" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24631775">24631775</a></text>
<text top="703" left="203" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24631775"> </a></text>
<text top="648" left="265" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="667" left="265" width="134" height="19" font="3">Retrospective cohort  </text>
<text top="685" left="265" width="3" height="19" font="3"> </text>
<text top="703" left="265" width="65" height="19" font="4"><b>Size:</b>   274<b> </b></text>
<text top="648" left="420" width="144" height="19" font="4"><b>Inclusion criteria:</b>  SUD </text>
<text top="667" left="420" width="142" height="19" font="3">channelopathy genetic </text>
<text top="685" left="420" width="164" height="19" font="3">testing in NYC 2008-2012.  </text>
<text top="703" left="420" width="121" height="19" font="3">LQTS, RYR2 testing. </text>
<text top="721" left="420" width="148" height="19" font="3">Ages ≤1 y, 141 patients, </text>
<text top="740" left="420" width="36" height="19" font="3">51%,  </text>
<text top="758" left="420" width="144" height="19" font="3">Age 1–58 y, 133 cases,  </text>
<text top="649" left="595" width="133" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Yield of </text>
<text top="667" left="595" width="204" height="19" font="3">channelopathy genetic screening </text>
<text top="686" left="595" width="210" height="19" font="3">in ethnically diverse population of </text>
<text top="704" left="595" width="37" height="19" font="3">SUCD </text>
<text top="722" left="595" width="3" height="19" font="3"> </text>
<text top="740" left="595" width="187" height="19" font="4"><b>Results:</b>  Gene positive: 13.5% </text>
<text top="759" left="595" width="125" height="19" font="3">infants, 19.5% older </text>
<text top="648" left="823" width="218" height="19" font="3">● Overall genetic testing positive in </text>
<text top="667" left="823" width="257" height="19" font="3">13.5%–19.5% of autopsy negative sudden </text>
<text top="685" left="823" width="39" height="19" font="3">death </text>
<text top="703" left="823" width="253" height="19" font="3">● “Genetic testing information should be </text>
<text top="721" left="823" width="230" height="19" font="3">provided to the family members with </text>
<text top="740" left="823" width="253" height="19" font="3">proper counseling along with the choices </text>
<text top="758" left="823" width="181" height="19" font="3">of further clinical evaluation” </text>
</page>
<page number="247" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">247 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="420" width="150" height="19" font="3"> African Americans 48%, </text>
<text top="127" left="420" width="152" height="19" font="3">Hispanic 22%, Caucasian </text>
<text top="145" left="420" width="29" height="19" font="3">16% </text>
<text top="164" left="420" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="182" left="420" width="103" height="19" font="3">autopsy positive </text>
<text top="109" left="595" width="207" height="19" font="3">SCN5A positive, 68% infants, 50% </text>
<text top="127" left="595" width="74" height="19" font="3">non-infants </text>
<text top="145" left="595" width="197" height="19" font="3">AA carried more SCN5A, KCNQ1 </text>
<text top="164" left="595" width="195" height="19" font="3">variants vs other ethnic groups; </text>
<text top="182" left="595" width="121" height="19" font="3">Whites: more RYR2 </text>
<text top="200" left="595" width="210" height="19" font="3">LQTS more prevalent during sleep </text>
<text top="219" left="595" width="170" height="19" font="3">related deaths, RYR2 active<b> </b></text>
<text top="238" left="130" width="100" height="19" font="3">● Kumar S et al. </text>
<text top="256" left="130" width="89" height="19" font="3">Heart Rhythm </text>
<text top="274" left="130" width="69" height="19" font="3">2013 (451) </text>
<text top="292" left="130" width="12" height="19" font="3">●<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23973953"> </a></text>
<text top="292" left="142" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23973953">23973953</a></text>
<text top="292" left="203" width="3" height="19" font="24"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23973953"><b> </b></a></text>
<text top="311" left="130" width="3" height="19" font="3"> </text>
<text top="237" left="265" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="256" left="265" width="3" height="19" font="3"> </text>
<text top="274" left="265" width="68" height="19" font="4"><b>Size:</b>  502  <b> </b></text>
<text top="237" left="420" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="256" left="420" width="157" height="19" font="3">Autopsy negative sudden </text>
<text top="274" left="420" width="117" height="19" font="3">unexplained death </text>
<text top="293" left="420" width="135" height="19" font="3">syndrome (SADS) and </text>
<text top="311" left="420" width="137" height="19" font="3">unexplained CA (UCA) </text>
<text top="329" left="420" width="136" height="19" font="3">(patients resuscitated </text>
<text top="347" left="420" width="146" height="19" font="3">successfully), mean age </text>
<text top="366" left="420" width="33" height="19" font="3">32 y. </text>
<text top="384" left="420" width="151" height="19" font="3">Clinical evaluation (ECG, </text>
<text top="402" left="420" width="136" height="19" font="3">EST, echo) w targeted </text>
<text top="421" left="420" width="132" height="19" font="3">genetic testing. SADS </text>
<text top="439" left="420" width="158" height="19" font="3">mean age 24 y, UCA 32 y. </text>
<text top="457" left="420" width="144" height="19" font="4"><b>Exclusion criteria:</b> N/A <b> </b></text>
<text top="238" left="595" width="189" height="19" font="4"><b>1</b>°<b> endpoint:</b> <b> </b>Evaluate yield of </text>
<text top="257" left="595" width="180" height="19" font="3">comprehensive evaluation of </text>
<text top="275" left="595" width="91" height="19" font="3">SADS and UCA </text>
<text top="293" left="595" width="3" height="19" font="3"> </text>
<text top="311" left="595" width="209" height="19" font="4"><b>Results:</b>  SADS: yield 18%; LQTS in </text>
<text top="330" left="595" width="201" height="19" font="3">young ≤20 y; Brugada in age ≥40 </text>
<text top="348" left="595" width="17" height="19" font="3">y.  </text>
<text top="367" left="595" width="204" height="19" font="3">UCA: yield 62%: mainly LQTS and </text>
<text top="385" left="595" width="194" height="19" font="3">BrS; CPVT, ER, ARVC, Short QT.  </text>
<text top="403" left="595" width="214" height="19" font="3">Targeted genetic tesing in patients </text>
<text top="422" left="595" width="158" height="19" font="3">with proven or suspected </text>
<text top="440" left="595" width="198" height="19" font="3">phenotoype: molecular dx SADS </text>
<text top="458" left="595" width="96" height="19" font="3">35%, UCA 48%. </text>
<text top="476" left="595" width="3" height="19" font="4"><b> </b></text>
<text top="495" left="595" width="3" height="19" font="4"><b> </b></text>
<text top="238" left="823" width="255" height="19" font="3">● Clinical + targeted genetics yield: SADS: </text>
<text top="256" left="823" width="92" height="19" font="3">18%, UCA 62% </text>
<text top="274" left="823" width="233" height="19" font="3">● Inherited cardiac disease diagnosed </text>
<text top="292" left="823" width="223" height="19" font="3">only in families with multiple events </text>
<text top="311" left="823" width="243" height="19" font="3">● Recommend ongoing periodic clinical </text>
<text top="329" left="823" width="221" height="19" font="3">evaluation of children/young family </text>
<text top="347" left="823" width="202" height="19" font="3">members for developing disease </text>
<text top="513" left="115" width="4" height="21" font="2"><b> </b></text>
<text top="570" left="115" width="898" height="21" font="2"><b>Data Supplement 50. Nonrandomized Trials, Observational Studies, and/or Registries of PVC-induced Cardiomyopathy - (Section 9) </b></text>
<text top="591" left="148" width="39" height="19" font="4"><b>Study </b></text>
<text top="609" left="136" width="64" height="19" font="4"><b>Acronym; </b></text>
<text top="627" left="142" width="51" height="19" font="4"><b>Author; </b></text>
<text top="646" left="152" width="31" height="19" font="4"><b>Year </b></text>
<text top="664" left="136" width="64" height="19" font="4"><b>Published </b></text>
<text top="591" left="255" width="39" height="19" font="4"><b>Study </b></text>
<text top="609" left="232" width="86" height="19" font="4"><b>Type/Design; </b></text>
<text top="627" left="242" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="591" left="370" width="48" height="19" font="4"><b>Patient </b></text>
<text top="609" left="358" width="72" height="19" font="4"><b>Population </b></text>
<text top="591" left="568" width="3" height="19" font="4"><b> </b></text>
<text top="591" left="719" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="609" left="732" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="627" left="763" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="591" left="926" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="609" left="955" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="683" left="123" width="73" height="19" font="3">● Ban et al. </text>
<text top="701" left="123" width="69" height="19" font="3">2013 (452) </text>
<text top="720" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23194696">● </a></text>
<text top="720" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23194696">23194696</a></text>
<text top="720" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23194696"> </a></text>
<text top="738" left="123" width="3" height="19" font="3"> </text>
<text top="683" left="225" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="701" left="225" width="66" height="19" font="3">Single Site </text>
<text top="720" left="225" width="99" height="19" font="3">Observationa<b>l</b>    </text>
<text top="738" left="225" width="3" height="19" font="3"> </text>
<text top="756" left="225" width="68" height="19" font="4"><b>Size:</b>    127 </text>
<text top="775" left="225" width="53" height="19" font="3">patients </text>
<text top="683" left="338" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="701" left="338" width="112" height="19" font="3">PVC burden &gt;10% </text>
<text top="720" left="338" width="99" height="19" font="3">per 24 h and no </text>
<text top="738" left="338" width="77" height="19" font="3">known SHD  </text>
<text top="756" left="338" width="3" height="19" font="3"> </text>
<text top="683" left="464" width="3" height="19" font="4"><b> </b></text>
<text top="683" left="689" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="701" left="689" width="193" height="19" font="3">Left ventricular dysfunction (EF </text>
<text top="720" left="689" width="194" height="19" font="3">&lt;50%) was present in 28 of 127 </text>
<text top="738" left="689" width="198" height="19" font="3">patients (22.0%). The mean PVC </text>
<text top="756" left="689" width="169" height="19" font="3">burden (31+11 vs. 22+10%, </text>
<text top="775" left="689" width="188" height="19" font="3">p&lt;0.001), the presence of non-</text>
<text top="683" left="914" width="150" height="19" font="3">● A PVC burden &gt;26%/d </text>
<text top="701" left="914" width="146" height="19" font="3">predicts LV dysfunction </text>
<text top="720" left="914" width="140" height="19" font="3">with sensitivity of 70% </text>
<text top="738" left="914" width="143" height="19" font="3">and specificity of 78%.  </text>
<text top="756" left="914" width="134" height="19" font="3">Thus, PVC induced LV </text>
<text top="775" left="914" width="151" height="19" font="3">dysfunction is reversible </text>
</page>
<page number="248" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">248 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="338" width="61" height="19" font="4"><b>Exclusion </b></text>
<text top="127" left="338" width="84" height="19" font="4"><b>criteria:</b>  SHD </text>
<text top="109" left="689" width="180" height="19" font="3">sustained VT (53.6 vs. 33.3%, </text>
<text top="127" left="689" width="189" height="19" font="3">p&lt;0.05), and the presence of a </text>
<text top="145" left="689" width="187" height="19" font="3">retrograde P-wave following a </text>
<text top="164" left="689" width="184" height="19" font="3">PVC (64.3 vs. 30.3%, p=0.001) </text>
<text top="182" left="689" width="210" height="19" font="3">were signiﬁcantly greater in those </text>
<text top="200" left="689" width="207" height="19" font="3">with LV dysfunction than in those </text>
<text top="219" left="689" width="204" height="19" font="3">with normal LV function. The cut-</text>
<text top="237" left="689" width="177" height="19" font="3">off PVC burden related to LV </text>
<text top="255" left="689" width="204" height="19" font="3">dysfunction was 26%/day, with a </text>
<text top="273" left="689" width="210" height="19" font="3">sensitivity of 70% and a speciﬁcity </text>
<text top="292" left="689" width="49" height="19" font="3">of 78%. </text>
<text top="310" left="689" width="210" height="19" font="3">The origin sites of PVCs, the acute </text>
<text top="328" left="689" width="201" height="19" font="3">success rate, and the recurrence </text>
<text top="347" left="689" width="201" height="19" font="3">rate during follow-up after RFCA </text>
<text top="365" left="689" width="185" height="19" font="3">were similar. In a multivariate </text>
<text top="383" left="689" width="184" height="19" font="3">analysis, the PVC burden (OR: </text>
<text top="402" left="689" width="208" height="19" font="3">2.94; 95% CI: 0.90–3.19, p=0.006) </text>
<text top="420" left="689" width="206" height="19" font="3">and the presence of retrograde P-</text>
<text top="438" left="689" width="188" height="19" font="3">waves (OR: 2.79; 95% CI: 1.08–</text>
<text top="457" left="689" width="125" height="19" font="3">7.19, p=0.034) were </text>
<text top="475" left="689" width="190" height="19" font="3">independently associated with </text>
<text top="493" left="689" width="188" height="19" font="3">PVC-mediated LV dysfunction. </text>
<text top="109" left="914" width="139" height="19" font="3">with catheter ablation </text>
<text top="127" left="914" width="129" height="19" font="3">though there is wide </text>
<text top="145" left="914" width="129" height="19" font="3">variability in the PVC </text>
<text top="164" left="914" width="146" height="19" font="3">burden associated with </text>
<text top="182" left="914" width="90" height="19" font="3">reduced LVEF. </text>
<text top="512" left="123" width="12" height="19" font="3">● </text>
<text top="531" left="123" width="82" height="19" font="3">Haïssaguerre </text>
<text top="549" left="123" width="67" height="19" font="3">et al. 2002 </text>
<text top="567" left="123" width="35" height="19" font="3">(442) </text>
<text top="586" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11879868">● </a></text>
<text top="586" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11879868">11879868</a></text>
<text top="586" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11879868"> </a></text>
<text top="512" left="225" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="531" left="225" width="82" height="19" font="3">Multi-Center </text>
<text top="549" left="225" width="89" height="19" font="3">Observational </text>
<text top="567" left="225" width="3" height="19" font="3"> </text>
<text top="585" left="225" width="60" height="19" font="4"><b>Size:</b>    16 </text>
<text top="604" left="225" width="53" height="19" font="3">patients </text>
<text top="512" left="338" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="531" left="338" width="102" height="19" font="3">16 patients with </text>
<text top="549" left="338" width="83" height="19" font="3">idiopathic VF </text>
<text top="567" left="338" width="79" height="19" font="3">treated with </text>
<text top="586" left="338" width="108" height="19" font="3">catheter ablation </text>
<text top="604" left="338" width="3" height="19" font="3"> </text>
<text top="622" left="338" width="61" height="19" font="4"><b>Exclusion </b></text>
<text top="640" left="338" width="83" height="19" font="4"><b>criteria:</b>  N/A </text>
<text top="512" left="464" width="3" height="19" font="4"><b> </b></text>
<text top="512" left="689" width="52" height="19" font="4"><b>Results: </b></text>
<text top="531" left="689" width="185" height="19" font="3">16 patients with idiopathic VF </text>
<text top="549" left="689" width="198" height="19" font="3">triggered by short coupled PVCs </text>
<text top="567" left="689" width="207" height="19" font="3">(mean 300 msec).  The mean PVC </text>
<text top="586" left="689" width="186" height="19" font="3">frequency per day was 9618.   </text>
<text top="604" left="689" width="185" height="19" font="3">The initiating focus was in the </text>
<text top="622" left="689" width="164" height="19" font="3">RVOT in 4 patients, the RV </text>
<text top="640" left="689" width="178" height="19" font="3">Purkinje in 4 patients, the LV </text>
<text top="659" left="689" width="194" height="19" font="3">Purkinje in 7 patients, and both </text>
<text top="677" left="689" width="194" height="19" font="3">the RV and LV Purkinje in 1 pt.   </text>
<text top="695" left="689" width="206" height="19" font="3">Initially successful ablation of the </text>
<text top="714" left="689" width="180" height="19" font="3">triggering PVC focus in 16/16 </text>
<text top="732" left="689" width="64" height="19" font="3">patients.   </text>
<text top="750" left="689" width="173" height="19" font="3">Long term freedom from VF </text>
<text top="769" left="689" width="157" height="19" font="3">observed in 13 patients.   </text>
<text top="512" left="914" width="144" height="19" font="3">● Idiopathic VF is often </text>
<text top="531" left="914" width="113" height="19" font="3">triggered by short </text>
<text top="549" left="914" width="142" height="19" font="3">coupled PVCs from the </text>
<text top="567" left="914" width="131" height="19" font="3">RVOT or the Purkinje </text>
<text top="586" left="914" width="137" height="19" font="3">system.  The initiating </text>
<text top="604" left="914" width="155" height="19" font="3">focus can be successfully </text>
<text top="622" left="914" width="146" height="19" font="3">ablated with low risk of </text>
<text top="640" left="914" width="95" height="19" font="3">complications.  </text>
</page>
<page number="249" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">249 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="12" height="19" font="3">● </text>
<text top="127" left="123" width="82" height="19" font="3">Haissaguerre </text>
<text top="145" left="123" width="67" height="19" font="3">et al. 2002 </text>
<text top="164" left="123" width="35" height="19" font="3">(444) </text>
<text top="182" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12186801">● </a></text>
<text top="182" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12186801">12186801</a></text>
<text top="182" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12186801"> </a></text>
<text top="109" left="225" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="127" left="225" width="75" height="19" font="3">Multicenter </text>
<text top="145" left="225" width="89" height="19" font="3">Observational </text>
<text top="164" left="225" width="60" height="19" font="4"><b>Size:</b>    27 </text>
<text top="182" left="225" width="53" height="19" font="3">patients </text>
<text top="109" left="338" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="127" left="338" width="72" height="19" font="3">27 patients </text>
<text top="145" left="338" width="73" height="19" font="3">undergoing </text>
<text top="164" left="338" width="108" height="19" font="3">catheter ablation </text>
<text top="182" left="338" width="98" height="19" font="3">of idiopathic VF </text>
<text top="200" left="338" width="80" height="19" font="3">without SHD </text>
<text top="109" left="464" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="689" width="59" height="19" font="4"><b>Results:   </b></text>
<text top="127" left="689" width="188" height="19" font="3">Premature beats were elicited </text>
<text top="145" left="689" width="181" height="19" font="3">from the Purkinje conducting </text>
<text top="164" left="689" width="194" height="19" font="3">system in 23 patients: from the </text>
<text top="183" left="689" width="24" height="19" font="3">left </text>
<text top="182" left="713" width="73" height="21" font="0">ventricular</text>
<text top="183" left="785" width="90" height="19" font="3"> septum in 10, </text>
<text top="202" left="689" width="198" height="19" font="3">from the anterior right ventricle </text>
<text top="220" left="689" width="210" height="19" font="3">in 9, and from both in 4, and from </text>
<text top="239" left="689" width="144" height="19" font="3">the RVOT in 4 patients. </text>
<text top="257" left="689" width="186" height="19" font="3">The interval from the Purkinje </text>
<text top="275" left="689" width="158" height="19" font="3">potential to the following </text>
<text top="294" left="689" width="209" height="19" font="3">myocardial activation varied from </text>
<text top="312" left="689" width="181" height="19" font="3">10–150 ms during premature </text>
<text top="330" left="689" width="180" height="19" font="3">beat but was 11±5 ms during </text>
<text top="348" left="689" width="202" height="19" font="3">sinus rhythm, indicating location </text>
<text top="367" left="689" width="135" height="19" font="3">at peripheral Purkinje </text>
<text top="385" left="689" width="81" height="19" font="3">arborization. </text>
<text top="404" left="689" width="182" height="19" font="3">The accuracy of mapping was </text>
<text top="422" left="689" width="210" height="19" font="3">confirmed by acute elimination of </text>
<text top="440" left="689" width="180" height="19" font="3">premature beats during local </text>
<text top="458" left="689" width="207" height="19" font="3">radiofrequency delivery. During a </text>
<text top="477" left="689" width="164" height="19" font="3">follow-up of 24±28 mo, 24 </text>
<text top="495" left="689" width="207" height="19" font="3">patients (89%) had no recurrence </text>
<text top="515" left="689" width="16" height="19" font="3">of </text>
<text top="513" left="705" width="17" height="21" font="0">VF</text>
<text top="515" left="722" width="86" height="19" font="3"> without drug </text>
<text top="109" left="914" width="139" height="19" font="3">● Idiopathic VF can be </text>
<text top="127" left="914" width="143" height="19" font="3">successfully ablated by </text>
<text top="145" left="914" width="140" height="19" font="3">targeting the initiating </text>
<text top="164" left="914" width="149" height="19" font="3">focus which is usually in </text>
<text top="182" left="914" width="140" height="19" font="3">the Purkinje system or </text>
<text top="200" left="914" width="41" height="19" font="3">RVOT. </text>
<text top="534" left="123" width="71" height="19" font="3">● Lee et al. </text>
<text top="553" left="123" width="69" height="19" font="3">2015 (453) </text>
<text top="571" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25940215?dopt=Citation">● </a></text>
<text top="571" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25940215?dopt=Citation">25940215</a></text>
<text top="571" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25940215?dopt=Citation"> </a></text>
<text top="534" left="225" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="553" left="225" width="88" height="19" font="3">Single Center, </text>
<text top="571" left="225" width="87" height="19" font="3">Retrospective </text>
<text top="589" left="225" width="86" height="19" font="3">review, 2004–</text>
<text top="608" left="225" width="37" height="19" font="3">2013  </text>
<text top="626" left="225" width="3" height="19" font="3"> </text>
<text top="644" left="225" width="58" height="19" font="4"><b>Size:</b> 100 </text>
<text top="534" left="338" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="553" left="338" width="105" height="19" font="3">Continuous Flow </text>
<text top="571" left="338" width="65" height="19" font="3">LVAD only </text>
<text top="589" left="338" width="3" height="19" font="3"> </text>
<text top="607" left="338" width="61" height="19" font="4"><b>Exclusion </b></text>
<text top="626" left="338" width="80" height="19" font="4"><b>criteria:</b> N/A </text>
<text top="534" left="464" width="3" height="19" font="4"><b> </b></text>
<text top="535" left="689" width="198" height="19" font="4"><b>1</b>°<b> endpoint:</b> All cause mortality </text>
<text top="553" left="689" width="3" height="19" font="3"> </text>
<text top="572" left="689" width="56" height="19" font="4"><b>Results:</b>  </text>
<text top="590" left="689" width="148" height="20" font="3">• 64 patients. Had ICDs. </text>
<text top="609" left="689" width="180" height="20" font="3">• Death occurred in 15 (38%) </text>
<text top="628" left="689" width="194" height="19" font="3">patients in the no ICD group vs. </text>
<text top="647" left="689" width="163" height="19" font="3">18 (30%) in the ICD group. </text>
<text top="665" left="689" width="208" height="19" font="3">Univariate analysis demonstrated </text>
<text top="683" left="689" width="198" height="19" font="3">a marginal early survival benefit </text>
<text top="701" left="689" width="207" height="19" font="3">at up to 1 y. No difference after 1 </text>
<text top="720" left="689" width="14" height="19" font="3">y. </text>
<text top="738" left="689" width="186" height="20" font="3">• Multivariate analysis did not </text>
<text top="757" left="689" width="202" height="19" font="3">show any significant predictor of </text>
<text top="775" left="689" width="54" height="19" font="3">survival. </text>
<text top="534" left="914" width="153" height="20" font="3">• ICD was not associated </text>
<text top="553" left="914" width="146" height="19" font="3">with improved survival. </text>
<text top="572" left="914" width="3" height="19" font="3"> </text>
</page>
<page number="250" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">250 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="689" width="165" height="20" font="3">• No patients died of SCD.  </text>
<text top="129" left="123" width="81" height="19" font="3">● Carballeira </text>
<text top="147" left="123" width="56" height="19" font="3">Pol et al. </text>
<text top="165" left="123" width="69" height="19" font="3">2014 (454) </text>
<text top="183" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24184787">● </a></text>
<text top="183" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24184787">24184787</a></text>
<text top="183" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24184787"> </a></text>
<text top="128" left="225" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="147" left="225" width="66" height="19" font="3">Single Site </text>
<text top="165" left="225" width="99" height="19" font="3">Observationa<b>l</b>    </text>
<text top="183" left="225" width="3" height="19" font="3"> </text>
<text top="202" left="225" width="60" height="19" font="4"><b>Size:</b>    45 </text>
<text top="220" left="225" width="53" height="19" font="3">patients </text>
<text top="128" left="338" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="147" left="338" width="77" height="19" font="3">Consecutive </text>
<text top="165" left="338" width="104" height="19" font="3">patients without </text>
<text top="183" left="338" width="85" height="19" font="3">SHD who had </text>
<text top="202" left="338" width="110" height="19" font="3">&gt;10% PVCs/d and </text>
<text top="220" left="338" width="79" height="19" font="3">normal LVEF </text>
<text top="239" left="338" width="111" height="19" font="3">(&gt;0.55) who were </text>
<text top="257" left="338" width="67" height="19" font="3">observed.  </text>
<text top="275" left="338" width="3" height="19" font="3"> </text>
<text top="293" left="338" width="61" height="19" font="4"><b>Exclusion </b></text>
<text top="311" left="338" width="59" height="19" font="4"><b>criteria:</b>   </text>
<text top="330" left="338" width="101" height="19" font="3">Structural Heart </text>
<text top="348" left="338" width="50" height="19" font="3">Disease </text>
<text top="367" left="338" width="3" height="19" font="3"> </text>
<text top="128" left="464" width="3" height="19" font="4"><b> </b></text>
<text top="128" left="689" width="59" height="19" font="4"><b>Results:   </b></text>
<text top="147" left="689" width="185" height="19" font="3">Of the 45 patients studied, 28 </text>
<text top="165" left="689" width="188" height="19" font="3">patients (62%) developed PVC-</text>
<text top="183" left="689" width="185" height="19" font="3">related LV dysfunction and 17 </text>
<text top="202" left="689" width="184" height="19" font="3">patients (38%) remained with </text>
<text top="220" left="689" width="130" height="19" font="3">normal LV function.   </text>
<text top="239" left="689" width="172" height="19" font="3">The PVC burden was similar </text>
<text top="257" left="689" width="203" height="19" font="3">(26.5% vs 26%) between the two </text>
<text top="275" left="689" width="93" height="19" font="3">groups (p=NS). </text>
<text top="293" left="689" width="137" height="19" font="3">The QRS duration was </text>
<text top="312" left="689" width="212" height="19" font="3">significantly greater for those who </text>
<text top="330" left="689" width="192" height="19" font="3">developed LV dysfunction than </text>
<text top="348" left="689" width="187" height="19" font="3">those who did not (159 vs 142 </text>
<text top="367" left="689" width="100" height="19" font="3">msec, p&lt;0.001). </text>
<text top="385" left="689" width="193" height="19" font="3">A PVC QRS duration &gt;153 msec </text>
<text top="403" left="689" width="200" height="19" font="3">best predicted the development </text>
<text top="422" left="689" width="207" height="19" font="3">of LV dysfunction (sensitivity 82% </text>
<text top="440" left="689" width="128" height="19" font="3">and specificity 75%). </text>
<text top="458" left="689" width="203" height="19" font="3">A non-outflow tract site of origin </text>
<text top="476" left="689" width="155" height="19" font="3">was also an independent </text>
<text top="495" left="689" width="173" height="19" font="3">predictor of LV dysfunction. </text>
<text top="129" left="914" width="142" height="19" font="3">● A QRS duration &gt;153 </text>
<text top="147" left="914" width="145" height="19" font="3">msec of high frequency </text>
<text top="165" left="914" width="149" height="19" font="3">PVCs and a non-outflow </text>
<text top="183" left="914" width="135" height="19" font="3">tract site of origin are </text>
<text top="202" left="914" width="152" height="19" font="3">predictors of developing </text>
<text top="220" left="914" width="99" height="19" font="3">PVC-induced LV </text>
<text top="239" left="914" width="79" height="19" font="3">dysfunction. </text>
<text top="514" left="123" width="87" height="19" font="3">● Deyell et al. </text>
<text top="532" left="123" width="69" height="19" font="3">2012 (455) </text>
<text top="550" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22640894">● </a></text>
<text top="550" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22640894">22640894</a></text>
<text top="550" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22640894"> </a></text>
<text top="514" left="225" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="532" left="225" width="84" height="19" font="3">Single Center </text>
<text top="550" left="225" width="90" height="19" font="3">observational  </text>
<text top="569" left="225" width="3" height="19" font="3"> </text>
<text top="587" left="225" width="68" height="19" font="4"><b>Size:</b>    114 </text>
<text top="605" left="225" width="53" height="19" font="3">patients </text>
<text top="514" left="338" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="532" left="338" width="102" height="19" font="3">114 consecutive </text>
<text top="550" left="338" width="111" height="19" font="3">patients with PVC </text>
<text top="569" left="338" width="98" height="19" font="3">burden &gt;10%/d </text>
<text top="587" left="338" width="73" height="19" font="3">undergoing </text>
<text top="605" left="338" width="119" height="19" font="3">catheter ablation.   </text>
<text top="624" left="338" width="98" height="19" font="3">66 patients had </text>
<text top="642" left="338" width="83" height="19" font="3">preserved LV </text>
<text top="660" left="338" width="99" height="19" font="3">function and 48 </text>
<text top="679" left="338" width="79" height="19" font="3">patients had </text>
<text top="697" left="338" width="76" height="19" font="3">impaired LV </text>
<text top="715" left="338" width="54" height="19" font="3">function </text>
<text top="734" left="338" width="3" height="19" font="3"> </text>
<text top="752" left="338" width="61" height="19" font="4"><b>Exclusion </b></text>
<text top="770" left="338" width="59" height="19" font="4"><b>criteria:</b>   </text>
<text top="514" left="464" width="3" height="19" font="4"><b> </b></text>
<text top="514" left="689" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="532" left="689" width="200" height="19" font="3">Over a median follow-up of 10.6 </text>
<text top="550" left="689" width="182" height="19" font="3">mo, 24 of 48 patients with LV </text>
<text top="569" left="689" width="185" height="19" font="3">dysfunction were classified as </text>
<text top="587" left="689" width="159" height="19" font="3">reversible and 13 of 48 as </text>
<text top="605" left="689" width="186" height="19" font="3">irreversible and 11 of 44 were </text>
<text top="624" left="689" width="196" height="19" font="3">excluded due to failed ablation. </text>
<text top="642" left="689" width="3" height="19" font="3"> </text>
<text top="660" left="689" width="204" height="19" font="3">There was a gradient of VPD QRS </text>
<text top="679" left="689" width="188" height="19" font="3">duration between the control, </text>
<text top="697" left="689" width="211" height="19" font="3">reversible, and irreversible groups </text>
<text top="715" left="689" width="212" height="19" font="3">(mean VPD QRS 135, 158, and 173 </text>
<text top="734" left="689" width="195" height="19" font="3">ms, respectively; p&lt;0.001). This </text>
<text top="752" left="689" width="192" height="19" font="3">gradient persisted even for the </text>
<text top="770" left="689" width="212" height="19" font="3">same site of origin. In multivariate </text>
<text top="514" left="914" width="157" height="19" font="3">● For patients with a PVC </text>
<text top="532" left="914" width="120" height="19" font="3">burden &gt;10%/d, LV </text>
<text top="550" left="914" width="153" height="19" font="3">dysfunction may reverse </text>
<text top="569" left="914" width="153" height="19" font="3">after successful catheter </text>
<text top="587" left="914" width="122" height="19" font="3">ablation.  The more </text>
<text top="605" left="914" width="118" height="19" font="3">prolonged the QRS </text>
<text top="624" left="914" width="147" height="19" font="3">duration of the PVC the </text>
<text top="642" left="914" width="138" height="19" font="3">higher the risk that LV </text>
<text top="660" left="914" width="123" height="19" font="3">dysfunction will not </text>
<text top="679" left="914" width="61" height="19" font="3">improve.  </text>
</page>
<page number="251" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">251 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="338" width="101" height="19" font="3">Structural Heart </text>
<text top="127" left="338" width="50" height="19" font="3">Disease </text>
<text top="145" left="338" width="3" height="19" font="3"> </text>
<text top="109" left="689" width="189" height="19" font="3">analysis, the only independent </text>
<text top="127" left="689" width="166" height="19" font="3">predictor of irreversible LV </text>
<text top="145" left="689" width="195" height="19" font="3">function was VPD QRS duration </text>
<text top="164" left="689" width="204" height="19" font="3">OR: 5.07; 95% CI: 1.22–21.01 per </text>
<text top="182" left="689" width="104" height="19" font="3">10-ms increase). </text>
<text top="201" left="123" width="79" height="19" font="3">● Del Carpio </text>
<text top="219" left="123" width="80" height="19" font="3">Munoz et al. </text>
<text top="238" left="123" width="66" height="19" font="3">2011(456) </text>
<text top="256" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21332870">● </a></text>
<text top="256" left="136" width="61" height="19" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21332870">21332870</a></text>
<text top="256" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21332870"> </a></text>
<text top="201" left="225" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="219" left="225" width="84" height="19" font="3">Single Center </text>
<text top="238" left="225" width="89" height="19" font="3">Observational </text>
<text top="256" left="225" width="3" height="19" font="3"> </text>
<text top="274" left="225" width="60" height="19" font="4"><b>Size:</b>    70 </text>
<text top="292" left="225" width="53" height="19" font="3">patients </text>
<text top="201" left="338" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="219" left="338" width="72" height="19" font="3">70 patients </text>
<text top="238" left="338" width="101" height="19" font="3">undergoing PVC </text>
<text top="256" left="338" width="105" height="19" font="3">ablation without </text>
<text top="274" left="338" width="36" height="19" font="3">SHD.  </text>
<text top="292" left="338" width="61" height="19" font="4"><b>Exclusion </b></text>
<text top="311" left="338" width="59" height="19" font="4"><b>criteria:</b>   </text>
<text top="329" left="338" width="74" height="19" font="3">Known SHD </text>
<text top="201" left="464" width="3" height="19" font="4"><b> </b></text>
<text top="201" left="689" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="219" left="689" width="169" height="19" font="3">Patients with reduced LVEF </text>
<text top="238" left="689" width="190" height="19" font="3">(N=17) as compared to normal </text>
<text top="256" left="689" width="184" height="19" font="3">LVEF (N=53) had an increased </text>
<text top="274" left="689" width="192" height="19" font="3">burden of PVCs (29.3±14.6% vs </text>
<text top="293" left="689" width="182" height="19" font="3">16.7±13.7%, p=0.004), higher </text>
<text top="311" left="689" width="212" height="19" font="3">prevalence of NSVT (VT) [13 (76%) </text>
<text top="329" left="689" width="200" height="19" font="3">vs 21 (40%), p=0.01], longer PVC </text>
<text top="347" left="689" width="148" height="19" font="3">duration (154.3±22.9 vs </text>
<text top="366" left="689" width="173" height="19" font="3">145.6±20.8 ms, p=0.03) and </text>
<text top="384" left="689" width="194" height="19" font="3">higher prevalence of multiform </text>
<text top="402" left="689" width="172" height="19" font="3">PVCs [15 (88%) vs 31 (58%), </text>
<text top="421" left="689" width="54" height="19" font="3">p=0.04]. </text>
<text top="439" left="689" width="151" height="19" font="3">There was no significant </text>
<text top="457" left="689" width="167" height="19" font="3">difference in prevalence of </text>
<text top="476" left="689" width="185" height="19" font="3">sustained VT, QRS duration of </text>
<text top="494" left="689" width="197" height="19" font="3">normally conducted complexes, </text>
<text top="512" left="689" width="204" height="19" font="3">PVC coupling interval, or delay in </text>
<text top="531" left="689" width="167" height="19" font="3">PVC intrinsicoid deflection. </text>
<text top="201" left="914" width="142" height="19" font="3">● A higher PVC burden </text>
<text top="219" left="914" width="121" height="19" font="3">and prolonged QRS </text>
<text top="238" left="914" width="132" height="19" font="3">duration during PVCs </text>
<text top="256" left="914" width="159" height="19" font="3">may predict patients with </text>
<text top="274" left="914" width="148" height="19" font="3">reversible, PVC-induced </text>
<text top="293" left="914" width="28" height="19" font="3">CM. </text>
<text top="550" left="123" width="86" height="19" font="3">● Olgun et al. </text>
<text top="568" left="123" width="69" height="19" font="3">2011 (457) </text>
<text top="586" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21376837">● </a></text>
<text top="586" left="136" width="61" height="19" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21376837">21376837</a></text>
<text top="586" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21376837"> </a></text>
<text top="605" left="123" width="3" height="19" font="3"> </text>
<text top="550" left="225" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="568" left="225" width="84" height="19" font="3">Single Center </text>
<text top="586" left="225" width="89" height="19" font="3">Observational </text>
<text top="605" left="225" width="3" height="19" font="3"> </text>
<text top="623" left="225" width="60" height="19" font="4"><b>Size:</b>    51 </text>
<text top="641" left="225" width="53" height="19" font="3">patients </text>
<text top="550" left="338" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="568" left="338" width="94" height="19" font="3">51 consecutive </text>
<text top="586" left="338" width="83" height="19" font="3">patients with </text>
<text top="605" left="338" width="106" height="19" font="3">PVCs undergoing </text>
<text top="623" left="338" width="105" height="19" font="3">24 h Ambulatory </text>
<text top="641" left="338" width="76" height="19" font="3">Monitoring, </text>
<text top="660" left="338" width="77" height="19" font="3">including 21 </text>
<text top="678" left="338" width="84" height="19" font="3">patients with </text>
<text top="696" left="338" width="81" height="19" font="3">PVC-induced </text>
<text top="714" left="337" width="103" height="19" font="3">cardiomyopathy </text>
<text top="733" left="337" width="98" height="19" font="3">and 30 patients </text>
<text top="751" left="337" width="51" height="19" font="3">without </text>
<text top="769" left="338" width="107" height="19" font="3">cardiomyopathy. </text>
<text top="550" left="464" width="3" height="19" font="4"><b> </b></text>
<text top="550" left="689" width="59" height="19" font="4"><b>Results:   </b></text>
<text top="568" left="689" width="209" height="19" font="3">Fourteen of the 21 patients (67%) </text>
<text top="586" left="689" width="160" height="19" font="3">with cardiomyopathy had </text>
<text top="605" left="689" width="212" height="19" font="3">interpolated PVCs, compared with </text>
<text top="623" left="689" width="166" height="19" font="3">only 6 of 30 patients (20%) </text>
<text top="641" left="689" width="132" height="19" font="3">without PVC-induced </text>
<text top="660" left="689" width="168" height="19" font="3">cardiomyopathy (p&lt;0.001). </text>
<text top="678" left="689" width="196" height="19" font="3">Patients with interpolated PVCs </text>
<text top="696" left="689" width="186" height="19" font="3">had a higher PVC burden than </text>
<text top="714" left="689" width="187" height="19" font="3">patients without interpolation </text>
<text top="733" left="689" width="154" height="19" font="3">(28%±12% vs. 15%±15%; </text>
<text top="751" left="689" width="151" height="19" font="3">p=0.002). The burden of </text>
<text top="769" left="689" width="210" height="19" font="3">interpolated PVCs correlated with </text>
<text top="550" left="914" width="113" height="19" font="3">● The presence of </text>
<text top="568" left="914" width="140" height="19" font="3">interpolated PVCs was </text>
<text top="586" left="914" width="104" height="19" font="3">predictive of the </text>
<text top="605" left="914" width="154" height="19" font="3">presence of PVC -related </text>
<text top="623" left="914" width="107" height="19" font="3">cardiomyopathy. </text>
<text top="641" left="914" width="160" height="19" font="3">Interpolation may play an </text>
<text top="660" left="914" width="131" height="19" font="3">important role in the </text>
<text top="678" left="914" width="115" height="19" font="3">generation of PVC-</text>
<text top="696" left="914" width="159" height="19" font="3">induced cardiomyopathy. </text>
</page>
<page number="252" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">252 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="338" width="3" height="19" font="3"> </text>
<text top="127" left="338" width="61" height="19" font="4"><b>Exclusion </b></text>
<text top="145" left="338" width="59" height="19" font="4"><b>criteria:</b>   </text>
<text top="164" left="338" width="101" height="19" font="3">Structural Heart </text>
<text top="182" left="338" width="50" height="19" font="3">Disease </text>
<text top="200" left="338" width="3" height="19" font="3"> </text>
<text top="109" left="689" width="126" height="19" font="3">the presence of PVC </text>
<text top="127" left="689" width="190" height="19" font="3">cardiomyopathy (21%±30% vs. </text>
<text top="145" left="689" width="180" height="19" font="3">4%±13%; p=0.008). Both PVC </text>
<text top="164" left="689" width="157" height="19" font="3">burden and interpolation </text>
<text top="182" left="689" width="183" height="19" font="3">independently predicted PVC-</text>
<text top="200" left="689" width="185" height="19" font="3">induced cardiomyopathy (OR: </text>
<text top="219" left="689" width="200" height="19" font="3">1.07; 95% CI: 1.01–1.13, p=0.02; </text>
<text top="237" left="689" width="210" height="19" font="3">and OR: 4.43; 95% CI: 1.06–18.48, </text>
<text top="255" left="689" width="160" height="19" font="3">p=0.04, respectively). The </text>
<text top="273" left="689" width="207" height="19" font="3">presence of ventriculoatrial block </text>
<text top="292" left="689" width="172" height="19" font="3">at a ventricular pacing cycle </text>
<text top="310" left="689" width="203" height="19" font="3">length of 600 ms correlated with </text>
<text top="329" left="689" width="182" height="19" font="3">the presence of interpolation </text>
<text top="347" left="689" width="149" height="19" font="3">(p=0.004). Patients with </text>
<text top="365" left="689" width="200" height="19" font="3">interpolation had a longer mean </text>
<text top="383" left="689" width="208" height="19" font="3">ventriculoatrial block cycle length </text>
<text top="402" left="689" width="136" height="19" font="3">than patients without </text>
<text top="420" left="689" width="195" height="19" font="3">interpolated PVCs (520±110 ms </text>
<text top="438" left="689" width="148" height="19" font="3">vs. 394±92 ms; p=0.01). </text>
<text top="457" left="123" width="74" height="19" font="3">● Hasdemir </text>
<text top="476" left="123" width="67" height="19" font="3">et al. 2011 </text>
<text top="494" left="123" width="35" height="19" font="3">(458) </text>
<text top="512" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21235667">● </a></text>
<text top="512" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21235667">21235667</a></text>
<text top="512" left="197" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21235667"><b> </b></a></text>
<text top="457" left="225" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="476" left="225" width="84" height="19" font="3">Single Center </text>
<text top="494" left="225" width="89" height="19" font="3">Observational </text>
<text top="512" left="225" width="3" height="19" font="3"> </text>
<text top="531" left="225" width="68" height="19" font="4"><b>Size:</b>    247 </text>
<text top="549" left="225" width="53" height="19" font="3">patients </text>
<text top="457" left="338" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="476" left="338" width="110" height="19" font="3">Seventeen of 247 </text>
<text top="494" left="338" width="84" height="19" font="3">patients with </text>
<text top="512" left="338" width="105" height="19" font="3">PVCs (6.8%) who </text>
<text top="531" left="338" width="102" height="19" font="3">had Ambulatory </text>
<text top="549" left="338" width="97" height="19" font="3">monitoring and </text>
<text top="567" left="338" width="64" height="19" font="3">ECHO had </text>
<text top="586" left="338" width="74" height="19" font="3">tachycardia </text>
<text top="604" left="338" width="52" height="19" font="3">induced </text>
<text top="622" left="338" width="103" height="19" font="3">cardiomyopathy </text>
<text top="640" left="338" width="56" height="19" font="3">(TICMP)  </text>
<text top="659" left="338" width="3" height="19" font="3"> </text>
<text top="677" left="338" width="61" height="19" font="4"><b>Exclusion </b></text>
<text top="695" left="338" width="59" height="19" font="4"><b>criteria:</b>   </text>
<text top="714" left="338" width="101" height="19" font="3">Structural Heart </text>
<text top="732" left="338" width="50" height="19" font="3">Disease </text>
<text top="750" left="338" width="3" height="19" font="3"> </text>
<text top="457" left="464" width="3" height="19" font="4"><b> </b></text>
<text top="457" left="689" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="476" left="689" width="208" height="19" font="3">Patients with TICMP compared to </text>
<text top="494" left="689" width="181" height="19" font="3">patients with preserved LVEF </text>
<text top="512" left="689" width="207" height="19" font="3">were more likely to be male (65% </text>
<text top="531" left="689" width="133" height="19" font="3">vs 39%, p=0.043) and </text>
<text top="549" left="689" width="165" height="19" font="3">asymptomatic (29% vs 9%, </text>
<text top="567" left="689" width="209" height="19" font="3">p=0.018), and were more likely to </text>
<text top="586" left="689" width="211" height="19" font="3">have higher PVC burden (29.4±9.2 </text>
<text top="604" left="689" width="203" height="19" font="3">vs 8.1±7.4, p&lt;0.001), persistence </text>
<text top="622" left="689" width="205" height="19" font="3">of PVCs throughout the day (65% </text>
<text top="640" left="689" width="199" height="19" font="3">vs 22%, p=0.001), and repetitive </text>
<text top="659" left="689" width="196" height="19" font="3">monomorphic VT (24% vs 0.9%, </text>
<text top="677" left="689" width="200" height="19" font="3">p&lt;0.001). PVC burden of 16% by </text>
<text top="695" left="689" width="212" height="19" font="3">ROC curve analysis best separated </text>
<text top="714" left="689" width="150" height="19" font="3">the patients with TICMP </text>
<text top="732" left="689" width="165" height="19" font="3">compared to patients with </text>
<text top="750" left="689" width="207" height="19" font="3">preserved LVEF (sensitivity 100%, </text>
<text top="457" left="914" width="142" height="19" font="3">● TICMP was relatively </text>
<text top="476" left="914" width="154" height="20" font="3">common (∼1 in every 15 </text>
<text top="494" left="914" width="134" height="19" font="3">patients) in our study </text>
<text top="512" left="914" width="100" height="19" font="3">population. The </text>
<text top="531" left="914" width="159" height="19" font="3">predictors of TICMP were </text>
<text top="549" left="914" width="153" height="19" font="3">male gender, absence of </text>
<text top="567" left="914" width="146" height="19" font="3">symptoms, PVC burden </text>
<text top="586" left="914" width="145" height="19" font="3">of ≥16%, persistence of </text>
<text top="604" left="914" width="159" height="19" font="3">PVCs throughout the day, </text>
<text top="622" left="914" width="125" height="19" font="3">and the presence of </text>
<text top="640" left="914" width="152" height="19" font="3">repetitive monomorphic </text>
<text top="659" left="914" width="19" height="19" font="3">VT </text>
</page>
<page number="253" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">253 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="689" width="204" height="19" font="3">specificity 87%, area under curve </text>
<text top="127" left="689" width="38" height="19" font="3">0.96). </text>
<text top="146" left="123" width="74" height="19" font="3">● Baman et </text>
<text top="164" left="123" width="87" height="19" font="3">al. 2010 (459) </text>
<text top="183" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20348027">● </a></text>
<text top="183" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20348027">20348027</a></text>
<text top="183" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20348027"> </a></text>
<text top="201" left="123" width="3" height="19" font="4"><b> </b></text>
<text top="146" left="225" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="164" left="225" width="84" height="19" font="3">Single Center </text>
<text top="183" left="225" width="89" height="19" font="3">Observational </text>
<text top="201" left="225" width="3" height="19" font="3"> </text>
<text top="219" left="225" width="68" height="19" font="4"><b>Size:</b>    174 </text>
<text top="238" left="225" width="53" height="19" font="3">patients </text>
<text top="146" left="338" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="164" left="338" width="77" height="19" font="3">Consecutive </text>
<text top="183" left="338" width="81" height="19" font="3">group of 174 </text>
<text top="201" left="338" width="107" height="19" font="3">patients referred </text>
<text top="219" left="338" width="90" height="19" font="3">for ablation of </text>
<text top="238" left="338" width="57" height="19" font="3">frequent </text>
<text top="256" left="338" width="97" height="19" font="3">idiopathic PVCs </text>
<text top="274" left="338" width="3" height="19" font="3"> </text>
<text top="292" left="338" width="61" height="19" font="4"><b>Exclusion </b></text>
<text top="311" left="338" width="59" height="19" font="4"><b>criteria:</b>   </text>
<text top="329" left="338" width="101" height="19" font="3">Structural Heart </text>
<text top="347" left="338" width="50" height="19" font="3">Disease </text>
<text top="366" left="338" width="3" height="19" font="3"> </text>
<text top="384" left="338" width="3" height="19" font="3"> </text>
<text top="146" left="464" width="3" height="19" font="4"><b> </b></text>
<text top="146" left="689" width="59" height="19" font="4"><b>Results:   </b></text>
<text top="164" left="689" width="209" height="19" font="3">A reduced LVEF (mean 0.37±0.10) </text>
<text top="183" left="689" width="206" height="19" font="3">was present in 57 of 174 patients </text>
<text top="201" left="689" width="203" height="19" font="3">(33%). Patients with a decreased </text>
<text top="219" left="689" width="184" height="19" font="3">EF had a mean PVC burden of </text>
<text top="238" left="689" width="212" height="19" font="3">33%±13% as compared with those </text>
<text top="256" left="689" width="171" height="19" font="3">with normal left ventricular </text>
<text top="274" left="689" width="203" height="19" font="3">function 13%±12% (p&lt;0.0001). A </text>
<text top="293" left="689" width="157" height="19" font="3">PVC burden of &gt;24% best </text>
<text top="311" left="689" width="205" height="19" font="3">separated the patient population </text>
<text top="329" left="689" width="200" height="19" font="3">with impaired as compared with </text>
<text top="347" left="689" width="212" height="19" font="3">preserved left ventricular function </text>
<text top="366" left="689" width="199" height="19" font="3">(sensitivity 79%, specificity 78%, </text>
<text top="384" left="689" width="212" height="19" font="3">area under curve 0.89) The lowest </text>
<text top="402" left="689" width="157" height="19" font="3">PVC burden resulting in a </text>
<text top="421" left="689" width="193" height="19" font="3">reversible cardiomyopathy was </text>
<text top="439" left="689" width="33" height="19" font="3">10%. </text>
<text top="146" left="914" width="152" height="19" font="3">● A PVC burden of &gt;24% </text>
<text top="164" left="914" width="119" height="19" font="3">was independently </text>
<text top="183" left="914" width="127" height="19" font="3">associated with PVC-</text>
<text top="201" left="914" width="159" height="19" font="3">induced cardiomyopathy. </text>
<text top="458" left="123" width="83" height="19" font="3">● Kanei et al. </text>
<text top="476" left="123" width="69" height="19" font="3">2008 (460) </text>
<text top="495" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20348027">● </a></text>
<text top="495" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20348027">20348027</a></text>
<text top="495" left="197" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20348027"><b> </b></a></text>
<text top="458" left="225" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="476" left="225" width="84" height="19" font="3">Single Center </text>
<text top="495" left="225" width="89" height="19" font="3">Observational </text>
<text top="513" left="225" width="3" height="19" font="3"> </text>
<text top="531" left="225" width="68" height="19" font="4"><b>Size:</b>    108 </text>
<text top="550" left="225" width="53" height="19" font="3">patients </text>
<text top="458" left="338" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="476" left="338" width="77" height="19" font="3">Consecutive </text>
<text top="495" left="338" width="81" height="19" font="3">group of 108 </text>
<text top="513" left="338" width="107" height="19" font="3">patients referred </text>
<text top="531" left="338" width="104" height="19" font="3">for evaluation of </text>
<text top="550" left="338" width="57" height="19" font="3">frequent </text>
<text top="568" left="338" width="97" height="19" font="3">idiopathic PVCs </text>
<text top="586" left="338" width="94" height="19" font="3">from the RVOT </text>
<text top="605" left="338" width="3" height="19" font="3"> </text>
<text top="623" left="338" width="61" height="19" font="4"><b>Exclusion </b></text>
<text top="641" left="338" width="55" height="19" font="4"><b>criteria:</b>  </text>
<text top="660" left="338" width="101" height="19" font="3">Structural Heart </text>
<text top="678" left="338" width="50" height="19" font="3">Disease </text>
<text top="696" left="338" width="3" height="19" font="3"> </text>
<text top="458" left="464" width="3" height="19" font="4"><b> </b></text>
<text top="458" left="689" width="52" height="19" font="4"><b>Results: </b></text>
<text top="476" left="689" width="209" height="19" font="3">24 patients had &lt;1000 PVCs/24 h, </text>
<text top="495" left="689" width="181" height="19" font="3">55 patients had 1000–10,000 </text>
<text top="513" left="689" width="194" height="19" font="3">PVCs/24 h, and 29 patients had </text>
<text top="531" left="689" width="148" height="19" font="3">≥10,000 PVCs/24 h. The </text>
<text top="550" left="689" width="206" height="19" font="3">prevalence of LV dysfunction was </text>
<text top="568" left="689" width="195" height="19" font="3">4%, 12%, and 34%, respectively </text>
<text top="586" left="689" width="204" height="19" font="3">(p=0.02). With logistic regression </text>
<text top="605" left="689" width="210" height="19" font="3">analysis, non-sustained VT was an </text>
<text top="623" left="689" width="175" height="19" font="3">independent predictor of LV </text>
<text top="641" left="689" width="206" height="19" font="3">dysfunction with OR: 3.6; 95% CI: </text>
<text top="660" left="689" width="65" height="19" font="3">1.3–10.1). </text>
<text top="458" left="914" width="134" height="19" font="3">● A new index, which </text>
<text top="476" left="914" width="160" height="19" font="3">incorporates PVC burden, </text>
<text top="495" left="914" width="152" height="19" font="3">QRS width and presence </text>
<text top="513" left="914" width="149" height="19" font="3">of SHD or suspected EPI </text>
<text top="531" left="914" width="158" height="19" font="3">origin that best predicted </text>
<text top="550" left="914" width="68" height="19" font="3">PVC-CMP.  </text>
<text top="715" left="123" width="76" height="19" font="3">● Hamon et </text>
<text top="733" left="123" width="87" height="19" font="3">al. 2016 (461) </text>
<text top="752" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26924618">● </a></text>
<text top="752" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26924618">26924618</a></text>
<text top="752" left="197" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26924618"><b> </b></a></text>
<text top="715" left="225" width="81" height="19" font="4"><b>Study type:   </b></text>
<text top="733" left="225" width="84" height="19" font="3">Single Center </text>
<text top="752" left="225" width="89" height="19" font="3">Observational<b> </b></text>
<text top="770" left="225" width="3" height="19" font="4"><b> </b></text>
<text top="715" left="338" width="118" height="19" font="4"><b>Inclusion criteria</b>:   </text>
<text top="733" left="338" width="102" height="19" font="3">107 consecutive </text>
<text top="752" left="338" width="111" height="19" font="3">patients (69 men; </text>
<text top="770" left="338" width="74" height="19" font="3">mean age = </text>
<text top="715" left="464" width="3" height="19" font="4"><b> </b></text>
<text top="715" left="689" width="52" height="19" font="4"><b>Results: </b></text>
<text top="733" left="689" width="168" height="19" font="3">Patients with decreased LV </text>
<text top="752" left="689" width="167" height="19" font="3">function had a greater PVC </text>
<text top="770" left="689" width="171" height="19" font="3">burden on a 24-hour Holter </text>
<text top="715" left="914" width="144" height="19" font="3">● LV dysfunction in the </text>
<text top="733" left="914" width="122" height="19" font="3">setting of frequent, </text>
<text top="752" left="914" width="127" height="19" font="3">idiopathic PVCs may </text>
<text top="770" left="914" width="122" height="19" font="3">represent a form of </text>
</page>
<page number="254" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">254 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="225" width="68" height="19" font="4"><b>Size:    </b>107 </text>
<text top="127" left="225" width="53" height="19" font="3">patients<b> </b></text>
<text top="109" left="338" width="86" height="19" font="3">56±16 y) with </text>
<text top="127" left="338" width="84" height="19" font="3">frequent PVC </text>
<text top="145" left="338" width="84" height="19" font="3">(23.1±11.5%) </text>
<text top="164" left="338" width="103" height="19" font="3">referred for PVC </text>
<text top="182" left="338" width="57" height="19" font="3">ablation. </text>
<text top="200" left="338" width="3" height="19" font="3"> </text>
<text top="218" left="338" width="61" height="19" font="4"><b>Exclusion </b></text>
<text top="237" left="338" width="59" height="19" font="4"><b>criteria:</b>   </text>
<text top="255" left="338" width="101" height="19" font="3">Structural Heart </text>
<text top="273" left="338" width="50" height="19" font="3">Disease </text>
<text top="292" left="338" width="3" height="19" font="3"> </text>
<text top="109" left="689" width="168" height="19" font="3">monitor than patients with </text>
<text top="127" left="689" width="152" height="19" font="3">normal EF (37%±13% vs. </text>
<text top="145" left="689" width="197" height="19" font="3">11%±10% of all QRS complexes; </text>
<text top="164" left="689" width="211" height="19" font="3">p&lt;0.0001). There was a significant </text>
<text top="182" left="689" width="199" height="19" font="3">inverse correlation between the </text>
<text top="200" left="689" width="187" height="19" font="3">PVC burden and the EF before </text>
<text top="219" left="689" width="173" height="19" font="3">ablation (r=0.73, p&lt;0.0001). </text>
<text top="237" left="689" width="170" height="19" font="3">PVCs originated in the right </text>
<text top="255" left="689" width="186" height="19" font="3">ventricular outflow tract in 31 </text>
<text top="273" left="689" width="172" height="19" font="3">(52%) of 60 patients, the LV </text>
<text top="292" left="689" width="181" height="19" font="3">outflow tract in 9 (15%) of 60 </text>
<text top="310" left="689" width="199" height="19" font="3">patients, and in other sites in 13 </text>
<text top="329" left="689" width="197" height="19" font="3">(22%) of 60 patients. The site of </text>
<text top="347" left="689" width="146" height="19" font="3">PVC origin could not be </text>
<text top="365" left="689" width="186" height="19" font="3">determined in seven patients. </text>
<text top="383" left="689" width="153" height="19" font="3">Ablation was completely </text>
<text top="402" left="689" width="209" height="19" font="3">successful in 48 (80%) patients. In </text>
<text top="420" left="689" width="182" height="19" font="3">patients with an abnormal EF </text>
<text top="438" left="689" width="174" height="19" font="3">before ablation, LV function </text>
<text top="457" left="689" width="178" height="19" font="3">normalized in 18 (82%) of 22 </text>
<text top="475" left="689" width="212" height="19" font="3">patients from a baseline of 34% to </text>
<text top="493" left="689" width="204" height="19" font="3">59%±7% (p&lt;0.0001) within 6 mo. </text>
<text top="512" left="689" width="159" height="19" font="3">In the 4 patients in whom </text>
<text top="530" left="689" width="194" height="19" font="3">ablation was ineffective, the EF </text>
<text top="548" left="689" width="198" height="19" font="3">further declined from 34%±10% </text>
<text top="566" left="689" width="169" height="19" font="3">to 25%±7% (p=0.06) during </text>
<text top="585" left="689" width="212" height="19" font="3">follow-up. In a control group of 11 </text>
<text top="603" left="689" width="166" height="19" font="3">patients with a similar PVC </text>
<text top="621" left="689" width="202" height="19" font="3">burden (30%±8%) and a reduced </text>
<text top="640" left="689" width="166" height="19" font="3">EF (28%±13%) who did not </text>
<text top="658" left="689" width="153" height="19" font="3">undergo ablation, the EF </text>
<text top="676" left="689" width="187" height="19" font="3">remained unchanged in 10/11 </text>
<text top="695" left="689" width="207" height="19" font="3">patients over 19±17 mo of follow-</text>
<text top="713" left="689" width="190" height="19" font="3">up and one patient underwent </text>
<text top="731" left="689" width="137" height="19" font="3">heart transplantation. </text>
<text top="109" left="914" width="156" height="19" font="3">cardiomyopathy that can </text>
<text top="127" left="914" width="149" height="19" font="3">be reversed by catheter </text>
<text top="145" left="914" width="130" height="19" font="3">ablation of the PVCs. </text>
</page>
<page number="255" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">255 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="88" height="19" font="3">● Bogun et al. </text>
<text top="127" left="123" width="69" height="19" font="3">2007 (462) </text>
<text top="145" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17599667">● </a></text>
<text top="145" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17599667">17599667</a></text>
<text top="145" left="197" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17599667"><b> </b></a></text>
<text top="109" left="225" width="81" height="19" font="4"><b>Study type:   </b></text>
<text top="127" left="225" width="84" height="19" font="3">Single Center </text>
<text top="145" left="225" width="89" height="19" font="3">Observational </text>
<text top="164" left="225" width="3" height="19" font="4"><b> </b></text>
<text top="182" left="225" width="60" height="19" font="4"><b>Size</b>:    60 </text>
<text top="200" left="225" width="53" height="19" font="3">patients<b> </b></text>
<text top="109" left="338" width="118" height="19" font="4"><b>Inclusion criteria:   </b></text>
<text top="127" left="338" width="94" height="19" font="3">60 consecutive </text>
<text top="145" left="338" width="83" height="19" font="3">patients with </text>
<text top="164" left="338" width="68" height="19" font="3">idiopathic, </text>
<text top="182" left="338" width="90" height="19" font="3">frequent PVCs </text>
<text top="200" left="338" width="63" height="19" font="3">(&gt;10/h), a </text>
<text top="219" left="338" width="89" height="19" font="3">reduced LV EF </text>
<text top="237" left="338" width="64" height="19" font="3">(EF; mean </text>
<text top="255" left="338" width="94" height="19" font="3">34%±13%) was </text>
<text top="273" left="338" width="83" height="19" font="3">present in 22 </text>
<text top="292" left="338" width="92" height="19" font="3">(37%) patients </text>
<text top="310" left="338" width="3" height="19" font="3"> </text>
<text top="328" left="338" width="61" height="19" font="4"><b>Exclusion </b></text>
<text top="347" left="338" width="55" height="19" font="4"><b>criteria:</b>  </text>
<text top="365" left="338" width="101" height="19" font="3">Structural Heart </text>
<text top="383" left="338" width="50" height="19" font="3">Disease<b> </b></text>
<text top="401" left="338" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="464" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="689" width="52" height="19" font="4"><b>Results: </b></text>
<text top="127" left="689" width="168" height="19" font="3">Patients with decreased LV </text>
<text top="145" left="689" width="167" height="19" font="3">function had a greater PVC </text>
<text top="164" left="689" width="202" height="19" font="3">burden on a 24 h Holter monitor </text>
<text top="182" left="689" width="180" height="19" font="3">than patients with normal EF </text>
<text top="200" left="689" width="212" height="19" font="3">(37%±13% vs. 11%±10% of all QRS </text>
<text top="219" left="689" width="207" height="19" font="3">complexes; p&lt;0.0001). There was </text>
<text top="237" left="689" width="194" height="19" font="3">a significant inverse correlation </text>
<text top="255" left="689" width="206" height="19" font="3">between the PVC burden and the </text>
<text top="273" left="689" width="166" height="19" font="3">EF before ablation (r=0.73, </text>
<text top="292" left="689" width="69" height="19" font="3">p&lt;0.0001). </text>
<text top="310" left="689" width="170" height="19" font="3">PVCs originated in the right </text>
<text top="328" left="689" width="186" height="19" font="3">ventricular outflow tract in 31 </text>
<text top="347" left="689" width="172" height="19" font="3">(52%) of 60 patients, the LV </text>
<text top="365" left="689" width="181" height="19" font="3">outflow tract in 9 (15%) of 60 </text>
<text top="383" left="689" width="199" height="19" font="3">patients, and in other sites in 13 </text>
<text top="402" left="689" width="197" height="19" font="3">(22%) of 60 patients. The site of </text>
<text top="420" left="689" width="146" height="19" font="3">PVC origin could not be </text>
<text top="438" left="689" width="186" height="19" font="3">determined in seven patients. </text>
<text top="457" left="689" width="153" height="19" font="3">Ablation was completely </text>
<text top="475" left="689" width="209" height="19" font="3">successful in 48 (80%) patients. In </text>
<text top="493" left="689" width="182" height="19" font="3">patients with an abnormal EF </text>
<text top="512" left="689" width="173" height="19" font="3">before ablation, LV function </text>
<text top="530" left="689" width="178" height="19" font="3">normalized in 18 (82%) of 22 </text>
<text top="548" left="689" width="212" height="19" font="3">patients from a baseline of 34% to </text>
<text top="566" left="689" width="204" height="19" font="3">59%±7% (p&lt;0.0001) within 6 mo. </text>
<text top="585" left="689" width="159" height="19" font="3">In the 4 patients in whom </text>
<text top="603" left="689" width="194" height="19" font="3">ablation was ineffective, the EF </text>
<text top="621" left="689" width="198" height="19" font="3">further declined from 34%±10% </text>
<text top="640" left="689" width="169" height="19" font="3">to 25%±7% (p=0.06) during </text>
<text top="658" left="689" width="212" height="19" font="3">follow-up. In a control group of 11 </text>
<text top="676" left="689" width="166" height="19" font="3">patients with a similar PVC </text>
<text top="695" left="689" width="202" height="19" font="3">burden (30%±8%) and a reduced </text>
<text top="713" left="689" width="166" height="19" font="3">EF (28%±13%) who did not </text>
<text top="731" left="689" width="153" height="19" font="3">undergo ablation, the EF </text>
<text top="750" left="689" width="187" height="19" font="3">remained unchanged in 10/11 </text>
<text top="109" left="914" width="144" height="19" font="3">● LV dysfunction in the </text>
<text top="127" left="914" width="122" height="19" font="3">setting of frequent, </text>
<text top="145" left="914" width="127" height="19" font="3">idiopathic PVCs may </text>
<text top="164" left="914" width="122" height="19" font="3">represent a form of </text>
<text top="182" left="914" width="156" height="19" font="3">cardiomyopathy that can </text>
<text top="200" left="914" width="149" height="19" font="3">be reversed by catheter </text>
<text top="219" left="914" width="126" height="19" font="3">ablation of the PVCs </text>
</page>
<page number="256" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">256 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="689" width="207" height="19" font="3">patients over 19±17 mo of follow-</text>
<text top="127" left="689" width="19" height="19" font="3">up<b> </b></text>
<text top="169" left="123" width="87" height="19" font="3">● Zhong et al. </text>
<text top="188" left="123" width="69" height="19" font="3">2014 (463) </text>
<text top="206" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24157533">● </a></text>
<text top="206" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24157533">24157533</a></text>
<text top="206" left="197" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24157533"><b> </b></a></text>
<text top="169" left="225" width="76" height="19" font="4"><b>Study Type: </b></text>
<text top="188" left="225" width="84" height="19" font="3">Single Center </text>
<text top="206" left="225" width="74" height="19" font="3">Prospective </text>
<text top="224" left="225" width="87" height="19" font="3">observational </text>
<text top="243" left="225" width="3" height="19" font="4"><b> </b></text>
<text top="261" left="225" width="35" height="19" font="4"><b>Size:  </b></text>
<text top="279" left="225" width="83" height="19" font="3">510 patients  </text>
<text top="169" left="338" width="113" height="19" font="4"><b>Inclusion Criteria: </b></text>
<text top="188" left="338" width="110" height="19" font="3">510 patients with </text>
<text top="206" left="338" width="90" height="19" font="3">frequent PVCs </text>
<text top="224" left="338" width="82" height="19" font="3">(&gt;1000/24 h) </text>
<text top="243" left="338" width="83" height="19" font="3">were treated </text>
<text top="261" left="338" width="101" height="19" font="3">either by RFA or </text>
<text top="279" left="338" width="93" height="19" font="3">with AAD from </text>
<text top="298" left="338" width="84" height="19" font="3">January 2005 </text>
<text top="316" left="338" width="52" height="19" font="3">through </text>
<text top="334" left="338" width="104" height="19" font="3">December 2010. </text>
<text top="353" left="338" width="95" height="19" font="3">Data from 24 h </text>
<text top="371" left="338" width="113" height="19" font="3">Holter monitoring </text>
<text top="389" left="338" width="26" height="19" font="3">and </text>
<text top="408" left="338" width="113" height="19" font="3">echocardiography </text>
<text top="426" left="338" width="104" height="19" font="3">before and 6–12 </text>
<text top="444" left="338" width="56" height="19" font="3">mo after </text>
<text top="462" left="338" width="100" height="19" font="3">treatment were </text>
<text top="481" left="338" width="65" height="19" font="3">compared </text>
<text top="499" left="338" width="81" height="19" font="3">between the </text>
<text top="517" left="338" width="77" height="19" font="3">treatment 2 </text>
<text top="536" left="338" width="45" height="19" font="3">groups </text>
<text top="554" left="338" width="3" height="19" font="3"> </text>
<text top="572" left="338" width="61" height="19" font="4"><b>Exclusion </b></text>
<text top="590" left="338" width="59" height="19" font="4"><b>criteria:</b>   </text>
<text top="609" left="338" width="101" height="19" font="3">Structural Heart </text>
<text top="627" left="338" width="50" height="19" font="3">Disease </text>
<text top="645" left="338" width="3" height="19" font="3"> </text>
<text top="169" left="464" width="3" height="19" font="4"><b> </b></text>
<text top="169" left="689" width="52" height="19" font="4"><b>Results: </b></text>
<text top="188" left="689" width="189" height="19" font="3">Of 510 patients identified, 215 </text>
<text top="206" left="689" width="189" height="19" font="3">(40%) underwent RFA and 295 </text>
<text top="224" left="689" width="154" height="19" font="3">(60%) received AAD. The </text>
<text top="243" left="689" width="197" height="19" font="3">reduction in PVC frequency was </text>
<text top="261" left="689" width="194" height="19" font="3">greater by RFA than with AAD (-</text>
<text top="279" left="689" width="172" height="19" font="3">21,799/24 h vs -8,376/24 h; </text>
<text top="298" left="689" width="209" height="19" font="3">p&lt;0.001). The LVEF was increased </text>
<text top="316" left="689" width="207" height="19" font="3">significantly after RFA (53%–56%; </text>
<text top="334" left="689" width="207" height="19" font="3">p&lt;0.001) but not after AAD (52%–</text>
<text top="353" left="689" width="174" height="19" font="3">52%; p=0.6) therapy. Of 121 </text>
<text top="371" left="689" width="212" height="19" font="3">(24%) patients with reduced LVEF, </text>
<text top="389" left="689" width="204" height="19" font="3">39 (32%) had LVEF normalization </text>
<text top="408" left="689" width="205" height="19" font="3">≥50%. LVEF was restored in 25 of </text>
<text top="426" left="689" width="176" height="19" font="3">53 (47%) patients in the RFA </text>
<text top="444" left="689" width="188" height="19" font="3">group compared with 14 of 68 </text>
<text top="462" left="689" width="199" height="19" font="3">(21%) patients in the AAD group </text>
<text top="481" left="689" width="199" height="19" font="3">(p=0.003). PVC coupling interval </text>
<text top="499" left="689" width="193" height="19" font="3">less than 450 ms, less impaired </text>
<text top="517" left="689" width="205" height="19" font="3">left ventricular function, and RFA </text>
<text top="536" left="689" width="197" height="19" font="3">were independent predictors of </text>
<text top="554" left="689" width="207" height="19" font="3">LVEF normalization performed by </text>
<text top="572" left="689" width="168" height="19" font="3">using multivariate analysis. </text>
<text top="169" left="914" width="126" height="19" font="3">● RFA appears to be </text>
<text top="188" left="914" width="154" height="19" font="3">more effective than AAD </text>
<text top="206" left="914" width="131" height="19" font="3">in PVC reduction and </text>
<text top="224" left="914" width="120" height="19" font="3">LVEF normalization </text>
<text top="665" left="123" width="81" height="19" font="3">● Kawamura </text>
<text top="683" left="123" width="67" height="19" font="3">et al. 2014 </text>
<text top="701" left="123" width="35" height="19" font="3">(464) </text>
<text top="719" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24157533">● </a></text>
<text top="719" left="136" width="61" height="19" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24157533">24157533</a></text>
<text top="719" left="197" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24157533"><b> </b></a></text>
<text top="664" left="225" width="81" height="19" font="4"><b>Study type:   </b></text>
<text top="683" left="225" width="84" height="19" font="3">Single Center </text>
<text top="701" left="225" width="89" height="19" font="3">Observational </text>
<text top="719" left="225" width="3" height="19" font="4"><b> </b></text>
<text top="738" left="225" width="68" height="19" font="4"><b>Size</b>:    214 </text>
<text top="756" left="225" width="53" height="19" font="3">patients<b> </b></text>
<text top="664" left="338" width="118" height="19" font="4"><b>Inclusion criteria:   </b></text>
<text top="683" left="338" width="79" height="19" font="3">214 patients </text>
<text top="701" left="338" width="73" height="19" font="3">undergoing </text>
<text top="719" left="338" width="65" height="19" font="3">successful </text>
<text top="738" left="338" width="103" height="19" font="3">ablation of PVCs </text>
<text top="756" left="338" width="112" height="19" font="3">who had no other </text>
<text top="664" left="464" width="3" height="19" font="4"><b> </b></text>
<text top="664" left="689" width="52" height="19" font="4"><b>Results: </b></text>
<text top="683" left="689" width="198" height="19" font="3">Among these patients, 51 (24%) </text>
<text top="701" left="689" width="203" height="19" font="3">had reduced LVEF and 163 (76%) </text>
<text top="719" left="689" width="203" height="19" font="3">had normal LV function. Patients </text>
<text top="738" left="689" width="150" height="19" font="3">with LV dysfunction had </text>
<text top="756" left="689" width="173" height="19" font="3">significantly longer coupling </text>
<text top="774" left="689" width="140" height="19" font="3">interval (CI) dispersion </text>
<text top="665" left="914" width="149" height="19" font="3">● In addition to the PVC </text>
<text top="683" left="914" width="158" height="19" font="3">burden, the CI-dispersion </text>
<text top="701" left="914" width="145" height="19" font="3">and BMI are associated </text>
<text top="719" left="914" width="111" height="19" font="3">with PVC-induced </text>
<text top="738" left="914" width="103" height="19" font="3">cardiomyopathy </text>
</page>
<page number="257" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">257 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="338" width="60" height="19" font="3">causes of </text>
<text top="127" left="338" width="103" height="19" font="3">cardiomyopathy </text>
<text top="145" left="338" width="3" height="19" font="3"> </text>
<text top="164" left="338" width="61" height="19" font="4"><b>Exclusion </b></text>
<text top="182" left="338" width="52" height="19" font="4"><b>criteria: </b></text>
<text top="200" left="338" width="101" height="19" font="3">Structural Heart </text>
<text top="219" left="338" width="50" height="19" font="3">Disease </text>
<text top="237" left="338" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="689" width="196" height="19" font="3">(maximum-CI-minimum-CI) and </text>
<text top="127" left="689" width="172" height="19" font="3">had significantly higher PVC </text>
<text top="145" left="689" width="197" height="19" font="3">burden compared to those with </text>
<text top="164" left="689" width="211" height="19" font="3">normal LV function (CI-dispersion: </text>
<text top="182" left="689" width="184" height="19" font="3">115±25 msec vs. 94±19 msec; </text>
<text top="200" left="689" width="185" height="19" font="3">p&lt;0.001; PVC burden: 19% vs. </text>
<text top="219" left="689" width="172" height="19" font="3">15%; p=0.04). Furthermore, </text>
<text top="237" left="689" width="203" height="19" font="3">patients with LV dysfunction had </text>
<text top="255" left="689" width="186" height="19" font="3">significantly higher body mass </text>
<text top="273" left="689" width="193" height="19" font="3">index (BMI) compared to those </text>
<text top="292" left="689" width="205" height="19" font="3">with normal LV function (BMI&gt;30 </text>
<text top="310" left="689" width="32" height="19" font="3">kg/m</text>
<text top="310" left="720" width="5" height="12" font="15">2</text>
<text top="310" left="725" width="151" height="19" font="3">; 37% vs. 13%; p=0.001). </text>
<text top="328" left="689" width="167" height="19" font="3">Logistic regression analysis </text>
<text top="347" left="689" width="194" height="19" font="3">showed that CI-dispersion, PVC </text>
<text top="365" left="689" width="168" height="19" font="3">burden, and BMI (&gt;30 kg/m</text>
<text top="365" left="857" width="5" height="12" font="15">2</text>
<text top="365" left="862" width="32" height="19" font="3">) are </text>
<text top="383" left="689" width="192" height="19" font="3">independent predictors of PVC-</text>
<text top="402" left="689" width="159" height="19" font="3">induced cardiomyopathy. </text>
<text top="421" left="123" width="78" height="19" font="3">● Yokokawa </text>
<text top="439" left="123" width="67" height="19" font="3">et al. 2013 </text>
<text top="457" left="123" width="35" height="19" font="3">(465) </text>
<text top="476" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24612052">● </a></text>
<text top="476" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24612052">24612052</a></text>
<text top="476" left="197" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24612052"><b> </b></a></text>
<text top="421" left="225" width="76" height="19" font="4"><b>Study Type: </b></text>
<text top="439" left="225" width="84" height="19" font="3">Single Center </text>
<text top="457" left="225" width="87" height="19" font="3">observational </text>
<text top="476" left="225" width="35" height="19" font="4"><b>Size:  </b></text>
<text top="494" left="225" width="83" height="19" font="3">264 patients  </text>
<text top="421" left="338" width="113" height="19" font="4"><b>Inclusion Criteria: </b></text>
<text top="439" left="338" width="88" height="19" font="3">A consecutive </text>
<text top="457" left="338" width="81" height="19" font="3">series of 264 </text>
<text top="476" left="338" width="83" height="19" font="3">patients with </text>
<text top="494" left="338" width="57" height="19" font="3">frequent </text>
<text top="512" left="338" width="97" height="19" font="3">idiopathic PVCs </text>
<text top="531" left="338" width="103" height="19" font="3">referred for PVC </text>
<text top="549" left="338" width="57" height="19" font="3">ablation, </text>
<text top="567" left="338" width="108" height="19" font="3">including 87 with </text>
<text top="586" left="338" width="93" height="19" font="3">LV dysfunction </text>
<text top="604" left="338" width="3" height="19" font="3"> </text>
<text top="622" left="338" width="61" height="19" font="4"><b>Exclusion </b></text>
<text top="640" left="338" width="59" height="19" font="4"><b>criteria:</b>   </text>
<text top="659" left="338" width="101" height="19" font="3">Structural Heart </text>
<text top="677" left="338" width="50" height="19" font="3">Disease </text>
<text top="695" left="338" width="3" height="19" font="3"> </text>
<text top="421" left="464" width="3" height="19" font="4"><b> </b></text>
<text top="421" left="689" width="52" height="19" font="4"><b>Results: </b></text>
<text top="439" left="689" width="211" height="19" font="3">The majority of patients (51 of 75, </text>
<text top="457" left="689" width="163" height="19" font="3">68%) with PVC-induced LV </text>
<text top="476" left="689" width="202" height="19" font="3">dysfunction had a recovery of LV </text>
<text top="494" left="689" width="206" height="19" font="3">function within 4 mo. In 24 (32%) </text>
<text top="512" left="689" width="202" height="19" font="3">patients, recovery of LV function </text>
<text top="531" left="689" width="209" height="19" font="3">took more than 4 mo (mean 12±9 </text>
<text top="549" left="689" width="211" height="19" font="3">mo; range 5-45 mo). An epicardial </text>
<text top="567" left="689" width="187" height="19" font="3">origin of PVCs was more often </text>
<text top="586" left="689" width="160" height="19" font="3">present (13 of 24, 54%) in </text>
<text top="604" left="689" width="208" height="19" font="3">patients with delayed recovery of </text>
<text top="622" left="689" width="202" height="19" font="3">LV function than in patients with </text>
<text top="640" left="689" width="210" height="19" font="3">early recovery of LV function (2 of </text>
<text top="659" left="689" width="200" height="19" font="3">51, 4%; p&lt;0.0001). The PVC-QRS </text>
<text top="677" left="689" width="198" height="19" font="3">width was significantly longer in </text>
<text top="695" left="689" width="192" height="19" font="3">patients with delayed recovery </text>
<text top="714" left="689" width="186" height="19" font="3">than in patients with recovery </text>
<text top="732" left="689" width="167" height="19" font="3">within 4 mo (170±21 ms vs </text>
<text top="750" left="689" width="143" height="19" font="3">159±16 ms; p=0.02). In </text>
<text top="769" left="689" width="180" height="19" font="3">multivariate analysis, only an </text>
<text top="421" left="914" width="93" height="19" font="3">● PVC-induced </text>
<text top="439" left="914" width="156" height="19" font="3">cardiomyopathy resolves </text>
<text top="457" left="914" width="157" height="19" font="3">within 4 mo of successful </text>
<text top="476" left="914" width="159" height="19" font="3">ablation in most patients. </text>
<text top="494" left="914" width="155" height="19" font="3">In about one-third of the </text>
<text top="512" left="914" width="126" height="19" font="3">patients, recovery is </text>
<text top="531" left="914" width="152" height="19" font="3">delayed and can take up </text>
<text top="549" left="914" width="145" height="19" font="3">to 45 mo. An epicardial </text>
<text top="567" left="914" width="142" height="19" font="3">origin predicts delayed </text>
<text top="586" left="914" width="149" height="19" font="3">recovery of LV function. </text>
</page>
<page number="258" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">258 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="689" width="156" height="19" font="3">epicardial PVC origin was </text>
<text top="127" left="689" width="204" height="19" font="3">predictive of delayed recovery of </text>
<text top="145" left="689" width="200" height="19" font="3">LV function in patients with PVC-</text>
<text top="164" left="689" width="155" height="19" font="3">induced cardiomyopathy </text>
<text top="182" left="115" width="4" height="23" font="10"><b> </b></text>
<text top="240" left="115" width="843" height="21" font="2"><b>Data Supplement 51. Nonrandomized Trials, Observational Studies, and/or Registries Related to Pregnancy - (Section 10.2) </b></text>
<text top="262" left="137" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="280" left="163" width="51" height="19" font="4"><b>Author; </b></text>
<text top="298" left="140" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="262" left="267" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="280" left="296" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="262" left="420" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="262" left="610" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="280" left="622" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="298" left="653" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="262" left="877" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="280" left="906" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="317" left="125" width="131" height="19" font="3">●  Jeejeebhoy et al. </text>
<text top="336" left="125" width="66" height="19" font="3">2015(466) </text>
<text top="354" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26443610">● </a></text>
<text top="354" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26443610">26443610</a></text>
<text top="354" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26443610"> </a></text>
<text top="372" left="125" width="3" height="19" font="3"> </text>
<text top="317" left="265" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="336" left="265" width="125" height="19" font="3">Scientific Statement </text>
<text top="354" left="265" width="73" height="19" font="3">of the AHA  </text>
<text top="372" left="265" width="3" height="19" font="4"><b> </b></text>
<text top="390" left="265" width="45" height="19" font="4"><b>Size:     </b></text>
<text top="409" left="265" width="27" height="19" font="3">N/A </text>
<text top="317" left="406" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="336" left="406" width="143" height="19" font="3">Comprehensive review </text>
<text top="354" left="406" width="141" height="19" font="3">and recommendations </text>
<text top="372" left="406" width="141" height="19" font="3">for management of CA </text>
<text top="391" left="406" width="110" height="19" font="3">during pregnancy<b> </b></text>
<text top="409" left="406" width="3" height="19" font="4"><b> </b></text>
<text top="427" left="406" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="445" left="406" width="27" height="19" font="3">N/A<b> </b></text>
<text top="464" left="406" width="3" height="19" font="4"><b> </b></text>
<text top="482" left="406" width="3" height="19" font="4"><b> </b></text>
<text top="500" left="406" width="3" height="19" font="4"><b> </b></text>
<text top="519" left="406" width="3" height="19" font="4"><b> </b></text>
<text top="537" left="406" width="3" height="19" font="4"><b> </b></text>
<text top="555" left="406" width="3" height="19" font="4"><b> </b></text>
<text top="318" left="568" width="88" height="19" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="336" left="568" width="27" height="19" font="3">N/A </text>
<text top="355" left="568" width="3" height="19" font="3"> </text>
<text top="373" left="568" width="52" height="19" font="4"><b>Results: </b></text>
<text top="391" left="568" width="180" height="19" font="3">Specific recommendation for </text>
<text top="410" left="568" width="190" height="19" font="3">management of CA during late </text>
<text top="428" left="568" width="225" height="19" font="3">pregnancy and delivery.  There are 2 </text>
<text top="446" left="568" width="217" height="19" font="3">of major importance that are given </text>
<text top="465" left="568" width="231" height="19" font="3">the force of Recommendations in the </text>
<text top="483" left="568" width="189" height="19" font="3">absence of supporting data on </text>
<text top="501" left="568" width="196" height="19" font="3">outcomes (LOE-C):  Left Uterine </text>
<text top="519" left="568" width="218" height="19" font="3">Displacement during CPR when the </text>
<text top="538" left="568" width="212" height="19" font="3">uterus is above the umbilicus; and </text>
<text top="556" left="568" width="206" height="19" font="3">the 4-5 min rule for emergency C-</text>
<text top="574" left="568" width="155" height="19" font="3">section during CA PMCD. </text>
<text top="317" left="816" width="215" height="19" font="3">● Both this Scientific Statement on </text>
<text top="336" left="816" width="255" height="19" font="3">Cardiac Arrest in Pregnancy and the 2015 </text>
<text top="354" left="816" width="240" height="19" font="3">American Heart Association Guidelines </text>
<text top="372" left="816" width="179" height="19" font="3">Update for Cardiopulmonary </text>
<text top="391" left="816" width="182" height="19" font="3">Resuscitation and Emergency </text>
<text top="409" left="816" width="225" height="19" font="3">Cardiovascular Care; Part 10: Special </text>
<text top="427" left="816" width="197" height="19" font="3">Circumstances of Resuscitation, </text>
<text top="446" left="816" width="257" height="19" font="3">recommend that in CA when the uterus is </text>
<text top="464" left="816" width="201" height="19" font="3">above the umbilicus, left uterine </text>
<text top="482" left="816" width="252" height="19" font="3">displacement (142) should be performed </text>
<text top="500" left="816" width="253" height="19" font="3">to relieve aortocaval compression during </text>
<text top="519" left="816" width="239" height="19" font="3">CPR. While there is limited data on the </text>
<text top="537" left="816" width="243" height="19" font="3">relief of aortocaval compression by this </text>
<text top="555" left="816" width="250" height="19" font="3">maneuver, there is no data on the effect </text>
<text top="574" left="816" width="227" height="19" font="3">of LUD on outcomes.  This is a Class I </text>
<text top="592" left="816" width="188" height="19" font="3">Recommendation, with LOE C. </text>
<text top="610" left="816" width="230" height="19" font="3">● There is no specific data to support </text>
<text top="629" left="816" width="260" height="19" font="3">these recommendations from the point of </text>
<text top="647" left="816" width="247" height="19" font="3">view of outcomes yet they are woven in </text>
<text top="665" left="816" width="224" height="19" font="3">to two recommendation documents </text>
<text top="683" left="816" width="112" height="19" font="3">recently released. </text>
<text top="702" left="816" width="243" height="19" font="3">● The 4-5 min window for PMCD is also </text>
<text top="720" left="816" width="244" height="19" font="3">based on limited theoretic information, </text>
<text top="739" left="816" width="229" height="19" font="3">but does not have any scientific basis </text>
<text top="757" left="816" width="238" height="19" font="3">supporting improved maternal or fetal </text>
<text top="775" left="816" width="155" height="19" font="3">outcomes. It is a Class IIa </text>
</page>
<page number="259" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">259 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="816" width="242" height="19" font="3">recommendation, LOE C. It is led to the </text>
<text top="127" left="816" width="212" height="19" font="3">recommendation that a scalpel be </text>
<text top="145" left="816" width="221" height="19" font="3">available for response teams on the </text>
<text top="164" left="816" width="251" height="19" font="3">obstetrical units, and a recommendation </text>
<text top="182" left="816" width="245" height="19" font="3">against moving the patient to operating </text>
<text top="200" left="816" width="245" height="19" font="3">room or delivery suite, but rather doing </text>
<text top="219" left="816" width="113" height="19" font="3">the PMCD on site. </text>
<text top="238" left="125" width="123" height="19" font="3">● Creagna A A, et al </text>
<text top="256" left="125" width="69" height="19" font="3">2014 (467) </text>
<text top="274" left="125" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880915/">● </a></text>
<text top="274" left="137" width="53" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880915/">3880915</a></text>
<text top="274" left="190" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880915/"> </a></text>
<text top="292" left="125" width="3" height="19" font="3"> </text>
<text top="237" left="265" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="256" left="265" width="68" height="19" font="3">Analysis of </text>
<text top="274" left="265" width="106" height="19" font="3">surveillance data </text>
<text top="293" left="265" width="100" height="19" font="3">accumulated by </text>
<text top="311" left="265" width="100" height="19" font="3">CDC (Division of </text>
<text top="329" left="265" width="85" height="19" font="3">Reproductive </text>
<text top="347" left="265" width="52" height="19" font="3">Health)  </text>
<text top="366" left="265" width="3" height="19" font="4"><b> </b></text>
<text top="384" left="265" width="32" height="19" font="4"><b>Size: </b></text>
<text top="402" left="265" width="115" height="19" font="3">Absolute numbers </text>
<text top="421" left="265" width="89" height="19" font="3">not specified   </text>
<text top="237" left="406" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="256" left="406" width="142" height="19" font="3">De-identified maternal </text>
<text top="274" left="406" width="104" height="19" font="3">and related fetal </text>
<text top="293" left="406" width="147" height="19" font="3">deaths reported to CDC </text>
<text top="311" left="406" width="15" height="19" font="3">by</text>
<text top="309" left="421" width="4" height="21" font="0"> </text>
<text top="311" left="425" width="80" height="19" font="3">52 voluntary </text>
<text top="329" left="406" width="147" height="19" font="3">reporting areas (50 U.S. </text>
<text top="347" left="406" width="136" height="19" font="3">states, New York City, </text>
<text top="366" left="406" width="89" height="19" font="3">and District of </text>
<text top="384" left="406" width="144" height="19" font="3">Columbia); based upon </text>
<text top="402" left="406" width="141" height="19" font="3">death certificate data   </text>
<text top="421" left="406" width="3" height="19" font="3"> </text>
<text top="439" left="406" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="457" left="406" width="94" height="19" font="3">None specified<b> </b></text>
<text top="238" left="568" width="230" height="19" font="3">1° endpoint:  Deaths during or within </text>
<text top="257" left="568" width="199" height="19" font="3">1 y after pregnancy, with causes </text>
<text top="275" left="568" width="216" height="19" font="3">based upon death certificate data.  </text>
<text top="293" left="568" width="3" height="19" font="3"> </text>
<text top="312" left="568" width="230" height="19" font="3">Results:  Pregnancy-related mortality </text>
<text top="330" left="568" width="200" height="19" font="3">ratio increased steadily from 7.2 </text>
<text top="348" left="568" width="228" height="19" font="3">deaths/100,000 live births in 1987 to </text>
<text top="367" left="568" width="208" height="19" font="3">17.8 deaths/100,000 live births in </text>
<text top="385" left="568" width="215" height="19" font="3">2009. The reasons for this increase </text>
<text top="403" left="568" width="79" height="19" font="3">are unclear.  </text>
<text top="422" left="568" width="3" height="19" font="3"> </text>
<text top="440" left="568" width="229" height="19" font="3">In parallel with this, there has been a </text>
<text top="458" left="568" width="205" height="19" font="3">decline in the contribution of the </text>
<text top="476" left="568" width="195" height="19" font="3">traditional causes of pregnancy-</text>
<text top="495" left="568" width="219" height="19" font="3">related mortality (i.e., hemorrhage, </text>
<text top="513" left="568" width="202" height="19" font="3">sepsis, hypertensive disorders of </text>
<text top="531" left="568" width="233" height="19" font="3">pregnancy), and the emergence of CV </text>
<text top="550" left="568" width="198" height="19" font="3">and other medical conditions as </text>
<text top="568" left="568" width="223" height="19" font="3">important contributors to mortality. </text>
<text top="586" left="568" width="200" height="19" font="3">For the most recent surveillance </text>
<text top="605" left="568" width="191" height="19" font="3">period shown (2006–2009), CV </text>
<text top="623" left="568" width="223" height="19" font="3">conditions alone accounted for over </text>
<text top="641" left="568" width="222" height="19" font="3">1/3 of all pregnancy-related deaths.<b> </b></text>
<text top="238" left="816" width="248" height="19" font="3">● Pregnancy-related mortality ratios are </text>
<text top="256" left="816" width="255" height="19" font="3">3–4 times higher among black than white </text>
<text top="274" left="816" width="49" height="19" font="3">women </text>
<text top="292" left="816" width="235" height="19" font="3">● The data do not distinguish CA from </text>
<text top="311" left="816" width="238" height="19" font="3">other mechanisms of CV death; nor do </text>
<text top="329" left="816" width="256" height="19" font="3">they distinguish tachyarrhythmic CA from </text>
<text top="347" left="816" width="120" height="19" font="3">other mechanisms. </text>
<text top="660" left="125" width="80" height="19" font="3">● <b>ZAHARA II </b></text>
<text top="679" left="125" width="111" height="19" font="3">● Kampman et al.<b> </b></text>
<text top="697" left="125" width="69" height="19" font="3">2015 (468) </text>
<text top="715" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25641540">● </a></text>
<text top="715" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25641540">25641540</a></text>
<text top="715" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25641540"> </a></text>
<text top="660" left="265" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="679" left="265" width="122" height="19" font="3">Prospective cohort  </text>
<text top="697" left="265" width="3" height="19" font="3"> </text>
<text top="715" left="265" width="68" height="19" font="4"><b>Size:</b>    172 </text>
<text top="660" left="406" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="679" left="406" width="139" height="19" font="3">Pregnant women with </text>
<text top="697" left="406" width="148" height="19" font="3">known congenital heart </text>
<text top="715" left="406" width="49" height="19" font="3">disease </text>
<text top="733" left="406" width="148" height="19" font="4"><b>Exclusion criteria:</b>   N/A </text>
<text top="661" left="568" width="221" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Cardiovascular events </text>
<text top="679" left="568" width="138" height="19" font="3">within 1 y postpartum </text>
<text top="698" left="568" width="3" height="19" font="3"> </text>
<text top="716" left="568" width="225" height="19" font="4"><b>Results:</b>  Women with events during </text>
<text top="734" left="568" width="232" height="19" font="3">pregnancy were 7.1 times more likely </text>
<text top="753" left="568" width="168" height="19" font="3">to have events postpartum </text>
<text top="660" left="816" width="245" height="19" font="3">● Postpartum risk is low among women </text>
<text top="679" left="816" width="201" height="19" font="3">free of events during pregnancy  </text>
<text top="697" left="816" width="214" height="19" font="3">● Women who have events during </text>
<text top="715" left="816" width="187" height="19" font="3">pregnancy should be followed </text>
<text top="734" left="816" width="255" height="19" font="3">postpartum for changes in cardiovascular </text>
<text top="752" left="816" width="44" height="19" font="3">status. </text>
</page>
<page number="260" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">260 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="816" width="217" height="19" font="3">● Arrhythmias were most common </text>
<text top="127" left="816" width="256" height="19" font="3">events, mostly atrial; others not specified </text>
<text top="146" left="125" width="68" height="19" font="3">● <b>ZAHARA </b></text>
<text top="164" left="125" width="107" height="19" font="3">● Drenthen et al.<b> </b></text>
<text top="183" left="125" width="69" height="19" font="3">2010 (469) </text>
<text top="201" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20584777">● </a></text>
<text top="201" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20584777">20584777</a></text>
<text top="201" left="198" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20584777"><b> </b></a></text>
<text top="146" left="265" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="164" left="265" width="84" height="19" font="3">retrospective </text>
<text top="183" left="265" width="116" height="19" font="3">analysis of registry </text>
<text top="201" left="265" width="37" height="19" font="3">data   </text>
<text top="219" left="265" width="3" height="19" font="3"> </text>
<text top="237" left="265" width="65" height="19" font="4"><b>Size:</b> 1302 </text>
<text top="256" left="265" width="118" height="19" font="3">pregnancies in 714 </text>
<text top="274" left="265" width="80" height="19" font="3">women with </text>
<text top="293" left="265" width="103" height="19" font="3">congenital heart </text>
<text top="311" left="265" width="59" height="19" font="3">disease    </text>
<text top="146" left="406" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="164" left="406" width="139" height="19" font="3">Pregnant women with </text>
<text top="183" left="406" width="148" height="19" font="3">known congenital heart </text>
<text top="201" left="406" width="49" height="19" font="3">disease </text>
<text top="219" left="406" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="238" left="406" width="143" height="19" font="3">Miscarriages at &lt;20 wk </text>
<text top="256" left="406" width="131" height="19" font="3">of gestation; elective </text>
<text top="274" left="406" width="65" height="19" font="3">abortions. </text>
<text top="147" left="568" width="222" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Cardiovascular events </text>
<text top="165" left="568" width="110" height="19" font="3">during pregnancy </text>
<text top="183" left="568" width="3" height="19" font="3"> </text>
<text top="202" left="568" width="233" height="19" font="4"><b>Results:</b> Cardiovascular complications </text>
<text top="220" left="568" width="233" height="19" font="3">occurred in 7.6% of pregnancies, with </text>
<text top="238" left="568" width="210" height="19" font="3">“clinically significant” arrhythmias </text>
<text top="257" left="568" width="214" height="19" font="3">most common events – 4.7%; type </text>
<text top="275" left="568" width="86" height="19" font="3">not specified. </text>
<text top="146" left="816" width="226" height="19" font="3">● Presence of cyanotic heart disease </text>
<text top="164" left="816" width="243" height="19" font="3">(corrected/uncorrected), use of cardiac </text>
<text top="183" left="816" width="247" height="19" font="3">medication before pregnancy, left heart </text>
<text top="201" left="816" width="193" height="19" font="3">obstruction, aortic or pulmonic </text>
<text top="219" left="816" width="227" height="19" font="3">regurgitation, and mechanical valves </text>
<text top="238" left="816" width="211" height="19" font="3">were most closely associated with </text>
<text top="256" left="816" width="183" height="19" font="3">cardiovascular complications. </text>
<text top="330" left="125" width="123" height="19" font="3">● Mhyre et al.<b> </b>2014 </text>
<text top="348" left="125" width="35" height="19" font="3">(470) </text>
<text top="366" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24694844">● </a></text>
<text top="366" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24694844">24694844</a></text>
<text top="366" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24694844"> </a></text>
<text top="385" left="125" width="7" height="19" font="3">  </text>
<text top="330" left="265" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="348" left="265" width="87" height="19" font="3">Retrospective </text>
<text top="366" left="265" width="116" height="19" font="3">cohort study of CA </text>
<text top="385" left="265" width="113" height="19" font="3">during admissions </text>
<text top="403" left="265" width="106" height="19" font="3">for delivery from </text>
<text top="422" left="265" width="98" height="19" font="3">the Nationwide </text>
<text top="440" left="265" width="107" height="19" font="3">Inpatient Sample </text>
<text top="458" left="265" width="36" height="19" font="3">(NIS)  </text>
<text top="476" left="265" width="3" height="19" font="3"> </text>
<text top="495" left="265" width="107" height="19" font="4"><b>Size:</b>  56,900,512 </text>
<text top="513" left="265" width="120" height="19" font="3">hospitalizations for </text>
<text top="531" left="265" width="109" height="19" font="3">delivery between </text>
<text top="550" left="265" width="94" height="19" font="3">1998 and 2011 </text>
<text top="330" left="406" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="348" left="406" width="94" height="19" font="3">Diagnosis code </text>
<text top="366" left="406" width="142" height="19" font="3">indicating delivery or a </text>
<text top="385" left="406" width="147" height="19" font="3">procedure code related </text>
<text top="403" left="406" width="68" height="19" font="3">to delivery </text>
<text top="422" left="406" width="3" height="19" font="3"> </text>
<text top="440" left="406" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="458" left="406" width="94" height="19" font="3">Diagnosis code </text>
<text top="476" left="406" width="125" height="19" font="3">indicating abnormal </text>
<text top="495" left="406" width="145" height="19" font="3">products of conception </text>
<text top="513" left="406" width="127" height="19" font="3">or a procedure code </text>
<text top="531" left="406" width="126" height="19" font="3">indicating abortion.  </text>
<text top="331" left="568" width="215" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Cardiac arrest during </text>
<text top="349" left="568" width="204" height="19" font="3">hospitalization for delivery in the </text>
<text top="367" left="568" width="203" height="19" font="3">United States between 1998 and </text>
<text top="386" left="568" width="197" height="19" font="3">2011. 2° outcomes included: (1) </text>
<text top="404" left="568" width="228" height="19" font="3">survival to hospital discharge; (2) the </text>
<text top="422" left="568" width="175" height="19" font="3">association between CA and </text>
<text top="441" left="568" width="204" height="19" font="3">demographic and socioeconomic </text>
<text top="459" left="568" width="199" height="19" font="3">characteristics, and medical and </text>
<text top="477" left="568" width="224" height="19" font="3">obstetric diagnoses and procedures; </text>
<text top="496" left="568" width="222" height="19" font="3">and (3) association between CA and </text>
<text top="514" left="568" width="225" height="19" font="3">the annual hospital delivery volume. </text>
<text top="532" left="568" width="3" height="19" font="3"> </text>
<text top="550" left="568" width="198" height="19" font="4"><b>Results:</b> 4,843 cardiopulmonary </text>
<text top="569" left="568" width="233" height="19" font="3">arrests (CPA) between 1998 and 2011 </text>
<text top="587" left="568" width="187" height="19" font="3">(event rate = 8.5 CPA/100,000 </text>
<text top="605" left="568" width="188" height="19" font="3">hospitalizations, or 1: 12,000). </text>
<text top="624" left="568" width="188" height="19" font="3">Incidence was higher for older </text>
<text top="642" left="568" width="217" height="19" font="3">subjects (&gt;35 y), black women, and </text>
<text top="660" left="568" width="210" height="19" font="3">Medicaid patients. The conditions </text>
<text top="679" left="568" width="213" height="19" font="3">most strongly associated with CPA </text>
<text top="697" left="568" width="192" height="19" font="3">were pulmonary hypertension, </text>
<text top="715" left="568" width="228" height="19" font="3">malignancy, CVD (i.e., ischemic heart </text>
<text top="734" left="568" width="208" height="19" font="3">disease, congenital heart disease, </text>
<text top="752" left="568" width="202" height="19" font="3">cardiac valvular disease, and pre-</text>
<text top="770" left="568" width="225" height="19" font="3">existing hypertension), liver disease, </text>
<text top="330" left="816" width="257" height="19" font="3">● CPA is rare among patients hospitalized </text>
<text top="348" left="816" width="255" height="19" font="3">for delivery, but considerably higher than </text>
<text top="366" left="816" width="225" height="19" font="3">the age adjusted incidence of CPA in </text>
<text top="385" left="816" width="126" height="19" font="3">general population.  </text>
<text top="403" left="816" width="229" height="19" font="3">● There is a trend towards improving </text>
<text top="422" left="816" width="253" height="19" font="3">survival to hospital discharge over the 14 </text>
<text top="440" left="816" width="242" height="19" font="3">y observation period, but the incidence </text>
<text top="458" left="816" width="183" height="19" font="3">has not changed significantly. </text>
<text top="476" left="816" width="192" height="19" font="3">● The most common etiologies </text>
<text top="495" left="816" width="211" height="19" font="3">numerically are those that are not </text>
<text top="513" left="816" width="249" height="19" font="3">associated with the tachyarrhythmic CA, </text>
<text top="531" left="816" width="253" height="19" font="3">but the incidence is highest among those </text>
<text top="550" left="816" width="225" height="19" font="3">conditions that are more likely to be </text>
<text top="568" left="816" width="249" height="19" font="3">associated with tachyarrhythmic events. </text>
<text top="586" left="816" width="249" height="19" font="3">● The cumulative number of CPAs in the </text>
<text top="605" left="816" width="239" height="19" font="3">sample was 4,843 over 14 y (average = </text>
<text top="623" left="816" width="244" height="19" font="3">346/y), but this number is based on the </text>
<text top="641" left="816" width="247" height="19" font="3">limitations of the sample size in the NIS. </text>
<text top="660" left="816" width="3" height="19" font="3"> </text>
</page>
<page number="261" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">261 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="568" width="221" height="19" font="3">and systemic lupus erythematosus.  </text>
<text top="127" left="568" width="234" height="19" font="3">However, the absolute numbers were </text>
<text top="145" left="568" width="161" height="19" font="3">highest for postpartum or </text>
<text top="164" left="568" width="230" height="19" font="3">antepartum hemorrhage combined = </text>
<text top="182" left="568" width="222" height="19" font="3">44.7%, HF, amniotic fluid embolism, </text>
<text top="200" left="568" width="70" height="19" font="3">and sepsis. </text>
<text top="219" left="125" width="101" height="19" font="3">● Siu et al. 2001 </text>
<text top="238" left="125" width="35" height="19" font="3">(471) </text>
<text top="256" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11479246">● </a></text>
<text top="256" left="137" width="61" height="19" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11479246">11479246</a></text>
<text top="256" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11479246"> </a></text>
<text top="274" left="125" width="3" height="19" font="3"> </text>
<text top="219" left="265" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="238" left="265" width="87" height="19" font="3">Retrospective </text>
<text top="256" left="265" width="77" height="19" font="3">analysis of a </text>
<text top="274" left="265" width="74" height="19" font="3">multicenter </text>
<text top="293" left="265" width="115" height="19" font="3">consecutive series </text>
<text top="311" left="265" width="124" height="19" font="3">of pregnant women </text>
<text top="329" left="265" width="107" height="19" font="3">with a Hx a heart </text>
<text top="347" left="265" width="66" height="19" font="3">disease.<b> </b>   <b> </b></text>
<text top="366" left="265" width="3" height="19" font="3"> </text>
<text top="384" left="265" width="45" height="19" font="4"><b>Size:</b>     </text>
<text top="402" left="265" width="118" height="19" font="3">599 pregnancies in </text>
<text top="421" left="265" width="102" height="19" font="3">562 consecutive </text>
<text top="439" left="265" width="55" height="19" font="3">referrals </text>
<text top="219" left="406" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="238" left="406" width="142" height="19" font="3">Congenital or acquired </text>
<text top="256" left="406" width="109" height="19" font="3">cardiac lesions or </text>
<text top="274" left="406" width="128" height="19" font="3">cardiac arrhythmias. </text>
<text top="293" left="406" width="110" height="19" font="3">Patients in whom </text>
<text top="311" left="406" width="145" height="19" font="3">cardiac arrhythmia was </text>
<text top="329" left="406" width="134" height="19" font="3">the 1° diagnosis must </text>
<text top="347" left="406" width="142" height="19" font="3">have had symptomatic </text>
<text top="366" left="406" width="62" height="19" font="3">sustained </text>
<text top="384" left="406" width="127" height="19" font="3">tachyarrhythmias or </text>
<text top="402" left="406" width="112" height="19" font="3">bradyarrhythmias </text>
<text top="421" left="406" width="124" height="19" font="3">requiring treatment </text>
<text top="439" left="406" width="118" height="19" font="3">before pregnancy.  </text>
<text top="457" left="406" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="476" left="406" width="127" height="19" font="3">Isolated mitral valve </text>
<text top="494" left="406" width="141" height="19" font="3">prolapse (moderate or </text>
<text top="512" left="406" width="70" height="19" font="3">mild mitral </text>
<text top="531" left="406" width="142" height="19" font="3">regurgitation) or those </text>
<text top="549" left="406" width="75" height="19" font="3">referred for </text>
<text top="567" left="406" width="92" height="19" font="3">termination of </text>
<text top="586" left="406" width="81" height="19" font="3">pregnancy.    </text>
<text top="604" left="406" width="3" height="19" font="3"> </text>
<text top="220" left="568" width="166" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Prepartum (2</text>
<text top="220" left="734" width="10" height="12" font="15">nd</text>
<text top="220" left="744" width="38" height="19" font="3"> and 3</text>
<text top="220" left="781" width="9" height="12" font="15">rd</text>
<text top="220" left="790" width="3" height="19" font="3"> </text>
<text top="238" left="568" width="177" height="19" font="3">trimesters), peripartum, and </text>
<text top="257" left="568" width="75" height="19" font="3">postpartum </text>
<text top="257" left="643" width="134" height="19" font="14">1° cardiac, 2° cardiac, </text>
<text top="275" left="568" width="227" height="19" font="14">neonatal, or obstetric complications. </text>
<text top="293" left="568" width="3" height="19" font="3"> </text>
<text top="311" left="568" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="330" left="568" width="196" height="19" font="3">The principal cardiac lesion was </text>
<text top="348" left="568" width="227" height="19" font="3">congenital in 445 pregnancies (74%), </text>
<text top="367" left="568" width="217" height="19" font="3">acquired in 127 pregnancies (22%), </text>
<text top="385" left="568" width="207" height="19" font="3">and arrhythmic in 27 pregnancies </text>
<text top="403" left="568" width="223" height="19" font="3">(4%, with the majority being SVT’s).  </text>
<text top="422" left="568" width="198" height="19" font="14">1° cardiac events occurred in 80 </text>
<text top="440" left="568" width="204" height="19" font="14">pregnancies (13%); 55% of which </text>
<text top="458" left="568" width="200" height="19" font="14">occurred prepartum. Pulmonary </text>
<text top="476" left="568" width="209" height="19" font="14">edema and/or cardiac arrhythmia </text>
<text top="495" left="568" width="209" height="19" font="14">accounted for most of the cardiac </text>
<text top="513" left="568" width="231" height="19" font="14">events, the majority SVT’s. Predictors </text>
<text top="531" left="568" width="207" height="19" font="14">of 1° cardiac events were HF, TIA, </text>
<text top="550" left="568" width="164" height="19" font="14">CVA, or arrhythmia before </text>
<text top="568" left="568" width="231" height="19" font="14">pregnancy; baseline NYHA class &gt;II or </text>
<text top="586" left="568" width="223" height="19" font="14">cyanosis; left heart obstruction; and </text>
<text top="605" left="568" width="73" height="19" font="14">LV EF&lt;40%. </text>
<text top="623" left="568" width="204" height="19" font="14">A 2° cardiac event occurred in 37 </text>
<text top="641" left="568" width="227" height="19" font="14">(6%). Worsening of NYHA class by &gt;2 </text>
<text top="660" left="568" width="202" height="19" font="14">classes occurred in 26 of the 579 </text>
<text top="678" left="568" width="209" height="19" font="14">pregnancies in which the baseline </text>
<text top="696" left="568" width="136" height="19" font="14">NYHA class was I or II. </text>
<text top="219" left="816" width="225" height="19" font="3">● A subgroup at high risk for 1° or 2° </text>
<text top="238" left="816" width="231" height="19" font="3">cardiac complications of pregnancy is </text>
<text top="256" left="816" width="259" height="19" font="3">identifiable, with a combined incidence of </text>
<text top="274" left="816" width="234" height="19" font="3">17%.  Among 1° events, 55% occurred </text>
<text top="293" left="816" width="74" height="19" font="3">during the 2</text>
<text top="292" left="890" width="10" height="12" font="15">nd</text>
<text top="292" left="900" width="37" height="19" font="3"> and 3</text>
<text top="292" left="937" width="9" height="12" font="15">rd</text>
<text top="292" left="946" width="73" height="19" font="3"> trimesters. </text>
<text top="311" left="816" width="263" height="19" font="3">● The majority of arrhythmias were SVT’s.  </text>
<text top="329" left="816" width="229" height="19" font="3">● Careful scrutiny of high risk cardiac </text>
<text top="347" left="816" width="249" height="19" font="3">patients during pregnancy, beginning no </text>
<text top="366" left="816" width="210" height="19" font="3">later than the second trimester, is </text>
<text top="384" left="816" width="246" height="19" font="3">warranted for both arrhythmic and non-</text>
<text top="402" left="816" width="224" height="19" font="3">arrhythmic 1° and 2° complications.  </text>
<text top="715" left="125" width="128" height="19" font="3">●  Einav et al. 2012 </text>
<text top="733" left="125" width="35" height="19" font="3">(472) </text>
<text top="752" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22613275">● </a></text>
<text top="752" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22613275">22613275</a></text>
<text top="752" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22613275"> </a></text>
<text top="770" left="125" width="3" height="19" font="3"> </text>
<text top="715" left="265" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="733" left="265" width="87" height="19" font="3">Retrospective </text>
<text top="752" left="265" width="67" height="19" font="3">analysis of </text>
<text top="770" left="265" width="112" height="19" font="3">published original </text>
<text top="715" left="406" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="733" left="406" width="125" height="19" font="3">(1) At least 5 clinical </text>
<text top="752" left="406" width="129" height="19" font="3">details regarding the </text>
<text top="770" left="406" width="89" height="19" font="3">case (e.g. age, </text>
<text top="716" left="568" width="88" height="19" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="734" left="568" width="210" height="19" font="3">Maternal and neonatal survival to </text>
<text top="753" left="568" width="164" height="19" font="3">hospital discharge and the </text>
<text top="715" left="816" width="12" height="19" font="3">● </text>
<text top="715" left="828" width="245" height="19" font="21">Maternal outcomes may not be as poor </text>
<text top="733" left="816" width="168" height="19" font="21">as in other CA populations. </text>
<text top="752" left="816" width="216" height="19" font="21">Mortality rates were higher among </text>
<text top="770" left="816" width="257" height="19" font="21">women who underwent PMCD compared </text>
</page>
<page number="262" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="28" size="11" family="Times" color="#0a0905"/>
	<fontspec id="29" size="12" family="Times" color="#0a0905"/>
<text top="803" left="585" width="29" height="21" font="0">262 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="265" width="124" height="19" font="3">articles, case series, </text>
<text top="127" left="265" width="105" height="19" font="3">case reports and </text>
<text top="145" left="265" width="123" height="19" font="3">letters to the editor </text>
<text top="164" left="265" width="103" height="19" font="3">regarding PMCD </text>
<text top="182" left="265" width="78" height="19" font="3">during CA in </text>
<text top="200" left="265" width="67" height="19" font="3">pregnancy </text>
<text top="218" left="265" width="45" height="19" font="4"><b>Size:     </b></text>
<text top="237" left="265" width="109" height="19" font="3">94 cases selected </text>
<text top="255" left="265" width="59" height="19" font="3">from 108 </text>
<text top="273" left="265" width="106" height="19" font="3">publications that </text>
<text top="292" left="265" width="123" height="19" font="3">met review criteria.<b> </b></text>
<text top="109" left="406" width="103" height="19" font="3">gravidity, parity, </text>
<text top="127" left="406" width="135" height="19" font="3">obstetric and medical </text>
<text top="145" left="406" width="143" height="19" font="3">Hx, presenting rhythm, </text>
<text top="164" left="406" width="142" height="19" font="3">location of arrest), and </text>
<text top="182" left="406" width="141" height="19" font="3">the care provided (e.g. </text>
<text top="200" left="406" width="121" height="19" font="3">chest compression, </text>
<text top="219" left="406" width="147" height="19" font="3">ventilation, monitoring, </text>
<text top="237" left="406" width="119" height="19" font="3">drugs given); (2) At </text>
<text top="255" left="406" width="99" height="19" font="3">least one of the </text>
<text top="273" left="406" width="147" height="19" font="3">following outcomes: (a) </text>
<text top="292" left="406" width="87" height="19" font="3">maternal non-</text>
<text top="310" left="406" width="102" height="19" font="3">return/return of </text>
<text top="329" left="406" width="82" height="19" font="3">spontaneous </text>
<text top="347" left="406" width="112" height="19" font="3">circulation or non-</text>
<text top="365" left="406" width="119" height="19" font="3">survival/survival to </text>
<text top="383" left="406" width="138" height="19" font="3">hospital discharge; (b) </text>
<text top="402" left="406" width="91" height="19" font="3">fetal/neonatal </text>
<text top="420" left="406" width="62" height="19" font="3">outcome. </text>
<text top="438" left="406" width="3" height="19" font="4"><b> </b></text>
<text top="457" left="406" width="109" height="19" font="4"><b>Exclusion criteria </b></text>
<text top="475" left="406" width="130" height="19" font="3">Maternal arrest post-</text>
<text top="493" left="406" width="106" height="19" font="3">delivery, no data </text>
<text top="512" left="406" width="122" height="19" font="3">enabling relation of </text>
<text top="530" left="406" width="90" height="19" font="3">case details to </text>
<text top="548" left="406" width="122" height="19" font="3">outcome, or if both </text>
<text top="566" left="406" width="98" height="19" font="3">outcomes were </text>
<text top="585" left="406" width="56" height="19" font="3">unclear.  </text>
<text top="109" left="568" width="227" height="19" font="3">relationship between PMCD and this </text>
<text top="127" left="568" width="62" height="19" font="3">outcome. </text>
<text top="145" left="568" width="52" height="19" font="4"><b>Results: </b></text>
<text top="164" left="568" width="193" height="19" font="3">ROSC was achieved in 60.6% of </text>
<text top="182" left="568" width="231" height="19" font="3">mothers (N=57), among whom 89.5% </text>
<text top="200" left="568" width="185" height="19" font="3">survived to hospital discharge </text>
<text top="219" left="568" width="216" height="19" font="3">(51/57). Time from arrest to PMCD </text>
<text top="237" left="568" width="229" height="19" font="3">was reported for only 57 cases of the </text>
<text top="255" left="568" width="185" height="19" font="3">76 (75%) receiving PMCD; the </text>
<text top="273" left="568" width="201" height="19" font="3">average time was 16.6±12.5 min </text>
<text top="292" left="568" width="219" height="19" font="3">(median 10, range 1–60, IQR 8–25), </text>
<text top="310" left="568" width="192" height="19" font="3">with only 4 cases achieving the </text>
<text top="329" left="568" width="176" height="19" font="3">recommended 4-min target. </text>
<text top="347" left="568" width="227" height="19" font="3">Overall survival to hospital discharge </text>
<text top="365" left="568" width="233" height="19" font="3">was 54.3%.  Among 23 with VT/VF, 15 </text>
<text top="383" left="568" width="207" height="19" font="3">survived to discharge.  Overall, in-</text>
<text top="402" left="568" width="225" height="19" font="3">hospital location and PMCD &lt;10 min </text>
<text top="420" left="568" width="172" height="19" font="3">were statistically significant.</text>
<text top="418" left="739" width="4" height="21" font="0"> </text>
<text top="438" left="568" width="218" height="19" font="3">Neurological outcomes of surviving </text>
<text top="457" left="568" width="213" height="19" font="3">mothers (N=51) were described as </text>
<text top="475" left="568" width="159" height="19" font="3">CPC 1/2 in 78.4% (40/51). </text>
<text top="493" left="568" width="233" height="19" font="3">The overall neonatal survival rate was </text>
<text top="512" left="568" width="173" height="19" font="3">63.6% (42/66). Neurological </text>
<text top="530" left="568" width="232" height="19" font="3">outcomes of surviving neonates were </text>
<text top="548" left="568" width="159" height="19" font="3">CPC 1/2 in 52.3% (22/42), </text>
<text top="109" left="816" width="254" height="19" font="21">with those who did not, possibly because </text>
<text top="127" left="816" width="252" height="19" font="21">of a subgroup with spontaneous or rapid </text>
<text top="145" left="816" width="40" height="19" font="21">ROSC. </text>
<text top="164" left="816" width="12" height="19" font="3">● </text>
<text top="164" left="828" width="233" height="19" font="21">The 4-min time goal for PMCD usually </text>
<text top="182" left="816" width="260" height="19" font="21">remains unmet (4 of 57, 7%), yet neonatal </text>
<text top="200" left="816" width="228" height="19" font="21">survival is still likely if delivery occurs </text>
<text top="219" left="816" width="237" height="19" font="21">within 10 or even 15 min of arrest and </text>
<text top="237" left="816" width="239" height="19" font="21">neonatal survival was most-powerfully </text>
<text top="255" left="816" width="257" height="19" font="21">associated with maternal arrest occurring </text>
<text top="273" left="816" width="231" height="19" font="21">in-hospital, regardless of the cause of </text>
<text top="292" left="816" width="43" height="19" font="21">arrest. </text>
<text top="604" left="125" width="113" height="19" font="3">● Citro et al.<b> </b>2013 </text>
<text top="622" left="125" width="35" height="19" font="3">(473) </text>
<text top="640" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23519095">● </a></text>
<text top="640" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23519095">23519095</a></text>
<text top="640" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23519095"> </a></text>
<text top="659" left="125" width="3" height="19" font="4"><b> </b></text>
<text top="604" left="265" width="113" height="19" font="4"><b>Study type:</b>   Case </text>
<text top="622" left="265" width="124" height="19" font="3">reports identified in </text>
<text top="640" left="265" width="68" height="19" font="3">systematic </text>
<text top="659" left="265" width="105" height="19" font="3">literature review </text>
<text top="677" left="265" width="3" height="19" font="3"> </text>
<text top="695" left="265" width="61" height="19" font="4"><b>Size:</b>    15 </text>
<text top="604" left="406" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="622" left="406" width="134" height="19" font="3">Diagnostic criteria for </text>
<text top="640" left="406" width="134" height="19" font="3">tako-tsubo syndrome </text>
<text top="659" left="406" width="132" height="19" font="3">based upon modified </text>
<text top="677" left="406" width="85" height="19" font="3">Mayo criteria </text>
<text top="695" left="406" width="3" height="19" font="3"> </text>
<text top="714" left="406" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="732" left="406" width="70" height="19" font="3">Preexisting </text>
<text top="750" left="406" width="119" height="19" font="3">cardiomyopathy or </text>
<text top="605" left="568" width="187" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Diagnosis of TTS </text>
<text top="623" left="568" width="3" height="19" font="3"> </text>
<text top="641" left="568" width="212" height="19" font="4"><b>Results:</b>  13 of 15 cases of TTS had </text>
<text top="660" left="568" width="178" height="19" font="3">onset 24 h after a C-section.  </text>
<text top="678" left="568" width="3" height="17" font="28"> </text>
<text top="694" left="568" width="210" height="17" font="28">13 patients had cardiac complications </text>
<text top="711" left="568" width="197" height="19" font="29">(pulmonary edema, cardiogenic </text>
<text top="729" left="568" width="117" height="19" font="29">shock, or CA [N=1])</text>
<text top="729" left="685" width="3" height="19" font="3"> </text>
<text top="748" left="568" width="229" height="19" font="3">All patients had return of LV function </text>
<text top="766" left="568" width="109" height="19" font="3">in 13.43±10.96 d. </text>
<text top="604" left="816" width="233" height="20" font="3">• Acute medical/surgical stressors are </text>
<text top="623" left="816" width="237" height="19" font="3">increasingly recognized as a trigger for </text>
<text top="641" left="816" width="25" height="19" font="3">TTS </text>
<text top="660" left="816" width="185" height="20" font="3">• Distinction from peripartum </text>
<text top="679" left="816" width="202" height="19" font="3">cardiomyopathy is important for </text>
<text top="697" left="816" width="123" height="19" font="3">prognostic reasons. </text>
<text top="715" left="816" width="222" height="20" font="3">• Cardiac arrest is infrequent in TTS. </text>
<text top="735" left="816" width="7" height="18" font="3">•</text>
<text top="734" left="822" width="4" height="21" font="0"> </text>
<text top="735" left="826" width="182" height="19" font="3">LQT2 more likely to have ACE </text>
<text top="753" left="816" width="157" height="19" font="3">postpartum vs LQT1 or 3  </text>
</page>
<page number="263" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">263 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="406" width="128" height="19" font="3">other known cardiac </text>
<text top="127" left="406" width="48" height="19" font="3">defects </text>
<text top="109" left="816" width="248" height="19" font="3">• Risk greatest during 9 mo postpartum: </text>
<text top="127" left="816" width="205" height="19" font="3">HR: 2.7, 95% CI: 1.8–4.3, p&lt;0.001 </text>
<text top="145" left="816" width="252" height="19" font="3">• risk reduced by using beta-bl, HR: 0.34, </text>
<text top="164" left="816" width="162" height="19" font="3">95% CI: 0.14-0.84, p=0.02. </text>
<text top="183" left="125" width="110" height="19" font="3">● Seth et al.<b> </b>2007 </text>
<text top="201" left="125" width="35" height="19" font="3">(474) </text>
<text top="219" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17349890">● </a></text>
<text top="219" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17349890">17349890</a></text>
<text top="219" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17349890"> </a></text>
<text top="238" left="125" width="3" height="19" font="3"> </text>
<text top="183" left="265" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="201" left="265" width="87" height="19" font="3">Retrospective </text>
<text top="219" left="265" width="98" height="19" font="3">analysis of data </text>
<text top="238" left="265" width="57" height="19" font="3">from the </text>
<text top="256" left="265" width="117" height="19" font="3">International LQTS </text>
<text top="274" left="265" width="56" height="19" font="3">Registry  </text>
<text top="292" left="265" width="3" height="19" font="3"> </text>
<text top="311" left="265" width="42" height="19" font="4"><b>Size:</b>    </text>
<text top="329" left="265" width="33" height="19" font="3">391   </text>
<text top="183" left="406" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="201" left="406" width="87" height="19" font="3">First live birth </text>
<text top="219" left="406" width="131" height="19" font="3">pregnancy in women </text>
<text top="238" left="406" width="128" height="19" font="3">with identified LQTS-</text>
<text top="256" left="406" width="140" height="19" font="3">related gene mutation </text>
<text top="274" left="406" width="122" height="19" font="3">or considered to be </text>
<text top="293" left="406" width="137" height="19" font="3">affected with LQTS on </text>
<text top="311" left="406" width="141" height="19" font="3">the basis of a QTc&gt;470 </text>
<text top="329" left="406" width="21" height="19" font="3">ms </text>
<text top="347" left="406" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="366" left="406" width="137" height="19" font="3">First live birth prior to </text>
<text top="384" left="406" width="38" height="19" font="3">1980. </text>
<text top="183" left="568" width="210" height="19" font="4"><b>1</b>°<b> endpoint:</b>  LQTS-related death, </text>
<text top="202" left="568" width="225" height="19" font="3">ACA, and/or syncope before, during, </text>
<text top="220" left="568" width="126" height="19" font="3">and after pregnancy </text>
<text top="238" left="568" width="3" height="19" font="3"> </text>
<text top="257" left="568" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="275" left="568" width="223" height="19" font="3">Compared to frequency of endpoint </text>
<text top="293" left="568" width="202" height="19" font="3">events prior to pregnancy, event </text>
<text top="312" left="568" width="220" height="19" font="3">rates during pregnancy were lower, </text>
<text top="330" left="568" width="220" height="19" font="3">but significantly higher during the 9 </text>
<text top="348" left="568" width="232" height="19" font="3">mo postpartum period.  Frequency of </text>
<text top="367" left="568" width="210" height="19" font="3">events returned to pre-pregnancy </text>
<text top="385" left="568" width="218" height="19" font="3">levels after 9 mo.  The post-partum </text>
<text top="403" left="568" width="218" height="19" font="3">increase was greatest among those </text>
<text top="422" left="568" width="137" height="19" font="3">with HERG mutations. </text>
<text top="183" left="816" width="200" height="19" font="3">● The data have implications for </text>
<text top="201" left="816" width="206" height="19" font="3">observation and pharmacological </text>
<text top="219" left="816" width="217" height="19" font="3">management during the 9 mo post-</text>
<text top="238" left="816" width="52" height="19" font="3">partum. </text>
<text top="441" left="125" width="128" height="19" font="3">●  Katz et al. 2005 </text>
<text top="459" left="125" width="35" height="19" font="3">(475) </text>
<text top="477" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15970850">● </a></text>
<text top="477" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15970850">15970850</a></text>
<text top="477" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15970850"> </a></text>
<text top="496" left="125" width="3" height="19" font="3"> </text>
<text top="514" left="125" width="3" height="19" font="3"> </text>
<text top="441" left="265" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="459" left="265" width="69" height="19" font="3">Systematic </text>
<text top="477" left="265" width="120" height="19" font="3">MEDLINE review of </text>
<text top="496" left="265" width="97" height="19" font="3">outcomes from </text>
<text top="514" left="265" width="77" height="19" font="3">perimortem </text>
<text top="532" left="265" width="116" height="19" font="3">cesarian deliveries </text>
<text top="550" left="265" width="45" height="19" font="4"><b>Size:     </b></text>
<text top="569" left="265" width="18" height="19" font="3">38 </text>
<text top="441" left="406" width="118" height="19" font="4"><b>Inclusion criteria:   </b></text>
<text top="459" left="406" width="96" height="19" font="3">Case reports of </text>
<text top="477" left="406" width="125" height="19" font="3">pregnant CA victims </text>
<text top="496" left="406" width="142" height="19" font="3">between 25 and 42 wk </text>
<text top="514" left="406" width="106" height="19" font="3">of gestation who </text>
<text top="532" left="406" width="116" height="19" font="3">underwent PMCD. </text>
<text top="550" left="406" width="3" height="19" font="4"><b> </b></text>
<text top="569" left="406" width="120" height="19" font="4"><b>Exclusion criteria:   </b></text>
<text top="587" left="406" width="121" height="19" font="3">Cesarean deliveries </text>
<text top="605" left="406" width="143" height="19" font="3">performed on mothers </text>
<text top="624" left="406" width="134" height="19" font="3">who were dying from </text>
<text top="642" left="406" width="145" height="19" font="3">mortal injuries, but still </text>
<text top="660" left="406" width="127" height="19" font="3">had vital signs, were </text>
<text top="679" left="406" width="62" height="19" font="3">excluded. </text>
<text top="441" left="568" width="88" height="19" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="460" left="568" width="229" height="19" font="3">Outcomes for fetus and mothers as a </text>
<text top="478" left="568" width="95" height="19" font="3">result of PMCD </text>
<text top="496" left="568" width="3" height="19" font="3"> </text>
<text top="515" left="568" width="52" height="19" font="4"><b>Results: </b></text>
<text top="533" left="568" width="222" height="19" font="21">In 30 of 38 PMCD’s surviving infants </text>
<text top="551" left="568" width="233" height="19" font="21">were delivered. One of the twins died </text>
<text top="570" left="568" width="215" height="19" font="21">in the neonatal period from anoxic </text>
<text top="588" left="568" width="168" height="19" font="21">injury and complications of </text>
<text top="606" left="568" width="203" height="19" font="21">prematurity.  In 12 of 22 cases in </text>
<text top="624" left="568" width="187" height="19" font="21">which hemodynamic data was </text>
<text top="643" left="568" width="230" height="19" font="21">reported, sudden return of pulse and </text>
<text top="661" left="568" width="208" height="19" font="21">BP occurred when the uterus was </text>
<text top="679" left="568" width="58" height="19" font="21">emptied. </text>
<text top="441" left="816" width="12" height="19" font="3">● </text>
<text top="441" left="828" width="234" height="19" font="21">The data reviewed supports, but does </text>
<text top="459" left="816" width="258" height="19" font="21">not prove, that PMCD within 4 minutes of </text>
<text top="477" left="816" width="251" height="19" font="21">onset of maternal CA improves maternal </text>
<text top="496" left="816" width="148" height="19" font="21">and neonatal outcomes.</text>
<text top="496" left="964" width="3" height="19" font="3"> </text>
<text top="514" left="816" width="238" height="19" font="21">A controlled trial will never be feasible.</text>
<text top="514" left="1054" width="3" height="19" font="3"> </text>
<text top="532" left="816" width="230" height="19" font="3">The conclusion is based upon general </text>
<text top="550" left="816" width="222" height="19" font="3">data on survival free of neurological </text>
<text top="569" left="816" width="237" height="19" font="3">injury during CA as a function of down-</text>
<text top="587" left="816" width="35" height="19" font="3">time. </text>
<text top="698" left="125" width="137" height="19" font="3">●  Dijkman  et al. </text>
<text top="717" left="125" width="69" height="19" font="3">2010 (476) </text>
<text top="735" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20078586">● </a></text>
<text top="735" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20078586">20078586</a></text>
<text top="735" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20078586"> </a></text>
<text top="753" left="125" width="3" height="19" font="3"> </text>
<text top="698" left="265" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="717" left="265" width="87" height="19" font="3">Retrospective </text>
<text top="735" left="265" width="116" height="19" font="3">cohort study of CA </text>
<text top="753" left="265" width="114" height="19" font="3">during pregnancy, </text>
<text top="772" left="265" width="108" height="19" font="3">with and without </text>
<text top="698" left="406" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="717" left="406" width="130" height="19" font="3">All cases of maternal </text>
<text top="735" left="406" width="133" height="19" font="3">CA during the second </text>
<text top="753" left="406" width="124" height="19" font="3">half of pregnancy in </text>
<text top="772" left="406" width="104" height="19" font="3">The Netherlands </text>
<text top="699" left="568" width="88" height="19" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="718" left="568" width="227" height="19" font="3">Frequency of use of PMCD over time </text>
<text top="736" left="568" width="215" height="19" font="3">and case fatality rate of those with </text>
<text top="754" left="568" width="205" height="19" font="3">PMCD (N=12) compared to those </text>
<text top="773" left="568" width="141" height="19" font="3">without PMCD (N=43). </text>
<text top="698" left="816" width="12" height="19" font="3">● </text>
<text top="698" left="828" width="227" height="19" font="21">Use of PMCD is increasing over time. </text>
<text top="717" left="816" width="240" height="19" font="21">Outcome for pregnant women with CA </text>
<text top="735" left="816" width="254" height="19" font="21">and PMCD remains dismal, but this study </text>
<text top="753" left="816" width="255" height="19" font="21">is limited by small numbers and apparent </text>
<text top="772" left="816" width="207" height="19" font="21">long delays to initiation of PMCD. </text>
</page>
<page number="264" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">264 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="265" width="123" height="19" font="3">PMCD during a 15 y </text>
<text top="127" left="265" width="47" height="19" font="3">period. </text>
<text top="145" left="265" width="3" height="19" font="3"> </text>
<text top="164" left="265" width="45" height="19" font="4"><b>Size:     </b></text>
<text top="182" left="265" width="84" height="19" font="3">55 CA among </text>
<text top="200" left="265" width="117" height="19" font="3">2,929,289 women, </text>
<text top="219" left="265" width="76" height="19" font="3">12 of whom </text>
<text top="237" left="265" width="119" height="19" font="3">underwent PMCD. <b> </b></text>
<text top="109" left="406" width="123" height="19" font="3">identified by survey </text>
<text top="127" left="406" width="109" height="19" font="3">from 1993-2008.  </text>
<text top="145" left="406" width="3" height="19" font="3"> </text>
<text top="164" left="406" width="113" height="19" font="4"><b>Exclusion criteria: </b></text>
<text top="182" left="406" width="94" height="19" font="3">None specified </text>
<text top="109" left="568" width="3" height="19" font="3"> </text>
<text top="127" left="568" width="52" height="19" font="4"><b>Results: </b></text>
<text top="145" left="568" width="215" height="19" font="3">A total of 8 of 55 mothers survived </text>
<text top="164" left="568" width="196" height="19" font="3">(15%). Among the 12 women in </text>
<text top="182" left="568" width="217" height="19" font="3">whom PMCS was performed, there </text>
<text top="200" left="568" width="221" height="19" font="3">were two maternal survivors (17%). </text>
<text top="219" left="568" width="221" height="19" font="3">In the 43 women in whom no PMCS </text>
<text top="237" left="568" width="190" height="19" font="3">was performed, there were six </text>
<text top="255" left="568" width="163" height="19" font="3">maternal survivors (14%).  </text>
<text top="273" left="568" width="225" height="19" font="3">No PMCD’s were performed prior to </text>
<text top="292" left="568" width="196" height="19" font="3">2000, and the use progressively </text>
<text top="310" left="568" width="217" height="19" font="3">increased after 2000. The maternal </text>
<text top="329" left="568" width="210" height="19" font="3">case fatality rate for PMCS for the </text>
<text top="347" left="568" width="221" height="19" font="3">entire 15 y period was 83% (10/12). </text>
<text top="365" left="568" width="202" height="19" font="3">For the period of August 2004 to </text>
<text top="383" left="568" width="229" height="19" font="3">August 2006 the case fatality rate for </text>
<text top="402" left="568" width="209" height="19" font="3">PMCS was 75% (3/4) and the case </text>
<text top="420" left="568" width="229" height="19" font="3">fatality rate for resuscitation without </text>
<text top="438" left="568" width="136" height="19" font="3">PMCS was 67% (6/9).  </text>
<text top="457" left="568" width="194" height="19" font="3">Neonatal case fatality rate with </text>
<text top="475" left="568" width="229" height="19" font="3">PMCD was 58%.  Corresponding data </text>
<text top="493" left="568" width="180" height="19" font="3">for no PMCD is not provided. </text>
<text top="109" left="816" width="12" height="19" font="3">● </text>
<text top="109" left="828" width="225" height="19" font="21">The data are reasonable for trend to </text>
<text top="127" left="816" width="243" height="19" font="21">increased used of PMCD, but outcomes </text>
<text top="145" left="816" width="252" height="19" font="21">cannot be relied upon because of factors </text>
<text top="164" left="816" width="81" height="19" font="21">cited above.  </text>
<text top="512" left="125" width="127" height="19" font="3">● Colletti et al. 2013 </text>
<text top="531" left="125" width="35" height="19" font="3">(477) </text>
<text top="549" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23436839">● </a></text>
<text top="549" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23436839">23436839</a></text>
<text top="549" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23436839"> </a></text>
<text top="512" left="265" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="531" left="265" width="124" height="19" font="3">Review and opinion </text>
<text top="549" left="265" width="119" height="19" font="3">article on radiation </text>
<text top="567" left="265" width="110" height="19" font="3">during pregnancy </text>
<text top="586" left="265" width="3" height="19" font="3"> </text>
<text top="604" left="265" width="45" height="19" font="4"><b>Size:     </b></text>
<text top="622" left="265" width="84" height="19" font="3">Not specified </text>
<text top="512" left="406" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="531" left="406" width="122" height="19" font="3">Studies of radiation </text>
<text top="549" left="406" width="137" height="19" font="3">exposure to fetus as a </text>
<text top="567" left="406" width="145" height="19" font="3">result of cardiovascular </text>
<text top="586" left="406" width="146" height="19" font="3">procedures in pregnant </text>
<text top="604" left="406" width="56" height="19" font="3">women.  </text>
<text top="622" left="406" width="3" height="19" font="3"> </text>
<text top="640" left="406" width="113" height="19" font="4"><b>Exclusion criteria: </b></text>
<text top="659" left="406" width="31" height="19" font="3">N/A  </text>
<text top="513" left="568" width="88" height="19" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="531" left="568" width="221" height="19" font="3">Magnitude of exposure risk to fetus </text>
<text top="550" left="568" width="194" height="19" font="3">based upon nature of radiation-</text>
<text top="568" left="568" width="212" height="19" font="3">associated procedure and stage of </text>
<text top="586" left="568" width="67" height="19" font="3">pregnancy </text>
<text top="605" left="568" width="3" height="19" font="3"> </text>
<text top="623" left="568" width="52" height="19" font="4"><b>Results: </b></text>
<text top="641" left="568" width="219" height="19" font="3">Most procedures entail a fetal dose </text>
<text top="660" left="568" width="227" height="19" font="3">well below the fetal risk threshold of </text>
<text top="678" left="568" width="203" height="19" font="3">50 mGy.  For the specific issue of </text>
<text top="696" left="568" width="182" height="19" font="3">fluoroscopic radiation for ICD </text>
<text top="714" left="568" width="236" height="19" font="3">implants, no specific data is available.  </text>
<text top="733" left="568" width="228" height="19" font="3">However, for groin-to-heart catheter </text>
<text top="751" left="568" width="203" height="19" font="3">procedures, the fetal exposure is </text>
<text top="769" left="568" width="194" height="19" font="3">0.094–0.244 mGy/min.  Thus, a </text>
<text top="512" left="816" width="12" height="19" font="3">● </text>
<text top="512" left="828" width="217" height="19" font="21">Even in light of these numbers, it is </text>
<text top="531" left="816" width="259" height="19" font="21">generally recommended that fluoroscopic </text>
<text top="549" left="816" width="258" height="19" font="21">procedures be avoided until after the first </text>
<text top="567" left="816" width="244" height="19" font="21">trimester, unless clinical circumstances, </text>
<text top="586" left="816" width="192" height="19" font="21">based on risk/potential benefit </text>
<text top="604" left="816" width="209" height="19" font="21">considerations, warrant an earlier </text>
<text top="622" left="816" width="83" height="19" font="21">intervention. </text>
</page>
<page number="265" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">265 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="568" width="205" height="19" font="3">fluoroscopic time of 1 h falls well-</text>
<text top="127" left="568" width="189" height="19" font="3">below the fetal risk threshold.  </text>
<text top="146" left="125" width="123" height="19" font="3">● Natale et al. 1997 </text>
<text top="164" left="125" width="35" height="19" font="3">(478) </text>
<text top="183" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9386142">● </a></text>
<text top="183" left="137" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9386142">9386142</a></text>
<text top="183" left="190" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9386142"> </a></text>
<text top="201" left="125" width="3" height="19" font="3"> </text>
<text top="146" left="265" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="164" left="265" width="75" height="19" font="3">Multicenter </text>
<text top="183" left="265" width="84" height="19" font="3">retrospective </text>
<text top="201" left="265" width="116" height="19" font="3">analysis of women </text>
<text top="219" left="265" width="103" height="19" font="3">with an ICD who </text>
<text top="238" left="265" width="118" height="19" font="3">became pregnant.  </text>
<text top="256" left="265" width="3" height="19" font="3"> </text>
<text top="274" left="265" width="45" height="19" font="4"><b>Size:</b>     </text>
<text top="292" left="265" width="18" height="19" font="3">44<b> </b></text>
<text top="146" left="406" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="164" left="406" width="125" height="19" font="3">Women with an ICD </text>
<text top="183" left="406" width="109" height="19" font="3">who completed a </text>
<text top="201" left="406" width="111" height="19" font="3">pregnancy or was </text>
<text top="219" left="406" width="125" height="19" font="3">currently pregnant.  </text>
<text top="238" left="406" width="95" height="19" font="3">(1). The clinical </text>
<text top="256" left="406" width="108" height="19" font="3">presentation and </text>
<text top="274" left="406" width="109" height="19" font="3">indication for ICD </text>
<text top="293" left="406" width="116" height="19" font="3">implantation were </text>
<text top="311" left="406" width="134" height="19" font="3">sudden cardiac death </text>
<text top="329" left="406" width="135" height="19" font="3">in 33 patients, VT in 9 </text>
<text top="347" left="406" width="133" height="19" font="3">patients, and VT with </text>
<text top="366" left="406" width="136" height="19" font="3">syncope in 2 patients. </text>
<text top="384" left="406" width="3" height="19" font="3"> </text>
<text top="402" left="406" width="148" height="19" font="4"><b>Exclusion criteria:</b>   N/A<b> </b></text>
<text top="147" left="568" width="88" height="19" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="165" left="568" width="197" height="19" font="3">Use, efficacy and safety of ICD’s </text>
<text top="183" left="568" width="114" height="19" font="3">during pregnancy. </text>
<text top="202" left="568" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="220" left="568" width="155" height="19" font="3">The EF at the time of ICD </text>
<text top="238" left="568" width="231" height="19" font="3">implantation was 49.8±9.7% (present </text>
<text top="257" left="568" width="190" height="19" font="3">EF was 51.4±9.5%). Underlying </text>
<text top="275" left="568" width="187" height="19" font="3">cardiac diseases were long-QT </text>
<text top="293" left="568" width="227" height="19" font="3">syndrome (N=13), idiopathic VF (17), </text>
<text top="312" left="568" width="230" height="19" font="3">cardiomyopathy (8), congenital heart </text>
<text top="330" left="568" width="207" height="19" font="3">disease (3), CAD with an ischemic </text>
<text top="348" left="568" width="211" height="19" font="3">cardiomyopathy (1), HCM (1), and </text>
<text top="367" left="568" width="64" height="19" font="3">ARVC (1).  </text>
<text top="367" left="632" width="165" height="19" font="14">The indications for the ICD </text>
<text top="385" left="568" width="219" height="19" font="14">were VF in 33 patients, VT in 9, and </text>
<text top="403" left="568" width="105" height="19" font="14">VT/syncope in 2. </text>
<text top="422" left="568" width="195" height="19" font="14">During the first pregnancy after </text>
<text top="440" left="568" width="220" height="19" font="14">implant, 33 women experienced no </text>
<text top="458" left="568" width="225" height="19" font="14">ICD discharge, 8 received one shock; </text>
<text top="476" left="568" width="225" height="19" font="14">1 experienced 5 firings in Afib; and 2 </text>
<text top="495" left="568" width="234" height="19" font="14">had 11 and 5 discharges, respectively, </text>
<text top="513" left="568" width="234" height="19" font="14">for monomorphic VT. During delivery, </text>
<text top="531" left="568" width="193" height="19" font="14">in the women in whom the ICD </text>
<text top="550" left="568" width="221" height="19" font="14">remained active, none received any </text>
<text top="568" left="568" width="228" height="19" font="14">shocks. In the 24 to 48 h period after </text>
<text top="586" left="568" width="183" height="19" font="14">delivery, 1 patient had an ICD </text>
<text top="605" left="568" width="212" height="19" font="14">discharge for VF. Overall, the total </text>
<text top="623" left="568" width="202" height="19" font="14">number of ICD discharges during </text>
<text top="641" left="568" width="220" height="19" font="14">pregnancy ranged from none to 11, </text>
<text top="660" left="568" width="217" height="19" font="14">with an average of 0.66±1.9 shocks </text>
<text top="678" left="568" width="132" height="19" font="14">(0.07 shock per mo).  </text>
<text top="696" left="568" width="202" height="19" font="14">There were no apparent adverse </text>
<text top="714" left="568" width="210" height="19" font="14">effects on the fetus among the 11 </text>
<text top="733" left="568" width="211" height="19" font="14">shocks delivered during pregnancy</text>
<text top="733" left="779" width="3" height="19" font="4"><b> </b></text>
<text top="146" left="816" width="226" height="19" font="3">● ICD’s are effective and safe for the </text>
<text top="164" left="816" width="108" height="19" font="3">pregnant female  </text>
<text top="183" left="816" width="260" height="19" font="3">● There were no apparent adverse effects </text>
<text top="201" left="816" width="81" height="19" font="3">on the fetus. </text>
</page>
<page number="266" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">266 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="770" left="115" width="4" height="21" font="0"> </text>
<text top="109" left="125" width="108" height="19" font="3">● Damilakis et al. </text>
<text top="127" left="125" width="69" height="19" font="3">2001 (479) </text>
<text top="145" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11514375">● </a></text>
<text top="145" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11514375">11514375</a></text>
<text top="145" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11514375"> </a></text>
<text top="164" left="125" width="3" height="19" font="3"> </text>
<text top="109" left="265" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="127" left="265" width="121" height="19" font="3">Radiation exposure </text>
<text top="145" left="265" width="101" height="19" font="3">and fluoroscopy </text>
<text top="164" left="265" width="60" height="19" font="3">tines to a </text>
<text top="182" left="265" width="104" height="19" font="3">theoretical fetus </text>
<text top="200" left="265" width="106" height="19" font="3">during simulated </text>
<text top="219" left="265" width="120" height="19" font="3">pregnancies during </text>
<text top="237" left="265" width="126" height="19" font="3">ablation procedures </text>
<text top="255" left="265" width="113" height="19" font="3">in female patients </text>
<text top="273" left="265" width="123" height="19" font="3">of childbearing age. </text>
<text top="292" left="265" width="123" height="19" font="3">Estimated radiation </text>
<text top="310" left="265" width="87" height="19" font="3">exposure was </text>
<text top="329" left="265" width="124" height="19" font="3">carried out for each </text>
<text top="347" left="265" width="106" height="19" font="3">projection of the </text>
<text top="365" left="265" width="100" height="19" font="3">cardiac ablation </text>
<text top="383" left="265" width="106" height="19" font="3">procedure, using </text>
<text top="402" left="265" width="96" height="19" font="3">fetal phantoms </text>
<text top="420" left="265" width="66" height="19" font="3">simulating </text>
<text top="438" left="265" width="106" height="19" font="3">pregnancy in the </text>
<text top="457" left="265" width="108" height="19" font="3">first, second, and </text>
<text top="475" left="265" width="33" height="19" font="3">third </text>
<text top="493" left="265" width="70" height="19" font="3">trimesters. </text>
<text top="512" left="265" width="3" height="19" font="3"> </text>
<text top="530" left="265" width="110" height="19" font="4"><b>Size:    </b>20 women </text>
<text top="109" left="406" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="127" left="406" width="146" height="19" font="3">Women of childbearing </text>
<text top="145" left="406" width="98" height="19" font="3">age undergoing </text>
<text top="164" left="406" width="108" height="19" font="3">catheter ablation </text>
<text top="182" left="406" width="93" height="19" font="3">procedures for </text>
<text top="200" left="406" width="103" height="19" font="3">supraventricular </text>
<text top="219" left="406" width="83" height="19" font="3">tachycardias. </text>
<text top="237" left="406" width="3" height="19" font="3"> </text>
<text top="255" left="406" width="113" height="19" font="4"><b>Exclusion criteria: </b></text>
<text top="273" left="406" width="27" height="19" font="3">N/A </text>
<text top="109" left="568" width="88" height="19" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="128" left="568" width="222" height="19" font="3">Radiation exposure and fluoroscopy </text>
<text top="146" left="568" width="182" height="19" font="3">times estimated for phantom </text>
<text top="165" left="568" width="219" height="19" font="3">simulated fetus, calculated for first, </text>
<text top="183" left="568" width="179" height="19" font="3">second, and third trimesters. </text>
<text top="201" left="568" width="52" height="19" font="4"><b>Results: </b></text>
<text top="219" left="568" width="209" height="19" font="3">The average radiation dose to the </text>
<text top="238" left="568" width="209" height="19" font="3">fetus was &lt;1 mGy in all periods of </text>
<text top="256" left="568" width="235" height="19" font="3">gestation. Average excess fatal cancer </text>
<text top="274" left="568" width="75" height="19" font="3">was 14.5/10</text>
<text top="274" left="642" width="9" height="12" font="15">6  </text>
<text top="274" left="652" width="145" height="19" font="3">fetuses exposed during </text>
<text top="293" left="568" width="208" height="19" font="3">the first trimester. Corresponding </text>
<text top="311" left="568" width="193" height="19" font="3">values for the second and third </text>
<text top="329" left="568" width="193" height="19" font="3">trimesters were 30 and 55.7/10</text>
<text top="329" left="761" width="5" height="12" font="15">6</text>
<text top="329" left="765" width="7" height="19" font="3">, </text>
<text top="348" left="568" width="219" height="19" font="3">respectively. The risk for hereditary </text>
<text top="366" left="568" width="204" height="19" font="3">effects in future generations was </text>
<text top="384" left="568" width="40" height="19" font="3">1.5/10</text>
<text top="384" left="608" width="7" height="12" font="15">6 </text>
<text top="384" left="615" width="167" height="19" font="3">cases for irradiation during </text>
<text top="402" left="568" width="208" height="19" font="3">the first trimester. Corresponding </text>
<text top="421" left="568" width="193" height="19" font="3">values for the second and third </text>
<text top="439" left="568" width="189" height="19" font="3">trimesters were 3.0 and 5.6/10</text>
<text top="439" left="757" width="5" height="12" font="15">6</text>
<text top="439" left="762" width="7" height="19" font="3">, </text>
<text top="457" left="568" width="80" height="19" font="3">respectively. </text>
<text top="109" left="816" width="258" height="19" font="3">● Catheter ablation procedures result in a </text>
<text top="127" left="816" width="244" height="19" font="3">very small increase in risk of potentially </text>
<text top="145" left="816" width="233" height="19" font="3">harmful radiation effects to the fetus. </text>
</page>
<page number="267" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">267 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="600" height="21" font="2"><b>Data Supplement 52. RCTs Comparing Medication-Induced Arrhythmias - (Section 10.7) </b></text>
<text top="129" left="142" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="147" left="168" width="55" height="19" font="4"><b>Author;  </b></text>
<text top="165" left="146" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="129" left="296" width="88" height="19" font="4"><b>Aim of Study; </b></text>
<text top="147" left="301" width="76" height="19" font="4"><b>Study Type; </b></text>
<text top="165" left="295" width="89" height="19" font="4"><b>Study Size (N) </b></text>
<text top="129" left="426" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="129" left="586" width="123" height="19" font="4"><b>Study Intervention  </b></text>
<text top="147" left="604" width="88" height="19" font="4"><b>(# patients) /  </b></text>
<text top="165" left="587" width="121" height="19" font="4"><b>Study Comparator  </b></text>
<text top="184" left="609" width="75" height="19" font="4"><b>(# patients) </b></text>
<text top="129" left="756" width="108" height="19" font="4"><b>Endpoint Results </b></text>
<text top="147" left="738" width="148" height="19" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="165" left="742" width="136" height="19" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="184" left="785" width="49" height="19" font="4"><b>95% CI) </b></text>
<text top="129" left="908" width="155" height="19" font="4"><b>Relevant  2</b>°<b> Endpoint (if </b></text>
<text top="148" left="969" width="35" height="19" font="4"><b>any); </b></text>
<text top="166" left="928" width="116" height="19" font="4"><b>Study Limitations; </b></text>
<text top="184" left="937" width="99" height="19" font="4"><b>Adverse Events </b></text>
<text top="204" left="123" width="47" height="19" font="3">● <b>CAST</b> </text>
<text top="222" left="123" width="87" height="19" font="3">● The Cardiac </text>
<text top="240" left="123" width="73" height="19" font="3">Arrhythmia </text>
<text top="258" left="123" width="108" height="19" font="3">Suppression Trial </text>
<text top="277" left="123" width="119" height="19" font="3">Investigators. 1989 </text>
<text top="295" left="123" width="35" height="19" font="3">(480) </text>
<text top="314" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2473403">● </a></text>
<text top="314" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2473403">2473403</a></text>
<text top="314" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2473403"> </a></text>
<text top="332" left="123" width="3" height="19" font="3"> </text>
<text top="203" left="276" width="61" height="19" font="4"><b>Aim: </b>Test </text>
<text top="222" left="276" width="98" height="19" font="3">hypothesis that </text>
<text top="240" left="276" width="92" height="19" font="3">suppression of </text>
<text top="258" left="276" width="114" height="19" font="3">ventricular ectopy </text>
<text top="277" left="276" width="101" height="19" font="3">post MI reduces </text>
<text top="295" left="276" width="116" height="19" font="3">incidence of SCA n </text>
<text top="314" left="276" width="96" height="19" font="3">patients whose </text>
<text top="332" left="276" width="72" height="19" font="3">ectopy was </text>
<text top="350" left="276" width="91" height="19" font="3">suppressed by </text>
<text top="368" left="276" width="66" height="19" font="3">encainide, </text>
<text top="387" left="276" width="79" height="19" font="3">flecainide or </text>
<text top="405" left="276" width="66" height="19" font="3">moricizine<b> </b></text>
<text top="423" left="276" width="3" height="19" font="4"><b> </b></text>
<text top="442" left="276" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="460" left="276" width="79" height="19" font="3">Randomized </text>
<text top="478" left="276" width="111" height="19" font="3">contolled, double-</text>
<text top="497" left="276" width="37" height="19" font="3">bllind </text>
<text top="515" left="276" width="3" height="19" font="3"> </text>
<text top="533" left="276" width="66" height="19" font="4"><b>Size: 1498</b> </text>
<text top="203" left="415" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="222" left="415" width="137" height="19" font="3">Post MI, 6 d to 2 y; six </text>
<text top="240" left="415" width="126" height="19" font="3">or more PVCs/h and </text>
<text top="258" left="415" width="140" height="19" font="3">no VT over 15 beats at </text>
<text top="277" left="415" width="90" height="19" font="3">120 bpm. 80% </text>
<text top="295" left="415" width="129" height="19" font="3">suppressioin of PVCs </text>
<text top="314" left="415" width="132" height="19" font="3">and 90% suppression </text>
<text top="332" left="415" width="55" height="19" font="3">of NSVT. </text>
<text top="350" left="415" width="3" height="19" font="3"> </text>
<text top="368" left="415" width="134" height="19" font="4"><b>Exclusion criteria:</b> No </text>
<text top="387" left="415" width="138" height="19" font="3">flecainide for EF&lt;30%. </text>
<text top="405" left="415" width="141" height="19" font="3">Moricizine was second </text>
<text top="423" left="415" width="115" height="19" font="3">choice if EF&gt;30%    </text>
<text top="442" left="415" width="3" height="19" font="3"> </text>
<text top="203" left="569" width="140" height="19" font="4"><b>Intervention:</b> Drugs as </text>
<text top="222" left="569" width="36" height="19" font="3">listed </text>
<text top="240" left="569" width="144" height="19" font="3">Encainide 432, placebo </text>
<text top="258" left="569" width="26" height="19" font="3">425 </text>
<text top="277" left="569" width="146" height="19" font="3">Flecainide 323, placebo </text>
<text top="295" left="569" width="30" height="19" font="3">318. </text>
<text top="314" left="569" width="7" height="19" font="3">  </text>
<text top="332" left="569" width="144" height="19" font="4"><b>Comparator:</b>  <b>  </b>Placebo </text>
<text top="350" left="569" width="3" height="19" font="4"><b> </b></text>
<text top="204" left="736" width="136" height="19" font="4"><b>1</b>°<b> endpoint:</b>  after 10 </text>
<text top="223" left="736" width="148" height="19" font="3">mo there was an excess </text>
<text top="241" left="736" width="102" height="19" font="3">in deaths due to </text>
<text top="259" left="736" width="148" height="19" font="3">arrhythmia (p=0.0004)   </text>
<text top="278" left="736" width="147" height="19" font="3">in patients treated with </text>
<text top="296" left="736" width="145" height="19" font="3">encainide or flecainide. </text>
<text top="314" left="736" width="3" height="19" font="3"> </text>
<text top="333" left="736" width="3" height="19" font="3"> </text>
<text top="351" left="736" width="119" height="19" font="4"><b>Safety endpoint (if </b></text>
<text top="369" left="736" width="92" height="19" font="4"><b>relevant):</b>  n/a </text>
<text top="388" left="736" width="3" height="19" font="3"> </text>
<text top="406" left="736" width="3" height="19" font="4"><b> </b></text>
<text top="204" left="897" width="157" height="19" font="3">● Excess in deaths due to </text>
<text top="222" left="897" width="166" height="19" font="3">shock due to recurrent MI. </text>
<text top="240" left="897" width="3" height="19" font="3"> </text>
<text top="258" left="897" width="3" height="19" font="3"> </text>
<text top="277" left="897" width="3" height="19" font="3"> </text>
<text top="552" left="123" width="59" height="19" font="3">●<b> CAST II</b> </text>
<text top="571" left="123" width="87" height="19" font="3">● The Cardiac </text>
<text top="589" left="123" width="73" height="19" font="3">Arrhythmia </text>
<text top="607" left="123" width="118" height="19" font="3">Suppression Trial II </text>
<text top="626" left="123" width="119" height="19" font="3">Investigators. 1992 </text>
<text top="644" left="123" width="35" height="19" font="3">(481) </text>
<text top="662" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1377359">● </a></text>
<text top="662" left="136" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1377359">1377359</a></text>
<text top="662" left="189" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1377359"> </a></text>
<text top="552" left="276" width="62" height="19" font="4"><b>Aim:</b>  test </text>
<text top="571" left="276" width="98" height="19" font="3">hypothesis that </text>
<text top="589" left="276" width="92" height="19" font="3">suppression of </text>
<text top="607" left="276" width="114" height="19" font="3">ventricular ectopy </text>
<text top="626" left="276" width="101" height="19" font="3">post MI reduces </text>
<text top="644" left="276" width="116" height="19" font="3">incidence of SCA n </text>
<text top="662" left="276" width="96" height="19" font="3">patients whose </text>
<text top="680" left="276" width="72" height="19" font="3">ectopy was </text>
<text top="699" left="276" width="91" height="19" font="3">suppressed by </text>
<text top="717" left="276" width="66" height="19" font="3">moricizine </text>
<text top="735" left="276" width="3" height="19" font="3"> </text>
<text top="754" left="276" width="3" height="19" font="3"> </text>
<text top="552" left="415" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="571" left="415" width="137" height="19" font="3">Post MI, 6 d to 2 y; six </text>
<text top="589" left="415" width="126" height="19" font="3">or more PVCs/h and </text>
<text top="607" left="415" width="140" height="19" font="3">no VT over 15 beats at </text>
<text top="626" left="415" width="90" height="19" font="3">120 bpm. 80% </text>
<text top="644" left="415" width="129" height="19" font="3">suppressioin of PVCs </text>
<text top="662" left="415" width="132" height="19" font="3">and 90% suppression </text>
<text top="680" left="415" width="55" height="19" font="3">of NSVT. </text>
<text top="699" left="415" width="3" height="19" font="3"> </text>
<text top="717" left="415" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="735" left="415" width="139" height="19" font="3">patients with any runs </text>
<text top="754" left="415" width="101" height="19" font="3">lasting 30 sec or </text>
<text top="552" left="569" width="153" height="19" font="4"><b>Intervention: </b>Moricizine </text>
<text top="571" left="569" width="7" height="19" font="3">  </text>
<text top="589" left="569" width="141" height="19" font="4"><b>Comparator:</b> Placebo,  </text>
<text top="607" left="569" width="3" height="19" font="4"><b> </b></text>
<text top="553" left="736" width="85" height="19" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="571" left="736" width="134" height="19" font="3">Terminated early due </text>
<text top="590" left="736" width="142" height="19" font="3">to excess mortality (17 </text>
<text top="608" left="736" width="128" height="19" font="3">of 665 with death or </text>
<text top="626" left="736" width="140" height="19" font="3">SCA with moricizine vs </text>
<text top="645" left="736" width="140" height="19" font="3">3 of 660 with placebo) </text>
<text top="663" left="736" width="3" height="19" font="3"> </text>
<text top="681" left="736" width="132" height="19" font="4"><b>Safety endpoint: n/a </b></text>
<text top="699" left="736" width="3" height="19" font="4"><b> </b></text>
<text top="552" left="897" width="40" height="19" font="3">● N/A </text>
<text top="571" left="897" width="3" height="19" font="3"> </text>
<text top="589" left="897" width="3" height="19" font="3"> </text>
<text top="607" left="897" width="3" height="19" font="3"> </text>
</page>
<page number="268" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">268 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="276" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="127" left="276" width="79" height="19" font="3">Randomized </text>
<text top="145" left="276" width="111" height="19" font="3">contolled, double-</text>
<text top="164" left="276" width="37" height="19" font="3">bllind<b> </b></text>
<text top="182" left="276" width="3" height="19" font="3"> </text>
<text top="200" left="276" width="76" height="19" font="4"><b>Size:</b>    1335 </text>
<text top="109" left="415" width="113" height="19" font="3">longer at a rate of </text>
<text top="127" left="415" width="131" height="19" font="3">≥120 complexes/min </text>
<text top="219" left="115" width="4" height="21" font="2"><b> </b></text>
<text top="275" left="115" width="933" height="21" font="2"><b>Data Supplement 53. Nonrandomized Trials, Observational Studies, and/or Registries of Medication-Induced Arrhythmias (Section 10.7) </b></text>
<text top="296" left="147" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="315" left="173" width="51" height="19" font="4"><b>Author; </b></text>
<text top="333" left="151" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="296" left="295" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="315" left="325" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="296" left="463" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="296" left="635" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="315" left="647" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="333" left="679" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="296" left="878" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="315" left="906" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="352" left="125" width="117" height="19" font="3">● Wyse et al. 2001 </text>
<text top="370" left="125" width="35" height="19" font="3">(482) </text>
<text top="389" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11704386">● </a></text>
<text top="389" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11704386">11704386</a></text>
<text top="389" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11704386"> </a></text>
<text top="407" left="125" width="3" height="19" font="3"> </text>
<text top="352" left="286" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="370" left="286" width="127" height="19" font="3">Prospective study of </text>
<text top="389" left="286" width="126" height="19" font="3">the registry of AVID, </text>
<text top="407" left="286" width="90" height="19" font="3">examining the </text>
<text top="425" left="286" width="127" height="19" font="3">outcome of patients </text>
<text top="444" left="286" width="118" height="19" font="3">with “transient” or </text>
<text top="462" left="286" width="129" height="19" font="3">“correctable” causes </text>
<text top="480" left="286" width="56" height="19" font="3">of VT/VF </text>
<text top="499" left="286" width="3" height="19" font="3"> </text>
<text top="517" left="286" width="137" height="19" font="4"><b>Size </b>278 patients with </text>
<text top="535" left="286" width="75" height="19" font="3">transient or </text>
<text top="553" left="286" width="131" height="19" font="3">correctable cause, of </text>
<text top="572" left="286" width="131" height="19" font="3">4450 in registry; only </text>
<text top="590" left="286" width="135" height="19" font="3">18 (6.5%) had an AAD </text>
<text top="608" left="286" width="54" height="19" font="3">reaction </text>
<text top="352" left="443" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="370" left="443" width="154" height="19" font="3">Patients with “transient” </text>
<text top="389" left="443" width="146" height="19" font="3">or “correctable” VT/VF, </text>
<text top="407" left="443" width="149" height="19" font="3">compared with patients </text>
<text top="425" left="443" width="133" height="19" font="3">with high risk in AVID </text>
<text top="444" left="443" width="121" height="19" font="3">registry. Patients in </text>
<text top="462" left="443" width="137" height="19" font="3">registry could have EF </text>
<text top="480" left="443" width="37" height="19" font="3">&gt;40% </text>
<text top="499" left="443" width="3" height="19" font="3"> </text>
<text top="517" left="443" width="148" height="19" font="4"><b>Exclusion criteria:</b>  N/A  </text>
<text top="535" left="443" width="3" height="19" font="3"> </text>
<text top="353" left="617" width="141" height="19" font="4"><b>1</b>°<b> endpoint: </b>Mortality </text>
<text top="371" left="617" width="3" height="19" font="3"> </text>
<text top="389" left="617" width="184" height="19" font="4"><b>Results:</b>  mortality of patients </text>
<text top="408" left="617" width="116" height="19" font="3">with a transient or </text>
<text top="426" left="617" width="73" height="19" font="3">correctable </text>
<text top="444" left="617" width="141" height="19" font="3">cause of VT/VF was no </text>
<text top="463" left="617" width="159" height="19" font="3">different or perhaps even </text>
<text top="481" left="617" width="156" height="19" font="3">worse than that of the 1° </text>
<text top="499" left="617" width="44" height="19" font="3">VT/VF. </text>
<text top="518" left="617" width="3" height="19" font="3"> </text>
<text top="352" left="818" width="241" height="19" font="3">● Mortality of patients with a transient </text>
<text top="370" left="818" width="230" height="19" font="3">or correctable cause of VT/VF was no </text>
<text top="389" left="818" width="231" height="19" font="3">different or perhaps even worse than </text>
<text top="407" left="818" width="128" height="19" font="3">that of the 1° VT/VF. </text>
<text top="425" left="818" width="242" height="19" font="3">However, the small number of patients </text>
<text top="444" left="818" width="223" height="19" font="3">with AAD reaction seemed to “most </text>
<text top="462" left="818" width="200" height="19" font="3">likely to presage better survival” </text>
<text top="627" left="125" width="130" height="19" font="3">● Monnig et al. 2012 </text>
<text top="646" left="125" width="35" height="19" font="3">(483) </text>
<text top="664" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21979994">● </a></text>
<text top="664" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21979994">21979994</a></text>
<text top="664" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21979994"> </a></text>
<text top="682" left="125" width="7" height="19" font="3">  </text>
<text top="627" left="286" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="646" left="286" width="129" height="19" font="3">center observational </text>
<text top="664" left="286" width="28" height="19" font="3">trial </text>
<text top="682" left="286" width="3" height="19" font="3"> </text>
<text top="701" left="286" width="3" height="19" font="3"> </text>
<text top="719" left="286" width="3" height="19" font="3"> </text>
<text top="737" left="286" width="3" height="19" font="3"> </text>
<text top="756" left="286" width="99" height="19" font="4"><b>Size </b>43 patients </text>
<text top="627" left="443" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="646" left="443" width="129" height="19" font="3">survival of CA due to </text>
<text top="664" left="443" width="77" height="19" font="3">acquired QT </text>
<text top="682" left="443" width="141" height="19" font="3">prolongation/TdP who </text>
<text top="701" left="443" width="158" height="19" font="3">received an ICD. 79% had </text>
<text top="719" left="443" width="144" height="19" font="3">drug-induced TdP from </text>
<text top="737" left="443" width="49" height="19" font="3">an AAD.</text>
<text top="736" left="492" width="4" height="21" font="0"> </text>
<text top="737" left="496" width="84" height="19" font="3">sotalol N=17; </text>
<text top="756" left="443" width="117" height="19" font="3">amiodarone N=12; </text>
<text top="774" left="443" width="61" height="19" font="3">quinidine </text>
<text top="628" left="617" width="145" height="19" font="4"><b>1</b>°<b> endpoint: ICD shock</b> </text>
<text top="647" left="617" width="3" height="19" font="3"> </text>
<text top="665" left="617" width="184" height="19" font="4"><b>Results:</b>  Over mean followup </text>
<text top="683" left="617" width="117" height="19" font="3">of 84 mo, 44% had </text>
<text top="701" left="617" width="146" height="19" font="3">appropriate shocks and </text>
<text top="720" left="617" width="175" height="19" font="3">inappropriate shocks in 30% </text>
<text top="738" left="617" width="188" height="19" font="3">(Only inappropriate in 3 of 43) </text>
<text top="756" left="617" width="3" height="19" font="3"> </text>
<text top="627" left="818" width="250" height="19" font="3">● ICD therapy was appropriate in 44% of </text>
<text top="646" left="818" width="189" height="19" font="3">patients with drug-induced QT </text>
<text top="664" left="818" width="232" height="19" font="3">prolongation/TdP, (where DI-TdP was </text>
<text top="682" left="818" width="144" height="19" font="3">due to an AAD in 79%). </text>
<text top="701" left="818" width="3" height="19" font="3"> </text>
<text top="719" left="818" width="233" height="19" font="3">● However, EF was not normal (mean </text>
<text top="737" left="818" width="46" height="19" font="3">41±12) </text>
<text top="756" left="818" width="3" height="19" font="3"> </text>
</page>
<page number="269" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">269 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="443" width="147" height="19" font="3">N=3; propafenone N=1; </text>
<text top="127" left="443" width="88" height="19" font="3">ajmaline N=1] </text>
<text top="145" left="443" width="3" height="19" font="3"> </text>
<text top="164" left="443" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="109" left="818" width="202" height="19" font="3">● Appropriate shocks were most </text>
<text top="127" left="818" width="255" height="19" font="3">common in those with structural disease. </text>
<text top="145" left="818" width="3" height="19" font="3"> </text>
<text top="164" left="818" width="243" height="19" font="3">● Beta blockers did not seem to reduce </text>
<text top="182" left="818" width="25" height="19" font="3">risk </text>
<text top="201" left="125" width="132" height="19" font="3">● Antman et al. 1990 </text>
<text top="219" left="125" width="35" height="19" font="3">(484) </text>
<text top="238" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2188752">● </a></text>
<text top="238" left="137" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2188752">2188752</a></text>
<text top="238" left="190" width="7" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2188752">  </a></text>
<text top="201" left="286" width="137" height="19" font="4"><b>Study type:</b>   An open-</text>
<text top="219" left="286" width="107" height="19" font="3">label multicenter </text>
<text top="238" left="286" width="114" height="19" font="3">clinical trial of Fab </text>
<text top="256" left="286" width="110" height="19" font="3">treatment for life-</text>
<text top="274" left="286" width="125" height="19" font="3">threatening digitalis </text>
<text top="293" left="286" width="75" height="19" font="3">intoxication </text>
<text top="311" left="286" width="3" height="19" font="3"> </text>
<text top="329" left="286" width="3" height="19" font="3"> </text>
<text top="347" left="286" width="3" height="19" font="3"> </text>
<text top="366" left="286" width="3" height="19" font="3"> </text>
<text top="384" left="286" width="54" height="19" font="4"><b>Size</b> 150 </text>
<text top="201" left="443" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="219" left="443" width="157" height="19" font="3">Digitalis intoxication with </text>
<text top="238" left="443" width="126" height="19" font="3">actual or potentially </text>
<text top="256" left="443" width="145" height="19" font="3">life-threatening cardiac </text>
<text top="274" left="443" width="133" height="19" font="3">rhythm disturbances, </text>
<text top="293" left="443" width="139" height="19" font="3">hyperkalemia, or both </text>
<text top="311" left="443" width="114" height="19" font="3">caused by digitalis </text>
<text top="329" left="443" width="160" height="19" font="3">intoxication; refractory to </text>
<text top="347" left="443" width="151" height="19" font="3">or likely to be refractory </text>
<text top="366" left="443" width="112" height="19" font="3">to treatment with </text>
<text top="384" left="443" width="157" height="19" font="3">conventional therapeutic </text>
<text top="402" left="443" width="71" height="19" font="3">modalities. </text>
<text top="421" left="443" width="139" height="19" font="3">46% had refractory VT </text>
<text top="439" left="443" width="105" height="19" font="3">and 33% had VF. </text>
<text top="457" left="443" width="3" height="19" font="3"> </text>
<text top="476" left="443" width="148" height="19" font="4"><b>Exclusion criteria:</b>   N/A </text>
<text top="494" left="443" width="3" height="19" font="3"> </text>
<text top="202" left="617" width="165" height="19" font="4"><b>1</b>°<b> endpoint: </b>Resolution of </text>
<text top="220" left="617" width="153" height="19" font="3">toxicity and time course. </text>
<text top="238" left="617" width="131" height="19" font="3">Dosing requirements </text>
<text top="257" left="617" width="3" height="19" font="3"> </text>
<text top="275" left="617" width="177" height="19" font="4"><b>Results:</b>  80% had resolution </text>
<text top="293" left="617" width="176" height="19" font="3">of all signs and symptoms of </text>
<text top="312" left="617" width="173" height="19" font="3">toxicity, 10% improved, and </text>
<text top="330" left="617" width="166" height="19" font="3">10% showed no response.  </text>
<text top="348" left="617" width="178" height="19" font="3">Median initial response time </text>
<text top="367" left="617" width="187" height="19" font="3">was 19 min. Time to complete </text>
<text top="385" left="617" width="181" height="19" font="3">response was 88 min median </text>
<text top="403" left="617" width="89" height="19" font="3">(30–360 min). </text>
<text top="422" left="617" width="188" height="19" font="3">54% of those with CA survived </text>
<text top="440" left="617" width="97" height="19" font="3">hospitalization. </text>
<text top="458" left="617" width="162" height="19" font="3">Adverse events in 14/148, </text>
<text top="476" left="617" width="128" height="19" font="3">with hypokalemia or </text>
<text top="495" left="617" width="98" height="19" font="3">worsening CHF. </text>
<text top="201" left="818" width="213" height="19" font="3">● 90% of patients had a treatment </text>
<text top="219" left="818" width="247" height="19" font="3">response in the setting of advanced and </text>
<text top="238" left="818" width="217" height="19" font="3">potentially life-threatening digitalis </text>
<text top="256" left="818" width="52" height="19" font="3">toxicity. </text>
<text top="514" left="125" width="114" height="19" font="3">● Chan et al. 2014 </text>
<text top="532" left="125" width="35" height="19" font="3">(485) </text>
<text top="550" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25089630">● </a></text>
<text top="550" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25089630">25089630</a></text>
<text top="550" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25089630"> </a></text>
<text top="569" left="125" width="7" height="19" font="3">  </text>
<text top="514" left="286" width="128" height="19" font="4"><b>Study type:</b>   Review </text>
<text top="532" left="286" width="103" height="19" font="3">of 10 case series </text>
<text top="550" left="286" width="3" height="19" font="3"> </text>
<text top="569" left="286" width="3" height="19" font="3"> </text>
<text top="587" left="286" width="3" height="19" font="3"> </text>
<text top="605" left="286" width="3" height="19" font="3"> </text>
<text top="624" left="286" width="62" height="19" font="4"><b>Size</b> 2080 </text>
<text top="514" left="443" width="159" height="19" font="4"><b>Inclusion criteria: </b>digoxin </text>
<text top="532" left="443" width="66" height="19" font="3">poisoning  </text>
<text top="550" left="443" width="3" height="19" font="3"> </text>
<text top="569" left="443" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="587" left="443" width="3" height="19" font="3"> </text>
<text top="515" left="617" width="169" height="19" font="4"><b>1</b>°<b> endpoint:  </b>Resolution of </text>
<text top="533" left="617" width="186" height="19" font="3">toxicity, time course to effect. </text>
<text top="551" left="617" width="3" height="19" font="3"> </text>
<text top="569" left="617" width="159" height="19" font="4"><b>Results:</b>  Response varied </text>
<text top="588" left="617" width="132" height="19" font="3">from 80-90% to 50%. </text>
<text top="606" left="617" width="160" height="19" font="3">Reversal of toxicity 30–45 </text>
<text top="624" left="617" width="31" height="19" font="3">min. </text>
<text top="643" left="617" width="133" height="19" font="3">Adverse events &lt;10% </text>
<text top="661" left="617" width="177" height="19" font="3">(exacerbated CHF, increased </text>
<text top="680" left="617" width="133" height="19" font="3">HR and hypokalemia) </text>
<text top="698" left="617" width="160" height="19" font="3">Lower dose requirements </text>
<text top="716" left="617" width="167" height="19" font="3">(1/2 of the full neutralizing </text>
<text top="734" left="617" width="178" height="19" font="3">dose) are appropriate unless </text>
<text top="753" left="617" width="99" height="19" font="3">CA is imminent. </text>
<text top="514" left="818" width="226" height="19" font="3">● Confirms efficacy, onset of action.  </text>
<text top="532" left="818" width="253" height="19" font="3">Suggests that lower doses (at lower cost) </text>
<text top="550" left="818" width="257" height="19" font="3">are appropriate in many situations due to </text>
<text top="569" left="818" width="254" height="19" font="3">pharmacokinetics of digoxin (unless CA is </text>
<text top="587" left="818" width="74" height="19" font="3">imminent).  </text>
</page>
<page number="270" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">270 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="148" height="19" font="3">● Hauptman et al. 1999 </text>
<text top="127" left="125" width="35" height="19" font="3">(486) </text>
<text top="145" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10069797">● </a></text>
<text top="145" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10069797">10069797</a></text>
<text top="145" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10069797"> </a></text>
<text top="164" left="125" width="7" height="19" font="3">  </text>
<text top="109" left="286" width="128" height="19" font="4"><b>Study type:</b>   Review </text>
<text top="127" left="286" width="97" height="19" font="3">of treatment of </text>
<text top="145" left="286" width="99" height="19" font="3">digoxin toxicity  </text>
<text top="164" left="286" width="3" height="19" font="3"> </text>
<text top="182" left="286" width="3" height="19" font="3"> </text>
<text top="200" left="286" width="55" height="19" font="4"><b>Size</b> N/A </text>
<text top="109" left="443" width="139" height="19" font="4"><b>Inclusion criteria:</b> N/A<b> </b></text>
<text top="127" left="443" width="3" height="19" font="3"> </text>
<text top="145" left="443" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="164" left="443" width="3" height="19" font="3"> </text>
<text top="109" left="617" width="109" height="19" font="4"><b>1</b>°<b> endpoint</b>: N/A </text>
<text top="128" left="617" width="3" height="19" font="3"> </text>
<text top="146" left="617" width="83" height="19" font="4"><b>Results:</b>  N/A </text>
<text top="165" left="617" width="3" height="19" font="3"> </text>
<text top="109" left="818" width="198" height="20" font="3">• More common manifestations </text>
<text top="128" left="818" width="218" height="19" font="3">(including occasional ectopic beats, </text>
<text top="146" left="818" width="251" height="19" font="3">marked first-degree AV block, or AF with </text>
<text top="165" left="818" width="252" height="19" font="3">a slow ventricular response) require only </text>
<text top="183" left="818" width="238" height="19" font="3">temporary withdrawal of the drug and </text>
<text top="201" left="818" width="75" height="19" font="3">monitoring. </text>
<text top="219" left="818" width="3" height="19" font="3"> </text>
<text top="238" left="818" width="3" height="19" font="3"> </text>
<text top="256" left="818" width="220" height="19" font="3">Administration of potassium salts is </text>
<text top="274" left="818" width="226" height="19" font="3">recommended for ectopic VA,  even  </text>
<text top="293" left="818" width="116" height="19" font="3">when  the  serum   </text>
<text top="311" left="818" width="250" height="19" font="3">potassium is within  the “normal” range. </text>
<text top="330" left="125" width="148" height="19" font="3">● Kelly et al. 1992 (487) </text>
<text top="348" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1626485">● </a></text>
<text top="348" left="137" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1626485">1626485</a></text>
<text top="348" left="190" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1626485"> </a></text>
<text top="367" left="125" width="3" height="19" font="3"> </text>
<text top="385" left="125" width="3" height="19" font="4"><b> </b></text>
<text top="330" left="286" width="128" height="19" font="4"><b>Study type:</b>   Review </text>
<text top="348" left="286" width="3" height="19" font="3"> </text>
<text top="367" left="286" width="3" height="19" font="3"> </text>
<text top="385" left="286" width="59" height="19" font="4"><b>Size: </b>N/A </text>
<text top="330" left="443" width="139" height="19" font="4"><b>Inclusion criteria: </b>N/A<b> </b></text>
<text top="348" left="443" width="3" height="19" font="3"> </text>
<text top="367" left="443" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="385" left="443" width="3" height="19" font="3"> </text>
<text top="331" left="617" width="105" height="19" font="4"><b>1</b>°<b> endpoint </b>N/A </text>
<text top="349" left="617" width="3" height="19" font="3"> </text>
<text top="367" left="617" width="83" height="19" font="4"><b>Results:</b>  N/A </text>
<text top="386" left="617" width="3" height="19" font="3"> </text>
<text top="330" left="818" width="223" height="19" font="3">● Describes VT with digoxin toxicity. </text>
<text top="348" left="818" width="246" height="19" font="3">● Notes exacerbation of digoxin toxicity </text>
<text top="367" left="818" width="233" height="19" font="3">with low and high K, hypothyroidism,  </text>
<text top="385" left="818" width="176" height="19" font="3">Notes benefit of magnesium </text>
<text top="403" left="818" width="97" height="19" font="3">administration. </text>
<text top="422" left="125" width="141" height="19" font="3">● Osmonov et al. 2012 </text>
<text top="441" left="125" width="35" height="19" font="3">(488) </text>
<text top="459" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22530749">● </a></text>
<text top="459" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22530749">22530749</a></text>
<text top="459" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22530749"> </a></text>
<text top="477" left="125" width="3" height="19" font="3"> </text>
<text top="496" left="125" width="7" height="19" font="3">  </text>
<text top="422" left="286" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="441" left="286" width="129" height="19" font="3">center observational </text>
<text top="459" left="286" width="42" height="19" font="3">series. </text>
<text top="477" left="286" width="3" height="19" font="3"> </text>
<text top="496" left="286" width="3" height="19" font="3"> </text>
<text top="514" left="286" width="3" height="19" font="3"> </text>
<text top="532" left="286" width="3" height="19" font="3"> </text>
<text top="550" left="286" width="58" height="19" font="4"><b>Size: </b>108 </text>
<text top="422" left="443" width="144" height="19" font="4"><b>Inclusion criteria: </b>drug-</text>
<text top="441" left="443" width="160" height="19" font="3">related symptomatic type </text>
<text top="459" left="443" width="153" height="19" font="3">2 second degree or third </text>
<text top="477" left="443" width="102" height="19" font="3">degree AV block </text>
<text top="496" left="443" width="3" height="19" font="3"> </text>
<text top="514" left="443" width="140" height="19" font="4"><b>Exclusion criteria:</b>  MI, </text>
<text top="532" left="443" width="160" height="19" font="3">electrolyte abnormalities, </text>
<text top="550" left="443" width="128" height="19" font="3">digitalis toxicity, and </text>
<text top="569" left="443" width="120" height="19" font="3">vasovagal syncope. </text>
<text top="587" left="443" width="166" height="19" font="3">Digoxin toxicity (a digoxin   </text>
<text top="605" left="443" width="141" height="19" font="3">level   from   a   blood   </text>
<text top="624" left="443" width="141" height="19" font="3">test   of   higher than 2 </text>
<text top="642" left="443" width="154" height="19" font="3">nmol/L  with  symptoms  </text>
<text top="660" left="443" width="105" height="19" font="3">such  as  nausea, </text>
<text top="679" left="443" width="160" height="19" font="3">vomiting, and color vision </text>
<text top="697" left="443" width="107" height="19" font="3">abnormalities or  </text>
<text top="715" left="443" width="161" height="19" font="3">Above 2.5 nmol/L with or  </text>
<text top="733" left="443" width="125" height="19" font="3">without  symptoms. </text>
<text top="423" left="617" width="184" height="19" font="4"><b>1</b>°<b> endpoint: </b>improvement or </text>
<text top="441" left="617" width="96" height="19" font="3">need for pacer. </text>
<text top="460" left="617" width="3" height="19" font="3"> </text>
<text top="478" left="617" width="174" height="19" font="4"><b>Results:</b>  39 patients had AV </text>
<text top="496" left="617" width="161" height="19" font="3">block with digoxin dosing, </text>
<text top="515" left="617" width="166" height="19" font="3">with 28 of them improving </text>
<text top="533" left="617" width="180" height="19" font="3">after withdrawal of the drug. </text>
<text top="551" left="617" width="3" height="19" font="3"> </text>
<text top="422" left="818" width="227" height="19" font="3">● Digoxin-induced AV block (without </text>
<text top="441" left="818" width="235" height="19" font="3">“toxicity”) usually improved (28 of 39) </text>
<text top="459" left="818" width="180" height="19" font="3">after withdrawal of the drug. </text>
<text top="753" left="125" width="126" height="19" font="3">● Tzivoni et al. 1988 </text>
<text top="771" left="125" width="35" height="19" font="3">(489) </text>
<text top="752" left="286" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="771" left="286" width="116" height="19" font="3">Consecutive series </text>
<text top="752" left="443" width="138" height="19" font="4"><b>Inclusion criteria:</b> TdP </text>
<text top="771" left="443" width="114" height="19" font="3">(9/12 due to AAD)<b> </b></text>
<text top="753" left="617" width="178" height="19" font="4"><b>1</b>°<b> endpoint </b>Abolition of TdP </text>
<text top="772" left="617" width="3" height="19" font="3"> </text>
<text top="753" left="818" width="243" height="19" font="3">● This established MgSO4 as treatment </text>
<text top="771" left="818" width="47" height="19" font="3">for TdP </text>
</page>
<page number="271" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">271 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3338130">● </a></text>
<text top="109" left="137" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3338130">3338130</a></text>
<text top="109" left="190" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3338130"> </a></text>
<text top="127" left="125" width="3" height="19" font="3"> </text>
<text top="145" left="125" width="7" height="19" font="3">  </text>
<text top="109" left="286" width="137" height="19" font="3">Provided 2 gm IV with </text>
<text top="127" left="286" width="120" height="19" font="3">second bolus of 2 g </text>
<text top="145" left="286" width="105" height="19" font="3">after 5-15 min. 9 </text>
<text top="164" left="286" width="135" height="19" font="3">received infusion at 3-</text>
<text top="182" left="286" width="137" height="19" font="3">20 mg/min for 7-48 h. </text>
<text top="200" left="286" width="3" height="19" font="3"> </text>
<text top="218" left="286" width="46" height="19" font="4"><b>Size </b>12 </text>
<text top="109" left="443" width="3" height="19" font="3"> </text>
<text top="127" left="443" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="145" left="443" width="3" height="19" font="3"> </text>
<text top="109" left="617" width="141" height="19" font="4"><b>Results:</b>  In nine of the </text>
<text top="127" left="617" width="176" height="19" font="3">patients a single bolus of 2 g </text>
<text top="145" left="617" width="183" height="19" font="3">completely abolished the TdP </text>
<text top="164" left="617" width="188" height="19" font="3">within 1 to 5 min, and in three </text>
<text top="182" left="617" width="177" height="19" font="3">others complete abolition of </text>
<text top="200" left="617" width="178" height="19" font="3">the TdP was achieved after a </text>
<text top="219" left="617" width="173" height="19" font="3">second bolus was given 5 to </text>
<text top="237" left="617" width="81" height="19" font="3">15 min later. </text>
<text top="256" left="125" width="119" height="19" font="3">● Keren et al. 1981 </text>
<text top="274" left="125" width="35" height="19" font="3">(490) </text>
<text top="292" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7296791">● </a></text>
<text top="292" left="137" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7296791">7296791</a></text>
<text top="292" left="190" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7296791"> </a></text>
<text top="311" left="125" width="3" height="19" font="3"> </text>
<text top="256" left="286" width="121" height="19" font="4"><b>Study type:</b>   Single </text>
<text top="274" left="286" width="81" height="19" font="3">center series </text>
<text top="292" left="286" width="3" height="19" font="3"> </text>
<text top="311" left="286" width="3" height="19" font="3"> </text>
<text top="329" left="286" width="3" height="19" font="3"> </text>
<text top="347" left="286" width="3" height="19" font="3"> </text>
<text top="366" left="286" width="130" height="19" font="4"><b>Size: </b>10 (9 on AAD, 4 </text>
<text top="384" left="286" width="127" height="19" font="3">treated with pacing) </text>
<text top="256" left="443" width="141" height="19" font="4"><b>Inclusion criteria: </b>TdP, </text>
<text top="274" left="443" width="79" height="19" font="3">QTc&gt;600 ms </text>
<text top="292" left="443" width="3" height="19" font="3"> </text>
<text top="311" left="443" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="329" left="443" width="3" height="19" font="3"> </text>
<text top="257" left="617" width="156" height="19" font="4"><b>1</b>°<b> endpoint: </b>response to </text>
<text top="275" left="617" width="153" height="19" font="3">therapy of isoproterenol </text>
<text top="293" left="617" width="162" height="19" font="3">and/or ventricular pacing<b>.</b> </text>
<text top="312" left="617" width="3" height="19" font="3"> </text>
<text top="330" left="617" width="181" height="19" font="4"><b>Results:</b>  Pacing effective in 4 </text>
<text top="348" left="617" width="175" height="19" font="3">of 4 patients, 2 who had not </text>
<text top="367" left="617" width="175" height="19" font="3">responded to isoproterenol. </text>
<text top="385" left="617" width="158" height="19" font="3">Continued up to 48 h and </text>
<text top="403" left="617" width="180" height="19" font="3">pacer removed after another </text>
<text top="422" left="617" width="182" height="19" font="3">24 h. Pacing rate was “lowest </text>
<text top="440" left="617" width="176" height="19" font="3">effective rate”, 88-105 bpm. </text>
<text top="458" left="617" width="3" height="19" font="3"> </text>
<text top="476" left="617" width="167" height="19" font="3">In 2 cases atrial pacing was </text>
<text top="495" left="617" width="164" height="19" font="3">tried, initially effective but </text>
<text top="513" left="617" width="128" height="19" font="3">unstable so V pacing </text>
<text top="531" left="617" width="62" height="19" font="3">provided. </text>
<text top="550" left="617" width="3" height="19" font="3"> </text>
<text top="568" left="617" width="186" height="19" font="3">Lidocaine was given in 4 cases </text>
<text top="586" left="617" width="141" height="19" font="3">without improvement. </text>
<text top="605" left="617" width="3" height="19" font="3"> </text>
<text top="623" left="617" width="114" height="19" font="3">Isoproterenol (2-8 </text>
<text top="641" left="616" width="181" height="19" font="3">microgram/min) was given in </text>
<text top="660" left="617" width="151" height="19" font="3">7 cases: effective in 5/7. </text>
<text top="256" left="818" width="242" height="19" font="3">● This confirmed the effectiveness of V </text>
<text top="274" left="818" width="178" height="19" font="3">pacing for DI-TdP, even after </text>
<text top="292" left="818" width="185" height="19" font="3">isoproterenol was ineffective. </text>
<text top="311" left="818" width="3" height="19" font="3"> </text>
<text top="329" left="818" width="220" height="19" font="3">● This confirms the effectiveness of </text>
<text top="347" left="818" width="236" height="19" font="3">isoproterenol as a first line treatment. </text>
<text top="366" left="818" width="3" height="19" font="3"> </text>
<text top="384" left="818" width="215" height="19" font="3">● Magnesium was not given in this </text>
<text top="402" left="818" width="42" height="19" font="3">series. </text>
<text top="679" left="125" width="114" height="19" font="3">● Choy et al. 1997 </text>
<text top="697" left="125" width="35" height="19" font="3">(373) </text>
<text top="715" left="125" width="16" height="19" font="3">● <a href="http://www.ncbi.nlm.nih.gov/pubmed/9337183"> </a></text>
<text top="715" left="140" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9337183">9337183</a></text>
<text top="715" left="194" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9337183"> </a></text>
<text top="733" left="125" width="3" height="19" font="3"> </text>
<text top="752" left="125" width="7" height="19" font="3">  </text>
<text top="678" left="286" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="697" left="286" width="82" height="19" font="3">Double-blind </text>
<text top="715" left="286" width="91" height="19" font="3">comparison of </text>
<text top="734" left="286" width="119" height="19" font="3">potassium infusion </text>
<text top="752" left="286" width="120" height="19" font="3">after quinidine and </text>
<text top="678" left="443" width="160" height="19" font="4"><b>Inclusion criteria: </b>healthy </text>
<text top="697" left="443" width="135" height="19" font="3">subjects (12) and CHF </text>
<text top="715" left="443" width="151" height="19" font="3">(mean EF 17%) with age-</text>
<text top="734" left="443" width="110" height="19" font="3">matched controls </text>
<text top="752" left="443" width="79" height="19" font="3">without CHF </text>
<text top="770" left="443" width="3" height="19" font="3"> </text>
<text top="679" left="617" width="176" height="19" font="4"><b>1</b>°<b> endpoint: </b>Effect on QTUc </text>
<text top="698" left="617" width="166" height="19" font="3">from KCl after quinidine or </text>
<text top="716" left="617" width="55" height="19" font="3">placebo. </text>
<text top="734" left="617" width="3" height="19" font="3"> </text>
<text top="752" left="617" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="679" left="818" width="209" height="19" font="3">● “Potentially arrhythmogenic QT </text>
<text top="697" left="818" width="256" height="19" font="3">abnormalities during quinidine treatment </text>
<text top="715" left="818" width="243" height="19" font="3">and in CHF can be nearly normalized by </text>
<text top="734" left="818" width="240" height="19" font="3">modest elevation of serum potassium” </text>
</page>
<page number="272" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">272 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="286" width="143" height="19" font="3">placebo sequentially in </text>
<text top="127" left="286" width="125" height="19" font="3">12 healthy subjects. </text>
<text top="145" left="286" width="134" height="19" font="3">Also, study on QTU in </text>
<text top="164" left="286" width="137" height="19" font="3">patients with CHF and </text>
<text top="182" left="286" width="136" height="19" font="3">age-matched controls </text>
<text top="200" left="286" width="116" height="19" font="3">who receive IV KCl </text>
<text top="219" left="286" width="3" height="19" font="3"> </text>
<text top="237" left="286" width="118" height="19" font="4"><b>Size:  </b>12 healthy, 8 </text>
<text top="255" left="286" width="93" height="19" font="3">CHF plus 8 age-</text>
<text top="273" left="286" width="110" height="19" font="3">matched controls </text>
<text top="109" left="443" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="127" left="443" width="3" height="19" font="3"> </text>
<text top="109" left="617" width="163" height="19" font="3">KCl was IV, 0.5 mEq/kg (to </text>
<text top="127" left="617" width="172" height="19" font="3">maximum of 40 meEq) over </text>
<text top="145" left="617" width="133" height="19" font="3">60-70 min resulted in </text>
<text top="164" left="617" width="165" height="19" font="3">normalization of quinidine-</text>
<text top="182" left="617" width="185" height="19" font="3">induced and CHF-related QTU </text>
<text top="200" left="617" width="82" height="19" font="3">prolongation </text>
<text top="292" left="125" width="148" height="19" font="3">● Yang et al. 1996 (491) </text>
<text top="311" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8565156">● </a></text>
<text top="311" left="137" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8565156">8565156</a></text>
<text top="311" left="190" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8565156"> </a></text>
<text top="329" left="125" width="3" height="19" font="3"> </text>
<text top="347" left="125" width="7" height="19" font="3">  </text>
<text top="292" left="286" width="127" height="19" font="4"><b>Study type: </b>Basis EP </text>
<text top="311" left="286" width="118" height="19" font="3">(cardiac myocytes) </text>
<text top="329" left="286" width="3" height="19" font="4"><b> </b></text>
<text top="347" left="286" width="3" height="19" font="4"><b> </b></text>
<text top="366" left="286" width="3" height="19" font="4"><b> </b></text>
<text top="384" left="286" width="3" height="19" font="4"><b> </b></text>
<text top="402" left="286" width="63" height="19" font="4"><b>Size:  </b>N/A<b> </b></text>
<text top="292" left="443" width="139" height="19" font="4"><b>Inclusion criteria:</b> N/A<b> </b></text>
<text top="311" left="443" width="3" height="19" font="4"><b> </b></text>
<text top="329" left="443" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="347" left="443" width="3" height="19" font="4"><b> </b></text>
<text top="293" left="617" width="175" height="19" font="4"><b>1</b>°<b> endpoint: </b>Change in IC50 </text>
<text top="312" left="617" width="170" height="19" font="3">for dofetilide and quinidine </text>
<text top="330" left="617" width="182" height="19" font="3">according to the extracellular </text>
<text top="348" left="617" width="100" height="19" font="3">K concentration<b> </b></text>
<text top="367" left="617" width="3" height="19" font="4"><b> </b></text>
<text top="385" left="617" width="183" height="19" font="4"><b>Results</b>:  Elevating [K+]o from </text>
<text top="403" left="617" width="175" height="19" font="3">1 to 8 mmol/L increased the </text>
<text top="422" left="617" width="182" height="19" font="3">IC50 for dofetilide block from </text>
<text top="440" left="617" width="179" height="19" font="3">2.7±0.9 to 79±32 nmol/L and </text>
<text top="458" left="617" width="150" height="19" font="3">for quinidine block from </text>
<text top="476" left="617" width="114" height="19" font="3">0.4±0.1 to 3.8±1.2 </text>
<text top="495" left="617" width="172" height="19" font="3">μmol/L.Increased K blunted </text>
<text top="513" left="617" width="174" height="19" font="3">drug effect of dofetilide and </text>
<text top="531" left="617" width="61" height="19" font="3">quinidine </text>
<text top="292" left="818" width="225" height="19" font="3">● Extracellular potassium is a critical </text>
<text top="311" left="818" width="233" height="19" font="3">determinant of drug block of IKr, with </text>
<text top="329" left="818" width="193" height="19" font="3">substantial clinical implications.</text>
<text top="328" left="1011" width="4" height="21" font="0"> </text>
<text top="329" left="1014" width="26" height="19" font="3">The </text>
<text top="347" left="818" width="228" height="19" font="3">increase in drug block with low [K+]o </text>
<text top="366" left="818" width="252" height="19" font="3">provides a mechanism to explain the link </text>
<text top="384" left="818" width="234" height="19" font="3">between hypokalemia and torsade de </text>
<text top="402" left="818" width="49" height="19" font="3">pointes </text>
<text top="550" left="125" width="120" height="19" font="3">● Hellestrand et al. </text>
<text top="569" left="125" width="69" height="19" font="3">1983 (492) </text>
<text top="587" left="125" width="16" height="19" font="3"> <a href="http://www.ncbi.nlm.nih.gov/pubmed/6195608">● </a></text>
<text top="587" left="140" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6195608">6195608</a></text>
<text top="587" left="194" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6195608"> </a></text>
<text top="605" left="125" width="7" height="19" font="3">  </text>
<text top="550" left="286" width="121" height="19" font="4"><b>Study type: </b>Clinical </text>
<text top="569" left="286" width="93" height="19" font="3">research study </text>
<text top="587" left="286" width="3" height="19" font="4"><b> </b></text>
<text top="605" left="286" width="3" height="19" font="4"><b> </b></text>
<text top="624" left="286" width="3" height="19" font="4"><b> </b></text>
<text top="642" left="286" width="3" height="19" font="4"><b> </b></text>
<text top="660" left="286" width="54" height="19" font="4"><b>Size:</b>  28<b> </b></text>
<text top="550" left="443" width="153" height="19" font="4"><b>Inclusion criteria: </b>Group </text>
<text top="569" left="443" width="125" height="19" font="3">I:11 with temporary </text>
<text top="587" left="443" width="144" height="19" font="3">pacer; Group II:10 with </text>
<text top="605" left="443" width="102" height="19" font="3">chronic pacer at </text>
<text top="624" left="443" width="157" height="19" font="3">generator change; Group </text>
<text top="642" left="443" width="154" height="19" font="3">III: 7 with programmable </text>
<text top="660" left="443" width="111" height="19" font="3">pacer with pacing </text>
<text top="679" left="443" width="107" height="19" font="3">threshold testing<b> </b></text>
<text top="697" left="443" width="3" height="19" font="4"><b> </b></text>
<text top="715" left="443" width="144" height="19" font="4"><b>Exclusion criteria: </b> N/A<b> </b></text>
<text top="733" left="443" width="3" height="19" font="4"><b> </b></text>
<text top="551" left="617" width="85" height="19" font="4"><b>1</b>°<b> endpoint:  </b></text>
<text top="569" left="617" width="3" height="19" font="4"><b> </b></text>
<text top="588" left="617" width="182" height="19" font="3">Results:  Given IV flecainide 2 </text>
<text top="606" left="617" width="163" height="19" font="3">mg/kg over 10 min. 7 with </text>
<text top="624" left="617" width="173" height="19" font="3">programmable pacers given </text>
<text top="643" left="617" width="156" height="19" font="3">oral 100-400 mg per day. </text>
<text top="661" left="617" width="87" height="19" font="3">I: 0.66–1.44 V </text>
<text top="680" left="617" width="91" height="19" font="3">II: 1.73–2.13 V </text>
<text top="698" left="617" width="186" height="19" font="3">III: 10 min: at 2.7 V: 0.14–0.22 </text>
<text top="716" left="617" width="153" height="19" font="3">msec; at 4.9 V 0.06–0.11 </text>
<text top="734" left="617" width="181" height="19" font="3">After 3 wk: at 2.7V 0.09–0.28 </text>
<text top="753" left="617" width="156" height="19" font="3">msec, at 4.9 V 0.06–0.16  </text>
<text top="550" left="818" width="247" height="19" font="3">● Flecainide significantly increased both </text>
<text top="569" left="818" width="230" height="19" font="3">acute and chronic thresholds and the </text>
<text top="587" left="818" width="221" height="19" font="3">most marked rise (&gt;200%) occurred </text>
<text top="605" left="818" width="173" height="19" font="3">during chronic oral therapy. </text>
</page>
<page number="273" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">273 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="145" height="19" font="3">● Echt et al. 1989 (493) </text>
<text top="127" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2469545">● </a></text>
<text top="127" left="137" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2469545">2469545</a></text>
<text top="127" left="190" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2469545"> </a></text>
<text top="145" left="125" width="7" height="19" font="3">  </text>
<text top="109" left="286" width="110" height="19" font="4"><b>Study type: Basic </b></text>
<text top="127" left="286" width="82" height="19" font="4"><b>canine study</b> </text>
<text top="145" left="286" width="3" height="19" font="3"> </text>
<text top="164" left="286" width="114" height="19" font="4"><b>Size:  </b>78 protocols </text>
<text top="182" left="286" width="32" height="19" font="3">total </text>
<text top="109" left="443" width="139" height="19" font="4"><b>Inclusion criteria:</b> N/A </text>
<text top="127" left="443" width="3" height="19" font="3"> </text>
<text top="145" left="443" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="164" left="443" width="3" height="19" font="3"> </text>
<text top="109" left="617" width="143" height="19" font="4"><b>1</b>°<b> endpoint:</b> change in </text>
<text top="128" left="617" width="180" height="19" font="3">defibrillation threshold (DFT) </text>
<text top="146" left="617" width="3" height="19" font="3"> </text>
<text top="164" left="617" width="186" height="19" font="4"><b>Results:</b>  ED90 increased from </text>
<text top="183" left="617" width="149" height="19" font="3">11 to 22 Joules (p&lt;0.01) </text>
<text top="201" left="617" width="3" height="19" font="3"> </text>
<text top="109" left="818" width="233" height="19" font="3">● Lidocaine doubled the defibrillation </text>
<text top="127" left="818" width="129" height="19" font="3">energy requirement  </text>
<text top="220" left="125" width="7" height="18" font="3">•</text>
<text top="219" left="131" width="4" height="21" font="0"> </text>
<text top="221" left="135" width="105" height="19" font="3">Crijns et al. 1988 </text>
<text top="239" left="125" width="35" height="19" font="3">(494) </text>
<text top="258" left="125" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3143257">3143257</a></text>
<text top="258" left="178" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3143257"> </a></text>
<text top="276" left="125" width="3" height="19" font="3"> </text>
<text top="294" left="125" width="3" height="19" font="3"> </text>
<text top="220" left="286" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="238" left="286" width="114" height="19" font="3">observational trial<b> </b></text>
<text top="257" left="286" width="3" height="19" font="4"><b> </b></text>
<text top="275" left="286" width="134" height="19" font="4"><b>Size:  </b>6 of 79 patients </text>
<text top="293" left="286" width="142" height="19" font="3">treated with flecainide </text>
<text top="312" left="286" width="126" height="19" font="3">developed this wide </text>
<text top="330" left="286" width="129" height="19" font="3">complex tachycardia<b> </b></text>
<text top="220" left="443" width="150" height="19" font="4"><b>Inclusion criteria: </b>Rate –</text>
<text top="238" left="443" width="147" height="19" font="3">related BBB giving wide </text>
<text top="257" left="443" width="102" height="19" font="3">QRS tachycardia </text>
<text top="275" left="443" width="3" height="19" font="4"><b> </b></text>
<text top="293" left="443" width="144" height="19" font="4"><b>Exclusion criteria:  </b>N/A<b> </b></text>
<text top="311" left="443" width="3" height="19" font="4"><b> </b></text>
<text top="221" left="617" width="109" height="19" font="4"><b>1</b>°<b> endpoint: </b>N/A </text>
<text top="239" left="617" width="3" height="19" font="4"><b> </b></text>
<text top="257" left="617" width="188" height="19" font="4"><b>Results:  </b>6 patients developed </text>
<text top="276" left="617" width="156" height="19" font="3">WCT, rates 145-200 BPM </text>
<text top="294" left="617" width="3" height="19" font="4"><b> </b></text>
<text top="220" left="818" width="228" height="20" font="3">• Wide complex tachycardia resulted </text>
<text top="239" left="818" width="245" height="19" font="3">from tachycardia and flecainide slowing </text>
<text top="258" left="818" width="253" height="19" font="3">conduction. This can appear to be VT but </text>
<text top="276" left="818" width="41" height="19" font="3">is not. </text>
<text top="349" left="125" width="7" height="18" font="3">•</text>
<text top="348" left="131" width="4" height="21" font="0"> </text>
<text top="350" left="135" width="136" height="19" font="3">Bajaj et al. 1989 (495) </text>
<text top="368" left="125" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2551538">2551538</a></text>
<text top="368" left="178" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2551538"> </a></text>
<text top="386" left="125" width="3" height="19" font="3"> </text>
<text top="405" left="125" width="7" height="19" font="3">  </text>
<text top="349" left="286" width="109" height="19" font="4"><b>Study type: </b>Basic </text>
<text top="367" left="286" width="44" height="19" font="3">canine </text>
<text top="386" left="286" width="3" height="19" font="4"><b> </b></text>
<text top="404" left="286" width="3" height="19" font="4"><b> </b></text>
<text top="422" left="286" width="3" height="19" font="4"><b> </b></text>
<text top="441" left="286" width="3" height="19" font="4"><b> </b></text>
<text top="459" left="286" width="50" height="19" font="4"><b>Size:</b> 30<b> </b></text>
<text top="349" left="443" width="139" height="19" font="4"><b>Inclusion criteria: </b>N/A<b> </b></text>
<text top="367" left="443" width="3" height="19" font="4"><b> </b></text>
<text top="386" left="443" width="144" height="19" font="4"><b>Exclusion criteria</b>:  N/A<b> </b></text>
<text top="404" left="443" width="3" height="19" font="4"><b> </b></text>
<text top="350" left="617" width="184" height="19" font="4"><b>1</b>°<b> endpoint: </b>After infusion of </text>
<text top="368" left="617" width="175" height="19" font="3">ODE, a potent metabolite of </text>
<text top="386" left="617" width="150" height="19" font="3">encainide, shortening in </text>
<text top="405" left="617" width="171" height="19" font="3">intervals (HV and QRS) with </text>
<text top="423" left="617" width="107" height="19" font="3">NaHCO3 or NaCl  </text>
<text top="441" left="617" width="3" height="19" font="4"><b> </b></text>
<text top="460" left="617" width="180" height="19" font="4"><b>Results:  </b>With NaHCO3, QRS: </text>
<text top="478" left="617" width="155" height="19" font="3">92–76 msec; HV 44 to 37 </text>
<text top="496" left="617" width="39" height="19" font="3">msec. </text>
<text top="349" left="818" width="245" height="20" font="3">• Short-term administration of NaHCO3 </text>
<text top="368" left="818" width="206" height="19" font="3">or NaCl can partially reverse ODE-</text>
<text top="386" left="818" width="124" height="19" font="3">induced conduction </text>
<text top="405" left="818" width="225" height="19" font="3">slowing, which may be an important </text>
<text top="423" left="818" width="201" height="19" font="3">factor in arrhythmia aggravation </text>
<text top="515" left="125" width="7" height="18" font="3">•</text>
<text top="514" left="131" width="4" height="21" font="0"> </text>
<text top="516" left="135" width="131" height="19" font="3">Myerburg et al. 1989 </text>
<text top="534" left="125" width="35" height="19" font="3">(496) </text>
<text top="553" left="125" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2480856">2480856</a></text>
<text top="553" left="178" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2480856"> </a></text>
<text top="571" left="125" width="3" height="19" font="3"> </text>
<text top="589" left="125" width="7" height="19" font="3">  </text>
<text top="515" left="286" width="106" height="19" font="4"><b>Study type: </b>Case </text>
<text top="534" left="286" width="39" height="19" font="3">series<b> </b></text>
<text top="552" left="286" width="3" height="19" font="4"><b> </b></text>
<text top="570" left="286" width="3" height="19" font="4"><b> </b></text>
<text top="588" left="286" width="3" height="19" font="4"><b> </b></text>
<text top="607" left="286" width="3" height="19" font="4"><b> </b></text>
<text top="625" left="286" width="139" height="19" font="4"><b>Size:  </b>4 (3 flecainide, 1 </text>
<text top="643" left="286" width="67" height="19" font="3">encainide)<b> </b></text>
<text top="515" left="443" width="144" height="19" font="4"><b>Inclusion criteria: </b>Prior </text>
<text top="534" left="443" width="119" height="19" font="3">CA or symptomatic </text>
<text top="552" left="443" width="133" height="19" font="3">sustained VT, treated </text>
<text top="570" left="443" width="156" height="19" font="3">with a Ic medication who </text>
<text top="589" left="443" width="114" height="19" font="3">developed runs of </text>
<text top="607" left="443" width="137" height="19" font="3">sustained VT, NSVT or </text>
<text top="625" left="443" width="107" height="19" font="3">increased ectopy </text>
<text top="643" left="443" width="3" height="19" font="4"><b> </b></text>
<text top="662" left="443" width="144" height="19" font="4"><b>Exclusion criteria:  </b>N/A<b> </b></text>
<text top="516" left="617" width="173" height="19" font="4"><b>1</b>°<b> endpoint: </b>suppression of </text>
<text top="534" left="617" width="162" height="19" font="3">drug-induced arrhythmias<b> </b></text>
<text top="553" left="617" width="3" height="19" font="4"><b> </b></text>
<text top="571" left="617" width="142" height="19" font="4"><b>Results:  </b>Drug-induced </text>
<text top="589" left="617" width="184" height="19" font="3">arrhythmias were suppressed </text>
<text top="608" left="617" width="96" height="19" font="3">in all 4 patients </text>
<text top="626" left="617" width="3" height="19" font="4"><b> </b></text>
<text top="515" left="818" width="7" height="18" font="3">•</text>
<text top="514" left="825" width="4" height="21" font="0"> </text>
<text top="516" left="829" width="206" height="19" font="3">Propranolol had failed to prevent </text>
<text top="534" left="818" width="210" height="19" font="3">inducibility of sustained VT during </text>
<text top="553" left="818" width="212" height="19" font="3">previous programmed stimulation </text>
<text top="571" left="818" width="248" height="19" font="3">studies in three of the four patients, but </text>
<text top="590" left="818" width="93" height="19" font="3">it reproducibly </text>
<text top="608" left="818" width="234" height="19" font="3">suppressed drug-induced arrhythmias </text>
<text top="626" left="818" width="245" height="19" font="3">that appeared only after administration </text>
<text top="644" left="818" width="197" height="19" font="3">of the IC agents in each patient. </text>
<text top="681" left="125" width="7" height="18" font="3">•</text>
<text top="680" left="131" width="4" height="21" font="0"> </text>
<text top="682" left="135" width="108" height="19" font="3">Schwartz PJ et al. </text>
<text top="700" left="125" width="69" height="19" font="3">2016 (497) </text>
<text top="718" left="125" width="7" height="18" font="3">•</text>
<text top="718" left="131" width="4" height="21" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27150690"> </a></text>
<text top="719" left="135" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27150690">27150690</a></text>
<text top="719" left="196" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27150690"> </a></text>
<text top="681" left="286" width="128" height="19" font="4"><b>Study type:</b>   Review </text>
<text top="681" left="443" width="139" height="19" font="4"><b>Inclusion criteria: </b>N/A </text>
<text top="699" left="443" width="3" height="19" font="3"> </text>
<text top="717" left="443" width="148" height="19" font="4"><b>Exclusion criteria:</b>  N/A  </text>
<text top="736" left="443" width="3" height="19" font="3"> </text>
<text top="681" left="617" width="27" height="19" font="3">N/A </text>
<text top="699" left="617" width="3" height="19" font="3"> </text>
<text top="681" left="818" width="214" height="20" font="3">• Review of Hx of drug-induced QT </text>
<text top="700" left="818" width="139" height="19" font="3">prolongation and TdP. </text>
<text top="718" left="818" width="246" height="20" font="3">• crediblemeds.org categorizes drugs as </text>
<text top="737" left="818" width="254" height="19" font="3">possible, conditional and known TdP risk. </text>
<text top="756" left="818" width="234" height="20" font="3">• Drugs associated with prolonged QT </text>
<text top="775" left="818" width="237" height="19" font="3">and TdP fall into a number of different </text>
</page>
<page number="274" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">274 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="818" width="233" height="19" font="3">pharmacologic classes, and the risk of </text>
<text top="127" left="818" width="237" height="19" font="3">TdP increases according to clinical and </text>
<text top="145" left="818" width="97" height="19" font="3">genetic factors. </text>
<text top="164" left="818" width="214" height="20" font="3">• Clinical decision support systems </text>
<text top="183" left="818" width="228" height="19" font="3">reduce prescription of QT prolonging </text>
<text top="201" left="818" width="231" height="19" font="3">drugs in patients at risk of TdP due to </text>
<text top="219" left="818" width="159" height="19" font="3">clinical or genetic factors. </text>
<text top="239" left="125" width="7" height="18" font="3">•</text>
<text top="238" left="131" width="4" height="21" font="0"> </text>
<text top="239" left="135" width="124" height="19" font="3">Kannankeril P, et al. </text>
<text top="258" left="125" width="138" height="19" font="3">Pharcological Reviews </text>
<text top="276" left="125" width="34" height="19" font="3">2010.</text>
<text top="274" left="159" width="4" height="21" font="0"> </text>
<text top="276" left="162" width="35" height="19" font="3">(374)<b> </b></text>
<text top="238" left="286" width="128" height="19" font="4"><b>Study type:</b>   Review </text>
<text top="257" left="286" width="3" height="19" font="3"> </text>
<text top="275" left="286" width="59" height="19" font="4"><b>Size: </b>N/A<b> </b></text>
<text top="238" left="443" width="139" height="19" font="4"><b>Inclusion criteria: </b>N/A<b> </b></text>
<text top="257" left="443" width="3" height="19" font="3"> </text>
<text top="275" left="443" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="293" left="443" width="3" height="19" font="4"><b> </b></text>
<text top="239" left="617" width="105" height="19" font="4"><b>1</b>°<b> endpoint </b>N/A </text>
<text top="258" left="617" width="3" height="19" font="3"> </text>
<text top="276" left="617" width="83" height="19" font="4"><b>Results:</b>  N/A </text>
<text top="294" left="617" width="3" height="19" font="3"> </text>
<text top="239" left="818" width="215" height="20" font="3">• Hypokalemia worsens risk of TdP </text>
<text top="258" left="818" width="257" height="19" font="3">Although no randomized prospective trial </text>
<text top="276" left="818" width="206" height="19" font="3">has been conducted, intravenous </text>
<text top="294" left="818" width="216" height="19" font="3">magnesium has become a first-line </text>
<text top="312" left="818" width="190" height="19" font="3">therapy for drug-induced TdP.  </text>
<text top="367" left="115" width="815" height="21" font="2"><b>Data Supplement 54. Nonrandomized Trials, Observational Studies, and/or Registries Related to ACHD - (Section 10.8)  </b></text>
<text top="388" left="128" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="407" left="153" width="51" height="19" font="4"><b>Author; </b></text>
<text top="425" left="131" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="388" left="282" width="39" height="19" font="4"><b>Study </b></text>
<text top="407" left="258" width="86" height="19" font="4"><b>Type/Design; </b></text>
<text top="425" left="268" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="407" left="380" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="388" left="607" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="407" left="619" width="126" height="19" font="4"><b>(P values; OR or RR; </b></text>
<text top="425" left="650" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="398" left="895" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="416" left="924" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="444" left="123" width="7" height="18" font="3">•</text>
<text top="443" left="130" width="4" height="21" font="0"> </text>
<text top="445" left="134" width="87" height="19" font="3">Basso C, et al. </text>
<text top="463" left="123" width="91" height="19" font="3">Virchows Arch </text>
<text top="481" left="123" width="69" height="19" font="3">2008 (498) </text>
<text top="500" left="123" width="7" height="18" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17952460">•</a></text>
<text top="499" left="130" width="4" height="21" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17952460"> </a></text>
<text top="501" left="134" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17952460">17952460</a></text>
<text top="500" left="195" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17952460"><b> </b></a></text>
<text top="444" left="247" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="462" left="247" width="47" height="19" font="3">Review </text>
<text top="481" left="247" width="3" height="19" font="3"> </text>
<text top="499" left="247" width="70" height="19" font="4"><b>Size:</b>    N/A </text>
<text top="444" left="367" width="142" height="19" font="4"><b>Inclusion criteria:</b>  N/A<b> </b></text>
<text top="462" left="367" width="3" height="19" font="4"><b> </b></text>
<text top="481" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="445" left="525" width="112" height="19" font="4"><b>1</b>°<b> endpoint:</b>  N/A </text>
<text top="463" left="525" width="311" height="19" font="3">Role of autopsy to establish cause of SCD: Assoc of </text>
<text top="481" left="525" width="287" height="19" font="3">European Cardiovascular Pathology developed </text>
<text top="500" left="525" width="65" height="19" font="3">guidelines </text>
<text top="518" left="525" width="303" height="19" font="3">Includes ARVC, athlete’s heart, HCM, myocarditis </text>
<text top="536" left="525" width="3" height="19" font="3"> </text>
<text top="555" left="525" width="83" height="19" font="4"><b>Results:</b>  N/A </text>
<text top="444" left="852" width="7" height="18" font="3">•</text>
<text top="443" left="859" width="4" height="21" font="0"> </text>
<text top="445" left="863" width="201" height="19" font="3">Discussed gross and microscopic </text>
<text top="463" left="852" width="119" height="19" font="3">pathologic findings </text>
<text top="481" left="852" width="3" height="19" font="3"> </text>
<text top="500" left="852" width="7" height="18" font="3">•</text>
<text top="499" left="859" width="4" height="21" font="0"> </text>
<text top="501" left="863" width="154" height="19" font="3">“Further tests in future”: </text>
<text top="519" left="852" width="146" height="19" font="3">molecular or toxicology </text>
<text top="574" left="123" width="7" height="18" font="3">•</text>
<text top="573" left="130" width="4" height="21" font="0"> </text>
<text top="575" left="134" width="86" height="19" font="3">Thorne SA, et </text>
<text top="593" left="123" width="18" height="19" font="3">al. </text>
<text top="611" left="123" width="96" height="19" font="3">Circ 1999 (499) </text>
<text top="630" left="123" width="7" height="18" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10402444">•</a></text>
<text top="629" left="130" width="4" height="21" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10402444"> </a></text>
<text top="630" left="134" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10402444">10402444</a></text>
<text top="630" left="195" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10402444"> </a></text>
<text top="574" left="247" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="592" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="610" left="247" width="74" height="19" font="3">multicenter </text>
<text top="629" left="247" width="3" height="19" font="3"> </text>
<text top="647" left="247" width="73" height="19" font="4"><b>Size:</b> 92 pts<b> </b></text>
<text top="574" left="367" width="115" height="19" font="4"><b>Inclusion criteria:  </b></text>
<text top="592" left="367" width="135" height="19" font="3">ACHD, mean age 34.9 </text>
<text top="610" left="367" width="72" height="19" font="3">y, receiving </text>
<text top="629" left="367" width="144" height="19" font="3">amiodarone for ≥6 mo; </text>
<text top="647" left="367" width="122" height="19" font="3">case-control group. </text>
<text top="665" left="367" width="120" height="19" font="3">Mean duration 3 y, </text>
<text top="684" left="367" width="119" height="19" font="3">mean dose 191 mg </text>
<text top="702" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="574" left="525" width="296" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Review side effects of chronic oral </text>
<text top="593" left="525" width="78" height="19" font="3">amiodarone </text>
<text top="611" left="525" width="3" height="19" font="3"> </text>
<text top="629" left="525" width="298" height="19" font="4"><b>Results:</b>  36% developed thyroid dysfunction: 19 </text>
<text top="648" left="525" width="286" height="19" font="3">hyper, 14 hypothyroid. Sig risk factors: Female </text>
<text top="666" left="525" width="287" height="19" font="3">gender (OR: 3.0) cyanotic HD (OR: 7.0); Fontan </text>
<text top="685" left="525" width="234" height="19" font="3">(OR: 4.0); dosage &gt;200 mg/d (OR: 4.0)<b> </b></text>
<text top="574" left="852" width="7" height="18" font="3">•</text>
<text top="573" left="859" width="4" height="21" font="0"> </text>
<text top="575" left="863" width="196" height="19" font="3">Patients with CHD at higher risk </text>
<text top="593" left="852" width="179" height="19" font="3">for amio adverse effects, esp </text>
<text top="611" left="852" width="210" height="19" font="3">women, cyanosis, Fontan, or dose </text>
<text top="629" left="852" width="56" height="19" font="3">&gt;200 mg </text>
<text top="721" left="123" width="90" height="20" font="3">• Deal B, et al. </text>
<text top="740" left="123" width="94" height="19" font="3">AJC 1987 (500) </text>
<text top="759" left="123" width="10" height="20" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3591695">• </a></text>
<text top="759" left="134" width="53" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3591695">3591695</a></text>
<text top="759" left="187" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3591695"> </a></text>
<text top="778" left="123" width="3" height="19" font="3"> </text>
<text top="721" left="247" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="739" left="247" width="81" height="19" font="3">single center </text>
<text top="758" left="247" width="88" height="19" font="3">retrospective  </text>
<text top="776" left="247" width="3" height="19" font="3"> </text>
<text top="721" left="367" width="142" height="19" font="4"><b>Inclusion criteria:</b>  TOF </text>
<text top="739" left="367" width="136" height="19" font="3">pts undergoing cath + </text>
<text top="758" left="367" width="128" height="19" font="3">EPS and drug testing </text>
<text top="776" left="367" width="63" height="19" font="3">Sust VT: 4 </text>
<text top="722" left="525" width="302" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Induction of VT in TOF, response to </text>
<text top="740" left="525" width="47" height="19" font="3">drug rx </text>
<text top="759" left="525" width="293" height="19" font="3">Mean 3.3 drugs/pt tested. Followup mean 2.2 y </text>
<text top="721" left="852" width="181" height="20" font="3">• TOF EPS reproduces clinical </text>
<text top="740" left="852" width="81" height="19" font="3">sustained VT </text>
<text top="759" left="852" width="211" height="19" font="3">Pts with freq PVC’s: 60% inducible </text>
<text top="777" left="852" width="47" height="19" font="3">sust VT </text>
</page>
<page number="275" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">275 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="247" width="50" height="19" font="4"><b>Size:</b>   9<b> </b></text>
<text top="109" left="367" width="52" height="19" font="3">PVC’s: 5 </text>
<text top="127" left="367" width="3" height="19" font="3"> </text>
<text top="145" left="367" width="120" height="19" font="4"><b>Exclusion criteria:</b>  <b> </b></text>
<text top="109" left="525" width="304" height="19" font="4"><b>Results:</b>  all pts with clinical sust VT had inducible </text>
<text top="127" left="525" width="81" height="19" font="3">sustained VT </text>
<text top="145" left="525" width="309" height="19" font="3">60% pts with frequent PVC’s had inducible sust VT </text>
<text top="164" left="525" width="299" height="19" font="3">Pts with RV hypertension did not respond to any </text>
<text top="182" left="525" width="78" height="19" font="3">medications </text>
<text top="200" left="525" width="256" height="19" font="3">4 pts underwent surgery: no recurrent VT<b> </b></text>
<text top="109" left="852" width="216" height="19" font="3">Surgery to improve hemodynamics </text>
<text top="127" left="852" width="91" height="19" font="3">eliminated VT  </text>
<text top="146" left="852" width="193" height="20" font="3">•<b> </b>Elevated RV pressure: did not </text>
<text top="165" left="852" width="154" height="19" font="3">respond to medicationss </text>
<text top="220" left="123" width="7" height="18" font="3">•</text>
<text top="219" left="130" width="4" height="21" font="0"> </text>
<text top="220" left="134" width="100" height="19" font="3">Gatzoulis MA et </text>
<text top="238" left="123" width="78" height="19" font="3">al.<b> </b>Circ 1995 </text>
<text top="257" left="123" width="35" height="19" font="3">(501)<b> </b></text>
<text top="275" left="123" width="7" height="18" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7600655">•</a></text>
<text top="274" left="130" width="4" height="21" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7600655"> </a></text>
<text top="276" left="134" width="53" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7600655">7600655</a></text>
<text top="276" left="187" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7600655"><b> </b></a></text>
<text top="219" left="247" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="238" left="247" width="82" height="19" font="3">Single center </text>
<text top="256" left="247" width="78" height="19" font="3">prospective  </text>
<text top="274" left="247" width="3" height="19" font="3"> </text>
<text top="292" left="247" width="61" height="19" font="4"><b>Size:</b>    41 </text>
<text top="219" left="367" width="142" height="19" font="4"><b>Inclusion criteria:  </b>TOF </text>
<text top="238" left="367" width="58" height="19" font="3">survivors </text>
<text top="256" left="367" width="3" height="19" font="3"> </text>
<text top="274" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="220" left="525" width="302" height="19" font="4"><b>1</b>°<b> endpoint:</b>  TOF mechano-electrical interaction </text>
<text top="238" left="525" width="125" height="19" font="3">Mean followup 24 y </text>
<text top="257" left="525" width="3" height="19" font="3"> </text>
<text top="275" left="525" width="281" height="19" font="4"><b>Results:</b>  41/178 patients evaluated serially, + </text>
<text top="293" left="525" width="98" height="19" font="3">reviewed 4 SCD </text>
<text top="312" left="525" width="306" height="19" font="3">QRS duration correlated with RV size on Echo and </text>
<text top="330" left="525" width="109" height="19" font="3">heart size on CXR </text>
<text top="348" left="525" width="280" height="19" font="3">VT 9 patients: QRS mean 199 msec, CTR 0.67; </text>
<text top="367" left="525" width="272" height="19" font="3">significantly different than those without VT </text>
<text top="220" left="852" width="7" height="18" font="3">•</text>
<text top="219" left="859" width="4" height="21" font="0"> </text>
<text top="220" left="863" width="188" height="19" font="3">TOF: QRS duration ≥ 180 msec </text>
<text top="238" left="852" width="126" height="19" font="3">predicts VT and SCD </text>
<text top="257" left="852" width="7" height="18" font="3">•</text>
<text top="256" left="859" width="4" height="21" font="0"> </text>
<text top="258" left="863" width="184" height="19" font="3">All patients with documented </text>
<text top="276" left="852" width="219" height="19" font="3">sustained VT and patients with SCD </text>
<text top="294" left="852" width="183" height="19" font="3">had QRS duration ≥ 180 msec </text>
<text top="312" left="852" width="110" height="19" font="3">(100% sensitivity) </text>
<text top="331" left="852" width="7" height="18" font="3">•</text>
<text top="330" left="859" width="4" height="21" font="0"> </text>
<text top="332" left="863" width="176" height="19" font="3">Chronic RV volume overload </text>
<text top="350" left="852" width="192" height="19" font="3">related to diastolic dysfunction </text>
<text top="386" left="123" width="7" height="18" font="3">•</text>
<text top="385" left="130" width="4" height="21" font="0"> </text>
<text top="386" left="134" width="84" height="19" font="3">Koyak Z et al. </text>
<text top="405" left="123" width="96" height="19" font="3">Circ 2012 (502)<b> </b></text>
<text top="423" left="123" width="7" height="18" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22991410">•</a></text>
<text top="422" left="130" width="4" height="21" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22991410"> </a></text>
<text top="424" left="134" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22991410">22991410</a></text>
<text top="424" left="195" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22991410"> </a></text>
<text top="386" left="247" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="404" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="422" left="247" width="79" height="19" font="3">multi-center </text>
<text top="441" left="247" width="62" height="19" font="3">with case-</text>
<text top="459" left="247" width="53" height="19" font="3">controls </text>
<text top="477" left="247" width="3" height="19" font="3"> </text>
<text top="495" left="247" width="68" height="19" font="4"><b>Size:</b>    213 </text>
<text top="386" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="404" left="367" width="106" height="19" font="3">ACHD patients in </text>
<text top="422" left="367" width="119" height="19" font="3">Canadian database </text>
<text top="441" left="367" width="3" height="19" font="3"> </text>
<text top="459" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="386" left="525" width="166" height="19" font="4"><b>1</b>°<b> endpoint:</b>  SCD in ACHD </text>
<text top="405" left="525" width="3" height="19" font="3"> </text>
<text top="423" left="525" width="267" height="19" font="4"><b>Results:</b>  1,189 deaths among 25,790 ACHD </text>
<text top="441" left="525" width="61" height="19" font="3">patients:  </text>
<text top="460" left="525" width="145" height="19" font="3">19% SCD<b> </b>(213 patients) </text>
<text top="478" left="525" width="139" height="19" font="3">Arrhythmic cause 80% </text>
<text top="496" left="525" width="263" height="19" font="3">SCD vs severity of congenital heart disease </text>
<text top="515" left="525" width="201" height="19" font="3">Mild 12%, mod 33%, severe 55% </text>
<text top="386" left="852" width="7" height="18" font="3">•</text>
<text top="385" left="859" width="4" height="21" font="0"> </text>
<text top="386" left="863" width="190" height="19" font="3">Risk for SCD in ACHD: SVT (OR: </text>
<text top="405" left="852" width="163" height="19" font="3">3.5), mod-severe systemic </text>
<text top="423" left="852" width="205" height="19" font="3">ventricular dysfunction (OR: 3.4), </text>
<text top="441" left="852" width="202" height="19" font="3">mod-severe sub-pulmonary vent </text>
<text top="460" left="852" width="198" height="19" font="3">dysfunction (OR: 3.4), increased </text>
<text top="478" left="852" width="222" height="19" font="3">QRS duration (OR: 1.34 per 10 msec </text>
<text top="496" left="852" width="59" height="19" font="3">increase) </text>
<text top="515" left="852" width="3" height="19" font="3"> </text>
<text top="534" left="123" width="7" height="18" font="3">•</text>
<text top="533" left="130" width="4" height="21" font="0"> </text>
<text top="534" left="134" width="93" height="19" font="3">Diller GP et al.  </text>
<text top="553" left="123" width="96" height="19" font="3">Circ 2012 (503)<b> </b></text>
<text top="571" left="123" width="7" height="18" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22496160">•</a></text>
<text top="570" left="130" width="4" height="21" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22496160"> </a></text>
<text top="572" left="134" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22496160">22496160</a></text>
<text top="572" left="195" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22496160"> </a></text>
<text top="534" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="552" left="247" width="82" height="19" font="3">Single center </text>
<text top="570" left="247" width="85" height="19" font="3">retrospective </text>
<text top="589" left="247" width="3" height="19" font="3"> </text>
<text top="607" left="247" width="68" height="19" font="4"><b>Size:</b>    413 </text>
<text top="534" left="367" width="142" height="19" font="4"><b>Inclusion criteria:</b>  TOF </text>
<text top="552" left="367" width="53" height="19" font="3">patients </text>
<text top="570" left="367" width="93" height="19" font="3">Mean age 36 y </text>
<text top="589" left="367" width="140" height="19" font="3">Median followup 2.9 y </text>
<text top="607" left="367" width="3" height="19" font="3"> </text>
<text top="625" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="534" left="525" width="307" height="19" font="4"><b>1</b>°<b> endpoint:</b> TOF: sustained VT, ACA/SCD, approp </text>
<text top="553" left="525" width="66" height="19" font="3">ICD shock  </text>
<text top="571" left="525" width="3" height="19" font="3"> </text>
<text top="589" left="525" width="197" height="19" font="4"><b>Results:</b>  4.6% sust VT/SCD/ACA </text>
<text top="608" left="525" width="292" height="19" font="3">(SCD 1.2%, Sustained VT, 2.2%, ICD shock 1.2%) </text>
<text top="626" left="525" width="313" height="19" font="3">Combination echo variables c/w poor outcome: RA </text>
<text top="644" left="525" width="256" height="19" font="3">area, RV fractional area change, LV global </text>
<text top="663" left="525" width="255" height="19" font="3">longitudinal strain, mitral annular systolic </text>
<text top="681" left="525" width="62" height="19" font="3">excursion </text>
<text top="534" left="852" width="7" height="18" font="3">•</text>
<text top="533" left="859" width="4" height="21" font="0"> </text>
<text top="534" left="863" width="192" height="19" font="3">TOF: sust VT/SCD1.2/ACA 4.6% </text>
<text top="553" left="852" width="159" height="20" font="3">• LV longitudinal function </text>
<text top="572" left="852" width="220" height="19" font="3">associated with greater risk SCD/VT </text>
<text top="590" left="852" width="3" height="19" font="3"> </text>
<text top="609" left="852" width="3" height="19" font="3"> </text>
<text top="700" left="123" width="7" height="18" font="3">•</text>
<text top="699" left="130" width="4" height="21" font="0"> </text>
<text top="701" left="134" width="93" height="19" font="3">Harrison DA et </text>
<text top="719" left="123" width="84" height="19" font="3">al. JACC 1997 </text>
<text top="737" left="123" width="35" height="19" font="3">(504) </text>
<text top="756" left="123" width="7" height="18" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9350941">•</a></text>
<text top="755" left="130" width="4" height="21" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9350941"> </a></text>
<text top="757" left="134" width="53" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9350941">9350941</a></text>
<text top="756" left="187" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9350941"><b> </b></a></text>
<text top="700" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="718" left="247" width="82" height="19" font="3">Single center </text>
<text top="737" left="247" width="85" height="19" font="3">retrospective </text>
<text top="755" left="247" width="3" height="19" font="3"> </text>
<text top="773" left="247" width="61" height="19" font="4"><b>Size:</b>    18 </text>
<text top="700" left="367" width="141" height="19" font="4"><b>Inclusion criteria   </b>TOF </text>
<text top="718" left="367" width="114" height="19" font="3">and VT, compared </text>
<text top="737" left="367" width="137" height="19" font="3">with 192 TOF patients </text>
<text top="755" left="367" width="123" height="19" font="3">without arrhythmia </text>
<text top="773" left="367" width="3" height="19" font="3"> </text>
<text top="701" left="525" width="220" height="19" font="4"><b>1</b>°<b> endpoint:</b>  TOF and sustained VT </text>
<text top="719" left="525" width="3" height="19" font="3"> </text>
<text top="737" left="525" width="311" height="19" font="4"><b>Results:</b>   Patients with VT had frequent PVC’s, low </text>
<text top="756" left="525" width="169" height="19" font="3">CI, RVOT aneurysms/PR/TR </text>
<text top="700" left="852" width="7" height="18" font="3">•</text>
<text top="699" left="859" width="4" height="21" font="0"> </text>
<text top="701" left="863" width="163" height="19" font="3">TOF patients with VT have </text>
<text top="719" left="852" width="219" height="19" font="3">anatomic aneurysms of RVOT or PR </text>
<text top="738" left="852" width="7" height="18" font="3">•</text>
<text top="737" left="859" width="13" height="21" font="0"> C</text>
<text top="739" left="872" width="200" height="19" font="3">ombined approach of correcting </text>
<text top="758" left="852" width="213" height="19" font="3">structural abnormalities + intra-op </text>
<text top="776" left="852" width="179" height="19" font="3">map-guided VT ablation may </text>
</page>
<page number="276" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">276 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="367" width="457" height="19" font="4"><b>Exclusion criteria:</b>  N/A  14 patients reoperated: 10/14 cryoablation map-</text>
<text top="127" left="525" width="176" height="19" font="3">guided: recurrent VT in 3/10 </text>
<text top="145" left="525" width="312" height="19" font="3">Two patients with VT developed severe CHF, died.  </text>
<text top="109" left="852" width="170" height="19" font="3">reduce risk of deteriorating </text>
<text top="127" left="852" width="156" height="19" font="3">function and optimize VT </text>
<text top="145" left="852" width="85" height="19" font="3">management </text>
<text top="203" left="123" width="107" height="20" font="3">• Knauth Al et al. </text>
<text top="222" left="123" width="107" height="19" font="3">Heart 2008 (505)<b> </b></text>
<text top="241" left="123" width="7" height="18" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17135219">•</a></text>
<text top="240" left="130" width="4" height="21" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17135219"> </a></text>
<text top="241" left="134" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17135219">17135219</a></text>
<text top="241" left="195" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17135219"> </a></text>
<text top="203" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="222" left="247" width="82" height="19" font="3">Single center </text>
<text top="240" left="247" width="85" height="19" font="3">retrospective </text>
<text top="258" left="247" width="3" height="19" font="3"> </text>
<text top="276" left="247" width="61" height="19" font="4"><b>Size:</b>    88 </text>
<text top="203" left="367" width="139" height="19" font="4"><b>Inclusion criteria:</b> TOF </text>
<text top="222" left="367" width="119" height="19" font="3">patients with CMR  </text>
<text top="240" left="367" width="3" height="19" font="3"> </text>
<text top="258" left="367" width="96" height="19" font="3">Median postop </text>
<text top="276" left="367" width="83" height="19" font="3">interval: 21 y </text>
<text top="295" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="204" left="525" width="312" height="19" font="4"><b>1</b>°<b> endpoint:</b>  <b>TOF major ACE:</b> death, sustained VT, </text>
<text top="222" left="525" width="219" height="19" font="3">NYHA Class III/IV, clinical predictors </text>
<text top="241" left="525" width="291" height="19" font="4"><b>Results:</b>  MACE: 20.5%: death 5%, Sustained VT </text>
<text top="259" left="525" width="200" height="19" font="3">10%, worsening NYHA class 11% </text>
<text top="277" left="525" width="296" height="19" font="3">QRS duration ≥180 msec correlated with RV size </text>
<text top="203" left="852" width="226" height="20" font="3">• TOF adverse outcomes predictors:  </text>
<text top="222" left="852" width="168" height="19" font="3">RVEDV z score ≥7, OR: 4.55 </text>
<text top="241" left="852" width="128" height="19" font="3">LVEF &lt;55%, OR: 8.05 </text>
<text top="259" left="852" width="71" height="19" font="3">RVEF &lt;45% </text>
<text top="277" left="852" width="153" height="19" font="3">QRS duration ≥180 msec </text>
<text top="314" left="123" width="107" height="20" font="3">• Therrien J et al. </text>
<text top="333" left="123" width="96" height="19" font="3">Circ 2001 (506)<b> </b></text>
<text top="351" left="123" width="7" height="18" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11369690">•</a></text>
<text top="351" left="130" width="4" height="21" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11369690"> </a></text>
<text top="352" left="134" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11369690">11369690</a></text>
<text top="352" left="195" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11369690"> </a></text>
<text top="314" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="332" left="247" width="81" height="19" font="3">cohort study </text>
<text top="350" left="247" width="3" height="19" font="3"> </text>
<text top="369" left="247" width="61" height="19" font="4"><b>Size:</b>    70 </text>
<text top="314" left="367" width="139" height="19" font="4"><b>Inclusion criteria: </b>PVR </text>
<text top="332" left="367" width="49" height="19" font="3">for TOF </text>
<text top="350" left="367" width="7" height="19" font="3">  </text>
<text top="369" left="367" width="88" height="19" font="3">VT preop 22% </text>
<text top="387" left="367" width="89" height="19" font="3">AT preop 17% </text>
<text top="405" left="367" width="3" height="19" font="3"> </text>
<text top="424" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="315" left="525" width="264" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Impact of PVR in TOF on QRS </text>
<text top="333" left="525" width="125" height="19" font="3">duration and VT, AT </text>
<text top="351" left="525" width="128" height="19" font="3">Mean followup 4.7 y </text>
<text top="369" left="525" width="287" height="19" font="4"><b>Results:</b>  Cryoablation 15 patients with intraop </text>
<text top="388" left="525" width="307" height="19" font="3">mapping: 9 VT, 6 AFL: none had recurrence of pre-</text>
<text top="406" left="525" width="121" height="19" font="3">existing arrhythmia </text>
<text top="424" left="525" width="218" height="19" font="3">VT post PVR 9% from 22%, p&lt;0.001 </text>
<text top="443" left="525" width="270" height="19" font="3">AFL/AF decreased from 17% to 12%, p=0.32 </text>
<text top="314" left="852" width="84" height="20" font="3">• PVR in TOF: </text>
<text top="333" left="852" width="145" height="19" font="3">QRS duration stabilized </text>
<text top="351" left="852" width="218" height="19" font="3">Concurrent cryoablation decreased </text>
<text top="370" left="852" width="97" height="19" font="3">incidence of VT </text>
<text top="388" left="852" width="3" height="19" font="3"> </text>
<text top="462" left="123" width="107" height="20" font="3">• Therrien J et al. </text>
<text top="481" left="123" width="94" height="19" font="3">AJC 2005 (507)<b> </b></text>
<text top="499" left="123" width="7" height="18" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15757612">•</a></text>
<text top="498" left="130" width="4" height="21" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15757612"> </a></text>
<text top="500" left="134" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15757612">15757612</a></text>
<text top="500" left="195" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15757612"> </a></text>
<text top="462" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="480" left="247" width="82" height="19" font="3">Single center </text>
<text top="498" left="247" width="85" height="19" font="3">retrospective </text>
<text top="517" left="247" width="3" height="19" font="3"> </text>
<text top="535" left="247" width="61" height="19" font="4"><b>Size:</b>    17 </text>
<text top="462" left="367" width="114" height="19" font="4"><b>Inclusion criteria   </b></text>
<text top="480" left="367" width="135" height="19" font="3">adult TOF undergoing </text>
<text top="498" left="367" width="104" height="19" font="3">pulmonary valve </text>
<text top="517" left="367" width="121" height="19" font="3">replacement (PVR)  </text>
<text top="535" left="367" width="3" height="19" font="3"> </text>
<text top="553" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="462" left="525" width="297" height="19" font="4"><b>1</b>°<b> endpoint:</b>  TOF and PVR: effect on RV volume </text>
<text top="481" left="525" width="138" height="19" font="3">Mean followup 21 mo </text>
<text top="499" left="525" width="223" height="19" font="4"><b>Results:</b>  PVR decreased RV volume: </text>
<text top="517" left="525" width="144" height="19" font="3">RVEDV: From 163 ml/m</text>
<text top="517" left="669" width="5" height="12" font="15">2</text>
<text top="517" left="674" width="67" height="19" font="3">–107 ml/m</text>
<text top="517" left="741" width="5" height="12" font="15">2</text>
<text top="517" left="746" width="3" height="19" font="3"> </text>
<text top="536" left="525" width="141" height="19" font="3">RVESV: 109 to 69 ml/m</text>
<text top="536" left="666" width="5" height="12" font="15">2</text>
<text top="536" left="671" width="3" height="19" font="3"> </text>
<text top="554" left="525" width="191" height="19" font="3">RVEF did not change: EF 32–34 </text>
<text top="573" left="525" width="3" height="19" font="3"> </text>
<text top="591" left="525" width="199" height="19" font="3"> Patients with RVEDV &gt;170 ml/m</text>
<text top="591" left="724" width="5" height="12" font="15">2</text>
<text top="591" left="728" width="89" height="19" font="3"> or RVESV &gt;85 </text>
<text top="609" left="525" width="33" height="19" font="3">ml/m</text>
<text top="609" left="558" width="5" height="12" font="15">2</text>
<text top="609" left="563" width="275" height="19" font="3">: no pt had normalization of RV volume after </text>
<text top="627" left="525" width="49" height="19" font="3">surgery </text>
<text top="462" left="852" width="99" height="20" font="3">• TOF and PVR:  </text>
<text top="481" left="852" width="140" height="19" font="3">Decreases RV volumes </text>
<text top="499" left="852" width="128" height="19" font="3">RVEF did not change </text>
<text top="518" left="852" width="201" height="20" font="3">• PVR before marked RV volume </text>
<text top="537" left="852" width="61" height="19" font="3">increase? </text>
<text top="555" left="852" width="3" height="19" font="3"> </text>
<text top="573" left="852" width="3" height="19" font="3"> </text>
<text top="647" left="123" width="97" height="20" font="3">• Harrild DM et </text>
<text top="666" left="123" width="78" height="19" font="3">al. Circ 2009 </text>
<text top="684" left="123" width="35" height="19" font="3">(508)<b> </b></text>
<text top="702" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19139389">  </a></text>
<text top="703" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19139389">19139389</a></text>
<text top="703" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19139389"> </a></text>
<text top="646" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="665" left="247" width="82" height="19" font="3">Single center </text>
<text top="683" left="247" width="88" height="19" font="3">retrospective  </text>
<text top="701" left="247" width="3" height="19" font="3"> </text>
<text top="720" left="247" width="61" height="19" font="4"><b>Size:</b>    98 </text>
<text top="646" left="367" width="141" height="19" font="4"><b>Inclusion criteria  </b> TOF </text>
<text top="665" left="367" width="110" height="19" font="3">patients with late </text>
<text top="683" left="367" width="104" height="19" font="3">pulmonary valve </text>
<text top="701" left="367" width="122" height="19" font="3">replacement for RV </text>
<text top="720" left="367" width="111" height="19" font="3">dilation; matched </text>
<text top="738" left="367" width="135" height="19" font="3">controls with TOF, RV </text>
<text top="756" left="367" width="121" height="19" font="3">dilation but no PVR </text>
<text top="775" left="367" width="3" height="19" font="3"> </text>
<text top="647" left="525" width="274" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Impact of PVR in TOF on major </text>
<text top="666" left="525" width="95" height="19" font="3">adverse events </text>
<text top="684" left="525" width="139" height="19" font="3">followup median 1.4 y </text>
<text top="702" left="525" width="3" height="19" font="3"> </text>
<text top="720" left="525" width="229" height="19" font="4"><b>Results:</b> <b> </b>Freedom from death or VT:  </text>
<text top="739" left="525" width="120" height="19" font="3">5 y: 80%, 10 y: 41% </text>
<text top="757" left="525" width="3" height="19" font="3"> </text>
<text top="647" left="852" width="201" height="20" font="3">• TOF with late PVR: VT or death </text>
<text top="666" left="852" width="114" height="19" font="3">every 20 patient-y </text>
<text top="684" left="852" width="215" height="20" font="3">• In matched comparison with TOF </text>
<text top="703" left="852" width="201" height="19" font="3">controls<b>,</b> PVR did not reduce the </text>
<text top="721" left="852" width="152" height="19" font="3">incidence of VT or death </text>
<text top="740" left="852" width="219" height="20" font="3">• NOTE: advanced RV enlargement, </text>
<text top="759" left="852" width="129" height="19" font="3">empiric cryoablation </text>
<text top="777" left="852" width="3" height="19" font="3"> </text>
</page>
<page number="277" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">277 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="367" width="104" height="19" font="3">Median age 21 y </text>
<text top="127" left="367" width="81" height="19" font="3">6% preop VT </text>
<text top="145" left="367" width="118" height="19" font="3">QRS duration &gt;180 </text>
<text top="164" left="367" width="68" height="19" font="3">msec: 19% </text>
<text top="182" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="109" left="525" width="287" height="19" font="3">Empiric cryoablation: 7 patients: 5/7 VT during </text>
<text top="127" left="525" width="57" height="19" font="3">followup </text>
<text top="145" left="525" width="269" height="19" font="3">Incidence death, VT, or both: 4.8/100 pt yrs </text>
<text top="164" left="525" width="154" height="19" font="3">All cause mortality: 6.1% </text>
<text top="182" left="525" width="269" height="19" font="3">No sig change in QRS duration after surgery </text>
<text top="201" left="123" width="97" height="20" font="3">• Adamson L et </text>
<text top="220" left="123" width="94" height="19" font="3">al. Interact CTS </text>
<text top="238" left="123" width="69" height="19" font="3">2009 (509)<b> </b></text>
<text top="257" left="123" width="7" height="18" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19567499">•</a></text>
<text top="256" left="130" width="4" height="21" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19567499"> </a></text>
<text top="258" left="134" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19567499">19567499</a></text>
<text top="257" left="195" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19567499"><b> </b></a></text>
<text top="201" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="219" left="247" width="87" height="19" font="3">meta-analysis </text>
<text top="238" left="247" width="88" height="19" font="3">medline 1950-</text>
<text top="256" left="247" width="34" height="19" font="3">2009 </text>
<text top="274" left="247" width="3" height="19" font="3"> </text>
<text top="292" left="247" width="76" height="19" font="4"><b>Size:</b>    1070 </text>
<text top="201" left="367" width="142" height="19" font="4"><b>Inclusion criteria   </b>PVR </text>
<text top="219" left="367" width="123" height="19" font="3">after TOF repair: 19 </text>
<text top="238" left="367" width="102" height="19" font="3">papers analyzed </text>
<text top="256" left="367" width="3" height="19" font="3"> </text>
<text top="274" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="202" left="525" width="301" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Effect of PVR in TOF on RV size and </text>
<text top="220" left="525" width="54" height="19" font="3">function </text>
<text top="238" left="525" width="3" height="19" font="3"> </text>
<text top="257" left="525" width="291" height="19" font="4"><b>Results:</b>  summarizes all 19 papers’ conclusions </text>
<text top="275" left="525" width="3" height="19" font="3"> </text>
<text top="201" left="852" width="88" height="20" font="3">• PVR in TOF:  </text>
<text top="220" left="852" width="88" height="19" font="3">Low mortality </text>
<text top="238" left="852" width="129" height="19" font="3">Reduces RV volumes </text>
<text top="257" left="852" width="134" height="19" font="3">RV function improves </text>
<text top="275" left="852" width="199" height="19" font="3">Symptoms and functional status </text>
<text top="293" left="852" width="60" height="19" font="3">improves </text>
<text top="313" left="123" width="105" height="20" font="3">• Sabate Rotes A </text>
<text top="332" left="123" width="95" height="19" font="3">et al. CAE 2015 </text>
<text top="350" left="123" width="35" height="19" font="3">(510)<b> </b></text>
<text top="368" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25416756">  </a></text>
<text top="369" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25416756">25416756</a></text>
<text top="369" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25416756"> </a></text>
<text top="312" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="331" left="247" width="82" height="19" font="3">Single center </text>
<text top="349" left="247" width="85" height="19" font="3">retrospective </text>
<text top="367" left="247" width="3" height="19" font="3"> </text>
<text top="386" left="247" width="68" height="19" font="4"><b>Size:</b>  205   </text>
<text top="312" left="367" width="139" height="19" font="4"><b>Inclusion criteria:</b> TOF </text>
<text top="331" left="367" width="110" height="19" font="3">patients with late </text>
<text top="349" left="367" width="104" height="19" font="3">pulmonary valve </text>
<text top="367" left="367" width="122" height="19" font="3">replacement for RV </text>
<text top="386" left="367" width="107" height="19" font="3">dilation between </text>
<text top="404" left="367" width="69" height="19" font="3">1988-2010 </text>
<text top="422" left="367" width="104" height="19" font="3">Median age 33 y </text>
<text top="441" left="367" width="74" height="19" font="3">Prior VT 8% </text>
<text top="459" left="367" width="106" height="19" font="3">LVEF &lt;50%:  16% </text>
<text top="477" left="367" width="3" height="19" font="3"> </text>
<text top="495" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="313" left="525" width="274" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Impact of PVR in TOF on major </text>
<text top="332" left="525" width="285" height="19" font="3">adverse events: VT, SCD/ACA, appropriate ICD </text>
<text top="350" left="525" width="38" height="19" font="3">shock </text>
<text top="368" left="525" width="3" height="19" font="3"> </text>
<text top="386" left="525" width="195" height="19" font="4"><b>Results:</b>  Freedom from MACE:  </text>
<text top="405" left="525" width="186" height="19" font="3">5 y: 95%, 10 y: 90%, 15 y: 79% </text>
<text top="423" left="525" width="258" height="19" font="3">More events occurred in patients without </text>
<text top="441" left="525" width="80" height="19" font="3">cryoablation </text>
<text top="460" left="525" width="304" height="19" font="3">Cryoablation of VT: 22 patients: (11%) 1/22 event </text>
<text top="478" left="525" width="305" height="19" font="3">after 7 y.<b> </b>Empiric Cryo performed in patients with </text>
<text top="496" left="525" width="271" height="19" font="3">VT, inducible VT at EPS not ablated, or Hx of </text>
<text top="515" left="525" width="273" height="19" font="3">unexplained syncope/pre-syncope; not map-</text>
<text top="533" left="525" width="45" height="19" font="3">guided </text>
<text top="551" left="525" width="3" height="19" font="3"> </text>
<text top="570" left="525" width="3" height="19" font="3"> </text>
<text top="313" left="852" width="99" height="20" font="3">• TOF and PVR:  </text>
<text top="332" left="852" width="174" height="19" font="3">Hx of VT and LV dysfunction </text>
<text top="350" left="852" width="216" height="19" font="3">associated with higher risk, HR: 4.7 </text>
<text top="368" left="852" width="160" height="20" font="3">•QRS duration ≥180 msec </text>
<text top="387" left="852" width="189" height="19" font="3">predictive of arrhythmic event </text>
<text top="406" left="852" width="205" height="20" font="3">• Surgical cryoablation of VT may </text>
<text top="425" left="852" width="88" height="19" font="3">be protective  </text>
<text top="443" left="852" width="3" height="19" font="3"> </text>
<text top="461" left="852" width="189" height="19" font="3">Recommend patients with risk </text>
<text top="480" left="852" width="182" height="19" font="3">factors for VT undergo pre-or </text>
<text top="498" left="852" width="71" height="19" font="3">postop EPS </text>
<text top="589" left="123" width="88" height="20" font="3">• Tsai SF et al. </text>
<text top="608" left="123" width="94" height="19" font="3">AJC 2010 (511) </text>
<text top="626" left="123" width="10" height="20" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20723654">• </a></text>
<text top="627" left="134" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20723654">20723654</a></text>
<text top="627" left="194" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20723654"><b> </b></a></text>
<text top="588" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="607" left="247" width="81" height="19" font="3">single center </text>
<text top="625" left="247" width="85" height="19" font="3">retrospective </text>
<text top="643" left="247" width="3" height="19" font="3"> </text>
<text top="662" left="247" width="61" height="19" font="4"><b>Size:</b>    80 </text>
<text top="588" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="607" left="367" width="128" height="19" font="3">ACHD patients ≥ 18y </text>
<text top="625" left="367" width="115" height="19" font="3">undergoing V stim </text>
<text top="643" left="367" width="93" height="19" font="3">Mean age 30 y </text>
<text top="662" left="367" width="3" height="19" font="3"> </text>
<text top="680" left="367" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="698" left="367" width="128" height="19" font="3">patients with clinical </text>
<text top="717" left="367" width="69" height="19" font="3">ventricular </text>
<text top="735" left="367" width="77" height="19" font="3">arrhythmias </text>
<text top="589" left="525" width="270" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Inducible VT in ACHD patients </text>
<text top="608" left="525" width="117" height="19" font="3">without clinical VA </text>
<text top="626" left="525" width="3" height="19" font="3"> </text>
<text top="644" left="525" width="196" height="19" font="4"><b>Results:</b>  Inducible sust VT: 29% </text>
<text top="663" left="525" width="131" height="19" font="3">(TOF 52%, TGA 26%)  </text>
<text top="681" left="525" width="279" height="19" font="3">Predictors: increased QRS, decreased VO2 on </text>
<text top="699" left="525" width="275" height="19" font="3">exercise, ventricular fibrosis on MRI (p &lt; .05) </text>
<text top="589" left="852" width="122" height="20" font="3">• Inducible VT: 29% </text>
<text top="608" left="852" width="194" height="20" font="3">• Combined fibrosis on MR and </text>
<text top="627" left="852" width="162" height="19" font="3">peak oxygen uptake &lt;80% </text>
<text top="645" left="852" width="211" height="19" font="3">predicted had 100% sensitivity for </text>
<text top="663" left="852" width="81" height="19" font="3">sustained VT </text>
<text top="682" left="852" width="195" height="20" font="3">• Consider using MRI, ex test as </text>
<text top="701" left="852" width="171" height="19" font="3">screening for V stim studies </text>
</page>
<page number="278" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">278 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="106" height="20" font="3">• Garson A et al.  </text>
<text top="128" left="123" width="102" height="19" font="3">JACC 1983 (512)<b> </b></text>
<text top="146" left="123" width="10" height="20" font="3">• </text>
<text top="147" left="134" width="3" height="19" font="18"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6853902"><b> </b></a></text>
<text top="147" left="137" width="53" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6853902">6853902</a></text>
<text top="147" left="190" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=6853902"> </a></text>
<text top="109" left="247" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="127" left="247" width="81" height="19" font="3">single center </text>
<text top="145" left="247" width="88" height="19" font="3">retrospective  </text>
<text top="164" left="247" width="3" height="19" font="3"> </text>
<text top="182" left="247" width="61" height="19" font="4"><b>Size:</b>   27  </text>
<text top="109" left="367" width="142" height="19" font="4"><b>Inclusion criteria:</b>  TOF </text>
<text top="127" left="367" width="145" height="19" font="3">patients undergoing EP </text>
<text top="145" left="367" width="3" height="19" font="3"> </text>
<text top="164" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="109" left="525" width="223" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Induction of VT in TOF </text>
<text top="128" left="525" width="3" height="19" font="3"> </text>
<text top="146" left="525" width="278" height="19" font="4"><b>Results:</b>  patients with syncope had inducible </text>
<text top="165" left="525" width="154" height="19" font="3">sustained or non-sust VT </text>
<text top="109" left="852" width="187" height="20" font="3">• TOF with inducible VT: more </text>
<text top="128" left="852" width="215" height="19" font="3">frequent PVC’s, longer HV interval, </text>
<text top="146" left="852" width="210" height="19" font="3">elevated RV pressure, reduced RV </text>
<text top="165" left="852" width="18" height="19" font="3">EF </text>
<text top="183" left="852" width="205" height="20" font="3">• Poor hemodynamics correlated </text>
<text top="202" left="852" width="111" height="19" font="3">with VT induction </text>
<text top="221" left="123" width="96" height="20" font="3">• Chandar JS et </text>
<text top="240" left="123" width="76" height="19" font="3">al. AJC 1990 </text>
<text top="258" left="123" width="35" height="19" font="3">(513)<b> </b></text>
<text top="277" left="123" width="10" height="20" font="3">• </text>
<text top="277" left="134" width="3" height="19" font="18"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1689935"><b> </b></a></text>
<text top="277" left="137" width="53" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1689935">1689935</a></text>
<text top="277" left="190" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1689935"> </a></text>
<text top="221" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="239" left="247" width="75" height="19" font="3">Multicenter </text>
<text top="258" left="247" width="85" height="19" font="3">retrospective </text>
<text top="276" left="247" width="3" height="19" font="3"> </text>
<text top="294" left="247" width="68" height="19" font="4"><b>Size:</b>    359 </text>
<text top="221" left="367" width="139" height="19" font="4"><b>Inclusion criteria:</b> TOF </text>
<text top="239" left="367" width="126" height="19" font="3">patients undergoing </text>
<text top="258" left="367" width="25" height="19" font="3">EPS </text>
<text top="276" left="367" width="125" height="19" font="3">Mean age repair 5 y </text>
<text top="294" left="367" width="117" height="19" font="3">Mean followup 7 y </text>
<text top="312" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b> N/A  </text>
<text top="222" left="525" width="209" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Inducible VT in TOF  </text>
<text top="240" left="525" width="3" height="19" font="3"> </text>
<text top="258" left="525" width="301" height="19" font="4"><b>Results:</b>  Induced VT correlated with delayed age </text>
<text top="277" left="525" width="296" height="19" font="3">at repair, longer followup, syncope, elevated RV </text>
<text top="295" left="525" width="214" height="19" font="3">pressure, frequent PVC’s on holter </text>
<text top="221" left="852" width="211" height="20" font="3">• Correlation poor hemodynamics </text>
<text top="240" left="852" width="109" height="19" font="3">with inducible VT </text>
<text top="258" left="852" width="3" height="19" font="3"> </text>
<text top="277" left="852" width="3" height="19" font="3"> </text>
<text top="295" left="852" width="3" height="19" font="3"> </text>
<text top="332" left="123" width="94" height="20" font="3">•<b> </b>Koyak Z et al. </text>
<text top="351" left="123" width="96" height="19" font="3">Circ 2012 (502)<b> </b></text>
<text top="369" left="123" width="10" height="20" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22991410">• </a></text>
<text top="370" left="134" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22991410">22991410</a></text>
<text top="370" left="194" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22991410"> </a></text>
<text top="331" left="247" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="350" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="368" left="247" width="79" height="19" font="3">multi-center </text>
<text top="386" left="247" width="62" height="19" font="3">with case-</text>
<text top="405" left="247" width="53" height="19" font="3">controls </text>
<text top="423" left="247" width="3" height="19" font="3"> </text>
<text top="441" left="247" width="68" height="19" font="4"><b>Size:</b>    213 </text>
<text top="331" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="350" left="367" width="106" height="19" font="3">ACHD patients in </text>
<text top="368" left="367" width="119" height="19" font="3">Canadian database </text>
<text top="386" left="367" width="3" height="19" font="3"> </text>
<text top="405" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="332" left="525" width="166" height="19" font="4"><b>1</b>°<b> endpoint:</b>  SCD in ACHD </text>
<text top="351" left="525" width="3" height="19" font="3"> </text>
<text top="369" left="525" width="260" height="19" font="4"><b>Results:</b>  1189 deaths among 25790 ACHD </text>
<text top="387" left="525" width="61" height="19" font="3">patients:  </text>
<text top="406" left="525" width="145" height="19" font="3">19% SCD (213 patients) </text>
<text top="424" left="525" width="139" height="19" font="3">Arrhythmic cause 80% </text>
<text top="442" left="525" width="263" height="19" font="3">SCD vs severity of congenital heart disease </text>
<text top="460" left="525" width="213" height="19" font="3">Mild: 12%, mod: 33%, severe: 55% </text>
<text top="332" left="852" width="147" height="20" font="3">• Risk for SCD in ACHD:  </text>
<text top="351" left="852" width="83" height="19" font="3">SVT (OR: 3.5) </text>
<text top="369" left="852" width="205" height="19" font="3"> mod-severe systemic ventricular </text>
<text top="387" left="852" width="132" height="19" font="3">dysfunction (OR: 3.4) </text>
<text top="406" left="852" width="202" height="19" font="3">mod-severe sub-pulmonary vent </text>
<text top="424" left="852" width="132" height="19" font="3">dysfunction (OR: 3.4) </text>
<text top="442" left="852" width="206" height="19" font="3">increased QRS duration (OR: 1.34 </text>
<text top="460" left="852" width="136" height="19" font="3">per 10 msec increase) </text>
<text top="479" left="852" width="3" height="19" font="3"> </text>
<text top="498" left="123" width="97" height="20" font="3">•<b> </b>Kella<b> </b>DK et al. </text>
<text top="517" left="123" width="96" height="19" font="3">PCE 2014 (514)<b> </b></text>
<text top="535" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24889130">  </a></text>
<text top="536" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24889130">24889130</a></text>
<text top="536" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24889130"> </a></text>
<text top="498" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="516" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="534" left="247" width="81" height="19" font="3">single center </text>
<text top="553" left="247" width="3" height="19" font="3"> </text>
<text top="571" left="247" width="61" height="19" font="4"><b>Size:</b>    59 </text>
<text top="498" left="367" width="136" height="19" font="4"><b>Inclusion criteria:</b> ICD </text>
<text top="516" left="367" width="107" height="19" font="3">in ACHD patients </text>
<text top="534" left="367" width="57" height="19" font="3">TOF 56% </text>
<text top="553" left="367" width="62" height="19" font="3">TGA 25%  </text>
<text top="571" left="367" width="3" height="19" font="3"> </text>
<text top="589" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="498" left="525" width="226" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ICD outcomes in ACHD </text>
<text top="517" left="525" width="140" height="19" font="3">Median followup 3.2 y </text>
<text top="535" left="525" width="3" height="19" font="3"> </text>
<text top="554" left="525" width="171" height="19" font="4"><b>Results:</b>  1° prevention 53% </text>
<text top="572" left="525" width="163" height="19" font="3">Approp ICD therapies 20% </text>
<text top="590" left="525" width="132" height="19" font="3">22% inapprop shocks </text>
<text top="609" left="525" width="307" height="19" font="3">TOF: 27% approp shocks, non-TOF: 11% (p=0.043) </text>
<text top="498" left="852" width="198" height="20" font="3">• Non-TOF patients less likely to </text>
<text top="517" left="852" width="167" height="19" font="3">receive appropriate shocks </text>
<text top="535" left="852" width="186" height="20" font="3">• ICD implantation indications </text>
<text top="554" left="852" width="193" height="19" font="3">should be ACHD lesion specific  </text>
<text top="573" left="852" width="3" height="19" font="3"> </text>
<text top="628" left="123" width="106" height="20" font="3">• Santharam S et </text>
<text top="647" left="123" width="78" height="19" font="3">al. Europace </text>
<text top="665" left="123" width="69" height="19" font="3">2016 (515)<b> </b></text>
<text top="683" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27234868">  </a></text>
<text top="684" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27234868">27234868</a></text>
<text top="684" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27234868"> </a></text>
<text top="628" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="646" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="664" left="247" width="81" height="19" font="3">single center </text>
<text top="683" left="247" width="3" height="19" font="3"> </text>
<text top="701" left="247" width="61" height="19" font="4"><b>Size:</b>   42  </text>
<text top="628" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="646" left="367" width="122" height="19" font="3">ACHD patients with </text>
<text top="664" left="367" width="93" height="19" font="3">ICD 2000-2014 </text>
<text top="683" left="367" width="93" height="19" font="3">Mean age 41 y </text>
<text top="701" left="367" width="119" height="19" font="3">TOF 50%, TGA 12% </text>
<text top="719" left="367" width="3" height="19" font="3"> </text>
<text top="737" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="628" left="525" width="229" height="19" font="4"><b>1</b>°<b> endpoint:</b>  <b>ICD outcomes in ACHD</b> </text>
<text top="647" left="525" width="117" height="19" font="3">Mean followup 5 y </text>
<text top="665" left="525" width="3" height="19" font="3"> </text>
<text top="683" left="525" width="133" height="19" font="4"><b>Results:</b>  Indications:  </text>
<text top="702" left="525" width="80" height="19" font="3">2° prev: 62% </text>
<text top="720" left="525" width="53" height="19" font="3">1° 38%.  </text>
<text top="738" left="525" width="151" height="19" font="3">Appropriate shocks 14% </text>
<text top="757" left="525" width="123" height="19" font="3">Complications: 45%<b> </b></text>
<text top="628" left="852" width="104" height="20" font="3">• ACHD and ICD: </text>
<text top="647" left="852" width="112" height="19" font="3">2.9%/y shock rate </text>
<text top="665" left="852" width="124" height="19" font="3">Complications 9%/y </text>
<text top="683" left="852" width="213" height="20" font="3">• Disease specific indications, risks </text>
<text top="702" left="852" width="158" height="19" font="3">must be clearly discussed </text>
<text top="721" left="852" width="193" height="20" font="3">• alternatives for 1° prevention </text>
<text top="740" left="852" width="53" height="19" font="3">ablation </text>
</page>
<page number="279" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">279 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="108" height="20" font="3">• Vehmeijer JT et </text>
<text top="128" left="123" width="76" height="19" font="3">al. EHJ 2016 </text>
<text top="146" left="123" width="35" height="19" font="3">(516)<b> </b></text>
<text top="165" left="123" width="10" height="20" font="3">• </text>
<text top="165" left="134" width="3" height="19" font="24"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26873095"><b> </b></a></text>
<text top="165" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26873095">26873095</a></text>
<text top="165" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26873095"> </a></text>
<text top="109" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="127" left="247" width="88" height="19" font="3">Meta-analysis </text>
<text top="145" left="247" width="58" height="19" font="3">EMBASE, </text>
<text top="164" left="247" width="64" height="19" font="3">MEDLINE, </text>
<text top="182" left="247" width="95" height="19" font="3">Google Scholar </text>
<text top="200" left="247" width="3" height="19" font="3"> </text>
<text top="218" left="247" width="76" height="19" font="4"><b>Size:</b>    2162 </text>
<text top="109" left="367" width="133" height="19" font="4"><b>Inclusion criteria:</b>  24 </text>
<text top="127" left="367" width="111" height="19" font="3">studies with 2162 </text>
<text top="145" left="367" width="122" height="19" font="3">ACHD patients with </text>
<text top="164" left="367" width="32" height="19" font="3">ICD:  </text>
<text top="182" left="367" width="93" height="19" font="3">Mean age 36 y </text>
<text top="200" left="367" width="57" height="19" font="3">TOF 50% </text>
<text top="219" left="367" width="3" height="19" font="3"> </text>
<text top="237" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="109" left="525" width="218" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ICD implants in ACHD </text>
<text top="128" left="525" width="128" height="19" font="3">Mean followup 3.6 y </text>
<text top="146" left="525" width="3" height="19" font="3"> </text>
<text top="164" left="525" width="150" height="19" font="4"><b>Results:</b>  1° 53%, 2° 47% </text>
<text top="183" left="525" width="259" height="19" font="3">Approp intervention (ATP or shock): 24%;  </text>
<text top="201" left="525" width="102" height="19" font="3">1° 22%, 2° 35%.  </text>
<text top="219" left="525" width="260" height="19" font="3">Inapprop shocks 25%; Complications: 26% </text>
<text top="238" left="525" width="147" height="19" font="3">All-cause mortality 10% </text>
<text top="109" left="852" width="221" height="20" font="3">• High rate appropriate ICD therapy </text>
<text top="128" left="852" width="144" height="19" font="3">in both 1° and 2° ACHD </text>
<text top="146" left="852" width="207" height="20" font="3">• High rates inappropriate shocks </text>
<text top="165" left="852" width="114" height="19" font="3">and complications </text>
<text top="184" left="852" width="144" height="20" font="3">• Case-by-case analysis </text>
<text top="203" left="852" width="147" height="19" font="3">costs/benefits essential </text>
<text top="257" left="123" width="108" height="20" font="3">• Moore JP et al.  </text>
<text top="276" left="123" width="96" height="19" font="3">CAE 2016 (517)<b> </b></text>
<text top="294" left="123" width="10" height="20" font="3">• </text>
<text top="295" left="134" width="3" height="19" font="18"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27635073"><b> </b></a></text>
<text top="295" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27635073">27635073</a></text>
<text top="295" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27635073"> </a></text>
<text top="257" left="247" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="275" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="293" left="247" width="90" height="19" font="3">multi-center 7 </text>
<text top="312" left="247" width="49" height="19" font="3">centers </text>
<text top="330" left="247" width="3" height="19" font="3"> </text>
<text top="348" left="247" width="61" height="19" font="4"><b>Size:</b>    21 </text>
<text top="257" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="275" left="367" width="122" height="19" font="3">subcut ICD in ACHD </text>
<text top="293" left="367" width="91" height="19" font="3">starting 2011.  </text>
<text top="312" left="367" width="115" height="19" font="3">Median age 33.9 y </text>
<text top="330" left="367" width="3" height="19" font="3"> </text>
<text top="348" left="367" width="114" height="19" font="3">Indication: limited </text>
<text top="367" left="367" width="121" height="19" font="3">venous access (10), </text>
<text top="385" left="367" width="122" height="19" font="3">right-to-left cardiac </text>
<text top="403" left="367" width="49" height="19" font="3">shunt 5 </text>
<text top="421" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="257" left="525" width="252" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Subcutaneous ICD in ACHD </text>
<text top="276" left="525" width="200" height="19" font="3">outcomes. Single ventricle 52%.  </text>
<text top="294" left="525" width="156" height="19" font="3">Median followup 14 mo.  </text>
<text top="312" left="525" width="260" height="19" font="4"><b>Results:</b>  1ary prevention: 67%, 2ary 33%.  </text>
<text top="331" left="525" width="308" height="19" font="3">Implant: VT induced 81%, converted ≤ 80 joules in </text>
<text top="349" left="525" width="129" height="19" font="3">all. Infection: 1 (5%); </text>
<text top="367" left="525" width="294" height="19" font="3">Shocks:  inapprop 21%, appropriate 1 (5%). One </text>
<text top="386" left="525" width="142" height="19" font="3">death due to asystole.  </text>
<text top="257" left="852" width="222" height="20" font="3">• Subcut ICD feasible in ACHD, most </text>
<text top="276" left="852" width="216" height="19" font="3">commonly single ventricle patients </text>
<text top="294" left="852" width="166" height="19" font="3">with limited venous access </text>
<text top="313" left="852" width="214" height="20" font="3">• Successful conversion of induced </text>
<text top="332" left="852" width="19" height="19" font="3">VT </text>
<text top="350" left="852" width="142" height="20" font="3">• “reasonable” rhythm </text>
<text top="369" left="852" width="90" height="19" font="3">discrimination </text>
<text top="387" left="852" width="3" height="19" font="3"> </text>
<text top="441" left="123" width="98" height="20" font="3">• Okamura H et </text>
<text top="460" left="123" width="86" height="19" font="3">al. Circ J 2016 </text>
<text top="478" left="123" width="35" height="19" font="3">(518)<b> </b></text>
<text top="497" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27109124">  </a></text>
<text top="497" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27109124">27109124</a></text>
<text top="497" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27109124"> </a></text>
<text top="441" left="247" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="459" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="477" left="247" width="85" height="19" font="3">single center  </text>
<text top="496" left="247" width="3" height="19" font="3"> </text>
<text top="514" left="247" width="68" height="19" font="4"><b>Size:</b>   100  </text>
<text top="441" left="367" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="459" left="367" width="92" height="19" font="3">ACHD patients </text>
<text top="477" left="367" width="131" height="19" font="3">undergong screening </text>
<text top="496" left="367" width="134" height="19" font="3">for subcutaneous ICD </text>
<text top="514" left="367" width="93" height="19" font="3">Mean age 48 y </text>
<text top="532" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="441" left="525" width="252" height="19" font="4"><b>1</b>°<b> endpoint:</b>  screening for suitability for </text>
<text top="460" left="525" width="244" height="19" font="3">subcutaneous ICD use in ACHD patients </text>
<text top="478" left="525" width="305" height="19" font="4"><b>Results:</b>  Left parasternal: failure 21%, reduced to </text>
<text top="496" left="525" width="174" height="19" font="3">12% using right parasternal. </text>
<text top="515" left="525" width="3" height="19" font="3"> </text>
<text top="441" left="852" width="200" height="20" font="3">• for use of subcutaneous ICD in </text>
<text top="460" left="852" width="203" height="19" font="3">ACHD, screening of left and right </text>
<text top="478" left="852" width="213" height="19" font="3">parasternal position may improve; </text>
<text top="496" left="852" width="202" height="19" font="3">QT interval and T wave inversion </text>
<text top="515" left="852" width="203" height="19" font="3">V2-V6 independent predictors of </text>
<text top="533" left="852" width="163" height="19" font="3">left parasternal screening. </text>
<text top="552" left="123" width="88" height="20" font="3">• Yap SC et al. </text>
<text top="571" left="123" width="94" height="19" font="3">EHJ 2007 (519)<b> </b></text>
<text top="590" left="123" width="10" height="20" font="3">• </text>
<text top="590" left="134" width="3" height="19" font="18"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17030523"><b> </b></a></text>
<text top="590" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17030523">17030523</a></text>
<text top="590" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17030523"> </a></text>
<text top="552" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="570" left="247" width="75" height="19" font="3">Multicenter </text>
<text top="589" left="247" width="88" height="19" font="3">retrospective, </text>
<text top="607" left="247" width="93" height="19" font="3">Dutch national </text>
<text top="625" left="247" width="49" height="19" font="3">registry </text>
<text top="643" left="247" width="3" height="19" font="3"> </text>
<text top="662" left="247" width="61" height="19" font="4"><b>Size:</b>    64 </text>
<text top="552" left="367" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="570" left="367" width="128" height="19" font="3">ACHD patients ≥18 y </text>
<text top="589" left="367" width="90" height="19" font="3">receiving ICD   </text>
<text top="607" left="367" width="115" height="19" font="3">Mean age 37±13 y </text>
<text top="625" left="367" width="116" height="19" font="3">2° prevention 60% </text>
<text top="644" left="367" width="3" height="19" font="3"> </text>
<text top="662" left="367" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="553" left="525" width="280" height="19" font="4"><b>1</b>°<b> endpoint: </b>ICD outcomes in ACHD patients: </text>
<text top="571" left="525" width="139" height="19" font="3">median followup 3.7 y </text>
<text top="589" left="525" width="3" height="19" font="3"> </text>
<text top="608" left="525" width="221" height="19" font="4"><b>Results:</b>  Early comps 13%, late 17% </text>
<text top="626" left="525" width="299" height="19" font="3">Approp shocks 23%, inapprop 41% <b>-</b>mainly SVT.   </text>
<text top="644" left="525" width="314" height="19" font="3">TOF fewer approp shocks vs other congenital heart </text>
<text top="663" left="525" width="103" height="19" font="3">disease, HR 0.29 </text>
<text top="552" left="852" width="213" height="20" font="3">• ACHD Appropriate shocks 6%/yr, </text>
<text top="571" left="852" width="219" height="19" font="3">no difference in 1° or 2° prevention </text>
<text top="590" left="852" width="171" height="20" font="3">• Inappropriate shocks 41% </text>
<text top="609" left="852" width="3" height="19" font="3"> </text>
<text top="682" left="123" width="100" height="20" font="3">• Khairy P et al.  </text>
<text top="701" left="123" width="96" height="19" font="3">Circ 2004 (520)<b> </b></text>
<text top="719" left="123" width="14" height="20" font="3">• <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15051640"><b> </b></a></text>
<text top="720" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15051640">15051640</a></text>
<text top="720" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15051640"> </a></text>
<text top="682" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="700" left="247" width="75" height="19" font="3">Multicenter </text>
<text top="718" left="247" width="44" height="19" font="3">cohort </text>
<text top="737" left="247" width="3" height="19" font="3"> </text>
<text top="755" left="247" width="68" height="19" font="4"><b>Size:</b>    252 </text>
<text top="682" left="367" width="142" height="19" font="4"><b>Inclusion criteria:</b>  TOF </text>
<text top="700" left="367" width="138" height="19" font="3">patients undergoing V </text>
<text top="718" left="367" width="30" height="19" font="3">stim </text>
<text top="737" left="367" width="90" height="19" font="3">followup 6.5 y </text>
<text top="755" left="367" width="3" height="19" font="3"> </text>
<text top="773" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="682" left="525" width="314" height="19" font="4"><b>1</b>°<b> endpoint:</b> <b> </b>TOF:  correlate V stim with outcomes </text>
<text top="701" left="525" width="306" height="19" font="4"><b>Results:</b>  sust monomorphic VT 30%, polymorphic </text>
<text top="719" left="525" width="52" height="19" font="3">VT 4.4% </text>
<text top="737" left="525" width="278" height="19" font="3">Independent risk factors: age ≥18 y (OR: 3.3), </text>
<text top="756" left="525" width="306" height="19" font="3">palpitations (OR: 2.8), frequent PVCs (OR: 5.6), CT </text>
<text top="774" left="525" width="194" height="19" font="3">ratio ≥0.6, prior shunt (OR: 3.1) </text>
<text top="682" left="852" width="203" height="20" font="3">• Multivariate analysis: inducible </text>
<text top="701" left="852" width="208" height="19" font="3">sustained VT independent risk for </text>
<text top="719" left="852" width="211" height="19" font="3">subsequent clinical VT or SCD (RR: </text>
<text top="737" left="852" width="27" height="19" font="3">4.7) </text>
<text top="756" left="852" width="3" height="19" font="3"> </text>
</page>
<page number="280" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">280 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="852" width="214" height="20" font="3">• Older age, prior shunts, frequent </text>
<text top="128" left="852" width="199" height="19" font="3">PVC’s, cardiomegaly—increased </text>
<text top="146" left="852" width="157" height="19" font="3">likelihood of inducible VT<b> </b></text>
<text top="165" left="123" width="100" height="20" font="3">• Khairy P et al. <b> </b></text>
<text top="184" left="123" width="96" height="19" font="3">Circ 2008 (521)<b> </b></text>
<text top="203" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18172030">  </a></text>
<text top="203" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18172030">18172030</a></text>
<text top="203" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18172030"> </a></text>
<text top="165" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="183" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="202" left="247" width="97" height="19" font="3">multicenter, 11 </text>
<text top="220" left="247" width="31" height="19" font="3">sites </text>
<text top="238" left="247" width="3" height="19" font="3"> </text>
<text top="257" left="247" width="68" height="19" font="4"><b>Size:</b>  121   </text>
<text top="165" left="367" width="142" height="19" font="4"><b>Inclusion criteria:</b>  TOF </text>
<text top="183" left="367" width="136" height="19" font="3">patients receiving ICD </text>
<text top="202" left="367" width="104" height="19" font="3">Median age 33 y </text>
<text top="220" left="367" width="3" height="19" font="3"> </text>
<text top="238" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="166" left="525" width="204" height="19" font="4"><b>1</b>°<b> endpoint:</b>  TOF ICD outcomes  </text>
<text top="184" left="525" width="140" height="19" font="3">Median followup 3.7 y </text>
<text top="203" left="525" width="3" height="19" font="3"> </text>
<text top="221" left="525" width="176" height="19" font="4"><b>Results:</b>  2° prevention: 44% </text>
<text top="239" left="525" width="169" height="19" font="3">Comps: total 30%, 5% early </text>
<text top="258" left="525" width="126" height="19" font="3">Approp shocks: 30% </text>
<text top="276" left="525" width="283" height="19" font="3">Annual rate approp: 1° 7.7%, 2° 9.8% (p=0.11) </text>
<text top="165" left="852" width="206" height="20" font="3">• TOF ICD shocks annual rate 7.7–</text>
<text top="184" left="852" width="203" height="19" font="3">9.8%, approx. equal for 1° and 2° </text>
<text top="203" left="852" width="70" height="19" font="3">prevention </text>
<text top="221" left="852" width="220" height="20" font="3">• Approp shocks: elevated EDP (HR: </text>
<text top="240" left="852" width="158" height="19" font="3">1.3), nonsust VT (HR: 3.7) </text>
<text top="258" left="852" width="187" height="20" font="3">• Inappropriate shocks 5.8%/y </text>
<text top="278" left="852" width="179" height="20" font="3">• Comps 30%: 21% leads, 6% </text>
<text top="296" left="852" width="64" height="19" font="3">generator </text>
<text top="316" left="123" width="110" height="20" font="3">• Zeppenfeld K et </text>
<text top="335" left="123" width="78" height="19" font="3">al. Circ 2007 </text>
<text top="353" left="123" width="35" height="19" font="3">(522) </text>
<text top="371" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17967973">  </a></text>
<text top="372" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17967973">17967973</a></text>
<text top="372" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17967973"> </a></text>
<text top="315" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="334" left="247" width="82" height="19" font="3">Single center </text>
<text top="352" left="247" width="85" height="19" font="3">retrospective </text>
<text top="371" left="247" width="3" height="19" font="3"> </text>
<text top="389" left="247" width="61" height="19" font="4"><b>Size:</b>    11 </text>
<text top="315" left="367" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="334" left="367" width="122" height="19" font="3">repaired congenital </text>
<text top="352" left="367" width="138" height="19" font="3">heart disease patients </text>
<text top="371" left="367" width="115" height="19" font="3">with sustained VT, </text>
<text top="389" left="367" width="121" height="19" font="3">undergoing voltage </text>
<text top="407" left="367" width="87" height="19" font="3">map, ablation </text>
<text top="426" left="367" width="3" height="19" font="3"> </text>
<text top="444" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="316" left="525" width="293" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Ablation of VT in congenital heart </text>
<text top="335" left="525" width="49" height="19" font="3">disease </text>
<text top="353" left="525" width="99" height="19" font="3">followup 30 mo </text>
<text top="371" left="525" width="299" height="19" font="4"><b>Results:</b>  SR voltage map, identify scar: anatomic </text>
<text top="390" left="525" width="310" height="19" font="3">isthmus:  between TV-RVOT, pulm annulus and RV </text>
<text top="408" left="525" width="312" height="19" font="3">free wall, pulm annulus and septal scar, septal scar </text>
<text top="426" left="525" width="45" height="19" font="3">and TV </text>
<text top="445" left="525" width="295" height="19" font="3">Ablation of isthmus (most common between TV </text>
<text top="463" left="525" width="293" height="19" font="3">and anterior RVOT) abolished all 15 VT circuits.  </text>
<text top="316" left="852" width="210" height="20" font="3">• VT ablation of anatomic isthmus </text>
<text top="335" left="852" width="219" height="19" font="3">successful: 91% without recurrence </text>
<text top="353" left="852" width="142" height="19" font="3">during 30 mo followup </text>
<text top="371" left="852" width="3" height="19" font="3"> </text>
<text top="390" left="852" width="3" height="19" font="3"> </text>
<text top="408" left="852" width="3" height="19" font="3"> </text>
<text top="482" left="123" width="106" height="20" font="3">• van Zyl M et al. </text>
<text top="501" left="123" width="90" height="19" font="3">HR 2016 (523) </text>
<text top="520" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26961296">  </a></text>
<text top="520" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26961296">26961296</a></text>
<text top="520" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26961296"> </a></text>
<text top="482" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="500" left="247" width="81" height="19" font="3">single center </text>
<text top="519" left="247" width="88" height="19" font="3">retrospective  </text>
<text top="537" left="247" width="3" height="19" font="3"> </text>
<text top="555" left="247" width="61" height="19" font="4"><b>Size:</b>  21   </text>
<text top="482" left="367" width="115" height="19" font="4"><b>Inclusion criteria: </b> </text>
<text top="500" left="367" width="122" height="19" font="3">repaired congenital </text>
<text top="519" left="367" width="138" height="19" font="3">heart disease patients </text>
<text top="537" left="367" width="123" height="19" font="3">with VT undergoing </text>
<text top="555" left="367" width="53" height="19" font="3">ablation </text>
<text top="573" left="367" width="93" height="19" font="3">Mean age 45 y </text>
<text top="592" left="367" width="69" height="19" font="3">71% males </text>
<text top="610" left="367" width="3" height="19" font="3"> </text>
<text top="628" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="483" left="525" width="297" height="19" font="4"><b>1</b>°<b> endpoint:</b>  outcome VT ablation in congenital </text>
<text top="501" left="525" width="271" height="19" font="3">heart disease: SCD or appropriate ICD shock </text>
<text top="519" left="525" width="138" height="19" font="3">Mean followup 33 mo </text>
<text top="538" left="525" width="237" height="19" font="4"><b>Results:</b>  Reentrant VT 67%, Focal 33% </text>
<text top="556" left="525" width="262" height="19" font="3">Isthmus dependent VT mechanism in 67%, </text>
<text top="574" left="525" width="200" height="19" font="3">conduction block confirmed in 8 </text>
<text top="482" left="852" width="221" height="20" font="3">• VT ablation in ACDH: reentrant VT </text>
<text top="501" left="852" width="165" height="19" font="3">targets anatomic isthmus:  </text>
<text top="519" left="852" width="216" height="19" font="3">with confirmed block, no recurrent </text>
<text top="538" left="852" width="19" height="19" font="3">VT </text>
<text top="556" left="852" width="3" height="19" font="3"> </text>
<text top="574" left="852" width="3" height="19" font="3"> </text>
<text top="593" left="852" width="3" height="19" font="3"> </text>
<text top="648" left="123" width="97" height="20" font="3">• Kapel GF et a. </text>
<text top="667" left="123" width="96" height="19" font="3">CAE 2014 (524) </text>
<text top="685" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25151630">  </a></text>
<text top="686" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25151630">25151630</a></text>
<text top="686" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25151630"> </a></text>
<text top="647" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="666" left="247" width="102" height="19" font="3">Retrospective, 2 </text>
<text top="684" left="247" width="49" height="19" font="3">centers </text>
<text top="702" left="247" width="3" height="19" font="3"> </text>
<text top="721" left="247" width="61" height="19" font="4"><b>Size:</b>    28 </text>
<text top="647" left="367" width="139" height="19" font="4"><b>Inclusion criteria: </b>TOF </text>
<text top="666" left="367" width="103" height="19" font="3">patients with VT </text>
<text top="684" left="367" width="53" height="19" font="3">ablation </text>
<text top="702" left="367" width="3" height="19" font="3"> </text>
<text top="721" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="648" left="525" width="281" height="19" font="4"><b>1</b>°<b> endpoint:</b>  TOF VT ablation in LV outcomes </text>
<text top="667" left="525" width="3" height="19" font="3"> </text>
<text top="685" left="525" width="302" height="19" font="4"><b>Results:</b>  Left sided mapping/ablation if right side </text>
<text top="703" left="525" width="187" height="19" font="3">RFA failed, part of circuit in LV </text>
<text top="722" left="525" width="222" height="19" font="3">4/28 VT ablations used LV approach </text>
<text top="740" left="525" width="258" height="19" font="3">Target anatomic isthmus with transection </text>
<text top="648" left="852" width="208" height="20" font="3">• TOF VT ablation in LV successful </text>
<text top="667" left="852" width="215" height="19" font="3">in 4 patients: no recurrence during </text>
<text top="685" left="852" width="48" height="19" font="3">20 mos </text>
<text top="703" left="852" width="221" height="20" font="3">• Rt side failure: septal hypertrophy </text>
<text top="722" left="852" width="195" height="19" font="3">2, pulmonary homograft 1, VSD </text>
<text top="741" left="852" width="52" height="19" font="3">patch 1  </text>
</page>
<page number="281" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">281 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="105" height="20" font="3">• Kapel GF, et al. </text>
<text top="128" left="123" width="79" height="19" font="3">Circ AE 2015 </text>
<text top="146" left="123" width="35" height="19" font="3">(525) </text>
<text top="165" left="123" width="10" height="20" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25422392">• </a></text>
<text top="165" left="134" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25422392">25422392</a></text>
<text top="165" left="194" width="3" height="19" font="27"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25422392"><b> </b></a></text>
<text top="184" left="123" width="3" height="19" font="3"> </text>
<text top="202" left="123" width="3" height="19" font="3"> </text>
<text top="109" left="247" width="85" height="19" font="4"><b>Study type:</b> 2 </text>
<text top="127" left="247" width="52" height="19" font="3">centers, </text>
<text top="145" left="247" width="85" height="19" font="3">retrospective </text>
<text top="164" left="247" width="3" height="19" font="3"> </text>
<text top="182" left="247" width="54" height="19" font="4"><b>Size</b>: 34<b>  </b></text>
<text top="109" left="367" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="127" left="367" width="107" height="19" font="3">repaired CHD pts </text>
<text top="145" left="367" width="126" height="19" font="3">undergoing ablation </text>
<text top="164" left="367" width="3" height="19" font="3"> </text>
<text top="182" left="367" width="93" height="19" font="3">Mean age 48 y </text>
<text top="200" left="367" width="63" height="19" font="3">74% male </text>
<text top="219" left="367" width="57" height="19" font="3">TOF 82% </text>
<text top="237" left="367" width="123" height="19" font="3">TGA; VSD, AVSD, PS </text>
<text top="255" left="367" width="111" height="19" font="3">Sustained VT 79% </text>
<text top="273" left="367" width="3" height="19" font="3"> </text>
<text top="292" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="109" left="525" width="219" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Ablation of VT in CHD </text>
<text top="128" left="525" width="189" height="19" font="3">followup 46 mo. 41% prior ICD </text>
<text top="146" left="525" width="3" height="19" font="3"> </text>
<text top="164" left="525" width="301" height="19" font="4"><b>Results:</b> complete success 25/34 pts: 74%; 18/25 </text>
<text top="183" left="525" width="113" height="19" font="3">had preserved fxn </text>
<text top="201" left="525" width="306" height="19" font="3">Procedural failure: hypertrophy, pulm homograft, </text>
<text top="219" left="525" width="194" height="19" font="3">prox to HBE, no critical reentry  </text>
<text top="238" left="525" width="154" height="19" font="3">79% discharged with ICD </text>
<text top="256" left="525" width="303" height="19" font="3">15/18 complete success + preserved function d/c </text>
<text top="274" left="525" width="173" height="19" font="3">on no AAD—no recurrences </text>
<text top="293" left="525" width="159" height="19" font="3">4 late deaths, 2 CHF, 2 CA<b> </b></text>
<text top="109" left="852" width="188" height="20" font="3">• Predictors of lack of success: </text>
<text top="128" left="852" width="204" height="19" font="3">No complete procedural success, </text>
<text top="146" left="852" width="139" height="19" font="3">decreased LV function </text>
<text top="165" left="852" width="222" height="20" font="3">• Transection of VT isthmus feasible </text>
<text top="184" left="852" width="44" height="19" font="3">in 74% </text>
<text top="312" left="123" width="101" height="20" font="3">• Kapel GF et al. </text>
<text top="331" left="123" width="94" height="19" font="3">EHJ 2017 (526) </text>
<text top="349" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27233946">  </a></text>
<text top="350" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27233946">27233946</a></text>
<text top="350" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27233946"> </a></text>
<text top="311" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="330" left="247" width="86" height="19" font="3">Single center  </text>
<text top="348" left="247" width="3" height="19" font="3"> </text>
<text top="367" left="247" width="61" height="19" font="4"><b>Size:</b>    74 </text>
<text top="311" left="367" width="115" height="19" font="4"><b>Inclusion criteria: </b> </text>
<text top="330" left="367" width="136" height="19" font="3">repaired TOF patients </text>
<text top="348" left="367" width="50" height="19" font="3">with VT </text>
<text top="367" left="367" width="120" height="19" font="3">induction/mapping </text>
<text top="385" left="367" width="63" height="19" font="3">63% male </text>
<text top="403" left="367" width="93" height="19" font="3">Mean age 40 y </text>
<text top="421" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b> N/A  </text>
<text top="312" left="525" width="270" height="19" font="4"><b>1</b>°<b> endpoint:</b>  TOF VT isthmus identification  </text>
<text top="331" left="525" width="3" height="19" font="3"> </text>
<text top="349" left="525" width="273" height="19" font="4"><b>Results:</b>   slow conducting anatomic isthmus </text>
<text top="367" left="525" width="310" height="19" font="3">identified by electroanatomical mapping: targeted </text>
<text top="386" left="525" width="78" height="19" font="3">for ablation  </text>
<text top="404" left="525" width="288" height="19" font="3">28 patients with inducible VT. Ablation in 18 of </text>
<text top="422" left="525" width="51" height="19" font="3">isthmus </text>
<text top="312" left="852" width="163" height="20" font="3">• TOF VT: slow conducting </text>
<text top="331" left="852" width="187" height="19" font="3">anatomic isthmus is dominant </text>
<text top="349" left="852" width="64" height="19" font="3">substrate  </text>
<text top="367" left="852" width="3" height="19" font="3"> </text>
<text top="386" left="852" width="3" height="19" font="3"> </text>
<text top="404" left="852" width="3" height="19" font="3"> </text>
<text top="441" left="123" width="97" height="20" font="3">• Khairy P et al. </text>
<text top="460" left="123" width="96" height="19" font="3">CAE 2008 (527) </text>
<text top="479" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19808416">  </a></text>
<text top="480" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19808416">19808416</a></text>
<text top="480" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19808416"> </a></text>
<text top="441" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="460" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="478" left="247" width="89" height="19" font="3">multicenter, 7 </text>
<text top="496" left="247" width="35" height="19" font="3">sites  </text>
<text top="515" left="247" width="3" height="19" font="3"> </text>
<text top="533" left="247" width="61" height="19" font="4"><b>Size:</b>    37 </text>
<text top="441" left="367" width="143" height="19" font="4"><b>Inclusion criteria:</b>  TGA </text>
<text top="460" left="367" width="127" height="19" font="3">s/p atrial baffle with </text>
<text top="478" left="367" width="24" height="19" font="3">ICD </text>
<text top="496" left="367" width="125" height="19" font="3">Mean age 28 y, 89% </text>
<text top="515" left="367" width="33" height="19" font="3">male </text>
<text top="533" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="442" left="525" width="298" height="19" font="4"><b>1</b>°<b> endpoint:</b> <b> </b>TGA s/p atrial baffle ICD outcomes </text>
<text top="460" left="525" width="3" height="19" font="3"> </text>
<text top="479" left="525" width="176" height="19" font="4"><b>Results:</b>  2° prevention: 38% </text>
<text top="497" left="525" width="179" height="19" font="3">Annual rates approp shocks:  </text>
<text top="515" left="525" width="91" height="19" font="3">1° 0.5%, 2° 6% </text>
<text top="534" left="525" width="305" height="19" font="3">Independent predictors: 2° prevention, lack of BB </text>
<text top="552" left="525" width="249" height="19" font="3">Approp shocks: None with inducible VT;  </text>
<text top="570" left="525" width="290" height="19" font="3">37% of patients without inducible VT (p=0.043) </text>
<text top="589" left="525" width="226" height="19" font="3">Comps 38%, 33% lead, 3% generator </text>
<text top="441" left="852" width="164" height="20" font="3">• TGA s/p atrial baffle: ICD </text>
<text top="460" left="852" width="179" height="19" font="3">appropriate shocks mainly in </text>
<text top="479" left="852" width="203" height="19" font="3">patients with 2° prevention, (HR: </text>
<text top="497" left="852" width="202" height="19" font="3">18; p=0.034) and lack of BB, (HR: </text>
<text top="515" left="852" width="84" height="19" font="3">16.7; p=0.03) </text>
<text top="534" left="852" width="176" height="20" font="3">• SVT preceded VT in 50% of </text>
<text top="553" left="852" width="91" height="19" font="3">approp shocks </text>
<text top="571" left="852" width="182" height="20" font="3">• Inducible VT did not predict </text>
<text top="590" left="852" width="194" height="19" font="3">appropriate shock treatment in </text>
<text top="609" left="852" width="29" height="19" font="3">TGA </text>
<text top="627" left="852" width="151" height="20" font="3">• Protective effect of BB </text>
<text top="647" left="123" width="104" height="20" font="3">• Tutarel O et al. </text>
<text top="666" left="123" width="78" height="19" font="3">Eur H J 2014 </text>
<text top="684" left="123" width="35" height="19" font="3">(528)<b> </b></text>
<text top="703" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23882067">  </a></text>
<text top="703" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23882067">23882067</a></text>
<text top="703" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23882067"> </a></text>
<text top="647" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="665" left="247" width="84" height="19" font="3">retrospective </text>
<text top="683" left="247" width="84" height="19" font="3">cohort, Royal </text>
<text top="702" left="247" width="65" height="19" font="3">Brompton </text>
<text top="720" left="247" width="3" height="19" font="3"> </text>
<text top="738" left="247" width="68" height="19" font="4"><b>Size:</b>    375 </text>
<text top="647" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="665" left="367" width="144" height="19" font="3">ACHD patients ≥60 y at </text>
<text top="683" left="367" width="96" height="19" font="3">entry, followed </text>
<text top="702" left="367" width="137" height="19" font="3">1/2000-3/2012, mean </text>
<text top="720" left="367" width="107" height="19" font="3">age 65 y, median </text>
<text top="738" left="367" width="90" height="19" font="3">followup 5.5 y </text>
<text top="757" left="367" width="3" height="19" font="3"> </text>
<text top="775" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="647" left="525" width="239" height="19" font="4"><b>1</b>°<b> endpoint:</b>  all-cause mortality ACHD </text>
<text top="666" left="525" width="3" height="19" font="3"> </text>
<text top="684" left="525" width="183" height="19" font="4"><b>Results:</b>  14.6% died (55/375) </text>
<text top="703" left="525" width="187" height="19" font="3">Cardiac deaths: 40% CHF, CAD </text>
<text top="721" left="525" width="308" height="19" font="3">Independent predictors mortality: CAD (HR: 5.05); </text>
<text top="739" left="525" width="310" height="19" font="3">CHF (HR: 2.36); NYHA class (HR: 1.96); mod-severe </text>
<text top="757" left="525" width="225" height="19" font="3">systemic vent dysfunction (HR: 1.90) </text>
<text top="647" left="852" width="207" height="20" font="3">•  9-fold (864%) increase in ACHD </text>
<text top="666" left="852" width="207" height="19" font="3">patients &gt;60 y between 2000 and </text>
<text top="684" left="852" width="34" height="19" font="3">2011 </text>
<text top="703" left="852" width="3" height="19" font="3"> </text>
<text top="721" left="852" width="3" height="19" font="3"> </text>
<text top="739" left="852" width="3" height="19" font="3"> </text>
</page>
<page number="282" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="30" size="12" family="Times" color="#365f91"/>
	<fontspec id="31" size="12" family="Times" color="#365f91"/>
<text top="803" left="585" width="29" height="21" font="0">282 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="95" height="20" font="3">•<b> </b>Koyak Z et al. </text>
<text top="128" left="123" width="94" height="19" font="3">Europace 2017 </text>
<text top="146" left="123" width="35" height="19" font="3">(529)<b> </b></text>
<text top="165" left="123" width="7" height="18" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27247006">•</a></text>
<text top="165" left="130" width="3" height="19" font="30"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27247006"><b> </b></a></text>
<text top="165" left="134" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27247006">27247006</a></text>
<text top="165" left="194" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27247006"><b> </b></a></text>
<text top="184" left="123" width="3" height="19" font="3"> </text>
<text top="109" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="127" left="247" width="75" height="19" font="3">Multicenter </text>
<text top="145" left="247" width="86" height="19" font="3">case-control:  </text>
<text top="164" left="247" width="61" height="19" font="3">CONCOR, </text>
<text top="182" left="247" width="103" height="19" font="3">Toronto, Leuven </text>
<text top="200" left="247" width="87" height="19" font="4"><b>Size:</b>    25,000 </text>
<text top="109" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="127" left="367" width="125" height="19" font="3">ACHD; age matched </text>
<text top="145" left="367" width="95" height="19" font="3">controls; mean </text>
<text top="164" left="367" width="78" height="19" font="3">followup 7 y </text>
<text top="182" left="367" width="3" height="19" font="3"> </text>
<text top="200" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="109" left="525" width="167" height="19" font="4"><b>1</b>°<b> endpoint:</b>  <b>SCD in ACHD</b> </text>
<text top="128" left="525" width="3" height="19" font="3"> </text>
<text top="146" left="525" width="228" height="19" font="4"><b>Results:</b>  131 SCD, mean age 36±14 y </text>
<text top="165" left="525" width="297" height="19" font="3">Increased risk: increase in QRS duration ≥5 ms/y </text>
<text top="183" left="525" width="291" height="19" font="3">(OR: 1.9), change in systemic vent fxn to severe </text>
<text top="201" left="525" width="238" height="19" font="3">(OR: 16.9; 95% CI: 1.8–120.1, p=0.008) </text>
<text top="109" left="852" width="173" height="20" font="3">• Increased risk SCD: severe </text>
<text top="128" left="852" width="202" height="19" font="3">ventricular dysfunction, increase </text>
<text top="146" left="852" width="137" height="19" font="3">QRS duration ≥5 ms/y </text>
<text top="165" left="852" width="3" height="19" font="3"> </text>
<text top="220" left="123" width="100" height="20" font="3">• Engelfriet P et </text>
<text top="239" left="123" width="76" height="19" font="3">al. EHJ 2005 </text>
<text top="258" left="123" width="35" height="19" font="3">(530)<b> </b></text>
<text top="276" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15996978">  </a></text>
<text top="277" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15996978">15996978</a></text>
<text top="277" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15996978"> </a></text>
<text top="220" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="238" left="247" width="74" height="19" font="3">multicenter </text>
<text top="257" left="247" width="88" height="19" font="3">retrospective  </text>
<text top="275" left="247" width="3" height="19" font="3"> </text>
<text top="293" left="247" width="76" height="19" font="4"><b>Size:</b>    4110 </text>
<text top="220" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="238" left="367" width="106" height="19" font="3">ACHD patients in </text>
<text top="257" left="367" width="115" height="19" font="3">Europe: ASD, VSD, </text>
<text top="275" left="367" width="94" height="19" font="3">TOF, coA, TGA, </text>
<text top="293" left="367" width="102" height="19" font="3">Marfan, Fontan, </text>
<text top="312" left="367" width="54" height="19" font="3">cyanotic </text>
<text top="330" left="367" width="3" height="19" font="3"> </text>
<text top="348" left="367" width="128" height="19" font="4"><b>Exclusion criteria:</b>  8 </text>
<text top="367" left="367" width="101" height="19" font="3">lesions included </text>
<text top="221" left="525" width="189" height="19" font="4"><b>1</b>°<b> endpoint:</b>  <b>ACHD morbidity</b> </text>
<text top="239" left="525" width="128" height="19" font="3">Median followup 5 y </text>
<text top="257" left="525" width="211" height="19" font="4"><b>Results:</b>  Ventricular arrhythmias:  </text>
<text top="276" left="525" width="302" height="19" font="3">TOF 14%<b>,</b> cyanotic 6%, VSD 3%, others 2% except </text>
<text top="294" left="525" width="61" height="19" font="3">Fontan: 0 </text>
<text top="312" left="525" width="293" height="19" font="3">SVT: Fontan 45%, ASD 28%, TGA 26%, TOF 20%, </text>
<text top="331" left="525" width="84" height="19" font="3">cyanotic 16% </text>
<text top="349" left="525" width="312" height="19" font="3">Endocarditis: VSD 7%, cyanotic 6%, TOF 4%, others </text>
<text top="367" left="525" width="34" height="19" font="3">0-2% </text>
<text top="220" left="852" width="165" height="20" font="3">• VEA highest in TOF 14%;  </text>
<text top="239" left="852" width="138" height="19" font="3">Cyanotic 6%, VSD 3%,  </text>
<text top="258" left="852" width="3" height="19" font="3"> </text>
<text top="276" left="852" width="3" height="19" font="3"> </text>
<text top="294" left="852" width="3" height="19" font="3"> </text>
<text top="387" left="123" width="104" height="20" font="3">• Gallego P et al. </text>
<text top="406" left="123" width="94" height="19" font="3">AJC 2012 (531) </text>
<text top="424" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22464215">  </a></text>
<text top="425" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22464215">22464215</a></text>
<text top="425" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22464215"> </a></text>
<text top="386" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="405" left="247" width="81" height="19" font="3">single center </text>
<text top="423" left="247" width="85" height="19" font="3">retrospective </text>
<text top="441" left="247" width="3" height="19" font="3"> </text>
<text top="460" left="247" width="61" height="19" font="4"><b>Size:</b>    22 </text>
<text top="386" left="367" width="137" height="19" font="4"><b>Inclusion criteria: </b>936 </text>
<text top="405" left="367" width="92" height="19" font="3">ACHD patients </text>
<text top="423" left="367" width="138" height="19" font="3">followed single center </text>
<text top="441" left="367" width="108" height="19" font="3">8387 patient-y of </text>
<text top="460" left="367" width="57" height="19" font="3">followup </text>
<text top="478" left="367" width="3" height="19" font="3"> </text>
<text top="496" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="387" left="525" width="241" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Causes SC arrest in ACHD </text>
<text top="406" left="525" width="3" height="19" font="3"> </text>
<text top="424" left="525" width="168" height="19" font="4"><b>Results:</b>  SCA 2.6/1000 pt y </text>
<text top="442" left="525" width="248" height="19" font="3">SCA occurred in 23% of severe subaortic </text>
<text top="460" left="525" width="295" height="19" font="3">ventricular dysfunction, vs 0.7% with nonsevere </text>
<text top="479" left="525" width="132" height="19" font="3">dysfunction, p&lt;0.001 </text>
<text top="497" left="525" width="288" height="19" font="3">80% of SCA occurred in TGA, UVH, coarctation, </text>
<text top="515" left="525" width="27" height="19" font="3">TOF </text>
<text top="387" left="852" width="94" height="20" font="3">• Highest SCA:  </text>
<text top="406" left="852" width="84" height="19" font="3">TGA 10/1000 </text>
<text top="424" left="852" width="139" height="19" font="3">UVH, coarctation, TOF </text>
<text top="442" left="852" width="185" height="20" font="3">• Severe subaortic ventricular </text>
<text top="461" left="852" width="127" height="19" font="3">dysfunction (HR: 29) </text>
<text top="480" left="852" width="3" height="19" font="3"> </text>
<text top="535" left="123" width="106" height="20" font="3">• Engelings CC et </text>
<text top="554" left="123" width="93" height="19" font="3">al. Int J Cardiol </text>
<text top="572" left="123" width="69" height="19" font="3">2016 (532) </text>
<text top="590" left="123" width="10" height="20" font="3">• </text>
<text top="591" left="134" width="3" height="19" font="31"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26970963"> </a></text>
<text top="591" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26970963">26970963</a></text>
<text top="591" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26970963"> </a></text>
<text top="534" left="247" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="553" left="247" width="102" height="19" font="3">National cohort  </text>
<text top="571" left="247" width="3" height="19" font="3"> </text>
<text top="589" left="247" width="76" height="19" font="4"><b>Size:</b>   2596  </text>
<text top="534" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="553" left="367" width="132" height="19" font="3">ACHD patients &gt;18 y, </text>
<text top="571" left="367" width="132" height="19" font="3">mean followup 3.7 y; </text>
<text top="590" left="367" width="123" height="19" font="3">between 1/01-1/15 </text>
<text top="608" left="367" width="3" height="19" font="3"> </text>
<text top="626" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="535" left="525" width="281" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Identify cause of death in ACHD </text>
<text top="554" left="525" width="3" height="19" font="3"> </text>
<text top="572" left="525" width="305" height="19" font="4"><b>Results:</b>  239 deaths, 9.2%, mean age 39.8±17.8 y </text>
<text top="590" left="525" width="277" height="19" font="3">Related to Cong HD: 72%: CHF 28%, SCD 23% </text>
<text top="609" left="525" width="191" height="19" font="3">Leading causes: CHF-UVH, TGA </text>
<text top="627" left="525" width="220" height="19" font="3">SCD: Eisenmenger, TOF, Marfan, AS </text>
<text top="645" left="525" width="242" height="19" font="3">Comparing 2001-2008 with 2009-2015: </text>
<text top="663" left="525" width="302" height="19" font="3">CHF increased from 23-30%, SCD decreased from </text>
<text top="682" left="525" width="49" height="19" font="3">29-20% </text>
<text top="535" left="852" width="211" height="20" font="3">• Leading causes of cardiac death: </text>
<text top="554" left="852" width="139" height="19" font="3">CHF 28%, Sudden 23%<b> </b></text>
<text top="572" left="852" width="212" height="20" font="3">• Sudden death highest: Marfan’s, </text>
<text top="591" left="852" width="222" height="19" font="3">AS, Eisenmenger syndrome, cc TGA, </text>
<text top="609" left="852" width="126" height="19" font="3">TGA, TOF, VSD, UVH </text>
<text top="628" left="852" width="136" height="20" font="3">• AICD under-utilized  </text>
</page>
<page number="283" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">283 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="92" height="20" font="3">• Fish FA (533) </text>
<text top="128" left="123" width="77" height="20" font="3">• JACC 1992 </text>
<text top="147" left="123" width="14" height="20" font="26">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1906902">  </a></text>
<text top="148" left="137" width="53" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1906902">1906902</a></text>
<text top="148" left="190" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=1906902"> </a></text>
<text top="109" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="127" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="145" left="247" width="79" height="19" font="3">multi-center </text>
<text top="164" left="247" width="3" height="19" font="3"> </text>
<text top="182" left="247" width="68" height="19" font="4"><b>Size:</b>    124 </text>
<text top="200" left="247" width="85" height="19" font="3">(entire study, </text>
<text top="219" left="247" width="31" height="19" font="3">579) </text>
<text top="109" left="367" width="141" height="19" font="4"><b>Inclusion criteria:</b>  Use </text>
<text top="127" left="367" width="133" height="19" font="3">of class Ic AA meds in </text>
<text top="145" left="367" width="96" height="19" font="3">124/579 young </text>
<text top="164" left="367" width="104" height="19" font="3">patients with VA </text>
<text top="182" left="367" width="95" height="19" font="3">Flecainide 103, </text>
<text top="200" left="367" width="81" height="19" font="3">encainide 21 </text>
<text top="219" left="367" width="3" height="19" font="3"> </text>
<text top="237" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="109" left="525" width="290" height="19" font="4"><b>1</b>°<b> endpoint: </b> Adverse events during treatment </text>
<text top="128" left="525" width="243" height="19" font="3">with flecainide or encainide for VA: Pro-</text>
<text top="146" left="525" width="117" height="19" font="3">arrhythmia, CA/SD </text>
<text top="165" left="525" width="3" height="19" font="3"> </text>
<text top="183" left="525" width="284" height="19" font="4"><b>Results:</b>  <b>Flecainide</b>: Pro-arrhythmia: 5.8%, CA </text>
<text top="201" left="525" width="154" height="19" font="3">3.9%, sudden death4.9% </text>
<text top="219" left="525" width="305" height="19" font="3">Encainide: pro-arrhythmia 9.5%, CA 9.5%, sudden </text>
<text top="238" left="525" width="69" height="19" font="3">death9.5% </text>
<text top="256" left="525" width="99" height="19" font="3">Efficacy 71-76% </text>
<text top="274" left="525" width="254" height="19" font="3">10 patients CA/Death: most on flecainide </text>
<text top="109" left="852" width="176" height="20" font="3">• Deaths 5.6%, CA 4.8%, pro-</text>
<text top="128" left="852" width="178" height="19" font="3">arrhythmia 6.4% for patients </text>
<text top="146" left="852" width="178" height="19" font="3">treatment for VA with either </text>
<text top="165" left="852" width="141" height="19" font="3">flecainide or encainide </text>
<text top="183" left="852" width="3" height="19" font="3"> </text>
<text top="201" left="852" width="193" height="20" font="3">• for SVT patients, risk higher if </text>
<text top="220" left="852" width="153" height="19" font="3">structural HD, not for VT </text>
<text top="238" left="852" width="3" height="19" font="3"> </text>
<text top="294" left="123" width="104" height="20" font="3">• Stan MN et al., </text>
<text top="312" left="123" width="69" height="19" font="3">2014 (534) </text>
<text top="331" left="123" width="10" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22518347">• </a></text>
<text top="332" left="134" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22518347">22518347</a></text>
<text top="332" left="194" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22518347"> </a></text>
<text top="293" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="312" left="247" width="81" height="19" font="3">single center </text>
<text top="330" left="247" width="3" height="19" font="3"> </text>
<text top="348" left="247" width="18" height="19" font="3">23 </text>
<text top="293" left="367" width="92" height="19" font="3">ACHD patients </text>
<text top="312" left="367" width="106" height="19" font="3">developing amio-</text>
<text top="330" left="367" width="141" height="19" font="3">induced thyrotoxicosis </text>
<text top="348" left="367" width="121" height="19" font="3">after ≥ 3 mos amio, </text>
<text top="367" left="367" width="109" height="19" font="3">Mayo Clinic 1987-</text>
<text top="385" left="367" width="87" height="19" font="3">2009; median </text>
<text top="403" left="367" width="101" height="19" font="3">followup3.1 yrs. </text>
<text top="294" left="525" width="289" height="19" font="4"><b>1</b>°<b> endpoint: </b>Identify incidence and risk factors </text>
<text top="312" left="525" width="34" height="19" font="3">amio </text>
<text top="331" left="525" width="3" height="19" font="3"> </text>
<text top="349" left="525" width="275" height="19" font="4"><b>Results:</b> Thyrotoxicosis13.6% (23/169) ACHD </text>
<text top="367" left="525" width="252" height="19" font="3">patients developed amio thryrotoxicosis. </text>
<text top="386" left="525" width="3" height="19" font="3"> </text>
<text top="404" left="525" width="3" height="19" font="3"> </text>
<text top="294" left="852" width="171" height="20" font="3">•Highest Risk: low BMI &lt;21, </text>
<text top="312" left="852" width="76" height="19" font="3">cyanotic HD </text>
<text top="443" left="123" width="99" height="20" font="3">• Silka MJ et al.  </text>
<text top="462" left="123" width="102" height="19" font="3">JACC 1998 (535)<b> </b></text>
<text top="481" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9669277">  </a></text>
<text top="481" left="137" width="53" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9669277">9669277</a></text>
<text top="481" left="190" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9669277"> </a></text>
<text top="443" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="462" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="480" left="247" width="63" height="19" font="3">statewide </text>
<text top="498" left="247" width="49" height="19" font="3">registry </text>
<text top="516" left="247" width="3" height="19" font="3"> </text>
<text top="535" left="247" width="61" height="19" font="4"><b>Size:</b>    41 </text>
<text top="443" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="462" left="367" width="103" height="19" font="3">congenital heart </text>
<text top="480" left="367" width="112" height="19" font="3">disease surgery in </text>
<text top="498" left="367" width="118" height="19" font="3">Oregon 1958-1996 </text>
<text top="516" left="367" width="87" height="19" font="3">3589 patients </text>
<text top="535" left="367" width="3" height="19" font="3"> </text>
<text top="553" left="367" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="571" left="367" width="119" height="19" font="3">single ventricle not </text>
<text top="590" left="367" width="59" height="19" font="3">included  </text>
<text top="444" left="525" width="277" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Population based risk of SCD in </text>
<text top="462" left="525" width="152" height="19" font="3">congenital heart disease </text>
<text top="481" left="525" width="3" height="19" font="3"> </text>
<text top="499" left="525" width="189" height="19" font="4"><b>Results:</b>  SCD 1/1118 patient-y </text>
<text top="517" left="525" width="278" height="19" font="3">37/41 late sudden deathoccurred in 4 lesions </text>
<text top="535" left="525" width="279" height="19" font="3">Causes SCD: arrhythmia 75%, CHF 10%, other </text>
<text top="554" left="525" width="255" height="19" font="3">cardiac 17% (embolic, aneurysm rupture) </text>
<text top="443" left="852" width="171" height="20" font="3">•<b> </b>Late SCD: 4 lesions: 1/454 </text>
<text top="462" left="852" width="59" height="19" font="3">patient-y </text>
<text top="481" left="852" width="93" height="19" font="3">Aortic stenosis </text>
<text top="499" left="852" width="74" height="19" font="3">Coarctation </text>
<text top="517" left="852" width="32" height="19" font="3">TGA  </text>
<text top="536" left="852" width="31" height="19" font="3">TOF  </text>
<text top="554" left="852" width="214" height="20" font="3">• Cause SCD: arrhythmia 75%, CHF </text>
<text top="573" left="852" width="29" height="19" font="3">10% </text>
<text top="609" left="123" width="102" height="20" font="3">•<b> </b>Oechslin EN et </text>
<text top="628" left="123" width="76" height="19" font="3">al. AJC 2000 </text>
<text top="646" left="123" width="35" height="19" font="3">(536)<b> </b></text>
<text top="665" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11074209">  </a></text>
<text top="665" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11074209">11074209</a></text>
<text top="665" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11074209"> </a></text>
<text top="609" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="627" left="247" width="81" height="19" font="3">single center </text>
<text top="645" left="247" width="88" height="19" font="3">retrospective  </text>
<text top="664" left="247" width="3" height="19" font="3"> </text>
<text top="682" left="247" width="68" height="19" font="4"><b>Size:</b>    197 </text>
<text top="609" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="627" left="367" width="92" height="19" font="3">ACHD patients </text>
<text top="645" left="367" width="113" height="19" font="3">followed Toronto, </text>
<text top="664" left="367" width="74" height="19" font="3">2609 adults </text>
<text top="682" left="367" width="3" height="19" font="3"> </text>
<text top="700" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="609" left="525" width="242" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Mortality causes in ACHD </text>
<text top="628" left="525" width="187" height="19" font="4"><b>Results:</b>  Mean age death 37 y </text>
<text top="646" left="525" width="264" height="19" font="3">Causes: sudden 26%, CHF 21%, periop 18% </text>
<text top="665" left="525" width="304" height="19" font="3">Youngest age at death: TGA, tricuspid atresia, PA, </text>
<text top="683" left="525" width="111" height="19" font="3">aortic coarc &lt;30 y </text>
<text top="701" left="525" width="101" height="19" font="3">&gt;50 y; ASD, PDA </text>
<text top="609" left="852" width="164" height="20" font="3">• Highest mortality lesions </text>
<text top="628" left="852" width="159" height="19" font="3">congenital heart disease:  </text>
<text top="646" left="852" width="122" height="19" font="3">univentricular 41%; </text>
<text top="665" left="852" width="78" height="19" font="3">ccTGA 26%,  </text>
<text top="683" left="852" width="100" height="19" font="3">TOF or PA 16%,  </text>
<text top="701" left="852" width="70" height="19" font="3">Ebstein 9% </text>
<text top="719" left="852" width="65" height="19" font="3">AVSD 7%,  </text>
<text top="739" left="123" width="109" height="20" font="3">• Nieminen HP et </text>
<text top="758" left="123" width="84" height="19" font="3">al. JACC 2007 </text>
<text top="776" left="123" width="35" height="19" font="3">(537) </text>
<text top="738" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="757" left="247" width="55" height="19" font="3">National </text>
<text top="738" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="757" left="367" width="101" height="19" font="3">Finland national </text>
<text top="775" left="367" width="132" height="19" font="3">registry of congenital </text>
<text top="739" left="525" width="285" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Causes of death in ACHD during  </text>
<text top="758" left="525" width="86" height="19" font="3">45 y followup </text>
<text top="776" left="525" width="3" height="19" font="3"> </text>
<text top="739" left="852" width="219" height="20" font="3">• Causes of late death in congenital </text>
<text top="758" left="852" width="197" height="19" font="3">heart disease: cardiac 67%: CHF </text>
</page>
<page number="284" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">284 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="10" height="20" font="3">• </text>
<text top="109" left="134" width="3" height="19" font="26"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17888844"> </a></text>
<text top="109" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17888844">17888844</a></text>
<text top="109" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17888844"> </a></text>
<text top="109" left="247" width="53" height="19" font="3">registry, </text>
<text top="127" left="247" width="85" height="19" font="3">retrospective </text>
<text top="145" left="247" width="3" height="19" font="3"> </text>
<text top="164" left="247" width="68" height="19" font="4"><b>Size:</b>    592 </text>
<text top="109" left="367" width="122" height="19" font="3">heart disease, 6024 </text>
<text top="127" left="367" width="138" height="19" font="3">patients surviving first </text>
<text top="145" left="367" width="63" height="19" font="3">operation </text>
<text top="164" left="367" width="3" height="19" font="3"> </text>
<text top="182" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="109" left="525" width="263" height="19" font="4"><b>Results:</b>  45 y survival 89%, lower than gen </text>
<text top="127" left="525" width="70" height="19" font="3">population </text>
<text top="145" left="525" width="225" height="19" font="3">Highest risk CD: TGA, UVH, TOF, VSD </text>
<text top="164" left="525" width="276" height="19" font="3">Other CVD: stroke, arrhythmia, pulm emboli, </text>
<text top="182" left="525" width="171" height="19" font="3">endocarditis, aortic rupture </text>
<text top="200" left="525" width="197" height="19" font="3">Increased non-cardiac mortality </text>
<text top="109" left="852" width="203" height="19" font="3">40%, periop 26%, SCD 22% other </text>
<text top="127" left="852" width="49" height="19" font="3">CV 12% </text>
<text top="146" left="852" width="219" height="20" font="3">• Highest risk of SCD: coA 42%, TOF </text>
<text top="165" left="852" width="92" height="19" font="3">and TGA: 30%  </text>
<text top="183" left="852" width="198" height="20" font="3">• Increased non-cardiac death 2 </text>
<text top="202" left="852" width="173" height="19" font="3">fold: neurologic, respiratory </text>
<text top="221" left="123" width="98" height="20" font="3">• Verheugt C et </text>
<text top="240" left="123" width="107" height="19" font="3">al. IJC 2008 (538) </text>
<text top="258" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18687485">  </a></text>
<text top="259" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18687485">18687485</a></text>
<text top="259" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18687485"> </a></text>
<text top="221" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="239" left="247" width="88" height="19" font="3">Meta-analysis </text>
<text top="258" left="247" width="95" height="19" font="3">MEDLINE 1980-</text>
<text top="276" left="247" width="34" height="19" font="3">2007 </text>
<text top="294" left="247" width="3" height="19" font="3"> </text>
<text top="312" left="247" width="76" height="19" font="4"><b>Size:</b>    7894 </text>
<text top="221" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="239" left="367" width="117" height="19" font="3">ASD, VSD, PS, TOF, </text>
<text top="258" left="367" width="105" height="19" font="3">coarctation, TGA </text>
<text top="276" left="367" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="294" left="367" width="125" height="19" font="3">univentricular heart </text>
<text top="222" left="525" width="228" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Complications in ACHD </text>
<text top="240" left="525" width="3" height="19" font="3"> </text>
<text top="258" left="525" width="295" height="19" font="4"><b>Results:</b>  Vent arrhythmias: TOF 14%, VSD 2.9%, </text>
<text top="277" left="525" width="62" height="19" font="3">TGA 1.9% </text>
<text top="295" left="525" width="203" height="19" font="3">SVT: TGA 26%, ASD 28%TOF 20% </text>
<text top="313" left="525" width="291" height="19" font="3">Summarizes endocarditis, CHF, CVA, MI, SVT by </text>
<text top="332" left="525" width="39" height="19" font="3">lesion </text>
<text top="221" left="852" width="203" height="20" font="3">• Ventricular arrhythmias overall </text>
<text top="240" left="852" width="130" height="19" font="3">7%, highest TOF 14% </text>
<text top="258" left="852" width="179" height="20" font="3">• MI highest” coarctation 5% </text>
<text top="278" left="852" width="136" height="20" font="3">• SVT: all lesions: 18% </text>
<text top="296" left="852" width="3" height="19" font="3"> </text>
<text top="351" left="123" width="103" height="20" font="3">• Pillutla P et al.  </text>
<text top="370" left="123" width="95" height="19" font="3">AHJ 2009 (539) </text>
<text top="388" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19853711">  </a></text>
<text top="389" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19853711">19853711</a></text>
<text top="389" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19853711"> </a></text>
<text top="351" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="369" left="247" width="78" height="19" font="3">CDC registry </text>
<text top="387" left="247" width="99" height="19" font="3">causes of death </text>
<text top="406" left="247" width="3" height="19" font="3"> </text>
<text top="424" left="247" width="45" height="19" font="4"><b>Size:</b>     </text>
<text top="351" left="367" width="143" height="19" font="4"><b>Inclusion criteria:</b>  CDC </text>
<text top="369" left="367" width="122" height="19" font="3">registry 1979-2005, </text>
<text top="387" left="367" width="103" height="19" font="3">congenital heart </text>
<text top="406" left="367" width="92" height="19" font="3">disease in USA </text>
<text top="424" left="367" width="3" height="19" font="3"> </text>
<text top="442" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="351" left="525" width="208" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ACHD death trends  </text>
<text top="370" left="525" width="3" height="19" font="3"> </text>
<text top="388" left="525" width="287" height="19" font="4"><b>Results:</b>  Cyanotic lesions: arrhythmia, then HF </text>
<text top="406" left="525" width="295" height="19" font="3">Non-cyanotic lesions, MI after 1990, arrhythmia </text>
<text top="425" left="525" width="83" height="19" font="3">prior to 1990 </text>
<text top="443" left="525" width="3" height="19" font="3"> </text>
<text top="351" left="852" width="211" height="20" font="3">• Decline in mortality among TGA, </text>
<text top="370" left="852" width="27" height="19" font="3">TOF </text>
<text top="388" left="852" width="3" height="19" font="3"> </text>
<text top="407" left="852" width="186" height="20" font="3">• MI leading cause of death in </text>
<text top="426" left="852" width="214" height="19" font="3">patients with non=cyanotic lesions </text>
<text top="462" left="123" width="104" height="20" font="3">• Verheugt CL et </text>
<text top="481" left="123" width="76" height="19" font="3">al. EHJ 2010 </text>
<text top="499" left="123" width="35" height="19" font="3">(540) </text>
<text top="518" left="123" width="10" height="20" font="3">• </text>
<text top="519" left="134" width="3" height="19" font="26"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20207625"> </a></text>
<text top="519" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20207625">20207625</a></text>
<text top="519" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20207625"> </a></text>
<text top="462" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="480" left="247" width="97" height="19" font="3">Dutch CONCOR </text>
<text top="499" left="247" width="107" height="19" font="3">national registry, </text>
<text top="517" left="247" width="88" height="19" font="3">retrospective  </text>
<text top="535" left="247" width="3" height="19" font="3"> </text>
<text top="554" left="247" width="68" height="19" font="4"><b>Size:</b>    197 </text>
<text top="462" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="480" left="367" width="129" height="19" font="3">6933 ACHD patients: </text>
<text top="499" left="367" width="108" height="19" font="3">197 deaths: 2.8% </text>
<text top="517" left="367" width="3" height="19" font="3"> </text>
<text top="535" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="463" left="525" width="222" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ACHD causes of death </text>
<text top="481" left="525" width="3" height="19" font="3"> </text>
<text top="499" left="525" width="210" height="19" font="4"><b>Results:</b>  Median age death 49 yrs </text>
<text top="518" left="525" width="265" height="19" font="3">77% CV cause: CHF 26% age 51 yrs, sudden </text>
<text top="536" left="525" width="130" height="19" font="3">death19% age 38 yrs </text>
<text top="554" left="525" width="285" height="19" font="3">Ventricular arrhythmias predicted SCD, HR 1.5 </text>
<text top="573" left="525" width="257" height="19" font="3">SVT and VT predicted CHF, HR 5.1 and 4.5 </text>
<text top="590" left="525" width="225" height="19" font="5"><i>See complications by lesion analysis! </i></text>
<text top="462" left="852" width="200" height="20" font="3">• Lesions with highest mortality: </text>
<text top="481" left="852" width="163" height="19" font="3">Univentricular heart 25%,  </text>
<text top="499" left="852" width="107" height="19" font="3">DORV + TOF 13% </text>
<text top="518" left="852" width="63" height="19" font="3">ccTGA 6% </text>
<text top="536" left="852" width="70" height="19" font="3">Ebstein 5% </text>
<text top="554" left="852" width="58" height="19" font="3">AVSD 5% </text>
<text top="573" left="852" width="51" height="19" font="3">TGA 3% </text>
<text top="610" left="123" width="107" height="20" font="3">• Zomer AC et al. </text>
<text top="629" left="123" width="89" height="19" font="3">IJC 2012 (541) </text>
<text top="648" left="123" width="10" height="20" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20934226">• </a></text>
<text top="648" left="134" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20934226">20934226</a></text>
<text top="648" left="194" width="3" height="19" font="26"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20934226"> </a></text>
<text top="667" left="123" width="3" height="19" font="3"> </text>
<text top="610" left="247" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="628" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="647" left="247" width="106" height="19" font="3">national registry  </text>
<text top="665" left="247" width="3" height="19" font="3"> </text>
<text top="683" left="247" width="68" height="19" font="4"><b>Size:</b>    231 </text>
<text top="610" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="628" left="367" width="113" height="19" font="3">causes of death in </text>
<text top="647" left="367" width="95" height="19" font="3">ACHD patients  </text>
<text top="665" left="367" width="3" height="19" font="3"> </text>
<text top="683" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="611" left="525" width="222" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ACHD causes of death </text>
<text top="629" left="525" width="163" height="19" font="3">Total followup 26,500 pt y </text>
<text top="647" left="525" width="3" height="19" font="3"> </text>
<text top="666" left="525" width="214" height="19" font="4"><b>Results:</b>  Median age at death 48 y </text>
<text top="684" left="525" width="298" height="19" font="3">Causes of death: CHF 26%, SCD 22%, malignancy </text>
<text top="702" left="525" width="123" height="19" font="3">9%, pneumonia 4%  </text>
<text top="721" left="525" width="106" height="19" font="3">SCD exercise 8%, </text>
<text top="739" left="525" width="226" height="19" font="3">Lower risk-ASD 3%, VSD 1.3%, AS 1% </text>
<text top="757" left="525" width="302" height="19" font="3">Youngest age: TGA 33 y, AVSD 37 y, ASD age 61 y </text>
<text top="610" left="852" width="159" height="20" font="3">•  SCD: 10% with exertion </text>
<text top="629" left="852" width="212" height="20" font="3">• Highest mortality: univentricular </text>
<text top="648" left="852" width="203" height="19" font="3">hearts 26%, TOF/DORV/PA  20%, </text>
<text top="667" left="852" width="195" height="19" font="3">TGA and cc TGA 10%, AVSD 6%, </text>
<text top="685" left="852" width="77" height="19" font="3">Ebstein 6%,  </text>
<text top="703" left="852" width="3" height="19" font="3"> </text>
<text top="722" left="852" width="3" height="19" font="3"> </text>
</page>
<page number="285" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">285 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="103" height="20" font="3">• Diller GP et al.  </text>
<text top="128" left="123" width="96" height="19" font="3">Circ 2015 (542) </text>
<text top="146" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26369353">  </a></text>
<text top="147" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26369353">26369353</a></text>
<text top="147" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26369353"> </a></text>
<text top="109" left="247" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="127" left="247" width="82" height="19" font="3">Single center </text>
<text top="145" left="247" width="51" height="19" font="3">cohort   </text>
<text top="164" left="247" width="3" height="19" font="3"> </text>
<text top="182" left="247" width="76" height="19" font="4"><b>Size:</b>    6969 </text>
<text top="109" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="127" left="367" width="92" height="19" font="3">ACHD patients </text>
<text top="145" left="367" width="129" height="19" font="3">followed 1991-2013, </text>
<text top="164" left="367" width="129" height="19" font="3">median followup 9.1 </text>
<text top="182" left="367" width="21" height="19" font="3">yrs </text>
<text top="200" left="367" width="3" height="19" font="3"> </text>
<text top="218" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="109" left="525" width="313" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Cause of death ACHD compared with </text>
<text top="128" left="525" width="273" height="19" font="3">general age/gender matched, calculate SMR </text>
<text top="146" left="525" width="183" height="19" font="3">(standardized mortality ratio) </text>
<text top="164" left="525" width="192" height="19" font="4"><b>Results:</b>  7.7% died, 0.72%/pt y </text>
<text top="183" left="525" width="293" height="19" font="3">Leading causes: CHF 42%, pneumonia 10%, <b>SCD </b></text>
<text top="201" left="525" width="196" height="19" font="4"><b>7%,</b> cancer 6%, hemorrhage 5% </text>
<text top="219" left="525" width="302" height="19" font="3">SCD highest: TGA arterial switch 33%, AVSD 14%, </text>
<text top="238" left="525" width="251" height="19" font="3">Fontan and single RV 13% each, complex </text>
<text top="256" left="525" width="293" height="19" font="3">congenital heart disease 11%, Eisenmenger 9%, </text>
<text top="274" left="525" width="49" height="19" font="3">TOF 6% </text>
<text top="109" left="852" width="209" height="20" font="3">• Highest mortality: Eisenmenger, </text>
<text top="128" left="852" width="210" height="19" font="3">complex congenital heart disease, </text>
<text top="146" left="852" width="31" height="19" font="3">UVH </text>
<text top="165" left="852" width="186" height="20" font="3">• SMR, p&lt;0.001: Fontan: 23.4, </text>
<text top="184" left="852" width="208" height="19" font="3">Complex congenital heart disease </text>
<text top="202" left="852" width="34" height="19" font="3">14.1, </text>
<text top="220" left="852" width="119" height="19" font="3">Eisenmenger 12.8,  </text>
<text top="239" left="852" width="102" height="19" font="3">systemic RV 4.9, </text>
<text top="257" left="852" width="81" height="19" font="3"> Ebstein 3.3,  </text>
<text top="275" left="852" width="188" height="19" font="3">TGA arterial switch 2.6 (0.08),  </text>
<text top="293" left="852" width="201" height="19" font="3">TOF 2.3, Marfan 2.2, coarctation </text>
<text top="312" left="852" width="22" height="19" font="3">1.7 </text>
<text top="331" left="123" width="103" height="20" font="3">• Raissadati A et </text>
<text top="350" left="123" width="84" height="19" font="3">al. JACC 2016 </text>
<text top="368" left="123" width="35" height="19" font="3">(543) </text>
<text top="387" left="123" width="14" height="20" font="31">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27470457">  </a></text>
<text top="387" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27470457">27470457</a></text>
<text top="387" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27470457"> </a></text>
<text top="331" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="349" left="247" width="74" height="19" font="3">Nationwide </text>
<text top="367" left="247" width="84" height="19" font="3">cohort study, </text>
<text top="386" left="247" width="48" height="19" font="3">Finland </text>
<text top="404" left="247" width="3" height="19" font="3"> </text>
<text top="422" left="247" width="87" height="19" font="4"><b>Size:</b>    10,964 </text>
<text top="331" left="367" width="115" height="19" font="4"><b>Inclusion criteria: </b> </text>
<text top="349" left="367" width="126" height="19" font="3">Patients undergoing </text>
<text top="367" left="367" width="132" height="19" font="3">cardiac surgery &lt;15 y </text>
<text top="386" left="367" width="115" height="19" font="3">old between 1953-</text>
<text top="404" left="367" width="41" height="19" font="3">2009   </text>
<text top="422" left="367" width="3" height="19" font="3"> </text>
<text top="441" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="331" left="525" width="253" height="19" font="4"><b>1</b>°<b> endpoint:</b> ACHD Late mortality causes </text>
<text top="350" left="525" width="3" height="19" font="3"> </text>
<text top="368" left="525" width="253" height="19" font="4"><b>Results:</b>  early mortality 5.6%; late 10.4% </text>
<text top="386" left="525" width="288" height="19" font="3">congenital heart disease related deaths: 6.6%:  </text>
<text top="405" left="525" width="310" height="19" font="3">causes-CHF 28%, reop 14%, SCD 13%, other CV 8% </text>
<text top="423" left="525" width="310" height="19" font="3">Sudden deaths: arrhythmia/unknown 78%, MI 7%, </text>
<text top="441" left="525" width="125" height="19" font="3">aortic dissection 5% </text>
<text top="460" left="525" width="7" height="19" font="4"><b> </b> </text>
<text top="478" left="525" width="313" height="19" font="3">Sudden death ages:<b> </b>ASD 40 y, TOF 30 y, coarc 29 y, </text>
<text top="496" left="525" width="304" height="19" font="3">Cancer higher than general population, especially </text>
<text top="515" left="525" width="110" height="19" font="3">females, (RR: 5.9)<b> </b></text>
<text top="331" left="852" width="219" height="20" font="3">• Late 40 yr survival: simple defects </text>
<text top="350" left="852" width="121" height="19" font="3">87%, complex 65%  </text>
<text top="368" left="852" width="215" height="20" font="3">• 40 y freedom sudden death: 99% </text>
<text top="387" left="852" width="180" height="19" font="3">simple, 91% severe, (HR: 9.9)<b> </b></text>
<text top="406" left="852" width="200" height="19" font="3">Highest CV mortality: UVH, TGA, </text>
<text top="424" left="852" width="100" height="19" font="3">TOF, VSD, coarc </text>
<text top="442" left="852" width="213" height="20" font="3">• Increased lung, neuro, infectious </text>
<text top="461" left="852" width="55" height="19" font="3">diseases </text>
<text top="480" left="852" width="3" height="19" font="3"> </text>
<text top="534" left="123" width="97" height="20" font="3">• Teuwen CP et </text>
<text top="553" left="123" width="107" height="19" font="3">al. IJC 2016 (544) </text>
<text top="571" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26805391">  </a></text>
<text top="572" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26805391">26805391</a></text>
<text top="572" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26805391"> </a></text>
<text top="534" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="552" left="247" width="84" height="19" font="3">retrospective </text>
<text top="570" left="247" width="44" height="19" font="3">cohort </text>
<text top="589" left="247" width="3" height="19" font="3"> </text>
<text top="607" left="247" width="68" height="19" font="4"><b>Size:</b>    145 </text>
<text top="534" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b> <b> </b></text>
<text top="552" left="367" width="123" height="19" font="4"><b>ACHD</b> patients with </text>
<text top="570" left="367" width="25" height="19" font="3">VA: </text>
<text top="589" left="367" width="112" height="19" font="3">Nonsust VT    71% </text>
<text top="607" left="367" width="111" height="19" font="3">Sustained VT 17% </text>
<text top="625" left="367" width="112" height="19" font="3">VF                    12% </text>
<text top="644" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="534" left="525" width="284" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ACHD Non-sustained VT: risk for </text>
<text top="553" left="525" width="102" height="19" font="3">sustained VT/VF </text>
<text top="571" left="525" width="115" height="19" font="3">Mean age 40±14 y </text>
<text top="589" left="525" width="3" height="19" font="3"> </text>
<text top="608" left="525" width="287" height="19" font="4"><b>Results:</b>  5/103 nonsust VT patients developed </text>
<text top="626" left="525" width="102" height="19" font="3">sustained VT/VF </text>
<text top="644" left="525" width="3" height="19" font="3"> </text>
<text top="534" left="852" width="220" height="20" font="3">•<b> </b>Sustained VT/VF developed rarely </text>
<text top="553" left="852" width="203" height="19" font="3">in patients with only non-sust VT </text>
<text top="571" left="852" width="214" height="20" font="3">• Recurrent sust VT/VF frequent in </text>
<text top="590" left="852" width="221" height="19" font="3">patients presenting with sust VT/VF </text>
<text top="609" left="852" width="174" height="20" font="3">• recommend “wait and see </text>
<text top="628" left="852" width="163" height="19" font="3">approach” for nonsust VT; </text>
<text top="646" left="852" width="222" height="19" font="3">aggressive treatment for sust VT/VF </text>
</page>
<page number="286" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">286 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="92" height="20" font="3">• Wells R et al. </text>
<text top="128" left="123" width="69" height="19" font="3">2009 (545) </text>
<text top="146" left="123" width="10" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19691680">• </a></text>
<text top="147" left="134" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19691680">19691680</a></text>
<text top="147" left="194" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19691680"> </a></text>
<text top="109" left="247" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="127" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="145" left="247" width="74" height="19" font="3">multicenter </text>
<text top="164" left="247" width="3" height="19" font="3"> </text>
<text top="182" left="247" width="107" height="19" font="4"><b>Size:</b>  20 patients<b> </b></text>
<text top="109" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b> <b> </b></text>
<text top="127" left="367" width="135" height="19" font="3">ACHD, mean age 34.9 </text>
<text top="145" left="367" width="72" height="19" font="3">y, receiving </text>
<text top="164" left="367" width="144" height="19" font="3">amiodarone for ≥6 mo; </text>
<text top="182" left="367" width="122" height="19" font="3">case-control group. </text>
<text top="200" left="367" width="120" height="19" font="3">Mean duration 3 y, </text>
<text top="219" left="367" width="119" height="19" font="3">mean dose 191 mg </text>
<text top="237" left="367" width="3" height="19" font="3"> </text>
<text top="255" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="109" left="525" width="245" height="19" font="3">Review side effects of chronic oral amio </text>
<text top="127" left="525" width="3" height="19" font="3"> </text>
<text top="145" left="525" width="303" height="19" font="3">36% developed thyroid dysfunction: 19 hyper, 14 </text>
<text top="164" left="525" width="301" height="19" font="3">hypothyroid. Sig risk factors: Female gender (OR: </text>
<text top="182" left="525" width="271" height="19" font="3">3.0) cyanotic HD (OR: 7.0); Fontan (OR: 4.0); </text>
<text top="200" left="525" width="173" height="19" font="3">dosage &gt;200 mg/d (OR: 4.0)<b> </b></text>
<text top="109" left="852" width="190" height="19" font="3"> Patients with congenital heart </text>
<text top="127" left="852" width="186" height="19" font="3">disease at higher risk for amio </text>
<text top="145" left="852" width="177" height="19" font="3">adverse effects, esp women, </text>
<text top="164" left="852" width="213" height="19" font="3">cyanosis, Fontan, or dose &gt;200 mg </text>
<text top="274" left="123" width="94" height="20" font="3">• Afilalo J et al. </text>
<text top="293" left="123" width="102" height="19" font="3">JACC 2011 (546) </text>
<text top="312" left="123" width="10" height="20" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21939837">• </a></text>
<text top="312" left="134" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21939837">21939837</a></text>
<text top="312" left="194" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21939837"> </a></text>
<text top="274" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="292" left="247" width="50" height="19" font="3">Quebec </text>
<text top="311" left="247" width="94" height="19" font="3">database 1993-</text>
<text top="329" left="247" width="34" height="19" font="3">2005 </text>
<text top="347" left="247" width="3" height="19" font="3"> </text>
<text top="366" left="247" width="76" height="19" font="4"><b>Size:</b>   3239  </text>
<text top="274" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="292" left="367" width="128" height="19" font="3">ACHD patients ≥65 y </text>
<text top="311" left="367" width="135" height="19" font="3">old at entry, followed </text>
<text top="329" left="367" width="64" height="19" font="3">up to 15 y </text>
<text top="347" left="367" width="3" height="19" font="3"> </text>
<text top="366" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="275" left="525" width="239" height="19" font="4"><b>1</b>°<b> endpoint:</b>  all-cause mortality ACHD </text>
<text top="293" left="525" width="3" height="19" font="3"> </text>
<text top="311" left="525" width="287" height="19" font="4"><b>Results:</b>  most common types congenital heart </text>
<text top="330" left="525" width="307" height="19" font="3">disease: shunt lesions 60%, valvar 37%, severe 3% </text>
<text top="348" left="525" width="256" height="19" font="3">Arrhythmias present: AF 25%, Ventricular </text>
<text top="367" left="525" width="114" height="19" font="3">arrhythmias 3–4% </text>
<text top="385" left="525" width="297" height="19" font="3">Mortality driven by co-morbidity: dementia (HR: </text>
<text top="403" left="525" width="301" height="19" font="3">3.24), GI bleed (HR: 2.79), chronic kidney disease </text>
<text top="422" left="525" width="279" height="19" font="3">(HR: 2.5); CHF (HR: 1.98), diabetes (HR: 1.76), </text>
<text top="440" left="525" width="106" height="19" font="3">COPD (HR: 1.67)  </text>
<text top="274" left="852" width="173" height="20" font="3">• Current ACHd populations </text>
<text top="293" left="852" width="215" height="19" font="3">surviving to age 65 y or greater, co-</text>
<text top="312" left="852" width="195" height="19" font="3">morbid diseases most powerful </text>
<text top="330" left="852" width="207" height="19" font="3">predictors of mortality; increased </text>
<text top="348" left="852" width="171" height="19" font="3">CAD 7% vs 5% age matched </text>
<text top="367" left="852" width="208" height="20" font="3">• Ventricular arrhythmias present </text>
<text top="386" left="852" width="51" height="19" font="3">in 3–4% </text>
<text top="404" left="852" width="220" height="20" font="3">• Prevalence ACHD in geriatrics: 3.7 </text>
<text top="423" left="852" width="220" height="19" font="3">/1000 (vs 4.2/1000 in non-geriatric) </text>
<text top="441" left="852" width="3" height="19" font="3"> </text>
<text top="461" left="123" width="105" height="20" font="3">• El Malti R et al. </text>
<text top="480" left="123" width="63" height="19" font="3">EJ Human </text>
<text top="498" left="123" width="90" height="19" font="3">Genetics 2016 </text>
<text top="516" left="123" width="35" height="19" font="3">(547) </text>
<text top="535" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26014430">  </a></text>
<text top="535" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26014430">26014430</a></text>
<text top="535" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26014430"> </a></text>
<text top="460" left="247" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="479" left="247" width="96" height="19" font="4"><b>retrospective</b>    </text>
<text top="497" left="247" width="3" height="19" font="3"> </text>
<text top="515" left="247" width="68" height="19" font="4"><b>Size:</b>   154  </text>
<text top="460" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="479" left="367" width="115" height="19" font="3">familial congenital </text>
<text top="497" left="367" width="133" height="19" font="3">heart disease genetic </text>
<text top="515" left="367" width="65" height="19" font="3">screening  </text>
<text top="534" left="367" width="3" height="19" font="3"> </text>
<text top="552" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="461" left="525" width="299" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Screening congenital heart disease </text>
<text top="480" left="525" width="149" height="19" font="3">for FATA4, NKX2.5, ZIC3 </text>
<text top="498" left="525" width="3" height="19" font="3"> </text>
<text top="516" left="525" width="263" height="19" font="4"><b>Results:</b>  10.4% identified with causal gene </text>
<text top="535" left="525" width="281" height="19" font="3">NKX2.5 identified in ASD/VSD and conduction </text>
<text top="553" left="525" width="141" height="19" font="3">disorders; 6/154, 3.9% </text>
<text top="571" left="525" width="149" height="19" font="3">ZIC3 1.9%, GATA4, 0.7% </text>
<text top="589" left="525" width="3" height="19" font="3"> </text>
<text top="461" left="852" width="214" height="20" font="3">• Familial AV block/ASD correlated </text>
<text top="480" left="852" width="78" height="19" font="3">with NKX2.5 </text>
<text top="498" left="852" width="202" height="20" font="3">• Can be used to screen high risk </text>
<text top="517" left="852" width="78" height="19" font="3">SCD families </text>
<text top="535" left="852" width="3" height="19" font="3"> </text>
<text top="554" left="852" width="3" height="19" font="3"> </text>
<text top="609" left="123" width="93" height="20" font="3">• Abou Hassan </text>
<text top="628" left="123" width="102" height="19" font="3">OK et al. Sci Rep </text>
<text top="646" left="123" width="69" height="19" font="3">2015 (548) </text>
<text top="664" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25742962">  </a></text>
<text top="665" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25742962">25742962</a></text>
<text top="665" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25742962"> </a></text>
<text top="608" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="627" left="247" width="88" height="19" font="3">retrospective  </text>
<text top="645" left="247" width="3" height="19" font="3"> </text>
<text top="663" left="247" width="68" height="19" font="4"><b>Size:</b>  188   </text>
<text top="608" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="627" left="367" width="103" height="19" font="3">congenital heart </text>
<text top="645" left="367" width="123" height="19" font="3">disease in Lebanon: </text>
<text top="663" left="367" width="107" height="19" font="3">high incidence of </text>
<text top="682" left="367" width="80" height="19" font="3">cosanguinity </text>
<text top="700" left="367" width="3" height="19" font="3"> </text>
<text top="718" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="609" left="525" width="285" height="19" font="4"><b>1</b>°<b> endpoint:</b> Screening NKX 2.5 gene defect in </text>
<text top="628" left="525" width="152" height="19" font="3">congenital heart disease </text>
<text top="646" left="525" width="3" height="19" font="3"> </text>
<text top="664" left="525" width="253" height="19" font="4"><b>Results:</b>  Familial ASD: 60% with NKX 2.5  </text>
<text top="683" left="525" width="307" height="19" font="3">Diversity of phenotypes: congenital heart disease, </text>
<text top="701" left="525" width="232" height="19" font="3">AV block, SCD, coronary sinus disease </text>
<text top="609" left="852" width="175" height="20" font="3">• Familial septal defects and </text>
<text top="628" left="852" width="166" height="19" font="3">conduction disorders: high </text>
<text top="646" left="852" width="149" height="19" font="3">prevalence NKX2.5, SCD </text>
<text top="664" left="852" width="3" height="19" font="3"> </text>
<text top="683" left="852" width="3" height="19" font="3"> </text>
<text top="701" left="852" width="3" height="19" font="3"> </text>
<text top="738" left="123" width="110" height="20" font="3">• Ellesoe SG et al. </text>
<text top="757" left="123" width="99" height="19" font="3">CHD 2016 (549) </text>
<text top="775" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26679770">  </a></text>
<text top="776" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26679770">26679770</a></text>
<text top="776" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26679770"> </a></text>
<text top="737" left="247" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="756" left="247" width="3" height="19" font="3"> </text>
<text top="774" left="247" width="61" height="19" font="4"><b>Size:</b>    39 </text>
<text top="737" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="756" left="367" width="139" height="19" font="3">Probands with familial </text>
<text top="738" left="525" width="270" height="19" font="4"><b>1</b>°<b> endpoint:</b>  NKX 2.5 occurrence in familial </text>
<text top="757" left="525" width="152" height="19" font="3">congenital heart disease </text>
<text top="775" left="525" width="3" height="19" font="3"> </text>
<text top="738" left="852" width="206" height="20" font="3">• Screen familial ASD patients for </text>
<text top="757" left="852" width="163" height="19" font="3">NKX 2.5, esp if conduction </text>
<text top="775" left="852" width="60" height="19" font="3">disorders </text>
</page>
<page number="287" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">287 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="367" width="103" height="19" font="3">congenital heart </text>
<text top="127" left="367" width="49" height="19" font="3">disease </text>
<text top="145" left="367" width="3" height="19" font="3"> </text>
<text top="164" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="109" left="525" width="256" height="19" font="4"><b>Results:</b>  NKX 2.5 found 2.5% of probands </text>
<text top="127" left="525" width="3" height="19" font="3"> </text>
<text top="145" left="525" width="3" height="19" font="3"> </text>
<text top="109" left="852" width="3" height="19" font="3"> </text>
<text top="127" left="852" width="3" height="19" font="3"> </text>
<text top="183" left="123" width="95" height="20" font="3">• Cuypers JA et </text>
<text top="202" left="123" width="89" height="19" font="3">al. Heart 2013 </text>
<text top="220" left="123" width="35" height="19" font="3">(550) </text>
<text top="239" left="123" width="10" height="20" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23886606">• </a></text>
<text top="239" left="134" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23886606">23886606</a></text>
<text top="239" left="194" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23886606"> </a></text>
<text top="183" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="201" left="247" width="79" height="19" font="3">Longitudinal </text>
<text top="219" left="247" width="44" height="19" font="3">cohort </text>
<text top="238" left="247" width="3" height="19" font="3"> </text>
<text top="256" left="247" width="68" height="19" font="4"><b>Size:</b>   135  </text>
<text top="183" left="367" width="143" height="19" font="4"><b>Inclusion criteria:</b>  ASD </text>
<text top="201" left="367" width="128" height="19" font="3">surgical repair 1968- </text>
<text top="219" left="367" width="34" height="19" font="3">1990 </text>
<text top="238" left="367" width="3" height="19" font="3"> </text>
<text top="256" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="183" left="525" width="266" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ASD surgical repair long-term </text>
<text top="202" left="525" width="65" height="19" font="4"><b>outcomes</b> </text>
<text top="220" left="525" width="127" height="19" font="3">Mean Followup 35 y </text>
<text top="238" left="525" width="3" height="19" font="3"> </text>
<text top="257" left="525" width="206" height="19" font="4"><b>Results:</b>  SVT: 16%, late SCD 1.5% </text>
<text top="275" left="525" width="100" height="19" font="3">Pacemaker 6%.  </text>
<text top="293" left="525" width="294" height="19" font="3">LVEF 58%, RVEF 51%.<b> </b>Low RVEF 31%,<b> d</b>ilated RV </text>
<text top="312" left="525" width="29" height="19" font="3">20% </text>
<text top="183" left="852" width="220" height="20" font="3">• Surgical repair ASD: late SCD 1.5% </text>
<text top="202" left="852" width="3" height="19" font="3"> </text>
<text top="220" left="852" width="3" height="19" font="3"> </text>
<text top="331" left="123" width="100" height="20" font="3">• Kuijpers JM et </text>
<text top="350" left="123" width="76" height="19" font="3">al. EHJ 2015 </text>
<text top="368" left="123" width="35" height="19" font="3">(551) </text>
<text top="387" left="123" width="10" height="20" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25883174">• </a></text>
<text top="387" left="134" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25883174">25883174</a></text>
<text top="387" left="194" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25883174"> </a></text>
<text top="331" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="349" left="247" width="93" height="19" font="3">Dutch national </text>
<text top="367" left="247" width="49" height="19" font="3">registry </text>
<text top="386" left="247" width="3" height="19" font="3"> </text>
<text top="404" left="247" width="76" height="19" font="4"><b>Size:</b>   2207  </text>
<text top="331" left="367" width="140" height="19" font="4"><b>Inclusion criteria: ASD </b></text>
<text top="349" left="367" width="122" height="19" font="4"><b>secundum</b> in Dutch </text>
<text top="367" left="367" width="49" height="19" font="3">registry </text>
<text top="386" left="367" width="93" height="19" font="3">Mean age 45 y </text>
<text top="404" left="367" width="69" height="19" font="3">Males 33% </text>
<text top="422" left="367" width="3" height="19" font="3"> </text>
<text top="441" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="331" left="525" width="293" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ASD secundum outcomes: gender </text>
<text top="350" left="525" width="72" height="19" font="3">differences </text>
<text top="368" left="525" width="199" height="19" font="3">Cumulative followup 13584 pt-y </text>
<text top="386" left="525" width="3" height="19" font="3"> </text>
<text top="405" left="525" width="314" height="19" font="4"><b>Results:</b>  Median survival: men 79.7 y, women 85.6 </text>
<text top="423" left="525" width="14" height="19" font="3">y. </text>
<text top="441" left="525" width="295" height="19" font="3">Compared w age/sex matched gen pop, survival </text>
<text top="460" left="525" width="220" height="19" font="3">for males lower; equal for females.  </text>
<text top="331" left="852" width="212" height="20" font="3">• ASD secundum outcomes: males </text>
<text top="350" left="852" width="139" height="19" font="3">higher risk conduction </text>
<text top="368" left="852" width="179" height="19" font="3">disturbances, SVT, CVA, CHF; </text>
<text top="386" left="852" width="187" height="19" font="3">decreased life expectancy c/w </text>
<text top="405" left="852" width="119" height="19" font="3">general population </text>
<text top="423" left="852" width="3" height="19" font="3"> </text>
<text top="441" left="852" width="3" height="19" font="3"> </text>
<text top="479" left="123" width="97" height="20" font="3">• Khairy P et al. </text>
<text top="498" left="123" width="96" height="19" font="3">Circ 2010 (552) </text>
<text top="516" left="123" width="10" height="20" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20713900">• </a></text>
<text top="517" left="134" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20713900">20713900</a></text>
<text top="517" left="194" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20713900"> </a></text>
<text top="479" left="247" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="497" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="515" left="247" width="83" height="19" font="3">multi-center  </text>
<text top="534" left="247" width="3" height="19" font="3"> </text>
<text top="552" left="247" width="68" height="19" font="4"><b>Size:</b>    556 </text>
<text top="479" left="367" width="142" height="19" font="4"><b>Inclusion criteria:</b>  TOF </text>
<text top="497" left="367" width="40" height="19" font="3">repair </text>
<text top="515" left="367" width="77" height="19" font="3">Female 54% </text>
<text top="534" left="367" width="93" height="19" font="3">Mean age 37 y </text>
<text top="552" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="479" left="525" width="261" height="19" font="4"><b>1</b>°<b> endpoint:</b>  TOF arrhythmia outcomes &amp; </text>
<text top="498" left="525" width="65" height="19" font="3">correlates </text>
<text top="516" left="525" width="3" height="19" font="3"> </text>
<text top="534" left="525" width="231" height="19" font="4"><b>Results:</b>  Sustained arrhythmia: 43%.  </text>
<text top="553" left="525" width="314" height="19" font="3">Prevalence AT 20%: RAE, HTN, number of surgeries<b> </b></text>
<text top="571" left="525" width="3" height="19" font="4"><b> </b></text>
<text top="589" left="525" width="273" height="19" font="3">ventricular 14.6%: number of surgeries, QRS </text>
<text top="608" left="525" width="263" height="19" font="3">duration, LV diastolic dysfunction (OR: 3.3) </text>
<text top="479" left="852" width="219" height="20" font="3">• TOF Ventricular arrhythmias 15%, </text>
<text top="498" left="852" width="165" height="19" font="3">increased with LV diastolic </text>
<text top="516" left="852" width="75" height="19" font="3">dysfunction </text>
<text top="535" left="852" width="165" height="20" font="3">• AF and Vent arrhythmias </text>
<text top="554" left="852" width="149" height="19" font="3">increased after age 45 y </text>
<text top="572" left="852" width="3" height="19" font="3"> </text>
<text top="590" left="852" width="3" height="19" font="3"> </text>
<text top="627" left="123" width="101" height="20" font="3">• Valente AM et </text>
<text top="646" left="123" width="89" height="19" font="3">al. Heart 2014 </text>
<text top="664" left="123" width="35" height="19" font="3">(553) </text>
<text top="683" left="123" width="10" height="20" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24179163">• </a></text>
<text top="683" left="134" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24179163">24179163</a></text>
<text top="683" left="194" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24179163"> </a></text>
<text top="627" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="645" left="247" width="74" height="19" font="3">Prospective </text>
<text top="663" left="247" width="79" height="19" font="3">multi-center </text>
<text top="682" left="247" width="74" height="19" font="4"><b>INDICATOR </b></text>
<text top="700" left="247" width="44" height="19" font="3">cohort </text>
<text top="718" left="247" width="3" height="19" font="3"> </text>
<text top="737" left="247" width="68" height="19" font="4"><b>Size:</b>    873 </text>
<text top="627" left="367" width="138" height="19" font="4"><b>Inclusion criteria</b>: TOF </text>
<text top="645" left="367" width="41" height="19" font="3">adults </text>
<text top="663" left="367" width="104" height="19" font="3">Median age 24 y </text>
<text top="682" left="367" width="3" height="19" font="3"> </text>
<text top="700" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="627" left="525" width="244" height="19" font="4"><b>1</b>°<b> endpoint:</b>  TOF risk factors death, VT </text>
<text top="646" left="525" width="3" height="19" font="3"> </text>
<text top="664" left="525" width="253" height="19" font="4"><b>Results:</b> 3.7% death/VT, median age 38 y </text>
<text top="683" left="525" width="225" height="19" font="3">Cos regression outcomes predictors: </text>
<text top="701" left="525" width="235" height="19" font="3">RV mass/volume ratio ≥0.3, (HR: 5.04) </text>
<text top="719" left="525" width="164" height="19" font="3">LVEF z score &lt;2, (HR: 3.34) </text>
<text top="737" left="525" width="87" height="19" font="3">AT, (HR: 3.65) </text>
<text top="627" left="852" width="158" height="20" font="3">• TOF predictors SCD, VT: </text>
<text top="646" left="852" width="218" height="19" font="3">RVH, ventricular dysfunction (RV or </text>
<text top="664" left="852" width="72" height="19" font="3">LV), and AT </text>
<text top="683" left="852" width="3" height="19" font="3"> </text>
<text top="701" left="852" width="193" height="19" font="3">Higher RV systolic pressure, HR </text>
<text top="719" left="852" width="30" height="19" font="3">1.39 </text>
<text top="737" left="852" width="3" height="19" font="3"> </text>
</page>
<page number="288" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">288 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="85" height="20" font="3">• Arya S et al. </text>
<text top="128" left="123" width="99" height="19" font="3">CHD 2014 (554) </text>
<text top="146" left="123" width="10" height="20" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24314315">• </a></text>
<text top="147" left="134" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24314315">24314315</a></text>
<text top="147" left="194" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24314315"> </a></text>
<text top="109" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="127" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="145" left="247" width="81" height="19" font="3">single center </text>
<text top="164" left="247" width="3" height="19" font="3"> </text>
<text top="182" left="247" width="68" height="19" font="4"><b>Size:</b>    109 </text>
<text top="109" left="367" width="139" height="19" font="4"><b>Inclusion criteria:</b> TOF </text>
<text top="127" left="367" width="90" height="19" font="3">Late followup  </text>
<text top="145" left="367" width="64" height="19" font="3">Male 49% </text>
<text top="164" left="367" width="81" height="19" font="3">Ages 17-58 y </text>
<text top="182" left="367" width="3" height="19" font="3"> </text>
<text top="200" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="109" left="525" width="270" height="19" font="4"><b>1</b>°<b> endpoint:</b>  TOF outcomes: risk changing? </text>
<text top="128" left="525" width="3" height="19" font="3"> </text>
<text top="146" left="525" width="302" height="19" font="4"><b>Results:</b>  Arrhythmias 54%: older postop interval, </text>
<text top="165" left="525" width="168" height="19" font="3">wide QRS mean 158 msec.  </text>
<text top="183" left="525" width="265" height="19" font="3">No correlation with surgical era, gender RV </text>
<text top="201" left="525" width="201" height="19" font="3">pressure, RVOT gradient, RVEDV </text>
<text top="109" left="852" width="129" height="20" font="3">• TOF late SCD: 1.8% </text>
<text top="128" left="852" width="3" height="19" font="3"> </text>
<text top="146" left="852" width="3" height="19" font="3"> </text>
<text top="165" left="852" width="3" height="19" font="3"> </text>
<text top="220" left="123" width="94" height="20" font="3">• Wu MH et al. </text>
<text top="239" left="123" width="90" height="19" font="3">HR 2015 (555) </text>
<text top="258" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25461497">  </a></text>
<text top="258" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25461497">25461497</a></text>
<text top="258" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25461497"> </a></text>
<text top="220" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="238" left="247" width="55" height="19" font="3">National </text>
<text top="257" left="247" width="106" height="19" font="3">database Taiwan </text>
<text top="275" left="247" width="88" height="19" font="3">retrospective  </text>
<text top="293" left="247" width="100" height="19" font="3">(national health </text>
<text top="312" left="247" width="105" height="19" font="3">insurance! Easily </text>
<text top="330" left="247" width="104" height="19" font="3">accessible care!) </text>
<text top="348" left="247" width="3" height="19" font="3"> </text>
<text top="367" left="247" width="76" height="19" font="4"><b>Size:</b>    4781 </text>
<text top="220" left="367" width="139" height="19" font="4"><b>Inclusion criteria: </b>TOF </text>
<text top="238" left="367" width="91" height="19" font="3">repair Taiwan; </text>
<text top="257" left="367" width="129" height="19" font="3">database those born </text>
<text top="275" left="367" width="129" height="19" font="3">2000-2010 reviewed </text>
<text top="293" left="367" width="111" height="19" font="3">for late outcomes </text>
<text top="312" left="367" width="69" height="19" font="3">58% males </text>
<text top="330" left="367" width="3" height="19" font="3"> </text>
<text top="348" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="221" left="525" width="274" height="19" font="4"><b>1</b>°<b> endpoint:</b>  TOF late arrhythmia outcomes </text>
<text top="239" left="525" width="3" height="19" font="3"> </text>
<text top="257" left="525" width="275" height="19" font="4"><b>Results:</b>  Prevalence TOF in adults 0.06/1000 </text>
<text top="276" left="525" width="113" height="19" font="3">Survival 10 y: 78% </text>
<text top="294" left="525" width="219" height="19" font="3">Arrhythmias 4.6%: 73% tachycardia </text>
<text top="312" left="525" width="314" height="19" font="3">Overall tachycardia: 3.3% (6.6% adults, 1.8% peds). </text>
<text top="331" left="525" width="117" height="19" font="3">AF 29%.  AVB 0.6% </text>
<text top="349" left="525" width="234" height="19" font="3">SVT/AT/AFL/AF = 80%, VT 18%, VF 3% </text>
<text top="367" left="525" width="202" height="19" font="3">Mortality with VT: 24%, VF 60%. <b> </b></text>
<text top="220" left="852" width="212" height="20" font="3">• TOF tachycardia in adults: 6.6%:  </text>
<text top="239" left="852" width="100" height="19" font="3">VT 18%, VF 3%,  </text>
<text top="258" left="852" width="177" height="20" font="3">• Median age VT/VF 23–25 y </text>
<text top="277" left="852" width="190" height="20" font="3">• Interventions for tachycardia </text>
<text top="296" left="852" width="133" height="19" font="3">2.4% annually, adults </text>
<text top="314" left="852" width="3" height="19" font="3"> </text>
<text top="387" left="123" width="96" height="20" font="3">• Heng EL et al. </text>
<text top="406" left="123" width="107" height="19" font="3">Heart 2015 (298) </text>
<text top="424" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25351509">  </a></text>
<text top="425" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25351509">25351509</a></text>
<text top="425" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25351509"> </a></text>
<text top="386" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="405" left="247" width="82" height="19" font="3">Single center </text>
<text top="423" left="247" width="75" height="19" font="3">prospective </text>
<text top="441" left="247" width="3" height="19" font="3"> </text>
<text top="460" left="247" width="61" height="19" font="4"><b>Size:</b>    90 </text>
<text top="386" left="367" width="142" height="19" font="4"><b>Inclusion criteria:  </b>TOF </text>
<text top="405" left="367" width="84" height="19" font="3">patients with </text>
<text top="423" left="367" width="131" height="19" font="3">age/gender matched </text>
<text top="441" left="367" width="57" height="19" font="3">controls. </text>
<text top="460" left="367" width="3" height="19" font="3"> </text>
<text top="478" left="367" width="132" height="19" font="3">BNP 1pmol/L = 3.472 </text>
<text top="496" left="367" width="40" height="19" font="3">pg/ml </text>
<text top="515" left="367" width="3" height="19" font="3"> </text>
<text top="533" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="387" left="525" width="275" height="19" font="4"><b>1</b>°<b> endpoint:</b>  TOF outcomes and biomarkers </text>
<text top="406" left="525" width="136" height="19" font="3">Median followup 10 y </text>
<text top="424" left="525" width="251" height="19" font="3">Measured aldosterone, ANP, BNP, renin, </text>
<text top="442" left="525" width="70" height="19" font="3">endothelin </text>
<text top="460" left="525" width="3" height="19" font="3"> </text>
<text top="479" left="525" width="156" height="19" font="4"><b>Results:</b>  Late deaths: 9% </text>
<text top="497" left="525" width="287" height="19" font="3">BNP ≥15 pmol/L: increased mortality (HR: 5.4), </text>
<text top="515" left="525" width="149" height="19" font="3">sustained VT, (HR: 2.06) </text>
<text top="387" left="852" width="176" height="20" font="3">• TOF: BNP level ≥15 pmol/L </text>
<text top="406" left="852" width="198" height="19" font="3">associated with 5 fold increased </text>
<text top="424" left="852" width="63" height="19" font="3">risk death </text>
<text top="442" left="852" width="167" height="20" font="3">• Incorporate BNP into risk </text>
<text top="461" left="852" width="81" height="19" font="3">stratification </text>
<text top="480" left="852" width="3" height="19" font="3"> </text>
<text top="552" left="123" width="94" height="20" font="3">• Drago F et al. </text>
<text top="571" left="123" width="89" height="19" font="3">IJC 2016 (556) </text>
<text top="590" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27505328">  </a></text>
<text top="590" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27505328">27505328</a></text>
<text top="590" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27505328"> </a></text>
<text top="552" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="570" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="589" left="247" width="81" height="19" font="3">single center </text>
<text top="607" left="247" width="3" height="19" font="3"> </text>
<text top="625" left="247" width="68" height="19" font="4"><b>Size:</b>    146 </text>
<text top="552" left="367" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="570" left="367" width="3" height="19" font="3"> </text>
<text top="588" left="367" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="553" left="525" width="302" height="19" font="4"><b>1</b>°<b> endpoint:</b> <b> </b>TOF voltage mapping of ventricular </text>
<text top="571" left="525" width="84" height="19" font="3">endocardium </text>
<text top="589" left="525" width="3" height="19" font="3"> </text>
<text top="608" left="525" width="203" height="19" font="4"><b>Results:</b>  97% with scar in RVOT.  </text>
<text top="626" left="525" width="307" height="19" font="3">Total scar extension c/w: QRS ≥180 ms, LV and RV </text>
<text top="644" left="525" width="284" height="19" font="3">dysfunction, PVC, prior shunt, re-intervention, </text>
<text top="663" left="525" width="209" height="19" font="3">duration of post surgical followup </text>
<text top="552" left="852" width="193" height="20" font="3">• TOF scar extension correlates </text>
<text top="571" left="852" width="220" height="19" font="3">with risk factors for life-threatening </text>
<text top="589" left="852" width="77" height="19" font="3">arrhythmias </text>
<text top="608" left="852" width="3" height="19" font="3"> </text>
<text top="626" left="852" width="3" height="19" font="3"> </text>
<text top="644" left="852" width="3" height="19" font="3"> </text>
<text top="663" left="852" width="3" height="19" font="3"> </text>
<text top="681" left="852" width="3" height="19" font="3"> </text>
<text top="700" left="123" width="101" height="20" font="3">• Kriebel T et al. </text>
<text top="719" left="123" width="102" height="19" font="3">JACC 2007 (557) </text>
<text top="738" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18036455">  </a></text>
<text top="738" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18036455">18036455</a></text>
<text top="738" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18036455"> </a></text>
<text top="700" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="718" left="247" width="81" height="19" font="3">single center </text>
<text top="737" left="247" width="85" height="19" font="3">retrospective </text>
<text top="755" left="247" width="3" height="19" font="3"> </text>
<text top="773" left="247" width="61" height="19" font="4"><b>Size:</b>    10 </text>
<text top="700" left="367" width="115" height="19" font="4"><b>Inclusion criteria:  </b></text>
<text top="718" left="367" width="136" height="19" font="3">repaired TOF patients </text>
<text top="737" left="367" width="123" height="19" font="3">with VT undergoing </text>
<text top="755" left="367" width="53" height="19" font="3">ablation </text>
<text top="773" left="367" width="129" height="19" font="3">Males 75%; Age 52 y </text>
<text top="701" left="525" width="296" height="19" font="4"><b>1</b>°<b> endpoint:</b>  TOF patients undergoing ablation<b>,</b> </text>
<text top="719" left="525" width="181" height="19" font="3">contact mapping, RF ablation </text>
<text top="737" left="525" width="3" height="19" font="3"> </text>
<text top="756" left="525" width="188" height="19" font="4"><b>Results:</b>  13 VT circuits, 2 focal </text>
<text top="774" left="525" width="236" height="19" font="3">ICD pre in 2, recommended post in all  </text>
<text top="700" left="852" width="198" height="20" font="3">• TOF VT Ablation acute success </text>
<text top="719" left="852" width="110" height="19" font="3">100% (8 patients) </text>
<text top="738" left="852" width="169" height="20" font="3">• Recurrence 25% in 35 mo </text>
<text top="757" left="852" width="3" height="19" font="3"> </text>
<text top="775" left="852" width="3" height="19" font="3"> </text>
</page>
<page number="289" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">289 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="367" width="3" height="19" font="3"> </text>
<text top="127" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="109" left="525" width="3" height="19" font="3"> </text>
<text top="146" left="123" width="100" height="20" font="3">• Witte KK et al. </text>
<text top="165" left="123" width="94" height="19" font="3">Europace 2008 </text>
<text top="183" left="123" width="35" height="19" font="3">(558) </text>
<text top="202" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18442962">  </a></text>
<text top="202" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18442962">18442962</a></text>
<text top="202" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18442962"> </a></text>
<text top="146" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="164" left="247" width="81" height="19" font="3">single center </text>
<text top="183" left="247" width="85" height="19" font="3">retrospective </text>
<text top="201" left="247" width="3" height="19" font="3"> </text>
<text top="219" left="247" width="61" height="19" font="4"><b>Size:</b>    20 </text>
<text top="146" left="367" width="118" height="19" font="4"><b>Inclusion criteria:   </b></text>
<text top="164" left="367" width="135" height="19" font="3">TOF patients with ICD </text>
<text top="183" left="367" width="141" height="19" font="3">compared with dilated </text>
<text top="201" left="367" width="24" height="19" font="3">CM </text>
<text top="219" left="367" width="3" height="19" font="3"> </text>
<text top="237" left="367" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="147" left="525" width="306" height="19" font="4"><b>1</b>°<b> endpoint:</b>  TOF patients with ICD vs dilated CM </text>
<text top="165" left="525" width="3" height="19" font="3"> </text>
<text top="183" left="525" width="301" height="19" font="4"><b>Results:</b>  TOF appropr shocks 25%; inapprop 20% </text>
<text top="146" left="852" width="221" height="20" font="3">• TOF patients: higher risk inapprop </text>
<text top="165" left="852" width="115" height="19" font="3">shocks 25% vs 4%, </text>
<text top="184" left="852" width="201" height="20" font="3">• Death rate for TOF 5%, &lt; DCM, </text>
<text top="203" left="852" width="29" height="19" font="3">21% </text>
<text top="257" left="123" width="95" height="20" font="3">• Lange R et al. </text>
<text top="276" left="123" width="96" height="19" font="3">Circ 2006 (559) </text>
<text top="294" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17060385">  </a></text>
<text top="295" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17060385">17060385</a></text>
<text top="295" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17060385"> </a></text>
<text top="257" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="275" left="247" width="82" height="19" font="3">Single center </text>
<text top="293" left="247" width="85" height="19" font="3">retrospective </text>
<text top="312" left="247" width="3" height="19" font="3"> </text>
<text top="330" left="247" width="68" height="19" font="4"><b>Size:</b>  417   </text>
<text top="257" left="367" width="143" height="19" font="4"><b>Inclusion criteria:</b>  TGA </text>
<text top="275" left="367" width="113" height="19" font="3">with atrial repair:  </text>
<text top="293" left="367" width="81" height="19" font="3">Senning 79% </text>
<text top="312" left="367" width="85" height="19" font="3">Mustard 21% </text>
<text top="330" left="367" width="3" height="19" font="3"> </text>
<text top="348" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="257" left="525" width="262" height="19" font="4"><b>1</b>°<b> endpoint:</b>  TGA atrial switch outcomes.  </text>
<text top="276" left="525" width="125" height="19" font="3">Mean followup 19 y </text>
<text top="294" left="525" width="3" height="19" font="3"> </text>
<text top="312" left="525" width="308" height="19" font="4"><b>Results:</b>  25 y survival: Mustard 76%, Senning 91%<b> </b></text>
<text top="331" left="525" width="62" height="19" font="3">(p=0.002) </text>
<text top="349" left="525" width="307" height="19" font="3">Mustard: die more often of arrhythmia (p&lt;0.001), </text>
<text top="367" left="525" width="153" height="19" font="3">reop baffles (p&lt;0.0001);  </text>
<text top="386" left="525" width="274" height="19" font="3">Independent risk SCD<b>:</b> VSD closure (HR: 2.3), </text>
<text top="404" left="525" width="112" height="19" font="3">Mustard (HR: 2.0) </text>
<text top="257" left="852" width="218" height="20" font="3">• TGA atrial baffle risk factors SCD:  </text>
<text top="276" left="852" width="211" height="19" font="3">Prior VSD closure, Mustard repair  </text>
<text top="294" left="852" width="3" height="19" font="3"> </text>
<text top="312" left="852" width="3" height="19" font="3"> </text>
<text top="331" left="852" width="3" height="19" font="3"> </text>
<text top="423" left="123" width="99" height="20" font="3">• Schwerzmann </text>
<text top="442" left="123" width="108" height="19" font="3">M et al. EHJ 2009 </text>
<text top="460" left="123" width="35" height="19" font="3">(560) </text>
<text top="479" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19465439">  </a></text>
<text top="480" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19465439">19465439</a></text>
<text top="480" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19465439"> </a></text>
<text top="423" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="441" left="247" width="82" height="19" font="3">Single center </text>
<text top="460" left="247" width="88" height="19" font="3">retrospective  </text>
<text top="478" left="247" width="3" height="19" font="3"> </text>
<text top="496" left="247" width="68" height="19" font="4"><b>Size:</b>    149 </text>
<text top="423" left="367" width="143" height="19" font="4"><b>Inclusion criteria:</b>  TGA<b> </b></text>
<text top="441" left="367" width="118" height="19" font="3">s/p Mustard repair </text>
<text top="460" left="367" width="93" height="19" font="3">Mean age 28 y </text>
<text top="478" left="367" width="3" height="19" font="3"> </text>
<text top="496" left="367" width="3" height="19" font="3"> </text>
<text top="515" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="424" left="525" width="255" height="19" font="4"><b>1</b>°<b> endpoint:</b>  TGA s/p Mustard outcomes </text>
<text top="442" left="525" width="117" height="19" font="3">Mean followup 9 y </text>
<text top="460" left="525" width="3" height="19" font="3"> </text>
<text top="479" left="525" width="271" height="19" font="4"><b>Results:</b>  Sustained VT/SCD 9%: risk factors:  </text>
<text top="497" left="525" width="293" height="19" font="3">Associated anatomic lesion (HR: 4.9), NYHA ≥ III </text>
<text top="515" left="525" width="269" height="19" font="3">(HR: 9.8), impaired subaortic RVEF (HR: 2.2) </text>
<text top="534" left="525" width="3" height="19" font="3"> </text>
<text top="552" left="525" width="306" height="19" font="3">AT 44%, not predictor of VT/SCD (HR: 2.7; 95% CI: </text>
<text top="570" left="525" width="50" height="19" font="3">0.6–13) </text>
<text top="423" left="852" width="192" height="20" font="3">• TGA s/p Mustard: late SCD or </text>
<text top="442" left="852" width="107" height="19" font="3">sustained VT: 9% </text>
<text top="461" left="852" width="211" height="20" font="3">• QRS duration ≥140 msec highest </text>
<text top="480" left="852" width="218" height="19" font="3">risk sVT/SCD (HR: 13.6; 95% CI: 2.9–</text>
<text top="498" left="852" width="35" height="19" font="3">63.4) </text>
<text top="516" left="852" width="3" height="19" font="3"> </text>
<text top="534" left="852" width="3" height="19" font="3"> </text>
<text top="590" left="123" width="98" height="20" font="3">• Wheeler M et </text>
<text top="608" left="123" width="81" height="19" font="3">al. CHD 2014 </text>
<text top="627" left="123" width="35" height="19" font="3">(561) </text>
<text top="645" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24151816">  </a></text>
<text top="646" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24151816">24151816</a></text>
<text top="646" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24151816"> </a></text>
<text top="589" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="608" left="247" width="82" height="19" font="3">Single center </text>
<text top="626" left="247" width="85" height="19" font="3">retrospective </text>
<text top="644" left="247" width="3" height="19" font="3"> </text>
<text top="662" left="247" width="61" height="19" font="4"><b>Size:</b>    89 </text>
<text top="589" left="367" width="143" height="19" font="4"><b>Inclusion criteria:  </b>TGA </text>
<text top="608" left="367" width="115" height="19" font="3">patients, s/p atrial </text>
<text top="626" left="367" width="118" height="19" font="3">switch, Mustard or </text>
<text top="644" left="367" width="52" height="19" font="3">Senning </text>
<text top="663" left="367" width="3" height="19" font="3"> </text>
<text top="681" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="590" left="525" width="281" height="19" font="4"><b>1</b>°<b> endpoint:</b>  TGA atrial switch late outcomes </text>
<text top="608" left="525" width="116" height="19" font="4"><b>Results:</b>  SCD 5.6% </text>
<text top="627" left="525" width="294" height="19" font="3">ICD 5.6% 1° prevention: no appropriate therapy </text>
<text top="645" left="525" width="265" height="19" font="3"> Patients with SCD: all with AT vs 29% AT in </text>
<text top="663" left="525" width="58" height="19" font="3">survivors </text>
<text top="590" left="852" width="160" height="20" font="3">• TGA s/p atrial switch: 1° </text>
<text top="608" left="852" width="206" height="19" font="3">prevention ICD-no appropriate rx </text>
<text top="627" left="852" width="212" height="20" font="3">• Higher risk: older age at surgery, </text>
<text top="646" left="852" width="180" height="19" font="3">presence of AT, earlier era of </text>
<text top="664" left="852" width="49" height="19" font="3">surgery </text>
<text top="683" left="852" width="3" height="19" font="3"> </text>
</page>
<page number="290" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">290 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="106" height="20" font="3">• Bouzeman A et </text>
<text top="128" left="123" width="107" height="19" font="3">al. IJC 2014 (562) </text>
<text top="146" left="123" width="7" height="18" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25499397">•</a></text>
<text top="147" left="130" width="68" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25499397">  25499397</a></text>
<text top="147" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25499397"> </a></text>
<text top="109" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="127" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="145" left="247" width="78" height="19" font="3">multicenter, </text>
<text top="164" left="247" width="3" height="19" font="3"> </text>
<text top="182" left="247" width="61" height="19" font="4"><b>Size:</b>    12 </text>
<text top="109" left="367" width="118" height="19" font="4"><b>Inclusion criteria:   </b></text>
<text top="127" left="367" width="129" height="19" font="3">TGA s/p atrial switch </text>
<text top="145" left="367" width="58" height="19" font="3">with ICD  </text>
<text top="164" left="367" width="104" height="19" font="3">Median age 34 y </text>
<text top="182" left="367" width="3" height="19" font="3"> </text>
<text top="200" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="109" left="525" width="306" height="19" font="4"><b>1</b>°<b> endpoint:</b>  TGA atrial switch and ICD outcomes </text>
<text top="128" left="525" width="149" height="19" font="3">Median followup 19 mo </text>
<text top="146" left="525" width="179" height="19" font="4"><b>Results:</b>  2° prevention 33%;  </text>
<text top="165" left="525" width="220" height="19" font="3">Implant:<b> </b>one death during DFT (8%) </text>
<text top="183" left="525" width="285" height="19" font="3">All patients with severe vent dysfunction; 54% </text>
<text top="201" left="525" width="254" height="19" font="3">worsening CHF, 5/11 (45%) transplanted. </text>
<text top="219" left="525" width="211" height="19" font="3">50% sustained AT during followup </text>
<text top="109" left="852" width="175" height="20" font="3">• TGA atrial switch and ICD:  </text>
<text top="128" left="852" width="210" height="20" font="3">• 9% appropriate therapy (1 pt, 1° </text>
<text top="147" left="852" width="218" height="19" font="3">prevention, successful ATP without </text>
<text top="165" left="852" width="43" height="19" font="3">shock) </text>
<text top="184" left="852" width="128" height="20" font="3">•complications: 27% </text>
<text top="203" left="852" width="167" height="20" font="3">• HF determines outcomes </text>
<text top="242" left="123" width="92" height="20" font="3">• Buber J et al. </text>
<text top="261" left="123" width="94" height="19" font="3">Europace 2016 </text>
<text top="279" left="123" width="35" height="19" font="3">(563) </text>
<text top="298" left="123" width="10" height="20" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2026705566">• </a></text>
<text top="298" left="134" width="64" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2026705566"> 26705566</a></text>
<text top="298" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2026705566"> </a></text>
<text top="242" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="260" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="278" left="247" width="81" height="19" font="3">single center </text>
<text top="297" left="247" width="3" height="19" font="3"> </text>
<text top="315" left="247" width="61" height="19" font="4"><b>Size:</b>    18 </text>
<text top="242" left="367" width="143" height="19" font="4"><b>Inclusion criteria:</b>  TGA </text>
<text top="260" left="367" width="131" height="19" font="3">s/p atrial switch with </text>
<text top="278" left="367" width="127" height="19" font="3">ICD implanted for 1° </text>
<text top="297" left="367" width="70" height="19" font="3">prevention </text>
<text top="315" left="367" width="104" height="19" font="3">Median age 26 y </text>
<text top="333" left="367" width="3" height="19" font="3"> </text>
<text top="351" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="242" left="525" width="310" height="19" font="4"><b>1</b>°<b> endpoint:</b>  TGA s/p atrial switch:  ICD outcomes </text>
<text top="261" left="525" width="132" height="19" font="3"> Median followup 4 y </text>
<text top="279" left="525" width="3" height="19" font="3"> </text>
<text top="297" left="525" width="289" height="19" font="4"><b>Results:</b>  EPS performed 72%: sust VT 54%, AFL </text>
<text top="316" left="525" width="292" height="19" font="3">31%. VT inducibility did not predict appropriate </text>
<text top="334" left="525" width="45" height="19" font="3">shock.  </text>
<text top="352" left="525" width="267" height="19" font="3">One pt received shock for VT; 39% for SVT,  </text>
<text top="371" left="525" width="266" height="19" font="3">Inappropriate shocks: 61%, mainly SVT/AFL </text>
<text top="242" left="852" width="205" height="20" font="3">• AT most common cause for ICD </text>
<text top="261" left="852" width="197" height="19" font="3">shocks in 1° prevention TGA s/p </text>
<text top="279" left="852" width="78" height="19" font="3">atrial switch </text>
<text top="298" left="852" width="202" height="20" font="3">• NOT predictive: VT inducibility, </text>
<text top="316" left="852" width="113" height="19" font="3">QRS duration, age </text>
<text top="335" left="852" width="128" height="20" font="3">• 50% complications </text>
<text top="390" left="123" width="96" height="20" font="3">• Backhoff D et </text>
<text top="409" left="123" width="78" height="19" font="3">al. PCE 2016 </text>
<text top="427" left="123" width="35" height="19" font="3">(564) </text>
<text top="446" left="123" width="10" height="20" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27503213">• </a></text>
<text top="446" left="134" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27503213">27503213</a></text>
<text top="446" left="194" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27503213"> </a></text>
<text top="390" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="408" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="426" left="247" width="89" height="19" font="3">multicenter, 4 </text>
<text top="445" left="247" width="101" height="19" font="3">German centers </text>
<text top="463" left="247" width="3" height="19" font="3"> </text>
<text top="481" left="247" width="61" height="19" font="4"><b>Size:</b>    33 </text>
<text top="390" left="367" width="143" height="19" font="4"><b>Inclusion criteria:</b>  TGA </text>
<text top="408" left="367" width="131" height="19" font="3">s/p atrial switch with </text>
<text top="426" left="367" width="32" height="19" font="3">ICD.  </text>
<text top="445" left="367" width="137" height="19" font="3">Median age 27 y, 85% </text>
<text top="463" left="367" width="41" height="19" font="3">male.  </text>
<text top="481" left="367" width="3" height="19" font="3"> </text>
<text top="500" left="367" width="3" height="19" font="3"> </text>
<text top="518" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="390" left="525" width="261" height="19" font="4"><b>1</b>°<b> endpoint:</b>  TGA s/p atrial switch:  ICD rx </text>
<text top="409" left="525" width="140" height="19" font="3">Median followup 4.8 y </text>
<text top="427" left="525" width="3" height="19" font="3"> </text>
<text top="445" left="525" width="139" height="19" font="4"><b>Results:</b>  2° prev 12%.  </text>
<text top="464" left="525" width="211" height="19" font="3">Shocks: Approp 9%, inapprop 24% </text>
<text top="482" left="525" width="251" height="19" font="3">Annual incidence approp rx: 1.9%/pt/yr.  </text>
<text top="500" left="525" width="209" height="19" font="3">Inducible VT/VF: no approp shock </text>
<text top="519" left="525" width="156" height="19" font="3">2° prev: no approp shock </text>
<text top="537" left="525" width="165" height="19" font="3">No predictors of approp rx </text>
<text top="390" left="852" width="213" height="20" font="3">• TGA s/p atrial switch: low rate of </text>
<text top="409" left="852" width="166" height="19" font="3">appropriate ICD shocks 9% </text>
<text top="427" left="852" width="155" height="19" font="3">&lt;&lt;&lt;inapprop shocks 24% </text>
<text top="446" left="852" width="205" height="20" font="3">• AT main cause of inappropriate </text>
<text top="465" left="852" width="44" height="19" font="3">shocks </text>
<text top="483" left="852" width="218" height="20" font="3">• Vigorous treatment of AT, careful </text>
<text top="502" left="852" width="209" height="19" font="3">ICD programming (inactivation VT </text>
<text top="520" left="852" width="197" height="19" font="3">zone, program VF zone 220-230 </text>
<text top="539" left="852" width="36" height="19" font="3">bpm) </text>
<text top="557" left="852" width="129" height="20" font="3">• Complications 21% </text>
<text top="576" left="852" width="3" height="19" font="3"> </text>
<text top="595" left="123" width="103" height="20" font="3">• Pundi KN et al. </text>
<text top="614" left="123" width="99" height="19" font="3">CHD 2016 (565) </text>
<text top="633" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27545004">  </a></text>
<text top="633" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27545004">27545004</a></text>
<text top="633" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27545004"> </a></text>
<text top="595" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="613" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="632" left="247" width="81" height="19" font="3">single center </text>
<text top="650" left="247" width="3" height="19" font="3"> </text>
<text top="668" left="247" width="68" height="19" font="4"><b>Size:</b>    996 </text>
<text top="595" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="613" left="367" width="99" height="19" font="3">Fontan patients </text>
<text top="632" left="367" width="113" height="19" font="3">operated at Mayo </text>
<text top="650" left="367" width="103" height="19" font="3">1973-2012, with </text>
<text top="668" left="367" width="118" height="19" font="3">questionnaire sent </text>
<text top="687" left="367" width="3" height="19" font="3"> </text>
<text top="705" left="367" width="113" height="19" font="4"><b>Exclusion criteria:</b> </text>
<text top="723" left="367" width="121" height="19" font="3">arrhythmia prior to </text>
<text top="742" left="367" width="98" height="19" font="3">Fontan surgery  </text>
<text top="596" left="525" width="266" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Fontan arrhythmia outcomes </text>
<text top="614" left="525" width="3" height="19" font="3"> </text>
<text top="632" left="525" width="277" height="19" font="4"><b>Results:</b>  Freedom from arrhythmia requiring </text>
<text top="651" left="525" width="264" height="19" font="3">treatment: 10 y: 71%; 20 y: 42%; 30 y 24%. </text>
<text top="669" left="525" width="247" height="19" font="3">AFL /AT 48%, AF 19%, SVT AC /AVN 4%,  </text>
<text top="687" left="525" width="110" height="19" font="3">VT 5%, SND 13%.  </text>
<text top="706" left="525" width="300" height="19" font="3">Predictors arrhythmia: AP Fontan, age at surgery </text>
<text top="724" left="525" width="165" height="19" font="3">&gt;16 y, AT postoperatively.  </text>
<text top="595" left="852" width="154" height="20" font="3">• Fontan late outcomes:  </text>
<text top="614" left="852" width="124" height="19" font="3"> 5% VT, 5% late SCD </text>
<text top="633" left="852" width="3" height="19" font="3"> </text>
<text top="651" left="852" width="207" height="20" font="3">• Risk factors: arrhythmias (65%), </text>
<text top="670" left="852" width="188" height="19" font="3">AVV replacement, post bypass </text>
<text top="688" left="852" width="176" height="19" font="3">Fontan pressure &gt;20 mm Hg </text>
<text top="707" left="852" width="3" height="19" font="3"> </text>
<text top="725" left="852" width="222" height="20" font="3">•Preop sinus rhythm was protective </text>
</page>
<page number="291" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">291 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="101" height="20" font="3">• Sakamoto T et </text>
<text top="128" left="123" width="88" height="19" font="3">al. Asian CVTS </text>
<text top="146" left="123" width="69" height="19" font="3">2016 (566) </text>
<text top="165" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27563102">  </a></text>
<text top="165" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27563102">27563102</a></text>
<text top="165" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27563102"> </a></text>
<text top="109" left="247" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="127" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="145" left="247" width="88" height="19" font="3">single center   </text>
<text top="164" left="247" width="3" height="19" font="3"> </text>
<text top="182" left="247" width="61" height="19" font="4"><b>Size:</b>   40  </text>
<text top="109" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="127" left="367" width="99" height="19" font="3">Fontan patients </text>
<text top="145" left="367" width="128" height="19" font="3">operated 1974-1986 </text>
<text top="164" left="367" width="3" height="19" font="3"> </text>
<text top="182" left="367" width="128" height="19" font="3">Surgery: AP 70%, RA-</text>
<text top="200" left="367" width="49" height="19" font="3">RV 25% </text>
<text top="218" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="109" left="525" width="227" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Late outcomes Fontan  </text>
<text top="128" left="525" width="108" height="19" font="3">20/40 (50%) died </text>
<text top="146" left="525" width="307" height="19" font="4"><b>Results:</b>  Causes of death in 20 patients: CHF 30%, </text>
<text top="165" left="525" width="231" height="19" font="3">SCD 20%, arrhythmia 20%, other 30% </text>
<text top="109" left="852" width="206" height="20" font="3">• Late SCD in Fontan: 10% overall </text>
<text top="128" left="852" width="210" height="20" font="3">• Timely conversion of AP Fontan, </text>
<text top="147" left="852" width="216" height="19" font="3">medication to decrease ventricular </text>
<text top="165" left="852" width="211" height="19" font="3">volume and pressure load needed </text>
<text top="238" left="123" width="99" height="20" font="3">• Alexander ME </text>
<text top="257" left="123" width="91" height="19" font="3">et al. JCE 1999 </text>
<text top="275" left="123" width="35" height="19" font="3">(567) </text>
<text top="294" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10466482">  </a></text>
<text top="294" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10466482">10466482</a></text>
<text top="294" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=10466482"> </a></text>
<text top="237" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="256" left="247" width="85" height="19" font="3">single center  </text>
<text top="274" left="247" width="3" height="19" font="3"> </text>
<text top="292" left="247" width="65" height="19" font="4"><b>Size:</b>   130 </text>
<text top="237" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="256" left="367" width="103" height="19" font="3">congenital heart </text>
<text top="274" left="367" width="101" height="19" font="3">disease patients </text>
<text top="293" left="367" width="116" height="19" font="3">undergoing V-stim </text>
<text top="311" left="367" width="126" height="19" font="3">TOF 33%, TGA 25%,  </text>
<text top="329" left="367" width="110" height="19" font="3">LVOT lesions 12% </text>
<text top="347" left="367" width="104" height="19" font="3">Median age 18 y </text>
<text top="366" left="367" width="3" height="19" font="3"> </text>
<text top="384" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="238" left="525" width="252" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Sustained VT inducibility in </text>
<text top="257" left="525" width="152" height="19" font="3">congenital heart disease </text>
<text top="275" left="525" width="3" height="19" font="3"> </text>
<text top="293" left="525" width="193" height="19" font="4"><b>Results:</b>  Sust VT inducible 25% </text>
<text top="312" left="525" width="212" height="19" font="3">Non-sust VT 12%, AFL or SVT: 32% </text>
<text top="330" left="525" width="3" height="19" font="3"> </text>
<text top="238" left="852" width="169" height="20" font="3">• Positive V stim correlated </text>
<text top="257" left="852" width="165" height="19" font="3">decreased survival (HR: 6), </text>
<text top="275" left="852" width="159" height="19" font="3">arrhythmic events (HR: 3) </text>
<text top="294" left="852" width="178" height="20" font="3">•  Patients with documented </text>
<text top="312" left="852" width="205" height="19" font="3">clinical VT: 33% negative V stim—</text>
<text top="331" left="852" width="144" height="19" font="3">frequent false negative </text>
<text top="349" left="852" width="3" height="19" font="3"> </text>
<text top="403" left="123" width="96" height="20" font="3">• Silka MJ et al. </text>
<text top="422" left="123" width="96" height="19" font="3">Circ 1993 (568) </text>
<text top="441" left="123" width="10" height="20" font="3">• </text>
<text top="441" left="134" width="3" height="19" font="25"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8443901"> </a></text>
<text top="441" left="137" width="53" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8443901">8443901</a></text>
<text top="441" left="190" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8443901"> </a></text>
<text top="403" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="422" left="247" width="75" height="19" font="3">Multicenter </text>
<text top="440" left="247" width="88" height="19" font="3">retrospective  </text>
<text top="458" left="247" width="3" height="19" font="3"> </text>
<text top="476" left="247" width="68" height="19" font="4"><b>Size:</b>    125 </text>
<text top="403" left="367" width="141" height="19" font="4"><b>Inclusion criteria:</b>  177 </text>
<text top="422" left="367" width="114" height="19" font="3">patients age &lt;20 y </text>
<text top="440" left="367" width="101" height="19" font="3">undergoing ICD; </text>
<text top="458" left="367" width="91" height="19" font="3"> 125 with data </text>
<text top="476" left="367" width="65" height="19" font="3">available.  </text>
<text top="495" left="367" width="104" height="19" font="3">Mean age 14.5 y </text>
<text top="513" left="367" width="137" height="19" font="3">Cardiomyopathy 54%, </text>
<text top="531" left="367" width="92" height="19" font="3">electrical 26%, </text>
<text top="550" left="367" width="103" height="19" font="3">congenital heart </text>
<text top="568" left="367" width="78" height="19" font="3">disease 18% </text>
<text top="586" left="367" width="3" height="19" font="3"> </text>
<text top="605" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="404" left="525" width="294" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ICD outcomes in younger patients </text>
<text top="422" left="525" width="128" height="19" font="3">Mean followup 2.6 y </text>
<text top="441" left="525" width="274" height="19" font="4"><b>Results:</b> <b> </b>2°: ACA 76%, refractory VT 10%. 1°: </text>
<text top="459" left="525" width="307" height="19" font="3">Syncope with HD and inducible sustained VT: 10% </text>
<text top="477" left="525" width="286" height="19" font="3">Shocks: appropriate 68% of patients, inapprop </text>
<text top="496" left="525" width="105" height="19" font="3">20%. 5 late SCD.  </text>
<text top="514" left="525" width="270" height="19" font="3">Predictors late mortality: abnormal vent fxn </text>
<text top="403" left="852" width="195" height="20" font="3">• Early ICD study: 2° prevention </text>
<text top="422" left="852" width="33" height="19" font="3">86%  </text>
<text top="441" left="852" width="115" height="20" font="3">• 5 y survival: 85% </text>
<text top="460" left="852" width="171" height="19" font="3">SCD free survival 5 yrs: 90% </text>
<text top="478" left="852" width="3" height="19" font="3"> </text>
<text top="496" left="852" width="3" height="19" font="3"> </text>
<text top="624" left="123" width="95" height="20" font="3">• Berul CI et al. </text>
<text top="643" left="123" width="102" height="19" font="3">JACC 2008 (569) </text>
<text top="661" left="123" width="10" height="20" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18436121">• </a></text>
<text top="662" left="134" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18436121">18436121</a></text>
<text top="662" left="194" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18436121"> </a></text>
<text top="624" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="642" left="247" width="75" height="19" font="3">Multicenter </text>
<text top="660" left="247" width="88" height="19" font="3">retrospective  </text>
<text top="679" left="247" width="3" height="19" font="3"> </text>
<text top="697" left="247" width="68" height="19" font="4"><b>Size:</b>   443  </text>
<text top="624" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="642" left="367" width="84" height="19" font="3">Pediatric and </text>
<text top="660" left="367" width="103" height="19" font="3">congenital heart </text>
<text top="679" left="367" width="101" height="19" font="3">disease patients </text>
<text top="697" left="367" width="109" height="19" font="3">receiving ICD in 4 </text>
<text top="715" left="367" width="117" height="19" font="3">centers 1992-2004 </text>
<text top="733" left="367" width="137" height="19" font="3">Median age 16 y; 69% </text>
<text top="752" left="367" width="92" height="19" font="3">structural HD:  </text>
<text top="770" left="367" width="123" height="19" font="3">TOF 19%, HCM 14% </text>
<text top="624" left="525" width="268" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ICD comps &amp; therapies young </text>
<text top="643" left="525" width="128" height="19" font="3">Mean followup 7.5 y </text>
<text top="661" left="525" width="132" height="19" font="4"><b>Results:</b>  2° prev 48% </text>
<text top="679" left="525" width="295" height="19" font="3">Comps: early 14%, late 29%, electrical storm 5% </text>
<text top="698" left="525" width="305" height="19" font="3">Appropriate shocks 26%, inapprop 21%--higher in </text>
<text top="716" left="525" width="307" height="19" font="3">electrical disease (31%) vs cardiomyopathy (13%), </text>
<text top="734" left="525" width="190" height="19" font="3">congenital heart disease (28%) </text>
<text top="753" left="525" width="49" height="19" font="3">SCD 1% </text>
<text top="624" left="852" width="177" height="20" font="3">• ICD in young patients: high </text>
<text top="643" left="852" width="175" height="19" font="3">inappropriate shocks 28% in </text>
<text top="661" left="852" width="152" height="19" font="3">congenital heart disease </text>
<text top="680" left="852" width="129" height="20" font="3">• Complications 43% </text>
<text top="698" left="852" width="3" height="19" font="3"> </text>
<text top="717" left="852" width="3" height="19" font="3"> </text>
</page>
<page number="292" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">292 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="367" width="88" height="19" font="3">Electrical 31% </text>
<text top="127" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="146" left="123" width="97" height="20" font="3">• Khanna AD et </text>
<text top="165" left="123" width="76" height="19" font="3">al. AJC 2011 </text>
<text top="183" left="123" width="35" height="19" font="3">(570) </text>
<text top="202" left="123" width="14" height="20" font="3">•<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21684513">  </a></text>
<text top="202" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21684513">21684513</a></text>
<text top="202" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21684513"> </a></text>
<text top="146" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="164" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="183" left="247" width="85" height="19" font="3">single center, </text>
<text top="201" left="247" width="38" height="19" font="3">Mayo </text>
<text top="219" left="247" width="3" height="19" font="3"> </text>
<text top="237" left="247" width="61" height="19" font="4"><b>Size:</b>    73 </text>
<text top="146" left="367" width="111" height="19" font="4"><b>Inclusion criteria:</b> </text>
<text top="164" left="367" width="122" height="19" font="3">ACHD patients with </text>
<text top="183" left="367" width="24" height="19" font="3">ICD </text>
<text top="201" left="367" width="57" height="19" font="3">TOF 44% </text>
<text top="219" left="367" width="75" height="19" font="3">cc-TGA 17% </text>
<text top="237" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="147" left="525" width="295" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ACHD patients with ICD outcomes </text>
<text top="165" left="525" width="128" height="19" font="3">Mean followup 2.2 y </text>
<text top="183" left="525" width="3" height="19" font="3"> </text>
<text top="202" left="525" width="171" height="19" font="4"><b>Results:</b>  1° prevention 64% </text>
<text top="220" left="525" width="208" height="19" font="3">Approp shock 19%, inapprop 15% </text>
<text top="146" left="852" width="221" height="20" font="3">• Appropriate ICD shock more likely </text>
<text top="165" left="852" width="154" height="19" font="3">in patients with elevated </text>
<text top="183" left="852" width="148" height="19" font="3">subpulmonary pressure </text>
<text top="202" left="852" width="3" height="19" font="3"> </text>
<text top="220" left="852" width="3" height="19" font="3"> </text>
<text top="238" left="852" width="3" height="19" font="3"> </text>
<text top="258" left="123" width="94" height="20" font="3">• Koyak Z et al. </text>
<text top="277" left="123" width="96" height="19" font="3">CAE 2012 (571) </text>
<text top="295" left="123" width="10" height="20" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22095638">• </a></text>
<text top="296" left="134" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22095638">22095638</a></text>
<text top="296" left="194" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22095638"> </a></text>
<text top="257" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="276" left="247" width="75" height="19" font="3">Multicenter </text>
<text top="294" left="247" width="103" height="19" font="3">retrospective 10 </text>
<text top="312" left="247" width="49" height="19" font="3">centers </text>
<text top="331" left="247" width="82" height="19" font="3">Netherlands, </text>
<text top="349" left="247" width="53" height="19" font="3">Belgium </text>
<text top="367" left="247" width="3" height="19" font="3"> </text>
<text top="386" left="247" width="68" height="19" font="4"><b>Size:</b>    136<b> </b></text>
<text top="257" left="367" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="276" left="367" width="92" height="19" font="3">ACHD patients </text>
<text top="294" left="367" width="83" height="19" font="3">receiving ICD </text>
<text top="312" left="367" width="93" height="19" font="3">Mean age 41 y </text>
<text top="331" left="367" width="144" height="19" font="3">TOF 51%, Septal defect </text>
<text top="349" left="367" width="104" height="19" font="3">20%, ccTGA 13% </text>
<text top="367" left="367" width="3" height="19" font="3"> </text>
<text top="386" left="367" width="3" height="19" font="3"> </text>
<text top="404" left="367" width="144" height="19" font="4"><b>Exclusion criteria:</b>  N/A<b> </b></text>
<text top="258" left="525" width="298" height="19" font="4"><b>1</b>°<b> endpoint:</b>  ACHD ICD approp shock risk score. </text>
<text top="277" left="525" width="140" height="19" font="3">Median followup 4.6 y </text>
<text top="295" left="525" width="171" height="19" font="4"><b>Results:</b>  2° prevention 50% </text>
<text top="313" left="525" width="313" height="19" font="3">Shocks: approp 29%, inapprop 30%, (SVT 69%)         </text>
<text top="332" left="525" width="74" height="19" font="3">Comps 29% </text>
<text top="350" left="525" width="310" height="19" font="3">63% underwent PES: 73% inducible sust VT/pmVT, </text>
<text top="368" left="525" width="306" height="19" font="3">VF: no difference in appropriate shocks: 33% with </text>
<text top="386" left="525" width="130" height="19" font="3">induc VT, 32% w/out </text>
<text top="405" left="525" width="303" height="19" font="3">In 1° prev patients, univariable risks symptomatic </text>
<text top="423" left="525" width="299" height="19" font="3">nonsust VT HR: 8; 95% CI: 2.3–27.1, p=0.001 and </text>
<text top="441" left="525" width="290" height="19" font="3">subpulmonary ventricular dysfunction, HR: 3.0; </text>
<text top="460" left="525" width="154" height="19" font="3">95% CI: 1.2–12.6, p=0.02 </text>
<text top="478" left="525" width="3" height="19" font="4"><b> </b></text>
<text top="258" left="852" width="199" height="20" font="3">• Appropriate shocks for ACHD:  </text>
<text top="277" left="852" width="146" height="19" font="3">2° prevention, (HR: 3.6) </text>
<text top="295" left="852" width="202" height="19" font="3">CAD, (HR: 2.7), and symptomatic </text>
<text top="313" left="852" width="127" height="19" font="3">nonsust VT (HR: 9.1) </text>
<text top="332" left="852" width="159" height="20" font="3">• High morbidity with ICD </text>
<text top="351" left="852" width="215" height="20" font="3">• No assoc between ICD treatment </text>
<text top="370" left="852" width="111" height="19" font="3">and QRS duration </text>
<text top="388" left="852" width="198" height="20" font="3">• Inducible sustained VT did not </text>
<text top="407" left="852" width="180" height="19" font="3">correlate with appropr shock </text>
<text top="426" left="852" width="168" height="20" font="3">•TGA patients: appropriate </text>
<text top="445" left="852" width="184" height="19" font="3">therapy: 29% 2° prev, 4.3% 1° </text>
<text top="463" left="852" width="202" height="20" font="3">• TOF patients: not at higher risk </text>
<text top="482" left="852" width="62" height="19" font="3">approp rx </text>
<text top="501" left="123" width="97" height="20" font="3">• Khairy P et al. </text>
<text top="520" left="123" width="90" height="19" font="3">HR 2014 (572) </text>
<text top="539" left="123" width="10" height="20" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24814377">• </a></text>
<text top="539" left="134" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24814377">24814377</a></text>
<text top="539" left="194" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24814377"> </a></text>
<text top="558" left="123" width="3" height="19" font="3"> </text>
<text top="501" left="247" width="250" height="19" font="3">PACES/HRS Expert Consensus Statement </text>
<text top="519" left="247" width="219" height="19" font="3">on recognition and management of </text>
<text top="538" left="247" width="130" height="19" font="3">arrhythmias in ACHD </text>
<text top="502" left="525" width="88" height="19" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="520" left="525" width="3" height="19" font="3"> </text>
<text top="538" left="525" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="557" left="525" width="3" height="19" font="3"> </text>
<text top="501" left="852" width="3" height="19" font="3"> </text>
<text top="519" left="852" width="3" height="19" font="3"> </text>
<text top="577" left="115" width="3" height="19" font="3"> </text>
<text top="595" left="115" width="3" height="19" font="3"> </text>
<text top="613" left="115" width="3" height="19" font="3"> </text>
<text top="613" left="331" width="3" height="19" font="3"> </text>
</page>
<page number="293" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">293 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="751" height="21" font="2"><b>Data Supplement 55. Nonrandomized Trials, Observational Studies, and/or Registries of S-ICD - (Section 11.1) </b></text>
<text top="129" left="132" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="147" left="158" width="51" height="19" font="4"><b>Author; </b></text>
<text top="165" left="135" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="129" left="296" width="39" height="19" font="4"><b>Study </b></text>
<text top="147" left="273" width="86" height="19" font="4"><b>Type/Design; </b></text>
<text top="165" left="282" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="129" left="427" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="129" left="643" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="147" left="656" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="165" left="687" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="129" left="908" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="147" left="936" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="184" left="125" width="85" height="19" font="3">● Bardy et al. </text>
<text top="203" left="125" width="69" height="19" font="3">2010 (573) </text>
<text top="221" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20463331">● </a></text>
<text top="221" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20463331">20463331</a></text>
<text top="221" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20463331"> </a></text>
<text top="239" left="125" width="3" height="19" font="4"><b> </b></text>
<text top="184" left="255" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="203" left="255" width="103" height="19" font="3">Prospective non-</text>
<text top="221" left="255" width="121" height="19" font="3">randomized clinical </text>
<text top="239" left="255" width="102" height="19" font="3">trials (covered 4 </text>
<text top="258" left="255" width="38" height="19" font="3">trials) </text>
<text top="276" left="255" width="3" height="19" font="3"> </text>
<text top="294" left="255" width="82" height="19" font="4"><b>Size:</b> N=78 in </text>
<text top="313" left="255" width="104" height="19" font="3">temporary S-ICD </text>
<text top="331" left="255" width="103" height="19" font="3">implantation for </text>
<text top="349" left="255" width="118" height="19" font="3">testing 4 electrode </text>
<text top="368" left="255" width="117" height="19" font="3">configurations and </text>
<text top="386" left="255" width="112" height="19" font="3">DFT testing; N=49 </text>
<text top="404" left="255" width="82" height="19" font="3">in a trial that </text>
<text top="423" left="255" width="119" height="19" font="3">compared the best </text>
<text top="441" left="255" width="118" height="19" font="3">of the tested S-ICD </text>
<text top="459" left="255" width="94" height="19" font="3">in the first trial </text>
<text top="478" left="255" width="119" height="19" font="3">with a transvenous </text>
<text top="496" left="255" width="74" height="19" font="3">ICD system, </text>
<text top="514" left="255" width="105" height="19" font="3">comparing DFTs; </text>
<text top="532" left="255" width="103" height="19" font="3">N=6 followed by </text>
<text top="551" left="255" width="113" height="19" font="3">N=55 in trials that </text>
<text top="569" left="255" width="113" height="19" font="3">tested permanent </text>
<text top="587" left="255" width="121" height="19" font="3">S-ICD implantation. </text>
<text top="184" left="389" width="169" height="19" font="4"><b>Inclusion criteria:</b>  Meeting </text>
<text top="203" left="389" width="194" height="19" font="3">class I, IIa, IIb criteria for an ICD </text>
<text top="221" left="389" width="3" height="19" font="3"> </text>
<text top="239" left="389" width="171" height="19" font="4"><b>Exclusion criteria:</b>  GFR &lt;30 </text>
<text top="258" left="389" width="107" height="19" font="3">ml/min, need for </text>
<text top="276" left="389" width="181" height="19" font="3">antibradycardia pacing, Hx of </text>
<text top="294" left="389" width="160" height="19" font="3">VT at rates &lt;170 bpm and </text>
<text top="313" left="389" width="180" height="19" font="3">documented VT known to be </text>
<text top="331" left="389" width="178" height="19" font="3">reliably terminated with ATP </text>
<text top="185" left="597" width="220" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Successful immediate </text>
<text top="204" left="597" width="230" height="19" font="3">conversion of 2 consecutive episodes </text>
<text top="222" left="597" width="225" height="19" font="3">of induced VF each with a single 65-j </text>
<text top="240" left="597" width="45" height="19" font="3">shock.  </text>
<text top="258" left="597" width="3" height="19" font="3"> </text>
<text top="277" left="597" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="295" left="597" width="215" height="19" font="3">● Mean age of the 78 patients was </text>
<text top="314" left="597" width="51" height="19" font="3">61±11 y </text>
<text top="332" left="597" width="231" height="19" font="3">● All 6 patients underwent successful </text>
<text top="350" left="597" width="243" height="19" font="3">implantation of the S-ICD, and in all the </text>
<text top="368" left="597" width="197" height="19" font="3">patients, defibrillation with 65-J </text>
<text top="387" left="597" width="213" height="19" font="3">submaximal shocks was successful </text>
<text top="405" left="597" width="203" height="19" font="3">during 2 consecutive episodes of </text>
<text top="423" left="597" width="243" height="19" font="3">induced VF. Of 18 induced VF episodes, </text>
<text top="442" left="597" width="227" height="19" font="3">all were successfully detected by the </text>
<text top="460" left="597" width="229" height="19" font="3">device. After 488 d of FU, there were </text>
<text top="478" left="597" width="111" height="19" font="3">no complications. </text>
<text top="497" left="597" width="59" height="19" font="3">● In the 4</text>
<text top="496" left="656" width="8" height="12" font="15">th</text>
<text top="497" left="664" width="141" height="19" font="3"> trial, 53 patients were </text>
<text top="515" left="597" width="242" height="19" font="3">evaluated for sensing and defibrillation </text>
<text top="533" left="597" width="229" height="19" font="3">during implantation. Of 137 episodes </text>
<text top="552" left="597" width="238" height="19" font="3">of induced VF, 100% were detected by </text>
<text top="570" left="597" width="232" height="19" font="3">the S-ICD. After 10 mo of FU, 53 of 55 </text>
<text top="588" left="597" width="225" height="19" font="3">patients were alive. Pocket infection </text>
<text top="606" left="597" width="242" height="19" font="3">developed in 2 patients. 12 episodes of </text>
<text top="625" left="597" width="208" height="19" font="3">VT in 3 patients were successfully </text>
<text top="643" left="597" width="149" height="19" font="3">treated during followup </text>
<text top="184" left="854" width="235" height="19" font="3">● In small, nonrandomized studies, an </text>
<text top="203" left="854" width="220" height="19" font="3">entirely S-ICD consistently detected </text>
<text top="221" left="854" width="224" height="19" font="3">and converted VF induced during EP </text>
<text top="239" left="854" width="49" height="19" font="3">testing. </text>
<text top="258" left="854" width="242" height="19" font="3">● The device also successfully detected </text>
<text top="276" left="854" width="184" height="19" font="3">and treated all 12 episodes of </text>
<text top="294" left="854" width="167" height="19" font="3">spontaneous, sustained VT </text>
<text top="313" left="854" width="3" height="19" font="3"> </text>
<text top="662" left="125" width="112" height="19" font="3">● Olde Nordkamp </text>
<text top="680" left="125" width="103" height="19" font="3">et al. 2012 (574) </text>
<text top="699" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23062537">● </a></text>
<text top="699" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23062537">23062537</a></text>
<text top="699" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23062537"> </a></text>
<text top="717" left="125" width="3" height="19" font="3"> </text>
<text top="662" left="255" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="680" left="255" width="87" height="19" font="3">Retrospective </text>
<text top="699" left="255" width="37" height="19" font="3">study </text>
<text top="717" left="255" width="3" height="19" font="3"> </text>
<text top="735" left="255" width="75" height="19" font="4"><b>Size:</b> N=118 </text>
<text top="662" left="389" width="190" height="19" font="4"><b>Inclusion criteria:</b>  Class I or IIa </text>
<text top="680" left="389" width="144" height="19" font="3">indication for a 1° or 2° </text>
<text top="699" left="389" width="95" height="19" font="3">prevention ICD </text>
<text top="717" left="389" width="3" height="19" font="3"> </text>
<text top="735" left="389" width="153" height="19" font="4"><b>Exclusion criteria:</b>  None </text>
<text top="663" left="597" width="235" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Effectiveness and safety </text>
<text top="681" left="597" width="76" height="19" font="3">of the S-ICD </text>
<text top="699" left="597" width="3" height="19" font="3"> </text>
<text top="718" left="597" width="232" height="19" font="4"><b>Results:</b>  Mean age=50 y. After 18 mo </text>
<text top="736" left="597" width="238" height="19" font="3">of followup, 8 patients experienced 45 </text>
<text top="755" left="597" width="218" height="19" font="3">successful appropriate shocks (98% </text>
<text top="773" left="597" width="215" height="19" font="3">first shock conversion efficacy). No </text>
<text top="662" left="854" width="234" height="19" font="3">● The S-ICD is effective at terminating </text>
<text top="680" left="854" width="21" height="19" font="3">VA </text>
<text top="699" left="854" width="218" height="19" font="3">● Rate of inappropriate shocks was </text>
<text top="717" left="854" width="29" height="19" font="3">13% </text>
<text top="735" left="854" width="237" height="19" font="3">● The rate of complications decreased </text>
<text top="754" left="854" width="190" height="19" font="3">with improved technology and </text>
<text top="772" left="854" width="150" height="19" font="3">implanter’s experience.  </text>
</page>
<page number="294" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">294 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="597" width="200" height="19" font="3">sudden deaths occurred. Fifteen </text>
<text top="127" left="597" width="234" height="19" font="3">patients (13%) received inappropriate </text>
<text top="145" left="597" width="182" height="19" font="3">shocks, mainly due to T-wave </text>
<text top="164" left="597" width="234" height="19" font="3">oversensing, which was mostly solved </text>
<text top="182" left="597" width="224" height="19" font="3">by a software upgrade and changing </text>
<text top="200" left="597" width="242" height="19" font="3">the sensing vector of the S-ICD. Sixteen </text>
<text top="219" left="597" width="170" height="19" font="3">patients (14%) experienced </text>
<text top="237" left="597" width="223" height="19" font="3">complications. Adverse events were </text>
<text top="255" left="597" width="177" height="19" font="3">more frequent in the first 15 </text>
<text top="273" left="597" width="228" height="19" font="3">implantations/center compared with </text>
<text top="292" left="597" width="166" height="19" font="3">subsequent implantations. </text>
<text top="311" left="125" width="114" height="19" font="3">● Kobe et al. 2013 </text>
<text top="329" left="125" width="35" height="19" font="3">(575) </text>
<text top="347" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23032867">● </a></text>
<text top="347" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23032867">23032867</a></text>
<text top="347" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23032867"> </a></text>
<text top="366" left="125" width="3" height="19" font="3"> </text>
<text top="311" left="255" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="329" left="255" width="87" height="19" font="3">Retrospective </text>
<text top="347" left="255" width="115" height="19" font="3">case-control study </text>
<text top="366" left="255" width="92" height="19" font="3">(matching was </text>
<text top="384" left="255" width="111" height="19" font="3">done on the basis </text>
<text top="402" left="255" width="95" height="19" font="3">of sex and age) </text>
<text top="421" left="255" width="3" height="19" font="3"> </text>
<text top="439" left="255" width="75" height="19" font="4"><b>Size: </b>N=138 </text>
<text top="311" left="389" width="167" height="19" font="4"><b>Inclusion criteria:</b>  Patients </text>
<text top="329" left="389" width="160" height="19" font="3">with a 1° or 2° prevention </text>
<text top="347" left="389" width="128" height="19" font="3">indication for an ICD </text>
<text top="366" left="389" width="3" height="19" font="3"> </text>
<text top="384" left="389" width="153" height="19" font="4"><b>Exclusion criteria:</b>  None </text>
<text top="402" left="389" width="70" height="19" font="3">mentioned </text>
<text top="311" left="597" width="210" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Short and long term </text>
<text top="330" left="597" width="150" height="19" font="3">effectiveness and safety </text>
<text top="348" left="597" width="3" height="19" font="3"> </text>
<text top="367" left="597" width="230" height="19" font="4"><b>Results:</b>  Conversion rates of induced </text>
<text top="385" left="597" width="227" height="19" font="3">VF were 89.5% with a 65J shock, and </text>
<text top="403" left="597" width="194" height="19" font="3">95.5% including reversed shock </text>
<text top="422" left="597" width="169" height="19" font="3">polarity in the study group. </text>
<text top="440" left="597" width="192" height="19" font="3">Termination of induced VF was </text>
<text top="458" left="597" width="207" height="19" font="3">successful in 90.8% of the control </text>
<text top="476" left="597" width="189" height="19" font="3">patients (p=0.815). Procedural </text>
<text top="495" left="597" width="223" height="19" font="3">complications were similar between </text>
<text top="513" left="597" width="238" height="19" font="3">the 2 groups. During a mean follow-up </text>
<text top="531" left="597" width="222" height="19" font="3">of 217 d, 3 patients with S-ICD were </text>
<text top="550" left="597" width="219" height="19" font="3">appropriately treated for VA. Three </text>
<text top="568" left="597" width="238" height="19" font="3">inappropriate shokcks (5.2%) occurred </text>
<text top="586" left="597" width="205" height="19" font="3">in 3 S-ICD patients due to T-wave </text>
<text top="605" left="597" width="220" height="19" font="3">oversensing, whereas AF with rapid </text>
<text top="623" left="597" width="206" height="19" font="3">conduction was the predominant </text>
<text top="641" left="597" width="219" height="19" font="3">reason for inappropriate therapy in </text>
<text top="660" left="597" width="197" height="19" font="3">conventional devices (p=0.745). </text>
<text top="311" left="854" width="230" height="19" font="3">● Failure of conversion of induced VF </text>
<text top="329" left="854" width="236" height="19" font="3">with the S-ICD set to standard polarity </text>
<text top="347" left="854" width="245" height="19" font="3">was 10.4%, and there were comparable </text>
<text top="366" left="854" width="239" height="19" font="3">inappropriate shock rates during short-</text>
<text top="384" left="854" width="99" height="19" font="3">term follow-up. </text>
<text top="679" left="125" width="87" height="19" font="3">● de Bie et al. </text>
<text top="697" left="125" width="73" height="19" font="3">2013 (576)  </text>
<text top="715" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23704324">● </a></text>
<text top="715" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23704324">23704324</a></text>
<text top="715" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23704324"> </a></text>
<text top="733" left="125" width="3" height="19" font="3"> </text>
<text top="678" left="255" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="697" left="255" width="87" height="19" font="3">Retrospective </text>
<text top="715" left="255" width="37" height="19" font="3">study </text>
<text top="733" left="255" width="3" height="19" font="3"> </text>
<text top="752" left="255" width="97" height="19" font="4"><b>Size:</b>    N=1,345 </text>
<text top="678" left="389" width="187" height="19" font="4"><b>Inclusion criteria:</b>  All patients </text>
<text top="697" left="389" width="185" height="19" font="3">who received a single- or dual </text>
<text top="715" left="389" width="164" height="19" font="3">chamber ICD in the Leiden </text>
<text top="734" left="389" width="161" height="19" font="3">University Medical Center </text>
<text top="752" left="389" width="155" height="19" font="3">between 2002 and 2011. </text>
<text top="770" left="389" width="3" height="19" font="3"> </text>
<text top="679" left="597" width="224" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Suitability for an S-ICD </text>
<text top="698" left="597" width="213" height="19" font="3">defined as not reaching one of the </text>
<text top="716" left="597" width="233" height="19" font="3">following endpoints during follow-up: </text>
<text top="734" left="597" width="220" height="19" font="3">(1) an atrial and/or right ventricular </text>
<text top="753" left="597" width="224" height="19" font="3">pacing indication, (2) successful anti-</text>
<text top="771" left="597" width="179" height="19" font="3">tachycardia pacing without a </text>
<text top="679" left="854" width="248" height="19" font="3">● After 5 y of follow-up, approximately:  </text>
<text top="696" left="854" width="223" height="20" font="3">i.  55% of the patients would have </text>
<text top="715" left="881" width="165" height="19" font="3">been suitable for an S-ICD. </text>
<text top="732" left="854" width="175" height="20" font="3">ii.  Significant predictors of </text>
<text top="752" left="881" width="208" height="19" font="3">unsuitability for an S-ICD were: 2° </text>
</page>
<page number="295" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="32" size="10" family="Times" color="#565656"/>
<text top="803" left="585" width="29" height="21" font="0">295 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="389" width="166" height="19" font="4"><b>Exclusion criteria:</b> Patients </text>
<text top="127" left="389" width="182" height="19" font="3">with a pre-existent indication </text>
<text top="145" left="389" width="145" height="19" font="3">for cardiac pacing were </text>
<text top="164" left="389" width="62" height="19" font="3">excluded. </text>
<text top="109" left="597" width="238" height="19" font="3">subsequent shock or (3) an upgrade to </text>
<text top="127" left="597" width="157" height="19" font="3">a CRT-defibrilator device. </text>
<text top="145" left="597" width="3" height="19" font="3"> </text>
<text top="164" left="597" width="237" height="19" font="4"><b>Results:</b>  During a median follow-up of </text>
<text top="182" left="597" width="222" height="19" font="3">3.4y, 463 patients (34%) reached an </text>
<text top="200" left="597" width="237" height="19" font="3">endpoint. The cumulative incidence of </text>
<text top="219" left="597" width="228" height="19" font="3">ICD recipients suitable for an initial S-</text>
<text top="237" left="597" width="232" height="19" font="3">ICD implantation was 55.5% after 5 y. </text>
<text top="255" left="597" width="230" height="19" font="3">Appropriate ATP and the necessity of </text>
<text top="273" left="597" width="182" height="19" font="3">cardiac pacing resulted in the </text>
<text top="292" left="597" width="169" height="19" font="3">unsuitability for an S-ICD in </text>
<text top="310" left="597" width="200" height="19" font="3">approximately 94% of the cases, </text>
<text top="329" left="597" width="179" height="19" font="3">whereas device upgrade was </text>
<text top="347" left="597" width="212" height="19" font="3">responsible for the unsuitability in </text>
<text top="365" left="597" width="193" height="19" font="3">approximately 6% of the cases. </text>
<text top="109" left="881" width="164" height="19" font="3">prevention, severe HF and </text>
<text top="127" left="881" width="154" height="19" font="3">prolonged QRS duration. </text>
<text top="144" left="854" width="237" height="20" font="3">iii.  No mention of patients with ESRD </text>
<text top="164" left="881" width="161" height="19" font="3">(mean GFR 85-89 ml/min) </text>
<text top="384" left="125" width="101" height="19" font="3">● Weiss R. et. al </text>
<text top="402" left="125" width="69" height="19" font="3">2013 (577) </text>
<text top="421" left="125" width="9" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23979626">●</a></text>
<text top="421" left="134" width="64" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23979626"> 23979626</a></text>
<text top="421" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23979626"> </a></text>
<text top="439" left="125" width="3" height="16" font="32"> </text>
<text top="437" left="127" width="3" height="19" font="3"> </text>
<text top="384" left="255" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="402" left="255" width="103" height="19" font="3">Prospective non-</text>
<text top="421" left="255" width="76" height="19" font="3">randomized </text>
<text top="439" left="255" width="102" height="19" font="3">multicenter trial </text>
<text top="457" left="255" width="3" height="19" font="3"> </text>
<text top="476" left="255" width="106" height="19" font="4"><b>Size:</b> N=321 (314 </text>
<text top="494" left="255" width="100" height="19" font="3">were implanted </text>
<text top="512" left="255" width="80" height="19" font="3">successfully) </text>
<text top="384" left="389" width="151" height="19" font="4"><b>Inclusion criteria:</b>  Adult </text>
<text top="402" left="389" width="152" height="19" font="3">patients with a standard </text>
<text top="421" left="389" width="132" height="19" font="3">indication for an ICD. </text>
<text top="439" left="389" width="3" height="19" font="3"> </text>
<text top="457" left="389" width="170" height="19" font="4"><b>Exclusion criteria:</b>  Patients </text>
<text top="476" left="389" width="172" height="19" font="3">who required pacing or had </text>
<text top="494" left="389" width="184" height="19" font="3">documented pace terminable </text>
<text top="512" left="389" width="23" height="19" font="3">VT. </text>
<text top="385" left="597" width="230" height="19" font="4"><b>1</b>°<b> endpoint:</b>  The 180 d S-ICD system </text>
<text top="403" left="597" width="235" height="19" font="3">complication-free rate compared with </text>
<text top="422" left="597" width="221" height="19" font="3">a pre-specified performance goal of </text>
<text top="440" left="597" width="33" height="19" font="3">79%. </text>
<text top="458" left="597" width="239" height="19" font="3">The 1° effectiveness end point was the </text>
<text top="476" left="597" width="234" height="19" font="3">induced VF conversion rate compared </text>
<text top="495" left="597" width="235" height="19" font="3">with a pre-specified performance goal </text>
<text top="513" left="597" width="206" height="19" font="3">of 88%, with success defined as 2 </text>
<text top="531" left="597" width="197" height="19" font="3">consecutive VF conversions of 4 </text>
<text top="550" left="597" width="63" height="19" font="3">attempts. </text>
<text top="568" left="597" width="3" height="19" font="3"> </text>
<text top="586" left="597" width="209" height="19" font="4"><b>Results:</b>  Followup was for 11 mo. </text>
<text top="605" left="597" width="233" height="19" font="3">Mean age was 52 y. The 180 d system </text>
<text top="623" left="597" width="227" height="19" font="3">complication-free rate was 99%, and </text>
<text top="641" left="597" width="211" height="19" font="3">sensitivity analysis of the acute VF </text>
<text top="660" left="597" width="241" height="19" font="3">conversion rate was &gt;90% in the entire </text>
<text top="678" left="597" width="191" height="19" font="3">cohort. There were 38 discrete </text>
<text top="696" left="597" width="195" height="19" font="3">spontaneous episodes of VT/VF </text>
<text top="714" left="597" width="225" height="19" font="3">recorded in 21 patients (6.7%), all of </text>
<text top="733" left="597" width="220" height="19" font="3">which successfully converted. Forty-</text>
<text top="751" left="597" width="204" height="19" font="3">one patients (13.1%) received an </text>
<text top="769" left="597" width="129" height="19" font="3">inappropriate shock. </text>
<text top="384" left="854" width="234" height="19" font="3">● This study supports the efficacy and </text>
<text top="402" left="854" width="208" height="19" font="3">safety of the S-ICD System for the </text>
<text top="421" left="854" width="204" height="19" font="3">treatment of life-threatening VA. </text>
</page>
<page number="296" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">296 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="597" width="226" height="19" font="3">There were no cases of lead failures, </text>
<text top="127" left="597" width="172" height="19" font="3">endocarditis or bacteremia, </text>
<text top="145" left="597" width="202" height="19" font="3">tamponade, cardiac perforation, </text>
<text top="164" left="597" width="197" height="19" font="3">pneumothorax, hemothorax, or </text>
<text top="182" left="597" width="224" height="19" font="3">subclavian vein occlusion associated </text>
<text top="200" left="597" width="226" height="19" font="3">with the S-ICD System. There was no </text>
<text top="219" left="597" width="178" height="19" font="3">electrode or pulse generator </text>
<text top="237" left="597" width="196" height="19" font="3">movement in 99% of implanted </text>
<text top="255" left="597" width="207" height="19" font="3">patients throughout the followup </text>
<text top="273" left="597" width="47" height="19" font="3">period. </text>
<text top="292" left="125" width="112" height="19" font="3">● Olde Nordkamp </text>
<text top="311" left="125" width="103" height="19" font="3">et al. 2014 (578) </text>
<text top="329" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24320684">● </a></text>
<text top="329" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24320684">24320684</a></text>
<text top="329" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24320684"> </a></text>
<text top="347" left="125" width="3" height="19" font="3"> </text>
<text top="292" left="255" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="311" left="255" width="103" height="19" font="3">Prospective non-</text>
<text top="329" left="255" width="113" height="19" font="3">randomized study </text>
<text top="347" left="255" width="3" height="19" font="3"> </text>
<text top="366" left="255" width="85" height="19" font="4"><b>Size:</b>   N=230  </text>
<text top="292" left="389" width="164" height="19" font="4"><b>Inclusion criteria:</b> Patients </text>
<text top="311" left="389" width="193" height="19" font="3">more than 18 y old with a prior </text>
<text top="329" left="389" width="176" height="19" font="3">ICD implantation visiting the </text>
<text top="347" left="389" width="131" height="19" font="3">ICD outpatient clinic. </text>
<text top="366" left="389" width="3" height="19" font="3"> </text>
<text top="384" left="389" width="170" height="19" font="4"><b>Exclusion criteria:</b>  Patients </text>
<text top="402" left="389" width="136" height="19" font="3">who were pacemaker-</text>
<text top="421" left="389" width="132" height="19" font="3">dependent or had an </text>
<text top="439" left="389" width="171" height="19" font="3">indication for pacing during </text>
<text top="457" left="389" width="187" height="19" font="3">implantation (i.e., ICD settings </text>
<text top="476" left="389" width="135" height="19" font="3">other than VVI ≤40 or </text>
<text top="494" left="389" width="191" height="19" font="3">DDI ≤40). Also patients with an </text>
<text top="512" left="389" width="85" height="19" font="3">indication for </text>
<text top="531" left="389" width="113" height="19" font="3">resynchronization </text>
<text top="549" left="389" width="47" height="19" font="3">pacing. </text>
<text top="293" left="597" width="194" height="19" font="4"><b>1</b>°<b> endpoint:</b>  To determine the </text>
<text top="312" left="597" width="217" height="19" font="3">prevalence of patients who are not </text>
<text top="330" left="597" width="73" height="19" font="3">suitable for </text>
<text top="348" left="597" width="190" height="19" font="3">a S-ICD according to the QRS-T </text>
<text top="367" left="597" width="209" height="19" font="3">morphology screening-ECG; (2) to </text>
<text top="385" left="597" width="239" height="19" font="3">identify clinical characteristics of these </text>
<text top="403" left="597" width="224" height="19" font="3">patients; and (3) to analyze whether </text>
<text top="422" left="597" width="234" height="19" font="3">standard 12-lead ECG parameters can </text>
<text top="440" left="597" width="232" height="19" font="3">be used to predict QRS-T morphology </text>
<text top="458" left="597" width="109" height="19" font="3">screening failure. </text>
<text top="476" left="597" width="242" height="19" font="3">Patients were defined suitable when at </text>
<text top="495" left="597" width="232" height="19" font="3">least 1 sensing vector was considered </text>
<text top="513" left="597" width="193" height="19" font="3">appropriate in both supine and </text>
<text top="531" left="597" width="112" height="19" font="3">standing position. </text>
<text top="550" left="597" width="3" height="19" font="3"> </text>
<text top="568" left="597" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="586" left="597" width="238" height="19" font="3">In total, 7.4% of patients, who were all </text>
<text top="605" left="597" width="239" height="19" font="3">male, were considered not suitable for </text>
<text top="623" left="597" width="190" height="19" font="3">a S-ICD according to the QRS-T </text>
<text top="641" left="597" width="172" height="19" font="3">morphology screening-ECG. </text>
<text top="660" left="597" width="241" height="19" font="3">Independent predictors for TMS failure </text>
<text top="678" left="597" width="224" height="19" font="3">were HCM (HCM; OR: 12.6), a heavy </text>
<text top="696" left="597" width="211" height="19" font="3">weight (OR: 1.5), a prolonged QRS </text>
<text top="714" left="597" width="238" height="19" font="3">duration (OR: 1.5) and a R:T ratio &lt;3 in </text>
<text top="733" left="597" width="228" height="19" font="3">the lead with the largest T wave on a </text>
<text top="751" left="597" width="213" height="19" font="3">standard 12-lead surface ECG (OR: </text>
<text top="769" left="597" width="38" height="19" font="3">14.6). </text>
<text top="292" left="854" width="235" height="19" font="3">● In patients without an indication for </text>
<text top="311" left="854" width="209" height="19" font="3">bradycardia- or resynchronization </text>
<text top="329" left="854" width="223" height="19" font="3">pacing, 7.3% were not suitable for S-</text>
<text top="347" left="854" width="238" height="19" font="3">ICD implantation according to the QRS-</text>
<text top="366" left="854" width="211" height="19" font="3">T morphology screening-ECG. This </text>
<text top="384" left="854" width="190" height="19" font="3">indicates that this prerequisite </text>
<text top="402" left="854" width="235" height="19" font="3">screening method is not limiting S-ICD </text>
<text top="421" left="854" width="170" height="19" font="3">selection for most patients. </text>
<text top="439" left="854" width="3" height="19" font="3"> </text>
</page>
<page number="297" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">297 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="97" height="19" font="3">● Randles et al. </text>
<text top="127" left="125" width="69" height="19" font="3">2014 (579) </text>
<text top="145" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24351884">● </a></text>
<text top="145" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24351884">24351884</a></text>
<text top="145" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24351884"> </a></text>
<text top="164" left="125" width="3" height="19" font="3"> </text>
<text top="109" left="255" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="127" left="255" width="103" height="19" font="3">Prospective non-</text>
<text top="145" left="255" width="113" height="19" font="3">randomized study </text>
<text top="164" left="255" width="3" height="19" font="3"> </text>
<text top="182" left="255" width="85" height="19" font="4"><b>Size:</b>    N=196 </text>
<text top="109" left="389" width="192" height="19" font="4"><b>Inclusion criteria:</b>  ICD patients </text>
<text top="127" left="389" width="166" height="19" font="3">with no ventricular pacing. </text>
<text top="145" left="389" width="3" height="19" font="3"> </text>
<text top="164" left="389" width="170" height="19" font="4"><b>Exclusion criteria:</b>  Patients </text>
<text top="182" left="389" width="183" height="19" font="3">with an S-ICD, patients with a </text>
<text top="200" left="389" width="154" height="19" font="3">paced QRS complex, and </text>
<text top="219" left="389" width="179" height="19" font="3">patients who were unable to </text>
<text top="237" left="389" width="186" height="19" font="3">stand for the time required to </text>
<text top="255" left="389" width="129" height="19" font="3">record an erect ECG. </text>
<text top="109" left="597" width="207" height="19" font="4"><b>1</b>°<b> endpoint:</b>  S-ICD eligibility that </text>
<text top="128" left="597" width="228" height="19" font="3">required ≥2 leads to satisfy the S-ICD </text>
<text top="146" left="597" width="229" height="19" font="3">screening template in both erect and </text>
<text top="165" left="597" width="106" height="19" font="3">supine positions. </text>
<text top="183" left="597" width="3" height="19" font="3"> </text>
<text top="201" left="597" width="216" height="19" font="4"><b>Results:</b>  Overall, 85.2% of patients </text>
<text top="219" left="597" width="230" height="19" font="3">(95% CI: 80.2–90.2%) fulfilled surface </text>
<text top="238" left="597" width="141" height="19" font="3">ECG screening criteria. </text>
<text top="256" left="597" width="239" height="19" font="3">The proportion of patients with 3, 2, 1, </text>
<text top="274" left="597" width="210" height="19" font="3">and 0 qualifying leads were 37.2% </text>
<text top="293" left="597" width="230" height="19" font="3">(95% CI: 30.4–44.0%), 48.0% (95% CI: </text>
<text top="311" left="597" width="203" height="19" font="3">41.0–55.0%), 11.2% (95% CI: 6.8–</text>
<text top="329" left="597" width="229" height="19" font="3">15.6%), and 3.6% (95% CI: 1.0–6.2%). </text>
<text top="348" left="597" width="210" height="19" font="3">The S-ICD screening template was </text>
<text top="366" left="597" width="212" height="19" font="3">satisfied more often by Lead III (1° </text>
<text top="384" left="597" width="218" height="19" font="3">vector, 83.7%, 95% CI: 78.5–88.9%) </text>
<text top="402" left="597" width="229" height="19" font="3">and Lead II (2° vector, 82.7%, 95% CI: </text>
<text top="421" left="597" width="144" height="19" font="3">77.4–88.0%) compared </text>
<text top="439" left="597" width="224" height="19" font="3">with Lead I (alternate vector, 52.6%, </text>
<text top="457" left="597" width="132" height="19" font="3">95% CI: 45.6–59.6%). </text>
<text top="109" left="854" width="212" height="19" font="3">● About 85.2% of patients with an </text>
<text top="127" left="854" width="239" height="19" font="3">indication for a 1° or 2° prevention ICD </text>
<text top="145" left="854" width="233" height="19" font="3">have a surface ECG that is suitable for </text>
<text top="164" left="854" width="242" height="19" font="3">S-ICD implantation when assessed with </text>
<text top="182" left="854" width="175" height="19" font="3">an S-ICD screening template.</text>
<text top="180" left="1029" width="4" height="21" font="0"> </text>
<text top="182" left="1033" width="12" height="19" font="3">A </text>
<text top="200" left="854" width="231" height="19" font="3">prolonged QRS duration was the only </text>
<text top="219" left="854" width="231" height="19" font="3">baseline characteristic independently </text>
<text top="237" left="854" width="224" height="19" font="3">associated with ineligibility for S-ICD </text>
<text top="255" left="854" width="85" height="19" font="3">implantation. </text>
<text top="476" left="125" width="102" height="19" font="3">● <b>EFFORTLESS S-</b></text>
<text top="495" left="125" width="79" height="19" font="4"><b>ICD Registry</b> </text>
<text top="513" left="125" width="107" height="19" font="3">● Lambiase et al. </text>
<text top="531" left="125" width="69" height="19" font="3">2014 (580) </text>
<text top="550" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24670710">● </a></text>
<text top="550" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24670710">24670710</a></text>
<text top="550" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24670710"> </a></text>
<text top="568" left="125" width="3" height="19" font="3"> </text>
<text top="476" left="255" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="495" left="255" width="101" height="19" font="3">Prospective and </text>
<text top="513" left="255" width="84" height="19" font="3">retrospective </text>
<text top="531" left="255" width="86" height="19" font="3">observational </text>
<text top="550" left="255" width="44" height="19" font="3">study   </text>
<text top="568" left="255" width="3" height="19" font="3"> </text>
<text top="586" left="255" width="109" height="19" font="4"><b>Size:</b>  N=472 (241 </text>
<text top="605" left="255" width="49" height="19" font="3">studied </text>
<text top="623" left="255" width="89" height="19" font="3">prospectively) </text>
<text top="476" left="389" width="167" height="19" font="4"><b>Inclusion criteria:</b>  Patients </text>
<text top="495" left="389" width="105" height="19" font="3">receiving a S-ICD </text>
<text top="513" left="389" width="3" height="19" font="3"> </text>
<text top="531" left="389" width="163" height="19" font="4"><b>Exclusion criteria:</b> Specific </text>
<text top="550" left="389" width="189" height="19" font="3">contraindications include class </text>
<text top="568" left="389" width="169" height="19" font="3">I indications for permanent </text>
<text top="586" left="389" width="174" height="19" font="3">pacing, pace-terminable VT, </text>
<text top="605" left="389" width="158" height="19" font="3">and previously implanted </text>
<text top="623" left="389" width="163" height="19" font="3">functional unipolar pacing </text>
<text top="641" left="389" width="54" height="19" font="3">system.  </text>
<text top="477" left="597" width="235" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Effectiveness and safety </text>
<text top="496" left="597" width="83" height="19" font="3">of the S-ICD.  </text>
<text top="514" left="597" width="3" height="19" font="3"> </text>
<text top="532" left="597" width="237" height="19" font="4"><b>Results:</b>  Complication-free rates were </text>
<text top="550" left="597" width="191" height="19" font="3">97 and 94%, at 30 d and 360 d, </text>
<text top="569" left="597" width="189" height="19" font="3">respectively. 317 spontaneous </text>
<text top="587" left="597" width="237" height="19" font="3">episodes were recorded in 85 patients </text>
<text top="606" left="597" width="230" height="19" font="3">during the follow-up period. Of these </text>
<text top="624" left="597" width="236" height="19" font="3">episodes, 169 (53%) received therapy, </text>
<text top="642" left="597" width="206" height="19" font="3">93 for VT/VF. One patient died of </text>
<text top="660" left="597" width="229" height="19" font="3">recurrent VF and severe bradycardia. </text>
<text top="679" left="597" width="215" height="19" font="3">First shock conversion efficacy was </text>
<text top="697" left="597" width="206" height="19" font="3">88% with 100% overall successful </text>
<text top="715" left="597" width="239" height="19" font="3">clinical conversion after a maximum of </text>
<text top="734" left="597" width="221" height="19" font="3">five shocks. The 360d inappropriate </text>
<text top="752" left="597" width="198" height="19" font="3">shock rate was 7% with the vast </text>
<text top="770" left="597" width="213" height="19" font="3">majority occurring for oversensing </text>
<text top="476" left="854" width="204" height="19" font="3">● This study showed appropriate </text>
<text top="495" left="854" width="242" height="19" font="3">system performance with clinical event </text>
<text top="513" left="854" width="220" height="19" font="3">rates and inappropriate shock rates </text>
<text top="531" left="854" width="223" height="19" font="3">comparable with those reported for </text>
<text top="550" left="854" width="112" height="19" font="3">transvenous ICDs. </text>
</page>
<page number="298" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">298 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="597" width="230" height="19" font="3">(62/73 episodes), primarily of cardiac </text>
<text top="127" left="597" width="236" height="19" font="3">signals (94% of oversensed episodes).  </text>
<text top="146" left="125" width="114" height="19" font="3">● Groh et al. 2014 </text>
<text top="164" left="125" width="35" height="19" font="3">(581) </text>
<text top="183" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24755323">● </a></text>
<text top="183" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24755323">24755323</a></text>
<text top="183" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24755323"> </a></text>
<text top="201" left="125" width="3" height="19" font="3"> </text>
<text top="146" left="255" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="164" left="255" width="103" height="19" font="3">Prospective non-</text>
<text top="183" left="255" width="116" height="19" font="3">randomized study  </text>
<text top="201" left="255" width="3" height="19" font="3"> </text>
<text top="219" left="255" width="85" height="19" font="4"><b>Size:</b>   N=100  </text>
<text top="146" left="389" width="167" height="19" font="4"><b>Inclusion criteria:</b>  Patients </text>
<text top="164" left="389" width="192" height="19" font="3">who had previously undergone </text>
<text top="183" left="389" width="186" height="19" font="3">implantation of a transvenous </text>
<text top="201" left="389" width="191" height="19" font="3">ICD for 1° or 2° prevention and </text>
<text top="219" left="389" width="147" height="19" font="3">who were not receiving </text>
<text top="238" left="389" width="192" height="19" font="3">bradycardia pacing and did not </text>
<text top="256" left="389" width="179" height="19" font="3">have an indication for pacing </text>
<text top="274" left="389" width="100" height="19" font="3">were identified. </text>
<text top="292" left="389" width="3" height="19" font="3"> </text>
<text top="311" left="389" width="190" height="19" font="4"><b>Exclusion criteria:</b>  See above.  </text>
<text top="147" left="597" width="242" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Rate of passing screening </text>
<text top="165" left="597" width="184" height="19" font="3">test and predictors of failure.  </text>
<text top="183" left="597" width="3" height="19" font="3"> </text>
<text top="202" left="597" width="208" height="19" font="4"><b>Results:</b>  8% of patients failed the </text>
<text top="220" left="597" width="93" height="19" font="3">screening test. </text>
<text top="238" left="597" width="234" height="19" font="3">Patients with T-wave inversions in the </text>
<text top="257" left="597" width="212" height="19" font="3">inferior leads had a 45% chance of </text>
<text top="275" left="597" width="133" height="19" font="3">failing the screening.  </text>
<text top="293" left="597" width="3" height="19" font="3"> </text>
<text top="146" left="854" width="213" height="19" font="3">● More work is needed on sensing </text>
<text top="164" left="854" width="216" height="19" font="3">algorithms on S-ICDs to increase pt </text>
<text top="183" left="854" width="155" height="19" font="3">eligibility for this device.  </text>
<text top="330" left="125" width="97" height="19" font="3">● <b>EFFORTLESS/ </b></text>
<text top="348" left="125" width="81" height="19" font="4"><b>IDE Registry</b>  </text>
<text top="366" left="125" width="85" height="19" font="3">● Burke et al. </text>
<text top="385" left="125" width="69" height="19" font="3">2015 (582) </text>
<text top="403" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25908064">● </a></text>
<text top="403" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25908064">25908064</a></text>
<text top="403" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25908064"> </a></text>
<text top="422" left="125" width="3" height="19" font="3"> </text>
<text top="330" left="255" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="348" left="255" width="101" height="19" font="3">Prospective and </text>
<text top="366" left="255" width="88" height="19" font="3">retrospective  </text>
<text top="385" left="255" width="3" height="19" font="3"> </text>
<text top="403" left="255" width="106" height="19" font="4"><b>Size:</b> N=882 (568 </text>
<text top="422" left="255" width="110" height="19" font="3">from EFFORTLESS </text>
<text top="440" left="255" width="109" height="19" font="3">and 308 from the </text>
<text top="458" left="255" width="62" height="19" font="3">IDE trials) </text>
<text top="330" left="389" width="167" height="19" font="4"><b>Inclusion criteria:</b>  Patients </text>
<text top="348" left="389" width="128" height="19" font="3">indicated for an ICD. </text>
<text top="366" left="389" width="3" height="19" font="3"> </text>
<text top="385" left="389" width="170" height="19" font="4"><b>Exclusion criteria:</b>  Patients </text>
<text top="403" left="389" width="159" height="19" font="3">with recurrent VT reliably </text>
<text top="422" left="389" width="156" height="19" font="3">terminated with ATP and </text>
<text top="440" left="389" width="165" height="19" font="3">patients in need of pacing. </text>
<text top="458" left="389" width="153" height="19" font="3">Patients with ESRD were </text>
<text top="476" left="389" width="180" height="19" font="3">excluded from the IDE trials.  </text>
<text top="331" left="597" width="236" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Safety and effectiveness </text>
<text top="349" left="597" width="76" height="19" font="3">of the S-ICD </text>
<text top="367" left="597" width="3" height="19" font="3"> </text>
<text top="386" left="597" width="208" height="19" font="4"><b>Results:</b>  Followup was for 651 d.  </text>
<text top="404" left="597" width="223" height="19" font="3">Spontaneous VT/VF events (N= 111) </text>
<text top="422" left="597" width="200" height="19" font="3">were treated in 59 patients; 100 </text>
<text top="441" left="597" width="241" height="19" font="3">(90.1%) events were terminated with 1 </text>
<text top="459" left="597" width="222" height="19" font="3">shock, and 109 events (98.2%) were </text>
<text top="477" left="597" width="206" height="19" font="3">terminated within the 5 available </text>
<text top="496" left="597" width="48" height="19" font="3">shocks. </text>
<text top="514" left="597" width="237" height="19" font="3">The estimated 3 y inappropriate shock </text>
<text top="532" left="597" width="208" height="19" font="3">rate was 13.1%. Estimated 3 y, all-</text>
<text top="550" left="597" width="211" height="19" font="3">cause mortality was 4.7% (95% CI: </text>
<text top="569" left="597" width="218" height="19" font="3">0.9%–8.5%), with 26 deaths (2.9%). </text>
<text top="587" left="597" width="238" height="19" font="3">Device-related complications occurred </text>
<text top="605" left="597" width="238" height="19" font="3">in 11.1% of patients at 3 y. There were </text>
<text top="624" left="597" width="218" height="19" font="3">no electrode failures, and no S-ICD–</text>
<text top="642" left="597" width="215" height="19" font="3">related endocarditis or bacteremia </text>
<text top="660" left="597" width="149" height="19" font="3">occurred. Three devices </text>
<text top="679" left="597" width="186" height="19" font="3">(0.3%) were replaced for right </text>
<text top="697" left="597" width="162" height="19" font="3">ventricular pacing. Themo </text>
<text top="715" left="597" width="195" height="19" font="3">complication rate decreased by </text>
<text top="734" left="597" width="138" height="19" font="3">quartile of enrollment </text>
<text top="752" left="597" width="234" height="19" font="3">(Q1: 8.9%; Q4: 5.5%), and there was a </text>
<text top="770" left="597" width="172" height="19" font="3">trend toward a reduction in </text>
<text top="331" left="854" width="12" height="19" font="3">● </text>
<text top="330" left="866" width="8" height="21" font="0">S</text>
<text top="331" left="874" width="220" height="19" font="3">-ICD demonstrated high efficacy for </text>
<text top="350" left="854" width="160" height="19" font="3">VT/VF. Complications and </text>
<text top="368" left="854" width="194" height="19" font="3">inappropriate shock rates were </text>
<text top="387" left="854" width="216" height="19" font="3">reduced consistently with strategic </text>
<text top="405" left="854" width="186" height="19" font="3">programming and as operator </text>
<text top="423" left="854" width="136" height="19" font="3">experience increased. </text>
</page>
<page number="299" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">299 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="597" width="219" height="19" font="3">inappropriate shocks (Q1: 6.9% Q4: </text>
<text top="127" left="597" width="41" height="19" font="3">4.5%). </text>
<text top="182" left="115" width="842" height="21" font="2"><b>Data Supplement 56. Nonrandomized Trials, Observational Studies, Guidelines, and/or Registries for WCD – (Section 11.2)  </b></text>
<text top="203" left="133" width="157" height="19" font="4"><b>Study Acronym; Author;  </b></text>
<text top="221" left="162" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="203" left="342" width="88" height="19" font="4"><b>Aim of Study; </b></text>
<text top="221" left="348" width="76" height="19" font="4"><b>Study Type; </b></text>
<text top="239" left="341" width="89" height="19" font="4"><b>Study Size (N) </b></text>
<text top="203" left="505" width="48" height="19" font="4"><b>Patient </b></text>
<text top="221" left="494" width="72" height="19" font="4"><b>Population </b></text>
<text top="203" left="616" width="108" height="19" font="4"><b>Endpoint Results </b></text>
<text top="221" left="598" width="148" height="19" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="239" left="602" width="136" height="19" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="258" left="645" width="49" height="19" font="4"><b>95% CI) </b></text>
<text top="203" left="845" width="146" height="19" font="4"><b>Summary/Conclusions  </b></text>
<text top="221" left="876" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="277" left="123" width="159" height="19" font="3">● Chung MK. Cardiol Clin. </text>
<text top="295" left="123" width="34" height="19" font="3">2014.</text>
<text top="294" left="157" width="4" height="21" font="0"> </text>
<text top="295" left="161" width="35" height="19" font="3">(583) </text>
<text top="314" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24793801">● </a></text>
<text top="314" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24793801">24793801</a></text>
<text top="314" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24793801"> </a></text>
<text top="277" left="309" width="89" height="19" font="3">Review article </text>
<text top="295" left="309" width="97" height="19" font="4"><b>Study size:</b> N/A </text>
<text top="277" left="476" width="27" height="19" font="3">N/A </text>
<text top="277" left="595" width="27" height="19" font="3">N/A </text>
<text top="277" left="757" width="273" height="19" font="3">Description of WCD indications, efficacy and </text>
<text top="295" left="757" width="72" height="19" font="3">limitations. </text>
<text top="333" left="123" width="148" height="19" font="3">● Chung MK, et al. J Am </text>
<text top="351" left="123" width="111" height="19" font="3">Coll Cardiol. 2010.</text>
<text top="349" left="234" width="4" height="21" font="0"> </text>
<text top="351" left="238" width="35" height="19" font="3">(584) </text>
<text top="369" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20620738">● </a></text>
<text top="369" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20620738">20620738</a></text>
<text top="369" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20620738"> </a></text>
<text top="333" left="309" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="351" left="309" width="122" height="19" font="3">observational, post-</text>
<text top="369" left="309" width="123" height="19" font="3">market registry and </text>
<text top="388" left="309" width="131" height="19" font="3">Social Security Death </text>
<text top="406" left="309" width="40" height="19" font="3">Index  </text>
<text top="424" left="309" width="76" height="19" font="4"><b>Size:</b>    3569 </text>
<text top="333" left="476" width="59" height="19" font="4"><b>Inclusion </b></text>
<text top="351" left="476" width="74" height="19" font="4"><b>criteria:  </b>All </text>
<text top="369" left="476" width="53" height="19" font="3">patients </text>
<text top="388" left="476" width="92" height="19" font="3">implanted and </text>
<text top="406" left="476" width="95" height="19" font="3">signed consent </text>
<text top="424" left="476" width="78" height="19" font="3">post-market<b> </b></text>
<text top="442" left="476" width="3" height="19" font="4"><b> </b></text>
<text top="461" left="476" width="61" height="19" font="4"><b>Exclusion </b></text>
<text top="479" left="476" width="80" height="19" font="4"><b>criteria:</b> N/A<b> </b></text>
<text top="333" left="595" width="85" height="19" font="4"><b>1</b>°<b> endpoint:  </b></text>
<text top="352" left="595" width="141" height="19" font="3">Observational study of </text>
<text top="370" left="595" width="100" height="19" font="3">compliance and </text>
<text top="388" left="595" width="84" height="19" font="3">effectiveness </text>
<text top="407" left="595" width="3" height="19" font="3"> </text>
<text top="333" left="757" width="293" height="19" font="3">Asystole was an important cause of mortality in </text>
<text top="351" left="757" width="75" height="19" font="3">SCA events. </text>
<text top="369" left="757" width="316" height="19" font="3">Compliance was satisfactory with 90% wear time in </text>
<text top="388" left="757" width="304" height="19" font="3">&gt;50% of patients and low sudden death mortality </text>
<text top="406" left="757" width="89" height="19" font="3">during usage.  </text>
<text top="424" left="757" width="309" height="19" font="3">80 sustained VT/VF events occurred in 59 patients </text>
<text top="442" left="757" width="297" height="19" font="3">(1.7%). First shock success was 76/76 (100%) for </text>
<text top="461" left="757" width="317" height="19" font="3">unconscious VT/VF and 79/80 (99%) for all VT/VF. 8 </text>
<text top="479" left="757" width="267" height="19" font="3">patients died after successful conversion of </text>
<text top="498" left="757" width="270" height="19" font="3">unconscious VT/VF (survival 89.5% of VT/VF </text>
<text top="516" left="757" width="312" height="19" font="3">events). Asystole occurred in 23 (17 died), PEA in 2 </text>
<text top="534" left="757" width="297" height="19" font="3">and respiratory arrest in 1 (3 died), representing </text>
<text top="552" left="757" width="317" height="19" font="3">24.5% of SCA. During WCD use, 3541/3569 patients </text>
<text top="571" left="757" width="316" height="19" font="3">(99.2%) survived overall. Survival occurred in 72/80 </text>
<text top="589" left="757" width="126" height="19" font="3">(90%) VT/VF events. </text>
<text top="607" left="757" width="315" height="19" font="3">Survival was comparable to that of implantable ICD </text>
<text top="626" left="757" width="57" height="19" font="3">patients. </text>
<text top="645" left="123" width="171" height="19" font="3">● Klein HU et al. Pacing Clin </text>
<text top="663" left="123" width="127" height="19" font="3">Electrophysiol. 2010.</text>
<text top="661" left="250" width="4" height="21" font="0"> </text>
<text top="663" left="254" width="35" height="19" font="3">(585) </text>
<text top="681" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19889186">● </a></text>
<text top="681" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19889186">19889186</a></text>
<text top="681" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19889186"> </a></text>
<text top="645" left="309" width="89" height="19" font="3">Review article </text>
<text top="663" left="309" width="97" height="19" font="4"><b>Study size:</b> N/A </text>
<text top="645" left="476" width="27" height="19" font="3">N/A<b> </b></text>
<text top="645" left="595" width="27" height="19" font="3">N/A<b> </b></text>
<text top="645" left="757" width="273" height="19" font="3">Description of WCD indications, efficacy and </text>
<text top="663" left="757" width="72" height="19" font="3">limitations. </text>
<text top="700" left="115" width="4" height="21" font="0"> </text>
<text top="720" left="115" width="4" height="21" font="0"> </text>
</page>
<page number="300" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">300 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="936" height="21" font="2"><b>Data Supplement 57. Nonrandomized Trials, Observational Studies, Guidelines, and/or Registries for Special Considerations for Catheter </b></text>
<text top="128" left="115" width="159" height="21" font="2"><b>Ablation – (Section 12) </b></text>
<text top="149" left="142" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="167" left="168" width="51" height="19" font="4"><b>Author; </b></text>
<text top="185" left="145" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="149" left="308" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="167" left="337" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="149" left="503" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="149" left="673" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="167" left="685" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="185" left="717" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="150" left="869" width="186" height="19" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="168" left="904" width="116" height="19" font="4"><b>Study Limitations; </b></text>
<text top="186" left="913" width="99" height="19" font="4"><b>Adverse Events </b></text>
<text top="205" left="125" width="123" height="19" font="3">● Blanck et al. 1993 </text>
<text top="224" left="125" width="35" height="19" font="3">(170) </text>
<text top="242" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8269297">● </a></text>
<text top="242" left="137" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8269297">8269297</a></text>
<text top="242" left="190" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8269297"> </a></text>
<text top="260" left="125" width="3" height="19" font="4"><b> </b></text>
<text top="205" left="275" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="224" left="275" width="131" height="19" font="3">Single Center Review </text>
<text top="242" left="275" width="3" height="19" font="3"> </text>
<text top="260" left="275" width="114" height="19" font="4"><b>Size:</b>    48 patients </text>
<text top="205" left="479" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="224" left="479" width="126" height="19" font="3">All patients at single </text>
<text top="242" left="479" width="117" height="19" font="3">center with BBRVT </text>
<text top="260" left="479" width="164" height="19" font="3">diagnosed at EPS between </text>
<text top="279" left="479" width="69" height="19" font="3">1980-1992 </text>
<text top="297" left="479" width="115" height="19" font="4"><b>Exlcusion Criteria: </b></text>
<text top="315" left="506" width="125" height="19" font="3">7)  Typical RBBB or </text>
<text top="334" left="533" width="62" height="19" font="3">LBBB QRS </text>
<text top="352" left="533" width="77" height="19" font="3">morphology </text>
<text top="370" left="533" width="62" height="19" font="3">during VT </text>
<text top="389" left="506" width="135" height="19" font="4"><b>8)  </b>QRS preceded by </text>
<text top="407" left="533" width="48" height="19" font="3">His and </text>
<text top="425" left="533" width="95" height="19" font="3">appropriate BB </text>
<text top="444" left="533" width="59" height="19" font="3">potential<b> </b></text>
<text top="462" left="506" width="130" height="19" font="4"><b>9)  </b>Stable HV, RB-V, </text>
<text top="480" left="533" width="97" height="19" font="3">or LB-V interval<b> </b></text>
<text top="498" left="506" width="88" height="19" font="4"><b>10)  </b>Induction </text>
<text top="517" left="533" width="111" height="19" font="3">dependent on HV </text>
<text top="535" left="533" width="36" height="19" font="3">delay<b> </b></text>
<text top="553" left="506" width="123" height="19" font="4"><b>11)  </b>Termination by </text>
<text top="572" left="533" width="78" height="19" font="3">block in HPS<b> </b></text>
<text top="590" left="506" width="123" height="19" font="4"><b>12)  </b>Noninducibility </text>
<text top="608" left="533" width="114" height="19" font="3">after RBB ablation<b> </b></text>
<text top="627" left="479" width="7" height="19" font="3">  </text>
<text top="205" left="661" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="224" left="661" width="165" height="19" font="3">45 of 48 patients had SHD  </text>
<text top="242" left="661" width="127" height="19" font="3">SHD was NICM in 16 </text>
<text top="260" left="661" width="171" height="19" font="3">patients, Ischemic CM in 23 </text>
<text top="279" left="661" width="166" height="19" font="3">patients, VHD in 2 patients </text>
<text top="297" left="661" width="3" height="19" font="3"> </text>
<text top="315" left="661" width="116" height="19" font="3">Mean LVEF=23.2% </text>
<text top="334" left="661" width="3" height="19" font="3"> </text>
<text top="352" left="661" width="131" height="19" font="4"><b>Clinical Presentation </b></text>
<text top="370" left="661" width="125" height="19" font="3">Aborted SCD in 26% </text>
<text top="389" left="661" width="99" height="19" font="3">Syncope in 51% </text>
<text top="407" left="661" width="153" height="19" font="3">Sustained palpitations in </text>
<text top="425" left="661" width="29" height="19" font="3">10% </text>
<text top="444" left="661" width="3" height="19" font="3"> </text>
<text top="462" left="661" width="159" height="19" font="3">Mean HV interval in sinus </text>
<text top="480" left="661" width="65" height="19" font="3">80.4 msec </text>
<text top="498" left="661" width="3" height="19" font="3"> </text>
<text top="517" left="661" width="143" height="19" font="4"><b>QRS morphology in VT </b></text>
<text top="535" left="661" width="121" height="19" font="3">LBBB in 46 patients </text>
<text top="553" left="661" width="115" height="19" font="3">RBBB in 5 patients </text>
<text top="572" left="661" width="164" height="19" font="3">Interfascicular reentry in 2 </text>
<text top="590" left="661" width="53" height="19" font="3">patients </text>
<text top="608" left="661" width="3" height="19" font="3"> </text>
<text top="626" left="661" width="114" height="19" font="4"><b>Catheter Ablation </b></text>
<text top="645" left="661" width="155" height="19" font="3">Performed in 28 patients </text>
<text top="663" left="661" width="143" height="19" font="3">targeting the RBB in 26 </text>
<text top="681" left="661" width="131" height="19" font="3">patients and LBB in 2 </text>
<text top="700" left="661" width="53" height="19" font="3">patients </text>
<text top="718" left="661" width="169" height="19" font="3">Successful ablation of VT in </text>
<text top="736" left="661" width="37" height="19" font="3">100% </text>
<text top="755" left="661" width="178" height="19" font="3">No Complications observed.  </text>
<text top="205" left="849" width="221" height="19" font="3">● BBRVT typically occurs in patients </text>
<text top="224" left="849" width="223" height="19" font="3">with SHD from a variety of causes in </text>
<text top="242" left="849" width="171" height="19" font="3">patients with prolonged HV </text>
<text top="260" left="849" width="131" height="19" font="3">conduction intervals. </text>
<text top="279" left="849" width="219" height="19" font="3">● BBRVT is associated with aborted </text>
<text top="297" left="849" width="191" height="19" font="3">SCD, Syncope, and Palpitations </text>
<text top="315" left="849" width="171" height="19" font="3">● BBRVT is most commonly </text>
<text top="334" left="849" width="171" height="19" font="3">associated with a LBBB QRS </text>
<text top="352" left="849" width="201" height="19" font="3">morphology, and less commonly </text>
<text top="370" left="849" width="202" height="19" font="3">with RBBB or Interfascicular QRS </text>
<text top="389" left="849" width="87" height="19" font="3">morphologies </text>
<text top="407" left="849" width="205" height="19" font="3">● Catheter ablation targeting the </text>
<text top="425" left="849" width="206" height="19" font="3">RBB or LBB is highly effective and </text>
<text top="444" left="849" width="222" height="19" font="3">associated with a low risk of serious </text>
<text top="462" left="849" width="92" height="19" font="3">complications. </text>
<text top="480" left="849" width="3" height="19" font="3"> </text>
</page>
<page number="301" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">301 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="125" height="19" font="3">● Lopera et al. 2004 </text>
<text top="127" left="125" width="35" height="19" font="3">(173) </text>
<text top="145" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15028072">● </a></text>
<text top="145" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15028072">15028072</a></text>
<text top="145" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15028072"> </a></text>
<text top="164" left="125" width="3" height="19" font="4"><b> </b></text>
<text top="182" left="125" width="3" height="19" font="3"> </text>
<text top="109" left="275" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="127" left="275" width="131" height="19" font="3">Single Center Review </text>
<text top="145" left="275" width="3" height="19" font="3"> </text>
<text top="164" left="275" width="114" height="19" font="4"><b>Size:</b>    20 patients </text>
<text top="109" left="479" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="127" left="479" width="146" height="19" font="3">His Bundle, LBB, or RBB </text>
<text top="145" left="479" width="103" height="19" font="3">potential closely </text>
<text top="164" left="479" width="157" height="19" font="3">associated with QRS with </text>
<text top="182" left="479" width="41" height="19" font="3">any of </text>
<text top="200" left="479" width="88" height="19" font="3">the following: </text>
<text top="219" left="506" width="103" height="19" font="3">4)  H-H interval </text>
<text top="237" left="533" width="57" height="19" font="3">variation </text>
<text top="255" left="533" width="108" height="19" font="3">preceding similar </text>
<text top="273" left="533" width="75" height="19" font="3">V-V interval </text>
<text top="292" left="533" width="62" height="19" font="3">variation; </text>
<text top="310" left="506" width="107" height="19" font="3">5)  Anterograde </text>
<text top="329" left="533" width="103" height="19" font="3">activation of the </text>
<text top="347" left="533" width="105" height="19" font="3">bundle branches </text>
<text top="365" left="533" width="43" height="19" font="3">during </text>
<text top="383" left="533" width="98" height="19" font="3">tachycardia; or, </text>
<text top="402" left="506" width="139" height="19" font="3">6)  Abolition of VT by </text>
<text top="420" left="533" width="92" height="19" font="3">bundle branch </text>
<text top="438" left="533" width="57" height="19" font="3">ablation. </text>
<text top="457" left="479" width="3" height="19" font="3"> </text>
<text top="475" left="479" width="153" height="19" font="4"><b>Exclusion criteria:</b>  None </text>
<text top="109" left="661" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="127" left="661" width="174" height="19" font="3">HPS VT induced in 20 of 234 </text>
<text top="145" left="661" width="129" height="19" font="3">consecutive patients </text>
<text top="164" left="661" width="148" height="19" font="3">referred for VT ablation </text>
<text top="182" left="661" width="3" height="19" font="3"> </text>
<text top="200" left="661" width="140" height="19" font="3">NICM: 9 of 81 patients </text>
<text top="219" left="661" width="111" height="19" font="3">(11%) had HPS VT </text>
<text top="237" left="661" width="149" height="19" font="3">ICM:  11 of 153 patients </text>
<text top="255" left="661" width="115" height="19" font="3">(7.1%) had HPS VT </text>
<text top="273" left="661" width="123" height="19" font="3">Mean LVEF 29+17% </text>
<text top="292" left="661" width="175" height="19" font="3"> 2 of 20 patients had normal </text>
<text top="310" left="661" width="32" height="19" font="3">LVEF </text>
<text top="329" left="661" width="3" height="19" font="3"> </text>
<text top="347" left="661" width="131" height="19" font="4"><b>Clinical Presentation </b></text>
<text top="365" left="661" width="156" height="19" font="3">ICD Shocks in 10 patients </text>
<text top="383" left="661" width="133" height="19" font="3">Syncope in 3 patients </text>
<text top="402" left="661" width="131" height="19" font="3">Other symptoms in 7 </text>
<text top="420" left="661" width="53" height="19" font="3">patients </text>
<text top="438" left="661" width="3" height="19" font="3"> </text>
<text top="457" left="661" width="160" height="19" font="4"><b>Typical BBRVT</b> in 16 of 20 </text>
<text top="475" left="661" width="53" height="19" font="3">patients </text>
<text top="493" left="661" width="111" height="19" font="3">(all had LBBB QRS </text>
<text top="512" left="661" width="82" height="19" font="3">morphology) </text>
<text top="530" left="661" width="150" height="19" font="3">13 of 16 patients BBRVT </text>
<text top="548" left="661" width="170" height="19" font="3">successfully ablated by RBB </text>
<text top="566" left="661" width="169" height="19" font="3">ablation and 3 of 16 by LBB </text>
<text top="585" left="661" width="57" height="19" font="3">ablation. </text>
<text top="603" left="661" width="170" height="19" font="3">HV interval prolonged from </text>
<text top="621" left="661" width="173" height="19" font="3">70+5.9 msec to 83+17 msec </text>
<text top="640" left="661" width="90" height="19" font="3">after ablation. </text>
<text top="658" left="661" width="3" height="19" font="3"> </text>
<text top="676" left="661" width="119" height="19" font="4"><b>Typical BBRVT and </b></text>
<text top="695" left="661" width="172" height="19" font="4"><b>Interfascicular VT</b> in 2 of 20 </text>
<text top="713" left="661" width="163" height="19" font="3">patients.  Ablation of both </text>
<text top="731" left="661" width="168" height="19" font="3">the RBB and portion of LBB </text>
<text top="750" left="661" width="135" height="19" font="3">eliminated VT in both </text>
<text top="109" left="849" width="197" height="19" font="3">● BBRVT occurs in patients with </text>
<text top="127" left="849" width="204" height="19" font="3">both NICM and ICM, usually with </text>
<text top="145" left="849" width="101" height="19" font="3">impaired LVEF.   </text>
<text top="164" left="849" width="171" height="19" font="3">● BBRVT is most commonly </text>
<text top="182" left="849" width="171" height="19" font="3">associated with a LBBB QRS </text>
<text top="200" left="849" width="201" height="19" font="3">morphology, and less commonly </text>
<text top="219" left="849" width="202" height="19" font="3">with RBBB or Interfascicular QRS </text>
<text top="237" left="849" width="87" height="19" font="3">morphologies </text>
<text top="255" left="849" width="205" height="19" font="3">● Catheter ablation targeting the </text>
<text top="273" left="849" width="206" height="19" font="3">RBB or LBB is highly effective and </text>
<text top="292" left="849" width="222" height="19" font="3">associated with a low risk of serious </text>
<text top="310" left="849" width="188" height="19" font="3">complications if only one BB is </text>
<text top="329" left="849" width="196" height="19" font="3">targeted and a higher risk of AV </text>
<text top="347" left="849" width="205" height="19" font="3">block if both BBs are targeted for </text>
<text top="365" left="849" width="57" height="19" font="3">ablation. </text>
<text top="383" left="849" width="3" height="19" font="3"> </text>
</page>
<page number="302" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">302 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="661" width="174" height="19" font="3">patients, complicated by AV </text>
<text top="127" left="661" width="81" height="19" font="3">block in 1 pt. </text>
<text top="145" left="661" width="3" height="19" font="3"> </text>
<text top="164" left="661" width="171" height="19" font="4"><b>Focal Mechanism from BBs</b> </text>
<text top="182" left="661" width="156" height="19" font="3">in 2 patients, one in RBB, </text>
<text top="200" left="661" width="126" height="19" font="3">one in LBB. Ablation </text>
<text top="219" left="661" width="168" height="19" font="3">eliminated focal VT in both </text>
<text top="237" left="661" width="174" height="19" font="3">patients, complicated by AV </text>
<text top="255" left="661" width="81" height="19" font="3">block in 1 pt. </text>
<text top="274" left="125" width="91" height="19" font="3">● Mehdirad et </text>
<text top="292" left="125" width="83" height="19" font="3">al.1995 (174) </text>
<text top="311" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8771124">● </a></text>
<text top="311" left="137" width="53" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8771124">8771124</a></text>
<text top="311" left="190" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8771124"> </a></text>
<text top="329" left="125" width="3" height="19" font="3"> </text>
<text top="274" left="275" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="292" left="275" width="131" height="19" font="3">Single Center Review </text>
<text top="311" left="275" width="3" height="19" font="3"> </text>
<text top="329" left="275" width="114" height="19" font="4"><b>Size:</b>    16 patients </text>
<text top="274" left="479" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="292" left="479" width="163" height="19" font="3">All patients undergoing RF </text>
<text top="311" left="479" width="148" height="19" font="3">catheter ablation of the </text>
<text top="329" left="479" width="93" height="19" font="3">RBB for BBRVT </text>
<text top="347" left="479" width="3" height="19" font="3"> </text>
<text top="274" left="661" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="292" left="661" width="155" height="19" font="3">HV interval 68+8 msec at </text>
<text top="311" left="661" width="54" height="19" font="3">baseline </text>
<text top="329" left="661" width="122" height="19" font="3">LVEF mean 31+15% </text>
<text top="347" left="661" width="3" height="19" font="3"> </text>
<text top="366" left="661" width="158" height="19" font="3">RBBB developed in 15/16 </text>
<text top="384" left="661" width="167" height="19" font="3">patients after RBB ablation </text>
<text top="402" left="661" width="156" height="19" font="3">AV block occurred in 1 pt </text>
<text top="421" left="661" width="160" height="19" font="3"> After mean of 19+10 mo, </text>
<text top="439" left="661" width="166" height="19" font="3">one patient died suddenly, </text>
<text top="457" left="661" width="113" height="19" font="3">2 received cardiac </text>
<text top="476" left="661" width="169" height="19" font="3">transplantation, and 1 died </text>
<text top="494" left="661" width="51" height="19" font="3">of CHF.  </text>
<text top="512" left="661" width="3" height="19" font="3"> </text>
<text top="531" left="661" width="3" height="19" font="3"> </text>
<text top="549" left="661" width="3" height="19" font="3"> </text>
<text top="567" left="661" width="3" height="19" font="3"> </text>
<text top="274" left="849" width="202" height="19" font="3">● Catheter ablation of the RBB is </text>
<text top="292" left="849" width="183" height="19" font="3">effective for the treatment of </text>
<text top="311" left="849" width="47" height="19" font="3">BBRVT  </text>
<text top="329" left="849" width="167" height="19" font="3">● BBRVT is associated with </text>
<text top="347" left="849" width="219" height="19" font="3">prolonged HV conduction intervals. </text>
<text top="366" left="849" width="221" height="19" font="3">● The medium-term follow-up after </text>
<text top="384" left="849" width="188" height="19" font="3">catheter ablation of the RBB is </text>
<text top="402" left="849" width="118" height="19" font="3">overall quite good. </text>
<text top="586" left="125" width="68" height="19" font="3">● <b>HELP-VT </b></text>
<text top="605" left="125" width="120" height="19" font="3">● Dinov 2014 (175) </text>
<text top="623" left="125" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24211823">● </a></text>
<text top="623" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24211823">24211823</a></text>
<text top="623" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24211823"> </a></text>
<text top="641" left="125" width="3" height="19" font="3"> </text>
<text top="660" left="125" width="3" height="19" font="3"> </text>
<text top="586" left="275" width="39" height="19" font="4"><b>Aim:</b>   </text>
<text top="605" left="275" width="183" height="19" font="3">To determine the outcome of </text>
<text top="623" left="275" width="142" height="19" font="3">VT catheter ablation in </text>
<text top="641" left="275" width="175" height="19" font="3">patients with NICM to those </text>
<text top="660" left="275" width="193" height="19" font="3">with ischemic cardiomyopathy  </text>
<text top="678" left="275" width="85" height="19" font="4"><b>Study type:</b>    </text>
<text top="696" left="275" width="183" height="19" font="3">Prospective, non-randomized </text>
<text top="714" left="275" width="121" height="19" font="4"><b>Size:</b>  227 patients   </text>
<text top="586" left="479" width="118" height="19" font="4"><b>Inclusion criteria:</b>   </text>
<text top="605" left="479" width="166" height="19" font="3">Patients with SHD referred </text>
<text top="623" left="479" width="164" height="19" font="3">for catheter ablation of VT </text>
<text top="641" left="479" width="153" height="19" font="3">with either NICM (N=63) </text>
<text top="660" left="479" width="149" height="19" font="3">or ischemic CM (N=164) </text>
<text top="678" left="479" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="696" left="479" width="120" height="19" font="3">Failure of informed </text>
<text top="714" left="479" width="52" height="19" font="3">consent </text>
<text top="733" left="479" width="89" height="19" font="4"><b>Intervention:</b>  </text>
<text top="751" left="479" width="134" height="19" font="3"> Catheter ablation for </text>
<text top="769" left="479" width="121" height="19" font="3">patients with NICM </text>
<text top="587" left="661" width="162" height="19" font="4"><b>1</b>°<b> endpoint:</b>  At 1y follow-</text>
<text top="605" left="661" width="147" height="19" font="3">up, VT free survival was </text>
<text top="624" left="661" width="106" height="19" font="3">57% for ischemic </text>
<text top="642" left="661" width="170" height="19" font="3">cardiomyopathy and 40.5% </text>
<text top="660" left="661" width="175" height="19" font="3">for NICM patients (HR: 1.62; </text>
<text top="679" left="661" width="173" height="19" font="3">95% CI: 1.12–2.34, p=0.01).  </text>
<text top="697" left="661" width="159" height="19" font="3">ischemic cardiomyopathy </text>
<text top="715" left="661" width="172" height="19" font="3">required epicardial ablation </text>
<text top="734" left="661" width="139" height="19" font="3">in only 2 of 164 (1.2%) </text>
<text top="752" left="661" width="149" height="19" font="3">whereas NICM required </text>
<text top="586" left="849" width="104" height="19" font="3">● <b>Complications </b></text>
<text top="605" left="849" width="219" height="19" font="3">Complications occurred in 11.1% of </text>
<text top="623" left="849" width="177" height="19" font="3">NICM and 11.1% of ischemic </text>
<text top="641" left="849" width="219" height="19" font="3">cardiomyopathy patients, including </text>
<text top="660" left="849" width="215" height="19" font="3">death in 4.8% of NICM and 3.7% of </text>
<text top="678" left="849" width="162" height="19" font="3">ischemic cardiomyopathy  </text>
<text top="696" left="849" width="3" height="19" font="3"> </text>
<text top="714" left="849" width="3" height="19" font="3"> </text>
</page>
<page number="303" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">303 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="479" width="93" height="19" font="4"><b>Comparator:</b>  <b>  </b></text>
<text top="127" left="479" width="125" height="19" font="3">Catheter ablation in </text>
<text top="145" left="479" width="140" height="19" font="3">patients with ischemic </text>
<text top="164" left="479" width="103" height="19" font="3">cardiomyopathy </text>
<text top="109" left="661" width="172" height="19" font="3">epicardial ablation in 30.8% </text>
<text top="127" left="661" width="73" height="19" font="3">(p=0.0001). </text>
<text top="145" left="661" width="3" height="19" font="3"> </text>
<text top="164" left="661" width="3" height="19" font="3"> </text>
<text top="182" left="661" width="3" height="19" font="4"><b> </b></text>
<text top="201" left="125" width="104" height="19" font="3">● <b>Euro-VT Study </b></text>
<text top="219" left="125" width="102" height="19" font="3">● Tanner H 2010</text>
<text top="218" left="226" width="4" height="21" font="0"> </text>
<text top="238" left="125" width="35" height="19" font="3">(176) </text>
<text top="256" left="125" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9656251">● </a></text>
<text top="256" left="137" width="53" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9656251">9656251</a></text>
<text top="256" left="190" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9656251"> </a></text>
<text top="201" left="275" width="28" height="19" font="4"><b>Aim </b></text>
<text top="219" left="275" width="176" height="19" font="3">To determine the safety and </text>
<text top="238" left="275" width="169" height="19" font="3">efficacy of electroanatomic </text>
<text top="256" left="275" width="157" height="19" font="3">mapping and irrigated RF </text>
<text top="274" left="275" width="181" height="19" font="3">catheter ablation for VT after </text>
<text top="293" left="275" width="20" height="19" font="3">MI </text>
<text top="311" left="275" width="3" height="19" font="3"> </text>
<text top="329" left="275" width="76" height="19" font="4"><b>Study Type: </b></text>
<text top="347" left="275" width="184" height="19" font="3">Multicenter, non-randomized </text>
<text top="366" left="275" width="3" height="19" font="3"> </text>
<text top="384" left="275" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="402" left="275" width="72" height="19" font="3">63 patients </text>
<text top="421" left="275" width="3" height="19" font="4"><b> </b></text>
<text top="201" left="479" width="109" height="19" font="4"><b>Inclusion Criteria </b></text>
<text top="219" left="479" width="102" height="19" font="3">Drug and device </text>
<text top="238" left="479" width="129" height="19" font="3">refractory, recurrent </text>
<text top="256" left="479" width="138" height="19" font="3">sustained VT after MI. </text>
<text top="274" left="479" width="153" height="19" font="3">&gt;4 episodes of sustained </text>
<text top="292" left="479" width="105" height="19" font="3">VT in prior 6 mo. </text>
<text top="311" left="479" width="3" height="19" font="4"><b> </b></text>
<text top="329" left="479" width="111" height="19" font="4"><b>Exclusion Criteria </b></text>
<text top="347" left="479" width="63" height="19" font="3">Age &lt;18 y </text>
<text top="366" left="479" width="96" height="19" font="3">MI within 2 mo </text>
<text top="384" left="479" width="83" height="19" font="3">LV Thrombus </text>
<text top="402" left="479" width="103" height="19" font="3">Unstable Angina </text>
<text top="421" left="479" width="105" height="19" font="3">Severe AS or MR </text>
<text top="439" left="479" width="104" height="19" font="3">Unwillingness to </text>
<text top="457" left="479" width="69" height="19" font="3">participate </text>
<text top="476" left="479" width="81" height="19" font="4"><b>Intervention </b></text>
<text top="494" left="479" width="160" height="19" font="3">Electroanatomic mapping </text>
<text top="512" left="479" width="166" height="19" font="3">and ablation with open-tip </text>
<text top="531" left="479" width="114" height="19" font="3">irrigated catheter. </text>
<text top="201" left="661" width="76" height="19" font="4"><b>1° Endpoint </b></text>
<text top="219" left="661" width="172" height="19" font="3">Acute success with ablation </text>
<text top="238" left="661" width="145" height="19" font="3">was achieved in 83% of </text>
<text top="256" left="661" width="161" height="19" font="3">mappable VTs and 40% of </text>
<text top="274" left="661" width="117" height="19" font="3">non-mappable VTs </text>
<text top="293" left="661" width="73" height="19" font="3">(p&lt;0.0001). </text>
<text top="311" left="661" width="3" height="19" font="3"> </text>
<text top="329" left="661" width="171" height="19" font="3">During 12 mo follow-up, VT </text>
<text top="347" left="661" width="173" height="19" font="3">recurred in 49% of patients. </text>
<text top="366" left="661" width="3" height="19" font="3"> </text>
<text top="384" left="661" width="131" height="19" font="3">The mean number of </text>
<text top="402" left="661" width="149" height="19" font="3">therapies dropped from </text>
<text top="421" left="661" width="160" height="19" font="3">60±70 prior to ablation to </text>
<text top="439" left="661" width="175" height="19" font="3">14±15 in the same period of </text>
<text top="457" left="661" width="161" height="19" font="3">time (6 mo) after ablation </text>
<text top="476" left="661" width="58" height="19" font="3">(p=0.02). </text>
<text top="494" left="661" width="3" height="19" font="3"> </text>
<text top="512" left="661" width="3" height="19" font="3"> </text>
<text top="201" left="849" width="104" height="19" font="3">● <b>Complications </b></text>
<text top="219" left="849" width="201" height="19" font="3">Major complications occurred in </text>
<text top="238" left="849" width="224" height="19" font="3">1.5% and minor complications in 5% </text>
<text top="256" left="849" width="180" height="19" font="3">of patients, particularly groin </text>
<text top="274" left="849" width="199" height="19" font="3">hematomas, with no procedural </text>
<text top="293" left="849" width="49" height="19" font="3">deaths. </text>
<text top="550" left="125" width="102" height="19" font="3">● <b>Post-approval </b></text>
<text top="568" left="125" width="109" height="19" font="4"><b>Thermocool Trial </b></text>
<text top="586" left="125" width="130" height="19" font="3">● Marchlinski F 2016 </text>
<text top="605" left="125" width="35" height="19" font="3">(177) </text>
<text top="623" left="125" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26868693">● </a></text>
<text top="623" left="137" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26868693">26868693</a></text>
<text top="623" left="198" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26868693"> </a></text>
<text top="641" left="125" width="3" height="19" font="3"> </text>
<text top="550" left="275" width="28" height="19" font="4"><b>Aim </b></text>
<text top="568" left="275" width="179" height="19" font="3">To evaluate long-term safety </text>
<text top="586" left="275" width="144" height="19" font="3">and effectiveness of RF </text>
<text top="605" left="275" width="163" height="19" font="3">catheter ablation for VT in </text>
<text top="623" left="275" width="190" height="19" font="3">patients with coronary disease </text>
<text top="641" left="275" width="3" height="19" font="3"> </text>
<text top="659" left="275" width="76" height="19" font="4"><b>Study Type: </b></text>
<text top="678" left="275" width="184" height="19" font="3">Multicenter, non-randomized </text>
<text top="696" left="275" width="3" height="19" font="3"> </text>
<text top="714" left="275" width="150" height="19" font="4"><b>Study Size:</b> 249 patients<b> </b></text>
<text top="733" left="275" width="3" height="19" font="3"> </text>
<text top="550" left="479" width="109" height="19" font="4"><b>Inclusion Criteria </b></text>
<text top="568" left="479" width="135" height="19" font="3">Patient with coronary </text>
<text top="586" left="479" width="158" height="19" font="3">disease, age ≥18 y and LV </text>
<text top="605" left="479" width="165" height="19" font="3">EF ≥10% with recurrent VT </text>
<text top="623" left="479" width="114" height="19" font="3">(either ≥4 episode </text>
<text top="641" left="479" width="146" height="19" font="3">documented by ICD, ≥2 </text>
<text top="660" left="479" width="150" height="19" font="3">episode documented by </text>
<text top="678" left="479" width="147" height="19" font="3">ECG in patients without </text>
<text top="696" left="479" width="124" height="19" font="3">ICD, incessant VT or </text>
<text top="714" left="479" width="150" height="19" font="3">symptomatic VT despite </text>
<text top="733" left="479" width="96" height="19" font="3">AAD treatment </text>
<text top="751" left="479" width="3" height="19" font="3"> </text>
<text top="769" left="479" width="111" height="19" font="4"><b>Exclusion Criteria </b></text>
<text top="550" left="661" width="76" height="19" font="4"><b>1° Endpoint </b></text>
<text top="568" left="661" width="155" height="19" font="3">At 6 mo: 62% without VT </text>
<text top="586" left="661" width="159" height="19" font="3">recurrence, proportion of </text>
<text top="605" left="661" width="146" height="19" font="3">patients with ICD shock </text>
<text top="623" left="661" width="166" height="19" font="3">reduced from 81.2 (pre) to </text>
<text top="641" left="661" width="170" height="19" font="3">26.8% and ≥ 50% reduction </text>
<text top="660" left="661" width="162" height="19" font="3">in VT episodes in 63.8% of </text>
<text top="678" left="661" width="60" height="19" font="3">patients.  </text>
<text top="696" left="661" width="3" height="19" font="3"> </text>
<text top="714" left="661" width="102" height="19" font="4"><b>Safety Endpoint </b></text>
<text top="733" left="661" width="166" height="19" font="3">CV specific AE in 3.9% with </text>
<text top="751" left="661" width="61" height="19" font="3">no stroke </text>
<text top="769" left="661" width="3" height="19" font="3"> </text>
<text top="550" left="849" width="71" height="19" font="4"><b>Comments </b></text>
<text top="568" left="849" width="223" height="19" font="3">Reduction in amiodarone usage and </text>
<text top="586" left="849" width="93" height="19" font="3">hospitalization </text>
<text top="605" left="849" width="3" height="19" font="3"> </text>
<text top="623" left="849" width="129" height="19" font="3">Improvement in QoL </text>
</page>
<page number="304" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">304 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="479" width="151" height="19" font="3">Mobile LV thrombus, MI </text>
<text top="127" left="479" width="167" height="19" font="3">within 3 mo, idiopathic VT, </text>
<text top="145" left="479" width="136" height="19" font="3">class IV HF, creatinine </text>
<text top="164" left="479" width="123" height="19" font="3">≥2.5, recent cardiac </text>
<text top="182" left="479" width="156" height="19" font="3">surgery, unstable angina, </text>
<text top="200" left="479" width="103" height="19" font="3">severe AS or MR<b> </b></text>
<text top="218" left="479" width="81" height="19" font="4"><b>Intervention </b></text>
<text top="237" left="479" width="160" height="19" font="3">Electroanatomic mapping </text>
<text top="255" left="479" width="166" height="19" font="3">and ablation with open-tip </text>
<text top="273" left="479" width="114" height="19" font="3">irrigated catheter. </text>
<text top="292" left="115" width="4" height="21" font="0"> </text>
<text top="312" left="115" width="4" height="21" font="0"> </text>
<text top="368" left="115" width="954" height="21" font="2"><b>Data Supplement 58.  Nonrandomized Trials, Observational Studies, and/or Registries Related to Post-Mortem Evaluation of SCD - (Section </b></text>
<text top="389" left="115" width="29" height="21" font="2"><b>13)  </b></text>
<text top="410" left="127" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="428" left="153" width="51" height="19" font="4"><b>Author; </b></text>
<text top="446" left="131" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="410" left="282" width="39" height="19" font="4"><b>Study </b></text>
<text top="428" left="258" width="86" height="19" font="4"><b>Type/Design; </b></text>
<text top="446" left="268" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="428" left="393" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="410" left="624" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="428" left="636" width="126" height="19" font="4"><b>(P values; OR or RR; </b></text>
<text top="446" left="668" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="419" left="900" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="437" left="929" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="465" left="123" width="104" height="19" font="3">● de Noronha et </text>
<text top="484" left="123" width="87" height="19" font="3">al. 2014 (586) </text>
<text top="502" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24148315">● </a></text>
<text top="502" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24148315">24148315</a></text>
<text top="502" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24148315"> </a></text>
<text top="520" left="177" width="3" height="19" font="4"><b> </b></text>
<text top="465" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="484" left="247" width="76" height="19" font="3">consecutive </text>
<text top="502" left="247" width="75" height="19" font="3">prospective </text>
<text top="521" left="247" width="86" height="19" font="3">observational </text>
<text top="539" left="247" width="37" height="19" font="3">study </text>
<text top="557" left="247" width="3" height="19" font="3"> </text>
<text top="575" left="247" width="68" height="19" font="4"><b>Size:</b>    720<b> </b></text>
<text top="465" left="368" width="142" height="19" font="4"><b>Inclusion criteria:</b>  SCD </text>
<text top="484" left="368" width="157" height="19" font="3">cases referred by general </text>
<text top="502" left="368" width="158" height="19" font="3">pathologist to specialized </text>
<text top="521" left="368" width="158" height="19" font="3">cardiac pathology center; </text>
<text top="539" left="368" width="159" height="19" font="3">SCD defined as witnessed </text>
<text top="557" left="368" width="166" height="19" font="3">SCA or unwitnessed SCD in </text>
<text top="575" left="368" width="167" height="19" font="3">an individual alive and well </text>
<text top="594" left="368" width="137" height="19" font="3">up to 24 hs prior; non-</text>
<text top="612" left="368" width="158" height="19" font="3">cardiac causes ecluded at </text>
<text top="630" left="368" width="89" height="19" font="3">initial autopsy </text>
<text top="649" left="368" width="3" height="19" font="3"> </text>
<text top="667" left="368" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="685" left="368" width="121" height="19" font="3">Non-sudden death; </text>
<text top="704" left="368" width="127" height="19" font="3">sudden-death in the </text>
<text top="722" left="368" width="164" height="19" font="3">context of worsening CHF; </text>
<text top="740" left="368" width="152" height="19" font="3">absence of age, sex, and </text>
<text top="759" left="368" width="145" height="19" font="3">circumstances of death<b> </b></text>
<text top="466" left="550" width="261" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Determine cause of SCD and </text>
<text top="485" left="550" width="289" height="19" font="3">compare initial diagnosis with that determined </text>
<text top="503" left="550" width="142" height="19" font="3">at specialized center.    </text>
<text top="521" left="550" width="291" height="19" font="4"><b>Results:</b>   Data were skewed by age (median 32 </text>
<text top="540" left="550" width="299" height="19" font="3">y, range 1-98 y, 58% &lt;35 y. Approximately 1/3 of </text>
<text top="558" left="550" width="274" height="19" font="3">the cases had a &#34;cardiomyopathy&#34;, including </text>
<text top="576" left="550" width="268" height="19" font="3">idiopathic LVH (26%), HCM (20%) and ARVC </text>
<text top="595" left="550" width="262" height="19" font="3">(14%), and a category of obesity CM (14%) </text>
<text top="613" left="550" width="276" height="19" font="3">Coronary artery abnormalities accounted for </text>
<text top="631" left="550" width="257" height="19" font="3">10%, with 79% of those being ASHD.   In a </text>
<text top="649" left="550" width="259" height="19" font="3">comparison of diagnoses of 200 autopsies </text>
<text top="668" left="550" width="261" height="19" font="3">examined after referral, a disparity in final </text>
<text top="686" left="550" width="286" height="19" font="3">diagnosis was observed in 41% of the cases.  A </text>
<text top="704" left="550" width="299" height="19" font="3">misdiagnosis of cardiomyopathy was reported in </text>
<text top="723" left="550" width="280" height="19" font="3">37% referred cases, ultimately determined to </text>
<text top="741" left="550" width="191" height="19" font="3">have to be structurally normal. </text>
<text top="759" left="698" width="3" height="19" font="4"><b> </b></text>
<text top="465" left="862" width="155" height="19" font="3">● The specialized cardiac </text>
<text top="484" left="862" width="202" height="19" font="3">pathology exam appears to have </text>
<text top="502" left="862" width="184" height="19" font="3">value for determining specific </text>
<text top="521" left="862" width="201" height="19" font="3">causes of SCD in this population. </text>
<text top="539" left="862" width="197" height="19" font="3">● Referring pathologists tended </text>
<text top="557" left="862" width="177" height="19" font="3">to have a more difficult time </text>
<text top="575" left="862" width="197" height="19" font="3">identifying anatomically normal </text>
<text top="594" left="862" width="168" height="19" font="3">hearts, and over-diagnoses </text>
<text top="612" left="862" width="117" height="19" font="3">cardiomyopathies. </text>
<text top="630" left="862" width="183" height="19" font="3">● The etiological data are not </text>
<text top="649" left="862" width="169" height="19" font="3">generalizable to the overall </text>
<text top="667" left="862" width="208" height="19" font="3">population because of skewing of </text>
<text top="685" left="862" width="206" height="19" font="3">age at time of SCD for specialized </text>
<text top="704" left="862" width="118" height="19" font="3">cardiac evaluation. </text>
<text top="722" left="967" width="3" height="19" font="4"><b> </b></text>
</page>
<page number="305" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">305 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="104" height="19" font="3">● Wu et al. 2016 </text>
<text top="127" left="123" width="35" height="19" font="3">(587) </text>
<text top="145" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26844513">● </a></text>
<text top="145" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26844513">26844513</a></text>
<text top="145" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26844513"> </a></text>
<text top="164" left="123" width="3" height="19" font="3"> </text>
<text top="109" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="127" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="145" left="247" width="86" height="19" font="3">observational </text>
<text top="164" left="247" width="96" height="19" font="3">cohort study of </text>
<text top="182" left="247" width="87" height="19" font="3">anatomic and </text>
<text top="200" left="247" width="108" height="19" font="3">histopathological </text>
<text top="219" left="247" width="93" height="19" font="3">findings in SCD </text>
<text top="237" left="247" width="104" height="19" font="3">victims between </text>
<text top="255" left="247" width="94" height="19" font="3">1998 and 2013 </text>
<text top="273" left="247" width="3" height="19" font="3"> </text>
<text top="292" left="247" width="93" height="19" font="4"><b>Size:</b> 1656 SCD </text>
<text top="310" left="247" width="106" height="19" font="3">identified from a </text>
<text top="328" left="247" width="82" height="19" font="3">total of 3770 </text>
<text top="347" left="247" width="93" height="19" font="3">sudden deaths </text>
<text top="365" left="247" width="100" height="19" font="3">(43.9%) from all </text>
<text top="383" left="247" width="87" height="19" font="3">causes during </text>
<text top="402" left="247" width="114" height="19" font="3">the study period   <b> </b></text>
<text top="109" left="368" width="164" height="19" font="4"><b>Inclusion criteria:</b>   Deaths </text>
<text top="127" left="368" width="168" height="19" font="3">that occur within 1 h of the </text>
<text top="145" left="368" width="90" height="19" font="3">sudden loss of </text>
<text top="164" left="368" width="133" height="19" font="3">consciousness due to </text>
<text top="182" left="368" width="140" height="19" font="3">various CVD, or during </text>
<text top="200" left="368" width="151" height="19" font="3">sleep or unwitnessed, in </text>
<text top="219" left="368" width="169" height="19" font="3">which the affected persons </text>
<text top="237" left="368" width="154" height="19" font="3">were considered healthy </text>
<text top="255" left="368" width="145" height="19" font="3">24 h before the event.   </text>
<text top="273" left="368" width="3" height="19" font="4"><b> </b></text>
<text top="292" left="368" width="166" height="19" font="4"><b>Exclusion criteria:</b>   Deaths </text>
<text top="310" left="368" width="118" height="19" font="3">due to non-cardiac </text>
<text top="328" left="368" width="118" height="19" font="3">conditions, such as </text>
<text top="347" left="368" width="124" height="19" font="3">injuries, poisonings, </text>
<text top="365" left="368" width="164" height="19" font="3">epilepsy, acute pulmonary </text>
<text top="383" left="368" width="157" height="19" font="3">embolisms, and allergies. </text>
<text top="109" left="550" width="258" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Causes of SCD, sub-grouped </text>
<text top="128" left="550" width="293" height="19" font="3">according to circumstances, sex and age groups </text>
<text top="146" left="550" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="165" left="550" width="290" height="19" font="3">The peak incidence occurred between the ages </text>
<text top="183" left="550" width="234" height="19" font="3">of 31 and 60, with a 5-7-fold excess of </text>
<text top="201" left="550" width="239" height="19" font="3">males/females in that age range.  Both </text>
<text top="219" left="550" width="278" height="19" font="3">incidence and male preponderance markedly </text>
<text top="238" left="550" width="270" height="19" font="3">decreased in younger and older age groups. </text>
<text top="256" left="550" width="249" height="19" font="3">Overall, 42% were due to CAD, 12% viral </text>
<text top="274" left="550" width="293" height="19" font="3">myocarditis, and 5% cardiomyopathy, with 15% </text>
<text top="293" left="550" width="272" height="19" font="3">being unexplained by autopsy.  In age group </text>
<text top="311" left="550" width="275" height="19" font="3">&lt;35, CAD was 17% of cases, viral myocarditis </text>
<text top="329" left="550" width="272" height="19" font="3">27%, and unexplained 32%. At age &gt;55, CAD </text>
<text top="348" left="550" width="289" height="19" font="3">accounted for 86%, viral &lt;2%, and unexplained </text>
<text top="366" left="550" width="40" height="19" font="3">&lt;1%.  <b> </b></text>
<text top="109" left="862" width="186" height="19" font="3">● The proportion of SCDs that </text>
<text top="127" left="862" width="169" height="19" font="3">were autopsy negative was </text>
<text top="145" left="862" width="196" height="19" font="3">strongly age-dependent, as was </text>
<text top="164" left="862" width="191" height="19" font="3">the common autopsy-provable </text>
<text top="182" left="862" width="48" height="19" font="3">causes. </text>
<text top="200" left="862" width="157" height="19" font="3">● The proportion of SCDs </text>
<text top="219" left="862" width="128" height="19" font="3">attributed to dilated </text>
<text top="237" left="862" width="203" height="19" font="3">cardiomyopathy was surprisingly </text>
<text top="255" left="862" width="195" height="19" font="3">low, especially in the age group </text>
<text top="273" left="862" width="99" height="19" font="3">older than 35 y. </text>
<text top="421" left="123" width="102" height="19" font="3">● Vassalini et al. </text>
<text top="439" left="123" width="69" height="19" font="3">2016 (588) </text>
<text top="457" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25575272">● </a></text>
<text top="457" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25575272">25575272</a></text>
<text top="457" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25575272"> </a></text>
<text top="421" left="247" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="439" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="457" left="247" width="96" height="19" font="3">cohort autopsy </text>
<text top="476" left="247" width="37" height="19" font="3">study </text>
<text top="494" left="247" width="3" height="19" font="3"> </text>
<text top="512" left="247" width="61" height="19" font="4"><b>Size:</b>   54 <b> </b></text>
<text top="421" left="368" width="157" height="19" font="4"><b>Inclusion criteria:</b>  SCD in </text>
<text top="439" left="368" width="131" height="19" font="3">subjects aged 1-40 y. </text>
<text top="457" left="368" width="3" height="19" font="3"> </text>
<text top="476" left="368" width="150" height="19" font="4"><b>Exclusion criteria:</b>  Prior </text>
<text top="494" left="368" width="124" height="19" font="3">Hx of heart disease; </text>
<text top="512" left="368" width="126" height="19" font="3">sudden infant death </text>
<text top="531" left="368" width="152" height="19" font="3">syndromes (under 1 y of </text>
<text top="549" left="368" width="156" height="19" font="3">age), extracardiac causes </text>
<text top="567" left="368" width="167" height="19" font="3">at autopsy; drug or alcohol </text>
<text top="586" left="368" width="95" height="19" font="3">abuse found at </text>
<text top="604" left="368" width="149" height="19" font="3">postmortem toxicology.<b> </b></text>
<text top="421" left="550" width="292" height="19" font="4"><b>1</b>°<b> endpoint:</b>   Clinical and postmortem findings </text>
<text top="440" left="550" width="285" height="19" font="3">of patients who died suddenly without a Hx of </text>
<text top="458" left="550" width="122" height="19" font="3">prior heart disease. </text>
<text top="476" left="550" width="261" height="19" font="4"><b>Results:</b>   Coronary artery abnormalities in </text>
<text top="495" left="550" width="250" height="19" font="3">18.5% (including one with an anomalous </text>
<text top="513" left="550" width="284" height="19" font="3">coronary artery origin); ARVD/C in 11.1%; LVH </text>
<text top="513" left="834" width="15" height="19" font="29">in </text>
<text top="531" left="550" width="244" height="19" font="29">5 cases (9.2%), 3 of whom had myocyte </text>
<text top="550" left="550" width="265" height="19" font="29">disarray; VHD in 7.4%; myocarditis in 7.4%; </text>
<text top="568" left="550" width="239" height="19" font="3">pathological changes in the specialized </text>
<text top="586" left="550" width="284" height="19" font="3">conducting system in 22.2%, in the absence of </text>
<text top="605" left="550" width="247" height="19" font="3">any other anatomic or histopathological </text>
<text top="623" left="550" width="52" height="19" font="3">findings;</text>
<text top="623" left="602" width="206" height="19" font="29"> in 12 cases (22.2%), autopsy was </text>
<text top="641" left="550" width="287" height="19" font="29">completely negative in 22.2%. No postmortem </text>
<text top="660" left="550" width="165" height="19" font="29">genetics done in this group</text>
<text top="659" left="715" width="3" height="19" font="4"><b> </b></text>
<text top="421" left="862" width="197" height="19" font="3">● Although this is a small study, </text>
<text top="439" left="862" width="178" height="19" font="3">the exclusion of a prior Hx of </text>
<text top="457" left="862" width="200" height="19" font="3">heart disease restricts this study </text>
<text top="476" left="862" width="185" height="19" font="3">to SCD that occurred as a first </text>
<text top="494" left="862" width="89" height="19" font="3">cardiac event. </text>
<text top="512" left="862" width="188" height="19" font="3">● One important finding is the </text>
<text top="531" left="862" width="199" height="19" font="3">association of SCD with the only </text>
<text top="549" left="862" width="182" height="19" font="3">abnormalities at postmortem </text>
<text top="567" left="862" width="148" height="19" font="3">found in the specialized </text>
<text top="586" left="862" width="180" height="19" font="3">conducting system in 22.2%   </text>
<text top="604" left="862" width="197" height="19" font="3">● A second is the autopsy being </text>
<text top="622" left="862" width="194" height="19" font="3">completely negative in another </text>
<text top="640" left="862" width="202" height="19" font="3">22.2%.  No postmortem genetics </text>
<text top="659" left="862" width="170" height="19" font="3">were done in this subgroup </text>
<text top="683" left="123" width="88" height="19" font="3">● Tester et al. </text>
<text top="701" left="123" width="69" height="19" font="3">2012 (589) </text>
<text top="719" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22677073">● </a></text>
<text top="719" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22677073">22677073</a></text>
<text top="719" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22677073"> </a></text>
<text top="738" left="123" width="3" height="19" font="3"> </text>
<text top="682" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="701" left="247" width="74" height="19" font="3">Prospective </text>
<text top="719" left="247" width="81" height="19" font="3">cohort study </text>
<text top="738" left="247" width="3" height="19" font="3"> </text>
<text top="756" left="247" width="68" height="19" font="4"><b>Size:</b>    173<b> </b></text>
<text top="682" left="368" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="701" left="368" width="145" height="19" font="3">Autopsy-negative SUDs </text>
<text top="719" left="368" width="139" height="19" font="3">referred for molecular </text>
<text top="738" left="368" width="163" height="19" font="3">autopsy.  Candidate genes </text>
<text top="756" left="368" width="129" height="19" font="3">restricted to KCNQ1, </text>
<text top="774" left="368" width="145" height="19" font="3">KCNH2, SCN5A, KCNE1, </text>
<text top="683" left="550" width="286" height="19" font="4"><b>1</b>°<b> endpoint:</b>   Identification of SUD-associated </text>
<text top="702" left="550" width="262" height="19" font="3">variants in KCNQ1, KCNH2, SCN5A, KCNE1, </text>
<text top="720" left="550" width="109" height="19" font="3">KCNE2, or RYR2.   </text>
<text top="738" left="550" width="3" height="19" font="3"> </text>
<text top="757" left="550" width="292" height="19" font="4"><b>Results:</b>   Pathogenic mutations were identified </text>
<text top="775" left="550" width="291" height="19" font="3">in 45 autopsy-negative SUD cases (26.0%).  LQT </text>
<text top="683" left="862" width="196" height="19" font="3">● Molecular autopsy provides a </text>
<text top="701" left="862" width="203" height="19" font="3">reasonable yield of putative SUD-</text>
<text top="719" left="862" width="196" height="19" font="3">associated variants, recognizing </text>
<text top="738" left="862" width="189" height="19" font="3">that the candidate genes were </text>
<text top="756" left="862" width="195" height="19" font="3">restricted to the common LQTS-</text>
</page>
<page number="306" position="absolute" top="0" left="0" height="918" width="1543">
	<fontspec id="33" size="12" family="Times" color="#000000"/>
<text top="803" left="585" width="29" height="21" font="0">306 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="368" width="146" height="19" font="3">KCNE2, and RYR2.  SUD-</text>
<text top="127" left="368" width="162" height="19" font="3">associated variants had to </text>
<text top="145" left="368" width="126" height="19" font="3">be nonsynonymous, </text>
<text top="164" left="368" width="164" height="19" font="3">involve a highly conserved </text>
<text top="182" left="368" width="156" height="19" font="3">residue, and absent from </text>
<text top="200" left="368" width="109" height="19" font="3">reference normal </text>
<text top="219" left="368" width="76" height="19" font="3">populations </text>
<text top="237" left="368" width="3" height="19" font="4"><b> </b></text>
<text top="255" left="368" width="159" height="19" font="4"><b>Exclusion criteria: </b>A prior </text>
<text top="273" left="368" width="127" height="19" font="3">documented Hx of a </text>
<text top="292" left="368" width="149" height="19" font="3">channelopathy in either </text>
<text top="310" left="368" width="118" height="19" font="3">probands or family </text>
<text top="329" left="368" width="133" height="19" font="3">members (Exception: </text>
<text top="347" left="368" width="151" height="19" font="3">History of long QT on an </text>
<text top="365" left="368" width="113" height="19" font="3">ECG mentioned in </text>
<text top="383" left="368" width="56" height="19" font="3">autopsy)<b> </b></text>
<text top="109" left="550" width="285" height="19" font="3">variants more likely to be associated with SUD </text>
<text top="127" left="550" width="289" height="19" font="3">during sleep; CPVT (RyR2) more like associated </text>
<text top="145" left="550" width="268" height="19" font="3">with SUD during exercise.  Family Hx of SCD </text>
<text top="164" left="550" width="268" height="19" font="3">positive among relatives of 11 of 45 variant-</text>
<text top="182" left="550" width="116" height="19" font="3">positive probands. </text>
<text top="200" left="550" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="862" width="191" height="19" font="3">associated genes and the most </text>
<text top="127" left="862" width="202" height="19" font="3">common CPVT-associated gene.  </text>
<text top="145" left="862" width="200" height="19" font="3">● It is likely that broader panels, </text>
<text top="164" left="862" width="207" height="19" font="3">including other genetic disorders, </text>
<text top="182" left="862" width="210" height="19" font="3">including structural disorders that </text>
<text top="200" left="862" width="202" height="19" font="3">may not be identified on routine </text>
<text top="219" left="862" width="177" height="19" font="3">autopsy, would increase this </text>
<text top="237" left="862" width="36" height="19" font="3">yield. </text>
<text top="402" left="123" width="79" height="19" font="3">● Tang et al. </text>
<text top="421" left="123" width="69" height="19" font="3">2014 (590) </text>
<text top="439" left="123" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24157219">24157219</a></text>
<text top="439" left="184" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24157219"> </a></text>
<text top="475" left="123" width="7" height="19" font="33"><i><b>  </b></i></text>
<text top="498" left="123" width="3" height="19" font="3"> </text>
<text top="402" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="421" left="247" width="108" height="19" font="3">Review article on </text>
<text top="439" left="247" width="64" height="19" font="3">molecular </text>
<text top="457" left="247" width="65" height="19" font="3">diagnostic </text>
<text top="476" left="247" width="104" height="19" font="3">protocol for SCD </text>
<text top="494" left="247" width="70" height="19" font="4"><b>Size:</b>    N/A<b> </b></text>
<text top="402" left="368" width="146" height="19" font="4"><b>Inclusion criteria:</b>   N/A </text>
<text top="421" left="368" width="3" height="19" font="3"> </text>
<text top="439" left="368" width="148" height="19" font="4"><b>Exclusion criteria:</b>   N/A<b> </b></text>
<text top="403" left="550" width="116" height="19" font="4"><b>1</b>°<b> endpoint:</b>   N/A </text>
<text top="422" left="550" width="3" height="19" font="3"> </text>
<text top="440" left="550" width="87" height="19" font="4"><b>Results:</b>   N/A </text>
<text top="458" left="550" width="3" height="19" font="4"><b> </b></text>
<text top="402" left="862" width="175" height="19" font="3">● Comprehensive review on </text>
<text top="421" left="862" width="207" height="19" font="3">postmortem molecular studies of </text>
<text top="439" left="862" width="158" height="19" font="3">SUD and autopsy-defined </text>
<text top="457" left="862" width="174" height="19" font="3">structural genetic disorders  </text>
<text top="476" left="862" width="3" height="19" font="3"> </text>
<text top="517" left="123" width="111" height="19" font="3">● Papadakis et al. </text>
<text top="535" left="123" width="69" height="19" font="3">2013 (591) </text>
<text top="554" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23671135">● </a></text>
<text top="554" left="136" width="61" height="19" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23671135">23671135</a></text>
<text top="554" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23671135"> </a></text>
<text top="572" left="123" width="3" height="19" font="3"> </text>
<text top="517" left="247" width="81" height="19" font="4"><b>Study type:</b>   </text>
<text top="535" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="554" left="247" width="84" height="19" font="3">cohort study, </text>
<text top="572" left="247" width="105" height="19" font="3">with prospective </text>
<text top="590" left="247" width="86" height="19" font="3">cardiogenetic </text>
<text top="609" left="247" width="83" height="19" font="3">evaluation of </text>
<text top="627" left="247" width="113" height="19" font="3">family members.   </text>
<text top="645" left="247" width="3" height="19" font="3"> </text>
<text top="664" left="247" width="68" height="19" font="4"><b>Size:</b>    340 </text>
<text top="682" left="247" width="51" height="19" font="3">families<b> </b></text>
<text top="517" left="368" width="158" height="19" font="4"><b>Inclusion criteria:</b>  Family </text>
<text top="535" left="368" width="166" height="19" font="3">members of SCD probands </text>
<text top="554" left="368" width="145" height="19" font="3">who died suddenly and </text>
<text top="572" left="368" width="130" height="19" font="3">had been apparently </text>
<text top="590" left="368" width="125" height="19" font="3">healthy, death from </text>
<text top="609" left="368" width="152" height="19" font="3">natural causes, last seen </text>
<text top="627" left="368" width="162" height="19" font="3">alive and well within 12 h, </text>
<text top="645" left="368" width="134" height="19" font="3">with autopsy findings </text>
<text top="664" left="368" width="116" height="19" font="3">showing structural </text>
<text top="682" left="368" width="165" height="19" font="3">abnormalities of uncertain </text>
<text top="700" left="368" width="114" height="19" font="3">causal effect (e.g., </text>
<text top="719" left="368" width="152" height="19" font="3">ventricular hypertrophy, </text>
<text top="737" left="368" width="139" height="19" font="3">myocardial fibrosis, or </text>
<text top="755" left="368" width="118" height="19" font="3">minor CAD (N=41). </text>
<text top="774" left="368" width="3" height="19" font="3"> </text>
<text top="518" left="550" width="285" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Identification of genetic variants </text>
<text top="536" left="550" width="293" height="19" font="3">associated with inherited arrhythmia syndrome </text>
<text top="555" left="550" width="293" height="19" font="3">in &gt;1 relative(s) of probands who had structural </text>
<text top="573" left="550" width="255" height="19" font="3">findings of uncertain significance (such as </text>
<text top="591" left="550" width="274" height="19" font="3">ventricular hypertrophy, myocardial fibrosis, </text>
<text top="610" left="550" width="274" height="19" font="3">and minor CAD).  Comparison group was the </text>
<text top="628" left="550" width="268" height="19" font="3">cohort of 163 families in whom the findings </text>
<text top="646" left="550" width="266" height="19" font="3">were consistent with SUD based on normal </text>
<text top="665" left="550" width="59" height="19" font="3">autopsy.  </text>
<text top="683" left="550" width="59" height="19" font="4"><b>Results:</b>   </text>
<text top="701" left="550" width="271" height="19" font="3">51% of the study group had genetic variants </text>
<text top="719" left="550" width="257" height="19" font="3">associated with SADS; for the comparison </text>
<text top="738" left="550" width="272" height="19" font="3">group, consistent with SADS, the proportion </text>
<text top="756" left="550" width="252" height="19" font="3">with positive genetic findings was 47%.   <b> </b></text>
<text top="517" left="862" width="197" height="19" font="3">● Victims of SCD with structural </text>
<text top="535" left="862" width="203" height="19" font="3">findings of uncertain significance </text>
<text top="554" left="862" width="172" height="19" font="3">are as likely to have genetic </text>
<text top="572" left="862" width="209" height="19" font="3">variants associated with inherited </text>
<text top="590" left="862" width="181" height="19" font="3">arrhythmia syndromes as are </text>
<text top="609" left="862" width="184" height="19" font="3">those with normal autopsies.  </text>
<text top="627" left="862" width="175" height="19" font="3">● Findings call for caution in </text>
<text top="645" left="862" width="201" height="19" font="3">interpreting uncertain structural </text>
<text top="664" left="862" width="208" height="19" font="3">findings, with particular regard to </text>
<text top="682" left="862" width="200" height="19" font="3">implications for family members </text>
<text top="700" left="862" width="88" height="19" font="3">of probands.   </text>
<text top="719" left="862" width="3" height="19" font="3"> </text>
</page>
<page number="307" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">307 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="368" width="120" height="19" font="4"><b>Exclusion criteria:</b>   </text>
<text top="127" left="368" width="152" height="19" font="3">Incomplete postmortem </text>
<text top="145" left="368" width="139" height="19" font="3">report, presence of an </text>
<text top="164" left="368" width="132" height="19" font="3">extracardiac cause of </text>
<text top="182" left="368" width="110" height="19" font="3">death, or positive </text>
<text top="200" left="368" width="113" height="19" font="3">toxicology screen.<b> </b></text>
<text top="219" left="123" width="99" height="19" font="3">● Harmon et al. </text>
<text top="238" left="123" width="69" height="19" font="3">2014 (592) </text>
<text top="256" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24585715">● </a></text>
<text top="256" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24585715">24585715</a></text>
<text top="256" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24585715"> </a></text>
<text top="274" left="123" width="3" height="19" font="3"> </text>
<text top="274" left="177" width="3" height="19" font="3"> </text>
<text top="292" left="123" width="14" height="19" font="3">    </text>
<text top="292" left="177" width="3" height="19" font="3"> </text>
<text top="219" left="247" width="78" height="19" font="4"><b>Study type</b>:  </text>
<text top="238" left="247" width="82" height="19" font="3">Cohort study </text>
<text top="256" left="247" width="72" height="19" font="3">from NCAA </text>
<text top="274" left="247" width="65" height="19" font="3">registry of </text>
<text top="293" left="247" width="83" height="19" font="3">athletes who </text>
<text top="311" left="247" width="89" height="19" font="3">died suddenly </text>
<text top="329" left="247" width="3" height="19" font="3"> </text>
<text top="347" left="247" width="32" height="19" font="4"><b>Size: </b></text>
<text top="366" left="247" width="22" height="19" font="3">45 <b> </b></text>
<text top="219" left="368" width="168" height="19" font="4"><b>Inclusion criteria:</b>  36 of 45 </text>
<text top="238" left="368" width="111" height="19" font="3">athlete SCDs with </text>
<text top="256" left="368" width="112" height="19" font="3">sufficient autopsy </text>
<text top="274" left="368" width="76" height="19" font="3">information<b> </b></text>
<text top="292" left="368" width="3" height="19" font="4"><b> </b></text>
<text top="311" left="368" width="3" height="19" font="4"><b> </b></text>
<text top="329" left="368" width="144" height="19" font="4"><b>Exclusion criteria</b>:  N/A<b> </b></text>
<text top="220" left="550" width="271" height="19" font="4"><b>1</b>°<b> endpoint: </b>Autopsy-defined cause of SCD  </text>
<text top="238" left="550" width="3" height="19" font="3"> </text>
<text top="257" left="550" width="59" height="19" font="4"><b>Results:   </b></text>
<text top="275" left="550" width="273" height="19" font="3">Autopsy-negative SUD in 11 (31%); coronary </text>
<text top="293" left="550" width="291" height="19" font="3">artery abnormalities in 5 (14%), dilated CM in 3 </text>
<text top="312" left="550" width="298" height="19" font="3">(8%), myocarditis in 3 (8%), aortic dissection in 3 </text>
<text top="330" left="550" width="274" height="19" font="3">(8%), and idiopathic LVH (possible HCM) in 3 </text>
<text top="348" left="550" width="299" height="19" font="3">(8%). There was 1 case each (3%) of HCM, ARVC, </text>
<text top="367" left="550" width="283" height="19" font="3">LQTS, commotio cordis, commotio cordis, and </text>
<text top="385" left="550" width="299" height="19" font="3">Kawasaki disease. There was 1 case of death in a </text>
<text top="403" left="550" width="274" height="19" font="3">sickle cell positive athlete who also had LVH. </text>
<text top="422" left="550" width="299" height="19" font="3">There was 1 case of death in a sickle cell positive </text>
<text top="440" left="550" width="166" height="19" font="3">athlete who also had LVH. <b> </b></text>
<text top="219" left="862" width="173" height="19" font="3">● The adjudicated diagnosis </text>
<text top="238" left="862" width="209" height="19" font="3">agreed with the official pathology </text>
<text top="256" left="862" width="171" height="19" font="3">report in only 59% of cases. </text>
<text top="274" left="862" width="179" height="19" font="3">● Autopsy-negative SUD was </text>
<text top="292" left="862" width="96" height="19" font="3">common (31%) </text>
<text top="459" left="123" width="94" height="19" font="3">● Bagnall et al. </text>
<text top="477" left="123" width="69" height="19" font="3">2014 (593) </text>
<text top="496" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24440382">● </a></text>
<text top="496" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24440382">24440382</a></text>
<text top="496" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24440382"> </a></text>
<text top="514" left="123" width="14" height="19" font="3">    </text>
<text top="459" left="247" width="81" height="19" font="4"><b>Study type:   </b></text>
<text top="477" left="247" width="87" height="19" font="3">Retrospective </text>
<text top="496" left="247" width="87" height="19" font="3">analysis of de-</text>
<text top="514" left="247" width="98" height="19" font="3">identified cases </text>
<text top="532" left="247" width="69" height="19" font="3">of autopsy-</text>
<text top="550" left="247" width="94" height="19" font="3">negative SUDs<b>  </b></text>
<text top="569" left="247" width="3" height="19" font="4"><b> </b></text>
<text top="587" left="247" width="35" height="19" font="4"><b>Size:  </b></text>
<text top="605" left="247" width="18" height="19" font="3">28<b> </b></text>
<text top="459" left="368" width="158" height="19" font="4"><b>Inclusion criteria</b>:  SUD in </text>
<text top="477" left="368" width="136" height="19" font="3">the 1–40 y age group, </text>
<text top="496" left="368" width="144" height="19" font="3">classified as SUD based </text>
<text top="514" left="368" width="158" height="19" font="3">upon sudden unexpected </text>
<text top="532" left="368" width="135" height="19" font="3">death with a negative </text>
<text top="550" left="368" width="62" height="19" font="3">autopsy.  <b> </b></text>
<text top="569" left="368" width="3" height="19" font="4"><b> </b></text>
<text top="587" left="368" width="117" height="19" font="4"><b>Exclusion criteria:  </b></text>
<text top="605" left="368" width="147" height="19" font="3">Previous Hx of systemic </text>
<text top="624" left="368" width="135" height="19" font="3">disease or alternative </text>
<text top="642" left="368" width="155" height="19" font="3">cause of death identified </text>
<text top="660" left="368" width="160" height="19" font="3">after a complete autopsy, </text>
<text top="679" left="368" width="156" height="19" font="3">including histopathologic </text>
<text top="697" left="368" width="146" height="19" font="3">and toxicologic analysis<b> </b></text>
<text top="460" left="550" width="14" height="19" font="4"><b>1</b>°</text>
<text top="459" left="564" width="2" height="12" font="9"><b> </b></text>
<text top="460" left="566" width="273" height="19" font="4"><b>endpoint</b>:  Comparison of the yield of whole </text>
<text top="478" left="550" width="284" height="19" font="3">exome sequencingto common candidate gene </text>
<text top="496" left="550" width="295" height="19" font="3">sequencing for identifying a potentially relevant </text>
<text top="515" left="550" width="288" height="19" font="3">variant associated with autopsy-negative SUDs </text>
<text top="533" left="550" width="168" height="19" font="3">in a population age 1–40 y. </text>
<text top="551" left="550" width="297" height="19" font="4"><b>Results</b>:  Based upon likely variants identified by </text>
<text top="570" left="550" width="277" height="19" font="3">WES, the yield increased from approximately </text>
<text top="588" left="550" width="201" height="19" font="3">10% of cases to as much as 30%.<b> </b></text>
<text top="459" left="862" width="160" height="19" font="3">● Study suggests the WES </text>
<text top="477" left="862" width="197" height="19" font="3">increases the yield of molecular </text>
<text top="496" left="862" width="196" height="19" font="3">autopsy in SUD by as much as 3-</text>
<text top="514" left="862" width="170" height="19" font="3">fold, compared to common </text>
<text top="532" left="862" width="184" height="19" font="3">candidate genes for LQTS and </text>
<text top="550" left="862" width="39" height="19" font="3">CPVT. </text>
<text top="569" left="862" width="190" height="19" font="3">● Nonetheless, the majority of </text>
<text top="587" left="862" width="189" height="19" font="3">molecular autopsies still fail to </text>
<text top="605" left="862" width="197" height="19" font="3">identify a highly-likely or known </text>
<text top="624" left="862" width="166" height="19" font="3">disease-causing mutation.  </text>
<text top="716" left="123" width="108" height="19" font="3">● Anderson et al. </text>
<text top="734" left="123" width="69" height="19" font="3">2016 (449) </text>
<text top="753" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27114410">● </a></text>
<text top="753" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27114410">27114410</a></text>
<text top="753" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27114410"> </a></text>
<text top="771" left="123" width="3" height="19" font="3"> </text>
<text top="716" left="247" width="85" height="19" font="4"><b>Study type:    </b></text>
<text top="734" left="247" width="88" height="19" font="3">Whole exome </text>
<text top="753" left="247" width="88" height="19" font="3">sequencing of </text>
<text top="771" left="247" width="107" height="19" font="3">stored DNA from </text>
<text top="716" left="368" width="155" height="19" font="4"><b>Inclusion criteria:</b> Stored </text>
<text top="734" left="368" width="139" height="19" font="3">DNA from SUD victims </text>
<text top="753" left="368" width="142" height="19" font="3">with previous negative </text>
<text top="771" left="368" width="126" height="19" font="3">molecular autopsies </text>
<text top="717" left="550" width="14" height="19" font="4"><b>1</b>°</text>
<text top="717" left="564" width="2" height="12" font="9"><b> </b></text>
<text top="717" left="566" width="250" height="19" font="4"><b>endpoint</b>: Putative variants identified by </text>
<text top="735" left="550" width="292" height="19" font="3">WES, excluding the previously studied common </text>
<text top="753" left="550" width="110" height="19" font="3">candidate genes.  </text>
<text top="772" left="550" width="3" height="19" font="4"><b> </b></text>
<text top="716" left="862" width="180" height="19" font="3">● There appears to be added </text>
<text top="734" left="862" width="178" height="19" font="3">valve to WES, compared to a </text>
<text top="753" left="862" width="204" height="19" font="3">limited candidate gene approach </text>
</page>
<page number="308" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">308 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="247" width="106" height="19" font="3">referred cases of </text>
<text top="127" left="247" width="67" height="19" font="3">SUDY with </text>
<text top="145" left="247" width="56" height="19" font="3">negative </text>
<text top="164" left="247" width="62" height="19" font="3">autopsies </text>
<text top="182" left="247" width="32" height="19" font="4"><b>Size: </b></text>
<text top="200" left="247" width="18" height="19" font="3">32<b> </b></text>
<text top="109" left="368" width="128" height="19" font="3">(21/32, 66%) using a </text>
<text top="127" left="368" width="154" height="19" font="3">common candidate gene </text>
<text top="145" left="368" width="159" height="19" font="3">protocol (KCNQ1, KCNH2, </text>
<text top="164" left="368" width="94" height="19" font="3">SCN5A, RYR2)   </text>
<text top="182" left="368" width="3" height="19" font="4"><b> </b></text>
<text top="200" left="368" width="117" height="19" font="4"><b>Exclusion criteria:  </b></text>
<text top="219" left="368" width="167" height="19" font="3">Previous identification of a </text>
<text top="237" left="368" width="128" height="19" font="3">putativelt significant </text>
<text top="255" left="368" width="161" height="19" font="3">variant in KCNQ1, KCNH2, </text>
<text top="273" left="368" width="147" height="19" font="3">SCN5A, or RYR2 (11/32, </text>
<text top="292" left="368" width="41" height="19" font="3">34%)  <b> </b></text>
<text top="109" left="550" width="283" height="19" font="4"><b>Results</b>: WES increased the yield compared to </text>
<text top="127" left="550" width="249" height="19" font="3">the candidate genes, to 44% from 34%.   </text>
<text top="145" left="550" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="862" width="207" height="19" font="3">for molecular autopsies following </text>
<text top="127" left="862" width="33" height="19" font="3">SUD. </text>
<text top="145" left="862" width="196" height="19" font="3">● Whether a broader candidate </text>
<text top="164" left="862" width="183" height="19" font="3">gene panel might achieve the </text>
<text top="182" left="862" width="213" height="19" font="3">same yield requires further study.  </text>
<text top="200" left="862" width="203" height="19" font="3">● The data suggest that the yield </text>
<text top="219" left="862" width="195" height="19" font="3">from WES is greater for the age </text>
<text top="237" left="862" width="204" height="19" font="3">group 1-10 y, compared to 11-19 </text>
<text top="255" left="862" width="207" height="19" font="3">y, but this is not conclusive based </text>
<text top="273" left="862" width="155" height="19" font="3">upon the small numbers. </text>
<text top="311" left="123" width="94" height="19" font="3">● Bagnall et al. </text>
<text top="329" left="123" width="69" height="19" font="3">2016 (594) </text>
<text top="347" left="123" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27332903">● </a></text>
<text top="347" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27332903">27332903</a></text>
<text top="347" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27332903"> </a></text>
<text top="366" left="123" width="3" height="19" font="3"> </text>
<text top="384" left="123" width="3" height="19" font="3"> </text>
<text top="311" left="247" width="85" height="19" font="4"><b>Study type:    </b></text>
<text top="329" left="247" width="78" height="19" font="3">Prospective, </text>
<text top="347" left="247" width="71" height="19" font="3">population-</text>
<text top="366" left="247" width="92" height="19" font="3">based, clinical, </text>
<text top="384" left="247" width="83" height="19" font="3">toxicological, </text>
<text top="402" left="247" width="82" height="19" font="3">autopsy, and </text>
<text top="421" left="247" width="101" height="19" font="3">genetic study of </text>
<text top="439" left="247" width="95" height="19" font="3">sudden cardiac </text>
<text top="457" left="247" width="84" height="19" font="3">death among </text>
<text top="476" left="247" width="79" height="19" font="3">children and </text>
<text top="494" left="247" width="85" height="19" font="3">young adults, </text>
<text top="512" left="247" width="73" height="19" font="3">age 1–35 y. </text>
<text top="531" left="247" width="3" height="19" font="3"> </text>
<text top="549" left="247" width="32" height="19" font="4"><b>Size: </b></text>
<text top="567" left="247" width="26" height="19" font="3">490<b> </b></text>
<text top="311" left="368" width="137" height="19" font="4"><b>Inclusion criteria:</b> 292 </text>
<text top="329" left="368" width="155" height="19" font="3">subjects with clinical and </text>
<text top="347" left="368" width="162" height="19" font="3">autopsy confirmed causes </text>
<text top="366" left="368" width="138" height="19" font="3">of SCD (60%), and 198 </text>
<text top="384" left="368" width="143" height="19" font="3">(40%) subjects without </text>
<text top="402" left="368" width="159" height="19" font="3">identified cause based on </text>
<text top="421" left="368" width="113" height="19" font="3">clinical or autopsy </text>
<text top="439" left="368" width="167" height="19" font="3">information, among whom </text>
<text top="457" left="368" width="145" height="19" font="3">113 underwent genetic </text>
<text top="476" left="368" width="56" height="19" font="3">testing.   </text>
<text top="494" left="368" width="3" height="19" font="4"><b> </b></text>
<text top="512" left="368" width="138" height="19" font="4"><b>Exclusion criteria:  </b>De-</text>
<text top="531" left="368" width="133" height="19" font="3">identified cases; DNA </text>
<text top="549" left="368" width="80" height="19" font="3">unavailable  <b> </b></text>
<text top="311" left="550" width="14" height="19" font="4"><b>1</b>°</text>
<text top="311" left="564" width="2" height="12" font="9"><b> </b></text>
<text top="311" left="566" width="266" height="19" font="4"><b>endpoint</b>: Identification of relevant genetic </text>
<text top="330" left="550" width="271" height="19" font="3">variants among subjects without autopsy or </text>
<text top="348" left="550" width="234" height="19" font="3">clinical identification of cause of SCD.  </text>
<text top="367" left="550" width="3" height="19" font="4"><b> </b></text>
<text top="385" left="550" width="285" height="19" font="4"><b>Results</b>:  Among the total cohort, 292 subjects </text>
<text top="403" left="550" width="290" height="19" font="3">had clinical and/or autopsy identified causes of </text>
<text top="422" left="550" width="300" height="19" font="3">SCD (60%).  The most common identified causes  </text>
<text top="440" left="550" width="187" height="19" font="3">were CAD (24%) and inherited </text>
<text top="458" left="550" width="297" height="19" font="3">cardiomyopathies (16%), while unexplained SCD </text>
<text top="476" left="550" width="226" height="19" font="3">accounted for 40% overall (N=198).   </text>
<text top="495" left="550" width="3" height="19" font="3"> </text>
<text top="513" left="550" width="282" height="19" font="3">Among the 113 of 198 unexplained cases that </text>
<text top="531" left="550" width="299" height="19" font="3">had post-mortem genetic testing, 31 (27%) were </text>
<text top="550" left="550" width="286" height="19" font="3">identified as having a clinically genetic variant.<b> </b></text>
<text top="311" left="862" width="162" height="19" font="3">● 40% of SCDs in children, </text>
<text top="329" left="862" width="207" height="19" font="3">adolescents and young adults are </text>
<text top="347" left="862" width="197" height="19" font="3">classified as unidentified causes </text>
<text top="366" left="862" width="182" height="19" font="3">based on autopsy and clinical </text>
<text top="384" left="862" width="80" height="19" font="3">information. </text>
<text top="402" left="862" width="181" height="19" font="3">● In the age group 30–35 y, a </text>
<text top="421" left="862" width="201" height="19" font="3">greater proportion of causes are </text>
<text top="439" left="862" width="158" height="19" font="3">identified, and CAD is the </text>
<text top="457" left="862" width="108" height="19" font="3">dominant cause.  </text>
<text top="476" left="862" width="188" height="19" font="3">● Based on a partial sample of </text>
<text top="494" left="862" width="188" height="19" font="3">cases with unidentified causes </text>
<text top="512" left="862" width="183" height="19" font="3">that underwent post-mortem </text>
<text top="531" left="862" width="209" height="19" font="3">genetic testing, an estimated 27% </text>
<text top="549" left="862" width="205" height="19" font="3">of such cases yielded evidence of </text>
<text top="567" left="862" width="168" height="19" font="3">a clinically relevant genetic </text>
<text top="586" left="862" width="50" height="19" font="3">variant. </text>
<text top="604" left="862" width="3" height="19" font="3"> </text>
<text top="659" left="115" width="878" height="21" font="2"><b>Data Supplement 59. Nonrandomized Trials, Observational Studies, Guidelines, and/or Registries of Terminal Care - (Section 14) </b></text>
<text top="680" left="150" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="698" left="176" width="51" height="19" font="4"><b>Author; </b></text>
<text top="716" left="153" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="680" left="300" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="698" left="329" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="680" left="469" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="680" left="642" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="698" left="654" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="716" left="685" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="680" left="885" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="698" left="914" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="736" left="125" width="7" height="18" font="3">•</text>
<text top="735" left="131" width="4" height="21" font="0"> </text>
<text top="736" left="135" width="123" height="19" font="3">Hill et al. 2015(595) </text>
<text top="755" left="125" width="7" height="18" font="3">•</text>
<text top="754" left="131" width="4" height="21" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25239128"> </a></text>
<text top="755" left="135" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25239128">25239128</a></text>
<text top="755" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25239128"> </a></text>
<text top="774" left="125" width="3" height="19" font="3"> </text>
<text top="735" left="291" width="144" height="19" font="4"><b>Study type: </b>Systematic </text>
<text top="754" left="291" width="119" height="19" font="3">narrative review of </text>
<text top="735" left="448" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="754" left="448" width="106" height="19" font="3">Empirical studies </text>
<text top="772" left="448" width="124" height="19" font="3">published in English </text>
<text top="736" left="622" width="175" height="19" font="4"><b>1</b>°<b> endpoint:</b>  N/A – concept </text>
<text top="755" left="622" width="174" height="19" font="3">mapping was performed for </text>
<text top="736" left="825" width="7" height="18" font="3">•</text>
<text top="735" left="832" width="4" height="21" font="0"> </text>
<text top="736" left="836" width="127" height="19" font="3">Three broad themes </text>
<text top="755" left="825" width="207" height="19" font="3">(1) Diverse preferences regarding </text>
<text top="773" left="825" width="178" height="19" font="3">discussion and deactivation.  </text>
</page>
<page number="309" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">309 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="291" width="110" height="19" font="3">published studies </text>
<text top="127" left="291" width="88" height="19" font="3">(2008 – 2014) </text>
<text top="145" left="291" width="3" height="19" font="3"> </text>
<text top="164" left="291" width="128" height="19" font="4"><b>Aim:</b> to evaluate the </text>
<text top="182" left="291" width="134" height="19" font="3">evidence on patients' </text>
<text top="200" left="291" width="86" height="19" font="3">perception of </text>
<text top="219" left="291" width="76" height="19" font="3">implantable </text>
<text top="237" left="291" width="78" height="19" font="3">cardioverter </text>
<text top="255" left="291" width="75" height="19" font="3">defibrillator </text>
<text top="273" left="291" width="137" height="19" font="3">deactivation at end of </text>
<text top="292" left="291" width="26" height="19" font="3">life. </text>
<text top="310" left="291" width="3" height="19" font="3"> </text>
<text top="328" left="291" width="114" height="19" font="4"><b>Size:</b> N=18 studies </text>
<text top="347" left="291" width="3" height="19" font="3"> </text>
<text top="109" left="448" width="150" height="19" font="3">language between 2008 </text>
<text top="127" left="448" width="122" height="19" font="3">and 2014, primarily </text>
<text top="145" left="448" width="149" height="19" font="3">related to adults (above </text>
<text top="164" left="448" width="147" height="19" font="3">18 y) with an implanted </text>
<text top="182" left="448" width="156" height="19" font="3">ICD and primarily related </text>
<text top="200" left="448" width="135" height="19" font="3">to the deactivation of </text>
<text top="219" left="448" width="111" height="19" font="3">ICDs at end of life </text>
<text top="109" left="622" width="169" height="19" font="3">emergent themes from the </text>
<text top="127" left="622" width="84" height="19" font="3">set of studies </text>
<text top="145" left="622" width="3" height="19" font="3"> </text>
<text top="164" left="622" width="152" height="19" font="4"><b>Results:</b> See conclusions </text>
<text top="109" left="825" width="249" height="19" font="3">(2) Ethical and legal considerations were </text>
<text top="127" left="825" width="246" height="19" font="3">predominant in Canadian and American </text>
<text top="145" left="825" width="217" height="19" font="3">literature. Advance directives were </text>
<text top="164" left="825" width="142" height="19" font="3">uncommon in Europe.  </text>
<text top="182" left="825" width="256" height="19" font="3">(3) ‘Living in the now’ was evident among </text>
<text top="200" left="825" width="64" height="19" font="3">patients.   </text>
<text top="366" left="125" width="7" height="18" font="3">•</text>
<text top="365" left="131" width="4" height="21" font="0"> </text>
<text top="366" left="135" width="132" height="19" font="3">Lewis et al. 2014 (37) </text>
<text top="385" left="125" width="7" height="18" font="3">•</text>
<text top="384" left="131" width="4" height="21" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24668214"> </a></text>
<text top="386" left="135" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24668214">24668214</a></text>
<text top="386" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24668214"> </a></text>
<text top="404" left="125" width="3" height="19" font="3"> </text>
<text top="422" left="125" width="3" height="19" font="3"> </text>
<text top="366" left="291" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="384" left="291" width="114" height="19" font="3">Integrative review </text>
<text top="402" left="291" width="3" height="19" font="3"> </text>
<text top="421" left="291" width="100" height="19" font="4"><b>Aim:</b> To explore </text>
<text top="439" left="291" width="112" height="19" font="3">patients’ decision-</text>
<text top="457" left="291" width="124" height="19" font="3">making experiences </text>
<text top="476" left="291" width="125" height="19" font="3">regarding ICDs from </text>
<text top="494" left="291" width="94" height="19" font="3">the decision to </text>
<text top="512" left="291" width="90" height="19" font="3">implant to the </text>
<text top="531" left="291" width="103" height="19" font="3">consideration of </text>
<text top="549" left="291" width="137" height="19" font="3">deactivation at end of </text>
<text top="567" left="291" width="26" height="19" font="3">life. </text>
<text top="586" left="291" width="3" height="19" font="3"> </text>
<text top="604" left="291" width="114" height="19" font="4"><b>Size:</b> N=25 studies </text>
<text top="622" left="291" width="3" height="19" font="3"> </text>
<text top="640" left="291" width="3" height="19" font="3"> </text>
<text top="366" left="448" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="384" left="448" width="153" height="19" font="3">original quantitative and </text>
<text top="402" left="448" width="124" height="19" font="3">qualitative research </text>
<text top="421" left="448" width="125" height="19" font="3">articles that directly </text>
<text top="439" left="448" width="120" height="19" font="3">studied the patient </text>
<text top="457" left="448" width="145" height="19" font="3">response regarding ICD </text>
<text top="476" left="448" width="110" height="19" font="3">decision-making.  </text>
<text top="494" left="448" width="125" height="19" font="3">18 y of age orolder,  </text>
<text top="512" left="448" width="3" height="19" font="3"> </text>
<text top="531" left="448" width="156" height="19" font="4"><b>Exclusion criteria</b> articles </text>
<text top="549" left="448" width="150" height="19" font="3">that did not incorporate </text>
<text top="567" left="448" width="158" height="19" font="3">the patient’s perspective, </text>
<text top="586" left="448" width="42" height="19" font="3">if they </text>
<text top="604" left="448" width="144" height="19" font="3">solely focused on living </text>
<text top="622" left="448" width="146" height="19" font="3">with or adjusting to the </text>
<text top="640" left="448" width="28" height="19" font="3">ICD.<b> </b></text>
<text top="366" left="622" width="123" height="19" font="4"><b>1</b>°<b> endpoint:</b>  N/A – </text>
<text top="385" left="622" width="114" height="19" font="3">integrative review </text>
<text top="403" left="622" width="3" height="19" font="3"> </text>
<text top="421" left="622" width="156" height="19" font="4"><b>Results:</b> See conclusions. </text>
<text top="366" left="825" width="7" height="18" font="3">•</text>
<text top="365" left="832" width="4" height="21" font="0"> </text>
<text top="366" left="836" width="139" height="19" font="3">A significant degree of </text>
<text top="385" left="825" width="243" height="19" font="3">misunderstanding and inaccurate recall </text>
<text top="403" left="825" width="248" height="19" font="3">of information regarding ICD function at </text>
<text top="422" left="825" width="71" height="19" font="3">all decision </text>
<text top="440" left="825" width="7" height="18" font="3">•</text>
<text top="439" left="832" width="4" height="21" font="0"> </text>
<text top="441" left="836" width="236" height="19" font="3">In terms of deactivation decisions, the </text>
<text top="459" left="825" width="239" height="19" font="3">majority of patients were not aware of </text>
<text top="477" left="825" width="76" height="19" font="3">this option.  </text>
<text top="496" left="825" width="3" height="19" font="3"> </text>
<text top="660" left="125" width="7" height="18" font="3">•</text>
<text top="659" left="131" width="4" height="21" font="0"> </text>
<text top="660" left="135" width="116" height="19" font="3">Kramer et al. 2016 </text>
<text top="679" left="125" width="35" height="19" font="3">(596) </text>
<text top="697" left="125" width="7" height="18" font="3">•</text>
<text top="696" left="131" width="4" height="21" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27016104"> </a></text>
<text top="698" left="135" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27016104">27016104</a></text>
<text top="698" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27016104"> </a></text>
<text top="716" left="125" width="7" height="19" font="3">  </text>
<text top="734" left="125" width="3" height="19" font="3"> </text>
<text top="659" left="291" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="678" left="291" width="131" height="19" font="3">Retrospective cohort </text>
<text top="696" left="291" width="136" height="19" font="3">study (NCDR linked to </text>
<text top="714" left="291" width="66" height="19" font="3">Medicare) </text>
<text top="733" left="291" width="3" height="19" font="3"> </text>
<text top="751" left="291" width="128" height="19" font="4"><b>Aim:</b> to describe the </text>
<text top="769" left="291" width="142" height="19" font="3">incidence and features </text>
<text top="659" left="448" width="113" height="19" font="4"><b>Inclusion Criteria: </b></text>
<text top="678" left="448" width="146" height="19" font="3">Patients &gt;65 y who had </text>
<text top="696" left="448" width="141" height="19" font="3">ICDs inserted between </text>
<text top="714" left="448" width="151" height="19" font="3">January 1, 2006 through </text>
<text top="733" left="448" width="102" height="19" font="3">March 31, 2010  </text>
<text top="751" left="448" width="3" height="19" font="3"> </text>
<text top="769" left="448" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="660" left="622" width="156" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Descriptive </text>
<text top="679" left="622" width="3" height="19" font="3"> </text>
<text top="697" left="622" width="56" height="19" font="4"><b>Results:</b>  </text>
<text top="715" left="622" width="182" height="19" font="3">5 y after device implantation, </text>
<text top="733" left="622" width="184" height="19" font="3">50.9% of patients were either </text>
<text top="752" left="622" width="146" height="19" font="3">deceased or in hospice. </text>
<text top="660" left="825" width="7" height="18" font="3">•</text>
<text top="659" left="832" width="4" height="21" font="0"> </text>
<text top="660" left="836" width="218" height="19" font="3">Half of patients over age 65 y don’t </text>
<text top="679" left="825" width="79" height="19" font="3">survive 5 y.   </text>
<text top="697" left="825" width="7" height="18" font="3">•</text>
<text top="696" left="832" width="4" height="21" font="0"> </text>
<text top="698" left="836" width="221" height="19" font="3">1/3 of the decedents utilize hospice </text>
<text top="716" left="825" width="56" height="19" font="3">services. </text>
</page>
<page number="310" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">310 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="291" width="116" height="19" font="3">of hospice use in a </text>
<text top="127" left="291" width="101" height="19" font="3">large, nationally </text>
<text top="145" left="291" width="140" height="19" font="3">representative sample </text>
<text top="164" left="291" width="104" height="19" font="3">of older patients </text>
<text top="182" left="291" width="84" height="19" font="3">following ICD </text>
<text top="200" left="291" width="128" height="19" font="3">implantation, and to </text>
<text top="219" left="291" width="95" height="19" font="3">identify factors </text>
<text top="237" left="291" width="98" height="19" font="3">associated with </text>
<text top="255" left="291" width="136" height="19" font="3">hospice enrollment in </text>
<text top="273" left="291" width="73" height="19" font="3">this cohort. </text>
<text top="292" left="291" width="3" height="19" font="3"> </text>
<text top="310" left="291" width="102" height="19" font="4"><b>Size:</b> N=194,969 </text>
<text top="328" left="291" width="3" height="19" font="4"><b> </b></text>
<text top="109" left="448" width="118" height="19" font="3">Not fee-for-service </text>
<text top="127" left="448" width="122" height="19" font="3">Medicare patients.  </text>
<text top="145" left="448" width="122" height="19" font="3">Patients enrolled in </text>
<text top="164" left="448" width="137" height="19" font="3">hospice before device </text>
<text top="182" left="448" width="72" height="19" font="3">placement. </text>
<text top="109" left="622" width="158" height="19" font="3">Among decedents, 36.8% </text>
<text top="127" left="622" width="165" height="19" font="3">received hospice services.  </text>
<text top="145" left="622" width="135" height="19" font="3">Factors most strongly </text>
<text top="164" left="622" width="177" height="19" font="3">associated with shorter time </text>
<text top="182" left="622" width="176" height="19" font="3">to hospice enrollment were: </text>
<text top="200" left="622" width="123" height="19" font="3">older age HR: 1.77;  </text>
<text top="219" left="622" width="130" height="19" font="3">class IV HF HR: 1.79;  </text>
<text top="237" left="622" width="113" height="19" font="3">EF &lt;20% HR: 1.57  </text>
<text top="255" left="622" width="182" height="19" font="3">Greater regional hospice use  </text>
<text top="348" left="125" width="7" height="18" font="3">•</text>
<text top="347" left="131" width="4" height="21" font="0"> </text>
<text top="348" left="135" width="137" height="19" font="3">Buchhalter et al. 2014 </text>
<text top="367" left="125" width="35" height="19" font="3">(597) </text>
<text top="385" left="125" width="11" height="22" font="0">•<a href="http://www.ncbi.nlm.nih.gov/pubmed/24276835"> </a></text>
<text top="387" left="136" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24276835">24276835</a></text>
<text top="387" left="197" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24276835"> </a></text>
<text top="406" left="125" width="3" height="19" font="3"> </text>
<text top="347" left="291" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="366" left="291" width="120" height="19" font="3">retrospective chart </text>
<text top="384" left="291" width="128" height="19" font="3">review – Mayo clinic </text>
<text top="402" left="291" width="3" height="19" font="3"> </text>
<text top="421" left="291" width="106" height="19" font="4"><b>Aim:</b> To describe </text>
<text top="439" left="291" width="80" height="19" font="3">features and </text>
<text top="457" left="291" width="133" height="19" font="3">outcomes of patients </text>
<text top="476" left="291" width="125" height="19" font="3">who underwent ICD </text>
<text top="494" left="291" width="83" height="19" font="3">deactivation. </text>
<text top="512" left="291" width="3" height="19" font="3"> </text>
<text top="531" left="291" width="75" height="19" font="4"><b>Size: </b>N=150 </text>
<text top="347" left="448" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="366" left="448" width="162" height="19" font="3">Patients with ICD referred </text>
<text top="384" left="448" width="154" height="19" font="3">to the cardiac service for </text>
<text top="402" left="448" width="86" height="19" font="3">deactivation.  </text>
<text top="421" left="448" width="3" height="19" font="3"> </text>
<text top="439" left="448" width="137" height="19" font="4"><b>Exclusion criteria</b> N/A </text>
<text top="348" left="622" width="156" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Descriptive </text>
<text top="367" left="622" width="3" height="19" font="3"> </text>
<text top="385" left="622" width="56" height="19" font="4"><b>Results:</b>  </text>
<text top="403" left="622" width="168" height="19" font="3">150 patients who had their </text>
<text top="422" left="622" width="103" height="19" font="3">ICD deactivated. </text>
<text top="440" left="622" width="146" height="19" font="3">Median of 2 d between </text>
<text top="458" left="622" width="148" height="19" font="3">deactivation and death. </text>
<text top="476" left="622" width="152" height="19" font="3">Advance directives were </text>
<text top="495" left="622" width="181" height="19" font="3">present for 85 (57%) of these </text>
<text top="513" left="622" width="174" height="19" font="3">patients, but only 1 of these </text>
<text top="531" left="622" width="189" height="19" font="3">made any mention of the ICD.  </text>
<text top="550" left="622" width="160" height="19" font="3">6 of the ICD deactivations </text>
<text top="568" left="622" width="128" height="19" font="3">were for pacemaker-</text>
<text top="586" left="622" width="127" height="19" font="3">dependent patients, </text>
<text top="605" left="622" width="180" height="19" font="3">Surprisingly, surrogates were </text>
<text top="623" left="622" width="152" height="19" font="3">responsible for over half </text>
<text top="641" left="622" width="157" height="19" font="3">(51%) of the deactivation </text>
<text top="660" left="622" width="67" height="19" font="3">decisions.  </text>
<text top="678" left="622" width="167" height="19" font="3">Palliative care consultation </text>
<text top="696" left="622" width="145" height="19" font="3">was obtained in 43% of </text>
<text top="714" left="622" width="57" height="19" font="3">patients. </text>
<text top="348" left="825" width="7" height="18" font="3">•</text>
<text top="347" left="832" width="4" height="21" font="0"> </text>
<text top="348" left="836" width="224" height="19" font="3">Patients have deactivation decisions </text>
<text top="367" left="825" width="197" height="19" font="3">very close to delay (median 2 d) </text>
<text top="385" left="825" width="7" height="18" font="3">•</text>
<text top="384" left="832" width="4" height="21" font="0"> </text>
<text top="386" left="836" width="241" height="19" font="3">Over half the time, this decision falls to </text>
<text top="404" left="825" width="77" height="19" font="3">a surrogate. </text>
<text top="423" left="825" width="7" height="18" font="3">•</text>
<text top="422" left="832" width="4" height="21" font="0"> </text>
<text top="423" left="836" width="194" height="19" font="3">Devices were not mentioned in </text>
<text top="441" left="825" width="120" height="19" font="3">advance directives. </text>
</page>
<page number="311" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">311 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="7" height="18" font="3">•</text>
<text top="108" left="131" width="4" height="21" font="0"> </text>
<text top="109" left="135" width="129" height="19" font="3">Goldstein et al. 2004 </text>
<text top="128" left="125" width="35" height="19" font="3">(598) </text>
<text top="146" left="125" width="7" height="18" font="3">•</text>
<text top="145" left="131" width="4" height="21" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15583224"> </a></text>
<text top="147" left="135" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15583224">15583224</a></text>
<text top="147" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15583224"> </a></text>
<text top="109" left="291" width="142" height="19" font="4"><b>Study type:</b> Telephone </text>
<text top="127" left="291" width="122" height="19" font="3">survey with next-of-</text>
<text top="145" left="291" width="98" height="19" font="3">kin of deceased </text>
<text top="164" left="291" width="53" height="19" font="3">patients </text>
<text top="182" left="291" width="3" height="19" font="3"> </text>
<text top="200" left="291" width="130" height="19" font="4"><b>Aim:</b> To describe the </text>
<text top="219" left="291" width="141" height="19" font="3">frequency, timing, and </text>
<text top="237" left="291" width="105" height="19" font="3">correlates of ICD </text>
<text top="255" left="291" width="79" height="19" font="3">deactivation </text>
<text top="273" left="291" width="75" height="19" font="3">discussions  </text>
<text top="292" left="291" width="3" height="19" font="3"> </text>
<text top="310" left="291" width="58" height="19" font="4"><b>Size:</b> 100 </text>
<text top="109" left="448" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="127" left="448" width="119" height="19" font="3">Deceased patients: </text>
<text top="145" left="448" width="161" height="19" font="3">median age 76 y at death; </text>
<text top="164" left="448" width="83" height="19" font="3">27% women; </text>
<text top="182" left="448" width="149" height="19" font="3">median implant time 27 </text>
<text top="200" left="448" width="27" height="19" font="3">mo. </text>
<text top="219" left="448" width="3" height="19" font="3"> </text>
<text top="237" left="448" width="151" height="19" font="3">Interviewed next-of-kin: </text>
<text top="255" left="448" width="97" height="19" font="3">median age 67; </text>
<text top="273" left="448" width="145" height="19" font="3">majority were spouses. </text>
<text top="109" left="622" width="156" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Descriptive </text>
<text top="128" left="622" width="3" height="19" font="3"> </text>
<text top="146" left="622" width="56" height="19" font="4"><b>Results:</b>  </text>
<text top="165" left="622" width="175" height="19" font="3">27% of next of kin recalled a </text>
<text top="183" left="622" width="127" height="19" font="3">discussion regarding </text>
<text top="201" left="622" width="173" height="19" font="3">deactivation of the ICD with </text>
<text top="219" left="622" width="92" height="19" font="3">their clinician.  </text>
<text top="238" left="622" width="159" height="19" font="3">21% chose to deactivate.  </text>
<text top="256" left="622" width="160" height="19" font="3">These discussions all took </text>
<text top="274" left="622" width="180" height="19" font="3">place in the last few d or h of </text>
<text top="293" left="622" width="110" height="19" font="3">the patient's life.  </text>
<text top="311" left="622" width="186" height="19" font="3">27 patients received shocks in </text>
<text top="329" left="622" width="117" height="19" font="3">the last mo of life,  </text>
<text top="348" left="622" width="168" height="19" font="3">8 patients received a shock </text>
<text top="366" left="622" width="155" height="19" font="3">from their ICD in the min </text>
<text top="384" left="622" width="87" height="19" font="3">before death. </text>
<text top="109" left="825" width="7" height="18" font="3">•</text>
<text top="108" left="832" width="4" height="21" font="0"> </text>
<text top="109" left="836" width="210" height="19" font="3">Deactivation discussions were not </text>
<text top="128" left="825" width="247" height="19" font="3">common and occurred late in the illness </text>
<text top="146" left="825" width="3" height="19" font="3"> </text>
<text top="165" left="825" width="7" height="18" font="3">•</text>
<text top="164" left="832" width="4" height="21" font="0"> </text>
<text top="165" left="836" width="73" height="19" font="4"><b>Limitations </b></text>
<text top="184" left="825" width="58" height="19" font="3"> 12 y old  </text>
<text top="202" left="825" width="239" height="19" font="3"> Relied on reports from the next-of-kin </text>
<text top="220" left="825" width="210" height="19" font="3"> Recall bias (interviews occurred a </text>
<text top="239" left="825" width="228" height="19" font="3">median of 2.3 y after patient death)   </text>
<text top="257" left="825" width="3" height="19" font="3"> </text>
<text top="275" left="825" width="3" height="19" font="3"> </text>
<text top="403" left="125" width="7" height="18" font="3">•</text>
<text top="402" left="131" width="4" height="21" font="0"> </text>
<text top="404" left="135" width="129" height="19" font="3">Goldstein et al. 2010 </text>
<text top="422" left="125" width="35" height="19" font="3">(599) </text>
<text top="441" left="125" width="7" height="18" font="3">•</text>
<text top="440" left="131" width="4" height="21" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20194235"> </a></text>
<text top="441" left="135" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20194235">20194235</a></text>
<text top="441" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20194235"> </a></text>
<text top="460" left="125" width="3" height="19" font="3"> </text>
<text top="403" left="291" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="422" left="291" width="133" height="19" font="3">Nationwide survey of </text>
<text top="440" left="291" width="111" height="19" font="3">hospice providers </text>
<text top="458" left="291" width="3" height="19" font="3"> </text>
<text top="476" left="291" width="118" height="19" font="4"><b>Aim:</b> To determine </text>
<text top="495" left="291" width="134" height="19" font="3">whether hospices are </text>
<text top="513" left="291" width="115" height="19" font="3">admitting patients </text>
<text top="531" left="291" width="119" height="19" font="3">with ICDs, whether </text>
<text top="550" left="291" width="108" height="19" font="3">such patients are </text>
<text top="568" left="291" width="133" height="19" font="3">receiving shocks, and </text>
<text top="586" left="291" width="138" height="19" font="3">how hospices manage </text>
<text top="605" left="291" width="34" height="19" font="3">ICDs. </text>
<text top="623" left="291" width="3" height="19" font="3"> </text>
<text top="641" left="291" width="61" height="19" font="4"><b>Size:</b> 414 <b> </b></text>
<text top="403" left="448" width="115" height="19" font="4"><b>Inclusion criteria:</b>  </text>
<text top="422" left="448" width="109" height="19" font="3">Hospice directors </text>
<text top="440" left="448" width="130" height="19" font="3">(nursing, clinician, or </text>
<text top="458" left="448" width="96" height="19" font="3">administrative) </text>
<text top="404" left="622" width="156" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Descriptive </text>
<text top="422" left="622" width="3" height="19" font="3"> </text>
<text top="441" left="622" width="56" height="19" font="4"><b>Results:</b>  </text>
<text top="459" left="622" width="160" height="19" font="3">97% of hospices admitted </text>
<text top="477" left="622" width="114" height="19" font="3">patients with ICDs </text>
<text top="496" left="622" width="183" height="19" font="3">58% reported that in the past </text>
<text top="514" left="622" width="152" height="19" font="3">year, a patient had been </text>
<text top="532" left="622" width="61" height="19" font="3">shocked.  </text>
<text top="550" left="622" width="169" height="19" font="3">Only 10% of hospices had a </text>
<text top="569" left="622" width="134" height="19" font="3">policy that addressed </text>
<text top="587" left="622" width="86" height="19" font="3">deactivation.  </text>
<text top="606" left="622" width="188" height="19" font="3">On average, 42% (95% CI, 37% </text>
<text top="624" left="622" width="180" height="19" font="3">to 48%) of patients with ICDs </text>
<text top="642" left="622" width="161" height="19" font="3">had the shocking function </text>
<text top="660" left="622" width="79" height="19" font="3">deactivated. </text>
<text top="403" left="825" width="7" height="18" font="3">•</text>
<text top="402" left="832" width="4" height="21" font="0"> </text>
<text top="404" left="836" width="242" height="19" font="3">Over half of hospices had had a patient </text>
<text top="422" left="825" width="253" height="19" font="3">get shocked by their ICD in the year prior </text>
<text top="441" left="825" width="91" height="19" font="3">to their death. </text>
<text top="459" left="825" width="3" height="19" font="3"> </text>
<text top="477" left="825" width="7" height="18" font="3">•</text>
<text top="477" left="832" width="4" height="21" font="0"> </text>
<text top="478" left="836" width="220" height="19" font="3">Older survey: more hospices have a </text>
<text top="496" left="825" width="73" height="19" font="3">policy now.<b> </b></text>
</page>
<page number="312" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">312 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="125" width="7" height="18" font="3">•</text>
<text top="108" left="131" width="4" height="21" font="0"> </text>
<text top="109" left="135" width="111" height="19" font="3">Berger et al. 2006 </text>
<text top="128" left="125" width="35" height="19" font="3">(600) </text>
<text top="146" left="125" width="7" height="18" font="3">•</text>
<text top="145" left="131" width="4" height="21" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16689116"> </a></text>
<text top="147" left="135" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16689116">16689116</a></text>
<text top="147" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16689116"> </a></text>
<text top="165" left="125" width="3" height="19" font="3"> </text>
<text top="109" left="291" width="78" height="19" font="4"><b>Study type:</b>  </text>
<text top="127" left="291" width="110" height="19" font="3">self-administered </text>
<text top="145" left="291" width="47" height="19" font="3">survey  </text>
<text top="164" left="291" width="3" height="19" font="4"><b> </b></text>
<text top="182" left="291" width="93" height="19" font="4"><b>Aim: </b>To assess </text>
<text top="200" left="291" width="143" height="19" font="3">whether ICD recipients </text>
<text top="219" left="291" width="103" height="19" font="3">have considered </text>
<text top="237" left="291" width="97" height="19" font="3">preferences for </text>
<text top="255" left="291" width="113" height="19" font="3">disabling the ICD.  </text>
<text top="273" left="291" width="3" height="19" font="3"> </text>
<text top="292" left="291" width="68" height="19" font="4"><b>Size: </b>N=57 </text>
<text top="310" left="291" width="3" height="19" font="3"> </text>
<text top="109" left="448" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="127" left="448" width="114" height="19" font="3">Patients with ICDs </text>
<text top="145" left="448" width="3" height="19" font="3"> </text>
<text top="164" left="448" width="141" height="19" font="4"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="109" left="622" width="119" height="19" font="3">36/57 did not have </text>
<text top="127" left="622" width="162" height="19" font="3">preferences for disabling.  </text>
<text top="145" left="622" width="180" height="19" font="3">21/57 described situations in </text>
<text top="164" left="622" width="146" height="19" font="3">which they would want </text>
<text top="182" left="622" width="86" height="19" font="3">deactivation.  </text>
<text top="200" left="622" width="160" height="19" font="3">Advanced directives were </text>
<text top="219" left="622" width="174" height="19" font="3">prepared by 35/57 subjects, </text>
<text top="237" left="622" width="156" height="19" font="3">none addressed the ICD.  </text>
<text top="109" left="825" width="7" height="18" font="3">•</text>
<text top="108" left="832" width="4" height="21" font="0"> </text>
<text top="109" left="836" width="187" height="19" font="3">Patients infrequently consider </text>
<text top="128" left="825" width="250" height="19" font="3">deactivation and rarely consider them in </text>
<text top="146" left="825" width="116" height="19" font="3">advance directives </text>
<text top="164" left="825" width="3" height="19" font="4"><b> </b></text>
<text top="183" left="825" width="7" height="18" font="3">•</text>
<text top="182" left="832" width="4" height="21" font="0"> </text>
<text top="183" left="836" width="77" height="19" font="4"><b>Limitations:</b> </text>
<text top="202" left="825" width="87" height="19" font="3">Retrospective </text>
<text top="220" left="825" width="87" height="19" font="3">Selection bias </text>
<text top="239" left="825" width="3" height="19" font="3"> </text>
<text top="329" left="125" width="7" height="18" font="3">•</text>
<text top="328" left="131" width="4" height="21" font="0"> </text>
<text top="330" left="135" width="117" height="19" font="3">Dodson et al. 2013 </text>
<text top="348" left="125" width="35" height="19" font="3">(601) </text>
<text top="367" left="125" width="7" height="18" font="3">•</text>
<text top="366" left="131" width="4" height="21" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23358714"> </a></text>
<text top="367" left="135" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23358714">23358714</a></text>
<text top="367" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23358714"> </a></text>
<text top="386" left="125" width="3" height="19" font="3"> </text>
<text top="329" left="291" width="140" height="19" font="4"><b>Study type:</b> telephone </text>
<text top="347" left="291" width="47" height="19" font="3">survey.<b> </b></text>
<text top="366" left="291" width="3" height="19" font="3"> </text>
<text top="384" left="291" width="106" height="19" font="4"><b>Aim:</b> To examine </text>
<text top="402" left="291" width="122" height="19" font="3">preferences for ICD </text>
<text top="421" left="291" width="94" height="19" font="3">deactivation in </text>
<text top="439" left="291" width="140" height="19" font="3">hypothetical scenarios </text>
<text top="457" left="291" width="3" height="19" font="3"> </text>
<text top="476" left="291" width="32" height="19" font="4"><b>Size: </b></text>
<text top="494" left="291" width="43" height="19" font="3">N=95.  </text>
<text top="329" left="448" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="347" left="448" width="157" height="19" font="3">Patients with ICDs, &gt;50 y, </text>
<text top="366" left="448" width="103" height="19" font="3">English speaking </text>
<text top="384" left="448" width="3" height="19" font="4"><b> </b></text>
<text top="402" left="448" width="141" height="19" font="4"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="329" left="622" width="167" height="19" font="3">Following an informational </text>
<text top="347" left="622" width="176" height="19" font="3">script regarding the benefits </text>
<text top="366" left="622" width="163" height="19" font="3">and harms of ICD therapy, </text>
<text top="384" left="622" width="181" height="19" font="3">67/95 (71%) subjects wanted </text>
<text top="402" left="622" width="181" height="19" font="3">ICD deactivation in 1 or more </text>
<text top="421" left="622" width="64" height="19" font="3">scenarios. </text>
<text top="329" left="825" width="7" height="18" font="3">•</text>
<text top="328" left="832" width="4" height="21" font="0"> </text>
<text top="330" left="836" width="228" height="19" font="3">Patients endorse preferences for ICD </text>
<text top="348" left="825" width="234" height="19" font="3">deactivation in hypothetical scenarios </text>
<text top="367" left="825" width="3" height="19" font="3"> </text>
<text top="385" left="825" width="7" height="18" font="3">•</text>
<text top="384" left="832" width="4" height="21" font="0"> </text>
<text top="386" left="836" width="77" height="19" font="4"><b>Limitations:</b> </text>
<text top="404" left="825" width="82" height="19" font="3">Single center </text>
<text top="422" left="825" width="7" height="19" font="3">  </text>
<text top="441" left="825" width="7" height="19" font="4"><b> </b> </text>
<text top="459" left="825" width="3" height="19" font="3"> </text>
<text top="513" left="125" width="7" height="18" font="3">•</text>
<text top="512" left="131" width="4" height="21" font="0"> </text>
<text top="514" left="135" width="129" height="19" font="3">Goldstein et al. 2008 </text>
<text top="532" left="125" width="35" height="19" font="3">(602) </text>
<text top="551" left="125" width="7" height="18" font="3">•</text>
<text top="550" left="131" width="4" height="21" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18095037"> </a></text>
<text top="551" left="135" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18095037">18095037</a></text>
<text top="551" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18095037"> </a></text>
<text top="513" left="291" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="531" left="291" width="106" height="19" font="3">Qualitative focus </text>
<text top="550" left="291" width="49" height="19" font="3">groups. </text>
<text top="568" left="291" width="3" height="19" font="3"> </text>
<text top="586" left="291" width="101" height="19" font="4"><b>Aim: </b>To identify </text>
<text top="605" left="291" width="91" height="19" font="3">barriers to ICD </text>
<text top="623" left="291" width="79" height="19" font="3">deactivation </text>
<text top="641" left="291" width="139" height="19" font="3">discussions in patients </text>
<text top="660" left="291" width="140" height="19" font="3">with advanced illness.  </text>
<text top="678" left="291" width="3" height="19" font="3"> </text>
<text top="696" left="291" width="68" height="19" font="4"><b>Size:</b> N=15 </text>
<text top="513" left="448" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="531" left="448" width="114" height="19" font="3">Patients with ICDs </text>
<text top="513" left="622" width="147" height="19" font="3">No participant had ever </text>
<text top="531" left="622" width="171" height="19" font="3">discussed deactivation with </text>
<text top="550" left="622" width="185" height="19" font="3">their physician, nor knew that </text>
<text top="568" left="622" width="172" height="19" font="3">deactivation was an option. </text>
<text top="586" left="622" width="185" height="19" font="3">Some subjects expressed that </text>
<text top="605" left="622" width="189" height="19" font="3">the physician should make the </text>
<text top="623" left="622" width="57" height="19" font="3">decision. </text>
<text top="513" left="825" width="7" height="18" font="3">•</text>
<text top="512" left="832" width="4" height="21" font="0"> </text>
<text top="514" left="836" width="244" height="19" font="3">Patients did not consider and had some </text>
<text top="532" left="825" width="206" height="19" font="3">confusion about ICD deactivation </text>
<text top="550" left="825" width="3" height="19" font="3"> </text>
<text top="569" left="825" width="7" height="18" font="3">•</text>
<text top="568" left="832" width="4" height="21" font="0"> </text>
<text top="569" left="836" width="77" height="19" font="4"><b>Limitations: </b></text>
<text top="588" left="825" width="86" height="19" font="3"> Single center </text>
<text top="606" left="825" width="113" height="19" font="3"> Small sample size </text>
<text top="624" left="825" width="3" height="19" font="3"> </text>
<text top="643" left="825" width="7" height="19" font="3">  </text>
<text top="661" left="825" width="3" height="19" font="3"> </text>
<text top="715" left="125" width="7" height="18" font="3">•</text>
<text top="714" left="131" width="4" height="21" font="0"> </text>
<text top="716" left="135" width="141" height="19" font="3">Habal et al. 2011 (603) </text>
<text top="735" left="125" width="7" height="18" font="3">•</text>
<text top="734" left="131" width="4" height="21" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21514785"> </a></text>
<text top="735" left="135" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21514785">21514785</a></text>
<text top="735" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21514785"> </a></text>
<text top="753" left="125" width="3" height="19" font="3"> </text>
<text top="715" left="291" width="108" height="19" font="4"><b>Study type:</b> semi-</text>
<text top="733" left="291" width="110" height="19" font="3">structured survey </text>
<text top="752" left="291" width="37" height="19" font="3">study </text>
<text top="770" left="291" width="3" height="19" font="3"> </text>
<text top="715" left="448" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="733" left="448" width="121" height="19" font="3">N=41 total patients </text>
<text top="752" left="448" width="91" height="19" font="3">N=19 with ICD </text>
<text top="770" left="448" width="3" height="19" font="3"> </text>
<text top="715" left="622" width="185" height="19" font="3">Focused on subset of patients </text>
<text top="733" left="622" width="61" height="19" font="3">with ICDs </text>
<text top="752" left="622" width="128" height="19" font="3">2/19 (11%) reported </text>
<text top="770" left="622" width="169" height="19" font="3">discussing the possibility of </text>
<text top="715" left="825" width="7" height="18" font="3">•</text>
<text top="714" left="832" width="4" height="21" font="0"> </text>
<text top="716" left="836" width="236" height="19" font="3">Patients expressed varied impressions </text>
<text top="734" left="825" width="118" height="19" font="3">about deactivation </text>
<text top="752" left="825" width="3" height="19" font="4"><b> </b></text>
<text top="772" left="825" width="10" height="19" font="4"><b> </b>•</text>
<text top="770" left="836" width="4" height="21" font="0"> </text>
<text top="772" left="839" width="77" height="19" font="4"><b>Limitations: </b></text>
</page>
<page number="313" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">313 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="291" width="138" height="19" font="4"><b>Aim: </b>To determine HF </text>
<text top="127" left="291" width="128" height="19" font="3">patients' awareness, </text>
<text top="145" left="291" width="125" height="19" font="3">comprehension and </text>
<text top="164" left="291" width="142" height="19" font="3">utilization of advanced </text>
<text top="182" left="291" width="92" height="19" font="3">care directives </text>
<text top="200" left="291" width="3" height="19" font="3"> </text>
<text top="218" left="291" width="142" height="19" font="4"><b>Size:</b> 41 (19 with ICDs)  </text>
<text top="109" left="448" width="3" height="19" font="3"> </text>
<text top="109" left="622" width="166" height="19" font="3">ICD deactivation with their </text>
<text top="127" left="622" width="67" height="19" font="3">physician.  </text>
<text top="145" left="622" width="173" height="19" font="3">Following clarification, 9/19 </text>
<text top="164" left="622" width="186" height="19" font="3">(47%) stated they would want </text>
<text top="182" left="622" width="166" height="19" font="3">their ICD turned off should </text>
<text top="200" left="622" width="173" height="19" font="3">their condition deteriorate.  </text>
<text top="219" left="622" width="182" height="19" font="3">5/19 (26%) would not want it </text>
<text top="237" left="622" width="82" height="19" font="3">deactivated.  </text>
<text top="109" left="825" width="143" height="19" font="3"> Convenience sampling </text>
<text top="127" left="825" width="86" height="19" font="3"> Single center </text>
<text top="145" left="825" width="113" height="19" font="3"> Small sample size </text>
<text top="256" left="125" width="7" height="18" font="3">•</text>
<text top="255" left="131" width="4" height="21" font="0"> </text>
<text top="257" left="135" width="136" height="19" font="3">Kirkpatrick et al. 2012 </text>
<text top="275" left="125" width="35" height="19" font="3">(604) </text>
<text top="294" left="125" width="7" height="18" font="3">•</text>
<text top="293" left="131" width="4" height="21" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21943937"> </a></text>
<text top="294" left="135" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21943937">21943937</a></text>
<text top="294" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21943937"> </a></text>
<text top="312" left="125" width="7" height="19" font="3">  </text>
<text top="256" left="291" width="104" height="19" font="4"><b>Study type:</b> Non-</text>
<text top="274" left="291" width="88" height="19" font="3">experimental, </text>
<text top="292" left="291" width="140" height="19" font="3">descriptive, telephone </text>
<text top="311" left="291" width="47" height="19" font="3">survey. </text>
<text top="329" left="291" width="3" height="19" font="3"> </text>
<text top="347" left="291" width="100" height="19" font="4"><b>Aim: </b>To explore </text>
<text top="366" left="291" width="133" height="19" font="3">patients' preferences </text>
<text top="384" left="291" width="139" height="19" font="3">for ICD deactivation in </text>
<text top="402" left="291" width="139" height="19" font="3">the setting of a do not </text>
<text top="421" left="291" width="107" height="19" font="3">resuscitate order </text>
<text top="439" left="291" width="126" height="19" font="3">and/or admission to </text>
<text top="457" left="291" width="54" height="19" font="3">hospice. </text>
<text top="476" left="291" width="3" height="19" font="3"> </text>
<text top="494" left="291" width="75" height="19" font="4"><b>Size:</b> N=278 </text>
<text top="512" left="291" width="3" height="19" font="3"> </text>
<text top="256" left="448" width="3" height="19" font="3"> </text>
<text top="274" left="448" width="83" height="19" font="3">30% women; </text>
<text top="292" left="448" width="98" height="19" font="3">85% Caucasian; </text>
<text top="311" left="448" width="110" height="19" font="3">median age 61 y;  </text>
<text top="329" left="448" width="138" height="19" font="3">mean implant time 61 </text>
<text top="347" left="448" width="27" height="19" font="3">mo; </text>
<text top="366" left="448" width="144" height="19" font="3">100% 2° education and </text>
<text top="384" left="448" width="50" height="19" font="3">higher;  </text>
<text top="402" left="448" width="150" height="19" font="3">38% with prior shock(s); </text>
<text top="421" left="448" width="149" height="19" font="3">mean number of shocks </text>
<text top="439" left="448" width="37" height="19" font="3">4.69.  </text>
<text top="257" left="622" width="156" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Descriptive </text>
<text top="275" left="622" width="3" height="19" font="3"> </text>
<text top="293" left="622" width="56" height="19" font="4"><b>Results:</b>  </text>
<text top="312" left="622" width="156" height="19" font="3">140 subjects either had a </text>
<text top="330" left="622" width="145" height="19" font="3">living will or a power of </text>
<text top="348" left="622" width="63" height="19" font="3">attorney.  </text>
<text top="367" left="622" width="179" height="19" font="3">Only 3 (2%) of these subjects </text>
<text top="385" left="622" width="178" height="19" font="3">included a plan for their ICD. </text>
<text top="403" left="622" width="190" height="19" font="3">96% had never discussed what </text>
<text top="422" left="622" width="183" height="19" font="3">to do with their ICD at end-of-</text>
<text top="440" left="622" width="114" height="19" font="3">life with a medical </text>
<text top="458" left="622" width="85" height="19" font="3">professional.  </text>
<text top="476" left="622" width="142" height="19" font="3">Nearly all wanted their </text>
<text top="495" left="622" width="188" height="19" font="3">physician to bring up the topic </text>
<text top="513" left="622" width="99" height="19" font="3">of deactivation. </text>
<text top="256" left="825" width="7" height="18" font="3">•</text>
<text top="255" left="832" width="4" height="21" font="0"> </text>
<text top="257" left="836" width="241" height="19" font="3">Majority of patients are not addressing </text>
<text top="275" left="825" width="192" height="19" font="3">their ICD in advance directives.<b> </b></text>
<text top="293" left="825" width="242" height="19" font="3">Patients want their doctors to have the </text>
<text top="312" left="825" width="204" height="19" font="3">conversation about deactivation.<b> </b></text>
<text top="330" left="825" width="3" height="19" font="4"><b> </b></text>
<text top="348" left="825" width="7" height="18" font="3">•</text>
<text top="347" left="832" width="4" height="21" font="0"> </text>
<text top="349" left="836" width="77" height="19" font="4"><b>Limitations: </b></text>
<text top="367" left="825" width="230" height="19" font="4"><b> </b>Study objectives not explicitly stated<b> </b></text>
<text top="386" left="825" width="86" height="19" font="3"> Single center </text>
<text top="532" left="125" width="7" height="18" font="3">•</text>
<text top="531" left="131" width="4" height="21" font="0"> </text>
<text top="533" left="135" width="116" height="19" font="3">Kramer et al. 2011 </text>
<text top="551" left="125" width="35" height="19" font="3">(605) </text>
<text top="570" left="125" width="7" height="18" font="3">•</text>
<text top="569" left="131" width="4" height="21" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21296323"> </a></text>
<text top="570" left="135" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21296323">21296323</a></text>
<text top="570" left="196" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21296323"> </a></text>
<text top="588" left="125" width="3" height="19" font="4"><b> </b></text>
<text top="532" left="291" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="550" left="291" width="118" height="19" font="3">Non-experimental, </text>
<text top="569" left="291" width="115" height="19" font="3">descriptive, online </text>
<text top="587" left="291" width="47" height="19" font="3">survey. </text>
<text top="605" left="291" width="7" height="19" font="3">  </text>
<text top="624" left="291" width="125" height="19" font="4"><b>Aim:</b> To identify the </text>
<text top="642" left="291" width="114" height="19" font="3">ethical beliefs and </text>
<text top="660" left="291" width="118" height="19" font="3">legal knowledge of </text>
<text top="679" left="291" width="117" height="19" font="3">patients with HCM </text>
<text top="697" left="291" width="134" height="19" font="3">relating to end-of-life </text>
<text top="715" left="291" width="80" height="19" font="3">care and the </text>
<text top="734" left="291" width="88" height="19" font="3">withdrawal of </text>
<text top="752" left="291" width="123" height="19" font="3">implantable cardiac </text>
<text top="770" left="291" width="104" height="19" font="3">device therapy.   </text>
<text top="532" left="448" width="115" height="19" font="4"><b>Inclusion criteria: </b> </text>
<text top="550" left="448" width="162" height="19" font="3">Members of Hypertrophic </text>
<text top="569" left="448" width="104" height="19" font="3">Cardiomyopathy </text>
<text top="587" left="448" width="73" height="19" font="3">Association </text>
<text top="605" left="448" width="3" height="19" font="3"> </text>
<text top="533" left="622" width="156" height="19" font="4"><b>1</b>°<b> endpoint:</b>  Descriptive </text>
<text top="551" left="622" width="3" height="19" font="3"> </text>
<text top="569" left="622" width="56" height="19" font="4"><b>Results:</b>  </text>
<text top="588" left="622" width="177" height="19" font="3">Widespread uncertainty and </text>
<text top="606" left="622" width="181" height="19" font="3">confusion regarding the legal </text>
<text top="624" left="622" width="183" height="19" font="3">status on implantable cardiac </text>
<text top="643" left="622" width="149" height="19" font="3">device deactivation was </text>
<text top="661" left="622" width="43" height="19" font="3">found. </text>
<text top="680" left="622" width="145" height="19" font="3">57% were unsure if ICD </text>
<text top="698" left="622" width="142" height="19" font="3">deactivation was legal. </text>
<text top="716" left="622" width="179" height="19" font="3">198 patients with an ICD had </text>
<text top="734" left="622" width="184" height="19" font="3">advanced directives, and only </text>
<text top="753" left="622" width="185" height="19" font="3">15 (8%) specifically addressed </text>
<text top="771" left="622" width="64" height="19" font="3">their ICD.  </text>
<text top="532" left="825" width="7" height="18" font="3">•</text>
<text top="531" left="832" width="4" height="21" font="0"> </text>
<text top="533" left="836" width="236" height="19" font="3">Legality of ICD deactivation is not well-</text>
<text top="551" left="825" width="143" height="19" font="3">known among patients<b> </b></text>
<text top="569" left="825" width="3" height="19" font="4"><b> </b></text>
<text top="588" left="825" width="7" height="19" font="4"><b> </b> </text>
<text top="606" left="825" width="3" height="19" font="3"> </text>
</page>
<page number="314" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">314 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="291" width="3" height="19" font="3"> </text>
<text top="127" left="291" width="79" height="19" font="4"><b>Size: </b> N=546 </text>
<text top="145" left="291" width="3" height="19" font="3"> </text>
<text top="164" left="115" width="4" height="21" font="0"> </text>
<text top="220" left="115" width="956" height="21" font="2"><b>Data Supplement 60. Nonrandomized Trials, Observational Studies, Guidelines, and/or Registries for Shared Decision Making – (Section 15) </b></text>
<text top="241" left="150" width="103" height="19" font="4"><b>Study Acronym; </b></text>
<text top="260" left="176" width="51" height="19" font="4"><b>Author; </b></text>
<text top="278" left="153" width="96" height="19" font="4"><b>Year Published </b></text>
<text top="241" left="300" width="125" height="19" font="4"><b>Study Type/Design; </b></text>
<text top="260" left="329" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="241" left="469" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="241" left="666" width="151" height="19" font="4"><b>1° Endpoint and Results </b></text>
<text top="260" left="678" width="133" height="19" font="4"><b>(P values; OR or RR;   </b></text>
<text top="278" left="710" width="63" height="19" font="4"><b>&amp; 95% CI) </b></text>
<text top="241" left="909" width="137" height="19" font="4"><b>Summary/Conclusion </b></text>
<text top="260" left="938" width="80" height="19" font="4"><b>Comment(s) </b></text>
<text top="297" left="125" width="152" height="19" font="3">● Lewis et al. 2014 (606) </text>
<text top="315" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24668214?dopt=Citation">● </a></text>
<text top="315" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24668214?dopt=Citation">24668214</a></text>
<text top="315" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24668214?dopt=Citation"> </a></text>
<text top="297" left="291" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="315" left="291" width="114" height="19" font="3">Integrative review </text>
<text top="334" left="291" width="3" height="19" font="3"> </text>
<text top="352" left="291" width="100" height="19" font="4"><b>Aim:</b> To explore </text>
<text top="370" left="291" width="112" height="19" font="3">patients’ decision-</text>
<text top="389" left="291" width="124" height="19" font="3">making experiences </text>
<text top="407" left="291" width="125" height="19" font="3">regarding ICDs from </text>
<text top="425" left="291" width="94" height="19" font="3">the decision to </text>
<text top="444" left="291" width="90" height="19" font="3">implant to the </text>
<text top="462" left="291" width="103" height="19" font="3">consideration of </text>
<text top="480" left="291" width="137" height="19" font="3">deactivation at end of </text>
<text top="499" left="291" width="26" height="19" font="3">life. </text>
<text top="517" left="291" width="3" height="19" font="3"> </text>
<text top="535" left="291" width="97" height="19" font="4"><b>Size:</b> 25 studies </text>
<text top="553" left="291" width="3" height="19" font="3"> </text>
<text top="572" left="291" width="3" height="19" font="3"> </text>
<text top="297" left="448" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="315" left="448" width="155" height="19" font="3">Original quantitative and </text>
<text top="334" left="448" width="124" height="19" font="3">qualitative research </text>
<text top="352" left="448" width="125" height="19" font="3">articles that directly </text>
<text top="370" left="448" width="120" height="19" font="3">studied the patient </text>
<text top="389" left="448" width="145" height="19" font="3">response regarding ICD </text>
<text top="407" left="448" width="110" height="19" font="3">decision-making.  </text>
<text top="425" left="448" width="61" height="19" font="3">age ≥18y  </text>
<text top="444" left="448" width="3" height="19" font="3"> </text>
<text top="462" left="448" width="156" height="19" font="4"><b>Exclusion criteria</b> articles </text>
<text top="480" left="448" width="150" height="19" font="3">that did not incorporate </text>
<text top="499" left="448" width="158" height="19" font="3">the patient’s perspective, </text>
<text top="517" left="448" width="42" height="19" font="3">if they </text>
<text top="535" left="448" width="144" height="19" font="3">solely focused on living </text>
<text top="553" left="448" width="146" height="19" font="3">with or adjusting to the </text>
<text top="572" left="448" width="28" height="19" font="3">ICD.<b> </b></text>
<text top="298" left="622" width="237" height="19" font="4"><b>1</b>°<b> endpoint:</b>  N/A – integrative review </text>
<text top="316" left="622" width="3" height="19" font="3"> </text>
<text top="334" left="622" width="152" height="19" font="4"><b>Results:</b> See conclusions </text>
<text top="297" left="874" width="152" height="19" font="3">● A significant degree of </text>
<text top="315" left="874" width="207" height="19" font="3">misunderstanding and inaccurate </text>
<text top="334" left="874" width="190" height="19" font="3">recall of information regarding </text>
<text top="352" left="874" width="165" height="19" font="3">ICD function at all decision </text>
<text top="370" left="874" width="45" height="19" font="3">points. </text>
<text top="389" left="874" width="196" height="19" font="3">● The majority of patients were </text>
<text top="407" left="874" width="167" height="19" font="3">not aware of deactivation.  </text>
<text top="425" left="874" width="177" height="19" font="3">● The desire to live trumped </text>
<text top="444" left="874" width="206" height="19" font="3">inconveniences for most patients </text>
<text top="462" left="874" width="157" height="19" font="3">but this appeared to be a </text>
<text top="480" left="874" width="150" height="19" font="3">function of health state. </text>
<text top="591" left="125" width="130" height="19" font="3">● Dodson et al. 2013 </text>
<text top="609" left="125" width="35" height="19" font="3">(601) </text>
<text top="627" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23358714?dopt=Citation">● </a></text>
<text top="627" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23358714?dopt=Citation">23358714</a></text>
<text top="627" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23358714?dopt=Citation"> </a></text>
<text top="646" left="125" width="3" height="19" font="3"> </text>
<text top="591" left="291" width="140" height="19" font="4"><b>Study type:</b> telephone </text>
<text top="609" left="291" width="47" height="19" font="3">survey.<b> </b></text>
<text top="627" left="291" width="3" height="19" font="3"> </text>
<text top="646" left="291" width="106" height="19" font="4"><b>Aim:</b> To examine </text>
<text top="664" left="291" width="122" height="19" font="3">preferences for ICD </text>
<text top="682" left="291" width="94" height="19" font="3">deactivation in </text>
<text top="701" left="291" width="140" height="19" font="3">hypothetical scenarios </text>
<text top="719" left="291" width="3" height="19" font="3"> </text>
<text top="737" left="291" width="75" height="19" font="4"><b>Size: </b>N=95.  </text>
<text top="591" left="448" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="609" left="448" width="142" height="19" font="3">Patients with ICDs, age </text>
<text top="627" left="448" width="143" height="19" font="3">&gt;50 y, English speaking </text>
<text top="646" left="448" width="3" height="19" font="4"><b> </b></text>
<text top="664" left="448" width="141" height="19" font="4"><b>Exclusion criteria: </b>N/A </text>
<text top="591" left="622" width="204" height="19" font="3">Following an informational script </text>
<text top="609" left="622" width="222" height="19" font="3">regarding the benefits and harms of </text>
<text top="627" left="622" width="210" height="19" font="3">ICD therapy, 67/95 (71%) subjects </text>
<text top="646" left="622" width="231" height="19" font="3">wanted ICD deactivation in 1 or more </text>
<text top="664" left="622" width="64" height="19" font="3">scenarios. </text>
<text top="591" left="874" width="195" height="19" font="3">● Patients endorse preferences </text>
<text top="609" left="874" width="139" height="19" font="3">for ICD deactivation in </text>
<text top="627" left="874" width="140" height="19" font="3">hypothetical scenarios </text>
<text top="646" left="874" width="172" height="19" font="3">● <b>Limitations: </b>Single center </text>
<text top="664" left="877" width="3" height="19" font="3"> </text>
<text top="682" left="877" width="3" height="19" font="3"> </text>
<text top="701" left="874" width="3" height="19" font="3"> </text>
<text top="756" left="125" width="152" height="19" font="3">● Lewis et al. 2014 (607) </text>
<text top="775" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25070249?dopt=Citation">● </a></text>
<text top="775" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25070249?dopt=Citation">25070249</a></text>
<text top="775" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25070249?dopt=Citation"> </a></text>
<text top="756" left="291" width="119" height="19" font="4"><b>Study type:</b> mailed </text>
<text top="775" left="291" width="43" height="19" font="3">survey<b> </b></text>
<text top="756" left="448" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="775" left="448" width="150" height="19" font="3">Adult patients with ICDs </text>
<text top="757" left="622" width="198" height="19" font="4"><b>1</b>°<b> endpoint:</b>  55 of 106 patients </text>
<text top="775" left="622" width="194" height="19" font="3">(51.9%) were unaware that ICD </text>
<text top="756" left="874" width="175" height="19" font="3">● Over half of patients were </text>
<text top="775" left="874" width="167" height="19" font="3">unaware that there was an </text>
</page>
<page number="315" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">315 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="291" width="3" height="19" font="3"> </text>
<text top="127" left="291" width="140" height="19" font="4"><b>Aim:</b> To assess patient </text>
<text top="145" left="291" width="121" height="19" font="3">awareness that ICD </text>
<text top="164" left="291" width="64" height="19" font="3">generator </text>
<text top="182" left="291" width="93" height="19" font="3">replacement is </text>
<text top="200" left="291" width="114" height="19" font="3">optional, to gauge </text>
<text top="219" left="291" width="140" height="19" font="3">their understanding of </text>
<text top="237" left="291" width="133" height="19" font="3">the risks and benefits </text>
<text top="255" left="291" width="125" height="19" font="3">of ICD replacement, </text>
<text top="273" left="291" width="143" height="19" font="3">and to gain insight into </text>
<text top="292" left="291" width="135" height="19" font="3">their decision-making </text>
<text top="310" left="291" width="54" height="19" font="3">process. </text>
<text top="328" left="291" width="3" height="19" font="3"> </text>
<text top="347" left="291" width="139" height="19" font="4"><b>Size: </b>N=106 (response </text>
<text top="365" left="291" width="69" height="19" font="3">rate 72%).  </text>
<text top="109" left="448" width="3" height="19" font="4"><b> </b></text>
<text top="127" left="448" width="117" height="19" font="4"><b>Exclusion criteria:</b>  </text>
<text top="145" left="448" width="27" height="19" font="3">CRT </text>
<text top="109" left="622" width="196" height="19" font="3">generator replacement was not </text>
<text top="127" left="622" width="78" height="19" font="3">compulsory. </text>
<text top="145" left="622" width="3" height="19" font="3"> </text>
<text top="164" left="622" width="56" height="19" font="4"><b>Results:</b>  </text>
<text top="182" left="622" width="221" height="19" font="3">If given the option, 15 of 55 (27.2%) </text>
<text top="200" left="622" width="175" height="19" font="3">stated that they would have </text>
<text top="219" left="622" width="182" height="19" font="3">considered nonreplacement.  </text>
<text top="237" left="622" width="230" height="19" font="3">For 88 of 106 patients (83.0%), it was </text>
<text top="255" left="622" width="218" height="19" font="3">“important” or “very important” to </text>
<text top="273" left="622" width="238" height="19" font="3">discuss risks and benefits of continued </text>
<text top="292" left="622" width="153" height="19" font="3">therapy before deciding. </text>
<text top="109" left="874" width="207" height="19" font="3">option to not replace the ICD and </text>
<text top="127" left="874" width="185" height="19" font="3">a portion of them would have </text>
<text top="145" left="874" width="90" height="19" font="3">considered it.  </text>
<text top="164" left="874" width="198" height="19" font="3">● <b>Limitations: </b>Single center and </text>
<text top="182" left="874" width="67" height="19" font="3">Recall bias </text>
<text top="384" left="125" width="148" height="19" font="3">● Hauptman et al. 2013 </text>
<text top="402" left="125" width="35" height="19" font="3">(608) </text>
<text top="421" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23420455?dopt=Citation">● </a></text>
<text top="421" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23420455?dopt=Citation">23420455</a></text>
<text top="421" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23420455?dopt=Citation"> </a></text>
<text top="439" left="125" width="3" height="19" font="3"> </text>
<text top="384" left="291" width="113" height="19" font="4"><b>Study type:</b> Focus </text>
<text top="402" left="291" width="131" height="19" font="3">groups; standardized </text>
<text top="421" left="291" width="123" height="19" font="3">patients (providers)<b> </b></text>
<text top="439" left="291" width="3" height="19" font="3"> </text>
<text top="457" left="291" width="106" height="19" font="4"><b>Aim:</b> To examine </text>
<text top="476" left="291" width="108" height="19" font="3">patient-physician </text>
<text top="494" left="291" width="138" height="19" font="3">communication at the </text>
<text top="512" left="291" width="121" height="19" font="3">time the decision is </text>
<text top="531" left="291" width="123" height="19" font="3">made to implant an </text>
<text top="549" left="291" width="28" height="19" font="3">ICD. </text>
<text top="567" left="291" width="3" height="19" font="3"> </text>
<text top="585" left="291" width="126" height="19" font="4"><b>Size: </b>41 patients, 11 </text>
<text top="604" left="291" width="61" height="19" font="3">providers </text>
<text top="384" left="448" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="403" left="448" width="147" height="20" font="3">•  Adult patients with </text>
<text top="422" left="475" width="30" height="19" font="3">ICDs </text>
<text top="440" left="448" width="109" height="20" font="3">•  Cardiologists </text>
<text top="459" left="448" width="3" height="19" font="4"><b> </b></text>
<text top="477" left="448" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="385" left="622" width="204" height="19" font="4"><b>1</b>°<b> endpoint: </b>Patient focus group </text>
<text top="403" left="622" width="161" height="19" font="3">findings and the results of </text>
<text top="422" left="622" width="196" height="19" font="3">standardized patient interviews </text>
<text top="440" left="622" width="3" height="19" font="3"> </text>
<text top="458" left="622" width="118" height="19" font="4"><b>Results - Patients:</b>  </text>
<text top="476" left="622" width="201" height="19" font="3">33/41 patients could not recall a </text>
<text top="495" left="622" width="200" height="19" font="3">discussion about complications.  </text>
<text top="513" left="622" width="225" height="19" font="3">Patients felt a score of 5.7 on a scale </text>
<text top="531" left="622" width="183" height="19" font="3">of 1-10 on “feeling informed” </text>
<text top="550" left="622" width="226" height="19" font="3">Mean number of patients out of 100 </text>
<text top="568" left="622" width="221" height="19" font="3">who would be saved by the ICD was </text>
<text top="586" left="622" width="30" height="19" font="3">87.9 </text>
<text top="605" left="622" width="3" height="19" font="3"> </text>
<text top="623" left="622" width="126" height="19" font="4"><b>Results - Clinicians:</b>  </text>
<text top="641" left="622" width="181" height="20" font="3">•  In 17 of 22 of interviews, </text>
<text top="660" left="649" width="194" height="19" font="3">cardiologists did not address or </text>
<text top="679" left="649" width="198" height="19" font="3">minimized or denied QOL issues </text>
<text top="697" left="649" width="196" height="19" font="3">and long-term consequences of </text>
<text top="715" left="649" width="92" height="19" font="3">ICD placement </text>
<text top="734" left="622" width="217" height="20" font="3">•  In 15 of 22 of the standardized </text>
<text top="753" left="649" width="198" height="19" font="3">patient interviews, cardiologists </text>
<text top="384" left="874" width="181" height="19" font="3">● Patients overestimated the </text>
<text top="402" left="874" width="179" height="19" font="3">benefits and felt uninformed </text>
<text top="421" left="874" width="123" height="19" font="3">regarding the risks.  </text>
<text top="439" left="874" width="121" height="19" font="3">● Patient-physician </text>
<text top="457" left="874" width="181" height="19" font="3">communication about ICDs is </text>
<text top="476" left="874" width="153" height="19" font="3">characterized by unclear </text>
<text top="494" left="874" width="194" height="19" font="3">representation and omission of </text>
<text top="512" left="874" width="145" height="19" font="3">information to patients </text>
</page>
<page number="316" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">316 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="649" width="201" height="19" font="3">used unexplained medical terms </text>
<text top="127" left="649" width="63" height="19" font="3">or jargon. </text>
<text top="146" left="125" width="131" height="19" font="3">● Stewart et al. 2010 </text>
<text top="164" left="125" width="35" height="19" font="3">(609) </text>
<text top="183" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20142021">● </a></text>
<text top="183" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20142021">20142021</a></text>
<text top="183" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20142021"> </a></text>
<text top="201" left="125" width="3" height="19" font="3"> </text>
<text top="146" left="291" width="119" height="19" font="4"><b>Study type:</b> Survey<b> </b></text>
<text top="164" left="291" width="3" height="19" font="3"> </text>
<text top="183" left="291" width="106" height="19" font="4"><b>Aim:</b> To examine </text>
<text top="201" left="291" width="128" height="19" font="3">patient expectations </text>
<text top="219" left="291" width="100" height="19" font="3">from ICDs for 1° </text>
<text top="238" left="291" width="134" height="19" font="3">prevention of sudden </text>
<text top="256" left="291" width="77" height="19" font="3">death in HF. </text>
<text top="274" left="291" width="3" height="19" font="3"> </text>
<text top="292" left="291" width="58" height="19" font="4"><b>Size: </b>105<b> </b></text>
<text top="146" left="448" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="165" left="448" width="128" height="20" font="3">•  Patients with EF </text>
<text top="183" left="475" width="37" height="19" font="3">&lt;35% </text>
<text top="202" left="448" width="130" height="20" font="3">•  Symptomatic HF </text>
<text top="221" left="448" width="3" height="19" font="4"><b> </b></text>
<text top="239" left="448" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="147" left="622" width="132" height="19" font="4"><b>1</b>°<b> endpoint/Results </b> </text>
<text top="165" left="622" width="228" height="19" font="3">Most patients anticipated more than </text>
<text top="183" left="622" width="83" height="19" font="3">10 y survival. </text>
<text top="202" left="622" width="235" height="19" font="3">54% expected an ICD to save ≥50 lives </text>
<text top="220" left="622" width="121" height="19" font="3">per 100 during 5 y.  </text>
<text top="239" left="622" width="224" height="19" font="3">70% of ICD recipients indicated they </text>
<text top="257" left="622" width="238" height="19" font="3">would keep the ICD on even if dying of </text>
<text top="275" left="622" width="51" height="19" font="3">cancer,  </text>
<text top="293" left="622" width="201" height="19" font="3">55% even if having daily shocks,  </text>
<text top="312" left="622" width="185" height="19" font="3">None would inactivate even if </text>
<text top="330" left="622" width="215" height="19" font="3">suffering constant dyspnea at rest. </text>
<text top="146" left="874" width="169" height="19" font="3">● Study demonstrated that </text>
<text top="164" left="874" width="161" height="19" font="3">patients overestimate the </text>
<text top="183" left="874" width="148" height="19" font="3">benefits of ICD therapy. </text>
<text top="349" left="125" width="146" height="19" font="3">● Ottenberg et al. 2014 </text>
<text top="367" left="125" width="35" height="19" font="3">(610) </text>
<text top="386" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24889010?dopt=Citation">● </a></text>
<text top="386" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24889010?dopt=Citation">24889010</a></text>
<text top="386" left="198" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24889010?dopt=Citation"><b> </b></a></text>
<text top="349" left="291" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="367" left="291" width="109" height="19" font="3">Qualitative Focus </text>
<text top="386" left="291" width="42" height="19" font="3">Group<b> </b></text>
<text top="404" left="291" width="3" height="19" font="3"> </text>
<text top="422" left="291" width="130" height="19" font="4"><b>Aim:</b> To describe the </text>
<text top="441" left="291" width="133" height="19" font="3">reasons why patients </text>
<text top="459" left="291" width="72" height="19" font="3">decline ICD </text>
<text top="477" left="291" width="82" height="19" font="3">implantation </text>
<text top="496" left="291" width="3" height="19" font="3"> </text>
<text top="514" left="291" width="119" height="19" font="4"><b>Size: </b>13 patients (3 </text>
<text top="532" left="291" width="50" height="19" font="3">groups) </text>
<text top="349" left="448" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="367" left="448" width="109" height="19" font="3">Patients who had </text>
<text top="386" left="448" width="157" height="19" font="3">declined ICD (12 ICD, one </text>
<text top="404" left="448" width="31" height="19" font="3">CRT)<b> </b></text>
<text top="422" left="448" width="3" height="19" font="4"><b> </b></text>
<text top="441" left="448" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="350" left="622" width="202" height="19" font="4"><b>1</b>°<b> endpoint/Results:</b> 5 Themes:  </text>
<text top="368" left="622" width="207" height="19" font="3">(1) don't mess with a good thing;  </text>
<text top="386" left="622" width="188" height="19" font="3">(2) my health is good enough;  </text>
<text top="405" left="622" width="210" height="19" font="3">(3) independent decision making;  </text>
<text top="423" left="622" width="213" height="19" font="3">(4) it's your job, but it's my choice; </text>
<text top="441" left="622" width="30" height="19" font="3">and  </text>
<text top="460" left="622" width="119" height="19" font="3">(5) gaps in learning </text>
<text top="349" left="874" width="207" height="19" font="3">● Interviews identified significant </text>
<text top="367" left="874" width="189" height="19" font="3">gaps for some patients in their </text>
<text top="386" left="874" width="183" height="19" font="3">understanding about the ICD. </text>
<text top="551" left="125" width="119" height="19" font="3">● Yuhas et al. 2012 </text>
<text top="570" left="125" width="35" height="19" font="3">(611) </text>
<text top="588" left="125" width="12" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22897624?dopt=Citation">● </a></text>
<text top="588" left="137" width="61" height="19" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22897624?dopt=Citation">22897624</a></text>
<text top="588" left="198" width="3" height="19" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22897624?dopt=Citation"> </a></text>
<text top="551" left="291" width="74" height="19" font="4"><b>Study type:</b> </text>
<text top="570" left="291" width="131" height="19" font="3">Qualitative interview<b> </b></text>
<text top="588" left="291" width="3" height="19" font="3"> </text>
<text top="606" left="291" width="100" height="19" font="4"><b>Aim:</b> To explore </text>
<text top="624" left="291" width="141" height="19" font="3">patients’ attitudes and </text>
<text top="643" left="291" width="138" height="19" font="3">perceptions of ICDs to </text>
<text top="661" left="291" width="115" height="19" font="3">better understand </text>
<text top="679" left="291" width="107" height="19" font="3">potential patient-</text>
<text top="698" left="291" width="114" height="19" font="3">related barriers to </text>
<text top="716" left="291" width="143" height="19" font="3">appropriate utilization. </text>
<text top="734" left="291" width="3" height="19" font="3"> </text>
<text top="752" left="291" width="120" height="19" font="4"><b>Size: </b>N=25. 12 who </text>
<text top="771" left="291" width="130" height="19" font="3">accepted referral, 13 </text>
<text top="551" left="448" width="111" height="19" font="4"><b>Inclusion criteria: </b></text>
<text top="570" left="448" width="135" height="19" font="3">outpatient cardiology </text>
<text top="588" left="448" width="138" height="19" font="3">patients with EF ≤35% </text>
<text top="606" left="448" width="128" height="19" font="3">and without an ICD.  </text>
<text top="624" left="448" width="3" height="19" font="4"><b> </b></text>
<text top="643" left="448" width="141" height="19" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="551" left="622" width="198" height="19" font="4"><b>1° Endpoint/Results</b>: 5 Themes: </text>
<text top="570" left="622" width="226" height="19" font="3">(1) Patients who refused ICD referral </text>
<text top="588" left="622" width="214" height="19" font="3">had a lack of insight into their own </text>
<text top="606" left="622" width="32" height="19" font="3">risk.  </text>
<text top="624" left="622" width="224" height="19" font="3">(2) Many patients who accepted ICD </text>
<text top="643" left="622" width="194" height="19" font="3">referral perceived that this was </text>
<text top="661" left="622" width="196" height="19" font="3">strongly recommended by their </text>
<text top="679" left="622" width="70" height="19" font="3">physicians. </text>
<text top="698" left="622" width="232" height="19" font="3">(3) Concerns over recall, malfunction, </text>
<text top="716" left="622" width="207" height="19" font="3">and surgical risk were common in </text>
<text top="734" left="622" width="39" height="19" font="3">both.  </text>
<text top="551" left="874" width="161" height="19" font="3">● People who decline had </text>
<text top="570" left="874" width="191" height="19" font="3">misunderstandings about their </text>
<text top="588" left="874" width="88" height="19" font="3">personal risk.  </text>
</page>
<page number="317" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">317 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="291" width="134" height="19" font="3">who declined referral </text>
<text top="127" left="291" width="136" height="19" font="3">(note: none had ICDs) </text>
<text top="109" left="622" width="201" height="19" font="3">(4) Many patients demonstrated </text>
<text top="127" left="622" width="231" height="19" font="3">inaccurate perceptions of ICD-related </text>
<text top="145" left="622" width="34" height="19" font="3">risks  </text>
<text top="164" left="622" width="210" height="19" font="3">(5) Feelings regarding invasive life-</text>
<text top="182" left="622" width="216" height="19" font="3">prolonging interventions played an </text>
<text top="200" left="622" width="226" height="19" font="3">important role in ICD referral refusal </text>
<text top="219" left="622" width="130" height="19" font="3">for some individuals. </text>
<text top="238" left="115" width="3" height="19" font="3"> </text>
<text top="292" left="115" width="942" height="21" font="2"><b>Data Supplement 61. Randomized Trials, Observational Studies, and/or Registries Related to Cost and Value Considerations - (Section 16) </b></text>
<text top="313" left="157" width="39" height="19" font="4"><b>Study </b></text>
<text top="331" left="156" width="40" height="19" font="4"><b>Name </b></text>
<text top="313" left="282" width="84" height="19" font="4"><b>Study Design </b></text>
<text top="331" left="291" width="67" height="19" font="4"><b>Study Size </b></text>
<text top="313" left="436" width="120" height="19" font="4"><b>Patient Population </b></text>
<text top="313" left="616" width="36" height="19" font="4"><b>Costs </b></text>
<text top="313" left="703" width="85" height="19" font="4"><b>Effectiveness </b></text>
<text top="313" left="842" width="39" height="19" font="4"><b>Value </b></text>
<text top="313" left="928" width="143" height="19" font="4"><b>Summary/Conclusions </b></text>
<text top="350" left="123" width="47" height="19" font="3">● <b>AVID </b></text>
<text top="368" left="123" width="106" height="19" font="3">● Larsen G, et al. </text>
<text top="387" left="123" width="69" height="19" font="3">2002 (612) </text>
<text top="405" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11980684">● </a></text>
<text top="405" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11980684">11980684</a></text>
<text top="405" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11980684"> </a></text>
<text top="350" left="243" width="161" height="19" font="4"><b>Study type: </b>RCT of ICD vs. </text>
<text top="368" left="243" width="129" height="19" font="3">antiarrhythimic drug </text>
<text top="387" left="243" width="99" height="19" font="3">therapy (largely </text>
<text top="405" left="243" width="86" height="19" font="3">amiodarone). </text>
<text top="423" left="243" width="3" height="19" font="3"> </text>
<text top="442" left="243" width="133" height="19" font="3">Within trial costs and </text>
<text top="460" left="243" width="155" height="19" font="3">outcomes to 3 y; lifetime </text>
<text top="478" left="243" width="70" height="19" font="3">projection. </text>
<text top="497" left="243" width="3" height="19" font="3"> </text>
<text top="515" left="243" width="32" height="19" font="4"><b>Size: </b></text>
<text top="533" left="243" width="91" height="19" font="3">1,008 patients </text>
<text top="350" left="418" width="90" height="19" font="3">2° prevention: </text>
<text top="368" left="418" width="114" height="19" font="3">resuscitated CA or </text>
<text top="387" left="418" width="143" height="19" font="3">sustained VT, EF ≤40%. </text>
<text top="350" left="587" width="80" height="19" font="3">Within trial:  </text>
<text top="368" left="587" width="84" height="19" font="3">ICD $87,479,  </text>
<text top="387" left="587" width="87" height="19" font="3">Antiarrythmic </text>
<text top="405" left="587" width="49" height="19" font="3">drug Tx </text>
<text top="423" left="587" width="53" height="19" font="3">$73,564 </text>
<text top="350" left="694" width="76" height="19" font="3">Within trial: </text>
<text top="368" left="694" width="72" height="19" font="3">ICD 2.48 y,  </text>
<text top="387" left="694" width="87" height="19" font="3">Antiarrythmic </text>
<text top="405" left="694" width="89" height="19" font="3">drug Tx 2.27 y </text>
<text top="350" left="811" width="91" height="19" font="3">Lifetime ICER= </text>
<text top="368" left="811" width="53" height="19" font="3">$67,100 </text>
<text top="387" left="811" width="3" height="19" font="3"> </text>
<text top="405" left="811" width="73" height="19" font="3">Within-trial </text>
<text top="423" left="811" width="91" height="19" font="3">ICER= $66,700 </text>
<text top="350" left="925" width="132" height="19" font="3">● Intermediate value </text>
<text top="368" left="925" width="119" height="19" font="3">based on ACC/AHA </text>
<text top="387" left="925" width="82" height="19" font="3">benchmarks. </text>
<text top="405" left="925" width="138" height="19" font="3">● Authors concluded:  </text>
<text top="423" left="925" width="132" height="19" font="3">ICD was “moderately </text>
<text top="442" left="925" width="123" height="19" font="3">cost-effective for 2° </text>
<text top="460" left="925" width="80" height="19" font="3">prevention.” </text>
<text top="478" left="925" width="3" height="19" font="3"> </text>
<text top="497" left="925" width="3" height="19" font="3"> </text>
<text top="572" left="123" width="44" height="19" font="3">● <b>CIDS </b></text>
<text top="591" left="123" width="98" height="19" font="3">● O’Brien BJ, et </text>
<text top="609" left="123" width="87" height="19" font="3">al. 2001 (613) </text>
<text top="627" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11245646">● </a></text>
<text top="627" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11245646">11245646</a></text>
<text top="627" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11245646"> </a></text>
<text top="572" left="243" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="591" left="243" width="87" height="19" font="3">RCT of ICD vs. </text>
<text top="609" left="243" width="81" height="19" font="3">amiodarone. </text>
<text top="627" left="243" width="3" height="19" font="3"> </text>
<text top="645" left="243" width="127" height="19" font="3">Within trial cost and </text>
<text top="664" left="243" width="120" height="19" font="3">survival to 6 y; 12 y </text>
<text top="682" left="243" width="137" height="19" font="3">projection of cost and </text>
<text top="700" left="243" width="54" height="19" font="3">survival. </text>
<text top="719" left="243" width="157" height="19" font="3">430 patients in economic </text>
<text top="737" left="243" width="62" height="19" font="3">substudy. </text>
<text top="755" left="243" width="143" height="19" font="4"><b>Size: </b>659 total patients </text>
<text top="572" left="418" width="94" height="19" font="3">2° prevention:  </text>
<text top="591" left="418" width="143" height="19" font="3">Resuscitated VF or VT.  </text>
<text top="572" left="587" width="83" height="19" font="3">Within trial:   </text>
<text top="591" left="587" width="92" height="19" font="3">ICD C$87,715;  </text>
<text top="609" left="587" width="77" height="19" font="3">amiodarone </text>
<text top="627" left="587" width="61" height="19" font="3">C$38,600 </text>
<text top="572" left="694" width="80" height="19" font="3">Within trial:  </text>
<text top="591" left="694" width="68" height="19" font="3">ICD 4.58 y; </text>
<text top="609" left="694" width="77" height="19" font="3">amiodarone </text>
<text top="627" left="694" width="40" height="19" font="3">4.35 y </text>
<text top="572" left="811" width="83" height="19" font="3">12 year ICER; </text>
<text top="591" left="811" width="61" height="19" font="3">C$99,400 </text>
<text top="609" left="811" width="78" height="19" font="3">(US$67,600) </text>
<text top="627" left="811" width="100" height="19" font="3">(with continued </text>
<text top="645" left="811" width="80" height="19" font="3">ICD benefit)  </text>
<text top="664" left="811" width="3" height="19" font="3"> </text>
<text top="682" left="811" width="72" height="19" font="3">Within trial </text>
<text top="700" left="811" width="38" height="19" font="3">ICER= </text>
<text top="719" left="811" width="68" height="19" font="3">C$213,500 </text>
<text top="737" left="811" width="86" height="19" font="3">(US$145,200) </text>
<text top="755" left="811" width="3" height="19" font="3"> </text>
<text top="572" left="925" width="132" height="19" font="3">● Intermediate value </text>
<text top="591" left="925" width="119" height="19" font="3">based on ACC/AHA </text>
<text top="609" left="925" width="85" height="19" font="3">benchmarks.  </text>
<text top="627" left="925" width="131" height="19" font="3">● Authors concluded </text>
<text top="645" left="925" width="147" height="19" font="3">that “ICD therapy is not </text>
<text top="664" left="925" width="127" height="19" font="3">attractive” based on </text>
<text top="682" left="925" width="127" height="19" font="3">Canadian standards. </text>
<text top="700" left="925" width="84" height="19" font="3">● No lifetime </text>
<text top="719" left="925" width="143" height="19" font="3">projections of cost and </text>
<text top="737" left="925" width="98" height="19" font="3">life expectancy. </text>
</page>
<page number="318" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">318 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="123" width="86" height="19" font="3">● Weiss, et al.</text>
<text top="107" left="209" width="4" height="21" font="0"> </text>
<text top="127" left="123" width="37" height="21" font="0">2002 </text>
<text top="128" left="161" width="35" height="19" font="3">(614) </text>
<text top="147" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12015242">● </a></text>
<text top="147" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12015242">12015242</a></text>
<text top="147" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12015242"> </a></text>
<text top="109" left="243" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="127" left="243" width="162" height="19" font="3">Propensity score matched </text>
<text top="145" left="243" width="128" height="19" font="3">analysis of Medicare </text>
<text top="164" left="243" width="119" height="19" font="3">patients. Costs and </text>
<text top="182" left="243" width="105" height="19" font="3">outcomes to 8 y. </text>
<text top="200" left="243" width="3" height="19" font="4"><b> </b></text>
<text top="218" left="243" width="159" height="19" font="4"><b>Size:</b> 7,619 matched pairs<b> </b></text>
<text top="109" left="418" width="90" height="19" font="3">2° prevention. </text>
<text top="127" left="418" width="125" height="19" font="3">Hospitalized with 1° </text>
<text top="145" left="418" width="134" height="19" font="3">diagnosis of VT or VF. </text>
<text top="109" left="587" width="85" height="19" font="3">Within study: </text>
<text top="127" left="587" width="84" height="19" font="3"> ICD $78,700; </text>
<text top="145" left="587" width="82" height="19" font="3">conventional </text>
<text top="164" left="587" width="51" height="19" font="3">therapy </text>
<text top="182" left="587" width="53" height="19" font="3">$37,200 </text>
<text top="109" left="694" width="89" height="19" font="3">Within study:  </text>
<text top="127" left="694" width="61" height="19" font="3">ICD 4.6 y; </text>
<text top="145" left="694" width="82" height="19" font="3">conventional </text>
<text top="164" left="694" width="83" height="19" font="3">therapy 4.1 y </text>
<text top="109" left="811" width="81" height="19" font="3">Within study </text>
<text top="127" left="811" width="91" height="19" font="3">ICER= $78,400 </text>
<text top="109" left="925" width="132" height="19" font="3">● Intermediate value </text>
<text top="127" left="925" width="119" height="19" font="3">based on ACC/AHA </text>
<text top="145" left="925" width="85" height="19" font="3">benchmarks.  </text>
<text top="164" left="925" width="84" height="19" font="3">● No lifetime </text>
<text top="182" left="925" width="143" height="19" font="3">projections of cost and </text>
<text top="200" left="925" width="98" height="19" font="3">life expectancy. </text>
<text top="238" left="123" width="93" height="19" font="3">● Buxton et al. </text>
<text top="256" left="123" width="69" height="19" font="3">2006 (615) </text>
<text top="274" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16904046">● </a></text>
<text top="274" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16904046">16904046</a></text>
<text top="274" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16904046"> </a></text>
<text top="237" left="243" width="124" height="19" font="4"><b>Study type:</b> Markov </text>
<text top="256" left="243" width="106" height="19" font="3">model, 20 y time </text>
<text top="274" left="243" width="143" height="19" font="3">horizons. Effectiveness </text>
<text top="293" left="243" width="139" height="19" font="3">inputs from RCTs, cost </text>
<text top="311" left="243" width="99" height="19" font="3">inputs from UK. </text>
<text top="329" left="243" width="3" height="19" font="4"><b> </b></text>
<text top="347" left="243" width="152" height="19" font="4"><b>Size:</b> Cost data from 535 </text>
<text top="366" left="243" width="108" height="19" font="3">patients with ICD </text>
<text top="384" left="243" width="134" height="19" font="3">implants in Liverpool. </text>
<text top="238" left="418" width="90" height="19" font="3">2° prevention. </text>
<text top="238" left="587" width="88" height="19" font="3">ICD:  £87,184; </text>
<text top="256" left="587" width="85" height="19" font="3">amiodarone:  </text>
<text top="274" left="587" width="53" height="19" font="3">£18,379 </text>
<text top="238" left="694" width="102" height="19" font="3">Life-y:  ICD 9.87; </text>
<text top="256" left="694" width="77" height="19" font="3">amiodarone </text>
<text top="274" left="694" width="33" height="19" font="3">8.41  </text>
<text top="292" left="694" width="3" height="19" font="3"> </text>
<text top="311" left="694" width="48" height="19" font="3">Quality-</text>
<text top="329" left="694" width="97" height="19" font="3">adjusted life-y:  </text>
<text top="347" left="694" width="58" height="19" font="3">ICD 7.41, </text>
<text top="366" left="694" width="77" height="19" font="3">amiodarone </text>
<text top="384" left="694" width="30" height="19" font="3">6.35 </text>
<text top="238" left="811" width="89" height="19" font="3">£48,700/life-y </text>
<text top="256" left="811" width="44" height="19" font="3">gained </text>
<text top="274" left="811" width="62" height="19" font="3">($64,700) </text>
<text top="292" left="811" width="3" height="19" font="3"> </text>
<text top="311" left="811" width="91" height="19" font="3">£65,000/QALY </text>
<text top="329" left="811" width="44" height="19" font="3">gained </text>
<text top="347" left="811" width="62" height="19" font="3">($86,200) </text>
<text top="238" left="925" width="132" height="19" font="3">● Intermediate value </text>
<text top="256" left="925" width="119" height="19" font="3">based on ACC/AHA </text>
<text top="274" left="925" width="82" height="19" font="3">benchmarks. </text>
<text top="292" left="925" width="131" height="19" font="3">● Authors concluded </text>
<text top="311" left="925" width="117" height="19" font="3">that ICDs were not </text>
<text top="329" left="925" width="146" height="19" font="3">cost-effective at the UK </text>
<text top="347" left="925" width="145" height="19" font="3">benchmark (&lt;£30,000). </text>
<text top="403" left="123" width="76" height="19" font="3">● <b>SCD-HeFT </b></text>
<text top="422" left="123" width="106" height="19" font="3">● Mark DB, et al. </text>
<text top="440" left="123" width="35" height="19" font="3">(616) </text>
<text top="458" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16818817">● </a></text>
<text top="458" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16818817">16818817</a></text>
<text top="458" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16818817"> </a></text>
<text top="403" left="243" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="422" left="243" width="87" height="19" font="3">RCT of ICD vs. </text>
<text top="440" left="243" width="153" height="19" font="3">amiodarone or placebo.  </text>
<text top="458" left="243" width="3" height="19" font="3"> </text>
<text top="476" left="243" width="153" height="19" font="3">Costs and outcomes to 5 </text>
<text top="495" left="243" width="146" height="19" font="3">y; lifetime projection of </text>
<text top="513" left="243" width="159" height="19" font="3">costs and life expectancy. </text>
<text top="531" left="243" width="105" height="19" font="3">1,692 patients in </text>
<text top="550" left="243" width="145" height="19" font="3">economic substudy (US </text>
<text top="568" left="243" width="60" height="19" font="3">centers),  </text>
<text top="586" left="243" width="3" height="19" font="3"> </text>
<text top="605" left="243" width="155" height="19" font="4"><b>Size: </b>2,521 total patients </text>
<text top="403" left="418" width="113" height="19" font="3">1° prevention:  HF </text>
<text top="422" left="418" width="134" height="19" font="3">(NYHA II or III) and EF </text>
<text top="440" left="418" width="41" height="19" font="3">≤35%. </text>
<text top="403" left="587" width="80" height="19" font="3">Within trial:  </text>
<text top="422" left="587" width="85" height="19" font="3">ICD $61,938;  </text>
<text top="440" left="587" width="51" height="19" font="3">placebo </text>
<text top="458" left="587" width="53" height="19" font="3">$42,971 </text>
<text top="476" left="587" width="3" height="19" font="3"> </text>
<text top="495" left="587" width="57" height="19" font="3">Lifetime: </text>
<text top="513" left="587" width="89" height="19" font="3">ICD $158,840; </text>
<text top="531" left="587" width="51" height="19" font="3">placebo </text>
<text top="550" left="587" width="53" height="19" font="3">$79,028 </text>
<text top="403" left="694" width="105" height="19" font="3">Life expectancy:  </text>
<text top="422" left="694" width="76" height="19" font="3">ICD 10.87 y; </text>
<text top="440" left="694" width="92" height="19" font="3">placebo 8.41 y </text>
<text top="458" left="694" width="3" height="19" font="3"> </text>
<text top="476" left="694" width="3" height="19" font="3"> </text>
<text top="495" left="694" width="3" height="19" font="3"> </text>
<text top="403" left="811" width="91" height="19" font="3">Lifetime ICER= </text>
<text top="422" left="811" width="53" height="19" font="3">$38,400 </text>
<text top="440" left="811" width="3" height="19" font="3"> </text>
<text top="458" left="811" width="72" height="19" font="3">Within trial </text>
<text top="476" left="811" width="98" height="19" font="3">ICER= $127,500 </text>
<text top="403" left="925" width="139" height="19" font="3">● High value based on </text>
<text top="422" left="925" width="142" height="19" font="3">ACC/AHA benchmarks. </text>
<text top="440" left="925" width="131" height="19" font="3">● Authors concluded </text>
<text top="458" left="925" width="80" height="19" font="3">that ICD was </text>
<text top="476" left="925" width="90" height="19" font="3">“economically </text>
<text top="495" left="925" width="134" height="19" font="3">attractive” compared </text>
<text top="513" left="925" width="144" height="19" font="3">with placebo as long as </text>
<text top="531" left="925" width="99" height="19" font="3">ICD benefit was </text>
<text top="550" left="925" width="126" height="19" font="3">maintained for ≥8 y. </text>
<text top="568" left="925" width="3" height="19" font="3"> </text>
<text top="586" left="925" width="3" height="19" font="3"> </text>
<text top="630" left="123" width="71" height="19" font="3">● <b>MADIT-II </b></text>
<text top="648" left="123" width="106" height="19" font="3">● Zwanziger J, et </text>
<text top="667" left="123" width="87" height="19" font="3">al. 2006 (617)<b> </b></text>
<text top="685" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16750701">● </a></text>
<text top="685" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16750701">16750701</a></text>
<text top="685" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16750701"> </a></text>
<text top="630" left="243" width="157" height="19" font="4"><b>Study type: </b>RCT of ICD vs </text>
<text top="648" left="243" width="134" height="19" font="3">conventional medical </text>
<text top="667" left="243" width="55" height="19" font="3">therapy. </text>
<text top="685" left="243" width="3" height="19" font="3"> </text>
<text top="703" left="243" width="133" height="19" font="3">Within trial costs and </text>
<text top="721" left="243" width="132" height="19" font="3">survival to 3.5 y; 12 y </text>
<text top="740" left="243" width="137" height="19" font="3">projection of cost and </text>
<text top="758" left="243" width="54" height="19" font="3">survival. </text>
<text top="776" left="243" width="3" height="19" font="4"><b> </b></text>
<text top="630" left="418" width="143" height="19" font="3">1° prevention: Patients </text>
<text top="648" left="418" width="145" height="19" font="3">with prior MI, EF ≤30%. </text>
<text top="630" left="587" width="80" height="19" font="3">Within trial:  </text>
<text top="648" left="587" width="81" height="19" font="3">ICD $84,100, </text>
<text top="667" left="587" width="82" height="19" font="3">conventional </text>
<text top="685" left="587" width="60" height="19" font="3">$44,900;  </text>
<text top="703" left="587" width="3" height="19" font="3"> </text>
<text top="721" left="587" width="49" height="19" font="3">12 year </text>
<text top="740" left="587" width="79" height="19" font="3">projections:  </text>
<text top="758" left="587" width="85" height="19" font="3">ICD $173,700 </text>
<text top="777" left="587" width="80" height="19" font="3">to $180,300, </text>
<text top="630" left="694" width="76" height="19" font="3">Within trial: </text>
<text top="648" left="694" width="68" height="19" font="3">ICD 2.89 y, </text>
<text top="667" left="694" width="82" height="19" font="3">conventional </text>
<text top="685" left="694" width="40" height="19" font="3">2.72 y </text>
<text top="630" left="811" width="67" height="19" font="3">12 y ICER= </text>
<text top="648" left="811" width="69" height="19" font="3">$78,600 to </text>
<text top="667" left="811" width="64" height="19" font="3">$114,000  </text>
<text top="685" left="811" width="3" height="19" font="3"> </text>
<text top="703" left="811" width="72" height="19" font="3">Within trial </text>
<text top="721" left="811" width="31" height="19" font="3">ICER </text>
<text top="740" left="811" width="72" height="19" font="3">=$235,000; </text>
<text top="758" left="811" width="3" height="19" font="3"> </text>
<text top="630" left="925" width="132" height="19" font="3">● Intermediate value </text>
<text top="648" left="925" width="119" height="19" font="3">based on ACC/AHA </text>
<text top="667" left="925" width="140" height="19" font="3">benchmarks, based on </text>
<text top="685" left="925" width="136" height="19" font="3">long-term projections </text>
<text top="703" left="925" width="108" height="19" font="3">of ICD outcomes. </text>
</page>
<page number="319" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">319 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="243" width="137" height="19" font="4"><b>Size: </b>1,095 patients in </text>
<text top="127" left="243" width="145" height="19" font="3">economic substudy (US </text>
<text top="145" left="243" width="62" height="19" font="3">patients), </text>
<text top="164" left="243" width="126" height="19" font="3">1,232 total patients  </text>
<text top="109" left="587" width="82" height="19" font="3">conventional </text>
<text top="127" left="587" width="53" height="19" font="3">$97,900 </text>
<text top="183" left="123" width="67" height="19" font="3">● <b>MADIT-I </b></text>
<text top="201" left="123" width="100" height="19" font="3">● Mushlin AI, et </text>
<text top="219" left="123" width="87" height="19" font="3">al. 1998 (618)<b> </b></text>
<text top="238" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9626173">● </a></text>
<text top="238" left="136" width="53" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9626173">9626173</a></text>
<text top="238" left="189" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9626173"> </a></text>
<text top="183" left="243" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="201" left="243" width="135" height="19" font="3">RCT of ICD or medical </text>
<text top="219" left="243" width="55" height="19" font="3">therapy. </text>
<text top="238" left="243" width="3" height="19" font="3"> </text>
<text top="256" left="243" width="153" height="19" font="3">Costs and outcomes to 4 </text>
<text top="274" left="243" width="14" height="19" font="3">y. </text>
<text top="293" left="243" width="3" height="19" font="3"> </text>
<text top="311" left="243" width="32" height="19" font="4"><b>Size: </b></text>
<text top="329" left="243" width="157" height="19" font="3">181 patients in economic </text>
<text top="347" left="243" width="144" height="19" font="3">study (US centers), 196 </text>
<text top="366" left="243" width="92" height="19" font="3">total patients.  </text>
<text top="183" left="418" width="147" height="19" font="3">1° prevention. Prior MI, </text>
<text top="201" left="418" width="118" height="19" font="3">asymptomatic non-</text>
<text top="219" left="418" width="143" height="19" font="3">sustained VT, EF ≤35%, </text>
<text top="238" left="418" width="102" height="19" font="3">inducible VT not </text>
<text top="256" left="418" width="91" height="19" font="3">suppressed by </text>
<text top="274" left="418" width="91" height="19" font="3">procainamide. </text>
<text top="183" left="587" width="76" height="19" font="3">Within trial: </text>
<text top="201" left="587" width="81" height="19" font="3">ICD $97,560; </text>
<text top="219" left="587" width="51" height="19" font="3">medical </text>
<text top="238" left="587" width="51" height="19" font="3">therapy </text>
<text top="256" left="587" width="53" height="19" font="3">$78,980 </text>
<text top="183" left="694" width="76" height="19" font="3">Within trial: </text>
<text top="201" left="694" width="68" height="19" font="3">ICD 3.66 y, </text>
<text top="219" left="694" width="102" height="19" font="3">medical therapy </text>
<text top="238" left="694" width="40" height="19" font="3">2.80 y </text>
<text top="183" left="811" width="72" height="19" font="3">Within trial </text>
<text top="201" left="811" width="38" height="19" font="3">ICER= </text>
<text top="219" left="811" width="53" height="19" font="3">$27,000 </text>
<text top="183" left="925" width="139" height="19" font="3">● High value based on </text>
<text top="201" left="925" width="142" height="19" font="3">ACC/AHA benchmarks. </text>
<text top="219" left="925" width="131" height="19" font="3">● Authors concluded </text>
<text top="238" left="925" width="102" height="19" font="3">that “ICD is cost-</text>
<text top="256" left="925" width="126" height="19" font="3">effective in selected </text>
<text top="274" left="925" width="145" height="19" font="3">individuals at high risk” </text>
<text top="293" left="925" width="116" height="19" font="3">for sudden cardiac </text>
<text top="311" left="925" width="43" height="19" font="3">death. </text>
<text top="329" left="925" width="3" height="19" font="3"> </text>
<text top="385" left="123" width="91" height="19" font="3">● Al-Khatib, et </text>
<text top="404" left="123" width="14" height="19" font="3">al.</text>
<text top="403" left="138" width="41" height="21" font="0"> 2005 </text>
<text top="404" left="179" width="35" height="19" font="3">(619) </text>
<text top="423" left="123" width="9" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=%2015838065">●</a></text>
<text top="423" left="132" width="64" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=%2015838065"> 15838065</a></text>
<text top="423" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=%2015838065"> </a></text>
<text top="385" left="243" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="403" left="243" width="157" height="19" font="3">Duke database outcomes </text>
<text top="422" left="243" width="118" height="19" font="3">and costs for 15 y.  </text>
<text top="440" left="243" width="160" height="19" font="3">Llifetime extrapolation by </text>
<text top="458" left="243" width="96" height="19" font="3">Markov model. </text>
<text top="476" left="243" width="3" height="19" font="4"><b> </b></text>
<text top="495" left="243" width="126" height="19" font="4"><b>Size: </b>1,285 patients  </text>
<text top="385" left="418" width="145" height="19" font="3">1° prevention. Post-MI, </text>
<text top="403" left="418" width="58" height="19" font="3">EF ≤30%. </text>
<text top="385" left="587" width="32" height="19" font="3">ICD:  </text>
<text top="403" left="587" width="64" height="19" font="3">$131,490; </text>
<text top="422" left="587" width="59" height="19" font="3">medical:  </text>
<text top="440" left="587" width="53" height="19" font="3">$40,661 </text>
<text top="385" left="694" width="105" height="19" font="3">Life expectancy:  </text>
<text top="403" left="694" width="68" height="19" font="3">ICD 8.59 y, </text>
<text top="422" left="694" width="91" height="19" font="3">medical 6.79 y </text>
<text top="385" left="811" width="77" height="19" font="3">$50,500 per </text>
<text top="403" left="811" width="78" height="19" font="3">life-y gained </text>
<text top="385" left="925" width="132" height="19" font="3">● Intermediate value </text>
<text top="403" left="925" width="78" height="19" font="3">by ACC/AHA </text>
<text top="422" left="925" width="81" height="19" font="3">benchmarks  </text>
<text top="440" left="925" width="138" height="19" font="3">● Authors concluded:  </text>
<text top="458" left="925" width="149" height="19" font="3">ICD therapy for patients </text>
<text top="476" left="925" width="125" height="19" font="3">eligible for MADIT-II </text>
<text top="495" left="925" width="117" height="19" font="3">was “economically </text>
<text top="513" left="925" width="86" height="19" font="3">attractive” by </text>
<text top="531" left="925" width="82" height="19" font="3">conventional </text>
<text top="550" left="925" width="67" height="19" font="3">standards. </text>
<text top="569" left="123" width="101" height="19" font="3">● Sanders, et al. </text>
<text top="587" left="123" width="69" height="19" font="3">2005 (620) </text>
<text top="605" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16207849">● </a></text>
<text top="605" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16207849">16207849</a></text>
<text top="605" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16207849"> </a></text>
<text top="569" left="243" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="587" left="243" width="146" height="19" font="3">Markov model, lifetime </text>
<text top="605" left="243" width="135" height="19" font="3">projection, applied to </text>
<text top="624" left="243" width="146" height="19" font="3">data from each of eight </text>
<text top="642" left="243" width="114" height="19" font="3">randomized trials. </text>
<text top="660" left="243" width="3" height="19" font="4"><b> </b></text>
<text top="678" left="243" width="123" height="19" font="4"><b>Size: </b>Not applicable </text>
<text top="569" left="418" width="120" height="19" font="3">1° prevention. Trial </text>
<text top="587" left="418" width="155" height="19" font="3">subjects in CABG-PATCH, </text>
<text top="605" left="418" width="150" height="19" font="3">COMPANION, DEFINITE, </text>
<text top="624" left="418" width="120" height="19" font="3">DINAMIT, MADIT-I, </text>
<text top="642" left="418" width="139" height="19" font="3">MADIT-II, MUSTT, and </text>
<text top="660" left="418" width="67" height="19" font="3">SCD-HeFT. </text>
<text top="569" left="587" width="93" height="19" font="3">ICD had higher </text>
<text top="587" left="587" width="81" height="19" font="3">costs in each </text>
<text top="605" left="587" width="77" height="19" font="3">population:  </text>
<text top="624" left="587" width="69" height="19" font="3">$55,700 to </text>
<text top="642" left="587" width="60" height="19" font="3">$100,500 </text>
<text top="569" left="694" width="93" height="19" font="3">ICD had higher </text>
<text top="587" left="694" width="95" height="19" font="3">life expectancy </text>
<text top="605" left="694" width="71" height="19" font="3">in six trials, </text>
<text top="624" left="694" width="82" height="19" font="3">ranging from </text>
<text top="642" left="694" width="100" height="19" font="3">1.46 to 4.14 life-</text>
<text top="660" left="694" width="52" height="19" font="3">y added </text>
<text top="569" left="811" width="81" height="19" font="3">≤$39,000 for </text>
<text top="587" left="811" width="87" height="19" font="3">COMPANION, </text>
<text top="605" left="811" width="62" height="19" font="3">DEFINITE, </text>
<text top="624" left="811" width="101" height="19" font="3">MADIT I, MADIT </text>
<text top="642" left="811" width="69" height="19" font="3">II, MUSTT;  </text>
<text top="660" left="811" width="3" height="19" font="3"> </text>
<text top="679" left="811" width="74" height="19" font="3">$50,700 for </text>
<text top="697" left="811" width="63" height="19" font="3">SCD-HeFT </text>
<text top="715" left="811" width="3" height="19" font="3"> </text>
<text top="733" left="811" width="76" height="19" font="3">Higher cost, </text>
<text top="752" left="811" width="41" height="19" font="3">worse </text>
<text top="770" left="811" width="85" height="19" font="3">outcomes for </text>
<text top="569" left="925" width="98" height="19" font="3">● High value by </text>
<text top="587" left="925" width="138" height="19" font="3">ACC/AHA benchmarks </text>
<text top="605" left="925" width="122" height="19" font="3">when projected life </text>
<text top="624" left="925" width="99" height="19" font="3">expectancy was </text>
<text top="642" left="925" width="120" height="19" font="3">increased by &gt;1.4 y </text>
</page>
<page number="320" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">320 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="109" left="811" width="87" height="19" font="3">CABG-PATCH, </text>
<text top="127" left="811" width="62" height="19" font="3">DINAMIT. </text>
<text top="146" left="123" width="88" height="19" font="3">● Smith, et al. </text>
<text top="164" left="123" width="30" height="19" font="3">2013</text>
<text top="163" left="154" width="4" height="21" font="0"> </text>
<text top="164" left="157" width="35" height="19" font="3">(621) </text>
<text top="183" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22584647">● </a></text>
<text top="183" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22584647">22584647</a></text>
<text top="183" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22584647"> </a></text>
<text top="146" left="243" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="164" left="243" width="146" height="19" font="3">Markov model, lifetime </text>
<text top="183" left="243" width="153" height="19" font="3">projection. Effectiveness </text>
<text top="201" left="243" width="147" height="19" font="3">from meta-analysis of 6 </text>
<text top="219" left="243" width="36" height="19" font="3">RCTs. </text>
<text top="237" left="243" width="3" height="19" font="4"><b> </b></text>
<text top="256" left="243" width="123" height="19" font="4"><b>Size: </b>Not applicable </text>
<text top="146" left="418" width="143" height="19" font="3">1° prevention. Patients </text>
<text top="164" left="418" width="132" height="19" font="3">with EF &lt;40%, due to </text>
<text top="183" left="418" width="141" height="19" font="3">either ischemic or non-</text>
<text top="201" left="418" width="104" height="19" font="3">ischemic causes. </text>
<text top="146" left="587" width="81" height="19" font="3">ICD €86,759; </text>
<text top="164" left="587" width="82" height="19" font="3">conventional </text>
<text top="183" left="587" width="58" height="19" font="3">therapy   </text>
<text top="201" left="587" width="53" height="19" font="3">€50,685 </text>
<text top="146" left="694" width="94" height="19" font="3">ICD 7.08 QALY; </text>
<text top="164" left="694" width="82" height="19" font="3">conventional </text>
<text top="183" left="694" width="81" height="19" font="3">therapy 6.26 </text>
<text top="201" left="694" width="36" height="19" font="3">QALY </text>
<text top="146" left="811" width="91" height="19" font="3">ICER= €44,000 </text>
<text top="164" left="811" width="62" height="19" font="3">($49,200) </text>
<text top="146" left="925" width="98" height="19" font="3">● High value by </text>
<text top="164" left="925" width="146" height="19" font="3">ACC/AHA benchmarks.  </text>
<text top="183" left="925" width="135" height="19" font="3">● Authors concluded: </text>
<text top="201" left="925" width="119" height="19" font="3">1° prophylactic ICD </text>
<text top="219" left="925" width="143" height="19" font="3">therapy had high value </text>
<text top="238" left="925" width="146" height="19" font="3">in the European setting </text>
<text top="256" left="925" width="122" height="19" font="3">for patients with EF </text>
<text top="274" left="925" width="41" height="19" font="3">&lt;40%. </text>
<text top="300" left="123" width="73" height="19" font="3">● Cowie, et </text>
<text top="318" left="123" width="45" height="19" font="3">al.2009</text>
<text top="317" left="168" width="4" height="21" font="0"> </text>
<text top="318" left="172" width="35" height="19" font="3">(622) </text>
<text top="337" left="123" width="12" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19359333">● </a></text>
<text top="337" left="136" width="61" height="19" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19359333">19359333</a></text>
<text top="337" left="197" width="3" height="19" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19359333"> </a></text>
<text top="300" left="243" width="74" height="19" font="4"><b>Study type: </b></text>
<text top="318" left="243" width="146" height="19" font="3">Markov model, lifetime </text>
<text top="337" left="243" width="153" height="19" font="3">projection. Effectiveness </text>
<text top="355" left="243" width="147" height="19" font="3">from meta-analysis of 6 </text>
<text top="373" left="243" width="137" height="19" font="3">RCTs. European costs. </text>
<text top="391" left="243" width="3" height="19" font="4"><b> </b></text>
<text top="410" left="243" width="123" height="19" font="4"><b>Size: </b>Not applicable </text>
<text top="300" left="418" width="143" height="19" font="3">1° prevention. Patients </text>
<text top="318" left="418" width="145" height="19" font="3">with EF &lt;35%, ischemic </text>
<text top="337" left="418" width="101" height="19" font="3">or non-ischemic </text>
<text top="355" left="418" width="56" height="19" font="3">etiology. </text>
<text top="300" left="587" width="81" height="19" font="3">ICD €64,600; </text>
<text top="318" left="587" width="82" height="19" font="3">conventional </text>
<text top="337" left="587" width="58" height="19" font="3">therapy   </text>
<text top="355" left="587" width="53" height="19" font="3">€18,187 </text>
<text top="300" left="694" width="88" height="19" font="3">ICD 8.58 life-y </text>
<text top="318" left="694" width="79" height="19" font="3">(7.27 QALY); </text>
<text top="337" left="694" width="82" height="19" font="3">conventional </text>
<text top="355" left="694" width="81" height="19" font="3">therapy 6.71 </text>
<text top="373" left="694" width="37" height="19" font="3">life-y  </text>
<text top="391" left="694" width="75" height="19" font="3">(5.70 QALY) </text>
<text top="300" left="811" width="96" height="19" font="3">ICER= €24,800/ </text>
<text top="318" left="811" width="78" height="19" font="3">life-y gained </text>
<text top="337" left="811" width="62" height="19" font="3">($27,700) </text>
<text top="355" left="811" width="3" height="19" font="3"> </text>
<text top="373" left="811" width="91" height="19" font="3">€29,500/QALY </text>
<text top="392" left="811" width="44" height="19" font="3">gained </text>
<text top="410" left="811" width="62" height="19" font="3">($33,000) </text>
<text top="300" left="925" width="98" height="19" font="3">● High value by </text>
<text top="318" left="925" width="146" height="19" font="3">ACC/AHA benchmarks.  </text>
<text top="337" left="925" width="135" height="19" font="3">● Authors concluded: </text>
<text top="355" left="925" width="103" height="19" font="3">Prophylactic ICD </text>
<text top="373" left="925" width="138" height="19" font="3">implantation had high </text>
<text top="392" left="925" width="96" height="19" font="3">value if current </text>
<text top="410" left="925" width="139" height="19" font="3">guidelines for patients </text>
<text top="428" left="925" width="108" height="19" font="3">with EF &lt;35% are </text>
<text top="446" left="925" width="60" height="19" font="3">followed. </text>
<text top="465" left="115" width="4" height="21" font="2"><b> </b></text>
<text top="486" left="115" width="3" height="19" font="3"> </text>
<text top="486" left="331" width="3" height="19" font="3"> </text>
</page>
<page number="321" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">321 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="122" width="4" height="21" font="0"> </text>
<text top="128" left="149" width="84" height="21" font="2"><b>References: </b></text>
<text top="148" left="115" width="953" height="21" font="0">1.  Ruwald MH, Hansen ML, Lamberts M, et al. The relation between age, sex, comorbidity, and pharmacotherapy and the risk of syncope: a </text>
<text top="168" left="149" width="892" height="21" font="0">Danish nationwide study. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on </text>
<text top="188" left="149" width="834" height="21" font="0">cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2012; 14:1506-14. </text>
<text top="208" left="115" width="793" height="21" font="0">2.  Soteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis of syncope. N. Engl. J. Med. 2002; 347:878-85. </text>
<text top="228" left="115" width="950" height="21" font="0">3.  Middlekauff HR, Stevenson WG, Stevenson LW, et al. Syncope in advanced heart failure: high risk of sudden death regardless of origin of </text>
<text top="249" left="149" width="292" height="21" font="0">syncope. J Am Coll Cardiol. 1993; 21:110-6. </text>
<text top="269" left="115" width="925" height="21" font="0">4.  Steinman RT, Herrera C, Schuger CD, et al. Wide QRS tachycardia in the conscious adult. Ventricular tachycardia is the most frequent </text>
<text top="289" left="149" width="214" height="21" font="0">cause. Jama. 1989; 261:1013-6. </text>
<text top="309" left="115" width="915" height="21" font="0">5.  Brugada P, Brugada J, Mont L, et al. A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex. </text>
<text top="329" left="149" width="206" height="21" font="0">Circulation. 1991; 83:1649-59. </text>
<text top="349" left="115" width="914" height="21" font="0">6.  Wellens HJ, Bar FW and Lie KI. The value of the electrocardiogram in the differential diagnosis of a tachycardia with a widened QRS </text>
<text top="370" left="149" width="248" height="21" font="0">complex. Am J Med. 1978; 64:27-33. </text>
<text top="389" left="115" width="911" height="21" font="0">7.  Elhendy A, Chandrasekaran K, Gersh BJ, et al. Functional and prognostic significance of exercise-induced ventricular arrhythmias in </text>
<text top="410" left="149" width="546" height="21" font="0">patients with suspected coronary artery disease. Am. J. Cardiol. 2002; 90:95-100. </text>
<text top="430" left="115" width="898" height="21" font="0">8.  Grady TA, Chiu AC, Snader CE, et al. Prognostic significance of exercise-induced left bundle-branch block. Jama. 1998; 279:153-6. </text>
<text top="450" left="115" width="960" height="21" font="0">9.  Costantini O, Hohnloser SH, Kirk MM, et al. The ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans </text>
<text top="470" left="149" width="620" height="21" font="0">to improve efficiency of sudden cardiac death prevention. J Am Coll Cardiol. 2009; 53:471-9. </text>
<text top="490" left="115" width="824" height="21" font="0">10.  Desai AD, Yaw TS, Yamazaki T, et al. Prognostic significance of quantitative QRS duration. Am J Med. 2006; 119:600-6. </text>
<text top="510" left="115" width="905" height="21" font="0">11.  Freedman RA, Alderman EL, Sheffield LT, et al. Bundle branch block in patients with chronic coronary artery disease: angiographic </text>
<text top="531" left="149" width="489" height="21" font="0">correlates and prognostic significance. J Am Coll Cardiol. 1987; 10:73-80. </text>
<text top="551" left="115" width="953" height="21" font="0">12.  Baldasseroni S, Opasich C, Gorini M, et al. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in </text>
<text top="571" left="149" width="919" height="21" font="0">5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am. Heart J. 2002; 143:398-</text>
<text top="591" left="149" width="33" height="21" font="0">405. </text>
<text top="611" left="115" width="939" height="21" font="0">13.  Zimetbaum PJ, Buxton AE, Batsford W, et al. Electrocardiographic predictors of arrhythmic death and total mortality in the multicenter </text>
<text top="631" left="149" width="399" height="21" font="0">unsustained tachycardia trial. Circulation. 2004; 110:766-9. </text>
<text top="651" left="115" width="940" height="21" font="0">14.  Buxton AE, Sweeney MO, Wathen MS, et al. QRS duration does not predict occurrence of ventricular tachyarrhythmias in patients with </text>
<text top="671" left="149" width="482" height="21" font="0">implanted cardioverter-defibrillators. J Am Coll Cardiol. 2005; 46:310-6. </text>
<text top="692" left="115" width="955" height="21" font="0">15.  Monasterio V, Martinez JP, Laguna P, et al. Prognostic value of average T-wave alternans and QT variability for cardiac events in MADIT-II </text>
<text top="712" left="149" width="366" height="21" font="0">patients. Journal of electrocardiology. 2013; 46:480-6. </text>
<text top="732" left="115" width="915" height="21" font="0">16.  Chow T, Kereiakes DJ, Onufer J, et al. Does microvolt T-wave alternans testing predict ventricular tachyarrhythmias in patients with </text>
<text top="752" left="149" width="920" height="21" font="0">ischemic cardiomyopathy and prophylactic defibrillators? The MASTER (Microvolt T Wave Alternans Testing for Risk Stratification of Post-</text>
<text top="772" left="149" width="491" height="21" font="0">Myocardial Infarction Patients) trial. J Am Coll Cardiol. 2008; 52:1607-15. </text>
</page>
<page number="322" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">322 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="967" height="21" font="0">17.  Gupta A, Hoang DD, Karliner L, et al. Ability of microvolt T-wave alternans to modify risk assessment of ventricular tachyarrhythmic events: </text>
<text top="128" left="149" width="323" height="21" font="0">a meta-analysis. Am. Heart J. 2012; 163:354-64. </text>
<text top="148" left="115" width="948" height="21" font="0">18.  Dhar R, Alsheikh-Ali AA, Estes NA, III, et al. Association of prolonged QRS duration with ventricular tachyarrhythmias and sudden cardiac </text>
<text top="168" left="149" width="746" height="21" font="0">death in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). Heart rhythm. 2008; 5:807-13. </text>
<text top="188" left="115" width="958" height="21" font="0">19.  Bloomfield DM, Steinman RC, Namerow PB, et al. Microvolt T-wave alternans distinguishes between patients likely and patients not likely </text>
<text top="208" left="149" width="923" height="21" font="0">to benefit from implanted cardiac defibrillator therapy: a solution to the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II </text>
<text top="228" left="149" width="292" height="21" font="0">conundrum. Circulation. 2004; 110:1885-9. </text>
<text top="249" left="115" width="963" height="21" font="0">20.  Iuliano S, Fisher SG, Karasik PE, et al. QRS duration and mortality in patients with congestive heart failure. Am. Heart J. 2002; 143:1085-91. </text>
<text top="269" left="115" width="949" height="21" font="0">21.  Perez-Rodon J, Martinez-Alday J, Baron-Esquivias G, et al. Prognostic value of the electrocardiogram in patients with syncope: data from </text>
<text top="289" left="149" width="655" height="21" font="0">the group for syncope study in the emergency room (GESINUR). Heart rhythm. 2014; 11:2035-44. </text>
<text top="309" left="115" width="837" height="21" font="0">22.  Barrett PM, Komatireddy R, Haaser S, et al. Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch </text>
<text top="329" left="149" width="408" height="21" font="0">electrocardiographic monitoring. Am J Med. 2014; 127:95-7. </text>
<text top="349" left="115" width="875" height="21" font="0">23.  de Asmundis C, Conte G, Sieira J, et al. Comparison of the patient-activated event recording system vs. traditional 24 h Holter </text>
<text top="370" left="149" width="877" height="21" font="0">electrocardiography in individuals with paroxysmal palpitations or dizziness. Europace : European pacing, arrhythmias, and cardiac </text>
<text top="389" left="149" width="914" height="21" font="0">electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European </text>
<text top="410" left="149" width="266" height="21" font="0">Society of Cardiology. 2014; 16:1231-5. </text>
<text top="430" left="115" width="927" height="21" font="0">24.  Turakhia MP, Hoang DD, Zimetbaum P, et al. Diagnostic utility of a novel leadless arrhythmia monitoring device. Am. J. Cardiol. 2013; </text>
<text top="450" left="149" width="76" height="21" font="0">112:520-4. </text>
<text top="470" left="115" width="958" height="21" font="0">25.  Linzer M, Pritchett EL, Pontinen M, et al. Incremental diagnostic yield of loop electrocardiographic recorders in unexplained syncope. Am. </text>
<text top="490" left="149" width="178" height="21" font="0">J. Cardiol. 1990; 66:214-9. </text>
<text top="510" left="115" width="920" height="21" font="0">26.  Bloch Thomsen PE, Jons C, Raatikainen MJ, et al. Long-term recording of cardiac arrhythmias with an implantable cardiac monitor in </text>
<text top="531" left="149" width="889" height="21" font="0">patients with reduced ejection fraction after acute myocardial infarction: the Cardiac Arrhythmias and Risk Stratification After Acute </text>
<text top="551" left="149" width="483" height="21" font="0">Myocardial Infarction (CARISMA) study. Circulation. 2010; 122:1258-64. </text>
<text top="571" left="115" width="959" height="21" font="0">27.  Volosin K, Stadler RW, Wyszynski R, et al. Tachycardia detection performance of implantable loop recorders: results from a large 'real-life' </text>
<text top="591" left="149" width="808" height="21" font="0">patient cohort and patients with induced ventricular arrhythmias. Europace : European pacing, arrhythmias, and cardiac </text>
<text top="611" left="149" width="914" height="21" font="0">electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European </text>
<text top="631" left="149" width="275" height="21" font="0">Society of Cardiology. 2013; 15:1215-22. </text>
<text top="651" left="115" width="916" height="21" font="0">28.  Krahn AD, Klein GJ, Yee R, et al. Use of an extended monitoring strategy in patients with problematic syncope. Reveal Investigators. </text>
<text top="671" left="149" width="198" height="21" font="0">Circulation. 1999; 99:406-10. </text>
<text top="692" left="115" width="936" height="21" font="0">29.  Solbiati M, Costantino G, Casazza G, et al. Implantable loop recorder versus conventional diagnostic workup for unexplained recurrent </text>
<text top="712" left="149" width="396" height="21" font="0">syncope. Cochrane Database Syst. Rev. 2016; 4:CD011637. </text>
<text top="732" left="115" width="961" height="21" font="0">30.  Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart </text>
<text top="752" left="149" width="341" height="21" font="0">failure, or both. N. Engl. J. Med. 2005; 352:2581-8. </text>
</page>
<page number="323" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">323 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="940" height="21" font="0">31.  Gula LJ, Klein GJ, Hellkamp AS, et al. Ejection fraction assessment and survival: an analysis of the Sudden Cardiac Death in Heart Failure </text>
<text top="128" left="149" width="344" height="21" font="0">Trial (SCD-HeFT). Am. Heart J. 2008; 156:1196-200. </text>
<text top="148" left="115" width="931" height="21" font="0">32.  Korngold EC, Januzzi JL, Jr., Gantzer ML, et al. Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein as </text>
<text top="168" left="149" width="560" height="21" font="0">predictors of sudden cardiac death among women. Circulation. 2009; 119:2868-76. </text>
<text top="188" left="115" width="940" height="21" font="0">33.  Patton KK, Sotoodehnia N, DeFilippi C, et al. N-terminal pro-B-type natriuretic peptide is associated with sudden cardiac death risk: the </text>
<text top="208" left="149" width="404" height="21" font="0">Cardiovascular Health Study. Heart rhythm. 2011; 8:228-33. </text>
<text top="228" left="115" width="930" height="21" font="0">34.  Scott PA, Barry J, Roberts PR, et al. Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: a </text>
<text top="249" left="149" width="329" height="21" font="0">meta-analysis. Eur. J Heart Fail. 2009; 11:958-66. </text>
<text top="269" left="115" width="929" height="21" font="0">35.  Blangy H, Sadoul N, Dousset B, et al. Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD </text>
<text top="289" left="149" width="904" height="21" font="0">recipients after myocardial infarction. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working </text>
<text top="309" left="149" width="880" height="21" font="0">groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2007; 9:724-9. </text>
<text top="329" left="115" width="934" height="21" font="0">36.  Ahmad T, Fiuzat M, Neely B, et al. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic </text>
<text top="349" left="149" width="304" height="21" font="0">heart failure. JACC. Heart Fail. 2014; 2:260-8. </text>
<text top="370" left="115" width="919" height="21" font="0">37.  Levine YC, Rosenberg MA, Mittleman M, et al. B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias. Heart </text>
<text top="389" left="149" width="183" height="21" font="0">rhythm. 2014; 11:1109-16. </text>
<text top="410" left="115" width="968" height="21" font="0">38.  Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. </text>
<text top="430" left="149" width="126" height="21" font="0">2002; 105:2392-7. </text>
<text top="450" left="115" width="942" height="21" font="0">39.  Buxton AE, Lee KL, Hafley GE, et al. Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with </text>
<text top="470" left="149" width="918" height="21" font="0">coronary artery disease: an analysis of patients enrolled in the multicenter unsustained tachycardia trial. Circulation. 2002; 106:2466-72. </text>
<text top="490" left="115" width="912" height="21" font="0">40.  Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. </text>
<text top="510" left="149" width="622" height="21" font="0">Multicenter Unsustained Tachycardia Trial Investigators. N. Engl. J. Med. 1999; 341:1882-90. </text>
<text top="531" left="115" width="946" height="21" font="0">41.  Buxton AE, Lee KL, DiCarlo L, et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden </text>
<text top="551" left="149" width="669" height="21" font="0">death. Multicenter Unsustained Tachycardia Trial Investigators. N. Engl. J. Med. 2000; 342:1937-45. </text>
<text top="571" left="115" width="934" height="21" font="0">42.  Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for </text>
<text top="591" left="149" width="858" height="21" font="0">ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N. Engl. J. Med. 1996; 335:1933-40. </text>
<text top="611" left="115" width="935" height="21" font="0">43.  Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. </text>
<text top="631" left="149" width="126" height="21" font="0">2005; 352:225-37. </text>
<text top="651" left="115" width="951" height="21" font="0">44.  Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection </text>
<text top="671" left="149" width="293" height="21" font="0">fraction. N. Engl. J. Med. 2002; 346:877-83. </text>
<text top="692" left="115" width="939" height="21" font="0">45.  Hilfiker G, Schoenenberger AW, Erne P, et al. Utility of electrophysiological studies to predict arrhythmic events. World J Cardiol. 2015; </text>
<text top="712" left="149" width="68" height="21" font="0">7:344-50. </text>
<text top="732" left="115" width="965" height="21" font="0">46.  Bourke JP, Richards DA, Ross DL, et al. Routine programmed electrical stimulation in survivors of acute myocardial infarction for prediction </text>
<text top="752" left="149" width="934" height="21" font="0">of spontaneous ventricular tachyarrhythmias during follow-up: results, optimal stimulation protocol and cost-effective screening. J Am Coll </text>
<text top="772" left="149" width="164" height="21" font="0">Cardiol. 1991; 18:780-8. </text>
</page>
<page number="324" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">324 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="959" height="21" font="0">47.  Bailey JJ, Berson AS, Handelsman H, et al. Utility of current risk stratification tests for predicting major arrhythmic events after myocardial </text>
<text top="128" left="149" width="318" height="21" font="0">infarction. J Am Coll Cardiol. 2001; 38:1902-11. </text>
<text top="148" left="115" width="944" height="21" font="0">48.  Schmitt C, Barthel P, Ndrepepa G, et al. Value of programmed ventricular stimulation for prophylactic internal cardioverter-defibrillator </text>
<text top="168" left="149" width="785" height="21" font="0">implantation in postinfarction patients preselected by noninvasive risk stratifiers. J Am Coll Cardiol. 2001; 37:1901-7. </text>
<text top="188" left="115" width="961" height="21" font="0">49.  Brembilla-Perrot B, Suty-Selton C, Beurrier D, et al. Differences in mechanisms and outcomes of syncope in patients with coronary disease </text>
<text top="208" left="149" width="799" height="21" font="0">or idiopathic left ventricular dysfunction as assessed by electrophysiologic testing. J Am Coll Cardiol. 2004; 44:594-601. </text>
<text top="228" left="115" width="949" height="21" font="0">50.  Bhandari AK, Shapiro WA, Morady F, et al. Electrophysiologic testing in patients with the long QT syndrome. Circulation. 1985; 71:63-71. </text>
<text top="249" left="115" width="921" height="21" font="0">51.  Giustetto C, Di MF, Wolpert C, et al. Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur. Heart J. 2006; </text>
<text top="269" left="149" width="76" height="21" font="0">27:2440-7. </text>
<text top="289" left="115" width="948" height="21" font="0">52.  Mahida S, Derval N, Sacher F, et al. Role of electrophysiological studies in predicting risk of ventricular arrhythmia in early repolarization </text>
<text top="309" left="149" width="304" height="21" font="0">syndrome. J Am Coll Cardiol. 2015; 65:151-9. </text>
<text top="329" left="115" width="935" height="21" font="0">53.  Giustetto C, Schimpf R, Mazzanti A, et al. Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol. 2011; 58:587-95. </text>
<text top="349" left="115" width="927" height="21" font="0">54.  Raczak G, Pinna GD, Maestri R, et al. Different predictive values of electrophysiological testing and autonomic assessment in patients </text>
<text top="370" left="149" width="437" height="21" font="0">surviving a sustained arrhythmic episode. Circ. J. 2004; 68:634-8. </text>
<text top="389" left="115" width="947" height="21" font="0">55.  Brodsky MA, Mitchell LB, Halperin BD, et al. Prognostic value of baseline electrophysiology studies in patients with sustained ventricular </text>
<text top="410" left="149" width="774" height="21" font="0">tachyarrhythmia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. Am. Heart J. 2002; 144:478-84. </text>
<text top="430" left="115" width="922" height="21" font="0">56.  Daubert JP, Zareba W, Hall WJ, et al. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or </text>
<text top="450" left="149" width="901" height="21" font="0">ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. J Am Coll Cardiol. 2006; 47:98-107. </text>
<text top="470" left="115" width="885" height="21" font="0">57.  Daubert JP, Winters SL, Subacius H, et al. Ventricular arrhythmia inducibility predicts subsequent ICD activation in nonischemic </text>
<text top="490" left="149" width="621" height="21" font="0">cardiomyopathy patients: a DEFINITE substudy. Pacing Clin. Electrophysiol. 2009; 32:755-61. </text>
<text top="510" left="115" width="943" height="21" font="0">58.  Gold MR, Bloomfield DM, Anderson KP, et al. A comparison of T-wave alternans, signal averaged electrocardiography and programmed </text>
<text top="531" left="149" width="623" height="21" font="0">ventricular stimulation for arrhythmia risk stratification. J Am Coll Cardiol. 2000; 36:2247-53. </text>
<text top="551" left="115" width="904" height="21" font="0">59.  Gatzoulis KA, Vouliotis AI, Tsiachris D, et al. Primary prevention of sudden cardiac death in a nonischemic dilated cardiomyopathy </text>
<text top="571" left="149" width="820" height="21" font="0">population: reappraisal of the role of programmed ventricular stimulation. Circ. Arrhythm. Electrophysiol. 2013; 6:504-12. </text>
<text top="591" left="115" width="909" height="21" font="0">60.  Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN </text>
<text top="611" left="149" width="430" height="21" font="0">randomised trial. Lancet (London, England). 2001; 357:1385-90. </text>
<text top="631" left="115" width="915" height="21" font="0">61.  Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. </text>
<text top="651" left="149" width="494" height="21" font="0">Carvedilol Heart Failure Study Group. N. Engl. J. Med. 1996; 334:1349-55. </text>
<text top="671" left="115" width="808" height="21" font="0">62.  The cardiac insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England). 1999; 353:9-13. </text>
<text top="692" left="115" width="969" height="21" font="0">63.  Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in </text>
<text top="712" left="149" width="914" height="21" font="0">patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study </text>
<text top="732" left="149" width="235" height="21" font="0">Group. Jama. 2000; 283:1295-302. </text>
<text top="752" left="115" width="966" height="21" font="0">64.  Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive </text>
<text top="772" left="149" width="324" height="21" font="0">heart failure. N. Engl. J. Med. 1991; 325:303-10. </text>
</page>
<page number="325" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">325 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="940" height="21" font="0">65.  Cohn JN and Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 2001; </text>
<text top="128" left="149" width="93" height="21" font="0">345:1667-75. </text>
<text top="148" left="115" width="915" height="21" font="0">66.  Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left </text>
<text top="168" left="149" width="470" height="21" font="0">ventricular dysfunction, or both. N. Engl. J. Med. 2003; 349:1893-906. </text>
<text top="188" left="115" width="909" height="21" font="0">67.  Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of </text>
<text top="208" left="149" width="551" height="21" font="0">Losartan in the Elderly Study, ELITE). Lancet (London, England). 1997; 349:747-52. </text>
<text top="228" left="115" width="953" height="21" font="0">68.  Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: </text>
<text top="249" left="149" width="756" height="21" font="0">randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet (London, England). 2000; 355:1582-7. </text>
<text top="269" left="115" width="892" height="21" font="0">69.  Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. </text>
<text top="289" left="149" width="602" height="21" font="0">Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999; 341:709-17. </text>
<text top="309" left="115" width="969" height="21" font="0">70.  Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial </text>
<text top="329" left="149" width="314" height="21" font="0">infarction. N. Engl. J. Med. 2003; 348:1309-21. </text>
<text top="349" left="115" width="958" height="21" font="0">71.  Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011; 364:11-</text>
<text top="370" left="149" width="25" height="21" font="0">21. </text>
<text top="389" left="115" width="963" height="21" font="0">72.  Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of </text>
<text top="410" left="149" width="411" height="21" font="0">death in heart failure patients. Eur. Heart J. 2015; 36:1990-7. </text>
<text top="430" left="115" width="960" height="21" font="0">73.  Carson P, Wertheimer J, Miller A, et al. The STICH trial (Surgical Treatment for Ischemic Heart Failure): mode-of-death results. JACC. Heart </text>
<text top="450" left="149" width="132" height="21" font="0">Fail. 2013; 1:400-8. </text>
<text top="470" left="115" width="932" height="21" font="0">74.  Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N. Engl. J. Med. 2016; </text>
<text top="490" left="149" width="93" height="21" font="0">374:1511-20. </text>
<text top="510" left="115" width="905" height="21" font="0">75.  Cook JR, Rizo-Patron C, Curtis AB, et al. Effect of surgical revascularization in patients with coronary artery disease and ventricular </text>
<text top="531" left="149" width="862" height="21" font="0">tachycardia or fibrillation in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Registry. Am. Heart J. 2002; 143:821-6. </text>
<text top="551" left="115" width="941" height="21" font="0">76.  Mondésert B, Khairy P, Schram G, et al. Impact of revascularization in patients with sustained ventricular arrhythmias, prior myocardial </text>
<text top="571" left="149" width="609" height="21" font="0">infarction, and preserved left ventricular ejection fraction. Heart rhythm. 2016; 13:1221-7. </text>
<text top="591" left="115" width="969" height="21" font="0">77.  Ngaage DL, Cale AR, Cowen ME, et al. Early and late survival after surgical revascularization for ischemic ventricular fibrillation/tachycardia. </text>
<text top="611" left="149" width="252" height="21" font="0">Ann. Thorac. Surg. 2008; 85:1278-81. </text>
<text top="631" left="115" width="963" height="21" font="0">78.  Every NR, Fahrenbruch CE, Hallstrom AP, et al. Influence of coronary bypass surgery on subsequent outcome of patients resuscitated from </text>
<text top="651" left="149" width="438" height="21" font="0">out of hospital cardiac arrest. J Am Coll Cardiol. 1992; 19:1435-9. </text>
<text top="671" left="115" width="960" height="21" font="0">79.  van der Burg AE, Bax JJ, Boersma E, et al. Impact of viability, ischemia, scar tissue, and revascularization on outcome after aborted sudden </text>
<text top="692" left="149" width="253" height="21" font="0">death. Circulation. 2003; 108:1954-9. </text>
<text top="712" left="115" width="949" height="21" font="0">80.  Dumas F, Cariou A, Manzo-Silberman S, et al. Immediate percutaneous coronary intervention is associated with better survival after out-</text>
<text top="732" left="149" width="929" height="21" font="0">of-hospital cardiac arrest: insights from the PROCAT (Parisian Region Out of hospital Cardiac ArresT) registry. Circ. Cardiovasc Interv. 2010; </text>
<text top="752" left="149" width="59" height="21" font="0">3:200-7. </text>
</page>
<page number="326" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">326 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="965" height="21" font="0">81.  Dumas F, Bougouin W, Geri G, et al. Emergency PCI in post-cardiac arrest patients without ST-segment elevation pattern: insights from the </text>
<text top="128" left="149" width="407" height="21" font="0">PROCAT II registry. JACC. Cardiovasc. Interv. 2016; 9:1011-8. </text>
<text top="148" left="115" width="915" height="21" font="0">82.  Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe </text>
<text top="168" left="149" width="398" height="21" font="0">coronary artery disease. N. Engl. J. Med. 2009; 360:961-72. </text>
<text top="188" left="115" width="958" height="21" font="0">83.  Milojevic M, Head SJ, Parasca CA, et al. Causes of death following PCI versus CABG in complex CAD: 5-year follow-up of SYNTAX. J Am Coll </text>
<text top="208" left="149" width="164" height="21" font="0">Cardiol. 2016; 67:42-55. </text>
<text top="228" left="115" width="960" height="21" font="0">84.  Al-Khatib SM, Hellkamp AS, Lee KL, et al. Implantable cardioverter defibrillator therapy in patients with prior coronary revascularization in </text>
<text top="249" left="149" width="723" height="21" font="0">the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). J. Cardiovasc. Electrophysiol. 2008; 19:1059-65. </text>
<text top="269" left="115" width="950" height="21" font="0">85.  Nageh MF, Kim JJ, Chen LH, et al. Implantable defibrillators for secondary prevention of sudden cardiac death in cardiac surgery patients </text>
<text top="289" left="149" width="641" height="21" font="0">with perioperative ventricular arrhythmias. Journal of the American Heart Association. 2014; 3. </text>
<text top="309" left="115" width="936" height="21" font="0">86.  Kumar S, Barbhaiya CR, Sobieszczyk P, et al. Role of alternative interventional procedures when endo- and epicardial catheter ablation </text>
<text top="329" left="149" width="595" height="21" font="0">attempts for ventricular arrhythmias fail. Circ. Arrhythm. Electrophysiol. 2015; 8:606-15. </text>
<text top="349" left="115" width="962" height="21" font="0">87.  Anter E, Hutchinson MD, Deo R, et al. Surgical ablation of refractory ventricular tachycardia in patients with nonischemic cardiomyopathy. </text>
<text top="370" left="149" width="326" height="21" font="0">Circ. Arrhythm. Electrophysiol. 2011; 4:494-500. </text>
<text top="389" left="115" width="835" height="21" font="0">88.  Bhavani SS, Tchou P, Saliba W, et al. Surgical options for refractory ventricular tachycardia. J Card Surg. 2007; 22:533-4. </text>
<text top="410" left="115" width="936" height="21" font="0">89.  Sartipy U, Albage A, Straat E, et al. Surgery for ventricular tachycardia in patients undergoing left ventricular reconstruction by the Dor </text>
<text top="430" left="149" width="313" height="21" font="0">procedure. Ann. Thorac. Surg. 2006; 81:65-71. </text>
<text top="450" left="115" width="933" height="21" font="0">90.  Choi EK, Nagashima K, Lin KY, et al. Surgical cryoablation for ventricular tachyarrhythmia arising from the left ventricular outflow tract </text>
<text top="470" left="149" width="275" height="21" font="0">region. Heart rhythm. 2015; 12:1128-36. </text>
<text top="490" left="115" width="958" height="21" font="0">91.  Patel M, Rojas F, Shabari FR, et al. Safety and Feasibility of Open Chest Epicardial Mapping and Ablation of Ventricular Tachycardia During </text>
<text top="510" left="149" width="697" height="21" font="0">the Period of Left Ventricular Assist Device Implantation. J. Cardiovasc. Electrophysiol. 2016; 27:95-101. </text>
<text top="531" left="115" width="904" height="21" font="0">92.  Mulloy DP, Bhamidipati CM, Stone ML, et al. Cryoablation during left ventricular assist device implantation reduces postoperative </text>
<text top="551" left="149" width="517" height="21" font="0">ventricular tachyarrhythmias. J Thorac. Cardiovasc. Surg. 2013; 145:1207-13. </text>
<text top="571" left="115" width="930" height="21" font="0">93.  Schwartz PJ, Motolese M and Pollavini G. Prevention of Sudden Cardiac Death After a First Myocardial Infarction by Pharmacologic or </text>
<text top="591" left="149" width="646" height="21" font="0">Surgical Antiadrenergic Interventions. Journal of cardiovascular electrophysiology. 1992; 3:2-16. </text>
<text top="611" left="115" width="959" height="21" font="0">94.  Krittayaphong R, Bhuripanyo K, Punlee K, et al. Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease: </text>
<text top="631" left="149" width="460" height="21" font="0">a randomized placebo-controlled study. Am. Heart J. 2002; 144:e10. </text>
<text top="651" left="115" width="966" height="21" font="0">95.  Vaseghi M, Gima J, Kanaan C, et al. Cardiac sympathetic denervation in patients with refractory ventricular arrhythmias or electrical storm: </text>
<text top="671" left="149" width="470" height="21" font="0">intermediate and long-term follow-up. Heart rhythm. 2014; 11:360-6. </text>
<text top="692" left="115" width="917" height="21" font="0">96.  Ajijola OA, Lellouche N, Bourke T, et al. Bilateral cardiac sympathetic denervation for the management of electrical storm. J Am Coll </text>
<text top="712" left="149" width="156" height="21" font="0">Cardiol. 2012; 59:91-2. </text>
<text top="732" left="115" width="940" height="21" font="0">97.  Ukena C, Mahfoud F, Ewen S, et al. Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter </text>
<text top="752" left="149" width="223" height="21" font="0">Registry. Clin. Res. Cardiol. 2016. </text>
<text top="772" left="115" width="870" height="21" font="0">98.  Grimaldi R, de LA, Kornet L, et al. Can spinal cord stimulation reduce ventricular arrhythmias? Heart rhythm. 2012; 9:1884-7. </text>
</page>
<page number="327" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">327 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="963" height="21" font="0">99.  Kudenchuk PJ, Brown SP, Daya M, et al. Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest. N. Engl. J. Med. 2016:1711-22. </text>
<text top="128" left="115" width="820" height="21" font="0">100. Joglar JA and Page RL. Out-of-Hospital Cardiac Arrest--Are Drugs Ever the Answer? N. Engl. J. Med. 2016; 374:1781-2. </text>
<text top="148" left="115" width="947" height="21" font="0">101. Jacobs IG, Finn JC, Jelinek GA, et al. Effect of adrenaline on survival in out-of-hospital cardiac arrest: A randomised double-blind placebo-</text>
<text top="168" left="149" width="331" height="21" font="0">controlled trial. Resuscitation. 2011; 82:1138-43. </text>
<text top="188" left="115" width="909" height="21" font="0">102. Piccini JP, Hranitzky PM, Kilaru R, et al. Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained </text>
<text top="208" left="149" width="865" height="21" font="0">ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial </text>
<text top="228" left="149" width="468" height="21" font="0">iNfarcTion trial [VALIANT] Registry). Am J Cardiol. 2008; 102:1427-32. </text>
<text top="249" left="115" width="932" height="21" font="0">103. Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N. Engl. J. Med. </text>
<text top="269" left="149" width="126" height="21" font="0">2002; 346:884-90. </text>
<text top="289" left="115" width="914" height="21" font="0">104. Hassan TB, Jagger C and Barnett DB. A randomised trial to investigate the efficacy of magnesium sulphate for refractory ventricular </text>
<text top="309" left="149" width="289" height="21" font="0">fibrillation. Emerg. Med. J. 2002; 19:57-62. </text>
<text top="329" left="115" width="966" height="21" font="0">105. Thel MC, Armstrong AL, McNulty SE, et al. Randomised trial of magnesium in in-hospital cardiac arrest. Duke Internal Medicine Housestaff. </text>
<text top="349" left="149" width="304" height="21" font="0">Lancet (London, England). 1997; 350:1272-6. </text>
<text top="370" left="115" width="967" height="21" font="0">106. Somberg JC, Bailin SJ, Haffajee CI, et al. Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant </text>
<text top="389" left="149" width="370" height="21" font="0">ventricular tachycardia. Am. J. Cardiol. 2002; 90:853-9. </text>
<text top="410" left="115" width="951" height="21" font="0">107. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. </text>
<text top="430" left="149" width="224" height="21" font="0">N. Engl. J. Med. 1999; 341:871-8. </text>
<text top="450" left="115" width="928" height="21" font="0">108. Callaham M, Madsen CD, Barton CW, et al. A randomized clinical trial of high-dose epinephrine and norepinephrine vs standard-dose </text>
<text top="470" left="149" width="457" height="21" font="0">epinephrine in prehospital cardiac arrest. Jama. 1992; 268:2667-72. </text>
<text top="490" left="115" width="948" height="21" font="0">109. Gueugniaud PY, Mols P, Goldstein P, et al. A comparison of repeated high doses and repeated standard doses of epinephrine for cardiac </text>
<text top="510" left="149" width="679" height="21" font="0">arrest outside the hospital. European Epinephrine Study Group. N. Engl. J. Med. 1998; 339:1595-601. </text>
<text top="531" left="115" width="945" height="21" font="0">110. Gorgels AP, van den Dool A, Hofs A, et al. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular </text>
<text top="551" left="149" width="285" height="21" font="0">tachycardia. Am. J. Cardiol. 1996; 78:43-6. </text>
<text top="571" left="115" width="917" height="21" font="0">111. Ho DS, Zecchin RP, Richards DA, et al. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained </text>
<text top="591" left="149" width="457" height="21" font="0">ventricular tachycardia. Lancet (London, England). 1994; 344:18-23. </text>
<text top="611" left="115" width="951" height="21" font="0">112. Levine JH, Massumi A, Scheinman MM, et al. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. </text>
<text top="631" left="149" width="566" height="21" font="0">Intravenous Amiodarone Multicenter Trial Group. J Am Coll Cardiol. 1996; 27:67-75. </text>
<text top="651" left="115" width="959" height="21" font="0">113. Teo KK, Yusuf S and Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results </text>
<text top="671" left="149" width="410" height="21" font="0">from randomized controlled trials. Jama. 1993; 270:1589-95. </text>
<text top="692" left="115" width="905" height="21" font="0">114. Elizari MV, Martinez JM, Belziti C, et al. Morbidity and mortality following early administration of amiodarone in acute myocardial </text>
<text top="712" left="149" width="924" height="21" font="0">infarction. GEMICA study investigators, GEMA Group, Buenos Aires, Argentina. Grupo de Estudios Multicentricos en Argentina. Eur. Heart </text>
<text top="732" left="149" width="139" height="21" font="0">J. 2000; 21:198-205. </text>
<text top="752" left="115" width="960" height="21" font="0">115. Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: Adult Advanced Cardiovascular Life Support: 2015 American Heart Association Guidelines </text>
<text top="772" left="149" width="759" height="21" font="0">Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015; 132:S444-S64. </text>
</page>
<page number="328" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">328 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="967" height="21" font="0">116. Herlitz J, Ekstrom L, Wennerblom B, et al. Lidocaine in out-of-hospital ventricular fibrillation. Does it improve survival? Resuscitation. 1997; </text>
<text top="128" left="149" width="84" height="21" font="0">33:199-205. </text>
<text top="148" left="115" width="936" height="21" font="0">117. Markel DT, Gold LS, Allen J, et al. Procainamide and survival in ventricular fibrillation out-of-hospital cardiac arrest. Acad. Emerg. Med. </text>
<text top="168" left="149" width="117" height="21" font="0">2010; 17:617-23. </text>
<text top="188" left="115" width="905" height="21" font="0">118. Stiell IG, Wells GA, Field B, et al. Advanced cardiac life support in out-of-hospital cardiac arrest. N. Engl. J. Med. 2004; 351:647-56. </text>
<text top="208" left="115" width="955" height="21" font="0">119. Hagihara A, Hasegawa M, Abe T, et al. Prehospital epinephrine use and survival among patients with out-of-hospital cardiac arrest. Jama. </text>
<text top="228" left="149" width="126" height="21" font="0">2012; 307:1161-8. </text>
<text top="249" left="115" width="965" height="21" font="0">120. Donnino MW, Salciccioli JD, Howell MD, et al. Time to administration of epinephrine and outcome after in-hospital cardiac arrest with non-</text>
<text top="269" left="149" width="662" height="21" font="0">shockable rhythms: retrospective analysis of large in-hospital data registry. BMJ. 2014; 348:g3028. </text>
<text top="289" left="115" width="921" height="21" font="0">121. Koscik C, Pinawin A, McGovern H, et al. Rapid epinephrine administration improves early outcomes in out-of-hospital cardiac arrest. </text>
<text top="309" left="149" width="215" height="21" font="0">Resuscitation. 2013; 84:915-20. </text>
<text top="329" left="115" width="956" height="21" font="0">122. Spaulding CM, Joly LM, Rosenberg A, et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N. Engl. J. Med. </text>
<text top="349" left="149" width="134" height="21" font="0">1997; 336:1629-33. </text>
<text top="370" left="115" width="960" height="21" font="0">123. Cronier P, Vignon P, Bouferrache K, et al. Impact of routine percutaneous coronary intervention after out-of-hospital cardiac arrest due to </text>
<text top="389" left="149" width="328" height="21" font="0">ventricular fibrillation. Crit. Care. 2011; 15:R122. </text>
<text top="410" left="115" width="969" height="21" font="0">124. Zanuttini D, Armellini I, Nucifora G, et al. Impact of emergency coronary angiography on in-hospital outcome of unconscious survivors after </text>
<text top="430" left="149" width="428" height="21" font="0">out-of-hospital cardiac arrest. Am. J. Cardiol. 2012; 110:1723-8. </text>
<text top="450" left="115" width="917" height="21" font="0">125. Kudenchuk PJ, Newell C, White L, et al. Prophylactic lidocaine for post resuscitation care of patients with out-of-hospital ventricular </text>
<text top="470" left="149" width="387" height="21" font="0">fibrillation cardiac arrest. Resuscitation. 2013; 84:1512-8. </text>
<text top="490" left="115" width="933" height="21" font="0">126. Nademanee K, Taylor R, Bailey WE, et al. Treating electrical storm : sympathetic blockade versus advanced cardiac life support-guided </text>
<text top="510" left="149" width="258" height="21" font="0">therapy. Circulation. 2000; 102:742-7. </text>
<text top="531" left="115" width="948" height="21" font="0">127. Sasson C, Rogers MA, Dahl J, et al. Predictors of survival from out-of-hospital cardiac arrest: a systematic review and meta-analysis. Circ. </text>
<text top="551" left="149" width="297" height="21" font="0">Cardiovasc. Qual. Outcomes. 2010; 3:63-81. </text>
<text top="571" left="115" width="956" height="21" font="0">128. Buxton AE, Marchlinski FE, Doherty JU, et al. Hazards of intravenous verapamil for sustained ventricular tachycardia. Am. J. Cardiol. 1987; </text>
<text top="591" left="149" width="84" height="21" font="0">59:1107-10. </text>
<text top="611" left="115" width="883" height="21" font="0">129. Pellis T, Kette F, Lovisa D, et al. Utility of pre-cordial thump for treatment of out of hospital cardiac arrest: a prospective study. </text>
<text top="631" left="149" width="207" height="21" font="0">Resuscitation. 2009; 80:17-23. </text>
<text top="651" left="115" width="967" height="21" font="0">130. Volkmann H, Klumbies A, Kuhnert H, et al. Terminating ventricular tachycardias by mechanical heart stimulation with precordial thumps. Z. </text>
<text top="671" left="149" width="173" height="21" font="0">Kardiol. 1990; 79:717-24. </text>
<text top="692" left="115" width="892" height="21" font="0">131. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular </text>
<text top="712" left="149" width="833" height="21" font="0">arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N. Engl. J. Med. 1997; 337:1576-83. </text>
<text top="732" left="115" width="959" height="21" font="0">132. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter </text>
<text top="752" left="149" width="447" height="21" font="0">defibrillator against amiodarone. Circulation. 2000; 101:1297-302. </text>
</page>
<page number="329" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">329 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="936" height="21" font="0">133. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients </text>
<text top="128" left="149" width="718" height="21" font="0">resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000; 102:748-54. </text>
<text top="148" left="115" width="952" height="21" font="0">134. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, </text>
<text top="168" left="149" width="866" height="21" font="0">CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable </text>
<text top="188" left="149" width="333" height="21" font="0">Defibrillator Study. Eur. Heart J. 2000; 21:2071-8. </text>
<text top="208" left="115" width="946" height="21" font="0">135. Lau EW, Griffith MJ, Pathmanathan RK, et al. The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions </text>
<text top="228" left="149" width="933" height="21" font="0">and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of </text>
<text top="249" left="149" width="921" height="21" font="0">sudden cardiac death. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac </text>
<text top="269" left="149" width="766" height="21" font="0">pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2004; 6:257-66. </text>
<text top="289" left="115" width="905" height="21" font="0">136. Claro JC, Candia R, Rada G, et al. Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death. </text>
<text top="309" left="149" width="341" height="21" font="0">Cochrane Database Syst. Rev. 2015; 12:CD008093. </text>
<text top="329" left="115" width="954" height="21" font="0">137. Raitt MH, Renfroe EG, Epstein AE, et al. &#34;Stable&#34; ventricular tachycardia is not a benign rhythm : insights from the antiarrhythmics versus </text>
<text top="349" left="149" width="485" height="21" font="0">implantable defibrillators (AVID) registry. Circulation. 2001; 103:244-52. </text>
<text top="370" left="115" width="960" height="21" font="0">138. Bass EB, Elson JJ, Fogoros RN, et al. Long-term prognosis of patients undergoing electrophysiologic studies for syncope of unknown origin. </text>
<text top="389" left="149" width="217" height="21" font="0">Am J Cardiol. 1988; 62:1186-91. </text>
<text top="410" left="115" width="967" height="21" font="0">139. Owens DK, Sanders GD, Heidenreich PA, et al. Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. </text>
<text top="430" left="149" width="199" height="21" font="0">Am Heart J. 2002; 144:440-8. </text>
<text top="450" left="115" width="967" height="21" font="0">140. Ahn JM, Lee KH, Yoo SY, et al. Prognosis of variant angina manifesting as aborted sudden cardiac death. J Am Coll Cardiol. 2016; 68:137-45. </text>
<text top="470" left="115" width="956" height="21" font="0">141. Yamashina Y, Yagi T, Namekawa A, et al. Favorable outcomes of patients with vasospastic angina associated with cardiac arrest. J Cardiol. </text>
<text top="490" left="149" width="101" height="21" font="0">2014; 63:41-5. </text>
<text top="510" left="115" width="906" height="21" font="0">142. Eschalier R, Souteyrand G, Jean F, et al. Should an implanted defibrillator be considered in patients with vasospastic angina? Arch. </text>
<text top="531" left="149" width="214" height="21" font="0">Cardiovasc Dis. 2014; 107:42-7. </text>
<text top="551" left="115" width="960" height="21" font="0">143. Matsue Y, Suzuki M, Nishizaki M, et al. Clinical implications of an implantable cardioverter-defibrillator in patients with vasospastic angina </text>
<text top="571" left="149" width="466" height="21" font="0">and lethal ventricular arrhythmia. J Am Coll Cardiol. 2012; 60:908-13. </text>
<text top="591" left="115" width="942" height="21" font="0">144. Takagi Y, Yasuda S, Tsunoda R, et al. Clinical characteristics and long-term prognosis of vasospastic angina patients who survived out-of-</text>
<text top="611" left="149" width="890" height="21" font="0">hospital cardiac arrest: multicenter registry study of the Japanese Coronary Spasm Association. Circ. Arrhythm. Electrophysiol. 2011; </text>
<text top="631" left="149" width="76" height="21" font="0">4:295-302. </text>
<text top="651" left="115" width="888" height="21" font="0">145. Meisel SR, Mazur A, Chetboun I, et al. Usefulness of implantable cardioverter-defibrillators in refractory variant angina pectoris </text>
<text top="671" left="149" width="868" height="21" font="0">complicated by ventricular fibrillation in patients with angiographically normal coronary arteries. Am. J. Cardiol. 2002; 89:1114-6. </text>
<text top="692" left="115" width="927" height="21" font="0">146. Chevalier P, Dacosta A, Defaye P, et al. Arrhythmic cardiac arrest due to isolated coronary artery spasm: long-term outcome of seven </text>
<text top="712" left="149" width="377" height="21" font="0">resuscitated patients. J Am Coll Cardiol. 1998; 31:57-61. </text>
<text top="732" left="115" width="934" height="21" font="0">147. Myerburg RJ, Kessler KM, Mallon SM, et al. Life-threatening ventricular arrhythmias in patients with silent myocardial ischemia due to </text>
<text top="752" left="149" width="393" height="21" font="0">coronary-artery spasm. N. Engl. J. Med. 1992; 326:1451-5. </text>
</page>
<page number="330" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">330 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="947" height="21" font="0">148. Saxon LA, Wiener I, Natterson PD, et al. Monomorphic versus polymorphic ventricular tachycardia after coronary artery bypass grafting. </text>
<text top="128" left="149" width="208" height="21" font="0">Am. J. Cardiol. 1995; 75:403-5. </text>
<text top="148" left="115" width="943" height="21" font="0">149. Ascione R, Reeves BC, Santo K, et al. Predictors of new malignant ventricular arrhythmias after coronary surgery: a case-control study. J </text>
<text top="168" left="149" width="228" height="21" font="0">Am Coll Cardiol. 2004; 43:1630-8. </text>
<text top="188" left="115" width="920" height="21" font="0">150. Steinberg JS, Gaur A, Sciacca R, et al. New-onset sustained ventricular tachycardia after cardiac surgery. Circulation. 1999; 99:903-8. </text>
<text top="208" left="115" width="946" height="21" font="0">151. Bigger JT, Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery </text>
<text top="228" left="149" width="803" height="21" font="0">bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N. Engl. J. Med. 1997; 337:1569-75. </text>
<text top="249" left="115" width="949" height="21" font="0">152. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N. </text>
<text top="269" left="149" width="214" height="21" font="0">Engl. J. Med. 2004; 351:2481-8. </text>
<text top="289" left="115" width="935" height="21" font="0">153. Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. N. Engl. J. Med. 2009; 361:1427-36. </text>
<text top="309" left="115" width="958" height="21" font="0">154. Piccini JP, Berger JS and O'Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled </text>
<text top="329" left="149" width="252" height="21" font="0">trials. Eur. Heart J. 2009; 30:1245-53. </text>
<text top="349" left="115" width="943" height="21" font="0">155. Cantero-Perez EM, Sobrino-Marquez JM, Grande-Trillo A, et al. Implantable cardioverter defibrillator for primary prevention in patients </text>
<text top="370" left="149" width="778" height="21" font="0">with severe ventricular dysfunction awaiting heart transplantation. Transplantation proceedings. 2013; 45:3659-61. </text>
<text top="389" left="115" width="960" height="21" font="0">156. Frohlich GM, Holzmeister J, Hubler M, et al. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart </text>
<text top="410" left="149" width="593" height="21" font="0">failure awaiting heart transplantation. Heart (British Cardiac Society). 2013; 99:1158-65. </text>
<text top="430" left="115" width="921" height="21" font="0">157. Gandjbakhch E, Rovani M, Varnous S, et al. Implantable cardioverter-defibrillators in end-stage heart failure patients listed for heart </text>
<text top="450" left="149" width="769" height="21" font="0">transplantation: Results from a large retrospective registry. Archives of cardiovascular diseases. 2016; 109:476-85. </text>
<text top="470" left="115" width="925" height="21" font="0">158. Vakil K, Duval S, Cogswell R, et al. Impact of implantable cardioverter-defibrillators on waitlist mortality among patients awaiting heart </text>
<text top="495" left="149" width="277" height="15" font="0">transplantation: an UNOS/OPTN analysis</text>
<text top="490" left="425" width="115" height="21" font="0">. JACCCEP. 2016. </text>
<text top="510" left="115" width="950" height="21" font="0">159. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks </text>
<text top="531" left="149" width="715" height="21" font="0">from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. Jama. 2006; 295:165-71. </text>
<text top="551" left="115" width="888" height="21" font="0">160. Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol </text>
<text top="571" left="149" width="591" height="21" font="0">Implantable Cardioverter-Defibrillator Study Group. N. Engl. J. Med. 1999; 340:1855-62. </text>
<text top="591" left="115" width="928" height="21" font="0">161. Kettering K, Mewis C, Dornberger V, et al. Efficacy of metoprolol and sotalol in the prevention of recurrences of sustained ventricular </text>
<text top="611" left="149" width="808" height="21" font="0">tachyarrhythmias in patients with an implantable cardioverter defibrillator. Pacing Clin. Electrophysiol. 2002; 25:1571-6. </text>
<text top="631" left="115" width="903" height="21" font="0">162. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac </text>
<text top="651" left="149" width="427" height="21" font="0">Arrhythmia Suppression Trial. N. Engl. J. Med. 1991; 324:781-8. </text>
<text top="671" left="115" width="881" height="21" font="0">163. Seidl K, Hauer B, Schwick NG, et al. Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the </text>
<text top="692" left="149" width="504" height="21" font="0">implantation of a cardioverter/defibrillator. Am. J. Cardiol. 1998; 82:744-8. </text>
<text top="712" left="115" width="895" height="21" font="0">164. Kuhlkamp V, Mewis C, Mermi J, et al. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no </text>
<text top="732" left="149" width="443" height="21" font="0">antiarrhythmic drug treatment. J Am Coll Cardiol. 1999; 33:46-52. </text>
<text top="752" left="115" width="948" height="21" font="0">165. Brodine WN, Tung RT, Lee JK, et al. Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients </text>
<text top="772" left="149" width="871" height="21" font="0">with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). Am. J. Cardiol. 2005; 96:691-5. </text>
</page>
<page number="331" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">331 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="941" height="21" font="0">166. Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N. Engl. J. Med. 2007; </text>
<text top="128" left="149" width="93" height="21" font="0">357:2657-65. </text>
<text top="148" left="115" width="920" height="21" font="0">167. Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N. Engl. J. Med. 2016; </text>
<text top="168" left="149" width="84" height="21" font="0">375:111-21. </text>
<text top="188" left="115" width="938" height="21" font="0">168. Kuck KH, Schaumann A, Eckardt L, et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients </text>
<text top="208" left="149" width="834" height="21" font="0">with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet (London, England). 2010; 375:31-40. </text>
<text top="228" left="115" width="930" height="21" font="0">169. Al-Khatib SM, Daubert JP, Anstrom KJ, et al. Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter </text>
<text top="249" left="149" width="632" height="21" font="0">defibrillator (CALYPSO) pilot trial. Journal of cardiovascular electrophysiology. 2015; 26:151-7. </text>
<text top="269" left="115" width="968" height="21" font="0">170. Blanck Z, Dhala A, Deshpande S, et al. Bundle branch reentrant ventricular tachycardia: cumulative experience in 48 patients. J. Cardiovasc. </text>
<text top="289" left="149" width="212" height="21" font="0">Electrophysiol. 1993; 4:253-62. </text>
<text top="309" left="115" width="940" height="21" font="0">171. Brugada J, Aguinaga L, Mont L, et al. Coronary artery revascularization in patients with sustained ventricular arrhythmias in the chronic </text>
<text top="329" left="149" width="846" height="21" font="0">phase of a myocardial infarction: effects on the electrophysiologic substrate and outcome. J Am Coll Cardiol. 2001; 37:529-33. </text>
<text top="349" left="115" width="943" height="21" font="0">172. Sears SF, Jr., Todaro JF, Lewis TS, et al. Examining the psychosocial impact of implantable cardioverter defibrillators: a literature review. </text>
<text top="370" left="149" width="238" height="21" font="0">Clinical cardiology. 1999; 22:481-9. </text>
<text top="389" left="115" width="945" height="21" font="0">173. Lopera G, Stevenson WG, Soejima K, et al. Identification and ablation of three types of ventricular tachycardia involving the his-purkinje </text>
<text top="410" left="149" width="553" height="21" font="0">system in patients with heart disease. J. Cardiovasc. Electrophysiol. 2004; 15:52-8. </text>
<text top="430" left="115" width="944" height="21" font="0">174. Mehdirad AA, Keim S, Rist K, et al. Long-term clinical outcome of right bundle branch radiofrequency catheter ablation for treatment of </text>
<text top="450" left="149" width="639" height="21" font="0">bundle branch reentrant ventricular tachycardia. Pacing Clin. Electrophysiol. 1995; 18:2135-43. </text>
<text top="470" left="115" width="945" height="21" font="0">175. Dinov B, Fiedler L, Schonbauer R, et al. Outcomes in catheter ablation of ventricular tachycardia in dilated nonischemic cardiomyopathy </text>
<text top="490" left="149" width="894" height="21" font="0">compared with ischemic cardiomyopathy: results from the Prospective Heart Centre of Leipzig VT (HELP-VT) Study. Circulation. 2014; </text>
<text top="510" left="149" width="84" height="21" font="0">129:728-36. </text>
<text top="531" left="115" width="918" height="21" font="0">176. Tanner H, Hindricks G, Volkmer M, et al. Catheter ablation of recurrent scar-related ventricular tachycardia using electroanatomical </text>
<text top="551" left="149" width="891" height="21" font="0">mapping and irrigated ablation technology: results of the prospective multicenter Euro-VT-study. J. Cardiovasc. Electrophysiol. 2010; </text>
<text top="571" left="149" width="68" height="21" font="0">21:47-53. </text>
<text top="591" left="115" width="918" height="21" font="0">177. Marchlinski FE, Haffajee CI, Beshai JF, et al. Long-term success of irrigated radiofrequency catheter ablation of sustained ventricular </text>
<text top="611" left="149" width="577" height="21" font="0">tachycardia: post-approval THERMOCOOL VT trial. J Am Coll Cardiol. 2016; 67:674-83. </text>
<text top="631" left="115" width="951" height="21" font="0">178. Tung R, Vaseghi M, Frankel DS, et al. Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved </text>
<text top="651" left="149" width="896" height="21" font="0">survival in patients with structural heart disease: An International VT Ablation Center Collaborative Group study. Heart rhythm. 2015; </text>
<text top="671" left="149" width="101" height="21" font="0">12:1997-2007. </text>
<text top="692" left="115" width="948" height="21" font="0">179. Mallidi J, Nadkarni GN, Berger RD, et al. Meta-analysis of catheter ablation as an adjunct to medical therapy for treatment of ventricular </text>
<text top="712" left="149" width="563" height="21" font="0">tachycardia in patients with structural heart disease. Heart rhythm. 2011; 8:503-10. </text>
<text top="732" left="115" width="931" height="21" font="0">180. Calkins H, Epstein A, Packer D, et al. Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled </text>
<text top="752" left="149" width="908" height="21" font="0">radiofrequency energy: results of a prospective multicenter study. Cooled RF Multi Center Investigators Group. J Am Coll Cardiol. 2000; </text>
<text top="772" left="149" width="84" height="21" font="0">35:1905-14. </text>
</page>
<page number="332" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">332 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="937" height="21" font="0">181. Stevenson WG, Wilber DJ, Natale A, et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent </text>
<text top="128" left="149" width="907" height="21" font="0">ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial. Circulation. 2008; </text>
<text top="148" left="149" width="93" height="21" font="0">118:2773-82. </text>
<text top="168" left="115" width="944" height="21" font="0">182. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies </text>
<text top="188" left="149" width="918" height="21" font="0">and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart </text>
<text top="208" left="149" width="909" height="21" font="0">Rhythm Association (EHRA). Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on </text>
<text top="228" left="149" width="843" height="21" font="0">cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2011; 13:1077-109. </text>
<text top="249" left="115" width="898" height="21" font="0">183. American Geriatrics Society Expert Panel on the Care of Older Adults with M. Guiding Principles for the Care of Older Adults with </text>
<text top="269" left="149" width="699" height="21" font="0">Multimorbidity: An Approach for Clinicians. Journal of the American Geriatrics Society. 2012; 60:E1-E25. </text>
<text top="289" left="115" width="933" height="21" font="0">184. Hershberger RE, Morales A and Siegfried JD. Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals. </text>
<text top="309" left="149" width="205" height="21" font="0">Genet. Med. 2010; 12:655-67. </text>
<text top="329" left="115" width="922" height="21" font="0">185. Piers SR, Tao Q, CF vHvT, et al. Contrast-enhanced MRI-derived scar patterns and associated ventricular tachycardias in nonischemic </text>
<text top="349" left="149" width="690" height="21" font="0">cardiomyopathy: implications for the ablation strategy. Circ. Arrhythm. Electrophysiol. 2013; 6:875-83. </text>
<text top="370" left="115" width="926" height="21" font="0">186. Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC. </text>
<text top="389" left="149" width="251" height="21" font="0">Cardiovasc. Imaging. 2013; 6:501-11. </text>
<text top="410" left="115" width="935" height="21" font="0">187. Kuruvilla S, Adenaw N, Katwal AB, et al. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular </text>
<text top="430" left="149" width="832" height="21" font="0">outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ. Cardiovasc. Imaging. 2014; 7:250-8. </text>
<text top="450" left="115" width="907" height="21" font="0">188. Tokuda M, Tedrow UB, Kojodjojo P, et al. Catheter ablation of ventricular tachycardia in nonischemic heart disease. Circ Arrhythm </text>
<text top="470" left="149" width="228" height="21" font="0">Electrophysiol. 2012; 5:992-1000. </text>
<text top="490" left="115" width="969" height="21" font="0">189. Oloriz T, Silberbauer J, Maccabelli G, et al. Catheter ablation of ventricular arrhythmia in nonischemic cardiomyopathy: anteroseptal versus </text>
<text top="510" left="149" width="500" height="21" font="0">inferolateral scar sub-types. Circ Arrhythm Electrophysiol. 2014; 7:414-23. </text>
<text top="531" left="115" width="955" height="21" font="0">190. Proietti R, Essebag V, Beardsall J, et al. Substrate-guided ablation of haemodynamically tolerated and untolerated ventricular tachycardia </text>
<text top="551" left="149" width="908" height="21" font="0">in patients with structural heart disease: effect of cardiomyopathy type and acute success on long-term outcome. Europace : European </text>
<text top="571" left="149" width="901" height="21" font="0">pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular </text>
<text top="591" left="149" width="492" height="21" font="0">electrophysiology of the European Society of Cardiology. 2015; 17:461-7. </text>
<text top="611" left="115" width="963" height="21" font="0">191. Haqqani HM, Tschabrunn CM, Tzou WS, et al. Isolated septal substrate for ventricular tachycardia in nonischemic dilated cardiomyopathy: </text>
<text top="631" left="149" width="523" height="21" font="0">incidence, characterization, and implications. Heart rhythm. 2011; 8:1169-76. </text>
<text top="651" left="115" width="938" height="21" font="0">192. Kuhne M, Abrams G, Sarrazin JF, et al. Isolated potentials and pace-mapping as guides for ablation of ventricular tachycardia in various </text>
<text top="671" left="149" width="685" height="21" font="0">types of nonischemic cardiomyopathy. Journal of cardiovascular electrophysiology. 2010; 21:1017-23. </text>
<text top="692" left="115" width="966" height="21" font="0">193. Cano O, Hutchinson M, Lin D, et al. Electroanatomic substrate and ablation outcome for suspected epicardial ventricular tachycardia in left </text>
<text top="712" left="149" width="527" height="21" font="0">ventricular nonischemic cardiomyopathy. J Am Coll Cardiol. 2009; 54:799-808. </text>
<text top="732" left="115" width="965" height="21" font="0">194. Delacretaz E, Stevenson WG, Ellison KE, et al. Mapping and radiofrequency catheter ablation of the three types of sustained monomorphic </text>
<text top="752" left="149" width="757" height="21" font="0">ventricular tachycardia in nonischemic heart disease. Journal of cardiovascular electrophysiology. 2000; 11:11-7. </text>
</page>
<page number="333" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">333 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="854" height="21" font="0">195. Desai AS, Fang JC, Maisel WH, et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic </text>
<text top="128" left="149" width="608" height="21" font="0">cardiomyopathy: a meta-analysis of randomized controlled trials. Jama. 2004; 292:2874-9. </text>
<text top="148" left="115" width="930" height="21" font="0">196. Ruwald MH, Okumura K, Kimura T, et al. Syncope in high-risk cardiomyopathy patients with implantable defibrillators: frequency, risk </text>
<text top="168" left="149" width="877" height="21" font="0">factors, mechanisms, and association with mortality: results from the multicenter automatic defibrillator implantation trial-reduce </text>
<text top="188" left="149" width="488" height="21" font="0">inappropriate therapy (MADIT-RIT) study. Circulation. 2014; 129:545-52. </text>
<text top="208" left="115" width="968" height="21" font="0">197. Knight BP, Goyal R, Pelosi F, et al. Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an </text>
<text top="228" left="149" width="416" height="21" font="0">implantable defibrillator. J Am Coll Cardiol. 1999; 33:1964-70. </text>
<text top="249" left="115" width="960" height="21" font="0">198. Brilakis ES, Shen WK, Hammill SC, et al. Role of programmed ventricular stimulation and implantable cardioverter defibrillators in patients </text>
<text top="269" left="149" width="668" height="21" font="0">with idiopathic dilated cardiomyopathy and syncope. Pacing Clin. Electrophysiol. 2001; 24:1623-30. </text>
<text top="289" left="115" width="959" height="21" font="0">199. Fonarow GC, Feliciano Z, Boyle NG, et al. Improved survival in patients with nonischemic advanced heart failure and syncope treated with </text>
<text top="309" left="149" width="487" height="21" font="0">an implantable cardioverter-defibrillator. Am. J. Cardiol. 2000; 85:981-5. </text>
<text top="329" left="115" width="950" height="21" font="0">200. Olshansky B, Poole JE, Johnson G, et al. Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study. J Am </text>
<text top="349" left="149" width="210" height="21" font="0">Coll Cardiol. 2008; 51:1277-82. </text>
<text top="370" left="115" width="955" height="21" font="0">201. Bänsch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy </text>
<text top="389" left="149" width="283" height="21" font="0">Trial (CAT). Circulation. 2002; 105:1453-8. </text>
<text top="410" left="115" width="958" height="21" font="0">202. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with </text>
<text top="430" left="149" width="876" height="21" font="0">nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT. J Am Coll Cardiol. 2003; </text>
<text top="450" left="149" width="84" height="21" font="0">41:1707-12. </text>
<text top="470" left="115" width="960" height="21" font="0">203. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N. Engl. J. </text>
<text top="490" left="149" width="165" height="21" font="0">Med. 2004; 350:2151-8. </text>
<text top="510" left="115" width="918" height="21" font="0">204. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced </text>
<text top="531" left="149" width="385" height="21" font="0">chronic heart failure. N. Engl. J. Med. 2004; 350:2140-50. </text>
<text top="551" left="115" width="893" height="21" font="0">205. Kober L, Bloch Thomsen PE, Moller M, et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular </text>
<text top="571" left="149" width="520" height="21" font="0">dysfunction: a randomised trial. Lancet (London, England). 2000; 356:2052-8. </text>
<text top="591" left="115" width="946" height="21" font="0">206. Grimm W, Christ M, Bach J, et al. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg </text>
<text top="611" left="149" width="375" height="21" font="0">Cardiomyopathy Study. Circulation. 2003; 108:2883-91. </text>
<text top="631" left="115" width="967" height="21" font="0">207. Goldberger JJ, Subacius H, Patel T, et al. Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy. J Am </text>
<text top="651" left="149" width="210" height="21" font="0">Coll Cardiol. 2014; 63:1879-89. </text>
<text top="671" left="115" width="946" height="21" font="0">208. Anselme F, Moubarak G, Savoure A, et al. Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction </text>
<text top="692" left="149" width="287" height="21" font="0">disorders. Heart rhythm. 2013; 10:1492-8. </text>
<text top="712" left="115" width="956" height="21" font="0">209. van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European </text>
<text top="732" left="149" width="338" height="21" font="0">cohort study. J Am Coll Cardiol. 2012; 59:493-500. </text>
<text top="752" left="115" width="925" height="21" font="0">210. Pasotti M, Klersy C, Pilotto A, et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol. 2008; </text>
<text top="772" left="149" width="84" height="21" font="0">52:1250-60. </text>
</page>
<page number="334" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">334 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="932" height="21" font="0">211. Van Berlo JH, de Voogt WG, van der Kooi AJ, et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do </text>
<text top="128" left="149" width="640" height="21" font="0">lamin A/C mutations portend a high risk of sudden death? J. Mol. Med. (Berl. ). 2005; 83:79-83. </text>
<text top="148" left="115" width="934" height="21" font="0">212. Kutyifa V, Moss AJ, Klein H, et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective </text>
<text top="168" left="149" width="791" height="21" font="0">Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry). Circulation. 2015; 132:1613-9. </text>
<text top="188" left="115" width="926" height="21" font="0">213. Singh M, Wang NC, Jain S, et al. Utility of the wearable cardioverter-defibrillator in patients with newly diagnosed cardiomyopathy: a </text>
<text top="208" left="149" width="504" height="21" font="0">decade-long single-center experience. J Am Coll Cardiol. 2015; 66:2607-13. </text>
<text top="228" left="115" width="965" height="21" font="0">214. Uyei J and Braithwaite RS. Effectiveness of wearable defibrillators: systematic review and quality of evidence. Int. J Technol. Assess. Health </text>
<text top="249" left="149" width="164" height="21" font="0">Care. 2014; 30:194-202. </text>
<text top="269" left="115" width="905" height="21" font="0">215. Al-Khatib SM, Fonarow GC, Joglar JA, et al. Primary prevention implantable cardioverter defibillators in patients with nonischemic </text>
<text top="289" left="149" width="394" height="21" font="0">cardiomyopathy: A meta-analysis. JAMA Cardiology. 2017. </text>
<text top="309" left="115" width="963" height="21" font="0">216. Quarta G, Muir A, Pantazis A, et al. Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised </text>
<text top="329" left="149" width="331" height="21" font="0">task force criteria. Circulation. 2011; 123:2701-9. </text>
<text top="349" left="115" width="938" height="21" font="0">217. Kapplinger JD, Landstrom AP, Salisbury BA, et al. Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated </text>
<text top="370" left="149" width="533" height="21" font="0">mutations from background genetic noise. J Am Coll Cardiol. 2011; 57:2317-27. </text>
<text top="389" left="115" width="911" height="21" font="0">218. Bhonsale A, James CA, Tichnell C, et al. Risk stratification in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated </text>
<text top="410" left="149" width="530" height="21" font="0">desmosomal mutation carriers. Circ. Arrhythm. Electrophysiol. 2013; 6:569-78. </text>
<text top="430" left="115" width="965" height="21" font="0">219. Marcus FI, Edson S and Towbin JA. Genetics of arrhythmogenic right ventricular cardiomyopathy: a practical guide for physicians. J Am Coll </text>
<text top="450" left="149" width="173" height="21" font="0">Cardiol. 2013; 61:1945-8. </text>
<text top="470" left="115" width="820" height="21" font="0">220. Bhonsale A, Groeneweg JA, James CA, et al. Impact of genotype on clinical course in arrhythmogenic right ventricular </text>
<text top="490" left="149" width="583" height="21" font="0">dysplasia/cardiomyopathy-associated mutation carriers. Eur. Heart J. 2015; 36:847-55. </text>
<text top="510" left="115" width="929" height="21" font="0">221. Rigato I, Bauce B, Rampazzo A, et al. Compound and digenic heterozygosity predicts lifetime arrhythmic outcome and sudden cardiac </text>
<text top="531" left="149" width="849" height="21" font="0">death in desmosomal gene-related arrhythmogenic right ventricular cardiomyopathy. Circ. Cardiovasc. Genet. 2013; 6:533-42. </text>
<text top="551" left="115" width="933" height="21" font="0">222. Groeneweg JA, Bhonsale A, James CA, et al. Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right </text>
<text top="571" left="149" width="741" height="21" font="0">Ventricular Dysplasia/Cardiomyopathy Patients and Family Members. Circ. Cardiovasc. Genet. 2015; 8:437-46. </text>
<text top="591" left="115" width="948" height="21" font="0">223. te Riele AS, James CA, Groeneweg JA, et al. Approach to family screening in arrhythmogenic right ventricular dysplasia/cardiomyopathy. </text>
<text top="611" left="149" width="202" height="21" font="0">Eur. Heart J. 2016; 37:755-63. </text>
<text top="631" left="115" width="856" height="21" font="0">224. Kamath GS, Zareba W, Delaney J, et al. Value of the signal-averaged electrocardiogram in arrhythmogenic right ventricular </text>
<text top="651" left="149" width="393" height="21" font="0">cardiomyopathy/dysplasia. Heart rhythm. 2011; 8:256-62. </text>
<text top="671" left="115" width="888" height="21" font="0">225. Marcus FI, Fontaine GH, Guiraudon G, et al. Right ventricular dysplasia: a report of 24 adult cases. Circulation. 1982; 65:384-98. </text>
<text top="692" left="115" width="819" height="21" font="0">226. Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular </text>
<text top="712" left="149" width="569" height="21" font="0">cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol. 1997; 30:1512-20. </text>
<text top="732" left="115" width="893" height="21" font="0">227. Link MS, Laidlaw D, Polonsky B, et al. Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, </text>
<text top="752" left="149" width="447" height="21" font="0">characteristics, and treatment. J Am Coll Cardiol. 2014; 64:119-25. </text>
</page>
<page number="335" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">335 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="960" height="21" font="0">228. Corrado D, Wichter T, Link MS, et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force </text>
<text top="128" left="149" width="356" height="21" font="0">consensus statement. Circulation. 2015; 132:441-53. </text>
<text top="148" left="115" width="895" height="21" font="0">229. Corrado D, Leoni L, Link MS, et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with </text>
<text top="168" left="149" width="621" height="21" font="0">arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation. 2003; 108:3084-91. </text>
<text top="188" left="115" width="923" height="21" font="0">230. Piccini JP, Dalal D, Roguin A, et al. Predictors of appropriate implantable defibrillator therapies in patients with arrhythmogenic right </text>
<text top="208" left="149" width="361" height="21" font="0">ventricular dysplasia. Heart rhythm. 2005; 2:1188-94. </text>
<text top="228" left="115" width="902" height="21" font="0">231. Bhonsale A, James CA, Tichnell C, et al. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with </text>
<text top="249" left="149" width="907" height="21" font="0">arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary </text>
<text top="269" left="149" width="327" height="21" font="0">prevention. J Am Coll Cardiol. 2011; 58:1485-96. </text>
<text top="289" left="115" width="931" height="21" font="0">232. Dalal D, Jain R, Tandri H, et al. Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right </text>
<text top="309" left="149" width="498" height="21" font="0">ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2007; 50:432-40. </text>
<text top="329" left="115" width="955" height="21" font="0">233. Garcia FC, Bazan V, Zado ES, et al. Epicardial substrate and outcome with epicardial ablation of ventricular tachycardia in arrhythmogenic </text>
<text top="349" left="149" width="502" height="21" font="0">right ventricular cardiomyopathy/dysplasia. Circulation. 2009; 120:366-75. </text>
<text top="370" left="115" width="910" height="21" font="0">234. Philips B, Madhavan S, James C, et al. Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular </text>
<text top="389" left="149" width="510" height="21" font="0">dysplasia/cardiomyopathy. Circ. Arrhythm. Electrophysiol. 2012; 5:499-505. </text>
<text top="410" left="115" width="906" height="21" font="0">235. Bai R, Di BL, Shivkumar K, et al. Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy: </text>
<text top="430" left="149" width="892" height="21" font="0">arrhythmia-free survival after endo-epicardial substrate based mapping and ablation. Circ. Arrhythm. Electrophysiol. 2011; 4:478-85. </text>
<text top="450" left="115" width="894" height="21" font="0">236. Berruezo A, Fernandez-Armenta J, Mont L, et al. Combined endocardial and epicardial catheter ablation in arrhythmogenic right </text>
<text top="470" left="149" width="753" height="21" font="0">ventricular dysplasia incorporating scar dechanneling technique. Circ. Arrhythm. Electrophysiol. 2012; 5:111-21. </text>
<text top="490" left="115" width="902" height="21" font="0">237. Philips B, te Riele AS, Sawant A, et al. Outcomes and ventricular tachycardia recurrence characteristics after epicardial ablation of </text>
<text top="510" left="149" width="797" height="21" font="0">ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart rhythm. 2015; 12:716-25. </text>
<text top="531" left="115" width="870" height="21" font="0">238. Santangeli P, Zado ES, Supple GE, et al. Long-term outcome with catheter ablation of ventricular tachycardia in patients with </text>
<text top="551" left="149" width="665" height="21" font="0">arrhythmogenic right ventricular cardiomyopathy. Circ. Arrhythm. Electrophysiol. 2015; 8:1413-21. </text>
<text top="571" left="115" width="954" height="21" font="0">239. James CA, Bhonsale A, Tichnell C, et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular </text>
<text top="591" left="149" width="706" height="21" font="0">dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013; 62:1290-7. </text>
<text top="611" left="115" width="931" height="21" font="0">240. Sawant AC, Bhonsale A, te Riele AS, et al. Exercise has a disproportionate role in the pathogenesis of arrhythmogenic right ventricular </text>
<text top="631" left="149" width="887" height="21" font="0">dysplasia/cardiomyopathy in patients without desmosomal mutations. Journal of the American Heart Association. 2014; 3:e001471. </text>
<text top="651" left="115" width="948" height="21" font="0">241. Ruwald AC, Marcus F, Estes NA, 3rd, et al. Association of competitive and recreational sport participation with cardiac events in patients </text>
<text top="671" left="149" width="914" height="21" font="0">with arrhythmogenic right ventricular cardiomyopathy: results from the North American multidisciplinary study of arrhythmogenic right </text>
<text top="692" left="149" width="483" height="21" font="0">ventricular cardiomyopathy. European heart journal. 2015; 36:1735-43. </text>
<text top="712" left="115" width="962" height="21" font="0">242. Sawant AC, te Riele AS, Tichnell C, et al. Safety of American Heart Association-recommended minimum exercise for desmosomal mutation </text>
<text top="732" left="149" width="283" height="21" font="0">carriers. Heart rhythm. 2016; 13:199-207. </text>
<text top="752" left="115" width="960" height="21" font="0">243. Saberniak J, Hasselberg NE, Borgquist R, et al. Vigorous physical activity impairs myocardial function in patients with arrhythmogenic right </text>
<text top="772" left="149" width="711" height="21" font="0">ventricular cardiomyopathy and in mutation positive family members. Eur. J Heart Fail. 2014; 16:1337-44. </text>
</page>
<page number="336" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">336 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="949" height="21" font="0">244. Sen-Chowdhry S, Syrris P, Prasad SK, et al. Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll </text>
<text top="128" left="149" width="181" height="21" font="0">Cardiol. 2008; 52:2175-87. </text>
<text top="148" left="115" width="925" height="21" font="0">245. Vermes E, Strohm O, Otmani A, et al. Impact of the revision of arrhythmogenic right ventricular cardiomyopathy/dysplasia task force </text>
<text top="168" left="149" width="585" height="21" font="0">criteria on its prevalence by CMR criteria. JACC. Cardiovascular imaging. 2011; 4:282-7. </text>
<text top="188" left="115" width="920" height="21" font="0">246. te Riele AS, Bhonsale A, James CA, et al. Incremental value of cardiac magnetic resonance imaging in arrhythmic risk stratification of </text>
<text top="208" left="149" width="929" height="21" font="0">arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013; 62:1761-9. </text>
<text top="228" left="115" width="918" height="21" font="0">247. Te Riele AS, James CA, Philips B, et al. Mutation-positive arrhythmogenic right ventricular dysplasia/cardiomyopathy: the triangle of </text>
<text top="249" left="149" width="559" height="21" font="0">dysplasia displaced. Journal of cardiovascular electrophysiology. 2013; 24:1311-20. </text>
<text top="269" left="115" width="949" height="21" font="0">248. Liu T, Pursnani A, Sharma UC, et al. Effect of the 2010 task force criteria on reclassification of cardiovascular magnetic resonance criteria </text>
<text top="289" left="149" width="899" height="21" font="0">for arrhythmogenic right ventricular cardiomyopathy. Journal of cardiovascular magnetic resonance : official journal of the Society for </text>
<text top="309" left="149" width="337" height="21" font="0">Cardiovascular Magnetic Resonance. 2014; 16:47. </text>
<text top="329" left="115" width="956" height="21" font="0">249. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification </text>
<text top="349" left="149" width="383" height="21" font="0">of the task force criteria. Circulation. 2010; 121:1533-41. </text>
<text top="370" left="115" width="906" height="21" font="0">250. Hershberger RE, Lindenfeld J, Mestroni L, et al. Genetic evaluation of cardiomyopathy--a Heart Failure Society of America practice </text>
<text top="389" left="149" width="351" height="21" font="0">guideline. Journal of cardiac failure. 2009; 15:83-97. </text>
<text top="410" left="115" width="952" height="21" font="0">251. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with </text>
<text top="430" left="149" width="440" height="21" font="0">hypertrophic cardiomyopathy. N. Engl. J. Med. 2000; 342:365-73. </text>
<text top="450" left="115" width="917" height="21" font="0">252. Christiaans I, van Langen IM, Birnie E, et al. Genetic counseling and cardiac care in predictively tested hypertrophic cardiomyopathy </text>
<text top="470" left="149" width="746" height="21" font="0">mutation carriers: the patients' perspective. American journal of medical genetics. Part A. 2009; 149a:1444-51. </text>
<text top="490" left="115" width="961" height="21" font="0">253. Hamang A, Eide GE, Rokne B, et al. Predictors of heart-focused anxiety in patients undergoing genetic investigation and counseling of long </text>
<text top="510" left="149" width="778" height="21" font="0">QT syndrome or hypertrophic cardiomyopathy: a one year follow-up. Journal of genetic counseling. 2012; 21:72-84. </text>
<text top="531" left="115" width="894" height="21" font="0">254. Bos JM, Will ML, Gersh BJ, et al. Characterization of a phenotype-based genetic test prediction score for unrelated patients with </text>
<text top="551" left="149" width="497" height="21" font="0">hypertrophic cardiomyopathy. Mayo Clinic proceedings. 2014; 89:727-37. </text>
<text top="571" left="115" width="961" height="21" font="0">255. O'Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM </text>
<text top="591" left="149" width="279" height="21" font="0">risk-SCD). Eur. Heart J. 2014; 35:2010-20. </text>
<text top="611" left="115" width="921" height="21" font="0">256. Elliott PM, Sharma S, Varnava A, et al. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic </text>
<text top="631" left="149" width="371" height="21" font="0">cardiomyopathy. J Am Coll Cardiol. 1999; 33:1596-601. </text>
<text top="651" left="115" width="913" height="21" font="0">257. Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic </text>
<text top="671" left="149" width="285" height="21" font="0">cardiomyopathy. Jama. 2007; 298:405-12. </text>
<text top="692" left="115" width="956" height="21" font="0">258. Lin G, Nishimura RA, Gersh BJ, et al. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with </text>
<text top="712" left="149" width="533" height="21" font="0">hypertrophic cardiomyopathy. Heart (British Cardiac Society). 2009; 95:709-14. </text>
<text top="732" left="115" width="941" height="21" font="0">259. Syska P, Przybylski A, Chojnowska L, et al. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy </text>
<text top="752" left="149" width="689" height="21" font="0">and complications of the therapy in long-term follow-up. J. Cardiovasc. Electrophysiol. 2010; 21:883-9. </text>
</page>
<page number="337" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">337 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="947" height="21" font="0">260. O'Mahony C, Lambiase PD, Quarta G, et al. The long-term survival and the risks and benefits of implantable cardioverter defibrillators in </text>
<text top="128" left="149" width="625" height="21" font="0">patients with hypertrophic cardiomyopathy. Heart (British Cardiac Society). 2012; 98:116-25. </text>
<text top="148" left="115" width="902" height="21" font="0">261. Melacini P, Maron BJ, Bobbo F, et al. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in </text>
<text top="168" left="149" width="533" height="21" font="0">hypertrophic cardiomyopathy. Heart (British Cardiac Society). 2007; 93:708-10. </text>
<text top="188" left="115" width="908" height="21" font="0">262. McKenna WJ, Oakley CM, Krikler DM, et al. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and </text>
<text top="208" left="149" width="348" height="21" font="0">ventricular tachycardia. Br. Heart J. 1985; 53:412-6. </text>
<text top="228" left="115" width="933" height="21" font="0">263. Olivotto I, Maron BJ, Montereggi A, et al. Prognostic value of systemic blood pressure response during exercise in a community-based </text>
<text top="249" left="149" width="616" height="21" font="0">patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999; 33:2044-51. </text>
<text top="269" left="115" width="915" height="21" font="0">264. Sadoul N, Prasad K, Elliott PM, et al. Prospective prognostic assessment of blood pressure response during exercise in patients with </text>
<text top="289" left="149" width="414" height="21" font="0">hypertrophic cardiomyopathy. Circulation. 1997; 96:2987-91. </text>
<text top="309" left="115" width="957" height="21" font="0">265. Sorajja P, Nishimura RA, Ommen SR, et al. Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of </text>
<text top="329" left="149" width="429" height="21" font="0">massive hypertrophy. J Am Soc. Echocardiogr. 2006; 19:788-95. </text>
<text top="349" left="115" width="909" height="21" font="0">266. Maki S, Ikeda H, Muro A, et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am. J. Cardiol. 1998; 82:774-8. </text>
<text top="370" left="115" width="924" height="21" font="0">267. Elliott PM, Gimeno JR, Tome MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic </text>
<text top="389" left="149" width="328" height="21" font="0">cardiomyopathy. Eur. Heart J. 2006; 27:1933-41. </text>
<text top="410" left="115" width="958" height="21" font="0">268. Monserrat L, Elliott PM, Gimeno JR, et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker </text>
<text top="430" left="149" width="493" height="21" font="0">of sudden death risk in young patients. J Am Coll Cardiol. 2003; 42:873-9. </text>
<text top="450" left="115" width="957" height="21" font="0">269. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. </text>
<text top="470" left="149" width="241" height="21" font="0">N. Engl. J. Med. 2000; 342:1778-85. </text>
<text top="490" left="115" width="945" height="21" font="0">270. Elliott PM, Gimeno Blanes JR, Mahon NG, et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with </text>
<text top="510" left="149" width="503" height="21" font="0">hypertrophic cardiomyopathy. Lancet (London, England). 2001; 357:420-4. </text>
<text top="531" left="115" width="963" height="21" font="0">271. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. </text>
<text top="551" left="149" width="117" height="21" font="0">2000; 36:2212-8. </text>
<text top="571" left="115" width="968" height="21" font="0">272. Ackerman MJ, VanDriest SL, Ommen SR, et al. Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and </text>
<text top="591" left="149" width="857" height="21" font="0">troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. J Am Coll Cardiol. 2002; 39:2042-8. </text>
<text top="611" left="115" width="905" height="21" font="0">273. Lopes LR, Rahman MS and Elliott PM. A systematic review and meta-analysis of genotype-phenotype associations in patients with </text>
<text top="631" left="149" width="814" height="21" font="0">hypertrophic cardiomyopathy caused by sarcomeric protein mutations. Heart (British Cardiac Society). 2013; 99:1800-11. </text>
<text top="651" left="115" width="940" height="21" font="0">274. Bos JM, Maron BJ, Ackerman MJ, et al. Role of family history of sudden death in risk stratification and prevention of sudden death with </text>
<text top="671" left="149" width="622" height="21" font="0">implantable defibrillators in hypertrophic cardiomyopathy. Am. J. Cardiol. 2010; 106:1481-6. </text>
<text top="692" left="115" width="940" height="21" font="0">275. Spirito P, Autore C, Rapezzi C, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation. 2009; 119:1703-10. </text>
<text top="712" left="115" width="962" height="21" font="0">276. Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. </text>
<text top="732" left="149" width="215" height="21" font="0">Circulation. 2009; 119:1085-92. </text>
<text top="752" left="115" width="932" height="21" font="0">277. Kuck KH, Kunze KP, Schluter M, et al. Programmed electrical stimulation in hypertrophic cardiomyopathy. Results in patients with and </text>
<text top="772" left="149" width="427" height="21" font="0">without cardiac arrest or syncope. Eur. Heart J. 1988; 9:177-85. </text>
</page>
<page number="338" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">338 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="937" height="21" font="0">278. Zhu DW, Sun H, Hill R, et al. The value of electrophysiology study and prophylactic implantation of cardioverter defibrillator in patients </text>
<text top="128" left="149" width="550" height="21" font="0">with hypertrophic cardiomyopathy. Pacing Clin. Electrophysiol. 1998; 21:299-302. </text>
<text top="148" left="115" width="914" height="21" font="0">279. Christiaans I, Birnie E, van Langen IM, et al. The yield of risk stratification for sudden cardiac death in hypertrophic cardiomyopathy </text>
<text top="168" left="149" width="732" height="21" font="0">myosin-binding protein C gene mutation carriers: focus on predictive screening. Eur. Heart J. 2010; 31:842-8. </text>
<text top="188" left="115" width="923" height="21" font="0">280. Olivotto I, Girolami F, Ackerman MJ, et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic </text>
<text top="208" left="149" width="339" height="21" font="0">cardiomyopathy. Mayo Clin. Proc. 2008; 83:630-8. </text>
<text top="228" left="115" width="918" height="21" font="0">281. Ingles J, Sarina T, Yeates L, et al. Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy. Genet. Med. 2013; </text>
<text top="249" left="149" width="68" height="21" font="0">15:972-7. </text>
<text top="269" left="115" width="953" height="21" font="0">282. Jensen MK, Havndrup O, Christiansen M, et al. Penetrance of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-</text>
<text top="289" left="149" width="601" height="21" font="0">up study of clinical screening and predictive genetic testing. Circulation. 2013; 127:48-54. </text>
<text top="309" left="115" width="932" height="21" font="0">283. Girolami F, Ho CY, Semsarian C, et al. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere </text>
<text top="329" left="149" width="411" height="21" font="0">protein gene mutations. J Am Coll Cardiol. 2010; 55:1444-53. </text>
<text top="349" left="115" width="944" height="21" font="0">284. Klues HG, Schiffers A and Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: </text>
<text top="370" left="149" width="899" height="21" font="0">morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol. 1995; </text>
<text top="389" left="149" width="93" height="21" font="0">26:1699-708. </text>
<text top="410" left="115" width="965" height="21" font="0">285. Adabag AS, Kuskowski MA and Maron BJ. Determinants for clinical diagnosis of hypertrophic cardiomyopathy. Am J Cardiol. 2006; 98:1507-</text>
<text top="430" left="149" width="25" height="21" font="0">11. </text>
<text top="450" left="115" width="965" height="21" font="0">286. Cooper LT, Jr., Berry GJ and Shabetai R. Idiopathic giant-cell myocarditis--natural history and treatment. Multicenter Giant Cell Myocarditis </text>
<text top="470" left="149" width="414" height="21" font="0">Study Group Investigators. N. Engl. J. Med. 1997; 336:1860-6. </text>
<text top="490" left="115" width="884" height="21" font="0">287. Kandolin R, Lehtonen J, Salmenkivi K, et al. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined </text>
<text top="510" left="149" width="351" height="21" font="0">immunosuppression. Circ. Heart Fail. 2013; 6:15-22. </text>
<text top="531" left="115" width="919" height="21" font="0">288. Maleszewski JJ, Orellana VM, Hodge DO, et al. Long-term risk of recurrence, morbidity and mortality in giant cell myocarditis. Am. J. </text>
<text top="551" left="149" width="181" height="21" font="0">Cardiol. 2015; 115:1733-8. </text>
<text top="571" left="115" width="935" height="21" font="0">289. Feldman AM, Klein H, Tchou P, et al. Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden </text>
<text top="591" left="149" width="535" height="21" font="0">death: results of the WEARIT/BIROAD. Pacing Clin. Electrophysiol. 2004; 27:4-9. </text>
<text top="611" left="115" width="926" height="21" font="0">290. Kao AC, Krause SW, Handa R, et al. Wearable defibrillator use in heart failure (WIF): results of a prospective registry. BMC Cardiovasc </text>
<text top="631" left="149" width="147" height="21" font="0">Disord. 2012; 12:123. </text>
<text top="651" left="115" width="940" height="21" font="0">291. Naruse Y, Sekiguchi Y, Nogami A, et al. Systematic treatment approach to ventricular tachycardia in cardiac sarcoidosis. Circ. Arrhythm. </text>
<text top="671" left="149" width="212" height="21" font="0">Electrophysiol. 2014; 7:407-13. </text>
<text top="692" left="115" width="967" height="21" font="0">292. Takaya Y, Kusano KF, Nakamura K, et al. Outcomes in patients with high-degree atrioventricular block as the initial manifestation of cardiac </text>
<text top="712" left="149" width="298" height="21" font="0">sarcoidosis. Am. J. Cardiol. 2015; 115:505-9. </text>
<text top="732" left="115" width="950" height="21" font="0">293. Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide </text>
<text top="752" left="149" width="251" height="21" font="0">study. Circulation. 2015; 131:624-32. </text>
</page>
<page number="339" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">339 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="958" height="21" font="0">294. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with </text>
<text top="128" left="149" width="309" height="21" font="0">prednisone. Am. J. Cardiol. 2001; 88:1006-10. </text>
<text top="148" left="115" width="940" height="21" font="0">295. Aizer A, Stern EH, Gomes JA, et al. Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients </text>
<text top="168" left="149" width="383" height="21" font="0">with cardiac sarcoidosis. Am. J. Cardiol. 2005; 96:276-82. </text>
<text top="188" left="115" width="910" height="21" font="0">296. Mehta D, Mori N, Goldbarg SH, et al. Primary prevention of sudden cardiac death in silent cardiac sarcoidosis: role of programmed </text>
<text top="208" left="149" width="461" height="21" font="0">ventricular stimulation. Circ. Arrhythm. Electrophysiol. 2011; 4:43-8. </text>
<text top="228" left="115" width="909" height="21" font="0">297. Coleman GC, Shaw PW, Balfour PC, Jr., et al. Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis: a </text>
<text top="249" left="149" width="476" height="21" font="0">systematic review and meta-analysis. JACC. Cardiovasc. Imaging. 2016. </text>
<text top="269" left="115" width="950" height="21" font="0">298. Heng EL, Bolger AP, Kempny A, et al. Neurohormonal activation and its relation to outcomes late after repair of tetralogy of Fallot. Heart </text>
<text top="289" left="149" width="292" height="21" font="0">(British Cardiac Society). 2015; 101:447-54. </text>
<text top="309" left="115" width="919" height="21" font="0">299. Murtagh G, Laffin LJ, Beshai JF, et al. Prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection </text>
<text top="329" left="149" width="755" height="21" font="0">fraction: risk stratification using cardiovascular magnetic resonance. Circ. Cardiovasc. Imaging. 2016; 9:e003738. </text>
<text top="349" left="115" width="930" height="21" font="0">300. Crawford T, Mueller G, Sarsam S, et al. Magnetic resonance imaging for identifying patients with cardiac sarcoidosis and preserved or </text>
<text top="370" left="149" width="818" height="21" font="0">mildly reduced left ventricular function at risk of ventricular arrhythmias. Circ. Arrhythm. Electrophysiol. 2014; 7:1109-15. </text>
<text top="389" left="115" width="906" height="21" font="0">301. Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with </text>
<text top="410" left="149" width="442" height="21" font="0">suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014; 63:329-36. </text>
<text top="430" left="115" width="915" height="21" font="0">302. Kron J, Sauer W, Schuller J, et al. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in </text>
<text top="450" left="149" width="922" height="21" font="0">patients with cardiac sarcoidosis. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups </text>
<text top="470" left="149" width="847" height="21" font="0">on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2013; 15:347-54. </text>
<text top="490" left="115" width="918" height="21" font="0">303. Mohsen A, Jimenez A, Hood RE, et al. Cardiac sarcoidosis: electrophysiological outcomes on long-term follow-up and the role of the </text>
<text top="510" left="149" width="564" height="21" font="0">implantable cardioverter-defibrillator. J. Cardiovasc. Electrophysiol. 2014; 25:171-6. </text>
<text top="531" left="115" width="936" height="21" font="0">304. Schuller JL, Zipse M, Crawford T, et al. Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. J. Cardiovasc. </text>
<text top="551" left="149" width="212" height="21" font="0">Electrophysiol. 2012; 23:925-9. </text>
<text top="571" left="115" width="950" height="21" font="0">305. Yodogawa K, Seino Y, Ohara T, et al. Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis. Ann. </text>
<text top="591" left="149" width="299" height="21" font="0">Noninvasive. Electrocardiol. 2011; 16:140-7. </text>
<text top="611" left="115" width="958" height="21" font="0">306. Segawa M, Fukuda K, Nakano M, et al. Time course and factors correlating with ventricular tachyarrhythmias after introduction of steroid </text>
<text top="631" left="149" width="534" height="21" font="0">therapy in cardiac sarcoidosis. Circ. Arrhythm. Electrophysiol. 2016; 9:e003353. </text>
<text top="651" left="115" width="958" height="21" font="0">307. Varr BC, Zarafshar S, Coakley T, et al. Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart rhythm. </text>
<text top="671" left="149" width="117" height="21" font="0">2014; 11:158-62. </text>
<text top="692" left="115" width="891" height="21" font="0">308. Kristen AV, Dengler TJ, Hegenbart U, et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac </text>
<text top="712" left="149" width="554" height="21" font="0">amyloidosis and high risk for sudden cardiac death. Heart rhythm. 2008; 5:235-40. </text>
<text top="732" left="115" width="911" height="21" font="0">309. Lubitz SA, Goldbarg SH and Mehta D. Sudden cardiac death in infiltrative cardiomyopathies: sarcoidosis, scleroderma, amyloidosis, </text>
<text top="752" left="149" width="380" height="21" font="0">hemachromatosis. Prog. Cardiovasc Dis. 2008; 51:58-73. </text>
</page>
<page number="340" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">340 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="946" height="21" font="0">310. Sandner SE, Wieselthaler G, Zuckermann A, et al. Survival benefit of the implantable cardioverter-defibrillator in patients on the waiting </text>
<text top="128" left="149" width="411" height="21" font="0">list for cardiac transplantation. Circulation. 2001; 104:I171-6. </text>
<text top="148" left="115" width="959" height="21" font="0">311. Opreanu M, Wan C, Singh V, et al. Wearable cardioverter-defibrillator as a bridge to cardiac transplantation: A national database analysis. </text>
<text top="168" left="149" width="876" height="21" font="0">The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2015; </text>
<text top="188" left="149" width="76" height="21" font="0">34:1305-9. </text>
<text top="208" left="115" width="895" height="21" font="0">312. Vakil K, Kazmirczak F, Sathnur N, et al. Implantable cardioverter-defibrillator use in patients with left ventricular assist devices: a </text>
<text top="228" left="149" width="467" height="21" font="0">systematic review and meta-analysis. JACC. Heart Fail. 2016; 4:772-9. </text>
<text top="249" left="115" width="923" height="21" font="0">313. Tsai VW, Cooper J, Garan H, et al. The efficacy of implantable cardioverter-defibrillators in heart transplant recipients: results from a </text>
<text top="269" left="149" width="364" height="21" font="0">multicenter registry. Circ. Heart Fail. 2009; 2:197-201. </text>
<text top="289" left="115" width="966" height="21" font="0">314. McDowell DL and Hauptman PJ. Implantable defibrillators and cardiac resynchronization therapy in heart transplant recipients: results of a </text>
<text top="309" left="149" width="831" height="21" font="0">national survey. The Journal of heart and lung transplantation : the official publication of the International Society for Heart </text>
<text top="329" left="149" width="231" height="21" font="0">Transplantation. 2009; 28:847-50. </text>
<text top="349" left="115" width="949" height="21" font="0">315. Neylon A, Canniffe C, Parlon B, et al. Implantable cardioverter-defibrillators in a heart transplant population: A single-center experience. </text>
<text top="370" left="149" width="927" height="21" font="0">The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2016; 35:682-</text>
<text top="389" left="149" width="16" height="21" font="0">4. </text>
<text top="410" left="115" width="912" height="21" font="0">316. Tanawuttiwat T, Wagner KR, Tomaselli G, et al. Left ventricular dysfunction and conduction disturbances in patients with myotonic </text>
<text top="430" left="149" width="444" height="21" font="0">muscular dystrophy type i and ii. JAMA Cardiology. 2017; 2:225-8. </text>
<text top="450" left="115" width="967" height="21" font="0">317. Merino JL, Carmona JR, Fernandez-Lozano I, et al. Mechanisms of sustained ventricular tachycardia in myotonic dystrophy: implications for </text>
<text top="470" left="149" width="313" height="21" font="0">catheter ablation. Circulation. 1998; 98:541-6. </text>
<text top="490" left="115" width="951" height="21" font="0">318. Diegoli M, Grasso M, Favalli V, et al. Diagnostic work-up and risk stratification in X-linked dilated cardiomyopathies caused by dystrophin </text>
<text top="510" left="149" width="294" height="21" font="0">defects. J Am Coll Cardiol. 2011; 58:925-34. </text>
<text top="531" left="115" width="953" height="21" font="0">319. Meune C, Van Berlo JH, Anselme F, et al. Primary prevention of sudden death in patients with lamin A/C gene mutations. N. Engl. J. Med. </text>
<text top="551" left="149" width="126" height="21" font="0">2006; 354:209-10. </text>
<text top="571" left="115" width="946" height="21" font="0">320. Lallemand B, Clementy N, Bernard-Brunet A, et al. The evolution of infrahissian conduction time in myotonic dystrophy patients: clinical </text>
<text top="591" left="149" width="406" height="21" font="0">implications. Heart (British Cardiac Society). 2012; 98:291-6. </text>
<text top="611" left="115" width="967" height="21" font="0">321. Wahbi K, Meune C, Porcher R, et al. Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and </text>
<text top="631" left="149" width="372" height="21" font="0">conduction system disease. Jama. 2012; 307:1292-301. </text>
<text top="651" left="115" width="937" height="21" font="0">322. McMurray JJV, Östergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular </text>
<text top="671" left="149" width="775" height="21" font="0">systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. The Lancet. 362:767-71. </text>
<text top="692" left="115" width="912" height="21" font="0">323. Ha AH, Tarnopolsky MA, Bergstra TG, et al. Predictors of atrio-ventricular conduction disease, long-term outcomes in patients with </text>
<text top="712" left="149" width="531" height="21" font="0">myotonic dystrophy types I and II. Pacing Clin. Electrophysiol. 2012; 35:1262-9. </text>
<text top="732" left="115" width="935" height="21" font="0">324. Laurent V, Pellieux S, Corcia P, et al. Mortality in myotonic dystrophy patients in the area of prophylactic pacing devices. Int. J. Cardiol. </text>
<text top="752" left="149" width="109" height="21" font="0">2011; 150:54-8. </text>
</page>
<page number="341" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">341 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="957" height="21" font="0">325. Bhakta D, Shen C, Kron J, et al. Pacemaker and implantable cardioverter-defibrillator use in a US myotonic dystrophy type 1 population. J. </text>
<text top="128" left="149" width="309" height="21" font="0">Cardiovasc. Electrophysiol. 2011; 22:1369-75. </text>
<text top="148" left="115" width="963" height="21" font="0">326. Nazarian S, Wagner KR, Caffo BS, et al. Clinical predictors of conduction disease progression in type I myotonic muscular dystrophy. Pacing </text>
<text top="168" left="149" width="245" height="21" font="0">Clin. Electrophysiol. 2011; 34:171-6. </text>
<text top="188" left="115" width="943" height="21" font="0">327. Bhakta D, Groh MR, Shen C, et al. Increased mortality with left ventricular systolic dysfunction and heart failure in adults with myotonic </text>
<text top="208" left="149" width="365" height="21" font="0">dystrophy type 1. Am. Heart J. 2010; 160:1137-41, 41. </text>
<text top="228" left="115" width="931" height="21" font="0">328. Groh WJ, Groh MR, Saha C, et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N. Engl. J. Med. </text>
<text top="249" left="149" width="134" height="21" font="0">2008; 358:2688-97. </text>
<text top="269" left="115" width="965" height="21" font="0">329. Laforêt P, de TC, Eymard B, et al. Cardiac involvement in genetically confirmed facioscapulohumeral muscular dystrophy. Neurology. 1998; </text>
<text top="289" left="149" width="76" height="21" font="0">51:1454-6. </text>
<text top="309" left="115" width="934" height="21" font="0">330. Stevenson WG, Perloff JK, Weiss JN, et al. Facioscapulohumeral muscular dystrophy: evidence for selective, genetic electrophysiologic </text>
<text top="329" left="149" width="372" height="21" font="0">cardiac involvement. J Am Coll Cardiol. 1990; 15:292-9. </text>
<text top="349" left="115" width="963" height="21" font="0">331. Costa J, Lopes CM, Barsheshet A, et al. Combined assessment of sex- and mutation-specific information for risk stratification in type 1 long </text>
<text top="370" left="149" width="297" height="21" font="0">QT syndrome. Heart rhythm. 2012; 9:892-8. </text>
<text top="389" left="115" width="927" height="21" font="0">332. Bai R, Napolitano C, Bloise R, et al. Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic </text>
<text top="410" left="149" width="354" height="21" font="0">testing. Circ. Arrhythm. Electrophysiol. 2009; 2:6-15. </text>
<text top="430" left="115" width="937" height="21" font="0">333. Gehi AK, Duong TD, Metz LD, et al. Risk stratification of individuals with the Brugada electrocardiogram: a meta-analysis. J. Cardiovasc. </text>
<text top="450" left="149" width="220" height="21" font="0">Electrophysiol. 2006; 17:577-83. </text>
<text top="470" left="115" width="942" height="21" font="0">334. Kim JA, Lopes CM, Moss AJ, et al. Trigger-specific risk factors and response to therapy in long QT syndrome type 2. Heart rhythm. 2010; </text>
<text top="490" left="149" width="84" height="21" font="0">7:1797-805. </text>
<text top="510" left="115" width="956" height="21" font="0">335. Migdalovich D, Moss AJ, Lopes CM, et al. Mutation and gender-specific risk in type 2 long QT syndrome: implications for risk stratification </text>
<text top="531" left="149" width="686" height="21" font="0">for life-threatening cardiac events in patients with long QT syndrome. Heart rhythm. 2011; 8:1537-43. </text>
<text top="551" left="115" width="927" height="21" font="0">336. Nannenberg EA, Sijbrands EJ, Dijksman LM, et al. Mortality of inherited arrhythmia syndromes: insight into their natural history. Circ. </text>
<text top="571" left="149" width="230" height="21" font="0">Cardiovasc. Genet. 2012; 5:183-9. </text>
<text top="591" left="115" width="902" height="21" font="0">337. Kimbrough J, Moss AJ, Zareba W, et al. Clinical implications for affected parents and siblings of probands with long-QT syndrome. </text>
<text top="611" left="149" width="206" height="21" font="0">Circulation. 2001; 104:557-62. </text>
<text top="631" left="115" width="908" height="21" font="0">338. Kaufman ES, McNitt S, Moss AJ, et al. Risk of death in the long QT syndrome when a sibling has died. Heart rhythm. 2008; 5:831-6. </text>
<text top="651" left="115" width="933" height="21" font="0">339. Wedekind H, Burde D, Zumhagen S, et al. QT interval prolongation and risk for cardiac events in genotyped LQTS-index children. Eur. J </text>
<text top="671" left="149" width="190" height="21" font="0">Pediatr. 2009; 168:1107-15. </text>
<text top="692" left="115" width="945" height="21" font="0">340. Goldenberg I, Horr S, Moss AJ, et al. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and </text>
<text top="712" left="149" width="472" height="21" font="0">normal-range corrected QT intervals. J Am Coll Cardiol. 2011; 57:51-9. </text>
<text top="732" left="115" width="944" height="21" font="0">341. Tester DJ, Will ML, Haglund CM, et al. Effect of clinical phenotype on yield of long QT syndrome genetic testing. J Am Coll Cardiol. 2006; </text>
<text top="752" left="149" width="68" height="21" font="0">47:764-8. </text>
</page>
<page number="342" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">342 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="897" height="21" font="0">342. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic </text>
<text top="128" left="149" width="359" height="21" font="0">ventricular tachycardia. Circulation. 2002; 106:69-74. </text>
<text top="148" left="115" width="914" height="21" font="0">343. Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER </text>
<text top="168" left="149" width="395" height="21" font="0">Brugada syndrome registry. Circulation. 2010; 121:635-43. </text>
<text top="188" left="115" width="964" height="21" font="0">344. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation. 2000; </text>
<text top="208" left="149" width="84" height="21" font="0">101:616-23. </text>
<text top="228" left="115" width="899" height="21" font="0">345. Zareba W, Moss AJ, Daubert JP, et al. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J. Cardiovasc. </text>
<text top="249" left="149" width="220" height="21" font="0">Electrophysiol. 2003; 14:337-41. </text>
<text top="269" left="115" width="962" height="21" font="0">346. Monnig G, Kobe J, Loher A, et al. Implantable cardioverter-defibrillator therapy in patients with congenital long-QT syndrome: a long-term </text>
<text top="289" left="149" width="288" height="21" font="0">follow-up. Heart rhythm. 2005; 2:497-504. </text>
<text top="309" left="115" width="932" height="21" font="0">347. Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular </text>
<text top="329" left="149" width="300" height="21" font="0">tachycardia. Circulation. 2009; 119:2426-34. </text>
<text top="349" left="115" width="947" height="21" font="0">348. Delise P, Allocca G, Marras E, et al. Risk stratification in individuals with the Brugada type 1 ECG pattern without previous cardiac arrest: </text>
<text top="370" left="149" width="652" height="21" font="0">usefulness of a combined clinical and electrophysiologic approach. Eur. Heart J. 2011; 32:169-76. </text>
<text top="389" left="115" width="865" height="21" font="0">349. Hiraoka M, Takagi M, Yokoyama Y, et al. Prognosis and risk stratification of young adults with Brugada syndrome. Journal of </text>
<text top="410" left="149" width="242" height="21" font="0">electrocardiology. 2013; 46:279-83. </text>
<text top="430" left="115" width="913" height="21" font="0">350. Garson A, Jr., Dick M, Fournier A, et al. The long QT syndrome in children. An international study of 287 patients. Circulation. 1993; </text>
<text top="450" left="149" width="84" height="21" font="0">87:1866-72. </text>
<text top="470" left="115" width="966" height="21" font="0">351. Hobbs JB, Peterson DR, Moss AJ, et al. Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. </text>
<text top="490" left="149" width="176" height="21" font="0">Jama. 2006; 296:1249-54. </text>
<text top="510" left="115" width="852" height="21" font="0">352. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N. Engl. J. Med. 2003; 348:1866-74. </text>
<text top="531" left="115" width="946" height="21" font="0">353. Jons C, Moss AJ, Goldenberg I, et al. Risk of fatal arrhythmic events in long QT syndrome patients after syncope. J Am Coll Cardiol. 2010; </text>
<text top="551" left="149" width="68" height="21" font="0">55:783-8. </text>
<text top="571" left="115" width="933" height="21" font="0">354. Barsheshet A, Goldenberg I, Uchi J, et al. Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: </text>
<text top="591" left="149" width="865" height="21" font="0">implications for mutation-specific response to beta-blocker therapy in type 1 long-QT syndrome. Circulation. 2012; 125:1988-96. </text>
<text top="611" left="115" width="944" height="21" font="0">355. Vincent GM, Schwartz PJ, Denjoy I, et al. High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and </text>
<text top="631" left="149" width="719" height="21" font="0">QT-prolonging drugs to the occurrence of beta-blocker treatment &#34;failures&#34;. Circulation. 2009; 119:215-21. </text>
<text top="651" left="115" width="958" height="21" font="0">356. Abu-Zeitone A, Peterson DR, Polonsky B, et al. Efficacy of different beta-blockers in the treatment of long QT syndrome. J Am Coll Cardiol. </text>
<text top="671" left="149" width="117" height="21" font="0">2014; 64:1352-8. </text>
<text top="692" left="115" width="928" height="21" font="0">357. Goldenberg I, Bradley J, Moss A, et al. Beta-blocker efficacy in high-risk patients with the congenital long-QT syndrome types 1 and 2: </text>
<text top="712" left="149" width="579" height="21" font="0">implications for patient management. J. Cardiovasc. Electrophysiol. 2010; 21:893-901. </text>
<text top="732" left="115" width="695" height="21" font="0">358. Sauer AJ, Moss AJ, McNitt S, et al. Long QT syndrome in adults. J Am Coll Cardiol. 2007; 49:329-37. </text>
<text top="752" left="115" width="944" height="21" font="0">359. Steinberg C, Padfield GJ, Al-Sabeq B, et al. Experience with bisoprolol in long-QT1 and long-QT2 syndrome. J Interv. Card Electrophysiol. </text>
<text top="772" left="149" width="41" height="21" font="0">2016. </text>
</page>
<page number="343" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">343 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="943" height="21" font="0">360. Villain E, Denjoy I, Lupoglazoff JM, et al. Low incidence of cardiac events with beta-blocking therapy in children with long QT syndrome. </text>
<text top="128" left="149" width="211" height="21" font="0">Eur. Heart J. 2004; 25:1405-11. </text>
<text top="148" left="115" width="957" height="21" font="0">361. Moltedo JM, Kim JJ, Friedman RA, et al. Use of a cardioselective beta-blocker for pediatric patients with prolonged QT syndrome. Pediatr. </text>
<text top="168" left="149" width="156" height="21" font="0">Cardiol. 2011; 32:63-6. </text>
<text top="188" left="115" width="933" height="21" font="0">362. Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the </text>
<text top="208" left="149" width="346" height="21" font="0">long-QT syndrome. Circulation. 2004; 109:1826-33. </text>
<text top="228" left="115" width="965" height="21" font="0">363. Bos JM, Bos KM, Johnson JN, et al. Left cardiac sympathetic denervation in long QT syndrome: analysis of therapeutic nonresponders. Circ. </text>
<text top="249" left="149" width="284" height="21" font="0">Arrhythm. Electrophysiol. 2013; 6:705-11. </text>
<text top="269" left="115" width="925" height="21" font="0">364. Schneider HE, Steinmetz M, Krause U, et al. Left cardiac sympathetic denervation for the management of life-threatening ventricular </text>
<text top="289" left="149" width="926" height="21" font="0">tachyarrhythmias in young patients with catecholaminergic polymorphic ventricular tachycardia and long QT syndrome. Clin. Res. Cardiol. </text>
<text top="309" left="149" width="117" height="21" font="0">2013; 102:33-42. </text>
<text top="329" left="115" width="957" height="21" font="0">365. Collura CA, Johnson JN, Moir C, et al. Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic </text>
<text top="349" left="149" width="699" height="21" font="0">polymorphic ventricular tachycardia using video-assisted thoracic surgery. Heart rhythm. 2009; 6:752-9. </text>
<text top="370" left="115" width="955" height="21" font="0">366. Hofferberth SC, Cecchin F, Loberman D, et al. Left thoracoscopic sympathectomy for cardiac denervation in patients with life-threatening </text>
<text top="389" left="149" width="463" height="21" font="0">ventricular arrhythmias. J Thorac. Cardiovasc. Surg. 2014; 147:404-9. </text>
<text top="410" left="115" width="958" height="21" font="0">367. Chattha IS, Sy RW, Yee R, et al. Utility of the recovery electrocardiogram after exercise: a novel indicator for the diagnosis and genotyping </text>
<text top="430" left="149" width="359" height="21" font="0">of long QT syndrome? Heart rhythm. 2010; 7:906-11. </text>
<text top="450" left="115" width="958" height="21" font="0">368. Aziz PF, Wieand TS, Ganley J, et al. Genotype- and mutation site-specific QT adaptation during exercise, recovery, and postural changes in </text>
<text top="470" left="149" width="533" height="21" font="0">children with long-QT syndrome. Circ Arrhythm Electrophysiol. 2011; 4:867-73. </text>
<text top="490" left="115" width="964" height="21" font="0">369. Laksman ZW, Hamilton RM, Chockalingam P, et al. Mutation location effect on severity of phenotype during exercise testing in type 1 long-</text>
<text top="510" left="149" width="838" height="21" font="0">QT syndrome: impact of transmembrane and C-loop location. Journal of cardiovascular electrophysiology. 2013; 24:1015-20. </text>
<text top="531" left="115" width="959" height="21" font="0">370. Sy RW, van der Werf C, Chattha IS, et al. Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in </text>
<text top="551" left="149" width="402" height="21" font="0">relatives of LQTS probands. Circulation. 2011; 124:2187-94. </text>
<text top="571" left="115" width="930" height="21" font="0">371. Spazzolini C, Mullally J, Moss AJ, et al. Clinical implications for patients with long QT syndrome who experience a cardiac event during </text>
<text top="591" left="149" width="285" height="21" font="0">infancy. J Am Coll Cardiol. 2009; 54:832-7. </text>
<text top="611" left="115" width="951" height="21" font="0">372. Zhang C, Kutyifa V, Moss AJ, et al. Long-QT Syndrome and Therapy for Attention Deficit/Hyperactivity Disorder. Journal of cardiovascular </text>
<text top="631" left="149" width="253" height="21" font="0">electrophysiology. 2015; 26:1039-44. </text>
<text top="651" left="115" width="965" height="21" font="0">373. Choy AM, Lang CC, Chomsky DM, et al. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation. 1997; </text>
<text top="671" left="149" width="84" height="21" font="0">96:2149-54. </text>
<text top="692" left="115" width="760" height="21" font="0">374. Kannankeril P, Roden DM and Darbar D. Drug-induced long QT syndrome. Pharmacol. Rev. 2010; 62:760-81. </text>
<text top="712" left="115" width="928" height="21" font="0">375. Roston TM, Vinocur JM, Maginot KR, et al. Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic </text>
<text top="732" left="149" width="774" height="21" font="0">strategies and outcomes from an international multicenter registry. Circ. Arrhythm. Electrophysiol. 2015; 8:633-42. </text>
<text top="752" left="115" width="951" height="21" font="0">376. Wilde AA, Bhuiyan ZA, Crotti L, et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N. </text>
<text top="772" left="149" width="214" height="21" font="0">Engl. J. Med. 2008; 358:2024-9. </text>
</page>
<page number="344" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">344 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="924" height="21" font="0">377. Li J, Liu Y, Yang F, et al. Video-assisted thoracoscopic left cardiac sympathetic denervation: a reliable minimally invasive approach for </text>
<text top="128" left="149" width="449" height="21" font="0">congenital long-QT syndrome. Ann. Thorac. Surg. 2008; 86:1955-8. </text>
<text top="148" left="115" width="919" height="21" font="0">378. van der Werf C, Kannankeril PJ, Sacher F, et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with </text>
<text top="168" left="149" width="621" height="21" font="0">catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol. 2011; 57:2244-54. </text>
<text top="188" left="115" width="946" height="21" font="0">379. Watanabe H, van der Werf C, Roses-Noguer F, et al. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in </text>
<text top="208" left="149" width="806" height="21" font="0">genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia. Heart rhythm. 2013; 10:542-7. </text>
<text top="228" left="115" width="917" height="21" font="0">380. Somani R, Krahn AD, Healey JS, et al. Procainamide infusion in the evaluation of unexplained cardiac arrest: from the Cardiac Arrest </text>
<text top="249" left="149" width="638" height="21" font="0">Survivors with Preserved Ejection Fraction Registry (CASPER). Heart rhythm. 2014; 11:1047-54. </text>
<text top="269" left="115" width="912" height="21" font="0">381. Mizusawa Y, Morita H, Adler A, et al. Prognostic significance of fever-induced Brugada syndrome. Heart rhythm. 2016; 13:1515-20. </text>
<text top="289" left="115" width="915" height="21" font="0">382. Priori SG, Gasparini M, Napolitano C, et al. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical </text>
<text top="309" left="149" width="486" height="21" font="0">stimUlation preDictive valuE) registry. J Am Coll Cardiol. 2012; 59:37-45. </text>
<text top="329" left="115" width="953" height="21" font="0">383. Casado-Arroyo R, Berne P, Rao JY, et al. Long-term trends in newly diagnosed Brugada syndrome: implications for risk stratification. J Am </text>
<text top="349" left="149" width="202" height="21" font="0">Coll Cardiol. 2016; 68:614-23. </text>
<text top="370" left="115" width="830" height="21" font="0">384. Belhassen B, Rahkovich M, Michowitz Y, et al. Management of Brugada Syndrome: Thirty-Three-Year Experience Using </text>
<text top="389" left="149" width="832" height="21" font="0">Electrophysiologically Guided Therapy With Class 1A Antiarrhythmic Drugs. Circ Arrhythm Electrophysiol. 2015; 8:1393-402. </text>
<text top="410" left="115" width="924" height="21" font="0">385. Nademanee K, Veerakul G, Chandanamattha P, et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter </text>
<text top="430" left="149" width="669" height="21" font="0">ablation over the anterior right ventricular outflow tract epicardium. Circulation. 2011; 123:1270-9. </text>
<text top="450" left="115" width="911" height="21" font="0">386. Sunsaneewitayakul B, Yao Y, Thamaree S, et al. Endocardial mapping and catheter ablation for ventricular fibrillation prevention in </text>
<text top="470" left="149" width="499" height="21" font="0">Brugada syndrome. J. Cardiovasc. Electrophysiol. 2012; 23 Suppl 1:S10-S6. </text>
<text top="490" left="115" width="932" height="21" font="0">387. Zhang P, Tung R, Zhang Z, et al. Characterization of the epicardial substrate for catheter ablation of Brugada syndrome. Heart rhythm. </text>
<text top="510" left="149" width="41" height="21" font="0">2016. </text>
<text top="531" left="115" width="916" height="21" font="0">388. Brugada J, Pappone C, Berruezo A, et al. Brugada syndrome phenotype elimination by epicardial substrate ablation. Circ. Arrhythm. </text>
<text top="551" left="149" width="220" height="21" font="0">Electrophysiol. 2015; 8:1373-81. </text>
<text top="571" left="115" width="908" height="21" font="0">389. McNamara DA, Goldberger JJ, Berendsen MA, et al. Implantable defibrillators versus medical therapy for cardiac channelopathies. </text>
<text top="591" left="149" width="316" height="21" font="0">Cochrane Database Syst. Rev. 2015:CD011168. </text>
<text top="611" left="115" width="934" height="21" font="0">390. Sieira J, Ciconte G, Conte G, et al. Asymptomatic Brugada syndrome: clinical characterization and long-term prognosis. Circ. Arrhythm. </text>
<text top="631" left="149" width="220" height="21" font="0">Electrophysiol. 2015; 8:1144-50. </text>
<text top="651" left="115" width="920" height="21" font="0">391. Konigstein M, Rosso R, Topaz G, et al. Drug-induced Brugada syndrome: Clinical characteristics and risk factors. Heart rhythm. 2016; </text>
<text top="671" left="149" width="76" height="21" font="0">13:1083-7. </text>
<text top="692" left="115" width="916" height="21" font="0">392. Sroubek J, Probst V, Mazzanti A, et al. Programmed ventricular stimulation for risk stratification in the brugada syndrome: a pooled </text>
<text top="712" left="149" width="266" height="21" font="0">analysis. Circulation. 2016; 133:622-30. </text>
<text top="732" left="115" width="924" height="21" font="0">393. Sieira J, Conte G, Ciconte G, et al. Clinical characterisation and long-term prognosis of women with Brugada syndrome. Heart (British </text>
<text top="752" left="149" width="232" height="21" font="0">Cardiac Society). 2016; 102:452-8. </text>
</page>
<page number="345" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">345 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="897" height="21" font="0">394. Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. </text>
<text top="128" left="149" width="206" height="21" font="0">Circulation. 2002; 105:1342-7. </text>
<text top="148" left="115" width="968" height="21" font="0">395. Fauchier L, Isorni MA, Clementy N, et al. Prognostic value of programmed ventricular stimulation in Brugada syndrome according to clinical </text>
<text top="168" left="149" width="683" height="21" font="0">presentation: an updated meta-analysis of worldwide published data. Int J Cardiol. 2013; 168:3027-9. </text>
<text top="188" left="115" width="929" height="21" font="0">396. Rodriguez-Manero M, Sacher F, de AC, et al. Monomorphic ventricular tachycardia in patients with Brugada syndrome: A multicenter </text>
<text top="208" left="149" width="354" height="21" font="0">retrospective study. Heart rhythm. 2016; 13:669-82. </text>
<text top="228" left="115" width="910" height="21" font="0">397. Sacher F, Probst V, Maury P, et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a </text>
<text top="249" left="149" width="386" height="21" font="0">multicenter study-part 2. Circulation. 2013; 128:1739-47. </text>
<text top="269" left="115" width="905" height="21" font="0">398. Rosso R, Kogan E, Belhassen B, et al. J-point elevation in survivors of primary ventricular fibrillation and matched control subjects: </text>
<text top="289" left="149" width="469" height="21" font="0">incidence and clinical significance. J Am Coll Cardiol. 2008; 52:1231-8. </text>
<text top="309" left="115" width="969" height="21" font="0">399. Conte G, Sieira J, Ciconte G, et al. Implantable cardioverter-defibrillator therapy in Brugada syndrome: a 20-year single-center experience. J </text>
<text top="329" left="149" width="228" height="21" font="0">Am Coll Cardiol. 2015; 65:879-88. </text>
<text top="349" left="115" width="966" height="21" font="0">400. Miyazaki S, Uchiyama T, Komatsu Y, et al. Long-term complications of implantable defibrillator therapy in Brugada syndrome. Am J Cardiol. </text>
<text top="370" left="149" width="134" height="21" font="0">2013; 111:1448-51. </text>
<text top="389" left="115" width="899" height="21" font="0">401. Takagi M, Sekiguchi Y, Yokoyama Y, et al. Long-term prognosis in patients with Brugada syndrome based on Class II indication for </text>
<text top="410" left="149" width="906" height="21" font="0">implantable cardioverter-defibrillator in the HRS/EHRA/APHRS Expert Consensus Statement: multicenter study in Japan. Heart rhythm. </text>
<text top="430" left="149" width="126" height="21" font="0">2014; 11:1716-20. </text>
<text top="450" left="115" width="888" height="21" font="0">402. Haissaguerre M, Sacher F, Nogami A, et al. Characteristics of recurrent ventricular fibrillation associated with inferolateral early </text>
<text top="470" left="149" width="468" height="21" font="0">repolarization role of drug therapy. J Am Coll Cardiol. 2009; 53:612-9. </text>
<text top="490" left="115" width="933" height="21" font="0">403. Tikkanen JT, Anttonen O, Junttila MJ, et al. Long-term outcome associated with early repolarization on electrocardiography. N. Engl. J. </text>
<text top="510" left="149" width="173" height="21" font="0">Med. 2009; 361:2529-37. </text>
<text top="531" left="115" width="908" height="21" font="0">404. Sinner MF, Porthan K, Noseworthy PA, et al. A meta-analysis of genome-wide association studies of the electrocardiographic early </text>
<text top="551" left="149" width="372" height="21" font="0">repolarization pattern. Heart rhythm. 2012; 9:1627-34. </text>
<text top="571" left="115" width="942" height="21" font="0">405. Adhikarla C, Boga M, Wood AD, et al. Natural history of the electrocardiographic pattern of early repolarization in ambulatory patients. </text>
<text top="591" left="149" width="225" height="21" font="0">Am. J. Cardiol. 2011; 108:1831-5. </text>
<text top="611" left="115" width="950" height="21" font="0">406. Siebermair J, Sinner MF, Beckmann BM, et al. Early repolarization pattern is the strongest predictor of arrhythmia recurrence in patients </text>
<text top="631" left="149" width="875" height="21" font="0">with idiopathic ventricular fibrillation: results from a single centre long-term follow-up over 20 years. Europace : European pacing, </text>
<text top="651" left="149" width="849" height="21" font="0">arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular </text>
<text top="671" left="149" width="501" height="21" font="0">electrophysiology of the European Society of Cardiology. 2016; 18:718-25. </text>
<text top="692" left="115" width="956" height="21" font="0">407. Tikkanen JT, Wichmann V, Junttila MJ, et al. Association of early repolarization and sudden cardiac death during an acute coronary event. </text>
<text top="712" left="149" width="309" height="21" font="0">Circ. Arrhythm. Electrophysiol. 2012; 5:714-8. </text>
<text top="732" left="115" width="961" height="21" font="0">408. Junttila MJ, Tikkanen JT, Kentta T, et al. Early repolarization as a predictor of arrhythmic and nonarrhythmic cardiac events in middle-aged </text>
<text top="752" left="149" width="279" height="21" font="0">subjects. Heart rhythm. 2014; 11:1701-6. </text>
<text top="772" left="115" width="842" height="21" font="0">409. Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: pharmacological treatment. J Am Coll Cardiol. 2004; 43:1494-9. </text>
</page>
<page number="346" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">346 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="898" height="21" font="0">410. Gollob MH, Redpath CJ and Roberts JD. The short QT syndrome: proposed diagnostic criteria. J Am Coll Cardiol. 2011; 57:802-12. </text>
<text top="128" left="115" width="963" height="21" font="0">411. Villafane J, Atallah J, Gollob MH, et al. Long-term follow-up of a pediatric cohort with short QT syndrome. J Am Coll Cardiol. 2013; 61:1183-</text>
<text top="148" left="149" width="25" height="21" font="0">91. </text>
<text top="168" left="115" width="955" height="21" font="0">412. Mazzanti A, Kanthan A, Monteforte N, et al. Novel insight into the natural history of short QT syndrome. J Am Coll Cardiol. 2014; 63:1300-</text>
<text top="188" left="149" width="16" height="21" font="0">8. </text>
<text top="208" left="115" width="959" height="21" font="0">413. Iribarren C, Round AD, Peng JA, et al. Short QT in a cohort of 1.7 million persons: prevalence, correlates, and prognosis. Ann. Noninvasive. </text>
<text top="228" left="149" width="226" height="21" font="0">Electrocardiol. 2014; 19:490-500. </text>
<text top="249" left="115" width="946" height="21" font="0">414. Guerrier K, Kwiatkowski D, Czosek RJ, et al. Short QT interval prevalence and clinical outcomes in a pediatric population. Circ. Arrhythm. </text>
<text top="269" left="149" width="212" height="21" font="0">Electrophysiol. 2015; 8:1460-4. </text>
<text top="289" left="115" width="892" height="21" font="0">415. Bun SS, Maury P, Giustetto C, et al. Electrical storm in short-QT syndrome successfully treated with Isoproterenol. J. Cardiovasc. </text>
<text top="309" left="149" width="228" height="21" font="0">Electrophysiol. 2012; 23:1028-30. </text>
<text top="329" left="115" width="908" height="21" font="0">416. Dhutia H, Malhotra A, Parpia S, et al. The prevalence and significance of a short QT interval in 18,825 low-risk individuals including </text>
<text top="349" left="149" width="288" height="21" font="0">athletes. Br. J Sports Med. 2016; 50:124-9. </text>
<text top="370" left="115" width="956" height="21" font="0">417. Ling Z, Liu Z, Su L, et al. Radiofrequency ablation versus antiarrhythmic medication for treatment of ventricular premature beats from the </text>
<text top="389" left="149" width="735" height="21" font="0">right ventricular outflow tract: prospective randomized study. Circ. Arrhythm. Electrophysiol. 2014; 7:237-43. </text>
<text top="410" left="115" width="818" height="21" font="0">418. Liao Z, Zhan X, Wu S, et al. Idiopathic ventricular arrhythmias originating from the pulmonary sinus cusp: prevalence, </text>
<text top="430" left="149" width="784" height="21" font="0">electrocardiographic/electrophysiological characteristics, and catheter ablation. J Am Coll Cardiol. 2015; 66:2633-44. </text>
<text top="450" left="115" width="951" height="21" font="0">419. Morady F, Kadish AH, DiCarlo L, et al. Long-term results of catheter ablation of idiopathic right ventricular tachycardia. Circulation. 1990; </text>
<text top="470" left="149" width="76" height="21" font="0">82:2093-9. </text>
<text top="490" left="115" width="948" height="21" font="0">420. Yamada T, Litovsky SH and Kay GN. The left ventricular ostium: an anatomic concept relevant to idiopathic ventricular arrhythmias. Circ. </text>
<text top="510" left="149" width="292" height="21" font="0">Arrhythm. Electrophysiol. 2008; 1:396-404. </text>
<text top="531" left="115" width="948" height="21" font="0">421. Yamada T, McElderry HT, Doppalapudi H, et al. Idiopathic ventricular arrhythmias originating from the left ventricular summit: anatomic </text>
<text top="551" left="149" width="521" height="21" font="0">concepts relevant to ablation. Circ. Arrhythm. Electrophysiol. 2010; 3:616-23. </text>
<text top="571" left="115" width="945" height="21" font="0">422. Mountantonakis SE, Frankel DS, Tschabrunn CM, et al. Ventricular arrhythmias from the coronary venous system: Prevalence, mapping, </text>
<text top="591" left="149" width="316" height="21" font="0">and ablation. Heart rhythm. 2015; 12:1145-53. </text>
<text top="611" left="115" width="948" height="21" font="0">423. Doppalapudi H, Yamada T, Ramaswamy K, et al. Idiopathic focal epicardial ventricular tachycardia originating from the crux of the heart. </text>
<text top="631" left="149" width="199" height="21" font="0">Heart rhythm. 2009; 6:44-50. </text>
<text top="651" left="115" width="924" height="21" font="0">424. Konstantinidou M, Koektuerk B, Wissner E, et al. Catheter ablation of right ventricular outflow tract tachycardia: a simplified remote-</text>
<text top="671" left="149" width="914" height="21" font="0">controlled approach. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac </text>
<text top="692" left="149" width="783" height="21" font="0">pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2011; 13:696-700. </text>
<text top="712" left="115" width="837" height="21" font="0">425. Ouyang F, Fotuhi P, Ho SY, et al. Repetitive monomorphic ventricular tachycardia originating from the aortic sinus cusp: </text>
<text top="732" left="149" width="683" height="21" font="0">electrocardiographic characterization for guiding catheter ablation. J Am Coll Cardiol. 2002; 39:500-8. </text>
<text top="752" left="115" width="954" height="21" font="0">426. Tada H, Ito S, Naito S, et al. Idiopathic ventricular arrhythmia arising from the mitral annulus: a distinct subgroup of idiopathic ventricular </text>
<text top="772" left="149" width="326" height="21" font="0">arrhythmias. J Am Coll Cardiol. 2005; 45:877-86. </text>
</page>
<page number="347" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">347 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="953" height="21" font="0">427. Tada H, Tadokoro K, Miyaji K, et al. Idiopathic ventricular arrhythmias arising from the pulmonary artery: prevalence, characteristics, and </text>
<text top="128" left="149" width="458" height="21" font="0">topography of the arrhythmia origin. Heart rhythm. 2008; 5:419-26. </text>
<text top="148" left="115" width="964" height="21" font="0">428. Tada H, Tadokoro K, Ito S, et al. Idiopathic ventricular arrhythmias originating from the tricuspid annulus: Prevalence, electrocardiographic </text>
<text top="168" left="149" width="620" height="21" font="0">characteristics, and results of radiofrequency catheter ablation. Heart rhythm. 2007; 4:7-16. </text>
<text top="188" left="115" width="966" height="21" font="0">429. Kamioka M, Mathew S, Lin T, et al. Electrophysiological and electrocardiographic predictors of ventricular arrhythmias originating from the </text>
<text top="208" left="149" width="732" height="21" font="0">left ventricular outflow tract within and below the coronary sinus cusps. Clin. Res. Cardiol. 2015; 104:544-54. </text>
<text top="228" left="115" width="938" height="21" font="0">430. Nagashima K, Choi EK, Lin KY, et al. Ventricular arrhythmias near the distal great cardiac vein: challenging arrhythmia for ablation. Circ. </text>
<text top="249" left="149" width="284" height="21" font="0">Arrhythm. Electrophysiol. 2014; 7:906-12. </text>
<text top="269" left="115" width="923" height="21" font="0">431. Yamada T, Maddox WR, McElderry HT, et al. Radiofrequency catheter ablation of idiopathic ventricular arrhythmias originating from </text>
<text top="289" left="149" width="919" height="21" font="0">intramural foci in the left ventricular outflow tract: efficacy of sequential versus simultaneous unipolar catheter ablation. Circ. Arrhythm. </text>
<text top="309" left="149" width="212" height="21" font="0">Electrophysiol. 2015; 8:344-52. </text>
<text top="329" left="115" width="958" height="21" font="0">432. Hai JJ, Chahal AA, Friedman PA, et al. Electrophysiologic characteristics of ventricular arrhythmias arising from the aortic mitral continuity-</text>
<text top="349" left="149" width="586" height="21" font="0">potential role of the conduction system. J. Cardiovasc. Electrophysiol. 2015; 26:158-63. </text>
<text top="370" left="115" width="930" height="21" font="0">433. Yamada T, McElderry HT, Okada T, et al. Idiopathic left ventricular arrhythmias originating adjacent to the left aortic sinus of valsalva: </text>
<text top="389" left="149" width="740" height="21" font="0">electrophysiological rationale for the surface electrocardiogram. J. Cardiovasc. Electrophysiol. 2010; 21:170-6. </text>
<text top="410" left="115" width="961" height="21" font="0">434. Doppalapudi H, Yamada T, McElderry HT, et al. Ventricular tachycardia originating from the posterior papillary muscle in the left ventricle: </text>
<text top="430" left="149" width="490" height="21" font="0">a distinct clinical syndrome. Circ. Arrhythm. Electrophysiol. 2008; 1:23-9. </text>
<text top="450" left="115" width="922" height="21" font="0">435. Yamada T, Doppalapudi H, McElderry HT, et al. Electrocardiographic and electrophysiological characteristics in idiopathic ventricular </text>
<text top="470" left="149" width="901" height="21" font="0">arrhythmias originating from the papillary muscles in the left ventricle: relevance for catheter ablation. Circ. Arrhythm. Electrophysiol. </text>
<text top="490" left="149" width="109" height="21" font="0">2010; 3:324-31. </text>
<text top="510" left="115" width="942" height="21" font="0">436. Yokokawa M, Good E, Desjardins B, et al. Predictors of successful catheter ablation of ventricular arrhythmias arising from the papillary </text>
<text top="531" left="149" width="269" height="21" font="0">muscles. Heart rhythm. 2010; 7:1654-9. </text>
<text top="551" left="115" width="962" height="21" font="0">437. Crawford T, Mueller G, Good E, et al. Ventricular arrhythmias originating from papillary muscles in the right ventricle. Heart rhythm. 2010; </text>
<text top="571" left="149" width="68" height="21" font="0">7:725-30. </text>
<text top="591" left="115" width="914" height="21" font="0">438. Ban JE, Lee HS, Lee DI, et al. Electrophysiological characteristics related to outcome after catheter ablation of idiopathic ventricular </text>
<text top="611" left="149" width="671" height="21" font="0">arrhythmia originating from the papillary muscle in the left ventricle. Korean Circ. J. 2013; 43:811-8. </text>
<text top="631" left="115" width="931" height="21" font="0">439. Nogami A, Naito S, Tada H, et al. Demonstration of diastolic and presystolic Purkinje potentials as critical potentials in a macroreentry </text>
<text top="651" left="149" width="692" height="21" font="0">circuit of verapamil-sensitive idiopathic left ventricular tachycardia. J Am Coll Cardiol. 2000; 36:811-23. </text>
<text top="671" left="115" width="905" height="21" font="0">440. Liu Y, Fang Z, Yang B, et al. Catheter ablation of fascicular ventricular tachycardia: long-term clinical outcomes and mechanisms of </text>
<text top="692" left="149" width="407" height="21" font="0">recurrence. Circ. Arrhythm. Electrophysiol. 2015; 8:1443-51. </text>
<text top="712" left="115" width="940" height="21" font="0">441. Lin D, Hsia HH, Gerstenfeld EP, et al. Idiopathic fascicular left ventricular tachycardia: linear ablation lesion strategy for noninducible or </text>
<text top="732" left="149" width="379" height="21" font="0">nonsustained tachycardia. Heart rhythm. 2005; 2:934-9. </text>
<text top="752" left="115" width="884" height="21" font="0">442. Haïssaguerre M, Shoda M, Jais P, et al. Mapping and ablation of idiopathic ventricular fibrillation. Circulation. 2002; 106:962-7. </text>
</page>
<page number="348" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">348 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="964" height="21" font="0">443. Noda T, Shimizu W, Taguchi A, et al. Malignant entity of idiopathic ventricular fibrillation and polymorphic ventricular tachycardia initiated </text>
<text top="128" left="149" width="778" height="21" font="0">by premature extrasystoles originating from the right ventricular outflow tract. J Am Coll Cardiol. 2005; 46:1288-94. </text>
<text top="148" left="115" width="966" height="21" font="0">444. Haïssaguerre M, Shah DC, Jais P, et al. Role of Purkinje conducting system in triggering of idiopathic ventricular fibrillation. Lancet (London, </text>
<text top="168" left="149" width="184" height="21" font="0">England). 2002; 359:677-8. </text>
<text top="188" left="115" width="942" height="21" font="0">445. Van HH, Zado ES, Haqqani H, et al. Catheter ablation of ventricular fibrillation: importance of left ventricular outflow tract and papillary </text>
<text top="208" left="149" width="326" height="21" font="0">muscle triggers. Heart rhythm. 2014; 11:566-73. </text>
<text top="228" left="115" width="942" height="21" font="0">446. Sadek MM, Benhayon D, Sureddi R, et al. Idiopathic ventricular arrhythmias originating from the moderator band: Electrocardiographic </text>
<text top="249" left="149" width="552" height="21" font="0">characteristics and treatment by catheter ablation. Heart rhythm. 2015; 12:67-75. </text>
<text top="269" left="115" width="966" height="21" font="0">447. Tester DJ, Medeiros-Domingo A, Will ML, et al. Unexplained drownings and the cardiac channelopathies: a molecular autopsy series. Mayo </text>
<text top="289" left="149" width="180" height="21" font="0">Clin. Proc. 2011; 86:941-7. </text>
<text top="309" left="115" width="969" height="21" font="0">448. Tzimas I, Zingraf JC, Bajanowski T, et al. The role of known variants of KCNQ1, KCNH2, KCNE1, SCN5A, and NOS1AP in water-related deaths. </text>
<text top="329" left="149" width="154" height="21" font="0">Int. J Legal Med. 2016. </text>
<text top="349" left="115" width="939" height="21" font="0">449. Anderson JH, Tester DJ, Will ML, et al. Whole-exome molecular autopsy after exertion-related sudden unexplained death in the young. </text>
<text top="370" left="149" width="272" height="21" font="0">Circ. Cardiovasc. Genet. 2016; 9:259-65. </text>
<text top="389" left="115" width="963" height="21" font="0">450. Wang D, Shah KR, Um SY, et al. Cardiac channelopathy testing in 274 ethnically diverse sudden unexplained deaths. Forensic Sci. Int. 2014; </text>
<text top="410" left="149" width="68" height="21" font="0">237:90-9. </text>
<text top="430" left="115" width="943" height="21" font="0">451. Kumar S, Peters S, Thompson T, et al. Familial cardiological and targeted genetic evaluation: low yield in sudden unexplained death and </text>
<text top="450" left="149" width="571" height="21" font="0">high yield in unexplained cardiac arrest syndromes. Heart rhythm. 2013; 10:1653-60. </text>
<text top="470" left="115" width="963" height="21" font="0">452. Ban JE, Park HC, Park JS, et al. Electrocardiographic and electrophysiological characteristics of premature ventricular complexes associated </text>
<text top="490" left="149" width="880" height="21" font="0">with left ventricular dysfunction in patients without structural heart disease. Europace : European pacing, arrhythmias, and cardiac </text>
<text top="510" left="149" width="914" height="21" font="0">electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European </text>
<text top="531" left="149" width="266" height="21" font="0">Society of Cardiology. 2013; 15:735-41. </text>
<text top="551" left="115" width="953" height="21" font="0">453. Lee W, Tay A, Subbiah RN, et al. Impact of Implantable Cardioverter Defibrillators on Survival of Patients with Centrifugal Left Ventricular </text>
<text top="571" left="149" width="402" height="21" font="0">Assist Devices. Pacing Clin. Electrophysiol. 2015; 38:925-33. </text>
<text top="591" left="115" width="902" height="21" font="0">454. Carballeira Pol L, Deyell MW, Frankel DS, et al. Ventricular premature depolarization QRS duration as a new marker of risk for the </text>
<text top="611" left="149" width="763" height="21" font="0">development of ventricular premature depolarization-induced cardiomyopathy. Heart rhythm. 2014; 11:299-306. </text>
<text top="631" left="115" width="944" height="21" font="0">455. Deyell MW, Park KM, Han Y, et al. Predictors of recovery of left ventricular dysfunction after ablation of frequent ventricular premature </text>
<text top="651" left="149" width="327" height="21" font="0">depolarizations. Heart rhythm. 2012; 9:1465-72. </text>
<text top="671" left="115" width="958" height="21" font="0">456. Del Carpio Munoz F, Syed FF, Noheria A, et al. Characteristics of premature ventricular complexes as correlates of reduced left ventricular </text>
<text top="692" left="149" width="899" height="21" font="0">systolic function: study of the burden, duration, coupling interval, morphology and site of origin of PVCs. J. Cardiovasc. Electrophysiol. </text>
<text top="712" left="149" width="109" height="21" font="0">2011; 22:791-8. </text>
<text top="732" left="115" width="891" height="21" font="0">457. Olgun H, Yokokawa M, Baman T, et al. The role of interpolation in PVC-induced cardiomyopathy. Heart rhythm. 2011; 8:1046-9. </text>
<text top="752" left="115" width="924" height="21" font="0">458. Hasdemir C, Ulucan C, Yavuzgil O, et al. Tachycardia-induced cardiomyopathy in patients with idiopathic ventricular arrhythmias: the </text>
<text top="772" left="149" width="817" height="21" font="0">incidence, clinical and electrophysiologic characteristics, and the predictors. J. Cardiovasc. Electrophysiol. 2011; 22:663-8. </text>
</page>
<page number="349" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">349 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="939" height="21" font="0">459. Baman TS, Lange DC, Ilg KJ, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart </text>
<text top="128" left="149" width="158" height="21" font="0">rhythm. 2010; 7:865-9. </text>
<text top="148" left="115" width="944" height="21" font="0">460. Kanei Y, Friedman M, Ogawa N, et al. Frequent premature ventricular complexes originating from the right ventricular outflow tract are </text>
<text top="168" left="149" width="623" height="21" font="0">associated with left ventricular dysfunction. Ann. Noninvasive. Electrocardiol. 2008; 13:81-5. </text>
<text top="188" left="115" width="885" height="21" font="0">461. Hamon D, Blaye-Felice MS, Bradfield JS, et al. A new combined parameter to predict premature ventricular complexes induced </text>
<text top="208" left="149" width="723" height="21" font="0">cardiomyopathy: impact and recognition of epicardial origin. J. Cardiovasc. Electrophysiol. 2016; 27:709-17. </text>
<text top="228" left="115" width="952" height="21" font="0">462. Bogun F, Crawford T, Reich S, et al. Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a </text>
<text top="249" left="149" width="442" height="21" font="0">control group without intervention. Heart rhythm. 2007; 4:863-7. </text>
<text top="269" left="115" width="898" height="21" font="0">463. Zhong L, Lee YH, Huang XM, et al. Relative efficacy of catheter ablation vs antiarrhythmic drugs in treating premature ventricular </text>
<text top="289" left="149" width="548" height="21" font="0">contractions: a single-center retrospective study. Heart rhythm. 2014; 11:187-93. </text>
<text top="309" left="115" width="959" height="21" font="0">464. Kawamura M, Badhwar N, Vedantham V, et al. Coupling interval dispersion and body mass index are independent predictors of idiopathic </text>
<text top="329" left="149" width="702" height="21" font="0">premature ventricular complex-induced cardiomyopathy. J. Cardiovasc. Electrophysiol. 2014; 25:756-62. </text>
<text top="349" left="115" width="916" height="21" font="0">465. Yokokawa M, Good E, Crawford T, et al. Recovery from left ventricular dysfunction after ablation of frequent premature ventricular </text>
<text top="370" left="149" width="287" height="21" font="0">complexes. Heart rhythm. 2013; 10:172-5. </text>
<text top="389" left="115" width="923" height="21" font="0">466. Jeejeebhoy FM, Zelop CM, Lipman S, et al. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. </text>
<text top="410" left="149" width="215" height="21" font="0">Circulation. 2015; 132:1747-73. </text>
<text top="430" left="115" width="962" height="21" font="0">467. Creanga AA, Berg CJ, Ko JY, et al. Maternal Mortality and Morbidity in the United States: Where Are We Now? Journal of Women's Health. </text>
<text top="450" left="149" width="92" height="21" font="0">2014; 23:3-9. </text>
<text top="470" left="115" width="968" height="21" font="0">468. Kampman MA, Balci A, Groen H, et al. Cardiac function and cardiac events 1-year postpartum in women with congenital heart disease. Am. </text>
<text top="490" left="149" width="189" height="21" font="0">Heart J. 2015; 169:298-304. </text>
<text top="510" left="115" width="954" height="21" font="0">469. Drenthen W, Boersma E, Balci A, et al. Predictors of pregnancy complications in women with congenital heart disease. Eur. Heart J. 2010; </text>
<text top="531" left="149" width="84" height="21" font="0">31:2124-32. </text>
<text top="551" left="115" width="958" height="21" font="0">470. Mhyre JM, Tsen LC, Einav S, et al. Cardiac arrest during hospitalization for delivery in the United States, 1998-2011. Anesthesiology. 2014; </text>
<text top="571" left="149" width="76" height="21" font="0">120:810-8. </text>
<text top="591" left="115" width="965" height="21" font="0">471. Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation. 2001; </text>
<text top="611" left="149" width="84" height="21" font="0">104:515-21. </text>
<text top="631" left="115" width="940" height="21" font="0">472. Einav S, Kaufman N and Sela HY. Maternal cardiac arrest and perimortem caesarean delivery: evidence or expert-based? Resuscitation. </text>
<text top="651" left="149" width="134" height="21" font="0">2012; 83:1191-200. </text>
<text top="671" left="115" width="878" height="21" font="0">473. Citro R, Giudice R, Mirra M, et al. Is Tako-tsubo syndrome in the postpartum period a clinical entity different from peripartum </text>
<text top="692" left="149" width="457" height="21" font="0">cardiomyopathy? J Cardiovasc Med (Hagerstown). 2013; 14:568-75. </text>
<text top="712" left="115" width="723" height="21" font="0">474. Seth R, Moss AJ, McNitt S, et al. Long QT syndrome and pregnancy. J Am Coll Cardiol. 2007; 49:1092-8. </text>
<text top="732" left="115" width="901" height="21" font="0">475. Katz V, Balderston K and DeFreest M. Perimortem cesarean delivery: were our assumptions correct? Am J Obstet. Gynecol. 2005; </text>
<text top="752" left="149" width="93" height="21" font="0">192:1916-20. </text>
</page>
<page number="350" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">350 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="938" height="21" font="0">476. Dijkman A, Huisman CM, Smit M, et al. Cardiac arrest in pregnancy: increasing use of perimortem caesarean section due to emergency </text>
<text top="128" left="149" width="260" height="21" font="0">skills training? BJOG. 2010; 117:282-7. </text>
<text top="148" left="115" width="874" height="21" font="0">477. Colletti PM, Lee KH and Elkayam U. Cardiovascular imaging of the pregnant patient. AJR. Am J Roentgenol. 2013; 200:515-21. </text>
<text top="168" left="115" width="922" height="21" font="0">478. Natale A, Davidson T, Geiger MJ, et al. Implantable cardioverter-defibrillators and pregnancy: a safe combination? Circulation. 1997; </text>
<text top="188" left="149" width="84" height="21" font="0">96:2808-12. </text>
<text top="208" left="115" width="904" height="21" font="0">479. Damilakis J, Theocharopoulos N, Perisinakis K, et al. Conceptus radiation dose and risk from cardiac catheter ablation procedures. </text>
<text top="228" left="149" width="198" height="21" font="0">Circulation. 2001; 104:893-7. </text>
<text top="249" left="115" width="914" height="21" font="0">480. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial </text>
<text top="269" left="149" width="728" height="21" font="0">infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N. Engl. J. Med. 1989; 321:406-12. </text>
<text top="289" left="115" width="894" height="21" font="0">481. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II </text>
<text top="309" left="149" width="327" height="21" font="0">Investigators. N. Engl. J. Med. 1992; 327:227-33. </text>
<text top="329" left="115" width="938" height="21" font="0">482. Wyse DG, Friedman PL, Brodsky MA, et al. Life-threatening ventricular arrhythmias due to transient or correctable causes: high risk for </text>
<text top="349" left="149" width="377" height="21" font="0">death in follow-up. J Am Coll Cardiol. 2001; 38:1718-24. </text>
<text top="370" left="115" width="962" height="21" font="0">483. Monnig G, Kobe J, Loher A, et al. Role of implantable cardioverter defibrillator therapy in patients with acquired long QT syndrome: a long-</text>
<text top="389" left="149" width="930" height="21" font="0">term follow-up. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, </text>
<text top="410" left="149" width="731" height="21" font="0">arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2012; 14:396-401. </text>
<text top="430" left="115" width="925" height="21" font="0">484. Antman EM, Wenger TL, Butler VP, Jr., et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab </text>
<text top="450" left="149" width="583" height="21" font="0">antibody fragments. Final report of a multicenter study. Circulation. 1990; 81:1744-52. </text>
<text top="470" left="115" width="903" height="21" font="0">485. Chan BS and Buckley NA. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Clin. Toxicol. . 2014; 52:824-36. </text>
<text top="490" left="115" width="484" height="21" font="0">486. Hauptman PJ and Kelly RA. Digitalis. Circulation. 1999; 99:1265-70. </text>
<text top="510" left="115" width="766" height="21" font="0">487. Kelly RA and Smith TW. Recognition and management of digitalis toxicity. Am. J. Cardiol. 1992; 69:108G-18G. </text>
<text top="531" left="115" width="966" height="21" font="0">488. Osmonov D, Erdinler I, Ozcan KS, et al. Management of patients with drug-induced atrioventricular block. Pacing Clin. Electrophysiol. 2012; </text>
<text top="551" left="149" width="76" height="21" font="0">35:804-10. </text>
<text top="571" left="115" width="850" height="21" font="0">489. Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation. 1988; 77:392-7. </text>
<text top="591" left="115" width="935" height="21" font="0">490. Keren A, Tzivoni D, Gavish D, et al. Etiology, warning signs and therapy of torsade de pointes. A study of 10 patients. Circulation. 1981; </text>
<text top="611" left="149" width="84" height="21" font="0">64:1167-74. </text>
<text top="631" left="115" width="916" height="21" font="0">491. Yang T and Roden DM. Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-</text>
<text top="651" left="149" width="289" height="21" font="0">dependence. Circulation. 1996; 93:407-11. </text>
<text top="671" left="115" width="939" height="21" font="0">492. Hellestrand KJ, Burnett PJ, Milne JR, et al. Effect of the antiarrhythmic agent flecainide acetate on acute and chronic pacing thresholds. </text>
<text top="692" left="149" width="283" height="21" font="0">Pacing Clin. Electrophysiol. 1983; 6:892-9. </text>
<text top="712" left="115" width="962" height="21" font="0">493. Echt DS, Black JN, Barbey JT, et al. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs. Sodium channel block </text>
<text top="732" left="149" width="440" height="21" font="0">and action potential prolongation. Circulation. 1989; 79:1106-17. </text>
<text top="752" left="115" width="928" height="21" font="0">494. Crijns HJ, Van Gelder IC and Lie KI. Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment. Am. J. </text>
<text top="772" left="149" width="173" height="21" font="0">Cardiol. 1988; 62:1303-6. </text>
</page>
<page number="351" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">351 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="905" height="21" font="0">495. Bajaj AK, Woosley RL and Roden DM. Acute electrophysiologic effects of sodium administration in dogs treated with O-desmethyl </text>
<text top="128" left="149" width="287" height="21" font="0">encainide. Circulation. 1989; 80:994-1002. </text>
<text top="148" left="115" width="892" height="21" font="0">496. Myerburg RJ, Kessler KM, Cox MM, et al. Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by </text>
<text top="168" left="149" width="285" height="21" font="0">propranolol. Circulation. 1989; 80:1571-9. </text>
<text top="188" left="115" width="931" height="21" font="0">497. Schwartz PJ and Woosley RL. Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes. J Am Coll Cardiol. </text>
<text top="208" left="149" width="126" height="21" font="0">2016; 67:1639-50. </text>
<text top="228" left="115" width="887" height="21" font="0">498. Basso C, Burke M, Fornes P, et al. Guidelines for autopsy investigation of sudden cardiac death. Virchows Arch. 2008; 452:11-8. </text>
<text top="249" left="115" width="928" height="21" font="0">499. Thorne SA, Barnes I, Cullinan P, et al. Amiodarone-associated thyroid dysfunction: risk factors in adults with congenital heart disease. </text>
<text top="269" left="149" width="206" height="21" font="0">Circulation. 1999; 100:149-54. </text>
<text top="289" left="115" width="940" height="21" font="0">500. Deal BJ, Scagliotti D, Miller SM, et al. Electrophysiologic drug testing in symptomatic ventricular arrhythmias after repair of tetralogy of </text>
<text top="309" left="149" width="253" height="21" font="0">Fallot. Am J Cardiol. 1987; 59:1380-5. </text>
<text top="329" left="115" width="950" height="21" font="0">501. Gatzoulis MA, Till JA, Somerville J, et al. Mechanoelectrical interaction in tetralogy of Fallot. QRS prolongation relates to right ventricular </text>
<text top="349" left="149" width="666" height="21" font="0">size and predicts malignant ventricular arrhythmias and sudden death. Circulation. 1995; 92:231-7. </text>
<text top="370" left="115" width="863" height="21" font="0">502. Koyak Z, Harris L, de Groot JR, et al. Sudden cardiac death in adult congenital heart disease. Circulation. 2012; 126:1944-54. </text>
<text top="389" left="115" width="944" height="21" font="0">503. Diller GP, Kempny A, Liodakis E, et al. Left ventricular longitudinal function predicts life-threatening ventricular arrhythmia and death in </text>
<text top="410" left="149" width="470" height="21" font="0">adults with repaired tetralogy of fallot. Circulation. 2012; 125:2440-6. </text>
<text top="430" left="115" width="924" height="21" font="0">504. Harrison DA, Harris L, Siu SC, et al. Sustained ventricular tachycardia in adult patients late after repair of tetralogy of Fallot. J Am Coll </text>
<text top="450" left="149" width="181" height="21" font="0">Cardiol. 1997; 30:1368-73. </text>
<text top="470" left="115" width="964" height="21" font="0">505. Knauth AL, Gauvreau K, Powell AJ, et al. Ventricular size and function assessed by cardiac MRI predict major adverse clinical outcomes late </text>
<text top="490" left="149" width="524" height="21" font="0">after tetralogy of Fallot repair. Heart (British Cardiac Society). 2008; 94:211-6. </text>
<text top="510" left="115" width="951" height="21" font="0">506. Therrien J, Siu SC, Harris L, et al. Impact of pulmonary valve replacement on arrhythmia propensity late after repair of tetralogy of Fallot. </text>
<text top="531" left="149" width="215" height="21" font="0">Circulation. 2001; 103:2489-94. </text>
<text top="551" left="115" width="938" height="21" font="0">507. Therrien J, Provost Y, Merchant N, et al. Optimal timing for pulmonary valve replacement in adults after tetralogy of Fallot repair. Am J </text>
<text top="571" left="149" width="173" height="21" font="0">Cardiol. 2005; 95:779-82. </text>
<text top="591" left="115" width="947" height="21" font="0">508. Harrild DM, Berul CI, Cecchin F, et al. Pulmonary valve replacement in tetralogy of Fallot: impact on survival and ventricular tachycardia. </text>
<text top="611" left="149" width="206" height="21" font="0">Circulation. 2009; 119:445-51. </text>
<text top="631" left="115" width="906" height="21" font="0">509. Adamson L, Vohra HA and Haw MP. Does pulmonary valve replacement post repair of tetralogy of Fallot improve right ventricular </text>
<text top="651" left="149" width="490" height="21" font="0">function? Interactive cardiovascular and thoracic surgery. 2009; 9:520-7. </text>
<text top="671" left="115" width="955" height="21" font="0">510. Sabate Rotes A, Connolly HM, Warnes CA, et al. Ventricular arrhythmia risk stratification in patients with tetralogy of Fallot at the time of </text>
<text top="692" left="149" width="509" height="21" font="0">pulmonary valve replacement. Circ Arrhythm Electrophysiol. 2015; 8:110-6. </text>
<text top="712" left="115" width="963" height="21" font="0">511. Tsai SF, Chan DP, Ro PS, et al. Rate of inducible ventricular arrhythmia in adults with congenital heart disease. Am J Cardiol. 2010; 106:730-</text>
<text top="732" left="149" width="16" height="21" font="0">6. </text>
<text top="752" left="115" width="948" height="21" font="0">512. Garson A, Jr., Porter CB, Gillette PC, et al. Induction of ventricular tachycardia during electrophysiologic study after repair of tetralogy of </text>
<text top="772" left="149" width="291" height="21" font="0">Fallot. J Am Coll Cardiol. 1983; 1:1493-502. </text>
</page>
<page number="352" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">352 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="922" height="21" font="0">513. Chandar JS, Wolff GS, Garson A, Jr., et al. Ventricular arrhythmias in postoperative tetralogy of Fallot. Am J Cardiol. 1990; 65:655-61. </text>
<text top="128" left="115" width="922" height="21" font="0">514. Kella DK, Merchant FM, Veledar E, et al. Lesion-specific differences for implantable cardioverter defibrillator therapies in adults with </text>
<text top="148" left="149" width="467" height="21" font="0">congenital heart disease. Pacing Clin Electrophysiol. 2014; 37:1492-8. </text>
<text top="168" left="115" width="956" height="21" font="0">515. Santharam S, Hudsmith L, Thorne S, et al. Long-term follow-up of implantable cardioverter-defibrillators in adult congenital heart disease </text>
<text top="188" left="149" width="891" height="21" font="0">patients: indications and outcomes. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working </text>
<text top="208" left="149" width="897" height="21" font="0">groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2017; 19:407-13. </text>
<text top="228" left="115" width="937" height="21" font="0">516. Vehmeijer JT, Brouwer TF, Limpens J, et al. Implantable cardioverter-defibrillators in adults with congenital heart disease: a systematic </text>
<text top="249" left="149" width="468" height="21" font="0">review and meta-analysis. European heart journal. 2016; 37:1439-48. </text>
<text top="269" left="115" width="952" height="21" font="0">517. Moore JP, Mondesert B, Lloyd MS, et al. Clinical Experience With the Subcutaneous Implantable Cardioverter-Defibrillator in Adults With </text>
<text top="289" left="149" width="434" height="21" font="0">Congenital Heart Disease. Circ Arrhythm Electrophysiol. 2016; 9. </text>
<text top="309" left="115" width="897" height="21" font="0">518. Okamura H, McLeod CJ, DeSimone CV, et al. Right Parasternal Lead Placement Increases Eligibility for Subcutaneous Implantable </text>
<text top="329" left="149" width="926" height="21" font="0">Cardioverter Defibrillator Therapy in Adults With Congenital Heart Disease. Circulation journal : official journal of the Japanese Circulation </text>
<text top="349" left="149" width="182" height="21" font="0">Society. 2016; 80:1328-35. </text>
<text top="370" left="115" width="917" height="21" font="0">519. Yap SC, Roos-Hesselink JW, Hoendermis ES, et al. Outcome of implantable cardioverter defibrillators in adults with congenital heart </text>
<text top="389" left="149" width="490" height="21" font="0">disease: a multi-centre study. European heart journal. 2007; 28:1854-61. </text>
<text top="410" left="115" width="935" height="21" font="0">520. Khairy P, Landzberg MJ, Gatzoulis MA, et al. Value of programmed ventricular stimulation after tetralogy of fallot repair: a multicenter </text>
<text top="430" left="149" width="276" height="21" font="0">study. Circulation. 2004; 109:1994-2000. </text>
<text top="450" left="115" width="902" height="21" font="0">521. Khairy P, Harris L, Landzberg MJ, et al. Implantable cardioverter-defibrillators in tetralogy of Fallot. Circulation. 2008; 117:363-70. </text>
<text top="470" left="115" width="912" height="21" font="0">522. Zeppenfeld K, Schalij MJ, Bartelings MM, et al. Catheter ablation of ventricular tachycardia after repair of congenital heart disease: </text>
<text top="490" left="149" width="685" height="21" font="0">electroanatomic identification of the critical right ventricular isthmus. Circulation. 2007; 116:2241-52. </text>
<text top="510" left="115" width="967" height="21" font="0">523. van Zyl M, Kapa S, Padmanabhan D, et al. Mechanism and outcomes of catheter ablation for ventricular tachycardia in adults with repaired </text>
<text top="531" left="149" width="396" height="21" font="0">congenital heart disease. Heart rhythm. 2016; 13:1449-54. </text>
<text top="551" left="115" width="952" height="21" font="0">524. Kapel GF, Reichlin T, Wijnmaalen AP, et al. Left-sided ablation of ventricular tachycardia in adults with repaired tetralogy of Fallot: a case </text>
<text top="571" left="149" width="356" height="21" font="0">series. Circ Arrhythm Electrophysiol. 2014; 7:889-97. </text>
<text top="591" left="115" width="968" height="21" font="0">525. Kapel GF, Reichlin T, Wijnmaalen AP, et al. Re-entry using anatomically determined isthmuses: a curable ventricular tachycardia in repaired </text>
<text top="611" left="149" width="480" height="21" font="0">congenital heart disease. Circ. Arrhythm. Electrophysiol. 2015; 8:102-9. </text>
<text top="631" left="115" width="948" height="21" font="0">526. Kapel GF, Sacher F, Dekkers OM, et al. Arrhythmogenic anatomical isthmuses identified by electroanatomical mapping are the substrate </text>
<text top="651" left="149" width="666" height="21" font="0">for ventricular tachycardia in repaired tetralogy of Fallot. European heart journal. 2017; 38:268-76. </text>
<text top="671" left="115" width="927" height="21" font="0">527. Khairy P, Harris L, Landzberg MJ, et al. Sudden death and defibrillators in transposition of the great arteries with intra-atrial baffles: a </text>
<text top="692" left="149" width="427" height="21" font="0">multicenter study. Circ Arrhythm Electrophysiol. 2008; 1:250-7. </text>
<text top="712" left="115" width="952" height="21" font="0">528. Tutarel O, Kempny A, Alonso-Gonzalez R, et al. Congenital heart disease beyond the age of 60: emergence of a new population with high </text>
<text top="732" left="149" width="655" height="21" font="0">resource utilization, high morbidity, and high mortality. European heart journal. 2014; 35:725-32. </text>
</page>
<page number="353" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">353 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="906" height="21" font="0">529. Koyak Z, de Groot JR, Bouma BJ, et al. Sudden cardiac death in adult congenital heart disease: can the unpredictable be foreseen? </text>
<text top="128" left="149" width="911" height="21" font="0">Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, </text>
<text top="148" left="149" width="625" height="21" font="0">and cardiac cellular electrophysiology of the European Society of Cardiology. 2017; 19:401-6. </text>
<text top="168" left="115" width="939" height="21" font="0">530. Engelfriet P, Boersma E, Oechslin E, et al. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year </text>
<text top="188" left="149" width="794" height="21" font="0">follow-up period. The Euro Heart Survey on adult congenital heart disease. European heart journal. 2005; 26:2325-33. </text>
<text top="208" left="115" width="961" height="21" font="0">531. Gallego P, Gonzalez AE, Sanchez-Recalde A, et al. Incidence and predictors of sudden cardiac arrest in adults with congenital heart defects </text>
<text top="228" left="149" width="393" height="21" font="0">repaired before adult life. Am J Cardiol. 2012; 110:109-17. </text>
<text top="249" left="115" width="950" height="21" font="0">532. Engelings CC, Helm PC, Abdul-Khaliq H, et al. Cause of death in adults with congenital heart disease - An analysis of the German National </text>
<text top="269" left="149" width="453" height="21" font="0">Register for Congenital Heart Defects. Int J Cardiol. 2016; 211:31-6. </text>
<text top="289" left="115" width="953" height="21" font="0">533. Fish FA, Gillette PC and Benson DW, Jr. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The </text>
<text top="309" left="149" width="472" height="21" font="0">Pediatric Electrophysiology Group. J Am Coll Cardiol. 1991; 18:356-65. </text>
<text top="329" left="115" width="884" height="21" font="0">534. Stan MN, Sathananthan M, Warnes C, et al. Amiodarone-induced thyrotoxicosis in adults with congenital heart disease-clinical </text>
<text top="349" left="149" width="504" height="21" font="0">presentation and response to therapy. Endocrine Practice. 2014; 21:33-40. </text>
<text top="370" left="115" width="927" height="21" font="0">535. Silka MJ, Hardy BG, Menashe VD, et al. A population-based prospective evaluation of risk of sudden cardiac death after operation for </text>
<text top="389" left="149" width="471" height="21" font="0">common congenital heart defects. J Am Coll Cardiol. 1998; 32:245-51. </text>
<text top="410" left="115" width="916" height="21" font="0">536. Oechslin EN, Harrison DA, Connelly MS, et al. Mode of death in adults with congenital heart disease. Am J Cardiol. 2000; 86:1111-6. </text>
<text top="430" left="115" width="916" height="21" font="0">537. Nieminen HP, Jokinen EV and Sairanen HI. Causes of late deaths after pediatric cardiac surgery: a population-based study. J Am Coll </text>
<text top="450" left="149" width="181" height="21" font="0">Cardiol. 2007; 50:1263-71. </text>
<text top="470" left="115" width="941" height="21" font="0">538. Verheugt CL, Uiterwaal CS, Grobbee DE, et al. Long-term prognosis of congenital heart defects: a systematic review. Int J Cardiol. 2008; </text>
<text top="490" left="149" width="76" height="21" font="0">131:25-32. </text>
<text top="510" left="115" width="967" height="21" font="0">539. Pillutla P, Shetty KD and Foster E. Mortality associated with adult congenital heart disease: Trends in the US population from 1979 to 2005. </text>
<text top="531" left="149" width="199" height="21" font="0">Am Heart J. 2009; 158:874-9. </text>
<text top="551" left="115" width="946" height="21" font="0">540. Verheugt CL, Uiterwaal CS, van der Velde ET, et al. Mortality in adult congenital heart disease. European heart journal. 2010; 31:1220-9. </text>
<text top="571" left="115" width="908" height="21" font="0">541. Zomer AC, Vaartjes I, Uiterwaal CS, et al. Circumstances of death in adult congenital heart disease. Int J Cardiol. 2012; 154:168-72. </text>
<text top="591" left="115" width="936" height="21" font="0">542. Diller GP, Kempny A, Alonso-Gonzalez R, et al. Survival Prospects and Circumstances of Death in Contemporary Adult Congenital Heart </text>
<text top="611" left="149" width="624" height="21" font="0">Disease Patients Under Follow-Up at a Large Tertiary Centre. Circulation. 2015; 132:2118-25. </text>
<text top="631" left="115" width="943" height="21" font="0">543. Raissadati A, Nieminen H, Haukka J, et al. Late Causes of Death After Pediatric Cardiac Surgery: A 60-Year Population-Based Study. J Am </text>
<text top="651" left="149" width="202" height="21" font="0">Coll Cardiol. 2016; 68:487-98. </text>
<text top="671" left="115" width="936" height="21" font="0">544. Teuwen CP, Ramdjan TT, Gotte M, et al. Non-sustained ventricular tachycardia in patients with congenital heart disease: An important </text>
<text top="692" left="149" width="250" height="21" font="0">sign? Int J Cardiol. 2016; 206:158-63. </text>
<text top="712" left="115" width="867" height="21" font="0">545. Wells R, Khairy P, Harris L, et al. Dofetilide for atrial arrhythmias in congenital heart disease: a multicenter study. Pacing Clin </text>
<text top="732" left="149" width="220" height="21" font="0">Electrophysiol. 2009; 32:1313-8. </text>
<text top="752" left="115" width="967" height="21" font="0">546. Afilalo J, Therrien J, Pilote L, et al. Geriatric congenital heart disease: burden of disease and predictors of mortality. J Am Coll Cardiol. 2011; </text>
<text top="772" left="149" width="84" height="21" font="0">58:1509-15. </text>
</page>
<page number="354" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">354 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="959" height="21" font="0">547. El Malti R, Liu H, Doray B, et al. A systematic variant screening in familial cases of congenital heart defects demonstrates the usefulness of </text>
<text top="128" left="149" width="627" height="21" font="0">molecular genetics in this field. European journal of human genetics : EJHG. 2016; 24:228-36. </text>
<text top="148" left="115" width="966" height="21" font="0">548. Abou Hassan OK, Fahed AC, Batrawi M, et al. NKX2-5 mutations in an inbred consanguineous population: genetic and phenotypic diversity. </text>
<text top="168" left="149" width="217" height="21" font="0">Scientific reports. 2015; 5:8848. </text>
<text top="188" left="115" width="909" height="21" font="0">549. Ellesoe SG, Johansen MM, Bjerre JV, et al. Familial Atrial Septal Defect and Sudden Cardiac Death: Identification of a Novel NKX2-5 </text>
<text top="208" left="149" width="567" height="21" font="0">Mutation and a Review of the Literature. Congenital heart disease. 2016; 11:283-90. </text>
<text top="228" left="115" width="958" height="21" font="0">550. Cuypers JA, Opic P, Menting ME, et al. The unnatural history of an atrial septal defect: longitudinal 35 year follow up after surgical closure </text>
<text top="249" left="149" width="427" height="21" font="0">at young age. Heart (British Cardiac Society). 2013; 99:1346-52. </text>
<text top="269" left="115" width="943" height="21" font="0">551. Kuijpers JM, van der Bom T, van Riel AC, et al. Secundum atrial septal defect is associated with reduced survival in adult men. European </text>
<text top="289" left="149" width="221" height="21" font="0">heart journal. 2015; 36:2079-86. </text>
<text top="309" left="115" width="965" height="21" font="0">552. Khairy P, Aboulhosn J, Gurvitz MZ, et al. Arrhythmia burden in adults with surgically repaired tetralogy of Fallot: a multi-institutional study. </text>
<text top="329" left="149" width="206" height="21" font="0">Circulation. 2010; 122:868-75. </text>
<text top="349" left="115" width="923" height="21" font="0">553. Valente AM, Gauvreau K, Assenza GE, et al. Contemporary predictors of death and sustained ventricular tachycardia in patients with </text>
<text top="370" left="149" width="750" height="21" font="0">repaired tetralogy of Fallot enrolled in the INDICATOR cohort. Heart (British Cardiac Society). 2014; 100:247-53. </text>
<text top="389" left="115" width="954" height="21" font="0">554. Arya S, Kovach J, Singh H, et al. Arrhythmias and sudden death among older children and young adults following tetralogy of Fallot repair </text>
<text top="410" left="149" width="753" height="21" font="0">in the current era: are previously reported risk factors still applicable? Congenital heart disease. 2014; 9:407-14. </text>
<text top="430" left="115" width="939" height="21" font="0">555. Wu MH, Lu CW, Chen HC, et al. Arrhythmic burdens in patients with tetralogy of Fallot: a national database study. Heart rhythm. 2015; </text>
<text top="450" left="149" width="68" height="21" font="0">12:604-9. </text>
<text top="470" left="115" width="949" height="21" font="0">556. Drago F, Pazzano V, Di Mambro C, et al. Role of right ventricular three-dimensional electroanatomic voltage mapping for arrhythmic risk </text>
<text top="490" left="149" width="935" height="21" font="0">stratification of patients with corrected tetralogy of Fallot or other congenital heart disease involving the right ventricular outflow tract. Int </text>
<text top="510" left="149" width="182" height="21" font="0">J Cardiol. 2016; 222:422-9. </text>
<text top="531" left="115" width="937" height="21" font="0">557. Kriebel T, Saul JP, Schneider H, et al. Noncontact mapping and radiofrequency catheter ablation of fast and hemodynamically unstable </text>
<text top="551" left="149" width="674" height="21" font="0">ventricular tachycardia after surgical repair of tetralogy of Fallot. J Am Coll Cardiol. 2007; 50:2162-8. </text>
<text top="571" left="115" width="946" height="21" font="0">558. Witte KK, Pepper CB, Cowan JC, et al. Implantable cardioverter-defibrillator therapy in adult patients with tetralogy of Fallot. Europace : </text>
<text top="591" left="149" width="916" height="21" font="0">European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac </text>
<text top="611" left="149" width="553" height="21" font="0">cellular electrophysiology of the European Society of Cardiology. 2008; 10:926-30. </text>
<text top="631" left="115" width="937" height="21" font="0">559. Lange R, Horer J, Kostolny M, et al. Presence of a ventricular septal defect and the Mustard operation are risk factors for late mortality </text>
<text top="651" left="149" width="827" height="21" font="0">after the atrial switch operation: thirty years of follow-up in 417 patients at a single center. Circulation. 2006; 114:1905-13. </text>
<text top="671" left="115" width="878" height="21" font="0">560. Schwerzmann M, Salehian O, Harris L, et al. Ventricular arrhythmias and sudden death in adults after a Mustard operation for </text>
<text top="692" left="149" width="515" height="21" font="0">transposition of the great arteries. European heart journal. 2009; 30:1873-9. </text>
<text top="712" left="115" width="963" height="21" font="0">561. Wheeler M, Grigg L and Zentner D. Can we predict sudden cardiac death in long-term survivors of atrial switch surgery for transposition of </text>
<text top="732" left="149" width="410" height="21" font="0">the great arteries? Congenital heart disease. 2014; 9:326-32. </text>
<text top="752" left="115" width="952" height="21" font="0">562. Bouzeman A, Marijon E, de Guillebon M, et al. Implantable cardiac defibrillator among adults with transposition of the great arteries and </text>
<text top="772" left="149" width="606" height="21" font="0">atrial switch operation: case series and review of literature. Int J Cardiol. 2014; 177:301-6. </text>
</page>
<page number="355" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">355 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="887" height="21" font="0">563. Buber J, Ackley TJ, Daniels CJ, et al. Outcomes following the implantation of cardioverter-defibrillator for primary prevention in </text>
<text top="128" left="149" width="929" height="21" font="0">transposition of the great arteries after intra-atrial baffle repair: a single-centre experience. Europace : European pacing, arrhythmias, and </text>
<text top="148" left="149" width="897" height="21" font="0">cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the </text>
<text top="168" left="149" width="343" height="21" font="0">European Society of Cardiology. 2016; 18:1016-22. </text>
<text top="188" left="115" width="906" height="21" font="0">564. Backhoff D, Kerst G, Peters A, et al. Internal Cardioverter Defibrillator Indications and Therapies after Atrial Baffle Procedure for d-</text>
<text top="208" left="149" width="696" height="21" font="0">Transposition of the Great Arteries: A Multicenter Analysis. Pacing Clin Electrophysiol. 2016; 39:1070-6. </text>
<text top="228" left="115" width="943" height="21" font="0">565. Pundi KN, Pundi KN, Johnson JN, et al. Sudden cardiac death and late arrhythmias after the Fontan operation. Congenital heart disease. </text>
<text top="249" left="149" width="109" height="21" font="0">2017; 12:17-23. </text>
<text top="269" left="115" width="905" height="21" font="0">566. Sakamoto T, Nagashima M, Hiramatsu T, et al. Fontan circulation over 30 years. What should we learn from those patients? Asian </text>
<text top="289" left="149" width="342" height="21" font="0">cardiovascular &amp; thoracic annals. 2016; 24:765-71. </text>
<text top="309" left="115" width="951" height="21" font="0">567. Alexander ME, Walsh EP, Saul JP, et al. Value of programmed ventricular stimulation in patients with congenital heart disease. Journal of </text>
<text top="329" left="149" width="353" height="21" font="0">cardiovascular electrophysiology. 1999; 10:1033-44. </text>
<text top="349" left="115" width="946" height="21" font="0">568. Silka MJ, Kron J, Dunnigan A, et al. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. The </text>
<text top="370" left="149" width="431" height="21" font="0">Pediatric Electrophysiology Society. Circulation. 1993; 87:800-7. </text>
<text top="389" left="115" width="945" height="21" font="0">569. Berul CI, Van Hare GF, Kertesz NJ, et al. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric </text>
<text top="410" left="149" width="504" height="21" font="0">and congenital heart disease patients. J Am Coll Cardiol. 2008; 51:1685-91. </text>
<text top="430" left="115" width="930" height="21" font="0">570. Khanna AD, Warnes CA, Phillips SD, et al. Single-center experience with implantable cardioverter-defibrillators in adults with complex </text>
<text top="450" left="149" width="388" height="21" font="0">congenital heart disease. Am J Cardiol. 2011; 108:729-34. </text>
<text top="470" left="115" width="955" height="21" font="0">571. Koyak Z, de Groot JR, Van Gelder IC, et al. Implantable cardioverter defibrillator therapy in adults with congenital heart disease: who is at </text>
<text top="490" left="149" width="410" height="21" font="0">risk of shocks? Circ Arrhythm Electrophysiol. 2012; 5:101-10. </text>
<text top="510" left="115" width="969" height="21" font="0">572. Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult </text>
<text top="531" left="149" width="932" height="21" font="0">Congenital Heart Disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart </text>
<text top="551" left="149" width="377" height="21" font="0">Rhythm Society (HRS). Heart rhythm. 2014; 11:e102-65. </text>
<text top="571" left="115" width="950" height="21" font="0">573. Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverter-defibrillator. N. Engl. J. Med. 2010; 363:36-44. </text>
<text top="591" left="115" width="968" height="21" font="0">574. Olde Nordkamp LR, Dabiri AL, Boersma LV, et al. The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience </text>
<text top="611" left="149" width="398" height="21" font="0">in a large Dutch cohort. J Am Coll Cardiol. 2012; 60:1933-9. </text>
<text top="631" left="115" width="908" height="21" font="0">575. Köbe J, Reinke F, Meyer C, et al. Implantation and follow-up of totally subcutaneous versus conventional implantable cardioverter-</text>
<text top="651" left="149" width="526" height="21" font="0">defibrillators: a multicenter case-control study. Heart rhythm. 2013; 10:29-36. </text>
<text top="671" left="115" width="957" height="21" font="0">576. de Bie MK, Thijssen J, van Rees JB, et al. Suitability for subcutaneous defibrillator implantation: results based on data from routine clinical </text>
<text top="692" left="149" width="395" height="21" font="0">practice. Heart (British Cardiac Society). 2013; 99:1018-23. </text>
<text top="712" left="115" width="953" height="21" font="0">577. Weiss R, Knight BP, Gold MR, et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation. 2013; </text>
<text top="732" left="149" width="84" height="21" font="0">128:944-53. </text>
<text top="752" left="115" width="951" height="21" font="0">578. Olde Nordkamp LR, Warnaars JL, Kooiman KM, et al. Which patients are not suitable for a subcutaneous ICD: incidence and predictors of </text>
<text top="772" left="149" width="588" height="21" font="0">failed QRS-T-wave morphology screening. J. Cardiovasc. Electrophysiol. 2014; 25:494-9. </text>
</page>
<page number="356" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">356 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="939" height="21" font="0">579. Randles DA, Hawkins NM, Shaw M, et al. How many patients fulfil the surface electrocardiogram criteria for subcutaneous implantable </text>
<text top="128" left="149" width="915" height="21" font="0">cardioverter-defibrillator implantation? Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working </text>
<text top="148" left="149" width="905" height="21" font="0">groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2014; 16:1015-21. </text>
<text top="168" left="115" width="957" height="21" font="0">580. Lambiase PD, Barr C, Theuns DA, et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the </text>
<text top="188" left="149" width="397" height="21" font="0">EFFORTLESS S-ICD Registry. Eur. Heart J. 2014; 35:1657-65. </text>
<text top="208" left="115" width="587" height="21" font="0">581. Groh WJ. Arrhythmias in the muscular dystrophies. Heart rhythm. 2012; 9:1890-5. </text>
<text top="228" left="115" width="965" height="21" font="0">582. Burke MC, Gold MR, Knight BP, et al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled </text>
<text top="249" left="149" width="584" height="21" font="0">analysis of the IDE study and EFFORTLESS registry. J Am Coll Cardiol. 2015; 65:1605-15. </text>
<text top="269" left="115" width="777" height="21" font="0">583. Chung MK. The role of the wearable cardioverter defibrillator in clinical practice. Cardiol Clin. 2014; 32:253-70. </text>
<text top="289" left="115" width="907" height="21" font="0">584. Chung MK, Szymkiewicz SJ, Shao M, et al. Aggregate national experience with the wearable cardioverter-defibrillator: event rates, </text>
<text top="309" left="149" width="418" height="21" font="0">compliance, and survival. J Am Coll Cardiol. 2010; 56:194-203. </text>
<text top="329" left="115" width="890" height="21" font="0">585. Klein HU, Meltendorf U, Reek S, et al. Bridging a temporary high risk of sudden arrhythmic death. Experience with the wearable </text>
<text top="349" left="149" width="517" height="21" font="0">cardioverter defibrillator (WCD). Pacing Clin Electrophysiol. 2010; 33:353-67. </text>
<text top="370" left="115" width="933" height="21" font="0">586. de Noronha SV, Behr ER, Papadakis M, et al. The importance of specialist cardiac histopathological examination in the investigation of </text>
<text top="389" left="149" width="921" height="21" font="0">young sudden cardiac deaths. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on </text>
<text top="410" left="149" width="834" height="21" font="0">cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2014; 16:899-907. </text>
<text top="430" left="115" width="964" height="21" font="0">587. Wu Q, Zhang L, Zheng J, et al. Forensic Pathological Study of 1656 Cases of Sudden Cardiac Death in Southern China. Medicine (Baltimore). </text>
<text top="450" left="149" width="112" height="21" font="0">2016; 95:e2707. </text>
<text top="470" left="115" width="904" height="21" font="0">588. Vassalini M, Verzeletti A, Restori M, et al. An autopsy study of sudden cardiac death in persons aged 1-40 years in Brescia (Italy). J </text>
<text top="490" left="149" width="327" height="21" font="0">Cardiovasc Med (Hagerstown). 2016; 17:446-53. </text>
<text top="510" left="115" width="911" height="21" font="0">589. Tester DJ, Medeiros-Domingo A, Will ML, et al. Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsy-</text>
<text top="531" left="149" width="750" height="21" font="0">negative sudden unexplained death referred for postmortem genetic testing. Mayo Clin. Proc. 2012; 87:524-39. </text>
<text top="551" left="115" width="945" height="21" font="0">590. Tang Y, Stahl-Herz J and Sampson BA. Molecular diagnostics of cardiovascular diseases in sudden unexplained death. Cardiovasc Pathol. </text>
<text top="571" left="149" width="92" height="21" font="0">2014; 23:1-4. </text>
<text top="591" left="115" width="904" height="21" font="0">591. Papadakis M, Raju H, Behr ER, et al. Sudden cardiac death with autopsy findings of uncertain significance: potential for erroneous </text>
<text top="611" left="149" width="420" height="21" font="0">interpretation. Circ. Arrhythm. Electrophysiol. 2013; 6:588-96. </text>
<text top="631" left="115" width="943" height="21" font="0">592. Harmon KG, Drezner JA, Maleszewski JJ, et al. Pathogeneses of sudden cardiac death in national collegiate athletic association athletes. </text>
<text top="651" left="149" width="326" height="21" font="0">Circ. Arrhythm. Electrophysiol. 2014; 7:198-204. </text>
<text top="671" left="115" width="929" height="21" font="0">593. Bagnall RD, Das KJ, Duflou J, et al. Exome analysis-based molecular autopsy in cases of sudden unexplained death in the young. Heart </text>
<text top="692" left="149" width="175" height="21" font="0">rhythm. 2014; 11:655-62. </text>
<text top="712" left="115" width="948" height="21" font="0">594. Bagnall RD, Weintraub RG, Ingles J, et al. A prospective study of sudden cardiac death among children and young adults. N. Engl. J. Med. </text>
<text top="732" left="149" width="134" height="21" font="0">2016; 374:2441-52. </text>
<text top="752" left="115" width="967" height="21" font="0">595. Hill L, McIlfatrick S, Taylor B, et al. Patients' perception of implantable cardioverter defibrillator deactivation at the end of life. Palliat. Med. </text>
<text top="772" left="149" width="117" height="21" font="0">2015; 29:310-23. </text>
</page>
<page number="357" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">357 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="948" height="21" font="0">596. Kramer DB, Reynolds MR, Normand SL, et al. Hospice use following implantable cardioverter-defibrillator implantation in older patients: </text>
<text top="128" left="149" width="577" height="21" font="0">results from the National Cardiovascular Data Registry. Circulation. 2016; 133:2030-7. </text>
<text top="148" left="115" width="933" height="21" font="0">597. Buchhalter LC, Ottenberg AL, Webster TL, et al. Features and outcomes of patients who underwent cardiac device deactivation. JAMA </text>
<text top="168" left="149" width="197" height="21" font="0">Intern. Med. 2014; 174:80-5. </text>
<text top="188" left="115" width="933" height="21" font="0">598. Goldstein NE, Lampert R, Bradley E, et al. Management of implantable cardioverter defibrillators in end-of-life care. Ann. Intern. Med. </text>
<text top="208" left="149" width="117" height="21" font="0">2004; 141:835-8. </text>
<text top="228" left="115" width="904" height="21" font="0">599. Goldstein N, Carlson M, Livote E, et al. Brief communication: Management of implantable cardioverter-defibrillators in hospice: A </text>
<text top="249" left="149" width="371" height="21" font="0">nationwide survey. Ann. Intern. Med. 2010; 152:296-9. </text>
<text top="269" left="115" width="921" height="21" font="0">600. Berger JT, Gorski M and Cohen T. Advance health planning and treatment preferences among recipients of implantable cardioverter </text>
<text top="289" left="149" width="431" height="21" font="0">defibrillators: an exploratory study. J Clin. Ethics. 2006; 17:72-8. </text>
<text top="309" left="115" width="962" height="21" font="0">601. Dodson JA, Fried TR, Van Ness PH, et al. Patient preferences for deactivation of implantable cardioverter-defibrillators. JAMA Intern. Med. </text>
<text top="329" left="149" width="117" height="21" font="0">2013; 173:377-9. </text>
<text top="349" left="115" width="961" height="21" font="0">602. Goldstein NE, Mehta D, Siddiqui S, et al. &#34;That's like an act of suicide&#34; patients' attitudes toward deactivation of implantable defibrillators. </text>
<text top="370" left="149" width="286" height="21" font="0">J Gen. Intern. Med. 2008; 23 Suppl 1:7-12. </text>
<text top="389" left="115" width="938" height="21" font="0">603. Habal MV, Micevski V, Greenwood S, et al. How aware of advanced care directives are heart failure patients, and are they using them? </text>
<text top="410" left="149" width="215" height="21" font="0">Can. J Cardiol. 2011; 27:376-81. </text>
<text top="430" left="115" width="939" height="21" font="0">604. Kirkpatrick JN, Gottlieb M, Sehgal P, et al. Deactivation of implantable cardioverter defibrillators in terminal illness and end of life care. </text>
<text top="450" left="149" width="208" height="21" font="0">Am. J. Cardiol. 2012; 109:91-4. </text>
<text top="470" left="115" width="920" height="21" font="0">605. Kramer DB, Kesselheim AS, Salberg L, et al. Ethical and legal views regarding deactivation of cardiac implantable electrical devices in </text>
<text top="490" left="149" width="525" height="21" font="0">patients with hypertrophic cardiomyopathy. Am. J. Cardiol. 2011; 107:1071-5. </text>
<text top="510" left="115" width="940" height="21" font="0">606. Lewis KB, Stacey D and Matlock DD. Making decisions about implantable cardioverter-defibrillators from implantation to end of life: an </text>
<text top="531" left="149" width="462" height="21" font="0">integrative review of patients' perspectives. Patient. 2014; 7:243-60. </text>
<text top="551" left="115" width="945" height="21" font="0">607. Lewis KB, Nery PB and Birnie DH. Decision making at the time of ICD generator change: patients' perspectives. JAMA Intern. Med. 2014; </text>
<text top="571" left="149" width="93" height="21" font="0">174:1508-11. </text>
<text top="591" left="115" width="934" height="21" font="0">608. Hauptman PJ, Chibnall JT, Guild C, et al. Patient perceptions, physician communication, and the implantable cardioverter-defibrillator. </text>
<text top="611" left="149" width="248" height="21" font="0">JAMA Intern. Med. 2013; 173:571-7. </text>
<text top="631" left="115" width="965" height="21" font="0">609. Stewart GC, Weintraub JR, Pratibhu PP, et al. Patient expectations from implantable defibrillators to prevent death in heart failure. Journal </text>
<text top="651" left="149" width="238" height="21" font="0">of cardiac failure. 2010; 16:106-13. </text>
<text top="671" left="115" width="937" height="21" font="0">610. Ottenberg AL, Mueller PS, Topazian RJ, et al. &#34;It's not broke, so let's not try to fix it&#34;: why patients decline a cardiovascular implantable </text>
<text top="692" left="149" width="430" height="21" font="0">electronic device. Pacing Clin. Electrophysiol. 2014; 37:1306-14. </text>
<text top="712" left="115" width="945" height="21" font="0">611. Yuhas J, Mattocks K, Gravelin L, et al. Patients' attitudes and perceptions of implantable cardioverter-defibrillators: potential barriers to </text>
<text top="732" left="149" width="533" height="21" font="0">appropriate primary prophylaxis. Pacing Clin. Electrophysiol. 2012; 35:1179-87. </text>
</page>
<page number="358" position="absolute" top="0" left="0" height="918" width="1543">
<text top="803" left="585" width="29" height="21" font="0">358 </text>
<text top="823" left="115" width="4" height="21" font="0"> </text>
<text top="844" left="115" width="803" height="21" font="0">© 2017 by the American College of Cardiology Foundation, American Heart Association, Inc., and Heart Rhythm Society </text>
<text top="108" left="115" width="937" height="21" font="0">612. Larsen G, Hallstrom A, McAnulty J, et al. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in </text>
<text top="128" left="149" width="935" height="21" font="0">survivors of serious ventricular tachyarrhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis </text>
<text top="148" left="149" width="283" height="21" font="0">substudy. Circulation. 2002; 105:2049-57. </text>
<text top="168" left="115" width="906" height="21" font="0">613. O'Brien BJ, Connolly SJ, Goeree R, et al. Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian </text>
<text top="188" left="149" width="474" height="21" font="0">Implantable Defibrillator Study (CIDS). Circulation. 2001; 103:1416-21. </text>
<text top="208" left="115" width="969" height="21" font="0">614. Weiss JP, Saynina O, McDonald KM, et al. Effectiveness and cost-effectiveness of implantable cardioverter defibrillators in the treatment of </text>
<text top="228" left="149" width="571" height="21" font="0">ventricular arrhythmias among medicare beneficiaries. Am J Med. 2002; 112:519-27. </text>
<text top="249" left="115" width="941" height="21" font="0">615. Buxton M, Caine N, Chase D, et al. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in </text>
<text top="269" left="149" width="898" height="21" font="0">different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context. Health Technol. Assess. </text>
<text top="289" left="149" width="114" height="21" font="0">2006; 10:iii-xi, 1. </text>
<text top="309" left="115" width="934" height="21" font="0">616. Mark DB, Nelson CL, Anstrom KJ, et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results </text>
<text top="329" left="149" width="644" height="21" font="0">from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation. 2006; 114:135-42. </text>
<text top="349" left="115" width="907" height="21" font="0">617. Zwanziger J, Hall WJ, Dick AW, et al. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter </text>
<text top="370" left="149" width="596" height="21" font="0">Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol. 2006; 47:2310-8. </text>
<text top="389" left="115" width="904" height="21" font="0">618. Mushlin AI, Hall WJ, Zwanziger J, et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. </text>
<text top="410" left="149" width="575" height="21" font="0">Multicenter Automatic Defibrillator Implantation Trial. Circulation. 1998; 97:2129-35. </text>
<text top="430" left="115" width="952" height="21" font="0">619. Al-Khatib SM, Anstrom KJ, Eisenstein EL, et al. Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation </text>
<text top="450" left="149" width="307" height="21" font="0">Trial-II. Ann. Intern. Med. 2005; 142:593-600. </text>
<text top="470" left="115" width="948" height="21" font="0">620. Sanders GD, Hlatky MA and Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N. Engl. J. Med. 2005; 353:1471-80. </text>
<text top="490" left="115" width="932" height="21" font="0">621. Smith T, Jordaens L, Theuns DA, et al. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with </text>
<text top="510" left="149" width="620" height="21" font="0">ischaemic or non-ischaemic heart disease: a European analysis. Eur. Heart J. 2013; 34:211-9. </text>
<text top="531" left="115" width="921" height="21" font="0">622. Cowie MR, Marshall D, Drummond M, et al. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in </text>
<text top="551" left="149" width="934" height="21" font="0">patients with reduced left ventricular systolic function: results of Markov modelling in a European population. Europace : European pacing, </text>
<text top="571" left="149" width="849" height="21" font="0">arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular </text>
<text top="591" left="149" width="501" height="21" font="0">electrophysiology of the European Society of Cardiology. 2009; 11:716-26. </text>
<text top="611" left="115" width="3" height="19" font="3"> </text>
</page>
<outline>
<item page="6">Data Supplement 1.  Nonrandomized Trials, Observational Studies, and/or Registries for History and Physical Examination – (Section 4.1)</item>
<item page="8">Data Supplement 2. Nonrandomized Trials, Observational Studies, and/or Registries of Noninvasive Evaluation (12-lead ECG, Exercise Testing and Electrocardiographic Monitoring) – (Section 4.2.1)</item>
<item page="14">Data Supplement 3. RCTs Comparing Ambulatory Electrocardiography – (Section 4.2.2)</item>
<item page="15">Data Supplement 4. Nonrandomized Trials, Observational Studies, and/or Registries of Ambulatory Monitors – (Section 4.2.2)</item>
<item page="16">Data Supplement 5. Nonrandomized Trials, Observational Studies, and/or Registries of Implanted Cardiac Monitors – (Section 4.2.3)</item>
<item page="18">Data Supplement 6. Nonrandomized Trials, Observational Studies, and/or Registries Comparing Noninvasive Cardiac Assessment– (Section 4.2.4)</item>
<item page="19">Data Supplement 7. Nonrandomized Trials, Observational Studies, and/or Registries Comparing Biomarkers – (Section 4.2.5)</item>
<item page="22">Data Supplement 8. RCTs Evaluating EP Study for VA – (Section 4.3.2)</item>
<item page="26">Data Supplement 9. Nonrandomized Trials, Observational Studies, and/or Registries of EP Study for VA - (Section 4.3.2)</item>
<item page="32">Data Supplement 10. RCTs for Preventing SCD with HF Medications - (Section 5.2)</item>
<item page="37">Data Supplement 11. RCTs and Nonrandomized Trials, Observational Studies, and/or Registries Related to Surgery and Revascularization Procedures – (Section 5.5)</item>
<item page="44">Data Supplement 12. Nonrandomized Trials, Observational Studies, and/or Registries of Arrhythmic Surgery and Revascularization for Arrhythmia Management – (Section 5.5.1)</item>
<item page="48">Data Supplement 13. RCTs for Autonomic Modulation – (Section 5.6)</item>
<item page="50">Data Supplement 14. Nonrandomized Trials, Observational Studies, Guidelines, and/or Registries for Autonomic Modulation – (Section 5.6)</item>
<item page="51">Data Supplement 15. RCTs Comparing Acute Management of Specific Arrythmias - (Section 6)</item>
<item page="58">Data Supplement 16. Nonrandomized Trials, Observational Studies, and/or Registries Comparing Acute Management of Specific Arrythmias – (Section 6)</item>
<item page="64">Data Supplement 17. RCTs Secondary Prevention Sudden Death in Ischemic Heart Disease – (Section 7.1.1)</item>
<item page="69">Data Supplement 18. Nonrandomized Trials, Observational Studies, and/or Registries for Secondary Prevention Sudden Death in Ischemic Heart Disease – (Section 7.1.1)</item>
<item page="71">Data Supplement 19. Nonrandomized Trials, Observational Studies, and/or Registries for Coronary Artery Spasm – (Section 7.1.1.1)</item>
<item page="75">Data Supplement 20. Nonrandomized Trials, Observational Studies, and/or Registries for Post CABG VT/VF – (Section 7.1.1.2)</item>
<item page="77">Data Supplement 21. RCTs and Nonrandomized Trials, Observational Studies, and/or Registries of ICDs Primary Prevention Ventricular Arrhythmias and Sudden Death in Patients with Ischemic Cardiomyopathy – (Section 7.1.2)</item>
<item page="84">Data Supplement 22. RCTs Evaluating Treatment and Prevention of Recurrent Ventricular Arrhythmias in Patients with Ischemic Heart Disease – (Section 7.1.3)</item>
<item page="90">Data Supplement 23. Nonrandomized Trials, Observational Studies, and/or Registries of Treatment of Recurrent Arrhythmias in IHD – (Section 7.1.3)</item>
<item page="98">Data Supplement 24. Nonrandomized Trials, Observational Studies, and/or Registries of NICM – (Section 7.2)</item>
<item page="107">Data Supplement 25. RCTs Secondary Prevention SCD in NICM – (Section 7.2.1)</item>
<item page="112">Data Supplement 26. Nonrandomized Trials, Observational Studies, and/or Registries of Secondary Prevention SCD in NICM – (Section 7.2.1)</item>
<item page="116">Data Supplement 27. RCTs Primary Prevention SCD in NICM – (Section 7.2.2)</item>
<item page="119">Data Supplement 28. Nonrandomized Trials, Observational Studies, and/or Registries of Primary Prevention of SCD in NICM – (Section 7.2.2)</item>
<item page="125">Data Supplement 29. RCTs and Nonrandomized Trials, Observational Studies, and/or Registries of Treatment of Recurrent VA in Patients With NICM – (Section 7.2.3)</item>
<item page="127">Data Supplement 30. Nonrandomized Trials, Observational Studies, and/or Registries of Arrhythmogenic Right Ventricular Cardiomyopathy – (Section 7.3)</item>
<item page="145">Data Supplement 31. Nonrandomized Trials, Observational Studies, and/or Registries of Hypertrophic Cardiomyopathy – (Section 7.4)</item>
<item page="159">Data Supplement 32. Nonrandomized Trials, Observational Studies, and/or Registries of Myocarditis – (Section 7.5)</item>
<item page="160">Data Supplement 33. Nonrandomized Trials, Observational Studies, and/or Registries of Cardiac Sarcoidosis – (Section 7.6)</item>
<item page="168">Data Supplement 34. Nonrandomized Trials, Observational Studies, and/or Registries of Other Infiltrative Cardiomyopathies – (Section 7.6.1)</item>
<item page="170">Data Supplement 35. Nonrandomized Trials, Observational Studies, and/or Registries of Use of ICD and WCD in Patients with HFrEF - (Section 7.8.1)</item>
<item page="173">Data Supplement 36. Nonrandomized Trials, Observational Studies, and/or Registries Related to LVAD – (Section 7.8.3)</item>
<item page="173">Data Supplement 37. Nonrandomized Trials, Observational Studies, and/or Registries Related to ICD Use After Heart Transplantation – (Section 7.8.4)</item>
<item page="175">Data Supplement 38. Nonrandomized Trials, Observational Studies, and/or Registries Evaluating the Risk of Sudden Death or Ventricular Arrhythmias in Patients with Neuromuscular Disorders – (Section 7.8)</item>
<item page="184">Data Supplement 39. Nonrandomized Trials Related to Cardiac Channelopathies – (Section 7.9)</item>
<item page="196">Data Supplement 40. Nonrandomized Trials Related to Congenital LQTS – (Section 7.9.1.1.)</item>
<item page="207">Data Supplement 41. Nonrandomized Trials Related to Catecholaminergic Polymorphic Ventricular Tachycardia – (Section 7.9.1.2.)</item>
<item page="211">Data Supplement 42. Nonrandomized Trials Related to Brugada Syndrome – (Secction7.9.1.3)</item>
<item page="221">Data Supplement 43. Nonrandomized Trials Related to Early Repolarization “J-wave” Syndrome – (Secction 7.9.1.4)</item>
<item page="225">Data Supplement 44. Nonrandomized Trials Related to Short-QT Syndrome – (Secction 7.9.1.5)</item>
<item page="228">Data Supplement 45.  RCTs Related to VA in the Structurally Normal Heart – (Section 8)</item>
<item page="230">Data Supplement 46.  Nonrandomized Trials, Observational Studies, and/or Registries Related to Outflow Tract and AV Annular VA – (Section 8.1)</item>
<item page="238">Data Supplement 47.  Nonrandomized Trials, Observational Studies, and/or Registries of Catheter Ablation in Papillary Muscle VA - (Section 8.2)</item>
<item page="241">Data Supplement 48.  Nonrandomized Trials, Observational Studies, and/or Registries Related to Interfascicular Reentrant VT (Belhassen Tachycardia)- (Section 8.3)</item>
<item page="242">Data Supplement 49. Nonrandomized Trials, Observational Studies, and/or Registries Related to Idiopathic Polymorphic VT/VF - (Section 8.5)</item>
<item page="247">Data Supplement 50. Nonrandomized Trials, Observational Studies, and/or Registries of PVC-induced Cardiomyopathy - (Section 9)</item>
<item page="258">Data Supplement 51. Nonrandomized Trials, Observational Studies, and/or Registries Related to Pregnancy - (Section 10.2)</item>
<item page="267">Data Supplement 52. RCTs Comparing Medication-Induced Arrhythmias - (Section 10.7)</item>
<item page="268">Data Supplement 53. Nonrandomized Trials, Observational Studies, and/or Registries of Medication-Induced Arrhythmias (Section 10.7)</item>
<item page="274">Data Supplement 54. Nonrandomized Trials, Observational Studies, and/or Registries Related to ACHD - (Section 10.8)</item>
<item page="293">Data Supplement 55. Nonrandomized Trials, Observational Studies, and/or Registries of S-ICD - (Section 11.1)</item>
<item page="299">Data Supplement 56. Nonrandomized Trials, Observational Studies, Guidelines, and/or Registries for WCD – (Section 11.2)</item>
<item page="300">Data Supplement 57. Nonrandomized Trials, Observational Studies, Guidelines, and/or Registries for Special Considerations for Catheter Ablation – (Section 12)</item>
<item page="304">Data Supplement 58.  Nonrandomized Trials, Observational Studies, and/or Registries Related to Post-Mortem Evaluation of SCD - (Section 13)</item>
<item page="306"> </item>
<item page="308">Data Supplement 59. Nonrandomized Trials, Observational Studies, Guidelines, and/or Registries of Terminal Care - (Section 14)</item>
<item page="314">Data Supplement 60. Nonrandomized Trials, Observational Studies, Guidelines, and/or Registries for Shared Decision Making – (Section 15)</item>
<item page="317">Data Supplement 61. Randomized Trials, Observational Studies, and/or Registries Related to Cost and Value Considerations - (Section 16)</item>
<item page="321">References:</item>
</outline>
</pdf2xml>
